"Rank","NCT Number","Title","Recruitment","Study Results","Conditions","Interventions","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Types","Study Designs","Other IDs","First Received","Start Date","Completion Date","Last Updated","Last Verified","Results First Received","Acronym","Primary Completion Date","Outcome Measures","URL"
1,"NCT01470586","Surgical Resection Lowers Oxidative Stress Markers in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Colon Rectal Resection|Oxidative Stress","Procedure: Surgery for colorectal cancer","G. Hatzikosta General Hospital|University of Ioannina","Both","25 Years to 80 Years   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)","GH-1948-08","November 5, 2011","May 2009","June 2011","November 10, 2011","November 2011","No Study Results Posted","null","October 2010","Comparison of Oxidative stress markers in patients with colorectal cancer and controls|Validation of oxidative stress markers in patients with colorectal cancer undergo surgical resection","https://ClinicalTrials.gov/show/NCT01470586"
2,"NCT02217865","Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Interviews - Colorectal Cancer Participants|Behavioral: Questionnaire|Behavioral: Focus Groups|Behavioral: Interviews - Caregivers of Colorectal Cancer Participants","M.D. Anderson Cancer Center|Patient-Centered Outcomes Research Institute|Alliance for Clinical Trials in Oncology","Both","21 Years and older   (Adult, Senior)","","180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PA13-1002|CE13-04-6855","August 13, 2014","July 2014","null","August 18, 2016","August 2016","No Study Results Posted","null","July 2017","Effectiveness of Colorectal Cancer (CRC) Surveillance","https://ClinicalTrials.gov/show/NCT02217865"
3,"NCT01244022","Cytokine Changes After Colorectal Cancer Resection","Completed","No Results Available","Colorectal Cancer","Procedure: colorectal cancer resection","University Hospital Dubrava","Both","20 Years to 90 Years   (Adult, Senior)","","28","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","DS-P03112010","November 12, 2010","August 2010","December 2012","July 15, 2013","July 2013","No Study Results Posted","null","December 2012","Postoperative changes of serum cytokine levels|Early postoperative complications","https://ClinicalTrials.gov/show/NCT01244022"
4,"NCT01465451","Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and Safety","Active, not recruiting","No Results Available","Colorectal Cancer","Procedure: curative resection for colorectal cancer|Drug: intra-operative 5-FU chemotherapy","Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","695","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","SYSU 5010-2010016 IOCCRC","November 1, 2011","March 2011","December 2019","August 10, 2016","August 2016","No Study Results Posted","IOCCRC","December 2019","disease-free survival|safety profiles","https://ClinicalTrials.gov/show/NCT01465451"
5,"NCT01072851","Tools for Improving Colorectal Cancer Screening Rates: Multimedia Versus Print","Completed","No Results Available","Colorectal Cancer","Behavioral: Multimedia Education|Behavioral: Print Media|Behavioral: Usual and customary waiting room process","Saint Francis Care|American Cancer Society, Inc.|Feinberg School of Medicine, Northwestern University","Both","50 Years to 80 Years   (Adult, Senior)","Phase 3","920","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Prevention","0910001-E","February 18, 2010","July 2008","September 2012","September 6, 2012","September 2012","No Study Results Posted","null","July 2012","Comparison of the acceptance of colorectal cancer screening by patients who view print or multimedia educational tools|Role of race/ethnicity and literacy levels on the comparative effects if the intervention|Comparative knowledge of colorectal cancer screening by patients who view the print or multi-media educational tools.","https://ClinicalTrials.gov/show/NCT01072851"
6,"NCT02323464","Prevalence of Sleep Apnea in Patients Undergoing Surgery for Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Sleep Apnea Syndromes|Hypoxemia","Procedure: Surgery for colorectal cancer","Karl A Franklin|Umeå University","Both","18 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Dnr 2012-375-31M","December 11, 2014","January 2013","December 2017","April 27, 2016","April 2016","No Study Results Posted","null","December 2017","Side effects after surgery for colorectal cancer|Mortality|Severity of cancer|Sleep apnea before and after surgery|Sleep quality|hypoxemia, hypercapnia|lung function|subjective sleepiness","https://ClinicalTrials.gov/show/NCT02323464"
7,"NCT01103479","Low-Literacy Physician-Patient Intervention Promoting Colorectal Cancer Screening","Completed","Has Results","Colorectal Cancer","Behavioral: Physician Intervention|Behavioral: Physician and Patient Intervention","Northwestern University|National Cancer Institute (NCI)","Both","50 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","569","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Health Services Research","R01CA140177-01|R01CA140177","April 12, 2010","April 2010","September 2013","April 14, 2015","April 2015","August 28, 2014","null","July 2013","Colorectal Cancer (CRC) Screening Completion|Provider Recommendation of CRC Screening","https://ClinicalTrials.gov/show/NCT01103479"
8,"NCT00161460","Colorectal Cancer Screening Intervention in UWPN Clinics","Completed","No Results Available","Colorectal Neoplasia","Behavioral: colorectal cancer screening intervention","University of Washington|National Cancer Institute (NCI)","Both","50 Years and older   (Adult, Senior)","","80","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","26840-J|1R21CA107157","September 8, 2005","June 2005","June 2008","May 11, 2016","May 2016","No Study Results Posted","null","June 2008","Colorectal cancer screening test utilization|Knowledge about colorectal cancer screening tests|Cancer worry score","https://ClinicalTrials.gov/show/NCT00161460"
9,"NCT02556281","Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III","Recruiting","No Results Available","Colorectal Neoplasms","Biological: Blood sampling","University Hospital, Rouen","Both","18 Years and older   (Adult, Senior)","","293","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2009/066/HP","September 18, 2015","October 2012","September 2019","May 10, 2016","May 2016","No Study Results Posted","CTC","July 2019","Presence of free tumoral DNA in blood of patient with colorectal cancer|Number of patient with a first relapse|Presence of tumoral cells in blood of patient with colorectal cancer|Number of tumoral cells in blood of patient with colorectal cancer|Number of free tumoral DNA in blood of patient with colorectal cancer","https://ClinicalTrials.gov/show/NCT02556281"
10,"NCT01519999","Colorectal Cancer Screening With Improved Shared Decision Making","Active, not recruiting","No Results Available","Colorectal Cancer Screening|Shared Decision Making","Behavioral: Shared Decision Making for Colorectal Cancer Screening","Virginia Commonwealth University|Allina Health System|Blue Cross Blue Shield","Both","50 Years to 75 Years   (Adult, Senior)","","5842","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","WISDM-106965","January 13, 2012","May 2012","December 2017","July 8, 2016","July 2016","No Study Results Posted","CRCS-WISDM","June 2017","Change in colorectal cancer screening adherence|Decisional conflict|Modality-specific colorectal cancer screening barriers|Colorectal cancer screening-related confusion|Patients' shared decision-making experience|Providers'/staff shared decision-making experience","https://ClinicalTrials.gov/show/NCT01519999"
11,"NCT00265720","Colorectal Cancer Screening Intervention Trial","Completed","No Results Available","Colorectal Cancer|Colorectal Cancer Screening","Other: Control|Other: Reduced out of pocket expense|Behavioral: one on one education|Behavioral: Group education","Morehouse School of Medicine|Centers for Disease Control and Prevention","Both","50 Years and older   (Adult, Senior)","","360","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label","H57/CCH420680-05","December 13, 2005","March 2003","July 2007","February 3, 2009","February 2009","No Study Results Posted","null","July 2007","Colorectal Cancer Screening Rate; This measurement(Impact) is taken 90 days from last intervention session. If a person is not screened, an additional measurement(Post-Impact) is taken 90 days from the Impact.|Knowledge, Attitudes and Beliefs; this measurement is taken at baseline and post intervention session. Sessions vary by intervention group after the initial recruitment sessions:","https://ClinicalTrials.gov/show/NCT00265720"
12,"NCT00558233","Effectiveness Study of a Computer-Based Colorectal Cancer Screening Decision Aid","Completed","No Results Available","Colorectal Cancer|Health Literacy","Behavioral: CHOICE decision aid|Behavioral: YourMeds patient education program","Wake Forest University|American Cancer Society, Inc.|University of North Carolina, Chapel Hill|Wake Forest School of Medicine","Both","50 Years to 75 Years   (Adult, Senior)","","350","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Health Services Research","CCCDA-05-162-01","November 13, 2007","November 2007","March 2009","April 20, 2010","April 2010","No Study Results Posted","InfoPC","March 2009","Receipt of colorectal cancer screening|Change in participants' readiness to be screened (Stage of Change)|Self-reported intent to discuss colorectal cancer screening with healthcare provider|Provider ordering a colorectal cancer screening test|Participant completion of computer program without assistance|Participant acceptance of computer program|Number of polyps and cancers found by screening tests performed","https://ClinicalTrials.gov/show/NCT00558233"
13,"NCT00927680","Familial Colorectal Cancer Registry in Hispanics","Recruiting","No Results Available","Colorectal Cancer","","University of Puerto Rico|National Cancer Institute (NCI)","Both","15 Years and older   (Child, Adult, Senior)","","5000","Other|NIH","Observational","Observational Model: Family-Based|Time Perspective: Prospective","R03CA130034-NCI","June 24, 2009","July 2007","January 2021","May 10, 2016","May 2016","No Study Results Posted","PURIFICAR","December 2020","We will recruit individuals with colorectal cancer with and without family history of CRC and their immediate family members and obtain the following: paraffin-embedded tumors blocks, blood samples, risk factor and food frequency questionnaires.|We will study the following parameters that we help us plan the larger population-based study such as: response rate of probands and their selected relatives, response rate of participants (probands and relatives), etcetera.","https://ClinicalTrials.gov/show/NCT00927680"
14,"NCT00906997","Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy","Active, not recruiting","No Results Available","Colorectal Cancer|Colorectal Neoplasm","Procedure: Immunochemical fecal occult blood test|Procedure: Colonoscopy","Hospital Clinic of Barcelona|Grupo Cooperativo para el Cribado del Cancer Colorrectal en España.|Gastrointestinal Oncology Group of the Spanish Gastroenterological Association|Fundacion Cientifica de la Asociacion Española contra el Cancer|Instituto de Salud Carlos III","Both","50 Years to 69 Years   (Adult, Senior)","Phase 3","55498","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","COLONPREV","May 19, 2009","November 2008","November 2021","March 31, 2015","March 2015","No Study Results Posted","null","November 2021","Colorectal cancer-related mortality|Compliance rate|Complication rate|Colorectal cancer incidence|Adherence rate|Advanced colorectal neoplasm detection rate","https://ClinicalTrials.gov/show/NCT00906997"
15,"NCT01972503","Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis|Liver Neoplasms","Drug: 5-FU and oxaliplatin|Procedure: colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)","Xu jianmin|Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","Octree Study","September 23, 2013","June 2008","September 2015","December 10, 2013","December 2013","No Study Results Posted","null","September 2013","3 years disease-free survival|3 years overall survival and metastasis-free survival","https://ClinicalTrials.gov/show/NCT01972503"
16,"NCT02368236","Facilitating Risk-Appropriate Colorectal Cancer Testing - Testing the Cancer Risk Intake System (CRIS)","Active, not recruiting","No Results Available","Colorectal Neoplasms|Colonic Neoplasms","Behavioral: Tailored Printout","University of Texas Southwestern Medical Center|National Cancer Institute (NCI)","Both","25 Years to 75 Years   (Adult, Senior)","","1012","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Screening","112010-132|R01CA122330","January 28, 2015","December 2008","null","April 11, 2016","April 2016","No Study Results Posted","null","February 2012","Participation in risk-appropriate colorectal cancer testing (i.e., participation in any CRIS-recommended test based on patients' risk factors).|Participation in any type of colorectal cancer testing.|Testing difference in receipt of any type of colorectal cancer testing.","https://ClinicalTrials.gov/show/NCT02368236"
17,"NCT02503969","Exploratory Analysis on the Impact of Morbidities on Colorectal Cancer Screening Uptake","Completed","No Results Available","Colorectal Cancer","Other: Exposure to having a long-term condition.","University of Sheffield","Both","60 Years to 69 Years   (Adult, Senior)","","8776","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","15/YH/0028","July 16, 2015","September 2015","December 2015","December 1, 2015","December 2015","No Study Results Posted","null","December 2015","Individual attended colorectal cancer screening|Individual accepted colorectal cancer screening after refusing the initial invitation for colorectal cancer screening","https://ClinicalTrials.gov/show/NCT02503969"
18,"NCT00786747","Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities","Completed","No Results Available","Colorectal Neoplasms","Behavioral: Personally tailored computer program|Behavioral: Non-tailored control computer program","University of California, Davis|University of Rochester|City University of New York, School of Public Health","Both","50 Years to 75 Years   (Adult, Senior)","","1164","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Screening","NCI -1R01CA131386-01A1|ARRA CA13138602S1","November 5, 2008","February 2010","November 2012","December 2, 2015","December 2015","No Study Results Posted","null","October 2011","Up to date colorectal cancer screening status|Up to date colonoscopy screening status|Up to date fecal occult blood testing status|Colorectal cancer screening self-efficacy|Perceived barriers to colorectal cancer screening|Readiness to undergo colorectal cancer screening","https://ClinicalTrials.gov/show/NCT00786747"
19,"NCT00965965","Comprehensibility of Colorectal Cancer Screening Educational Materials: Effects on Patient Knowledge and Motivation","Completed","No Results Available","Colorectal Neoplasms","Behavioral: New colorectal cancer screening patient education document|Behavioral: Traditional colorectal cancer screening education document","University of California, Davis|California Academy of Family Physicians","Both","50 Years to 75 Years   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","200917361-1","August 20, 2009","August 2009","April 2010","April 26, 2012","April 2012","No Study Results Posted","null","April 2010","Comprehension of randomly assigned educational document|Colorectal cancer screening knowledge|Self-efficacy for undergoing colorectal cancer screening|Perceived barriers to undergoing colorectal cancer screening|Readiness to undergo colorectal cancer screening","https://ClinicalTrials.gov/show/NCT00965965"
20,"NCT01085331","MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Mek Inhibitor MSC1936369B|Drug: Mek Inhibitor MSC1936369B|Drug: Placebo|Drug: FOLFIRI","EMD Serono","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","16","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR200066_004","March 4, 2010","March 2010","April 2012","April 20, 2015","April 2015","No Study Results Posted","null","April 2012","Part 1 or Safety Run-in Part: To determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D) of MSC1936369B in combination with FOLFIRI as second-line treatment in subjects with K-Ras mutated metastatic colorectal cancer|Part 2 or Phase II Randomized part: To assess the anti-tumor activity of MSC1936369B in combination with with FOLFIRI in subjects with K-Ras mutated metastatic colorectal cancer in terms of Progression-Free survival|Part 1 or Safety Run-in Part: To assess the pharmacokinetics of MSC1936369B and irinotecan|Part 1 or Safety Run-in Part: To explore the anti-tumor activity of MSC1936369B and FOLFIRI in subjects with K-Ras mutated metastatic colorectal cancer|Part 1 or Safety Run-in Part: To explore candidate markers for tumor characteristics and predictive of antitumor activity|Part 1 or Safety Run-in Part: To explore circulating markers in serum|Part 2 or Phase II Randomized part: To determine the safety and tolerability of MSC1936369B and FOLFIRI in subjects with K-Ras mutated metastatic colorectal cancer|Part 2 or Phase II Randomized part: To assess the antitumor activity in terms of response rate, clinical benefit, overall survival, and tile to progression|Part 2 or Phase II Randomized part: To explore candidate markers for tumor characteristics and predictive of antitumor activity|Part 2 or Phase II Randomized part: To explore circulating markers in serum","https://ClinicalTrials.gov/show/NCT01085331"
21,"NCT02727894","Colorectal Cancer Study: Screening v.s. Other Diagnostics","Completed","No Results Available","Colorectal Cancer","","Institute for Clinical and Experimental Medicine|Private practice at Hluboká nad Vltavou|Klaudian Hospital Mladá Boleslav|Masaryk Hospital Rakovník|Brno University Hospital|Medic Kral Ltd.|Chomutov Hospital|T. Bata Hospital Zlín|Military University Hospital, Prague|Frýdek-Místek Hospital|The University Hospital Plzeň|Vitkovice Hospital","Both","Child, Adult, Senior","","276","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","00023001-2015","March 30, 2016","March 2013","January 2016","March 30, 2016","March 2016","No Study Results Posted","CRC","December 2015","Colorectal Cancer Stage (pTNM)|Colorectal Cancer Grade|Colorectal Cancer Resection Margins|Colorectal Cancer Metastatis|Colorectal Cancer Surgery|Colorectal Cancer Paliative Therapy","https://ClinicalTrials.gov/show/NCT02727894"
22,"NCT02535988","Abscopal Effect for Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Cancer|Metastatic Colorectal Cancer|Thymalfasin","Radiation: Radiation therapy|Drug: Thymalfasin","Zhejiang Provincial People’s Hospital","Both","19 Years and older   (Adult, Senior)","Phase 2","29","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZhejiangPPH","August 26, 2015","September 2015","December 2017","August 28, 2015","August 2015","No Study Results Posted","null","January 2017","The proportion of patients with an abscopal response assessed at 7-8 weeks after the initiation of treatment.|The number of participants with adverse events from the date of enrollment until 2 years from the opening of the study.|The proportion of patients alive with abscopal responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study.","https://ClinicalTrials.gov/show/NCT02535988"
23,"NCT01196260","Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III","Recruiting","No Results Available","Colorectal Cancer","Drug: Capecitabine and Oxaliplatin","State Key Laboratory of Cancer Biology|Tianjin Union Medical Center|Beihua University|Chengdu Medical College|Shanghai Jiao Tong University School of Medicine","Both","18 Years to 90 Years   (Adult, Senior)","Phase 2|Phase 3","8000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dake Chu-200401|StateKeyLab","September 3, 2010","January 2004","December 2014","October 10, 2014","October 2014","No Study Results Posted","null","December 2014","To determine the objective response rate of patients with metastatic colorectal cancer received the combination of drugs|To determine the relapse of patients with metastatic colorectal cancer received the combination of drugs|To determine prognosis of patients with metastatic colorectal cancer received the combination of drugs|To evaluate the time to progression of metastatic colorectal cancer after treatment","https://ClinicalTrials.gov/show/NCT01196260"
24,"NCT02238821","Role of the MET Oncogene in Human Colorectal Cancer - A Translational Study","Recruiting","No Results Available","Colorectal Cancer","","Fondazione del Piemonte per l'Oncologia","Both","18 Years to 80 Years   (Adult, Senior)","","60","Other","Observational","Time Perspective: Prospective","MET/colon 06","September 1, 2014","October 2007","December 2016","August 19, 2016","August 2016","No Study Results Posted","COMET","September 2016","Scoring MET expression in colorectal tissue sections by immunohistochemical analysis|Scoring the expression of Plasminogen Activator Inhibitor -1 in colorectal cancer tissue sections by Immunohistochemical analysis|Scoring the expression of COX-2 in colorectal cancer tissue sections by Immunohistochemical analysis","https://ClinicalTrials.gov/show/NCT02238821"
25,"NCT01286064","Colorectal Cancer Detection by Means of Optical Fluoroscopy","Recruiting","No Results Available","Colorectal Cancer","Device: Optical Fluoroscopy|Device: Optical Fluoroscopy","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Both","18 Years to 75 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Screening","INT-D178768","January 27, 2011","October 2010","April 2011","January 28, 2011","September 2010","No Study Results Posted","null","December 2010","Colorectal cancer detection by means of optical fluoroscopy","https://ClinicalTrials.gov/show/NCT01286064"
26,"NCT02008383","Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Biological: Panitumumab|Drug: Cabozantinib","John Strickler, M.D.|Exelixis|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00049983","December 3, 2013","January 2014","January 2019","September 17, 2016","September 2016","No Study Results Posted","CaboMAb","January 2018","Recommended phase II dose (RPTD) for the combination of cabozantinib and panitumumab|Objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer|Non-dose limiting toxicities of cabozantinib and panitumumab.|Response rate of cabozantinib and panitumumab|Progression free survival associated with the cabozantinib and panitumumab regimen|Overall survival associated with the cabozantinib and panitumumab regimen|Progression free survival associated with cabozantinib monotherapy in patients with MET amplified colorectal cancer|Overall survival associated with cabozantinib monotherapy in patients with MET amplified colorectal cancer|To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer","https://ClinicalTrials.gov/show/NCT02008383"
27,"NCT01385579","Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population","Completed","Has Results","Malignant Neoplasm of Large Intestine","Other: Care manager outreach","Northwestern University","Both","50 Years to 80 Years   (Adult, Senior)","","202","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","STU00015652","June 28, 2011","January 2010","June 2010","November 18, 2013","November 2013","November 18, 2013","null","June 2010","Completion of a Colorectal Cancer Screening","https://ClinicalTrials.gov/show/NCT01385579"
28,"NCT00836303","Trial of a Multilevel Intervention to Increase Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Behavioral: Colorecatal Cancer Screening Activation","New York University School of Medicine","Both","50 Years and older   (Adult, Senior)","","130","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","T01CD000146","February 2, 2009","December 2005","July 2007","February 2, 2009","February 2009","No Study Results Posted","null","June 2007","Completion of Colorectal cancer screening|physician recommendation for colorectal cancer screening|Patient adherence to physician recommended colorectal cancer screening test","https://ClinicalTrials.gov/show/NCT00836303"
29,"NCT01526239","Reminding Patients of the Important of Colorectal Cancer Screening Results in Patient-Initiated Promoting Colorectal Cancer Screening Via Colonoscopy","Completed","No Results Available","Colon Cancer","Other: Colorectal cancer screening pamphlet","University of Oklahoma","Both","45 Years and older   (Adult, Senior)","","274","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Screening","14225","January 3, 2012","November 2008","November 2010","February 2, 2012","January 2012","No Study Results Posted","null","November 2010","Communication with primary care physicians about CRC screening","https://ClinicalTrials.gov/show/NCT01526239"
30,"NCT01850654","Ohio Colorectal Cancer Prevention Initiative","Recruiting","No Results Available","Lynch Syndrome|Colorectal Cancer","Genetic: LS tumor screening|Genetic: Genetic testing|Behavioral: Genetic Counseling|Other: Biorepository|Behavioral: Questionnaire","Ohio State University Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","","5000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","OSU-12170","May 3, 2013","December 2012","September 2018","August 23, 2016","August 2016","No Study Results Posted","OCCPI","June 2017","Determine the Incidence of Hereditary Cancer Syndromes among Newly Diagnosed Colorectal Cancer Patients","https://ClinicalTrials.gov/show/NCT01850654"
31,"NCT00777192","Longitudinal Study of Symptoms in Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Behavioral: Questionnaires","M.D. Anderson Cancer Center|AstraZeneca","Both","18 Years and older   (Adult, Senior)","","500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2007-0637","October 20, 2008","August 2008","null","February 18, 2016","February 2016","No Study Results Posted","null","August 2017","Association between inflammatory cytokines and development of treatment-related symptom burden in colorectal cancer patients|Primary afferent function in colorectal cancer patients receiving chemotherapy by quantitative sensory testing over time|Neurocognitive and neuropsychiatric symptoms in colorectal cancer patients","https://ClinicalTrials.gov/show/NCT00777192"
32,"NCT00578721","Trial of Aspirin and Arginine Restriction in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Aspirin","University of California, Irvine","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","UCI 07-47","December 18, 2007","September 2008","December 2013","January 28, 2013","January 2013","No Study Results Posted","null","May 2013","To demonstrate a > 50% decrease in rectal tissue putrescine levels from baseline in study subjects, as a measure of polyamine reduction in the target tissue of colorectal cancer patients|To determine this intervention's side-effect profile in a population of optimally-treated colorectal cancer patients. We expect to demonstrate biomarker alterations without clinical side effects","https://ClinicalTrials.gov/show/NCT00578721"
33,"NCT02503631","Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers","Recruiting","No Results Available","Colorectal Neoplasms|Digestive System Diseases|Colonic Diseases|Colorectal Cancer","Device: Stool Sample Collection Kit","Exact Sciences Corporation","Both","40 Years to 90 Years   (Adult, Senior)","","300","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2014-02","July 17, 2015","October 2014","July 2017","August 9, 2016","August 2016","No Study Results Posted","null","March 2017","To provide stool and blood specimens to assess new markers for the detection of CRC|To provide stool and blood specimens for use as controls when assessing new markers for the detection of neoplasms in other locations within the digestive tract (esophagus, stomach, pancreas, etc.)|To provide stool and blood specimens for a biorepository for future cancer-related diagnostic test development|To provide quality control material for use in assessing performance of developed assays","https://ClinicalTrials.gov/show/NCT02503631"
34,"NCT01234246","Sexual Dysfunction and the Quality of Sexual Life in Patients With Colorectal Cancer and Their Partners.","Recruiting","No Results Available","Colorectal Cancer Patients and Their Partners","","University of Tilburg|Dutch Cancer Society","Both","18 Years to 75 Years   (Adult, Senior)","","1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL32121.008.10|UVT 2009-4495","November 3, 2010","March 2010","March 2014","November 3, 2010","August 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01234246"
35,"NCT02820389","CT Colonography as the Initial Diagnostic Imaging Tool for Patients With Suspected Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Cancer","Procedure: Optical colonoscopy|Procedure: CTC","Guy's and St Thomas' NHS Foundation Trust|King's College London","Both","40 Years and older   (Adult, Senior)","","246","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Colon CT study","June 3, 2016","June 2016","July 2018","June 28, 2016","June 2016","No Study Results Posted","CTCS","January 2018","3-month cost analysis per patient undergoing either Optical Colonoscopy or CTC as the initial imaging modality (measured in £ per patient)|6-month cost analysis per patient undergoing either Optical Colonoscopy or CTC as the initial imaging modality (measured in £ per patient)|3-month cost-effectiveness analysis per patient undergoing either CTC or Optical Colonoscopy as the initial imaging modality (measured in £ per QALY)|6-month cost-effectiveness analysis per patient undergoing either CTC or Optical|Frequency of incidental findings using CTC as the initial diagnostic imaging tool (measured as a %, number of patients with incidental findings in CTC / number of CTC scans)|Likelihood ratio of CTC as the initial diagnostic imaging tool against the optical colonoscopy in patients with initial positive CTC findings for medium to large polyps and colorectal cancer (estimated using the p-value)|Time taken (measured in days) to reach a definitive diagnosis and first major treatment decision based on the the initial CTC scan in comparison to Optical Colonoscopy as the initial imaging modality.|Do not Attend (DNA) or On the Day Cancellation rate associated with the pathway using Colonoscopy or CTC as the initial imaging test (measured as a percentage)|Patient satisfaction associated with both clinical pathways (i.e. using CTC or Optical Colonoscopy as the initial imaging scan)|Patient's self perceived quality of life - measured using EQ-5D-5L questionnaire|Cost per correctly diagnosed medium to large polyps (≥6mm) and colorectal cancer using CTC as the initial investigation (measured in £ per patient)","https://ClinicalTrials.gov/show/NCT02820389"
36,"NCT00507598","Metabolomics-Based Detection of Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: No intervention","Indiana University","Both","18 Years and older   (Adult, Senior)","Phase 1","69","Other","Observational","Time Perspective: Prospective","0706-03: IUCRO-0198","July 24, 2007","July 2007","November 2012","September 10, 2014","September 2014","No Study Results Posted","metabolomics","March 2009","•Perform metabolic profiling of tissue,serum & urine from pts w/ colorectal cancer (stages I-IV), healthy controls & pts w/ colorectal polyps & correlate results.|Correlate changes of serum & urine biomarkers /p trt to predict response or toxicity,& correlate w/other treatment outcomes. Compare the metabolic profile between pts w/various stages of colorectal cancer.","https://ClinicalTrials.gov/show/NCT00507598"
37,"NCT02442583","Reducing Sedentary Behaviors Among Colorectal Cancer Survivors","Active, not recruiting","No Results Available","Colorectal Cancer","Other: Brochure regarding sedentary behavior","Duke University","Both","18 Years and older   (Adult, Senior)","","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00060174","May 7, 2015","May 2015","April 2017","May 20, 2016","January 2016","No Study Results Posted","null","April 2017","Feasibility of the print brochure, as measured by Likert scale.|Change in number of minutes per day of light to strenuous physical activity.|Change in number of minutes per day of bouts of sedentary behaviors.|Covariation between baseline use of an ActiGraph, and self-reporting of sedentary behaviors","https://ClinicalTrials.gov/show/NCT02442583"
38,"NCT01723969","Screening Platform for Clinical Trials in Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Advanced Colorectal Cancer","Genetic: Tumour markers testing","European Organisation for Research and Treatment of Cancer - EORTC|Alliance Boots","Both","18 Years and older   (Adult, Senior)","","2600","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","EORTC-40CRC|2012-003714-14","November 5, 2012","September 2013","February 2017","June 9, 2016","June 2016","No Study Results Posted","SPECTAcolor","December 2016","Tumour markers assessment","https://ClinicalTrials.gov/show/NCT01723969"
39,"NCT00838318","Colon Cancer Screening in First-Degree Relatives of Hispanic Colorectal Cancer (CRC) Patients","Completed","No Results Available","Colorectal Cancer","Behavioral: Interview","M.D. Anderson Cancer Center","Both","18 Years to 70 Years   (Adult, Senior)","","26","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2004-0039","February 5, 2009","February 2004","March 2010","July 26, 2012","July 2012","No Study Results Posted","null","March 2010","To look at the knowledge, beliefs, and attitudes toward screening for colorectal cancer among Hispanic colorectal cancer patients and their close relatives.|To study how these families communicate with each other and health care providers about colorectal cancer risk and screening.","https://ClinicalTrials.gov/show/NCT00838318"
40,"NCT00264979","Evaluation of 2 Resection Strategies of Synchronous Colorectal Cancer Metastases","Recruiting","No Results Available","Colorectal Cancer|Hepatic Metastases","Procedure: Simultaneous surgery|Procedure: Sequential surgery","Rennes University Hospital|Ministry of Health, France","Both","18 Years and older   (Adult, Senior)","","222","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DGS 2005/0193|PHRC/04-01|CIC0203/030","December 12, 2005","December 2005","December 2019","March 21, 2016","March 2016","No Study Results Posted","METASYNC","June 2017","Rate of patients with at least one postoperative severe complication within 60 days after each surgery|Death rate during hospitalization or within 60 days after each surgery|Rate and number of severe general, digestive or hepatic complications|Rate of unachieved hepatic resection|Global survival distribution and 2 years global survival rate|Recurrence-free survival distribution and 2 years recurrence-free survival rate|Two years recurrence rate","https://ClinicalTrials.gov/show/NCT00264979"
41,"NCT01909362","Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)","Completed","No Results Available","Colorectal Neoplasms|Advanced Metastatic Colorectal Cancer","","US Oncology Research|Quintiles, Inc.","Both","18 Years and older   (Adult, Senior)","","52","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","12246","July 19, 2013","July 2013","February 2014","February 25, 2014","February 2014","No Study Results Posted","null","February 2014","number of drug targetable genetic changes found in tumor tissue sample|number and cause of failed analyses after registration and tissue submission|number of physicians who took into consideration regimens that were suggested by the results of the sequencing analysis when deciding their patients' next line of therapies.","https://ClinicalTrials.gov/show/NCT01909362"
42,"NCT00961129","The Continuing Care Needs in Colorectal Cancer Patients in Different Stages","Recruiting","No Results Available","Colorectal Cancer","","National Taiwan University Hospital","Both","18 Years and older   (Adult, Senior)","","269","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","200902016R","August 16, 2009","March 2009","December 2011","April 11, 2010","April 2010","No Study Results Posted","null","April 2010","supportive cancer care needs","https://ClinicalTrials.gov/show/NCT00961129"
43,"NCT00855348","PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Other: All eligible subjects will provide blood for SEPT9 biomarker testing","Epigenomics, Inc","Both","50 Years and older   (Adult, Senior)","","7929","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Epigenomics_SPR0006","February 4, 2009","June 2008","April 2010","August 1, 2014","August 2014","No Study Results Posted","PRESEPT","January 2010","Clinical/surgical diagnosis of invasive colorectal adenocarcinoma detected by optical colonoscopy and confirmed by histology compared to the Septin 9 Biomarker classification.|Detection of adenomatous polyp(s) equal to or greater than 10 mm, flat lesion (s) or non-invasive adenocarcinoma by colonoscopy and confirmed by histology compared to the Septin 9 Biomarker classification will also be described.","https://ClinicalTrials.gov/show/NCT00855348"
44,"NCT00251485","A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Cetuximab","Veeda Oncology|Bristol-Myers Squibb|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","82","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I-03-002","November 8, 2005","March 2004","June 2005","August 20, 2008","August 2008","No Study Results Posted","null","June 2005","To assess the response rate, progression-free survival, and overall safety profile of a modified FOLFOX 6 plus cetuximab regimen in the first-line treatment of patients with metastatic colorectal cancer.|To assess overall survival of patients with metastatic colorectal cancer who receive first-line therapy with a modified FOLFOX 6 + cetuximab regimen","https://ClinicalTrials.gov/show/NCT00251485"
45,"NCT02754856","Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.","Recruiting","No Results Available","Colorectal Cancer|Liver Metastases","Drug: Tremelimumab|Drug: Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Bevacizumab|Drug: MEDI4736|Procedure: Liver Resection","M.D. Anderson Cancer Center|MedImmune LLC","Both","18 Years and older   (Adult, Senior)","Phase 1","35","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-0828|NCI-2016-00772","April 26, 2016","July 2016","null","July 29, 2016","July 2016","No Study Results Posted","null","July 2021","Feasibility of Tremelimumab plus MEDI4736 with FOLFOX and Bevacizumab in Candidates for Resection of Colorectal Cancer Liver Metastases|Relapse-free survival (RFS) of Tremelimumab plus MEDI4736 with FOLFOX and Bevacizumab in Candidates for Resection of Colorectal Cancer Liver Metastases","https://ClinicalTrials.gov/show/NCT02754856"
46,"NCT01804179","Colorectal Cancer Awareness, Research, Education and Screening (CARES)","Active, not recruiting","No Results Available","Colorectal Cancer","Other: Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Other: Standard Intervention (SI) Educational Materials|Other: CARES Intervention Educational Materials|Other: Baseline Visit Survey|Other: Follow-up Questionnaire","H. Lee Moffitt Cancer Center and Research Institute","Both","50 Years to 75 Years   (Adult, Senior)","","514","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","MCC-16447","March 1, 2013","February 2011","January 2017","June 10, 2016","June 2016","No Study Results Posted","null","January 2017","Frequency of Immunochemical Fecal Occult Blood Test (I-FOBT) Kit Use|Overall Colorectal Cancer Screening (CRCS) With Any Test","https://ClinicalTrials.gov/show/NCT01804179"
47,"NCT02515344","Impact of the Distribution to Attending Physicians of a Nominative List of Their Patients Not Participating in the Organised Screening of Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: Providing a list of patients not compliant with CRC sreening|Other: Providing general information about CRC sreening","Nantes University Hospital|Public Health Insurance|Université de Nantes|Organisms in charge of local cancer screening programs - France|Local Cancer Registry - France","Both","25 Years to 74 Years   (Adult, Senior)","","48649","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","RC12_0497","July 21, 2015","August 2015","August 2016","September 15, 2016","September 2016","No Study Results Posted","IDLN","August 2016","Patient participation rate to colorectal cancer screening|Number of cancers screened in (versus diagnosed outside) the screening procedure.","https://ClinicalTrials.gov/show/NCT02515344"
48,"NCT02901600","Expression of DMBT1 in Colorectal Cancer Patients","Completed","No Results Available","DMBT1 Protein, Human|Colorectal Cancer","Other: Detection of the expression of DMTB1 by immunohistochemistry","Lille Catholic University","Both","18 Years and older   (Adult, Senior)","","145","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","RT-06","September 12, 2016","June 2013","November 2015","September 12, 2016","September 2016","No Study Results Posted","DMBT1","June 2015","Semi-quantitative determination of the histological expression of DMBT1|Determination of the histological localisation of DMBT1","https://ClinicalTrials.gov/show/NCT02901600"
49,"NCT02151032","Using Multimedia Approaches to Communicate Probabilities in Patient Decision Aids for Low-Literacy Populations: Randomized Trial","Active, not recruiting","No Results Available","Colorectal Cancer","Behavioral: Booklet|Behavioral: Audio CD|Behavioral: Video with Non-Moving Images|Behavioral: Video with Animated Images|Behavioral: Questionnaires","M.D. Anderson Cancer Center|Foundation for Informed Medical Decision Making","null","45 Years to 75 Years   (Adult, Senior)","","201","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","2011-0632|0619-1","May 27, 2014","November 2012","null","June 1, 2016","June 2016","No Study Results Posted","null","November 2017","Gist and Verbatim Knowledge for a Colorectal Cancer Screening Program","https://ClinicalTrials.gov/show/NCT02151032"
50,"NCT00632515","Screening for Familial Colorectal Cancer (CRC) Patients","Active, not recruiting","No Results Available","Colorectal Cancer","Behavioral: Questionnaire","M.D. Anderson Cancer Center","Both","up to 60 Years   (Child, Adult)","","325","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","2004-0316","March 3, 2008","January 2008","null","February 4, 2016","February 2016","No Study Results Posted","null","January 2018","Psychosocial + External factors influencing CRC patients' communication with FDRs about CRC risk & screening information","https://ClinicalTrials.gov/show/NCT00632515"
51,"NCT01364454","General Practitioners (GP) Involvement in Colorectal Cancer (CRC) Screening","Completed","No Results Available","Colorectal Cancer","Other: Eligible patients' paper-based reminder","Paris 12 Val de Marne University","Both","50 Years to 74 Years   (Adult, Senior)","Phase 0","8140","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","DUERMG","May 31, 2011","June 2010","June 2011","August 18, 2016","August 2016","No Study Results Posted","null","June 2011","Patient's participation to colorectal cancer screening program","https://ClinicalTrials.gov/show/NCT01364454"
52,"NCT01722903","Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer","Completed","No Results Available","Stage IV Colorectal Cancer|Liver Metastases|Lung Metastases","","Milton S. Hershey Medical Center","Both","18 Years and older   (Adult, Senior)","","25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","39748EP","November 5, 2012","August 2012","June 2015","September 12, 2016","September 2016","No Study Results Posted","null","May 2013","Quantity of CTCs isolated during liver and/or lung metastasectomy|Overall survival","https://ClinicalTrials.gov/show/NCT01722903"
53,"NCT00114946","A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: Avastin","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 4","800","Industry","Interventional","Primary Purpose: Treatment","AVF3430n","June 20, 2005","May 2005","December 2007","May 26, 2006","May 2006","No Study Results Posted","null","null","To compare the efficacy, as measured by progression-free survival (PFS), of FOLFOX/Avastin followed by FOLFIRI/Avastin versus FOLFOX/Avastin followed by 5-FU/LV/Avastin as first-line therapy for previously untreated metastatic colorectal cancer.|To evaluate the tolerability of sequential treatment in subjects and to evaluate the safety of an irinotecan/Avastin-based regimen versus a 5-FU/Avastin regimen for previously untreated metastatic colorectal cancer.","https://ClinicalTrials.gov/show/NCT00114946"
54,"NCT00898378","Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps","Completed","No Results Available","Colorectal Cancer|Healthy, no Evidence of Disease|Precancerous Condition","Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Genetic: protein expression analysis|Genetic: proteomic profiling|Other: gas chromatography|Other: laboratory biomarker analysis|Other: liquid chromatography|Other: mass spectrometry|Other: questionnaire administration","Indiana University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","551","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","0808-24; IUCRO-0221|P30CA082709|IUCRO-0221","May 9, 2009","January 2009","March 2014","September 17, 2014","September 2014","No Study Results Posted","null","March 2014","Metabolomic, lipidomic, glycoproteomic, proteomic, and genomic (OMIC) profiling|Creation of an OMIC profile to predict the risk of colorectal cancer (CRC)|Creation of an OMIC profile to predict response and toxicity to specific therapies for CRC|Identification of interactive molecular pathways that underlie the development and progression of CRC","https://ClinicalTrials.gov/show/NCT00898378"
55,"NCT00929097","Implementation of Guidelines on Hereditary or Familial Colorectal Cancer","Enrolling by invitation","No Results Available","Colorectal Neoplasms, Hereditary Nonpolyposis","Other: Implementation aids|Other: Control","ZonMw: The Netherlands Organisation for Health Research and Development|Cardiff University|Erasmus Medical Center|Leiden University Medical Center|University Medical Center Groningen|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Comprehensive Cancer Centres|Radboud University","Both","18 Years to 70 Years   (Adult, Senior)","","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","ZonMw 80-82315-98-09005","June 25, 2009","October 2009","January 2012","June 25, 2009","June 2009","No Study Results Posted","RISCO","July 2011","The number of colorectal cancer patients following the most optimal follow up program according to the guidelines.|The number of patients for whom MSI testing was performed based on the MIPA criteria|The number of CRC patients for whom a correct familial CRC risk is calculated by clinicians (as compared to formally calculated risks)|The number of CRC patients for whom a calculated familial CRC risk is correctly interpreted by clinicians|The number of CRC patients with whom a calculated familial CRC risk and/or follow up policy is communicated by clinicians|Patients' uptake of the follow up policy|Actual exposure to the different elements of the implementation strategy|Experiences of clinicians and patients with the different elements of the implementation strategy|Costs of the implementation procedure","https://ClinicalTrials.gov/show/NCT00929097"
56,"NCT02488161","Factors Related to Adverse Events in Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: No intervention","Hospital Galdakao-Usansolo|Fondo de Investigacion Sanitaria|Departamento de Sanidad del Gobierno Vasco (País Vasco, Spain)","Both","18 Years and older   (Adult, Senior)","","2600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PS09/00314|PS09/00910|PS09/00746|PS09/00805|PI09/90460|PI09/90490|PI09/90453|PI09/90441|PI09/90397|2010111098|PI13/01692|PI13/00013","June 16, 2015","June 2010","June 2015","August 23, 2016","August 2016","No Study Results Posted","CARESS-CCR","December 2012","Mortality|Number of participants with Readmission|Number of participants with Reintervention|Changes in health-related quality of life (in the questionnaires employed in the study)|Number of participants with Complications|Number of participants with Cancer recurrence","https://ClinicalTrials.gov/show/NCT02488161"
57,"NCT01026753","Innovative Tools to Improve Colorectal Cancer Screening Rates in Manitoba","Completed","No Results Available","Colorectal Cancer","Behavioral: Refrigerator Magnet","University of Manitoba|Canadian Institutes of Health Research (CIHR)|CancerCare Manitoba","Both","50 Years to 74 Years   (Adult, Senior)","","2395","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","H2009:312","December 2, 2009","August 2010","December 2011","June 7, 2013","June 2013","No Study Results Posted","null","July 2011","Fecal Occult Blood Test (FOBT) completion rate|The most common patient questions and comments about colorectal cancer, screening, and the fecal occult blood test during the intervention(s). A patient and primary care provider survey.","https://ClinicalTrials.gov/show/NCT01026753"
58,"NCT02304978","Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults","Recruiting","No Results Available","Colorectal Cancer","Biological: Group CRC|Biological: Group control","University Hospital, Lille","Both","18 Years and older   (Adult, Senior)","Phase 0","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2008-09/0908|2009-A00264-53","June 24, 2014","June 2009","June 2020","May 12, 2016","May 2016","No Study Results Posted","TF","June 2018","TNM primary colorectal tumor stage|TF (blood levels of soluble TF)|TF intratumoral (blood levels of TF intratumoral)|E- selectin and CRP|ACE|Interaction plate / tumor cell","https://ClinicalTrials.gov/show/NCT02304978"
59,"NCT02032485","Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Peritoneal Carcinomatosis","Drug: Indocyanine Green","Jules Bordet Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","10","Other","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2013-000653-42","November 20, 2013","March 2013","September 2014","October 14, 2014","July 2014","No Study Results Posted","OC-AP-ICG-IV","September 2014","fluorescence intensity of tumoral and healthy tissues after IV injection of ICG to patients with peritoneal carcinomatosis from colorectal origin.","https://ClinicalTrials.gov/show/NCT02032485"
60,"NCT01260168","Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies","Completed","No Results Available","Colorectal Neoplasms|Digestive System Diseases|Colonic Diseases|Colorectal Cancer","","Exact Sciences Corporation","Both","40 Years to 90 Years   (Adult, Senior)","","435","Industry","Observational","Observational Model: Case-Only","Exact Sciences 2010-A","December 6, 2010","October 2010","November 2013","May 12, 2015","May 2015","No Study Results Posted","null","November 2013","The primary endpoints are point estimates of the sensitivity of the diagnostic tests for detection of colorectal neoplasms.|To collect samples from patients diagnosed with colorectal cancers.","https://ClinicalTrials.gov/show/NCT01260168"
61,"NCT02027363","Maintenance Treatment With Capecitabine in Colorectal Cancer Patients","Active, not recruiting","No Results Available","Colorectal Neoplasms|Neoplasms Metastasis","Drug: Capecitabine|Other: Observation","Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","245","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Maintenance study","December 15, 2013","January 2010","June 2014","January 2, 2014","January 2014","No Study Results Posted","null","December 2013","progression-free survival (PFS)|overall survival (OS)|overall response(ORR)|Safety","https://ClinicalTrials.gov/show/NCT02027363"
62,"NCT00690677","Phase II Trial of LBH589 in Refractory Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: LBH589","Swedish Medical Center|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 2","29","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLBH589BUS19T|CRC GOLP CNOV 0823","June 3, 2008","June 2008","December 2011","January 16, 2012","January 2012","No Study Results Posted","null","December 2011","To evaluate the effect of LBH589 on overall survival (OS) in patients with colorectal cancer|Time to tumor progression and response rates","https://ClinicalTrials.gov/show/NCT00690677"
63,"NCT02298946","AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma","Drug: AMP-224|Radiation: Stereotactic Body Radiation Therapy(SBRT)|Drug: Cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","17","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","150021|15-C-0021","November 21, 2014","November 2014","November 2017","September 8, 2016","September 2016","No Study Results Posted","null","November 2015","To assess safety, tolerability and feasibility of AMP-224 in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer|To evaluate response rate, progression-free survival and overall survival in patients with colorectal cancer during and following treatment with AMP-224 in combination with SBRT|To characterize the pharmacokinetic (PK) parameters of AMP-224 in combination with SBRT in patients with metastatic colorectal cancer","https://ClinicalTrials.gov/show/NCT02298946"
64,"NCT00441311","Dissemination of Colorectal Cancer Screening to Primary Care Physicians","Completed","No Results Available","Colorectal Cancer","Behavioral: Academic Detailing","Columbia University|American Cancer Society, Inc.","Both","50 Years to 80 Years   (Adult, Senior)","Phase 4","264","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","AAAA6315","February 26, 2007","May 2003","September 2006","January 28, 2011","January 2011","No Study Results Posted","null","July 2006","Colorectal cancer screening recommendations","https://ClinicalTrials.gov/show/NCT00441311"
65,"NCT01604798","Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Other: Serum proteomics","Fudan University","Both","18 Years to 90 Years   (Adult, Senior)","","547","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","ZSCG-001|30973416","May 17, 2012","January 2007","May 2012","May 22, 2012","May 2012","No Study Results Posted","null","May 2012","Serum peptide mass fingerprinting (PMF)|Expressed peptide peaks","https://ClinicalTrials.gov/show/NCT01604798"
66,"NCT01397747","Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer","Completed","Has Results","Colorectal Neoplasms|Digestive System Diseases|Colonic Diseases|Colorectal Cancer","","Exact Sciences Corporation","Both","50 Years to 84 Years   (Adult, Senior)","","12776","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Exact Sciences 2011-01","July 18, 2011","June 2011","May 2013","December 1, 2015","November 2015","December 1, 2015","DeeP-C","February 2013","Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer.","https://ClinicalTrials.gov/show/NCT01397747"
67,"NCT00820456","Metastatic Colorectal Cancer: Treatment Response With Dynamic Contrast MRI","Active, not recruiting","No Results Available","Colorectal Neoplasm|Hepatic Neoplasm","Other: DCE-MRI","American College of Radiology Imaging Network|Pennsylvania Department of Health","Both","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ACRIN PA 4002|SAP #4100031303","January 9, 2009","April 2008","null","December 20, 2011","March 2010","No Study Results Posted","null","null","To determine the reproducibility of DCE-MRI measures of tumor Ktrans, kep, and ve for colorectal metastases to the liver (Arm A) and any cancer metastatic to the liver (Arm B), using projection interleaved back-projection DCE-MRI techniques.|To determine the alteration in tumor vascularity (assessed by percentage change in tumor Ktrans) in Arm A participants with metastatic colorectal cancer to the liver after one cycle of chemotherapy including bevacizumab compared to baseline Ktrans value.|To determine the relationship between initial tumor vascularity (absolute tumor Ktrans) and change in tumor vascularity (percentage change in tumor Ktrans after one cycle of chemotherapy) and PFS in participants in Arm A.|To evaluate the perfusional difference between the dominant tumor and the global tumor burden (Arms A and B).|To evaluate the feasibility of exporting back-projection DCE-MRI imaging across multiple MRI scanner vendor platforms for use in a multi-site chemotherapy trial.|To determine the functional status as a predictor of response or disease-free survival in participants in Arm A.","https://ClinicalTrials.gov/show/NCT00820456"
68,"NCT00137592","Promoting Colorectal Cancer Screening in Rural Colorado","Completed","No Results Available","Colorectal Cancer","Behavioral: small media, group education (multicomponent)","Centers for Disease Control and Prevention|University of Colorado, Denver","Both","50 Years and older   (Adult, Senior)","","480","U.S. Fed|Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CDC-NCCDPHP-4547|PRC SIP 20-04","August 26, 2005","October 2005","December 2008","September 6, 2012","September 2012","No Study Results Posted","null","December 2008","colorectal cancer screening|colorectal cancer screening knowledge","https://ClinicalTrials.gov/show/NCT00137592"
69,"NCT00879385","KRAS Wild-type Metastatic Colorectal Cancer Trial","Completed","No Results Available","Colorectal Cancer","Drug: Dacogen™ (decitabine)|Drug: Vectibix® (panitumumab)","University of Utah|Amgen|Eisai Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCI31116","April 8, 2009","December 2009","January 2013","October 29, 2014","October 2014","No Study Results Posted","null","January 2013","Evaluate safety & feasibility of sequential use of a DNA methyltransferase (DNMT) inhibitor (decitabine) with targeted biological agent against EGFR (panitumumab) for KRAS wild type tumors in second or third line treatment of colorectal cancer.|To examine re-expression or a reduction in promoter methylation in genes involved in tumor suppressor pathways known to be important in colorectal cancer (CRC) or involved in EGFR signaling pathway.|Evaluate overall response (OR = CR +PR) according to RECIST criteria at 2, 4, and 6 cycles. Progression free survival, measured as the first evidence of tumor growth from the start of treatment will also be assessed.|Measure CEA levels at the beginning of each cycle to examine if they correlate with treatment response or disease progression.","https://ClinicalTrials.gov/show/NCT00879385"
70,"NCT01191411","Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs","Completed","Has Results","Colorectal Cancer","Other: Mailed invitations for FIT test kits|Other: Mailed invitations for a colonoscopy|Other: Visit Based Care","University of Texas Southwestern Medical Center|Cancer Prevention Research Institute of Texas|Polymedco Corporation","Both","54 Years to 64 Years   (Adult)","","5970","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","STU 012011-152","August 27, 2010","October 2010","September 2013","June 7, 2016","June 2016","October 13, 2014","null","September 2013","Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem.","https://ClinicalTrials.gov/show/NCT01191411"
71,"NCT00955344","Increasing Primary Care Physician Colorectal Cancer Screening Rates","Completed","No Results Available","Colorectal Cancer Screening","Behavioral: eToolbox|Behavioral: no link to eToolbox","University of Pennsylvania|National Cancer Institute (NCI)|National Institutes of Health (NIH)|Department of Health and Human Services","Both","Child, Adult, Senior","","134","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","K22CA133186-01","August 6, 2009","September 2009","November 2011","August 15, 2016","August 2016","No Study Results Posted","null","November 2011","Colorectal Cancer Screening Rates|Content of practice improvement plan","https://ClinicalTrials.gov/show/NCT00955344"
72,"NCT01877018","Colorectal Cancer Screening in Primary Care","Completed","No Results Available","Colorectal Neoplasms","Behavioral: electronic reminder","Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III","Both","50 Years to 69 Years   (Adult, Senior)","","41042","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","PI10/01994","June 2, 2013","September 2010","May 2013","August 29, 2016","August 2016","No Study Results Posted","COLO-ALERT","March 2013","Patient's status participation to colorectal cancer screening program","https://ClinicalTrials.gov/show/NCT01877018"
73,"NCT00742729","Increasing Colorectal Cancer Screening Among Filipino Americans","Completed","No Results Available","Colorectal Cancer","Behavioral: Arm 1|Behavioral: Arm 2|Behavioral: Arm 3","Jonsson Comprehensive Cancer Center|American Cancer Society, Inc.","Both","50 Years to 70 Years   (Adult, Senior)","","906","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","RSGT-04-210-01-CPPB","August 27, 2008","September 2004","June 2009","July 28, 2016","November 2010","No Study Results Posted","null","June 2009","Receipt of a colorectal cancer screening test|Knowledge and attitudes regarding CRC screening.","https://ClinicalTrials.gov/show/NCT00742729"
74,"NCT01856322","Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer","Terminated","Has Results","Colorectal Cancer|Liver Metastasis|Colorectal Adenocarcinoma","Drug: Sulindac|Drug: Placebo|Other: Validate assays and shipping methods","National Cancer Institute (NCI)|Charite University, Berlin, Germany|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","Phase 2","3","NIH|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","130126|13-C-0126","May 14, 2013","April 2013","January 2015","October 22, 2015","October 2015","March 25, 2015","null","January 2015","Difference in Circulating S100A4 Transcript in Patients Receiving Sulindac 150 mg BD (Twice Daily) by Mouth Following Resection of Colorectal Cancer Metastases Compared to Those Who do Not.","https://ClinicalTrials.gov/show/NCT01856322"
75,"NCT00136227","Use and Decision-making About Colorectal Cancer Screening Among Hispanic Men and Women","Completed","No Results Available","Colorectal Cancer","Behavioral: small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention","Centers for Disease Control and Prevention","Both","50 Years and older   (Adult, Senior)","","521","U.S. Fed","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CDC-NCCDPHP-4527|U48/DP000057 (SIP 18-04)","August 25, 2005","October 2005","April 2010","September 6, 2012","September 2012","No Study Results Posted","null","April 2010","colorectal cancer screening initiation rate|decisional balance|self-efficacy|knowledge about colorectal cancer screening|perceived risk of colorectal cancer|perceived survivability|perceived guilt|outcome expectations|subjective norms|intention to undergo colorectal cancer screening|making decisions about colorectal cancer screening that are consistent with their values and preferences","https://ClinicalTrials.gov/show/NCT00136227"
76,"NCT00199654","Positron Emission Tomography (PET) Interest in the Follow Up of Colorectal Cancer Stage II and III","Completed","No Results Available","Colorectal Cancer","Procedure: PET","University Hospital, Limoges","Both","18 Years and older   (Adult, Senior)","Phase 3","376","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","I03001","September 14, 2005","February 2004","April 2013","April 8, 2013","April 2013","No Study Results Posted","null","November 2012","Time to colorectal cancer relapse|Evaluation of overall survival in the two groups|Evaluation of the rate of curative surgery|Comparison of the medical cost in the two detection strategies","https://ClinicalTrials.gov/show/NCT00199654"
77,"NCT00278889","Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)","Completed","Has Results","Colorectal Cancer","Drug: AZD2171|Drug: 5-fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Bevacizumab","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","215","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D8480C00041|EUDRACT number 2005-003443-31|HORIZON I","January 17, 2006","January 2006","October 2009","September 24, 2012","September 2012","July 26, 2012","HORIZON I","November 2007","Progression Free Survival|Objective Response Rate|Overall Survival|Quality Of Live(QOL) : Time to Worsening of Tissue Oxygen Index (TOI)|QOL: Time to Worsening of Treatment-free Survival (TFS)|QOL: Time to Worsening of Clear Cell Sarcoma (CCS)|QOL: Time to Worsening of FACT Colorectal Cancer Symptom Index(FCSI)","https://ClinicalTrials.gov/show/NCT00278889"
78,"NCT01211379","The FLU-FOBT Program in Primary Care Settings Where Disparities Persist","Completed","No Results Available","Colorectal Cancer","Behavioral: FLU-FOBT Program","University of California, San Francisco|San Francisco Department of Public Health|Centers for Disease Control and Prevention","Both","50 Years to 75 Years   (Adult, Senior)","","1372","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","1R18DP001566-01","September 25, 2010","October 2009","August 2010","October 14, 2010","September 2010","No Study Results Posted","null","April 2010","Change in Colorectal Cancer Screening Rate","https://ClinicalTrials.gov/show/NCT01211379"
79,"NCT01464151","Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study","Recruiting","No Results Available","Inflammatory Bowel Disease|Colorectal Cancer","","UMC Utrecht|Merck Sharp & Dohme Corp.|Ferring Pharmaceuticals","Both","18 Years to 70 Years   (Adult, Senior)","","700","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","11-050","October 31, 2011","July 2011","December 2018","December 4, 2015","December 2015","No Study Results Posted","null","July 2018","low- or high grade dysplasia or colorectal cancer during follow-up","https://ClinicalTrials.gov/show/NCT01464151"
80,"NCT00199797","Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: huA33 antibody plus chemotherapy","Ludwig Institute for Cancer Research","Both","18 Years and older   (Adult, Senior)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LUD2003-005","September 12, 2005","October 2004","July 2007","March 2, 2009","March 2009","No Study Results Posted","null","July 2007","To determine the safety of the combination of huA33 and 5FU plus leucovorin and oxaliplatin in patients with metastatic colorectal cancer|To measure the immunogenicity of huA33 when given in combination with 5FU plus leucovorin with oxaliplatin|To document tumor responses in patients receiving huA33 and 5FU plus leucovorin and oxaliplatin.","https://ClinicalTrials.gov/show/NCT00199797"
81,"NCT00145314","FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: FLOX (5-fluorouracil/folinic acid/oxaliplatin)|Drug: FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|Drug: FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab","The Nordic Colorectal Cancer Biomodulation Group","Both","18 Years to 74 Years   (Adult, Senior)","Phase 3","571","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Nordic VII|EudraCT no.: 2005-000117-34","September 2, 2005","May 2005","August 2010","January 13, 2011","January 2011","No Study Results Posted","null","May 2009","To compare efficacy, as measured by time to disease progression, of treatment with cetuximab in combination with the FLOX regimen compared to FLOX alone, in first- line treatment of patients with metastatic cororectal cancer|To measure response rates, response duration, secondary surgical curative resection frequency, safety profile, overall survival and quality of life in the treatment groups.","https://ClinicalTrials.gov/show/NCT00145314"
82,"NCT01056809","Treatment Strategies for Primarily Generalized Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Procedure: Chemotherapy and surgery","Vrinnevi Hospital|Medical Research Council of Southeast Sweden","Both","Child, Adult, Senior","","15","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PGC-8","January 25, 2010","January 2010","May 2012","May 30, 2012","May 2012","No Study Results Posted","PGC","May 2012","Overall survival|3 year survival for patients treated with curative intent|Palliative patients not receiving chemotherapy treated with the traditional strategy|Quality of life|Health care consumption|Complications and side effects","https://ClinicalTrials.gov/show/NCT01056809"
83,"NCT01915472","A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: IMMU 130","Immunomedics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMMU 130-03","August 1, 2013","September 2013","null","August 1, 2013","August 2013","No Study Results Posted","null","August 2015","Safety|Efficacy","https://ClinicalTrials.gov/show/NCT01915472"
84,"NCT02078804","Colonoscopy and FIT as Colorectal Cancer Screening Test in the Average Risk Population","Enrolling by invitation","No Results Available","Colorectal Cancer","Procedure: Colonoscopy","Uppsala University Hospital|Swedish Association of Local Authorities and Regions|The Regional Cancer Centers of Sweden","Both","59 Years to 62 Years   (Adult)","","200000","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Screening","2012/2058- 31/3","February 11, 2014","March 2014","December 2034","June 3, 2015","June 2015","No Study Results Posted","null","March 2017","Mortality from colorectal cancer in the Swedish population.|Incidence of colorectal cancer in the Swedish population.|To study compliance with the screening program (read study) and what factors are of importance for the adherence rate.|To study health economy and costs for colorectal cancer screening.|To study the emotional impact of screening on participants and non-participants including eventual change in lifestyle after invitation and/or participation.|To study quality control aspects and side effects of screening with colonoscopy.|To study pathology by means of quality registries and digital pathology.|To study surveillance strategies for adenomas found at colonoscopy.|To study associations of DNA in blood with findings at colonoscopy.|To study the flora of fecal bacteria among participants and outcome of FIT and colonoscopy.","https://ClinicalTrials.gov/show/NCT02078804"
85,"NCT00558051","Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Biological: DC-based vaccine|Biological: DC-based vaccine|Biological: DC-based vaccine","Pawel Kalinski|University of Pittsburgh","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","05-063","November 13, 2007","January 2008","April 2014","March 31, 2016","March 2016","No Study Results Posted","null","December 2011","The primary endpoint of this study is to evaluate the feasibility and safety of semi-continuous intralymphatic vaccination dendritic cells.|The secondary objective of this study is to evaluate the immunity results from either single injections or semi-continuous infusion, intradermal or intranodal, administered immunization with the DC vaccine for colorectal cancer (CRC) patients.","https://ClinicalTrials.gov/show/NCT00558051"
86,"NCT02872779","Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Circulating Markers|Metastatic Colorectal Cancer","Procedure: Blood sampling for free mutant DNA analysis","University Hospital, Rouen","Both","18 Years and older   (Adult, Senior)","","74","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2015/076/HP","August 16, 2016","August 2016","August 2020","August 16, 2016","August 2016","No Study Results Posted","COCA-MACS","August 2020","Difference from baseline in the number of free mutant DNA in blood|Evaluation of response based on the RECIST 1.1 guideline","https://ClinicalTrials.gov/show/NCT02872779"
87,"NCT00823810","Treatment Monitoring of Advanced Colorectal Cancer With 18F-FDG PET/CT","Terminated","No Results Available","Colorectal Cancer","Other: PET/CT","Turku University Hospital","Both","40 Years to 80 Years   (Adult, Senior)","","20","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","RESCORE","January 15, 2009","December 2008","December 2011","October 8, 2014","October 2014","No Study Results Posted","RESCORE","December 2011","Survival|Time to progression","https://ClinicalTrials.gov/show/NCT00823810"
88,"NCT02364154","Colorectal Cancer Detected by 1H-NMR Spectroscopy","Recruiting","No Results Available","Colorectal Cancer","Other: Blood sampling|Other: Blood sampling","Hasselt University|Ziekenhuis Oost-Limburg","Both","40 Years to 90 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","14/070U","February 10, 2015","December 2014","September 2015","February 16, 2015","February 2015","No Study Results Posted","BIOCOR","June 2015","metabolic phenotype of colorectal cancer|tumor histology|tumor stage","https://ClinicalTrials.gov/show/NCT02364154"
89,"NCT02596113","Νew Molecular Biomarkers for the Prevention and Early Detection of Precancerous or Cancerous Colorectal Lesions During Screening for Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","","Evangelismos Hospital|National and Kapodistrian University of Athens","Both","50 Years to 75 Years   (Adult, Senior)","","90","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","galanopoulosm","October 3, 2015","July 2015","May 2019","November 3, 2015","November 2015","No Study Results Posted","null","June 2016","Genes' mutations rate in patients who are submitted screening colonoscopy and they presented with no endoscopic findings|Genes' mutations rate in patients who are submitted screening colonoscopy and they presented with adenomatous polyp bigger than 1 cm|Genes' mutations rate in patients who are submitted screening colonoscopy and they presented with cancerous lesion","https://ClinicalTrials.gov/show/NCT02596113"
90,"NCT01492049","R-21 Colorectal Cancer Screening (CRCS) Pilot Trial","Recruiting","No Results Available","Colorectal Neoplasms","Behavioral: CRCS patient decision aid (PtDA) video|Behavioral: Questionnaires|Behavioral: Essential Hypertension video","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","49 Years to 75 Years   (Adult, Senior)","","180","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","2010-0698|R21CA132669|NCI-2015-01899","December 12, 2011","August 2012","null","April 1, 2016","April 2016","No Study Results Posted","null","August 2018","Colorectal cancer screening (CRCS) Rate of Participants","https://ClinicalTrials.gov/show/NCT01492049"
91,"NCT01885351","An Interactive Preventive Health Record to Increase Colorectal Cancer Screening","Recruiting","No Results Available","Colorectal Cancer Screening","Behavioral: MyCRCS+Prefs|Behavioral: MyCRCS+Prefs+Barriers","Virginia Commonwealth University|National Cancer Institute (NCI)","Both","50 Years to 75 Years   (Adult, Senior)","","832","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MYCRCS-302259|R01CA166375-01A1","April 23, 2013","August 2013","December 2018","May 4, 2016","May 2016","No Study Results Posted","MyCRCS","December 2018","CRCS adherence provided by the electronic medical record|Self-reported CRCS adherence|EHR Paradata|Psychosocial Constructs|General and test-specific colorectal cancer screening barriers|Feasibility of MyCRCS+ in target setting - patient survey","https://ClinicalTrials.gov/show/NCT01885351"
92,"NCT00807313","Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer","Completed","No Results Available","Colon Cancer|Rectal Cancer|Colorectal Cancer","","Universitair Ziekenhuis Brussel","Both","18 Years and older   (Adult, Senior)","","53","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RCT501","December 10, 2008","December 2008","July 2011","April 29, 2013","April 2013","No Study Results Posted","tomoligo","July 2011","Metabolic complete remission rate|Acute toxicity|Progression free survival|Local control|Survival|Late toxicity","https://ClinicalTrials.gov/show/NCT00807313"
93,"NCT00737646","Evaluation of an Intervention to Increase Colorectal Cancer Screening in Primary Care Clinics","Completed","No Results Available","Colorectal Cancer","Behavioral: Usual care|Behavioral: Clinic-focused intervention|Behavioral: Clinic- and patient-focused","Centers for Disease Control and Prevention","Both","50 Years to 75 Years   (Adult, Senior)","","5066","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Prevention","CDC-NCCDPHP-4555","August 15, 2008","July 2009","December 2011","December 14, 2012","December 2012","No Study Results Posted","null","June 2010","Changes in colorectal cancer screening rates (4 modalities)|Changes in the frequency of secondary behavioral outcomes (e.g., clinician-patient discussions about CRC screening)|Changes in measures of attitudes, beliefs, opinions, and social influence surrounding CRC screening among patients, clinicians, and clinical staff.","https://ClinicalTrials.gov/show/NCT00737646"
94,"NCT02786329","Anesthesia and Postoperative Outcome in Colorectal Cancer Patients","Not yet recruiting","No Results Available","Colorectal Cancer.","Drug: TIVA+lidocaine|Drug: Sevoflurane+lidocaine|Drug: TIVA+placebo|Drug: Sevoflurane+placebo","Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor|Prof. Dr. I. Chiricuta Institute of Oncology","Both","18 Years to 80 Years   (Adult, Senior)","Phase 0","450","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","53/14.03.2016","May 23, 2016","June 2016","December 2021","May 25, 2016","May 2016","No Study Results Posted","null","December 2019","Survival after TIVA vs sevoflurane anesthesia in patients operated for colorectal cancer|Incidence of recurrences:|Morphine consumption during the first 24 postoperative hours|Severity of postoperative pain - verbal response pain (VRPS) score in recovery room and during the first 48 hrs postoperatively|Resumption of bowel function|Length of hospital stay|Postoperative chronic pain","https://ClinicalTrials.gov/show/NCT02786329"
95,"NCT00324753","Quality Improvement of Patient-Provider Communication For Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Behavioral: Communication|Behavioral: Standard of care","VA Office of Research and Development","Both","50 Years to 74 Years   (Adult, Senior)","","450","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","IIR 03-252","May 9, 2006","April 2007","June 2010","April 24, 2015","April 2015","No Study Results Posted","null","June 2010","(1) completion of colorectal cancer screening tests; (2) quality of communication; and (3) communication content|(1) patient perception of colorectal cancer screening discussions; and (2) usefulness of the intervention","https://ClinicalTrials.gov/show/NCT00324753"
96,"NCT02571374","Symbiotics to Prevent Postoperative Infection in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Surgical Site Infection","Dietary Supplement: symbiotic group|Dietary Supplement: placebo group","Hospital de Clinicas de Porto Alegre","Both","18 Years to 85 Years   (Adult, Senior)","","92","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","symbioticcolorectalcancer","April 11, 2014","October 2013","December 2016","October 7, 2015","October 2015","No Study Results Posted","null","December 2015","Number of participants with colorectal cancer on symbiotic to prevent postoperative infection","https://ClinicalTrials.gov/show/NCT02571374"
97,"NCT00493857","Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: Nimotuzumab Humanized Monoclonal Antibody|Drug: Nimotuzumab","YM BioSciences","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","YMB 1000-015","June 27, 2007","June 2007","December 2008","November 14, 2008","November 2008","No Study Results Posted","null","August 2008","The primary goal is to assess the Objective Response Rate (ORR) that the combination of irinotecan and nimotuzumab will produce in patients with irinotecan-refractory metastatic colorectal cancer|Assess the incidence of acneiform rash,drug reaction,adverse events, the assessment of progression-free survival,stable disease,time to disease progression, overall survival, objective response rates, safety and trough levels in the serum of patients.","https://ClinicalTrials.gov/show/NCT00493857"
98,"NCT01154335","Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer","Completed","Has Results","Metastatic Colorectal Cancer","Drug: OSI-906|Drug: Everolimus","SCRI Development Innovations, LLC|Novartis Pharmaceuticals|OSI Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI GI 124","June 29, 2010","July 2010","May 2013","January 6, 2015","January 2015","January 6, 2015","null","May 2013","To Determine the Maximum Tolerated Dose (MTD) of the Combination of OSI-906 and Everolimus for the Treatment of Patients With Refractory Metastatic Colorectal Cancer.|Progression-Free Survival (PFS)|Overall Survival (OS)|Response Rate","https://ClinicalTrials.gov/show/NCT01154335"
99,"NCT01700283","Developing Objective Fatigue Indicators in Colorectal Cancer Survivors.","Recruiting","No Results Available","Colorectal Cancer","Behavioral: exercise education and walking program","National Taiwan University Hospital|National Science Council, Taiwan","Both","20 Years and older   (Adult, Senior)","","306","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","201208026RIC","October 2, 2012","October 2012","July 2015","November 12, 2012","October 2012","No Study Results Posted","null","July 2015","Developing Objective Fatigue Indicators: Exploring the Relationships Among Fatigue, Muscle Power and Metabolomics Through Fatigue Management and Individualized Exercise Education Program in Colorectal Cancer Survivors","https://ClinicalTrials.gov/show/NCT01700283"
100,"NCT01433146","Effect of Temperament, Anxiety and Depression on Immuninity in Colorectal Cancer Patients. Effetti Del Temperamento, Dell'Ansia e Della Depressione Sulla Sopravvivenza Globale e Sulla Risposta Immunitaria Del Paziente Affetto da Adenocarcinoma Colo-Rettale.","Completed","No Results Available","Temperament|Anxiety|Depression|Colorectal Cancer","","University of Roma La Sapienza","Both","30 Years to 80 Years   (Adult, Senior)","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","65422-SU-CE","September 10, 2011","September 2011","June 2012","June 4, 2012","June 2012","No Study Results Posted","null","January 2012","Temperament in non-metastatic colorectal cancer patients","https://ClinicalTrials.gov/show/NCT01433146"
101,"NCT02877056","Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: Endoscopy","M.D. Anderson Cancer Center|American Society of Colon and Rectal Surgeons Research","Both","18 Years and older   (Adult, Senior)","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LAB04-0962|R33 CA118505-01","August 17, 2016","August 2005","null","August 19, 2016","August 2016","No Study Results Posted","null","August 2022","Predictive Tumor Cell Biomarkers After Chemoradiation Treatment for Colorectal Cancer","https://ClinicalTrials.gov/show/NCT02877056"
102,"NCT01080547","Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer","Recruiting","No Results Available","Length of Stay|Complications|Adverse Drug Event|Quality of Life|Hospital Costs","Procedure: Laparoscopic Surgery for Colorectal Cancer|Drug: XELOX Chemotherapy|Drug: mFolfox6 chemotherapy|Other: Fast Track Perioperative Treatment|Other: Conventional Perioperative Treatment|Procedure: Open Surgery for Colorectal Cancer","Zhejiang University","Both","18 Years and older   (Adult, Senior)","","220","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009C13017","March 1, 2010","March 2010","January 2013","April 12, 2010","April 2010","No Study Results Posted","null","January 2013","hospitalization day|surgical complications|chemotherapy related adverse event|quality of life|hospitalization costs","https://ClinicalTrials.gov/show/NCT01080547"
103,"NCT00496509","Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: ZD6474 (Zactima) 100mg|Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|Procedure: Biomarker Draws|Drug: ZD6474 (Zactima) 300mg","Genzyme, a Sanofi Company|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D4200C00050","July 3, 2007","August 2006","October 2007","August 25, 2016","August 2016","No Study Results Posted","null","October 2007","Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases.|Assessment of appropriate Pharmacokinetic parameters|Determine the population PK of ZD6474 and assess the relationship between both free and total plasma PK and measures of Pharmacological activity|Assessment of the effectiveness of ZD6474 as measured by objective response rate and progression free survival based on RECIST.","https://ClinicalTrials.gov/show/NCT00496509"
104,"NCT00743678","Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis","Completed","No Results Available","Colorectal Cancer|Unresectable Liver Metastasis","Drug: FOLFOX6/cetuximab","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","73","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-04-018","August 27, 2008","June 2008","June 2012","June 13, 2013","June 2013","No Study Results Posted","null","January 2012","To evaluate overall R0 resection rates following neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis|Response rate (according to RECIST)|Progression-free survival time|Overall survival timeToxicity profile (according to NCI CTCAE v3)|Correlative analyses between pretreatment EGFR, KRAS mutation and response rate/survival","https://ClinicalTrials.gov/show/NCT00743678"
105,"NCT02859155","Prognostic Factors Affecting Outcomes in Multivisceral en Bloc Resection for Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Procedure: Multivisceral en bloc resection surgery","University of Sao Paulo|CAIO SERGIO NAHAS|SERGIO CARLOS NAHAS|Ulysses Ribeiro Junior|Carlos Frederico Sparapan Marques|Rodrigo Ambar Pinto|Antonio Rocco Imperiale|Guilherme Cutait Cotti|William Carlos Nahas|Daher Cezar Chade|Dariane Sampaio Piato|Fabio Busnardo|Ivan Cecconello","Both","18 Years to 70 Years   (Adult, Senior)","","105","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07081980","August 1, 2016","January 2009","April 2016","August 5, 2016","August 2016","No Study Results Posted","null","February 2014","Survival|Recurrence","https://ClinicalTrials.gov/show/NCT02859155"
106,"NCT00120172","Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer|Neoplasm Metastasis","Drug: oxaliplatin, capecitabine, bevacizumab","Geriatric Oncology Consortium|Sanofi","Both","65 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOC-GI-010","July 8, 2005","May 2005","June 2006","November 15, 2007","November 2007","No Study Results Posted","null","null","To evaluate the efficacy (measured by time to progression) of oxaliplatin, capecitabine, and bevacizumab as first-line therapy in elderly patients with metastatic colorectal cancer.|Overall response|Duration of response|Safety and tolerability (NCI CTCAE v3.0, discontinuations, dose intensity)|Vulnerable Elders Survey (VES-13) and Geriatric Depression Scale (GDS) scores","https://ClinicalTrials.gov/show/NCT00120172"
107,"NCT02394769","ASPirin Intervention for the REDuction of Colorectal Cancer Risk","Enrolling by invitation","No Results Available","Colorectal Cancer","Drug: Aspirin|Drug: Placebo for Aspirin","Massachusetts General Hospital|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","","180","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","14-496|R01CA137178","March 16, 2015","June 2015","July 2028","March 14, 2016","March 2016","No Study Results Posted","ASPIRED","September 2018","Urinary prostaglandin metabolites (PGE-M).|Plasma macrophage inhibitory cytokine-1 (MIC-1), an inflammatory biomarker|Chromatin binding|Expression of Wnt-associated signaling genes (CTNNB1, AXIN2 and MYC)|Spectral Biomarkers of Colorectal Cancer","https://ClinicalTrials.gov/show/NCT02394769"
108,"NCT01969591","Fast Track Laparoscopic Surgery: A Better Option for Treating Colorectal Cancer Than Conventional Laparoscopic Surgery","Completed","No Results Available","Colorectal Cancer","Procedure: fast-track surgery|Other: conventional postoperative surgery","Quan Wang|First Hospital of Jilin University","Both","up to 75 Years   (Child, Adult, Senior)","","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","2013-171","October 8, 2013","January 2011","September 2013","October 21, 2013","October 2013","No Study Results Posted","FTS","July 2012","Length of hospital stay|Postoperative days|First flatus time|First defecation time|solid diet time|Analgesics|CRP (mg/L)|Complications:anastomotic leakage,intestinal obstruction,wound infection","https://ClinicalTrials.gov/show/NCT01969591"
109,"NCT00230399","Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Celecoxib|Drug: Capecitabine|Drug: Irinotecan","University of Michigan Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 3-24","September 9, 2005","June 2003","March 2008","April 20, 2015","April 2015","No Study Results Posted","null","January 2006","To determine the objective response rate to the combination of celecoxib, capecitabine, and irinotecan in patients with metastatic colorectal cancer.|To evaluate the time to progression of metastatic colorectal cancer after treatment with celecoxib, capecitabine, and irinotecan.","https://ClinicalTrials.gov/show/NCT00230399"
110,"NCT00503737","Pilot Study of the National Colorectal Cancer Roundtable Toolbox (NCCRT) to Increase Colorectal Cancer Screening Rates","Not yet recruiting","No Results Available","Colorectal Cancer Screening","Behavioral: National Colorectal Cancer Roundtable Toolbox","Penn State University","Both","30 Years and older   (Adult, Senior)","","15","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","25737","July 17, 2007","September 2007","September 2010","November 2, 2007","July 2007","No Study Results Posted","null","null","Increase the knowledge of providers as it pertains to current guidelines and strategies about CRCS; assist offices design a CRCS policy, assist offices adopt a CRC reminder system and increase the screening rates of CRC.|synthesize information about the strengths and weaknesses of the toolbox from the primary care physician's (PCP) point of view to aid in future development of an interactive, web-based version of the Toolbox.","https://ClinicalTrials.gov/show/NCT00503737"
111,"NCT02162563","Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","Recruiting","No Results Available","Colorectal Cancer|Liver Metastases","Drug: FOLFOX/ FOLFIRI with bevacizumab|Drug: FOLFOXIRI with bevacizumab|Drug: FOLFOX/ FOLFIRI with panitumumab","Dutch Colorectal Cancer Group","Both","18 Years and older   (Adult, Senior)","Phase 3","640","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CAIRO5|2013-005435-24","June 5, 2014","July 2014","July 2025","August 15, 2016","August 2016","No Study Results Posted","CAIRO5","July 2020","Progression-free survival (PFS)|R0/1 secondary resection rate|Median overall survival|Response rate|Toxicity (AE)|Pathological complete response rate (pCR)|Postoperative morbidity|Correlation of evaluation by the panel with outcome","https://ClinicalTrials.gov/show/NCT02162563"
112,"NCT01595256","Exploration the Effect of Walking Program in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Behavioral: muscular strength","National Taiwan University Hospital|National Science Council, Taiwan","Both","18 Years to 65 Years   (Adult)","","237","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","201109041RB","April 4, 2012","October 2011","February 2013","October 13, 2014","October 2014","No Study Results Posted","null","February 2013","Exploration the Effect of Walking Program in Patients With Colorectal Cancer.","https://ClinicalTrials.gov/show/NCT01595256"
113,"NCT01239082","Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)","Recruiting","No Results Available","Colorectal Cancer","Procedure: Colonoscopy|Procedure: FIT","VA Office of Research and Development","Both","50 Years to 75 Years   (Adult, Senior)","","50000","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","577","November 9, 2010","April 2012","September 2027","August 25, 2016","August 2016","No Study Results Posted","CONFIRM","September 2027","The primary outcome is colorectal cancer mortality.","https://ClinicalTrials.gov/show/NCT01239082"
114,"NCT01075633","Colorectal Cancer Screening in Familiar-Risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy","Completed","No Results Available","Colorectal Cancer","Procedure: Immunochemical fecal occult blood test And colonoscopy if test is positive|Procedure: Colonoscopy with sedation","Enrique Quintero|Fundación Canaria Rafael Clavijo para la Investigación Biomédica","Both","40 Years to 75 Years   (Adult, Senior)","Phase 3","1501","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","COLONFAM","February 24, 2010","January 2006","June 2013","January 7, 2014","January 2014","No Study Results Posted","COLONFAM","December 2011","Advanced colorectal neoplasm detection rate [Time Frame: 2 years] [Designated as safety issue: No]|Complications rate","https://ClinicalTrials.gov/show/NCT01075633"
115,"NCT02191969","Physical Activity Intervention for Older Patients During Chemotherapy for Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Fatigue","Behavioral: Walk With Ease","UNC Lineberger Comprehensive Cancer Center|LCCC Geriatric Oncology Program","Both","60 Years and older   (Adult, Senior)","","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","LCCC1324","June 17, 2014","June 2014","June 2017","July 17, 2016","July 2016","No Study Results Posted","null","June 2017","To measure the change in fatigue after three months between the intervention and control arm|To measure changes in physical function at baseline between the intervention and control groups.|To measure adherence to the physical activity intervention|To measure the difference in p16INK4a levels before and after chemotherapy in the control and intervention groups|To measure the change in muscle mass measurements before and after chemotherapy between the intervention and control arms|To measure the association of p16INK4a and muscle mass with any differences in fatigue o physical function or QOL during chemotherapy|To measure changes in Quality of Life at baseline between the intervention and control groups.|To measure changes in ADLs at baseline between the intervention and control groups.|To measure changes in Instrumental Activities of Daily Living at baseline between the intervention and control groups.|To measure changes in Self-Efficacy at baseline between the intervention and control groups.","https://ClinicalTrials.gov/show/NCT02191969"
116,"NCT01793207","Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population","Completed","No Results Available","Colorectal Neoplasms|Adenoma|Colorectal Tumors","","Cairo University|National Cancer Institute (NCI)|science and technology development fund, Egypt","Both","18 Years to 85 Years   (Adult, Senior)","","316","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","CRCS001|3023","February 13, 2013","December 2012","March 2015","May 4, 2015","May 2015","No Study Results Posted","null","March 2015","Methylation markers present in peripheral blood of patients with colorectal cancer(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects|Methylation markers present in peripheral blood of patients with colorectal adenomas (Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects|Methylation markers present in peripheral blood of patients with hyperplastic polyps(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects","https://ClinicalTrials.gov/show/NCT01793207"
117,"NCT00459901","Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: Erlotinib and capecitabine","Peter Kozuch|Hoffmann-La Roche|Genentech, Inc.|Beth Israel Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","13","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","022-03|XEL308","April 11, 2007","June 2004","June 2005","April 28, 2015","April 2015","No Study Results Posted","null","June 2005","To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer|To determine the qualitative and quantitative toxicity of this combination and sequence of drug administration","https://ClinicalTrials.gov/show/NCT00459901"
118,"NCT00159445","Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Colon Cancer","Drug: gemcitabine, capecitabine","University of Southern California|Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","53","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-03-12","September 7, 2005","March 2004","November 2007","May 20, 2014","May 2014","No Study Results Posted","null","March 2007","To assess time to progression in patients with metastatic colorectal cancer treated with a combination of gemcitabine and capecitabine after progressing on two or more therapies for advanced disease, and having failed both CPT-11 and Oxaliplatin bas|To assess the response rate and survival in patients with metastatic colorectal cancer treated with a combination of gemcitabine and capecitabine after progressing on two or more therapies for advanced disease. To assess the toxicity of this regimen.|To assess whether polymorphisms of thegenes involved in the 5-FU metabolic pathway are associated with efficacy of chemotherapy and toxicity.|To test the hypothesis that increased gene expression levels predict chemoresistance to capecitabine.","https://ClinicalTrials.gov/show/NCT00159445"
119,"NCT01889680","Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer","Withdrawn","No Results Available","Colorectal Cancer|Metastatic Colorectal Cancer","Drug: 5-FU|Drug: LV|Drug: ziv-aflibercept|Drug: mFOLFOX6","NSABP Foundation Inc|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP FC-8","June 25, 2013","November 2014","May 2018","November 25, 2014","November 2014","No Study Results Posted","null","May 2016","The time to disease progression|Measurement of disease status by continuous tumor measurement|The frequency of adverse events|The severity of adverse events","https://ClinicalTrials.gov/show/NCT01889680"
120,"NCT01139138","Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal","Drug: Panitumumab|Drug: Irinotecan|Drug: Everolimus","The Queen Elizabeth Hospital|Amgen|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","49","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AU-2009-0003/CRAD001CAU06T","May 28, 2010","June 2010","June 2017","February 8, 2016","February 2016","No Study Results Posted","PIE","August 2015","Dose limiting toxicities|Safety & toxicity|Response rate|Progression free survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01139138"
121,"NCT00123851","Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Neoplasm Metastasis","Drug: Tarceva (OSI-774)|Drug: Capecitabine|Drug: Oxaliplatin","Dana-Farber Cancer Institute|Sanofi-Synthelabo|OSI Pharmaceuticals|Hoffmann-La Roche|Genentech, Inc.|Massachusetts General Hospital|Beth Israel Deaconess Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","32","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-269","July 25, 2005","March 2003","August 2006","April 27, 2009","April 2009","No Study Results Posted","null","August 2006","To determine the response rate of OSI-774 when given in combination with oxaliplatin and capecitabine in patients with previously-treated locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma|To assess overall survival, progression-free survival, time to progression and duration of response|To evaluate the toxicities of the combination of OSI-774, oxaliplatin and capecitabine in this population of patients with colorectal cancer","https://ClinicalTrials.gov/show/NCT00123851"
122,"NCT01736813","CCR5-blockade in Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Neoplasm Metastasis|Liver Metastases","Drug: Maraviroc","National Center for Tumor Diseases, Heidelberg|University Hospital Heidelberg","Both","18 Years and older   (Adult, Senior)","","12","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MARACON-001|2012-000861-18","October 24, 2012","November 2012","September 2014","October 1, 2014","July 2014","No Study Results Posted","MARACON","December 2013","safety as occurence of adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria, that are definitely, probably, or possible related to the administration of the investigational agent|Progression Free Survival|Tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST)|Tissue level responses of growth inhibition via the CCR5 axis|Overall survival","https://ClinicalTrials.gov/show/NCT01736813"
123,"NCT00294827","Liver Transplantation and Metastatic Colo-rectal Cancer.","Active, not recruiting","No Results Available","Colo-rectal Cancer","Procedure: Liver transplantation and colo-rectal cancer","Oslo University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S-05409 (SECA I)","February 21, 2006","February 2006","May 2023","March 30, 2016","March 2016","No Study Results Posted","null","May 2022","Survival|Time to progression side-effects","https://ClinicalTrials.gov/show/NCT00294827"
124,"NCT01427647","Inflammatory Response After Colorectal Cancer Surgery","Completed","No Results Available","Colorectal Cancer","Procedure: Laparoscopic technique and thoracic epidural anesthesia","Universidad Complutense de Madrid|Hospital General Universitario Gregorio Marañon","Both","18 Years and older   (Adult, Senior)","","63","Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Complutense University 1","August 29, 2011","June 2007","February 2010","July 21, 2016","July 2016","No Study Results Posted","CRC","May 2009","Plasma levels of several cytokines after colorectal cancer surgery|Incidence of adverse clinical outcomes between groups","https://ClinicalTrials.gov/show/NCT01427647"
125,"NCT02117557","Safety Study of Transumbilical Single Incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: Single incision laparoscopic surgery|Procedure: Conventional laparoscopic surgery","Guoxin Li|Nanfang Hospital of Southern Medical University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","198","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NFGS-SILS-01","April 16, 2014","April 2014","April 2022","April 17, 2014","April 2014","No Study Results Posted","null","April 2017","Early morbidity rate|Operative outcomes|Pathological outecomes|Postoperative recovery course|Pain score|Cosmetic assessment|3-year disease free survival rate|5-year overall survival rate|Inflammatory and immune response","https://ClinicalTrials.gov/show/NCT02117557"
126,"NCT02202928","Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Neoplasms|Intestinal Neoplasms|Digestive System Neoplasms|Gastrointestinal Diseases","Biological: DC-CIK|Radiation: Radiotherapy|Drug: Chemotherapy","Shenzhen Hornetcorn Bio-technology Company, LTD|Jingzhou Central Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HYK-Colorectal Cancer","July 25, 2014","July 2014","December 2017","December 23, 2015","July 2015","No Study Results Posted","null","December 2017","Progress-free survival|Overall survival|Quality of life (QOL)|Phenotypic analysis of T cells","https://ClinicalTrials.gov/show/NCT02202928"
127,"NCT02186236","Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients","Recruiting","No Results Available","Lung Cancer|Colorectal Cancer","","Memorial Sloan Kettering Cancer Center|Trovagene Inc","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-114","July 7, 2014","July 2014","null","April 26, 2016","April 2016","No Study Results Posted","null","July 2017","EGFR detection in urinary cell free DNA [cfDNA]|To validate the Trovagene urine assay|EGFR detection in plasma circulating tumor cells [CTC] and plasma cfDNA)","https://ClinicalTrials.gov/show/NCT02186236"
128,"NCT00675636","Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Hereditary Nonpolyposis Colorectal Cancer|Precancerous Condition","Other: study of socioeconomic and demographic variables|Procedure: evaluation of cancer risk factors|Procedure: study of high risk factors","Vanderbilt University|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","500","Other|NIH","Observational","Time Perspective: Prospective","CDR0000587344|P30CA068485|VU-VICC-GI-0721|VU-VICC-061182","May 8, 2008","January 2007","null","April 1, 2011","April 2011","No Study Results Posted","null","April 2012","Identification of patients at high risk of developing hereditary colorectal cancer|Establishment of a tissue and data repository","https://ClinicalTrials.gov/show/NCT00675636"
129,"NCT01151007","KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009","Not yet recruiting","No Results Available","Colorectal Carcinoma","","University Hospital Center of Martinique","Both","18 Years and older   (Adult, Senior)","","250","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","10/E/11","June 24, 2010","July 2010","October 2010","June 25, 2010","June 2010","No Study Results Posted","KRAS","October 2010","Frequency of KRAS mutation|The incidence of the colorectal carcinoma","https://ClinicalTrials.gov/show/NCT01151007"
130,"NCT02138422","A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer","Active, not recruiting","No Results Available","Symptomatic Colorectal Cancer|Advanced Colorectal Cancer|Colorectal Cancer With Cachexia","Biological: Xilonix|Biological: Placebo","XBiotech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","276","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014-PT026","May 12, 2014","July 2014","March 2016","January 4, 2016","January 2016","No Study Results Posted","null","November 2015","Response Rate","https://ClinicalTrials.gov/show/NCT02138422"
131,"NCT01531621","A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland","Recruiting","No Results Available","Metastatic Colorectal Cancer","Other: Biomarker sampling","Pia Osterlund|Helsinki University Central Hospital","Both","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2011-003158-24","February 3, 2012","February 2012","December 2025","March 25, 2015","March 2015","No Study Results Posted","RAXO","December 2025","Resectability|Efficacy|Safety|Radiological assessment","https://ClinicalTrials.gov/show/NCT01531621"
132,"NCT01943786","RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: FOLFIRI + Cetuximab","Sofia Perea, Director Clinical Trials Unit.|Grupo Hospital de Madrid","Both","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BEAMING","April 29, 2013","April 2013","December 2015","March 13, 2015","March 2015","No Study Results Posted","BEAMING","April 2015","To estimate the proportion of patients with advanced colorectal cancer in whom KRAS mutation can be detected in circulating extracellular DNA|To estimate the proportion of patients with metastatic colorectal cancer who switch from BEAMing negative to BEAMing positive while being treated with first line FOLFIRI-Cetuximab|To estimate the response rate, in biopsy-proven K-ras wild-type patients according to KRAS status in circulating extracellular DNA.|Disease control rate according to KRAS status in circulating extracellular DNA.|Complete response rate according to KRAS status in circulating extracellular DNA.|Duration of response according to KRAS status in circulating extracellular DNA.|Early tumor shrinkage|Number of each adverse event per cycle","https://ClinicalTrials.gov/show/NCT01943786"
133,"NCT02083653","Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Sym004|Drug: Sym004|Other: Best supportive care (BSC)|Drug: Fluorouracil (5-FU)|Drug: Capecitabine","Symphogen A/S","Both","18 Years and older   (Adult, Senior)","Phase 2","254","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR200637-002|2013-003829-29","March 7, 2014","March 2014","July 2016","October 29, 2015","July 2015","No Study Results Posted","null","July 2016","Overall survival (OS) Time|Best overall response according to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)|Progression Free Survival (PFS) Time|Time to treatment failure|Relative dose intensity of Sym004|Pharmacokinetic parameters: AUC (0-168 hours), t1/2, CL, Vd, Cmax, tmax and C(trough)|Host immune response: Number of subjects with anti-drug antibodies (ADAs)|Biomarkers level related to the Epidermal growth factor receptor (EGFR) pathway|Quality of life assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 30 (EORTC QLQ-C30) (Version 3)|Quality of life assessed by EORTC QLQ module for colorectal cancer (EORTC QLQ-CR29)|Quality of life assessed by Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFR 18)|Number of subjects with adverse events (AEs), serious AEs, treatment emergent AEs, AEs leading to death, and AEs with National Cancer Institute-Common Terminology Criteria for AEs (NCI−CTCAE Version 4.03) Grade greater than or equal to 3","https://ClinicalTrials.gov/show/NCT02083653"
134,"NCT00575562","Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: KRN330","Kyowa Kirin Pharmaceutical Development, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","28","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KRN330-US-01","December 14, 2007","June 2007","null","June 22, 2010","December 2007","No Study Results Posted","null","null","The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.|The secondary objectives are to determine the degree of immunogenicity, gain information on the pharmacokinetic profile, assess the anti-tumor effects of KRN330 and determine the maximum tolerated dose (MTD).","https://ClinicalTrials.gov/show/NCT00575562"
135,"NCT01732783","Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients","Active, not recruiting","No Results Available","Wild-type RAS Metastatic Colorectal Cancer","Other: Observational","Amgen","Both","18 Years and older   (Adult, Senior)","","242","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20120100","November 20, 2012","December 2012","November 2016","February 26, 2016","February 2016","No Study Results Posted","null","November 2016","Treatment patterns of Vectibix® and concomitant chemotherapy for mCRC|Healthcare resource utilization|Demography of disease population|Response to Vectibix®|Planned anti-cancer treatment initiated post Vectibix","https://ClinicalTrials.gov/show/NCT01732783"
136,"NCT00788957","Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)","Completed","Has Results","Colon Cancer|Colorectal Cancer|Gastrointestinal Cancer|Metastatic Colorectal Cancer|Rectal Cancer","Drug: Panitumumab|Drug: Ganitumab|Drug: Rilotumumab|Drug: Placebo","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","153","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","20060447","October 23, 2008","October 2008","October 2013","June 23, 2015","June 2015","March 24, 2015","null","February 2012","Part 1: Number of Participants With Dose-limiting Toxicities (DLT)|Part 2: Percentage of Participants With an Objective Response|Part 2: Duration of Response|Part 2: Time to Response|Part 2: Percentage of Participants With Disease Control|Progression-free Survival|On-treatment Progression-free Survival|Overall Survival|Number of Participants With Adverse Events (AEs)|Number of Participants With Grade 3 or Higher Laboratory Toxicities|Number of Participants With Antibody Formation to Panitumumab, Rilotumumab and Ganitumab|Part 1: Maximum Observed Drug Concentration (Cmax) and Minimum Drug Concentration (Cmin) for Panitumumab and Rilotumumab|Part 1: Area Under the Drug Concentration-time Curve During a Dosing Interval (AUCtau) for Panitumumab and Rilotumumab|Part 2: Maximum Observed Drug Concentration During the Dosing Interval (Cmax) for Panitumumab|Part 2: Minimum Observed Drug Concentration During the Dosing Interval (Cmin) for Panitumumab|Part 2: Maximum Observed Drug Concentration During the Dosing Interval (Cmax) for Rilotumumab|Part 2: Minimum Observed Drug Concentration During the Dosing Interval (Cmin) for Rilotumumab|Part 2: Maximum Observed Drug Concentration During the Dosing Interval (Cmax) for Ganitumab|Part 2: Minimum Observed Drug Concentration During the Dosing Interval (Cmin) for Ganitumab","https://ClinicalTrials.gov/show/NCT00788957"
137,"NCT02869503","Institut Paoli Calmettes Colorectal Cancer Database","Recruiting","No Results Available","Colorectal Neoplasms","Other: Data collection","Institut Paoli-Calmettes","Both","18 Years to 95 Years   (Adult, Senior)","","22000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BDD-COLON-IPC","August 11, 2016","January 2001","December 2030","August 16, 2016","August 2016","No Study Results Posted","null","January 2030","Survival of patients with colorectal cancer|Collection of patients characteristics","https://ClinicalTrials.gov/show/NCT02869503"
138,"NCT00012922","Low Literacy Intervention for Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Behavioral: Low Literacy Intervention for Colorectal Cancer Screening","VA Office of Research and Development","Male","50 Years and older   (Adult, Senior)","","2400","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","PCI 99-158","March 14, 2001","null","April 2003","April 6, 2015","February 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00012922"
139,"NCT01387880","Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Everolimus|Drug: Everolimus","Herlev Hospital|Odense University Hospital|Aalborg Universitetshospital","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GI 0923 ICE","June 27, 2011","January 2010","March 2012","March 18, 2012","March 2012","No Study Results Posted","ICE","November 2011","Clinical benefit (SD+PR+CR)","https://ClinicalTrials.gov/show/NCT01387880"
140,"NCT00536809","Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer","Completed","Has Results","Metastatic Colorectal Cancer|Responsive to Fluoropyrimidines|Advanced Colorectal Cancer|Neoplasms, Colorectal","Drug: lapatinib|Drug: oxaliplatin|Drug: capecitabine","GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EGF108991","September 27, 2007","September 2007","November 2008","March 15, 2012","February 2011","January 19, 2010","null","October 2008","Overall Response in Phase II|Relationship Between Pretreatment Plasma TS mRNA and Pretreatment Tumor TS mRNA in Colon Tumor Biopsies.|Effect of Lapatinib, Oxaliplatin, and Capecitabine on Plasma TS mRNA and the Relationship Between Plasma TS mRNA and Clinical Response|Tumor-derived Biomarkers (Encoded in Protein or RNA) Associated With Clinical Outcome to Treatment|Genetic Aberrations in Somatic (Tumor) DNA Derived From the Tumor Tissue Biopsies That May Associate With Clinical Outcomes in Response to Therapy|Genetic Variants in Germline (Host) DNA and Comparison to the Efficacy and Safety of the Study Drugs|Progression-free Survival (PFS) After Lapatinib, Oxaliplatin, and Capecitabine Administered at the MTD Level of Phase II|Change From Baseline to Study Completion in Weight|Change From Baseline to Study Completion in Heart Rate|Change From Baseline to Study Completion in Blood Pressure|Change From Baseline to Study Completion in Hemoglobin and Neutrophils|Change From Baseline to Study Completion in White Blood Cells and Platelets|Change From Baseline to Study Completion in Prothrombin Time and Partial Thromboplastin Time|Change From Baseline to Study Completion in International Normalized Ratio|Change From Baseline to Study Completion in Sodium, Potassium, and Calcium|Change From Baseline to Study Completion in Creatinine, Total Bilirubin, and Direct Bilirubin|Change From Baseline to Study Completion in Creatinine Clearance|Change From Baseline to Study Completion in Aspartate Aminotransferase, Alanine Aminotranferease, and Alkaline Phosphatase","https://ClinicalTrials.gov/show/NCT00536809"
141,"NCT00159484","Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colon Cancer|Colorectal Cancer","Drug: EPO906, celecoxib","University of Southern California|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","80","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3c-03-19","September 8, 2005","October 2004","January 2017","March 25, 2015","March 2015","No Study Results Posted","null","December 2015","To determine the maximum tolerated dose (MTD) of Celebrex in combination with EPO906 in patients with metastatic colorectal cancer.|Once MTD is established we propose to expand the dose level of the MTD to 62 new patients to evaluate whether the addition of Celebrex to EPO906 can reduce the incidence of grade 3-4 diarrhea to 6% or less.|To estimate the time to progression, survival and response rate in patients with metastatic colorectal cancer who failed 5-FU/LV, CPT-11 and/or oxaliplatin based hemotherapy and receive Celebrex in combination with EPO906.|To further assess toxicity of this regimen.|To investigate whether the molecular biomarkers including protein expression changes from plasma, the expression levels of VEGF, E-cadherin, TP, COX-2, and β-tubulin in tumor tissue associated with clinical outcome for this regimen.","https://ClinicalTrials.gov/show/NCT00159484"
142,"NCT00199862","Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Neoplasms|Colorectal Cancer|Colorectal Tumor|COlorectal Carcinoma","Drug: Iodine-124 labeled humanized A33 (antibody)","Memorial Sloan Kettering Cancer Center|Ludwig Institute for Cancer Research","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","03-124","September 13, 2005","February 2004","June 2017","April 28, 2016","April 2016","No Study Results Posted","null","June 2017","To determine and quantify tumor uptake of radiolabeled antibody from measurements with:|PET imaging/Dosimetry|Autoradiographs - tumor or biopsy samples|Ex vivo radioactivity estimates - tumor, normal tissue and serum samples|Toxicity defined by NCI Common Toxicity Criteria|Serum radioactivity, volume of distribution, and half-life following IV and IA 124I-huA33|HAHA levels - measured by plasmon resonance surface (Biacore®) assay","https://ClinicalTrials.gov/show/NCT00199862"
143,"NCT00394992","Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer|Liver Metastases","Drug: oxaliplatin+capecitabine|Drug: Oxaliplatin+capecitabine+bevacizumab","Dutch Colorectal Cancer Group|Sanofi|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 3","79","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HEPATICA","November 1, 2006","December 2006","August 2013","February 3, 2014","February 2014","No Study Results Posted","null","August 2013","3-year disease free survival, defined as the percentage of disease free patients 3 year after randomisation.|Overall survival, defined as the percentage of patients alive 5 year after randomisation.","https://ClinicalTrials.gov/show/NCT00394992"
144,"NCT02116894","Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: PF-03446962|Drug: Regorafenib","Herbert Hurwitz, MD|Pfizer|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00051541","April 8, 2014","August 2014","null","February 9, 2016","February 2016","No Study Results Posted","REGAL-1","March 2018","Recommended phase II dose (RPTD) for the combination of PF-03446962 plus regorafenib|To evaluate the safety and tolerability of PF 03446962 administered in combination with regorafenib|Response rate of PF 03446962 plus regorafenib|Progression free survival associated with PF 03446962 plus with regorafenib","https://ClinicalTrials.gov/show/NCT02116894"
145,"NCT00594113","""Touch 2 Screen"" Multi-media Colorectal Cancer Screening Intervention","Completed","No Results Available","Colorectal Cancer","Other: Touch 2 Screen|Other: Touch screen intervention","Allen A. Greiner, MD, MPH|National Institutes of Health (NIH)|University of Kansas Medical Center Research Institute","Both","50 Years and older   (Adult, Senior)","","470","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","1RO1CA119098-01","January 3, 2008","August 2007","January 2012","June 18, 2012","June 2012","No Study Results Posted","null","May 2010","CRC screening completion|PAPM stage and perceived barriers among participants preferring various screening methods (iFOBT, Colonoscopy)","https://ClinicalTrials.gov/show/NCT00594113"
146,"NCT02549456","Natural Orifice Transluminal Endoscopic Surgery for Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: natural orifice specimen extraction|Procedure: Laparoendoscopic resection","Mansoura University|Universidade da Coruña","Both","Child, Adult, Senior","","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MD/148","August 29, 2015","December 2015","February 2018","March 15, 2016","March 2016","No Study Results Posted","NOTES","December 2017","Feasibility|operative time|Operative blood loss|Wound complications|Major intraoperative complications|Major postoperative complications|Adequacy of lymphadenectomy|Grading of quality and completeness of mesorectal excision|Longitudinal safety margin|short term oncologic outcome|Functional outcome","https://ClinicalTrials.gov/show/NCT02549456"
147,"NCT00399750","TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: oxaliplatin|Drug: fluoropyrimidine|Drug: bevacizumab","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","373","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","L_8851","November 13, 2006","November 2002","June 2005","October 14, 2009","October 2009","No Study Results Posted","null","null","To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2)|The overall incidence of grade 3 and grade 4 adverse events during the first 12 weeks of treatment for each of the oxaliplatin-fluoropyrimidine regimens used without bevacizumab (TREE1)|Type, frequency, severity, timing, and relatedness of all adverse events during treatment and for 30 days following discontinuation of treatment for each of the oxaliplatin-fluoropyrimidine regimens when used with or without bevacizumab(TREE1 and TREE2)|Actual treatment administration as characterized by median, mean, and range of doses given; dose modifications, omissions, and delays; and actual and relative dose intensity (TREE1 and TREE2)|Tumor response rate (overall and confirmed) based on application of the Response Evaluation Criteria in Solid Tumors (RECIST) (TREE1 and TREE2)|Time to treatment failure (TTF) (TREE1 and TREE2)|Time to tumor progression (TTP) (TREE1 and TREE2)|Median survival (TREE1 and TREE2)|STUDY DESIGN|A randomized, controlled, open-label multicenter trial to assess the safety & efficacy of 3 oxaliplatin-fluoropyrimidine containing regimens (mFOLFOX6; bFOL; XELOX) +Avastin (TREE1 & TREE2) as first line therapy of advanced metastatic colorectal cancer|Patients enrolled prior to the initiation of Amendment 3 (TREE1) will not be eligible to receive Avastin as a component of their treatment regimen.","https://ClinicalTrials.gov/show/NCT00399750"
148,"NCT01762293","A Study of Famitinib in Patients With Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Colorectal Cancer Metastatic|Colorectal Cancer Recurrent","Drug: Famitinib","Jiangsu HengRui Medicine Co., Ltd.|Beijing Cancer Hospital|Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","150","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FMTN-IIb-CRC","January 4, 2013","April 2012","January 2014","January 4, 2013","January 2013","No Study Results Posted","null","October 2013","Progression Free Survival(PFS)|Objective response rate(ORR)|Disease Control Rate(DCR)|Overall Survival(OS)|Quality of Life|Number of Participants with Adverse Events as a Measure of Safety","https://ClinicalTrials.gov/show/NCT01762293"
149,"NCT01303393","Information Needs After Surgery for Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","","Region Skane|Lund University","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Etics review Dnr 558/2006","February 23, 2011","January 2007","August 2009","February 23, 2011","February 2011","No Study Results Posted","null","August 2009","Information needs - patients' and next of kins'","https://ClinicalTrials.gov/show/NCT01303393"
150,"NCT01983371","Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer","Withdrawn","No Results Available","Colorectal Cancer","Drug: Ferumoxytol|Other: Magnetic Resonance Imaging","Scott Potenta, MD, PhD|University of Vermont","Both","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CHRMS 14-096","November 5, 2013","December 2013","June 2016","May 19, 2016","May 2016","No Study Results Posted","null","June 2016","Prospectively evaluate the diagnostic accuracy of ferumoxytol-enhanced MRI in the setting of colorectal cancer with histopathologic analysis as the gold standard.","https://ClinicalTrials.gov/show/NCT01983371"
151,"NCT01596582","Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Behavioral: Risk Assessment","Boston Medical Center","Both","50 Years to 75 Years   (Adult, Senior)","","341","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","NCI-CA131197","May 7, 2012","April 2012","June 2016","July 18, 2016","July 2016","No Study Results Posted","null","February 2016","Concordance between patient and patients test preference|Screening test ordered|Screening test completion date|Satisfaction with decision-making process|Provider satisfaction|Screening intentions","https://ClinicalTrials.gov/show/NCT01596582"
152,"NCT01605318","Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer|Colon Cancer|Rectal Cancer","Drug: IMMU-130","Immunomedics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","104","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IM-T-IMMU-130-02","May 22, 2012","September 2012","December 2016","March 18, 2016","March 2016","No Study Results Posted","null","December 2016","Safety|Efficacy","https://ClinicalTrials.gov/show/NCT01605318"
153,"NCT02425683","Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX","Recruiting","No Results Available","Colorectal Neoplasms|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum","Drug: Regorafenib","US Oncology Research|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","Both","18 Years and older   (Adult, Senior)","Phase 2","264","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13050","April 21, 2015","March 2015","September 2019","September 15, 2016","September 2016","No Study Results Posted","null","March 2017","Starting Dose of Regorafenib|Number of Patients Completing Full 6 Cycles|Overall survival|Number of Adverse Events (AEs)|Disease-free survival (DFS)","https://ClinicalTrials.gov/show/NCT02425683"
154,"NCT02002299","Does Surface Tell us About the Invasive Front in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","","Roskilde County Hospital","Both","Child, Adult, Senior","","150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CRCtopfront1","August 2, 2013","August 2013","August 2014","November 29, 2013","July 2013","No Study Results Posted","CRC1","August 2014","invasive front growth pattern","https://ClinicalTrials.gov/show/NCT02002299"
155,"NCT01274143","Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)","Completed","No Results Available","Colorectal Cancer","Behavioral: TeleCARE|Behavioral: Pamphlet intervention","University of Utah|National Cancer Institute (NCI)","Both","30 Years to 74 Years   (Adult, Senior)","","496","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","IRB_00017894|7R01CA125194-06","December 10, 2010","May 2008","April 2013","April 6, 2016","May 2015","No Study Results Posted","Family CARE","April 2013","Colonoscopy|Fecal occult blood test (FOBT)/Fecal Immunochemical Test (FIT)|Perceived Control|Perceived Risk|Psychological distress|Knowledge|Decisional Conflict","https://ClinicalTrials.gov/show/NCT01274143"
156,"NCT02863107","Young-Onset Microsatellite-Stable Colorectal Cancer","Recruiting","No Results Available","Colon Cancer|Rectal Cancer","Behavioral: Questionnaires|Procedure: Blood Draw","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PA11-0566|2015-00051016-Y1|2016-00051406","August 8, 2016","June 2012","null","August 15, 2016","August 2016","No Study Results Posted","null","June 2022","Genomes of Participants Diagnosed with Young-Onset Microsatellite Stable (MSS) Colorectal Cancers (CRCs) vs. Later Onset Microsatellite Stable (MSS) Colorectal Cancers (CRCs)|Polymorphism Variants and/or New Mutations of Participants Diagnosed with Young-Onset Microsatellite Stable (MSS) Colorectal Cancers (CRCs) vs. Later Onset Microsatellite Stable (MSS) Colorectal Cancers (CRCs)","https://ClinicalTrials.gov/show/NCT02863107"
157,"NCT00977613","Adherence to a Recommended Exercise Regimen in Colorectal Cancer Patients","Completed","Has Results","Colorectal Cancer (CRC)","Behavioral: exercise counseling","Beth Israel Medical Center","Both","Child, Adult, Senior","","50","Other","Interventional","Intervention Model: Single Group Assignment","003-07","September 15, 2009","April 2007","May 2010","March 1, 2011","March 2011","November 30, 2010","null","April 2010","Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater|Disease-free Survival|Recurrence-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00977613"
158,"NCT00489697","Evaluation of Contrast-Enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases","Recruiting","No Results Available","Metastatic Colorectal Cancer","Device: real-time contrast-enhanced ultrasound imaging (CEUS)","University Hospital, Tours","Both","18 Years to 80 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","INCA06-FT/STIC-AVASTIN","June 20, 2007","January 2007","March 2010","February 19, 2009","February 2009","No Study Results Posted","null","March 2010","functional vascular changes in tumour vascularity of hepatic metastases|Pharmacokinetic of bevacizumab between each cure of bevacizumab based chemotherapy|ratio cost/benefit of a strategy of therapeutic monitoring by contrast-enhanced ultrasound|evaluation of the response to bevacizumab based chemotherapy by RECIST criteria|bevacizumab-related toxicity|response duration|time to disease progression|survival time","https://ClinicalTrials.gov/show/NCT00489697"
159,"NCT01110941","Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China","Completed","No Results Available","Colorectal Cancer","Drug: S-1, leucovorin, oxaliplatin","Shen Lin|307 Hospital of PLA|Beijing Union Hosptial|Tianjin Medical University Cancer Institute and Hospital|Hebei Provincial Cancer Hospital|Peking University","Both","20 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SOL feasibility study","April 21, 2010","September 2009","October 2010","May 17, 2015","May 2015","No Study Results Posted","SCI-101","March 2010","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and follow up till disease progression or withdrawal from study due to intolerable adverse events (AE)","https://ClinicalTrials.gov/show/NCT01110941"
160,"NCT00498407","A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer","Completed","No Results Available","Advanced Colorectal Cancer|Colorectal Cancer","Drug: CP-4055","Clavis Pharma","Both","18 Years and older   (Adult, Senior)","Phase 2","16","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CP4055-202|Grantor: CDER|IND/IDE Number: NA","July 9, 2007","May 2007","December 2008","June 3, 2009","January 2009","No Study Results Posted","null","December 2008","• Objective response rate (RR)|• Time to progression (TTP)|• Duration of tumor response|• Characterize the quantitative and the qualitative toxicities of the CP-4055 treatment in this patient population","https://ClinicalTrials.gov/show/NCT00498407"
161,"NCT00122187","Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention","Completed","Has Results","Colorectal Cancer","Device: Electronic Consult System","VA Office of Research and Development","Both","Child, Adult, Senior","","8","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CRT 02-059","July 18, 2005","August 2005","May 2008","April 6, 2015","September 2013","December 5, 2013","null","May 2008","Percent of Patients Receiving GI Consult for FOBT+ Results|Percent of Patients Receiving GI Consult Plus Anatomic Workup for FOBT+ Results","https://ClinicalTrials.gov/show/NCT00122187"
162,"NCT01661972","Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Capecitabine and aflibercept","John Strickler, M.D.|Sanofi|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","64","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00037688","July 31, 2012","August 2012","June 2018","September 17, 2016","September 2016","No Study Results Posted","X-TRAP","June 2016","Recommended Phase II dose (RPTD) for the capecitabine and aflibercept doublet combination|Progression free survival associated with the regimen|Frequency of best response|Overall survival","https://ClinicalTrials.gov/show/NCT01661972"
163,"NCT01141114","Study of Patient Navigation to Promote Colon Cancer Screening","Completed","No Results Available","Colorectal Cancer Screening","Other: Patient navigation|Other: Usual care","Cambridge Health Alliance|American Cancer Society, Inc.|Harvard University","Both","52 Years to 75 Years   (Adult, Senior)","","465","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Screening","MRSGT-05-007-01-CPPB","June 9, 2010","September 2008","March 2010","June 9, 2010","June 2010","No Study Results Posted","null","March 2010","completion of colorectal cancer screening|Comparison of detection of polyps and cancers in intervention vs. control groups","https://ClinicalTrials.gov/show/NCT01141114"
164,"NCT01260415","A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases","Completed","No Results Available","Colorectal Cancer|Liver Metastases","Drug: Panitumumab, Oxaliplatin, 5-FU","University Health Network, Toronto","Both","18 Years and older   (Adult, Senior)","Phase 2","59","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PMH DDP - CRCLM1","December 13, 2010","August 2010","null","July 6, 2015","July 2015","No Study Results Posted","null","June 2013","To determine the 2 year disease-free survival rate in patients with resectable colorectal liver metastases treated with FOLFOX/FOLFIRI + panitumumab for 2 months pre-operatively and 4 months post-operatively, followed by panitumumab alone for 6 months.|To evaluate the objective response rate (ORR) to preoperative FOLFOX/FOLFIRI plus panitumumab (by RECIST criteria) in patients with wild type KRAS.|To evaluate the pathologic complete response rate.|To determine overall survival and toxicity.|To explore correlative biomarkers of clinical response (EGFR, PTEN, MET, BRAF and PI3KCA).|To explore for correlation between available tissue from biopsy, primary tumor and metastatic lesion with regards to aforementioned pathologic biomarkers.|To determine the incidence of hepatocellular damage (fibrosis, steatosis) in normal liver tissue induced by preoperative chemotherapy.","https://ClinicalTrials.gov/show/NCT01260415"
165,"NCT01507545","Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)","Completed","No Results Available","Metastatic Colorectal Cancer|Colorectal Cancer","Drug: MORAb-004|Drug: Placebo","Morphotek","Both","18 Years and older   (Adult, Senior)","Phase 2","126","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MORAb-004-202-CRC","December 5, 2011","March 2012","December 2013","September 4, 2015","September 2015","No Study Results Posted","null","October 2013","Progression-free survival|Timeframe between first treatment until death for all subjects|Number of subjects with adverse events|Quality of Life|Overall response rate based on RECIST criteria","https://ClinicalTrials.gov/show/NCT01507545"
166,"NCT02284529","Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer","Completed","No Results Available","Stage-Ⅱ Colorectal Cancer","Drug: Orectalip","Sinphar Pharmaceutical Co., Ltd|Taichung Veterans General Hospital","Both","20 Years to 75 Years   (Adult, Senior)","Phase 4","20","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","SF12099","October 23, 2014","October 2012","September 2014","November 3, 2014","October 2014","No Study Results Posted","Oxaliplatin","August 2014","To evaluate the incidence of grade 0-3 neurosensory symptoms (paresthesia) in the end of study","https://ClinicalTrials.gov/show/NCT02284529"
167,"NCT02502630","Microwave Ablation for Pulmonary Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Device: microwave ablation","The First People's Hospital of Changzhou","Both","18 Years to 75 Years   (Adult, Senior)","","32","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRC-MW-001","July 15, 2015","June 2010","July 2015","August 11, 2016","August 2016","No Study Results Posted","null","June 2015","Overall Survival (OS)|Treatment related adverse events","https://ClinicalTrials.gov/show/NCT02502630"
168,"NCT00910819","Tumour Registry Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","","iOMEDICO AG|Arbeitskreis Klinische Studien|Arbeitsgemeinschaft fur Internistische Onkologie","Both","18 Years and older   (Adult, Senior)","","6500","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IOM TKK","May 28, 2009","September 2006","March 2020","June 27, 2016","June 2016","No Study Results Posted","TKK","March 2020","Course of Antineoplastic Treatment","https://ClinicalTrials.gov/show/NCT00910819"
169,"NCT00856375","NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: NKTR-102|Drug: irinotecan","Nektar Therapeutics","Both","18 Years and older   (Adult, Senior)","Phase 2","83","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","08-PIR-03","March 3, 2009","December 2008","December 2014","February 6, 2015","January 2015","No Study Results Posted","null","July 2014","Progression Free Survival","https://ClinicalTrials.gov/show/NCT00856375"
170,"NCT00625651","Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer|Colon Cancer|Colorectal Cancer|Rectal Cancer","Drug: Placebo|Drug: AMG 655|Drug: Modified FOLFOX6|Drug: Bevacizumab","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","202","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","20060464","February 14, 2008","October 2007","September 2011","March 28, 2014","March 2014","No Study Results Posted","null","August 2010","Progression-free survival|Objective response rate|Duration of response|Time-to-response|Overall survival|AMG 655 pharmacokinetic parameters|The incidence of anti-AMG 655 antibody formation","https://ClinicalTrials.gov/show/NCT00625651"
171,"NCT00677443","Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: S-1 & Oxaliplatin|Drug: Capecitabine & Oxaliplatin","Samsung Medical Center|National Cancer Center, Korea|Seoul National University Bundang Hospital|Seoul National University Hospital|Gachon University Gil Medical Center|Yonsei University|Asan Medical Center|Chonnam National University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","344","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-03-012","May 12, 2008","June 2008","January 2011","June 12, 2013","June 2013","No Study Results Posted","null","September 2009","To compare the combination of S-1 and oxaliplatin to the combination of capecitabine and oxaliplatin in terms of progression free survival in patients previously untreated by systemic therapy for advanced or metastatic colorectal carcinoma.|To evaluate and compare the efficacy (overall survival and response rate) in the two treatment groups.|To evaluate and compare the quality of life of the patients and safety profiles of the two treatment groups.","https://ClinicalTrials.gov/show/NCT00677443"
172,"NCT02079220","A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer","Withdrawn","No Results Available","Metastatic Colorectal Cancer","Drug: Arm A|Drug: Arm B","University of Pittsburgh|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13-145","March 3, 2014","March 2014","March 2018","November 20, 2014","November 2014","No Study Results Posted","null","March 2018","anti-tumor activity of ziv-aflibercept in combination with XELOX in the first-line treatment of patients with metastatic colorectal cancer (mCRC)|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02079220"
173,"NCT01333475","MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma","Completed","Has Results","Colorectal Neoplasms","Drug: MK-2206 + AZD6244","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","Phase 2","21","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","110117|11-C-0117","April 9, 2011","March 2011","September 2014","September 29, 2015","November 2014","November 19, 2014","null","November 2013","pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced Colorectal Cancer|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT01333475"
174,"NCT00624260","Impact of PET Scan on the Curative Strategy of Colo-rectal Cancers : A Randomized Study","Completed","No Results Available","Colorectal Cancer","Other: semi-annual systematic PET-TDM|Other: PET-TDM for current indication","Assistance Publique - Hôpitaux de Paris","Both","18 Years and older   (Adult, Senior)","","240","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","P070142","February 15, 2008","June 2008","June 2015","March 17, 2016","March 2016","No Study Results Posted","ITEP","June 2015","Percentage of patients with a non removable recurrence|Survival without non removable tumor|Overall survival|Cost of the strategy","https://ClinicalTrials.gov/show/NCT00624260"
175,"NCT01299493","Systems Intervention to Promote Colorectal Cancer (CRC) Screening","Recruiting","No Results Available","Carcinoma","Other: Systems-level intervention to promote colon cancer screening","Washington University School of Medicine|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","18","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Screening","10-1131 (201110005)|U54CA153460","February 16, 2011","June 2012","August 2017","May 10, 2016","May 2016","No Study Results Posted","null","August 2017","Practice-level colon cancer screening rate","https://ClinicalTrials.gov/show/NCT01299493"
176,"NCT00040599","Safety Study of 90Y-hMN14 to Treat Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Colon Cancer|Rectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Tumor","Drug: hMN14 (labetuzumab)","Immunomedics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","72","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IM-T-hMN14-02","July 1, 2002","January 2000","January 2004","January 8, 2008","January 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00040599"
177,"NCT00561470","Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen","Completed","Has Results","Colorectal Neoplasms|Neoplasm Metastasis","Drug: Placebo|Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)","Sanofi|Regeneron Pharmaceuticals|NSABP Foundation Inc","Both","18 Years and older   (Adult, Senior)","Phase 3","1226","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","EFC10262|EudraCT 2007-000820-42","November 20, 2007","November 2007","June 2012","September 27, 2012","March 2012","August 17, 2012","VELOUR","February 2011","Overall Survival (OS)|Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)|Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria|Number of Participants With Adverse Events (AE)|Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay","https://ClinicalTrials.gov/show/NCT00561470"
178,"NCT01047293","RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma","Completed","No Results Available","Colorectal Cancer","Drug: RAD011|Drug: FOLFOX|Drug: Bevacizumab","University of Utah|Novartis","Both","Child, Adult, Senior","Phase 1|Phase 2","47","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCI38815","January 8, 2010","May 2010","August 2015","November 11, 2015","November 2015","No Study Results Posted","null","August 2015","Evaluate PFS for combination of FOLFOX+ Bevacizumab + RAD001 in previously untreated metastatic or advanced colorectal cancers|Evaluate safety of the combination at a daily dosing of 2.5mg RAD001, 5 mg RAD001 or 10 mg RAD001 (Phase 1 part)|To study the toxicity profile of the combination|To study the Response Rate (RR) of the combination|To determine the serum proteomic profiles of patients treated with combination therapy (Both phase I and II portions)","https://ClinicalTrials.gov/show/NCT01047293"
179,"NCT01453894","Improving Rates of Repeat Colorectal Cancer Screening","Completed","Has Results","Colorectal Neoplasms","Behavioral: Reminder and Outreach Intervention","Northwestern University|Agency for Healthcare Research and Quality (AHRQ)","Both","51 Years to 75 Years   (Adult, Senior)","","450","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Screening","1P01HS021141-01-PROJECT1","October 13, 2011","March 2012","August 2013","July 24, 2014","July 2014","July 24, 2014","null","August 2013","Completion of a Fecal Occult Blood Test (FOBT)","https://ClinicalTrials.gov/show/NCT01453894"
180,"NCT02466009","Regorafenib in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib","University of Rochester|Bayer","Both","70 Years and older   (Senior)","Phase 2","60","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","55555","April 9, 2015","March 2015","July 2018","August 12, 2016","August 2016","No Study Results Posted","null","July 2018","Number of subjects who experience grade 3-5 toxicity as a measure of safety and tolerability.|Number of subjects who respond to study treatment.|Association of adverse events with the Comprehensive Geriatric Assessments.|Subject's quality of life as assessed by the Comprehensive Geriatric Assessment form while receiving study treatment.","https://ClinicalTrials.gov/show/NCT02466009"
181,"NCT01628328","Colonic Stent and Tumor Cell Dissemination","Completed","No Results Available","Colorectal Cancer","","The University of Hong Kong","Both","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","colonstent","June 21, 2012","July 2010","January 2012","June 21, 2012","June 2012","No Study Results Posted","null","December 2011","Changes of circulating tumor cell level before and after colonic stenting for patients with obstructive colorectal cancer","https://ClinicalTrials.gov/show/NCT01628328"
182,"NCT01506687","Increasing Colorectal Cancer Screening Uptake With a Patient Navigator","Completed","No Results Available","Colorectal Cancer","Behavioral: Health counselling by nurse navigator|Behavioral: Usual primary care counselling","Cancer Care Ontario|Canadian Institutes of Health Research (CIHR)","Both","50 Years to 74 Years   (Adult, Senior)","Phase 3","750","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","10-163","June 27, 2011","January 2010","June 2012","December 2, 2013","December 2013","No Study Results Posted","null","June 2012","Completion of verified CRC screening event (FOBT;colonoscopy) event in experimental vs. control groups within 48 weeks|Screening preferences; predictors of CRC screening and screening preference.","https://ClinicalTrials.gov/show/NCT01506687"
183,"NCT01762813","Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: open and laparoscopic surgery","Helse Stavanger HF","Both","18 Years and older   (Adult, Senior)","","850","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","29034/2012","January 3, 2013","August 2012","December 2027","August 20, 2016","August 2016","No Study Results Posted","ACROBATICC","December 2027","Cancer-specific survival|Recurrence-free survival","https://ClinicalTrials.gov/show/NCT01762813"
184,"NCT02192034","Optimizing Navigation to Successful Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer Screening","Behavioral: Navigation","Rush University Medical Center|American Cancer Society, Inc.","Both","40 Years to 75 Years   (Adult, Senior)","","156","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Screening","ACS255086","June 2, 2014","March 2013","June 2014","October 26, 2015","October 2015","No Study Results Posted","null","April 2014","Navigation role in colorectal cancer screening","https://ClinicalTrials.gov/show/NCT02192034"
185,"NCT02645084","Identifying Patients With Hereditary and Familial Colorectal Cancer by Using an Online Risk Tool","Enrolling by invitation","No Results Available","Colorectal Cancer|Lynch Syndrome|Familial Colorectal Cancer","Other: Offering an online risk assessment questionnaire","Prof. Evelien Dekker, MD, PhD|Dutch Digestive Diseases Foundation|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Both","Child, Adult, Senior","","104","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Prevention","14_301#14.17.0363","December 29, 2015","February 2015","October 2016","January 3, 2016","January 2016","No Study Results Posted","FR-QUENT","October 2016","Percentage of all included patients who have received a recommendation for regular surveillance colonoscopies for himself/herself and/or relatives, provided by a clinical geneticist.|Percentage of all included patients with a referral to a clinical geneticist|Percentage of referred patients fulfilling referral criteria for a Lynch syndrome suspicion|Percentage of all included patients with genetically confirmed Lynch syndrome|Percentage of all included patients with confirmed other hereditary CRC syndromes (such as polyposis syndromes)|Percentage of referred patients fulfilling FCC criteria|Percentage of all included patients who receive a surveillance advice per time period (month or season)|Percentage of referred patients not fulfilling referral criteria for FCC, a Lynch syndrome suspicion or other hereditary CRC syndromes|Percentage of patients not adhering to referral advice|The number of changes in family history after verification of the completed questionnaire at the outpatient clinic|Patients' reasons for not filling out the questionnaire as reported by a nurse or gastroenterologist|Usability of the questionnaire for health care providers and patients by using a self-created online or paper questionnaire","https://ClinicalTrials.gov/show/NCT02645084"
186,"NCT01004159","Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan","Terminated","Has Results","Colorectal Cancer","Drug: cetuximab with irinotecan","Roswell Park Cancer Institute|Bristol-Myers Squibb","Both","18 Years to 99 Years   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 152009","October 28, 2009","September 2009","May 2012","September 29, 2015","September 2015","December 26, 2013","null","May 2012","12-week Progression Free Survival Rate Upon Escalation of Cetuximab Dose to 500mg/m2 in Combination With Irinotecan After Progression on Standard Dose Therapy in Patients With KRS Wild Type Colorectal Cancer|Response Rate of Cetuximab 500mg/m2/Week in Combination With Irinotecan in the Enrolled Patient Population","https://ClinicalTrials.gov/show/NCT01004159"
187,"NCT01688232","The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Surgical Resection of the Colorectal Tumor","","Assistance Publique - Hôpitaux de Paris|Ministry of Health, France","Both","18 Years and older   (Adult, Senior)","","459","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NI11033","September 14, 2012","October 2012","October 2019","September 1, 2016","August 2016","No Study Results Posted","IMMUCOL","October 2019","relapse in relation with the immunoscore determined on a tumor section.|relapse in relation with the immunoscore on biopsies|relapse in relation with the genetic features of the tumor|relapse in relation with the immunological events and psychological status of the patient during the monitoring","https://ClinicalTrials.gov/show/NCT01688232"
188,"NCT00853203","Expressive Disclosure and Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Behavioral: Interviews|Behavioral: Questionnaires|Other: Electronically Activated Recorder (EAR)|Behavioral: Group Meetings|Behavioral: Written Materials","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","174","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","2003-1028|1R21CA107306-01A2","February 27, 2009","January 2009","null","October 28, 2015","October 2015","No Study Results Posted","null","January 2017","To collect information about factors affecting colon and rectal cancer patients' quality of life (QOL) in order to develop a QOL program.|To look at acceptability of an Expressive Disclosure Group Program for colon and rectal cancer patients, and examine its effect on quality of life.","https://ClinicalTrials.gov/show/NCT00853203"
189,"NCT01925274","A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: PF-05212384|Drug: irinotecan|Drug: Cetuximab|Drug: Irinotecan","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","19","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","B2151005|2013-002095-40","August 15, 2013","November 2013","April 2016","May 15, 2016","May 2016","No Study Results Posted","null","April 2016","Progression-Free Survival (PFS)|Number of participants with Dose-limiting toxicities (DLT)|Number of Participants With Objective Response|Duration of Response (DR)|Overall Survival (OS)|Number of Participants Using Healthcare Resources|Area under the Concentration-Time Curve (AUC)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Levels of signaling proteins in paired and single tumor biopsies|Gene sequences and/or gene copy numbers in paired tumor biopsies","https://ClinicalTrials.gov/show/NCT01925274"
190,"NCT00137683","Colorectal Cancer Control in Appalachian Churches","Withdrawn","No Results Available","Colorectal Cancer","Behavioral: one-on-one education, group education, small media","Centers for Disease Control and Prevention|West Virginia University","Both","50 Years and older   (Adult, Senior)","Phase 2|Phase 3","0","U.S. Fed|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CDC-NCCDPHP-9998|U57/CCU320638","August 27, 2005","September 2001","March 2005","March 13, 2012","March 2012","No Study Results Posted","null","null","colorectal cancer screening|physical activity|diet|knowledge","https://ClinicalTrials.gov/show/NCT00137683"
191,"NCT01214681","Chemoprevention of Colorectal Cancer: the Role of Non-digestible Carbohydrates","Active, not recruiting","No Results Available","Colorectal Cancer","Dietary Supplement: Maltodextrin and Amioca starch|Dietary Supplement: Hi-maize 260|Dietary Supplement: Polydextrose|Dietary Supplement: Hi-maize 260 and polydextrose","Newcastle University|Northumbria Healthcare NHS Foundation Trust","Both","16 Years to 85 Years   (Child, Adult, Senior)","","75","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","002","October 1, 2010","May 2010","December 2012","October 25, 2011","October 2011","No Study Results Posted","null","June 2012","Faecal calprotectin concentration|Serum C reactive protein concentration|COX 2 expression in mucosal biopsies|Number and distribution of mitotic and apoptotic cells within colonic crypts (mucosal cell kinetics)|Cellular CDK 4 RNA expression|Cellular GADD45A RNA expression|Target gene methylation (p16, GSTP1, RARβ2, CDH1 GATA4 APC, SFRP1, 2, 4 and 5, AXIN2, DKK1 and WIF1)|Global genetic methylation|Cellular protein biomarker (CK8) expression|Faecal pH|Faecal bacterial abundance and population|Faecal short chain fatty acid concentration|Urinary short chain fatty acid concentration|Plasma short chain fatty acid concentration","https://ClinicalTrials.gov/show/NCT01214681"
192,"NCT00133913","Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Neoplasm Metastasis","Procedure: Phlebotomy","Immunicon","Both","18 Years and older   (Adult, Senior)","","486","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMMC-06","August 22, 2005","March 2004","January 2009","March 17, 2008","March 2008","No Study Results Posted","IMMC-06","January 2007","","https://ClinicalTrials.gov/show/NCT00133913"
193,"NCT00355004","Computerized and Mailed Reminders in Increasing the Rate of Colorectal Cancer Screening in Adults With an Average Risk for Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: counseling intervention|Procedure: fecal occult blood test|Procedure: screening colonoscopy","Harvard Medical School|National Cancer Institute (NCI)","Both","50 Years to 80 Years   (Adult, Senior)","","21860","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Screening","CDR0000486405|HMS-M11960-103|HCHP-1305","July 19, 2006","March 2005","February 2009","December 18, 2013","January 2007","No Study Results Posted","null","null","Rate of colorectal cancer screening|Number of patients with adenomatous polyps and colon cancer diagnosed|Number of stool cards returned and abnormal stool cards|Number and dates of sigmoidoscopies and colonoscopies scheduled and performed","https://ClinicalTrials.gov/show/NCT00355004"
194,"NCT00862680","4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis","Recruiting","No Results Available","Colorectal Cancer|Lung Cancer|Liver Cancer","Procedure: PET/CT Scan","M.D. Anderson Cancer Center|GE Healthcare","Both","18 Years and older   (Adult, Senior)","","75","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0853|NCI-2011-00528","March 16, 2009","March 2009","null","September 12, 2016","September 2016","No Study Results Posted","null","March 2018","Comparison lesion maximum standardized uptake value (SUVmax) between gated and non-gated PET imaging scans in Lung and Colorectal Cancer with Liver Metastasis","https://ClinicalTrials.gov/show/NCT00862680"
195,"NCT00803647","A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver","Completed","Has Results","Metastatic Colorectal Cancer","Biological: cetuximab|Drug: 5-FU|Drug: oxaliplatin|Drug: leucovorin","NSABP Foundation Inc|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP FC-6","December 4, 2008","January 2010","November 2014","July 26, 2016","July 2016","October 19, 2015","null","July 2013","The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or Ablated With no Postoperative Evidence of Residual Malignant Disease (R0 Resection).|Reported Adverse Events.|Overall Survival (OS). Time From Study Entry Until Death From Any Cause.|Objective Clinical Response Rate (cRR). Measureable Lesions That Can be Accurately Measured in at Least One Dimension With Conventional Radiologic Techniques or Spiral CT.|Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.","https://ClinicalTrials.gov/show/NCT00803647"
196,"NCT02706301","Pain Coping Skills for Colorectal Cancer Survivors","Not yet recruiting","No Results Available","Colorectal Cancer","Behavioral: Telephone-Based Coping Skills Training (CST)","Duke University|American Cancer Society, Inc.","Both","21 Years to 80 Years   (Adult, Senior)","","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00063330","March 8, 2016","March 2016","June 2018","March 15, 2016","March 2016","No Study Results Posted","null","June 2018","Change in Pain Severity assessed using the Brief Pain Inventory (BPI)|Change in Psychological Distress assessed using the Brief Symptom Inventory (BSI)|Change in Quality of Life assessed using the FACT-G, version 4.0|Change in Self-Efficacy for Pain Control assessed using the subscale of the Chronic Pain Self-Efficacy Scale","https://ClinicalTrials.gov/show/NCT02706301"
197,"NCT00327093","Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases","Terminated","No Results Available","Colorectal Cancer|Neoplasm Metastasis","Drug: cetuximab|Drug: bevacizumab","Hospices Civils de Lyon","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","31","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-401","May 17, 2006","May 2006","October 2008","February 6, 2009","February 2009","No Study Results Posted","null","October 2008","Elaboration of a predictive model, based on biological and functional imaging parameters, for the response to monoclonal antibodies as assessed through RECIST criteria 2 months after the beginning of treatment|Correlation between the response at 2 months and that at 6 months of treatment (taking into account the therapeutic adjustments during the 6-month follow-up)","https://ClinicalTrials.gov/show/NCT00327093"
198,"NCT00055419","A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Biological: Cetuximab","ImClone LLC|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 2","744","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA225-041","February 28, 2003","February 2003","August 2004","April 8, 2010","April 2010","No Study Results Posted","null","July 2004","The objective of this study will be to monitor the safety of administering cetuximab,via an access program, to subjects with metastatic colorectal carcinoma who have exhausted all standard therapies or treatment options.","https://ClinicalTrials.gov/show/NCT00055419"
199,"NCT01669720","Adjuvant Aflibercept for Metastatic Colorectal Cancer","Terminated","Has Results","Metastatic Colorectal Cancer","Drug: Aflibercept","Brown University|Rhode Island Hospital|The Miriam Hospital|Lifespan|University of California, San Diego|Montefiore Medical Center|University of Florida","Both","18 Years and older   (Adult, Senior)","Phase 2","10","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG C261","August 7, 2012","December 2012","January 2016","February 11, 2016","February 2016","January 8, 2016","C261","December 2015","Number of Patients Who Progressed|Adverse Events for Patients Receiving Adjuvant Aflibercept, up to 2-years of Duration, for Patients Who Previously Received Systemic Chemotherapy and Surgical Resection/Ablation.","https://ClinicalTrials.gov/show/NCT01669720"
200,"NCT00352638","Educational Intervention With or Without Telephone Counseling in Increasing Colorectal Cancer Screening Compliance in Brothers and Sisters of Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: counseling intervention|Other: educational intervention|Other: study of socioeconomic and demographic variables","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","40 Years and older   (Adult, Senior)","Phase 3","660","Other|NIH","Interventional","Allocation: Randomized","FCCC-FCRB-04-004-P|CDR0000485294|FCCC-00-841","July 13, 2006","August 2005","November 2013","May 15, 2014","May 2014","No Study Results Posted","null","February 2012","Colorectal cancer screening compliance|Impact on movement in stage of adoption|Increased knowledge and attitudes|Cost","https://ClinicalTrials.gov/show/NCT00352638"
201,"NCT00984048","Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Other: Needle core biopsies of liver metastasis","Jewish General Hospital|Quebec Clinical Research Organization in Cancer|Terry Fox Research Institute|Fonds de la Recherche en Santé du Québec","Both","18 Years and older   (Adult, Senior)","","180","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Q-CROC-01","September 23, 2009","August 2009","September 2018","March 30, 2016","March 2016","No Study Results Posted","null","September 2017","Changes in biomarkers in patients that have acquired clinical resistance.|Number of participants with adverse events relating to the liver biopsy procedure","https://ClinicalTrials.gov/show/NCT00984048"
202,"NCT02289053","Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Colon Polyps|Adenomatous Polyp of Colon","","University of Michigan|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","40 Years to 49 Years   (Adult)","","1623","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","K24-DK|1K24DK084208","February 26, 2014","April 2006","June 2016","December 3, 2015","December 2015","No Study Results Posted","null","June 2016","Prevalence of advanced adenomas among 40-49 year old individuals with and without a family history of colorectal cancer|Absolute prevalence of advanced adenomas in 40-49 year olds with a family history of colorectal cancer|Absolute prevalence of advanced adenomas in 40-49 year old individuals with a family history of colorectal polyps","https://ClinicalTrials.gov/show/NCT02289053"
203,"NCT01075893","Changes in Stem Cells of the Colon in Response to Increased Risk of Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","","Newcastle University|Northumbria Healthcare NHS Foundation Trust","Both","18 Years to 85 Years   (Adult, Senior)","","150","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","McCallum-001","February 24, 2010","February 2010","October 2012","October 25, 2011","October 2011","No Study Results Posted","null","October 2012","Number of stem cells in the colonic crypt|Stem cell position in colonic crypt","https://ClinicalTrials.gov/show/NCT01075893"
204,"NCT01126112","Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: Panitumumab","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Amgen","Both","70 Years and older   (Senior)","Phase 2","33","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-09-03|2009-016661-28","May 17, 2010","May 2010","July 2014","March 23, 2015","March 2015","No Study Results Posted","FRAIL","July 2014","Progression-free survival rate at 6 months|Progression-free survival|Objective Response Rate|Disease control rate|Time to response|Time to progression|Time to treatment failure|Duration of response|Duration of stable disease|Overall survival|Changes in patient-reported outcomes|Adverse events|Evaluation of molecular predictive markers for response.","https://ClinicalTrials.gov/show/NCT01126112"
205,"NCT01109615","Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: Pemetrexed|Drug: Gemcitabine","Vejle Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-018700-90","April 20, 2010","April 2010","March 2012","April 17, 2012","April 2012","No Study Results Posted","PG","August 2011","Response rate|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01109615"
206,"NCT00478946","A Study of Picoplatin in Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: (FOLPI) Picoplatin with 5-FU and Leucovorin|Drug: FOLPI|Drug: FOLFOX","Poniard Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","43","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0501","May 23, 2007","April 2006","June 2010","January 20, 2009","January 2009","No Study Results Posted","null","December 2009","dose-limiting toxicity|maximum tolerated dose|safety and efficacy","https://ClinicalTrials.gov/show/NCT00478946"
207,"NCT00982059","Colorectal Cancer Screening for Cancer Survivors","Active, not recruiting","No Results Available","Colorectal Cancer","Other: Colonoscopic examination","University Health Network, Toronto|Princess Margaret Hospital, Canada","Both","35 Years to 49 Years   (Adult)","","140","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","UHN REB 07-0708-CE","November 21, 2008","May 2008","December 2016","June 21, 2016","June 2016","No Study Results Posted","null","December 2014","The proportion of screened patients with any polyp or any high risk polyp will be calculated.|Proportion calculation/identification of: demographic/treatment influences on polyp prevalence; subgroups w/polyp prevalence >20%; pts with polyps beyond 30cm flexible sigmoidoscope; pts with adenomatous polyp(s) on colonoscopy in/outside prior RT fields","https://ClinicalTrials.gov/show/NCT00982059"
208,"NCT00444678","Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Neoplasm Metastasis","Drug: Cetuximab|Drug: Oxaliplatin|Drug: Capecitabine","New York University School of Medicine|ImClone LLC|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 2","38","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NYU# 04-10 H11817|CA225056","March 7, 2007","June 2004","June 2015","January 25, 2016","January 2016","No Study Results Posted","null","August 2012","Response rate for the combination treatment|Toxicity rates|Time to progression|Survival","https://ClinicalTrials.gov/show/NCT00444678"
209,"NCT02597075","Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy","Recruiting","No Results Available","Metastatic Colorectal Cancer","Other: standard therapy + physical activity program|Other: standard therapy","Swiss Group for Clinical Cancer Research","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","524","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 41/14 - ACTIVE-2|2015-003733-10","October 22, 2015","January 2016","December 2026","September 19, 2016","September 2016","No Study Results Posted","null","September 2016","Progression-free survival (PFS)|Change in Patient-reported symptoms as measured by ESAS-r|Overall survival|Best Objective Response|Selected adverse events|Chemotherapy-completion-rate|Initiation or increase of anti-hypertensive drugs","https://ClinicalTrials.gov/show/NCT02597075"
210,"NCT02128425","FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFOXIRI|Drug: FOLFOX","Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","162","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GIHSYSU06","April 15, 2014","April 2014","April 2018","May 6, 2014","April 2014","No Study Results Posted","null","February 2017","Progression-free survival after induction and maintenance chemotherapy (PFS1)|Progression-free survival after re-introduction of chemotherapy (PFS2)|Response rate during re-introduction of chemotherapy|Early tumor shrinkage rate in 8 weeks after induction treatment|Overall survival|toxicity and safety|QLQ (QLQ C30) - scores according to EORTC QLQ-C30 scoring manual (Quality of life)|Translational research","https://ClinicalTrials.gov/show/NCT02128425"
211,"NCT00838578","Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer","Terminated","Has Results","Colorectal Cancer","Biological: KRN330|Drug: Irinotecan","Kyowa Hakko Kirin Pharma, Inc.|Kyowa Kirin Pharmaceutical Development, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","65","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KRN330-US-02","February 4, 2009","March 2009","October 2012","November 5, 2015","November 2015","March 19, 2014","null","July 2012","Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0","https://ClinicalTrials.gov/show/NCT00838578"
212,"NCT01985763","Genistein in Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Colon Cancer|Rectal Cancer|Colorectal Cancer","Drug: Genistein","Randall F. Holcombe|DSM Nutritional Products, Inc.|Icahn School of Medicine at Mount Sinai","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GCO 13-1697","November 9, 2013","November 2013","May 2018","January 14, 2016","January 2016","No Study Results Posted","null","May 2018","tolerability of genistein treatment|Response Rate (RR) CEA|Response Rate (RR) imaging|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01985763"
213,"NCT02489916","Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: CM4307","Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","47","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZGDC1B","September 28, 2014","March 2014","December 2015","January 3, 2016","October 2014","No Study Results Posted","null","October 2015","Number of participants with Adverse Events|Progression Free Survival","https://ClinicalTrials.gov/show/NCT02489916"
214,"NCT00326495","BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: BAY 43-9006","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","Phase 2","51","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","060164|06-C-0164","May 16, 2006","May 2006","November 2014","September 29, 2015","September 2015","July 10, 2015","null","November 2014","Overall Rate of Response|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00326495"
215,"NCT00007618","The Identification of Prognostic Factors of Late Stage Disease, Particularly Those That Are Modifiable, That Might Explain the Worsened Prognosis With Colorectal Cancer Among Veterans.","Completed","No Results Available","Colorectal Cancer","","VA Office of Research and Development","Both","40 Years to 79 Years   (Adult, Senior)","","null","U.S. Fed","Observational","","707D","December 29, 2000","January 1998","null","February 2, 2011","February 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00007618"
216,"NCT01051596","A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Temozolomide and ABT-888","Georgetown University|Abbott","Both","18 Years and older   (Adult, Senior)","Phase 2","75","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-170","January 8, 2010","September 2009","December 2013","February 12, 2014","February 2014","No Study Results Posted","null","June 2013","Disease control rate defined as stable disease, partial response, or complete response according to the Response Evaluation Criteria in Solid Tumors (RECIST).|Progression-free survival defines as the time in days from study study entry until progression or death|Overall survival defined as the time in days from study entry until death|Objective response rate defined as partial response or complete response according to RECIST criteria|Safety as assessed by study drug exposure, adverse events,, serious adverse events, oncology-related events, deaths, and changes in laboratory determinations and vital sign parameters","https://ClinicalTrials.gov/show/NCT01051596"
217,"NCT02688023","Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1","Chinese Academy of Medical Sciences|Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-052","February 11, 2016","March 2014","December 2019","February 17, 2016","February 2016","No Study Results Posted","null","December 2018","3-year disease-free survival|objective response rate|Surgical complete resection rate (R0)|overall survival|Number of participants with adverse events that are related to treatment|Number of participants with surgery complications","https://ClinicalTrials.gov/show/NCT02688023"
218,"NCT01742169","Improving Rates of Colorectal Cancer Screening Among Never Screened Patients","Completed","No Results Available","Colorectal Neoplasms","Behavioral: Outreach and Reminder Intervention","Northwestern University|Agency for Healthcare Research and Quality (AHRQ)","Both","50 Years to 75 Years   (Adult, Senior)","","420","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Screening","1P01HS021141-01-PROJECT1B","December 3, 2012","January 2013","June 2014","January 6, 2015","January 2015","No Study Results Posted","null","April 2014","Completion of fecal occult blood test (FOBT)","https://ClinicalTrials.gov/show/NCT01742169"
219,"NCT01570452","Matrilysin Expression in Different Stages of Colorectal Tumors","Completed","No Results Available","Colorectal Cancer Stage 0|Colorectal Cancer Stage I|Colorectal Cancer Stage II|Colorectal Cancer Stage III|Colorectal Cancer Stage IV","Procedure: colonic or colorectal resection","University of Roma La Sapienza","Both","40 Years to 83 Years   (Adult, Senior)","","38","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","andreapolistena1","March 31, 2012","September 2005","February 2012","April 3, 2012","March 2012","No Study Results Posted","MMP7","September 2008","","https://ClinicalTrials.gov/show/NCT01570452"
220,"NCT02328677","ColoCare Study - Colorectal Cancer Cohort","Recruiting","No Results Available","Colorectal Cancer","","Fred Hutchinson Cancer Research Center|German Cancer Research Center|H. Lee Moffitt Cancer Center and Research Institute|Huntsman Cancer Institute","Both","18 Years to 89 Years   (Adult, Senior)","","5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","6407","November 17, 2014","March 2007","October 2030","August 10, 2016","August 2016","No Study Results Posted","null","October 2030","Disease-free and overall survival|Recurrence|Health-related quality of life|Treatment toxicities","https://ClinicalTrials.gov/show/NCT02328677"
221,"NCT00719199","Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: IMO-2055|Drug: Cetuximab|Drug: FOLFIRI","EMD Serono","Both","18 Years and older   (Adult, Senior)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMO-2055-210|EMR200068_210","July 17, 2008","January 2009","August 2011","October 21, 2013","October 2013","No Study Results Posted","null","April 2011","• The primary objective of this study is to determine the recommended phase 2 dose of IMO 2055 when combined with FOLFIRI and cetuximab in patients with histologically proven advanced or metastatic colorectal cancer (CRC).|• To evaluate the safety of weekly IMO 2055 combined with FOLFIRI plus cetuximab.|• To investigate the pharmacokinetics (PK) of IMO-2055.|• To investigate the tolerability and pharmacodynamic (PD) effects of dexamethasone scheduling with IMO 2055 and FOLFIRI.|• To investigate potential signs of efficacy using the Response Evaluation Criteria for Solid Tumors (RECIST) response rate in patients with measurable disease.|• To investigate progression-free survival (PFS) and overall survival for up to one year in all patients.|• To investigate results of subsequent therapy (if any) in all patients.|• To investigate potential markers of IMO 2055 immune activation and effect on cellular immunity.","https://ClinicalTrials.gov/show/NCT00719199"
222,"NCT00145860","Do Patients With Colorectal Cancer Understand That Their Family is at Risk?","Terminated","No Results Available","Colorectal Cancer","","University of Chicago","Both","18 Years and older   (Adult, Senior)","","650","Other","Observational","Time Perspective: Prospective","11589A","September 1, 2005","April 2002","August 2005","September 4, 2013","September 2013","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00145860"
223,"NCT02804802","Impact of DietarY and LIfestyle Risk Factors on Colorectal Cancer Screening","Recruiting","No Results Available","Colorectal Cancer","Other: questionnaire","University Hospital, Angers","Both","50 Years to 75 Years   (Adult, Senior)","","49000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PHRC-K 2011","June 14, 2016","February 2013","September 2016","June 23, 2016","June 2016","No Study Results Posted","IDYLIC","July 2016","Colorectal cancer diagnosed by colonoscopy after a positive fecal occult blood test (Hemoccult II)","https://ClinicalTrials.gov/show/NCT02804802"
224,"NCT00522665","Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Irinotecan|Biological: Cetuximab|Biological: RAD001","Hoosier Cancer Research Network|Novartis Pharmaceuticals|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","41","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","GI05-102","August 28, 2007","August 2007","February 2015","May 14, 2015","May 2015","No Study Results Posted","null","May 2011","To determine the MTD of RAD001 in combination with irinotecan and cetuximab as second line therapy in patients with metastatic colorectal cancer|To evaluate the objective response (CR or PR) rates of patients treated with irinotecan and cetuximab with or without RAD001 in patients with metastatic colorectal cancer|To evaluate the pharmacokinetic (PK) profile for RAD001 after one cycle of therapy, on cycle 2 day 1|To evaluate the time to progression, duration of objective response (CR or PR) and overall survival of patients treated with irinotecan and cetuximab with or without RAD001","https://ClinicalTrials.gov/show/NCT00522665"
225,"NCT01309126","Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: Imprime PGG + cetuximab|Drug: Cetuximab","Biothera","Both","18 Years and older   (Adult, Senior)","Phase 3","795","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BT-CL-PGG-CRC1031","February 8, 2011","April 2011","December 2016","December 8, 2015","July 2015","No Study Results Posted","PRIMUS","April 2016","Overall Survival (OS)|Progression Free Survival (PFS)|Rate of complete response (CR)|Rate of partial response (PR)|Rate of overall response (CR + PR)|Safety and tolerability of the dosing regimen as measured by the incidence and severity of adverse events observed in study participants|Sparse pharmacokinetic profile of Imprime PGG will be determined to expand current Imprime PGG PK data|Change in Quality of Life","https://ClinicalTrials.gov/show/NCT01309126"
226,"NCT01669109","Hatha Yoga for Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Behavioral: Hatha yoga","Universität Duisburg-Essen","Both","18 Years and older   (Adult, Senior)","","54","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","12-4957-BO","August 16, 2012","September 2012","December 2013","January 9, 2014","January 2014","No Study Results Posted","YoCo","December 2013","Health-related quality of life|Fatigue|Anxiety, depression|Sleep quality|Safety|Spiritual well-being","https://ClinicalTrials.gov/show/NCT01669109"
227,"NCT00172159","Influence of Neoadjuvant Therapy on the Resectability of Hepatic Metastases From Colorectal Cancers","Recruiting","No Results Available","Colorectal Cancer","Procedure: Hepatic resection","National Taiwan University Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","170CL6","September 12, 2005","January 2000","June 2005","June 22, 2010","January 2000","No Study Results Posted","null","null","Response rate and resectability after neoadjuvant therapy.|Survival of the patients.","https://ClinicalTrials.gov/show/NCT00172159"
228,"NCT01032590","Internet-Based Weight-Loss Program for Colorectal Cancer Survivors","Active, not recruiting","No Results Available","Cancer Survivor|Colorectal Cancer|Weight Changes","Behavioral: Internet weight loss intervention","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey","Both","21 Years to 120 Years   (Adult, Senior)","","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","130902|P30CA072720|CDR0000660594","December 13, 2009","July 2009","July 2017","July 13, 2016","July 2016","No Study Results Posted","null","December 2016","Feasibility of implementing an Internet-based weight-loss intervention for colorectal cancer survivors|Impact of an Internet-based intervention on weight loss|Impact of an Internet-based intervention on waist circumference, physical activity, diet, weight-control strategies, weight-loss intention, exercise and diet self-efficacy, and perceived weight-loss barriers|Potential moderators of weight loss","https://ClinicalTrials.gov/show/NCT01032590"
229,"NCT00164879","Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers","Recruiting","No Results Available","Colorectal Cancer|Bowel Obstruction","Procedure: Endoscopic stenting followed by elective laparoscopic resection","Chinese University of Hong Kong","Both","18 Years and older   (Adult, Senior)","Phase 3","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRE-2002.445-T","September 12, 2005","January 2000","null","August 6, 2007","September 2005","No Study Results Posted","null","null","The success rate of relieving obstruction after stent insertion|The stoma rate in the two groups of patients|Morbidity and mortality rates in the two groups|Hospital stay","https://ClinicalTrials.gov/show/NCT00164879"
230,"NCT01461148","Vaccination Against MSI Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: FSP peptides","Oryx GmbH & Co. KG","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","22","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MicOryx","October 25, 2011","August 2011","May 2015","June 22, 2015","June 2015","No Study Results Posted","null","March 2015","immune response against FSP peptides|Tumor response|safety","https://ClinicalTrials.gov/show/NCT01461148"
231,"NCT01486745","Urine Metabolomics and Colorectal Cancer Screening","Recruiting","No Results Available","Colorectal Cancer|Colorectal Polyps","","University of Alberta","Both","18 Years to 90 Years   (Adult, Senior)","","1800","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","MTI-2008|514","December 3, 2011","April 2008","June 2018","May 12, 2016","May 2016","No Study Results Posted","null","December 2017","","https://ClinicalTrials.gov/show/NCT01486745"
232,"NCT00524706","Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: S-1, oral Leucovorin, Oxaliplatin","Shizuoka Cancer Center","Both","20 Years to 74 Years   (Adult, Senior)","Phase 1|Phase 2","42","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCC-07-01","September 4, 2007","August 2007","April 2011","November 12, 2008","November 2008","No Study Results Posted","null","null","Determine the RD of S-1, Leucovorin, and Oxaliplatin in phase I setting|Evaluate the response rate of S-1, Leucovorin, and Oxaliplatin with recommended dose in phase II|Phase I - Safety - Pharmacokinetic drug-drug interaction - Response rate - Time to treatment failure (TTF) - Progression free survival (PFS) - Overall survival (OS)|Phase II - Safety - Time to treatment failure (TTF) - Progression free survival (PFS) - Overall survival (OS)","https://ClinicalTrials.gov/show/NCT00524706"
233,"NCT01032746","Personal Electronic Health Records in Improving Screening Rates for Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Other: educational intervention|Other: internet-based intervention|Procedure: evaluation of cancer risk factors|Procedure: fecal occult blood test|Procedure: screening colonoscopy","Harvard University|National Cancer Institute (NCI)","Both","50 Years to 75 Years   (Adult, Senior)","","1000","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Screening","CDR0000661288|HMS-11960","December 13, 2009","March 2005","null","December 17, 2013","June 2011","No Study Results Posted","null","September 2010","Receipt of colorectal cancer screening exam (fecal occult blood test, flexible sigmoidoscopy, or colonoscopy) within 4 months following delivery of an electronic message within the personal health record|Proportion of participants who access the web-based risk-assessment tool|Distribution of risk-status among participants who complete the web-based risk-assessment tool","https://ClinicalTrials.gov/show/NCT01032746"
234,"NCT01318161","Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery","Recruiting","No Results Available","Colorectal Cancer|Pain|Other Complications","Drug: Ropivacaine + opioid epidurally|Drug: Morphine","Örebro University, Sweden|University Hospital, Linkoeping","Both","40 Years to 80 Years   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2010/415-31","March 17, 2011","March 2011","December 2018","February 14, 2016","February 2016","No Study Results Posted","EPICOL","May 2018","Long-term (up to 5 yrs) all-cause mortality|Cancer recurrence detected by MRI; perioperative complications","https://ClinicalTrials.gov/show/NCT01318161"
235,"NCT00296062","Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: bevacizumab|Drug: capecitabine|Drug: irinotecan hydrochloride|Drug: oxaliplatin","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE1205|U01CA062502|P30CA043703|NCI-7325","February 23, 2006","March 2006","May 2011","January 13, 2012","January 2012","No Study Results Posted","null","October 2009","Phase II: Bevacizumab plus dose-intense capecitabine in combination with alternating full-dose irinotecan hydrochloride and oxaliplatin as first-line treatment leads to an improved response rate in patients with metastatic colorectal cancer|Phase II: Determine the toxicity of bevacizumab in combination with this regimen in patients with metastatic colorectal cancer.|Phase I: Maximum tolerated dose in patients ≥ 65 years of age measured by CTC version 3.0 at end of Safety in the Elderly component of study","https://ClinicalTrials.gov/show/NCT00296062"
236,"NCT00816777","Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer","Terminated","Has Results","Unresectable Metastatic Colo-rectal Cancer","Procedure: Chemoembolization with irinotecan Bead|Drug: Irinotecan","Generic Devices Consulting, Inc.|Biocompatibles UK Ltd","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","4","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA1013|IDE G070122","January 2, 2009","December 2008","March 2011","August 17, 2015","August 2015","August 12, 2014","PARAGON","January 2011","Progression Free Survival|Toxicity, Adverse Events and Serious Adverse Events (NCI CTCAE v3.0)|Tumor Response (RECIST)|Local Tumor Response (Extent of Necrosis in the Treated Lesions)|Hepatic Progression Free Survival|Change in Tumor Marker|Performance Status (ECOG)|Overall Survival","https://ClinicalTrials.gov/show/NCT00816777"
237,"NCT00126256","Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastasis","Drug: 5-fluorouracil|Drug: leucovorin|Drug: irinotecan|Drug: oxaliplatin","Gustave Roussy, Cancer Campus, Grand Paris|Fondation Francaise de Cancerologie Digestive|Sanofi","Both","up to 75 Years   (Child, Adult, Senior)","Phase 3","570","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FFCD 2000 - 05|CET 815","August 2, 2005","February 2002","February 2006","August 11, 2015","August 2015","No Study Results Posted","null","February 2006","Progression-free survival after two lines of chemotherapy, defined as the time duration from randomization until progression after two lines of chemotherapy or death whatever the cause in the absence of progression or last-follow-up|Overall survival|Secondary surgery|Response rate|Progression-free survival after the first and the third line of chemotherapy|Safety|Quality of life|Costs","https://ClinicalTrials.gov/show/NCT00126256"
238,"NCT02591667","Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Peritoneal Metastasis","Procedure: Upfront staging laparoscopy + peritoneal biopsy|Drug: Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|Procedure: Surgical re-exploration","Medical University of Vienna","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-002917-30","October 13, 2015","March 2016","February 2020","April 2, 2016","April 2016","No Study Results Posted","CARCINOSIS","February 2019","Percentage of viable cells within the resected peritoneal deposits after completion of neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab.|Change in the percentage of viable cells in peritoneal tumor deposits before and after completion of neoadjuvant chemotherapy.|Change in Peritoneal Cancer Index (PCI) between baseline and after completion of neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab.|Change in resectability (the ability to achieve a complete surgical cytoreduction) between initial surgical exploration and surgical re-exploration after administration of combination chemotherapy with FOLFOXIRI + bevacizumab.|Radiologic response to combination chemotherapy with FOLFOXIRI + bevacizumab as assessed by 18F-2-fluoro-2-deoxy-D-glucose (FDG)-PET CT/MRI.|Incidence of treatment-emergent adverse events.|Relapse-free survival (RFS)|Progression-free survival (PFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02591667"
239,"NCT01428752","Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","","Asan Medical Center","Both","30 Years to 49 Years   (Adult)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADENOMA 30-49 YO","September 2, 2011","September 2011","September 2014","September 8, 2011","September 2011","No Study Results Posted","null","September 2014","prevalence of colorectal adenoma(any size)|prevalence of advanced adenoma","https://ClinicalTrials.gov/show/NCT01428752"
240,"NCT00966667","Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey","Both","21 Years and older   (Adult, Senior)","","222","Other|NIH","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","130901|R21CA131611|P30CA072720|K07CA133100|CDR0000653167|0220090178","August 26, 2009","November 2009","August 2017","August 29, 2016","August 2016","No Study Results Posted","null","August 2017","Self-efficacy for changing physical activity and dietary practices|Outcome expectations with regard to physical activity and dietary practices|Behavioral self-regulation of physical activity and dietary practices|Perceived role of physical activity and dietary factors in causing colorectal cancer (CRC) and preventing recurrence (CRC illness representations)|Perceived risk of CRC recurrence|Cancer-related anxiety and worry about cancer recurrence (emotional representations of CRC)|Receipt of healthcare provider recommendations to alter physical activity and diet|Normative influences of family and friends","https://ClinicalTrials.gov/show/NCT00966667"
241,"NCT00501410","FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: 5-FU|Drug: Cetuximab|Drug: Dasatinib|Drug: Leucovorin|Drug: Oxaliplatin","M.D. Anderson Cancer Center|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1","83","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0842|NCI-2010-00677","July 12, 2007","April 2007","null","January 6, 2016","January 2016","No Study Results Posted","null","April 2018","Maximum Tolerated Dose (MTD) of Dasatinib, Cetuximab and FOLFOX|Response-Rate of Dasatinib and Modified FOLFOX6 With or Without Cetuximab","https://ClinicalTrials.gov/show/NCT00501410"
242,"NCT02063529","FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFOXIRI + Cetuximab|Drug: FOLFOXIRI","Sun Yat-sen University","Both","18 Years to 65 Years   (Adult)","Phase 2","138","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GIHSYSU05","February 8, 2014","February 2014","February 2020","September 19, 2016","September 2016","No Study Results Posted","FOCULM","February 2018","the percentage of patients who had a curative liver treatment following protocol treatment, i.e., liver metastases that can be completely resected and/or ablated with no evidence of residual malignant disease.|Reported adverse events.|Response rate|Progression free survival|Time to recurrence|Quality of life (QLQ C30)","https://ClinicalTrials.gov/show/NCT02063529"
243,"NCT01270698","Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: IMMU-130","Immunomedics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IM-T-IMMU-130-01","January 3, 2011","May 2011","December 2014","January 14, 2015","January 2015","No Study Results Posted","null","December 2014","Safety|efficacy","https://ClinicalTrials.gov/show/NCT01270698"
244,"NCT01574677","Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test","Withdrawn","No Results Available","Colorectal Cancer","","Epigenomics, Inc|Kaiser Permanente|Emory University","Both","49 Years to 80 Years   (Adult, Senior)","","0","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Septin 9 Colorectal Biomarker","March 20, 2012","June 2012","null","August 1, 2014","August 2014","No Study Results Posted","null","null","Performance characteristics of the Septin 9 biomarker among patients who have a positive FIT result|Concordance and discordance (Kappa scores) between Septin 9 test results and colonoscopy findings associated with patient demographic factors.|Concordance and discordance (Kappa scores) between Septin 9 test results and colonoscopy findings associated with co-morbid conditions.|Concordance and discordance (Kappa scores) between Septin 9 test results and colonoscopy findings associated with specific medication use practices.","https://ClinicalTrials.gov/show/NCT01574677"
245,"NCT01193517","Azacitidine and CAPOX in Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Azacitidine|Drug: Capecitabine|Drug: Oxaliplatin|Drug: Azacitidine MTD","M.D. Anderson Cancer Center|Celgene","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","54","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0625|NCI-2010-01973","August 31, 2010","August 2010","null","August 17, 2016","August 2016","No Study Results Posted","null","August 2017","Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)|Response Rate of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)","https://ClinicalTrials.gov/show/NCT01193517"
246,"NCT00579891","Tissue and Serum Collection From Colorectal Cancer Patients","Active, not recruiting","No Results Available","Colorectal Cancer","","Memorial Sloan Kettering Cancer Center","Both","Child, Adult, Senior","","1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","89-006","December 20, 2007","March 1989","January 2017","February 2, 2016","February 2016","No Study Results Posted","null","January 2017","establish a serum and tissue bank","https://ClinicalTrials.gov/show/NCT00579891"
247,"NCT01529164","Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Endostatins (Endostar)|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-fluorouracil","Chinese Academy of Medical Sciences|Simcere Pharmaceutical Co., Ltd","Both","18 Years and older   (Adult, Senior)","Phase 2","51","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-023","February 4, 2012","October 2011","September 2014","November 26, 2013","November 2013","No Study Results Posted","null","September 2014","response rate|progression free survival|overall survival|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01529164"
248,"NCT01196130","Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Cancer Symptom Questionnaire|Other: Biomarker Testing","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","1200","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2009-0091|R01CA172670|RP110584","September 3, 2010","August 2010","null","April 15, 2016","April 2016","No Study Results Posted","null","August 2021","Rate of Successful Biomarker Determination","https://ClinicalTrials.gov/show/NCT01196130"
249,"NCT02328365","Screening and Systematic Follow-up for Cardiopulmonary Comorbidity in Patients Having Surgery for Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Other: Structured medical follow-up after operation","Vejle Hospital","Both","18 Years and older   (Adult, Senior)","","180","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","Comorbidity","December 10, 2014","March 2014","June 2017","September 13, 2016","September 2016","No Study Results Posted","null","March 2017","Postoperative mortality at one year|Short-term postoperative mortality|Medical complications","https://ClinicalTrials.gov/show/NCT02328365"
250,"NCT02316028","Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)","Recruiting","No Results Available","Liver Metastasis|Colorectal Cancer","Drug: Decitabine","Universitair Ziekenhuis Brussel|Janssen, LP","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","6","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UZB-BN-2013-002","December 3, 2014","March 2014","July 2017","September 14, 2016","September 2016","No Study Results Posted","DECIT","December 2016","toxicity of escalating doses of decitabine administered by HAI|overall survival|progression free survival|best objective tumor response|measuring Global DNA methylation of tumoral DNA|measuring Global DNA methylation of cell free DNA","https://ClinicalTrials.gov/show/NCT02316028"
251,"NCT00251862","Shared Decision-Making for Colorectal Cancer Screening","Completed","Has Results","Colorectal Cancer","Behavioral: Web-based decision aid plus personalized risk assessment|Behavioral: Web-based decision aid alone|Behavioral: Generic website","Agency for Healthcare Research and Quality (AHRQ)","Both","50 Years to 75 Years   (Adult, Senior)","","825","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Prevention","5R01HS013912-05","November 9, 2005","January 2005","December 2010","December 2, 2013","September 2013","July 23, 2013","null","December 2010","Patient Adherence (Test Completion)|Patient Knowledge|Patient Satisfaction With Decision Making Process|Screening Intentions","https://ClinicalTrials.gov/show/NCT00251862"
252,"NCT02726243","Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease","Recruiting","No Results Available","Inflammatory Bowel Disease|Colorectal Cancer","","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France","Both","18 Years and older   (Adult, Senior)","","240","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","NI13006","March 29, 2016","November 2014","April 2017","March 31, 2016","March 2016","No Study Results Posted","DYSCOLIC","April 2017","Composition of fecal microbiota by 16S sequencing|Profile of fecal bile acids","https://ClinicalTrials.gov/show/NCT02726243"
253,"NCT01504477","Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: Panitumumab and bortezomib","Georgetown University|Millennium Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","6","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-033|X05374","December 14, 2011","December 2011","February 2014","July 22, 2015","February 2014","No Study Results Posted","null","February 2014","Maximum tolerated dose|Disease control rate|Overall response rate|Overall survival|Duration of disease control|Pharmacodynamic effects","https://ClinicalTrials.gov/show/NCT01504477"
254,"NCT00792285","RCT of Automated Telephone Outreach to Improve Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Behavioral: Automated Telephone Outreach with Speech Recognition","Harvard Pilgrim Health Care","Both","50 Years to 64 Years   (Adult)","","80000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","ATO-SR CRC","November 13, 2008","March 2005","March 2006","November 13, 2008","November 2008","No Study Results Posted","null","March 2006","colorectal cancer screening|colonoscopy screening","https://ClinicalTrials.gov/show/NCT00792285"
255,"NCT01344538","Ginger for Colorectal Cancer Prevention","Completed","Has Results","Colorectal Cancer","Drug: Ginger Root Extract (Pure Encapsulations)|Dietary Supplement: Placebo Capsule","University of Michigan","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Ginger-01HR","April 27, 2011","April 2007","December 2012","June 30, 2016","June 2016","June 16, 2014","null","May 2011","Evaluate Whether 2.0g of Ginger Taken Daily, Standardized to 5%-Gingerols for Four Weeks Will Result in Bioactive Levels in Colonic Tissue Sufficient to Reduce Mucosal Prostaglandin E2 (PGE2), a Marker of Cyclooxygenase Function Versus Placebo.","https://ClinicalTrials.gov/show/NCT01344538"
256,"NCT02558881","Colon Capsule Versus Virtual Colonoscopy for Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Procedure: Virtual colonoscopy|Procedure: Colon capsule","Hospices Civils de Lyon","Both","50 Years and older   (Adult, Senior)","","664","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","2012-757","September 18, 2015","June 2014","March 2015","September 23, 2015","September 2015","No Study Results Posted","COCAGI","February 2015","Acceptance rate of colonic capsule versus virtual colonoscopy.|Success rate of virtual colonoscopy and colon capsule: full review rate of colonic mucosa.|Failure rate of examinations by cause|Diagnostic performance of virtual colonoscopy and colon capsule|Achievement rate of optical colonoscopy if a lesion is found, either by virtual colonoscopy, or by colonic capsule|Sensitivity of virtual colonoscopy and colonic capsule for the diagnosis of cancer, significant additional colorectal polyps, or other polyps|Specificity of virtual colonoscopy and colonic capsule for the diagnosis of cancer, significant additional colorectal polyps, or other polyps|Positive and negative predictive values of virtual colonoscopy and colonic capsule for the diagnosis of cancer, significant additional colorectal polyps, or other polyps|Percentage of cancers diagnosed through virtual colonoscopy or colonic capsule|Additional costs generated by the implementation of a complementary action of screening for patients with a positive FOBT and did not realize optical colonoscopy","https://ClinicalTrials.gov/show/NCT02558881"
257,"NCT00116506","Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Neoplasm Metastasis","Drug: erlotinib|Drug: FOLFOX|Drug: bevacizumab","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Genentech, Inc.|Sanofi-Synthelabo","Both","18 Years and older   (Adult, Senior)","Phase 2","35","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-365","June 29, 2005","January 2005","July 2007","December 19, 2007","December 2007","No Study Results Posted","null","July 2007","Evaluate 1 year progression-free survival|Determination of the observed response rate, median duration of response and overall survival","https://ClinicalTrials.gov/show/NCT00116506"
258,"NCT01549067","The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey","Recruiting","No Results Available","Advanced Malignant Neoplasm|Colorectal Cancer","","Chinese Medical Doctor Association","Both","Child, Adult, Senior","","3700","Other","Observational","Time Perspective: Cross-Sectional","Sprit","March 6, 2012","September 2011","December 2012","March 13, 2012","March 2012","No Study Results Posted","Sprit","December 2012","","https://ClinicalTrials.gov/show/NCT01549067"
259,"NCT02149784","Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients","Recruiting","No Results Available","Colorectal Cancer Metastatic","Procedure: Surgical resection of primary tumor","Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","480","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20140413","May 18, 2014","September 2015","July 2019","November 18, 2015","November 2015","No Study Results Posted","null","July 2016","Overall survival|Number of Participants with Adverse Events both in surgery group and chemotherapy group","https://ClinicalTrials.gov/show/NCT02149784"
260,"NCT02056691","EDICT - Exercise inDuced Changes In Colorectal Cancer Tissues","Recruiting","No Results Available","Colorectal Cancer","Procedure: Exercise programme|Procedure: Muscle biopsy","The Royal Bournemouth Hospital","Both","18 Years and older   (Adult, Senior)","","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","ed-1","February 5, 2014","October 2014","October 2017","April 4, 2016","April 2016","No Study Results Posted","EDICT","April 2017","Assess the feasibility of carrying out a two week preoperative exercise program in patients with colorectal cancer and assess the effects of preoperative exercise on the proliferation of colorectal cancer cells|Changes in molecular markers for the effects of exercise and/or diet on AMPK/ mammilian target of rapamycin signalling pathway|Changes in AKT expression normal colonic tissue|Assessing Apoptosis index|Changes in molecular markers that may mediate or modify exercise/dietary effects in tumour tissues|Assessing gene expression profiles|Assessing the 11 gene signature|Blood methylation profiles.|Cortisol levels|Postoperative complications up to 30 days postoperatively|Moderator variables|Irisin levels","https://ClinicalTrials.gov/show/NCT02056691"
261,"NCT02651974","Evidence Based Colorectal Cancer Screening for the Uninsured - Sub-study","Enrolling by invitation","No Results Available","Colorectal Cancer","Behavioral: Control condition|Behavioral: Cost condition|Behavioral: Cost/Future condition","University of Texas Southwestern Medical Center|Cancer Prevention Research Institute of Texas","Both","50 Years to 64 Years   (Adult)","","2124","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Health Services Research","082012-086 Sub-study","November 2, 2015","September 2015","August 2018","January 19, 2016","January 2016","No Study Results Posted","null","May 2018","Percentage of individuals who complete FIT screening measured by return FIT kit|Percentage of individuals who receive a positive (abnormal) FIT result that then call to receive additional information about potential follow-up test.|Percentage of individuals who schedule a pre-operative clinic visit (if recommended).|Percentage of individuals who complete a colonoscopy (if recommended).|Pre-post analysis of current results reporting strategy (which will utilize a white envelope for normal results, and a red envelope for abnormal results) to prior generic envelope for FIT result reporting for both normal and abnormal results.","https://ClinicalTrials.gov/show/NCT02651974"
262,"NCT00208546","Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: 21Capecitabine + bevacizumab + oxaliplatin|Drug: 1Capecitabine + oxaliplatin + bevacizumab + cetuximab","Dutch Colorectal Cancer Group|Koningin Wilhelmina Fonds|Sanofi|Roche Pharma AG|Immunicon","Both","18 Years and older   (Adult, Senior)","Phase 3","750","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CAIRO2","September 13, 2005","June 2005","December 2009","February 1, 2012","February 2012","No Study Results Posted","null","July 2009","progression free survival|toxicity|tumour response (complete response [CR], partial response [PR] or stable disease [SD])|response duration|overall survival|quality of life|translational research","https://ClinicalTrials.gov/show/NCT00208546"
263,"NCT00689364","Comprehensive Therapy to Relieving the Risk of Recurrence and Metastasis for Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","","Ministry of Science and Technology of the People´s Republic of China|National Research Centre of Complementary and Alternative Medicine, Norway","Both","18 Years to 75 Years   (Adult, Senior)","","480","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WJB730603","May 27, 2008","April 2007","March 2014","July 20, 2011","June 2011","No Study Results Posted","null","March 2012","The recurrence and metastasis rates for 1、2、3、4 and 5-year.|Survival index: the survival rate for1、2、3、4 and 5-year.","https://ClinicalTrials.gov/show/NCT00689364"
264,"NCT01569620","Improving Colorectal Cancer Screening for Diverse Hispanics in Urban Primary Care","Completed","No Results Available","Colorectal Cancer Screening","Behavioral: Best clinical practices plus culturally targeted print materials|Behavioral: Best clinical practices plus standard print materials|Behavioral: Best clinical practices alone","Icahn School of Medicine at Mount Sinai|Memorial Sloan Kettering Cancer Center","Both","50 Years to 85 Years   (Adult, Senior)","","386","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","GCO 08-1159","March 29, 2012","April 2012","December 2015","January 28, 2016","January 2016","No Study Results Posted","null","December 2015","Change from baseline of colonoscopy at 3 months, 6 months, and 12 months.","https://ClinicalTrials.gov/show/NCT01569620"
265,"NCT02119026","Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Capecitabine|Drug: Capecitabine|Drug: Bevacizumab|Drug: Oxaliplatin|Drug: Irinotecan","Prof. Dr. Werner Scheithauer|Medical University of Vienna","Both","18 Years and older   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25153_PASSION","April 1, 2014","February 2011","December 2014","May 6, 2014","May 2014","No Study Results Posted","PASSION","December 2014","Efficacy Duration of disease control by tumor assessment (CT/MRI/clinical examination)|first line progression free survival (PFS)|second line PFS|overall response rate|time to response|duration of response|overall survival of XELIRI plus bevacizumab and XELOX plus bevacizumab|tumour assessments (based on RECIST criteria)","https://ClinicalTrials.gov/show/NCT02119026"
266,"NCT00172757","Association of Colorectal Cancer With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations in Taiwan","Recruiting","No Results Available","Colorectal Cancer","","National Taiwan University Hospital","Both","Child, Adult, Senior","Phase 2","1000","Other","Observational","Observational Model: Case Control|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","9361701298","September 12, 2005","January 2002","June 2005","November 25, 2005","January 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00172757"
267,"NCT02812550","Full-spectrum Endoscopy in Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Procedure: colonoscopy procedure","Hospital del Río Hortega","Both","50 Years to 69 Years   (Adult, Senior)","","249","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","GRS 1073/A/15","June 15, 2016","May 2015","June 2016","June 21, 2016","June 2016","No Study Results Posted","null","May 2016","adenoma detection rate in the two different colonoscopies|time to caecal intubation in each group|total procedure time in each group|Adverse events|advance adenoma rate in each group|polyp detection rate in right and left colon in each group|polyp retrieval rate in each group|caecal intubation rate in each group|colonoscopy withdrawal time","https://ClinicalTrials.gov/show/NCT02812550"
268,"NCT01839539","Study of DC-CIK to Treat Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Biological: dendritic and cytokine-induced killer cells","Guangxi Medical University","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRC-01","April 14, 2013","March 2013","March 2018","April 22, 2013","April 2013","No Study Results Posted","null","March 2018","Progression-free survival (PFS)|Overall survival (OS)|Quality of life (QOL)|Laboratory findings (The number of CD3+ (or CD8+ or CD4+ or CD56+)T cell)","https://ClinicalTrials.gov/show/NCT01839539"
269,"NCT01754272","A Non-Interventional Follow-Up to the VELOUR Study - Translational Research","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","","Katholieke Universiteit Leuven","Both","18 Years and older   (Adult, Senior)","","1226","Other","Observational","Time Perspective: Retrospective","ADX11080","December 12, 2012","January 2012","December 2013","December 18, 2012","December 2012","No Study Results Posted","null","December 2013","Primary colorectal cancer tumor blocks|Metastatic tumor blocks","https://ClinicalTrials.gov/show/NCT01754272"
270,"NCT02567045","Uptake to Colorectal Cancer Screening in Familial-risk Population","Not yet recruiting","No Results Available","Colorectal Cancer|Screening Uptake of Colonoscopy and FIT","Procedure: annual FIT and colonoscopy in case of a positive test|Procedure: colonoscopy with sedation","Hospital Universitario de Canarias","Both","18 Years to 40 Years   (Adult)","Phase 3","1076","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","Colorectal cancer screening","September 29, 2015","October 2015","March 2019","October 1, 2015","October 2015","No Study Results Posted","null","December 2018","Proportion of patients who participate in each screening arm|Efficacy measure: QALYs (Quality adjusted life years).|Costs measure: cost (euros) of the procedures associated with each screening strategy and treatment of advanced neoplastic lesions","https://ClinicalTrials.gov/show/NCT02567045"
271,"NCT00696345","Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay","Completed","No Results Available","Colorectal Cancer","","Epigenomics, Inc","Both","40 Years and older   (Adult, Senior)","","700","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","Septin-9-2006","June 10, 2008","January 2005","February 2007","June 13, 2008","June 2008","No Study Results Posted","null","October 2006","","https://ClinicalTrials.gov/show/NCT00696345"
272,"NCT01975454","Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Chemotherapy|Drug: Herbal therapy","Shanghai University of Traditional Chinese Medicine|Chongqing Three Gorges Central Hospital","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","72","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TCM-mCRC|LHYY-11495801300","October 23, 2013","April 2012","December 2016","November 23, 2015","October 2015","No Study Results Posted","null","June 2016","Progression-free survival(PFS)|Overall Survival (OS)|Symptoms|Adverse events","https://ClinicalTrials.gov/show/NCT01975454"
273,"NCT02863172","Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes","Recruiting","No Results Available","Hereditary Colorectal Cancer Syndrome","Behavioral: Questionnaires|Procedure: Blood Draw/Saliva Sample","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","","2000","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","PA11-0567|2015-00051016-Y1|2016-00051406","August 8, 2016","May 2012","null","August 10, 2016","August 2016","No Study Results Posted","null","May 2022","Variations in Clinical Features Compared Between Proband Group and Family Member Group|Variations in the Overall Disease Phenotype Between Proband Group and Family Member Group","https://ClinicalTrials.gov/show/NCT02863172"
274,"NCT01946282","Evidence-Based Colorectal Cancer Screening for the Uninsured","Enrolling by invitation","No Results Available","Colorectal Cancer","Other: FIT Invitation Only|Other: FIT plus Incentive","University of Texas Southwestern Medical Center|Cancer Prevention Research Institute of Texas","Both","50 Years to 64 Years   (Adult)","","10000","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Health Services Research","PP120229 (IRB# 082012-86)","September 13, 2013","September 2013","August 2018","December 29, 2015","December 2015","No Study Results Posted","null","May 2018","screening rate improvement after expanding screening outreach to all unscreened patients.|rates of initial and repeat screening completion among 1) Patients offered a modest financial incentive to complete screening, in addition to outreach invitations, vs. 2) Patients offered outreach invitations alone.","https://ClinicalTrials.gov/show/NCT01946282"
275,"NCT00147134","A Trial to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Procedure: open colectomy|Procedure: laparoscopic colectomy","Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan","Both","20 Years to 75 Years   (Adult, Senior)","Phase 3","1050","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG0404|C000000105","September 5, 2005","November 2004","March 2014","August 2, 2009","August 2009","No Study Results Posted","null","March 2014","Overall survival|Relapse-free survival|Short-term clinical outcomes|Adverse events|The proportion of conversion from LAP to OPEN|The proportion of completion of LAP","https://ClinicalTrials.gov/show/NCT00147134"
276,"NCT02106806","Zinc Supplementation on Markers of Oxidative Stress in Post Operative Colorectal Cancer During Chemotherapy Cycles","Completed","No Results Available","Chemotherapy|Colorectal Cancer","Dietary Supplement: Zinc|Other: Placebo","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","Both","18 Years and older   (Adult, Senior)","","55","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","FAPESP 2011/07867-4","March 31, 2014","May 2011","December 2012","April 3, 2014","April 2014","No Study Results Posted","null","October 2011","oxidative stress markers|FACIT-F","https://ClinicalTrials.gov/show/NCT02106806"
277,"NCT00228189","Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients","Completed","No Results Available","Colorectal Cancer|Liver Metastases","Biological: CEA-loaded dendritic cell vaccine","Radboud University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","920-03-250|NWO920-03-250","September 27, 2005","December 2003","November 2010","November 26, 2010","November 2010","No Study Results Posted","null","November 2010","immunological response against carcinoembryonic antigen and the control protein KLH|Toxicity","https://ClinicalTrials.gov/show/NCT00228189"
278,"NCT01304602","A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Irinotecan|Drug: BKM120","University of Kansas Medical Center|University of Kansas Medical Center Research Institute","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12480","February 18, 2011","February 2011","January 2016","November 30, 2015","November 2015","No Study Results Posted","null","April 2014","Maximum tolerated dose|area under the plasma concentration versus time curve (AUC) of irinotecan|Change in tumor size|Peak Plasma Concentration (Cmax) of irinotecan|biological half-life of irinotecan|Peak Plasma Concentration (Cmax) of BKM120|area under the plasma concentration versus time curve (AUC) of BKM120|Biological half life of BKM120","https://ClinicalTrials.gov/show/NCT01304602"
279,"NCT02842203","Use of ctDNA for Monitoring of Stage III Colorectal Cancer","Not yet recruiting","No Results Available","Stage III Colorectal Cancer","","University of Pittsburgh|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","150","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PRO16020374|U01CA152753","July 20, 2016","September 2016","September 2021","July 21, 2016","July 2016","No Study Results Posted","null","September 2021","ctDNA assessment and relation to clinical outcome|ctDNA versus CEA","https://ClinicalTrials.gov/show/NCT02842203"
280,"NCT01589900","Identification the Expression of Sox2 in Colorectal Cancer Tissues","Completed","No Results Available","Colorectal Cancer","","Sun Yat-sen University","Both","24 Years to 79 Years   (Adult, Senior)","","136","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SYSU","April 30, 2012","January 2005","March 2012","May 2, 2012","May 2012","No Study Results Posted","null","December 2006","","https://ClinicalTrials.gov/show/NCT01589900"
281,"NCT01911988","Study of Association Between Peripheral Immune Cells and Recurrence in Stage II/III Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","Both","18 Years to 90 Years   (Adult, Senior)","","1","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XHGC 001","July 23, 2013","June 2013","null","October 20, 2014","October 2014","No Study Results Posted","PICC-1","December 2020","Disease Free Survival|5 years overall survival","https://ClinicalTrials.gov/show/NCT01911988"
282,"NCT00396487","Tailored Treatment in Metastatic Colorectal Cancer","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat","Vejle Hospital","Both","60 Years and older   (Adult, Senior)","Phase 3","1","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TT-2006-002957-56","November 6, 2006","November 2006","February 2008","June 10, 2015","June 2015","No Study Results Posted","null","null","The primary end point is|Response according to RECIST criteria.|Secondary end points are|Progression free survival|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00396487"
283,"NCT00713128","Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy","Completed","No Results Available","Colorectal Cancer","","Steward St. Elizabeth's Medical Center of Boston, Inc.","Both","18 Years and older   (Adult, Senior)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","00455","July 7, 2008","April 2008","December 2009","April 11, 2011","February 2009","No Study Results Posted","null","December 2009","frequency of delayed emesis (vomiting/retching)|Freq. of mild-severe nausea D 2-6 Freq. use of antiemetics D 2-6, Pts.with complete response(no emesis/use of rescue antiemtics)D 1, Pts. with total control (no:emesis,nausea, use of rescue antiemetics)D 2-6, Overall satisfaction","https://ClinicalTrials.gov/show/NCT00713128"
284,"NCT00912743","Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status","Completed","No Results Available","Colorectal Cancer","Drug: olaparib","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","33","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D9010C00008|AGICC 09CRC01","May 28, 2009","May 2009","March 2012","May 20, 2013","May 2013","No Study Results Posted","null","March 2012","Tumor response as assessed by RECIST","https://ClinicalTrials.gov/show/NCT00912743"
285,"NCT00677924","Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer","Terminated","Has Results","Colorectal Cancer","Drug: Zalutumumab","Genmab","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","9","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEN206","May 13, 2008","April 2008","April 2009","November 21, 2011","November 2011","September 12, 2011","GEN206","April 2009","Adverse Events|Best Overall Response","https://ClinicalTrials.gov/show/NCT00677924"
286,"NCT01801930","A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: OCV-103 and OCV-104|Drug: OCV-103 and OCV-104|Drug: OCV-103 and OCV-104|Drug: OCV-103 and OCV-104","Otsuka Pharmaceutical Co., Ltd.","Both","20 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","293-12-001","February 27, 2013","March 2013","May 2016","April 1, 2016","April 2016","No Study Results Posted","null","May 2016","Dose Limiting Toxicity|Adverse Events|Tumor response|Immune-response","https://ClinicalTrials.gov/show/NCT01801930"
287,"NCT02071069","Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer","Recruiting","No Results Available","Incurable Colorectal Cancer|RAS-wild-type","Drug: Cetuximab|Drug: irinotecan|Drug: fluorouracil","Tianshu Liu|Shanghai Zhongshan Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","54","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZS-ON-05","February 19, 2014","July 2013","July 2016","November 17, 2015","November 2015","No Study Results Posted","null","May 2016","The progression free-survival|Overall survival|Grade 3 and 4 adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT02071069"
288,"NCT02700555","Surveillance of Metabolic Parameters in Patients With Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","","Kangbuk Samsung Hospital","Both","20 Years to 80 Years   (Adult, Senior)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CA02","February 24, 2016","February 2016","October 2022","August 29, 2016","August 2016","No Study Results Posted","SPRING","October 2020","Incidence of newly developed diabetes mellitus|Pre-operative incidence of diabetes|Incidence of developed poorly controlled glucose level|3-year recurrence-free survival & 5-year recurrence-free survival","https://ClinicalTrials.gov/show/NCT02700555"
289,"NCT00952016","Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency","Recruiting","No Results Available","Advanced Colorectal Cancer","Drug: Methotrexate","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 2","29","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCR3107","July 31, 2009","February 2009","July 2014","December 3, 2013","August 2009","No Study Results Posted","MESH","July 2014","Objective response rate, to include complete response and partial response, as defined radiologically using RECIST (Response, Evaluation Criteria in Solid Tumours) on imaging CT scans performed during treatment.|Disease stabilisation rate; progression free survival; 1 year survival and median overall survival; Quality of Life assessment; toxicity assessment.","https://ClinicalTrials.gov/show/NCT00952016"
290,"NCT00063427","Study Evaluating MAC-321 in Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms|Colonic Neoplasms|Rectal Neoplasms","Drug: MAC-321","Wyeth is now a wholly owned subsidiary of Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","3128K1-200","June 26, 2003","null","February 2004","August 20, 2009","August 2009","No Study Results Posted","null","February 2004","","https://ClinicalTrials.gov/show/NCT00063427"
291,"NCT01531595","Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Bevacizumab plus alternating Xelox/Xeliri","Pia Osterlund|Helsinki University Central Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-003137-33","February 3, 2012","February 2012","December 2025","March 25, 2015","March 2015","No Study Results Posted","null","December 2025","Resectability|Efficacy|Response","https://ClinicalTrials.gov/show/NCT01531595"
292,"NCT00868569","Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer","Recruiting","No Results Available","Liver Metastasis|Colorectal Cancer","Procedure: TACE + folfox 4|Procedure: TAC + folfox4","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-03","March 24, 2009","January 2008","December 2010","March 24, 2009","March 2009","No Study Results Posted","null","December 2010","overall survival|resection rate of liver metastasis progression-free survival","https://ClinicalTrials.gov/show/NCT00868569"
293,"NCT02785068","Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: MM-151|Drug: nal-IRI|Drug: Leucovorin|Drug: 5-FU","Merrimack Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","28","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM-151-06-12-04","May 11, 2016","July 2016","October 2018","August 2, 2016","August 2016","No Study Results Posted","null","May 2018","To find the phase II dose of MM-151 based on safety and tolerability of MM-151 + nal-IRI + 5-FU + Leucovorin that will be assessed through evaluation of dose limiting toxicity reporting.|To correlate disease response according to RECIST with levels of irinotecan and SN-38 in tumor tissue|The number of participants with adverse events (AE) related to treatment with MM-151 + nal-IRI + 5-FU + leucovorin, assessed according to NCI CTCAE v4.0|The PK parameters of MM-151 and nal-IRI will be described per Cmax|The PK parameters of MM-151 and nal-IRI will be described per AUC|Objective response based on RECIST|Measure pre-treatment and on-treatment levels of EGFR ligands|Presence of anti-drug antibodies will be assessed","https://ClinicalTrials.gov/show/NCT02785068"
294,"NCT02138370","Comprehensive Immune-landscape in Localized Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Immune Landscape","","University of Zurich|Medical University of Graz","Both","18 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Immuno_CRC_001","May 12, 2014","April 2015","null","May 27, 2015","May 2015","No Study Results Posted","null","September 2016","Time to disease recurrence|overall survival","https://ClinicalTrials.gov/show/NCT02138370"
295,"NCT00005586","Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed","Completed","No Results Available","Colorectal Cancer","Drug: L-leucovorin|Drug: fluorouracil|Procedure: adjuvant therapy","Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","2500","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000067660|NCRI-QUASAR1|EU-99053|UKCCCR-QUASAR1|ISRCTN82375386","May 2, 2000","October 1997","null","December 17, 2013","March 2007","No Study Results Posted","null","null","All-cause mortality|Death from colorectal cancer|Disease recurrence","https://ClinicalTrials.gov/show/NCT00005586"
296,"NCT00483834","A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Bevacizumab|Drug: Irinotecan|Drug: Capecitabine","University Health Network, Toronto|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XELIRI-A","June 6, 2007","December 2006","July 2011","March 19, 2012","March 2012","No Study Results Posted","null","July 2011","To determine the objective response rate (ie. the rate of partial response plus complete response as defined by RECIST criteria) of irinotecan, capecitabine and bevacizumab (XELIRI-A) in patients with previously untreated metastatic colorectal cancer.","https://ClinicalTrials.gov/show/NCT00483834"
297,"NCT00537823","Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement","Terminated","No Results Available","Colorectal Cancer|Metastases","Drug: Cetuximab|Drug: Bevacizumab|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Fluorouracil","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","Phase 2","9","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07-0182","September 27, 2007","June 2007","July 2011","July 22, 2013","July 2013","No Study Results Posted","null","December 2009","Total postoperative complication rate (Fraction of patients with any grade of complication I-V)|Major postoperative complication rate (Fraction of patients with any complication grades IV and V)|All-cause mortality postoperatively|Study postoperative recurrence patters (liver only vs distant disease)|Calculate liver recurrence-free survival at one, three, and five years|Document the histologic hepatic toxicity at operation|Provide the nonalcoholic steatohepatitis score (0-3)|Provide the liver injury scale score (0-27)|Describe the effect of preoperative chemotherapy on tumor size|Calculate change in tumor size from pretreatment to preoperative CT scan","https://ClinicalTrials.gov/show/NCT00537823"
298,"NCT02837159","A Mobile Aplication for the Promotion of Healthy Lifestyle Habits in Patients With Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Cancer","Other: mHealth application","Universidad de Granada","Both","18 Years to 85 Years   (Adult, Senior)","Phase 1|Phase 2","54","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","CO217","July 14, 2016","October 2016","July 2019","July 19, 2016","July 2016","No Study Results Posted","null","July 2017","Body Mass Index|Fat mass|Wait circunferemce|Hip circunferemce|Expenditure energy|Eating habits|Quality of life|Cardiorespiratory fitness|Isometric abdominal strength|Lower-body flexibility","https://ClinicalTrials.gov/show/NCT02837159"
299,"NCT01047475","A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)","Completed","Has Results","Colorectal Cancer","Drug: MB-6|Drug: Placebo","Microbio Co Ltd","Both","20 Years and older   (Adult, Senior)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MB104CLCT01","December 22, 2009","October 2009","December 2011","April 28, 2015","April 2015","April 28, 2015","null","April 2011","The Primary Efficacy Endpoint of This Study is the Best Overall Response (Complete Response + Partial Response)","https://ClinicalTrials.gov/show/NCT01047475"
300,"NCT01251666","Comparison of Hemoccult, Magstream and OC-Sensor Faecal Occult Blood Tests in Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Other: Colonoscopy","University Hospital, Caen|National Cancer Institute, France|Ligue contre le cancer, France","Both","50 Years to 74 Years   (Adult, Senior)","Phase 3","19797","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Screening","2008-A01463-52","November 29, 2010","June 2008","August 2012","August 31, 2012","August 2012","No Study Results Posted","HeMO","June 2012","Ratio of sensitivities (RSN) for detection of advanced neoplasias|Ratio of False Positives (RFP) for detection of invasive cancers|RFP for detection of advanced neoplasias|Relative Receiver Operating Characteristics(ROC) curves|Detection rate of invasive cancer|Detection rate of advanced neoplasias|Cost-effectiveness analysis|Predictive positive value for detection of invasive cancers|Predictive value for detection of advanced neoplasias|Positivity rate","https://ClinicalTrials.gov/show/NCT01251666"
301,"NCT02226289","Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment","Recruiting","No Results Available","Neoplasm|Colorectal Cancer|Metastatic Neoplasm","Drug: Bevacizumab","Sixth Affiliated Hospital, Sun Yat-sen University","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BATTLE","August 25, 2014","August 2014","November 2018","August 27, 2014","August 2014","No Study Results Posted","BATTLE","November 2016","Response rate|Overall survival|Progression free survival|Toxicity","https://ClinicalTrials.gov/show/NCT02226289"
302,"NCT01289288","A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese","Completed","No Results Available","Colorectal Cancer","Behavioral: Mailed printed materials and in-office training","Georgetown University|Temple University|National Cancer Institute (NCI)","Both","50 Years to 74 Years   (Adult, Senior)","Phase 1|Phase 2","480","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","2007-297|R01CA121023","February 2, 2011","July 2007","July 2012","May 20, 2013","May 2013","No Study Results Posted","CRC","July 2012","Receipt of CRC screening","https://ClinicalTrials.gov/show/NCT01289288"
303,"NCT02135757","Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","","PeriPharm|Personalized Medicine Partnership for Cancer","Both","18 Years and older   (Adult, Senior)","","23","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PMPC-02","May 8, 2014","August 2014","null","January 13, 2016","January 2016","No Study Results Posted","null","July 2017","The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting|Identification of blood biomarkers that confer significant improvement in progression-free survival in patients treated with panitumumab.","https://ClinicalTrials.gov/show/NCT02135757"
304,"NCT00868816","Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles","Completed","No Results Available","Colorectal Cancer","Drug: 12 cycles of oxaliplatine based adjuvant chemotherapy|Drug: 8 cycles of oxaliplatine based adjuvant chemotherapy","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-02","March 24, 2009","January 2005","December 2007","March 24, 2009","March 2009","No Study Results Posted","null","December 2007","disease-free survival|overall survival liver metastasis-free survival","https://ClinicalTrials.gov/show/NCT00868816"
305,"NCT02181556","Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFIR + Aflibercept","Federation Francophone de Cancerologie Digestive","Both","18 Years and older   (Adult, Senior)","Phase 2","54","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FFCD 1302","July 2, 2014","October 2014","November 2017","August 10, 2016","May 2016","No Study Results Posted","null","February 2017","progression-free survival rate|Overall survival|Time to progression|Progression-free survival|Objective response rate|Disease control rate|Best response|Toxicities","https://ClinicalTrials.gov/show/NCT02181556"
306,"NCT00874406","Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: tac + folfox4|Drug: folfox4","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-04","April 1, 2009","January 2008","December 2009","April 1, 2009","April 2009","No Study Results Posted","null","December 2009","progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT00874406"
307,"NCT02439385","Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis","Enrolling by invitation","No Results Available","Colorectal Cancer","Drug: Avastin/FOLFIRI|Dietary Supplement: Curcumin","Gachon University Gil Medical Center|Aju Pharm","Both","20 Years and older   (Adult, Senior)","Phase 2","44","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GAIRB2015-87","May 2, 2015","August 2015","March 2019","August 19, 2016","August 2016","No Study Results Posted","null","May 2017","Progression-free survival|Overall survival rate|Overall response rate|Safety (assessed by toxicity grades defined by NCI-CTCAE (version 4.0)|Quality of life (QoL)|Fatigue (FACIT-Fatigue scale (version 4, Korean version)","https://ClinicalTrials.gov/show/NCT02439385"
308,"NCT02264496","Prospective Randomised Trial of Exercise and / or Antioxidants in COlorectal Cancer Patients Undergoing Surgery.","Completed","No Results Available","Colorectal Cancer","Behavioral: Exercise","Hull and East Yorkshire Hospitals NHS Trust|University of Hull","Both","18 Years and older   (Adult, Senior)","","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13/YH/0322 V3","October 7, 2014","March 2014","November 2015","February 18, 2016","February 2016","No Study Results Posted","PEACOCS","August 2015","Length of stay|Antioxidant capacity|Exercise capacity|Complications|Quality of Life","https://ClinicalTrials.gov/show/NCT02264496"
309,"NCT02715882","Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: CBLB502|Drug: Placebo","BioLab 612 LLC|Cleveland BioLabs, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","BL612-CBLB502","March 17, 2016","November 2015","November 2016","July 19, 2016","July 2016","No Study Results Posted","null","September 2016","Safety and tolerability evaluation as measured by adverse events and assessed as changes in vital signs and clinical laboratory measurements, physical examination findings and ECG readings|Assessment of immune cells change in tumor by H&E and ICH staining|Determination of levels of cytokine IL-6 in blood by multiplex assays|Determination of levels of cytokine IL-8 in blood by multiplex assays|Determination of levels of cytokine IL-10 in blood by multiplex assays|Determination of levels of cytokine G-CSF in blood by multiplex assays|Determination of levels of cytokine TNFа in blood by multiplex assays|Specific T-cell responses measured by ELIspot|Antibody titer to CBLB502 as measured by ELISA|Blood leukocytes by FACS","https://ClinicalTrials.gov/show/NCT02715882"
310,"NCT02907086","Circulating Tumor Material in Colorectal Cancer and Melanoma","Recruiting","No Results Available","Colorectal Cancer and Melanoma","Other: blood collection","Abramson Cancer Center of the University of Pennsylvania","Both","18 Years and older   (Adult, Senior)","","110","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","UPCC 12916","September 13, 2016","August 2016","null","September 15, 2016","September 2016","No Study Results Posted","null","August 2020","Number of blood samples collected","https://ClinicalTrials.gov/show/NCT02907086"
311,"NCT02665312","Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine","Recruiting","No Results Available","Colorectal Cancer","","Fondazione del Piemonte per l'Oncologia","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CheckPoint","January 23, 2016","January 2016","January 2019","September 6, 2016","September 2016","No Study Results Posted","null","January 2018","Assessment of the incidence of cardiovascular events during the first three cycles of therapy with capecitabine or 5-FU","https://ClinicalTrials.gov/show/NCT02665312"
312,"NCT01575340","Study to Assess the Effect of Consumption of Fish Oil Encapsulated on Inflammatory Markers in Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Inflammation","Dietary Supplement: fish oil encapsuled","Universidade Federal de Santa Catarina|Fundação de Amparo à Pesquisa e a Inovação do Estado de Santa Catarina|Centro de Pesquisas Oncológicas de Florianópolis","Both","19 Years and older   (Adult, Senior)","","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","20.179/2010-0","October 5, 2011","July 2011","July 2012","September 5, 2012","September 2012","No Study Results Posted","null","May 2012","change in inflammatory markers|change in body composition|change in nutritional status|Changes in plasma lipid profile|assessing the risk of inflammatory and nutritional complications","https://ClinicalTrials.gov/show/NCT01575340"
313,"NCT01566942","FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: Oxaliplatin|Drug: Irinotecan","Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-170","March 26, 2012","June 2012","June 2017","March 27, 2012","March 2012","No Study Results Posted","null","May 2014","disease-free survival（DFS）|overall survival(OS)","https://ClinicalTrials.gov/show/NCT01566942"
314,"NCT01367275","Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF","Terminated","No Results Available","Colorectal Cancer|Colorectal Adenocarcinoma","Drug: Brivanib|Drug: Irinotecan","M.D. Anderson Cancer Center|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 2","8","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-0378","June 3, 2011","August 2011","November 2013","January 7, 2015","January 2015","No Study Results Posted","null","November 2013","Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01367275"
315,"NCT01279278","Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?","Recruiting","No Results Available","Colorectal Cancer","Other: Co-signed letter|Other: Classical Letter","University of Paris 5 - Rene Descartes|Adeca 75|Société de Formation Thérapeutique du Généraliste|Hotel Dieu Hospital","Both","50 Years to 74 Years   (Adult, Senior)","","2700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","PAGEDOCC1","January 18, 2011","September 2010","April 2011","January 18, 2011","September 2010","No Study Results Posted","Pagedocc1","April 2011","Completion of Fecal Occult Blod Test|Measure the impact of co-signing on deadline for completion of the test after the mailing.|Compare the proportion of uninterpretable tests.|Compare the rate of completion of colonoscopy after a positive test (information received by ADECA in the follow-up), according to the specifications.","https://ClinicalTrials.gov/show/NCT01279278"
316,"NCT02119676","Study of Ruxolitinib in Colorectal Cancer Patients","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Ruxolitinib|Drug: Regorafenib|Drug: Placebo","Incyte Corporation","Both","18 Years and older   (Adult, Senior)","Phase 2","373","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","INCB18424-267","April 17, 2014","March 2014","October 2016","March 1, 2016","March 2016","No Study Results Posted","null","February 2016","Part 1: Determination of the dose of ruxolitinib that is safe and tolerable in combination with regorafenib as measured by the number of dose-limiting toxicities (DLTs) observed in the evaluation cohort|Part 2: Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate|Duration of Response|Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.|Disease Control","https://ClinicalTrials.gov/show/NCT02119676"
317,"NCT01959061","Efficacy and Safety Study of Raltitrexed to Treat Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: Raltitrexed|Drug: Oxaliplatin|Drug: lipiodol","Nanjing Chia-tai Tianqing Pharmaceutical","Both","18 Years and older   (Adult, Senior)","Phase 4","320","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NJCTTQ-01","September 18, 2013","September 2013","null","October 7, 2013","October 2013","No Study Results Posted","TACE","December 2014","lesion|ECOG","https://ClinicalTrials.gov/show/NCT01959061"
318,"NCT00752570","A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma","Completed","No Results Available","Cancer|Carcinoma|Colon Cancer|Colorectal Cancer|Gastrointestinal Cancer|Metastases|Metastatic Cancer|Metastatic Colorectal Cancer|Oncology|Rectal Cancer","Drug: AMG 386|Drug: AMG 386 Placebo|Drug: FOLFIRI","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","144","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","20070307","September 11, 2008","November 2008","June 2012","August 14, 2015","August 2015","No Study Results Posted","null","September 2010","To estimate the treatment effect as measured by progression free survival (PFS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo.|To evaluate other measures of efficacy or clinical response including objective response rate (ORR), duration of response (DOR), overall survival (OS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo|To evaluate progression free survival and measures of efficacy by KRAS status|To evaluate patient reported outcomes (PROs), relative dose intensity, incidence of anti AMG 386 antibody formation, pharmacokinetics of AMG 386 (Cmax and AUC) and safety (incidence of AEs and significant laboratory changes)","https://ClinicalTrials.gov/show/NCT00752570"
319,"NCT00354978","Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients","Completed","Has Results","Colorectal Cancer","Drug: 5-Fluorouracil|Drug: Bevacizumab|Drug: Leucovorin|Drug: Irinotecan","M.D. Anderson Cancer Center|Genentech, Inc.|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","49","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0614","July 18, 2006","January 2005","March 2011","September 14, 2011","September 2011","June 14, 2011","null","March 2011","Median Progression-free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00354978"
320,"NCT00991003","A New Method for Colorectal Cancer Screening: Colon Capsule Endoscopy Compared to Conventional Endoscopy","Completed","No Results Available","Colorectal Cancer","Procedure: Colon capsule endoscopy|Procedure: Conventional Colonoscopy","University Hospital, Basel, Switzerland","Both","18 Years to 85 Years   (Adult, Senior)","","59","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","EKBB25407","October 6, 2009","November 2007","May 2008","October 6, 2009","October 2009","No Study Results Posted","null","May 2008","The primary endpoint was the number of cancerous lesions and polyps detected on CCE compared to conventional colonoscopy|Secondary endpoints were completeness of the exam completeness, patient acceptance and adherence to preparation regimen","https://ClinicalTrials.gov/show/NCT00991003"
321,"NCT01279330","Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?","Recruiting","No Results Available","Colorectal Cancer","Other: Co-signed Letter|Other: Control","University of Paris 5 - Rene Descartes|Adeca 75|Société de Formation Thérapeutique du Généraliste|Hotel Dieu Hospital","Both","50 Years to 74 Years   (Adult, Senior)","","1569","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","PAGEDOCC2","January 18, 2011","September 2010","April 2011","January 18, 2011","September 2010","No Study Results Posted","Pagedocc2","April 2011","Completion of Fecal Occult Blod Test|Delays from receipt of the letter and the completion of the test.|Proportion of uninterpretable test.","https://ClinicalTrials.gov/show/NCT01279330"
322,"NCT01736904","wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients","Recruiting","No Results Available","Colorectal Cancer","Drug: wXELIRI regimen|Drug: FOLFIRI regimen","Fudan University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","wXELIRI vs FOLFIRI in CRC","November 21, 2012","May 2012","December 2015","November 26, 2012","November 2012","No Study Results Posted","null","December 2014","Progression free survival which is calculated from the start of treatment to disease progression or death|Objective response rate which includes complete response(CR) and partial response(PR) participants","https://ClinicalTrials.gov/show/NCT01736904"
323,"NCT01472770","A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Gemcitabine + Capecitabine","Vejle Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","49","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GemCap","November 1, 2011","October 2011","May 2014","December 3, 2014","December 2014","No Study Results Posted","GemCaP","May 2013","Rate of patients progression free at 3 months|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01472770"
324,"NCT02503150","Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Biological: APDC + Chemotherapy|Drug: Chemotherapy","Second Military Medical University|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Changhai Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Fudan University|Shanghai Changzheng Hospital|Zhejiang Cancer Hospital|Chinese PLA General Hospital|Beijing Cancer Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|RenJi Hospital|Second Affiliated Hospital, School of Medicine, Zhejiang University|First People's Hospital of Hangzhou|The 307th Hospital of Chinese People`s Liberation Army|Huashan Hospital|Ruijin Hospital|Shanghai Haixin Biotechnology Co. Ltd","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","480","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SMMU, Shanghai","July 16, 2015","July 2015","December 2020","July 29, 2015","July 2015","No Study Results Posted","null","December 2019","Progression Free Survival, PFS|Objective Response|Overall Survival, OS|Clinical benefit Rate|Quality of Life|Adverse Events","https://ClinicalTrials.gov/show/NCT02503150"
325,"NCT00384176","First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX","Active, not recruiting","Has Results","Colorectal Cancer","Drug: Cediranib|Drug: Bevacizumab|Drug: 5-fluorouracil ( in FOLFOX)|Drug: Leucovorin (in FOLFOX)|Drug: Oxaliplatin (in FOLFOX)","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","1814","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D8480C00013|Eudract Number 2005-003440-66","October 3, 2006","August 2006","December 2015","June 18, 2015","June 2015","March 7, 2012","HORIZON III","November 2009","Progression Free Survival|Overall Survival|Objective Response Rate|Duration of Response|Percentage Change in Tumour Size|Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)","https://ClinicalTrials.gov/show/NCT00384176"
326,"NCT02419677","Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases","Completed","No Results Available","Colorectal Cancer","Procedure: Radiofrequency ablation|Biological: Cytokine-induced killer cells","The First People's Hospital of Changzhou","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FirstPHChangzhou","April 9, 2015","January 2010","December 2014","April 14, 2015","April 2015","No Study Results Posted","null","December 2014","Recurrence-free survival|Adverse events","https://ClinicalTrials.gov/show/NCT02419677"
327,"NCT01032291","A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer","Terminated","Has Results","Colorectal Cancer","Drug: cetuximab|Drug: lenalidomide","Celgene Corporation|Celgene","Both","18 Years and older   (Adult, Senior)","Phase 2","51","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CC-5013-COLO-001|2009-012665-61","December 14, 2009","December 2009","January 2011","April 1, 2013","April 2013","April 1, 2013","null","January 2011","Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period|Percentage of Participants With a Response to Treatment During the Proof of Concept Period|Kaplan-Meier Estimates for Progression Free Survival (PFS)|Kaplan-Meier Estimates for Duration of Response|Percentage of Participants With Disease Control|Kaplan-Meier Estimates for Overall Survival|Participants With Treatment-Emergent Adverse Events (TEAE)","https://ClinicalTrials.gov/show/NCT01032291"
328,"NCT01591590","Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Other: FDG PET-CT|Other: Diffusion MRI|Other: Blood samples (plasma preparation and CTC)","Jules Bordet Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CORIOLAN|2011-006280-21","May 2, 2012","June 2012","June 2017","September 6, 2016","September 2016","No Study Results Posted","CORIOLAN","June 2017","Mortality|Tumour Progression","https://ClinicalTrials.gov/show/NCT01591590"
329,"NCT01212510","Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Other: Blood sampling","University Hospital, Rouen","Both","18 Years to 95 Years   (Adult, Senior)","","200","Other","Interventional","Endpoint Classification: Bio-availability Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2009/170/HP","September 29, 2010","October 2010","July 2016","August 16, 2016","August 2016","No Study Results Posted","Coca-Colon","July 2016","Prediction of tumor progression|Prediction of tumor response","https://ClinicalTrials.gov/show/NCT01212510"
330,"NCT00291785","Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: CT-2106|Drug: Folinic acid|Drug: 5-FU (fluorouracil)","CTI BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","48","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CAM201","February 14, 2006","January 2004","September 2008","June 6, 2011","June 2011","No Study Results Posted","null","August 2007","Phase I: determine the Maximum Tolerated Dose, dose limiting toxicities, safety profile and antitumor activity","https://ClinicalTrials.gov/show/NCT00291785"
331,"NCT01071655","Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|Drug: BVZ+XELOX","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","195","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-09-01(ML25052)|2009-012562-31","February 15, 2010","February 2010","November 2013","March 23, 2015","March 2014","No Study Results Posted","SETICC","November 2013","progression-free survival|overall survival|Objective response rate|% of patients whose disease becomes resectable|Adverse events|Evaluation of KRAS status as a molecular marker","https://ClinicalTrials.gov/show/NCT01071655"
332,"NCT00875771","Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Capecitabine+Irinotecan+Bevacizumab","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-08-03|EudraCT number:2008-004688-20","March 30, 2009","April 2009","September 2012","February 19, 2013","February 2013","No Study Results Posted","AVAXIRI","September 2012","Progression free survival (PFS)|overall survival (SG)|Overall Response rate|Toxicity|Duration of response|Quality of life|Rate of hepatic metastases resection","https://ClinicalTrials.gov/show/NCT00875771"
333,"NCT00444041","Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Bevacizumab","Austrian Society Of Surgical Oncology","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","43","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACO-ASSO-LM1","March 5, 2007","January 2007","December 2009","January 29, 2013","January 2013","No Study Results Posted","ASSO-LM1","December 2009","The primary objective of this study is the Resectability (R0) rate after neoadjuvant Bevacizumab in potentially resectable mCRC.|Feasibility with regards to GI bleeding and wound healing complications after surgery of liver metastases|Overall Response Rate (ORR)|Recurrence Free Survival (RFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00444041"
334,"NCT00692211","Interventions to Improve Colorectal Cancer Screening","Completed","Has Results","Colorectal Neoplasms","Other: Mailed fecal occult blood tests|Other: Mailed fecal immunochemical tests","VA Office of Research and Development","Both","50 Years to 80 Years   (Adult, Senior)","","404","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","SHP 08-177","June 3, 2008","June 2008","April 2009","April 28, 2015","April 2015","August 11, 2014","null","April 2009","Colorectal Cancer Screening","https://ClinicalTrials.gov/show/NCT00692211"
335,"NCT01386242","Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Recombinant anti-tumor and anti-virus protein for injection|Drug: Recombinant anti-tumor and anti-virus protein for injection|Other: Saline Injection|Drug: Recombinant anti-tumor and anti-virus protein for injection","The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Beijing Genova Biotech Company, Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 2","108","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","JH-RC-001","June 27, 2011","May 2011","May 2014","January 4, 2016","April 2015","No Study Results Posted","null","May 2013","Overall survival (OS)|Progression-free survival (PFS)|Quality of life (QoL)|Adverse Events(AEs)|pharmacodynamics|Disease Control Rate","https://ClinicalTrials.gov/show/NCT01386242"
336,"NCT01024504","Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Oxaliplatin|Drug: Capecitabine|Drug: Bevacizumab","Hellenic Oncology Research Group|University Hospital of Crete","Both","70 Years and older   (Senior)","Phase 2","46","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/06.12","November 26, 2009","March 2006","March 2010","April 8, 2010","April 2010","No Study Results Posted","null","March 2010","Overall response rate|Toxicity profile|Time to tumor progression|Overall survival","https://ClinicalTrials.gov/show/NCT01024504"
337,"NCT01193452","S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: S-1, Leucovorin|Drug: leucovorin, 5-fluorouracil","Fudan University","Both","65 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SL-eCRC","August 31, 2010","August 2010","February 2012","September 1, 2010","August 2010","No Study Results Posted","null","February 2011","response rate|progression free survival|disease control rate|time to treatment failure|overall survival|quality of life|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01193452"
338,"NCT00514761","Phase II Efficacy Study of AZD6244 in Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: AZD6244|Drug: Capecitabine","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D1532C00011","August 9, 2007","September 2006","July 2008","August 12, 2014","August 2014","No Study Results Posted","null","June 2007","Progression event count|safety and tolerability","https://ClinicalTrials.gov/show/NCT00514761"
339,"NCT00209742","Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: UFT|Drug: USEL/Leucovorin|Drug: Krestin","Hokkaido Gastrointestinal Cancer Study Group|Hokkaido University Hospital","Both","20 Years to 80 Years   (Adult, Senior)","Phase 3","340","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HGCSG-CAD","September 12, 2005","April 2005","December 2012","May 24, 2010","May 2010","No Study Results Posted","null","December 2012","3-years disease-free survival rate (DFS)|Dose intensity (compliance), 5-year disease-free survival rate, 3- and 5-year survival rate, incidence of other adverse drug reactions, QOL","https://ClinicalTrials.gov/show/NCT00209742"
340,"NCT01378143","Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy","Completed","No Results Available","Colorectal Cancer","Drug: OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI","Oncozyme Pharma Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","53","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OP-103-C","June 15, 2011","March 2011","July 2014","October 20, 2014","February 2013","No Study Results Posted","null","March 2014","Tumor size (CT scan)|Progression free survival (PFS)|Overall survival (OS)|Peak plasma concentration (Cmax) of OCZ103-OS|Number of participants with Adverse Events (AE) as a Measure of Safety and Tolerability|Objective response (OR)|Duration of response (DR)","https://ClinicalTrials.gov/show/NCT01378143"
341,"NCT00497107","Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: UFT, Calcium Folinate, PSK|Drug: UFT, Calcium Folinate","Iwate Medical University","Both","20 Years to 79 Years   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ICOG-CC01","July 5, 2007","July 2007","May 2013","July 30, 2008","July 2008","No Study Results Posted","ICOG","null","Disease-free survival|Overall survival, compliance, adverse events, QOL, tumor markers","https://ClinicalTrials.gov/show/NCT00497107"
342,"NCT00842257","Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: panitumumab","Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","32","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-287|20070602","February 10, 2009","September 2010","March 2011","May 3, 2010","May 2010","No Study Results Posted","null","March 2011","To determine the response rate of single agent panitumumab among patients with KRAS wild-type colorectal cancer previously treated with cetuximab.|To determine progression free survival, disease control rate and overall survival.","https://ClinicalTrials.gov/show/NCT00842257"
343,"NCT00757965","Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom","Recruiting","No Results Available","Colorectal Cancer","Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: questionnaire administration","Cancer Research UK|National Cancer Institute (NCI)","Both","18 Years to 69 Years   (Adult, Senior)","","2000","Other","Observational","","CDR0000598882|MREC-SEARCH-COLORECTAL|MREC-07/MRE05/17","September 22, 2008","February 2008","null","August 23, 2013","September 2008","No Study Results Posted","null","null","Acquisition of epidemiological information and biological material|Proportion of colorectal cancer incidence attributable to mutations in known predisposing genes (e.g., MLH1 and MSH2)|Exploration of mutations at other loci that may predispose to endometrial cancer","https://ClinicalTrials.gov/show/NCT00757965"
344,"NCT00041691","Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery","Terminated","No Results Available","Colorectal Neoplasms","Drug: hMN14 (labetuzumab)","Immunomedics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IM-T-hMN14-06","July 12, 2002","null","null","June 23, 2005","January 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00041691"
345,"NCT01651624","Screening for Colorectal Cancer With FOBT, Virtual Colonoscopy and Optical Colonoscopy. A Randomized Clinical Trial in the Florence District","Recruiting","No Results Available","Colorectal Cancer","Other: Invitation to screening","Cancer Prevention and Research Institute, Italy|University of Florence","Both","55 Years to 64 Years   (Adult)","","14000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","D65C09002710007|432/10","July 20, 2012","December 2012","December 2018","August 12, 2016","August 2016","No Study Results Posted","SAVE","December 2018","Participation rate to faecal occult blood test (FOBT), computed tomographic colonography (CTC) and colonoscopy|Detection rate for cancer or advanced adenomas of CTC versus three rounds of FOBT every second year|Referral rate for colonoscopy induced by primary CTC versus three rounds of FOBT every second year|Costs of the three different screening strategies proposed|Expected and perceived burden of colonoscopy and CTC|Number and type of complications in all groups","https://ClinicalTrials.gov/show/NCT01651624"
346,"NCT01941953","Metformin and 5-fluorouracil for Refractory Colorectal Cancer.","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Metformin and Fluorouracil","Instituto do Cancer do Estado de São Paulo","Both","16 Years and older   (Child, Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NP 273/12","September 4, 2013","November 2012","March 2015","April 6, 2015","April 2015","No Study Results Posted","null","November 2014","Disease Control Rate according to RECIST 1.1|Progression-free Survival|Overall Survival|Adverse Events","https://ClinicalTrials.gov/show/NCT01941953"
347,"NCT00044343","GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin","Completed","No Results Available","Colorectal Cancer","Drug: lapatinib","GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EGF20004","August 26, 2002","September 2002","October 2003","July 9, 2014","July 2014","No Study Results Posted","null","October 2003","Tumor response rate (complete or partial).|Time to response duration of response time to progression 4-month progression-free survival 6-month progression-free survival overall survival safety data biomarkers","https://ClinicalTrials.gov/show/NCT00044343"
348,"NCT02738606","Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA)","Recruiting","No Results Available","Colorectal Cancer|Other Diseases of Intestines","Procedure: Liver Resection Surgery|Drug: Chemotherapy|Behavioral: Survey","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-1133|NCI-2016-00740","April 12, 2016","May 2016","null","May 25, 2016","May 2016","No Study Results Posted","LUNA","May 2020","Overall Survival","https://ClinicalTrials.gov/show/NCT02738606"
349,"NCT00089635","ABX-EGF (Panitumumab) Monotherapy in Subjects With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer|Metastases","Drug: ABX-EGF (panitumumab)","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","203","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20030250","August 9, 2004","August 2004","December 2008","October 7, 2013","October 2013","August 6, 2010","null","May 2007","Objective Tumor Response Through Week 16|Duration of Response|Objective Tumor Response Throughout the Study|Time to Initial Objective Response|Progression-free Survival Time|Time to Disease Progression|Time to Treatment Failure|Duration of Stable Disease|Overall Survival","https://ClinicalTrials.gov/show/NCT00089635"
350,"NCT00043199","A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies","Active, not recruiting","No Results Available","Colorectal Neoplasms","Drug: Aroplatin (Liposomal NDDP, L-NDDP)","Aronex Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C-726-01","August 6, 2002","null","null","June 23, 2005","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00043199"
351,"NCT01740947","Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?","Recruiting","No Results Available","Colorectal Cancer","Drug: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)","H. Jaap Bonjer, PhD|MaagLeverDarm Stichting|VU University Medical Center","Both","Child, Adult, Senior","Phase 4","762","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2011-002211-28","November 27, 2012","January 2013","February 2021","December 8, 2015","December 2015","No Study Results Posted","SELECT","January 2018","anastomotic leakage and/or abscess|Disease free survival","https://ClinicalTrials.gov/show/NCT01740947"
352,"NCT01916239","Pomegranate Extract Supplementation in Colorectal Cancer Patients","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: Standard pomegranate extract formulation|Dietary Supplement: Pomegranate extract formulation-1|Dietary Supplement: Pomegranate extract formulation-2","National Research Council, Spain|Hospital Universitario Reina Sofia","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","CEBAS-CSIC-2","July 30, 2013","June 2012","April 2015","April 13, 2015","April 2015","No Study Results Posted","POMEcolon","February 2015","Phenolics and derived metabolites in colon tissues, plasma and urine.|Gene expression profiling in colon tissues|IGF-1 (insulin-like growth factor-1)|CEA (carcnoembryonic antigen)|Number of patients with adverse events as a measure of safety and tolerability|microRNA expression profiling in colon tissues","https://ClinicalTrials.gov/show/NCT01916239"
353,"NCT01910610","Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer Metastatic","Biological: FOLFIRI-cetuximab|Biological: mFOLFOX6-bevacizumab|Biological: OPTIMOX-bevacizumab|Biological: irinotecan-based chemo + bevacizumab|Biological: Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|Biological: XELOX + bevacizumab","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","474","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","STRATEGIC-1 C12- 2|2013-001928-19","July 23, 2013","July 2013","December 2019","September 12, 2016","August 2016","No Study Results Posted","STRATEGIC-1","December 2019","Duration of Disease Control|Quality of life|Overall Survival|Time to Failure of Strategy|Progression-free survival (PFS) per sequence of therapy|Tumor Response Rate (RR)|Curative salvage surgery rate|Safety profile of each treatment sequence","https://ClinicalTrials.gov/show/NCT01910610"
354,"NCT00316745","IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer","Suspended","No Results Available","Metastatic Colorectal Cancer","Drug: Campto, Topotesin|Drug: TS-1|Drug: L-Plat|Drug: Isovorin|Drug: 5-FU","Hokkaido Gastrointestinal Cancer Study Group|Hokkaido University Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","HGCSG0601|IFOX study","April 19, 2006","April 2006","March 2009","October 31, 2007","October 2007","No Study Results Posted","null","null","PFS of 1st line treatment|OS|objective tumor response|PFS of 2nd line treatment|safety","https://ClinicalTrials.gov/show/NCT00316745"
355,"NCT00689624","Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Irinotecan|Drug: Leukovorin|Drug: Oxaliplatin|Drug: 5-FLUOROURACIL|Drug: Cetuximab","University Hospital of Crete","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/06.21","May 29, 2008","July 2007","December 2010","September 25, 2015","September 2015","No Study Results Posted","null","December 2010","Objective Response Rate|Resectability rates|Time to Tumor Progression|Overall Survival|Toxicity profile|Pharmacogenomic analysis|Q-Twist analysis of Quality of life","https://ClinicalTrials.gov/show/NCT00689624"
356,"NCT01163305","PET-CT and Circulating Tumor Cells in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Metastasis","Drug: Chemotherapy","Chinese University of Hong Kong","Both","18 Years and older   (Adult, Senior)","","96","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COL016","June 24, 2010","June 2010","June 2016","January 28, 2016","January 2016","No Study Results Posted","null","June 2016","Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy|Overall survival|Progression-free survival|serum carcinoembryonic antigen (CEA) level|Circulating tumor cells level changes at 4 weeks after chemotherapy|RECIST-based tumor response at 10 weeks after chemotherapy","https://ClinicalTrials.gov/show/NCT01163305"
357,"NCT00681876","Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: Irinotecan|Drug: Avastin|Drug: Erbitux","Hellenic Oncology Research Group|University Hospital of Crete","Both","18 Years to 72 Years   (Adult, Senior)","Phase 2","16","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/05.32","May 19, 2008","April 2008","February 2010","February 12, 2013","February 2013","No Study Results Posted","null","February 2010","Time To Progression|Objective Response Rate|Toxicity profile|Quality of life, Symptoms improvement","https://ClinicalTrials.gov/show/NCT00681876"
358,"NCT01607957","Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: TAS-102|Drug: Placebo","Taiho Oncology, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TPU-TAS-102-301|2012-000109-66","May 24, 2012","June 2012","April 2016","December 21, 2015","December 2015","No Study Results Posted","RECOURSE","February 2016","Overall survival|Progression-free survival|Safety and tolerability evaluation will focus on adverse events and laboratory assessments","https://ClinicalTrials.gov/show/NCT01607957"
359,"NCT00854971","Efficacy Study of TKcell in Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Advanced Colorectal Cancer","Biological: TKCell","Binex","Both","19 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","86","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BX-TK-002","February 28, 2009","January 2009","January 2010","May 15, 2009","March 2009","No Study Results Posted","null","January 2010","Determine response rate|Determine safety of combination,time to treatment failure, overall survival time","https://ClinicalTrials.gov/show/NCT00854971"
360,"NCT00003225","Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: amifostine trihydrate|Drug: irinotecan hydrochloride","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|ALZA","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","23","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066087|P30CA016042|UCLA-HSPC-970304601B|ALZA-UCLA-HSPC-970304601B|NCI-G98-1390","November 1, 1999","July 1997","June 2001","September 30, 2015","July 2012","No Study Results Posted","null","March 2000","To assess the toxicity profile of Irinotecan and Ethyol when administered together on this schedule.|To assess the total dose of Irinotecan received per 6 week cycle|To determine incidence of Irinotecan-induced leukopenia and neutropenia|To determine the incidence of Irinotecan-induced diarrhea|To determine the response rate for patients with metastatic colorectal carcinoma receiving Irinotecan and Ethyol on this dosing schedule (as measured by time response, duration of response time to progression, time of treatment failure survival).|To determine the clinical benefit of intravenous Irinotecan and Ethyol in patients with colorectal cancer, as measured by performance status, analgesic consumption, quality of life and survival.","https://ClinicalTrials.gov/show/NCT00003225"
361,"NCT00885885","Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases","Completed","No Results Available","Colorectal Cancer","Drug: Panitumumab+FOLFOX-4|Drug: Panitumumab+FOLFIRI","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Amgen","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-08-04|EudraCT: 2008-006766-28","April 21, 2009","May 2009","August 2015","September 14, 2015","September 2015","No Study Results Posted","PLANET","August 2015","Objective response rate|% of patients whose disease becomes resectable|Time to resection|Duration of response|Progression-free survival|Time to treatment failure|Time to disease relapse following surgery.|Adverse Events|Evaluation of molecular predictive markers for response.","https://ClinicalTrials.gov/show/NCT00885885"
362,"NCT01550055","Study of Cetuximab to Treat KRAS Wild Type Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab plus Irinotecan Synchronously|Drug: Irinotecan and Cetuximab Subsequently","Shanghai Zhangjiang Biotechnology Limited Company|Shanghai Biomabs Pharmaceuticals Co Ltd","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","512","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CMAB009mCRCⅡ/Ⅲ|CMAB009","March 7, 2012","March 2009","December 2015","December 20, 2015","December 2015","No Study Results Posted","CRC009","December 2015","Overall response rate|Progression-free Survival","https://ClinicalTrials.gov/show/NCT01550055"
363,"NCT01960023","Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Cetuximab|Drug: Neratinib","NSABP Foundation Inc","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","22","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP FC-7","September 17, 2013","October 2013","December 2016","May 5, 2016","May 2016","No Study Results Posted","null","June 2016","The safety and tolerability of cetuximab and neratinib during the Phase I portion of the study.|Number of patients with Overall response rate (ORR)(complete response/partial response) and progression free survival (PFS) during the Phase II portion of the study|Progression-free survival (PFS). The time to progression and the time to progression based on tumor HER2 status.|Tumor measurement to determine objective tumor decrease and stable disease|Measure molecular and genetic correlatives for neratinib and cetuximab|The frequency and severity of adverse events to evaluate the overall toxicity in the Phase II portion of the study.","https://ClinicalTrials.gov/show/NCT01960023"
364,"NCT00113763","Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer|Metastases","Other: Best supportive care|Drug: Panitumumab","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 3","463","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20020408","June 10, 2005","January 2004","June 2009","July 15, 2014","July 2014","August 6, 2010","null","October 2008","Progression-free Survival Time|Overall Survival|Objective Tumor Response|Duration of Response|Time to Response|Time to Disease Progression|Time to Treatment Failure|Duration of Stable Disease","https://ClinicalTrials.gov/show/NCT00113763"
365,"NCT02086656","PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES","Recruiting","No Results Available","Colorectal Cancer Liver Metastases","Drug: capecitabine, oxaliplatin, irinotecan and bevacizumab","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Both","18 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COI-B","December 20, 2013","June 2013","null","March 11, 2014","March 2014","No Study Results Posted","COI-B","June 2016","Pathological response rate|RECIST Response rate","https://ClinicalTrials.gov/show/NCT02086656"
366,"NCT01103323","Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo|Other: Best Supportive Care (BSC)","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 3","760","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14387|2009-012787-14","April 8, 2010","April 2010","January 2014","May 28, 2015","May 2015","October 19, 2012","null","July 2011","Overall Survival|Progression-free Survival (Based on Investigator's Assessment)|Objective Tumor Response|Disease Control|Tumor Response","https://ClinicalTrials.gov/show/NCT01103323"
367,"NCT01853813","First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer Stage II","Drug: Bevacizumab and FOLFIRI","Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|Azienda Ospedaliero, Universitaria Ospedali Riuniti","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","85","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","2012-005048-46","March 21, 2013","May 2013","July 2015","July 14, 2015","July 2015","No Study Results Posted","CENTRAL","May 2015","Response Rate|Progression free survival|evaluation of serum IL-8, bFGF, HGF, PlGF, SDF-1, MCP-3","https://ClinicalTrials.gov/show/NCT01853813"
368,"NCT02519582","Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: Niclosamide","Charite University, Berlin, Germany|Center for Molecular Medicine","Both","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCCC-mCRC-01","July 30, 2015","August 2015","February 2018","August 6, 2015","August 2015","No Study Results Posted","Nikolo","February 2018","Progression free survival|Overall survival|Time to progression|Disease control rate|Number of Adverse Events > grade 2 toxicities according to NCI Common Toxicity Criteria for Adverse Effects v 4.03|Number of Serious Adverse Events","https://ClinicalTrials.gov/show/NCT02519582"
369,"NCT01276379","Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFIRI (m)|Drug: FOLFOX-6 (m)|Drug: Cetuximab","Grupo Espanol Multidisciplinario del Cancer Digestivo","Both","18 Years and older   (Adult, Senior)","Phase 2","170","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","GEMCAD-1002|2010-019236-12","January 12, 2011","January 2011","December 2016","August 10, 2016","August 2016","No Study Results Posted","POSIBA","December 2016","Progression free survival|Overall survival|Response duration|Toxicity|Secondary biomarkers analysis|Tumoral response","https://ClinicalTrials.gov/show/NCT01276379"
370,"NCT01523431","Individual Dosage Selection of Irinotecan(CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: CPT-11","The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","Both","18 Years and older   (Adult, Senior)","Phase 2","500","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCRC-307PLAH-XJM","January 19, 2012","March 2012","September 2014","December 26, 2013","December 2013","No Study Results Posted","null","December 2013","Association between UGT1A1 polymorphism and incidence of neutropenia and diarrhea|Association between UGT1A1 polymorphism and irinotecan pharmacokinetics|Progression-free survival|Response rate","https://ClinicalTrials.gov/show/NCT01523431"
371,"NCT02314819","A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: fruquintinib|Drug: placebo","Hutchison Medipharma Limited|Fudan University|Eighty-One Hospital of People's Liberation Army","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","416","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2013-013-00CH1","December 8, 2014","December 2014","June 2017","August 29, 2016","August 2016","No Study Results Posted","FRESCO","March 2017","overall survival|progression free survival|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Safety and tolerance evaluated by incidence, severity and outcomes of AEs","https://ClinicalTrials.gov/show/NCT02314819"
372,"NCT01075048","ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Tivantinib (ARQ 197) + cetuximab + irinotecan|Drug: Placebo + cetuximab + irinotecan","Daiichi Sankyo Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","150","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ARQ197-A-U252","February 17, 2010","January 2010","September 2014","October 22, 2015","October 2015","No Study Results Posted","null","January 2013","Phase 1: To evaluate the safety and tolerability of ARQ 197 when administered with irinotecan and cetuximab in subjects who have received front-line systemic therapy|Phase 2: To estimate the difference in progression-free survival (PFS) between the study and control arms in subjects with CRC with wild-type KRAS who have received front-line therapy.|Phase 1: To define the recommended dose of ARQ 197, in combination with irinotecan and cetuximab for the Phase 2 study.|Evaluate overall survival (OS), objective response rate (ORR), and safety profile of ARQ 197 in combination with cetuximab and irinotecan.","https://ClinicalTrials.gov/show/NCT01075048"
373,"NCT00972465","Study of Nimotuzumab to Treat Colorectal Cancer","Recruiting","No Results Available","Advanced Colorectal Cancer","Drug: Nimotuzumab and chemotherapy","Peking University|Biotech Pharmaceutical Co., Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BT-CRC-T","September 4, 2009","June 2009","April 2010","September 4, 2009","September 2009","No Study Results Posted","null","December 2009","Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.|To determine the complete response rate, partial rate, disease response rate, disease control rate in the patients subject to treatment","https://ClinicalTrials.gov/show/NCT00972465"
374,"NCT00209651","Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Campto, Topotesin|Drug: TS-1","Hokkaido Gastrointestinal Cancer Study Group|Hokkaido University Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HGCSG0302|IRIS","September 13, 2005","January 2004","December 2007","October 31, 2007","October 2007","No Study Results Posted","null","null","objective tumor response|Response duration, time to progression, overall survival, and safety will also be assessed.","https://ClinicalTrials.gov/show/NCT00209651"
375,"NCT00033306","BMS-247550 in Treating Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: ixabepilone|Drug: Fluoropyrimidine|Drug: Irinotecan","University of Alabama at Birmingham|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","2","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000069272|UAB-0145|BMS-CA163-012|UAB-F011029021|NCI-G02-2051","April 9, 2002","February 2002","July 2005","August 1, 2013","August 2013","No Study Results Posted","null","July 2005","Determine the clinical activity of BMS-247550, as measured by the tumor response rate, in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine and irinotecan.|Determine the safety of this drug in these patients.|Determine the response duration, time to progression, and survival in patients treated with this drug.","https://ClinicalTrials.gov/show/NCT00033306"
376,"NCT01057017","Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras","Terminated","Has Results","Colorectal Cancer","Biological: intervention","Brown University|Rhode Island Hospital|The Miriam Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","5","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG-CR-218","January 20, 2010","January 2010","December 2011","June 18, 2014","June 2014","May 9, 2013","null","April 2011","Number of Patients With Toxicity to Combination of Panitumumab and Bevacizumab","https://ClinicalTrials.gov/show/NCT01057017"
377,"NCT00345761","Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Bevacizumab|Drug: Oxaliplatin|Drug: Capecitabine","Chugai Pharmaceutical|Yakult Honsha Co., LTD","Both","20 Years to 74 Years   (Adult, Senior)","Phase 1|Phase 2","64","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JO19380","June 27, 2006","February 2006","July 2010","August 13, 2010","August 2010","No Study Results Posted","null","October 2008","Response rate: Response Evaluation Criteria in Solid Tumors (RECIST)|Safety (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)|time to progression|overall survival|time to response|duration of response|concentrations of R340 and its metabolites|concentrations of platinum|concentrations of bevacizumab|concentrations of vascular endothelial growth factor (VEGF)|concentrations of anti-bevacizumab antibody","https://ClinicalTrials.gov/show/NCT00345761"
378,"NCT01448655","Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)","Recruiting","No Results Available","Colorectal Cancer","","IFAG AG|Hiscia Society for Cancer Research|IFAG Basel AG (CRO), both Switzerland","Both","18 Years to 85 Years   (Adult, Senior)","","300","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ISC-4.1.5|2010-018682-31","March 29, 2011","September 2010","June 2017","July 1, 2013","July 2013","No Study Results Posted","null","December 2016","Disease-free survival time (DFS).|Number of patients with at least one therapy or disease induced symptom (surrogate parameter for quality of life)|Mean values of Karnofsky performance status, Eastern Cooperative Oncology Group (ECOG) score|Interim analysis on overall survival time (OS) in UICC stage IV patients|Safety of Iscador® Qu (number of patients with systemic or local adverse events (AE) to Iscador® Qu)|Number of patients with unexpected adverse events (UAE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy).","https://ClinicalTrials.gov/show/NCT01448655"
379,"NCT01996969","Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib","Seoul National University Hospital|Bayer","Both","20 Years and older   (Adult, Senior)","","117","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","Regorafenib biomarker","October 24, 2013","October 2013","May 2016","March 26, 2016","March 2016","No Study Results Posted","null","June 2015","Predictive biomarker in terms of disease control rate|Disease control rate|Progression-free survival|Overall survival|number of participants with adverse events|Progression-free survival according to biomarker status|Overall survival according to biomarker status|Assessment of adequate response evaluation modality after regorafenib treatment","https://ClinicalTrials.gov/show/NCT01996969"
380,"NCT00327119","Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: ABX-EGF (panitumumab)","Amgen","Both","20 Years and older   (Adult, Senior)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20050216","May 16, 2006","April 2006","null","September 11, 2009","September 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00327119"
381,"NCT02641873","A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: BBI608|Drug: FOLFIRI + Bevacizumab","Sumitomo Dainippon Pharma Co., Ltd.","Both","20 Years and older   (Adult, Senior)","Phase 1","6","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D8809001","December 21, 2015","December 2015","null","December 24, 2015","December 2015","No Study Results Posted","null","December 2016","Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]|Number of participants with Dose-limiting toxicities (DLT) [Safety and Tolerability]|Cmax (Peak plasma concentration)|AUC0-24h (Area under the plasma concentration versus time curve)|Preliminary anti-tumour activity|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02641873"
382,"NCT00173472","Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Chemotherapy","National Taiwan University Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","200","Other","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","9461700674","September 12, 2005","July 2002","July 2005","November 23, 2005","July 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00173472"
383,"NCT00202774","Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: (capecitabine, oxaliplatin, 5-fluorouracil)","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","Both","18 Years and older   (Adult, Senior)","Phase 3","348","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","03-TTD-01","September 12, 2005","April 2002","December 2005","February 19, 2013","February 2013","No Study Results Posted","null","August 2004","Determine time to disease progression|Determine safety of combination, objetive response rate, time to onset of response , duration of response, time to treatment failure, one year survival time, overall survival time","https://ClinicalTrials.gov/show/NCT00202774"
384,"NCT00780169","Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: sorafenib + FOLFIRI","Ottawa Hospital Research Institute|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OTT 06-08","October 23, 2008","October 2008","December 2012","May 9, 2013","May 2013","No Study Results Posted","null","May 2011","Toxicity spectrum of Sorafenib (MTD, DLT) and the recommended dose (RD) for phase II studies of Sorafenib when combined with FOLFIRI in first line patients with metastatic colorectal cancer (mCRC)|Pharmacokinetics of Irinotecan in the presence of Sorafenib|Response according to Response Evaluation Criteria in Solid Tumors (RECIST)|Time to Progression and Overall Survival","https://ClinicalTrials.gov/show/NCT00780169"
385,"NCT01003600","Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information","Completed","No Results Available","Colon Cancer|Rectal Cancer","Behavioral: Questionnaire","Memorial Sloan Kettering Cancer Center|Queens Cancer Center of Queens Hospital","Both","18 Years and older   (Adult, Senior)","","177","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","09-133","October 28, 2009","October 2009","November 2014","November 26, 2014","November 2014","No Study Results Posted","null","November 2014","Assess colorectal cancer survivors' basic knowledge of their own cancer history, including date of diagnosis, stage, and treatments received.|Assess survivors' knowledge of medical issues relevant to colorectal cancer survivors.|Describe the types of health care providers that survivors have visited since completing treatment for colorectal cancer.|Assess survivors' preferences for the content, format, and delivery of survivorship care plans.|Assess whether survivors who had concerns about working after cancer treatment spoke with health care professionals about their concerns.","https://ClinicalTrials.gov/show/NCT01003600"
386,"NCT00852228","Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer|Liver Metastases|Hepatic Lesions","Drug: IV cetuximab|Drug: HAI chronomodulated chemotherapy|Drug: HAI conventional chemotherapy","Association pour la Recherche sur le Temps Biologique et la Chronothérapie|Gustave Roussy, Cancer Campus, Grand Paris|Merck Serono International SA|Pfizer|CRESGE","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OPTILIV07|EUDRACT number: 2007-004632-24","February 25, 2009","July 2008","December 2015","December 10, 2013","December 2013","No Study Results Posted","OPTILIV","March 2012","Incidence of complete macroscopic resections (R0+R1) of unresectable liver metastases following chemotherapy.|The rate and site(s) of relapse in the resected patients throughout the 3-year span that follows hepatectomy|The relapse-free survival in the resected patients|The progression-free and the overall survival in the patients receiving at least 4 full courses of HAI therapy and in all the patients (intent to treat)|The objective response rate|The rate of adverse events|The per-operative and post-operative complications associated to liver surgery","https://ClinicalTrials.gov/show/NCT00852228"
387,"NCT00254137","Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: capecitabine|Drug: irinotecan|Drug: oxaliplatin|Drug: cetuximab","Ludwig-Maximilians - University of Munich|Merck Sharp & Dohme Corp.|Sanofi|Pfizer|Hoffmann-La Roche","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","92","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRC-02-2004","November 14, 2005","September 2004","November 2006","October 27, 2010","September 2004","No Study Results Posted","null","null","Objective response rate (CR+PR)|Time to progression.|Disease control rate (CR+PR+SD).|Safety profile.|Grade 3/4- toxicities.","https://ClinicalTrials.gov/show/NCT00254137"
388,"NCT00286130","Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|Drug: FOLFOX 6|Drug: FOLFIRI","Central European Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CECOG/Core 1.2.001|EUDRACT number 2004-002391-42","February 2, 2006","July 2005","October 2007","April 30, 2012","April 2012","No Study Results Posted","null","null","the percentage of patients surviving without disease progression in each arm at 9 months|PFS rates at 3,6,12 months|Response rates|Overall survival (OS) in each arm|Safety","https://ClinicalTrials.gov/show/NCT00286130"
389,"NCT00725400","Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma","Withdrawn","No Results Available","Colorectal Carcinoma","Other: Cetuximab and Radiation Therapy|Procedure: Surgery and Radiation Therapy","American Scitech International|ImClone LLC|Bristol-Myers Squibb","Both","40 Years and older   (Adult, Senior)","Phase 2","450","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ASI-CRO0000192008|JLRH-0000292008|IORG-0000392008|BMS-192008|IMCL-II-ASI-IORG-92008|ASI-CRCII0708","July 28, 2008","February 2010","February 2014","July 19, 2011","July 2011","No Study Results Posted","null","February 2014","Objective tumor response rate|Tolerability|Progression free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT00725400"
390,"NCT00388700","A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: GM-CT-01|Drug: 5-Fluorouracil, Leukovorin, bevacizumab","Galectin Therapeutics Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","10","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DAVFU006","October 13, 2006","October 2006","June 2009","August 8, 2016","August 2016","No Study Results Posted","null","June 2009","Primary Outcomes: Assess the efficacy and safety of GM-CT-01 administered with 5-FU, LV, and Avastin® in the first-line treatment of unresectable, locally advanced, and/or metastatic CRC.|To evaluate the safety of the DAVANAT®/5-FU, LV plus Avastin® regimen.|Explore progression-free survival (PFS) and survival","https://ClinicalTrials.gov/show/NCT00388700"
391,"NCT01250015","Does Numerical And Pictorial Information On Risk And Benefit Affects The Uptake Of Colorectal Cancer Screening?","Completed","No Results Available","Colorectal Cancer Screening","","County Durham and Darlington NHS Foundation Trust|Internal funding Local Gastroenterology Research fund (Questionnaire only study)","Both","60 Years to 70 Years   (Adult, Senior)","","400","Other","Observational","Time Perspective: Prospective","1|CDDFT (UK)|CDDFT, UK","November 29, 2010","September 2007","September 2008","November 29, 2010","March 2008","No Study Results Posted","null","September 2008","Comparison of the two groups' overall wish to be screened|Impact of different summary points on subject's desire to be screened","https://ClinicalTrials.gov/show/NCT01250015"
392,"NCT02332499","Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Anlotinib|Drug: Placebo","Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","450","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALTN-07-IIB","December 31, 2014","December 2014","December 2016","January 11, 2016","January 2016","No Study Results Posted","ALTER0703","December 2016","Overall Survival (OS)|Progress free survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT02332499"
393,"NCT00081536","Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies","Active, not recruiting","No Results Available","Colorectal Neoplasms","Drug: Aroplatin (Liposomal NDDP) in combination with capecitabine","Aronex Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","105","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","C-726-03","April 15, 2004","null","null","June 23, 2005","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00081536"
394,"NCT01219920","FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFIRI|Drug: FOLFOXIRI","Gruppo Oncologico del Nord-Ovest","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","244","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ASL601LIOM03|2007-002886-11","October 8, 2010","November 2001","November 2009","March 10, 2015","March 2015","No Study Results Posted","null","November 2005","Response rate (RR)|Progression-free survival (PFS)|Overall survival (OS)|Postchemotherapy radical (R0) surgical resection rate of metastases|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Quality of life (QoL)","https://ClinicalTrials.gov/show/NCT01219920"
395,"NCT02068131","Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Novaferon|Drug: Capecitabine","The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JH-RC-006","February 17, 2014","February 2014","December 2016","January 4, 2016","August 2015","No Study Results Posted","null","November 2016","Overall response rate(ORR)|Disease control rate(DCR)|Progression-free survival (PFS)|Overall survival (OS)|Adverse Events(AEs)","https://ClinicalTrials.gov/show/NCT02068131"
396,"NCT00598975","A Phase 2a/2b Multicenter, Open-Label Study to Evaluate NKTR 102 in Combination With Cetuximab Versus Irinotecan in Combination With Cetuximab in Second Line Colorectal Cancer Patients","Completed","No Results Available","Tumor|Colorectal Cancer","Drug: NKTR-102 + Cetuximab","Nektar Therapeutics","Both","18 Years and older   (Adult, Senior)","Phase 2","18","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-PIR-02","January 11, 2008","January 2008","May 2009","August 12, 2014","August 2014","No Study Results Posted","null","May 2009","Establish the recommended Phase 2a dose (RPTD) of the combination of NKTR-102 and cetuximab|Safety, pharmacokinetics, and tumor response of NKTR-102 in combination with cetuximab.","https://ClinicalTrials.gov/show/NCT00598975"
397,"NCT02613221","A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: panitumumab, TAS-102","Takeda","Both","20 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","58","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Panitumumab-1501|U1111-1176-3692","November 20, 2015","November 2015","December 2017","December 7, 2015","December 2015","No Study Results Posted","APOLLON","June 2017","Progression free survival rate at 6 months|Overall Survival (OS)|Progression Free survival (PFS)|Response rate (RR)|Duration of response (DOR)|Percentage of participants with adverse events","https://ClinicalTrials.gov/show/NCT02613221"
398,"NCT00958386","Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab+irinotecan","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","61","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-08-06","August 12, 2009","August 2009","July 2014","March 23, 2015","March 2015","No Study Results Posted","SPECTRA","July 2014","Objective response rate|disease control rate|duration of response|time to progression|time to response|time to treatment failure|duration of stable disease|Progression free survival|Overall survival|Safety profile|Evaluation of molecular predictive markers","https://ClinicalTrials.gov/show/NCT00958386"
399,"NCT00810771","Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening","Completed","Has Results","Colorectal Neoplasms","Behavioral: Standard Information|Behavioral: Preference-tailored Information","VA Office of Research and Development","Both","50 Years to 78 Years   (Adult, Senior)","","466","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Health Services Research","IIR 06-205","December 16, 2008","February 2009","August 2012","June 1, 2015","June 2015","March 26, 2015","EPIIC","May 2012","Colorectal Cancer (CRC) Screening Rate.|Number of Elements of Braddock's Informed Decision Making (IDM) Model Discussed With Provider|Colorectal Cancer Screening (CRCS) Knowledge and Attitudes.|Decisional Satisfaction|Intent to Get Colorectal Cancer Screening.|Self Efficacy.|If Colorectal Cancer Screening Screening (CRCS) Discussed With Provider.","https://ClinicalTrials.gov/show/NCT00810771"
400,"NCT02677389","Survivorship Care Plan in Promoting Physical Activity in Breast or Colorectal Cancer Survivors in Wisconsin","Recruiting","No Results Available","Cancer Survivor|Healthy Subject|Stage I Colorectal Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIA Colorectal Cancer|Stage IIB Breast Cancer|Stage IIB Colorectal Cancer|Stage IIC Colorectal Cancer|Stage IIIA Breast Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Breast Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Breast Cancer|Stage IIIC Colorectal Cancer","Other: Educational Intervention|Other: Internet-Based Intervention|Device: Monitoring Device|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","University of Wisconsin, Madison|National Cancer Institute (NCI)","Both","30 Years to 75 Years   (Adult, Senior)","","100","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","UW15059|NCI-2016-00111|P30CA014520","February 1, 2016","December 2015","null","August 19, 2016","August 2016","No Study Results Posted","null","February 2017","Feasibility as defined by recruitment rate|Physical activity as measured by the ActiGraph GT3X+ accelerometer (Arm I)|Physical activity as measured by the ActiGraph GT3X+ accelerometer (Arm II)","https://ClinicalTrials.gov/show/NCT02677389"
401,"NCT01311050","A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab","King Faisal Specialist Hospital & Research Center","Both","14 Years to 85 Years   (Child, Adult, Senior)","","46","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","RAC# 2081-068","March 6, 2011","January 2009","null","December 11, 2011","December 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01311050"
402,"NCT01001377","ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer","Active, not recruiting","Has Results","Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: Panitumumab","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 3","1010","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20080763|ASPECCT|2009-010715-32","October 22, 2009","February 2010","December 2016","June 1, 2016","May 2016","February 3, 2014","null","February 2013","Overall Survival|Progression-free Survival|Objective Response|Duration of Response|Time to Response|Time to Treatment Failure|Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score|Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Visual Analog Scale (VAS)|Change From Baseline in National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index (NCCN FCSI ) Symptoms Score|Change From Baseline in NCCN FCSI Physical Well-being Scale Score|Change From Baseline in NCCN FCSI Functional Well-being Scale Score|Number of Participants With Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT01001377"
403,"NCT02352688","RCT on Elderly Patients Undergoing Colorectal Cancer Surgery With Enhanced Geriatric Care","Recruiting","No Results Available","Colorectal Cancer","Procedure: Enhanced Colorectal Geriatric Care","Chinese University of Hong Kong","Both","70 Years and older   (Senior)","","78","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CRE-2014.550-T","January 19, 2015","May 2015","October 2017","April 1, 2016","April 2016","No Study Results Posted","null","April 2017","Length of postoperative hospital stay|30-day morbidity|30-day mortality","https://ClinicalTrials.gov/show/NCT02352688"
404,"NCT02248038","A Multicenter Clinical Trial on Laparoscopic Colorectal Cancer Surgery Compared With Open Surgery","Active, not recruiting","No Results Available","Colorectal Cancer","Procedure: open surgery|Procedure: laparoscopic surgery","Cai Kailin|Huazhong University of Science and Technology|Nanfang Hospital of Southern Medical University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Peking Union Medical College Hospital","Both","up to 80 Years   (Child, Adult, Senior)","Phase 3","1300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ChiCTR-TRC-14004767","September 9, 2014","June 2014","June 2019","September 23, 2014","September 2014","No Study Results Posted","null","June 2019","5 years diseases free survival rate|5 years overall survival rate","https://ClinicalTrials.gov/show/NCT02248038"
405,"NCT01570010","Effect of the New Norwegian Food Based Dietary Guidelines on Chronic Diseases in Colorectal Cancer Survivors","Recruiting","No Results Available","Colorectal Cancer","Other: new norwegian food based dietary guidelines","University of Oslo|Oslo University Hospital|National Institute for Health and Welfare, Finland|University Hospital, Akershus|Asker & Baerum Hospital|Sykehuset Buskerud HF|Norwegian Cancer Society|The Research Council of Norway","Both","50 Years to 75 Years   (Adult, Senior)","","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","Norwegian Foods Study|2011/836","March 22, 2012","March 2012","March 2040","December 4, 2015","December 2015","No Study Results Posted","NFS","March 2040","Change in biomarkers of comorbid conditions over the intervention period|Change in biomarkers of inflammation and oxidative stress from baseline to 6 and 12 months|Compliance to intervention up to 12 months|Change in physical function over the first 12 months|Change in dietary patterns during first 12 months|Mortality|colorectal cancer-free survival and disease-free survival|Fatigue and quality of life|Biomarkers of thromboembolic disease|25 hydroxy vitamin D|whole genome transcription profiles and methylation patterns|Co-morbidity|Change in biomarkers of comorbid conditions compared to baseline|Change in biomarkers of inflammation and oxidative stress|Continued ompliance to intervention during follow up|Change in physical function up to 15 years|Change in dietary patterns up to 15 years","https://ClinicalTrials.gov/show/NCT01570010"
406,"NCT00399035","Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","Active, not recruiting","Has Results","Metastatic Colorectal Cancer","Drug: Cediranib|Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|Drug: XELOX (Capecitabine and Oxaliplatin)|Drug: Cediranib Placebo","AstraZeneca","Both","18 Years to 130 Years   (Adult, Senior)","Phase 3","1254","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D8480C00051|EUDRACT No 2006-001194-14|HORIZON II","November 13, 2006","November 2006","January 2017","July 6, 2016","July 2016","March 29, 2012","HORIZON II","March 2010","Progression-free Survival|Overall Survival|Overall Response Rate|Best Percentage Change in Tumour Size|Duration of Response|Rate of Resection of Liver Metastases|Time to Wound Healing Complications","https://ClinicalTrials.gov/show/NCT00399035"
407,"NCT00660153","Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers","Completed","No Results Available","Colorectal Cancer|Gastrointestinal Cancer","Drug: Tivozanib (AV-951) plus FOLFOX6","AVEO Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AV-951-103","April 15, 2008","June 2008","June 2012","August 24, 2012","August 2012","No Study Results Posted","null","June 2012","To determine the safety, tolerability, and maximum tolerated dose of tivozanib (AV-951) in combination with FOLFOX6 chemotherapy.|To characterize the pharmacokinetic profile of tivozanib (AV-951) and FOLFOX6 chemotherapy when administered together, and to assess the antineoplastic activity of the combination of tivozanib (AV-951) and FOLFOX6 chemotherapy.","https://ClinicalTrials.gov/show/NCT00660153"
408,"NCT00997685","Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)","Not yet recruiting","No Results Available","Potentially Resectable Liver Metastasis From CRC|Colorectal Cancer","Drug: Capecitabine plus oxaliplatin","Guangdong General Hospital","Both","18 Years to 65 Years   (Adult)","Phase 2","110","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML22298","October 18, 2009","November 2009","October 2015","October 18, 2009","October 2009","No Study Results Posted","null","October 2015","To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer|To investigate the response rate|To evaluate the R0 resection rate|To evaluate the safety profile of XELOX peri-operative treatment","https://ClinicalTrials.gov/show/NCT00997685"
409,"NCT01468623","Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6","Terminated","No Results Available","Colorectal Cancer, Metastatic","Other: Pharmacokinetic 5-FU dose adjustment using OnDose® assay|Other: Standard of care","Myriad Genetic Laboratories, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 4","51","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PROFUSE-2011","November 1, 2011","September 2011","December 2016","January 29, 2013","January 2013","No Study Results Posted","PROFUSE","September 2016","Overall response rate (ORR)|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT01468623"
410,"NCT00209625","Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: irinotecan|Drug: leucovorin|Drug: fluorouracil","Hokkaido Gastrointestinal Cancer Study Group","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","23","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HGCSG0001","September 13, 2005","April 2000","November 2004","September 13, 2005","April 2000","No Study Results Posted","null","null","objective tumor response|Response duration, time to progression, median survival time, and safety","https://ClinicalTrials.gov/show/NCT00209625"
411,"NCT00793455","Outreach for Patients With Uncompleted Colorectal Cancer Screening Orders","Completed","Has Results","Colorectal Cancer Screening|Prevention & Control","Behavioral: Educational outreach","Northwestern University|Agency for Healthcare Research and Quality (AHRQ)","Both","Child, Adult, Senior","","628","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Health Services Research","1R18HS017163-01","November 17, 2008","October 2008","November 2009","October 24, 2011","October 2011","September 1, 2011","UPQUAL","November 2009","Colorectal Cancer Screening Completion.|Colorectal Cancer Screening Completion","https://ClinicalTrials.gov/show/NCT00793455"
412,"NCT01226719","FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only","Completed","Has Results","Colorectal Cancer","Drug: Panitumumab|Drug: Oxaliplatin|Drug: Irinotecan|Drug: Leucovorin|Drug: 5-Fluorouracil","SCRI Development Innovations, LLC|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","15","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI GI 134","October 15, 2010","December 2010","March 2014","May 7, 2015","May 2015","February 26, 2015","null","March 2014","Overall Response Rate (ORR)|R0 Resection Rate|Progression-free Survival (PFS)|To Determine the Acute Toxicity Produced by This Regimen.|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01226719"
413,"NCT01966289","SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: CY|Biological: GVAX|Drug: SGI-110","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years to 100 Years   (Adult, Senior)","Phase 1","32","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J13138|NA_00087578","October 10, 2013","December 2013","null","June 9, 2016","June 2016","No Study Results Posted","null","December 2017","Difference in CD45RO+ tumor infiltrating lymphocytes (TILs) measured by immunohistochemistry in pre and post-treatment tumor biopsies from patients with metastatic colorectal cancer|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall Survival (OS)|Time To Progression (TTP)|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01966289"
414,"NCT01134640","A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment","Completed","No Results Available","Metastatic Colorectal Cancer","","Merck KGaA","Both","Child, Adult, Senior","","286","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ESST","May 17, 2010","January 2008","November 2010","May 8, 2014","May 2014","No Study Results Posted","null","November 2010","Safety and toxicity of Erbitux in clinical practice","https://ClinicalTrials.gov/show/NCT01134640"
415,"NCT00233623","Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer","Withdrawn","No Results Available","Metastatic Colorectal Cancer","Drug: Iressa (Gefitinib)|Drug: Irinotecan|Drug: 5Fluorouracil|Drug: Leucovorin","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","190","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1839IL/0138","October 4, 2005","July 2004","January 2006","January 25, 2011","January 2011","No Study Results Posted","null","January 2006","Time to progression (6 months after Last patient in)|Objective Response Rate, Duration of Response, Disease control rate, Overall Survival, (6 months after Last patient in)","https://ClinicalTrials.gov/show/NCT00233623"
416,"NCT01008475","EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer","Completed","Has Results","Metastatic Colorectal Cancer","Drug: EMD 525797 250 mg|Drug: EMD 525797 500 mg|Drug: EMD 525797 750 mg|Drug: EMD 525797 1000 mg|Drug: Cetuximab|Drug: Irinotecan","Merck KGaA","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","232","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR62242-004","October 19, 2009","October 2009","April 2015","February 26, 2016","February 2016","February 26, 2016","POSEIDON","April 2015","Safety Part: Number of Subjects Experiencing DLTs (Dose Limiting Toxicity)|Randomized Part: Progression Free Survival (PFS)|Overall Survival (OS) Time|Time to Progression (TTP)|Number of Subjects With Tumor Response|Time to Treatment Failure (TTF)","https://ClinicalTrials.gov/show/NCT01008475"
417,"NCT02310477","Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: regorafenib","Centre Oscar Lambret|Bayer","Both","18 Years and older   (Adult, Senior)","","704","Other|Industry","Observational","Observational Model: Cohort","REBECCA-1305","October 8, 2014","February 2014","December 2014","August 8, 2016","January 2016","No Study Results Posted","REBECCA","October 2014","Overall survival (OS)|Patients and tumor baseline characteristics|Time under REG treatment|Compliance|Safety of REG|Potential predictive factors|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02310477"
418,"NCT00442637","Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: capecitabine + bevacizumab|Other: observation","Dutch Colorectal Cancer Group|Koningin Wilhelmina Fonds|Sanofi|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","635","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CAIRO3","February 28, 2007","January 2007","December 2013","December 11, 2013","December 2013","No Study Results Posted","CAIRO3","September 2013","Progression-free survival after re-introduction of MTD chemotherapy and bevacizumab (PFS2)|Progression-free survival between observation versus maintenance therapy (PFS1)|Response rate during re-introduction of MTD chemotherapy and bevacizumab|Toxicity|Quality of life|Overall survival|Translational research","https://ClinicalTrials.gov/show/NCT00442637"
419,"NCT00109226","A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Avastin (Bevacizumab)","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Masking: Double-Blind|Primary Purpose: Treatment","AVF2192g","April 26, 2005","August 2000","September 2003","April 7, 2014","April 2014","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00109226"
420,"NCT01640405","Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: modified FOLFOX6 + bevacizumab|Drug: FOLFOXIRI + Bevacizumab","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Roche Pharma AG","Both","18 Years to 70 Years   (Adult, Senior)","Phase 3","350","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-12-01|2012-000846-37","June 13, 2012","July 2012","June 2017","June 13, 2016","June 2016","No Study Results Posted","VISNU-1","June 2017","Progression free survival (PFS)|Overall survival (OS)|Response rate (RR)|Radical Resection (R0) surgery rate|Circulating Tumour Cells (CTC) count basal and correlate to PFS, OS, RR|Correlation of RAS, BRAF and PI3K mutations and clinical anti-tumour activity outcome ( PFS, OS, RR)|Adverse events|Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)","https://ClinicalTrials.gov/show/NCT01640405"
421,"NCT01344304","Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial","Recruiting","No Results Available","Colorectal Cancer","Drug: Aprepitant / Fosaprepitant","Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group","Both","20 Years and older   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","SENRI","April 27, 2011","April 2011","March 2014","October 22, 2012","October 2012","No Study Results Posted","null","March 2014","Patient diary recording nausea, emesis, food ingestion, and rescue therapy","https://ClinicalTrials.gov/show/NCT01344304"
422,"NCT01035385","Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)","Recruiting","No Results Available","Colorectal Cancer|Liver Metastasis","Drug: FOFLOX4","Guangdong General Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","340","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VORP019","December 16, 2009","September 2009","December 2015","December 17, 2009","September 2009","No Study Results Posted","null","October 2012","progression free survival (PFS)|response rate, incidence of postoperative complications,pathological response rate,R0 resection rate, 5-year overall survival,duration of disease control","https://ClinicalTrials.gov/show/NCT01035385"
423,"NCT00660582","FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab (Erbitux)|Drug: Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid","Per Pfeiffer|Odense University Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","152","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Nordic 7.5","April 11, 2008","April 2008","February 2013","January 20, 2015","January 2015","No Study Results Posted","null","May 2011","","https://ClinicalTrials.gov/show/NCT00660582"
424,"NCT00636610","A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Vismodegib 150 mg|Drug: Placebo to vismodegib|Drug: Bevacizumab|Drug: Modified FOLFOX|Drug: FOLFIRI","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","199","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SHH4429g","March 5, 2008","May 2008","December 2010","June 1, 2012","June 2012","February 14, 2012","null","December 2010","Progression-free Survival (PFS)|Progression-free Survival (PFS) in Patients With Various Degrees of Hedgehog Antigen Tumor Expression","https://ClinicalTrials.gov/show/NCT00636610"
425,"NCT01719380","Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: LGX818|Drug: Cetuximab|Drug: BYL719","Array BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","150","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLGX818X2103|2012-002138-35","October 30, 2012","November 2012","null","February 11, 2016","February 2016","No Study Results Posted","null","August 2016","Incidence rate of dose-limiting toxicities|Progression free survival|Incidence and severity of adverse events|Plasma concentration|Overall response rate|Duration of response|Time to response|Overall survival|Baseline molecular status of potential predictive markers of tumor response or resistance","https://ClinicalTrials.gov/show/NCT01719380"
426,"NCT02188264","Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer","Recruiting","No Results Available","Recurrent Colorectal Carcinoma|Solid Neoplasm|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Drug: Cyclosporine|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Selumetinib","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","64","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2014-01484|13-2628|9571|P30CA016672|UM1CA186686|UM1CA186688|UM1CA186704|UM1CA186709|UM1CA186712","July 10, 2014","August 2014","null","September 9, 2016","July 2016","No Study Results Posted","null","October 2016","Incidence of DLT defined as any grade 3 non-hematological toxicity or grade 4 hematological toxicity attributed to selumetinib or cyclosporine graded per National Cancer Institute (NCI) CTCAE version 4.0|Incidence of adverse events that occur after course 1, day 1 assessed using NCI CTCAE version 4.0|Objective tumor response based on computed tomography scans (or magnetic resonance imaging if patients are allergic to iodinated contrast) per RECIST 1.1 criteria|Pharmacokinetic (PK) parameters, including the distribution of area under the curve and maximum concentration|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02188264"
427,"NCT01651013","Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras","Recruiting","No Results Available","Metastatic Colorectal Cancer","","National Cancer Institute, Naples","Both","18 Years and older   (Adult, Senior)","Phase 2","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CALLAS","July 24, 2012","October 2010","October 2016","November 25, 2015","November 2015","No Study Results Posted","CALLAS","October 2016","percentage of patients enrolled in a clinical trial|percentage of patients who undergo K-Ras mutation study|Percentage of patients with K-Ras mutation","https://ClinicalTrials.gov/show/NCT01651013"
428,"NCT01998152","Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT)","Recruiting","No Results Available","Advanced or Recurrent Colorectal Cancer, Stage IV","Procedure: Nutritional counseling","VU University Medical Center","Both","18 Years and older   (Adult, Senior)","","110","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Treatment","2013230","November 11, 2013","November 2013","null","April 28, 2016","April 2016","No Study Results Posted","COLONUT","September 2016","Change in skeletal muscle area (cm2)between individualized nutritional counselling versus usual nutritional care|Change in total body lean body mass and segmental lean body mass (DEXA) in patients with stage IV colorectal cancer during 9 weeks of palliative chemotherapy between individualized nutritional counseling versus usual nutritional care|Change in skeletal muscle area in patients with stage IV colorectal cancer during 20 weeks of palliative chemotherapy between individualized nutritional counseling.versus usual nutritional care.|Composite of treatment toxicity, treatment intensity, treatment outcome, survival, physical functioning, quality of life and hand grip strength of both study arms|Associations of (changes in) muscle area with (changes in) mid-upper arm muscle circumference, whole body fat free mass (BIA) and whole body lean body mass (DEXA).","https://ClinicalTrials.gov/show/NCT01998152"
429,"NCT01453452","S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors","Active, not recruiting","No Results Available","Anxiety Disorder|Breast Cancer|Cognitive/Functional Effects|Colorectal Cancer|Depression|Fatigue|Pain|Psychosocial Effects of Cancer and Its Treatment|Weight Changes","Behavioral: behavioral dietary intervention|Behavioral: exercise intervention|Other: counseling intervention|Procedure: quality-of-life assessment","Southwest Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","50","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","S1008|U10CA037429|NCI-2011-03539","October 14, 2011","March 2012","June 2016","September 17, 2015","September 2015","No Study Results Posted","null","August 2015","Attendance of ≥ 2 Curves sessions/week for a minimum of 36 of the 52 weeks of intervention|Increase in fruit and vegetable consumption by 1 full serving per day (not including iceberg lettuce, potatoes, or fruit juices) OR reduce caloric intake by 100 kcal/day|Changes in anthropometric measures (weight, BMI, waist circumference, hip circumference)|Changes in body composition (% body fat as assessed by DXA scan at 12 months only)|Changes in minutes spent per week in moderate-to-vigorous intensity aerobic activity using Curves attendance records and a 7-day physical activity recall assessment|Changes in dietary intake patterns based on three separate 24-hour diet recalls|Changes in metabolic and hormonal biomarkers associated with breast and colorectal cancer-recurrence risk (fasting insulin, fasting glucose, hemoglobin A1C, bioavailable estradiol, free testosterone, and adiponectin)|Changes in anxiety, depression, fatigue, sleep, satisfaction with social roles, pain, and physical function as measured by the PROMIS-43|DNA methylation patterns","https://ClinicalTrials.gov/show/NCT01453452"
430,"NCT00853684","Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer","Recruiting","No Results Available","Advanced Colorectal Cancer","Drug: OXCE|Drug: Endostar","Shanghai Jiao Tong University School of Medicine","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","44","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200902024","February 26, 2009","February 2009","March 2011","September 17, 2009","September 2009","No Study Results Posted","OXCE","December 2010","Time to progression|Overall survival","https://ClinicalTrials.gov/show/NCT00853684"
431,"NCT00422773","Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab","Technische Universität Dresden","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TUD-COFI-014","January 15, 2007","January 2007","null","February 26, 2009","February 2009","No Study Results Posted","null","June 2008","To assess a maximal tolerable dose and the safety of a chemotherapy-combination of cetuximab, irinotecan, oxaliplatin and 5-FU/folinic acid as first-line treatment for metastatic colorectal cancer|To assess the treatment regarding the following: feasibility, toxicity, response rate, resection rate, progression free and overall survival","https://ClinicalTrials.gov/show/NCT00422773"
432,"NCT01858662","Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors","Terminated","No Results Available","Metastatic Colorectal Cancer","Procedure: Metastases Resection ( multiple steep surgery possible)|Drug: 5-Fluorouracile|Drug: leucovorin L|Drug: Oxaliplatin|Drug: Irinotecan|Drug: Cetuximab","Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Grand Hôpital de Charleroi","Both","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CET-ONCO2012|2012-005249-19","May 7, 2013","January 2014","November 2015","April 13, 2016","April 2016","No Study Results Posted","null","November 2015","Major Pathological Response Rate|progression free survival|Overall survival|Clinical response rate|Metabolic response rate|post operative complications|Curative resection rate|Chemotherapy-associated hepatotoxicity:","https://ClinicalTrials.gov/show/NCT01858662"
433,"NCT00154102","Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)","Completed","Has Results","Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)","Merck KGaA","Both","18 Years and older   (Adult, Senior)","Phase 3","1221","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62202-013","September 8, 2005","May 2004","March 2011","June 13, 2014","June 2014","November 30, 2010","CRYSTAL","December 2006","Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments|Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments|Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments|Overall Survival Time (OS)|Overall Survival Time (KRAS Wild-Type Population)|Overall Survival Time (KRAS Mutant Population)|Best Overall Response Rate - Independent Review Committee (IRC) Assessments|Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments|Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments|Disease Control Rate - Independent Review Committee (IRC) Assessments|Duration of Response - Independent Review Committee (IRC) Assessments|Participants With No Residual Tumor After Metastatic Surgery|Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status|Quality of Life Assessment (EORTC QLQ-C30) Social Functioning|Safety - Number of Patients Experiencing Any Adverse Event","https://ClinicalTrials.gov/show/NCT00154102"
434,"NCT02211443","Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer","Enrolling by invitation","No Results Available","Metastatic Colorectal Cancer","Biological: Recombinant full human Anti-EGFR Monoclonal Antibody","Sinocelltech Ltd.","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","SCT200mCRCI","August 5, 2014","January 2015","December 2015","April 8, 2015","April 2015","No Study Results Posted","null","December 2015","Number of participants with SCT200-related adverse events|Area Under the plasma concentration versus time curve (AUC) of SCT200","https://ClinicalTrials.gov/show/NCT02211443"
435,"NCT00531245","A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: TS-1, oxaliplatin","Samsung Medical Center","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","77","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-01-024","September 17, 2007","August 2006","March 2009","June 29, 2009","August 2007","No Study Results Posted","null","June 2008","In a phase I study, to determine the maximum tolerated dose(MTD) In a phase II study, to evaluate the efficacy(response rates) and toxicities|To investigate the time to progression(TTP), overall survival and toxicity","https://ClinicalTrials.gov/show/NCT00531245"
436,"NCT02135887","A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.","Recruiting","No Results Available","Stage III Colorectal Cancer|Neutropenia","Drug: MB-6|Drug: Placebo","Microbio Co Ltd","Both","20 Years to 80 Years   (Adult, Senior)","Phase 3","184","Industry","Observational","Time Perspective: Prospective","MB104CLCT02","May 6, 2014","November 2013","March 2018","September 13, 2016","September 2016","No Study Results Posted","MB-6","December 2017","The primary endpoint is the incidence of grade 4 neutropenia during the chemotherapy period, defined as an absolute neutrophil count (ANC) <500/mm3.|Time to first Grade 4 Neutropenia|Incidence of Febrile Neutropenia|Incidence of Grade 3 or 4 Neutropenia|Change in Serum Creatinine level|Health-Related Quality of Life (HRQoL) - QLQ-C30|Quality of Life -VAS on Fatigue, Constipation, Appetite|Compliance with Chemotherapy|Increase in Body Weight","https://ClinicalTrials.gov/show/NCT02135887"
437,"NCT00364013","PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: FOLFOX regimen","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 3","1183","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20050203","August 10, 2006","August 2006","March 2013","February 19, 2016","February 2016","February 13, 2014","null","August 2009","Progression-free Survival|Overall Survival|Percentage of Participants With an Objective Response|Time to Progression|Duration of Response|Number of Participants With Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT00364013"
438,"NCT02139215","Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","","PeriPharm|Personalized Medicine Partnership for Cancer","Both","18 Years and older   (Adult, Senior)","","72","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PMPC-01","May 13, 2014","April 2014","null","January 13, 2016","January 2016","No Study Results Posted","null","July 2017","The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting","https://ClinicalTrials.gov/show/NCT02139215"
439,"NCT01715441","Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors","Recruiting","No Results Available","Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors","Drug: Sorafenib and irinotecan combination|Drug: Sorafenib monotherapy|Drug: Irinotecan monotherapy","Institut du Cancer de Montpellier - Val d'Aurelle","Both","18 Years and older   (Adult, Senior)","Phase 2","160","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","NEXIRI2|2012-000644-94","October 19, 2012","September 2012","September 2015","March 2, 2015","March 2015","No Study Results Posted","NEXIRI2","March 2015","Non-progression rate|Disease control rate|Treatment-related toxicity|Overall survival|Quality of life|Progression Free Survival|Response rate","https://ClinicalTrials.gov/show/NCT01715441"
440,"NCT02673710","A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Survivors Treated With Chemotherapy Combined With Bevacizumab","Recruiting","No Results Available","Metastatic Colorectal Cancer","Other: No intervention","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","200","Industry","Observational","Observational Model: Cohort","ML29985","January 27, 2016","March 2016","March 2019","September 1, 2016","September 2016","No Study Results Posted","null","March 2019","Progression Free Survival 2 defined as the time interval between study entry and the date of progression or death for any cause, whichever occurs first|Sarcopenia quantified via CT-scan defined as a skeletal muscle index at the 3rd lumbar vertebra below 41 for women and below 43 or 53 for men with a Body Mass Index below or above 25 respectively|Participants body weight at initial diagnosis of mCRC|Participants body mass index at initial diagnosis of mCRC|Participants skeletal muscle mass at initial diagnosis of mCRC|Participants visceral fat mass, subcutaneous fat mass, total fat mass at SE|Participants Eastern Cooperative Oncology Group Performance status at SE|Participant muscle strength at initial diagnosis of mCRC|Participants primary and metastases location at Initial Diagnosis|Participants mutation status at Initial Diagnosis|Participants C-Reactive Protein and Albumin blood values at Initial Diagnosis|Participants Date of diagnosis of non-metastatic CRC disease at Initial Diagnosis|Participant with 1st line Chemotherapeutic regimen at Initial Diagnosis|Functional status using Functional Assessment for Cancer Treatment - specific for Colorectal cancer participants|Participant Physical status expressed in muscle strength|Participant Physical status expressed in Body Weight|Participant Physical status expressed in Body Mass Index|Nutritional status using the Patient-Generated Subjective Global Assessment questionnaire|Nutritional status using Visual Analogue Scale for appetite|Treatment related toxicity using MD Anderson Symptom Inventory scale|Number of participants with Number of chemotherapy cycles|Number of participants with Number of bevacizumab administrations|Number of participants with Treatment changes and treatment (un)changed until Second Progressive Disease|Number of participants with Reason for treatment changes|Intake dietary supplements|Dietary and physical counselling|Number of Participants with Adverse Events|Progression Free Survival 1 is defined as the time between initial diagnosis and first progressive disease","https://ClinicalTrials.gov/show/NCT02673710"
441,"NCT01919879","Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab + Afatinib|Drug: Cetuximab","UNICANCER","Both","18 Years and older   (Adult, Senior)","Phase 2","75","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","UCGI 25","March 1, 2013","October 2012","October 2017","June 16, 2016","June 2016","No Study Results Posted","null","November 2015","Non progression rate at 6 months|Overall response rate (OR)|Progression free survival|Overall and specific survival|Quality of life|Tolerance of the treatment","https://ClinicalTrials.gov/show/NCT01919879"
442,"NCT01704703","Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques","Active, not recruiting","No Results Available","Stage IV Colorectal Cancer","Drug: panitumumab|Drug: FOLFIRI","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","Both","18 Years and older   (Adult, Senior)","Phase 2","82","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-12-03|2012-001955-38","September 27, 2012","October 2012","October 2016","November 17, 2015","March 2015","No Study Results Posted","ULTRA","October 2016","Objective response rate (TRO)|disease control rate (TCE)|duration of response (DR)|time to response(THR)|time to progression (THP)|time to treatment failure (THF)|duration of stable disease (DEE)|Progression free survival (SLP)|Overall survival (SG)|Adverse events","https://ClinicalTrials.gov/show/NCT01704703"
443,"NCT00155727","Comparison of Laparoscopic Colectomy Versus Open Colectomy for Colorectal Cancer: … A Prospective Randomized Trial","Recruiting","No Results Available","Colorectal Cancer","","National Taiwan University Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","600","Other","Observational","Allocation: Random Sample|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","9100017028","September 9, 2005","January 2000","July 2005","December 19, 2005","July 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00155727"
444,"NCT02476045","Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: 5-fluorouracil,leucovorin,panitumumab|Drug: panitumumab|Drug: Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Both","18 Years and older   (Adult, Senior)","Phase 2","224","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","INT 70/15","June 11, 2015","June 2015","July 2018","September 13, 2016","September 2016","No Study Results Posted","Valentino","July 2018","Efficacy|Safety in terms of number of participants with adverse events.|Quality of life|Response rate|duration of response|time to progression|time to treatment failure|overall survival","https://ClinicalTrials.gov/show/NCT02476045"
445,"NCT01754636","Inclusion of Elderly Patients With Colorectal Cancer in Clinical Trials","Recruiting","No Results Available","Colorectal Cancer","Other: No intervention","Assistance Publique - Hôpitaux de Paris","Both","18 Years and older   (Adult, Senior)","","696","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NI 11006","December 18, 2012","January 2012","November 2015","July 30, 2015","July 2015","No Study Results Posted","SAGE","November 2015","Inclusion in at least one Clinical trial (amendment n°3 -02/2014)|Eligibility to participate in in at least one Clinical trial (amendment n°3 -02/2014)|Invitation to participate in in at least one Clinical trial (amendment n°3 -02/2014)","https://ClinicalTrials.gov/show/NCT01754636"
446,"NCT00199173","Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only","Completed","No Results Available","Colorectal Neoplasm|Secondary Malignant Neoplasm of Liver","Device: SIR Spheres intra-arterial hepatic","Jules Bordet Institute|University Hospital, Ghent","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Sir-Spheres1","September 13, 2005","null","January 2010","February 23, 2011","February 2011","No Study Results Posted","null","January 2010","","https://ClinicalTrials.gov/show/NCT00199173"
447,"NCT02394834","An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus. mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer.","Recruiting","No Results Available","Colorectal Cancer","Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab","Takeda","Both","20 Years to 79 Years   (Adult, Senior)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","Panitumumab-4004|U1111-1167-3521|JapicCTI-152837","March 16, 2015","May 2015","September 2018","July 26, 2016","July 2016","No Study Results Posted","null","September 2018","Relationship between overall survival (OS) and mutation of each gene|Progression-Free Survival (PFS)|Percentage of Participants who Achieve or Maintain Any Best Response Category during the Treatment Period.|Duration of response (DOR)|Proportion of patients who proceeded to surgical resection|Proportion of patients with early tumor shrinkage|Degree of the maximum tumor shrinkage (depth of response)|Evaluation of the relationship of each biomarker in plasma free DNA and tumor samples from baseline of the main study|Evaluation of the relationship between a change in each biomarker in plasma free DNA from baseline of the main study and efficacy|Evaluation of the relationship between a change in each biomarker in plasma free DNA from baseline to discontinuation of the protocol treatment of the main study, and efficacy|Evaluation of the relationship between a change in each biomarker in tumor tissue from baseline to discontinuation of the protocol treatment of the main study, and efficacy","https://ClinicalTrials.gov/show/NCT02394834"
448,"NCT02423720","Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers","Not yet recruiting","No Results Available","Colorectal Cancer","Behavioral: Audio-Based Mindfulness","University of California, San Francisco","Both","18 Years and older   (Adult, Senior)","","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","15455","April 17, 2015","May 2015","June 2016","April 21, 2015","April 2015","No Study Results Posted","Mindfulness","December 2015","Proportion of eligible patients and caregivers who agree to be screened, consent to participate, and complete or partially complete the intervention, as a measure of feasibility and acceptability.|Adherence to the intervention, as assessed by frequency and duration of practicing the exercises (recorded in a log and responses to text messages)|Reasons for ineligibility, as a measure of feasibility|Proportion of enrolled patients and caregivers who refuse to participate in or complete the intervention, as a measure of feasibility and acceptability|Reasons for non-participation/non-continuation of the intervention, as a measure of feasibility and acceptability","https://ClinicalTrials.gov/show/NCT02423720"
449,"NCT02553031","Application of MR-PET in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Device: The imaging biomarkers determined by MR-PET","National Taiwan University Hospital","Both","20 Years to 90 Years   (Adult, Senior)","Phase 3","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","201403082MIND","September 10, 2015","July 2014","May 2017","April 12, 2016","April 2016","No Study Results Posted","null","December 2016","The recurrence rate at 1 year after surgery|The overall survival at 1 year after surgery","https://ClinicalTrials.gov/show/NCT02553031"
450,"NCT01161316","Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|Drug: 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","194","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-09-04|2009-017194-38","July 12, 2010","August 2010","June 2015","July 24, 2015","July 2015","No Study Results Posted","MACRO-2","June 2015","progression-free survival|overall survival|rate of objective responses|disease's resectability (R0)|evaluate hypomagnesaemia as a predictive factor in the treatment's efficacy|Adverse events","https://ClinicalTrials.gov/show/NCT01161316"
451,"NCT00079872","Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Pemetrexed","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","2929|H3E-MC-JMAZ","March 17, 2004","February 2004","May 2006","November 5, 2007","November 2007","No Study Results Posted","null","null","The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer|The secondary objectives of the study are as follows:|to assess the following time to event efficacy endpoints for patients in both treatment arms:|overall survival|progression free survival|duration of response|to characterize the quantitative and qualitative toxicities of both treatment arms in this patient population","https://ClinicalTrials.gov/show/NCT00079872"
452,"NCT00531115","Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: cetuximab 5mg/ml","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Merck Sharp & Dohme Corp.","Both","70 Years and older   (Senior)","Phase 2","28","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-06-05|EudraCT Nº: 2006-007062-11","September 17, 2007","November 2007","April 2009","February 19, 2013","February 2013","No Study Results Posted","null","April 2009","Confirmed objective response rate|Disease control, Time to progression, progression-free survival,Time to treatment failure,Determine time to onset of response, Duration of response, Overall survival, To determine biologic prognostic factors|Treatment safety","https://ClinicalTrials.gov/show/NCT00531115"
453,"NCT02542436","Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Other: No intervention","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","300","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ML29965","September 2, 2015","September 2015","December 2015","December 1, 2015","December 2015","No Study Results Posted","null","December 2015","Overall Survival (OS)|Response Rate (RR)|Progression Free Survival (PFS)|Percentage of Participants with Adverse Events of Special Interest","https://ClinicalTrials.gov/show/NCT02542436"
454,"NCT01150877","High Dose Vitamin D Study","Recruiting","No Results Available","Colorectal Cancer","Drug: Vitamin D","University of British Columbia|Lotte & John Hecht Memorial Foundation","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H10-00028","June 22, 2010","January 2011","July 2017","March 26, 2015","March 2015","No Study Results Posted","null","March 2016","The metabolic consequences, including tolerability and toxicity, of prolonged, high-dose physiological vitamin D in patients with colorectal cancer.|Patient survival with regards to high-dose vitamin D supplementation.","https://ClinicalTrials.gov/show/NCT01150877"
455,"NCT02027545","Promoting Veteran-Centered Colorectal Cancer Screening","Enrolling by invitation","No Results Available","Colorectal Cancer","Behavioral: Decision Aid|Behavioral: Provider Education|Behavioral: Performance Measure Modification|Behavioral: Simple Informational Booklet","VA Office of Research and Development","Both","70 Years to 75 Years   (Senior)","","440","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","IIR 12-411","December 18, 2013","October 2015","May 2018","August 9, 2016","August 2016","No Study Results Posted","PROM-IS","April 2018","CRC screening ordered","https://ClinicalTrials.gov/show/NCT02027545"
456,"NCT00860249","Outreach for Patients That Are Newly Eligible for Colorectal Cancer Screening","Terminated","Has Results","Colorectal Cancer","Behavioral: Letter Only|Behavioral: Letter and Educational DVD","Northwestern University|Agency for Healthcare Research and Quality (AHRQ)","Both","50 Years to 50 Years   (Adult)","","60","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Health Services Research","1R18HS017163-02","March 11, 2009","March 2009","December 2009","November 30, 2011","November 2011","September 2, 2011","UPQUAL","December 2009","Completion of CRC Screening|The Secondary Outcome for the Study is the Time to Screening Completion.","https://ClinicalTrials.gov/show/NCT00860249"
457,"NCT02015754","Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: DEBIRI|Device: LC Bead M1|Procedure: TACE","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1305|NA_00078095 [JHMIRB]","December 13, 2013","February 2014","null","July 2, 2014","July 2014","No Study Results Posted","null","June 2015","Success of DEBIRI-M1 Procedure as a Measure of Feasibility|Collection of Adverse Events Related to Study Device as a Measure of Safety|Efficacy","https://ClinicalTrials.gov/show/NCT02015754"
458,"NCT01839877","Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study","Recruiting","No Results Available","Colorectal Cancer With Non Resectable Hepatic Metastasis","Drug: HIA DEBIRI + systemic FOLFOX","Federation Francophone de Cancerologie Digestive|Biocompatibles UK Ltd","Both","18 Years and older   (Adult, Senior)","Phase 2","58","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FFCD 1201 DEBIRI","April 12, 2013","May 2013","July 2017","August 10, 2016","May 2016","No Study Results Posted","null","January 2017","Progression-free survival rate at 9 months|safety of the study treatment|Overall survival","https://ClinicalTrials.gov/show/NCT01839877"
459,"NCT02331927","PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Biological: Aflibercept","University of Ulm|Hubertus-Wald-Cancer Center Hamburg, Germany|Sanofi|Assign Data Management and Biostatistics GmbH","Both","18 Years and older   (Adult, Senior)","Phase 2","200","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PERMAD|2012-005657-24","September 10, 2014","March 2015","March 2021","December 2, 2015","December 2015","No Study Results Posted","PERMAD","March 2019","Run-in phase: Progression free survival (PFS1) of first line treatment|Randomized part: PFS rate at 6 months after first cycle after randomization|Predictive value of CAF particularly PlGF and VEGF-B for early detection of progression during treatment with chemotherapy and bevacizumab|Determination and validation of a CAF profile based on PlGF and VEGF-B predicting tumor progression before radiologic progression|PFS1, after first cycle after randomization (PFSr) and of second line treatment (PFS2)|Time to randomization (TTR)|Overall survival (OS)|Overall response rate (RR) and Secondary resection rate (sRR)|Toxicity, Quality of life (QoL)|Changes in CAF during early marker-driven switch and conventional treatment approach|Prognostic value of CAF at baseline and/or during treatment","https://ClinicalTrials.gov/show/NCT02331927"
460,"NCT02909114","Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Radiation: Stereotactic body radiotherapy","Jing Jin, M.D.|Chinese Academy of Medical Sciences","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-096","September 12, 2016","January 2016","December 2020","September 20, 2016","September 2016","No Study Results Posted","null","December 2020","local control assessed by RECIST|>= Grade 3 treatment-related adverse events as assessed by CTCAE v4.0|overall survival","https://ClinicalTrials.gov/show/NCT02909114"
461,"NCT00920751","Comparison of on Demand Sedation With Study Method Versus on Demand Sedation With Conventional Method for Performing Colonoscopy for Colorectal Cancer Screening and Surveillance","Recruiting","No Results Available","Colorectal Cancer Screening","Procedure: Water infusion|Procedure: Air insufflation","East Bay Institute for Research and Education","Both","50 Years to 80 Years   (Adult, Senior)","","100","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","EBIRE-GI-003","June 11, 2009","March 2009","null","June 12, 2009","June 2009","No Study Results Posted","null","null","Primary outcome - success of cecal intubation without sedation|Diagnostic yield, patients' current experience, willingness to repeat future colonoscopy, turn around time, and staff rating of satisfaction, and medication-related complications.","https://ClinicalTrials.gov/show/NCT00920751"
462,"NCT02543762","Usefulness of Chromoendoscopy for the Early Detection of Colorectal Cancer Associated With Inflammatory Bowel Disease","Completed","No Results Available","Inflammatory Bowel Disease|Colorectal Cancer","Procedure: Chromoendoscopy","Hospital Clinic of Barcelona|Complexo Hospitalario de Ourense|Hospital de Manresa|Hospital Universitario Ramon y Cajal|Hospital Universitario 12 de Octubre|Hospital de Calella|Hospital General de Mostoles|Hospital del Mar|Hospital Universitario La Fe|Puerta de Hierro University Hospital|Hospital Universitario de Canarias|Hospital Universitari de Bellvitge|Hospital de Sant Pau|Complexo Hospitalario Universitario de Vigo|Hospital Universitario Doctor Peset","Both","18 Years and older   (Adult, Senior)","","350","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","3-Ceron","May 20, 2014","February 2012","May 2015","September 4, 2015","September 2015","No Study Results Posted","CE","June 2014","Prevalence and incidence of dysplasia and colitis-associated colorectal cancer in patients with longstanding colonic inflammatory bowel disease (N-IBD), in Spain|Usefulness of advanced endoscopy in displasia characterization (chromoendoscopy ) for the diagnosis and endoscopic differential diagnosis of NIBD.","https://ClinicalTrials.gov/show/NCT02543762"
463,"NCT00176774","Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma","Completed","No Results Available","Colorectal Carcinoma","Drug: Irinotecan|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Tetrathiomolybdate","University of Michigan Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 0075","September 12, 2005","February 2001","April 2004","February 5, 2012","February 2012","No Study Results Posted","null","February 2004","OBJECTIVES|To determine the tolerability and toxicity of tetrathiomolybdate (TM) in combination with irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer.|Toxicity|To evaluate the progression free survival in patients with metastatic colorectal cancer when treated with this regimen.|To determine the success rate of TM leading to target levels of copper depletion in patients treated concurrently with chemotherapy","https://ClinicalTrials.gov/show/NCT00176774"
464,"NCT02052050","Core Stability Program in Colorectal Cancer Survivors","Completed","No Results Available","Colorectal Cancer","Other: core stability","Universidad de Granada","Both","18 Years to 75 Years   (Adult, Senior)","","40","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","CEI2013-MP-18","January 28, 2014","September 2012","April 2015","June 1, 2015","January 2014","No Study Results Posted","null","January 2014","Abdominal isometric endurance|Fatigue|Body composition:|Pain:|Static balance|Flexibility|Functional capacity|Fitness perceived|Lower back muscle strength","https://ClinicalTrials.gov/show/NCT02052050"
465,"NCT01555762","An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)","Completed","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","75 Years and older   (Senior)","","403","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML27829","March 14, 2012","March 2012","June 2016","September 1, 2016","September 2016","No Study Results Posted","null","June 2016","Progression-free survival|Clinical/nutritional profile of elderly patients with metastatic colorectal cancer initiated on Avastin treatment|Change in autonomy (ADL/IADL questionnaires, Balducci classification)|Overall survival|Avastin dosage/regimen|Safety: Incidence of adverse events","https://ClinicalTrials.gov/show/NCT01555762"
466,"NCT00229554","Survey of ColoRectal Cancer Education and Environment Needs","Completed","No Results Available","Colorectal Neoplasms|Mass Screening|Patient Compliance","","VA Office of Research and Development","Both","50 Years to 75 Years   (Adult, Senior)","","4644","U.S. Fed","Observational","Time Perspective: Retrospective","IIR 04-042","September 27, 2005","March 2006","March 2008","April 6, 2015","January 2009","No Study Results Posted","SCREEN","May 2007","colorectal cancer screening compliance","https://ClinicalTrials.gov/show/NCT00229554"
467,"NCT00242788","IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure","Completed","No Results Available","Colorectal Cancer","Drug: Gefitinib and capecitabine","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1839IL/0505","October 20, 2005","February 2004","November 2005","April 22, 2009","April 2009","No Study Results Posted","null","null","Objective tumour response (CR and PR) at study closure based on the RECIST|Incidence of controlled disease (CR, PR and SD) at study closure","https://ClinicalTrials.gov/show/NCT00242788"
468,"NCT02607072","Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial","Recruiting","No Results Available","Colorectal Cancer","Drug: Acetylsalicylic acid (ASA)/aspirin 200 mg daily|Drug: Acetylsalicylic acid (ASA)/aspirin 100 mg daily|Drug: Placebo","The Fourth Affiliated Hospital of Anhui Medical University|The First Affiliated Hospital of Anhui Medical University|Anhui Provincial Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","3000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","APREMEC-01","November 15, 2015","October 2015","October 2022","November 16, 2015","November 2015","No Study Results Posted","APREMEC","October 2020","3-year disease free survival","https://ClinicalTrials.gov/show/NCT02607072"
469,"NCT01538550","Pilot Study of a National Screening Programme for Bowel Cancer in Norway","Enrolling by invitation","No Results Available","Colorectal Cancer|Colorectal Adenomas","Procedure: Flexible sigmoidoscopy|Procedure: iFOBT","Norwegian Department of Health and Social Affairs","Both","50 Years to 74 Years   (Adult, Senior)","Phase 3","140000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","CRCpilotNorway","February 13, 2012","March 2012","December 2030","April 13, 2015","April 2015","No Study Results Posted","null","December 2015","colorectal cancer mortality|Colorectal cancer incidence|Complications and quality assurance|Psychological effects of screening","https://ClinicalTrials.gov/show/NCT01538550"
470,"NCT01198743","Presence of Circulating Tumor DNA in Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Neoplasms","","Assistance Publique - Hôpitaux de Paris","Both","18 Years to 85 Years   (Adult, Senior)","","261","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P040433","June 2, 2010","November 2005","May 2017","July 31, 2016","July 2016","No Study Results Posted","ALGECOLS","May 2017","local recidivism or metastasis reappearance|specificity and global safety","https://ClinicalTrials.gov/show/NCT01198743"
471,"NCT02540850","CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population","Completed","Has Results","Colorectal Cancer|Adenomatous Polyp of Colon|Polyps|Other Disease/Injury|Other Cancers","","BioChain (Beijing) Science and Technology, Inc.|Peking Union Medical College Hospital|General Hospital of Beijing PLA Military Region|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Cancer Hospital","Both","17 Years to 88 Years   (Child, Adult, Senior)","","1031","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RESEPT","August 12, 2015","February 2014","October 2015","January 7, 2016","January 2016","October 13, 2015","RESEPT","September 2015","Ct Value (Ct Values From PCR Reaction)|Sensitivity (Sensitivity of mSEPT9 Assay in Detecting Colorectal Cancer)|Specificity (Specificity of mSEPT9 Assay in Non-CRC Diseases and NED (no Evidence of Diseases))|PPV (the Positive Predictive Value of mSEPT9 Assay in the Population)|NPV (the Negative Predictive Value of mSEPT9 Assay in the Population)|Positivity Rate (The Ratio of Positive mSEPT9 Results in the Population)|Consistency (the Overall Ratio of True Positive and True Negative)","https://ClinicalTrials.gov/show/NCT02540850"
472,"NCT02125409","Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: Acetylsalicylic acid|Procedure: Screening colonoscopy","Aragon Institute of Health Sciences|G. d'Annunzio University|Catholic University, Italy","Both","18 Years to 69 Years   (Adult, Senior)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","D-13-01|2013-004269-15","April 25, 2014","May 2014","null","May 2, 2014","May 2014","No Study Results Posted","null","May 2015","Assessment of the degree of COX-1 acetylation by ASA administered for 1 week.|Changes from baseline in different biomarkers.|Changes from baseline in eicosanoid generation in vivo by measuring urinary metabolites derived from COXs.|Changes in baseline platelet COX-1|Change from baseline in plasma proteins of markers of angiogenesis.|Assessment of ASA plasma levels.|Changes from baseline of proteomic profile of selected angiogenesis factors, ie VEGF, FGF2, TGFbeta, EGF, PDGF, MMP, angiogenin, and angiogenesis inhibitors, ie endostatin, PF4, thrombospondin 1, alpha-macroglobulin, PAI 1 and angiostatin.|Change from baseline in eicosanoid biosynthesis and protein expression of markers of growth and progression of colorectal cancer (such as COX-2, NF-Kb and PI3K/Akt/mTOR pathway).","https://ClinicalTrials.gov/show/NCT02125409"
473,"NCT01904656","CBPR Strategies to Increase Colorectal Cancer Screening in Ohio Appalachia","Active, not recruiting","No Results Available","Colon Cancer|Rectal Cancer","Behavioral: ""Get Behind your health""|Behavioral: Peaches","Ohio State University Comprehensive Cancer Center|National Institute on Minority Health and Health Disparities (NIMHD)","Both","51 Years to 75 Years   (Adult, Senior)","","4320","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","OSU-08168|NCI-2012-00605|R24MD002785","July 12, 2013","September 2009","December 2017","April 8, 2016","April 2016","No Study Results Posted","null","December 2014","Rates of colorectal cancer screening-within-guidelines (status obtained by medical record review).|Confounding - Measurement of prognostic factors measured at baseline for evidence of any imbalance|Effect Modification","https://ClinicalTrials.gov/show/NCT01904656"
474,"NCT02777814","Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Entecavir","Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRC-HBV","April 1, 2016","May 2015","May 2018","May 17, 2016","May 2016","No Study Results Posted","null","May 2017","Incidence of hepatitis B virus associated hepatitis|Incidence of hepatitis B virus reactivation|Interruption of chemotherapy due to hepatitis","https://ClinicalTrials.gov/show/NCT02777814"
475,"NCT01074216","Vitamin D Levels in Stage IV Colorectal Cancer Patients","Completed","Has Results","Colorectal Cancer","Drug: vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","45","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-143","February 22, 2010","February 2010","October 2014","January 4, 2016","January 2016","January 4, 2016","null","October 2014","To Achieve Target Vitamin D Level","https://ClinicalTrials.gov/show/NCT01074216"
476,"NCT02798224","A Patient Portal Tool, e-Assist, for Supporting CRC Screening","Not yet recruiting","No Results Available","Colorectal Cancer","Behavioral: The interactive e-Assist tool|Other: Usual Care (Healthwise CRC Screening document)","Virginia Commonwealth University|National Cancer Institute (NCI)","Both","50 Years to 75 Years   (Adult, Senior)","","3600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Health Services Research","MCC-15-11489|HM20002925|1R01CA197205","June 3, 2016","February 2017","July 2020","June 8, 2016","June 2016","No Study Results Posted","null","January 2019","CRC Screening use","https://ClinicalTrials.gov/show/NCT02798224"
477,"NCT00614393","Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004 AM9)","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: dalotuzumab|Drug: irinotecan hydrochloride|Drug: cetuximab|Drug: Placebo","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","560","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","0646-004|2007_529","January 17, 2008","December 2007","March 2012","October 5, 2015","October 2015","No Study Results Posted","null","June 2010","Overall survival.|Progression-free survival.|Percentage of patients that have clinical or laboratory Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 to 5 toxicity|Percentage of patients that have drug related clinical or laboratory CTCAE Grade 3 to 5 toxicity|Percentage of patients that discontinue study therapy due to adverse event (AE)|Percentage of patients that have a dose modification due to AE|Percentage of patients that experience infusion reactions|Objective response rate of dalotuzumab in combination with Cetuximab (+) Irinotecan versus objective response rate of Cetuximab (+) Irinotecan alone in patients with wild type of colorectal cancer","https://ClinicalTrials.gov/show/NCT00614393"
478,"NCT01791309","Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: combination panitumumab and vemurafenib","Memorial Sloan Kettering Cancer Center|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-221","February 12, 2013","January 2013","March 2015","January 4, 2016","January 2016","No Study Results Posted","null","March 2015","objective response rate (ORR)|progression-free survival (PFS)|overall survival (OS)|safety, tolerability, and adverse event profile|efficacy","https://ClinicalTrials.gov/show/NCT01791309"
479,"NCT02070146","Prospective Data Collection Initiative on Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","","Dutch Colorectal Cancer Group","Both","18 Years and older   (Adult, Senior)","","10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-510","August 7, 2013","May 2013","January 2051","September 9, 2016","September 2016","No Study Results Posted","PLCRC","January 2050","Progression free survival|Health related quality of life|Grade 3/4 (serious) adverse events|Disease free survival|Overall survival|Work Ability Index (WAI)","https://ClinicalTrials.gov/show/NCT02070146"
480,"NCT00551213","A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)","Completed","Has Results","Colorectal Cancer","Biological: Robatumumab|Drug: Irinotecan|Biological: Cetuximab|Drug: Capecitabine|Drug: FOLFOX|Drug: CAPEOX/XELOX|Drug: FOLFIRI","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","67","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P04721|MK-7454-003","October 29, 2007","November 2007","June 2009","December 22, 2015","December 2015","November 10, 2015","null","June 2009","Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism: Fluorodeoxyglucose (FDG) Standardized Uptake Value (SUV) in the Target Lesion|Number of Participants Who Experienced One or More Adverse Events (AEs)|Best Overall Tumor Response Per Investigator Review|Number of Participants Who Discontinued Study Drug Due to an AE|Best Overall Tumor Response Per Central Review|Change From Baseline in Tumor Growth Rate","https://ClinicalTrials.gov/show/NCT00551213"
481,"NCT01070355","Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases","Completed","No Results Available","Colorectal Cancer","Drug: Eicosapentaenoic acid free fatty acid|Drug: Placebo","University of Leeds","Both","18 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GA09/9094|2009-015903-22","February 12, 2010","April 2010","October 2011","October 20, 2011","October 2011","No Study Results Posted","EMT","October 2011","Histological Ki67 cancer cell proliferation index|Histological neo-CK18 cancer cell apoptosis index|Histological tumour CD31-positive cell microvessel density|Safety and tolerability of EPA treatment|Metastatic tissue and healthy liver tissue fatty acid composition and prostaglandin levels|Plasma markers of prostaglandin metabolism|Platelet aggregation|Urinary markers of prostaglandin metabolism","https://ClinicalTrials.gov/show/NCT01070355"
482,"NCT00835185","Study of IMC-11F8 in Participants With Colorectal Cancer","Completed","Has Results","Metastatic Colorectal Cancer","Biological: IMC-11F8 (necitumumab)|Drug: Oxaliplatin|Drug: Folinic acid (FA)|Drug: 5-FU","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","44","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13926|2006-003147-23|CP11-0602|I4X-IE-JFCD","February 2, 2009","August 2007","October 2010","December 21, 2015","December 2015","December 21, 2015","null","January 2010","Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response )|Overall Survival (OS)|Progression-Free Survival (PFS)|Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) or Death|Duration of Response|Serum Anti-IMC-11F8 Antibody Assessment (Immunogenicity)|Maximum Concentration (Cmax) of IMC-11F8 at Study Day 1 of Cycle 1|Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-∞)] of IMC-11F8 at Study Day 1 of Cycle 1|Half-Life (t1/2) of IMC-11F8 at Study Day 1 of Cycle 1|Clearance (CL) of IMC-11F8 at Study Day 1 of Cycle 1|Volume of Distribution (Vss) of IMC-11F8 at Study Day 1 of Cycle 1|Cmax at Study Day 1 of Cycles 2 Through 6|Area Under the Curve (AUC) at Study Day 1 of Cycles 2 Through 6|t1/2 at Study Day 1 of Cycles 2 Through 6|CL at Study Day 1 of Cycles 2 Through 6|Vss at Study Day 1 of Cycles 2 Through 6|Change From Baseline in Tumor Size|Kirsten Rat Sarcoma (KRAS) Mutation Status","https://ClinicalTrials.gov/show/NCT00835185"
483,"NCT00049335","S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine","Southwest Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","29","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000258049|S0030|U10CA032102","November 12, 2002","February 2003","June 2007","January 2, 2013","January 2013","No Study Results Posted","null","June 2007","Feasibility of enrolling patients aged 70 years or older to a Phase II trial including pharmacokinetic sampling|Efficacy of capecitabine for management of advanced colorectal cancer patients aged 70 years or older based on objective response rate and 2 year survival|Toxicity|Assess parameters of clinical pharmacology of capecitabine in patients aged 70 years or older including half life value(s), AUC (area under curve) and steady state levels|Assess whether patients under 60 years have clinical pharmacologic parameters similar to those reported in the literature|Explore, at a preliminary level, the feasibility of studying genetic polymorphisms and gene expression levels of enzymes involved in drug metabolism and resistance to capecitabine","https://ClinicalTrials.gov/show/NCT00049335"
484,"NCT00004193","ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: ISIS 2503","University of Alabama at Birmingham|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","25","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067434|UAB-9860|ISIS-2503-CS6|NCI-G99-1649","January 21, 2000","January 1999","November 2000","April 10, 2013","April 2013","No Study Results Posted","null","November 2000","Determine the response rate, duration of response, and time to progression in patients with metastatic and/or locally recurrent adenocarcinoma of the colon or rectum treated with ISIS 2503, an antisense inhibitor of H-ras|Determine the safety profile of this regimen in these patients.","https://ClinicalTrials.gov/show/NCT00004193"
485,"NCT00766220","Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver","Withdrawn","No Results Available","Colon Cancer|Colorectal Cancer","Drug: SIR-spheres Agent Administration|Drug: Cetuximab|Drug: Irinotecan","M.D. Anderson Cancer Center|Sirtex Medical","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","2004-0779","October 1, 2008","October 2009","January 2012","December 28, 2012","December 2012","No Study Results Posted","null","January 2012","Progression Free Survival","https://ClinicalTrials.gov/show/NCT00766220"
486,"NCT00073138","A Study of ABT-751 in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: ABT-751","Abbott","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M02-446","November 17, 2003","August 2003","February 2005","November 28, 2007","November 2007","No Study Results Posted","null","null","Objective Response Rate in subjects with Recurrent Colorectal Cancer|Time to Tumor Progression (TTP)|Survival|Toxicities associated with treatment administration","https://ClinicalTrials.gov/show/NCT00073138"
487,"NCT02029326","Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab","Recruiting","No Results Available","Colorectal Cancer","","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2009-09-074","September 5, 2013","February 2010","null","January 5, 2014","January 2014","No Study Results Posted","null","January 2014","To explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform|1. RTK activation status during cetuximab treatment using circulating tumor cells|2. signal transduction pathway attributable to cetuximab resistance|3. To analyze correlation between the quantity of circulating tumor cells and treatment response to cetuximab","https://ClinicalTrials.gov/show/NCT02029326"
488,"NCT02753127","A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Napabucasin|Drug: Fluorouracil|Drug: Leucovorin|Drug: Irinotecan|Drug: Bevacizumab","Boston Biomedical, Inc","Both","18 Years and older   (Adult, Senior)","Phase 3","1250","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CanStem303C|BB608-303CRC|2016-001627-31","April 25, 2016","June 2016","null","September 12, 2016","September 2016","No Study Results Posted","CanStem303C","June 2019","Overall Survival|Overall Survival in biomarker positive patients|Progression Free Survival|Progression Free Survival in biomarker positive patients|Objective Response Rate|Disease Control Rate|Objective Response Rate in biomarker positive patients|Disease Control Rate in biomarker positive patients|Number of Patients with Adverse Events|Quality of Life (QoL)","https://ClinicalTrials.gov/show/NCT02753127"
489,"NCT00033748","Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: monoclonal antibody 11D10 anti-idiotype|Biological: monoclonal antibody 3H1 Alu Gel","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","56","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-89903|U10CA031946|CDR0000069324","April 9, 2002","December 2001","June 2010","July 15, 2016","July 2016","No Study Results Posted","null","March 2007","Recurrence free survival|Toxicity","https://ClinicalTrials.gov/show/NCT00033748"
490,"NCT01068132","Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.","Completed","No Results Available","Colorectal Cancer","Drug: Cetuximab|Drug: FOLFIRI","Regione Lombardia|Mario Negri Institute for Pharmacological Research|Istituto Clinico Humanitas|A.O. Ospedale Papa Giovanni XXIII","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","54","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-007524-25","May 4, 2009","April 2009","October 2013","May 9, 2014","May 2014","No Study Results Posted","null","October 2013","Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01068132"
491,"NCT01696981","Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)","Active, not recruiting","Has Results","Colon Carcinoma|Rectal Carcinoma","Other: Screening Questionnaire Administration|Procedure: Sigmoidoscopy","National Cancer Institute (NCI)","Both","55 Years to 74 Years   (Adult, Senior)","","154900","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Screening","NCI-2012-01757|PLCO-1|CDR0000078532|NCI-P93-0050|PLCO-Colorectal","September 28, 2012","November 1993","null","July 6, 2016","July 2016","August 30, 2013","null","May 2012","Colorectal Cancer Deaths|Colorectal Cancer Death Rates|Deaths From All Causes|Death Rates From All Causes|Colorectal Cancer Incidence|Colorectal Cancer Incidence Rates|Complications of Diagnostic Evaluation Following a Positive Screening Test|T0 (Baseline) FSG Screening Results|T3/T5 FSG Screening Result","https://ClinicalTrials.gov/show/NCT01696981"
492,"NCT01564810","Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis|Liver Neoplasms","Drug: Cetuximab|Drug: chemotherapy of mFOLFOX6 or FOLFIRI","Xu jianmin|Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-03","March 26, 2012","September 2006","September 2015","October 23, 2012","October 2012","No Study Results Posted","null","June 2012","the rate of patients converted to resection for liver metastases|progression free survival|overall survival|tumor response","https://ClinicalTrials.gov/show/NCT01564810"
493,"NCT00250029","Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen","Completed","No Results Available","Colonic Diseases|Cancer","Drug: Oxaliplatin","New Mexico Cancer Care Alliance","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0104C","November 3, 2005","April 2004","March 2006","September 23, 2011","April 2010","No Study Results Posted","null","September 2005","To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen","https://ClinicalTrials.gov/show/NCT00250029"
494,"NCT00385970","A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Tegafur-uracil (UFT)|Drug: Calcium folinate (LV)|Drug: Krestin (PSK)","Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group","Both","20 Years to 80 Years   (Adult, Senior)","Phase 3","380","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MCSGO-CCTG-0501","October 8, 2006","March 2006","April 2015","October 25, 2012","October 2012","No Study Results Posted","null","April 2015","3-Year recurrence-free survival rate|5-Year survival rate, incidence of adverse events, treatment compliance, QOL, type of metastasis/recurrence, and 3-year and 5-year recurrence-free survival rates and survival rates based on each parameter including colon/rectum, stage, and IAP.","https://ClinicalTrials.gov/show/NCT00385970"
495,"NCT00631410","Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer","Completed","Has Results","Colorectal Neoplasms","Drug: sunitinib + mFOLFOX6|Drug: sunitinib + mFOLFOX6","Pfizer","Both","20 Years and older   (Adult, Senior)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181148","January 2, 2008","January 2008","March 2010","March 11, 2011","March 2011","July 21, 2010","null","July 2009","Number of Participants With Adverse Events|Plasma Concentration of Sunitinib|Plasma Concentration of Sunitinib Active Metabolite (SU012662)|Plasma Concentration of the Total Drug (Sunitinib Plus SU012662)|Best Overall Response Based on Response Evaluation Criteria in Solid Tumors (RECIST)|Duration of Response (DR)|Progression-Free Survival (PFS)|Sunitinib Relative Dose Intensity in the Treatment Arm A|Sunitinib Relative Dose Intensity in the Treatment Arm B","https://ClinicalTrials.gov/show/NCT00631410"
496,"NCT00673322","Trial of Second Generation Designer T Cells in Colorectal Carcinoma","Terminated","No Results Available","Colorectal Cancer","Biological: Gene Modified T Cells","Roger Williams Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1","1","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","298-04","May 5, 2008","May 2008","August 2012","June 16, 2016","June 2016","No Study Results Posted","null","August 2012","Determine the safety of using modified T cells by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).|Tumor Response|Pharmacokinetics|Pharmacodynamics","https://ClinicalTrials.gov/show/NCT00673322"
497,"NCT01183780","A Study in Second Line Metastatic Colorectal Cancer","Active, not recruiting","Has Results","Colorectal Cancer","Biological: Ramucirumab|Biological: Placebo|Drug: Irinotecan|Drug: Folinic Acid|Drug: 5-Fluorouracil","Eli Lilly and Company|ImClone LLC","Both","18 Years and older   (Adult, Senior)","Phase 3","1072","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13856|I4T-MC-JVBB|CP12-0920|2010-021037-32|CTRI/2011/07/001900","August 4, 2010","December 2010","December 2016","July 18, 2016","July 2016","June 19, 2015","null","July 2014","Overall Survival (OS)|Progression-free Survival (PFS) Time|Percentage of Participants Achieving an Objective Response (Objective Response Rate)|Change From Baseline in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Global Health Status|Change From Baseline in EuroQol- 5D (EQ-5D)|Percentage of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies|Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab","https://ClinicalTrials.gov/show/NCT01183780"
498,"NCT00672828","Interactive Computer Program or Brochure in Increasing Colorectal Cancer Screening Among African Americans","Completed","No Results Available","Colorectal Cancer","Behavioral: Non-tailored CRC screening brochure|Behavioral: Interactive computer intervention","Indiana University|National Cancer Institute (NCI)","Both","51 Years to 80 Years   (Adult, Senior)","","693","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","IUSN-0604-01B|CDR0000584262|5R01CA115983-05","May 3, 2008","January 2008","April 2012","August 16, 2013","August 2013","No Study Results Posted","PACT","April 2012","Self-reported colorectal cancer (CRC) screening adherence with medical record verification of screening test completion|Self-reported CRC discussion and screening test recommendation from provider on intervention/clinic visit date|Provider documentation of CRC discussion and screening test recommendation on intervention/clinic visit date|Self-reported CRC health beliefs|Self-reported stage of CRC screening test adoption","https://ClinicalTrials.gov/show/NCT00672828"
499,"NCT01858649","Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.","Recruiting","No Results Available","Metastatic Colorectal Cancer","Procedure: Metastases resection|Drug: Bevacizumab|Drug: 5 FU|Drug: Oxaliplatin|Drug: Irinotecan","Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Grand Hôpital de Charleroi","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BEV-ONCO2012|2012-005376-34","May 7, 2013","May 2013","null","April 13, 2016","April 2016","No Study Results Posted","BEV-ONCO2012","May 2017","the major pathological response rate|Progression free survival|Overall Survival|Clinical Response Rate|Metabolic Response Rate|Post operative complication","https://ClinicalTrials.gov/show/NCT01858649"
500,"NCT00869271","Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer","Completed","No Results Available","Unresectable Liver Metastasis of Colorectal Cancer","Procedure: tac + folfox4|Procedure: Folfox4","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-01","March 24, 2009","January 2005","December 2007","March 24, 2009","March 2009","No Study Results Posted","null","December 2007","overall survival|progression free survival","https://ClinicalTrials.gov/show/NCT00869271"
501,"NCT02864485","Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases","Recruiting","No Results Available","Colorectal Cancer|Liver Metastases","Procedure: live donor liver transplantation","University Health Network, Toronto","Both","18 Years to 65 Years   (Adult)","","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-9382-C","August 4, 2016","August 2016","December 2023","September 16, 2016","September 2016","No Study Results Posted","null","September 2023","patient survival|disease-free survival|patterns of cancer recurrence after liver transplantation|types of cancer recurrence treatments|Number of participants that drop out of study prior to receiving intervention (transplantation surgery) due to chemotherapy-related adverse events, as assessed by CTCAE v4.0|self-reported quality of life as assessed by EORTC QLQ-C30 questionnaire|survival of intervention vs standard treatment","https://ClinicalTrials.gov/show/NCT02864485"
502,"NCT02715141","Molecular Stool Testing for Colorectal Cancer Surveillance","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Collection of stool sample","The Netherlands Cancer Institute|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Maastricht University Medical Center","Both","50 Years to 75 Years   (Adult, Senior)","","4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","M15MOC|NL52708.018.15","February 17, 2016","October 2015","July 2017","June 17, 2016","June 2016","No Study Results Posted","MOCCAS","July 2017","accuracy of molecular stool test (Cologuard) and FIT|cost-effectiveness of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model|life time health effects of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model|risk of CRC|presence of Cologuard marker pannel on resected tissue of polyps|presence of previously identified progression biomarker on resected tissue samples of polyps","https://ClinicalTrials.gov/show/NCT02715141"
503,"NCT00813137","FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Folfox4 plus recombinant human endostatin (Endostar)","Simcere Pharmaceutical Co., Ltd|The Affiliated Changzhou Tumor Hospital of Suzhou University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","simcere0803","December 19, 2008","October 2008","October 2010","December 6, 2009","December 2009","No Study Results Posted","null","October 2010","Time to progression","https://ClinicalTrials.gov/show/NCT00813137"
504,"NCT02088333","Effectiveness of an mHealth Colorectal Cancer Screening Intervention","Active, not recruiting","No Results Available","Colorectal Neoplasms","Behavioral: mCRC intervention|Behavioral: Healthy Lifestyles video","Wake Forest School of Medicine|National Cancer Institute (NCI)|University of North Carolina, Charlotte","Both","50 Years to 74 Years   (Adult, Senior)","","450","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Health Services Research","CCCWFU 59A13|1R01CA178941","March 10, 2014","June 2014","October 2016","June 2, 2016","June 2016","No Study Results Posted","mCRC","May 2016","Completion of CRC Screening|CRC Screening Attitudes and Beliefs|Intention to receive CRC screening|Self-efficacy|Ability to make a screening decision|CRC screening discussions|Satisfaction with screening decision|CRC screening test order|Cost of the mCRC intervention|Usability of the mCRC system","https://ClinicalTrials.gov/show/NCT02088333"
505,"NCT00457691","Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer","Completed","Has Results","Metastatic Colorectal Cancer","Drug: 5 fluorouracil|Drug: irinotecan|Drug: levo- leucovorin|Drug: sunitinib|Drug: 5 fluorouracil|Drug: irinotecan|Drug: levo- leucovorin|Drug: placebo","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 3","768","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A6181122","April 4, 2007","June 2007","March 2010","March 10, 2015","March 2015","March 9, 2011","null","March 2010","Progression-free Survival (PFS)|Overall Survival (OS)|Number of Participants With Overall Confirmed Objective Response|Duration of Response (DR)|Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Assessment Inventory of Gastrointestinal Symptoms (MDASI-GI) Symptom Intensity Score|Change From Baseline in MDASI-GI Symptom Interference Score|Change From Baseline in European Quality of Life (EuroQol) EQ-5D Self-Report Questionnaire|Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS)","https://ClinicalTrials.gov/show/NCT00457691"
506,"NCT02837263","PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Cancer|Colorectal Adeonocarcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer|Metastatic Carcinoma in the Liver","Radiation: Stereotactic body radiotherapy (SBRT)|Drug: Pembrolizumab","University of Wisconsin, Madison|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1","15","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UW15063|P30CA014520|NCI-2016-01077|2016-0303","July 15, 2016","July 2016","December 2020","July 19, 2016","July 2016","No Study Results Posted","null","March 2018","Recurrence rate at 1 year|Time to recurrence estimated using the Kaplan-Meier method|Disease-free survival estimated using the Kaplan-Meier method|Overall survival estimated using the Kaplan-Meier method","https://ClinicalTrials.gov/show/NCT02837263"
507,"NCT01450319","Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype","Completed","Has Results","Colorectal Neoplasms","Drug: Cetuximab","Merck KGaA|Merck, S.L., Spain","Both","18 Years and older   (Adult, Senior)","Phase 2","70","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 062202-529|2010-023580-18","October 7, 2011","December 2011","December 2014","May 10, 2016","May 2016","May 10, 2016","MUTEX","December 2014","Overall Survival (OS) Time|Percentage of Subjects With Disease Control Rate (DCR)|Progression Free Survival (PFS) Time|Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, AEs Leading to Death|Number of Subjects With Fcγ Receptors (FCγR) IIa/IIIa Polymorphisms|Overall Survival (OS) Related to Codon G13D|Overall Survival (OS) Related to Killer Inhibitory Receptors 2DS4 (KIR2DS4) Functional Receptor (f/d) and Non-functional Receptor (NFR)|Beta 2-microglobulin","https://ClinicalTrials.gov/show/NCT01450319"
508,"NCT00190515","A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)","Active, not recruiting","No Results Available","Colorectal Neoplasms","Drug: 5FU+l-leucovorin|Drug: UFT+Leucovorin","Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan","Both","20 Years to 75 Years   (Adult, Senior)","Phase 3","1101","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG-0205-MF|C000000193","September 12, 2005","February 2003","November 2011","February 2, 2009","February 2009","No Study Results Posted","null","November 2011","Disease-free survival|Overall survival|Rate of adverse event","https://ClinicalTrials.gov/show/NCT00190515"
509,"NCT00928928","Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: Open colectomy|Procedure: laparoscopic colectomy","G. Hatzikosta General Hospital|University of Ioannina","Both","Child, Adult, Senior","Phase 4","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)","GH-1948-03|GHDS-12345-3","June 25, 2009","January 2008","null","June 25, 2009","June 2009","No Study Results Posted","null","June 2009","Oxidative stress markers in patients with colorectal cancer operated with open or laparoscopic approach","https://ClinicalTrials.gov/show/NCT00928928"
510,"NCT00819780","PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors","Completed","Has Results","Colon Cancer|Colorectal Cancer|Rectal Cancer|Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: Bevacizumab|Drug: mFOLFOX6","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","285","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20070509","November 6, 2008","April 2009","July 2016","July 21, 2016","July 2016","July 10, 2014","null","May 2012","Progression-free Survival (PFS)|Overall Survival|Percentage of Participants With an Objective Response|Duration of Response|Time to Disease Progression|Time to Initial Objective Response|Resection Rate|Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)|Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)|Overall Survival in Participants With Wild-type RAS|Overall Survival in Participants With Wild-type RAS / BRAF|Percentage of Participants With an Objective Response for Participants With Wild-type RAS|Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF|Number of Participants With Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT00819780"
511,"NCT02613728","Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Questionnaires|Behavioral: Fluid Diary|Device: TeleRecovery Device","M.D. Anderson Cancer Center|American Society of Colon and Rectal Surgeons","Both","18 Years and older   (Adult, Senior)","","32","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-0583|NCI-2016-00742","November 23, 2015","May 2016","null","September 12, 2016","September 2016","No Study Results Posted","null","May 2018","Cumulative Hospital Length of Stay (LOS)|Failure Rate (FR) in the RecoverMI Arm|Patient Satisfaction Ratings","https://ClinicalTrials.gov/show/NCT02613728"
512,"NCT02246634","Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)","Recruiting","No Results Available","Colorectal Neoplasms|Neoplasm Metastases|Hepatic Neoplasms","Other: Diffusion Weighted MRI scan","Royal Marsden NHS Foundation Trust|Pelican Cancer Foundation","Both","18 Years and older   (Adult, Senior)","Phase 2","58","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCR 4156","September 5, 2014","August 2014","August 2019","September 24, 2014","September 2014","No Study Results Posted","SERENADE","August 2019","To measure a >5% increase in the incidence of synchronous liver metastases additionally diagnosed by DW-MRI when CT is negative or does not confirm the presence of metastatic disease.|To measure the quality of life and patient reported outcome measures using EORTC QLQ - CR29 questionnaire, collected at one year after registration.","https://ClinicalTrials.gov/show/NCT02246634"
513,"NCT00188331","Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy","Completed","No Results Available","Cognition|Fatigue|Colorectal Neoplasm","Behavioral: Neuropsychological Testing","University Health Network, Toronto|Canadian Cancer Trials Group|Young Investigator Award - American Society of Clinical Oncologists|Peterborough K.M. Hunter Graduate Studentship","Both","18 Years to 75 Years   (Adult, Senior)","","441","Other","Observational","Time Perspective: Prospective","COIT1|NCIC Grant No. #15261","September 9, 2005","November 2003","September 2015","March 21, 2016","March 2016","No Study Results Posted","null","September 2015","","https://ClinicalTrials.gov/show/NCT00188331"
514,"NCT02202096","A Pilot Randomized Trial of a Comprehensive Transitional Care Program for Colorectal Cancer Patients","Withdrawn","No Results Available","Colorectal Cancer|Comprehensive Transitional Care Program","Other: Patient education: One-on-one visit|Other: Discharge planning: Assessment of barriers to discharge|Other: Medication reconciliation: Patient medication review|Other: Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Other: Transition coach|Other: Patient-centered discharge instructions: Enhanced|Other: Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|Other: Timely follow-up: Barriers to clinic follow-up visits will be discussed|Other: Timely PCP communication|Other: Follow-up telephone call|Other: Patient hotline: 24 hour follow-up following call to Ask My Nurse number","The University of Texas Health Science Center, Houston","Both","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment","HSC-MS-13-0336","May 19, 2014","February 2015","null","June 13, 2016","June 2016","No Study Results Posted","null","February 2016","Number of post-operative ER visits and readmissions","https://ClinicalTrials.gov/show/NCT02202096"
515,"NCT02103062","Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Neoplasms","Drug: ABI-007","Celgene Corporation","Both","18 Years and older   (Adult, Senior)","Phase 2","41","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ABI-007-COLO-001","March 31, 2014","May 2014","January 2015","March 24, 2016","March 2016","October 27, 2015","null","November 2014","Progression Free Survival (PFS) Rate as Measured at Week 8|Overall Survival|Overall Response Rate (ORR)|Percentage of Participants With Stable Disease for ≥ 8 Weeks, or Complete or Partial Response According to RECIST Version 1.1; Disease Control Rate (DCR)|Duration of Response (DOR)|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT02103062"
516,"NCT02508077","FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer","Recruiting","No Results Available","Recurrent Colorectal Carcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Drug: Fluorouracil|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Biological: Panitumumab","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","25","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15117|NCI-2015-01241|118713","July 22, 2015","February 2016","null","August 18, 2016","August 2016","No Study Results Posted","null","February 2018","PFS assessed by the revised RECIST guideline (version 1.1)|RR assessed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)|Impact of PFS on prior anti-EGFR therapy|Impact of response on prior anti-EGFR therapy|Impact of time since last anti-EGFR exposure on the PFS|Impact of time since last anti-EGFR exposure on the RR","https://ClinicalTrials.gov/show/NCT02508077"
517,"NCT02465502","Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 2","59","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","17217","June 4, 2015","July 2015","July 2017","September 13, 2016","September 2016","No Study Results Posted","null","March 2017","Percentage of participants without disease progression or death at the end of 8 weeks|Progression-Free Survival (PFS)|Overall Survival (OS)|Response Rate (RR)|Disease Control Rate (DCR)|Metabolic response measured by [18F] fluorodeoxyglucose positron emission tomography (FDG PET)|Percentage of participants with grade 1 or higher adverse events, using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03","https://ClinicalTrials.gov/show/NCT02465502"
518,"NCT02873195","Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Recurrent Colorectal Carcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Drug: Atezolizumab|Biological: Bevacizumab|Drug: Capecitabine|Other: Laboratory Biomarker Analysis|Other: Placebo","Academic and Community Cancer Research United|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","135","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RU021416I|NCI-2016-01263|P30CA015083","August 16, 2016","August 2016","null","August 16, 2016","August 2016","No Study Results Posted","null","November 2020","Progression free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1|Objective response rate defined as partial response plus compete response as assessed using RECIST v 1.1 and irRC|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02873195"
519,"NCT00947206","Lay Health Workers and Colorectal Cancer Screening Among Chinese Americans","Completed","No Results Available","Colorectal Neoplasms","Behavioral: LHWO about CRC|Behavioral: Nutrition Education + CRC brochure","University of California, San Francisco|San Francisco State University|NICOS Chinese Health Coalition","Both","50 Years to 75 Years   (Adult, Senior)","","909","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","1R01CA138778-01A1","July 24, 2009","September 2009","May 2014","May 6, 2014","May 2014","No Study Results Posted","null","May 2014","ever had a CRC screening test|up-to-date for CRC screening","https://ClinicalTrials.gov/show/NCT00947206"
520,"NCT02829385","Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Apatinib and XELOX combined treatment group","Shoucheng Ma|LanZhou University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","53","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LZU-123","July 8, 2016","June 2016","September 2018","July 11, 2016","July 2016","No Study Results Posted","null","December 2017","Objective Response Rate (ORR)|Progression-free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02829385"
521,"NCT01292681","Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Other: Multi-modality imaging","Radboud University","Both","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","MICC","February 1, 2011","August 2009","null","September 7, 2011","September 2011","No Study Results Posted","null","January 2012","Correlation early changes in imaging and treatment outcome|Correlation pretreatment imaging values and treatment outcome","https://ClinicalTrials.gov/show/NCT01292681"
522,"NCT01875380","Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms|Metastatic Disease","Drug: Regorafenib","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 2","46","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-13-01|2013-000236-94","June 7, 2013","June 2013","June 2016","June 13, 2016","June 2016","No Study Results Posted","REFRAME","April 2016","Progression-free survival rate at 6 months|Objective response rate|Disease control rate|Time to response|Time to progression|Progression-free survival|Time to treatment failure|Response duration|Duration of stable disease|Overall survival|Incidence and severity of Adverse Events (NCI CTC, version 4.0)|Changes in laboratory values (transaminases, bilirubin, lactate dehydrogenase (LDH), anaemia,neutropenia and thrombocytopenia)|Change in vital signs (weight loss and hypertension)|Incidence of dose adjustments and compliance|Incidence of concomitant medication|Changes in ECOG performance status over time from baseline","https://ClinicalTrials.gov/show/NCT01875380"
523,"NCT01310478","Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasm","Drug: recombinant human endostatin (Endostat)","Fudan University","Both","17 Years to 70 Years   (Child, Adult, Senior)","Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SIM-85","March 7, 2011","August 2010","null","March 7, 2011","June 2010","No Study Results Posted","null","May 2011","Dose limiting toxicity and maximum tolerance dose of continous intravenous Endostar in combination with mFOLFOX6|Parameters of human pharmacokinetics of continous intravenous Endostar in combination with mFOLFOX6","https://ClinicalTrials.gov/show/NCT01310478"
524,"NCT00841282","RCT of Air Insufflation Versus Water Infusion Colonoscopy by Supervised Trainees","Completed","No Results Available","Colorectal Cancer","Procedure: Colonoscopy for colorectal cancer screening|Procedure: Water Infusion Colonoscopy|Procedure: Air insufflation colonoscopy","East Bay Institute for Research and Education","Both","50 Years to 80 Years   (Adult, Senior)","","62","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","EBIRE-GI-002","February 9, 2009","October 2008","February 2009","February 10, 2009","February 2009","No Study Results Posted","null","February 2009","Increments of medications used for sedation|pain score during colonoscopy|success of cecal intubation|willingness to repeat colonoscopy","https://ClinicalTrials.gov/show/NCT00841282"
525,"NCT02321813","Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Randomised Trial in Colorectal Cancer Patients","Active, not recruiting","No Results Available","Quality of Life|Colorectal Neoplasms","Behavioral: quality of life pathway|Other: placebo control","Tumorzentrum Regensburg e.V.|German Federal Ministry of Education and Research","Both","18 Years and older   (Adult, Senior)","Phase 2","220","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","TUZ-QL-CRC-14|01GY1339","December 11, 2014","January 2014","April 2017","January 12, 2016","January 2016","No Study Results Posted","DIQOL","October 2016","proportion of patients in both groups with diseased quality of life (<50 points in at least one dimension)|rates of patients with diseased quality of life in each dimension of the profile","https://ClinicalTrials.gov/show/NCT02321813"
526,"NCT00006015","Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Biological: trastuzumab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","26","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068024|U10CA031946|CALGB-89902","July 5, 2000","May 2000","February 2003","May 1, 2013","June 2011","No Study Results Posted","null","December 2002","Response rate|Time to progression|Overall toxicity","https://ClinicalTrials.gov/show/NCT00006015"
527,"NCT02139475","Factors Influencing Quality of Bowel Cleansing for Colonoscopy in Patients With Colorectal Cancer Surgery; Prospective Observational Study","Recruiting","No Results Available","Colorectal Cancer","Procedure: Colonoscopy","Yonsei University","Both","20 Years and older   (Adult, Senior)","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","4-2013-0772","May 13, 2014","May 2014","December 2014","May 14, 2014","May 2014","No Study Results Posted","null","December 2014","Boston bowel preparation scale (BBPS)","https://ClinicalTrials.gov/show/NCT02139475"
528,"NCT00625625","Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: isosulfan blue|Genetic: polymerase chain reaction|Other: diagnostic laboratory biomarker analysis|Other: immunohistochemistry staining method|Procedure: diagnostic lymphadenectomy|Procedure: therapeutic conventional surgery|Procedure: therapeutic lymphadenectomy","John Wayne Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","225","Other|NIH","Interventional","Primary Purpose: Diagnostic","CDR0000586464|JWCI-GULS-CRCSLN-0104","February 27, 2008","March 2004","null","September 16, 2013","February 2008","No Study Results Posted","null","November 2007","Sensitivity and accuracy of lymphatic mapping in colorectal cancer|Overall survival|Disease-free survival","https://ClinicalTrials.gov/show/NCT00625625"
529,"NCT01939223","COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy","Active, not recruiting","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 3","25","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15983|2012-004369-42","September 6, 2013","December 2013","August 2016","August 25, 2016","August 2016","No Study Results Posted","COAST","August 2016","Disease Free Survival (DFS) as assessed by investigator|Overall Survival (OS)|Number of participants with adverse events as a measure of safety and tolerability.","https://ClinicalTrials.gov/show/NCT01939223"
530,"NCT02559024","Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: MEDI6469","Providence Health & Services|MedImmune LLC","Both","18 Years and older   (Adult, Senior)","Phase 1","44","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","14-102A","September 22, 2015","September 2015","September 2021","June 23, 2016","June 2016","No Study Results Posted","null","September 2020","Safety (side-effects or complications related to the study drug)|Immune Score","https://ClinicalTrials.gov/show/NCT02559024"
531,"NCT02713373","Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery","Recruiting","No Results Available","Recurrent Colorectal Carcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Biological: Cetuximab|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","42","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 274515|NCI-2016-00228|P30CA016056","March 11, 2016","August 2016","January 2018","August 15, 2016","August 2016","No Study Results Posted","null","January 2018","Incidence of adverse events, categorized and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)|Progression free survival (PFS), evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1|Tumor response rate, evaluated according to RECIST 1.1|Objective tumor response using immune-related RECIST|Overall survival (OS)|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02713373"
532,"NCT01853319","Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy","Active, not recruiting","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (BAY73- 4506)","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 3","100","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","16754","May 6, 2013","July 2013","September 2016","August 24, 2016","August 2016","No Study Results Posted","REGARD","April 2015","Number of participants with adverse events as a measure of safety and tolerability|Number of participants with adverse events which caused withdrawal, dose reduction, interruption or discontinuation|Number of death|Number of participants with serious adverse events as a measure of safety and tolerability|Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01853319"
533,"NCT01591109","A Reversal in the Vascularity of Metastatic Liver Tumors From Colorectal Cancer After the Cessation of Anti-VEGF Therapy","Completed","No Results Available","Colorectal Cancer","","NHO - Matsumoto Medical Center","Both","Child, Adult, Senior","","20","Other","Observational","Time Perspective: Retrospective","24-1","May 2, 2012","January 2010","April 2012","May 2, 2012","May 2012","No Study Results Posted","null","April 2012","","https://ClinicalTrials.gov/show/NCT01591109"
534,"NCT00332163","Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy","Completed","Has Results","Metastatic Colorectal Cancer|Skin Rash|Skin Toxicities|Colon Cancer|Colorectal Cancer","Biological: Panitumumab|Drug: Irinotecan|Drug: FOLFIRI|Drug: Pre-emptive Skin Treatment|Drug: Reactive Skin Treatment","Amgen","Both","18 Years to 90 Years   (Adult, Senior)","Phase 2","95","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20050184","May 31, 2006","April 2006","September 2008","January 26, 2016","January 2016","January 12, 2016","STEPP","January 2008","Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period|Percentage of Participants With Any Grade 2 or Higher Skin Toxicity of Any Type During the 6-week Skin Treatment Period|Time to First Occurrence of Specific Grade 2 or Higher Skin Toxicities of Interest|Most Severe Specific Grade 2 or Higher Skin Toxicities of Interest|Time to First Most Severe Specific Grade 2 or Higher Skin Toxicities of Interest|Percentage of Participants With Panitumumab Dose Reductions Due to the Specific Skin Toxicities of Interest|Response Rate at First Scheduled Assessment|Best Overall Response Rate|Rate of Disease Control at First Scheduled Assessment|Time to Treatment Failure|Time to Progression|Overall Survival|Progression-free Survival|Change From Baseline in Overall Dermatologic Quality of Life Index (DLQI) Score","https://ClinicalTrials.gov/show/NCT00332163"
535,"NCT02368886","Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer","Recruiting","No Results Available","Colon Adenocarcinoma|Rectal Adenocarcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Drug: Clobetasol Propionate|Other: Pharmacological Study|Other: Quality-of-Life Assessment|Drug: Regorafenib","Academic and Community Cancer Research United|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RU021407I|NCI-2015-00011|Mod14-008756-03|P30CA015083","February 16, 2015","March 2015","null","September 12, 2016","September 2016","No Study Results Posted","null","February 2018","Proportion of patients in each arm who complete 2 courses of treatment and who intend to initiate course 3 if no progression is noted on the planned disease evaluation|Changes in QOL (according to the HFS14 questionnaire)|Changes in QOL (according to the LASA questionnaire)|Cumulative (total) dose of regorafenib received by patients in the first two courses|OS|PFS|Proportion of patients overall and within each arm experiencing grade 3 or 4 HFS or fatigue|TTP","https://ClinicalTrials.gov/show/NCT02368886"
536,"NCT01892527","Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic|C-met Overexpression","Drug: Tivantinib (ARQ197)","Armando Santoro, MD|Istituto Clinico Humanitas","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","43","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC-2012-001","May 6, 2013","March 2013","March 2017","February 15, 2016","February 2016","No Study Results Posted","null","May 2016","Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects with Locally Advanced or Metastatic Colorectal Cancer with Wild-Type KRAS|Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects","https://ClinicalTrials.gov/show/NCT01892527"
537,"NCT00825110","SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","3750","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCR3085","January 16, 2009","November 2008","June 2016","January 16, 2009","January 2009","No Study Results Posted","null","June 2016","the primary endpoint is the identification of cases with evidence of loss of the product of one of the four main MMR genes on tumour histology.|Secondary outcome measure is the survival and response to treatment of the identified cases.","https://ClinicalTrials.gov/show/NCT00825110"
538,"NCT01589146","ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.","Recruiting","No Results Available","The Primary Study Objective is to Assess the Efficacy and|Safety of Extended 4-week Heparin Prophylaxis Compared to|Prophylaxis Given for 8±2 Days After Planned Laparoscopic|Surgery for Colorectal Cancer.|The Clinical Benefit Will be Evaluated as the Difference in|the Incidence of VTE or VTE-related Death Occurring Within 30 Days|From Surgery in the Two Study Groups.","Drug: Heparin, Low-Molecular-Weight","University Of Perugia","Both","18 Years and older   (Adult, Senior)","Phase 3","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","Unipg-CRU-01-2012","April 28, 2012","September 2010","null","April 28, 2012","April 2012","No Study Results Posted","PRO-LAPS I","December 2012","symptomatic objectively confirmed VTE, asymptomatic ultrasonography-confirmed DVT or VTE-related death","https://ClinicalTrials.gov/show/NCT01589146"
539,"NCT02316535","Low-dose Capecitabine Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Capecitabine","West China Hospital","Both","70 Years to 90 Years   (Senior)","Phase 3","710","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LcACEC-201474","December 9, 2014","November 2014","May 2018","September 10, 2016","September 2016","No Study Results Posted","LcACEC","December 2017","disease free survival|overall survival|toxic and adverse effects|completion rate|quality of life","https://ClinicalTrials.gov/show/NCT02316535"
540,"NCT00548236","The Active After Cancer Trial (AACT)","Active, not recruiting","No Results Available","Breast Cancer|Colorectal Cancer","Behavioral: Telephone-Based exercise intervention","Dana-Farber Cancer Institute|Cancer and Leukemia Group B","Both","18 Years and older   (Adult, Senior)","","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","07-266","October 22, 2007","October 2007","July 2017","June 1, 2016","June 2016","No Study Results Posted","AACT","March 2010","To evaluate the ability of a multi-center, telephone-based physical activity intervention to increase weekly physical activity levels in sedentary patients treated with adjuvant chemotherapy for Stage I-III breast or colorectal cancer.|To evaluate the impact of a physical activity intervention upon fitness, exercise self-efficacy, anthropometric measures, and quality of life in a group of patients with stage I-III breast or colorectal cancer.","https://ClinicalTrials.gov/show/NCT00548236"
541,"NCT02195011","Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases","Recruiting","No Results Available","Colorectal Neoplasms","Device: SIR-Spheres|Drug: Regorafenib","SCRI Development Innovations, LLC|Sirtex Medical","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI GI 189","July 17, 2014","June 2014","December 2016","May 6, 2016","May 2016","No Study Results Posted","null","September 2016","Number of participants with serious and non-serious adverse events|Overall Response Rate (ORR)|Progression Free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02195011"
542,"NCT01040000","Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Pancreatic Cancer|Metastatic Colorectal Cancer","Drug: NPC-1C/NEO-102","Precision Biologics, Inc","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","116","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Neogenix 0901","December 23, 2009","January 2012","April 2018","November 25, 2015","November 2015","No Study Results Posted","null","January 2018","Efficacy will be assessed by analysis of CT scans pre and post therapy, clinical laboratory tests, and physical examinations.|Efficacy OS|Safety will be assessed by analysis of adverse experiences, clinical laboratory tests, and physical examinations.|Pharmacokinetics and select immune responses to the antibody will be assessed.","https://ClinicalTrials.gov/show/NCT01040000"
543,"NCT02175654","Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab","Terminated","No Results Available","Colorectal Neoplasms|Metastatic Disease","Drug: Regorafenib","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 2","15","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-14-01|2014-000703-26","June 12, 2014","June 2014","May 2016","July 18, 2016","July 2016","No Study Results Posted","PREVIUM","May 2016","Progression free survival rate at 6 months|Objective response rate based on the Response Evaluation Criteria in Solid Tumors criteria|Disease control rate|Response according other criteria (Appendix 9)|Time to response|Progression free survival|Time to treatment failure|Response duration|Duration of stable disease|Overall survival|Time to progression|Incidence and severity of adverse events (AE) (NCI CTC, version 3.0)|Changes in laboratory values|Change in vital signs (weight loss and hypertension)|Incidence of dose adjustments and compliance|Incidence of concomitant medication|Changes in ECOG performance status over time from baseline","https://ClinicalTrials.gov/show/NCT02175654"
544,"NCT02495532","Clinical Trial Comparing Carnoy's and GEWF Solutions for Lymph Node Clearing Technique in Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis","Other: Lymph node clearing technique with Carnoy solution|Other: Lymph node clearing technique with GEWF solution","Hospital Moinhos de Vento|Federal University of Health Science of Porto Alegre","Both","18 Years and older   (Adult, Senior)","","126","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","39919814.7.0000.5330","April 16, 2015","March 2015","March 2018","July 8, 2015","July 2015","No Study Results Posted","null","February 2018","Lymph nodes harvested|Lymph node metastasis|Upstage of lymph nodes|Adjuvant therapy","https://ClinicalTrials.gov/show/NCT02495532"
545,"NCT00609622","Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer","Terminated","Has Results","Colorectal Neoplasms","Drug: sunitinib|Drug: mFOLFOX6|Drug: bevacizumab|Drug: mFOLFOX6","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","191","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181104","January 25, 2008","April 2008","July 2011","September 10, 2012","September 2012","July 6, 2012","null","July 2011","Progression-free Survival (PFS)|Overall Survival (OS)|One Year Survival Probability|Two Year Survival Probability|Percentage of Participants With Objective Response (OR)|Duration of Response (DR)|Change From Baseline in Functional Assessment of Cancer Treatment - Colorectal (FACT-C) Score|Change From Baseline in Functional Assessment of Cancer Treatment - Gynecologic Oncology Group Oxaliplatin-Specific Neurotoxicity (FACT&GOG-Ntx) Score","https://ClinicalTrials.gov/show/NCT00609622"
546,"NCT00905047","Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: XELODA|Drug: TEGAFUR URACIL - FOLINIC ACID","Centre Oscar Lambret","Both","18 Years and older   (Adult, Senior)","Phase 3","89","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","COLOCROSS","May 18, 2009","September 2005","September 2011","July 20, 2012","July 2012","No Study Results Posted","COLOCROSS","June 2010","patients preference after randomization and cross-over|safety of each treatment","https://ClinicalTrials.gov/show/NCT00905047"
547,"NCT01307878","New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction","Recruiting","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis|Liver Neoplasms|Chemotherapy; Maternal, Affecting Fetus","Drug: chemotherapy ± targeted therapy","Fudan University|Zhejiang University|Second Affiliated Hospital, School of Medicine, Zhejiang University|The First Affiliated Hospital with Nanjing Medical University|Shanghai 6th People's Hospital|Shanghai 9th People's Hospital|Ruijin Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20110101","March 2, 2011","January 2011","December 2015","December 10, 2013","December 2013","No Study Results Posted","null","December 2013","liver metastasis resection rate|progression free survival|recurrence rate|overall survival","https://ClinicalTrials.gov/show/NCT01307878"
548,"NCT01293942","IXO+A in mCRC With Liver-only Metastases","Withdrawn","No Results Available","Metastatic Colorectal Cancer","Drug: irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab","Ottawa Hospital Research Institute|Hoffmann-La Roche|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OTT 10-01","February 8, 2011","March 2011","February 2012","June 4, 2013","June 2013","No Study Results Posted","null","February 2012","conversion to resectability during downsizing therapy with IXO+A patients with initially unresectable liver-only metastases associated with colorectal cancer|Recurrence-free survival (RFS)|Progression-free survival (PFS)|Time to response (TTR)|Overall survival (OS)|Pathological complete response (pCR) rate|Overall response rate (ORR)|Number of participants with Adverse Events as a measure of Safety and Tolerability|Surgical safety (frequency of surgical complications)|Pathological changes in the non-tumoural liver following therapy with IXO+A|R0, R1, R2 resection rate after up to 8 cycles of downsizing therapy with IXO+A","https://ClinicalTrials.gov/show/NCT01293942"
549,"NCT00440310","Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases","Completed","Has Results","Liver Metastases|Colorectal Neoplasms|Neoplasm Metastasis|Neoplasm Recurrence, Local","Drug: Talaporfin sodium|Procedure: Percutaneous placement of device in liver metastases|Device: Interstitial light emitting diodes|Drug: FOLFOX4 regimen|Drug: FOLFIRI regimen","Light Sciences Oncology","Both","18 Years and older   (Adult, Senior)","Phase 3","483","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LSO-OL006","February 23, 2007","February 2007","October 2011","July 28, 2015","July 2015","July 28, 2015","null","May 2011","Overall Survival","https://ClinicalTrials.gov/show/NCT00440310"
550,"NCT00225641","Assessment of Frequency of Surveillance After Curative Resection in Patients With Stage II and III Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Procedure: CT-scan, CEA, X-ray of lungs|Procedure: CT-scan, CEA, X-ray of lungs","Bispebjerg Hospital|Nordic Cancer Union|Danish Cancer Society|Danish Colorectal Cancer Group","Both","18 Years to 75 Years   (Adult, Senior)","","2500","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","COLOFOL|Danish Cancer Union 56 100 306","September 22, 2005","March 2006","December 2015","December 21, 2015","December 2015","No Study Results Posted","null","December 2015","Overall and cancer-specific mortality|Quality of life. Cost-effectiveness of follow-up","https://ClinicalTrials.gov/show/NCT00225641"
551,"NCT00314353","Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon","Terminated","Has Results","Colorectal Neoplasms","Drug: Bevacizumab|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Irinotecan","NSABP Foundation Inc|Genentech, Inc.|Hoffmann-La Roche|International Drug Development Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","7","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP FC-BV-003","April 11, 2006","March 2006","June 2010","June 8, 2010","June 2010","November 7, 2008","null","May 2008","One-year Progression-free Survival (PFS)|Objective Response Rate|Toxicity - Adverse Events|Overall Survival|Duration of Response","https://ClinicalTrials.gov/show/NCT00314353"
552,"NCT01545141","Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal","Drug: Chemokine modulatory regimen","Pawel Kalinski|Hemispherx Biopharma|University of Pittsburgh","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10-131","February 29, 2012","October 2012","August 2017","December 23, 2015","December 2015","No Study Results Posted","null","August 2016","Change in the number of tumor-infiltrating CD8+ cells.|Number of adverse events related to study treatment","https://ClinicalTrials.gov/show/NCT01545141"
553,"NCT00478309","Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants","Completed","No Results Available","Colorectal Cancer|Healthy, no Evidence of Disease","Other: counseling intervention|Other: educational intervention","Fox Chase Cancer Center","Both","50 Years and older   (Adult, Senior)","","697","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CDR0000538405|IRB#06807","May 23, 2007","March 2007","null","March 1, 2016","March 2016","No Study Results Posted","null","March 2014","Comparison of Genetic Epidemiology and Risk Assessment (GERA) feedback vs usual care (UC) in terms of colorectal cancer (CRC) screening utilization|Impact of GERA feedback and UC on psychological distress|Comparison of GERA feedback vs UC in terms of intention to have CRC screening, perceived CRC risk, CRC knowledge, salience and coherence of CRC screening, and support for CRC screening|Factors that moderate the impact of GERA feedback on CRC screening utilization","https://ClinicalTrials.gov/show/NCT00478309"
554,"NCT00078468","Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment","Completed","No Results Available","Colorectal Neoplasms","Drug: PELITREXOL/AG-2037","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","56","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4371004","February 27, 2004","December 2003","September 2004","November 8, 2006","August 2006","No Study Results Posted","null","null","To determine the overall objective response rate (complete and partial responses) of AG-2037 in patients with metastatic colorectal cancer who failed treatment with 5FU/LV regimen and up to one other chemotherapeutic regimen.|To estimate time to progression (TTP).|To evaluate the overall survival (1-year) of patients treated with AG-2037.|To assess changes in patient reported outcomes using health-related quality of life questionnaires.|To evaluate the safety of AG-2037.|To evalutate the PK and PD of AG-2037.|To correlate the various genetic markers of MTAP, folate and purine metabolism with clinical response.","https://ClinicalTrials.gov/show/NCT00078468"
555,"NCT00630786","Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study","Completed","Has Results","Colon Cancer|Colorectal Cancer|Rectal Cancer|Metastatic Colorectal Cancer|Oncology","Drug: Panitumumab|Drug: Conatumumab","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","53","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20060332|2007-004722-25","February 28, 2008","January 2008","November 2010","February 5, 2014","February 2014","August 6, 2010","null","May 2009","Part 1: Number of Participants With Dose-limiting Toxicities|Number of Participants With an Objective Response|Progression-free Survival|Overall Survival|Number of Participants With Disease Control|Time to Response|Duation of Response|Number of Participants With Anti-therapeutic Antibodies|Number of Participants With Adverse Events (AEs)|Number of Participants With Post-baseline Laboratory Values Grade 3 or Higher","https://ClinicalTrials.gov/show/NCT00630786"
556,"NCT00825240","Formative Study of Tailored Survivor Health Promotion","Completed","No Results Available","Colorectal Cancer","Behavioral: One-time Questionnaire + Recorded Qualitative Interview","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","","15","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","2008-0296","January 15, 2009","December 2008","November 2014","March 6, 2015","March 2015","No Study Results Posted","null","November 2014","Colorectal Cancer Patients' Concerns + Behavior Changes Post Treatment","https://ClinicalTrials.gov/show/NCT00825240"
557,"NCT00061815","Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: oxaliplatin|Drug: leucovorin|Drug: 5-fluorouracil|Drug: 5-fluorouracil|Biological: cetuximab","ImClone LLC|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 3","102","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA225-014","June 4, 2003","March 2003","November 2005","April 8, 2010","April 2010","No Study Results Posted","null","December 2004","Compare overall survival in subjects with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-FU, and LV (FOLFOX4) and cetuximab with FOLFOX4 alone.|Compare the response rates between the two treatment arms.|Compare progression-free survival between the two treatment arms.|Duration of response within each treatment arm.|Time to response within each treatment arm.|Compare the safety profiles between the two treatment arms.|Compare the quality of life (QOL)between the two treatment arms.|Conduct an economic assessment comparing healthcare resource utilization between the two treatment arms.","https://ClinicalTrials.gov/show/NCT00061815"
558,"NCT02717923","A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Other: maintenance treatment with capecitabine plus cetuximab","Huazhong University of Science and Technology","Both","Child, Adult, Senior","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TJCC005","March 18, 2016","January 2014","null","April 3, 2016","April 2016","No Study Results Posted","null","January 2019","Progression-Free Survival of maintaining treatment（mPFS）","https://ClinicalTrials.gov/show/NCT02717923"
559,"NCT01082315","A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment","Completed","No Results Available","Colorectal Neoplasms","Drug: Erbitux (Cetuximab)","Merck KGaA","Both","Child, Adult, Senior","","730","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","EMR 62202-509 (EMR 62202-551)","March 3, 2010","April 2009","July 2014","August 28, 2014","August 2014","No Study Results Posted","null","July 2014","Safety|Clinical efficacy","https://ClinicalTrials.gov/show/NCT01082315"
560,"NCT00115765","PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study","Completed","Has Results","Colorectal Cancer","Drug: Oxaliplatin Based Chemotherapy|Drug: Panitumumab|Drug: Irinotecan Based Chemotherapy|Drug: Bevacizumab","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 3","1053","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20040249","June 26, 2005","June 2005","December 2009","June 13, 2013","June 2013","August 19, 2010","null","March 2007","Progression-Free Survival (Oxaliplatin)|Objective Tumor Response Through Week 12 (Irinotecan)|Overall Survival (Oxaliplatin)|Objective Tumor Response Rate (Oxaliplatin)|Time to Progression (Oxaliplatin)|Time to Treatment Failure (Oxaliplatin)|Overall Survival (Irinotecan)|Progression-free Survival (Irinotecan)|Objective Tumor Response Rate (Irinotecan)|Time to Progression (Irinotecan)|Time to Treatment Failure (Irinotecan)","https://ClinicalTrials.gov/show/NCT00115765"
561,"NCT02781337","Epidemiological and Molecular Colorectal Cancer Registry","Recruiting","No Results Available","Colorectal Neoplasms|Colorectal Cancer","","Hospital Italiano de Buenos Aires","Both","18 Years and older   (Adult, Senior)","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1513|REM-CCR","May 17, 2016","May 2012","null","May 19, 2016","May 2016","No Study Results Posted","EMR-CRC","December 2020","Overall survival|Disease-free survival|Molecular characteristics of colorectal adenocarcinoma.","https://ClinicalTrials.gov/show/NCT02781337"
562,"NCT00973609","Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)","Completed","No Results Available","Colorectal Neoplasms","Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab","AIO-Studien-gGmbH|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 3","853","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AIO-KRK-0207|ML21768|EudraCT-Nr.: 2008-007974-39","August 19, 2009","August 2009","August 2015","August 31, 2015","August 2015","No Study Results Posted","null","December 2014","Time to failure of maintenance and reinduction treatment strategy measured from randomization|TFS, Toxicity, QoL, PFS 1, PFS 2, ORR (first induction), ORR (reind. treatm.), Treatment free interval/duration of maintenance therapy, second. Resection rate, Reasons for discontinuation, OS, Translational research.","https://ClinicalTrials.gov/show/NCT00973609"
563,"NCT00036517","Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer","Terminated","No Results Available","Colorectal Neoplasms|Diarrhea","Drug: PHY906","PhytoCeutica","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double-Blind|Primary Purpose: Treatment","PHY906-2000-1","May 10, 2002","February 2002","March 2003","June 23, 2005","September 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00036517"
564,"NCT00361842","Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection","Celator Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 2","59","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Protocol CLTR0105-201","August 7, 2006","July 2006","December 2008","July 25, 2016","May 2012","No Study Results Posted","null","December 2008","Response rate will be assessed using RECIST criteria.|Incidence and severity of adverse experiences and changes in laboratory values","https://ClinicalTrials.gov/show/NCT00361842"
565,"NCT00582335","Identification of New Colorectal Cancer Genes","Active, not recruiting","No Results Available","Colorectal Cancer","","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","","337","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","98-003","December 21, 2007","February 1998","December 2016","January 4, 2016","January 2016","No Study Results Posted","null","December 2016","Evidence of mutations in selected candidate genes","https://ClinicalTrials.gov/show/NCT00582335"
566,"NCT02392143","Promoting CRC Screening in an Urban Minority Population","Completed","No Results Available","Colorectal Cancer","Other: Printed Education Material|Other: Academic Detailing|Other: Academic Detailing+Telephone Education","Teachers College, Columbia University|Columbia University|1199SEIU Benefit and Pension Funds","Both","50 Years to 75 Years   (Adult, Senior)","","564","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Screening","542376","March 12, 2015","January 2009","September 2014","March 17, 2015","March 2015","No Study Results Posted","null","September 2014","Colorectal Cancer Screening","https://ClinicalTrials.gov/show/NCT02392143"
567,"NCT02413853","Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Adenocarcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Drug: CBP/beta-catenin Antagonist PRI-724|Biological: Bevacizumab|Drug: Leucovorin Calcium|Drug: Oxaliplatin|Drug: Fluorouracil|Other: Laboratory Biomarker Analysis","University of Southern California|National Cancer Institute (NCI)|Prism Pharma Co., Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Other|NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-13-3|NCI-2015-00436|R01CA166161|P30CA014089","April 7, 2015","November 2015","November 2018","September 24, 2015","September 2015","No Study Results Posted","PRIMIER","November 2017","Progression free survival (PFS)|Overall survival (OS)|Overall response rate|Incidence of adverse events evaluated according to the National Cancer Institute CTCAE version 4.0|Survivin mRNA expression levels","https://ClinicalTrials.gov/show/NCT02413853"
568,"NCT00411450","Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment","Completed","Has Results","Colon Cancer|Colorectal Cancer|Rectal Cancer|Cancer|Metastatic Cancer|Metastatic Colorectal Cancer|Oncology","Biological: Panitumumab|Drug: FOLFIRI","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","116","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20060277","December 12, 2006","November 2006","October 2010","January 15, 2016","January 2016","January 15, 2016","PRECEPT","January 2009","Objective Response Rate at Weeks 17 and 25|Best Response During Second-Line Treatment|Progression-free Survival Rate at Weeks 17 and 25|Progression-free Survival Time|Disease Control Rate at Weeks 17 and 25|Duration of Response|Overall Survival|Time to Treatment Failure|Time to Progression|Time to Response|Number of Participants With Adverse Events|Number of Participants With Grade 4 Laboratory Toxicities|Number of Participants Who Developed Antibodies to Panitumumab","https://ClinicalTrials.gov/show/NCT00411450"
569,"NCT02703571","Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors","Recruiting","No Results Available","Solid Tumors|Pancreatic Cancer|Colorectal Cancer","Drug: ribociclib|Drug: Trametinib","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","84","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTMT212X2106|2015-005019-34","March 4, 2016","June 2016","October 2018","September 4, 2016","September 2016","No Study Results Posted","null","October 2018","Incidence of dose limiting toxicities (DLTs)|Objective Response Rate (ORR)|Duration of response (DOR)|Time to response|Disease control rate|Progression disease rate|Progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT02703571"
570,"NCT02654639","Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: TAS-102 and Bevacizumab","Georgetown University","Both","18 Years and older   (Adult, Senior)","Phase 2","45","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-0959","January 8, 2016","February 2016","February 2020","August 17, 2016","August 2016","No Study Results Posted","ALEXANDRIA","October 2019","Progression-Free Survival","https://ClinicalTrials.gov/show/NCT02654639"
571,"NCT02305758","Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Untreated Metastatic Colorectal Cancer","Drug: Veliparib|Drug: Placebo","AbbVie","Both","18 Years to 99 Years   (Adult, Senior)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","M14-217|2014-002866-65","December 1, 2014","December 2014","May 2017","August 2, 2016","August 2016","No Study Results Posted","null","May 2017","Progression-free survival (PFS)|Overall Survival|Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT02305758"
572,"NCT00724503","FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Colorectal Carcinoma|Liver Metastases","Drug: Systemic chemotherapy (FOLFOX)|Device: SIR-Spheres yttrium-90 microspheres|Drug: Systemic chemotherapy (FOLFOX)","Sirtex Medical","Both","18 Years and older   (Adult, Senior)","","518","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","STX0206","July 25, 2008","August 2006","April 2018","December 4, 2015","December 2015","No Study Results Posted","SIRFLOX","January 2017","progression free survival","https://ClinicalTrials.gov/show/NCT00724503"
573,"NCT02066688","Study of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: folic acid|Drug: folic acid calcium vitamin D3|Drug: calcium","Shanghai Jiao Tong University School of Medicine|Ministry of Science and Technology of the People´s Republic of China","Both","50 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","2400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SQ2011SF12RJ|SQ2011SF12-20121010","February 17, 2014","January 2013","December 2017","February 18, 2014","February 2014","No Study Results Posted","null","December 2015","The primary objective of this study is to investigate the incidence of colorectal adenoma (CRA) after Folic acid, calcium and vitamin D intervention.|the incidence of advanced colorectal adenoma (A-CRA) after Folic acid, calcium and vitamin D intervention.|changes in serum calcium|changes in serum FA|the incidence of colorectal cancer (CRC) after Folic acid, calcium and vitamin D intervention.|changes in clinical symptoms scores (positive immunochemical fecal occult blood test (iFOBT), diarrhea, or constipation et al)|differences in Histological types of CRA OR CRC","https://ClinicalTrials.gov/show/NCT02066688"
574,"NCT00476970","Colorectal Cancer Screening Navigator Program for Low Income and Non-English Speaking Populations","Completed","No Results Available","Colorectal Cancer","Behavioral: Patient Navigation","Massachusetts General Hospital","Both","52 Years to 79 Years   (Adult, Senior)","","1223","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","2006P 002254","May 21, 2007","September 2007","September 2008","September 20, 2016","September 2016","No Study Results Posted","null","September 2008","Percentage of Eligible Patients In Study and Control Groups Who Undergo CRC Screening|Type of CRC Screening Test Performed in Study vs Control Groups|Number of Polyps and Cancers per 100 Patients in the Study vs Control Group","https://ClinicalTrials.gov/show/NCT00476970"
575,"NCT02487992","The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Neoplasms","Biological: Cytokine-Induced Killer Cells","The First People's Hospital of Changzhou","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CZYY-CRC-001","June 30, 2015","July 2015","July 2045","February 23, 2016","February 2016","No Study Results Posted","null","July 2043","Overall Survival(OS)|Disease-free survival","https://ClinicalTrials.gov/show/NCT02487992"
576,"NCT00813605","Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma","Completed","No Results Available","Metastatic Colorectal Cancer","Other: FOLFIRI|Biological: AMG 655|Other: Placebo|Biological: AMG 479","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","155","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","20060579","December 22, 2008","March 2009","June 2012","April 27, 2016","April 2016","No Study Results Posted","null","January 2011","Progression Free Survival|Overall Survival, Objective Response, Duration of Response, Time to Response|Incidence of adverse events|Significant laboratory abnormalities|Incidence of antibody formation","https://ClinicalTrials.gov/show/NCT00813605"
577,"NCT00720993","Colorectal Cancer Screening Validation Study","Enrolling by invitation","No Results Available","Colorectal Cancer Screening","","IntelliGeneScan, Inc.|BiotechNiks / Molecular Medicine Research Institute","Both","50 Years and older   (Adult, Senior)","","165","Industry|Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IGS-08-001","July 21, 2008","August 2008","May 2009","April 22, 2009","February 2009","No Study Results Posted","CRC screening","May 2009","- To select a threshold for Mahalanobis distance to determine the best operating characteristics (sensitivity and specificity) in subjects with cancer and subjects without cancer. - To explore other empirical metrics based on previous exploratory data|- To obtain data to estimate sensitivity, specificity, and the ROC curve for a test based on M-distance. - To determine the variability of sensitivity and specificity estimates","https://ClinicalTrials.gov/show/NCT00720993"
578,"NCT02038283","Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening","Completed","No Results Available","Colorectal Neoplasms","","The University of Hong Kong|Queen Mary Hospital, Hong Kong|Food and Health Bureau, Hong Kong","Both","18 Years and older   (Adult, Senior)","","587","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HKCTR-973","August 28, 2013","October 2009","June 2012","May 13, 2016","May 2016","No Study Results Posted","null","July 2010","SF-6D Preference-based Value|Quality-adjusted life years for each screening strategy|Direct Health Care Costs for each CRC screening strategy|HRQOL by SF-12v2 and FACT-C|Health Service Utilizations|Factors Associated with HRQOL","https://ClinicalTrials.gov/show/NCT02038283"
579,"NCT01629524","Influence of Tumor Associated Immunity on the Number of Lymph Node Retrieved After Colorectal Cancer Surgery (Preliminary Study)","Completed","No Results Available","Colorectal Cancer","","Yonsei University","Both","20 Years to 80 Years   (Adult, Senior)","","25","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2012-08","June 25, 2012","June 2012","December 2012","January 28, 2013","January 2013","No Study Results Posted","null","December 2012","Association between immune related cytokine and number of lymph nodes retrieved.","https://ClinicalTrials.gov/show/NCT01629524"
580,"NCT00867334","New Individualized Therapy Trial for Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasm|Colorectal Cancer","Drug: Imatinib mesylate followed by a combination of imatinib mesylate & panitumumab|Drug: Standard-of-care treatment with panitumumab","Inova Health Care Services|Novartis Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSTI571BUS278T","March 19, 2009","June 2009","August 2011","March 11, 2014","March 2014","No Study Results Posted","NITMEC","August 2011","Assess the safety and tolerability of the combination imatinib mesylate and panitumumab in this population.|Stabilization or reduction in tumor size by imaging of the hepatic metastasis.","https://ClinicalTrials.gov/show/NCT00867334"
581,"NCT02246725","Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.","Recruiting","No Results Available","Tumor in Upper Gastrointestinal Canal or Patients With Colorectal Cancer.","Other: Contact with palliative care unit.","Lund University Hospital","Both","18 Years and older   (Adult, Senior)","","108","Other","Observational","Time Perspective: Prospective","MS01","September 19, 2014","October 2014","October 2019","September 13, 2016","September 2016","No Study Results Posted","ALLAN","October 2018","Quality of life|Survival","https://ClinicalTrials.gov/show/NCT02246725"
582,"NCT01143285","Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Other: Early and active nutritional support.","Centre Hospitalier Universitaire de Nice|UNICANCER|Centre Leon Berard|Centre Val d'Aurelle|University Hospital, Montpellier|Assistance Publique Hopitaux De Marseille|Centre hospitalier de Perpignan|Institut Sainte Catherine","Both","18 Years and older   (Adult, Senior)","","180","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","09-APN-03","July 21, 2009","April 2010","April 2016","April 22, 2016","April 2016","No Study Results Posted","CHIMIODIET","December 2014","Toxicities frequently associated with chemotherapy|Nutritional status of patients|Appetite measures|Quality of life|Number of occurrences of grades 1 and 2 toxicities|The number of hospital days|Overall survival","https://ClinicalTrials.gov/show/NCT01143285"
583,"NCT00506168","Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Neoplasms|Secondary|Drug Therapy, Combination","Drug: Irinotecan, Capecitabine","National Cancer Center, Korea","Both","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-01-024","July 23, 2007","November 2001","July 2007","July 23, 2007","July 2007","No Study Results Posted","null","null","Maximal response rate and toxicities|Progression-free survival and overall survival","https://ClinicalTrials.gov/show/NCT00506168"
584,"NCT01555450","Study of Patient Navigation to Reduce Social Inequalities","Completed","No Results Available","Colorectal Cancer Screening","Other: Patient Navigation","Institut National de la Santé Et de la Recherche Médicale, France|National Cancer Institute, France","Both","50 Years to 74 Years   (Adult, Senior)","","28929","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Screening","R10051EE","March 13, 2012","March 2011","November 2013","February 23, 2015","March 2012","No Study Results Posted","PRADO","November 2013","Completion of colorectal cancer screening|Reduction of social inequalities|Estimation of Cost effectiveness|Evaluation of psychological mechanisms","https://ClinicalTrials.gov/show/NCT01555450"
585,"NCT00025025","Screening Tests in Detecting Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: sample testing","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Mayo Clinic","Both","65 Years to 80 Years   (Adult, Senior)","","4482","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NCCTG-MC9944|P30CA015083|MAYO-MC9944|NCI-P01-0185","October 11, 2001","October 2001","June 2009","July 1, 2016","July 2016","No Study Results Posted","null","June 2009","","https://ClinicalTrials.gov/show/NCT00025025"
586,"NCT00812942","Participation to Colorectal Cancer Screening With Fecal Occult Blood Test and Colonoscopy","Completed","No Results Available","Colorectal Cancer","Procedure: colonoscopy|Procedure: faecal test","Istituto Superiore di Sanità","Both","55 Years to 64 Years   (Adult)","","9889","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","1","December 18, 2008","November 2003","November 2008","December 19, 2008","December 2008","No Study Results Posted","null","November 2005","Participation to colorectal cancer screening","https://ClinicalTrials.gov/show/NCT00812942"
587,"NCT01972490","Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: avastin+chemotherapy of mFOLFOX6 or FOLFIRI|Drug: chemotherapy of mFOLFOX6 or FOLFIRI","Xu jianmin|Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACCMCC","September 23, 2013","June 2011","March 2016","December 9, 2014","December 2014","No Study Results Posted","ACCMCC","December 2014","the rate of patients converted to resection for liver metastases|progression free survival|overall survival|tumor response","https://ClinicalTrials.gov/show/NCT01972490"
588,"NCT01228734","A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab + Oxaliplatin + 5FU/FA|Drug: Oxaliplatin + 5FU/FA","Merck KGaA","Both","18 Years and older   (Adult, Senior)","Phase 3","503","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR62202-057","September 9, 2010","August 2010","January 2017","May 23, 2016","May 2016","No Study Results Posted","TAILOR","January 2016","Progression free survival (PFS)|Overall survival time|Best overall response rate|Time to treatment failure|Rate of curative surgery for liver metastases","https://ClinicalTrials.gov/show/NCT01228734"
589,"NCT01885702","Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: DC vaccination","Radboud University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT 2008-005584-33","June 18, 2013","October 2010","June 2016","April 6, 2016","April 2016","No Study Results Posted","null","April 2016","Safety and feasibility of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients|To evaluate whether peptide-loaded DC can induce or enhance an immune response to tumor-associated antigen CEA and specific frameshift-derived neoantigens in the study population|Pathological responses|Clinical responses, e.g. disease-free survival, determined according to the standard protocol.","https://ClinicalTrials.gov/show/NCT01885702"
590,"NCT01380262","Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment","Recruiting","No Results Available","Colorectal Cancer|Skin Toxicities","","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology","Both","18 Years to 85 Years   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STLDD-1","June 22, 2011","June 2010","September 2011","June 24, 2011","June 2011","No Study Results Posted","STLDD-1","September 2011","number of patients with a severe skin toxicity|total occurence of skin toxicities|number of patients with delayed administration of cetuximab or panitumumab due to severe skin toxicity|quality of life assessed with DLQI","https://ClinicalTrials.gov/show/NCT01380262"
591,"NCT01815879","Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project","Active, not recruiting","No Results Available","Colorectal Cancer|Liver Metastases","","Andrew Kennedy|Sirtex Medical|Sarah Cannon","Both","18 Years and older   (Adult, Senior)","","1000","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","MORE","December 18, 2012","December 2012","null","March 20, 2013","March 2013","No Study Results Posted","MORE","June 2013","Adverse events at day 0-90 post 90Y therapy using CTCae 3.0 criteria.|Radiographic response rate at 90 days (+/- 45 days) from treatment day, compared to pretreatment scans.","https://ClinicalTrials.gov/show/NCT01815879"
592,"NCT00741481","PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.","Completed","No Results Available","Colorectal Cancer Metastatic|Early Response Evaluation|Fdg-PET","Procedure: FDG-PET imaging","Jules Bordet Institute","Both","18 Years and older   (Adult, Senior)","","40","Other","Observational","Time Perspective: Prospective","earlyPETmCRC|comité éthique IJB n° 1377","August 25, 2008","June 2006","July 2010","February 23, 2011","February 2011","No Study Results Posted","earlyPETmCRC","July 2010","compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by time to disease progression|compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by tumour response rate following RECIST criteria.","https://ClinicalTrials.gov/show/NCT00741481"
593,"NCT01657773","Study of the Association of Nonalcoholic Fatty Liver Disease With Colorectal Malignant Neoplasm","Completed","No Results Available","Colorectal Neoplasms|Nonalcoholic Fatty Liver Disease","Other: Ultrasound examination and Colonoscopy examination","Wenzhou Medical University","Both","10 Years and older   (Child, Adult, Senior)","","2315","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","wenzhouMC 001","July 29, 2012","April 2012","July 2012","August 3, 2012","August 2012","No Study Results Posted","NWC","June 2012","Ultrasound examination|Colonoscopy examination|Statistical analysis|Patients' baseline characteristics|Laboratory Assay and Measurement","https://ClinicalTrials.gov/show/NCT01657773"
594,"NCT01675128","ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer","Completed","Has Results","Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Tumors","Drug: ISIS 183750|Drug: Irinotecan","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","120187|12-C-0187","August 25, 2012","August 2012","December 2015","March 22, 2016","March 2016","November 30, 2015","null","December 2014","Maximum Tolerated Dose (MTD) of ISIS 183750 in Advanced Solid Tumors|Maximum Tolerated Dose of Irinotecan in Advanced Solid Tumors|Number of Participants With a Change in the Level of a Particular Gene Called elF4E [Eukaryotic Initiation Factors (elF)4e Messenger Ribonucleic Acid (mRNA) Levels] in Matched Pre and Post Tumor Biopsies|Number of Participants With a Change in elF4e Protein Levels in Matched Pre and Post Tumor Biopsies|Number of Participants With Adverse Events|Objective Response|Number of Participants With Progression Free Survival|Overall Survival|AUC(ALL) (Area Under the Plasma Concentration vs. Time Curve for All Time Points)|Number of Participants With Intracellular and Stromal Presence of ISIS in Tumor Tissue|Number of Participants With a Reduced Effect of elF4E Inhibition on Relevant Regulated Proteins|Number of Participants With a Decrease in elF4E mRNA Expression in Peripheral Blood","https://ClinicalTrials.gov/show/NCT01675128"
595,"NCT01220063","RSHF in Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Radiation: RSHF|Drug: irinotécan","Institut Cancerologie de l'Ouest","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06/9-R","October 11, 2010","October 2007","June 2018","August 30, 2016","August 2016","No Study Results Posted","RS CAMPTO","June 2018","tumor response accoording to recist criteria","https://ClinicalTrials.gov/show/NCT01220063"
596,"NCT01721954","FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: FOLFOX6m|Device: SIR-Spheres microspheres","Sirtex Medical","Both","18 Years and older   (Adult, Senior)","Phase 3","200","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","STX0112","October 26, 2012","February 2013","December 2019","August 30, 2016","August 2016","No Study Results Posted","FOXFIREGlobal","December 2017","Overall Survival|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01721954"
597,"NCT00862784","A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer","Completed","Has Results","Colorectal Carcinoma","Biological: IMC-1121B (ramucirumab)|Drug: Oxaliplatin|Drug: Folinic acid|Drug: 5-FU|Drug: 5-FU","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13897|2008-004936-19|CP12-0709|I4T-IE-JVBH","March 16, 2009","April 2009","August 2011","May 16, 2014","May 2014","May 16, 2014","null","April 2011","Progression-Free Survival (PFS)|Percentage of Participants With Complete Response or Partial Response [Objective Response Rate (ORR)]|Overall Survival (OS)|Duration of Response|Number of Participants With IMC-1121B (Ramucirumab)-Related Adverse Events (AEs)|Number of Participants With IMC-1121B (Ramucirumab)-Related Severe Adverse Events (SAEs)|Maximum Concentration (Cmax) at Day 1 of Cycle 1|Area Under the Concentration (AUC) at Day 1 of Cycle 1|Half-Life (t1/2) at Day 1 of Cycle 1|Clearance (CL) at Day 1 of Cycle 1|Steady State Volume of Distribution (Vss) at Day 1 of Cycle 1|Maximum Concentration (Cmax) at Day 1 of Cycles 5, 9, 13, 17, and 21|Area Under the Concentration (AUC) at Day 1 of Cycles 5, 9, 13, 17, and 21|Half-Life (t1/2) at Day 1 of Cycles 5, 9, 13, 17, and 21|Clearance (CL) at Day 1 of Cycles 5, 9, 13, 17, and 21|Steady State Volume of Distribution (Vss) at Day 1 of Cycles 5, 9, 13, 17, and 21|Serum Anti-IMC-1121B (Immunogenicity) at Day 1","https://ClinicalTrials.gov/show/NCT00862784"
598,"NCT00677144","Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasm","Drug: OS (oxalipaltin+S-1)|Drug: XELOX (oxalipaltin+capecitabine)","Hallym University Medical Center|Sanofi","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","88","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HMC-HO-GI-0712","May 7, 2008","April 2008","April 2012","October 4, 2012","October 2012","No Study Results Posted","null","April 2012","overall response rate|Safety, time to progression, and overall survival","https://ClinicalTrials.gov/show/NCT00677144"
599,"NCT01321658","Geriatric Intervention in Frail Elderly Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Other: Geriatric intervention","Oslo University Hospital|Norwegian Cancer Society|University Hospital, Akershus","Both","65 Years and older   (Adult, Senior)","","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","2010/1634","March 18, 2011","February 2011","October 2015","October 20, 2015","October 2015","No Study Results Posted","null","October 2015","Postoperative complications|Reoperation|Readmission|Length of hospital stay|Survival|Quality of life|Living at home or in institution","https://ClinicalTrials.gov/show/NCT01321658"
600,"NCT01210235","FLU-FIT Program at Kaiser Permanente Northern California","Completed","No Results Available","Colorectal Cancer Screening","Behavioral: FLU-FIT Program","University of California, San Francisco|Kaiser Permanente|American Cancer Society, Inc.","Both","50 Years to 75 Years   (Adult, Senior)","","7465","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","RSGPB-09-010-01-CPPB","September 25, 2010","October 2009","April 2012","March 5, 2015","March 2015","No Study Results Posted","null","December 2011","Completion of colorectal cancer screening by eligible patients within 3 months of their flu shot","https://ClinicalTrials.gov/show/NCT01210235"
601,"NCT01415479","Trial of a Computer-Based Presentation of Quantitative Information About Colorectal Cancer Screening","Completed","No Results Available","Colonic Neoplasms","Behavioral: Control|Behavioral: Quantitative|Behavioral: Default","Indiana University","Both","50 Years to 75 Years   (Adult, Senior)","","212","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Screening","CCCDA-10-085-01-A|VFR-320-A","August 2, 2011","August 2011","March 2013","April 29, 2013","April 2013","No Study Results Posted","null","August 2012","Intention to undergo CRC screening in the next six months|Preferred CRC screening test|Knowledge of CRC risk and the benefit of CRC screening|Decision conflict|Completion of CRC screening","https://ClinicalTrials.gov/show/NCT01415479"
602,"NCT00545545","Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma","Completed","No Results Available","Recurrent Colorectal Carcinoma|Progressive Colorectal Carcinoma","Biological: Safety and efficacy of escalating doses|Biological: Safety and efficacy of escalating doses.","Biothera","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","48","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BT-CL-PGG-CRC0713","October 16, 2007","October 2007","December 2009","March 30, 2010","March 2010","No Study Results Posted","null","December 2009","To determine safety and maximum tolerated dosage of Imprime PGGwhen used in combination with cetuximab with and without irinotecan therapy in patients with recurrent/progressive colorectal carcinoma previously treated with a 5-FU regimen.|To determine the pharmacokinetic (PK) profile of Imprime PGG administered in combination with cetuximab with concomitant irinotecan therapy in patients with colorectal cancer.|To determine the tumor response rates (complete response, partial response, stable disease, overall response rate), time to progression, duration of overall tumor response, and the duration of stable disease in patients receiving the combination therapy.","https://ClinicalTrials.gov/show/NCT00545545"
603,"NCT01993472","Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Neoplasms","Drug: Andrographolides|Drug: Capecitabine","Gu Yanhong|The First Affiliated Hospital with Nanjing Medical University","Both","65 Years and older   (Adult, Senior)","Phase 2","308","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AGCRC-013|ANDRO-JSPPH-2013","November 12, 2013","November 2013","June 2016","November 20, 2013","November 2013","No Study Results Posted","AGCRC-013","December 2015","Progression free survival (PFS)|overall survival|Response Rate|Quality of Life","https://ClinicalTrials.gov/show/NCT01993472"
604,"NCT00122720","The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery","Completed","No Results Available","Colorectal Cancer","Drug: Darbepoetin Alfa","Herning Hospital|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 4","200","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment","2612-2277","July 20, 2005","June 2003","January 2006","July 3, 2006","January 2006","No Study Results Posted","null","null","The functional capacity measured by postoperative fatigue, work capacity, balance, and quality of life|Muscular strength|Weight|Body composition|Blood transfusion|Postoperative complications","https://ClinicalTrials.gov/show/NCT00122720"
605,"NCT01805622","Educational Program to Increase Colorectal Cancer Screening: a Cluster Trial","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Active Arm #1, #2, Passive Arm #1, #2","Morehouse School of Medicine|National Cancer Institute (NCI)","Both","50 Years to 74 Years   (Adult, Senior)","","7200","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","EPICS cRCT|1R01CA166785","March 1, 2013","August 2012","March 2017","March 4, 2013","March 2013","No Study Results Posted","EPICS","March 2017","Reach (RE-AIM Framework)|Effectiveness (RE-AIM Framework)|Adoption (RE-AIM Framework)|Implementation (RE-AIM Framework)","https://ClinicalTrials.gov/show/NCT01805622"
606,"NCT00154713","Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment","Recruiting","No Results Available","Colorectal Cancer","Biological: CEA pulsed dendritic cells","National Taiwan University Hospital|National Health Research Institutes, Taiwan","Both","20 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","37","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","27MD02","September 8, 2005","July 2005","July 2005","September 8, 2005","July 2005","No Study Results Posted","null","null","evaluate the clinical responses of vaccinated patients 6 weeks after the first injection|evaluate the safety of this treatment and the immune responses against CEA before and after the treatment 6 weeks after the first injection","https://ClinicalTrials.gov/show/NCT00154713"
607,"NCT01251536","Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Dose escalation of cetuximab|Drug: Standard first line treatment with cetuximab + Folfiri","Universitaire Ziekenhuizen Leuven|Merck KGaA","Both","18 Years and older   (Adult, Senior)","Phase 2","375","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S51532|2009-009992-36","December 1, 2010","December 2010","March 2019","May 11, 2016","April 2016","No Study Results Posted","Everest2","June 2016","PFS rate at 9 months in the dose escalation arm|Safety profile (NCI-CTCAE v. 4.0) of the combination in treatment arms|Skin toxicity and correlations between outcome, PK and dose escalations|Overall response and response rate in liver-limited disease|Disease control rates|Duration of response|Progression free survival and overall survival|R0 resection rate for metastatic lesions|Pharmacokinetic parameters in patients in both treatment arms in selected centers only|To perform biomarker analyses: proteomics, microarray and PCR studies on plasma and tumour respectively, in both treatment arms.","https://ClinicalTrials.gov/show/NCT01251536"
608,"NCT02247336","Impact of Family History and Decision Support on High-risk Cancer Screening","Not yet recruiting","No Results Available","Colorectal Cancer","Behavioral: MeTree","VA Office of Research and Development","Both","40 Years to 64 Years   (Adult)","","650","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","IIR 12-378","September 18, 2014","October 2016","March 2018","June 13, 2016","June 2016","No Study Results Posted","null","September 2017","Provider referral for risk-appropriate colorectal cancer screening|Patient uptake of risk-appropriate colorectal cancer screening|Referral for genetic consultation","https://ClinicalTrials.gov/show/NCT02247336"
609,"NCT01759238","Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer|Metastases","Drug: Capecitabine|Drug: Bevacizumab|Radiation: Radiotherapy","Universitätsklinikum Hamburg-Eppendorf","Both","18 Years and older   (Adult, Senior)","Phase 2","1","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OLGA|2011-005296-16","December 17, 2012","May 2013","October 2014","February 4, 2015","February 2015","No Study Results Posted","OLGA","October 2014","Progression free survival rate|Time to progression (TTP) in 2 cohorts|Overall Response Rate|Overall survival (OS)|Quality of life (QoL)|Prognostic and predictive value of PET scan|Toxicity","https://ClinicalTrials.gov/show/NCT01759238"
610,"NCT02748772","Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Drug: Pure chemotherapy（Xelox）","The First People's Hospital of Hefei|Anhui Cancer Hospital|Anhui Jimin Cancer Hospital|Simcere Pharmaceutical Co., Ltd","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","148","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","FirstPeoplesHHeFei","April 20, 2016","January 2016","December 2018","April 21, 2016","April 2016","No Study Results Posted","null","December 2017","PFS|RR","https://ClinicalTrials.gov/show/NCT02748772"
611,"NCT00777478","Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: capiri-sutent","Radboud University","Both","18 Years and older   (Adult, Senior)","Phase 1","32","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCNONCO20083","October 21, 2008","December 2008","December 2012","February 2, 2012","January 2012","No Study Results Posted","sutent-capiri","May 2012","Maximum Tolerated Dose|determine the safety and toxicity profile using the CTCAE criteria.","https://ClinicalTrials.gov/show/NCT00777478"
612,"NCT00643877","Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Procedure: Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR|Procedure: surgery","Fudan University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Ruijin Hospital|Shanghai 9th People's Hospital|First Affiliated Hospital of Zhejiang University|Jiangyin People's Hospital|Liaoning Tumor Hospital & Institute","Both","18 Years to 74 Years   (Adult, Senior)","Phase 3","600","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","2008－46","March 24, 2008","December 2008","December 2014","March 24, 2009","March 2009","No Study Results Posted","PHRAC","December 2009","5 years disease-free survival|5 years overall survival and liver metastasis-free survival","https://ClinicalTrials.gov/show/NCT00643877"
613,"NCT02751177","Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer Metastatic","Genetic: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA","Institut de Cancérologie de Lorraine","Both","18 Years and older   (Adult, Senior)","","236","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2015-A01272-47","March 3, 2016","March 2016","December 2016","July 18, 2016","July 2016","No Study Results Posted","ColoBEAM","October 2016","KRAS, NRAS et BRAF mutational status","https://ClinicalTrials.gov/show/NCT02751177"
614,"NCT00005076","Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: irinotecan hydrochloride","University of Alabama at Birmingham|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","110","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067683|UAB-9926|IMCL-CP02-9923|MSKCC-99089|UAB-F990927004|UCLA-9908082|NCI-G00-1723","April 6, 2000","October 1999","July 2005","April 10, 2013","April 2013","No Study Results Posted","null","July 2005","Determine the complete and partial response rates and time to progression in patients with refractory advanced colorectal carcinoma treated with cetuximab and irinotecan.|Determine the safety and toxicity profile of this regimen in these patients.|Assess the quality of life of patients treated with this regimen.|Determine the tumor epidermal growth factor receptor levels in patients treated with this regimen","https://ClinicalTrials.gov/show/NCT00005076"
615,"NCT02458664","BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer","Active, not recruiting","No Results Available","Rectum Cancer|Cancer of Colon","Genetic: Genetic analysis on tumor kept in tumor bank","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France","Both","18 Years and older   (Adult, Senior)","","597","Other","Observational","Observational Model: Cohort","NI12029|2013-A01080-45","May 27, 2015","November 2013","November 2018","November 30, 2015","November 2015","No Study Results Posted","BASE HSP110","November 2018","Recurrence free survival and Recurrence free survival after resection of the colon cancer|Overall survival","https://ClinicalTrials.gov/show/NCT02458664"
616,"NCT01862562","Trial to Evaluate Laparoscopic Versus Open Surgery in Elderly Colorectal Cancer Patients","Active, not recruiting","No Results Available","Colorectal Cancer","Procedure: Open surgery|Procedure: Laparoscopic surgery","Shoichi Fujii, MD, PhD|Yokohama City University Medical Center","Both","75 Years and older   (Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","YCUMC-D1108015|YokohamaCUMC34","May 16, 2013","August 2008","August 2017","November 24, 2013","November 2013","No Study Results Posted","null","August 2012","Early complication rate|Overall survival|Recurrence-free survival|Length of postoperative hospital stay|Health-related QOL score","https://ClinicalTrials.gov/show/NCT01862562"
617,"NCT01477814","Interventions to Improve Colon Cancer Screening in Poor Rural Iowa Counties","Active, not recruiting","No Results Available","Colorectal Cancer","Behavioral: Physician chart reminder|Behavioral: usual care|Behavioral: chart reminder, mailed education, FIT|Behavioral: chart reminder, mailed education, FIT, telephone call","University of Iowa|American Cancer Society, Inc.","Both","52 Years to 79 Years   (Adult, Senior)","","743","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Screening","RSGT-08-148-01-CPPB","November 18, 2011","July 2008","June 2012","November 18, 2011","November 2011","No Study Results Posted","null","June 2012","colorectal cancer screening|cost-effectiveness of various strategies for screening","https://ClinicalTrials.gov/show/NCT01477814"
618,"NCT01212718","Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase","Completed","No Results Available","Colorectal Cancer|Non Resectable Metastasis|Reference Lesion|Biopsy|Thymidylate Synthase Quantitation","Drug: FUFA|Drug: systemic chemotherapy","University of Ulm|Pfizer, Berlin Germany|Medac, Hamburg, Germany|Study Group Oncology of Gastrointestinal Tumors (FOGT)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","168","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FOGT5","September 9, 2010","July 2001","September 2010","September 30, 2010","September 2010","No Study Results Posted","FOGT5","June 2010","Best response to first-line chemotherapy (recist)|overall survival, toxicity, treatment related complications, time to progression","https://ClinicalTrials.gov/show/NCT01212718"
619,"NCT01652196","Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer","Active, not recruiting","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer","Biological: aflibercept|Drug: oxaliplatin|Drug: leucovorin|Drug: fluorouracil|Other: Correlative Studies|Procedure: DCE MRI|Radiation: f18FDG-PET|Procedure: PET (positron emission tomography)","Richard Goldberg|Sanofi|Ohio State University Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","56","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU 11182|NCI-2012-01167","July 25, 2012","November 2012","null","July 15, 2016","July 2016","No Study Results Posted","null","September 2016","Proportion of patients alive and progression-free|Objective response rate (ORR) defined as the proportion of patients who achieve a PR or CR based on RECIST 1.1 criteria divided by the total number of evaluable patients|Percentage of patients able to undergo surgery|Progression free survival (PFS)|Overall survival|Incidence of severe (grade 3+) adverse events or toxicities, assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0|Tolerability in terms of number of patients who require dose modifications and/or dose delays|Proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial","https://ClinicalTrials.gov/show/NCT01652196"
620,"NCT02584998","Reducing Colorectal Cancer Death Through Mailed Outreach Screening","Active, not recruiting","No Results Available","Colorectal Cancer","Other: Mailed-FIT|Other: Screening invitation-reminder","Corporal Michael J. Crescenz VA Medical Center|University of Pennsylvania","Both","50 Years to 74 Years   (Adult, Senior)","","783","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","PPO 14-369-2 -- 01522","October 21, 2015","October 2015","December 2016","August 12, 2016","August 2016","No Study Results Posted","null","December 2016","The completion rate of FIT within 6 months of the mailing of the screening invitation. Absence of screening completion data in the VA medical record system will be recorded as failure to complete screening.|The receipt of any colorectal cancer screening test in the 6-month period after enrollment into the study.","https://ClinicalTrials.gov/show/NCT02584998"
621,"NCT01490866","A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)","Completed","No Results Available","Colorectal Cancer","Drug: Axitinib|Drug: Bevacizumab|Drug: 5-Fluorouracil|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin","SCRI Development Innovations, LLC|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","70","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI GI 154","November 7, 2011","December 2011","July 2015","April 1, 2016","April 2016","No Study Results Posted","null","July 2015","Progression-free survival|Objective Response Rate (ORR)|Frequency and severity of adverse events as a measure of safety|Time To Progression (TTP)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01490866"
622,"NCT00002842","Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: floxuridine|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: adjuvant therapy|Procedure: conventional surgery","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","49","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","94080|P30CA033572|CHNMC-IRB-94080|NCI-V96-1031|CDR0000065077","November 1, 1999","September 1994","May 2014","June 3, 2015","June 2015","No Study Results Posted","null","May 2014","To evaluate the effect of hepatic resection of colorectal carcinoma followed by systemic chemotherapy on 2 year disease free survival .","https://ClinicalTrials.gov/show/NCT00002842"
623,"NCT02573220","Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer","Recruiting","No Results Available","Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Biological: Cetuximab|Drug: Fluorouracil|Drug: Irinotecan Hydrochloride|Drug: Leucovorin Calcium","University of Chicago|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","45","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB15-0081|NCI-2015-01432|P30CA014599","September 21, 2015","June 2015","November 2017","March 31, 2016","March 2016","No Study Results Posted","null","November 2017","Maximum Tolerated Dose (MTD)|Response rate|Progression-free survival (PFS)|metastectomy (with curative intent) rate","https://ClinicalTrials.gov/show/NCT02573220"
624,"NCT00110721","GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: GM-CT-01 plus 5-Fluorouracil","Galectin Therapeutics Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DAVFU-003","May 12, 2005","May 2005","February 2008","March 5, 2012","March 2012","No Study Results Posted","null","June 2007","frequency of objective complete or partial tumor response|frequency of stable disease|safety of GM-CT-01 plus 5-FU","https://ClinicalTrials.gov/show/NCT00110721"
625,"NCT02222753","Immunological Markers Screening for Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","","State Key Laboratory of Cancer Biology|Shanghai Jiao Tong University School of Medicine|Fourth Military Medical University|Second Military Medical University|China-Japan Friendship Hospital|Chinese Academy of Medical Sciences|Beijing Cancer Hospital|Chinese PLA General Hospital","Both","18 Years to 90 Years   (Adult, Senior)","","5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2014AA020801","August 20, 2014","January 2014","null","August 20, 2014","August 2014","No Study Results Posted","null","December 2018","Disease-specific survival|Overall survival","https://ClinicalTrials.gov/show/NCT02222753"
626,"NCT00806663","FOLFIRI and Sunitinib in Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer|Liver Metastases","Drug: sunitinib added to FOLFIRI","Central European Society for Anticancer Drug Research","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","22","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C-II-005 /2008-001515-37","December 10, 2008","August 2008","September 2011","September 7, 2012","September 2012","No Study Results Posted","null","July 2010","reduction of tumor vessel permeability (TVP) and blood flow (BF) measured by DCE-MRI and DCE-USI, measured on liver metastases.|Antitumour response|Time to progression (TTP)|pharmacokinetics|drug treatment safety","https://ClinicalTrials.gov/show/NCT00806663"
627,"NCT02380443","Increased Frequency of AlloStim® Dosing in Combination With Cryoablation in Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Cancer Metastatic","Biological: AlloStim|Procedure: Cryoablation","Immunovative Therapies, Ltd.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ITL-019-CORK-CRYVAC","March 2, 2015","September 2016","November 2018","August 7, 2016","August 2016","No Study Results Posted","null","May 2018","To determine the safety of increased frequency of dosing (Part 1) (whether a Dose Limiting Toxicity (DLT) has occurred)|To evaluate the anti-tumor effect of AlloStim combined with cryoablation at the new proposed dose and frequency schedule (Part 2)|To assess change from baseline in Health-Related Quality of Life (HRQoL)","https://ClinicalTrials.gov/show/NCT02380443"
628,"NCT01238094","Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Simvastatin","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 3","258","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2009-11-017","June 22, 2010","April 2010","May 2014","June 13, 2013","January 2012","No Study Results Posted","null","November 2013","Progression free survival","https://ClinicalTrials.gov/show/NCT01238094"
629,"NCT00436072","ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: ZD6474|Drug: Cetuximab|Drug: Irinotecan","Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 1","46","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-177","February 15, 2007","February 2007","August 2012","October 3, 2012","October 2012","No Study Results Posted","null","February 2012","To determine the tolerability and maximum tolerated dose of combining ZD6474, cetuximab and irinotecan in patients with metastatic colorectal cancer refractory to prior cytotoxic chemotherapy.|Determine response rate, progression-free survival and overall survival of adding ZD6474 to cetuximab and irinotecan in this patient population.","https://ClinicalTrials.gov/show/NCT00436072"
630,"NCT02450422","The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment","Completed","No Results Available","Neoplastic Cells, Circulating","Other: Flow cytometry (FCM)|Other: RT-PCR","Fuda Cancer Hospital, Guangzhou","Both","18 Years to 75 Years   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Colorectal Cancer CTC 001","May 19, 2015","June 2013","December 2015","December 28, 2015","December 2015","No Study Results Posted","null","December 2015","The number of Circulating Tumor Cells (CTCs)","https://ClinicalTrials.gov/show/NCT02450422"
631,"NCT02502656","RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","","Association des Gastroentérologues Oncologues","Both","18 Years and older   (Adult, Senior)","","405","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RASANC","July 16, 2015","July 2015","August 2017","December 15, 2015","December 2015","No Study Results Posted","RASANC","August 2017","Concordance regarding the mutation of RAS (yes vs no, dichotomous variable) between the two methods|Comparison of the timelines to obtain results between the two methods|Comparisons of the costs between the two methods","https://ClinicalTrials.gov/show/NCT02502656"
632,"NCT00284258","Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: CPT-11 and TS-1|Drug: CPT-11, 5-FU and l-LV","Taiho Pharmaceutical Co., Ltd.|Daiichi Sankyo Co., Ltd.","Both","20 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","426","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","01023010 / TOP-003","January 30, 2006","January 2006","August 2010","November 1, 2012","November 2012","No Study Results Posted","null","July 2010","Progression free survival|Over all survival, Response rate, Adverse event, Medical economy","https://ClinicalTrials.gov/show/NCT00284258"
633,"NCT00653484","Energy Balance Interventions for Colorectal Cancer Prevention","Completed","No Results Available","Colorectal Cancer|Obesity","Behavioral: Physical Activity|Behavioral: Energy Restriction|Behavioral: Physical Activity and Energy Restriction","Vanderbilt University|National Cancer Institute (NCI)","Both","50 Years and older   (Adult, Senior)","","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CDR0000592809|VU-VICC-GI-0810|VU-VICC-061020","April 4, 2008","March 2008","June 2013","December 16, 2013","December 2013","No Study Results Posted","null","May 2009","Physical activity-energy expenditure|Dietary-energy intake (kcal/d) and quality|Body weight and composition","https://ClinicalTrials.gov/show/NCT00653484"
634,"NCT01413295","Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: Dendritic Cell Vaccine|Other: Supportive treatment","Fundacion Clinic per a la Recerca Biomédica","Both","18 Years and older   (Adult, Senior)","Phase 2","52","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MCBRVP|2009-017247-33|TRA-082","August 9, 2011","August 2011","September 2014","November 3, 2014","November 2014","No Study Results Posted","null","September 2014","Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01413295"
635,"NCT00006001","SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: semaxanib","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","37","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02345|UCCRC-NCI-52|NCI-52|CDR0000068009","July 5, 2000","August 2000","August 2009","May 31, 2013","February 2009","No Study Results Posted","null","February 2007","","https://ClinicalTrials.gov/show/NCT00006001"
636,"NCT01534923","Doctor-Patient Communication About Colorectal Cancer Screening","Active, not recruiting","No Results Available","Colorectal Cancer Screening","Behavioral: surveys","Memorial Sloan Kettering Cancer Center|Albert Einstein College of Medicine of Yeshiva University|HHC, Gun HIll and Tremont|NYC RING, Director|Virginia Commonwealth University","Both","50 Years to 75 Years   (Adult, Senior)","","225","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-017","February 10, 2012","February 2012","February 2017","February 2, 2016","February 2016","No Study Results Posted","null","February 2017","describe doctor-patient communication about CRC screening|quality of doctor-patient communication about CRC screening and low-income patients' screening outcomes.|examine the association between the quality of doctor-patient communication about CRC screening and low-income patients' screening outcomes","https://ClinicalTrials.gov/show/NCT01534923"
637,"NCT00202787","Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFOX-4+cetuximab|Drug: FOLFOX-4","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Merck Sharp & Dohme Corp.","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","136","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-04-02|eudract-number: 2004-001700-12","September 12, 2005","February 2005","February 2009","February 19, 2013","February 2013","No Study Results Posted","null","February 2009","Determine confirmed objective response rate|Determine safety of combination, surgical resectability and R0 resections, clinical benefit, time to disease progression, time to onset of response, duration of response, time to treatment failure, overall survival time|determination of polymorphisms of the intron 1 of the EGFR gene, TS, XRCC1, XPD, serum levels of EGFR and ATP7A and ATP7B, nº of copies of EGFR gene, the levels of PTEN, EGFR, AKT y MAPK proteins, and mutations at EGFR, PI3KCA, K-RAS y B-RAF genes","https://ClinicalTrials.gov/show/NCT00202787"
638,"NCT00540943","Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer","Completed","No Results Available","Neoplasms, Colorectal|Colorectal Cancer","Drug: pazopanib","GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VEG108925","October 5, 2007","July 2007","May 2010","March 15, 2012","February 2011","No Study Results Posted","null","May 2010","The safety and tolerability of the maximum tolerated dose defined as a dose regimen where no more than 1 of 6 subjects experiences a dose limiting toxicity.|pharmacokinetics disease assessment|Clearance of irinotecan (if data permit) and AUC, Cmax, tmax, and t1/2 of irinotecan and SN-38 after administration of irinotecan plus cetuximab.|AUC(0-24), Cmax, tmax, and t1/2 of pazopanib when administered with irinotecan and cetuximab|AUC(0-24), Cmax, and tmax of cetuximab when administered with irinotecan alone|AUC(0-24), Cmax, and tmax of cetuximab when administered with irinotecan plus pazopanib.|The ratio of SN-38 AUC(0-24) and irinotecan AUC(0-24) on Cycle 1 Day 1 and on Cycle 2 Day 1.|Objective response rate (complete response (CR) plus partial response (PR)) will be the primary measure of antitumor activity|Stable disease (SD) at 4 months|Time to progression","https://ClinicalTrials.gov/show/NCT00540943"
639,"NCT00784446","First-line Therapy of Stage IV Colorectal Cancer","Completed","No Results Available","Stage IV Colorectal Cancer","Drug: Oxaliplatin, Capecitabine, Bevacizumab, Imatinib","University of Cologne|Roche Pharma AG|Novartis|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","51","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AIO KRK 0205|ML20344","November 3, 2008","April 2008","December 2012","January 4, 2013","January 2013","No Study Results Posted","null","August 2010","Dose limiting toxicity.|Assessment of overall response rate and progression free survival.","https://ClinicalTrials.gov/show/NCT00784446"
640,"NCT00003354","Conventional Surgery Compared With Laparoscopic-Assisted Surgery in Treating Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: conventional surgery|Procedure: laparoscopic surgery","Medical Research Council|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","1200","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066336|MRC-CLASICC|NYCTRU-CLASICC|EU-98014|ISRCTN74883561","November 1, 1999","July 1996","December 2009","December 3, 2013","January 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003354"
641,"NCT02157454","Effect of a Website Offering Individual Patients' Experiences for Cancer Patients","Completed","No Results Available","Colorectal Cancer","Other: Website access","Berlin School of Public Health|Federal Ministry of Health, Germany","Both","18 Years and older   (Adult, Senior)","","212","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","NKP-332-041","May 27, 2014","June 2014","November 2015","November 9, 2015","November 2015","No Study Results Posted","DIPExRCT","September 2015","Self-efficacy for coping with cancer (measured by the German short form of the Cancer Behavior Inventory)|Change in self-efficacy for coping with cancer (measured by the German short form of the Cancer Behavior Inventory)|Patient competence (assessed by a self-rating measure of patient competence in oncology in validation process)","https://ClinicalTrials.gov/show/NCT02157454"
642,"NCT01273402","Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: TF2/IMP288","Immunomedics, Inc.|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Industry|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C-072-09 (NCI 5R01CA107088-04)|5R01CA107088-04","January 5, 2011","February 2011","August 2018","September 24, 2012","September 2012","No Study Results Posted","null","February 2013","Safety|Efficacy will be evaluating using CT scans and possibly PET imaging.","https://ClinicalTrials.gov/show/NCT01273402"
643,"NCT00165568","Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Neoplasm Metastasis","Drug: Bevacizumab","Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women's Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","04-415","September 12, 2005","July 2005","October 2006","October 30, 2009","October 2009","No Study Results Posted","null","null","To compare the percent change in tumor radioactivity uptake and retention after radiolabeled fluorouracil administration in subjects who receive bevacizumab versus those who do not receive bevacizumab.|To compare the percent change in tumor flow induced by bevacizumab and fluorouracil|to evaluate the relationship between initial change in tumor radioactivity uptake and retention.","https://ClinicalTrials.gov/show/NCT00165568"
644,"NCT00313755","Magnification Narrow Band Imaging Colonoscopy for Hereditary Non-Polyposis Colorectal Cancer Surveillance","Completed","No Results Available","Colorectal Neoplasms, Hereditary Nonpolyposis","Procedure: Narrow Band Imaging","London North West Healthcare NHS Trust","Both","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","06/NBI5/15","April 10, 2006","April 2006","September 2007","November 15, 2007","November 2006","No Study Results Posted","null","null","Number of patients with at least one adenoma|after white light endoscopy compared with the number of patients|with at least one adenoma after white light NBI in the right colon.|Total number of lesions detected with white light vs NBI.|Number of advanced neoplasm detected with white light vs NBI.|Number of hyperplastic polyps detected by white light vs NBI.","https://ClinicalTrials.gov/show/NCT00313755"
645,"NCT00388206","A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)","Completed","No Results Available","Colorectal Cancer|Non-Small Cell Lung Cancer","","Genentech, Inc.","Both","Child, Adult, Senior","Phase 4","3998","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AVF3991n","October 12, 2006","May 2006","March 2012","December 14, 2012","December 2012","No Study Results Posted","ARIES","March 2012","","https://ClinicalTrials.gov/show/NCT00388206"
646,"NCT01632020","Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth","Terminated","Has Results","Colorectal Neoplasms","Drug: Placebo|Drug: Metformin","University of Arkansas","Both","18 Years and older   (Adult, Senior)","Phase 2","7","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","134190","June 27, 2012","August 2012","January 2015","May 31, 2016","May 2016","February 19, 2016","null","January 2015","Proliferation Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy|Mucosal Apoptotic Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy","https://ClinicalTrials.gov/show/NCT01632020"
647,"NCT01238939","Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer","Completed","No Results Available","Advanced Solid Tumors|Metastatic Colorectal Cancer","Drug: NK012 and 5-FU","Nippon Kayaku Co.,Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 1","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6012113US","November 2, 2010","August 2010","March 2014","November 12, 2014","November 2014","No Study Results Posted","null","December 2013","Number of patients with dose-limiting toxicity as determinant of the maximum tolerated dose/recommended dose|Number of patients with adverse events as a measure of safety and tolerability|Tumor measurements, as a measure of efficacy|Area under the plasma concentration versus time curve (AUC) of NK012 and fluorouracil|Peak Plasma Concentration (Cmax) of NK012 and fluorouracil","https://ClinicalTrials.gov/show/NCT01238939"
648,"NCT00335595","Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients","Completed","No Results Available","Colorectal Cancer","Drug: XELOXA|Drug: XELOXA-A","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Sanofi|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 3","480","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-05-02|EudraCT Nº: 2005-003325-67","June 9, 2006","July 2006","June 2012","February 19, 2013","February 2013","No Study Results Posted","null","June 2012","Determine the free time to disease progression|Overall survival|Overall response rate|Time to onset of response|Duration of response|Treatment cycles number|Number of patients who need medicine dose reduction|adverse events|Prognostic and predictive factor of Circulating endothelial cells (CEC) and circulating tumors cells (CTC) baseline and after 3 cycle|Prognostic factor of the K-Ras gene mutation","https://ClinicalTrials.gov/show/NCT00335595"
649,"NCT00717990","Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: Capecitabine|Drug: Bevacizumab|Drug: Irinotecan","University Hospital of Crete","Both","18 Years to 72 Years   (Adult, Senior)","Phase 2","15","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/05.35","July 16, 2008","April 2008","December 2012","October 6, 2015","October 2015","No Study Results Posted","null","December 2012","Objective Response Rate|Time To Progression|Toxicity profile|Quality of life|Symptoms improvement|Overall Survival","https://ClinicalTrials.gov/show/NCT00717990"
650,"NCT01531777","Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Apatinib|Drug: apatinib","Jiangsu HengRui Medicine Co., Ltd.|Fudan University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","APTN-II-CRC","February 7, 2012","April 2011","November 2014","April 2, 2015","February 2012","No Study Results Posted","null","November 2014","ORR (Objective Response Rate)|DCR (Disease Control Rate)|PFS|OS (Overall Survival)|QoL (Quality of Life)","https://ClinicalTrials.gov/show/NCT01531777"
651,"NCT00883792","The Northern-European Initiative on Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: Colonoscopy","Norwegian Department of Health and Social Affairs|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Erasmus Medical Center|Landspitali University Hospital|Uppsala University Hospital|Karolinska Institutet|Riga Eastern Clinical University Hospital, Riga, Latvia|Memorial Sloan Kettering Cancer Center|Harvard School of Public Health","Both","55 Years to 64 Years   (Adult)","Phase 3","66000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","NordICC","April 17, 2009","May 2009","July 2036","June 9, 2011","June 2011","No Study Results Posted","NordICC","June 2026","Comparison of the screening group vs. the control group in an intention-to-treat model after 15 years of follow-up with regard to CRC mortality and CRC incidence|CRC mortality and CRC incidence of screening attendees compared to the control group and non-attendees|Mortality from all causes","https://ClinicalTrials.gov/show/NCT00883792"
652,"NCT00593060","Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Colorectal Adenocarcinoma","Drug: Temsirolimus|Drug: Cetuximab","Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Wyeth is now a wholly owned subsidiary of Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-172","December 28, 2007","October 2007","October 2010","December 1, 2011","December 2011","No Study Results Posted","null","October 2009","To determine the dose-limiting toxicities and maximal tolerated doses of cetuximab combined with temsirolimus.|To determine the dosing regimen appropriate for Phase 2 studies of the combination.|To determine the pharmacokinetics of combined treatment with cetuximab and temsirolimus.|To document objective response rate and progression-free survival in patients treated with the combination.","https://ClinicalTrials.gov/show/NCT00593060"
653,"NCT01478594","A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy","Completed","Has Results","Colorectal Cancer","Drug: Tivozanib|Drug: Bevacizumab|Drug: mFOLFOX6","AVEO Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","265","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4130-CL-0201|2011-003502-24","November 21, 2011","December 2011","January 2015","June 9, 2015","June 2015","February 19, 2015","null","September 2013","Investigator-assessed Progression-Free Survival (PFS)|Progression-Free Survival (PFS) Based on Independent Radiological Review (IRR)|Overall Survival (OS)|Objective Response Rate (ORR)|Duration of Response (DoR)|Time to Treatment Failure (TTF)|Health Related Quality of Life (HRQoL)|Safety as Assessed by Physical Examination, Vital Signs, Laboratory Assessments, 12-lead Electrocardiogram (ECGs), and Adverse Events (AEs)|Progression-free Survival Events by Lactate Dehydrogenase (LDH) Level|Progression-free Survival Events by Serum Vascular Endothelial Growth Factor-A (VEGF-A) Level|Progression-free Survival Events by Serum Vascular Endothelial Growth Factor-C (VEGF-C) Level|Progression-free Survival Events by Serum VEGF-C / VEGF-A Ratio|Progression-Free Survival Events by Soluble Vascular Endothelial Growth Factor Receptor-2 (sVEGFR-2) Level|Progression-Free Survival Events by Soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3) Level|Progression-Free Survival Events by Serum Interleukin-8 (IL-8) Level|Progression-Free Survival Events by Serum Neuropilin Level|Progression-Free Survival Events by Tumor VEGF-A Ribonucleic Acid (RNA) Level|Progression-Free Survival Events by Tumor VEGF-C RNA Level|Progression-Free Survival Events by Tumor VEGF-C / VEGF-A RNA Ratio|Progression-Free Survival Events by Tumor VEGF-D RNA Level|Progression-Free Survival Events by Tumor Placental Growth Factor (PIGF) RNA Level","https://ClinicalTrials.gov/show/NCT01478594"
654,"NCT00862342","Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Bevacizumab (Avastin)","Asan Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","78","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-2008-0487","March 13, 2009","January 2009","June 2012","July 16, 2012","July 2012","No Study Results Posted","SAFE","December 2010","Progression free survival|Overall survival|Toxicity profiles","https://ClinicalTrials.gov/show/NCT00862342"
655,"NCT00003186","Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: isosulfan blue|Procedure: lymphangiography|Procedure: sentinel lymph node biopsy","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","","null","Other|NIH","Interventional","Primary Purpose: Diagnostic","DS 96-57|RPCI-DS-96-57|NCI-G98-1371","November 1, 1999","April 1997","null","February 4, 2013","February 2013","No Study Results Posted","null","March 2005","","https://ClinicalTrials.gov/show/NCT00003186"
656,"NCT01298570","Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: Regorafenib (BAY 73-4506)|Drug: FOLFIRI|Drug: Placebo|Drug: FOLFIRI","UNC Lineberger Comprehensive Cancer Center|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 2","181","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","LCCC 1029|10-2176","February 16, 2011","February 2011","February 2021","February 10, 2016","February 2016","No Study Results Posted","null","February 2019","Progression Free Survival (PFS)|Overall Response(OR)rate|disease control (DC) rate|Overall Survival (OS)|Drug Metabolism|Toxicity Assessments According to NCI CTCAE v. 4.0","https://ClinicalTrials.gov/show/NCT01298570"
657,"NCT02575859","Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients","Completed","No Results Available","Colorectal Neoplasm|Metastasis","Drug: adjuvant HIPEC|Procedure: surgery","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Azienda Usl di Bologna","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","35/13","September 21, 2015","January 2006","December 2011","October 13, 2015","September 2015","No Study Results Posted","null","June 2010","Positive predictive value of preoperative/intraoperative assessment of primary tumor-related risk factors for the development of metachronous peritoneal metastases in patients undergoing curative surgery for colorectal cancer.|Number of patients with postoperative treatment-related adverse events.|Peritoneal progression-free survival","https://ClinicalTrials.gov/show/NCT02575859"
658,"NCT01317433","Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer Metastatic|Skin Toxicity","Drug: Doxycycline|Drug: Cetuximab","ICO Paul Papin","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","130","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CPP-450|2010-019140-39","March 16, 2011","December 2010","November 2015","February 28, 2012","February 2012","No Study Results Posted","SKINUX","November 2012","reduction of Grade > or = 2 acne-like skin rash by 30%|skin tolerance assessment|Non skin toxicities assessment|Efficacy Objective Response (OR) assessment|Biological correlation with response and survival|Time To Progression and Overall Survival|Resectability rate","https://ClinicalTrials.gov/show/NCT01317433"
659,"NCT01557101","Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population","Completed","No Results Available","Colorectal Cancer, Genetics of","Procedure: COLON CAPSULE ENDOSCOPY ADHERENCE|Procedure: OPTICAL COLONOSCOPY ADHERENCE","Hospital Universitario de Canarias","Both","40 Years to 65 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CEC_cribado_CCR","March 13, 2012","April 2012","June 2013","January 8, 2014","January 2014","No Study Results Posted","CRIBADO","April 2013","Participation to colorectal cancer screening in first-degree relatives of patients with colorectal cancer","https://ClinicalTrials.gov/show/NCT01557101"
660,"NCT02403024","Feasibility and Efficacy of Interval Walking in Patients With Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Behavioral: InterWalk|Behavioral: Waiting list control","Rigshospitalet, Denmark|Hvidovre University Hospital","Both","18 Years and older   (Adult, Senior)","","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","I-Walk-CRC","March 24, 2015","August 2015","December 2017","July 14, 2016","July 2016","No Study Results Posted","null","December 2017","Change in VO2peak|Change in Body composition|Changes in bloodbiochemistry from fasting blood samples|Changes in patient-reported Quality of Life|Changes in cognitive function|Changes in insulin sensityvity by measure of Oral Glucose Tolerance Test (OGTT)|Change in VO2peak (secondary comparisons)","https://ClinicalTrials.gov/show/NCT02403024"
661,"NCT01290926","Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: chemotherapy","Jules Bordet Institute|Erasme University Hospital|INDC Entité Jolimontoise|Centre Hospitalier Chretien|Universiteit Antwerpen|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Hospital Ambroise Paré Paris","Both","18 Years and older   (Adult, Senior)","Phase 2","97","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT 2010-023695-91","February 4, 2011","February 2011","January 2016","February 23, 2016","February 2016","No Study Results Posted","SoMore","January 2016","Overall survival at 6 months fixed endpoint|To estimate the Progression Free Survival (PFS) distribution of the study population|To determine the objective response rate of the study population as assessed by standard imaging|To describe the adverse reactions associated with the study regimen in the study population.|To determine the correlation of early metabolic response, as assessed by FDG-PET/CT immediately before the first and the second cycles of treatment with the study regimen, with overall survival, progression-free survival, and response.|To determine the correlation of growth modulation index (GMI), defined as the time to progression under the study regimen over the time to progression un-der the latest prior regimen administered to the patient, with overall survival and progression-free","https://ClinicalTrials.gov/show/NCT01290926"
662,"NCT02483832","Message Framing and Colorectal Cancer Screening","Recruiting","No Results Available","Colorectal Neoplasms","Behavioral: Educational materials","Duke University","Both","50 Years to 75 Years   (Adult, Senior)","","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","Pro00057568","June 25, 2015","February 2015","null","June 20, 2016","June 2016","No Study Results Posted","CRC","February 2017","CRC screening follow-up rate|Changes in attitudes towards CRC and CRC screening as measured by survey","https://ClinicalTrials.gov/show/NCT02483832"
663,"NCT00564694","Studying a Quality of Life Questionnaire in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","350","NIH","Observational","","CDR0000574769|EORTC-QLQ-CR29|EU-20783","November 27, 2007","May 2007","null","October 28, 2013","August 2009","No Study Results Posted","null","June 2009","Reliability and clinical and psychometric validity of the European Organization of Research for the Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-CR29)","https://ClinicalTrials.gov/show/NCT00564694"
664,"NCT02215642","Nutrition and Lifestyle Study Cohort of Colorectal Cancer in China","Recruiting","No Results Available","Colorectal Cancer","","State Key Laboratory of Cancer Biology|Tang-Du Hospital|Tianjin Union Medical Center|Chengdu Medical College|Beihua University|Shanghai Jiao Tong University School of Medicine|Second Military Medical University|China-Japan Friendship Hospital|Chinese Academy of Medical Sciences|Beijing Cancer Hospital|Chinese PLA General Hospital|Third Military Medical University","Both","19 Years to 90 Years   (Adult, Senior)","","50000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","cdk-201001","August 12, 2014","January 2009","null","October 30, 2014","October 2014","No Study Results Posted","null","December 2016","Disease-specific survival|Overall survival","https://ClinicalTrials.gov/show/NCT02215642"
665,"NCT00779311","A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer","Terminated","Has Results","Metastatic Colorectal Cancer","Drug: sorafenib|Drug: bevacizumab|Drug: mFOLFOX6 regimen","Accelerated Community Oncology Research Network|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 1","8","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AFMSMCRC0706","October 23, 2008","October 2008","March 2011","October 31, 2011","October 2011","September 9, 2011","null","March 2011","Determination of the Maximum Tolerated Dose (MTD) of Sorafenib When Given in Combination With mFOLFOX6 and Bevacizumab|Determination of Progression Free Survival (PFS) Among Patients on This Regimen|Determination of Quality of Life (QoL) as Indicated by Patient Care Monitor (PCM) Data Among Patients on This Regimen","https://ClinicalTrials.gov/show/NCT00779311"
666,"NCT00044967","Genetic Study of Young Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Genetic: microsatellite instability analysis","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years to 49 Years   (Adult)","","651","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ACOSOG-Z0190|CDR0000069465","September 6, 2002","May 2002","December 2004","July 1, 2016","July 2016","No Study Results Posted","null","December 2004","overall survival","https://ClinicalTrials.gov/show/NCT00044967"
667,"NCT00207155","An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 1","110","Industry","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA225-045","September 12, 2005","December 2003","February 2006","October 26, 2015","October 2015","No Study Results Posted","null","February 2006","Prediction of response to Erbitux in subjects with metastatic colorectal cancer|Radiographic Response","https://ClinicalTrials.gov/show/NCT00207155"
668,"NCT02295930","Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient","Completed","No Results Available","Metastatic Colorectal Cancer","Other: folfoxiri+cetuximab+surgery+cetuximab|Other: folfoxiri+cetuximab+surgery+bevacizumab","Gruppo Oncologico del Nord-Ovest","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","143","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3306|2011-000840-70","February 4, 2014","October 2011","null","March 11, 2015","March 2015","No Study Results Posted","MACBETH","March 2015","10 months-progression free rate (10m-PFR)|Best overall response rate|10 month resection rate|Time to strategy failure|Time to 2nd progressive disease|Progression free survival (PFS)|Overall survival (OS)|Toxicity rate|Overall toxicity rate","https://ClinicalTrials.gov/show/NCT02295930"
669,"NCT01668680","Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma","Terminated","No Results Available","Colorectal Cancer Metastatic","Drug: CAPECITABINE, CELECOXIB and METHOTREXATE","HaEmek Medical Center, Israel|Clalit Health Services","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMC-0047-11","March 11, 2012","September 2012","December 2014","July 6, 2015","July 2015","No Study Results Posted","null","December 2013","Length of progression free survival (PFS), measured in months.|Toxicity profile of treatment, defined by CTCAE Version 4.0.|Changes in levels of angiogenic factors while under treatment: VEGF, PDGF, TSP-1|Quality of life, as expressed by FACT-C.","https://ClinicalTrials.gov/show/NCT01668680"
670,"NCT02699073","Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: regorafenib","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","Both","18 Years and older   (Adult, Senior)","Phase 2","55","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TEXCAN C15-2","February 23, 2016","February 2016","December 2018","August 25, 2016","August 2016","No Study Results Posted","TEXCAN","March 2018","Tumor response rate at 2 months according Choi Criteria|Tumor response rate at 1 and 2 months according to RECIST1.1|Tumor response rate at 1 month according to Choi criteria|Best overall response rate (BOR) according to Choi criteria and to RECIST 1.1|Disease control rate (DCR)|Overall Survival (OS)|Progression free survival (PFS)|Specificity of Choi criteria at 1 month in identifying patients with long or short OS (using median OS as cut-off value).|Evaluation of tumor heterogeneity with TexRAD software|Serious adverse events( SAE) and adverse event (AE)|Identify early prognostic biomarkers of regorafenib|Correlation between Baseline cell free DNA and survival outcomes (PFS and OS)","https://ClinicalTrials.gov/show/NCT02699073"
671,"NCT00159432","Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: Oxaliplatin|Drug: Bevacizumab|Drug: Capecitabine","University of Southern California|Hoffmann-La Roche|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","63","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-04-10","September 7, 2005","February 2005","March 2013","July 22, 2014","July 2014","November 27, 2013","null","June 2009","Median Time for Progression Free Survival|Number of Participants With Grade 3 or Higher Toxicity","https://ClinicalTrials.gov/show/NCT00159432"
672,"NCT00005640","Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: Preoperative Endoscopy|Radiation: Technetium Tc 99m Sulfur Colloid|Procedure: Gamma Probe|Procedure: Biopsy of Sentinel Lymph Nodes","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","17","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","MCC-11785|NCI-G00-1780","May 2, 2000","June 1999","February 2002","September 24, 2012","September 2012","No Study Results Posted","null","February 2002","Number of Procedures Resulting in Improved Detection","https://ClinicalTrials.gov/show/NCT00005640"
673,"NCT02633098","A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Cancer|Bowel Cancer","Drug: Artesunate 200mg|Drug: Placebo","St George's, University of London","Both","18 Years and older   (Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15.0154","November 18, 2015","May 2016","May 2023","March 14, 2016","December 2015","No Study Results Posted","NeoART","May 2020","Recurrence free survival at 2 years|Recurrence free survival at 5 years|Overall survival at 2 and 5 years|Colon cancer specific death at 2 and 5 years|Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0|Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0|Pathological assessment of tumour regression (involvement of lymph nodes; serosa; resection margin)|Patient quality of life|Surgical complications|Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy|Immunohistochemical analyses of paraffin-embedded tumour sections to assess Kirsten rat sarcoma viral oncogene homolog (Kras) mutation status|Immunohistochemical analyses of paraffin-embedded tumour sections to assess Mismatch Repair (MMR) status|Immunohistochemical analyses of paraffin-embedded tumour for v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation status|Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor (PDGF) expression|Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor receptor (PDGFR) expression|Immunohistochemical analyses of paraffin-embedded tumour for Vascular endothelial Growth Factor (VEGF) expression|Immunohistochemical analyses of paraffin-embedded tumour on Vascular endothelial Growth Factor Receptor (VEGFR) expression|Determination of proliferative activity (Ki-67 staining, Cluster of Differentiation 31 protein (CD31) staining)|Determination of activation of the Deoxyribonucleic acid damage response (DDR) pathway|Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins)|Determination of cell-free circulating tumour Deoxyribonucleic acid (ctDNA) levels in patient blood plasma samples","https://ClinicalTrials.gov/show/NCT02633098"
674,"NCT02437071","Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Pembrolizumab|Radiation: Radiotherapy|Procedure: Radiofrequency ablation","Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","15-069","April 22, 2015","April 2015","null","August 12, 2016","August 2016","No Study Results Posted","null","April 2017","response rate|Toxicity","https://ClinicalTrials.gov/show/NCT02437071"
675,"NCT02568046","Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Sym004|Drug: Irinotecan|Drug: Folinic Acid|Drug: Fluorouracil","Symphogen A/S","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Sym004-09","September 30, 2015","March 2016","June 2018","June 2, 2016","June 2016","No Study Results Posted","null","May 2018","Phase 1b: Dose-Limiting Toxicities (DLT) observed during Cycle 1 of Sym004 administration in combination with FOLFIRI.|Phase 2a: Confirmed objective antitumor response.|Number of participants with treatment-related adverse events (AEs) as assessed by NCI-CTCAE v4.03|Dose-normalized area under the concentration-time curve from End of Infusion (EOI) to 336 hours (AUCNorm, 0-336h)|Preliminary evaluation of the antineoplastic effect of Sym004 plus FOLFIRI as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Area under the concentration-time curve from EOI to 336 hours (AUC0-336h)|Maximum concentration (Cmax)|Time to reach maximum concentration (Tmax)|Trough concentration (Ctrough)|Elimination half-life (T½)|Clearance (CL)|Volume of distribution (V)|Urine and peripheral blood collection for assessment of biomarkers related to the EGFR pathway|Other potential biomarkers to be determined (i.e. genes, gene transcripts and proteins of the receptor tyrosine kinases (RTKs))","https://ClinicalTrials.gov/show/NCT02568046"
676,"NCT01952730","GVAX for Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Biological: GVAX","Massachusetts General Hospital","Both","18 Years and older   (Adult, Senior)","","15","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","12-436","April 26, 2013","July 2013","July 2025","September 25, 2013","September 2013","No Study Results Posted","null","July 2015","number of patients who fail to receive the first six scheduled vaccinations because of toxicity|Progression Free Survival|Immune Response|Two year survival","https://ClinicalTrials.gov/show/NCT01952730"
677,"NCT02647099","Adjuvant Low Dose Aspirin in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Acetylsalicylic acid|Drug: Placebo","Anna Martling|Uppsala University Hospital|Skane University Hospital|Karolinska Institutet","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","816","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","921-2014-7074","January 5, 2016","March 2016","January 2023","September 8, 2016","September 2016","No Study Results Posted","ALASCCA","March 2021","Time To Recurrence (TTR)|Disease free survival (DFS)|Overall survival (OS)|Frequency and severity of adverse events (AE)","https://ClinicalTrials.gov/show/NCT02647099"
678,"NCT02827565","Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Other: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA","Institut de Cancérologie de Lorraine","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","2015-A00922-47","July 6, 2016","February 2016","October 2016","July 8, 2016","July 2016","No Study Results Posted","CircuLOR-1","October 2016","Technical Optimization of KRAS, BRAF and NRAS mutations detection|KRAS, NRAS et BRAF mutational status","https://ClinicalTrials.gov/show/NCT02827565"
679,"NCT02415699","DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: Fluorouracil|Drug: Oxaliplatin|Drug: Leucovorin|Biological: DC-CIK","Sixth Affiliated Hospital, Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015045010","April 9, 2015","August 2015","July 2020","April 13, 2015","April 2015","No Study Results Posted","null","July 2017","Disease free survival|Overall survival|Side Effect","https://ClinicalTrials.gov/show/NCT02415699"
680,"NCT00598247","A Pilot Study of PPX in Women With Metastatic Colorectal Cancer","Completed","No Results Available","Advanced Colorectal Cancer","Drug: Paclitaxel Poliglumex","University of Southern California|CTI BioPharma|ASCEND Therapeutics","Female","18 Years and older   (Adult, Senior)","Phase 1","15","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-07-3","January 10, 2008","January 2008","July 2011","February 5, 2014","February 2014","No Study Results Posted","null","September 2008","RECIST Response|Time to progression|Toxicity","https://ClinicalTrials.gov/show/NCT00598247"
681,"NCT00197405","Comparison of Fecal Ribonucleic Acid (RNA) Test With Fecal Occult Blood Test (FOBT) for Detecting Colorectal Cancer and Adenoma","Recruiting","No Results Available","Colorectal Cancer","","Hamamatsu University","Both","18 Years and older   (Adult, Senior)","","400","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","CRC-FRT-001","September 12, 2005","August 1999","December 2010","August 3, 2009","August 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00197405"
682,"NCT01909830","Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients","Completed","No Results Available","Colorectal Cancer Metastatic","Drug: Arm A : Gemcitabine + Pemetrexed","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","Both","18 Years and older   (Adult, Senior)","Phase 2","18","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRST153.03|2010-019841-25","June 19, 2013","July 2012","March 2014","June 18, 2015","June 2015","No Study Results Posted","null","March 2014","Objective Response Rate (ORR)|safety profile of study treatment|Time to Progression (TTP)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01909830"
683,"NCT02809716","High Definition Single Cell Analysis in Colorectal Cancer","Not yet recruiting","No Results Available","Metastatic Carcinoma in the Liver|Stage IV Colorectal Cancer","Other: Biomarker Analysis|Other: Cytology Specimen Collection Procedure","University of Southern California|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","45","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","3C-15-4|NCI-2016-00736|P30CA014089","June 19, 2016","June 2016","December 2018","June 19, 2016","June 2016","No Study Results Posted","null","June 2018","HD-SCA liquid biopsy biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles|HD-SCA solid tumor biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles|HD-SCA biosignatures in pre-resection liquid biopsy samples assessed by cell morphology, protein expression, and whole genome CNV profiles","https://ClinicalTrials.gov/show/NCT02809716"
684,"NCT02278133","Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: WNT974|Drug: LGX818|Biological: Cetuximab","Array BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWNT974X2102C","October 6, 2014","December 2014","null","August 15, 2016","August 2016","No Study Results Posted","null","June 2017","Incidence of Dose Limiting Toxicities and exposure (AUC C1D15) to WNT974 and LGX818 (phase lb)|Overall response rate in phase II|Overall response rate (ORR) (phase lb)|Overall survival (OS) (phase lb/ll)|Duration of response (DOR) (phase lb/ll)|Time to response (TTR) (phase lb/ll)|Progression free survival (PFS) (phase lb/ll)|Disease control rate (DCR) (phase lb/ll)|Plasma concentration of WNT974, LHA333, LGX818 (phase lb/ll)|Number of participants with Adverse Events as a measure of safety and tolerability (phase lb/ll)|Number of participants with Serious Adverse Events as a measure of safety and tolerability(phase lb/ll)|Biomarker activations for WNT and RTK-MAPK pathways (phase Ib/II)|Number of participants with dose interruptions and dose reductions (phase Ib/II)","https://ClinicalTrials.gov/show/NCT02278133"
685,"NCT00273585","Study of Using Computerized Education to Increase Patients' Confidence in Their Ability to Be Screened for Colon Cancer","Completed","No Results Available","Colorectal Cancer Screening","Device: Personally-tailored educational software program","University of California, Davis","Both","50 Years and older   (Adult, Senior)","Phase 3","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Prevention","200412524-2","January 6, 2006","August 2005","February 2006","September 6, 2006","September 2006","No Study Results Posted","null","null","Colorectal cancer screening self-efficacy|Colorectal cancer screening intention|Colorectal cancer screening decisional conflict","https://ClinicalTrials.gov/show/NCT00273585"
686,"NCT01371942","Mutational Profiling in Colorectal Tumors to Determine Its Role in the Diagnosis, Prognostic Significance and Their Impact in Clinical Management","Active, not recruiting","No Results Available","Colorectal Cancer","","Taipei Medical University WanFang Hospital","Both","20 Years and older   (Adult, Senior)","","300","Other","Observational","","99064","June 10, 2011","May 2010","May 2013","June 10, 2011","June 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01371942"
687,"NCT02607787","EXercise And Colo-Rectal Cancer Trial","Recruiting","No Results Available","Colo-rectal Cancer","Behavioral: Exercise|Other: Control","University of Ulster|Belfast Health and Social Care Trust","Both","18 Years to 90 Years   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","14/0061 (EXACT Study)|14127JG-SS|14/NI/1048","July 8, 2015","April 2015","December 2016","November 17, 2015","November 2015","No Study Results Posted","EXACT","April 2016","Feasibility|Physical activity|Cardiovascular Endurance|Lower limb strength|Quality of life|Demographics|Height|Venous blood sample|Weight|Hip and waist circumference|Capillary blood sample","https://ClinicalTrials.gov/show/NCT02607787"
688,"NCT00004252","Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: semaxanib","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Primary Purpose: Treatment","SUGEN-SU5416.031|CDR0000067499|UCLA-9909008","January 28, 2000","November 1999","September 2007","September 10, 2012","September 2012","No Study Results Posted","null","September 2007","","https://ClinicalTrials.gov/show/NCT00004252"
689,"NCT02179970","To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers","Recruiting","No Results Available","Pancreatic Adenocarcinoma Metastatic|Ovarian Serous Adenocarcinoma|Colorectal Cancer Metastatic","Drug: Plerixafor","CCTU- Cancer Theme|Sanofi|Stand Up To Cancer|CRUK Cambridge Institute|Lustgarten Foundation|National Institute for Health Research, United Kingdom|Cambridge University Hospitals NHS Foundation Trust","Both","16 Years and older   (Child, Adult, Senior)","Phase 1","28","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CAM-PLEX|2014-000117-31","July 1, 2014","June 2015","June 2017","July 12, 2016","July 2016","No Study Results Posted","CAM-PLEX","December 2016","Safety|Pharmacokinetics","https://ClinicalTrials.gov/show/NCT02179970"
690,"NCT00064181","Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: capecitabine|Drug: celecoxib|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years and older   (Adult, Senior)","Phase 3","86","Other","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Treatment","EORTC-40015","July 8, 2003","May 2003","null","September 20, 2012","September 2012","No Study Results Posted","null","January 2005","","https://ClinicalTrials.gov/show/NCT00064181"
691,"NCT00373022","Moderate Physical Activity in Helping Patients Recover Physically and Emotionally From Stage II Or Stage III Colorectal Cancer","Completed","No Results Available","Anxiety Disorder|Colorectal Cancer|Depression|Psychosocial Effects of Cancer and Its Treatment","Behavioral: exercise intervention|Other: flow cytometry|Other: laboratory biomarker analysis|Procedure: management of therapy complications|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","University of Arizona|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","45","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","CDR0000491199|P30CA023074|UARIZ-A04.04","September 6, 2006","January 2004","December 2006","May 26, 2010","December 2006","No Study Results Posted","null","December 2006","Effect of moderate physical activity on quality of life as measured by the Functional Assessment of Cancer Therapy-Colon questionnaire|Effect of moderate physical activity on depression and anxiety as measured by the Beck Depression Inventory and the Spielberger State-Trait Anxiety Inventory|Effect of moderate physical activity on attitudes related to physical activity as measured by the American Council on Exercise History questionnaire|Serum levels and patterns of immune function as measured by cytokine, neutrophil, T cell, B cell, natural killer (NK) cell, and immunoglobulin levels|Correlation of serum levels and patterns of immune function (cytokine, neutrophil, T cell, B cell, NK cell, and immunoglobulin levels) with physical activity levels","https://ClinicalTrials.gov/show/NCT00373022"
692,"NCT00155558","A Phase I Trial of HDFL48 in Recurrent or Metastatic Colorectal Cancers","Completed","No Results Available","Recurrent or Metastatic Colorectal Cancer","Drug: 5-Fluorouracil, Leucovorin","National Taiwan University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","159I13","September 9, 2005","March 2001","December 2005","July 23, 2007","November 2000","No Study Results Posted","null","null","To determine the maximum tolerated dose and dose limiting toxicity|response","https://ClinicalTrials.gov/show/NCT00155558"
693,"NCT02350530","FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFOXIRI + Bevacizumab|Drug: FOLFOXIRI","Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","138","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GIHSYSU09","January 24, 2015","January 2015","January 2020","September 19, 2016","September 2016","No Study Results Posted","FORBES","January 2018","The conversion rate of liver metastases|Toxicity assessed using the NCI common toxicity criteria, version 4.0.|Response rate|Overall survival time|Progression free survival|Quality of life (QLQ C30)","https://ClinicalTrials.gov/show/NCT02350530"
694,"NCT01881932","Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)","Terminated","Has Results","Breast Cancer|Colorectal Cancer","Device: Acupuncture using Seirin® needles|Device: Sham Acupuncture using Park Sham placebo acupuncture device","University of Maryland","Both","18 Years and older   (Adult, Senior)","","19","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","HP-00053394|GCC1232","March 13, 2013","February 2013","April 2015","September 3, 2015","September 2015","April 21, 2015","null","June 2014","Proportion of Colorectal and Breast Cancer Patients in Each Arm Who Require Dose Reduction or Discontinuation Due to Chemotherapy-induced Peripheral Neuropathy.","https://ClinicalTrials.gov/show/NCT01881932"
695,"NCT00565708","Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers","Recruiting","No Results Available","Colorectal Cancer","Other: placebo|Drug: Acetylsalicylic acid","National Cancer Centre, Singapore|University of Oxford|Australasian Gastro-Intestinal Trials Group|INDOX Cancer Research Network","Both","18 Years and older   (Adult, Senior)","Phase 3","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CDR0000577892|SINGAPORE-ICR-02|SINGAPORE-ASCOLT","November 29, 2007","December 2008","June 2022","February 23, 2016","February 2016","No Study Results Posted","ASCOLT","December 2021","Disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00565708"
696,"NCT00019747","Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer","Terminated","Has Results","Colorectal Cancer","Drug: thalidomide|Procedure: adjuvant therapy|Other: Placebo","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","39","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","990102|99-C-0102|CDR0000067098","July 11, 2001","August 1999","December 2008","October 6, 2015","September 2015","September 25, 2012","null","December 2008","Time to Progression","https://ClinicalTrials.gov/show/NCT00019747"
697,"NCT02271464","Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Maintenance:BEVACIZUMAB|Drug: Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE","Azienda Ospedaliero, Universitaria Pisana","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","222","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MOMA261111|2011-006332-23","October 20, 2014","March 2012","March 2016","March 10, 2015","March 2015","No Study Results Posted","MOMA","June 2015","progression-free survival (PFS)|Best overall response rate (ORR)|Duration of response|Resection rate|Time to strategy failure (TSF)|Time to 2nd progressive disease|Overall survival (OS)|Toxicity rate|Overall toxicity rate","https://ClinicalTrials.gov/show/NCT02271464"
698,"NCT02477553","Information With or Without Numbers For Optimizing Reasoning About Medical Decisions","Enrolling by invitation","No Results Available","Colorectal Cancer Screening","Behavioral: DA - Quantitative|Behavioral: DA - Verbal","Indiana University|Patient-Centered Outcomes Research Institute","Both","50 Years to 75 Years   (Adult, Senior)","","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","1502774679|CDR-1403-11040","June 15, 2015","June 2015","December 2016","March 4, 2016","March 2016","No Study Results Posted","INFORM","December 2016","Self-report CRC screening completion with medical record verification of screening test completion|Self-report CRC screening intention|Self-report perceived risk of CRC|Self-report perceived benefits of CRC screening with FIT and colonoscopy|Self-report perceived barriers to CRC screening with FIT or colonoscopy|Knowledge of CRC and screening as measured by questionnaire|Decision conflict as measured by the Decision Conflict Scale","https://ClinicalTrials.gov/show/NCT02477553"
699,"NCT00002893","Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: raltitrexed","Medical Research Council|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 3","900","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065216|MRC-CR06|EU-96049","November 1, 1999","June 1995","null","December 18, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002893"
700,"NCT02557061","Prognostic Value of the Lymphocytic Infiltrate in Colon Cancers","Active, not recruiting","No Results Available","Colorectal Cancer","Procedure: Colorectal surgery (resection)|Biological: Blood sampling","University Hospital, Rouen","Both","18 Years and older   (Adult, Senior)","","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2008/118/HP","September 21, 2015","April 2009","August 2016","May 10, 2016","September 2015","No Study Results Posted","TIL","August 2016","Number of patients with tumor infiltrate by T-lymphocytes (CD3+)|Number of alive patients|Rate of preoperative blood T-lymphocytes","https://ClinicalTrials.gov/show/NCT02557061"
701,"NCT02090101","Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: ANAKINRA","Centre Georges Francois Leclerc","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","32","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-003367-55","March 13, 2014","June 2014","null","April 22, 2016","April 2016","No Study Results Posted","IRAFU","October 2016","Response rate after 2 months in patients with colorectal cancer with liver metastases treated with anakinra and LV5FU2/bevacizumab|Response rate by echography|Tumor control rate|Overall survival|Rate and safety profile according to NCI-CTCAE v4","https://ClinicalTrials.gov/show/NCT02090101"
702,"NCT00889343","Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer","Terminated","No Results Available","Colorectal Neoplasms","Drug: Sorafenib|Drug: Placebo|Drug: Oxaliplatin or Irinotecan|Drug: Leucovorin|Drug: 5-Fluorouracil","AIO-Studien-gGmbH","Both","18 Years and older   (Adult, Senior)","Phase 2","101","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AIO KRK 0307","April 17, 2009","March 2009","December 2012","March 1, 2013","March 2013","No Study Results Posted","FOSCO","November 2011","To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo|Disease control rate|Overall survival|Response rates|Safety","https://ClinicalTrials.gov/show/NCT00889343"
703,"NCT00973869","Curcumin in Preventing Colorectal Cancer in Patients Undergoing Colorectal Endoscopy or Colorectal Surgery","Recruiting","No Results Available","Colorectal Cancer","Dietary Supplement: curcumin|Other: high performance liquid chromatography|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: diagnostic endoscopic procedure|Procedure: therapeutic conventional surgery","University of Leicester|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Primary Purpose: Prevention","CDR0000648267|LRI-UL-CURCUMIN|EUDRACT-2007-001971-13|EU-20961","September 5, 2009","July 2009","null","June 23, 2014","September 2009","No Study Results Posted","null","January 2010","Concentration of curcumin in colorectal tissue after treatment|Tolerability and compliance|Presence of curcumin and its metabolites in peripheral blood and urine","https://ClinicalTrials.gov/show/NCT00973869"
704,"NCT00503685","Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy","Completed","No Results Available","Colorectal Cancer","Biological: IMC-A12|Biological: cetuximab","ImClone LLC","Both","18 Years and older   (Adult, Senior)","Phase 2","65","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13936|CP02-0657|CP13-0605|I5A-IE-JAEL","July 17, 2007","June 2007","March 2009","October 12, 2011","October 2011","No Study Results Posted","null","March 2009","Objective response rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)|Duration of stable disease (SD)|Duration of Overall response|Summary Listing of Participants Reporting Treatment-Emergent Adverse Events (AEs)|Summary Listing of Participants Reporting Treatment-Emergent Severe Adverse Events (SAEs)|Maximum concentration (Cmax)|Minimum concentration (Cmin)|Area under Serum Concentration (AUC)|Potential associations between KRAS mutations and response rate (cetuximab)|Evaluate tumors for expression of Type I IGF receptors (IGF-IR), IGF binding proteins (IGFBP2, IGFBP3), and related signaling molecules, and potential association|Evaluate tumors for expression of Type I IGF receptors (IGF-IR), IGF binding proteins (IGFBP2, IGFBP3), and related signaling molecules, and assess potential association","https://ClinicalTrials.gov/show/NCT00503685"
705,"NCT00466505","Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery","Completed","Has Results","Colorectal Cancer","Biological: cetuximab|Drug: celecoxib|Genetic: proteomic profiling|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: mass spectrometry","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","17","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC GI 0410|P30CA068485|VU-VICC-GI-0410|VU-IRB-040227","April 25, 2007","May 2005","November 2008","December 14, 2012","December 2012","August 15, 2011","null","July 2008","Progression-free Survival (PFS)|Patient Response to Treatment|Overall Survival|One Year Survival Rate|Number of Patients With Each Worst-grade Toxicity Response|Urinary PGE-M : Treatment Cycle 1|Serum TGF-alpha: Treatment Cycle 1|Urinary PGE-M : Treatment Cycle 2|Serum TGF-alpha: Treatment Cycle 2","https://ClinicalTrials.gov/show/NCT00466505"
706,"NCT02522520","Pedometer Intervention and Health Effects for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Pedometer intervention|Behavioral: Pedometer + hospital based intervention|Device: Omron Walking Style pro. 20","Rigshospitalet, Denmark|Copenhagen University Hospital at Herlev|Novo Nordisk A/S|Danish Cancer Society|TrygFonden, Denmark","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","CIRE-15","August 4, 2015","June 2015","December 2017","April 6, 2016","April 2016","No Study Results Posted","null","December 2017","Maximum oxygen uptake - ( VO2 peak)|Health related Quality of Life|Symptoms and side-effects|Anxiety and Depression|Lifestyle factors|Physical activity level|Dual Energy X-ray Absorptiometry scan|Blood cholesterols|Blood pressure / pulse|Pedometer Step Count","https://ClinicalTrials.gov/show/NCT02522520"
707,"NCT02244632","Modufolin® in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasm","Drug: Modufolin|Drug: Fluorouracil|Drug: Oxaliplatin|Drug: Irinotecan","Isofol Medical AB","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","39","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ISO-CC-005|2014-001862-84","September 17, 2014","September 2014","June 2018","August 30, 2016","August 2016","No Study Results Posted","null","March 2017","Frequency and severity of dose limiting toxicity (DLT) or other Adverse Events (AE)","https://ClinicalTrials.gov/show/NCT02244632"
708,"NCT00749450","Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: fluorouracil|Drug: oxaliplatin","Cancer Research UK, Glasgow","Both","18 Years and older   (Adult, Senior)","Phase 3","9500","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000613042|CRUK-SCOT|ISRCTN59757862|EudraCT 2007-003957-10|EU-20874|SCOT-2007-01","September 6, 2008","March 2008","null","April 23, 2012","April 2012","No Study Results Posted","null","March 2013","3-year disease-free survival|Overall survival|Cost-effectiveness|Toxicity according to NCI CTCAE Version 3.0|Quality of life as assessed by EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and GOG Ntx4","https://ClinicalTrials.gov/show/NCT00749450"
709,"NCT01634126","Maximizing Yield of the Fecal Immunochemical Test for Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Behavioral: 1 FIT kit|Behavioral: 2 FIT kit","Kaiser Permanente|National Cancer Institute (NCI)","Both","50 Years to 75 Years   (Adult, Senior)","Phase 0","2761","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","5R01CA154982|1R01CA154982","July 2, 2012","August 2012","April 2016","September 14, 2016","September 2016","No Study Results Posted","MY-FIT","April 2016","FIT Kit adherence","https://ClinicalTrials.gov/show/NCT01634126"
710,"NCT01106261","A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Pulmonary Metastases","Procedure: Metastasectomy|Procedure: Active monitoring","University College, London|Royal Brompton & Harefield NHS Foundation Trust|University of Cambridge|University of Sussex","Both","16 Years and older   (Child, Adult, Senior)","","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Reference No: 08/0390|CRUK/09/022","April 13, 2010","April 2010","June 2025","June 10, 2015","June 2015","No Study Results Posted","PulMiCC","June 2025","Feasibility of recruitment|Survival","https://ClinicalTrials.gov/show/NCT01106261"
711,"NCT00031863","Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: rofecoxib|Procedure: adjuvant therapy","Cancer Research Campaign Clinical Trials Centre|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Treatment","CRC-TU-VICTOR|CDR0000069235|EU-20054|CRC-TU-COX2|ISRCTN98278138|NCCTG-N004B","March 8, 2002","February 2001","September 2007","August 1, 2013","June 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00031863"
712,"NCT02227667","Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer","Recruiting","No Results Available","Advanced Colorectal Cancer","Drug: MEDI4736","Memorial Sloan Kettering Cancer Center|MedImmune LLC|AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14-109","July 17, 2014","October 2014","null","July 12, 2016","July 2016","No Study Results Posted","null","July 2017","best response rate|Safety|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02227667"
713,"NCT00006103","Combination Chemotherapy in Treating Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 3","400","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-9864|U10CA031946|CLB-9864|E-C9864|CDR0000068113","August 3, 2000","July 2000","April 2002","July 1, 2016","July 2016","No Study Results Posted","null","April 2002","overall survival","https://ClinicalTrials.gov/show/NCT00006103"
714,"NCT00205322","Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)","University of Wisconsin, Madison","Both","18 Years and older   (Adult, Senior)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M-2003-0544 (CO03216)","September 13, 2005","April 2004","October 2007","December 2, 2011","December 2011","No Study Results Posted","null","October 2007","Does the combination of oxaliplatin, 5-FU, leucovorin and capecitabine improve the activity of the FOLFOX regimens in metastatic colorectal cancer patients|Is the oral drug an advantage in this patient population","https://ClinicalTrials.gov/show/NCT00205322"
715,"NCT00873275","Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Drug: ursodiol|Genetic: RNA analysis|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: western blotting|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: positron emission tomography (PET)","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08005|P30CA033572|CHNMC-08005|CDR0000637521|NCI-2010-00926","March 31, 2009","March 2009","null","August 10, 2016","August 2016","No Study Results Posted","null","September 2017","Maximum-tolerated dose of ursodiol|Toxicities as assessed by NCI CTCAE 3.0|Survival|Time to failure|Pharmacokinetics of ursodiol","https://ClinicalTrials.gov/show/NCT00873275"
716,"NCT00729677","Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin","Completed","Has Results","Colorectal Cancer|Nausea|Vomiting","","Beth Israel Medical Center","Both","18 Years and older   (Adult, Senior)","","64","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","237-04|BIMCP-NV-SURVEY|BIMCP-IRB-37-04|MERCK-BIMCP-NV-SURVEY","August 6, 2008","June 2005","December 2008","October 5, 2015","October 2015","September 15, 2009","null","November 2008","Percentages of Participants by Gender Who Reported Nausea During the First Week of Chemotherapy|Impact of Nausea and Vomiting on the Patient's Quality of Life as Measured by the Functional Living Index - Emesis Scale at 5-7 Days|Number of Participants by History of Nausea Who Reported Nausea During the First Week of Chemotherapy","https://ClinicalTrials.gov/show/NCT00729677"
717,"NCT00006786","Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068328|ECOG-E2200","December 6, 2000","November 2000","September 2006","June 20, 2013","September 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006786"
718,"NCT02423785","Ocular Blood Flow in Colorectal Cancer Patients","Recruiting","No Results Available","Metastatic Colorectal Cancer","","Medical University of Vienna","Both","18 Years to 99 Years   (Adult, Senior)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OBF-13","July 31, 2014","May 2014","null","September 12, 2016","September 2016","No Study Results Posted","null","May 2018","Correlation between ocular blood flow (retinal blood flow) and treatment response|Correlation between retinal vessel diameter and treatment response|Changes in retinal surface before and after therapy as measured by optical coherence tomography","https://ClinicalTrials.gov/show/NCT02423785"
719,"NCT00224601","CHROENDOHNPCC: Early Detection of Pre-cancer Lesions in Adults With Hereditary Nonpolyposis Colorectal Cancer Syndrome","Completed","No Results Available","Colorectal Neoplasms, Hereditary Nonpolyposis","Procedure: Colonoscopy with chromoscopy","Assistance Publique - Hôpitaux de Paris","Both","25 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","P040423","September 16, 2005","July 2005","January 2008","February 17, 2011","July 2007","No Study Results Posted","null","January 2008","Number of pre-cancer lesions or early cancer detected.|Anatomopathologic criteria (size of lesions, …).","https://ClinicalTrials.gov/show/NCT00224601"
720,"NCT00006468","Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000068282|FRE-GERCOR-OPTIMOX-2000|EU-20034","November 6, 2000","January 2000","null","January 10, 2009","December 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006468"
721,"NCT02164916","S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: irinotecan hydrochloride|Drug: vemurafenib","Southwest Oncology Group|National Cancer Institute (NCI)|Genentech/Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","106","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","S1406|U10CA180888|NCI-2014-00814","June 13, 2014","November 2014","January 2020","April 4, 2016","April 2016","No Study Results Posted","null","June 2017","PFS (Arms I and II)|PFS (Crossover)|Overall survival (Arms I and II)|Overall response rate|Incidence of adverse events graded according to the National Cancer Institute CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02164916"
722,"NCT02141945","Microbiome Test for the Detection of Colorectal Polyps and Cancer","Suspended","No Results Available","Colorectal Neoplasms|Colorectal Cancer","","Metabiomics Corp","Both","45 Years to 80 Years   (Adult, Senior)","","200","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MB-01","May 14, 2014","March 2014","December 2016","March 28, 2016","March 2016","No Study Results Posted","null","December 2016","Performance of Metabiomics Colon Polyp and Colorectal Cancer Assay","https://ClinicalTrials.gov/show/NCT02141945"
723,"NCT00642746","Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)","Terminated","Has Results","Metastatic Colorectal Cancer","Drug: Erlotinib|Drug: Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Irinotecan","OHSU Knight Cancer Institute|Genentech, Inc.|OSI Pharmaceuticals","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3753","March 24, 2008","March 2008","December 2011","September 24, 2014","September 2014","February 12, 2014","null","December 2011","Response Rates of Radiographically Measurable Disease|Second-line Progression Free Survival|Time to Second Progression (From Start of First-Line Regimen)","https://ClinicalTrials.gov/show/NCT00642746"
724,"NCT00002570","Immediate Compared With Delayed Chemotherapy in Treating Patients With Advanced Colorectal Cancer Without Signs or Symptoms of Disease","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium","NCIC Clinical Trials Group|North Central Cancer Treatment Group|Canadian Cancer Trials Group","Both","18 Years to 79 Years   (Adult, Senior)","Phase 3","67","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CO10|CAN-NCIC-CO10|NCCTG-JCO10|NCCTG-JCO.10|NCI-V94-0463|CDR0000063607","November 1, 1999","July 1994","February 2009","September 20, 2012","September 2011","No Study Results Posted","null","November 2000","Survival|Quality of life|Toxicity|Time to progression|response rate|response duration","https://ClinicalTrials.gov/show/NCT00002570"
725,"NCT00656123","Vaccine Therapy and Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Liver Metastases Due to Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: GM-K562 cell vaccine|Biological: allogeneic tumor cell vaccine|Drug: cyclophosphamide|Genetic: gene expression analysis|Genetic: protein analysis|Other: immunoenzyme technique|Other: immunologic technique|Other: laboratory biomarker analysis","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","18","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000589230|JHOC-J0745|JHOC-NA_00009345","April 9, 2008","March 2008","null","December 17, 2013","July 2009","No Study Results Posted","null","February 2009","Safety and toxicity after course 2|Cellular vaccine response","https://ClinicalTrials.gov/show/NCT00656123"
726,"NCT01286883","Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells","Recruiting","No Results Available","Colorectal Cancer","","Milton S. Hershey Medical Center","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PSHCI 10-066|PSHMC IRB No. 34902EP","January 28, 2011","February 2011","December 2014","January 3, 2014","January 2014","No Study Results Posted","null","November 2014","Primary endpoint: correlation of stem cell markers on CTCs with response to therapy|Secondary Outcome: Correlation of stem cell markers in primary tumors with stem cell markers in CTCs","https://ClinicalTrials.gov/show/NCT01286883"
727,"NCT00107315","Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer","Terminated","Has Results","Colorectal Cancer","Biological: bevacizumab|Drug: capecitabine","Roswell Park Cancer Institute","Both","70 Years and older   (Senior)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 22204|RPCI-I-22204|GENENTECH-RPCI-I-22204","April 5, 2005","July 2004","null","June 3, 2014","June 2014","January 8, 2014","null","June 2008","Time to Progression|Response Rate|Median Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00107315"
728,"NCT01315990","FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: FOLFIRI + Cetuximab","Dr. Carl Schimanski|Johannes Gutenberg University Mainz","Both","18 Years and older   (Adult, Senior)","Phase 4","165","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DERMATUX","March 11, 2011","January 2011","March 2018","December 17, 2013","December 2013","No Study Results Posted","DERMATUX","March 2015","Progression-free survival|ORR|OS|Duration until development of acneiforme follicular exanthema >= grade 2|Development of paronychia|Development of skin fissure (hand and foot)|Rate of secondary resections of metastasis of liver with a curative approach|Assessment of safety and tolerability|Development of acneiforme follicular exanthema >= grade2","https://ClinicalTrials.gov/show/NCT01315990"
729,"NCT00560365","Follow-Up Study of Patients Who Have Undergone Surgery for Stage I, Stage II, or Stage III Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Other: laboratory biomarker analysis|Procedure: computed tomography|Procedure: magnetic resonance imaging|Procedure: quality-of-life assessment","University Hospital Southampton NHS Foundation Trust.|National Cancer Institute (NCI)","Both","50 Years and older   (Adult, Senior)","","4760","Other","Observational","","CDR0000576476|USCTU-FACS|ISRCTN41458548|EU-20788","November 16, 2007","March 2004","null","August 5, 2011","August 2009","No Study Results Posted","null","December 2013","Overall survival by intention-to-treat analysis|Quality of life|Cost of National Health Service (NHS) services utilized|NHS cost per life-year saved","https://ClinicalTrials.gov/show/NCT00560365"
730,"NCT00274872","Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","600","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000453890|GERCOR-OPTIMOX2|GERCOR-OPTIMOX2-2003|GERCOR-OPTIMOX2-C02-2|EU-20566|SANOFI-GERCOR-OPTIMOX2","January 10, 2006","January 2004","null","January 29, 2010","May 2007","No Study Results Posted","null","null","Overall survival|Time to disease control|Response as measured by RECIST criteria|Toxicity|Quality of life as assessed by EUROQOL- 5 Dimensional Instrument or Functional Assessment of Cancer Therapy-Neurotoxicity module version 4.0 at baseline and periodically during study treatment|Pharmaco-economic evaluation","https://ClinicalTrials.gov/show/NCT00274872"
731,"NCT00337545","Phase II Trial of RAD001 in Refractory Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: RAD001","Swedish Medical Center|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 2","22","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD0012467|Swedish Cancer Institute 05128","June 15, 2006","May 2006","April 2007","October 5, 2007","October 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00337545"
732,"NCT00002716","Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: dexamethasone|Drug: floxuridine|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: laparotomy|Procedure: conventional surgery","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","135","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-9481|U10CA031946|CDR0000064553","November 1, 1999","January 1996","August 2006","July 12, 2016","July 2016","No Study Results Posted","null","March 2006","Overall survival|Time to progression","https://ClinicalTrials.gov/show/NCT00002716"
733,"NCT01516216","Study of Vitamin D in Untreated Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFOX + bevacizumab|Dietary Supplement: Vitamin D|Dietary Supplement: Vitamin D","Dana-Farber Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","11-436","January 13, 2012","March 2012","null","August 4, 2016","August 2016","No Study Results Posted","null","November 2016","Progression Free Survival|Overall Survival|Objective tumor response rate|Safety|Incidence of vitamin D deficiency|Proportion of participants able to achieve and maintain vitamin D sufficiency|Time course of change in plasma 25-hydroxyvitamin D3 levels|Association between plasma 25(OH)D levels and PFS and OS","https://ClinicalTrials.gov/show/NCT01516216"
734,"NCT00952029","Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: FOLFIRI regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Federation Francophone de Cancerologie Digestive","Both","18 Years to 120 Years   (Adult, Senior)","Phase 2|Phase 3","492","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000636983|FFCD-PRODIGE-9|FFCD-0802|EU-20912|EU-21030|EUDRACT-2008-007928-25|EUDRACT-2009-017996-11","August 1, 2009","March 2010","December 2016","August 2, 2016","August 2016","No Study Results Posted","null","December 2015","Disease-control duration|Objective response rate|Rate of non-hematologic grade 3-4 toxicities (except alopecia)|Overall toxicity rate|Duration of chemotherapy-free interval|Progression-free survival|Overall survival|Time-to-treatment failure|Quality of life as assessed by EORTC QLQ-C30|Geriatric evaluation","https://ClinicalTrials.gov/show/NCT00952029"
735,"NCT00072553","Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: celecoxib|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000340181|GERCOR-OPTIMOX2-CELECOXIB-2002|EU-20325","November 4, 2003","September 2003","null","February 6, 2009","May 2007","No Study Results Posted","null","null","Response rate|Toxicity|Time of disease control (progression-free survival)|Salvage surgery rate|Duration of chemotherapy-free intervals|Tolerability|Quality of life","https://ClinicalTrials.gov/show/NCT00072553"
736,"NCT00004885","Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years and older   (Adult, Senior)","Phase 3","430","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-40986","March 7, 2000","July 1999","null","September 20, 2012","September 2012","No Study Results Posted","null","July 2001","","https://ClinicalTrials.gov/show/NCT00004885"
737,"NCT00995202","Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Other: diagnostic laboratory biomarker analysis|Procedure: computed tomography|Procedure: diagnostic colonoscopy|Procedure: standard follow-up care|Procedure: ultrasound imaging","Federation Francophone de Cancerologie Digestive","Both","18 Years to 120 Years   (Adult, Senior)","Phase 3","1997","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CDR0000654114|FFCD-PRODIGE-13|2009-A00536-51|EU-20979","October 14, 2009","September 2009","null","August 2, 2016","August 2016","No Study Results Posted","null","April 2018","Overall survival rate|Disease-free survival rate|Cost-effectiveness study|Quality of life","https://ClinicalTrials.gov/show/NCT00995202"
738,"NCT02324114","Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Device: Hsp90","Protgen Ltd","Both","Child, Adult, Senior","","1100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","hsp90a2011-03","December 14, 2014","September 2012","December 2014","December 22, 2014","December 2014","No Study Results Posted","null","December 2014","Hsp90α Concentration(ng/ml) of plasma","https://ClinicalTrials.gov/show/NCT02324114"
739,"NCT00893295","Increasing Colorectal Cancer Screening in African Americans","Recruiting","No Results Available","Colorectal Cancer","Other: informational intervention|Other: medical chart review|Other: screening questionnaire administration|Other: study of socioeconomic and demographic variables|Procedure: barium enema injection|Procedure: colon imaging study|Procedure: screening colonoscopy|Procedure: sigmoidoscopy","Kimmel Cancer Center (KCC)|National Cancer Institute (NCI)","Both","50 Years to 79 Years   (Adult, Senior)","Phase 3","896","Other|NIH","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Screening","CDR0000635953|TJUH-RSGT-08-017-01-CPPB|08G.89","May 2, 2009","February 2008","null","December 17, 2013","July 2009","No Study Results Posted","null","December 2011","Intervention impact on colorectal cancer (CRC) screening utilization over the 6-month observation period|Intervention impact on CRC screening preference, based on data obtained from both the endpoint chart audit and the endpoint survey|Intervention impact on population health-management representations related to CRC screening, as assessed by perceived salience and coherence and self-efficacy-related CRC screening measured with 6 to 10 Likert-type items on both the baseline and end ...","https://ClinicalTrials.gov/show/NCT00893295"
740,"NCT00008060","Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: FOLFOX regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","Medical Research Council|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000068372|MRC-CR08-FOCUS|EU-20038|ISRCTN79877428","January 6, 2001","May 2000","December 2003","December 18, 2013","March 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00008060"
741,"NCT00109070","A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Avastin (bevacizumab)","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","AVF2107g","April 22, 2005","September 2000","April 2003","June 19, 2013","June 2013","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00109070"
742,"NCT00940316","Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: panitumumab|Drug: erlotinib hydrochloride|Drug: irinotecan hydrochloride","Northwestern University|Genentech, Inc.|OSI Pharmaceuticals|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","96","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 07I4|STU00004101|OSI 4263s","July 15, 2009","July 2009","July 2018","June 16, 2016","June 2016","No Study Results Posted","null","July 2017","Determine the tumor response rate|Determine the time to disease progression|Determine the time to treatment failure|Collect data on the toxicity of the combination of study drugs","https://ClinicalTrials.gov/show/NCT00940316"
743,"NCT01549327","The Effect of a Virtual Navigator on Colorectal Cancer Patient Empowerment","Completed","No Results Available","Colorectal Cancer","Other: Oncology Interactive Navigator|Other: Routine Care","McGill University","Both","18 Years and older   (Adult, Senior)","","129","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","TEN-C|MOP 106710","February 29, 2012","May 2012","May 2015","March 22, 2016","March 2016","No Study Results Posted","null","May 2015","Empowerment|Cost-effectiveness","https://ClinicalTrials.gov/show/NCT01549327"
744,"NCT01205711","Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: zibotentan|Other: laboratory biomarker analysis|Other: pharmacogenomic studies","Cardiff University","Both","18 Years and older   (Adult, Senior)","Phase 2","111","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","CDR0000685062|WCTU-FOLFERA|EUDRACT-2009-012151-23|ISRCTN-73199181|CRUK-09/023|WCTU-SPON-671-09|EU-21071|ZENECA-WCTU-FOLFERA","September 17, 2010","April 2010","September 2012","July 7, 2014","July 2014","No Study Results Posted","FOLFERA","July 2011","Progression-free survival|Tolerability (side effects) and feasibility of use (number of participants requiring dose delays or reductions and/or treatment withdrawal)|Objective response rate as assessed by RECIST criteria|Overall survival","https://ClinicalTrials.gov/show/NCT01205711"
745,"NCT01565811","Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis","Completed","No Results Available","Colorectal Cancer With Liver Metastasis","Procedure: perihepatic lymphadenectomy","Gachon University Gil Medical Center","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","girba2291","March 27, 2012","August 2010","December 2013","August 28, 2015","August 2015","No Study Results Posted","LN","March 2012","complication rate|To evaluate prognostic significance of perihepatic LN involvement with overall survival and disease free survival","https://ClinicalTrials.gov/show/NCT01565811"
746,"NCT01320319","Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery Patients","Recruiting","No Results Available","Colorectal Cancer","Other: Placebo|Dietary Supplement: Experimental: Nutritional Supplementation with EPA","University of Nottingham|Derby Hospitals NHS Foundation Trust","Both","18 Years to 85 Years   (Adult, Senior)","Phase 2|Phase 3","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","11005","March 2, 2011","March 2011","March 2013","December 3, 2012","December 2012","No Study Results Posted","EPA-colo","December 2012","Nutritional supplementation with 960mg EPA three times a day positively affects muscle function and mass|The secondary aim is to look at the aerobic performance.","https://ClinicalTrials.gov/show/NCT01320319"
747,"NCT00004142","Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: Floxuridine|Drug: Fluorouracil (5-FU)|Procedure: Conventional surgery|Procedure: Radiofrequency ablation","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID98-035|P30CA016672|MDA-ID-98035|NCI-G99-1616|CDR0000067373","December 10, 1999","September 1999","December 2003","July 27, 2012","July 2012","No Study Results Posted","null","December 2003","Patient Tumor Response Rate","https://ClinicalTrials.gov/show/NCT00004142"
748,"NCT00003260","Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: FOLFOX regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","109","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066151|FRE-GERCOR-C97-3/CPTF308|FRE-C97-3/CPTF301|FRE-C97-3/CPTF308|RP-FRE-C97-3/CPTF308|EU-97044","November 1, 1999","January 1998","null","January 10, 2009","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003260"
749,"NCT01279681","Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Cognitive/Functional Effects|Colorectal Cancer|Neurotoxicity","Biological: bevacizumab|Drug: capecitabine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Cancer and Leukemia Group B","Both","70 Years and older   (Senior)","Phase 3","380","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","N0949|NCCTG-N0949|CDR0000692257|NCI-2011-02622","January 18, 2011","January 2011","null","August 11, 2016","August 2016","No Study Results Posted","null","September 2014","PFS using RECIST version 1.1|Overall survival|Response rate, defined as the proportion of patients in each arm who have an objective status of complete response or partial response, confirmed by a second assessment measured at least 6 weeks from the initial assessment, using RECIST version 1.1|Incidence of adverse events per the Cancer Therapy Evaluation Program (CTEP) Active Version of the NCI CTCAE version 4.0 grading","https://ClinicalTrials.gov/show/NCT01279681"
750,"NCT00003287","Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","554","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-05963","November 1, 1999","March 1998","null","June 29, 2012","June 2012","No Study Results Posted","null","March 2002","","https://ClinicalTrials.gov/show/NCT00003287"
751,"NCT00449163","Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer","Terminated","Has Results","Colorectal Cancer","Biological: bevacizumab|Drug: floxuridine|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy","University of Miami Sylvester Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMIAMI-20060042|SCCC-2005145|WIRB-20060252","March 15, 2007","March 2006","March 2010","July 25, 2014","August 2013","January 23, 2013","null","March 2010","Overall Survival up to 2 Years|Response Rate (Complete Response and Partial Response)|Median Progression-free Survival in Months|Toxicity","https://ClinicalTrials.gov/show/NCT00449163"
752,"NCT01312857","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: panitumumab|Drug: Randomization to No Panitumumab","Memorial Sloan Kettering Cancer Center|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","78","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10-137","March 8, 2011","March 2011","March 2017","July 26, 2016","July 2016","No Study Results Posted","null","March 2017","to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases|to assess toxicity as per the NCI Common Toxicity Criteria|to determine survival|to analyze tumor tissue for predictive biomarkers","https://ClinicalTrials.gov/show/NCT01312857"
753,"NCT01281761","Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: cetuximab/irinotecan/simvastatin","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","52","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SMC IRB 2010-08-006","January 20, 2011","November 2010","December 2012","June 12, 2013","June 2013","No Study Results Posted","null","September 2012","response rate","https://ClinicalTrials.gov/show/NCT01281761"
754,"NCT02723578","Pemetrexed and Erlotinib for Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Pemetrexed|Drug: Erlotinib","Yonsei University","Both","19 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2015-0617","March 9, 2016","December 2015","July 2018","July 12, 2016","July 2016","No Study Results Posted","null","July 2017","Overall response rate|Progression-free survival|Overall survival|Disease control rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02723578"
755,"NCT00262171","Hereditary Nonpolyposis Colorectal Cancer in Taiwan－Related Genetic Study and Clinical Applications","Active, not recruiting","No Results Available","Hereditary Nonpolyposis Colorectal Cancer","","National Health Research Institutes, Taiwan|Chang Gung Memorial Hospital","Both","20 Years and older   (Adult, Senior)","","1014","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","EC9012005","December 5, 2005","May 2002","August 2016","April 5, 2016","March 2016","No Study Results Posted","null","August 2016","","https://ClinicalTrials.gov/show/NCT00262171"
756,"NCT01991873","Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Maintenance Chemotherapy|Drug: Panitumumab (Within maintenance phase)|Drug: mFOLFOX6 (Within re-induction phase)|Drug: Panitumumab (Within re-induction phase)","AIO-Studien-gGmbH|ClinAssess GmbH|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","380","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AIO-KRK-0212|2012-005422-30|PanaMa_DE-2009-0003","October 22, 2013","April 2014","June 2018","March 18, 2016","March 2016","No Study Results Posted","PanaMa","December 2017","Progression-free survival|failure of treatment strategy|Progression-free survival of re-induction|Objective response after 12 weeks of induction chemotherapy|Objective best response during maintenance and re-induction|Overall survival|Safety|Health and skin related Quality of life","https://ClinicalTrials.gov/show/NCT01991873"
757,"NCT01086618","Chemotherapy With or Without Surgery in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","Completed","No Results Available","Colorectal Cancer","Drug: systemic chemotherapy|Procedure: adjuvant therapy|Procedure: quality-of-life assessment|Procedure: therapeutic conventional surgery","University College London Hospitals|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000667364|UCL-08/0079|UCL-ISAAC|ISRCTN10963271|EU-21008|CRUK-C32436/A10431|EUDRACT-2008-005911-16|MREC-09/H1102/60|NCRI-UCL-08/0079","March 12, 2010","January 2010","July 2013","August 23, 2013","March 2010","No Study Results Posted","null","January 2013","Accrual rate in months 10 to 12 (phase II)|Overall survival for ≥ 2 years (phase III)|Morbidity of surgery (phase II)|Percentage of patients who receive chemotherapy following surgery (must be over 80%) (phase II)|Morbidity of chemotherapy and surgery (phase III)|Quality of life (phase III)|Economic evaluation (phase III)","https://ClinicalTrials.gov/show/NCT01086618"
758,"NCT00021281","Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: semaxanib","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068766|UCLA-001003701|SUGEN-SU5416.035|NCI-G01-1980","July 11, 2001","December 2000","null","December 18, 2013","September 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00021281"
759,"NCT00544700","Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: bevacizumab|Other: no maintenance","Swiss Group for Clinical Cancer Research","Both","18 Years and older   (Adult, Senior)","Phase 3","265","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 41/06|SWS-SAKK-41/06|EU-20762|CDR0000569866","October 13, 2007","October 2007","December 2017","April 14, 2016","April 2016","No Study Results Posted","null","May 2012","Time to progression|Overall survival|Progression-free survival PFS|Adverse events (AE)|Long-term bevacizumab treatment costs","https://ClinicalTrials.gov/show/NCT00544700"
760,"NCT00323011","FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab","University of Southern California|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","5","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-05-2","May 5, 2006","May 2006","November 2007","May 20, 2014","May 2014","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00323011"
761,"NCT02817178","Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Other: Additional biological samples","Centre Hospitalier Universitaire de Besancon","Both","18 Years and older   (Adult, Senior)","","258","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","Epitopes-CRC02","June 27, 2016","March 2013","March 2020","June 28, 2016","June 2016","No Study Results Posted","Epitopes-CRC02","March 2020","Progression-free survival","https://ClinicalTrials.gov/show/NCT02817178"
762,"NCT01822444","ANGIOPREDICT. ICORG 12-16, V3","Active, not recruiting","No Results Available","Advanced Colorectal Cancer","Other: Biomarker analysis","Cancer Trials Ireland","Both","18 Years and older   (Adult, Senior)","","224","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ICORG 12-16","February 25, 2013","November 2012","null","June 27, 2016","June 2016","No Study Results Posted","null","October 2017","Identification of biomarkers|Validation of identified biomarkers","https://ClinicalTrials.gov/show/NCT01822444"
763,"NCT00920803","A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases","Completed","No Results Available","Neoplasms, Colorectal|Colorectal Cancer","Drug: Placebo|Drug: SRT501","Sirtris, a GSK Company|GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 1","9","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Basic Science","113221","June 12, 2009","August 2008","November 2009","August 4, 2011","August 2011","No Study Results Posted","null","November 2009","To determine the safety and tolerability of SRT501 when administered once daily for 14 days.|To characterize the pharmacokinetic profile of SRT501 in blood and normal and malignant metastatic tissues when administered once daily for 14 days.|To examine the pharmacodynamics of SRT501 activity in both normal and malignant tissue samples and blood.","https://ClinicalTrials.gov/show/NCT00920803"
764,"NCT01596790","COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Other: Blood analysis by EPISPOT and Cellsearch","University Hospital, Montpellier|National Cancer Institute, France|Direction Générale de l'Offre de Soins|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 2","168","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","UF 8748|ID-RCB 2011-A01130-41","May 4, 2012","April 2012","April 2016","December 3, 2014","December 2014","No Study Results Posted","null","February 2016","Predictive value of the CTC on the Progression Free Survival|Prognostic value of the CTC detected by EPISPOT|Predictive value of the CTC on the overall survival|VEGF expressions by the CTC|Comparison of the results with the CellSearch system vs EPISPOT","https://ClinicalTrials.gov/show/NCT01596790"
765,"NCT01776307","A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: BBI608|Drug: Panitumumab|Drug: Capecitabine|Drug: Cetuximab","Boston Biomedical, Inc","Both","18 Years and older   (Adult, Senior)","Phase 2","150","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BBI608-224","January 21, 2013","March 2012","null","September 13, 2016","September 2016","No Study Results Posted","null","December 2016","Disease Control Rate|Overall Survival|Progression Free Survival|Safety|Pharmacokinetics|Pharmacodynamics","https://ClinicalTrials.gov/show/NCT01776307"
766,"NCT00423696","Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: capecitabine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Procedure: quality-of-life assessment","UNICANCER|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","144","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000523435|FRE-FNCLCC-ACCORD-13-0503|EU-20666|EUDRACT-2005-000070-43","January 16, 2007","January 2006","null","September 28, 2011","September 2011","No Study Results Posted","null","null","Progression-free survival at 6 months|Percentage of objective responses|Percentage of stable disease responses|Duration of objective response and stable disease|Progression-free survival|Overall survival|Toxicities|Quality of life","https://ClinicalTrials.gov/show/NCT00423696"
767,"NCT01079780","Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy","Recruiting","No Results Available","Colorectal Cancer","Biological: cetuximab|Biological: ramucirumab|Drug: irinotecan hydrochloride","Pam Cogliano|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 2","147","Other|NIH","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000666736|ECOG-E7208","March 2, 2010","November 2010","null","September 19, 2014","June 2012","No Study Results Posted","null","June 2017","Progression-free survival|Response rate (complete response, partial response, stable disease)|Toxicity|Overall survival","https://ClinicalTrials.gov/show/NCT01079780"
768,"NCT00819754","A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: IXO regimen + bevacizumab","Ottawa Hospital Research Institute|Hoffmann-La Roche|Pfizer|Sanofi|Ottawa Regional Cancer Foundation","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","23","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0TT 03-03","January 8, 2009","November 2003","May 2012","January 10, 2014","January 2014","No Study Results Posted","IXO+A","February 2012","Phase I: Assess the MTD and RD for phase II of IXO and bevacizumab combination given every 3 weeks in 1st line patients with mCRC|Phase II: Using the RD established in phase I, assess efficacy of the IXO with bevacizumab combination as measured by progression-free survival|Response rates and duration of response|Overall survival|Qualitative and quantitative toxicity","https://ClinicalTrials.gov/show/NCT00819754"
769,"NCT01175291","FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer","Withdrawn","No Results Available","Metastatic Colorectal Cancer","Drug: MK-0646|Drug: Placebo","H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","MCC-16145","August 2, 2010","September 2010","July 2012","December 2, 2011","December 2011","No Study Results Posted","null","July 2012","Progression Free Survival|Objective Radiographic Response|Overall Survival|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01175291"
770,"NCT00541125","G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: bevacizumab|Biological: filgrastim|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Federation Francophone de Cancerologie Digestive","Both","18 Years to 74 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000564089|FFCD-0604|EU-20757|EUDRACT-2007-001772-37","October 5, 2007","November 2007","December 2013","May 27, 2016","May 2016","No Study Results Posted","null","September 2013","Rate of neutropenia grade 4 or fever|Toxicities by NCI-CTC v. 2.0|Objective response at 6 months by RECIST|Tolerance (except neutropenia) by NCI-CTC v. 2.0|Progression-free survival|Overall survival|Time to treatment failure","https://ClinicalTrials.gov/show/NCT00541125"
771,"NCT01105169","Personalized Prevention of Colorectal Cancer Trial","Recruiting","No Results Available","Colorectal Cancer","Dietary Supplement: Magnesium glycinate|Dietary Supplement: Placebo","Vanderbilt University","Both","40 Years to 85 Years   (Adult, Senior)","","250","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","100106","April 14, 2010","August 2010","June 2017","December 10, 2015","December 2015","No Study Results Posted","null","June 2016","biomarkers directly related to tumorigenesis|other biomarkers related to the protective effects","https://ClinicalTrials.gov/show/NCT01105169"
772,"NCT00303771","Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Federation Francophone de Cancerologie Digestive","Both","75 Years to 120 Years   (Senior)","Phase 3","282","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000453855|FFCD-2001-02|EU-20546|AVENTIS-FFCD-2001-02|PFIZER-FFCD-2001-02","March 15, 2006","June 2003","January 2011","May 27, 2016","May 2016","No Study Results Posted","null","January 2011","Progression Free Survival (survie sans progression)|Overall Survival (survie globale)","https://ClinicalTrials.gov/show/NCT00303771"
773,"NCT00098787","Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer","Active, not recruiting","Has Results","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: Oxaliplatin","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","247","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000398096|E4203|U10CA021115","December 8, 2004","July 2005","April 2016","October 6, 2015","October 2015","May 27, 2014","null","November 2013","Objective Response Rate|Progression-Free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00098787"
774,"NCT00020501","Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: FOLFIRI regimen|Drug: floxuridine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: melphalan|Procedure: hyperthermia treatment","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","null","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","010093|NCI-01-C-0093|CDR0000068562","July 11, 2001","March 2001","January 2005","March 7, 2012","March 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00020501"
775,"NCT02075086","Angiogenic Switch in Patients With Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Xelox or Xeliri Bevacizumab","Grupo Hospital de Madrid","Both","18 Years to 85 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ANGIOSWITCH2011","November 17, 2011","July 2011","May 2015","March 13, 2015","March 2015","No Study Results Posted","ANGIOSWITCH","May 2015","Progression Free Survival|Feasibility","https://ClinicalTrials.gov/show/NCT02075086"
776,"NCT00003843","Irinotecan in Treating Patients With Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: irinotecan hydrochloride|Genetic: mutation analysis|Genetic: polymorphism analysis","California Cancer Consortium|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","28","Other|NIH","Observational","","CDR0000067003|LAC-USC-3C981|NCI-G99-1513","November 1, 1999","October 1998","February 2001","February 13, 2015","September 2013","No Study Results Posted","null","February 2001","","https://ClinicalTrials.gov/show/NCT00003843"
777,"NCT01523639","A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis","Terminated","No Results Available","Colorectal Cancer|Steatohepatitis","Drug: Metformin/Placebo","Austrian Breast & Colorectal Cancer Study Group|Merck Gesellschaft mbH, Austria","Both","18 Years and older   (Adult, Senior)","Phase 2","8","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","G-LUCAS|200084-610|2011-001010-34","January 26, 2012","April 2012","May 2014","March 7, 2014","March 2014","No Study Results Posted","G-LUCAS","November 2013","Reduction in the chemotherapy-associated steatosis|Progression Free Survival|Overall Survival|Safety assessment of all randomized subjects with at least one administration of study treatment|Occured Adverse Events of all randomized subjects with at least one administration of study treatment|Objective response rate (CR/PR)|Reduction in chemo-therapy associated steatohepatitis (CASH)","https://ClinicalTrials.gov/show/NCT01523639"
778,"NCT01859858","A Prospective Evaluation of the Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors.","Active, not recruiting","No Results Available","Advanced Colorectal Cancer","Dietary Supplement: curcumin|Drug: Irinotecan","UNC Lineberger Comprehensive Cancer Center","Both","21 Years to 99 Years   (Adult, Senior)","Phase 1","23","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","LCCC 1227","May 17, 2013","June 2013","June 2020","July 1, 2016","July 2016","No Study Results Posted","null","June 2019","Maximum tolerated dose (MTD)|Pharmacokinetics","https://ClinicalTrials.gov/show/NCT01859858"
779,"NCT01522612","Colorectal Cancer (CRC) Cetuximab Elderly Frail","Terminated","No Results Available","Colorectal Cancer Metastatic","Drug: Cetuximab|Drug: 5-fluorouracil|Drug: leucovorin","European Organisation for Research and Treatment of Cancer - EORTC|Merck KGaA","Both","70 Years and older   (Senior)","Phase 2","5","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-40085-75083|2011-002947-83","January 27, 2012","April 2013","January 2015","June 9, 2016","June 2016","No Study Results Posted","null","January 2015","Progression free survival|Overall Survival|Response Rate|Change in Instrumental Activities of Daily Living (IADL) score|Change in G8 geriatric assessment screening tool|Change in social situation|Score of Quality of Life (EORTC-QLQ C30 and QLQ-ELD14)|Occurrence of adverse events|Health Economy assessments|Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by G8 instrument|Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by Instrumental Activities of Daily Life (IADL) questionnaire|Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by social situation questionnaire","https://ClinicalTrials.gov/show/NCT01522612"
780,"NCT01362361","TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)","Recruiting","No Results Available","Colorectal Cancer","Drug: mFOLFOX6 + BIBF 1120|Drug: mFOLFOX6+placebo","Martin-Luther-Universität Halle-Wittenberg|GALMED GmbH, Halle, Germany","Both","18 Years and older   (Adult, Senior)","Phase 2","2","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TRICC-C (AIO-KRK-0111)|2010-023050-37","May 25, 2011","June 2011","December 2013","April 5, 2012","April 2012","No Study Results Posted","AIO-KRK-0111","June 2013","progression free survival","https://ClinicalTrials.gov/show/NCT01362361"
781,"NCT01688817","The Magnitude of Effect of PCP Counseling on Participation Rate and Sedation Rate in Colonoscopy-based Screening Program","Completed","No Results Available","Colorectal Neoplasms","Other: Physician's counseling|Other: Information leaflet","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Medical Centre of Postgraduate Education, Poland","Both","50 Years to 65 Years   (Adult)","","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","CMKP-2008","September 17, 2012","May 2008","May 2010","September 24, 2012","September 2012","No Study Results Posted","null","December 2009","Effect of primary care physician's (PCP) counseling on participation rate in primary colonoscopy screening program|Effect of primary care physician's (PCP) counseling on a patient's decision to choose unsedated colonoscopy (not in sedation).","https://ClinicalTrials.gov/show/NCT01688817"
782,"NCT00769405","Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Primary Peritoneal Cavity Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: hyperthermia treatment","UNICANCER","Both","18 Years to 70 Years   (Adult, Senior)","Phase 3","264","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000595024|FRE-FNCLCC-ACCORD-15/0608|EUDRACT-2006-006175-20|EU-20847","October 8, 2008","February 2008","null","August 29, 2016","August 2016","No Study Results Posted","null","December 2015","Overall survival|Recurrence-free survival|Toxicity by NCI CTCAE v.3.0|Morbidity from surgical complications (abdominal, extra-abdominal, aplasia)","https://ClinicalTrials.gov/show/NCT00769405"
783,"NCT01358812","FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colo-rectal Cancer","Drug: FOLFOXIRI + Panitumumab","Gruppo Oncologico del Nord-Ovest","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","37","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2934|2009-014556-29","May 19, 2011","March 2010","null","March 10, 2015","March 2015","No Study Results Posted","TRIP","October 2011","Response Rate|Progression Free Survival|Overall Survival|Safety Profile|Secondary Radical Surgery on Metastases|Analyses of Potential Predictive Factors","https://ClinicalTrials.gov/show/NCT01358812"
784,"NCT00003063","Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: recombinant interferon alfa|Drug: fluorouracil|Drug: leucovorin calcium|Drug: levamisole hydrochloride","European Institute of Oncology|National Cancer Institute (NCI)","Both","up to 75 Years   (Child, Adult, Senior)","Phase 3","1050","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065728|CNR-TONE-01|EU-97011","November 1, 1999","November 1991","null","September 19, 2013","November 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003063"
785,"NCT00303745","Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: irinotecan hydrochloride","Federation Francophone de Cancerologie Digestive|National Cancer Institute (NCI)","Both","75 Years and older   (Senior)","Phase 2","78","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000453857|FFCD-0305|EU-20545|EUDRACT-2004-004742-40","March 15, 2006","June 2006","null","July 23, 2008","December 2006","No Study Results Posted","null","null","Objective response|Stable disease rate|Tolerability|Quality of life|Progression-free and overall survival","https://ClinicalTrials.gov/show/NCT00303745"
786,"NCT02813278","Simo Decoction and Acupuncture on POI in Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: simo decoction|Other: gum chewing","Guangxi Medical University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","600","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","SMD/POI","June 22, 2016","February 2014","February 2016","June 23, 2016","June 2016","No Study Results Posted","SMD/POI","February 2016","First flatus time|Length of hospital stay","https://ClinicalTrials.gov/show/NCT02813278"
787,"NCT01456923","Chemotherapy With DNA Damaging Agents In Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: Treatment with chemotherapy|Other: Only chemotherapy treatment for study cohort|Procedure: surgery","Centro Hospitalar Nordeste","Both","40 Years to 90 Years   (Adult, Senior)","Phase 1","null","Other","Interventional","Primary Purpose: Treatment","ACCRC10","October 18, 2011","null","null","October 20, 2011","September 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01456923"
788,"NCT01670721","Colorectal Cancer Metastatic","Completed","No Results Available","Colorectal Cancer Metastatic","Drug: AFLIBERCEPT AVE0005|Drug: irinotecan|Drug: fluorouracil|Drug: Leucovorin","Sanofi|Regeneron Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 3","183","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AFLIBL06266|2012-000048-89|U1111-1128-9325","July 13, 2012","August 2012","June 2015","August 3, 2015","August 2015","No Study Results Posted","AFEQT","June 2015","Number of participants reporting Adverse Events|Health Related Quality of Life (HRQL) assessed by using changes from baseline in score derived from the 2 HRQL""questionnaires""","https://ClinicalTrials.gov/show/NCT01670721"
789,"NCT00277303","Study of XL999 in Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: XL999","Symphony Evolution, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","17","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XL999-206","January 12, 2006","December 2005","February 2007","February 18, 2010","February 2010","No Study Results Posted","null","August 2006","Response rate|Safety and tolerability|Progression-free survival|Duration of response|Overall survival|Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters","https://ClinicalTrials.gov/show/NCT00277303"
790,"NCT02277093","Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Pacritinib","Washington University School of Medicine|CTI BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 2","11","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201412087","October 24, 2014","September 2015","May 2017","June 9, 2016","June 2016","No Study Results Posted","null","September 2016","Progression-free survival (PFS)|Toxicity profile and tolerability|Overall response rate (ORR)|Time to progression (TTP)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02277093"
791,"NCT00087360","Genetic and Environmental Risk Assessment for Colorectal Cancer in Healthy Participants","Completed","No Results Available","Colorectal Cancer","Other: counseling intervention|Other: physiologic testing|Procedure: evaluation of cancer risk factors","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","50 Years to 74 Years   (Adult, Senior)","","null","Other|NIH","Interventional","Primary Purpose: Screening","FCCC-03030|CDR0000374972","July 8, 2004","November 2003","May 2007","July 10, 2013","July 2013","No Study Results Posted","null","May 2007","Colorectal cancer (CRC) screening rates by chart review at 4 months|Knowledge regarding CRC risk by questionnaires at 4 and 12 months|CRC risk perception by questionnaires at 4 and 12 months","https://ClinicalTrials.gov/show/NCT00087360"
792,"NCT00220155","Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Gemcitabine","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 2","16","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2398","September 20, 2005","May 2004","null","December 15, 2009","December 2009","No Study Results Posted","null","null","Proportion of patients obtaining disease control in the form of tumour response or stabilisation|Treatment related toxicity|Progression free survival","https://ClinicalTrials.gov/show/NCT00220155"
793,"NCT00003431","Flt3L in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: recombinant flt3 ligand","Duke University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066457|DUMC-98032|NCI-G98-1454","November 1, 1999","June 1998","May 2001","March 4, 2013","March 2013","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003431"
794,"NCT02796820","Huaier Granule As Adjuvant Therapy for Colorectal Cancer After Radical Surgery","Recruiting","No Results Available","Colorectal Cancer","Drug: Huaier Granule","Sixth Affiliated Hospital, Sun Yat-sen University|Qidong Gaitianli Medicines Co., Ltd","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","230","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","zsly Huaier-2","May 20, 2016","June 2016","June 2018","June 14, 2016","June 2016","No Study Results Posted","null","January 2018","Disease-free survival (DFS)|Overall survival (OS)|Relapse-free survival (RFS)|Metastasis-free survival (MFS)","https://ClinicalTrials.gov/show/NCT02796820"
795,"NCT00209703","Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: Oxaliplatin|Drug: l-Leucovorin|Drug: 5-Fluorouracil","Hokkaido Gastrointestinal Cancer Study Group","Both","15 Years to 75 Years   (Child, Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HGCSG0501","September 13, 2005","January 2005","June 2007","April 19, 2006","April 2006","No Study Results Posted","null","null","Incidence and severity of adverse event|Determine the clinical response rate, disease-free survival(DFS), overall survival(OS)","https://ClinicalTrials.gov/show/NCT00209703"
796,"NCT00891332","Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: S-1 plus LV (The combination therapy of S-1 and Leucovorin)","Taiho Pharmaceutical Co., Ltd.","Both","20 Years and older   (Adult, Senior)","Phase 2","73","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Taiho10020400","April 30, 2009","October 2008","November 2011","January 16, 2012","January 2012","No Study Results Posted","null","July 2011","Overall Response Rate (ORR)|Safety|Progression free survival (PFS)|Disease control rate(DCR)|Time to treatment failure (TTF)|Overall survival (OS)|Feasibility|Pharmacokinetics","https://ClinicalTrials.gov/show/NCT00891332"
797,"NCT00227734","Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine and oxaliplatin + cetuximab|Drug: capecitabine and oxaliplatin","Swiss Group for Clinical Cancer Research","Both","18 Years and older   (Adult, Senior)","Phase 2","74","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 41/04|EU-20525","September 26, 2005","June 2004","February 2006","June 4, 2012","June 2012","No Study Results Posted","null","October 2005","Objective response (complete response [CR] and partial response [PR]) measured after completion of study treatment|Clinical benefit (CR, PR, and stable disease [SD]) measured at 18 weeks after randomization|Time to progression|Overall survival|Time to treatment failure measured after completion of study treatment|Adverse drug reactions measured after completion of study treatment","https://ClinicalTrials.gov/show/NCT00227734"
798,"NCT01375816","Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: FOLFIRI 1-Bevacizumab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: liposome-encapsulated irinotecan hydrochloride PEP02|Drug: Bevacizumab","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","55","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000701454|FRE-GERCOR-PEPCOL-C10-1|EU-21115|EUDRACT-2010-020468-39|PHARMAENGINE-FRE-GERCOR-PEPCOL","June 16, 2011","May 2011","December 2014","June 3, 2015","November 2013","No Study Results Posted","PEPCOL","June 2014","Tumor response|Safety|Progression-free survival|Overall survival|Quality of life|Correlation of UGT1A family polymorphism and the toxicity of liposome-encapsulated irinotecan hydrochloride PEP02 or irinotecan hydrochloride","https://ClinicalTrials.gov/show/NCT01375816"
799,"NCT00538291","Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment","Terminated","Has Results","Colorectal Cancer","Biological: cetuximab|Drug: capecitabine|Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: polymorphism analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunohistochemistry staining method","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","13","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05033|P30CA033572|CHNMC-05033|CDR0000567432","October 1, 2007","August 2005","null","August 19, 2014","August 2014","June 12, 2014","null","February 2009","Response Rate","https://ClinicalTrials.gov/show/NCT00538291"
800,"NCT00005833","S9923 R115777 in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: R115777","Southwest Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","62","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067847|S9923|U10CA032102","June 2, 2000","June 2000","July 2006","June 12, 2012","June 2012","No Study Results Posted","null","July 2006","Confirmed complete and partial response rate to R115777|Time to treatment failure and survival|Frequency & severity of toxicities","https://ClinicalTrials.gov/show/NCT00005833"
801,"NCT00007943","Gemcitabine in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: gemcitabine hydrochloride","Wake Forest Baptist Health|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068355|CCCWFU-59198|NCI-914","January 6, 2001","September 2000","null","August 20, 2009","August 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00007943"
802,"NCT00473980","Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients","Completed","No Results Available","Colorectal Cancer","Drug: Indomethacin, celecoxib, esomeprazole","Göteborg University","Both","40 Years to 80 Years   (Adult, Senior)","Phase 4","28","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","kl4501122","May 15, 2007","December 1998","May 2007","March 30, 2012","March 2012","No Study Results Posted","null","null","Immune reactivity","https://ClinicalTrials.gov/show/NCT00473980"
803,"NCT01471353","Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: Sorafenib Plus Capecitabine (SorCape)","University of Florida","Both","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC2010-23","November 10, 2011","November 2011","December 2017","March 29, 2016","March 2016","No Study Results Posted","SorCape","October 2015","Sorafenib activity|Overall survival|Progression free survival|Response rate|Time to progression|Toxicity|Correlative tissue analysis","https://ClinicalTrials.gov/show/NCT01471353"
804,"NCT00062426","Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: capecitabine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Prologue Research International|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000304771|PROLOGUE-SANOFI-ARD5099|SANOFI-ARD5099","June 5, 2003","May 2003","February 2011","November 5, 2013","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00062426"
805,"NCT01305980","Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: SB injection","SBPharmaceutical IND, Co., LTD","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SB injection-C002","February 25, 2011","December 2010","March 2012","March 3, 2011","March 2011","No Study Results Posted","null","December 2011","Evaluating Tumor Response Rate|Pain Scores on the Visual Analog Scale|evaluate patient's performance by measuring Eastern Cooperative Oncology Group scale|Determine duration of response rate by measuring time to progression","https://ClinicalTrials.gov/show/NCT01305980"
806,"NCT00129870","CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: oxaliplatin","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 4","180","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","L_9444","August 10, 2005","February 2005","December 2007","February 12, 2009","February 2009","No Study Results Posted","null","null","Time to treatment failure (TTF) for the conventional oxaliplatin (CO) schedule in comparison with the intermittent oxaliplatin (IO) schedule|The incidence of adverse events, including neurotoxicity, as determined using the National Cancer Institute (NCI) Common Toxicity Criteria version 3.0 (CTCAE v3.0)|Quality of life, including oxaliplatin-specific neurologic symptoms determined using the PNQoxali|Tumor response rate (overall and confirmed) based on application of the Response Evaluation Criteria in Solid Tumors (RECIST)|Time to tumor progression (TTP)|Time of tumor control (TTC)|Overall survival (OS)|Reasons for treatment discontinuation","https://ClinicalTrials.gov/show/NCT00129870"
807,"NCT00052507","Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: bortezomib","University Health Network, Toronto|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","PMH-PHL-012|CDR0000258488|NCI-5890","January 24, 2003","January 2003","null","July 22, 2015","July 2015","No Study Results Posted","null","August 2005","","https://ClinicalTrials.gov/show/NCT00052507"
808,"NCT00640081","Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: capecitabine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Cheryl Pugh|Medical Research Council","Both","18 Years to 100 Years   (Adult, Senior)","Phase 2","169","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000589635|MRC-CTU-COIN-B/CR11|EUDRACT:2006-003049-17|ISRCTN38375681|EU-20828|MERCK-MRC-CTU-COIN-B/CR11","March 19, 2008","July 2007","September 2015","March 22, 2016","March 2016","No Study Results Posted","null","June 2010","Failure-free survival at 10 months|Safety of cetuximab reintroduction, in terms of risk of grade 3-4 allergic reactions|Proportion of patients achieving disease control (complete response plus partial response plus stable disease) at 24 weeks|Overall survival|Progression-free survival|Response rates|Toxicity of each treatment regimen by NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00640081"
809,"NCT01322152","Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: irinotecan, capecitabine","Fudan University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","52","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XELIRIcrc","March 23, 2011","March 2011","June 2013","June 10, 2013","June 2013","No Study Results Posted","null","May 2013","Rate of Diarrhea|Progression free survival|Response rate|Disease control rate|Overall survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01322152"
810,"NCT02228785","A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Biological: G17DT","Cancer Advances Inc.","Male","18 Years and older   (Adult, Senior)","Phase 2","5","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Masking: Open Label|Primary Purpose: Treatment","CC1C","August 27, 2014","May 1994","null","August 28, 2014","August 2014","No Study Results Posted","CC1C","October 1994","Injection Site Reaction|Antibody Levels|Intra-gastric pH","https://ClinicalTrials.gov/show/NCT02228785"
811,"NCT00188305","A Randomized Trial of Cancer Risk and Health Education in Relatives of Colorectal Cancer Patients","Completed","No Results Available","Colon Cancer|Colonic Neoplasms","Behavioral: General health counselling and risk information","University Health Network, Toronto|Canadian Institutes of Health Research (CIHR)","Both","25 Years to 65 Years   (Adult)","Phase 3","252","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","UHN04-0729-CE","September 9, 2005","January 2005","August 2009","August 14, 2015","August 2015","No Study Results Posted","null","June 2009","Colorectal cancer risk comprehension and screening knowledge|Intent to screen the colon|Colon screening behaviour|Personality|Psychosocial functioning|Satisfaction","https://ClinicalTrials.gov/show/NCT00188305"
812,"NCT02512172","A Pilot Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Oral CC - 486|Drug: Romidepsin|Drug: MK - 3475","Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp.|Celgene Corporation","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","J1538|IRB00060125","July 2, 2015","June 2015","June 2018","April 20, 2016","April 2016","No Study Results Posted","null","June 2017","Degree of change in tumor infiltrating lymphocytes","https://ClinicalTrials.gov/show/NCT02512172"
813,"NCT02129257","﻿Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: AFLIBERCEPT|Drug: Irinotecan|Drug: 5-Fluorouracil|Drug: Folinic Acid","Hellenic Cooperative Oncology Group|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","73","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HE 6A/13|2013-002567-26","April 28, 2014","May 2014","December 2017","May 12, 2016","May 2016","No Study Results Posted","AMALTHEA","May 2017","Progression-Free Survival (PFS) rate at 1 year|Evaluation of Objective Response Rate (ORR) defined as the proportion of patients with complete response (CR) or partial response (PR) among all patients, as assessed according to Response Evaluation Criteria for Solid Tumors (RECIST) v1.1|Evaluation of Overall Survival (OS)|Evaluation of Progression-Free Survival (PFS)|Number of participants with Serious and Non-Serious Adverse Events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Tumor tissue mRNA levels of VEGFA-121, VEGFA121b, VEGF-B, PlGF, VEGF-C, Semaphorins, HIF1, VEGFR1, VEGFR2, Neuropilins 1,2, Thrombospondin, Angiopoietins 1,2. Predictive significance for response rate, PFS, OS.|Steady-state concentration of free Aflibercept and VEGF-bound Aflibercept in plasma. Predictive significance for response rate, PFS, OS.|Enzyme-linked immunosorbent assay (ELISA) plasma concentrations of VEGFA, soluble VEGFR1, soluble VEGFR2, VEGF-B, PlGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF). Predictive significance for response rate, PFS, OS.","https://ClinicalTrials.gov/show/NCT02129257"
814,"NCT00467142","Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","Completed","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Genetic: polymorphism analysis","Institut Bergonié|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","61","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000540522|IB-2006-31|IB-OMEGA|INCA-RECF0387|EUDRACT-2006-003901-22","April 25, 2007","January 2007","null","May 13, 2011","July 2009","No Study Results Posted","null","May 2011","Partial or complete response rate|Duration of response|Overall and progression-free survival|Tolerance to treatment|Modified genetic polymorphisms and pharmacogenetics","https://ClinicalTrials.gov/show/NCT00467142"
815,"NCT00005864","Chloroquinoxaline Sulfonamide in Treating Patients With Stage IV Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: chloroquinoxaline sulfonamide","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067896|OSU-NCI-56|NCI-56","June 2, 2000","April 2000","February 2004","January 30, 2013","September 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005864"
816,"NCT00230646","Promoting Physical Activity After Colorectal Cancer","Completed","No Results Available","Colon Cancer|Rectal Cancer","Behavioral: Exercise counseling","The Miriam Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","46","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)","CA101770","September 29, 2005","July 2005","November 2009","October 4, 2010","September 2005","No Study Results Posted","null","November 2009","Minutes of moderate-intensity physical activity (PA) at 3 months among 134 sedentary patients who have completed treatment for colorectal cancer (CRC).|Examine the effects of the intervention on survivors' physical functioning, fitness, vigor, fatigue and body esteem at 3 months.|Examine the maintenance of outcomes (minutes of moderate intensity activity, physical functioning, vigor, fatigue and body esteem) at 6 and 12 months.","https://ClinicalTrials.gov/show/NCT00230646"
817,"NCT00005085","Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: becatecarin","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","37","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067695|AECM-T99-0109|NCI-T99-0109","April 6, 2000","February 2000","null","February 8, 2013","December 2002","No Study Results Posted","null","June 2002","","https://ClinicalTrials.gov/show/NCT00005085"
818,"NCT00182715","Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: capecitabine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Velindre NHS Trust|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","2421","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000440085|UKM-MRC-COIN-CR10|EU-20516|EUDRACT-2004-002951-16|ISRCTN27286448","September 15, 2005","March 2005","null","September 16, 2013","December 2007","No Study Results Posted","null","May 2009","Overall survival at 2 years|Progression-free survival at 2 years|Failure-free survival at 2 years|Response by RECIST criteria at 12 and 24 weeks|Toxicity by NCI Common Toxicity Criteria version 3 throughout treatment and at follow-up|Time of disease control at 2 years","https://ClinicalTrials.gov/show/NCT00182715"
819,"NCT00268463","Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer","Terminated","Has Results","Colorectal Cancer|Metastatic Cancer","Drug: capecitabine|Drug: floxuridine|Drug: oxaliplatin","NSABP Foundation Inc|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","22","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP C-09|U10CA012027","December 20, 2005","January 2006","June 2008","May 10, 2013","May 2013","February 5, 2013","null","June 2008","Progression-free Interval (PFI)|Liver PFI as Measured by Time to Hepatic Progression.|Survival as Measured by Time to Death From Any Cause.|Scales Specific to Social/Family, Emotional, and Functional Well-being, Perceived Convenience of Care, and Self-reported Symptoms|Quality of Life as Measured by the Functional Assessment of Cancer Therapy Trial Outcome Index at Baseline, at 4-6 Weeks Following Surgery (Before Initiation of Chemotherapy), and Periodically During Study","https://ClinicalTrials.gov/show/NCT00268463"
820,"NCT00003544","Irinotecan in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: irinotecan hydrochloride|Procedure: surgical procedure","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","98-057|CDR0000066598|NCI-G98-1476","November 1, 1999","June 1998","March 2001","June 24, 2013","June 2013","No Study Results Posted","null","March 2001","","https://ClinicalTrials.gov/show/NCT00003544"
821,"NCT01955837","Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: TAS-102|Drug: Placebo","Taiho Pharmaceutical Co., Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","10040090","September 19, 2013","September 2013","December 2016","August 9, 2016","August 2016","No Study Results Posted","TERRA","February 2016","Overall Survival|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT01955837"
822,"NCT00005616","Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Procedure: conventional surgery|Procedure: neoadjuvant therapy|Procedure: radionuclide imaging|Radiation: iodine I 131 monoclonal antibody F19","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Primary Purpose: Treatment","99-035A|CDR0000067753|BOEH-1152.5|LUDWIG-LUD98-006|NCI-G00-1756","May 2, 2000","September 1999","August 2000","June 18, 2013","June 2013","No Study Results Posted","null","August 2000","","https://ClinicalTrials.gov/show/NCT00005616"
823,"NCT02204332","Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment","Terminated","No Results Available","Colorectal Cancer","Drug: Cabazitaxel|Other: Best Supportive Care","Hospital Clinico Universitario de Santiago|Fundación Ramón Domínguez","Both","18 Years and older   (Adult, Senior)","Phase 2","38","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RLL-CAB-2011-01","July 23, 2014","March 2013","null","July 29, 2014","July 2014","No Study Results Posted","COMETA","September 2013","The efficacy of cabazitaxel measured by estimating the overall response rate (ORR), as the percentage of individuals who achieve a complete tumor response (CR) or partial tumor response (PR) in each arm and between arms.|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02204332"
824,"NCT00111761","Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: Irinotecan|Biological: Panitumumab|Drug: 5-Fluorouracil|Drug: Leucovorin","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","43","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20025409","May 25, 2005","July 2002","October 2008","November 15, 2013","November 2013","August 6, 2010","null","February 2008","Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)|Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)|Number of Participants With an Objective Tumor Response (Part 2)|Time to Disease Progression (Part 2)|Progression-free Survival Time (Part 2)|Survival Time (Part 2)|Number of Participants Who Died (Part 2)|Number of Participants With Objective Tumor Response (Part 1)|Progression-free Survival Time (Part 1)|Time to Disease Progression (Part 1)|Survival Time (Part 1)|Time to Treatment Failure (Part 1)|Time to Initial Objective Tumor Response (Part 1)","https://ClinicalTrials.gov/show/NCT00111761"
825,"NCT00720512","Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab","Terminated","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","Gruppo Oncologico del Nord-Ovest","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000598567|GONO-BEBYP-ASL607LIOM03|GONO-AIFA - FARM5C4FB4|EUDRACT:2007-002886-11","July 19, 2008","June 2008","March 2014","March 10, 2015","March 2015","No Study Results Posted","BEBYP","February 2013","Progression-free survival|Overall survival|Response rate|Safety","https://ClinicalTrials.gov/show/NCT00720512"
826,"NCT02848443","Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Trifluridine/tipiracil hydrochloride (S 95005)|Drug: Oxaliplatin|Drug: Bevacizumab","Institut de Recherches Internationales Servier|Servier","Both","18 Years and older   (Adult, Senior)","Phase 1","54","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CL1-95005-001","February 24, 2016","May 2016","February 2018","July 25, 2016","July 2016","No Study Results Posted","null","February 2018","Maximum Tolerated Dose (MTD) of S95005 when given in combination with oxaliplatin|Dose Limiting Toxicity (DLT) of S95005 when given in combination with oxaliplatin|Number of participants with adverse events as a measure of safety and tolerability|Changes in standard hematology as a measure of safety and tolerability|Changes in biochemistry as a measure of safety and tolerability|Changes in coagulation as a measure of safety and tolerability|Changes in urinalysis as a measure of safety and tolerability|Changes in vital signs as a measure of safety|Changes in ECOG (Eastern Cooperative Oncology Group) performance status as a measure of safety and tolerability|Antitumor activity assessed by RECIST (Response Evaluation Criteria in Solid Tumors)","https://ClinicalTrials.gov/show/NCT02848443"
827,"NCT00311610","Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: SN-38 liposome","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-80402|U10CA031946|CDR0000467234","April 5, 2006","January 2006","June 2010","June 28, 2016","June 2016","No Study Results Posted","null","January 2007","Objective response rate|Toxicity|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00311610"
828,"NCT01811108","Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","","Hellenic Oncology Research Group","Both","18 Years and older   (Adult, Senior)","","670","Other","Observational","Observational Model: Cohort","CT/10.12","February 21, 2013","July 2009","December 2013","October 23, 2014","October 2014","No Study Results Posted","null","December 2013","Number of Participants with AE|Number of Participants with Response Rate|Percentage of Patients with Progression Free Survival|Patients Overall Survival","https://ClinicalTrials.gov/show/NCT01811108"
829,"NCT00003441","Irofulven in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Irofulven (MGI-114)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","26","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM97-308|P30CA016672|U01CA070172|MDA-DM-97308|NCI-T97-0113|CDR0000066469","November 1, 1999","August 1998","November 2000","July 27, 2012","July 2012","No Study Results Posted","null","November 2000","Antitumor Activity of MGI-114","https://ClinicalTrials.gov/show/NCT00003441"
830,"NCT00203411","Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Capecitabine (Xeloda)|Drug: Bevacizumab","Translational Oncology Research International|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TORI GI-04","September 13, 2005","March 2006","null","February 16, 2011","February 2011","No Study Results Posted","null","February 2012","To determine the anti-tumor activity of bevacizumab plus capecitabine based on time to disease progression|To evaluate the tolerability of bevacizumab plus capecitabine treatment in a patient population that is elderly or frail (poor performance)|To determine response rates and duration of response|To evaluate the effect of bevacizumab plus capecitabine treatment on the quality of life of patients|To evaluate cost-effectiveness|To measure the rate of the functional decline","https://ClinicalTrials.gov/show/NCT00203411"
831,"NCT01668498","Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer","Completed","No Results Available","Ras-wildtype Colorectal Cancer","Drug: Erythromycin|Drug: Doxycycline","AIO-Studien-gGmbH","Both","18 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","AIO-LQ-0110|2010-022938-85","August 16, 2012","May 2011","March 2016","April 18, 2016","April 2016","No Study Results Posted","null","January 2015","Percentage of patients developing no skin toxicity ≥ grade 2|Quality of life|Assess Skin toxicity|Correlation between skin-related and global quality of life|late skin toxicity|Skin-toxicity related dose reductions of panitumumab","https://ClinicalTrials.gov/show/NCT01668498"
832,"NCT00467129","Genes That Affect Disease Outcome in Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Genetic: microarray analysis|Genetic: mutation analysis|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: questionnaire administration","University of Sheffield|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","800","Other","Observational","","CDR0000540670|SHEFF-SSREC01/271|SHEFF-USMS-SSREC01/271|EU-20727","April 25, 2007","July 2002","null","December 17, 2013","May 2007","No Study Results Posted","null","null","Survival|Progressive disease-free survival","https://ClinicalTrials.gov/show/NCT00467129"
833,"NCT00325871","Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: concurrent chemoradiation","Mackay Memorial Hospital","Both","30 Years to 60 Years   (Adult)","","30","Other","Observational","Observational Model: Case Control|Time Perspective: Longitudinal|Time Perspective: Prospective","MMH-I-S-243","May 12, 2006","April 2006","null","May 12, 2006","March 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00325871"
834,"NCT02316340","Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Vorinostat|Drug: Hydroxychloroquine|Drug: Regorafenib","The University of Texas Health Science Center at San Antonio","Both","18 Years and older   (Adult, Senior)","Phase 2","76","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","CTMS 14-2015","December 9, 2014","February 2015","January 2018","November 4, 2015","November 2015","No Study Results Posted","null","January 2018","Efficacy based on progression free survival of vorinostat and hydroxychloroquine compared to Regorafenib","https://ClinicalTrials.gov/show/NCT02316340"
835,"NCT00028015","SarCNU in Treating Patients With Recurrent or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: SarCNU","NCIC Clinical Trials Group|Canadian Cancer Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","I146|CAN-NCIC-IND146|NCI-NCIC-146|CDR0000069113","December 7, 2001","October 2001","null","November 7, 2010","March 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00028015"
836,"NCT00286000","High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study","Completed","No Results Available","Advanced Colorectal Cancer","Drug: Administration of high dose simplified folfiri","University Hospital, Ghent","Both","18 Years to 69 Years   (Adult, Senior)","Phase 2","106","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004/195","February 1, 2006","June 2004","December 2005","December 19, 2007","December 2007","No Study Results Posted","null","null","Response rate|Resectability|Safety|TTP","https://ClinicalTrials.gov/show/NCT00286000"
837,"NCT00389870","Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil","Recruiting","No Results Available","Colorectal Cancer","Biological: panitumumab|Drug: cyclosporine|Drug: irinotecan hydrochloride","University of Leeds|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","1269","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000510284|CTRU-PICCOLO-MO-05-7289|EUDRACT-2005-003492-20|CTAAC-CTRU-PICCOLO-MO-05-7289|AMGEN-CTRU-PICCOLO-MO-05-7289|EU-20647","October 18, 2006","December 2006","null","August 23, 2013","July 2007","No Study Results Posted","null","March 2010","Proportion of patients treated with irinotecan hydrochloride (Ir) alone vs Ir and cyclosporine (IrC) who are progression-free at 12 weeks|Overall survival of patients treated with Ir vs Ir and panitumumab (IrP) and no prior cetuximab|Proportion of patients free from treatment failure at 12 weeks in patients treated with Ir vs IrC|Overall survival in patients treated with Ir vs IrC|Nurse-assessed toxicity (all-cause mortality, diarrhea ≥ grade 3 at 12 weeks) in patients treated with Ir vs IrC|Progression-free at 12 weeks in patients treated with Ir vs IrP and no prior cetuximab|Nurse assessed toxicity (all-cause mortality) in patients treated with Ir vs IrP and no prior cetuximab|Progression-free survival in patients treated with Ir vs IrP and prior cetuximab|Best response at 1 year in patients treated with Ir vs IrP and prior cetuximab|Patient-assessed symptom/quality of life/acceptability scores at 12 and 24 weeks in patients treated with Ir vs IrP and prior cetuximab","https://ClinicalTrials.gov/show/NCT00389870"
838,"NCT02873455","Effects of Video Information on Preoperative Anxiety in Patients With Colorectal Cancer","Enrolling by invitation","No Results Available","Colorectal Cancer|Video Information","Other: Short video clip including the circumstance of operation theater, and surgeon's interview","Seoul National University Hospital","Both","20 Years to 75 Years   (Adult, Senior)","","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","B-1608-359-302","August 9, 2016","August 2016","March 2017","September 20, 2016","September 2016","No Study Results Posted","null","December 2016","Change of APAIS ((Amsterdam preoperative anxiety and information scale) from baseline APAIS to watching video.|Change of HADS (Hospital Anxiety and Depression Scale) from baseline HADS to watching video.|Postoperative hospital stay","https://ClinicalTrials.gov/show/NCT02873455"
839,"NCT01679327","Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Oxaliplatin|Drug: Xeloda|Drug: Calcium folinate (CF)|Drug: 5-FU|Drug: Bevacizumab","Chinese Academy of Medical Sciences","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","WY0524","August 18, 2012","March 2012","September 2014","September 5, 2012","September 2012","No Study Results Posted","null","June 2014","Overall response rate|progression free survival|overall survival|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01679327"
840,"NCT02869269","A Study of Circulating Immune Cell Activity Changes in Blood of Colorectal Cancer Patients","Recruiting","No Results Available","Colorectal Cancer","Device: Early stage|Device: Late stage","Konkuk University Medical Center","Both","20 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","KUH1160096","July 15, 2016","October 2015","October 2018","August 11, 2016","August 2016","No Study Results Posted","null","October 2018","Circulating helper T cell activity|Cytotoxic T cell and natural killer cell activity","https://ClinicalTrials.gov/show/NCT02869269"
841,"NCT02718430","VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis","Recruiting","No Results Available","Colorectal Cancer","Drug: VXM01","Vaximm GmbH","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VXM01-03-DE","March 16, 2016","February 2016","March 2018","March 18, 2016","March 2016","No Study Results Posted","null","March 2018","Safety and tolerability taking into account treatment-limiting toxicities (TLTs)|Immune Response by Enzme Linked Immuno Spot (ELISpot)|Immune biomarker by tumor tissue immunohistochemistry staining|Tumor vasculature by tumor tissue immunohistochemistry staining|Serum biomarker Response by Enzyme Linked Immuno Sorbent Assay (ELISA)|Clinical Response including tumor staging according to the response criteria in solid tumors (RECIST)|Biodistribution and shedding of VXM01","https://ClinicalTrials.gov/show/NCT02718430"
842,"NCT02300922","Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Antibody TF2|Drug: 90-Y-IMP-288|Drug: 111-In-IMP-288","Nantes University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","31","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","RC14_0003","November 20, 2014","December 2014","December 2016","March 24, 2016","March 2016","No Study Results Posted","RITCOLON","October 2016","To determine the maximum tolerated dose for 90Y-IMP288.","https://ClinicalTrials.gov/show/NCT02300922"
843,"NCT00062023","Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: Acetylsalicylic acid (Aspirin)|Drug: Sulindac|Drug: Ursodiol|Other: Sulindac Placebo","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","40 Years to 80 Years   (Adult, Senior)","Phase 2","12","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","ID01-454|P30CA016672|MDA-ID-01454|CDR0000304433","June 5, 2003","June 2003","May 2006","July 27, 2012","July 2012","No Study Results Posted","null","April 2005","Percentage Change in Colorectal ACF Patients Treated with Sulindac, Aspirin or Ursodiol","https://ClinicalTrials.gov/show/NCT00062023"
844,"NCT02567331","A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Capecitabine","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 4","28","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18017","October 1, 2015","October 2004","April 2006","September 1, 2016","September 2016","No Study Results Posted","null","April 2006","Incidence of adverse events|Response rate, ie, percentage of participants with complete, partial, and overall response|Pharmacoeconomic analysis: Treatment-related and AE-related spending/savings\n","https://ClinicalTrials.gov/show/NCT02567331"
845,"NCT01775644","An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (Koralle)","Active, not recruiting","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","2947","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML28120","January 23, 2013","December 2012","March 2018","August 1, 2016","August 2016","No Study Results Posted","null","March 2018","Differences in progression-free survival of patient subgroups|Clinical/demographic patient characteristics at initiation of treatment|Progression-free survival in daily routine|Overall response in daily routine|Response rate in daily routine|Treatment schemes in daily routine|Safety: incidence of adverse events|Reason for treatment modifications/discontinuation","https://ClinicalTrials.gov/show/NCT01775644"
846,"NCT01568151","Testing Interventions to Motivate and Educate","Active, not recruiting","No Results Available","Colorectal Cancer","Behavioral: Clinic-directed intervention program|Behavioral: Individual Patient-Directed Program","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","50 Years to 85 Years   (Adult, Senior)","Phase 4","551","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Screening","TIME|1R01CA116487|OSU 08073","March 19, 2012","April 2009","December 2017","April 8, 2016","April 2016","No Study Results Posted","TIME","December 2013","Number of participants who undergo colorectal screening because of interventions|Number of problems associated with intervention program","https://ClinicalTrials.gov/show/NCT01568151"
847,"NCT02630420","Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: cetuximab and savolitinib","Yale University","Both","18 Years and older   (Adult, Senior)","Phase 1","33","Other","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1502015402","December 1, 2015","January 2017","January 2018","August 23, 2016","August 2016","No Study Results Posted","null","January 2018","Safety and tolerability based on regular clinical assessment and NCI Common Terminology Criteria for Adverse Events|Response to treatment measured by RECIST (Response Evaluation Criteria in Solid tumors) criteria|Progression free survival","https://ClinicalTrials.gov/show/NCT02630420"
848,"NCT01832948","Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Endostar|Drug: Oxaliplatin|Drug: Folinic acid|Drug: 5-FU","Zhejiang Cancer Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20121201E-mCRC","March 31, 2013","January 2013","January 2015","April 11, 2013","April 2013","No Study Results Posted","null","January 2015","Objective Response Rate (ORR)|Blood perfusion in tumor tissue|Ratio of blood perfusion in tumor tissue to blood perfusion in surrounding normal tissue|Incidence of Adverse Events","https://ClinicalTrials.gov/show/NCT01832948"
849,"NCT01674907","An Observational Study of Avastin (Bevacizumab) in First Line in Patients With Metastatic Colorectal Cancer (AVANiS)","Completed","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","27","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML22399","August 22, 2012","March 2010","April 2012","September 1, 2016","September 2016","No Study Results Posted","null","April 2012","Dosage/schedule of 1st-line Avastin|Duration of treatment|Chemotherapy regimens used in clinical practice|Clinical/demographic patient characteristics at baseline|Progression-free survival|Relationship between termination of Avastin treatment and time point of progression","https://ClinicalTrials.gov/show/NCT01674907"
850,"NCT02785146","Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Huaier Granule|Drug: Oxaliplatin|Drug: Calcium folinate|Drug: 5-fluorouracil","Sixth Affiliated Hospital, Sun Yat-sen University|Qidong Gaitianli Medicines Co., Ltd","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","230","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","zsly Huaier-1","May 19, 2016","June 2016","June 2018","June 7, 2016","June 2016","No Study Results Posted","null","January 2018","Disease-free survival (DFS)|Overall survival (OS)|Relapse-free survival (RFS)|Metastasis-free survival (MFS)","https://ClinicalTrials.gov/show/NCT02785146"
851,"NCT00040820","Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: oxaliplatin","Roswell Park Cancer Institute","Both","18 Years and older   (Adult, Senior)","","null","Other","Interventional","Primary Purpose: Treatment","CDR0000069410|RPCI-DS-0130","July 8, 2002","January 2002","March 2004","March 3, 2011","March 2011","No Study Results Posted","null","August 2003","","https://ClinicalTrials.gov/show/NCT00040820"
852,"NCT00022698","Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: Capecitabine|Drug: Irinotecan","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","67","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML16323","August 10, 2001","May 2001","December 2004","March 16, 2016","February 2005","March 16, 2016","null","December 2004","Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0)|Time to Disease Progression|Time to Treatment Failure|Percentage of Participants With One-year Survival|Overall Survival|Time To Objective Response|Duration of Overall Response|Duration of Overall Complete Response|Number of Participants With Any Adverse Events, Serious Adverse Events and Deaths","https://ClinicalTrials.gov/show/NCT00022698"
853,"NCT02291289","A Multi-Center Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Cetuximab|Drug: FOLFOX induction regimen|Drug: Fluoropyrimidine (5-FU or capecitabine)|Drug: MPDL3280A [TECENTRIQ]|Drug: Vemurafenib|Drug: bevacizumab","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","610","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MO29112|2014-001017-61","November 11, 2014","April 2015","February 2019","August 18, 2016","August 2016","No Study Results Posted","null","February 2019","Proportion of patients with a 20% reduction in tumor size in the Maintenance Treatment Phase after 2 months of treatment|Progression-free survival (PFS) evaluated according to RECIST 1.1|Overall survival|Overall response rate, calculated as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) determined according to RECIST 1.1|Disease control rate, calculated as the proportion of patients with a best overall response of CR, PR or stable disease (SD) as determined according to RECIST 1.1|Time to treatment response, calculated as the time from randomization to the first occurrence of a documented objective response (CR or PR) determined according to RECIST 1.1|Duration of response, defined as the time from the first assessment of CR or PR until disease progression or death from any cause, whichever occurs first|Change in ECOG performance status|Incidence of adverse events (AEs)","https://ClinicalTrials.gov/show/NCT02291289"
854,"NCT01639326","Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Irinotecan high doses|Drug: Irinotecan standard doses","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","96","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IIBSP-IRI-2011-134","July 10, 2012","July 2012","September 2018","May 6, 2015","June 2012","No Study Results Posted","FOLFIRI-AD","July 2018","Overall objective response rate (RR) by RECIST criteria v1.1|Adverse Events|Progression free survival|Overall survival|overall response duration","https://ClinicalTrials.gov/show/NCT01639326"
855,"NCT01172860","Endoscopic Treatment of Inoperable Colorectal Cancer With the EndoVe System","Active, not recruiting","No Results Available","Colorectal Cancer","Device: EndoVe endoscopic electroporation","Mercy University Hospital, Cork, Ireland|St. James Hospital, Dublin|The Adelaide and Meath Hospital","Both","18 Years and older   (Adult, Senior)","Phase 1","10","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT:2012-001248-23","July 29, 2010","January 2014","December 2017","January 8, 2016","January 2016","No Study Results Posted","CCEE EndoVe","July 2016","Tumor regression|treatment safety","https://ClinicalTrials.gov/show/NCT01172860"
856,"NCT02286492","Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer","Approved for marketing","No Results Available","Colorectal Cancer Metastatic","Drug: TAS-102","Taiho Oncology, Inc.","Both","18 Years and older   (Adult, Senior)","","null","Industry","Expanded Access","","TO-TAS-102-401","November 5, 2014","null","null","June 9, 2016","June 2016","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT02286492"
857,"NCT01215539","Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients","Completed","No Results Available","Colorectal Cancer","Drug: panitumumab","Hellenic Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 2","78","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HE 6A/09|2009-012655-26","September 29, 2010","September 2010","December 2014","March 17, 2015","March 2015","No Study Results Posted","null","August 2014","Objective Response|Overall Survival (OS)|Progression-Free Survival(PFS)|Adverse Events (AE)of all participants will be recorded and assessed upon signature of the informed consent form, until 30 days after the last administration of study treatment.|Economic evaluation","https://ClinicalTrials.gov/show/NCT01215539"
858,"NCT00336141","Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Suberoylanilide hydroxamic acid","University of Southern California|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1","10","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-05-3","June 9, 2006","June 2006","April 2009","May 19, 2014","May 2014","No Study Results Posted","null","April 2009","Toxicity|Response","https://ClinicalTrials.gov/show/NCT00336141"
859,"NCT01998009","Study of In-home Tests for Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: fecal occult blood tests","Centers for Disease Control and Prevention|Battelle Memorial Institute|University of Minnesota - Clinical and Translational Science Institute|Indiana University|Park Nicollet Health Services","Both","50 Years to 75 Years   (Adult, Senior)","","1382","U.S. Fed|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","CDC-NCCDPHP-5985","November 6, 2013","May 2011","September 2014","February 4, 2015","February 2015","No Study Results Posted","SIT","September 2014","The proportion of participants with a positive colonoscopy finding indicating an advanced colorectal neoplasia who also have a positive fecal occult blood test result|The proportion of participants with a negative colonoscopy finding who also have a negative fecal occult blood test result","https://ClinicalTrials.gov/show/NCT01998009"
860,"NCT02751892","The Feasibility of an Active Lifestyle Programme in Patients Recovering From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Behavioral: Active lifestyle programme","University of East Anglia","Both","Child, Adult, Senior","","28","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","13/EE/0060","April 21, 2016","October 2013","September 2014","April 21, 2016","April 2016","No Study Results Posted","MOVE","September 2014","Change in minutes spent in moderate and vigorous intensity physical activity measure with the International Physical Activity Questionnaire long version|Change in behavioural regulation measure with the Behavioural Regulation in Exercise Questionnaire version 2|Change in psychological needs satisfaction measured with the psychological needs satisfaction in exercise scale|Change in quality of life measure with the Functional Assessment of Cancer Therapy general|Change in quality of life measure with the Functional Assessment of Cancer Therapy-colorectal|Change in fatigue with the Functional Assessment of Cancer Therapy - fatigue|Change in intention to exercise|Change in barriers to exercise|Change in physical fitness|Change in upper body strength-grip strength|Change in upper body strength-upper arm strength|Change in lower body strength|Changes in body composition (% body fat) assessed with bioelectrical impedance analysis|Change in antropometric measures (waist circumference, hip circumference|Changes in anthropometric measures (height, weight, BMI)|Change in minutes spent in moderate and vigorous intensity physical activity with accelerometry","https://ClinicalTrials.gov/show/NCT02751892"
861,"NCT00897754","Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab","Active, not recruiting","No Results Available","Colorectal Cancer","Genetic: gene expression analysis|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: immunologic technique","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","200","Other|NIH","Observational","","CDR0000560986|ECOG-E3200T2","May 9, 2009","July 2007","null","May 16, 2009","September 2007","No Study Results Posted","null","null","Mean scores for VEGFb and pan-VEGF gene expression by IHC|Comparison of outcome of bevacizumab treatment for groups on either side of the median split of VEGFb:pan-VEGF expression ratios|Gene expression as measured by tissue microarrays|Splice form expression as measured by reverse transcriptase-PCR|VEGF165b protein expression as measured by ELISA","https://ClinicalTrials.gov/show/NCT00897754"
862,"NCT00004860","Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: leucovorin calcium|Drug: tegafur-uracil","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","75 Years and older   (Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067511|E-1299","March 7, 2000","June 2000","null","August 22, 2013","August 2013","No Study Results Posted","null","October 2005","","https://ClinicalTrials.gov/show/NCT00004860"
863,"NCT01801904","A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab","National Cancer Institute, Naples|Azienda Ospedaliera G. Rummo","Both","18 Years and older   (Adult, Senior)","Phase 2","52","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PACER|2010-024490-39","January 15, 2013","December 2012","July 2017","March 3, 2016","March 2016","No Study Results Posted","PACER","July 2016","number of patients alive and without disease progression|response rate|progression free survival|overall survival|worst grade toxicity per patient","https://ClinicalTrials.gov/show/NCT01801904"
864,"NCT00955188","Computer-Based Tailored or Standard Information for Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Other: computer-assisted intervention|Other: educational intervention|Other: medical chart review","University of Michigan Cancer Center|National Cancer Institute (NCI)","Both","50 Years to 79 Years   (Adult, Senior)","","345","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CDR0000632080|R01CA131041|P30CA046592|H8000-32900-01","August 7, 2009","August 2004","May 2008","December 19, 2012","December 2012","No Study Results Posted","null","April 2007","Adherence to colorectal cancer screening at 12 months post-intervention|Elements of informed decision making|Knowledge about screening options|Decisional conflict and satisfaction|Intention to get screened","https://ClinicalTrials.gov/show/NCT00955188"
865,"NCT00932724","CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: CY-503|Drug: Placebo","Cytavis Biopharma GmbH|ClinAssess GmbH|Medical University Innsbruck|Charite University, Berlin, Germany","Both","18 Years and older   (Adult, Senior)","Phase 2","77","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CY503C2|EudraCT no. 2008-005536-32","June 25, 2009","July 2009","August 2012","July 9, 2013","June 2011","No Study Results Posted","CY503C2","August 2012","Tumor assessment by using CT scans and/or MRIs|Assessment of Adverse Events|Assessment of quality of life using a standardized questionaire|Assessment of survival by ""physical exam""","https://ClinicalTrials.gov/show/NCT00932724"
866,"NCT00003446","Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: trimetrexate glucuronate","Grupo Oncologico Cooperativo del Sur|National Cancer Institute (NCI)","Both","18 Years to 74 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","GOCS-12-CR-97|CDR0000066475|NCI-V98-1457","November 1, 1999","December 1997","August 2005","June 25, 2013","September 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003446"
867,"NCT00003254","SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil","Completed","No Results Available","Colorectal Cancer","Drug: ethynyluracil|Drug: fluorouracil","Southwest Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","75","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066138|S9635|U10CA032102","November 1, 1999","April 1998","October 2003","March 6, 2012","March 2012","No Study Results Posted","null","November 2002","Confirmed Response Rate|Progression and Survival|Toxicities","https://ClinicalTrials.gov/show/NCT00003254"
868,"NCT01243372","Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Genetic: mutation analysis|Other: laboratory biomarker analysis","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","1142","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CALGB-SWOG-150506-80405-BRAF|CDR0000688745","November 17, 2010","November 2009","null","July 12, 2016","July 2016","No Study Results Posted","null","January 2100","Progression-free survival as measured by RECIST|overall survival|tumor response as measured by RECIST","https://ClinicalTrials.gov/show/NCT01243372"
869,"NCT00134589","CHOICE: Communicating Health Options Through Information and Cancer Education","Completed","No Results Available","Colorectal Neoplasms","Behavioral: Academic Detailing (Medical Practices)+Decision Aids (Patients)","Centers for Disease Control and Prevention|University of North Carolina|Aetna, Inc.","Both","52 Years to 75 Years   (Adult, Senior)","Phase 4","450","U.S. Fed|Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind","CDC-NCCDPHP-R-01-PH-000018","August 23, 2005","April 2005","April 2009","August 3, 2009","July 2007","No Study Results Posted","null","April 2009","Completion of colorectal cancer screening|Patient's intention to ask/patient asking medical provider for colorectal cancer screening","https://ClinicalTrials.gov/show/NCT00134589"
870,"NCT01266564","An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","205","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25198","December 20, 2010","September 2010","October 2016","September 1, 2016","September 2016","No Study Results Posted","null","October 2016","Progression-free survival in a real life setting assessed by computer tomography|Overall response rate assessed by computer tomography|Response of Avastin according to the sites of metastases assessed by computer tomography|Chemotherapy regimens used in combination with Avastin|Patient demographics eligible to receive Avastin|Safety: incidence of adverse events","https://ClinicalTrials.gov/show/NCT01266564"
871,"NCT00031616","NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: brivudine phosphoramidate","NewBiotics|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000069205|NB-1011-1001|NCI-V01-1689","March 8, 2002","December 2001","null","December 17, 2013","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00031616"
872,"NCT01144195","A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab + FOLFIRI","Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACROSS-08-01|2009-010975-26","June 7, 2010","September 2009","null","November 9, 2010","November 2010","No Study Results Posted","ACTIVE","December 2011","Objective Response Rate|disease control rate|duration of response|time to response|progression-free survival|time to progression|time to treatment failure|duration of stable disease|Incidence of adverse events","https://ClinicalTrials.gov/show/NCT01144195"
873,"NCT02497157","Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Oxaliplatin (L-OHP)|Drug: Irinotecan hydrochloride hydrate (CPT-11)|Drug: Continuous intravenous infusion of fluorouracil (CIV 5-FU)|Drug: Levofolinate calcium (l-LV)|Drug: Bevacizumab (Bmab)","Translational Research Informatics Center, Kobe, Hyogo, Japan|Hiroshima Prefectural Hospital|National Hospital Organization Shikoku Cancer Center","Both","20 Years to 70 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TRICC1414|UMIN000017102","June 25, 2015","April 2015","September 2018","July 13, 2016","July 2016","No Study Results Posted","BeTRI","September 2018","Response rate (RR) by response evaluation criteria in solid tumors (RECIST v1.1)|Time to treatment failure (TTF)|Progression-free survival (PFS)|Overall survival (OS)|R0 resection rate|Relative dose intensity (RDI)|Incidence of adverse events","https://ClinicalTrials.gov/show/NCT02497157"
874,"NCT00003995","Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2","Completed","No Results Available","Colorectal Cancer","Biological: trastuzumab|Drug: irinotecan hydrochloride","National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 2","32","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02307|PCI-98-056|NCI-T98-0078|CDR0000067205","November 1, 1999","September 1999","null","February 7, 2013","June 2007","No Study Results Posted","null","March 2006","","https://ClinicalTrials.gov/show/NCT00003995"
875,"NCT00569699","Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)","Completed","No Results Available","Colorectal Cancer","Drug: S-1, Bevacizumab","Taiho Pharmaceutical Co., Ltd.","Both","65 Years and older   (Adult, Senior)","Phase 2","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01023019","December 5, 2007","October 2007","March 2011","November 1, 2012","November 2012","No Study Results Posted","null","March 2011","Progression free survival|Safety, Response rate, Time to progression, Time to treatment failure, Overall survival, Treatment situation","https://ClinicalTrials.gov/show/NCT00569699"
876,"NCT01532804","2nd-line Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: bevacizumab, oxaliplatin and 5FU combination|Drug: Bevacizumab, oxaliplatin and raltitrexed combination","Institut du Cancer de Montpellier - Val d'Aurelle","Both","18 Years and older   (Adult, Senior)","Phase 2","124","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BEVATOMOX|2010-023447-15","February 10, 2012","July 2011","December 2018","March 2, 2015","March 2015","No Study Results Posted","BEVATOMOX","July 2018","Disease-free survival|Treatment-related toxicity|Objective response rate|Overall survival|Cost-effectiveness study|Quality of life","https://ClinicalTrials.gov/show/NCT01532804"
877,"NCT00003786","Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer","Withdrawn","No Results Available","Colorectal Cancer","Drug: irofulven","University of Chicago|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9635|UCCRC-9635|NCI-T98-0008","November 1, 1999","April 1999","November 2000","March 6, 2014","March 2014","No Study Results Posted","null","November 2000","Clinical Response Rate","https://ClinicalTrials.gov/show/NCT00003786"
878,"NCT00039611","Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","National Cancer Institute (NCI)","Both","15 Years and older   (Child, Adult, Senior)","","null","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000069434|CTEP-TRC-0201","June 6, 2002","May 2002","October 2007","June 18, 2013","July 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00039611"
879,"NCT00048139","A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Irinotecan|Drug: capecitabine [Xeloda]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","52","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MO16461","October 24, 2002","October 2001","June 2005","September 1, 2016","September 2016","No Study Results Posted","null","June 2005","Tumor measurement (RECIST criteria)|Efficacy: Time to progression, time to response, duration of response, time to treatment failure, survival.","https://ClinicalTrials.gov/show/NCT00048139"
880,"NCT00084721","Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Diarrhea","Drug: celecoxib|Drug: irinotecan hydrochloride","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","2","Other|NIH","Interventional","Primary Purpose: Treatment","RP 02-24|RPCI-RP-0224","June 10, 2004","March 2005","null","January 30, 2013","January 2013","No Study Results Posted","null","October 2005","","https://ClinicalTrials.gov/show/NCT00084721"
881,"NCT01609075","An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)","Completed","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","437","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML27907","May 29, 2012","June 2012","June 2013","September 1, 2016","September 2016","No Study Results Posted","null","June 2013","Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events|Proportion of patients with treatment discontinuation due to other causes|Incidence of other causes for treatment discontinuation|Second-line treatments initiated|Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes)","https://ClinicalTrials.gov/show/NCT01609075"
882,"NCT00721916","Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|Drug: mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)","Taiho Pharmaceutical Co., Ltd.|Yakult Honsha Co., LTD","Both","20 Years and older   (Adult, Senior)","Phase 2","107","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Taiho10020390","July 23, 2008","July 2008","May 2012","October 31, 2012","October 2012","No Study Results Posted","null","March 2012","Progression free survival (PFS)|Safety","https://ClinicalTrials.gov/show/NCT00721916"
883,"NCT01097018","Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Capecitabine|Drug: Perifosine|Drug: Placebo","AEterna Zentaris","Both","18 Years and older   (Adult, Senior)","Phase 3","468","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Protocol 343","March 30, 2010","April 2010","April 2012","June 25, 2013","June 2013","No Study Results Posted","X-PECT","April 2012","Overall Survival|Progression-free Survival","https://ClinicalTrials.gov/show/NCT01097018"
884,"NCT00569790","Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: S-1, Irinotecan, Bevacizumab","Taiho Pharmaceutical Co., Ltd.","Both","20 Years and older   (Adult, Senior)","Phase 2","53","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01023018","December 5, 2007","October 2007","March 2010","November 1, 2012","November 2012","No Study Results Posted","null","March 2010","Safety|Progression-free survival, Response rate, Overall survival, Treatment situation","https://ClinicalTrials.gov/show/NCT00569790"
885,"NCT00026364","ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: gefitinib|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","22","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02425|DFCI-01142|NCI-3792|CDR0000069023","November 9, 2001","November 2001","null","March 19, 2013","September 2002","No Study Results Posted","null","December 2006","","https://ClinicalTrials.gov/show/NCT00026364"
886,"NCT00048126","A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Irinotecan|Drug: capecitabine [Xeloda]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","57","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MO16460","October 24, 2002","July 2001","January 2005","September 1, 2016","September 2016","No Study Results Posted","null","January 2005","Tumor measurements (RECIST criteria)|Time to progression, time to response, duration of response, time to treatment failure, survival.\n","https://ClinicalTrials.gov/show/NCT00048126"
887,"NCT01904630","Sequencing to Identify Gene Variants in Familial Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Genetic: gene sequencing","Norwegian University of Science and Technology|St. Olavs Hospital","Both","20 Years and older   (Adult, Senior)","","14","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","2012/1707","April 23, 2013","December 2012","June 2016","July 13, 2016","July 2016","No Study Results Posted","null","June 2016","Data on association between sequence variants in exons and CRC risk","https://ClinicalTrials.gov/show/NCT01904630"
888,"NCT00165217","Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma","Completed","No Results Available","Colorectal Adenocarcinoma","Drug: Capecitabine|Drug: Thalidomide","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-141","September 9, 2005","November 2001","December 2005","December 20, 2007","December 2007","No Study Results Posted","null","December 2005","To assess the anti-tumor activity of capecitabine and thalidomide when administered to patients with previously treated metastatic colorectal cancer.|To evaluate the safety of capecitabine and thalidomide in this patient population.","https://ClinicalTrials.gov/show/NCT00165217"
889,"NCT02726334","A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.","Recruiting","No Results Available","Colorectal Cancer","Drug: BNC101 Solution for Infusion|Drug: BNC101 in combination with FOLFIRI","Bionomics Limited|CPR Pharma Services Pty Ltd, Australia","Both","18 Years and older   (Adult, Senior)","Phase 1","54","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BNC101. 001","March 28, 2016","March 2016","null","July 3, 2016","July 2016","No Study Results Posted","null","April 2019","Maximum Tolerated Dose","https://ClinicalTrials.gov/show/NCT02726334"
890,"NCT00258232","Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: celecoxib|Drug: irinotecan hydrochloride","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000445439|P30CA022453|WSU-C-2424","November 22, 2005","January 2002","August 2007","April 5, 2013","April 2013","No Study Results Posted","null","March 2007","Response rate by RECIST criteria at every other course|Time to progression|Toxicity|Overall survival|Time to treatment failure","https://ClinicalTrials.gov/show/NCT00258232"
891,"NCT02849106","Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: biopsy to obtain a chemogram","Institut Curie","Both","18 Years and older   (Adult, Senior)","","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","IC 2009-08","July 13, 2016","May 2011","January 2015","July 26, 2016","July 2016","No Study Results Posted","CULTURE3D","January 2015","Number of interpretable chemogram|Correlation between chemogram results obtained by 3D culture and RECIST 1.1 response assessement.|Chemosensitivity evaluated on 3D culture.|time to obtain chemogram","https://ClinicalTrials.gov/show/NCT02849106"
892,"NCT00925015","Phase I Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Colorectal Cancer Patients (0646-016)","Completed","No Results Available","Colorectal Cancer","Drug: dalotuzumab (MK0646)|Drug: Comparator: cetuximab|Drug: Comparator: irinotecan","Merck Sharp & Dohme Corp.","Both","20 Years and older   (Adult, Senior)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0646-016|2009_602","June 17, 2009","June 2009","December 2010","January 29, 2015","January 2015","No Study Results Posted","null","July 2010","Any clinical or laboratory adverse experiences|Pharmacokinetic drug-drug interactions|Human Anti-Human Antibody","https://ClinicalTrials.gov/show/NCT00925015"
893,"NCT00027729","Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: etaracizumab","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","01-078|CDR0000069061|MEDIMMUNE-MI-CP068|NCI-G01-2032","December 7, 2001","June 2001","November 2004","June 4, 2013","June 2013","No Study Results Posted","null","November 2004","","https://ClinicalTrials.gov/show/NCT00027729"
894,"NCT00559676","Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin|Other: laboratory biomarker analysis|Other: pharmacological study","Centre Hospital Regional Universitaire de Limoges|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 4","200","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000574159|CHUL-BIO-COLON|INCA-RECF0356","November 15, 2007","March 2005","null","May 13, 2011","July 2009","No Study Results Posted","null","May 2011","Oncogenetic parameters|Pharmacogenetic and pharmacokinetic predictors of therapeutic response and toxic effects|Correlations between the pharmacogenetic and pharmacokinetic parameters|Predictive value of pharmacogenetic and pharmacokinetic parameters on disease-free and overall survival","https://ClinicalTrials.gov/show/NCT00559676"
895,"NCT00039208","Combination Chemotherapy in Treating Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-05011","June 6, 2002","February 2002","null","July 12, 2012","July 2012","No Study Results Posted","null","August 2005","Peak delivery time for CPT11 tolerability over the first 3 courses of treatment in patients who started therapy|Peak delivery time for CPT11 tolerability over the first 3 courses of treatment in patients who started therapy, excluding those who stopped prior to course 3 for reasons other than toxicity|Peak delivery time for CPT11 activity over the first 3 courses|Peak delivery time for CPT11 tolerability and efficacy over the first 6 courses|Severe toxic events assessed by CTC v2.0 after each course of chemotherapy|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00039208"
896,"NCT02594150","Single Center Randomized Pilot Study Of Colorectal Cancer Screening Outreach","Enrolling by invitation","No Results Available","Colorectal Cancer","Other: Financial Incentive","University of Pennsylvania","Both","50 Years to 75 Years   (Adult, Senior)","","1080","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Screening","823388","October 29, 2015","December 2015","October 2016","August 24, 2016","August 2016","No Study Results Posted","CRCSO","September 2016","Increase in return rate of completed FIT","https://ClinicalTrials.gov/show/NCT02594150"
897,"NCT00004195","Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: eniluracil|Procedure: conventional colon surgery","University of Alabama at Birmingham|National Cancer Institute (NCI)|Glaxo Wellcome","Both","19 Years to 80 Years   (Adult, Senior)","Phase 2","28","Other|NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CDR0000067438|F980826006","January 21, 2000","September 1998","May 2001","June 12, 2015","June 2015","No Study Results Posted","null","October 1999","Primary Goal to demonstrate that eniluracil at current clinical doses|Evaluate DPD recovery and uracil levels","https://ClinicalTrials.gov/show/NCT00004195"
898,"NCT00019591","Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: aldesleukin|Biological: ras peptide cancer vaccine|Procedure: adjuvant therapy","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000066874|NCI-99-C-0023L|NCI-T98-0034","July 11, 2001","March 1999","November 2005","June 19, 2013","November 2005","No Study Results Posted","null","null","Response rate every 3 months for up to a year after completion of study treatment","https://ClinicalTrials.gov/show/NCT00019591"
899,"NCT00081237","OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: OSI-7904L|Drug: oxaliplatin","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","EORTC-16033|OSI-EORTC-16033","April 7, 2004","February 2004","null","June 11, 2013","June 2013","No Study Results Posted","null","August 2005","Maximum tolerated dose and recommended dose for future trials as measured by CTC v3.0|Safety profile as measured by CTC v3.0|Response as measured by RECIST every 6 weeks (2 courses)|Pharmacodynamics as measured by drug concentration in the blood during course 1|Time to progression as measured by Kaplan Meier and RECIST every 6 weeks during treatment and then every 8 weeks","https://ClinicalTrials.gov/show/NCT00081237"
900,"NCT01418222","FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: 5-FU|Drug: FOLFOX regimen|Drug: Placebo|Drug: bevacizumab [Avastin]|Drug: leucovorin|Drug: onartuzumab [MetMAb]","Genentech, Inc.|SCRI Development Innovations, LLC","Both","18 Years and older   (Adult, Senior)","Phase 2","194","Industry|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","GO27827","August 15, 2011","September 2011","March 2013","September 1, 2016","September 2016","No Study Results Posted","null","March 2013","Progression-free survival: time from randomization to tumor progression or death, tumor assessments according to RECIST criteria|Response rate (complete response + partial response)|Time to treatment failure: from randomization to treatment discontinuation for any reason including disease progression, treatment toxicity, and death|Overall survival|Safety: Incidence of adverse events","https://ClinicalTrials.gov/show/NCT01418222"
901,"NCT01676714","Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer","Completed","No Results Available","Non-Small Cell Lung Cancer|Colorectal Cancer","Drug: Dovitinib","University of California, Davis|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 2","10","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCDCC#231|CTKI258AUS21T","August 27, 2012","February 2013","June 2016","June 20, 2016","June 2016","No Study Results Posted","null","January 2016","Overall Response|Disease Control Rate|Progression Free Survival|Toxicity","https://ClinicalTrials.gov/show/NCT01676714"
902,"NCT02870582","Donafenib for Previously Treated Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Donafenib|Drug: Placebo","Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","510","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZGDC3","August 12, 2016","August 2016","August 2018","August 22, 2016","August 2016","No Study Results Posted","null","December 2017","Overall Survival (OS)|Progression-free Survival (PFS)|Disease Control Rate (DCR)|Safety variables will be summarized using descriptive statistics based on adverse events collection","https://ClinicalTrials.gov/show/NCT02870582"
903,"NCT00005877","Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: rubitecan","Astex Pharmaceuticals|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000067914|SUPERGEN-RFS2000-18|PCI-99-037","June 2, 2000","September 1999","null","December 3, 2013","April 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005877"
904,"NCT00003950","Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: cyclosporine|Drug: CPT-11","University of Chicago|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","16","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9824|UCCRC-T98-0049|NCI-T98-0049","November 1, 1999","January 2000","January 2005","March 6, 2014","March 2014","No Study Results Posted","null","December 2001","Reduction in occurrences of severe diarrhea due to CPT-11 administration","https://ClinicalTrials.gov/show/NCT00003950"
905,"NCT02223078","Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.","Completed","No Results Available","Colorectal Cancer","Biological: G17DT","Cancer Advances Inc.","Both","18 Years to 90 Years   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CC4","July 2, 2014","July 2000","November 2001","August 20, 2014","August 2014","No Study Results Posted","CC4","August 2001","Antibody Levels|pharmacodynamic|Number of Participants with Serious and Non-Serious Adverse Events","https://ClinicalTrials.gov/show/NCT02223078"
906,"NCT00030797","Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Irinotecan 70 mg/m2|Drug: Irinotecan 240 mg/m2","Swiss Group for Clinical Cancer Research","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","75","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 41/00|EU-20141","February 14, 2002","February 2001","December 2003","May 14, 2012","May 2012","No Study Results Posted","null","May 2002","","https://ClinicalTrials.gov/show/NCT00030797"
907,"NCT00091286","Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine","University of Virginia|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","15","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000386177|UVACC-GI37|UVACC-23302|UVACC-HIC-9976","September 7, 2004","March 2003","null","November 13, 2010","October 2007","No Study Results Posted","null","April 2011","Safety of the 4-peptide mixture if fewer than 33% of patients experience a dose-limiting toxicity at day 22|Immunogenicity of the peptide mixture by Elispot assay at day 22","https://ClinicalTrials.gov/show/NCT00091286"
908,"NCT00005050","Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: ethynyluracil|Drug: fluorouracil|Drug: oxaliplatin","New York University School of Medicine|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067642|P30CA016087|NYU-9907|NCI-G00-1718","April 6, 2000","August 1999","null","March 25, 2011","March 2011","No Study Results Posted","null","June 2001","","https://ClinicalTrials.gov/show/NCT00005050"
909,"NCT00072098","Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: adenovirus vector|Biological: interleukin-12 gene","Icahn School of Medicine at Mount Sinai|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","36","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000335463|MTS-GCO-975642|MTS-GCO-971592","November 4, 2003","September 2003","null","June 9, 2009","June 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00072098"
910,"NCT01437618","First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFOXIRI plus bevacizumab","Azienda Ospedaliero, Universitaria Pisana","Both","18 Years to 75 Years   (Adult, Senior)","","15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BRAF-0809-TRIBV","July 12, 2011","June 2009","May 2011","September 20, 2011","September 2011","No Study Results Posted","null","null","Progression-Free Survival","https://ClinicalTrials.gov/show/NCT01437618"
911,"NCT01623206","Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding","Recruiting","No Results Available","Colorectal Cancer|Rectal Bleeding","Drug: Desmopressin","Laboratorio Elea S.A.C.I.F. y A.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","30","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","DDAVP-R01-02","May 28, 2012","April 2013","March 2017","August 1, 2016","August 2016","No Study Results Posted","null","December 2016","Presence or absence of grade 3 or 4 adverse events related to the study drug, in a maximum of 2 out of 6 patients assessed in each dose level.|Number of patients with grade 3 or 4 local adverse events|Number of patients with grade 3 or 4 systemic adverse events|Number of withdrawn from treatment|Number of patients with partial or complete response in clinical endpoints","https://ClinicalTrials.gov/show/NCT01623206"
912,"NCT00450424","Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer","Completed","Has Results","Colorectal Cancer|Hereditary Non-polyposis Colon Cancer","Other: counseling intervention|Other: CD-ROM intervention","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","21 Years and older   (Adult, Senior)","","239","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","CDR0000443988|04827|R01CA109332-05","March 20, 2007","June 2007","November 2011","September 4, 2014","September 2014","August 5, 2014","null","November 2011","Impact of Standard Informed Consent vs CD-ROM Educational Intervention on Knowledge About Microsatellite Instability (MSI) Testing|Differential Impact of CD-ROM on Satisfaction With MSI Test Decision, Difficulty Making Decision & Decisional Conflict; Attitude; General & Cancer-related Distress; Discussions With Family About MSI Test & Familial Colorectal Cancer Risk|Impact of Demographic Factors, Disease/Family History Characteristics, Family Support, and Cancer-related Distress on Satisfaction With and Completeness of the Informed Consent Process|Patient Satisfaction With the Preparation to Make a Decision","https://ClinicalTrials.gov/show/NCT00450424"
913,"NCT01930864","Metformin Plus Irinotecan for Refractory Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Neoplasms|Adenocarcinoma","Drug: Metformin|Drug: Irinotecan","Barretos Cancer Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MetIri","August 26, 2013","September 2015","December 2016","July 30, 2015","July 2015","No Study Results Posted","null","September 2016","Non-Progression at week 12th of treatment|Progression-free survival|Overall Survival|Quality of life|Safety","https://ClinicalTrials.gov/show/NCT01930864"
914,"NCT01189942","A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: OMP-21M18","OncoMed Pharmaceuticals, Inc.|Novotech (Australia) Pty Limited","Both","21 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M18-003","August 25, 2010","September 2010","February 2011","September 16, 2016","September 2016","No Study Results Posted","null","February 2011","To the determine the maximum tolerated dose of OMP-21M18 plus FOLFIRI|To determine the safety of FOLFIRI plus OMP-21M18 at two dose levels|To determine the rates of immunogenicity of FOLFIRI plus OMP-21M18|To determine population pharmacokinetics|To determine the exploratory biomarker changes of FOLFIRI plus OMP 21M18|To determine the preliminary efficacy of FOLFIRI plus OMP-21M18","https://ClinicalTrials.gov/show/NCT01189942"
915,"NCT01064375","Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)|Device: Derma Vax (electroporation device)|Biological: GM-CSF|Drug: Cyclophosphamide","Maria Liljefors|Karolinska Institutet|Swedish Institute for Infectious Disease Control|Cyto Pulse Sciences, Inc.|Karolinska University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","El-porCEA|2009-009863-75","February 5, 2010","December 2009","October 2017","May 5, 2015","May 2015","No Study Results Posted","El-porCEA","February 2017","To evaluate the safety and immunogenicity of a DNA immunisation approach where tetwtCEA DNA will be administered in combination with electroporation.|To assess the efficiency of boosting immunological responses to CEA by intradermal administration of tetwtCEA DNA in combination with electroporation in subjects already vaccinated with CEA DNA|To compare effects (safety and immunogenicity) of additional adjuvance with GM-CSF","https://ClinicalTrials.gov/show/NCT01064375"
916,"NCT00191984","A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer","Completed","Has Results","Metastatic Colorectal Cancer","Drug: pemetrexed|Drug: irinotecan","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","46","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","8673|H3E-FP-S057","September 12, 2005","June 2004","May 2008","January 3, 2011","January 2011","April 27, 2009","null","February 2007","Best Overall Tumor Response|Duration of Response|Progression-Free Survival (PFS)|Time to Treatment Failure|Overall Survival","https://ClinicalTrials.gov/show/NCT00191984"
917,"NCT02251977","Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Chemotherapy-induced Neutropenia","Drug: GM1|Drug: placebo|Drug: mFOLFOX6 or XELOX","Yuhong Li|Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","188","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","GOXL-18","September 21, 2014","September 2014","August 2016","April 21, 2016","April 2016","No Study Results Posted","null","August 2016","rates of grade 2 or more chronic cumulative neurotoxicity of both arms|rates of chronic cumulative neurotoxicity of both arms|time to grade 2 or more neurotoxicity of both arms|rates of dose reduction or withdrawal due to oxaliplatin induced neurotoxicity of both arms|rates of acute neurotoxicity of both arms|rates and grades of adverse reactions of both arms|rates of 3 year disease free survival of both arms","https://ClinicalTrials.gov/show/NCT02251977"
918,"NCT01696695","AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","882","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML27791","September 27, 2012","July 2011","December 2014","August 1, 2016","August 2016","No Study Results Posted","null","December 2014","Progression-free survival with different Xeloda-based chemotherapy regimens|Objective response rate (complete response + partial response)|Clinical benefit rate (complete response + partial response + stable disease)|Metastasectomy rate|Mean duration of Xeloda treatment|Dose modification rate for Xeloda|Safety: Incidence of adverse events","https://ClinicalTrials.gov/show/NCT01696695"
919,"NCT00083616","Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy","Completed","Has Results","Colorectal Cancer|Metastatic Cancer","Biological: Panitumumab","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","185","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20030167","May 26, 2004","March 2004","December 2008","December 10, 2013","December 2013","August 6, 2010","null","May 2007","Number of Participants With Objective Tumor Response Through Week 16|Duration of Response|Number of Participants With Objective Tumor Response Throughout Study|Time to Response|Progression-free Survival Time|Time to Disease Progression|Time to Treatment Failure|Duration of Stable Disease|Overall Survival","https://ClinicalTrials.gov/show/NCT00083616"
920,"NCT00851045","Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer (CRC)","Drug: Irinotecan|Drug: 5-Fluorouracil (bolus)|Drug: 5-Fluorouracil (infusional)|Drug: Leucovorin calcium|Drug: CT-322|Drug: Bevacizumab|Drug: Bevacizumab Placebo (saline solution)","Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 2","17","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CA196-004|EUDRACT # 2008-006561-89","February 23, 2009","October 2009","October 2011","September 23, 2015","September 2015","No Study Results Posted","null","September 2011","Progression free survival based on tumor assessments (CT/MRI)|Overall survival (OS), defined as the time the subject is randomized until death, in each arm|Objective tumor response rate (ORR), defined as the proportion of randomized subjects in each arm whose best response is CR (complete response) or PR (partial response) using RECIST guidelines as determined by the site investigator|Safety in the CT-322 plus irinotecan, 5-FU and leucovorin arm as measured by incidence of serious and non-serious adverse events, significant laboratory evaluations and significant physical examination findings in subjects","https://ClinicalTrials.gov/show/NCT00851045"
921,"NCT00844233","Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Device: Irinotecan Bead","Biocompatibles UK Ltd","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","40","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA1016","February 9, 2009","February 2009","October 2012","March 28, 2013","September 2011","No Study Results Posted","PARAGON-II","September 2011","Tumour resectability at surgery|Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0)","https://ClinicalTrials.gov/show/NCT00844233"
922,"NCT00006115","Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: FOLFOX regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068128|FRE-GERCOR-C98-3-FIREFOX|EU-20023","August 3, 2000","April 1999","null","January 10, 2009","January 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006115"
923,"NCT00004187","Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: oxaliplatin","Swiss Group for Clinical Cancer Research","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","null","Other","Interventional","Primary Purpose: Treatment","SAKK 41/99|SWS-SAKK-41-99|EU-99026","January 21, 2000","June 1999","April 2004","May 14, 2012","May 2012","No Study Results Posted","null","April 2004","","https://ClinicalTrials.gov/show/NCT00004187"
924,"NCT00989469","Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Nexavar (Sorafenib) and irinotecan (Campto)","Institut du Cancer de Montpellier - Val d'Aurelle|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","64","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NEXIRI","October 2, 2009","February 2009","February 2012","February 9, 2012","February 2012","No Study Results Posted","NEXIRI","February 2011","disease control|toxicity|progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT00989469"
925,"NCT00055822","Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: oblimersen sodium|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","The University of Texas Health Science Center at San Antonio|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","16","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000271308|U01CA069853|P30CA054174|SACI-IDD-02-23|NCI-5793","March 6, 2003","October 2002","October 2004","July 3, 2012","July 2012","No Study Results Posted","null","October 2004","","https://ClinicalTrials.gov/show/NCT00055822"
926,"NCT01319877","An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","609","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25391","March 18, 2011","March 2011","March 2015","July 22, 2016","July 2016","April 21, 2016","null","March 2015","Percentage of Participants With Adverse Events|Percentage of Participants With Serious Adverse Events|Percentage of Participants With Adverse Events of Special Interest|Percentage of Participants With Bevacizumab-Related Adverse Events|Percentage of Participants With Bevacizumab-related Serious Adverse Events|Percentage of Participants Achieving an Overall Response|Progression-free Survival|One-year Progression-free Survival Rate|One-year Survival Rate|Percentage of Participants Achieving an Overall Response Per Kirsten Rat Sarcoma Viral (KRAS) Oncogene Subgroup|One-year Progression-free Survival Rate Per KRAS Subgroup|One-year Survival Rate by the KRAS Subgroup|Percentage of Participants Achieving an Overall Response by the Chemotherapy Regimen Subgroup|One-year Progression-free Survival Rate Per Chemotherapy Regimen Subgroup|One-year Survival Rate by the Chemotherapy Regimen Subgroup|Quality of Life: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire","https://ClinicalTrials.gov/show/NCT01319877"
927,"NCT00220116","Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Capecitabine, Oxaliplatin","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 2","172","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2147","September 19, 2005","August 2002","null","January 5, 2010","January 2010","No Study Results Posted","null","null","Objective response rates|Treatment related toxicity|Progression free survival (If not resected)|Disease free Survival (From metastastectomy, if resected)|Overall Survival|60 Day all cause mortality|Number undergoing liver resections/curative resection (Ro) rate","https://ClinicalTrials.gov/show/NCT00220116"
928,"NCT00080951","Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","Phase 2","14","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N0341|NCI-2012-02581|CDR0000357571","April 7, 2004","March 2004","February 2008","August 12, 2016","August 2016","No Study Results Posted","null","February 2008","tumor response rate|time to progression|overall survival|time to treatment failure|quality of life","https://ClinicalTrials.gov/show/NCT00080951"
929,"NCT02564224","Study Comparing Pursestring Wound Closure vs Conventional Closure to Reverse Stoma of Colorectal Cancer Patients","Recruiting","No Results Available","Colorectal Cancer|Stoma Closure Technic","Procedure: Pursestring Wound Closure|Procedure: Conventional Wound Closure|Device: prolene","Zhejiang University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRCCZ-S01","September 29, 2015","September 2015","September 2019","May 17, 2016","May 2016","No Study Results Posted","PURSE","September 2018","VSS（Vancouver Scar score）|surgical site infection rate","https://ClinicalTrials.gov/show/NCT02564224"
930,"NCT01159171","A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.","Completed","Has Results","Colorectal Cancer","Drug: bevacizumab [Avastin]|Drug: capecitabine [Xeloda]|Drug: oxaliplatin","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18523","July 7, 2010","January 2006","July 2010","July 24, 2014","July 2014","May 20, 2014","null","July 2010","Percentage of Participants With Objective Response (OR)|Percentage of Participants by Best Overall Response|Duration of Response - Percentage of Participants With an Event by 24 Months|Duration of Response|Duration of Stable Disease - Percentage of Participants With an Event by 24 Months|Duration of Stable Disease|Time to Treatment Failure (TTF) - Percentage of Participants With an Event by 24 Months|Time to Treatment Failure|Time to Progression (TTP) - Percentage of Participants With an Event by 24 Months|Time to Progression|Overall Survival (OS) - Percentage of Participants With an Event by 24 Months|Overall Survival","https://ClinicalTrials.gov/show/NCT01159171"
931,"NCT01163396","First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer Metastatic","Drug: Bevacizumab|Drug: Irinotecan|Drug: Oxaliplatin|Drug: 5-fluorouracil/leucovorin","Gruppo Oncologico del Nord-Ovest","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","57","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ASL606LIOM01","July 9, 2010","July 2007","April 2010","March 10, 2015","March 2015","No Study Results Posted","FOIB","April 2009","Progression-free survival (PFS)|Response rate (RR)|Overall survival (OS)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Evaluation of potential surrogate markers predictive of bevacizumab activity","https://ClinicalTrials.gov/show/NCT01163396"
932,"NCT00003057","Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Diarrhea","Drug: loperamide hydrochloride|Drug: octreotide acetate","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|Cancer and Leukemia Group B","Both","18 Years and older   (Adult, Senior)","Phase 3","500","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","CDR0000065713|E-E1295|CLB-9770|SWOG-E1295|NCI-P97-0081","November 1, 1999","November 1996","null","May 9, 2009","January 2009","No Study Results Posted","null","May 2000","","https://ClinicalTrials.gov/show/NCT00003057"
933,"NCT01321957","Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Oxaliplatin, 5FU/LV, Bevacizumab|Drug: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan","Martin-Luther-Universität Halle-Wittenberg|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 2","250","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AIO-0209","March 23, 2011","May 2011","January 2017","December 2, 2014","December 2014","No Study Results Posted","CHARTA","January 2015","progression free survival rate|tumour response according to RECIST v 1.1|Secondary resection rate|Progression free survival rate|Overall survival|Adverse events|Quality of life","https://ClinicalTrials.gov/show/NCT01321957"
934,"NCT02110082","Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Head and Neck Cancer","Biological: Urelumab|Biological: Cetuximab","Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1","104","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA186-018","April 8, 2014","April 2014","January 2017","September 19, 2016","September 2016","No Study Results Posted","null","January 2017","The primary safety endpoint is the incidence, potential significance, and clinical importance of adverse events|Objective response rate (ORR)|Duration of Objective Response (DOR)|Progression Free Survival (PFS)|Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-663513|Maximum observed serum concentration (Cmax) of BMS-663513 in combination with Cetuximab|Time of maximum observed serum concentration (Tmax) of BMS-663513 in combination with Cetuximab|Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-663513 in combination with Cetuximab|Area under the serum concentration-time curve from time zero to the time of last quantifiable serum concentration (AUC(0-T)) of BMS-663513 in combination with Cetuximab|Elimination half-life (T-HALF) of BMS-663513 in combination with Cetuximab|Total body clearance (CLT) of BMS-663513 in combination with Cetuximab|Volume of distribution at steady-state (Vss) of BMS-663513 in combination with Cetuximab|Trough observed concentration (Cmin) of BMS-663513 in combination with Cetuximab","https://ClinicalTrials.gov/show/NCT02110082"
935,"NCT00252564","Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer Metastatic","Drug: Bevacizumab|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil|Drug: Cetuximab","US Oncology Research|Bristol-Myers Squibb|Memorial Sloan Kettering Cancer Center|Prologue Research International","Both","18 Years and older   (Adult, Senior)","Phase 3","247","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","05-041","November 9, 2005","September 2005","June 2009","February 15, 2011","February 2011","February 15, 2011","null","June 2007","Progression-Free Survival (PFS)|Progression-free Survival (PFS)|Overall Survival (OS)|Overall Response Rate","https://ClinicalTrials.gov/show/NCT00252564"
936,"NCT00974610","Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. ICORG 07-12","Active, not recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Melanoma (Skin)|Pancreatic Cancer","","Cancer Trials Ireland","Both","Child, Adult, Senior","","300","Other","Observational","Time Perspective: Prospective","07-12 ICORG|ICORG-07-12|EU-20949","September 9, 2009","August 2008","null","February 15, 2016","February 2016","No Study Results Posted","null","December 2015","Detection of peptide and protein markers in serum|Identification of the protein/peptide involved","https://ClinicalTrials.gov/show/NCT00974610"
937,"NCT02624726","Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: 5 Fluorouracil|Drug: Leucovorin|Drug: Irinotecan|Drug: Aflibercept","Hellenic Oncology Research Group","Both","18 Years and older   (Adult, Senior)","Phase 2","89","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/14.01","November 24, 2015","January 2016","January 2019","April 12, 2016","April 2016","No Study Results Posted","MINOAS","January 2019","Overall Response Rate|Progression Free Survival|Overall Survival|Toxicity profile (CTCAE v4.0)","https://ClinicalTrials.gov/show/NCT02624726"
938,"NCT00119912","NORCCAP: Norwegian Colorectal Cancer Prevention Trial","Active, not recruiting","No Results Available","Colorectal Cancer|Adenoma","Procedure: A 1 Intervention arm Flex Sig|Procedure: A 2 Intervention arm Flex Sig + iFOBT","Norwegian Department of Health and Social Affairs|Norwegian Cancer Society","Both","50 Years to 64 Years   (Adult)","Phase 2|Phase 3","100000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","NORCCAP-1|Shdir 97/08614","July 6, 2005","January 1999","March 2017","April 28, 2015","April 2015","No Study Results Posted","null","March 2017","1. Evaluate the effect on CRC mortality and morbidity by screen detection of CRC and removal of precursor lesions (polypectomy of adenomatous polyps).First evaluation after 5 years.|1. Determine the prevalence of known types familial CRC in a general population and try to define other groups with intermediate increased risk. Results ""in press"" 2005.|2. Clarify possible psychosocial effects of endoscopic screening and how it may influence lifestyle and lifestyle related morbidity and overall mortality. Evaluation in 2005.","https://ClinicalTrials.gov/show/NCT00119912"
939,"NCT00087334","Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: gefitinib|Drug: oxaliplatin","Roswell Park Cancer Institute","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","10","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","I 17403|RPCI-I-17403|ZENECA-IRUSIRES0414","July 8, 2004","January 2004","null","January 31, 2013","January 2013","No Study Results Posted","null","November 2005","Maximum tolerated dose|Response rate|Toxicity|1-year survival (phase II)|Progression-free survival (phase II)|Overall survival in (phase II)","https://ClinicalTrials.gov/show/NCT00087334"
940,"NCT00912327","Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: Imprime PGG","Biothera","Both","18 Years and older   (Adult, Senior)","","18","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","BT-CL-PGG-CRC0821","June 1, 2009","June 2009","February 2012","February 14, 2012","February 2012","No Study Results Posted","null","February 2012","Objective response rate (ORR)|Disease control rate (DCR) and duration of disease control|Complete response (CR), partial response (PR), and stable disease (SD) rates|Duration of objective tumor response|Duration of stable disease|Time to progression (TTP)|Progression-free survival (PFS)|Safety of the dosing regimen|Overall survival","https://ClinicalTrials.gov/show/NCT00912327"
941,"NCT02388256","Acupuncture for Enhanced Recovery After Surgery in Patients Undergoing Laparoscopic Colorectal Cancer Resection","Completed","No Results Available","Colorectal Cancer","Device: acupuncture|Other: early recovery program after surgery","Korean Medicine Hospital of Pusan National University","Both","18 Years to 75 Years   (Adult, Senior)","","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","03-2014-012","March 1, 2015","March 2015","April 2016","June 25, 2016","June 2016","No Study Results Posted","null","February 2016","Recovery of physical function|Pain intensity|Time to first flatus|Time to tolerate soft diet|Time to first defecation|Time to independent walk|Number of insertions of nasogastric tube|Incidence of nausea/vomiting|Time to first removal of Foley catheter|Number of reinsertions of Foley catheter|Number of clean intermittent catheterizations|Quality of life measured by EORTC QLQ C30|Patient's global assessment after surgery|Use of medication|Anxiety and depression|Postoperative complications|Serious adverse events|Adverse events related to acupuncture","https://ClinicalTrials.gov/show/NCT02388256"
942,"NCT00535353","AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: irinotecan hydrochloride|Drug: olaparib","NCIC Clinical Trials Group|Canadian Cancer Trials Group","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","26","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I187|CAN-NCIC-IND187|IND187|CDR0000565189","September 25, 2007","August 2007","February 2015","May 2, 2016","February 2015","No Study Results Posted","null","September 2012","Recommended phase II dose of AZD2281 and irinotecan hydrochloride|Safety|Tolerability|Dose-limiting toxicities|Pharmacokinetic profile|Correlation, if any, between the toxicity profile and pharmacokinetics|Efficacy|Pharmacodynamic outcomes","https://ClinicalTrials.gov/show/NCT00535353"
943,"NCT00002664","Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: edrecolomab|Biological: sargramostim","George Washington University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000064248|GWCC-5095|NCI-V95-0686","November 1, 1999","July 1995","null","February 6, 2009","February 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002664"
944,"NCT00077337","FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: romidepsin","Southwest Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000350199|SWOG-S0336","February 10, 2004","April 2004","April 2006","June 21, 2013","November 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00077337"
945,"NCT00416494","Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Biological: bevacizumab|Drug: oxaliplatin|Drug: Capecitabine|Drug: Capecitabine","Herbert Hurwitz, MD|National Cancer Institute (NCI)|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00008646|DUMC-4951-05-7R2|GENENTECH-DUMC-4951-05-7R2|SANOFI-DUMC-4951-05-7R2|ROCHE-DUMC-4951-05-7R2|CDR0000449971","December 27, 2006","September 2003","August 2014","August 25, 2014","August 2014","February 12, 2013","null","January 2008","Response Rate (Percentage of Participants With Partial or Complete Response)|Time to Progression|Disease Free Survival|Overall Survival|Safety and Tolerability","https://ClinicalTrials.gov/show/NCT00416494"
946,"NCT00827684","Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Irinotecan|Drug: Temsirolimus","Vejle Hospital","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","2008-007665-22","January 22, 2009","March 2009","June 2011","June 7, 2011","June 2011","No Study Results Posted","TIRASMUS","January 2011","Objective response rates|Progression free survival|Overall survival|Translational Research","https://ClinicalTrials.gov/show/NCT00827684"
947,"NCT02039635","Korean Red Ginseng in Treating Patients With Fatigue Caused by Chemotherapy for Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Dietary Supplement: Korean Red Ginseng|Dietary Supplement: Placebo","Korea Ginseng Corporation","Both","20 Years and older   (Adult, Senior)","","438","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","KGC-S-02","December 16, 2013","December 2013","January 2017","March 3, 2016","March 2016","No Study Results Posted","KRG","September 2016","Area Under Curve (AUC) of Brief Fatigue Index (BFI) on the intake trial drugs up to 16 weeks|Area Under Curve (AUC) of Brief Fatigue Index (BFI) on the intake of trial drugs up to 8 weeks|Change in Functional Assessment of Chronic Illness Therapy-Fatigue Trial Outcome Index (FACIT-F TOI) after 8 and 16 weeks of trial drug intake|Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) total score after 8 and 16 weeks of trial drug in take|The percentage of subjects whom the Functional Assessment of Cancer Therapy-General (FACT-G) score decreased more than 20 scores after 8 and 16 weeks of trial drug intake|Change in blood cytokine (IL-1, IL-6, TNF-alpha) level after 16 weeks of trial drug intake|Change in blood cortisol level after 16 weeks of trial drug intake|Perceived Stress Scale (PSS) change after 16 weeks of trial drug intake|adverse events","https://ClinicalTrials.gov/show/NCT02039635"
948,"NCT00047762","Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Erlotinib (aka Tarceva or OSI-774)|Drug: Bevacizumab (aka Avastin or Rhu MAb VEGF)","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Masking: Open Label|Primary Purpose: Treatment","OSI2520g","October 16, 2002","October 2002","null","June 23, 2005","November 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00047762"
949,"NCT02612077","Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)","Completed","Has Results","Metastatic Colorectal Cancer","Other: Observational Chemotherapy|Drug: Concomitant Bevacizumab","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","765","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML21696","November 19, 2015","May 2008","October 2012","February 12, 2016","February 2016","January 15, 2016","CONCERT","October 2012","Progression-free Survival|Overall Survival|Quality of Life - Global Health Status","https://ClinicalTrials.gov/show/NCT02612077"
950,"NCT00975897","Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: bevacizumab|Biological: cetuximab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin|Genetic: RNA analysis|Genetic: cytogenetic analysis|Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: protein expression analysis|Other: diagnostic laboratory biomarker analysis|Other: immunohistochemistry staining method|Other: questionnaire administration|Procedure: cognitive assessment","Medical Research Council|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","3240","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Diagnostic","CDR0000648235|UKM-MRC-FOCUS3-CR12|EUDRACT-2008-008323-15|ISRCTN83171665|EU-20960","September 11, 2009","July 2009","December 2012","December 18, 2013","August 2011","No Study Results Posted","null","August 2010","Topoisomerase-1 (topo-1) and K-ras, BRAF results obtained within 10 working days after registration|Number of patients in which the interval between registration and randomization (RZ) is ≤ 10 days|Efficacy of fluorouracil with vs without irinotecan hydrochloride, fluorouracil, and leucovorin calcium (IrMdG) in low topo-1 tumors|Progression-free survival of patients with high topo-1 tumors treated with IrMdG with or without oxaliplatin|Efficacy of IrMdG with vs without cetuximab in K-ras wildtype tumors|Efficacy of IrMdG with vs without bevacizumab in K-ras mutant tumors|Time from release of tumor block to receipt by pathology lab|If applicable, reason that RZ did not occur|Time from registration to treatment start|Time from data presentation to investigator to date of RZ|Reproducibility of K-ras, BRAF, and topo-1 results|Distribution frequencies|Costs of molecular testing|Toxicity according to NCI CTCAE v.3|Response rates|Progression-free survival|Attitudes of patients about tests and treatment","https://ClinicalTrials.gov/show/NCT00975897"
951,"NCT02619435","Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer","Recruiting","No Results Available","Advanced Colorectal Cancer","Drug: regorafenib","National Cancer Institute, Naples","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","46","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","STREAM|2015-001105-13","November 30, 2015","November 2015","November 2017","December 1, 2015","November 2015","No Study Results Posted","STREAM","November 2016","the rate of evaluable patients alive and not progressed at 6 months|worst grade toxicity per patient|number of patients with complete plus partial response|progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT02619435"
952,"NCT01803009","Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool","Completed","No Results Available","Colorectal Cancer","Behavioral: Patient views NCI CRC RAT|Behavioral: View presentation regarding current chance of having an advanced adenoma","Indiana University","Both","50 Years to 75 Years   (Adult, Senior)","","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","1210009869","February 15, 2013","November 2012","October 2013","April 1, 2014","April 2014","No Study Results Posted","CRC-RAT","March 2013","Satisfaction with NCI CRC RAT|Perceived risk of developing CRC|Intent to be screened within six months|Stage of readiness to screen|Preferred CRC screening test|Uptake of CRC screening","https://ClinicalTrials.gov/show/NCT01803009"
953,"NCT00004870","Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: oblimersen sodium|Drug: irinotecan hydrochloride","The University of Texas Health Science Center at San Antonio|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067529|SACI-IDD-98-32|UTHSC-IDD-98-32|NCI-T98-0094","March 7, 2000","June 2000","September 2002","February 19, 2013","February 2013","No Study Results Posted","null","September 2002","","https://ClinicalTrials.gov/show/NCT00004870"
954,"NCT00550563","DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: cholecalciferol|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Genetic: western blotting|Other: high performance liquid chromatography|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: adjuvant therapy|Procedure: immunoscintigraphy","Roswell Park Cancer Institute","Both","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","I 99207|RPCI-I-99207","October 25, 2007","August 2007","July 2010","June 22, 2015","June 2015","No Study Results Posted","null","April 2009","Identification of CYP24 single nucleotide polymorphisms (SNPs)|Effect of CYP24 SNPs on baseline serum vitamin D3 metabolites (25-D3, 24,25-D3, and 1,25-D3), and parathyroid hormone levels (PTH)|Effect of CYP24 SNPs on serum vitamin D3 metabolites and PTH levels during cholecalciferol treatment|CYP24 splicing, protein expression, and enzyme activity at baseline and during cholecalciferol treatment|Relationship between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity","https://ClinicalTrials.gov/show/NCT00550563"
955,"NCT00433927","5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)","Active, not recruiting","No Results Available","Neoplasm Metastasis|Colorectal Cancer","Drug: 5-FU|Drug: folinic acid|Drug: irinotecan|Drug: cetuximab|Drug: bevacizumab","PD Dr. med. Volker Heinemann|Merck KGaA|Ludwig-Maximilians - University of Munich","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","568","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FIRE-3","February 9, 2007","January 2007","December 2016","March 13, 2014","March 2014","No Study Results Posted","null","April 2014","Objective response rate|Median progression free survival|Median overall survival|Secondary resection rate with curative intent|Safety and toxicity (according to NCI-CTCAE)","https://ClinicalTrials.gov/show/NCT00433927"
956,"NCT02457390","The Value of CE-LUS During Robot-assisted Surgery for Primary Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: CE-LUS","Odense University Hospital","Both","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","20140154","May 5, 2015","January 2015","January 2016","January 25, 2016","January 2015","No Study Results Posted","CE-LUS","January 2016","Detection of synchronous liver metastases with CE-LUS|CE-LUS feasibility","https://ClinicalTrials.gov/show/NCT02457390"
957,"NCT00099346","MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)","Terminated","No Results Available","Colorectal Cancer|Advanced Solid Tumors","Drug: MK0457, VX-680 (Aurora Kinase Inhibitor)","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0457-001|MK0457-001|2004_095","December 10, 2004","January 2005","April 2007","June 16, 2015","June 2015","No Study Results Posted","null","April 2007","","https://ClinicalTrials.gov/show/NCT00099346"
958,"NCT00098982","Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: bortezomib|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","EORTC-16029|MILLENNIUM-EORTC-16029|2004-001763-21","December 8, 2004","September 2004","null","June 11, 2013","June 2013","No Study Results Posted","null","January 2007","Maximum tolerated dose and recommended dose of bortezomib as measured by CTC v3.0|Safety as measured by CTC v3.0|Response as measured by RECIST every 8 weeks|Time to progression as measured by Kaplan Meier and RECIST every 8 weeks","https://ClinicalTrials.gov/show/NCT00098982"
959,"NCT01588990","A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFIRI|Drug: XELOX|Drug: bevacizumab [Avastin]|Drug: bevacizumab [Avastin]|Drug: bevacizumab [Avastin]|Drug: mFOLFOX6","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 4","128","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25753","April 27, 2012","June 2012","September 2016","September 1, 2016","September 2016","No Study Results Posted","null","September 2016","Prognostic value of the host inflammatory response as assessed by the neutrophil/lymphocyte ratio on progression-free survival|Progression-free survival during Phase A|Progression-free survival during Phase B|Time to failure of strategy|Duration of disease control|Overall survival from the start of treatment to study completion|Survival beyond 1st progression|Overall survival during Phase B|Overall response rate|Rate of liver resection|Safety: incidence of adverse events","https://ClinicalTrials.gov/show/NCT01588990"
960,"NCT00294359","The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Mitomycin C; Capecitabine; Bevacizumab","Australasian Gastro-Intestinal Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","333","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AG0501CR","February 21, 2006","June 2005","July 2007","August 21, 2007","August 2007","No Study Results Posted","null","null","Phase II: - treatment related toxicity|Phase III: - progression free survival|Phase II: - treatment response|Phase III:|- treatment related toxicity|- treatment response|- overall survival|- symptoms of disease, treatment and quality of life|- cost of therapy and assessment of gain in quality-adjusted progression free survival","https://ClinicalTrials.gov/show/NCT00294359"
961,"NCT02060669","Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Xeloda","Samsung Medical Center|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 3","270","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-02-047","January 19, 2012","June 2010","September 2014","February 10, 2014","February 2014","No Study Results Posted","null","May 2014","Progression free survival","https://ClinicalTrials.gov/show/NCT02060669"
962,"NCT00967616","Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy","Completed","No Results Available","Colorectal Cancer|Neoplasms, Colorectal","Drug: CS7017|Drug: irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)","Daiichi Sankyo Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CS7017-A-U203","August 27, 2009","September 2009","April 2013","May 7, 2014","May 2014","No Study Results Posted","null","April 2013","Estimate difference between proportion of subjects with progression free survival (PFS) who failed first-line chemotherapy and treated with combination of CS-7017/irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI) or FOLFIRI alone.|To determine progression free survival, overall survival, objective response rate, duration of objective response.","https://ClinicalTrials.gov/show/NCT00967616"
963,"NCT00305643","Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer","Terminated","Has Results","Breast Cancer|Colorectal Cancer|Pain","Drug: Capecitabine|Drug: Celecoxib|Procedure: Radiation Therapy|Drug: Placebo","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 3","11","Other|NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Supportive Care","2005-0328|MDA-CCC-0326|MDA-2005-0328|CDR0000458042","March 21, 2006","February 2006","October 2008","November 19, 2015","November 2015","January 25, 2012","null","October 2008","Incidence of Hand/Foot Syndrome (HFS) > Grade 1 at 16 Weeks Based on the CTC 3.0 Criteria.|Incidence of Hand/Foot Syndrome (HFS) > Grade 1 at 16 Weeks Based on WHO Criteria.","https://ClinicalTrials.gov/show/NCT00305643"
964,"NCT01060423","TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: Cetuximab|Drug: Irinotecan|Device: Irinotecan eluting BEADS","Martin-Luther-Universität Halle-Wittenberg|Biocompatibles UK Ltd","Both","18 Years and older   (Adult, Senior)","Phase 2","8","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT: 2009-014728-44","January 27, 2010","February 2010","September 2013","June 25, 2013","June 2013","No Study Results Posted","DEBIRITUX","December 2012","Progression free survival rate|Tumour Response (according to RECIST v1.1)|Time to progression|Number of adverse events in study patients|Local tumour response|Overall survival","https://ClinicalTrials.gov/show/NCT01060423"
965,"NCT01343901","An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)","Completed","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","221","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML22999","April 27, 2011","September 2010","June 2015","July 1, 2016","July 2016","No Study Results Posted","null","June 2015","Response rate, defined as rate of patients without detectable metastases (after 1st-line treatment with or without surgery)|Clinical characteristics (diagnosis, treatments, comorbidities) of patients initiated on Avastin treatment|Response (no detectable metastases after 1st-line treatment with or without surgery) according to clinical characteristics (number of cycles, chemotherapy, comorbidity)|Progression-free survival|Relapse-free survival after surgery|Overall survival|Histo-pathologic response (assessed at surgery)|Treatment schedules (dosage, intervals, number of cycles)|Safety: Incidence of adverse events","https://ClinicalTrials.gov/show/NCT01343901"
966,"NCT02906059","Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: AZD1775|Drug: Irinotecan","New York University School of Medicine|AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 1","32","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S14-01168","September 9, 2016","September 2016","September 2019","September 14, 2016","September 2016","No Study Results Posted","null","September 2018","Number of participants dose limiting toxicities with treatment-related adverse events as assessed by common terminology criteria for adverse events (CTCAE), version 4.|Tumor assessment by imaging techniques using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1","https://ClinicalTrials.gov/show/NCT02906059"
967,"NCT00508404","Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: FOLFIRI","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","154","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20060314|EUDRACT Number 2006-006739-36","July 26, 2007","May 2007","June 2012","December 18, 2015","December 2015","December 18, 2015","null","June 2009","Objective Response Rate|Objective Response by 17 Weeks|Disease Control Rate|Duration of Response|Time to Initial Objective Response|Progression-free Survival|Time to Disease Progression|Duration of Stable Disease|Time to Treatment Failure|Time to Disease Relapse Following Surgical Intervention|Resection Rate","https://ClinicalTrials.gov/show/NCT00508404"
968,"NCT01493713","Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Hepatic Metastasis","Other: Evaluate the correlation of overall different objective response.","Grupo Espanol Multidisciplinario del Cancer Digestivo","Both","18 Years and older   (Adult, Senior)","Phase 4","83","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","GEMCAD-1006","November 22, 2011","November 2011","December 2017","September 16, 2016","September 2016","No Study Results Posted","AVAMET","December 2017","Correlation of overall objective responses evaluated by conventional imaging techniques with the morphologic response evaluated by MDCT and the histopathologic response after the resection of hepatic metastases.|R0/R1/R2 resectability rate.|Progression-free survival (PFS), only in patients who do not undergo metastasis resection.|Recurrence-free survival (RFS) in patients who undergo metastasis resection.|Safety and toxicity (surgical and therapeutic) of the therapy graded according to CTC v.4.0|Overall survival (OS) at 2 and 3 years.|Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on overall objective response|Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on surgical resection rate|Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on survival|Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on progression free survival","https://ClinicalTrials.gov/show/NCT01493713"
969,"NCT00459030","Traditional Print Communication Methods, Simple Electronic Communication Methods, or Usual Care in Increasing How Often Older Women Undergo Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer","Other: educational intervention via internet|Other: educational intervention mailed|Other: No additional educational intervention","Fox Chase Cancer Center|National Cancer Institute (NCI)","Female","50 Years and older   (Adult, Senior)","","904","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","FCCC-05016|CDR0000538413|IRB05-016|R01CA102695","April 9, 2007","October 2005","December 2012","August 16, 2013","August 2013","No Study Results Posted","null","December 2012","Comparison of traditional print versus simple electronic communication versus usual care in terms of increasing colorectal cancer (CRC) screening rates|Moderating role of attentional style and background variables on the impact of the interventions|Mediating effect of potential cognitive-affective factors related to CRC screening","https://ClinicalTrials.gov/show/NCT00459030"
970,"NCT00748215","Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan","Completed","No Results Available","Chemotherapeutic Agent Toxicity|Colorectal Cancer|Diarrhea","Drug: calcium aluminosilicate anti-diarrheal|Other: placebo","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Supportive Care","MDA-2008-0005|CDR0000612205","September 5, 2008","February 2009","null","August 14, 2014","August 2014","No Study Results Posted","null","August 2014","Incidence of grade 3 or 4 diarrhea as assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Number of Stools per day|Chemotherapy dose reductions and delays due to diarrhea|Quality of life as assessed by the MD Anderson Symptom Inventory","https://ClinicalTrials.gov/show/NCT00748215"
971,"NCT00008294","Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: FOLFOX regimen|Drug: dexamethasone|Drug: floxuridine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","00-009|P30CA008748|MSKCC-00009|NCI-G00-1896","January 6, 2001","August 2000","null","January 17, 2013","January 2013","No Study Results Posted","null","May 2006","","https://ClinicalTrials.gov/show/NCT00008294"
972,"NCT00408551","Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver","Recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: floxuridine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","Goshen Health System|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000515900|CCCGHS-CHEMO-SIRT","December 6, 2006","November 2005","null","December 18, 2013","June 2009","No Study Results Posted","null","June 2009","Tumor response as measured by carcinoembryonic antigen (CEA) level, RECIST criteria, and positron emission tomography (PET) scan|Hepatic toxicity|Therapeutic efficacy based on time from selective internal radiation therapy (SIRT) to in-liver disease progression|Therapeutic efficacy based on the proportion of patients who achieve down-staging among all chemo-SIRT treated patients","https://ClinicalTrials.gov/show/NCT00408551"
973,"NCT02698462","Adding Family History of Colorectal Cancer to the Dutch FIT-based Screening Program","Enrolling by invitation","No Results Available","Colorectal Neoplasms","Other: Family history questionnaire","Prof. Evelien Dekker, MD, PhD|Dutch Digestive Diseases Foundation|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Both","59 Years to 75 Years   (Adult, Senior)","","6000","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","821748-140305-PG|TC 12-05","February 29, 2016","March 2016","September 2017","March 7, 2016","March 2016","No Study Results Posted","null","September 2017","Diagnostic yield|Participation rate|Positive predictive value","https://ClinicalTrials.gov/show/NCT02698462"
974,"NCT00483080","Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)","Completed","No Results Available","Colorectal Cancer (CRC)","Drug: NGR-hTNF","MolMed S.p.A.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","46","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NGR006|2006-005451-15","June 5, 2007","December 2006","April 2013","May 29, 2014","May 2014","No Study Results Posted","null","June 2009","Antitumour activity defined as Progression Free Survival (PFS)|Tumor Growth Control Rate (TGCR) according to RECIST criteria|Overall survival (OS)|Circulating tumor cells (CTCs)|Experimental imaging study (DCE-MRI)|﻿Pharmacokinetic in patients treated with weekly schedule|Safety","https://ClinicalTrials.gov/show/NCT00483080"
975,"NCT01539824","A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Biological: Mycobacterium obuense|Radiation: SBRT","Immodulon Therapeutics Ltd","Both","18 Years and older   (Adult, Senior)","Phase 2","12","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMM-101-007|2011-003958-85","February 22, 2012","February 2012","August 2014","September 23, 2014","January 2014","No Study Results Posted","null","August 2014","Disease stabilisation rate|safety and tolerability profiles|Objective response rate|Overall disease stabilisation rate|Overall response rate|Progression-free survival|Survival|Tumour Markers","https://ClinicalTrials.gov/show/NCT01539824"
976,"NCT01739608","Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy","Recruiting","No Results Available","Colorectal Cancer","Other: Invitation to screening","Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte|im3D S.p.A.|Regione Piemonte|Candiolo Cancer Institute","Both","58 Years to 60 Years   (Adult)","Phase 4","20000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","14334-c27.2","May 23, 2012","December 2010","December 2015","November 29, 2012","November 2012","No Study Results Posted","Proteus","December 2013","Detection rate for cancer and advanced adenoma of CT Colonography versus FS in an invitational CRC screening program|Participation rate to FS and CT Colonography|Number of participants with severe adverse events in both screening groups|Costs of a CRC screening based on CTC|Type of false positive detections of Computer-aided detection for CTC in a CRC screening program","https://ClinicalTrials.gov/show/NCT01739608"
977,"NCT00700570","A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: bevacizumab [Avastin]|Drug: capecitabine [Xeloda]|Drug: oxaliplatin","Hoffmann-La Roche","Both","up to 75 Years   (Child, Adult, Senior)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21209","June 17, 2008","August 2008","November 2011","September 1, 2016","September 2016","August 19, 2015","null","November 2011","Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases|Percentage of Participants With Disease Progression|Time to Disease Progression|Percentage of Participants With a Best Overall Tumor Response of Complete Response (CR) or PR According to RECIST Version 1.1|Percentage of Participants by Best Overall Tumor Response According to RECIST Version 1.1","https://ClinicalTrials.gov/show/NCT00700570"
978,"NCT00025142","Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: gefitinib|Drug: leucovorin calcium|Drug: oxaliplatin","Stanford University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","SUMC-670|CDR0000068923|NCI-4370","October 11, 2001","July 2001","November 2006","May 14, 2013","February 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00025142"
979,"NCT01847495","Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis","Recruiting","No Results Available","Colorectal Cancer","Drug: Irinotecan|Radiation: CyberKnife","Advocate Health Care","Both","18 Years and older   (Adult, Senior)","","41","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","5443","April 12, 2013","October 2013","October 2025","May 18, 2016","April 2016","No Study Results Posted","null","October 2020","Number of participants with adverse events related to toxicities from concurrent SBRT and irinotecan|Tumor response rate|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01847495"
980,"NCT01328171","FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFOXIRI + Panitumumab|Drug: FOLFOXIRI","AIO-Studien-gGmbH|Amgen|ClinAssess GmbH","Both","18 Years and older   (Adult, Senior)","Phase 2","93","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AIO KRK 0109|2009-017731-17","March 30, 2011","April 2011","June 2017","March 18, 2016","March 2016","No Study Results Posted","VOLFI","December 2016","overall response rate|overall response rate in each cohort|secondary resection rate with curative intent for patients cohort I|pathological response in liver surgery specimen|disease control rate|progression free survival|duration of response|time to response|overall survival|time to recurrence (cohort II in case of secondary resection)|toxicity and feasibility|liver toxicity for resected patients (central histological review); biopsies should be obtained for all patients pre-treatment|QL (QLQ C30)|translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes","https://ClinicalTrials.gov/show/NCT01328171"
981,"NCT02057991","Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers","Recruiting","No Results Available","Anxiety Disorder|Colon Cancer|Depression|Fatigue|Rectal Cancer","Other: educational intervention|Procedure: CAM exercise therapy|Other: caregiver-related intervention or procedure|Other: questionnaire administration|Other: laboratory biomarker analysis","University of Southern California|National Cancer Institute (NCI)","Both","18 Years to 65 Years   (Adult)","","300","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","3C-13-6|NCI-2014-00164|R01CA155101|P30CA014089","February 5, 2014","January 2014","January 2017","June 20, 2015","June 2015","No Study Results Posted","null","January 2016","Change in self-reported stress levels assessed using pre- and post-test assessments|Change in colorectal cancer knowledge assessed using pre- and post-test assessments|Changes in salivary cortisol levels using chemiluminescence immunoassay","https://ClinicalTrials.gov/show/NCT02057991"
982,"NCT02456285","Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways","Recruiting","No Results Available","Colorectal Neoplasms|Liver Neoplasms|Neoplasm Metastasis","Procedure: Primary/Bowel-first Surgery|Procedure: Liver-first surgery|Procedure: Synchronous resection surgery|Procedure: No surgery","Anthony Chan|University of Durham|Central Manchester University Hospitals NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","R03880","May 20, 2015","April 2015","March 2021","July 25, 2016","July 2016","No Study Results Posted","CoSMIC","March 2018","Adherence to an evidence-informed common pathway assessed using guidelines suggested by the European Society of Medical Oncology (ESMO)","https://ClinicalTrials.gov/show/NCT02456285"
983,"NCT02386826","INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients","Recruiting","No Results Available","Glioblastoma Multiforme|Gliosarcoma|Colorectal Cancer|Renal Cell Carcinoma","Drug: INC280|Biological: bevacizumab","SCRI Development Innovations, LLC|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","63","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI REFMAL 365","March 6, 2015","July 2015","May 2018","April 14, 2016","April 2016","No Study Results Posted","null","November 2017","Number of GBM patients with adverse events as a measure of safety and tolerability|Progression-free Survival|Overall Response Rate","https://ClinicalTrials.gov/show/NCT02386826"
984,"NCT01051167","Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab","Martin Schuler, Prof. Dr. med.|Universität Duisburg-Essen","Both","18 Years and older   (Adult, Senior)","Phase 2","59","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TT1-2007|2007-000460-24","January 15, 2010","February 2009","December 2018","May 17, 2016","May 2016","No Study Results Posted","CEBIFOX","October 2016","Response rate (RECIST-Criteria)|Secondary objectives: Safety, Quality of life","https://ClinicalTrials.gov/show/NCT01051167"
985,"NCT00075595","Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000347378|FRE-GERCOR-FOLFIRI3-C00-2|EU-20333","January 9, 2004","June 2002","null","January 3, 2009","August 2007","No Study Results Posted","null","null","Time to progression|Time to death from progression|Objective response|Stabilization rate|Time to treatment failure|Duration of response|Overall survival rate|Incidence of grade 3 or 4 toxicity","https://ClinicalTrials.gov/show/NCT00075595"
986,"NCT02045030","Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: aflibercept + FOLFIRI","CR-CSSS Champlain-Charles-Le Moyne|Sanofi|Regeneron Pharmaceuticals|Quebec Clinical Research Organization in Cancer","Both","18 Years and older   (Adult, Senior)","Phase 2","52","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Q-CROC-04","January 20, 2014","January 2014","October 2016","August 12, 2016","August 2016","No Study Results Posted","null","October 2016","A biomarker (in blood or tissue) that may be predictive of level of response to aflibercept|Progression free survival (PFS)|Response rate|Disease control rate|Number of participants with adverse events|The quality of life impact of treating with FOLFIRI in combination with Aflibercept","https://ClinicalTrials.gov/show/NCT02045030"
987,"NCT00089401","Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: isolated perfusion|Drug: melphalan|Procedure: conventional surgery","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","8","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","040229|04-C-0229|CDR0000378323","August 4, 2004","July 2004","March 2008","May 11, 2012","May 2012","No Study Results Posted","null","November 2006","Response|Duration of response|Patterns of tumor recurrence (liver vs systemic)|Progression-free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT00089401"
988,"NCT00217711","Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Colorectal Cancer","Drug: Capecitabine|Drug: irinotecan hydrochloride|Drug: oxaliplatin","Swiss Group for Clinical Cancer Research","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","23","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 41/03|EU-20524","September 20, 2005","May 2005","October 2011","June 2, 2012","June 2012","No Study Results Posted","null","August 2007","capecitabine + oxaliplatin + irinotecan dose finding|Efficacy of Oxaliplatin, Irinotecan, and Capecitabine|Objective response (CR or PR) as measured after completion of study treatment|Adverse events as measured after completion of study treatment|Time to progression|Time to treatment failure as measured after completion of study treatment|Overall survival","https://ClinicalTrials.gov/show/NCT00217711"
989,"NCT01135498","A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.","Completed","Has Results","Colorectal Cancer","Drug: bevacizumab [Avastin]|Drug: eloxatin|Drug: capecitabine [Xeloda]|Drug: erlotinib [Tarceva]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","90","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML19875","June 1, 2010","November 2006","April 2010","January 22, 2015","January 2015","November 5, 2014","null","April 2010","Percentage of Participants With Disease Progression or Death|Progression-Free Survival|Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR])|Percentage of Participants Achieving Disease Control (CR, PR, or No Change [NC])|Percentage of Participants Who Died|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01135498"
990,"NCT00484939","A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: Bevacizumab|Drug: Capecitabine","Hoffmann-La Roche","Both","70 Years and older   (Senior)","Phase 3","280","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MO19286","June 11, 2007","July 2007","March 2013","January 7, 2015","January 2015","March 7, 2014","null","March 2013","Progression-free Survival|Best Overall Response (BOR)|Duration of Response|Time to Response|Overall Survival|Eastern Cooperative Oncology Group (ECOG) Performance Status|Percentage of Participants Requiring Additional Treatment for Malignancy|Duration of Follow-up|AEs, Laboratory Parameters, Vital Signs","https://ClinicalTrials.gov/show/NCT00484939"
991,"NCT01288339","Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab + FOLFOX (DP)|Drug: Panitumumab + FOLFOX (no-DP)","Grupo Espanol Multidisciplinario del Cancer Digestivo|Amgen|TFS Trial Form Support","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEMCAD-0903|2009-017331-18","December 24, 2010","November 2010","September 2015","March 10, 2015","November 2012","No Study Results Posted","PULSE","January 2015","Progression-free survival time according to the MMP7 status (PFS)|Duration of response (DOR)|Time to response (TTR)|Time to treatment failure (TtTF)|Objective response rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS)|Time To Progression (TTP)|Duration of Stable Disease (DoSD)|Incidence and severity of AEs|Molecular predictive markers for response.","https://ClinicalTrials.gov/show/NCT01288339"
992,"NCT02005913","A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence","Not yet recruiting","No Results Available","Colorectal Cancer (CRC)","","National Taiwan University Hospital","Both","20 Years and older   (Adult, Senior)","","600","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","201309068RINC","December 4, 2013","January 2014","January 2019","December 4, 2013","December 2013","No Study Results Posted","null","January 2019","tumor recurrence","https://ClinicalTrials.gov/show/NCT02005913"
993,"NCT01712347","An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Bevacizumab|Drug: Chemotherapy","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","351","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML28233","October 19, 2012","October 2012","June 2016","July 1, 2016","July 2016","No Study Results Posted","null","June 2016","Overall survival from the time of starting first-line therapy|Progression-free survival from the time of starting first-line therapy, assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria|Percentage of participants with best overall response, assessed according to RECIST v.1.1 criteria|Percentage of participants with liver resection|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01712347"
994,"NCT00458809","Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer","Completed","No Results Available","Carcinoma of the Appendix|Colorectal Cancer|Primary Peritoneal Cavity Cancer","Drug: oxaliplatin","Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000540283|P30CA012197|CCCWFU-59106|CCCWFU-IRB00000847|CCCWFU-59106 IPHC","April 9, 2007","March 2007","null","April 26, 2012","April 2012","No Study Results Posted","null","November 2007","Maximum tolerated dose|Pharmacokinetics|Change in the phenotypic expression of proteins involved in the apoptotic and heat-stress inducible pathways","https://ClinicalTrials.gov/show/NCT00458809"
995,"NCT01676922","An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)","Completed","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","70 Years and older   (Senior)","","256","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML27768","August 27, 2012","August 2011","May 2015","September 1, 2016","September 2016","No Study Results Posted","null","May 2015","Treatment duration in patients receiving chemotherapy with Avastin as first-line therapy in daily clinical practice|Treatment duration in patients receiving chemotherapy alone as first-line therapy in daily clinical practice|Safety: Incidence of adverse events/adverse events of special interest|Clinical/demographic patient characteristics at baseline|Dosage/regimen|Correlation between Comprehensive Geriatric Assessment (CGA) scores and initial treatment","https://ClinicalTrials.gov/show/NCT01676922"
996,"NCT00002796","Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer","Terminated","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: fluorouracil|Drug: sodium phenylbutyrate|Drug: indomethacin|Biological: recombinant interferon gamma","National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 1|Phase 2","46","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2013-00038|96-322 ME*|CDR0000064879","November 1, 1999","May 1997","null","January 31, 2013","January 2013","No Study Results Posted","null","December 2004","Toxicity of flurouracil (FU) when given in escalating doses in combination with fixed doses of phenlylbutyrate (PB), indomethacin and recombinant human interferon-gamma (rhIFNg) to patients with advanced colorectal cancer (Phase I)|Efficacy of FU in combination with PB, indomethacin and rhIFNg in patients with advanced colorectal cancer (Phase II)","https://ClinicalTrials.gov/show/NCT00002796"
997,"NCT00118261","Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: erlotinib hydrochloride|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","17","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE2204|P30CA043703|NCI-2009-01287","July 8, 2005","March 2005","January 2011","August 31, 2012","August 2012","No Study Results Posted","null","January 2011","Number of patients that develop study drug related toxicity|Patient Response to Treatment Measured by RECIST Criteria|Number of patients that can increase the erlotinib dose to 200mg","https://ClinicalTrials.gov/show/NCT00118261"
998,"NCT01110785","Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Biological: panitumumab|Drug: simvastatin|Other: laboratory biomarker analysis","Leiden University Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000671002|DUT-LUMC-30012009|EUDRACT-2009-014452-30|EU-21033|DUT-LUMC-RASTAT-P|NL-29611-058-09","April 23, 2010","April 2010","null","September 16, 2013","April 2011","No Study Results Posted","null","April 2012","Percentage of patients free from progression and alive at 11 weeks after the first dose of panitumumab measured by RECIST v 1.1|Toxicity measured by NCICTC v 3.0|Median and mean overall survival|Median and mean progression-free survival|Objective response rate|Correlation between skin toxicity and response to treatment|Serum cholesterol and subsequent treatment response|Correlation between PTEN, PIK3CA, b-raf, ERK, and MEK status and objective response rate|Correlation between single nucleotide polymorphisms and objective response rate|Correlation between proteomics and objective response rate","https://ClinicalTrials.gov/show/NCT01110785"
999,"NCT00454116","A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients","Completed","Has Results","Colorectal Cancer","Drug: Vandetanib|Drug: FOLFIRI","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","106","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4200C00048","March 28, 2007","March 2007","November 2009","April 27, 2011","April 2011","April 27, 2011","null","March 2008","Number of Patients With an Objective Disease Progression Event","https://ClinicalTrials.gov/show/NCT00454116"
1000,"NCT01099826","Increasing Colorectal Cancer (CRC) Screening In Primary Care","Completed","No Results Available","Colorectal Cancer Screening","Behavioral: Tailored counseling|Behavioral: Motivational Interview|Behavioral: control","Arizona State University|University of Illinois at Chicago|Jesse Brown VA Medical Center|University of Utah|Vanderbilt University|Penn State University|Portland State University","Both","50 Years and older   (Adult, Senior)","Phase 3","511","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","R01NR008425","April 6, 2010","October 2004","January 2010","April 7, 2010","April 2010","No Study Results Posted","null","November 2009","completing CRC screening test","https://ClinicalTrials.gov/show/NCT01099826"
1001,"NCT00066274","Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: FOLFOX regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","UNICANCER|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000315384|FRE-FNCLCC-ACCORD-08/0103|EU-20233","August 6, 2003","May 2002","null","January 10, 2009","May 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00066274"
1002,"NCT00559741","Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Other: pharmacological study","ICO Paul Papin|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000574065|CPP-FOLFIRICETUX|INCA-RECF0108","November 15, 2007","October 2005","null","May 12, 2011","May 2011","No Study Results Posted","null","May 2011","Improvement of hematologic and gastrointestinal tolerance to therapy|Efficacy|Genetic and genomic tumor parameters that could interfere with and predict the toxicity and/or antitumor efficacy of therapy|Time to progression","https://ClinicalTrials.gov/show/NCT00559741"
1003,"NCT01190462","Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: simvastatin|Other: laboratory biomarker analysis","Leiden University Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","51","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","DUT-LUMC-838|CDR0000683942|NL-30642-058-10|EUDRACT-2009-017384-42|EU-21065","August 26, 2010","August 2010","null","August 9, 2013","April 2011","No Study Results Posted","null","August 2012","Percentage of patients free from progression and alive after 12.5 weeks following the first dose of treatment|Correlation between overall response rate, progression-free survival, overall survival, and safety with skin toxicity and efficacy","https://ClinicalTrials.gov/show/NCT01190462"
1004,"NCT01277120","An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)","Terminated","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","174","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25178","January 13, 2011","April 2010","April 2016","September 14, 2016","September 2016","No Study Results Posted","null","April 2016","Correlation of the time from the start of chemotherapy to the start of Avastin treatment with progression-free survival|Overall survival|Safety: Incidence of adverse events","https://ClinicalTrials.gov/show/NCT01277120"
1005,"NCT00290615","Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery","Completed","Has Results","Colorectal Cancer","Biological: bevacizumab|Biological: cetuximab|Drug: capecitabine|Drug: oxaliplatin","Herbert Hurwitz|National Cancer Institute (NCI)|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00007431 (CDR0000449945)|DUMC-7118-05-4R0","February 9, 2006","January 2006","January 2011","March 25, 2013","March 2013","February 12, 2013","null","January 2009","Response Rate (Percentage of Participants With Partial or Complete Response)|Safety and Tolerability|Progression-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00290615"
1006,"NCT00719797","Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","Gruppo Oncologico del Nord-Ovest","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","509","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000598582|GONO-TRIBE|ASL608LIOM04|EUDRACT:2008-001537-10","July 19, 2008","July 2008","null","March 10, 2015","March 2015","No Study Results Posted","TRIBE","May 2011","Progression free survival|Overall response rate|Duration of response|Secondary R0 surgery rates of metastases|Overall survival|Surrogate markers predictive of bevacizumab activity","https://ClinicalTrials.gov/show/NCT00719797"
1007,"NCT00588900","Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab","Completed","No Results Available","Colorectal Cancer","Drug: cediranib maleate|Drug: irinotecan hydrochloride","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-80502|CDR0000580967","December 20, 2007","March 2008","November 2011","August 11, 2016","August 2016","No Study Results Posted","null","May 2010","The proportion of patients who are progression-free at 12 weeks from the start of second-line therapy|Radiographic response rate|Overall survival","https://ClinicalTrials.gov/show/NCT00588900"
1008,"NCT00899210","Matrix Metalloproteinases After Surgery and/or Radiofrequency Ablation in Patients With Liver Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Other: laboratory biomarker analysis|Procedure: cryosurgery|Procedure: radiofrequency ablation|Procedure: therapeutic conventional surgery","University Hospital, Grenoble|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","75","Other","Observational","","CDR0000574192|CHUG-METALLO-1|RECF0455","May 9, 2009","September 2003","null","May 14, 2011","May 2011","No Study Results Posted","null","May 2011","Kinetics of postoperative changes of serum matrix metalloproteinases (MMP) and their inhibitors (TIMP)|Predictive value of postoperative risk of recurrence|Correlation of risk of recurrence with surgical technique|Elevated serum levels of MMP vs carcinoembryonic antigen as a marker of hepatic or extrahepatic recurrence|Correlation of postoperative serum HGF/SF with plasma levels in MMPs","https://ClinicalTrials.gov/show/NCT00899210"
1009,"NCT00577109","A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.","Withdrawn","No Results Available","Colorectal Cancer","Drug: bevacizumab [Avastin]|Drug: Irinotecan|Drug: Leucovorin|Drug: 5 FU|Drug: Cetuximab","Hoffmann-La Roche|Merck KGaA","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20452","December 18, 2007","null","June 2012","August 23, 2016","August 2016","No Study Results Posted","null","null","Progression-free survival|Objective response rate, rate of resection of hepatic metastases, overall survival.|AEs, laboratory parameters.","https://ClinicalTrials.gov/show/NCT00577109"
1010,"NCT00897819","Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200","Not yet recruiting","No Results Available","Colorectal Cancer","Genetic: DNA methylation analysis|Genetic: loss of heterozygosity analysis|Genetic: microsatellite instability analysis|Other: laboratory biomarker analysis","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","350","Other|NIH","Observational","","CDR0000534281|ECOG-E3200T1","May 9, 2009","null","null","May 9, 2009","March 2007","No Study Results Posted","null","null","Progression-free survival|Overall survival|Microsatellite instability|Loss of heterozygosity","https://ClinicalTrials.gov/show/NCT00897819"
1011,"NCT02173990","Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Aflibercept-FOLFIRI","Centre Oscar Lambret|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PULSAR-1303|2013-004540-33","February 17, 2014","July 2014","July 2017","February 15, 2016","February 2016","No Study Results Posted","PULSAR","July 2017","Progression-Free Rate will be assessed according to RECIST 1.1 with central radiological review.|Overall Response Rate (ORR) will be determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.|Best Response Rate (BRR)|Progression-free survival (PFS)|Progression-free survival rate|Patterns of PFS according to DCE-US early assessment|Pharmacodynamic activity|Safety","https://ClinicalTrials.gov/show/NCT02173990"
1012,"NCT00268333","Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: neoadjuvant therapy","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","39","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000453784|GERCOR-C04-1|EU-20568|SANOFI-GERCOR-C04-1","December 20, 2005","August 2005","null","February 6, 2009","May 2007","No Study Results Posted","null","January 2006","Response rate|Overall survival|Disease-free survival|Primary site of recurrence|Time to recurrence|Quality of life","https://ClinicalTrials.gov/show/NCT00268333"
1013,"NCT00003753","Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: dexamethasone|Drug: floxuridine|Drug: irinotecan hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","98-072|CDR0000066876|MSKCC-98072A(9)|NCI-H99-0024","November 1, 1999","September 1998","April 2004","June 20, 2013","June 2013","No Study Results Posted","null","April 2004","","https://ClinicalTrials.gov/show/NCT00003753"
1014,"NCT00707889","Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer","Completed","No Results Available","Advanced Colorectal Cancer|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum","Drug: ABT-869|Drug: bevacizumab|Drug: oxaliplatin|Drug: folinic acid|Drug: fluorouracil|Drug: ABT-869","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","Both","18 Years and older   (Adult, Senior)","Phase 2","159","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M10-300|2007-007081-38","June 27, 2008","October 2008","May 2012","May 7, 2013","May 2013","No Study Results Posted","null","May 2012","Progression-free survival|Overall survival|12-month overall survival rate|Objective response rate","https://ClinicalTrials.gov/show/NCT00707889"
1015,"NCT00265824","Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)","Completed","No Results Available","Colorectal Cancer","Drug: bevacizumab|Drug: bevacizumab, erlotinib","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","700","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000453861|GERCOR-C04-2|EU-20565|GERCOR-OPTIMOX3|GERCOR-DREAM- C04-2","December 14, 2005","May 2005","null","December 10, 2015","March 2014","No Study Results Posted","DREAM","March 2012","Progression-free survival during maintenance therapy","https://ClinicalTrials.gov/show/NCT00265824"
1016,"NCT01326000","A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFIRI|Drug: RO5083945|Drug: cetuximab","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","169","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BP25438","March 29, 2011","April 2011","December 2013","February 5, 2015","February 2015","No Study Results Posted","null","December 2013","Progression-free survival: tumour assessments by CT scan or MRI according to RECIST criteria|Overall Response Rate: tumour assessments by CT scan or MRI according to RECIST criteria|Duration of response: time from complete or partial response to disease progression or death|Clinical benefit rate: stable disease for >6 weeks, complete response or partial response; tumour assessments by CT scan or MRI according to RECIST criteria|Overall survival|Safety: Incidence of adverse events|Effect of concomitant FOLFIRI on pharmacokinetics of RO5083945 and vice versa","https://ClinicalTrials.gov/show/NCT01326000"
1017,"NCT00628810","Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Federation Francophone de Cancerologie Digestive","Both","18 Years to 74 Years   (Adult, Senior)","Phase 2","86","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000564065|FFCD-0504|EUDRACT-2006-003157-25|EU-20755","March 4, 2008","January 2007","January 2008","May 27, 2016","May 2016","No Study Results Posted","null","January 2008","Objective response at 6 months by RECIST|Tolerability evaluated by NCI CTC v. 2.0 criteria|Progression-free and overall survival|Time to treatment failure|Quality of life using the EuroQOL EQ5D questionnaire","https://ClinicalTrials.gov/show/NCT00628810"
1018,"NCT02831842","A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: Anti-EGFR-Containing Regimen|Drug: Bevacizumab-containing regimen|Drug: Chemotherapy","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","4239","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MO30177","July 12, 2016","June 2016","October 2016","September 1, 2016","September 2016","No Study Results Posted","null","October 2016","Overall Survival (OS) in Participants With mCRC and a Documented KRAS Mutation who Received Bevacizumab-Containing Treatment or Chemotherapy Alone in Routine Clinical Practice|OS in Participants With mCRC and a Documented KRAS Wild Type Status who Received Bevacizumab-Containing Treatment or Anti-EGFR Treatment in Routine Clinical Practice","https://ClinicalTrials.gov/show/NCT02831842"
1019,"NCT00103298","Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: isolated perfusion|Drug: leucovorin calcium|Drug: melphalan|Drug: oxaliplatin","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000409754|NCI-05-C-0025","February 7, 2005","December 2004","July 2006","June 18, 2013","February 2006","No Study Results Posted","null","null","Response and duration of response|Patterns of recurrence|Progression-free and overall survival|Correlation of health-related quality of life with length of survival","https://ClinicalTrials.gov/show/NCT00103298"
1020,"NCT00778102","A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.","Completed","Has Results","Colorectal Cancer","Drug: 5-FU|Drug: 5-FU|Drug: 5-FU|Drug: Irinotecan|Drug: Leucovorin|Drug: Leucovorin|Drug: Oxaliplatin|Drug: bevacizumab [Avastin]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MO18725|2007-007863-26","October 22, 2008","October 2008","October 2013","September 1, 2016","September 2016","July 10, 2015","null","October 2013","Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor|Time to Resection|Percentage of Participants With Histopathological Response|Percentage of Participants With Complete or Major Histopathological Response|Percentage of Participants Experiencing Relapse Following Curative Resection|Relapse-Free Survival (RFS)|Percentage of Participants Experiencing Death or Disease Progression|Progression-Free Survival (PFS)|Percentage of Participants Who Died|Overall Survival (OS)|Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0|Time to Response|Percentage of Participants With Complications Related to First Resective Surgery|Percentage of Participants With Complications Related to Second Resective Surgery","https://ClinicalTrials.gov/show/NCT00778102"
1021,"NCT00343408","AZD2171 and Standard Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer or Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Lung Cancer","Drug: cediranib maleate|Drug: cisplatin|Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","NCIC Clinical Trials Group|Canadian Cancer Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","I175|CAN-NCIC-IND175|CDR0000481443","June 22, 2006","August 2005","September 2008","November 7, 2010","March 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00343408"
1022,"NCT00069108","A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: 5 FU|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Oxaliplatin|Drug: capecitabine [Xeloda]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","627","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NO16967","September 15, 2003","July 2003","August 2006","March 3, 2016","March 2016","January 27, 2016","null","August 2006","Progression Free Survival|Progression Free Survival Based on Independent Review Committee Assessment|Progression Free Survival Based on Treatment Analysis- Intent To Treat Population|Progression Free Survival Based on Treatment Analysis- Per Population|Best Overall Response, Investigators' Assessments|Best Overall Response, Independent Review Committee Assessment|Overall Survival|Time To Response|Duration Of Response|Time To Treatment Failure|Number of Participants With Marked Post-baseline Laboratory Abnormalities by Trial Treatment","https://ClinicalTrials.gov/show/NCT00069108"
1023,"NCT00974389","S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery","Recruiting","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: tegafur-gimeracil-oteracil potassium","Osaka Medical College|National Cancer Institute (NCI)","Both","20 Years to 80 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","OSAKA-TRICC0901|CDR0000649021","September 9, 2009","July 2009","null","August 9, 2013","September 2009","No Study Results Posted","null","June 2010","Disease-control rate|Response rate|Progression-free survival|Overall survival|Safety","https://ClinicalTrials.gov/show/NCT00974389"
1024,"NCT00890188","Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer","Recruiting","No Results Available","Colon Cancer","Drug: THALIDOMIDE and UFUR","National Cheng-Kung University Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","34","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HR-97-035","April 22, 2009","January 2009","June 2011","May 5, 2009","May 2009","No Study Results Posted","UFUR","December 2010","Overall response(CR+PR) and Clinical benefit (CR+PR+SD)|To determine the progression free survival, overall survival (OS)and assess the safety profile","https://ClinicalTrials.gov/show/NCT00890188"
1025,"NCT00496704","Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan","Recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: gemcitabine hydrochloride|Drug: oxaliplatin","Yonsei University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","56","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000549901|YONSEI-YCC-4-20060231","July 3, 2007","January 2007","null","August 20, 2009","August 2009","No Study Results Posted","null","August 2009","Overall response rate as assessed by RECIST criteria|Progression-free survival|Duration of response|Time to treatment failure|Overall survival|Time to response","https://ClinicalTrials.gov/show/NCT00496704"
1026,"NCT02448810","Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Biological: BAX69 + infusional 5-FU/LV|Biological: BAX69 + panitumumab|Biological: BAX69 + 5-FU/LV|Biological: BAX69 + panitumumab|Drug: Standard of Care|Biological: Standard of Care","Baxalta US Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","112","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","391401|2015-000896-28","May 15, 2015","May 2015","May 2017","August 15, 2016","August 2016","No Study Results Posted","null","May 2017","Occurrence of Dose Limiting Toxicity (DLT)|Progression-Free Survival (PFS)|Occurrence of binding and/or neutralizing BAX69 antibodies|Incidence and severity of infusion reactions after BAX69|Occurrence of serious adverse events (SAEs) and/or treatment-emergent adverse events (TEAEs)|Response evaluation according to RECIST v1.1|Overall survival (OS) defined as time from randomization to death of any cause|Quality of Life (QoL) measure - European Organization for Research and Treatment of Cancer Quality of life Questionnaire Core 30 (EORTC QLQ-C30) questionnaire","https://ClinicalTrials.gov/show/NCT02448810"
1027,"NCT01363739","Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab","Recruiting","No Results Available","Metastatic Colorectal Cancer","","Azienda Ospedaliero, Universitaria Pisana","Both","Child, Adult, Senior","","265","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","3108","May 31, 2011","April 2009","null","May 31, 2011","May 2011","No Study Results Posted","PROVETTA","null","Progression-Free Survival|Response Rate|Overal survival","https://ClinicalTrials.gov/show/NCT01363739"
1028,"NCT00327457","Coordinated Endoscopic Colorectal Cancer Screening","Completed","No Results Available","Preventive Health Services","Behavioral: Help with physician office and patient management|Behavioral: Tailored physician recommendation letter","University of Pittsburgh|Association of Schools of Public Health|Centers for Disease Control and Prevention","Both","50 Years to 79 Years   (Adult, Senior)","","599","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Health Services Research","S1796-21/23 (NCE)","May 16, 2006","June 2002","March 2005","February 18, 2011","February 2011","No Study Results Posted","null","null","Medical record verified flexible sigmoidoscopy or colonoscopy","https://ClinicalTrials.gov/show/NCT00327457"
1029,"NCT01022541","Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Capecitabine|Drug: Oxaliplatin|Drug: Bevacizumab|Procedure: Liver metastasectomy","Royal Marsden NHS Foundation Trust|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 2","47","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2676","January 23, 2006","June 2006","February 2015","November 23, 2015","May 2013","No Study Results Posted","null","December 2010","Overall response rates|Complete resection (R0) rate|Safety and feasibility of adding bevacizumab to neoadjuvant capecitabine and oxaliplatin in patients undergoing liver metastasectomy|Other parameters of efficacy (response and survival) in patients with unresectable liver-only metastases treated with this neoadjuvant combination","https://ClinicalTrials.gov/show/NCT01022541"
1030,"NCT01274624","Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer","Recruiting","No Results Available","KRAS Mutant Metastatic Colorectal Cancer","Biological: REOLYSIN®|Drug: Irinotecan|Drug: Leucovorin|Drug: Fluorouracil (5-FU)|Drug: Bevacizumab","Oncolytics Biotech|Montefiore Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1","32","Industry|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","REO 022","January 7, 2011","December 2010","January 2017","August 29, 2016","August 2016","No Study Results Posted","null","December 2016","Dose limiting toxicity to define maximum tolerated dose and recommended Phase 2 dose|Pharmacokinetic parameters for irinotecan and 5-FU when combined with REOLYSIN®|CEA and Objective Response, Clinical Benefit Rate (PR, CR, SD), progression-free survival, and overall survival (PFS and OS)|Safety and tolerability of REOLYSIN® when administered in combination with FOLFIRI and bevacizumab|Correlative studies including determination of specific genetic mutations and aberrant signalling pathways from tumor tissue to identify novel biomarkers of response and efficacy|In vitro studies in human-derived colorectal cancer cells including the isogenic cell lines, to study the mechanism and scientific basis of synergy between irinotecan and reovirus","https://ClinicalTrials.gov/show/NCT01274624"
1031,"NCT00556413","Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","Institut du Cancer de Montpellier - Val d'Aurelle|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","39","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000574149|CLCC-ERBIRINOX|INCA-RECF0288|EUDRACT-2005-004746-13|MERCK-CLCC-ERBIRINOX","November 9, 2007","September 2005","null","May 13, 2011","May 2011","No Study Results Posted","null","May 2011","Complete response rate|Objective response rate|Tolerability|Time to response|Time to progression|Survival","https://ClinicalTrials.gov/show/NCT00556413"
1032,"NCT02409472","Intensive Versus Minimal Surveillance of Patients With Resected Dukes B2-C Colorectal Carcinoma","Completed","No Results Available","Colorectal Cancer|Surveillance","Other: surveillance program after completion of primary treatment","Mario Negri Institute for Pharmacological Research","Both","18 Years and older   (Adult, Senior)","","1242","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","GILDA","April 1, 2015","April 1998","December 2012","April 8, 2015","April 2015","No Study Results Posted","GILDA","December 2012","Overall Survival (OS)|Health Related Quality of Life|Disease free survival (DFS)","https://ClinicalTrials.gov/show/NCT02409472"
1033,"NCT02743221","A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Trifluridine/tipiracil hydrochloride (S 95005)|Drug: Capecitabine|Drug: Bevacizumab|Drug: Bevacizumab","Institut de Recherches Internationales Servier|Servier","Both","18 Years and older   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CL2-95005-002","February 24, 2016","April 2016","April 2019","September 2, 2016","September 2016","No Study Results Posted","TASCO1","April 2019","Progression free survival (PFS)|Overall Response Rate (ORR)|Duration of Response (DR)|Disease control rate (DCR)|Overall Survival (OS)|Safety and tolerability assessed by incidence of Adverse Events|Safety and tolerability assessed by laboratory tests|Safety and tolerability assessed by physical examination|Safety and tolerability assessed by performance status (ECOG)|Safety and tolerability assessed by vital signs|Safety and tolerability assessed by 12-leads ECG parameters|Quality of Life assessed by a quality of life questionnaire.","https://ClinicalTrials.gov/show/NCT02743221"
1034,"NCT01691391","Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET","Recruiting","No Results Available","Colorectal Cancer","Behavioral: pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles","VU University Medical Center","Both","18 Years and older   (Adult, Senior)","","25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2010/323","May 15, 2012","January 2012","null","April 28, 2016","April 2016","No Study Results Posted","null","January 2017","The detection of 89Zr-cetuximab uptake in non-hepatic tumor lesions|The % uptake (of total injected) 89Zr-cetuximab in non-hepatic tumor lesions|The % uptake (of total injected) 89Zr-cetuximab in liver lesions|[18F-]FDG PET measurements|Grade of skin toxicity","https://ClinicalTrials.gov/show/NCT01691391"
1035,"NCT00004087","Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer","Completed","No Results Available","Colorectal Cancer|Pancreatic Cancer","Biological: filgrastim|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: indium In 111 monoclonal antibody MN-14|Radiation: yttrium Y 90 monoclonal antibody MN-14","Garden State Cancer Center at the Center for Molecular Medicine and Immunology|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","15","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067300|P01CA054425|CMMI-C-033-98|NCI-H99-0042|NCI-V99-1571","December 10, 1999","March 1997","null","June 21, 2011","June 2011","No Study Results Posted","null","May 2001","maximum tolerated dose","https://ClinicalTrials.gov/show/NCT00004087"
1036,"NCT01733628","Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer|Metastatic Breast Cancer","","Spanish Breast Cancer Research Group|Roche Farma, S.A","Both","18 Years and older   (Adult, Senior)","","137","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GEICAM/2011-04|GEI-BEV-2011-02","November 20, 2012","November 2012","December 2015","May 18, 2015","June 2013","No Study Results Posted","BRECOL","December 2013","Blood Pressure|Biomarkers in serum, plasma and tumoral tissue","https://ClinicalTrials.gov/show/NCT01733628"
1037,"NCT02777710","Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers","Recruiting","No Results Available","Colorectal Cancer|Pancreatic Cancer|Metastatic Cancer|Advanced Cancer","Drug: Pexidartinib|Drug: Durvalumab","Centre Leon Berard|AstraZeneca|Plexxikon","Both","18 Years and older   (Adult, Senior)","Phase 1","58","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ET15-037 (MEDIPLEX)|2015-002438-31","May 12, 2016","June 2016","June 2019","July 1, 2016","July 2016","No Study Results Posted","MEDIPLEX","September 2018","part 1 (dose escalation part) : Dose-Limiting Toxicities (DLT)|part 2 (extension part) : objective response rate (ORR)|The duration of response (DoR)|Progression-Free Survival (PFS)|Adverse events reporting|Area under the Pexidartinib plasma concentration (AUC) versus time curve|Peak Pexidartinib plasma concentration (Cmax)","https://ClinicalTrials.gov/show/NCT02777710"
1038,"NCT00118755","A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: capecitabine|Drug: Oxaliplatin|Drug: bevacizumab|Drug: capecitabine|Drug: Oxaliplatin|Drug: bevacizumab","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","435","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18491","July 1, 2005","July 2005","null","February 9, 2011","February 2011","April 25, 2010","null","April 2009","Progression-free Survival (PFS)|Overall Survival|Best Overall Clinical Response|Duration of Overall Clinical Response (CR or PR)","https://ClinicalTrials.gov/show/NCT00118755"
1039,"NCT01591421","P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: BKM120|Drug: Panitumumab","Canadian Cancer Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","22","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I208","May 2, 2012","May 2012","September 2016","March 22, 2016","March 2016","No Study Results Posted","null","September 2015","Recommended phase II dose of BKM120 (Phase I Component)|Anti-tumour activity (Phase II Component)|Translational Research","https://ClinicalTrials.gov/show/NCT01591421"
1040,"NCT00069095","A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: Oxaliplatin 130 mg/m^2|Drug: Capecitabine 1000 mg/m^2|Drug: Bevacizumab 7.5 mg/kg|Drug: Placebo for bevacizumab 7.5 mg/kg|Drug: Oxaliplatin 85 mg/m^2|Drug: Leucovorin 200 mg/m^2|Drug: Fluorouracil 400 mg/m^2|Drug: Bevacizumab 5 mg/kg|Drug: Placebo for bevacizumab 5 mg/kg","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","2035","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NO16966","September 15, 2003","July 2003","April 2009","December 11, 2015","December 2015","December 11, 2015","null","January 2006","Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4|PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone|PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4|PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone|PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4|PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone|PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4|PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone|Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4|Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone|Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4|Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone|BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4|BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone|Time to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4|Time to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone|Time to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4|Time to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone|Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4|Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone|Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4|Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone","https://ClinicalTrials.gov/show/NCT00069095"
1041,"NCT00602329","MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","University of Pennsylvania|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Diagnostic","CDR0000580810|UPCC-09205|GENENTECH-UPCC-09205|UPCC-804021","January 19, 2008","February 2006","null","July 7, 2009","July 2009","No Study Results Posted","null","December 2009","Analysis of tumor blood flow, assessed by DCE-MRI as percentage change in Ktrans, after 2 courses of FOLFOX and bevacizumab or FOLFOX alone compared to baseline value|Analysis of tumor markers of angiogenesis and apoptosis, and the effect of treatment|Correlation of tumor blood flow with time to progression|Correlation of markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival","https://ClinicalTrials.gov/show/NCT00602329"
1042,"NCT00700102","A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.","Completed","Has Results","Colorectal Cancer","Drug: Chemotherapy|Drug: Bevacizumab","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","820","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18147|2006-004634-32","June 17, 2008","February 2006","May 2013","July 2, 2015","July 2015","July 2, 2015","null","May 2013","Overall Survival: Time From Randomization to Death From Any Cause|Overall Survival: Months From Time of First Line Therapy|Participants With Progression Free Survival Event|Progression Free Survival: Time to Event|Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria|Response Rate: Participants With Response Status Based on RECIST Criteria","https://ClinicalTrials.gov/show/NCT00700102"
1043,"NCT01791140","BEVERLY-C: An Observational Study of Avastin (Bevacizumab) in First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","65 Years and older   (Adult, Senior)","","3","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25630","February 12, 2013","March 2011","May 2011","September 1, 2016","September 2016","No Study Results Posted","null","May 2011","Median progression-free survival|Overall response rate (complete response + partial response)|Clinical benefit rate (complete response + partial response + stable disease)|Metastasectomy rate|Mean duration of Avastin treatment|Safety: Incidence of adverse events|Median progression-free survival in subgroup receiving Avastin plus fluorouracil monotherapy|Median progression-free survival according to age group (65-74 years; >/= 75 years)","https://ClinicalTrials.gov/show/NCT01791140"
1044,"NCT01695772","A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: 5-FU based doublet chemotherapy|Drug: bevacizumab","Hoffmann-La Roche","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","50","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML28419","September 27, 2012","October 2012","April 2016","July 28, 2016","June 2016","June 17, 2016","null","April 2015","Percentage of Participants Achieving Complete Resection (R0 Resection)|Percentage of Participants Achieving Incomplete Tumor Resection (R1 Resection)|Percentage of Participants Achieving Objective Response|Percentage of Participants With Disease Progression or Relapse or Death|Progression Free Survival (PFS)|Percent Probability (PP) of Being Alive and Progression Free at Months 3, 6, 9, 12, 15, and 18|Percentage of Participants With Disease Relapse or Death|Disease Free Survival (DFS)|Percent Probability Of Being Alive and Disease Free at Months 3, 6, 9, and 12","https://ClinicalTrials.gov/show/NCT01695772"
1045,"NCT00063960","Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: floxuridine|Drug: irinotecan hydrochloride","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","94","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACOSOG-Z05032|CDR0000305857","July 8, 2003","August 2003","December 2004","July 1, 2016","July 2016","No Study Results Posted","null","December 2004","overall survival|time to hepatic recurrence or progression","https://ClinicalTrials.gov/show/NCT00063960"
1046,"NCT00544349","Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: cetuximab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000564063|FRE-IGR-CHOICE|IGR-1207|INCA-RECF0449","October 13, 2007","October 2006","null","May 14, 2011","July 2009","No Study Results Posted","null","May 2011","Efficacy: objective tumor response rate (RECIST criteria)|Toxicity as assessed by NCI CTCAE v3.0|Duration of response|Duration and rate of tumor control|Secondary resectability of hepatic metastases|Progression-free survival|Overall survival|Tumor progression rate","https://ClinicalTrials.gov/show/NCT00544349"
1047,"NCT00642603","A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer","Terminated","Has Results","Colorectal Cancer","Drug: capecitabine [Xeloda]|Drug: capecitabine [Xeloda]|Drug: bevacizumab [Avastin]|Drug: oxaliplatin|Drug: irinotecan","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","41","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21567","March 19, 2008","May 2008","September 2012","May 31, 2011","May 2011","June 10, 2010","null","March 2009","Progression-free Survival (PFS) in U.S. Patients Only","https://ClinicalTrials.gov/show/NCT00642603"
1048,"NCT01533740","Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: fluorouracil/irinotecan/levo-folinic acid/bevacizumab","University of Rome Tor Vergata","Both","Child, Adult, Senior","","31","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ONCOPTV-01-2012","February 10, 2012","March 2012","February 2014","February 1, 2014","February 2014","No Study Results Posted","null","February 2014","Impact of Tregs frequency on overall survival|Impact of Tregs frequency progression free survival|Impact of Tregs frequency radiologic response rate","https://ClinicalTrials.gov/show/NCT01533740"
1049,"NCT01903395","Risk-adapted Screening in First-degree Relatives of Patients With Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Behavioral: Nurse-led counselling","Martin-Luther-Universität Halle-Wittenberg","Both","45 Years and older   (Adult, Senior)","","492","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","NKP332-032","July 11, 2013","March 2012","December 2015","December 1, 2014","December 2014","No Study Results Posted","FAMKOL","December 2015","utilization of preventive colonoscopy|Rate of advanced adenomas or carcinomas in situ|post-operative complications associated with the colonoscopy|barriers to the use of preventive colonoscopy|effectiveness and cost-effectiveness of nurse-led counselling|time delay between signed informed consent and utilization of colonoscopy","https://ClinicalTrials.gov/show/NCT01903395"
1050,"NCT00497497","A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)","Completed","No Results Available","Colorectal Cancer","Drug: bevacizumab|Drug: cetuximab|Drug: FOLFIRI regimen|Drug: irinotecan|Drug: PRO95780","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","20","Industry","Interventional","Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","APM4187g","July 3, 2007","October 2007","null","February 15, 2011","February 2011","No Study Results Posted","null","null","Incidence and nature of dose-limiting toxicities|Incidence, nature, and severity of adverse events|Change in vital signs|Incidence and severity of infusion reactions","https://ClinicalTrials.gov/show/NCT00497497"
1051,"NCT00066846","Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy","Completed","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: leucovorin calcium","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000320506|CTEP-TRC-0301","August 6, 2003","August 2003","July 2007","June 18, 2013","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00066846"
1052,"NCT00642577","A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.","Completed","No Results Available","Colorectal Cancer","Drug: bevacizumab [Avastin]|Drug: irinotecan|Drug: leucovorin|Drug: fluorouracil","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","214","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BO20696","March 19, 2008","July 2007","December 2010","October 7, 2013","October 2013","No Study Results Posted","null","December 2010","Progression-free survival.|Overall response rate, time to response, duration of response, overall survival.|AEs, laboratory tests","https://ClinicalTrials.gov/show/NCT00642577"
1053,"NCT01792934","Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases","Recruiting","No Results Available","Multi-organ Metastatic Colorectal Cancer","Drug: XELOX regimen according to standard procedures|Drug: FOLFOX regimen according to standard procedures|Procedure: Surgery|Other: radiofrequency ablation (RFA)|Other: transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|Radiation: stereotactic body radiation therapy (SBRT)|Drug: Bevacizumab|Procedure: tumor biopsy","VU University Medical Center|Erasmus Medical Center","Both","18 Years and older   (Adult, Senior)","","478","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-073","December 20, 2012","December 2012","null","December 8, 2015","December 2015","No Study Results Posted","ORCHESTRA","July 2017","Overall survival|Progression free survival rates|Response rates|Safety and efficacy of the additional local treatment measured by number of serious adverse events.","https://ClinicalTrials.gov/show/NCT01792934"
1054,"NCT01632722","Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets","Recruiting","No Results Available","Colorectal Cancer|Liver Metastasis","Drug: Bevacizumab, mFOLFOX, FOLFIRI|Drug: Bevacizumab, mFOLFOX, FOLFIRI","Yonsei University","Both","20 Years to 80 Years   (Adult, Senior)","Phase 2","218","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2012-0166","June 28, 2012","June 2012","August 2018","July 12, 2016","July 2016","No Study Results Posted","null","August 2017","2 years recurrence-free survival (2Y-RFS)","https://ClinicalTrials.gov/show/NCT01632722"
1055,"NCT00436514","Colonoscopy by Videocapsuls Versus Standard Colonoscopy. Intra-individual Comparison for the Subject With a Medium or High Risk of Colorectal Cancer.","Completed","No Results Available","Colorectal Cancer","Behavioral: diet and absorption of ColoPEG|Procedure: Colonoscopy with colic videocapsule|Procedure: Standard colonoscopy","Nantes University Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","550","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","BRD 06/12-L","February 16, 2007","April 2007","July 2009","July 21, 2009","July 2009","No Study Results Posted","null","July 2009","","https://ClinicalTrials.gov/show/NCT00436514"
1056,"NCT01077739","A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin","Completed","Has Results","Colorectal Cancer","Drug: fluorouracil (5FU)|Drug: leucovorin|Drug: bevacizumab [Avastin]|Drug: capecitabine [Xeloda]|Drug: oxaliplatin","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","75","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML22519|2009-012090-36","February 26, 2010","July 2009","January 2012","December 8, 2014","December 2014","July 15, 2014","null","January 2012","Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression|PFS From the Start of First-Line Therapy|Percentage of Participants With an Overall Response of Complete Response (CR) or Partial Response (PR)|Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression","https://ClinicalTrials.gov/show/NCT01077739"
1057,"NCT00072748","Study Evaluating EKB-569 in Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms|Colonic Neoplasms|Rectal Neoplasms","Drug: EKB-569","Wyeth is now a wholly owned subsidiary of Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","63","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Masking: Open Label|Primary Purpose: Treatment","3095A1-200","November 10, 2003","null","October 2004","August 20, 2009","August 2009","No Study Results Posted","null","October 2004","","https://ClinicalTrials.gov/show/NCT00072748"
1058,"NCT00312000","Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma","Completed","No Results Available","Advanced Colorectal Cancer","Drug: capecitabine-irinotecan|Drug: capecitabine+irinotecan (1st line)","Dutch Colorectal Cancer Group|Koningin Wilhelmina Fonds|Sanofi|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","820","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CAIRO1","April 5, 2006","January 2003","December 2006","September 5, 2008","September 2008","No Study Results Posted","null","February 2006","Overall survival|Tumour response|Progression free survival|Quality of life|Toxicity profile","https://ClinicalTrials.gov/show/NCT00312000"
1059,"NCT00659022","Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth","Recruiting","No Results Available","Colorectal Neoplasms|Liver Neoplasms","Procedure: immediate surgery (resection of primary colorectal tumor)|Drug: neo-adjuvant treatment with bevacizumab|Drug: neoadjuvant treatment with capecitabine and oxaliplatin|Drug: neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin","Radboud University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SILENT","April 3, 2008","July 2008","April 2014","September 9, 2011","February 2009","No Study Results Posted","null","March 2014","Difference in response of liver metastases between control group and experimental groups determined by histopathological scoring of vascular density,apoptotic and mitotic index|Difference in response of liver metastases between control group and experimental groups determined by FDG-PET|Toxicity of neo-adjuvant treatment|Complications of surgery","https://ClinicalTrials.gov/show/NCT00659022"
1060,"NCT00492999","Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver","Active, not recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: dexamethasone|Drug: floxuridine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","Phase 2","64","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","06-075|MSKCC-06075","June 25, 2007","May 2007","May 2017","June 1, 2016","June 2016","No Study Results Posted","null","May 2017","Resectability rate|Antitumor activity|Response rate|Median time to progression|Survival","https://ClinicalTrials.gov/show/NCT00492999"
1061,"NCT00571740","Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer","Withdrawn","No Results Available","Colorectal Cancer","Biological: bevacizumab|Biological: cetuximab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","N0548|CDR0000578111|NCI-2009-00651","December 11, 2007","null","null","July 1, 2016","July 2016","No Study Results Posted","null","null","Progression-free survival (PFS) rate at 6 months|Tumor response rate associated with second-line therapy|Time to progression during second-line therapy|Duration of response|Quality of life","https://ClinicalTrials.gov/show/NCT00571740"
1062,"NCT00059930","Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: FOLFOX regimen|Drug: dexamethasone|Drug: floxuridine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: conventional surgery","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|University of Medicine and Dentistry of New Jersey","Both","18 Years and older   (Adult, Senior)","Phase 1","38","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03-005|MSKCC-03005","May 6, 2003","January 2003","June 2016","October 18, 2015","October 2015","No Study Results Posted","null","June 2016","Maximum tolerated dose|Correlate thymidylate synthase, dihydropyrimidine dehydrogenase, and ERCC-1 with survival and recurrence as measured by normal and tumor liver tissue","https://ClinicalTrials.gov/show/NCT00059930"
1063,"NCT00655499","Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: panitumumab|Drug: irinotecan hydrochloride|Genetic: chromogenic in situ hybridization|Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Other: laboratory biomarker analysis","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","68","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000593012|GERCOR-PIMABI-C07-1|EUDRACT 2007-004806-28|EU-20836|AMGEN-GERCOR-PIMABI-C07-1","April 9, 2008","June 2008","June 2012","August 22, 2012","August 2012","No Study Results Posted","null","June 2012","Objective response rate (ORR; radiologically confirmed complete response [CR] or partial response [PR]) during the combination therapy phase|ORR during the entire treatment phase (i.e., combination therapy and monotherapy)|Disease control rate (DCR)|Duration of response|Time to response|Progression-free survival time|Time to progression|Duration of stable disease|Time to treatment failure|Correlation between KRAS and KRAF mutations, EGFR gene copy number, and ORR and DCR|Incidence and severity of adverse events|Changes in laboratory values|Change in vital signs|Investigational medicinal product compliance|Incidence of dose adjustments|Incidence of concurrent medications|Changes from baseline over time in WHO performance status|Biomarkers (EGFR amplification status by chromogenic in situ hybridization and FISH, KRAS and KRAF mutations, and STAT3 expression","https://ClinicalTrials.gov/show/NCT00655499"
1064,"NCT00478634","A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal","Drug: RAD001, Cetuximab, Irinotecan","Novartis Pharmaceuticals|Novartis","Both","18 Years to 65 Years   (Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001C2242","May 24, 2007","May 2007","September 2009","November 1, 2012","November 2012","No Study Results Posted","null","September 2009","Dose Limiting Toxicities|Pharmacokinetics of RAD001, Irinotecan and SN-38|Progressions Free Survival|Overall Survival|Objective Response Rate","https://ClinicalTrials.gov/show/NCT00478634"
1065,"NCT02141295","A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE)","Recruiting","No Results Available","Colorectal Cancer","Drug: 5-fluorouracil (5-FU)|Drug: RO5520985|Drug: bevacizumab [Avastin]|Drug: folinic acid|Drug: oxaliplatin","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","198","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","BP29262|RG7221","May 15, 2014","June 2014","December 2017","September 1, 2016","September 2016","No Study Results Posted","null","December 2017","Progression-free survival (PFS) based on response evaluation criteria in solid tumors (RECIST) v. 1.1|Objective response rate (ORR) as per RECIST v. 1.1|Duration of response|Overall Survival|Incidence of adverse events|Area under the concentration-time curve (AUC) of RO5520985","https://ClinicalTrials.gov/show/NCT02141295"
1066,"NCT01412957","Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer","Active, not recruiting","Has Results","Metastatic Colorectal Cancer","Other: Best Supportive Care (BSC)|Drug: Panitumumab","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 3","377","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20100007|2010-022951-49","March 31, 2011","November 2011","December 2016","June 1, 2016","May 2016","March 2, 2016","null","June 2014","Overall Survival|Progression-free Survival|Overall Survival in Participants With Wild-type RAS|Progression Free Survival (PFS) in Participants With Wild-type RAS|Objective Response Rate|Objective Response Rate in Participants With Wild-type RAS|Number of Participants With Adverse Events (AEs)|Maximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval","https://ClinicalTrials.gov/show/NCT01412957"
1067,"NCT01571284","Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: AFLIBERCEPT AVE0005|Drug: FOLFIRI","Sanofi|Regeneron Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 3","900","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AFLIBC06097|2011-005724-17|U1111-1125-8949","April 3, 2012","May 2012","October 2016","September 19, 2016","September 2016","No Study Results Posted","null","October 2016","Number of participants reporting adverse events|Number of participants reporting laboratory abnormalities|Health-Related Quality of Life (HRQL) assessed by using changes from baseline in scores derived from the 3 HRQL questionnaires","https://ClinicalTrials.gov/show/NCT01571284"
1068,"NCT00494221","A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX","Completed","Has Results","Metastatic Colorectal Cancer","Drug: AZD2171|Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|Drug: Placebo Cediranib","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","172","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D8480C00039","June 27, 2007","June 2007","August 2012","February 26, 2014","February 2014","March 28, 2012","null","October 2009","Progression Free Survival|Objective Tumour Response Rate|Best Percentage Change in Tumour Size|Duration of Response|Overall Survival","https://ClinicalTrials.gov/show/NCT00494221"
1069,"NCT02316496","Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: cetuximab|Drug: Irinotecan","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","Both","18 Years and older   (Adult, Senior)","Phase 2","2","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","REGAIN C13-2","December 8, 2014","January 2015","March 2017","August 22, 2016","August 2016","No Study Results Posted","REGAIN","September 2016","Objective response rate (ORR)|Disease control rate (DCR)|Progression-free survival (PFS)|Duration of response (DOR)|Time to response (TTR)|Time to progression (TTP)|Time to treatment failure (TTF)|Duration of stable disease (DoSD)|Overall survival (OS)|Adverse Events (CTCAE v.4.03)|Quality of life|Respose rate|PFS","https://ClinicalTrials.gov/show/NCT02316496"
1070,"NCT02909478","Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer","Not yet recruiting","No Results Available","Chemotherapy-induced Nausea and Vomiting|Colorectal Cancer","Drug: Aprepitant+Tropisetron|Drug: Dexamethasone+Tropisetron","Sun Yat-sen University","Both","18 Years and older   (Adult, Senior)","Phase 3","298","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","GIHSYSU12","September 19, 2016","December 2016","null","September 19, 2016","September 2016","No Study Results Posted","null","December 2017","Complete response|Nausea score|Time to First Vomiting Episode or Use of Rescue Medication|Frequency of rescue medication|Functional Living Index -Emesis (FLIE)","https://ClinicalTrials.gov/show/NCT02909478"
1071,"NCT00853931","Biomarker - Panitumumab Response With KRAS Wild Type MCC","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab","British Columbia Cancer Agency","Both","18 Years and older   (Adult, Senior)","","52","Other","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label","CA-2008-0012|KRAS wild type|metastatic colorectal cancer","February 26, 2009","October 2009","September 2015","November 27, 2015","November 2015","No Study Results Posted","null","September 2015","Response rate|Clinical Benefit Rate|Progression free survival (PFS)|Overall survival","https://ClinicalTrials.gov/show/NCT00853931"
1072,"NCT01628211","Second Look Laparoscopy in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: Laparoscopy|Procedure: peritonectomy|Drug: Folinic Acid|Drug: 5-Fluorouracil|Drug: Oxaliplatin|Drug: systemic chemotherapy","National Cancer Institute, Naples","Both","18 Years to 65 Years   (Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HIPEC","June 20, 2012","April 2012","June 2017","November 27, 2015","November 2015","No Study Results Posted","HIPEC","June 2016","overall survival|number of patients with peritoneal carcinosis diagnosed at laparoscopy in the experimental arm|changes in quality of life|worst grade adverse event per patient|number of patients with radiologic evidence of disease after initial surgery|list of therapies and clinical outcomes of patients who had radiologic evidence of disease within 6 months after initial surgery","https://ClinicalTrials.gov/show/NCT01628211"
1073,"NCT00954876","Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer","Withdrawn","No Results Available","Metastatic Colorectal Cancer","Drug: capecitabine and cetuximab","Translational Drug Development|ImClone LLC","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MED-P02-07003","July 17, 2009","August 2009","January 2010","January 27, 2012","January 2012","No Study Results Posted","null","January 2010","Primary objective is to assess PFS in patients with WT KRAS CRC treated with the combination regimen of capecitabine and cetuximab|To assess the response rate in patients with metastatic WT KRAS CRC treated with capecitabine and cetuximab|To assess the overall survival rate among patients with metastatic WT KRAS CRC treated with capecitabine and cetuximab|To characterize the toxic effects and AEs of the combination regimen of capecitabine and cetuximab in this patient population|To perform exploratory analyses of serum and tumor biomarkers (EGFR mutations and genotyping) on toxicity and efficacy.","https://ClinicalTrials.gov/show/NCT00954876"
1074,"NCT01863303","Epidemiological Study of Colorectal Cancer in WuHan","Active, not recruiting","No Results Available","Diarrhea|Constipation|Melena|Neoplasm|Colonic Neoplasms|Pain","","Wuhan Pu-Ai Hospital|Wuhan University|Hubei Cancer Hospital|Huazhong University of Science and Technology|Wuhan Iron and Steel Workers' Hospital","Both","40 Years to 74 Years   (Adult, Senior)","","1","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","R201206DCAPC","May 22, 2013","June 2012","June 2018","May 24, 2013","May 2013","No Study Results Posted","null","June 2017","incidence of CRC","https://ClinicalTrials.gov/show/NCT01863303"
1075,"NCT01821105","2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer","Completed","Has Results","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV A Bladder Cancer|Stage IV A Rectal Cancer|Stage IV B Colon Cancer|Stage IV B Rectal Cancer","Procedure: PET Scan|Procedure: CT Scan|Radiation: fludeoxyglucose F 18|Procedure: computer-aided detection/diagnosis","Ohio State University Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","21","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","OSU-0375|NCI-2012-01242","August 9, 2012","March 2004","November 2009","February 3, 2016","February 2016","November 23, 2015","null","November 2009","Detection of Position Accuracy With Handheld Probe on Anatomical Location.|All Adverse Events and Complications|Tumor Detection","https://ClinicalTrials.gov/show/NCT01821105"
1076,"NCT02453464","A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Sevacizumab|Drug: Irinotecan|Drug: 5-FU|Drug: Leucovorin","Jiangsu Simcere Pharmaceutical Co., Ltd.","Both","18 Years to 74 Years   (Adult, Senior)","Phase 1","36","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SIM129-mCRC-01","May 19, 2015","August 2015","null","April 19, 2016","April 2016","No Study Results Posted","null","December 2016","Maximum Tolerated Dose (MTD)|Adverse Events (NCI-CTC 4.0)|Plasma pharmacokinetics (PK) parameters for Sevacizumab|Plasma pharmacokinetics (PK) parameters (Cmax, Tmax, AUC, T1/2) for Irinotecan and its major metabolite SN-38|Plasma pharmacokinetics (PK) parameters for 5-FU|Potential biomarkers, including VEGF and ADA|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02453464"
1077,"NCT02026583","A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Simvastatin","Samsung Medical Center","Both","20 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB no : 2013-07-088","December 31, 2013","December 2013","February 2017","April 30, 2015","April 2015","No Study Results Posted","null","December 2015","Progression free survival","https://ClinicalTrials.gov/show/NCT02026583"
1078,"NCT01399684","A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: 5-Fluorouracil|Drug: Bevacizumab|Drug: Folinic acid|Drug: MEGF0444A|Drug: Oxaliplatin|Drug: Placebo","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","127","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MEF4982g|GO27812|2011-001867-28","July 20, 2011","November 2011","February 2014","August 24, 2016","August 2016","No Study Results Posted","null","February 2014","Progression-Free Survival Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 as Determined by the Investigator|Percentage of Participants with Objective Response (Complete Response [CR] or Partial Response [PR] Based on RECIST v 1.1 as Determined by the Investigator|Duration of Response Based on RECIST v 1.1 as Determined by the Investigator|Overall Survival (OS)|Percentage of Participants with Adverse Events|Maximum Serum Concentration (Cmax) of MEGF0444A|Minimum Serum Concentration (Cmin) of MEGF0444A|Cmax of Bevacizumab|Cmin of Bevacizumab|Plasma Concentration of 5-Fluorouracil|Plasma Concentration of Oxaliplatin|Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to MEGF0444A|Change From Baseline in ATAs Levels of MEGF0444A","https://ClinicalTrials.gov/show/NCT01399684"
1079,"NCT00438737","Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: bevacizumab|Biological: cetuximab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000530116|EORTC-40051|EUDRACT-2005-002825-29|EU-20776","February 20, 2007","January 2007","null","September 1, 2011","September 2007","No Study Results Posted","null","null","Response rate (preoperative response rate)|Safety (rate of perioperative safety findings)|Progression-free survival|Pathological resection rate|Overall survival","https://ClinicalTrials.gov/show/NCT00438737"
1080,"NCT00107250","AZD2171 and Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)","Completed","No Results Available","Colorectal Cancer|Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: capecitabine|Drug: carboplatin|Drug: cediranib maleate|Drug: paclitaxel","NCIC Clinical Trials Group|Canadian Cancer Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I171|CAN-NCIC-IND171|CDR0000422357","April 5, 2005","January 2005","January 2011","January 18, 2011","January 2011","No Study Results Posted","null","January 2011","Dose limiting toxicity|Safety|Anti-tumour activity|Tumour Response","https://ClinicalTrials.gov/show/NCT00107250"
1081,"NCT01661270","A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy","Completed","Has Results","Colorectal Cancer Metastatic","Drug: Aflibercept|Drug: Placebo","Sanofi|Regeneron Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 3","332","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","EFC11338|U1111-1115-7227","August 7, 2012","July 2012","July 2015","October 22, 2015","October 2015","October 22, 2015","AFLAME","October 2014","Progression-free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01661270"
1082,"NCT01348412","Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure","Recruiting","No Results Available","Colorectal Cancer|Liver Metastases","Drug: oxaliplatin|Drug: raltitrexed|Drug: other intravenous chemotherapy drugs","Centre Georges Francois Leclerc|National Cancer Institute, France|Hospira, Inc.","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0329-1ghfr09","April 27, 2011","December 2010","null","April 22, 2016","April 2016","No Study Results Posted","HEARTO","December 2016","progression-free survival|Estimate the parameters of tumor perfusion using arterial CT Scan data|Estimate the rate of objective response according to the criteria of CHOI and RECIST|Estimate the overall survival which will be compared with the median of overall survival in other studies published in the literature|Estimate the rate of secondary resectable hepatic metastases|Estimate the tolerance of the treatment (NCI-CTCAE version 4.0)|Estimate the quality of life (QLQ C30) and the fatigue MFI20","https://ClinicalTrials.gov/show/NCT01348412"
1083,"NCT01763450","Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer","Active, not recruiting","No Results Available","Liver Metastases|Colorectal Cancer","Drug: bevacizumab plus chemotherapy","Liaoning Tumor Hospital & Institute","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Avastin Study","December 28, 2012","September 2012","September 2014","January 28, 2013","September 2012","No Study Results Posted","null","May 2013","To assess the objective response rate(ORR)|To assess the R0 resection rate of liver metastases","https://ClinicalTrials.gov/show/NCT01763450"
1084,"NCT00111774","Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma","Completed","No Results Available","Colorectal Cancer|Carcinoma","Drug: ABX-EGF","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","150","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20025405","May 25, 2005","March 2002","null","May 10, 2013","May 2013","No Study Results Posted","null","null","To assess Objective Response at Week 8 of Cycle 1|To evaluate additional measures of the clinical efficacy of ABX-EGF in subjects with metastatic colorectal carcinoma. (progression free survival, survival time, best overall response, and time to disease progression)|To determine the safety of ABX-EGF in subjects with metastatic colorectal carcinoma. (incidence of AEs, laboratory abnormalities, and other safety parameters)|To evaluate the safety and efficacy of ABX-EGF in subjects with lower tumor epidermal growth factor receptor (EGFr) expression","https://ClinicalTrials.gov/show/NCT00111774"
1085,"NCT01074333","An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment","Terminated","No Results Available","Colorectal Neoplasm","Drug: Cetuximab","Merck KGaA|Merck Ltd.","Both","Child, Adult, Senior","","146","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMR 62202-507","February 22, 2010","September 2008","January 2012","June 16, 2014","June 2014","No Study Results Posted","null","December 2011","Safety and toxicity of Erbitux treatment|Clinical efficacy of Erbitux treatment","https://ClinicalTrials.gov/show/NCT01074333"
1086,"NCT01126840","Survivorship in Lynch Syndrome Families","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Telephone Interview|Behavioral: Questionnaire","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","610","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2010-0160|CA57730","May 18, 2010","December 2010","null","September 8, 2016","September 2016","No Study Results Posted","null","July 2018","Compare Predictors of Health-Related Quality of Life (QOL) among Colorectal Cancer (CRC) Survivors who have Lynch Syndrome (LS) with patients who have Sporadic CRC","https://ClinicalTrials.gov/show/NCT01126840"
1087,"NCT02821559","Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: TOMOX|Drug: Bevacizumab","Centre Hospitalier Universitaire de Besancon|Hospira, Inc.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","37","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","EROS|2011-005811-96","March 29, 2016","July 2012","null","June 29, 2016","March 2016","No Study Results Posted","EROS","August 2014","Evolution of Raltitrexed plasma levels|treatment-related adverse events as assessed by CTCAE v4.0|objective response rate evaluated by RECIST 1.1 criteria|progression-free survival (PFS)|overall survival (OS)","https://ClinicalTrials.gov/show/NCT02821559"
1088,"NCT00419159","Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy","Completed","Has Results","Colorectal Cancer","Drug: Everolimus (RAD001)","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 2","199","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001C2241","January 4, 2007","December 2006","March 2009","November 4, 2011","November 2011","December 17, 2010","null","March 2009","Disease Control Rate (DCR) and Objective Response Rate (ORR) According to the Response Evaluation Criteria in Solid Tumors (RECIST)|The Number of Participants With Best Overall Response: Complete Response (CR, No Lesions), Partial Response (PR, 30% Decrease in Lesions), and Stable Disease (SD, None of the Above) According to Response Evaluation Criteria in Solid Tumors (RECIST)|Progression-free Survival (PFS)|Overall Survival (OS)|Number of Patients Who Died, Had an Serious Adverse Event (SAE), Had Grade 3 to 4 Adverse Event (AE), Discontinued Due to an AE, or Had a Clinical Notable AE by Treatment (tr).|Biomarkers Predictive of Clinical Benefit on Everolimus (RAD001)","https://ClinicalTrials.gov/show/NCT00419159"
1089,"NCT00895323","Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Other: enzyme-linked immunosorbent assay|Other: pharmacological study|Procedure: whole-body scintigraphy|Radiation: iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2","Garden State Cancer Center at the Center for Molecular Medicine and Immunology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","9","Other","Interventional","Masking: Open Label|Primary Purpose: Diagnostic","CDR0000636332|CMMI-C-071A-07","May 7, 2009","November 2008","null","September 16, 2013","July 2009","No Study Results Posted","null","March 2010","Pharmacokinetics|Tissue distribution","https://ClinicalTrials.gov/show/NCT00895323"
1090,"NCT02615574","A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Biological: αDC1 vaccine|Drug: CKM","Pawel Kalinski|University of Pittsburgh","Both","18 Years and older   (Adult, Senior)","Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-023","November 24, 2015","March 2016","December 2018","March 31, 2016","March 2016","No Study Results Posted","null","June 2018","overall survival|immune-related Overall Response Rate (irORR)|immune-related Progression-Free Survival (irPFS)","https://ClinicalTrials.gov/show/NCT02615574"
1091,"NCT01619423","A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Advanced Metastatic (Stage IV) Colorectal Cancer","Drug: PledOx (2 µmol/kg)|Drug: PledOx (5 µmol/kg)|Drug: Placebo (0,9% NaCl)","PledPharma AB|Pharma Consulting Group AB","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","165","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","PP095, (PLIANT)|2012-001367-76","May 25, 2012","September 2012","November 2016","April 10, 2015","April 2015","No Study Results Posted","PLIANT","March 2016","Presence of neuropathy grade 2 or higher (according to the Sanofi-NCI criteria for oxaliplatin related paraesthesiae/dysaesthesiae)|Febrile neutropenia|CT or MRI of thorax, abdomen and pelvis|Presence of positive cold allodynia test assessed by subjects|Oxaliplatin-associated sensory neuropathy|Change in Absolute Neutrophil count from both baseline and in between readings|Oral mucositis|Change in white blood cell count both from baseline and in between readings|Change in platelet count from both baseline and in between readings|Change in haemoglobin from both baseline and in between readings|Change in FOLFOX6 dose frequency and intensity|Survival|Change in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) from baseline|Plasma concentration half-life of of PledOx (metabolites ZnDPDP, ZnPLED, ZnDPMP)|The maximum plasma concentration (Cmax) and the corresponding time (Tmax) of PledOx (metabolites ZnDPDP, ZnPLED, ZnDPMP)|Area under the plasma concentration versus time curve (AUC) of PledOx (metabolites ZnDPDP, ZnPLED, ZnDPMP)|Electrocardiogram (ECG)|Manganese level in whole blood","https://ClinicalTrials.gov/show/NCT01619423"
1092,"NCT01409005","Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer","Completed","No Results Available","Metastatic or Recurrent Colorectal Cancer|Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan|Salvage Chemotherapy","Drug: Gemcitabine and UFTE chemotherapy","Seoul National University Bundang Hospital|Seoul National University Hospital|SMG-SNU Boramae Medical Center|Yuhan Pharmaceutical Company|Jeil Pharmaceutical Company","Both","18 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRC-SNU-2011-01","July 29, 2011","June 2011","null","February 10, 2014","January 2014","No Study Results Posted","null","February 2013","8-weeks progression free survival rate (PFS rate)|Overall survival (OS)|Response rate (RR)|Percentage of Patients with Adverse Events","https://ClinicalTrials.gov/show/NCT01409005"
1093,"NCT00381862","Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting","Completed","Has Results","Colorectal Cancer|Nausea and Vomiting","Drug: aprepitant|Drug: dexamethasone|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin|Drug: palonosetron hydrochloride|Procedure: quality-of-life assessment","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","Phase 2","54","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000503649|OHSU-SOL-06006-LM|OHSU-IRB-2302","September 26, 2006","June 2006","July 2008","February 9, 2016","February 2016","June 10, 2011","null","March 2008","Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.|Percentage of Patients With no Emesis and no Rescue Therapy During Repeated Courses of Chemotherapy|Effects of Aprepitant on Nausea, Appetite, Taste Changes, (Via Visual Analogue Scale [VAS]), Nutritional Intake, and Mucositis in the Colorectal Cancer (CRC) Population.|To Assess the Safety of the Combination of Aprepitant, Palonosetron, and Dexamethasone in the Colorectal Cancer(CRC) Population in the First and Subsequent Cycles of Chemotherapy.|Percentage of Patients With no Emesis and no Rescue Therapy Within 5 Days of the First Course of Chemotherapy","https://ClinicalTrials.gov/show/NCT00381862"
1094,"NCT01963182","Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","First Line Metastatic Colorectal Cancer","Drug: Irinotecan","Centre Jean Perrin","Both","18 Years and older   (Adult, Senior)","Phase 2","47","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-001275-21","October 10, 2013","October 2013","December 2016","July 5, 2016","July 2016","No Study Results Posted","IriGen","July 2016","severe toxicity (according to NCI-CTC cotation) and response with adapted dose of irinotecan|Study of the blood concentration (pharmacokinetic) of irinotecan, the SN38 and SN38-G, and bevacizumab|evaluation of treatment efficacy (progression-free survival, duration of response)","https://ClinicalTrials.gov/show/NCT01963182"
1095,"NCT01955629","Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient","Terminated","Has Results","Colorectal Cancer Metastatic","Drug: Aflibercept AVE0005|Drug: Oxaliplatin|Drug: Capecitabine","Sanofi|Regeneron Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","4","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AFLIBC06561|2013-000858-22|U1111-1143-3015","September 13, 2013","December 2013","March 2015","March 18, 2016","March 2016","March 18, 2016","AMOR","March 2015","Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)|Part 2: Number of Participants With Progression Free Survival (PFS) at 6 Months After the Start of Maintenance Therapy|Part 1: Number of Participants With Tumor Responses (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD])|Part 2: Progression Free Survival (PFS)|Part 2: Overall Survival (OS)|Part 2: Overall Rate of Resectability of Metastatic Lesions|Part 2: Number of Participants With CR or PR|Part 2: Pharmacodynamic Parameters: Modulation of Circulating Analytes|Part 2: Aflibercept Biomarkers Evaluation","https://ClinicalTrials.gov/show/NCT01955629"
1096,"NCT00961571","Sunitinib and Capecitabine for First Line Colon Cancer","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: sunitinib and capecitabine","Georgetown University|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","11","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GA61822D|2008-308","August 18, 2009","August 2009","March 2011","February 4, 2014","February 2014","No Study Results Posted","null","March 2011","Progression-free survival|Toxicity|Overall survival|Objective Response","https://ClinicalTrials.gov/show/NCT00961571"
1097,"NCT01550510","Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA","Terminated","No Results Available","Stage IV Colorectal Cancer","Drug: Vitamin C","Thomas Jefferson University","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","4","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11D.459","February 23, 2012","December 2011","February 2015","February 10, 2015","February 2015","No Study Results Posted","null","February 2015","Safety|Efficacy|Survival","https://ClinicalTrials.gov/show/NCT01550510"
1098,"NCT02301962","Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer","Recruiting","No Results Available","Cancer","Drug: Panitumumab","GlaxoSmithKline|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 4","58","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200092","November 24, 2014","July 2015","November 2017","August 10, 2016","August 2016","No Study Results Posted","null","November 2017","Number of subjects with adverse event.|Progression free survival.|Overall Response Rate.|Duration of response.","https://ClinicalTrials.gov/show/NCT02301962"
1099,"NCT01394939","Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma","Completed","No Results Available","Colorectal Carcinoma|CRC","Biological: JX-594|Drug: Irinotecan","Jennerex Biotherapeutics|Transgene|SillaJen, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","52","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JX594-CRC019","July 13, 2011","January 2012","October 2015","January 6, 2016","January 2016","No Study Results Posted","null","June 2015","Determine the maximally-tolerated dose (MTD) or maximum feasible dose (MFD) of JX-594 administered by 5 IV infusions alone and in combination with irinotecan|Determine the safety of JX-594 administered by 5 IV infusions followed by up to 3 IV JX-594 boosts alone and in combination with irinotecan|Determine radiographic response rate of patients enrolled in the Phase 2a portion of the study|Progression Free Disease|Survival","https://ClinicalTrials.gov/show/NCT01394939"
1100,"NCT02469480","Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: FerInject|Drug: Ferro sanol","Krankenhaus Nordwest","Both","18 Years and older   (Adult, Senior)","Phase 2","64","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","FERINJECT","May 13, 2015","March 2015","March 2018","August 15, 2016","August 2016","No Study Results Posted","null","December 2017","Rise or normalization of hemoglobin|Fatigue as measured by EORTC-QLQ-FA13|Quality of life as measured by EORTC-C30|Handgrip strength as measured by Hydraulic Hand Dynamometer|Number of allogenic blood transfusions (in total and per patient)|Time until rise or normalisation of hemoglobin|Genesis of the iron deficiency anemia|Number of therapy with recombinant erythropoietin|Dose of therapy with recombinant erythropoietin|Duration of therapy with recombinant erythropoietin|Inflammatory parameters|Influence nutritional status on iron deficiency anemia as measured by Nutritional Risk Screening (NRS 2002)|Influence nutritional status on therapy success as measured by Nutritional Risk Screening (NRS 2002)|Tolerance|Toxicity|Dropout rate due to toxicity or patient will|Overall survival","https://ClinicalTrials.gov/show/NCT02469480"
1101,"NCT01664494","An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer","Completed","Has Results","Breast Cancer, Colorectal Cancer, Gastric Cancer","Drug: Capecitabine","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","563","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25281","August 10, 2012","April 2010","July 2012","March 29, 2016","March 2016","November 19, 2015","null","July 2012","Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment|Median Dose of Capecitabine","https://ClinicalTrials.gov/show/NCT01664494"
1102,"NCT01057953","Oligogenic Determinism of Colorectal Cancer","Completed","No Results Available","Cancer","Genetic: Blood drawn","University Hospital, Rouen","Both","18 Years to 61 Years   (Adult)","","1550","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2009/082/HP","January 27, 2010","January 2010","January 2013","October 15, 2013","October 2013","No Study Results Posted","DOCC","January 2013","genetic variation assessment","https://ClinicalTrials.gov/show/NCT01057953"
1103,"NCT01878422","Sequential Treatment Strategy for Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Arm A: FOLFIRI or FOLFOX + Bevacizumab|Drug: Arm B: FOLFIRI or FOLFOX|Drug: Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Drug: Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","Both","18 Years and older   (Adult, Senior)","Phase 3","350","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IRST153.01|2007-004539-44","June 7, 2013","November 2007","March 2016","June 18, 2015","June 2015","No Study Results Posted","ITACa","March 2014","Progression Free Survival (PFS) of first and second line treatment strategy|Overal Response Rate (ORR) of first and second line treatment strategy|Overal Survival (OS) of second line treatment|Number of partecipants with adverse events as a measure of safety and tolerability","https://ClinicalTrials.gov/show/NCT01878422"
1104,"NCT01139242","Increasing Colorectal Cancer Screening in Urban African American Communities Via Churches","Completed","No Results Available","Colorectal Cancer","Behavioral: Body & Soul nutritional intervention|Behavioral: Experimental: newsletters and peer counseling","University of North Carolina, Chapel Hill|Centers for Disease Control and Prevention","Both","50 Years and older   (Adult, Senior)","Phase 0","955","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","05-1271|U48DP000059-02S1","June 4, 2010","February 2008","May 2010","June 7, 2010","June 2010","No Study Results Posted","ACTS","August 2009","Higher incidence of CRC screening, if needed, among experimental participants.","https://ClinicalTrials.gov/show/NCT01139242"
1105,"NCT02248805","Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma","Recruiting","No Results Available","Colorectal Carcinoma","Drug: MGD007","MacroGenics","Both","18 Years and older   (Adult, Senior)","Phase 1","158","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CP-MGD007-01","September 18, 2014","September 2014","March 2017","September 6, 2016","September 2016","No Study Results Posted","null","January 2017","Characterize dose limiting toxicity and establish a maximum tolerated dose and schedule|Characterize the PK and Immunogenicity of MGD07|Describe any evidence of anti-tumor activity","https://ClinicalTrials.gov/show/NCT02248805"
1106,"NCT02015923","Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases","Recruiting","No Results Available","Colonic Cancer|Unresectable Metastasis Originating in Colonic Cancer","Procedure: Colonic resection|Drug: Chemotherapy- scheme","Hospital Universitari de Bellvitge|Instituto de Salud Carlos III","Both","18 Years and older   (Adult, Senior)","Phase 4","336","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","01CCRe-IV|2013-001688-22","November 28, 2013","December 2013","November 2016","March 23, 2016","March 2016","No Study Results Posted","CCRe-IV","November 2016","Assess the impact of overall survival in patients with unresectable metastatic colorectal cancer treated with chemotherapy alone vs surgery followed by chemotherapy.|Postoperative morbidity and mortality.|Complications in patients treated with systemic chemotherapy|Quality of life|Study of possible survival factors","https://ClinicalTrials.gov/show/NCT02015923"
1107,"NCT00778830","Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: FOLFIRI|Drug: FOLFOX","Merck KGaA|Merck Pte. Ltd., Singapore","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","289","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62202-505","October 22, 2008","February 2009","April 2014","April 28, 2015","April 2015","April 28, 2015","APEC","April 2014","Percentage of Subjects With Best Overall Confirmed Response Rate (BORR)|Progression-Free Survival (PFS) Time|Overall Survival (OS) Time|Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation and TEAEs Leading to Death","https://ClinicalTrials.gov/show/NCT00778830"
1108,"NCT01862003","Phase I/II Trial of Antagonism of HER in GI Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer|Recurrent Colorectal Cancer","Drug: AZD8931|Drug: Irinotecan|Drug: Folinic Acid|Drug: Fluorouracil|Drug: Fluorouracil","University College, London|Cancer Research UK|AstraZeneca|National Institute for Health Research, United Kingdom","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL/12/0136","May 7, 2013","May 2014","May 2018","March 15, 2016","March 2016","No Study Results Posted","PANTHER","June 2016","Occurrence of Dose Limiting Toxicity|Measurement of Pharmacokinetic parameters (AUC, Cmax, t1/2) of AZD8931, Irinotecan and metabolite concentrations|Change in tumour size from baseline at 12 weeks using RECIST v1.1|Best overall response|Progression Free Survival|Overall Survival|Occurrence and Severity of Adverse Events","https://ClinicalTrials.gov/show/NCT01862003"
1109,"NCT01765582","STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: 5-fluorouracil|Drug: bevacizumab [Avastin]|Drug: capecitabine [Xeloda]|Drug: fluoropyrimidine-based chemotherapy|Drug: irinotecan|Drug: leucovorin|Drug: oxaliplatin","Hoffmann-La Roche","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML28442","January 9, 2013","January 2013","March 2016","August 1, 2016","August 2016","No Study Results Posted","null","March 2016","Overall response rate (ORR1) during first-line therapy, assessed by the investigator according to RECIST v.1.1 criteria|Progression-free survival (PFS1), defined as time from randomization to first occurrence of disease progression or death, whichever occurs first, during first-line therapy|Overall response rate during second-line therapy (ORR2), defined as proportion of patients with complete response or partial response during second-line therapy|Progression-free survival during second-line therapy (PFS2), defined as time from reinduction of second-line therapy to disease progression or death from any cause, whichever occurs first|Time to PFS2, defined as time from randomization to first occurrence of disease progression after reintroduction of second-line therapy|Overall survival, defined as time from randomization to death of any cause|Liver resection rate: Proportion of patients who undergo liver metastases resections|Rates of conversion from unresectable to resectable disease (liver-limited and non-liver-limited disease)|Safety: Incidence of adverse events","https://ClinicalTrials.gov/show/NCT01765582"
1110,"NCT02623621","Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: chemotherapy plus bevacizumab","Azienda Ospedaliero, Universitaria Pisana","Both","18 Years and older   (Adult, Senior)","","97","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIRCUS","December 1, 2015","November 2015","December 2017","December 3, 2015","December 2015","No Study Results Posted","CIRCUS","December 2016","Progression Free Survival","https://ClinicalTrials.gov/show/NCT02623621"
1111,"NCT02843217","Regional Native American Community Networks Program (RNACNP)","Completed","No Results Available","Colorectal Cancer Screening","Behavioral: Lifestyle, screening","Washington State University","Both","50 Years to 75 Years   (Adult, Senior)","","null","Other","Interventional","Intervention Model: Crossover Assignment|Primary Purpose: Screening","U54CA153498","June 15, 2016","September 2010","August 2015","July 20, 2016","June 2016","No Study Results Posted","null","August 2015","Colorectal Cancer Screening, beginning age 50","https://ClinicalTrials.gov/show/NCT02843217"
1112,"NCT02704988","Clinical Trial Comparing Carnoy's and GEWF Solutions","Recruiting","No Results Available","Lymph Node Metastasis|Colorectal Cancer","Procedure: Carnoy Solution|Procedure: GEWF Solution","Hospital Moinhos de Vento","Both","18 Years and older   (Adult, Senior)","","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","HMV-CRC1","February 22, 2016","March 2015","February 2018","March 6, 2016","February 2016","No Study Results Posted","null","February 2018","Increased lymph node sample|Additional lymph node metastases|Change of lymph node staging|Indication for adjuvant treatment","https://ClinicalTrials.gov/show/NCT02704988"
1113,"NCT02024412","Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC","Recruiting","No Results Available","Colorectal Cancer","Drug: monosialotetrahexosylganglioside Sodium|Other: placebo","Tianjin Medical University Cancer Institute and Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","240","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","20131123|E2013109A","November 24, 2013","November 2013","December 2017","September 24, 2015","September 2015","No Study Results Posted","null","December 2016","The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity|Objective response rate|Progress Free Survival|overall Survival|quality of life","https://ClinicalTrials.gov/show/NCT02024412"
1114,"NCT00647153","Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: pharmacological study|Procedure: single photon emission computed tomography|Radiation: iodine I 123 anti-CEA recombinant diabody T84.66","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","1","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","04085|P30CA033572|CHNMC-04085|CDR0000590136","March 28, 2008","May 2006","October 2012","June 3, 2015","June 2015","No Study Results Posted","null","October 2012","Tumor targeting properties of iodine I 123 anti-CEA recombinant diabody T84.66|Clinical pharmacokinetics of iodine I 123 anti-CEA recombinant diabody T84.66|Immunogenicity properties of iodine I 123 anti-CEA recombinant diabody T84.66|Safety of iodine I 123 anti-CEA recombinant diabody T84.66","https://ClinicalTrials.gov/show/NCT00647153"
1115,"NCT00711672","Study of the Therapeutic Use of Language in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","","Hematology and Oncology Associates of NE Pennsylvania","Both","18 Years and older   (Adult, Senior)","","5","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","808231","July 7, 2008","July 2008","October 2009","June 2, 2015","June 2011","No Study Results Posted","null","October 2009","Correlation of degree of ""narrative agreement"" with validated quality of life measures","https://ClinicalTrials.gov/show/NCT00711672"
1116,"NCT02529774","Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer","Not yet recruiting","No Results Available","Resected Liver Metastases From Colorectal Cancer","Drug: Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|Drug: Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)","Ye Xu|Fudan University","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","432","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1507149-6","August 18, 2015","September 2015","September 2021","August 18, 2015","August 2015","No Study Results Posted","null","September 2020","Overall Survival|Liver Relapse-Free Survival Rate|Disease free survival","https://ClinicalTrials.gov/show/NCT02529774"
1117,"NCT01896856","Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer","Recruiting","No Results Available","Previously Treated Metastatic Colorectal Cancer","Drug: SGI-110|Drug: Irinotecan|Drug: regorafenib|Drug: TAS-102","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","108","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1369|NA_00085870","July 8, 2013","September 2013","September 2019","September 13, 2016","September 2016","No Study Results Posted","null","September 2018","Phase 1/2: SGI-110 + irinotecan versus regorafenib or TAS-102 adverse events|Phase 1/2: Response|Phase 1/2: survival","https://ClinicalTrials.gov/show/NCT01896856"
1118,"NCT01949194","Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib","Gerald Batist|Bayer|Quebec Clinical Research Organization in Cancer|Jewish General Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","52","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","QCROC-06","September 11, 2013","September 2013","December 2017","August 3, 2016","August 2016","No Study Results Posted","null","March 2017","A biomarker (in blood or tissue) that may be predictive of level of response to regorafenib|Number of participants with adverse events|Progression free survival (PFS) time|Objective Response Rate (RR)","https://ClinicalTrials.gov/show/NCT01949194"
1119,"NCT02600949","Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma","Enrolling by invitation","No Results Available","Pancreatic Cancer|Colorectal Cancer","Biological: Peptide Vaccine|Behavioral: Phone Call","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","40","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-1029|NCI-2016-00015","November 6, 2015","May 2016","null","September 2, 2016","September 2016","No Study Results Posted","null","May 2021","Feasibility of Developing a Personalized Vaccine Within a Reasonable Timeframe for Participants with Metastatic Pancreatic Ductal Adenocarcinoma (PDA) and Colorectal Cancer (CRC)|Toxicity of Personalized Vaccine in Participants with Metastatic Pancreatic Ductal Adenocarcinoma (PDA) and Colorectal Cancer (CRC)|Progression-Free Survival","https://ClinicalTrials.gov/show/NCT02600949"
1120,"NCT02904031","Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients","Recruiting","No Results Available","Elderly Metastatic Colorectal Cancer Patients","Drug: 5-fluorouracil|Drug: oxaliplatin|Drug: l-leucovorin|Drug: panitumumab","Gruppo Oncologico del Nord-Ovest","Both","70 Years and older   (Senior)","Phase 2","180","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PANDA_2016","July 11, 2016","July 2016","March 2019","September 15, 2016","September 2016","No Study Results Posted","PANDA","November 2018","Progression Free Survival (PFS). PFS is defined as the time from randomization to the first documentation of objective disease progression or death due to any cause, whichever occurs first.","https://ClinicalTrials.gov/show/NCT02904031"
1121,"NCT02401802","Low-fiber Diet for Colorectal Cancer Screening Colonoscopy","Completed","No Results Available","Colonic Diseases","Dietary Supplement: Low-residue diet|Dietary Supplement: Usual care","Parc de Salut Mar","Both","18 Years and older   (Adult, Senior)","Phase 3","276","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","DIETCOL","March 17, 2015","January 2015","December 2015","April 11, 2016","April 2016","No Study Results Posted","DIETCOL","June 2015","Inadequate bowel preparation.|Cecal intubation rate|Adenoma detection rate|Polyp detection rate|Abdominal pain|Nausea|Hunger|Bloating|Adverse events|Adherence to the planned bowel cleansing method (questionnaire)|Acceptability of the preparation (interference with work, leisure activities or sleep","https://ClinicalTrials.gov/show/NCT02401802"
1122,"NCT00030524","ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: gefitinib","The University of Texas Health Science Center at San Antonio|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000069174|UTHSC-0015011185|SACI-IDD-01-01|NCI-3753","February 14, 2002","January 2002","September 2003","October 26, 2012","October 2012","No Study Results Posted","null","September 2003","","https://ClinicalTrials.gov/show/NCT00030524"
1123,"NCT01831310","Nutrition for Colorectal Cancer Patients and Neutrophil Functions","Completed","No Results Available","Malnutrition|Colorectal Cancer","Dietary Supplement: Standard (Kabiven)|Dietary Supplement: Standard-Glutamine|Dietary Supplement: Standard-Omega 3 fatty acid|Dietary Supplement: Standard-glutamine-omega 3","Kocaeli University","Both","50 Years to 70 Years   (Adult, Senior)","Phase 4","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","Canturkz1|KOUNutrition1","April 1, 2013","January 2007","January 2008","April 10, 2013","April 2013","No Study Results Posted","null","January 2008","neutrophil functions|Length of stay","https://ClinicalTrials.gov/show/NCT01831310"
1124,"NCT01460745","A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice","Completed","No Results Available","Metastatic Colorectal Cancer","","Merck KGaA|Merck Serono Limited, UK","Both","18 Years and older   (Adult, Senior)","","60","Industry","Observational","Time Perspective: Retrospective","EMR062202-546","October 25, 2011","November 2011","December 2012","February 3, 2014","February 2014","No Study Results Posted","RESECT","December 2012","Percentage of patients who undergo liver resection following downsizing chemotherapy with or without Erbitux|Percentage of liver resection outcomes R0, R1 and R2","https://ClinicalTrials.gov/show/NCT01460745"
1125,"NCT00002933","Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: irinotecan hydrochloride","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU1296|P30CA043703|NCI-T96-0081","November 1, 1999","September 1996","January 2001","June 9, 2010","June 2010","No Study Results Posted","null","July 2000","Effectiveness of irinotecan in treating patients who have metastatic or recurrent colorectal cancer.","https://ClinicalTrials.gov/show/NCT00002933"
1126,"NCT00044863","Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma","Completed","No Results Available","Colorectal Neoplasms|Metastases, Neoplasm","Biological: Erbitux (Cetuximab)","ImClone LLC","Both","18 Years and older   (Adult, Senior)","Phase 2","250","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CP02-0144","September 5, 2002","August 2002","December 2005","February 21, 2011","February 2011","No Study Results Posted","null","December 2005","Determine the response rate of cetuximab in patients with EGFR-positive, metastatic carcinoma","https://ClinicalTrials.gov/show/NCT00044863"
1127,"NCT02054598","Improving Colon Cancer Screening for Diverse Populations","Completed","No Results Available","Colorectal Cancer","Behavioral: Decision aid and navigation","University of North Carolina, Chapel Hill|University of New Mexico|Carolinas Healthcare System","Both","50 Years to 75 Years   (Adult, Senior)","","265","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","09-0537","January 31, 2014","January 2014","March 2016","September 1, 2016","September 2016","No Study Results Posted","null","March 2016","Colorectal cancer screening completion|Colorectal cancer screening knowledge|Colorectal cancer screening related self-efficacy|Colorectal cancer screening related intent","https://ClinicalTrials.gov/show/NCT02054598"
1128,"NCT01767857","A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Xilonix|Drug: Placebo","XBiotech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012-PT023","January 8, 2013","March 2013","June 2017","June 28, 2016","June 2016","No Study Results Posted","XCITE","December 2016","Overall Survival|Change in Lean Body Mass|Quality of life questionnaire|Progression Free Survival|Objective Response Rate","https://ClinicalTrials.gov/show/NCT01767857"
1129,"NCT02291198","Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy","Completed","No Results Available","Natural Killer Cell Cytokine Production","Device: NK Vue: NK cell activity in stimulated whole blood","ATGen Canada Inc|Maisonneuve-Rosemont Hospital","Both","40 Years and older   (Adult, Senior)","","1046","Industry|Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","ATG-001","November 10, 2014","October 2014","January 2016","January 20, 2016","January 2016","No Study Results Posted","null","January 2016","NK cell activity","https://ClinicalTrials.gov/show/NCT02291198"
1130,"NCT01262417","Resorbable Barrier for the Prevention of Abdominal and Peri-hepatic Adhesion Formation","Completed","No Results Available","Colorectal Cancer","Procedure: - use of resorbable membrane Seprafilm|Procedure: without resorbable barrier (seprafilm)","Centre Leon Berard|Ministry of Health, France","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","SEPRAC2T","December 15, 2010","July 2008","null","December 16, 2010","May 2010","No Study Results Posted","SEPRAC2T","November 2010","abdominal and peri-hepatic adhesion during the second operation|immediate complications during the first surgical procedure in relation with operating procedure and use of resorbable membrane|early complications (after the 1st surgical procedure)in relation with operating procedure and use of resorbable membrane|late complications (after the 1st surgical procedure)in relation with operating procedure and use of resorbable membrane|abdominal and peri-hepatic adhesion (at the site of the 1st surgery), with qualitative and quantitative description|intestinal adhesion (in the small intestine), with quantitative description|immediate complications in relation with operating procedure.|early complications (after 2ng operation) in relation with operating procedure.|late complications in relation with operating procedure.|post-operative rehabilitation|tumour evolution in patients","https://ClinicalTrials.gov/show/NCT01262417"
1131,"NCT00893503","Scope Pilot Research Study","Completed","No Results Available","Colorectal Cancer","Procedure: colonoscopy","University of Alberta|Royal Alexandra Hospital","Both","40 Years to 75 Years   (Adult, Senior)","","1248","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AHS-160408-SP|Pro00002130","May 5, 2009","April 2008","October 2009","March 7, 2011","March 2011","No Study Results Posted","SCOPE","October 2009","Compare the diagnostic performance characteristics of the guaiac based Hemoccult II FOBT and two FIT's, the Hemoccult ICT and MagStream HemSp, using colonoscopy as the gold standard.|Estimate the probability of participants of the SCOPE pilot who have adenomas or colorectal cancer using urine metabolomics and correlate those with results from the FOBT / FIT's and screening colonoscopy.","https://ClinicalTrials.gov/show/NCT00893503"
1132,"NCT00617071","Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants","Recruiting","No Results Available","Colorectal Cancer","Other: medical chart review|Other: survey administration|Procedure: fecal occult blood test|Procedure: screening colonoscopy","Kimmel Cancer Center (KCC)|National Cancer Institute (NCI)","Both","50 Years to 74 Years   (Adult, Senior)","Phase 3","900","Other|NIH","Interventional","Allocation: Randomized|Masking: Single Blind|Primary Purpose: Health Services Research","CDR0000584278|TJUH-2006-44","February 14, 2008","January 2007","null","December 17, 2013","July 2009","No Study Results Posted","null","December 2010","Screening utilization over the 6-month observation period|Screening preference|Perceived salience and coherence and self-efficacy related to colorectal cancer (CRC) screening|Number and length of contacts with each participant and the type of communication during those contacts|Identification of predictors of CRC screening use and screening preference","https://ClinicalTrials.gov/show/NCT00617071"
1133,"NCT01819766","Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease","Active, not recruiting","No Results Available","Inflammatory Bowel Disease (IBD)|Primary Sclerosing Cholangitis (PSC)|Colorectal Neoplasms|Colorectal Cancer","","Exact Sciences Corporation","Both","18 Years to 84 Years   (Adult, Senior)","","440","Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","Exact Sciences 2013-01","March 25, 2013","March 2013","April 2017","August 9, 2016","August 2016","No Study Results Posted","OCEANIA","December 2016","Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC.|Determine Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC and HGD.","https://ClinicalTrials.gov/show/NCT01819766"
1134,"NCT02523911","Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening","Recruiting","No Results Available","Colorectal Cancer","Drug: Simethicone|Drug: Placebo|Drug: sodium sulfate/potassium sulfate/magnesium sulfate solution","Mercy Medical Center, Des Moines, Iowa","Both","18 Years and older   (Adult, Senior)","","800","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Screening","MMC2015-31","August 12, 2015","March 2016","July 2019","March 23, 2016","March 2016","No Study Results Posted","null","July 2019","Overall bowel cleansing|Number of patients with adverse effects|Number of patients completing the bowel preparation","https://ClinicalTrials.gov/show/NCT02523911"
1135,"NCT01923337","Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer","Active, not recruiting","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IIIA Colon Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: irinotecan hydrochloride|Drug: alisertib","University of California, Davis|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","42","Other|NIH|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCDCC#234|NCI-2013-01387|P30CA093373|X14013","August 13, 2013","August 2013","December 2016","February 16, 2016","February 2016","No Study Results Posted","null","August 2016","MTD, defined as the highest dose tested in which fewer than 33% of patients experience dose-limiting toxicity (DLT) attributable to the study drugs, graded using the National Cancer Institute (NCI) CTCAE version 4.0|Incidence of toxicities observed at each dose level graded according to NCI CTCAE version 4.0|Response rates, as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1|Survival|Time to failure","https://ClinicalTrials.gov/show/NCT01923337"
1136,"NCT00005882","Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients With Benign Colorectal Polyps","Completed","No Results Available","Colorectal Cancer","Drug: eflornithine plus sulindac","University of California, Irvine|Chao Family Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","40 Years to 80 Years   (Adult, Senior)","Phase 2","324","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","CDR0000067922|1997-96|NCI-P00-0150","June 2, 2000","June 2000","December 2011","January 28, 2013","January 2013","No Study Results Posted","null","June 2008","To measure the efficacy of DFMO plus Sulindac versus placebo in modulating biomarkers of colorectal neoplasia.","https://ClinicalTrials.gov/show/NCT00005882"
1137,"NCT00705731","Adherence and the Economics of Colon Cancer Screening","Completed","No Results Available","Colorectal Cancer Screening","","University of California, San Francisco|National Cancer Institute (NCI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","50 Years to 79 Years   (Adult, Senior)","","1000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","A105658|R01CA106773|K24DK080941|3R01CA106773-04S1","June 24, 2008","March 2007","November 2011","June 11, 2012","June 2012","No Study Results Posted","null","November 2011","Adherence to colorectal cancer (CRC) screening, defined as completion of the screening strategy (the subject agrees to pursue/scheduled by the primary care provider).|Preventive Intention: Of those who agree to colonoscopy or FOBT, the proportion of patients who have colonoscopy scheduled or take home FOBT cards.|Preventive Behavior: Of the subjects with a positive FOBT result, determine the proportion adhering to the follow-up colonoscopy.|Identification of variables in the survey (based on the Health Belief Model) which are associated with non-adherence to screening.","https://ClinicalTrials.gov/show/NCT00705731"
1138,"NCT01929421","A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.","Completed","No Results Available","Advanced Colorectal Cancer","Drug: Gemcitabine/S-1","Gachon University Gil Medical Center","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-GIRBA-2075","August 19, 2013","December 2009","null","August 21, 2013","August 2013","No Study Results Posted","null","July 2013","Response rate|overall survival|number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01929421"
1139,"NCT00012389","Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: irinotecan hydrochloride|Drug: oxaliplatin","Sanofi|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000068524|SANOFI-EFC4585","March 3, 2001","December 2000","October 2008","December 18, 2013","October 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00012389"
1140,"NCT00008281","Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Sanofi|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000068394|SANOFI-EFC4584|BRCC-00036","January 6, 2001","October 2000","null","January 3, 2014","April 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00008281"
1141,"NCT00026299","Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: ZD1839|Drug: oxaliplatin","University of Chicago|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11089A|UCCRC-11089|NCI-3857","November 9, 2001","September 2001","February 2005","September 4, 2013","September 2013","No Study Results Posted","null","December 2002","Recommended dose of ZD1839 in combination with oxaliplatin","https://ClinicalTrials.gov/show/NCT00026299"
1142,"NCT00437268","A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumor","Drug: enzastaurin|Drug: irinotecan|Drug: cetuximab","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","26","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10538|H6Q-MC-S018","February 16, 2007","March 2007","May 2009","April 16, 2010","April 2010","No Study Results Posted","null","May 2009","Progression-free survival (PFS) rate|Tumor response rate|Duration of response|Overall survival|Safety and adverse events","https://ClinicalTrials.gov/show/NCT00437268"
1143,"NCT00056459","Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.","Completed","No Results Available","Colorectal Neoplasms|Colonic Neoplasms|Rectal Neoplasms","Drug: Vatalanib","Novartis|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 3","1168","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","CPTK787 0135/306241|CONFIRM 1","March 13, 2003","February 2003","null","November 18, 2009","November 2009","No Study Results Posted","null","January 2007","Progression free survival|Time to progression|Time to treatment failure|Best overall response rate|Tolerability and safety profile","https://ClinicalTrials.gov/show/NCT00056459"
1144,"NCT02521727","To Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas","Recruiting","No Results Available","Colorectal Cancer|Colorectal Adenoma","","Chinese University of Hong Kong","Both","40 Years to 70 Years   (Adult, Senior)","","828","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NonAA","August 6, 2015","November 2015","June 2019","April 13, 2016","April 2016","No Study Results Posted","NonAA","December 2018","number of participants having advanced neoplasms.|number of participants having colorectal neoplasms|number of participants having advanced neoplasms depending on site of non-advanced adenoma in proband|number of participants having advanced neoplasms based on the gender of the proband|number of participants having advanced neoplasms based on age of the proband","https://ClinicalTrials.gov/show/NCT02521727"
1145,"NCT02412683","Neurotoxic Symptoms in Adjuvant Chemotherapy in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Other: oxaliplatin","Jenny Drott|Linkoeping University","Both","18 Years and older   (Adult, Senior)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NTOX-123","January 16, 2015","January 2014","September 2016","September 6, 2016","September 2016","No Study Results Posted","null","September 2016","Oxaliplatin-Specific Neurotoxicity Scale|Health related quality of life (Fact-G) Questionnaire|Sense of Coherence scale (SOC-scale)","https://ClinicalTrials.gov/show/NCT02412683"
1146,"NCT01722162","Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: Bevacizumab|Drug: Capecitabine|Drug: Levocetirizine","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","Phase 2","47","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201303043","October 29, 2012","April 2013","October 2015","July 21, 2016","July 2016","No Study Results Posted","null","October 2015","progression free survival|Incidence and severity of adverse events","https://ClinicalTrials.gov/show/NCT01722162"
1147,"NCT01836653","Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases","Active, not recruiting","No Results Available","Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer","Drug: Bevacizumab|Drug: Cetuximab|Drug: L-OHP|Drug: l-LV|Drug: 5-FU|Drug: 5-FU","EPS Corporation","Both","20 Years to 80 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ATOM|UMIN000010209","April 14, 2013","May 2013","null","March 27, 2016","March 2016","No Study Results Posted","ATOM","May 2017","Progression-free survival|Response rate","https://ClinicalTrials.gov/show/NCT01836653"
1148,"NCT00056446","Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms|Colonic Neoplasms|Rectal Neoplasms","Drug: Vatalanib","Novartis Pharmaceuticals|Bayer|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 3","855","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","CPTK787 0133/304946","March 13, 2003","January 2003","January 2007","January 26, 2016","January 2016","No Study Results Posted","null","January 2007","Overall survival|Progression free survival|Time to progression|Time to treatment failure|Tumor response rate|Tolerability and safety profile","https://ClinicalTrials.gov/show/NCT00056446"
1149,"NCT02748811","Effect of Geriatric Intervention in Frail Elderly Patients Receiving Chemotherapy for Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Other: Intervention group","University of Copenhagen|Danish Cancer Society","Both","70 Years and older   (Senior)","","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","GERICO","March 31, 2016","May 2015","December 2018","April 28, 2016","April 2016","No Study Results Posted","GERICO","December 2017","Number of patients completing planned treatment without dose reductions|Occurrence of dose reductions|delay of treatment|Adverse events to treatment|time to recurrence|Survival|Cancer specific mortality|Quality of Life prior","https://ClinicalTrials.gov/show/NCT02748811"
1150,"NCT01152437","A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Neoplasms","Drug: BIBW 2992|Drug: Cetuximab","Boehringer Ingelheim","Both","18 Years and older   (Adult, Senior)","Phase 2","94","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1200.74|2009-011996-59","June 28, 2010","June 2010","null","May 27, 2014","May 2014","August 8, 2013","null","March 2012","Percentage of Participants With Objective Response|Percentage of Participants With Disease Control (DC)|Progression Free Survival (PFS)|Overall Survival (OS) Time|Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 8 (Cpre,ss,8)","https://ClinicalTrials.gov/show/NCT01152437"
1151,"NCT01902849","Anesthetic Technique on Immune Response in Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Other: blood sampling for IL measurement","Iuliu Hatieganu University of Medicine and Pharmacy","Both","18 Years and older   (Adult, Senior)","","70","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","TICC","July 13, 2013","February 2012","August 2013","March 9, 2014","March 2014","No Study Results Posted","T-IL-Co-ReCa","July 2013","measurement of interleukins IL6 and IL 10 plasmatic level|measurement of interleukins IL6, IL10 plasmatic level|measurement of interleukins IL6 and IL10 plasmatic level|total opioid analgesic dose (mg)","https://ClinicalTrials.gov/show/NCT01902849"
1152,"NCT01157039","A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin","Withdrawn","No Results Available","Colorectal Carcinoma|Neoplasms, Colorectal|Colorectal Cancer|Colorectal Tumors|Metastasis","Dietary Supplement: Glutamine","AHS Cancer Control Alberta|Cross Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","25070","July 2, 2010","October 2011","null","February 23, 2016","October 2011","No Study Results Posted","null","September 2012","To evaluate potential pharmacokinetic interactions between oxaliplatin and glutamine at 30g and 40g in patients with metastatic colorectal cancer.|To evaluate effects of glutamine supplementation on neuropathy and diarrhea related to oxaliplatin, and on dose reductions and in patients with metastatic colorectal cancer.|To compare the toxicity profile of glutamine and FOLFOX to historical data.","https://ClinicalTrials.gov/show/NCT01157039"
1153,"NCT02642978","Robot-assisted Procedure Versus Open Simultaneous Resection of Colorectal Cancer With Liver Metastases","Recruiting","No Results Available","Colorectal Liver Metastasis","Procedure: RSRCLM|Procedure: Open","Xu jianmin|Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RSRCLM","September 8, 2015","September 2015","September 2019","December 28, 2015","December 2015","No Study Results Posted","null","September 2017","disease-free survival(DFS)|Treatment-Related Adverse Events","https://ClinicalTrials.gov/show/NCT02642978"
1154,"NCT01220999","An Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: 111In-CS-1008, CS-1008","Ludwig Institute for Cancer Research|Daiichi Sankyo Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","19","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LUD2010-002","October 12, 2010","October 2010","September 2012","February 27, 2013","February 2013","No Study Results Posted","null","June 2012","Biodistribution and tumour uptake of CS1008 based on gamma camera imaging following initial single infusion 111In-CS-1008 and changes following continuous sequential doses of CS-1008.|Pharmacokinetics of 111In-CS-1008 and CS-1008 protein by gamma counting and ELISA of serum samples following initial single infusion 111In-CS-1008 and changes following continuous sequential doses of CS-1008.|Tumour metabolism response to CS‐1008 will be assessed by 18F‐FDG PET|Tumour response to CS-1008 measured by RECIST (v1.1).|Changes in serum apoptotic biomarkers following treatment with CS-1008.|Changes in serum tumour response markers following treatment with CS-1008.","https://ClinicalTrials.gov/show/NCT01220999"
1155,"NCT02866344","Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases","Recruiting","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis|Hepatic Neoplasms","Device: Microwave ablation|Procedure: Hepatic resection","Carolinas Medical Center","Both","18 Years to 75 Years   (Adult, Senior)","","164","Other","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","06-16-02A","August 10, 2016","August 2016","January 2022","August 13, 2016","August 2016","No Study Results Posted","null","January 2019","Local disease control at the site of intervention|Overall survival|Intrahepatic disease-free survival|Postoperative morbidity|Postoperative mortality","https://ClinicalTrials.gov/show/NCT02866344"
1156,"NCT02347852","Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Bayer","Both","18 Years and older   (Adult, Senior)","","25","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17816|SV1415AT","December 22, 2014","January 2015","October 2016","September 2, 2016","September 2016","No Study Results Posted","REGO-ACT","October 2016","Amount of physical activity assessed by a pedometer (smartLAB) and an international physical activity questionnaire|Relation of the amount of physical activity to QoL (Quality of Life) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')|Relation of the amount of physical activity to fatigue data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')|Relation of the amount of physical activity to DCR (Disease Control Rate) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')|Relation of the amount of physical activity to OS (Overall Survival) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')|Relation of the amount of physical activity to PFS (Progression Free Survival) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')","https://ClinicalTrials.gov/show/NCT02347852"
1157,"NCT00065117","Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.","Terminated","No Results Available","Colorectal Neoplasms|Metastases, Neoplasm","Drug: ZD6126|Drug: Placebo|Drug: 5-fluorouracil|Drug: leucovorin|Drug: oxaliplatin","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","D2820C00007|6126IL/00007","July 17, 2003","September 2003","February 2004","January 25, 2011","January 2011","No Study Results Posted","null","February 2004","","https://ClinicalTrials.gov/show/NCT00065117"
1158,"NCT01880658","Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Capecitabine","Sun Yat-sen University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GIHSYSU03","June 5, 2013","June 2013","May 2019","February 8, 2014","July 2013","No Study Results Posted","CAMCO","May 2016","Disease-free Survival rate(DFS)|Over all survival,genetic patterns, quality of life, toxic effects, convenience","https://ClinicalTrials.gov/show/NCT01880658"
1159,"NCT02652663","Liver MRI for Colorectal Cancer Liver Metastasis: Comparative Effectiveness Research for the Choice of Contrast Agents","Active, not recruiting","No Results Available","Colorectal Cancer","","Yonsei University","Both","20 Years to 90 Years   (Adult, Senior)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","4-2015-1045","January 6, 2016","January 2016","December 2016","January 8, 2016","January 2016","No Study Results Posted","null","December 2016","Disease free survival","https://ClinicalTrials.gov/show/NCT02652663"
1160,"NCT01048463","Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor","Recruiting","No Results Available","Gastric Cancer|Colorectal Cancer|Chemotherapy","Drug: Nutriall|Drug: LDEPA|Drug: Placebo|Drug: HDEPA|Drug: Chemotherapy","Sun Yat-sen University","Both","Child, Adult, Senior","Phase 3","90","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","EPACT","January 12, 2010","December 2009","January 2012","October 4, 2011","October 2011","No Study Results Posted","null","December 2011","Serum level of proalbumin|Weight in light clothing|Height and BMI|mid upper arm circumference and triceps skinfold thickness|Fat ratio and fat mass|Fat-free mass, muscle mass and muscle function|CD distribution of T cells|Serum level of different types of immunoglobulin|Serum level of different types of cytokines|Serum level of Cortisol|Serum level of transferrin|Serum level of ALT and AST|Serum level of creatine and BUN|Serum level of total triglyceride, total cholesterol, LDL, HDL|Records of EPA intake|Records of chemotherapy-associated side effects|Serum level of albumin|Serum level of CEA, CA125, CA199|Records of Nutriall intake|Records of food intake","https://ClinicalTrials.gov/show/NCT01048463"
1161,"NCT00313859","Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC","Completed","No Results Available","Colorectal Cancer|Metastasis","Drug: simvastatin","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SMC IRB 2005-08-011","April 11, 2006","September 2005","August 2007","January 31, 2012","January 2012","No Study Results Posted","null","null","overall response rate|progression-free survival|overall survival|toxicity|duration of response","https://ClinicalTrials.gov/show/NCT00313859"
1162,"NCT01843400","Regorafenib Post-marketing Surveillance","Recruiting","No Results Available","Colorectal Neoplasms","Drug: BAY73-4506_Regorafenib","Bayer","Both","Child, Adult, Senior","","1250","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16472|STIVARGA-CRC-01","April 26, 2013","April 2013","March 2021","September 2, 2016","September 2016","No Study Results Posted","null","September 2016","Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib|Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.|Determination of patient's background to affect the safety and efficacy of Regorafenib using standard observational survey and follow-up survey","https://ClinicalTrials.gov/show/NCT01843400"
1163,"NCT00311272","Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Biological: MelCancerVac","University Hospital, Gentofte, Copenhagen","Both","25 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","2612-1970","April 3, 2006","November 2004","September 2007","February 17, 2009","February 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00311272"
1164,"NCT01906008","Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients","Recruiting","No Results Available","Colorectal Cancer","Drug: Minocycline|Drug: Placebo|Behavioral: Questionnaires|Behavioral: Sensory Test","M.D. Anderson Cancer Center|American Cancer Society, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","166","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2013-0323|NCI-2014-01291|RSG-13-241-01-PCSM","July 18, 2013","November 2013","null","September 20, 2016","September 2016","No Study Results Posted","null","November 2018","Reduction of Acute Peripheral Neuropathy During Oxaliplatin-Based Chemotherapy","https://ClinicalTrials.gov/show/NCT01906008"
1165,"NCT02216487","Trial of FOLF(HA)Iri With Cetuximab in mCRC","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: HA-Irinotecan","Western General Hospital, Australia|Alchemia Oncology|Merck Serono International SA","Both","18 Years and older   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACO-004","August 12, 2014","June 2014","November 2016","August 27, 2014","August 2014","No Study Results Posted","Chime","June 2016","Safety","https://ClinicalTrials.gov/show/NCT02216487"
1166,"NCT00594529","Feasibility Study of Neoadjuvant Chemotherapy Modified FOLFOX6 for Resectable Liver Metastases of Colorectal Cancers","Recruiting","No Results Available","Colorectal Cancer|Liver Metastasis","Procedure: Surgery","Kyoto University","Both","20 Years to 80 Years   (Adult, Senior)","Phase 2","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C-206|UMIN000000961","January 4, 2008","January 2008","May 2013","June 22, 2011","August 2009","No Study Results Posted","null","May 2010","Curative resection rates of liver metastases|Completion rates of neoadjuvant chemotherapy","https://ClinicalTrials.gov/show/NCT00594529"
1167,"NCT01384994","Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients","Recruiting","No Results Available","Colorectal Cancer|KRAS Wildtype|After Resection of Liver Metastases","Drug: Folic Acid|Drug: 5-FU|Drug: 5-FU|Drug: Oxaliplatin|Drug: Panitumumab|Drug: Panitumumab|Drug: Folic Acid|Drug: 5-FU|Drug: 5-FU|Drug: Oxaliplatin","PD Dr. med. Volker Heinemann|Amgen|Ludwig-Maximilians - University of Munich","Both","18 Years and older   (Adult, Senior)","Phase 2","111","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PARLIM","May 2, 2011","August 2011","August 2014","July 5, 2012","July 2012","No Study Results Posted","null","August 2013","Progression Free Survival|Tolerability and side effects|Overall Survival","https://ClinicalTrials.gov/show/NCT01384994"
1168,"NCT00070122","Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer","Terminated","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: oxaliplatin|Drug: leucovorin calcium|Drug: capecitabine|Biological: bevacizumab|Drug: fluorouracil|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","2200","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NCI-2012-02556|S0303|U10CA032102|CDR0000330000","October 3, 2003","April 2004","null","January 24, 2013","January 2013","No Study Results Posted","null","January 2007","Overall survival in patients with colorectal cancer treated with fluorouracil/leucovorin calcium and oxaliplatin with and without becavizumab versus those treated with capecitabine and oxaliplatin with our without bevacizumab|Time to treatment failure|Progression-free survival|Response (among patients with measurable disease)|Treatment toxicities graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 3.0)|Change in FACT-C TOI|Change in Chemotherapy Convenience and Satisfaction Questionnaire scores|Whether gene expression variables are predictive of survival and progression-free survival","https://ClinicalTrials.gov/show/NCT00070122"
1169,"NCT00677586","I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Procedure: simultaneous resection of liver metastasis and the colorectal primary tumor|Procedure: staged resection of liver metastasis and the colorectal primary tumor","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20080507","May 12, 2008","January 2000","December 2007","March 24, 2009","March 2009","No Study Results Posted","null","December 2007","post-operative complication, peri-operative mortality|5 years survival","https://ClinicalTrials.gov/show/NCT00677586"
1170,"NCT00843375","Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas","Completed","No Results Available","Colonic Neoplasms","","University of Michigan|Early Detection Research Network|M.D. Anderson Cancer Center|St. Michael's Hospital, Toronto|Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Dartmouth-Hitchcock Medical Center","Both","18 Years and older   (Adult, Senior)","","695","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","GLNE 007|5U01CA086400-08","February 12, 2009","December 2005","April 2010","March 15, 2011","March 2011","No Study Results Posted","null","April 2010","","https://ClinicalTrials.gov/show/NCT00843375"
1171,"NCT00920868","XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib","Completed","No Results Available","Solid Tumor|Metastatic Colorectal Cancer","Drug: dasatinib|Drug: bevacizumab|Drug: Oxaliplatin|Drug: Capecitabine","Herbert Hurwitz, MD|Bristol-Myers Squibb|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 1","22","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00010354","June 10, 2009","May 2009","August 2014","February 2, 2016","February 2016","No Study Results Posted","XAD","May 2010","To determine the maximum tolerated dose(MTD)/recommended phase II dose (RPTD) of capecitabine/oxaliplatin/bevacizumab/dasatinib for patients with advanced solid tumors.|To further describe dose-limiting and non-dose-limiting toxicities associated with this regimen.|To describe clinical activity (partial response (PR), complete response (CR) or stable disease (SD)>6 months, time to progression, and overall survival) associated with this regimen for patients with previously untreated metastatic and/or re|To explore any correlation between blood, urine, and paraffin biomarkers and clinical outcomes","https://ClinicalTrials.gov/show/NCT00920868"
1172,"NCT00387387","Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)","Completed","No Results Available","Neoplasms, Colorectal|Colorectal Cancer","Drug: pazopanib","GlaxoSmithKline","Both","21 Years and older   (Adult, Senior)","Phase 1","70","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VEG105424","October 11, 2006","October 2006","June 2009","May 31, 2012","April 2011","No Study Results Posted","null","June 2009","Plasma AUC(0-24) of pazopanib on Day 1, 14 and 21 Plasma AUC(0-46) of 5-FU and AUC(0-8) of platinum on Day 1 Plasma AUC(0-24) of capecitabine, 5-FU, and platinum on Day 1|Pharmacokinetic endpoints (AUC, C24, Cmax, tmax, and half-life)collected predose and 1, 2, 3, 4, 5, 6, 8, and 24 hours on Day 1. Assessment of disease by imaging","https://ClinicalTrials.gov/show/NCT00387387"
1173,"NCT01842971","ALPPS (Liver Partition and Portal Vein Ligation) for Two-stage Hepatectomy for Colorectal Liver Metastasis","Recruiting","No Results Available","Colorectal Cancer","Procedure: two stage hepatectomy","Centre Hospitalier Universitaire, Amiens","Both","18 Years and older   (Adult, Senior)","Phase 3","44","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PI 2012-843-0028|A41707-36","April 24, 2013","May 2013","December 2015","July 28, 2015","July 2015","No Study Results Posted","null","December 2015","number of complete surgical procedure|overall mortality|number of patient with hepatocellular insufficiency|overall morbidity|preoperative liver volumetry|quality of life","https://ClinicalTrials.gov/show/NCT01842971"
1174,"NCT01703390","Biomarker Directed Treatment in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFIRI + Cetuximab|Drug: modifiedFOLFOX6 + Cetuximab","Arbeitsgemeinschaft medikamentoese Tumortherapie|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AGMT_ERCC1|2011-003217-41","October 4, 2012","August 2012","null","March 6, 2015","March 2015","No Study Results Posted","null","August 2016","Response|Feasibility|Response rate|Patient characteristics|Secondary resection rate|Molecular markers for toxicity|Toxicity","https://ClinicalTrials.gov/show/NCT01703390"
1175,"NCT01766479","Non-cathartic Computed Tomographic Colonography to Screen Subjects With a Family History of Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasia","Radiation: CT colonography","Istituto Clinico Humanitas","Both","40 Years and older   (Adult, Senior)","","844","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Screening","MTedeschi","December 31, 2012","May 2009","November 2012","January 10, 2013","January 2013","No Study Results Posted","null","September 2011","Number of patients in whom colorectal polyps and colorectal neoplasia have been detected by CT colonography, by adopting colonoscopy as gold standard, as a measure of efficacy.","https://ClinicalTrials.gov/show/NCT01766479"
1176,"NCT00640471","Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: brivanib alaninate","NCIC Clinical Trials Group|Canadian Cancer Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 3","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CO20|CAN-NCIC-CO20|CAN-NCIC-CA182009|CDR0000590316","March 20, 2008","May 2008","January 2013","July 16, 2013","November 2012","No Study Results Posted","null","March 2011","Overall survival|Progression-free survival|Objective response rate|Duration of response|Quality of life (using EORTC QLQ-C30 and Skindex-16 Dermatology Survey)|Health utilities (using HUI3 Health Utilities Index)|Economic evaluation|Safety profile|Molecular markers","https://ClinicalTrials.gov/show/NCT00640471"
1177,"NCT00037180","For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy","Terminated","No Results Available","Neoplasm Metastasis|Colorectal Neoplasms","Drug: Celecoxib|Drug: Irinotecan|Drug: 5-fluorouracil|Drug: Leucovorin","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","212","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","IQ8-01-02-016","May 16, 2002","April 2002","January 2003","September 25, 2008","September 2008","No Study Results Posted","null","null","Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy|Severity of all grades of diarrhea, overall and by cycle|Duration of diarrhea, by cycle|Diarrhea grade, by day, by cycle|Stool count, by day, by cycle|Severity of asthenia (fatigue), by week.|Asthenia will be assessed with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scale.|Duration of asthenia, by week, as measured by the FACIT-Fatigue scale|Type, frequency, severity, timing, and relatedness of all adverse events CPT-11/5-FU/LV treatment administration as characterized by median, mean, and range of doses given; dose modifications, omissions, and delays; and actual and relative dose intensity|Compliance with celecoxib use Incidence, quantity, and duration of loperamide use|Tumor response rate (overall and confirmed)using the World Health Organization [WHO] Response Evaluation Criteria in Solid Tumors [RECIST 2000]|Serum tumor marker (carcinoembryonic antigen [CEA]) response rate (as characterized by a 50% reduction from baseline)|Time to tumor progression (TTP)|Time to treatment failure (TTF)|Survival Post-study anticancer treatment|Peak plasma levels and AUC 0-24 values for CPT-11 and its major metabolites, SN-38, SN-38 glucuronide (SN-38G), and aminopentane carboxylic acid (APC)|Inflammatory cytokines which may serve as biomarkers for cancer-related outcomes Beta-glucuronidase as a potential biomarker for tumor response|Health resource utilization (collected data to be evaluated separately from this protocol)","https://ClinicalTrials.gov/show/NCT00037180"
1178,"NCT01801085","Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens","Recruiting","No Results Available","Colorectal Cancer","","Vivian Wing Yan Lee|Hoffmann-La Roche|Queen Elizabeth Hospital, Hong Kong|Princess Margaret Hospital, Hong Kong|Chinese University of Hong Kong","Both","18 Years and older   (Adult, Senior)","","30","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Roche-TR116581|TR116581VLKZ002","September 5, 2012","October 2011","December 2014","February 11, 2014","February 2014","No Study Results Posted","null","December 2014","Composite preparation, dispensing and administration time|Capital item utilization (hospital bed and infusion pump)","https://ClinicalTrials.gov/show/NCT01801085"
1179,"NCT00309179","A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors","Active, not recruiting","No Results Available","Advanced Colorectal Cancer","Drug: E7820 plus cetuximab","Eisai Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","41","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E7820-A001-204","March 29, 2006","September 2007","April 2017","August 9, 2016","July 2016","No Study Results Posted","null","December 2009","Objective tumor response (CR or PR) and disease control (CR, PR or SD) rates will be evaluated in this study based on RECIST criteria and modified WHO criteria.|Pharmacokinetics: Blood samples will be taken on Days 1, 2, and 15 during Cycle 1 and Day 1. Pharmacodynamics: Blood will be taken prior to dosing on Day 1, Days 1, 2, and 15 during Cycle 1 and Day 1.","https://ClinicalTrials.gov/show/NCT00309179"
1180,"NCT01416714","Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy","Recruiting","No Results Available","Gastric Cancers","","University of Chicago","Both","Child, Adult, Senior","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","16294A","August 20, 2010","July 2008","October 2017","July 20, 2016","July 2016","No Study Results Posted","null","October 2017","Collect and store blood samples|create a database for the collected tissue|To create tissue microarrays for each gastrointestinal cancer subtype","https://ClinicalTrials.gov/show/NCT01416714"
1181,"NCT01640444","Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)","Recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: FOLFIRI + bevacizumab|Drug: FOLFIRI + cetuximab","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Roche Pharma AG","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","240","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-12-02|2012-000840-90","June 13, 2012","July 2012","June 2017","June 13, 2016","June 2016","No Study Results Posted","VISNU-2","June 2017","progression free survival (PFS)|Overall survival (OS)|Response rate (RR)|Radical Resection (R0) surgery rate|CTC count basal and correlate to PFS, OS, RR|Adverse events|Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)","https://ClinicalTrials.gov/show/NCT01640444"
1182,"NCT00035087","EPO906 Therapy in Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms|Colonic Neoplasms","Drug: epothilone b","Novartis Pharmaceuticals|Novartis","Both","18 Years to 85 Years   (Adult, Senior)","Phase 2","62","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CEPO906A2201","May 2, 2002","May 2002","March 2003","December 3, 2013","December 2013","No Study Results Posted","null","March 2003","Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)|Time to progression|Overall survival","https://ClinicalTrials.gov/show/NCT00035087"
1183,"NCT00060411","A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer","Completed","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: erlotinib hydrochloride|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Biological: bevacizumab","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","24","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03157|NCI-5869|JHOC-J0220|JHOC-02072506|J0220 02-07-25-06|5869|U01CA070095","May 6, 2003","June 2003","null","September 27, 2013","September 2013","No Study Results Posted","null","July 2007","Maximum tolerated dose (MTD) of OSI-774 given in combination with FOLFOX 4 and Bevacizumab, in patients with advanced colorectal cancer|Toxicity profile of this regimen evaluated using the NCI Common Toxicity Criteria Version 2.0|Antitumor activity of this combination determined using the RECIST criteria|Overall survival|Progression-free survival|The relationship between CYP3A4 activity and OSI-774 clearance|Pharmacokinetics of OSI-774 given with FOLFOX 4, and Bevacizumab","https://ClinicalTrials.gov/show/NCT00060411"
1184,"NCT02210364","Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).","Active, not recruiting","No Results Available","Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).","Drug: lurbinectedin (PM01183)|Drug: capecitabine","PharmaMar","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","40","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PM1183-A-006-12","August 5, 2014","April 2013","null","May 12, 2016","May 2016","No Study Results Posted","null","June 2016","Recommended dose of PM01183 in combination with capecitabine","https://ClinicalTrials.gov/show/NCT02210364"
1185,"NCT02564835","Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Other: Yoga|Other: Physical Activity","University of Michigan|Oncology Nursing Society Foundation","Both","21 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","HUM00096913","September 23, 2015","September 2015","December 2016","September 29, 2015","September 2015","No Study Results Posted","null","December 2016","Program Evaluation|Attention Network Test|Digit Span|Digit Symbol Substitution Test|Trail Making Test|Attentional Function Index|Functional Assessment of Cancer Therapy - Cognitive Function|Pro-inflammatory Markers","https://ClinicalTrials.gov/show/NCT02564835"
1186,"NCT00079066","Cetuximab and Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Quality of Life","Biological: cetuximab|Procedure: quality-of-life assessment","NCIC Clinical Trials Group|Australasian Gastro-Intestinal Trials Group|Canadian Cancer Trials Group","Both","16 Years and older   (Child, Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CO17|CAN-NCIC-CO17|AGITG-CAN-NCIC-CO17|BMS-CA225-025|IMCL-CAN-NCIC-CO17|CDR0000353486","March 8, 2004","August 2003","February 2009","October 31, 2013","March 2010","No Study Results Posted","null","March 2006","Overall survival|Time to progression|Objective response rate|Quality of life by European Organization for Research of the Treatment of Cancer Quality of Life Questionnaire -C30 (EORTC QLQ-C30)|Health utilities by Health Utilities Index 13 (HU 13)|Economic evaluation|Safety profile","https://ClinicalTrials.gov/show/NCT00079066"
1187,"NCT00234429","A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma","Completed","No Results Available","Colorectal Cancer","Drug: Gefitinib, raltitrexed","AstraZeneca","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","74","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment","1839IL/0143","October 5, 2005","November 2003","June 2006","December 14, 2007","December 2007","No Study Results Posted","null","null","Determine the progression free survival|Determine objective tumor response","https://ClinicalTrials.gov/show/NCT00234429"
1188,"NCT00040391","A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Neoplasms|Diarrhea","Drug: Investigational drug|Drug: Irinotecan|Drug: 5-fluorouracil|Drug: Leucovorin","Celgene Corporation|Pfizer|Celgene","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","440E-ONC-0020-315","June 26, 2002","null","null","March 13, 2007","March 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00040391"
1189,"NCT02077868","Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment","Recruiting","No Results Available","Metastatic Colorectal Cancer","Other: Usual Maintenance|Drug: MGN1703 treatment","Mologen AG","Both","18 Years and older   (Adult, Senior)","Phase 3","540","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MGN1703-C06","February 28, 2014","September 2014","June 2019","October 5, 2015","October 2015","No Study Results Posted","IMPALA","October 2017","Overall survival|Progression Free Survival (PFS)|Safety|Overall Response rate|Quality of life (QoL)","https://ClinicalTrials.gov/show/NCT02077868"
1190,"NCT02746432","Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial","Recruiting","No Results Available","Colon Cancer","Drug: Hyper insulinemic euglycemic clamp","King Saud University","Both","18 Years and older   (Adult, Senior)","Phase 4","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","KSULDRCCRCMH001","April 6, 2016","March 2016","March 2021","April 21, 2016","April 2016","No Study Results Posted","null","March 2021","The anti-inflammatory effects of intraoperative hyper-insulinimic euglycemic therapy in patients undergoing colorectal cancer surgery.|The immunomodulatory effect of intraoperative hyper-insulinimic euglycemic infusion.","https://ClinicalTrials.gov/show/NCT02746432"
1191,"NCT00113776","Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: ABX-EGF","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20030194","June 10, 2005","null","null","January 20, 2011","January 2011","No Study Results Posted","null","null","Incidence of Adverse events|Changes in Lab values|Incidence of HAHA formation","https://ClinicalTrials.gov/show/NCT00113776"
1192,"NCT01708824","Diet and Physical Activity Intervention in CRC Survivors","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Dietary|Behavioral: Physical activity","The University of Hong Kong|World Cancer Research Fund International","Both","18 Years and older   (Adult, Senior)","Phase 2","224","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","WCRF 2012/595","October 11, 2012","April 2013","June 2017","May 11, 2016","May 2016","No Study Results Posted","null","December 2016","Whether the PA and dietary intake targets are met at the end of intervention;|Magnitude of change in PA level using objective accelerometry|Magnitude of change in each component of dietary target using validated food frequency questionnaire (FFQ);|Rate and determinants of compliance with intervention;|Facilitators and barriers to intervention|Measurement of theoretical constructs underlying PA and dietary interventions|Other possible health benefits arising from the intervention|Possible side effects arising from the intervention","https://ClinicalTrials.gov/show/NCT01708824"
1193,"NCT02706184","E. Coli Nissle in Oncology","Recruiting","No Results Available","Gastric Cancer|Colorectal Cancer","Drug: E. coli Nissle suspension|Drug: Placebo","University of Hohenheim|Ardeypharm GmbH","Both","18 Years and older   (Adult, Senior)","Phase 3","80","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ZKES-EcNO-2015","February 23, 2016","July 2015","June 2017","March 15, 2016","March 2016","No Study Results Posted","EcNO","June 2017","Common toxicity criteria for diarrhea Version 4.0|Quality of life by SF-12 questionnaire|Quality of life by FACIT-D questionnaire|stool consistency by Bristol stool scale|Body mass index in kg/m^2|Phase angle|C-reactive protein|Hematocrit|alpha-1-Antitrypsin|Calprotectin|Body cell mass in kg|ECM/BCM-Index","https://ClinicalTrials.gov/show/NCT02706184"
1194,"NCT01346917","Effect of Intravenous Lidocaine on the Tolerability of Early Oral Feeding After Laparoscopic Colorectal Surgery","Completed","No Results Available","Colorectal Cancer","Drug: Lidocaine|Drug: Normal saline","Kangbuk Samsung Hospital","Both","18 Years and older   (Adult, Senior)","","77","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","KHO10-1","April 29, 2011","April 2011","June 2012","October 15, 2012","October 2012","No Study Results Posted","null","June 2012","Prevalence of postoperative nausea and vomiting.|Time to first flatus.|Time to first passage of stool.|Degree of postoperative pain.|Postoperative opioid consumption.|Time to tolerance of regular diet|Postoperative complications|Duration of postoperative hospital stay.","https://ClinicalTrials.gov/show/NCT01346917"
1195,"NCT01741363","Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing","Recruiting","No Results Available","Colorectal Cancer|Stomach Disease","Other: FIT(Eiken OC-Sensor) Two-day sampling|Other: FIT(Eiken OC-Sensor) One-year interval|Other: FIT(Eiken OC-Sensor) One-day sampling|Other: FIT(Eiken OC-Sensor) Two-year interval|Other: HpSA (Firstep Helicobacter pylori Antigen Rapid Test)","National Taiwan University Hospital","Both","50 Years to 75 Years   (Adult, Senior)","","40000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","201205030RIB","October 5, 2012","July 2012","December 2017","October 23, 2015","October 2015","No Study Results Posted","null","December 2017","Detection rate for advanced adenoma and cancer|Detection rate of upper gastrointestinal tract diseases|Participation rate for the FIT and/or HpSA|Detection rates for non-advanced adenoma|Confirmatory examination referral rate|Mortality rate from colorectal cancer|Incidence of colorectal cancer|Incidence of stomach cancer|Mortality rate from stomach cancer|Helicobacter pylori eradication rate","https://ClinicalTrials.gov/show/NCT01741363"
1196,"NCT01926769","A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer","Recruiting","No Results Available","Previously Treated Advanced Colorectal Cancer","Drug: Metformin","Gachon University Gil Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-GIRBA-2675","August 19, 2013","February 2012","null","August 19, 2013","August 2013","No Study Results Posted","null","January 2015","Disease Control Rate|Response Rate|Overall Survival|Number of participants with adverse events|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01926769"
1197,"NCT00291486","Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: Capecitabine|Drug: 131I-huA33 (131-Iodine on humanised monoclonal antibody A33)","Ludwig Institute for Cancer Research","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LUD2002-017|NIH grant R21-CA108145-01A1","February 10, 2006","October 2003","December 2008","March 2, 2009","March 2009","No Study Results Posted","null","December 2008","- Safety and tolerability of 131I-huA33 combined with capecitabine (NCI-CTCAE)|Pharmacokinetics of 131I-huA33 when combined with capecitabine, measured by blood sample analysis (gamma scintillation);|Biodistribution of 131I-huA33 when combined with capecitabine measured by gamma camera planar and SPECT image analysis;|Immune response (HAHA) to 131I-huA33 when combined with capecitabine, measured by blood sample analysis.|Tumour response (RECIST) to 131I-huA33 when combined with capecitabine, measured with radiological imaging (scans)","https://ClinicalTrials.gov/show/NCT00291486"
1198,"NCT00469443","Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC","Completed","No Results Available","Colorectal Cancer","Drug: Irinotecan|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Capecitabine|Drug: Bevacizumab|Drug: Bevacizumab|Drug: Irinotecan","Hellenic Oncology Research Group|University Hospital of Crete","Both","18 Years to 72 Years   (Adult, Senior)","Phase 3","330","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/05.16","May 3, 2007","December 2006","February 2010","August 18, 2010","August 2010","No Study Results Posted","null","February 2010","Time To Progression|Objective Response Rate|Overall Survival|Toxicity profile|Quality of life|Symptoms improvement","https://ClinicalTrials.gov/show/NCT00469443"
1199,"NCT00212589","Patients Preference for Oral or i.v. Therapy","Completed","No Results Available","Colorectal Cancer","Drug: Capecitabine|Drug: Fluorouracil + folinic acid","Odense University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double-Blind|Primary Purpose: Treatment","11.02","September 13, 2005","December 2002","April 2004","September 13, 2005","May 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00212589"
1200,"NCT00022477","BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: BMS-247550","University of Chicago|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","24","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11003B|UCCRC-11003B|NCI-3670","August 10, 2001","September 2001","December 2004","September 4, 2013","September 2013","No Study Results Posted","null","October 2002","Response rate of BMS-247550 in colon cancer","https://ClinicalTrials.gov/show/NCT00022477"
1201,"NCT02575378","Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Metronimic chemotherapy plus Chinese Traditional Medicine|Drug: Metronimic chemotherapy","Ruijin Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","159","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ZHYY-ZYYZX-rjzl","October 10, 2015","September 2015","December 2018","October 13, 2015","October 2015","No Study Results Posted","null","June 2018","Progression-free survival","https://ClinicalTrials.gov/show/NCT02575378"
1202,"NCT00846313","Can Malnutrition be Prevented in Patient With Colorectal Cancer Stage Dukes D?","Withdrawn","No Results Available","Colorectal Neoplasm","Other: Individual dietary counseling.","Norwegian University of Science and Technology|St. Olavs Hospital","Both","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2002.127|10641|03/05111","February 16, 2009","December 2003","February 2009","April 7, 2015","April 2015","No Study Results Posted","ColErn","February 2009","Body weight|Body composition|Quality of life|Oncologic treatment|Dietary intake","https://ClinicalTrials.gov/show/NCT00846313"
1203,"NCT00904839","BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Neoplasms","Drug: BIBF 1120|Drug: BIBF 1120|Drug: mFolfox|Drug: Bevacizumab|Drug: mFolfox 6|Drug: bevacizumab","Boehringer Ingelheim","Both","18 Years and older   (Adult, Senior)","Phase 2","128","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1199.51|2008-005364-14","May 18, 2009","May 2009","January 2012","February 3, 2015","February 2015","November 14, 2014","null","January 2012","Progression-free Survival Rate at 9 Months (PFS-9)|Overall Survival|Progression-free Survival (PFS)|Confirmed Objective Response Rate|Unconfirmed Objective Response Rate|Resection Rate|Tumor Shrinkage|Incidence and Intensity of Adverse Events With Grading According CTCAE|Percentage of Patients With Dose Limit Toxicity (DLTs) Incidence During the First Two Treatment Cycles (Phase I).|Maximum Tolerable Dose (MTD)|Area Under the Plasma Concentration Time-curve Over 12 Hours for Nintedanib in the Dosing Interval at Steady State and Normalized by the Dosing Unit Administered (AUCtau,ss,Norm) (Phase I)|Maximum Plasma Concentration for Nintedanib at Steady State and Normalized by the Dosing Unit Administered (Cmax,ss,Norm) (Phase I)|Quality of Life Evaluation by a Standardised Questionnaires of EORTC: EORTC-QLQ-C30 for the Change From Baseline at 9 Months of Global Health Status Scores.|Quality of Life Evaluation by a Standardised Questionnaires of EORTC: EORTC-QLQ-CR38 for the Change From Baseline at 9 Months.|Number of Participants for Quality of Life Evaluation by a Standardised Questionnaires of EORTC: EORTC-QLQ-CR38 for the First Use of Stoma Bag.|Exploratory Biomarker and Pharmacogenetic Analysis for VEGF","https://ClinicalTrials.gov/show/NCT00904839"
1204,"NCT00006046","Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: monoclonal antibody Hu3S193","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068062|MSKCC-00005|NCI-G00-1820","July 5, 2000","January 2000","null","February 6, 2009","March 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006046"
1205,"NCT02860546","A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC","Recruiting","No Results Available","Refractory Metastatic Colorectal Cancer","Drug: TAS-102|Drug: nivolumab","Taiho Oncology, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","35","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TAS-102-203","July 13, 2016","August 2016","March 2018","September 9, 2016","September 2016","No Study Results Posted","null","September 2017","Immune-related overall response rate (irORR)|Recommended Phase 2 dose for the combination therapy of TAS 102 and nivolumab|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Overall Response Rate (ORR)|Progression Free Survival (PFS) based on irRC|Progression Free Survival (PFS) based on RECIST|Disease Control Rate (DCR) based on irRC|Disease Control Rate (DCR) based on RECIST|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02860546"
1206,"NCT01631539","Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC","Withdrawn","No Results Available","Liver Metastases|Colorectal Cancer","Device: DC Bead™|Drug: Cetuximab|Drug: 5 FU|Drug: Irinotecan","Universitaire Ziekenhuizen Leuven|Biocompatibles UK Ltd","Both","18 Years and older   (Adult, Senior)","","0","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-018384-42","September 14, 2011","September 2012","December 2014","December 3, 2014","December 2014","No Study Results Posted","null","December 2014","Feasibility of chemoembolization with DC Bead loaded with Irinotecan|progression-free survival","https://ClinicalTrials.gov/show/NCT01631539"
1207,"NCT00003360","Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Radiation: iodine I 131 monoclonal antibody A33","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Other|NIH","Interventional","Primary Purpose: Treatment","98-011|MSKCC-98011|NCI-H98-0017","November 1, 1999","April 1998","null","January 15, 2013","January 2013","No Study Results Posted","null","August 2000","","https://ClinicalTrials.gov/show/NCT00003360"
1208,"NCT00020930","Cetuximab in Treating Patients With Stage IV Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: cetuximab","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068731|MSKCC-01034|IMCL-CP02-0141|NCI-G01-1970","July 11, 2001","March 2001","null","December 3, 2009","December 2009","No Study Results Posted","null","August 2002","","https://ClinicalTrials.gov/show/NCT00020930"
1209,"NCT00021268","Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: tocladesine","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","ICN-2000-1|UCLA-0006008|CDR0000068764|NCI-G01-1979","July 11, 2001","April 2001","null","August 1, 2013","October 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00021268"
1210,"NCT00019760","Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver","Completed","No Results Available","Recurrent Colon Cancer|Liver Metastases|Stage IV Rectal Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer","Drug: floxuridine|Drug: leucovorin calcium|Drug: melphalan","National Institutes of Health Clinical Center (CC)","null","Child, Adult, Senior","Phase 2","null","NIH","Interventional","Primary Purpose: Treatment","990093|99-C-0093|CDR0000067199","March 2, 2007","April 1999","March 2002","March 21, 2012","March 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00019760"
1211,"NCT00017082","Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: oxaliplatin","Prologue Research International|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","PROLOGUE-EFC4759|CDR0000068647|SANOFI-EFC4759","June 6, 2001","April 2001","December 2010","June 25, 2013","December 2010","No Study Results Posted","null","June 2003","","https://ClinicalTrials.gov/show/NCT00017082"
1212,"NCT01574027","Efficacy of Vitamin D in Colorectal Cancer Chemoprevention","Completed","No Results Available","Colorectal Cancer","Drug: Vitamin D3 (cholecalciferol)|Drug: Placebo","University of Illinois at Chicago","Both","50 Years and older   (Adult, Senior)","Phase 2","55","Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","R01CA122299","March 30, 2012","April 2008","October 2011","April 5, 2012","April 2012","No Study Results Posted","null","October 2011","Reduction in ACF biomarkers","https://ClinicalTrials.gov/show/NCT01574027"
1213,"NCT01697462","An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)","Completed","Has Results","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","258","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML22585","September 28, 2012","July 2009","December 2012","December 16, 2015","November 2015","December 16, 2015","null","December 2012","Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Disease Progression|Progression-Free Survival (PFS)|Number of Participants With Hand-Foot Syndrome (HFS)","https://ClinicalTrials.gov/show/NCT01697462"
1214,"NCT00475293","Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab and CPT-11","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","85","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-06-04","May 17, 2007","May 2007","March 2010","September 12, 2013","February 2013","No Study Results Posted","null","March 2010","objective response rate|disease control rate, duration of response, time to response, progression-free survival, time to progression,time to treatment failure,duration of stable disease|adverse events","https://ClinicalTrials.gov/show/NCT00475293"
1215,"NCT00039273","Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: panitumumab","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","44","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069368|UCLA-0112063|IMMUNEX-054-0005|NCI-G02-2073","June 6, 2002","July 2002","null","January 7, 2013","January 2013","No Study Results Posted","null","May 2003","","https://ClinicalTrials.gov/show/NCT00039273"
1216,"NCT01157052","Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients","Not yet recruiting","No Results Available","Neoplasms, Colorectal|Colorectal Cancer|Colorectal Carcinoma","Other: (supplement) Calcium and Magnesium","AHS Cancer Control Alberta","Both","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","25408","July 2, 2010","January 2015","September 2015","September 29, 2014","September 2014","No Study Results Posted","null","September 2015","The primary objective of this study is to determine potential pharmacokinetic interactions between oxaliplatin and calcium and magnesium.","https://ClinicalTrials.gov/show/NCT01157052"
1217,"NCT01325909","Exercise Training in Colorectal Cancer Patients","Completed","No Results Available","Rectal Cancer","Behavioral: Exercise programme","Michelle Mossa|University Hospital Southampton NHS Foundation Trust.|Aintree University Hospitals NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","35","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","11/H1002/12","March 29, 2011","March 2011","April 2014","April 4, 2014","April 2014","No Study Results Posted","null","April 2014","Maintain or improve physical fitness (anaerobic threshold measured by CPET)after treatment with neoadjuvant chemoradiotherapy in colorectal cancer patients.|Other measures of physical fitness measured in CPET or the VO2 kinetics test|Adherence to a 6 week interval exercise intervention.|Optimal time for surgery indicating optimal oncological and physiological fitness|Health related quality of life improvement as measured by SF36, EORCT c30 v3|Outcome from major surgery measured by 5 day POMS|Activity levels before during and after neoadjuvant chemoradiotherapy","https://ClinicalTrials.gov/show/NCT01325909"
1218,"NCT00016978","Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan","Completed","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","40","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01859|NCCTG-N9946|CDR0000068638","June 6, 2001","April 2001","null","February 4, 2013","August 2007","No Study Results Posted","null","June 2007","","https://ClinicalTrials.gov/show/NCT00016978"
1219,"NCT01329809","Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors","Terminated","No Results Available","Colorectal Carcinoma","Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)","Jennerex Biotherapeutics","Both","18 Years and older   (Adult, Senior)","Phase 2","2","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JX594-HEP012","April 4, 2011","October 2011","March 2013","April 9, 2013","July 2011","No Study Results Posted","null","January 2012","Delivery to and replication within tumors|JX-594 spread to, and replication within, non-injected tumors after IT JX-594 injection|Modified Choi response assessment|Toxicity: Grade I-IV Adverse Events (according to CTCAE)","https://ClinicalTrials.gov/show/NCT01329809"
1220,"NCT02557490","Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases","Recruiting","No Results Available","Colon Cancer Liver Metastasis","Drug: oxaliplatin and raltitrexed","Zhu Xu|Beijing Cancer Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 4","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014YJZ16","September 22, 2015","January 2015","December 2017","September 22, 2015","July 2015","No Study Results Posted","null","December 2016","Progression-free survival (PFS)|overall survival (OS)","https://ClinicalTrials.gov/show/NCT02557490"
1221,"NCT02175095","[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib","Recruiting","No Results Available","Colorectal Cancer","Drug: Regorafenib","Asan Medical Center","Both","20 Years and older   (Adult, Senior)","","68","Other","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","FLT-PET-regorafenib","June 23, 2014","July 2014","April 2017","January 12, 2016","January 2016","No Study Results Posted","null","April 2016","[18F]FLT-PET SUV_MAX|Response evaluation by RECIST 1.1","https://ClinicalTrials.gov/show/NCT02175095"
1222,"NCT02198274","Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: BIBH 1","Boehringer Ingelheim","Both","18 Years and older   (Adult, Senior)","Phase 2","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1152.10","July 22, 2014","February 2000","null","July 22, 2014","July 2014","No Study Results Posted","null","October 2000","Anti-tumour response|Time to tumour progression|Time to loss of response|Disease progression-free survival time|Changes in titers of human anti-human antibody (HAHA)|Incidence and intensity of adverse events graded by Common toxicity criteria (CTC)|Assessment of the maximum toxicity grade observed for each patient|Frequency of on-study deaths|Maximum drug concentration (Cmax)|Minimum drug concentration (Cmin)|Area under the concentration-time curve (AUC)|Total serum clearance (CL)|Volume of distribution at steady state (Vss)|Terminal half-life (t1/2)|Mean residence time (MRT)","https://ClinicalTrials.gov/show/NCT02198274"
1223,"NCT01750918","BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)","Active, not recruiting","No Results Available","Cancer","Drug: Dabrafenib|Drug: Trametinib|Drug: Panitumumab|Drug: 5-fluorouracil","GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 2","170","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","116833","December 6, 2012","December 2012","March 2018","August 25, 2016","August 2016","No Study Results Posted","null","March 2018","Part 1, Part 2, Part 4A and Part 4B: Composite safety parameters including adverse events and changes in laboratory values, vital signs and dose interruptions, modifications and discontinuations|Part 2 and Part 4B: Response rate (Complete Response [CR] + Partial Response [PR]) in subjects in the dosing groups|Part 3: Progression -free survival (PFS)|Part 1: Plasma pharmacokinetics (PK) profile of dabrafenib, trametinib and panitumumab in combination dosing|Part 1: Response rate (CR +PR) of dabrafenib dosed orally in combination with panitumumab|Part 1 and Part 2: Progression free survival of subjects treated with dabrafenib dosed orally in combination with panitumumab|Part 1 and Part 2: Duration of response of dabrafenib dosed orally in combination with panitumumab|Part 1: Response rate (CR +PR) of trametinib dosed orally in combination with dabrafenib and panitumumab|Part 1 and Part 2: Progression free survival subjects treated with trametinib dosed orally in combination with dabrafenib and panitumumab|Part 1 and Part 2: Duration of response of trametinib dosed orally in combination with dabrafenib and panitumumab|Part 1, Part 2, Part 4A and Part 4B: Change in levels of proteins/ Ribonucleic acid (RNA) in pre- and post-dose tumor tissue|Part 2: Plasma pharmacokinetics profile of of dabrafenib and trametinib dosed orally in combination with anti-EGFR antibody (panitumumab)|Part 2: Overall survival (OS) of subjects treated with dabrafenib dosed orally in combination with panitumumab|Part 2: OS of subjects treated with trametinib dosed orally in combination with dabrafenib and panitumumab|Part 3: Response rate (CR +PR) of dabrafenib/ panitumumab or trametinib/ dabrafenib/panitumumab combinations as compared to standard of care therapy|Part 3: Duration of response to dabrafenib/ panitumumab or trametinib/ dabrafenib/panitumumab combinations as compared to standard of care therapy|Part 3: OS of subjects treated with dabrafenib/ panitumumab or trametinib/ dabrafenib/panitumumab combinations as compared to standard of care therapy|Part 3: To evaluate and compare the PFS of the trametinib/dabrafenib/panitumumab combination as compared to the dabrafenib/panitumumab combination|Part 3: Composite safety parameters including adverse events and changes in laboratory values, vital signs and dose interruptions, modifications and discontinuations|Part 4A: Plasma pharmacokinetics profile of trametinib and panitumumab after combination therapy|Part 4A: Response rate (CR +PR) of panitumumab/trametinib combination therapy in patient populations|Part 4A and Part 4B: Progression free survival of panitumumab/trametinib combination therapy in patient populations|Part 4A and Part 4B: Duration of response of panitumumab/trametinib combination therapy in patient populations|Part 4B Plasma pharmacokinetics profile of trametinib dosed orally in combination with anti-EGFR antibody (panitumumab)|Part 4B Overall survival of response with trametinib dosed in combination with panitumumab","https://ClinicalTrials.gov/show/NCT01750918"
1224,"NCT00002828","Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: raltitrexed","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other","Interventional","Primary Purpose: Treatment","95-021|CDR0000065019|ZENECA-MSKCC-95021A4|NCI-V96-0987","November 1, 1999","April 1995","November 2001","June 20, 2013","June 2013","No Study Results Posted","null","November 2001","","https://ClinicalTrials.gov/show/NCT00002828"
1225,"NCT00164944","Screening for Colorectal Neoplasm in First Degree Relatives of the Affected","Recruiting","No Results Available","Colorectal Cancer Screening","Procedure: Colonoscopy|Procedure: Colonoscopy","Chinese University of Hong Kong","Both","40 Years to 70 Years   (Adult, Senior)","","1000","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","FDR","September 9, 2005","April 2004","June 2017","March 7, 2016","March 2016","No Study Results Posted","null","December 2016","To find the prevalence of adenomas and advanced neoplasms of the first degree relatives","https://ClinicalTrials.gov/show/NCT00164944"
1226,"NCT01661764","Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention","Active, not recruiting","No Results Available","Colorectal Adenomatous Polyps","Drug: Eicosapentanoic acid and docosahexanoic acid|Drug: Oleic Acid","Vanderbilt University|National Cancer Institute (NCI)","Both","40 Years to 79 Years   (Adult, Senior)","Phase 2","142","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","11165|R01CA160938","August 7, 2012","September 2012","December 2016","December 7, 2015","December 2015","No Study Results Posted","null","December 2016","rectal epithelial cell proliferation|rectal epithelial cell apoptosis|Rectal epithelial cell COX-2 expression|Rectal epithelial cell 15-PGDH expression|Rectal epithelial cell phospholipid fatty acid content|Rectal epithelial cell production of PGE2 and PGE3","https://ClinicalTrials.gov/show/NCT01661764"
1227,"NCT00339183","Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: FOLFIRI","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 3","1186","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20050181","June 16, 2006","June 2006","November 2010","February 19, 2016","February 2016","April 3, 2014","null","April 2009","Progression-free Survival (PFS)|Overall Survival|Percentage of Participants With an Objective Response|Time to Disease Progression|Duration of Response|Number of Participants With Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT00339183"
1228,"NCT01567917","Incidence of Venous Thromboembolism Following Surgery in Patients With Colorectal Cancer","Recruiting","No Results Available","Symptomatic Venous Thromboembolism|Asymptomatic Venous Thromboembolism","Procedure: CRC surgery","Seoul National University Bundang Hospital","Both","20 Years and older   (Adult, Senior)","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CRC-SNUBH-2012-01","March 28, 2012","June 2011","December 2013","March 29, 2012","March 2012","No Study Results Posted","null","June 2013","The incidence of symptomatic or asymptomatic VTE|Risk factors for the development of VTE","https://ClinicalTrials.gov/show/NCT01567917"
1229,"NCT00197873","Lactobacillus Rhamnosus in Prevention of Chemotherapy-related Diarrhoea","Active, not recruiting","No Results Available","Colorectal Cancer","Dietary Supplement: Lactobacillus Rhamnosus supplementation|Other: Placebo administration.","Helsinki University|Helsinki University Central Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","84","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ML18581","September 12, 2005","September 2005","October 2016","March 4, 2016","March 2016","No Study Results Posted","null","May 2016","Effect on the treatment-related grade 2 to 4 diarrhoea|Effect on treatment related toxicity other than diarrhea|Association between supplementation and response|Effect on resectability of liver metastases|Effect on serum growth factor levels","https://ClinicalTrials.gov/show/NCT00197873"
1230,"NCT00004102","Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","New York University School of Medicine|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067321|P30CA016087|NYU-9863|SANOFI-EFC7132|NCI-G99-1593","December 10, 1999","January 1999","null","March 25, 2011","March 2011","No Study Results Posted","null","November 2001","","https://ClinicalTrials.gov/show/NCT00004102"
1231,"NCT02577588","Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Carcinoma","Biological: re-activated T cells","National Center for Tumor Diseases, Heidelberg|German Cancer Research Center|University Hospital Heidelberg","Both","18 Years and older   (Adult, Senior)","Phase 1","10","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCT-2009-11-03-1055","May 6, 2015","May 2016","March 2018","June 15, 2016","March 2016","No Study Results Posted","ATACC","December 2017","Safety|evaluation of p53 specific T cell Responses by analysing data from EliSpot assay","https://ClinicalTrials.gov/show/NCT02577588"
1232,"NCT00016250","Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: MKC-1","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","00-139|CDR0000068613|ROCHE-16113|ROCHE-RO31-7453|NCI-G01-1945","May 6, 2001","December 2000","June 2002","June 17, 2013","June 2013","No Study Results Posted","null","June 2002","","https://ClinicalTrials.gov/show/NCT00016250"
1233,"NCT02870153","SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasm","Drug: SOX|Drug: XELOX","The First People's Hospital of Changzhou","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CZYY-CRC-007","August 12, 2016","January 2013","June 2019","August 17, 2016","August 2016","No Study Results Posted","null","January 2019","Response Rate|Side-effect|Time to Progression|Overall Survival","https://ClinicalTrials.gov/show/NCT02870153"
1234,"NCT00049101","Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: erlotinib hydrochloride|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000257808|MSKCC-02039|NCI-5371","November 12, 2002","August 2002","August 2004","June 21, 2013","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00049101"
1235,"NCT00582452","Attitudes Towards Prophylactic Colectomy in Hereditary Non-polyposis Colorectal Cancer (HNPCC) Patients","Completed","No Results Available","Colorectal Cancer","Other: Telephone survey","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","16","Other|NIH","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","04-127|NCI CA101511|CA109236","December 21, 2007","November 2004","December 2009","December 9, 2009","December 2009","No Study Results Posted","null","December 2009","To assess levels of intention in prophylactic colectomy among individuals at increased familial risk of colorectal cancer and to identify distinctive decision types based on profiles of perceived pros and cons of prophylactic colectomy;","https://ClinicalTrials.gov/show/NCT00582452"
1236,"NCT00003543","Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: monoclonal antibody A33|Drug: carmustine|Drug: fluorouracil|Drug: streptozocin|Drug: vincristine sulfate","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","18","Other|NIH","Interventional","Primary Purpose: Treatment","98-056|CDR0000066597|NCI-H98-0022","November 1, 1999","June 1998","August 2002","June 25, 2013","June 2013","No Study Results Posted","null","August 2002","","https://ClinicalTrials.gov/show/NCT00003543"
1237,"NCT00532909","Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer","Completed","No Results Available","Anal, Colon, and Rectal Cancers|Colorectal Neoplasms|Colon/Rectal Cancer","Drug: Vandetanib|Drug: Capecitabine|Drug: Oxaliplatin|Drug: Bevacizumab","Branimir Sikic|AstraZeneca|Stanford University","Both","18 Years and older   (Adult, Senior)","Phase 1","13","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COR0006|97132","September 20, 2007","July 2006","May 2010","July 12, 2012","July 2012","No Study Results Posted","null","May 2010","Maximum tolerated dose of vandetanib in combination with capecitabine, oxaliplatin and bevacizumab|Effect of vandetanib on the pharmacokinetics (PK) of capecitabine and oxaliplatin|Effects of this treatment on tumor remission, progression free survival, and overall survival of patients|Dose limiting toxicities associated with the combination","https://ClinicalTrials.gov/show/NCT00532909"
1238,"NCT00005030","SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver","Withdrawn","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: SCH 66336|Procedure: conventional surgery","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067553|MDA-ID-99229|SPRI-C98-546|NCI-G00-1713|ID99-229","April 6, 2000","June 2000","September 2000","October 5, 2012","October 2012","No Study Results Posted","null","September 2000","","https://ClinicalTrials.gov/show/NCT00005030"
1239,"NCT00003001","Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium","Stony Brook University|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 1|Phase 2","63","Other","Interventional","Primary Purpose: Treatment","CDR0000065561|SUNY-HSC-97-2824|NCI-V97-1256","November 1, 1999","April 1997","null","July 23, 2008","April 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003001"
1240,"NCT00016952","Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","19","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N0048|NCI-2012-02383|CDR0000068635","June 6, 2001","April 2001","October 2009","August 12, 2016","August 2016","No Study Results Posted","null","October 2009","tumor response rate|time to tumor progression|time to treatment failure|overall survival|quality of life","https://ClinicalTrials.gov/show/NCT00016952"
1241,"NCT00068068","Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases","Completed","No Results Available","Liver Metastasis|Colorectal Neoplasms|Liver Neoplasms|Neoplasm Metastasis","Drug: Talaporfin sodium (LS11)|Device: LED-based light infusion device|Device: Light emitting diodes (LED)|Procedure: Photodynamic therapy|Procedure: Phototherapy|Procedure: Chemotherapy","Light Sciences LLC","Both","18 Years and older   (Adult, Senior)","Phase 2","25","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LSC-OL002","September 4, 2003","October 2003","null","September 18, 2006","September 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00068068"
1242,"NCT00077259","Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: epothilone D","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","03-113|MSKCC-03113|ROCHE-NO17320","February 10, 2004","October 2003","null","January 15, 2013","January 2013","No Study Results Posted","null","September 2004","","https://ClinicalTrials.gov/show/NCT00077259"
1243,"NCT00077987","Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.","Completed","No Results Available","Colorectal Neoplasms","Drug: SU011248","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","84","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181003","February 13, 2004","December 2003","April 2005","January 9, 2007","October 2005","No Study Results Posted","null","null","Anti-tumor efficacy|Tumor control survival safety","https://ClinicalTrials.gov/show/NCT00077987"
1244,"NCT00016042","Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Kidney Cancer","Biological: lymphokine-activated killer cells|Biological: recombinant interferon alfa|Biological: sargramostim|Drug: fluorouracil","St. Luke's Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068588|STLMC-IMM-0001|NCI-V01-1656","May 6, 2001","January 2001","null","September 19, 2013","October 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00016042"
1245,"NCT01506167","An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)","Active, not recruiting","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","719","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML27971","January 5, 2012","July 2012","October 2016","September 1, 2016","September 2016","No Study Results Posted","null","October 2016","Safety (incidence of serious adverse events)|Safety (incidence of Grade3-5 Avastin related events)|Progression-free survival|Duration of survival|Safety (incidence of Avastin related adverse of special interest)|Type of treatment regimen|Reason for treatment discontinuation|Difference of patient demographics in this trial and in other studies|Treatment compliance|Treatment regimen for metastatic colorectal cancer after 1st line treatment with chemotherapy and Avastin|Quality of Life questionnaire (EQ-5D 5L)|Burden of Illness questionnaire","https://ClinicalTrials.gov/show/NCT01506167"
1246,"NCT01479608","Liver Transplantation and Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Liver Metastasis","Procedure: Liver transplantation and liver resection","Oslo University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","25","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SECA-II","November 22, 2011","November 2011","December 2027","April 6, 2016","March 2016","No Study Results Posted","null","December 2025","Overall survival","https://ClinicalTrials.gov/show/NCT01479608"
1247,"NCT00460603","Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Neoplasms","Drug: bevacizumab|Drug: AG-013726|Drug: AG-013736 (axitinib)","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","187","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A4061020","April 13, 2007","January 2006","November 2012","November 7, 2013","November 2013","March 28, 2013","null","April 2012","Percentage of Participants With Objective Response: Phase 2|Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Axitinib: Phase 1|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Axitinib: Phase 1|Maximum Observed Plasma Concentration (Cmax) For Axitinib: Phase 1|Minimum Observed Plasma Trough Concentration (Cmin) For Axitinib: Phase 1|Apparent Oral Clearance (CL/F) For Axitinib: Phase 1|Plasma Decay Half-Life (t1/2) For Axitinib: Phase 1|Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Oxaliplatin: Phase 1|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Oxaliplatin: Phase 1|Maximum Observed Plasma Concentration (Cmax) For Oxaliplatin: Phase 1|Minimum Observed Plasma Trough Concentration (Cmin) For Oxaliplatin: Phase 1|Clearance (CL) For Oxaliplatin: Phase 1|Plasma Decay Half-Life (t1/2) For Oxaliplatin: Phase 1|Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For 5-Fluorouracil: Phase 1|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For 5-Fluorouracil: Phase 1|Maximum Observed Plasma Concentration (Cmax) For 5-Fluorouracil: Phase 1|Minimum Observed Plasma Trough Concentration (Cmin) For 5-Fluorouracil: Phase 1|Clearance (CL) For 5-Fluorouracil: Phase 1|Plasma Decay Half-Life (t1/2) For 5-Fluorouracil: Phase 1|Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Irinotecan: Phase 1|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Irinotecan: Phase 1|Maximum Observed Plasma Concentration (Cmax) For Irinotecan: Phase 1|Minimum Observed Plasma Trough Concentration (Cmin) For Irinotecan: Phase 1|Clearance (CL) For Irinotecan: Phase 1|Plasma Decay Half-Life (t1/2) For Irinotecan: Phase 1|Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Bevacizumab: Phase 1|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Bevacizumab: Phase 1|Maximum Observed Plasma Concentration (Cmax) For Bevacizumab: Phase 1|Minimum Observed Plasma Trough Concentration (Cmin) For Bevacizumab: Phase 1|Clearance (CL) For Bevacizumab: Phase 1|Plasma Decay Half-Life (t1/2) For Bevacizumab: Phase 1|Duration of Response (DR): Phase 2|Progression-Free Survival (PFS): Phase 2|Time to Treatment Failure (TTF): Phase 2|Overall Survival (OS): Phase 2|Change From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2","https://ClinicalTrials.gov/show/NCT00460603"
1248,"NCT01243047","Intermittent Versus Continuous Tarceva Study","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Chemotherapy","Chinese University of Hong Kong","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","COL012","November 17, 2010","September 2007","October 2012","November 20, 2012","November 2012","No Study Results Posted","null","October 2012","To evaluate two different schedules of erlotinib in combination with a modified XELOX regimen in terms of response rate|To evaluate two different schedules of erlotinib and modified XELOX regimen in terms of toxicity, their duration of response and effect on time to progression, progression-free survival and overall survival.|To determine the effect of intermittent versus continuous erlotinib administration on pharmacodynamic endpoints using tumor biopsies","https://ClinicalTrials.gov/show/NCT01243047"
1249,"NCT01483027","Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer Metastatic","Device: TheraSphere","BTG International Inc.|Biocompatibles UK Ltd","Both","18 Years and older   (Adult, Senior)","Phase 3","340","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TS-102","November 24, 2011","January 2012","February 2019","September 15, 2016","June 2016","No Study Results Posted","EPOCH","September 2018","Progression free survival","https://ClinicalTrials.gov/show/NCT01483027"
1250,"NCT00735241","FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma","Withdrawn","No Results Available","Colorectal Carcinoma|Liver Metastases","Device: SIR-Spheres microspheres|Drug: FOLFOX6 cycles 1-3|Drug: FOLFOX6 cycles 4 onwards|Drug: Bevacizumab cycles 3 onwards","Sirtex Medical","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","0","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","STX0207","August 13, 2008","July 2008","March 2009","May 21, 2015","May 2015","No Study Results Posted","FAST","March 2009","Toxicity and safety","https://ClinicalTrials.gov/show/NCT00735241"
1251,"NCT00251186","First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients","Terminated","No Results Available","Colorectal Cancer","Drug: Capecitabine and Cetuximab","University of Medicine and Dentistry of New Jersey|Rutgers Cancer Institute of New Jersey|Bristol-Myers Squibb|Rutgers, The State University of New Jersey","Both","18 Years and older   (Adult, Senior)","Phase 2","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","5536|CINJ 070502","November 7, 2005","April 2006","April 2006","January 25, 2010","January 2010","No Study Results Posted","null","April 2006","Primary Objective|To measure the response (CR/PR) for a novel chemotherapy/biologic combination-capecitabine/cetuximab for patients with metastatic colorectal cancer who are too fragile for more intensive chemotherapy doublet regimens.|Secondary Objectives|To measure progression-free survival and document overall survival in this patient population.|To assess the toxicity of capecitabine/cetuximab|To describe the baseline quality of life and functional characteristics of elderly patients or those with multiple comorbidities enrolled in this study and assess the impact of disease and its treatment on such functional characteristics.","https://ClinicalTrials.gov/show/NCT00251186"
1252,"NCT00103142","Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer","Completed","Has Results","Colorectal Cancer|Metastatic Cancer","Biological: falimarev|Biological: inalimarev|Biological: sargramostim|Biological: therapeutic autologous dendritic cells","Michael Morse, MD|National Cancer Institute (NCI)|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 2","74","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00007616|DUMC-5883-04-6RO|CDR000041079","February 7, 2005","February 2005","March 2013","October 11, 2015","October 2015","January 16, 2014","null","June 2009","Recurrence-free Survival at 2 Years|Positive Immune Response as Measured by (Enzyme-linked Immunosorbent Spot) ELISpot Assay","https://ClinicalTrials.gov/show/NCT00103142"
1253,"NCT02149108","Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)","Completed","No Results Available","Colorectal Neoplasms","Drug: Nindetanib (BIBF 1120)|Drug: Placebo|Drug: BSC|Drug: BSC","Boehringer Ingelheim","Both","18 Years and older   (Adult, Senior)","Phase 3","768","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","1199.52|2012-000095-42","May 26, 2014","September 2014","August 2016","August 26, 2016","August 2016","No Study Results Posted","null","May 2016","Progression-free Survival (PFS) by Central Review Assessment|Overall Survival (OS) by Central Review Assessment|Objective Tumour Response (Complete Response + Partial Response) by Central Review Assessment|Disease control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment","https://ClinicalTrials.gov/show/NCT02149108"
1254,"NCT02394795","Panitumumab and RAS, DIagnostically-useful Gene Mutation for mCRC).","Recruiting","No Results Available","Colorectal Cancer","Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab","Takeda","Both","20 Years to 79 Years   (Adult, Senior)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Panitumumab-3001|U1111-1164-9167|JapicCTI-142731","March 16, 2015","May 2015","February 2020","July 27, 2016","July 2016","No Study Results Posted","PARADIGM","February 2020","Overall survival (OS)|Progression-Free Survival (PFS)|Percentage of Participants who Achieve or Maintain Any Best Response Category during the Treatment Period.|Duration of response (DOR)|Percentage of participants treated with surgical resection after chemotherapy|Percentage of participants with adverse events","https://ClinicalTrials.gov/show/NCT02394795"
1255,"NCT00865527","Pilot Study of Colon Cancer Screening Tests","Terminated","No Results Available","Colorectal Cancer|Colon Cancer|Adenomatous Polyps","Other: Fecal occult blood test|Procedure: Virtual colonoscopy|Procedure: Optical colonoscopy","Hamilton Health Sciences Corporation|McMaster University","Both","50 Years to 70 Years   (Adult, Senior)","","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","CTC1.0","March 18, 2009","March 2010","September 2011","March 29, 2016","March 2016","No Study Results Posted","null","March 2011","Proportion of enrolled patients who attend for their assigned screening test|Proportion of non-responders to mailed invitations, who respond to telephone or mail reminders.|Proportion of patients requiring polypectomy after virtual colonoscopy who receive same or next day optical colonoscopy for polypectomy|Proportion of subjects who cross over to another arm of the study|Proportion of patients found to have an advanced adenoma|Proportion of patients found to have invasive colorectal carcinoma","https://ClinicalTrials.gov/show/NCT00865527"
1256,"NCT00020917","Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","01-037|CDR0000068730|IMCL-CP02-0038|NCI-G01-1969","July 11, 2001","February 2001","February 2004","June 17, 2013","June 2013","No Study Results Posted","null","February 2004","","https://ClinicalTrials.gov/show/NCT00020917"
1257,"NCT02046174","Nonrandomized, Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancers","Biological: RENCA macrobeads","The Rogosin Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RI-MB-203|1310014396","January 21, 2014","January 2014","December 2017","May 23, 2016","February 2016","No Study Results Posted","null","December 2016","Overall Survival|Change in levels of tumor markers (CEA and CA19-9)|Change in clinical status, as measured by ECOG performance status score and Global clinical assessment|Change in quality of life, as measured by the EORTC QLQ C30 Questionnaire|Tumor marker response rate|Change in quality of life, as measured by the KPS","https://ClinicalTrials.gov/show/NCT02046174"
1258,"NCT02830139","Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer","Not yet recruiting","No Results Available","Malignant Neoplasm of Colorectum","Procedure: Hyperthermic intraperitoneal chemotherapy (HIPEC)|Procedure: Radical colorectal resection|Drug: Oxaliplatin , Capecitabine|Drug: Normal saline , Paclitaxel , 5-Fu","Wuhan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WuhanU_HIPEC_colon","July 8, 2016","July 2016","July 2021","July 11, 2016","July 2016","No Study Results Posted","null","July 2021","overall survival|progression-free survival|distant metastasis rate|peritoneal metastasis rate|local recurrence rate|complication rate","https://ClinicalTrials.gov/show/NCT02830139"
1259,"NCT00884767","Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin","Recruiting","No Results Available","Chemotherapeutic Agent Toxicity|Colorectal Cancer|Neurotoxicity","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Genetic: gene expression analysis|Genetic: protein expression analysis|Genetic: proteomic profiling|Other: laboratory biomarker analysis|Other: pharmacogenomic studies","ICO Paul Papin|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","206","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000633477|CPP-NEUROTOXALI|CPP-CPP340|INCA-RECF0453|EUDRACT-2007-001287-75","April 18, 2009","September 2007","null","July 7, 2009","July 2009","No Study Results Posted","null","August 2009","Correlation of genetic profiles and peptide, protein, and neurotrophic factors with neurological toxicity","https://ClinicalTrials.gov/show/NCT00884767"
1260,"NCT00337389","Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer|Colon Cancer|Rectal Cancer","Drug: 5- Fluorouracil (5-FU)|Drug: bevacizumab (Avastin)|Drug: Leucovorin|Drug: CoFactor (ANX-510)","Mast Therapeutics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","1200","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","510-05","June 14, 2006","May 2006","null","November 15, 2007","November 2007","No Study Results Posted","null","null","Progression Free Survival|Response Rate|Overall Survival|Incidence and Severity of Adverse Events","https://ClinicalTrials.gov/show/NCT00337389"
1261,"NCT00030342","Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Kidney Cancer","Biological: recombinant interferon alfa|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: fluorouracil","St. Luke's Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Other","Interventional","Primary Purpose: Treatment","STLMC-IMM-0104|CDR0000069153|STLMC-L-01108|NCI-V01-1686","February 14, 2002","November 2001","January 2008","June 25, 2013","October 2008","No Study Results Posted","null","October 2007","Response as measured by RECIST guidelines and Kaplan-Meier method at 5 years|Survival as measured by the Kaplan-Meier method at 5 years|Safety as measured by NCI common toxicity table at study completion","https://ClinicalTrials.gov/show/NCT00030342"
1262,"NCT00449137","Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment","Completed","No Results Available","Colorectal Cancer","Drug: Arsenic trioxide|Drug: Fluorouracil|Drug: Leucovorin calcium|Other: Plasma levels of elemental arsenic|Genetic: Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis|Procedure: Tumor Biopsy (Fine-Needle Aspiration)","University of Miami Sylvester Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","13","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMIAMI-20050801|SCCC-2004162","March 15, 2007","June 2005","December 2010","July 25, 2014","August 2013","No Study Results Posted","null","February 2010","Maximum tolerated dose|Thymidylate synthase expression","https://ClinicalTrials.gov/show/NCT00449137"
1263,"NCT00001428","A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: 5-fluorouracil","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","Child, Adult, Senior","Phase 2","65","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","950067|95-C-0067","November 3, 1999","February 1995","December 2000","March 3, 2008","January 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001428"
1264,"NCT02188342","Assessing The Effectiveness of a Preoperative High Intensity Interval Training Programme In Older Colorectal Cancer Patients","Recruiting","No Results Available","Preoperative Care|Colorectal Neoplasms|Aged|Exercise","Behavioral: HIT","University of Nottingham|Derby Hospitals NHS Foundation Trust","Both","18 Years to 88 Years   (Adult, Senior)","","24","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","HITCa","July 10, 2014","November 2014","February 2017","July 11, 2016","July 2016","No Study Results Posted","HITCa","October 2016","VO2 peak|Anaerobic threshold|Muscle protein synthesis|Body composition|Feasibility|Quality of life","https://ClinicalTrials.gov/show/NCT02188342"
1265,"NCT00582829","Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients","Completed","No Results Available","Colorectal|Cancer|Screening|Intervention","Other: Generic Print Intervention|Other: Tailored Print Intervention|Other: Tailored print plus tailored phone intervention","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Fox Chase Cancer Center|Icahn School of Medicine at Mount Sinai|Lombardi Comprehensive Cancer Center|Micromass Communications, Cary, NC|University of Pennsylvania|Christiana Care Health Services|Pinnacle Health Regional Cancer Center, Harrisburg, PA|Temple University|St. Mary Regional Cancer Center, Langhorne, PA|South Jersey Regional Cancer Center, Bridgton, New Jersey|Hunterdon Cancer Center|Northeast Regional Cancer Institute|Virtua Memorial Hospital and Virtua West|Jersey Hospital|Rutgers Cancer Institute of New Jersey|Massachusetts General Hospital|Main Line Health|Roswell Park Cancer Institute|HematologyOncology|Associates of Central New York|Augusta University","Both","40 Years and older   (Adult, Senior)","Phase 0","213","Other|NIH","Observational","","03-043","December 21, 2007","June 2003","May 2008","November 6, 2008","November 2008","No Study Results Posted","null","May 2008","Phone follow-up interview. Participants will be contacted by study assistant and the survey administered.","https://ClinicalTrials.gov/show/NCT00582829"
1266,"NCT00675012","NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colon Cancer","Drug: NGR-hTNF|Drug: Oxaliplatin|Drug: capecitabine","MolMed S.p.A.","Both","18 Years and older   (Adult, Senior)","Phase 2","24","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NGR005|2007-003668-24","May 5, 2008","December 2007","May 2013","May 29, 2014","May 2014","No Study Results Posted","null","December 2010","To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.|Document the preliminary antitumor activity in terms of objective response rate (according to RECIST criteria) and progression-free survival|Evaluate the pharmacokinetic profile of NGRhTNF and to measure plasma levels of sTNF-RI and sTNF-RII","https://ClinicalTrials.gov/show/NCT00675012"
1267,"NCT01600209","Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing","Completed","No Results Available","Colorectal Neoplasms|Digestive System Diseases|Colonic Diseases|Colorectal Cancer","","Exact Sciences Corporation","Both","50 Years to 84 Years   (Adult, Senior)","","674","Industry","Observational","Observational Model: Case-Only","Exact Sciences 2011-N","May 11, 2012","October 2011","September 2012","May 12, 2015","May 2015","No Study Results Posted","null","August 2012","Sensitivity and Specificity of the Exact CRC diagnostic screening test.","https://ClinicalTrials.gov/show/NCT01600209"
1268,"NCT01584830","Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (BAY73-4506)|Drug: Placebo","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 3","204","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","15808","April 24, 2012","April 2012","January 2016","February 5, 2016","February 2016","No Study Results Posted","CONCUR","November 2013","Overall Survival (OS)|Progression-free Survival (PFS)|The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR).|Disease Control Rate (DCR)|Safety variables will be summarized using descriptive statistics based on adverse events collection","https://ClinicalTrials.gov/show/NCT01584830"
1269,"NCT01718808","Cetuximab for Elderly Patients With mCRC","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: Capecitabine","Swiss Group for Clinical Cancer Research","Both","70 Years and older   (Senior)","Phase 2","24","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 41/10","October 22, 2012","November 2012","December 2017","April 14, 2016","April 2016","No Study Results Posted","null","December 2015","Progression free survival in week 12|Quality of life (QL)|Adverse events (CTCAE v 4.0)|Overall Response (OR)|Progression free survival (PFS)|Overall Survival (OS)|Overall treatment utility (OTU) (predefined composite endpoint including clinical benefit, tolerability and acceptability of the treatment)","https://ClinicalTrials.gov/show/NCT01718808"
1270,"NCT00403052","A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Neoplasms","Drug: 1018 ISS immunostimulatory oligonucleotide","Dynavax Technologies Corporation","Both","18 Years and older   (Adult, Senior)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DV2-ONC-01","November 21, 2006","November 2006","December 2007","August 23, 2016","August 2016","No Study Results Posted","null","December 2007","Occurrence of adverse events|Time to tumor progression|Overall survival time","https://ClinicalTrials.gov/show/NCT00403052"
1271,"NCT02376452","Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients","Recruiting","No Results Available","Colorectal Carcinoma","Drug: Raltitrexed|Drug: Irinotecan|Drug: 5-fluorouracil|Drug: Leucovorin","Fudan University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RALIRI","February 12, 2015","September 2014","December 2016","March 2, 2015","February 2015","No Study Results Posted","null","December 2015","progression free survival|overall survival|overall response rate|disease control rate|Number of Participants with Adverse Events|quality of life questionnaire","https://ClinicalTrials.gov/show/NCT02376452"
1272,"NCT02384850","Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasm","Drug: Selinexor|Drug: Oxaliplatin|Drug: 5-FU|Drug: Folinic Acid","GSO Global Clinical Research BV|Karyopharm Therapeutics, Inc","Both","18 Years and older   (Adult, Senior)","Phase 1","27","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SENTINEL","March 2, 2015","March 2015","April 2018","August 10, 2015","August 2015","No Study Results Posted","SENTINEL","June 2016","Determination of the maximum tolerated dose|Overall response rate|Progression free survival|Overall survival|Incidence of patients experiencing adverse events","https://ClinicalTrials.gov/show/NCT02384850"
1273,"NCT00002793","Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: fluorouracil|Drug: leucovorin calcium","Johann Wolfgang Goethe University Hospital|National Cancer Institute (NCI)","Both","18 Years to 76 Years   (Adult, Senior)","Phase 3","336","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064871|GER-ALM-03/95|EU-96007","November 1, 1999","January 1991","null","September 16, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002793"
1274,"NCT00016198","Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Prologue Research International|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","PROLOGUE-EFC4760|CDR0000068606|SANOFI-EFC4760","May 6, 2001","May 2001","December 2010","June 25, 2013","December 2010","No Study Results Posted","null","April 2003","","https://ClinicalTrials.gov/show/NCT00016198"
1275,"NCT01006369","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","Suspended","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: XELOX regimen|Drug: hydroxychloroquine","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","47","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","070806|CINJ-070806|P30CA072720","October 30, 2009","May 2009","June 2016","December 10, 2014","December 2014","No Study Results Posted","null","June 2016","Progression-free survival|Overall response rate|Duration of response|Disease-control rate","https://ClinicalTrials.gov/show/NCT01006369"
1276,"NCT00030563","Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: irinotecan hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: radiofrequency ablation","University of Washington|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069177|UWASH-1200|CWRU-040106|UWASH-440E-ONC-0020-250|NCI-G01-2045|CWRU-UWMC-1200","February 14, 2002","May 2001","October 2005","November 28, 2012","November 2012","No Study Results Posted","null","October 2004","","https://ClinicalTrials.gov/show/NCT00030563"
1277,"NCT00063141","Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: cetuximab|Drug: Irinotecan|Drug: Irinotecan","ImClone LLC|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 3","1302","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA225-006","June 20, 2003","April 2003","October 2007","April 8, 2010","April 2010","No Study Results Posted","null","June 2006","Overall Survival|Progression Free Survival|Response|Duration of Response|Time to Response|Disease Control Rate|Safety|Quality of Life|Health Economics","https://ClinicalTrials.gov/show/NCT00063141"
1278,"NCT00950820","Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer","Terminated","No Results Available","Colorectal Neoplasms","Drug: Oxaliplatin, Capecitabine, Panitumumab|Drug: Oxaliplatin, Capecitabine","AIO-Studien-gGmbH|iOMEDICO AG","Both","18 Years and older   (Adult, Senior)","Phase 2","9","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AIO KRK 0107","July 31, 2009","September 2009","March 2012","March 1, 2013","March 2013","No Study Results Posted","VOXEL","November 2011","Progression-free survival rate at 6 months for subjects with KRAS wild-type tumours|PFS|Objective-response-rate|Disease-control-rate|Time-to-response|time-to-progression|duration-of-stable-disease|time-to-treatment-failure|overall-survival|safety-endpoints","https://ClinicalTrials.gov/show/NCT00950820"
1279,"NCT01538680","Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy","No longer available","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (BAY73-4506)","Bayer","Both","18 Years and older   (Adult, Senior)","","null","Industry","Expanded Access","","15967|2011-005836-25","February 21, 2012","null","null","June 29, 2016","June 2016","No Study Results Posted","CONSIGN","null","","https://ClinicalTrials.gov/show/NCT01538680"
1280,"NCT00149396","Safety and Efficacy of a Genetically Engineered Herpes Simplex Virus NV1020 to Treat Colorectal Cancer Metastatic to Liver","Completed","No Results Available","Colorectal Cancer|Liver Neoplasms","Drug: NV1020","MediGene","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","27","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT1030","September 6, 2005","July 2004","December 2008","December 12, 2008","December 2008","No Study Results Posted","null","October 2008","Incidence of adverse events and dose limiting adverse events|Clinical laboratory safety results|NV1020 pharmacokinetics-presence of NV1020 in body fluids/skin|Tumor response after administration of NV1020 followed by a minimum of 2 cycles of chemotherapy, determined by radiological (computed tomography [CT] scan) assessment of liver size and positron emission tomography (PET) scan|Mean change from baseline in serum carcinoembryonic antigen (CEA) after administration of NV1020 and 2 cycles of chemotherapy|Pharmacodynamic effects of NV1020 (NV1020 neutralizing antibody titer assay, cytokines, CEA)|Time to disease progression; Survival time","https://ClinicalTrials.gov/show/NCT00149396"
1281,"NCT01715363","Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer","Terminated","No Results Available","Patients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated","Drug: Oxaliplatin|Drug: Folinic Acid|Drug: Fluorouracile","Gustave Roussy, Cancer Campus, Grand Paris","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","3","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-003446-41|2010/1676","October 24, 2012","July 2012","June 2014","February 9, 2016","February 2016","No Study Results Posted","PRIMM","June 2014","Clinical tolerance of immediate preoperative chemotherapy","https://ClinicalTrials.gov/show/NCT01715363"
1282,"NCT00921661","Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis","Drug: AVE0005 (aflibercept)","Sanofi|Regeneron Pharmaceuticals","Both","20 Years and older   (Adult, Senior)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TCD10794","June 15, 2009","June 2009","June 2012","November 8, 2012","November 2012","No Study Results Posted","null","June 2012","Dose-limiting toxicity (DLT) combination with FOLFIRI|physical examination, laboratory safety tests, adverse events|Pharmacokinetics|Tumor burden, endogenous free VEGF|Immunogenicity","https://ClinicalTrials.gov/show/NCT00921661"
1283,"NCT02503696","Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)","Completed","No Results Available","Inflammatory Bowel Disease|Colorectal Neoplasms|Digestive System Diseases|Colonic Diseases|Colorectal Cancer","Device: Stool Collection Kit","Exact Sciences Corporation","Both","18 Years to 84 Years   (Adult, Senior)","","697","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2014-05","July 17, 2015","September 2014","June 2016","August 9, 2016","August 2016","No Study Results Posted","null","November 2015","Sensitivity and Specificity of the Exact CRC diagnostic screening test.","https://ClinicalTrials.gov/show/NCT02503696"
1284,"NCT02614339","Effect of Adjunctive Metformin on Recurrence of Non-DM Stage III Colorectal Cancer: Open-label Randomized Controlled Study","Not yet recruiting","No Results Available","Non-DM Stage III Colorectal Cancer","Drug: metformin|Drug: control","Yonsei University","Both","20 Years to 80 Years   (Adult, Senior)","Phase 3","593","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","4-2015-0533","November 23, 2015","December 2015","November 2021","November 23, 2015","November 2015","No Study Results Posted","null","July 2021","Disease free survival|5-year overall survival|recurrence rate of polyps after polypectomy","https://ClinicalTrials.gov/show/NCT02614339"
1285,"NCT01134666","An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Neoplasms","Drug: Cetuximab","Merck KGaA|Merck Ltd., India","Both","Child, Adult, Senior","","165","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMR 062202-517","May 28, 2010","November 2009","April 2017","November 7, 2014","November 2014","No Study Results Posted","null","July 2013","Safety and tolerability evaluated based on the incidence and severity of AEs.|Response rate","https://ClinicalTrials.gov/show/NCT01134666"
1286,"NCT00485316","Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma","Completed","No Results Available","Colorectal Carcinoma","Procedure: Laparoscopic assisted resection of colorectal carcinoma","Chinese University of Hong Kong","Both","Child, Adult, Senior","Phase 3","null","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRE-8118","June 11, 2007","September 1993","October 2008","March 30, 2009","March 2009","No Study Results Posted","null","October 2008","Overall survival and disease-free survival|Operative time|Blood loss|Postoperative analgesic requirements|Recovery of gastrointestinal function (time to resume normal diet, time first passing flatus, time of first bowel motion)|Time to walk independently|Duration of hospital stay|Morbidity and mortality|Direct cost","https://ClinicalTrials.gov/show/NCT00485316"
1287,"NCT00972036","Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy","Completed","No Results Available","Colon Cancer|Rectal Cancer","Device: SIR-spheres® (Selective Internal Radiation Therapy)","Memorial Sloan Kettering Cancer Center|Sirtex Medical","Both","18 Years and older   (Adult, Senior)","Phase 1","32","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-030","September 3, 2009","August 2009","December 2014","December 10, 2014","December 2014","No Study Results Posted","null","December 2014","To determine the safety, toxicity, and maximum tolerated dose of SIR-Spheres® in patients with unresectable metastatic colorectal cancer to the liver (CLM) who have received previous hepatic arterial infusion chemotherapy (HAC).|To obtain preliminary evidence of any clinical efficacy of the SIRT therapy in these heavily pretreated patients with unresectable CLM who have received hepatic arterial infusion pump and have failed at least one line of prior chemotherapy.","https://ClinicalTrials.gov/show/NCT00972036"
1288,"NCT00940303","OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: 5-FU|Drug: bevacizumab [Avastin]|Drug: irinotecan|Drug: leucovorin|Drug: oxaliplatin","Hoffmann-La Roche","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","97","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20514|2008-001180-11","July 6, 2009","June 2009","February 2014","September 1, 2016","September 2016","No Study Results Posted","null","February 2014","Progression-free survival|Overall survival; proportion of patients achieving R0 resectability; objective response rate (complete response [CR] and partial response [PR]); proportion of patients completing 12 cycles of chemotherapy.|Proportion of patients with NCI-CTC grade 3-5 adverse events; adverse events, laboratory parameters, ECOG performance status.","https://ClinicalTrials.gov/show/NCT00940303"
1289,"NCT02885753","Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastic Colorectal Cancer Restricted to the Liver","Not yet recruiting","No Results Available","Colorectal Neoplasms","Drug: Oxaliplatin intravenous|Drug: 5 Fu|Drug: Folinic Acid|Drug: Oxaliplatin intra-arteriel|Drug: Panitumumab|Drug: Bevacizumab","Federation Francophone de Cancerologie Digestive","Both","18 Years and older   (Adult, Senior)","Phase 3","268","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PRODIGE 49","August 23, 2016","September 2016","June 2023","August 26, 2016","August 2016","No Study Results Posted","OSCAR","September 2018","hepatic progression-free survival","https://ClinicalTrials.gov/show/NCT02885753"
1290,"NCT02251782","Adherence to Minimally Invasive Testing","Completed","No Results Available","Colorectal Cancer","Device: Epi proColon Test|Device: Fecal Immunochemical Test (FIT)","Epigenomics, Inc","Both","50 Years to 76 Years   (Adult, Senior)","","490","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","SPR 0026","September 24, 2014","October 2014","June 2015","June 29, 2015","June 2015","No Study Results Posted","ADMIT","April 2015","Comparison of Adherence to Screening for Each Group|Adherence to follow-up colonoscopy for tests with a positive result:|Diagnostic yield of colonoscopy:","https://ClinicalTrials.gov/show/NCT02251782"
1291,"NCT02037646","Quantitative Versus Qualitative Fecal Immunochemical Tests (FIT) to Prioritize Urgency of Colonoscopy Referral","Recruiting","No Results Available","Colorectal Cancer","Other: Qualitative fecal immunochemical test|Other: Quantitative fecal immunochemical test|Procedure: Colonoscopy|Other: Cost analysis|Other: Anxiety scores|Other: Patient satisfaction scores","University of Malaya","Both","50 Years and older   (Adult, Senior)","","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Screening","926.24","January 14, 2014","June 2012","December 2015","January 15, 2014","January 2014","No Study Results Posted","null","December 2015","Time to diagnosis of advanced colorectal neoplasms|Analysis of screening costs|Patient anxiety levels|Patient satisfaction scores","https://ClinicalTrials.gov/show/NCT02037646"
1292,"NCT00001576","A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver","Completed","No Results Available","Colorectal Neoplasm|Liver Neoplasm|Neoplasm Metastasis","Drug: Melphalan|Drug: Floxuridine|Drug: Leucovorin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","Child, Adult, Senior","Phase 1","28","NIH","Interventional","Endpoint Classification: Safety Study|Primary Purpose: Treatment","970111|97-C-0111","November 3, 1999","July 1997","March 2002","March 3, 2008","March 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001576"
1293,"NCT02096354","A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: RRx-001|Drug: Regorafenib|Drug: Irinotecan","EpicentRx, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RRx001-21-02","March 20, 2014","May 2014","May 2018","April 6, 2016","April 2016","No Study Results Posted","ROCKET","May 2017","Overall Survival|Number of Participants with Serious and Non-Serious Adverse Events|Objective Response Rate|Clinical Benefit Rate|Progression Free Survival|Duration of Response|Duration of Clinical Benefit|Time to Progression|Response to subsequent therapies|Quality of life (QOL) by QOL questionnaire","https://ClinicalTrials.gov/show/NCT02096354"
1294,"NCT00780988","Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer","Withdrawn","No Results Available","Colorectal Neoplasms|Anal, Colon, and Rectal Cancers","Biological: Autologous tumor cell + CpG vaccine|Procedure: Autologous hematopoietic and immune cell rescue (transplantation)","Stanford University","Both","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SU-09112008-1298|COR0008","October 23, 2008","null","null","January 21, 2012","January 2012","No Study Results Posted","null","null","To assess the feasibility of using an autologous tumor cell vaccine in combination with standard chemotherapy followed by investigational autologous hematopoietic and immune cell rescue in terms of acceptable clinical toxicity.|Preliminary efficacy in terms of response and time to progression|Ex vivo analysis of immune response","https://ClinicalTrials.gov/show/NCT00780988"
1295,"NCT00615056","A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen","Completed","Has Results","Colorectal Neoplasms","Drug: Bevacizumab (avastin)|Drug: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Drug: AG-013736 (axitinib)|Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Drug: AG-013736 (axitinib)|Drug: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Drug: Bevacizumab (avastin)|Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","171","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A4061034","February 1, 2008","March 2008","April 2012","April 12, 2013","April 2013","March 28, 2012","null","March 2011","Progression Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants With Objective Response (OR)|Duration of Response (DR)|Change From Baseline in MD Anderson Symptoms Inventory Diarrhea (MDASI-D) Symptom Severity Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal|Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal","https://ClinicalTrials.gov/show/NCT00615056"
1296,"NCT01793805","NSABP Patient Registry and Biospecimen Profiling Repository","Recruiting","No Results Available","Colorectal Cancer","","NSABP Foundation Inc","Both","18 Years and older   (Adult, Senior)","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NSABP MPR-1","February 11, 2013","February 2013","June 2016","January 19, 2016","January 2016","No Study Results Posted","null","June 2016","To characterize common genetic/molecular profiles associated with colorectal cancer (CRC)|To identify subpopulations of registry patients on the basis of their molecular profiles that may be eligible for participation in available NSABP clinical trials involving novel agents|To conduct further analysis of tumor samples for the discovery of new potential targets and mechanisms of drug resistance","https://ClinicalTrials.gov/show/NCT01793805"
1297,"NCT02118064","Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma","Completed","No Results Available","Colorectal Cancer","Biological: G17DT-Irinotecan","Cancer Advances Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","161","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CC6","April 16, 2014","March 2001","null","April 17, 2014","January 2014","No Study Results Posted","CC6","December 2002","Tumor response|Survival time|Number of Patients with Serious and Non-Serious Adverse Events","https://ClinicalTrials.gov/show/NCT02118064"
1298,"NCT01287130","AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer","Completed","No Results Available","Colonic Neoplasms|Cancer of the Colon|Colon Cancer|Colon Neoplasms|Colonic Cancer","Drug: Cetuximab|Drug: AZD6244","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","10","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","110075|11-C-0075","January 29, 2011","January 2011","August 2013","August 6, 2016","February 2016","No Study Results Posted","null","August 2013","To determine the dose limiting toxicities and the maximum tolerated dose of AZD6244 in combination with cetuximab in advanced, refractory solid tumors.|To assess for evidence of anti-tumor activity with this combination, per tumor measurements|To evaluate the pharmacokinetics of AZD6244 and cetuximab when administered concomitantly|To evaluate the safety and tolerability of the combination of AZD6244 and cetuximab in patients with K-RAS mutated metastatic colorectal cancer","https://ClinicalTrials.gov/show/NCT01287130"
1299,"NCT00513266","Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery","Active, not recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: bevacizumab|Biological: cetuximab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: biopsy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Centre Hospitalier Universitaire Vaudois|National Cancer Institute (NCI)","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000559146|CHUV-CH-OCFL-BC|EU-20741","August 6, 2007","June 2007","null","August 6, 2009","June 2009","No Study Results Posted","null","null","Pathological complete response rate of lesions of less than or equal to 30 mm in size assessed by pathologic examination in resected specimens|Response as assessed by NCIC criteria|Toxicity as assessed by NCIC criteria","https://ClinicalTrials.gov/show/NCT00513266"
1300,"NCT02143115","Comparative Effectiveness of CTC & OC","Recruiting","No Results Available","Colorectal Cancer","Procedure: Optical colonoscopy|Radiation: CT-Colonography","Fox Chase Cancer Center","Both","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","R01CA155347","May 15, 2014","August 2011","June 2016","September 2, 2015","September 2015","No Study Results Posted","null","June 2016","Compare the test characteristics (sensitivity, specificity, positive and negative predictive value) of Computed Tomography colonography (CT-C) in the post-Colorectal cancer resection using optical colonoscopy as the reference stanard|Compare the costs and outcomes of Computed Tomography Colonography versus independent Optical Colonoscopy plus Computed Tomography for post Colorectal Cancer resection surveillance.","https://ClinicalTrials.gov/show/NCT02143115"
1301,"NCT02249650","To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: TSB-9-W1","Taiwan Sunpan Biotechnology Development Co., Ltd.","Both","20 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","SUNTSBA20110201","September 4, 2014","May 2016","November 2017","April 22, 2016","April 2016","No Study Results Posted","TSB-9-W1","November 2017","Maximum Tolerated Dose (MTD)|Dose limiting toxicities (DLTs)","https://ClinicalTrials.gov/show/NCT02249650"
1302,"NCT02892721","Performance and Evaluation for CT Colonography Screening","Not yet recruiting","No Results Available","Colonic Neoplasms|Colorectal Neoplasms","Other: Training with feedback","London North West Healthcare NHS Trust|University College London Hospitals","Both","Child, Adult, Senior","","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","RD16/055","September 2, 2016","October 2016","March 2018","September 2, 2016","September 2016","No Study Results Posted","PERFECTS","December 2017","Difference in sensitivity between arms|Difference in sensitivity between intervention and controls for colorectal cancer/ polyps at the 12 month post-training test set (i.e. to test longer-term durability of one-off training supplemented by individualized feedback).|Difference in specificity between intervention and controls at 1 month.|Difference in specificity between intervention and controls at 12 months.|Difference in sensitivity between intervention and controls at 6 months.|Difference in specificity between intervention and controls at 6 months.|Difference in raw score between the control and intervention arms on the knowledge questions as compared to true answers.|Association between interpretation time and diagnostic performance of radiologists on all test sets.|Characteristics of radiologists performing well versus those that do not.","https://ClinicalTrials.gov/show/NCT02892721"
1303,"NCT01804621","RCT to Examine the Effects of Scanning","Completed","No Results Available","Cancer|Breast Cancer|Colorectal Cancer","Behavioral: Health Newsletter","University of Pennsylvania|National Cancer Institute (NCI)","Both","50 Years to 70 Years   (Adult, Senior)","","15824","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","811285|3P20CA095856-07S1","February 25, 2013","April 2010","June 2011","March 4, 2013","December 2012","No Study Results Posted","null","May 2011","Exercise Behavior|Fruit & Vegetable Consumption|Mammography Screening Behavior|Colorectal cancer screening","https://ClinicalTrials.gov/show/NCT01804621"
1304,"NCT00784667","Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: Erlotinib","Austin Health|Ballarat Health Services|Queen Elizabeth Hospital, Adelaide|Royal North Shore Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H2008/03282","November 3, 2008","October 2008","February 2011","November 29, 2010","November 2008","No Study Results Posted","Dux","January 2010","To determine the response rate (RECIST criteria). Responses will be evaluated for the whole patient group and separately for k-ras wild-type and k-ras mutant tumours|Toxicity|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00784667"
1305,"NCT01186705","Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer","Terminated","Has Results","Colon Cancer|Rectal Cancer","Drug: MK-2206","Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","1","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-068","August 20, 2010","August 2010","August 2011","October 17, 2015","October 2015","April 7, 2015","null","August 2011","Overall Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT01186705"
1306,"NCT02732860","Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host","Enrolling by invitation","No Results Available","Colorectal Neoplasms|Colorectal Cancer|Breast Cancer|Breast Neoplasms","Other: Molecular Profiling & In Vivo drug testing in pPDX","University Health Network, Toronto","Both","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REFLECT-001","February 10, 2016","December 2015","November 2017","July 11, 2016","July 2016","No Study Results Posted","REFLECT","November 2017","Measure of drug sensitive pPDX to a panel of drugs as a predictor of clinical response in matched host|Rate of results reporting|Rate of pPDX engraftment|Comparison of actionable alterations identified in clinical and pPDX samples|Number of patients with molecular abnormalities in pPDX as identified via NGS eliciting clinical responses while receiving matched treatments.","https://ClinicalTrials.gov/show/NCT02732860"
1307,"NCT02332213","Volatile Markers in Digestive Cancer","Recruiting","No Results Available","Colorectal Cancer|Colorectal Adenoma|Gastric Cancer|Peptic Ulcer Disease|Atrophic Gastritis|Intestinal Metaplasia|H.Pylori Infection|Normal Control|Average-risk General Population","Procedure: Breath sampling for volatile marker detection|Procedure: Upper endoscopy with biopsies|Procedure: Colonoscopy with biopsies or lesion removal when required|Procedure: Plasma/serum sampling|Procedure: Faecal sample acquisition|Procedure: Histological evaluation of the surgery material","University of Latvia|Technion, Israel Institute of Technology|Lithuanian University of Health Sciences|Karolinska Institutet|German Cancer Research Center|Digestive Diseases Centre Gastro (Latvia)|Riga East University Hospital (Latvia)|Academic Histology Laboratory (Latvia)|JLM Innovation GmbH (Germany)","Both","18 Years and older   (Adult, Senior)","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2914|LZP Nr. 2014.10-5","December 30, 2014","January 2014","December 2017","January 2, 2015","January 2015","No Study Results Posted","VOLGACORE","May 2017","Performance of nanoarray sensor testing to detect target lesions|VOCs differentiating the study groups|Identification of characteristic VOC pattern in risk age groups|VOC pattern changes following treatment|Groups of gastrointestinal microbiota correlating to VOCs","https://ClinicalTrials.gov/show/NCT02332213"
1308,"NCT01294826","Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer","Completed","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum","Drug: AUY922|Drug: Cetuximab","Swedish Medical Center|Novartis Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","20","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CAUY922AUS06T","February 8, 2011","February 2011","May 2015","June 4, 2015","June 2015","No Study Results Posted","null","May 2015","Incidence of dose limiting toxicity (DLT)|Patient response rate to the AUY922.|Time to tumor progression following treatment with AUY922.|Overall survival of patients treated with AUY922.","https://ClinicalTrials.gov/show/NCT01294826"
1309,"NCT02660671","Behavioral Economic Approaches to Increase Colorectal Cancer Screening","Active, not recruiting","No Results Available","Cancer of the Colon","Behavioral: Email outreach|Behavioral: Active choice|Behavioral: Financial incentive","University of Pennsylvania","Both","50 Years to 64 Years   (Adult)","","2250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Health Services Research","822504","January 19, 2016","January 2016","December 2016","September 13, 2016","September 2016","No Study Results Posted","null","December 2016","Colonoscopy participation|Email engagement|Scheduling of colonoscopy","https://ClinicalTrials.gov/show/NCT02660671"
1310,"NCT01860144","An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Bevacizumab","Peking University","Both","Child, Adult, Senior","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CGOG2001","May 19, 2013","June 2012","December 2015","May 17, 2015","May 2015","No Study Results Posted","null","December 2015","Objective response rate|overall survival|progression free survival|Proportion of patients with bevacizumab treatment discontinuation|resection rate","https://ClinicalTrials.gov/show/NCT01860144"
1311,"NCT02792023","Usefulness of Fecal Immunochemical Test in Iron Deficiency Anemia (IDAFIT)","Not yet recruiting","No Results Available","Colorectal Cancer","Other: Immunochemical fecal occult blood test|Device: Colonoscopy|Device: Upper endoscopy","Hospital Universitario de Canarias","Both","18 Years and older   (Adult, Senior)","","550","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","FIT-Iron deficiency anemia","May 20, 2016","June 2016","June 2017","June 7, 2016","June 2016","No Study Results Posted","IDAFIT","April 2017","The number of patients with colorectal cancer among those with a positive immunochemical fecal test (Positive predictive value)|The number of patients with a significant lesion among those with a positive immunochemical fecal test (Positive predictive value) after the colonoscopy and after the upper endoscopy|The number of patients without a significant lesion among those with a negative immunochemical fecal test (negative predictive value) after the colonoscopy and after the upper endoscopy","https://ClinicalTrials.gov/show/NCT02792023"
1312,"NCT00005981","Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: O6-benzylguanine|Drug: carmustine","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","13","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU1298|U01CA063200|P30CA043703|CWRU-1298|NCI-89","July 5, 2000","June 2000","November 2003","June 9, 2010","June 2010","No Study Results Posted","null","November 2003","Determine the response rate of patients with metastatic colorectal carcinoma treated with O6-benzylguanine and carmustine.","https://ClinicalTrials.gov/show/NCT00005981"
1313,"NCT00220246","Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Neoplasms","","Radboud University","Both","up to 51 Years   (Child, Adult)","","130","Other","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Retrospective","EOMSD2004","September 20, 2005","March 2004","September 2008","February 28, 2007","February 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00220246"
1314,"NCT00730158","A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: KD018|Drug: Irinotecan|Drug: Placebo","University of Pittsburgh|Kadmon Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 2","165","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12-005|ACS IRG 58-012-49","August 4, 2008","December 2008","June 2018","February 16, 2016","February 2016","No Study Results Posted","null","June 2018","The effect of KD018 on irinotecan toxicity with the goal of achieving a 30% reduction in the overall incidence of grade 2-4 toxicity during the first 3 months of the study treatment|The effect of KD018 on irinotecan overall response rate (RR).|The effect of KD018 on irinotecan progression-free survival (PFS).|The effect of KD018 on irinotecan overall survival (OS)","https://ClinicalTrials.gov/show/NCT00730158"
1315,"NCT01575990","Elders Preferences in Care Decisions","Completed","No Results Available","Early Detection of Cancer|Colon Cancer|Decision Making|Patient-Centered Care","Behavioral: Making A Decision About CRC Screening|Behavioral: Drivers 65 Plus","University of North Carolina, Chapel Hill|Duke University|Agency for Healthcare Research and Quality (AHRQ)","Both","70 Years to 84 Years   (Senior)","","424","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","11-1638|P01HS021133-01","March 29, 2012","March 2012","February 2015","May 27, 2015","May 2015","No Study Results Posted","EPIC-D","February 2015","Appropriate colorectal cancer screening|Appropriate colorectal cancer screening decisions|Appropriate screening and mediators|Appropriate screening for health strata|Appropriate screening for stool cards","https://ClinicalTrials.gov/show/NCT01575990"
1316,"NCT01014039","Telemark Polyp Study, a Trial on Colonoscopy Screening","Active, not recruiting","No Results Available","Colorectal Cancer","Procedure: Flexible Sigmoidoscopy Screening arm","Norwegian Department of Health and Social Affairs","Both","55 Years to 64 Years   (Adult)","","1600","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","TPS","November 13, 2009","March 1983","December 2020","April 28, 2015","April 2015","No Study Results Posted","TPS","December 2020","Colorectal cancer mortality|All cause mortality|colorectal cancer incidence","https://ClinicalTrials.gov/show/NCT01014039"
1317,"NCT01084746","Tailored Interactive Intervention to Increase CRCS","Completed","No Results Available","Colorectal Cancer Screening","Behavioral: Tailored interactive intervention to increasing CRCS","The University of Texas Health Science Center, Houston|National Cancer Institute (NCI)","Both","50 Years to 64 Years   (Adult)","","1224","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Prevention","HSC-SPH-01-084|R01CA097263-05","March 9, 2010","January 2005","June 2008","March 9, 2010","March 2010","No Study Results Posted","PCCaSO","June 2008","Increase patient completion of colorectal cancer screening (CRCS) among patients ages 50 to 64 years old.|Secondary goals are to increase understanding of factors that predict completion of CRCS and to assess the cost-effectiveness of the intervention.","https://ClinicalTrials.gov/show/NCT01084746"
1318,"NCT02419716","A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval","Active, not recruiting","No Results Available","Colorectal Cancer Screening|Colorectal Cancer","Device: Cologuard","Exact Sciences Corporation","Both","50 Years and older   (Adult, Senior)","","2173","Industry","Observational","Time Perspective: Prospective","Exact Sciences 2014-01","April 9, 2015","April 2015","July 2019","July 28, 2016","July 2016","No Study Results Posted","null","March 2019","Positive and Negative Predictive Value|Colorectal Cancer Incidence","https://ClinicalTrials.gov/show/NCT02419716"
1319,"NCT02337946","Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma","Recruiting","No Results Available","Colorectal Carcinoma","Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab","Takeda","Both","20 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Panitumumab-2003|U1111-1161-8871|183/NRP-005","September 30, 2014","October 2014","September 2017","January 13, 2015","January 2015","No Study Results Posted","SAPPHIRE","September 2016","Progression-Free Survival rate (PFS rate) at 9 months after randomization|Progression-Free Survival (PFS)|Overall survival (OS)|Response rate (RR)|Time to treatment failure (TTF)|Frequency of adverse events rate","https://ClinicalTrials.gov/show/NCT02337946"
1320,"NCT01845753","Molecular Screening for Lynch Syndrome in Denmark","Active, not recruiting","No Results Available","Colorectal Cancer|Lynch Syndrome|HNPCC","Other: Observation","Vejle Hospital","Both","Child, Adult, Senior","","5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MS-LS-DK-02","April 30, 2013","October 2012","October 2016","November 25, 2015","November 2015","No Study Results Posted","null","February 2015","Rate of Lynch Syndrome in a population of primary colorectal cancer","https://ClinicalTrials.gov/show/NCT01845753"
1321,"NCT01221324","Diagnostic Value of C-reactive Protein and White Blood Cell Counts for Early Detection of Inflammatory Complications After Open Resection of Colorectal Cancer","Completed","No Results Available","Given Indication for Open Resection of Colorectal Cancer","","Cantonal Hospital of St. Gallen","Both","18 Years and older   (Adult, Senior)","","1200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","EKSG10/126","October 14, 2010","November 2010","November 2010","February 10, 2012","February 2012","No Study Results Posted","null","November 2010","postoperative inflammatory complications|Anastomotic leakage","https://ClinicalTrials.gov/show/NCT01221324"
1322,"NCT02123862","Cultured Circulating Tumor Cells in Prostate and Other Cancers","Recruiting","No Results Available","Prostate Cancer","","Oscar Goodman, Jr.|Comprehensive Cancer Centers of Nevada|Roseman University of Health Sciences","Both","18 Years and older   (Adult, Senior)","","220","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","11.08.002","February 3, 2014","April 2014","April 2018","January 15, 2015","January 2015","No Study Results Posted","null","April 2017","Evaluate novel CTC assay method as a predictive tool for prostate, breast and colorectal cancers.|Sensitivity and specificity comparison|Develop in vitro assay for chemotherapy sensitivity testing|IC50 correlation with CTC response and clinical outcome|Attempt growth of long-term tumor cell lines for evaluation","https://ClinicalTrials.gov/show/NCT02123862"
1323,"NCT02273206","Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)","Active, not recruiting","No Results Available","Depression|Breast Cancer Screening|Cervical Cancer Screening|Colorectal Cancer Screening","Behavioral: Preventive Care Management for Depression|Behavioral: Preventive Care Management for Cancer Screening","Clinical Directors Network","Female","50 Years to 64 Years   (Adult)","","802","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","IH-12-11-4522","October 17, 2014","January 2014","December 2017","July 25, 2016","July 2016","No Study Results Posted","PCM3","December 2017","Changes from baseline in number of participants with colorectal, breast, and/or cervical cancer screening|Change from Baseline in Patient Health Questionnaire (PHQ)-9 at 6 month|Change from Baseline in Patient Health Questionnaire (PHQ)-9 at 12 month|Change from Baseline in The Hopkins Symptom Checklist (SCL-20) at 6 month|Change from Baseline in The Hopkins Symptom Checklist (SCL-20) at 12 month|Mental Health Care Utilization: assessed by chart review and patient report|Satisfaction with Decision to Participate in Screening and Mental Health Care as assessed by Decision Scale|Physician Recommendation of Screening/mental Health Care|Generalized Anxiety Disorder|Medical Outcomes Study Health Survey- Short Form|Breast, Cervical and Colorectal Cancer Screening attitudes|Satisfaction with Decision Scale- Cancer screening|Satisfaction with Decision Scale- Mental Health|Devaluation-Discrimination Scale|Ambulatory Care Experiences as assessed by Ambulatory Care Experiences Survey|Medication Adherence|Self-efficacy and Behavior towards Cancer Screening/Mental Health Utilization|Past History of Cancer and Family History of Cancer|Sociodemographics","https://ClinicalTrials.gov/show/NCT02273206"
1324,"NCT01210313","Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma","Completed","No Results Available","Colorectal Carcinoma","","Austrian Breast & Colorectal Cancer Study Group","Both","18 Years and older   (Adult, Senior)","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ABCSG C07|EXERCISE","September 23, 2010","October 2010","April 2013","March 6, 2014","March 2014","No Study Results Posted","null","April 2013","feasibility of physical activity|increase of physical efficiency|Quality of Life|vascular and metabolic effects|changes of cytokines and adiponectines|gen- and metabolic signs","https://ClinicalTrials.gov/show/NCT01210313"
1325,"NCT01959269","Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy","Active, not recruiting","No Results Available","Colorectal Neoplasm","Drug: Regorafenib (Stivarga, BAY 73-4506)","Bayer","Both","18 Years and older   (Adult, Senior)","","483","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16665|SV1313","October 8, 2013","October 2013","June 2017","September 13, 2016","September 2016","No Study Results Posted","RECORA","March 2017","Overall survival|Progression-free survival|Time to progression|Disease control rate (DCR)|Duration of Stivarga treatment|Tumor status at different visits|Incidence of treatment emergent adverse events (TEAE)","https://ClinicalTrials.gov/show/NCT01959269"
1326,"NCT00936572","Probiotics In Colorectal Cancer Patients","Completed","No Results Available","Colorectal Cancer","Procedure: Probiotics (La1, BB536)|Biological: probiotics (La1, BB536)|Biological: placebo","University of Milano Bicocca","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","02.06.CLI","July 7, 2009","October 2006","October 2007","July 9, 2009","July 2009","No Study Results Posted","null","June 2007","Primary Efficacy Parameters: morphological and microbiological evaluation of the colonic microflora, gastrointestinal function|Secondary Efficacy Parameters: immune and inflammatory response, bacterial translocation","https://ClinicalTrials.gov/show/NCT00936572"
1327,"NCT01508000","Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases","Terminated","No Results Available","Colorectal Cancer Metastatic|Liver Metastases|KRAS Wild Type Colorectal Cancer","Drug: FOLFOX6|Biological: Bevacizumab|Biological: Panitumumab|Procedure: Surgery","European Organisation for Research and Treatment of Cancer - EORTC|Amgen|Roche Pharma AG","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","44","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-40091|2010-019238-29","January 9, 2012","June 2013","December 2016","January 28, 2016","January 2016","No Study Results Posted","BOS2","December 2015","Progression free survival|Pathological response rate|Resection rate|Overall survival|Safety","https://ClinicalTrials.gov/show/NCT01508000"
1328,"NCT00865709","Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)","Bayer|Onyx Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 2","198","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13162|2008-005025-11","February 2, 2009","March 2009","February 2012","November 25, 2014","November 2014","January 31, 2012","null","January 2011","Progression-Free Survival (PFS)|Overall Survival (OS)|Time to Progression (TTP)|Overall Response|Duration of Response","https://ClinicalTrials.gov/show/NCT00865709"
1329,"NCT01533311","Prevalence and Characteristics of Nonpolypoid Colorectal Neoplasms - A Chinese Cohort Study","Completed","No Results Available","Nonpolypoid Colorectal Neoplasms(NP-CRN)","","Shanghai Jiao Tong University School of Medicine","Both","18 Years to 90 Years   (Adult, Senior)","","1342","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","rjxhnk03","February 11, 2012","January 2009","December 2010","February 14, 2012","February 2012","No Study Results Posted","null","December 2010","","https://ClinicalTrials.gov/show/NCT01533311"
1330,"NCT01112046","Endoscopic Submucosal Dissection Versus Laparoscopic Resection for Early Colorectal Neoplasms","Recruiting","No Results Available","Colorectal Neoplasms","Procedure: Endoscopic submucosal dissection|Procedure: Laparoscopic resection","Chinese University of Hong Kong|United Christian Hospital|Queen Elizabeth Hospital, Hong Kong","Both","18 Years and older   (Adult, Senior)","Phase 3","124","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRE-2009.625","April 26, 2010","April 2010","April 2015","February 10, 2014","February 2014","No Study Results Posted","null","April 2015","Short-term morbidity|Systemic cytokine and C-reactive protein levels|Post-ESD/surgery recovery|Quality of life|Direct and indirect medical costs|Local recurrence","https://ClinicalTrials.gov/show/NCT01112046"
1331,"NCT02842125","Safety and Efficacy of Intra-Arterial Ad-p53 in Liver Metastases of Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Ad-P53|Drug: Xeloda","MultiVir, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MultiVir Ad-p53","July 1, 2016","June 2016","July 2018","July 19, 2016","July 2016","No Study Results Posted","null","July 2018","Safety assessed by CTCAE|Incidence of dose-limiting toxicities (DLTs)|Determination of maximum-tolerated dose (MTD)|Progression-Free Survival (PFS) of patients using RECIST 1.1|Efficacy determined by Immune Related Response Criteria (irRC) [Wolchok 2009]|Efficacy as determined by carcinoembryonic antigen (CEA) level testing","https://ClinicalTrials.gov/show/NCT02842125"
1332,"NCT02635503","Safety Study of Totally Laparoscopic Resection With Natural Orifice Specimen Extraction (NOSE) for Rectosigmoid Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: transrectal specimen extraction|Procedure: Conventional laparoscopic surgery","Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","366","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC2015SF-04","November 30, 2015","November 2015","December 2025","September 1, 2016","September 2016","No Study Results Posted","null","December 2020","Early morbidity rate|Duration of the intervention|Peritoneal bacterial contamination|Pain score|3-year disease free survival rate|5-year overall survival rate|Plasma levels of several cytokines after colorectal cancer surgery","https://ClinicalTrials.gov/show/NCT02635503"
1333,"NCT01937715","A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer","Terminated","Has Results","Metastatic Colorectal Carcinoma","Drug: PF-05212384|Drug: FOLFIRI regimen|Biological: Bevacizumab|Drug: FOLFIRI","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","B2151007|2013-002096-18","August 27, 2013","February 2014","August 2015","July 8, 2016","July 2016","July 8, 2016","null","August 2015","Percentage of Participants With Dose-Limiting Toxicities (DLTs) in First Cycle of Therapy|Progression-Free Survival (PFS)|Number of Participants With Best Overall Response (Phase 1B)|Number of Participants With All Causality Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations by Relationship and Seriousness|Number of Participants With All Causality AEs by System Organ Class (SOC)|Number of Participants With Treatment-Emergent AEs by Worst On-Study Grade|Number of Participants With Hematological Test Abnormalities|Number of Participants With Coagulation Test Abnormalities|Number of Participants With Chemistry Test Abnormalities|Number of Participants With Urinalysis Test Abnormalities|Maximum Observed Plasma Concentration (Cmax): PF-05212384, Irinotecan, and Fluorouracil|Time to Reach Maximum Observed Plasma Concentration (Tmax): PF-05212384, Irinotecan, and Fluorouracil|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): PF-05212384 and Irinotecan|Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf): PF-05212384 and Irinotecan|Terminal Elimination Half-Life (t1/2): PF-05212384 and Irinotecan|Number of Participants Meeting Maximum Post-Baseline QTc Interval Values|Number of Participants With Expression of Gene Sequences or Gene Amplications in Biopsied Tumor Tissue|Number of Participants With Gene and/or Protein Expression Biomarkers Relating to the PI3K and/or mTOR Pathway Activation in Biopsied Tumor Tissue|Number of Participants With Best Overall Response (Phase 2)|Duration of Response (Phase 2)|Overall Survival (Phase 2)|Number of Participants With Evidence of Pathway Signaling Related Genes and/or Proteins in Biopsied Tumor Tissue (Phase 2)|Change From Baseline in Functional Assessment of Cancer Therapy-Colorectal (FACT-C) (Phase 2)","https://ClinicalTrials.gov/show/NCT01937715"
1334,"NCT00378066","Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Bevacizumab","Asan Medical Center","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","49","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-0277","September 18, 2006","August 2006","October 2008","January 21, 2013","January 2013","No Study Results Posted","null","August 2006","time to progression|overall survival, safety, response","https://ClinicalTrials.gov/show/NCT00378066"
1335,"NCT01791361","Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe","Completed","No Results Available","Metastatic Colorectal Cancer","Other: Other","Amgen","Both","18 Years and older   (Adult, Senior)","","439","Industry","Observational","Time Perspective: Retrospective","20101120","June 5, 2012","September 2012","June 2015","October 23, 2015","October 2015","No Study Results Posted","null","June 2015","The prevalence of KRAS testing and impact of the KRAS test results on patterns of Vectibix use in patients with metastatic colorectal cancer (mCRC) treated with Vectibix|The proportion of oncologists who agree to participate in the study|The proportion of oncologists that conduct a KRAS testing prior to Vectibix prescription in patients with mCRC treated with Vectibix|The proportion of laboratories that participate in the European Society of Pathology (ESP) Quality Assurance Scheme or are certified by an ESP approved accreditation body|The proportion of laboratories that use a CE-marked or otherwise validated KRAS detection method|To characterize the results of KRAS testing in the three rounds of chart abstraction that will be carried out at 0, 12 and 24 months to indicate if there are any differences in results from each of the three rounds","https://ClinicalTrials.gov/show/NCT01791361"
1336,"NCT01646554","Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases","Withdrawn","No Results Available","Colorectal Cancer Metastatic|Liver Metastases|KRAS Mutated Colorectal Cancer","Drug: Modified FOLFOX6|Biological: Aflibercept|Procedure: Surgery","European Organisation for Research and Treatment of Cancer - EORTC|Sanofi","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-1207|2012-002317-18","July 16, 2012","December 2012","December 2016","February 19, 2015","February 2015","No Study Results Posted","BOS3","December 2015","Progression free survival|Pathological response rate|Resection rate|Overall survival|Safety","https://ClinicalTrials.gov/show/NCT01646554"
1337,"NCT00220142","Molecular Markers of Prognosis in Colorectal Cancer Patients","Completed","No Results Available","Colorectal Cancer","","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","103","Other","Observational","Time Perspective: Prospective","2348","September 20, 2005","November 2003","null","May 30, 2013","May 2013","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00220142"
1338,"NCT01348256","Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma","Recruiting","No Results Available","Colorectal Carcinoma|Hepatic Metastasis","Drug: Dendritic cells vaccine","Clinica Universidad de Navarra, Universidad de Navarra","Both","18 Years and older   (Adult, Senior)","Phase 2","58","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CD-2009-01|2008-007795-23","May 3, 2011","November 2010","June 2014","May 6, 2013","November 2012","No Study Results Posted","null","December 2013","Progression Free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01348256"
1339,"NCT00212615","XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","C04.588.274.476.411.307","Drug: Oxaliplatin (Eloxatin)|Drug: Capecitabine (Xeloda)","Odense University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","116","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","XELOX III|KFE 03.17","September 13, 2005","February 2004","October 2008","October 16, 2009","October 2009","No Study Results Posted","null","null","Toxicity: before treatment (each 3 weeks) and by SAE (Serious Adverse Event)|Physical examination: before treatment (each 3 weeks)|Performance status: before treatment (each 3 weeks)|Haematology: before treatment (each 3 weeks)|Tumor biology: after 1st treatment, every 9th weeks herafter|Biochemistry: after every 3rd treatment (each 9th weeks)|Tumor assesment: after every 3rd treatment (each 9th weeks)","https://ClinicalTrials.gov/show/NCT00212615"
1340,"NCT01558583","Online Study of Colorectal Cancer and Prostate Cancer Screening Decision Making","Completed","No Results Available","Colorectal Cancer|Colon Cancer|Prostate Cancer","Other: Rating and Ranking Task|Other: Discrete Choice Task|Other: Balance Sheet Task","University of North Carolina, Chapel Hill","Both","50 Years to 75 Years   (Adult, Senior)","","1831","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","UCRF-CARR2-11-0861","February 7, 2012","July 2011","October 2011","July 9, 2012","July 2012","No Study Results Posted","CARR2","October 2011","Participant-reported most important attribute from survey|Participant-reported intent to undergo screening from survey|Unlabeled screening test options","https://ClinicalTrials.gov/show/NCT01558583"
1341,"NCT00405561","Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003","Terminated","No Results Available","Colorectal Carcinoma","Drug: AMT2003","Auron Healthcare GmbH","Both","18 Years to 79 Years   (Adult, Senior)","Phase 2|Phase 3","67","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMT/P2GI/001 Part III|LC001Auron2005","November 29, 2006","October 2006","January 2010","March 19, 2013","March 2013","No Study Results Posted","null","January 2010","Progression free survival;at 18 weeks after registration|Best overall response rate (ORR, CR and PR) within 18 weeks after registration|Progression Free survival time (PFS), over complete observation period|Overall Survival (OS) time|Quality of Life (EORTC QLQ-C30) and Performance Status (Karnofsky Index)|Safety and Tolerability","https://ClinicalTrials.gov/show/NCT00405561"
1342,"NCT02652702","Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients","Not yet recruiting","No Results Available","Colorectal Carcinoma","Procedure: circular stapler-assisted colostomy|Procedure: conventional hand-stitching colostomy","Zhejiang University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRCCZ-D01","December 29, 2015","February 2016","February 2020","January 9, 2016","December 2015","No Study Results Posted","STAPLER","February 2018","colostomy associated complications","https://ClinicalTrials.gov/show/NCT02652702"
1343,"NCT02510001","MErCuRIC1: MEK and MET Inhibition in Colorectal Cancer","Recruiting","No Results Available","Solid Tumour|Colorectal Cancer","Drug: PF-02341066|Drug: PD-0325901|Drug: Binimetinib","University of Oxford|Queen's University, Belfast|Oxford University Hospitals NHS Trust|Velindre NHS Trust|University Hospital, Antwerp|Hospital Vall d'Hebron|Hopital St Antoine, Paris|European Georges Pompidou Hospital|Pfizer|University of Turin, Italy|Belfast Health and Social Care Trust|Beaumont Hospital|European Commission|Array BioPharma|Q2 solutions|Covance|QPS Holdings","Both","16 Years and older   (Child, Adult, Senior)","Phase 1","78","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OCTO-049","June 18, 2015","November 2014","April 2018","August 31, 2016","August 2016","No Study Results Posted","MErCuRIC1","January 2018","Maximal tolerated dose (MTD) of PD-0325901 or Binimetinib with PF-02341066|Clinical response to Binimetinib combined with PF-02341066|Radiological response to Binimetinib with PF-02341066|Recommended phase II (RPII) dose and schedule guided by the number of participants with adverse events related to safety blood samples for haematology, biochemistry and coagulation data.|Recommended phase II (RPII) dose and schedule guided by the number of participants with adverse events related to ECOG data.|Recommended phase II (RPII) dose and schedule guided by the number of participants with adverse events related to vital signs of temperature, blood pressure and heart rate data.|Recommended phase II (RPII) dose and schedule guided by the number of participants with adverse events related to ECG measurements.|Recommended phase II (RPII) dose and schedule guided by the number of participants with adverse events related to weight measurements.|Recommended phase II (RPII) dose and schedule guided by the number of participants with adverse events related to ophthalmic measurements.|Recommended phase II (RPII) dose and schedule guided by PK data.|Recommended phase II (RPII) dose and schedule guided by PD data.|Pharmacokinetic peak plasma concentration (Cmax) for PF-02341066 and PD-0325901 or Binimetinib.|Pharmacokinetic minimum plasma trough concentration (Cmin) for PF-02341066 and PD-0325901 or Binimetinib.|Pharmacokinetic area under the plasma concentration versus time curve (AUC) for PF-02341066 and PD‐0325901(and its metabolite) or Binimetinib.|Pharmacokinetic plasma oral clearance and t1/2 etc for PF-02341066 and PD-0325901 or Binimetinib.|Pharmacodynamic (PD) biomarkers of PD-0325901 or Binimetinib and PF-02341066 in paired skin biopsies, tumour biopsies (where possible), in serum and PBMCs.|Tumour assessment using CT scan and modified RECIST version 1.1 and progression free and overall survival.|Carinoembryonic antigen blood level assessments.|Tumour Marker blood level assessments.|Tumour assessment using CT scan and modified RECIST version 1.1, and progression free and overall survival.|Tumour Marker blood level assessment.|Adverse events according to NCI CTCAE v4.03 across all treatment cycles.|Pharmacokinetic peak plasma concentration (Cmax) for PF-02341066 and Binimetinib.|Pharmacokinetic minimum plasma trough concentration (Cmin) for PF-02341066 and Binimetinib.|Pharmacokinetic area under the plasma concentration versus time curve (AUC) for PF-02341066 and Binimetinib.|Pharmacokinetic oral clearance and plasma t1/2 for PF-02341066 and Binimetinib.|Measurement of pharmacodynamic (PD) effect of PF-02341066 in combination with PD‐0325901 or Binimetinib in paired skin biopsies.|Measurement of pharmacodynamic (PD) effect of PF-02341066 in combination with PD‐0325901 or Binimetinib in paired tumour biopsies (where possible).|Measurement of pharmacodynamic (PD) effect of PF-02341066 in combination with Binimetinib in paired tumour biopsies (where possible).|Measurement of pharmacodynamic (PD) effect of PF-02341066 in combination with PD‐0325901 or Binimetinib in plasma blood samples.|Measurement of pharmacodynamic (PD) effect of PF-02341066 in combination with PD‐0325901 or Binimetinib in plasma PBMC blood samples.","https://ClinicalTrials.gov/show/NCT02510001"
1344,"NCT01944540","Brief Title : Optimized Endoscopic Submucosal Dissection With Snaring for Colorectal Neoplasm","Recruiting","No Results Available","Colorectal Neoplasms","Procedure: Optimized ESD with snaring|Procedure: Conventional ESD","Asan Medical Center","Both","18 Years and older   (Adult, Senior)","","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","optESDs2013AMC","September 13, 2013","August 2013","null","September 16, 2013","September 2013","No Study Results Posted","null","March 2014","procedure time|En Bloc resection rate|histologic complete resection rate|complication rate","https://ClinicalTrials.gov/show/NCT01944540"
1345,"NCT02364024","Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas","Completed","No Results Available","Metastatic Colorectal Cancer","","Federation Francophone de Cancerologie Digestive","Both","18 Years to 74 Years   (Adult, Senior)","","856","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PETACC8-BIO1","February 10, 2015","November 2005","null","May 27, 2016","May 2016","No Study Results Posted","CD3-OncoQuant","May 2009","Time to Recurrence (TTR)|Overall Survival (OS)|Disease-Free Survival (DFS)","https://ClinicalTrials.gov/show/NCT02364024"
1346,"NCT01742065","Strategies and Opportunities to Stop Colon Cancer in Priority Populations","Recruiting","No Results Available","Colorectal Cancer","Other: Auto Plus","Kaiser Permanente|National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health (NIH)|Group Health Cooperative","Both","50 Years to 74 Years   (Adult, Senior)","Phase 2","20000","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","UH3CA188640|1UH2AT007782-01","December 3, 2012","January 2013","December 2017","August 29, 2016","August 2016","No Study Results Posted","STOPCRC","September 2017","Increased Screening Rates","https://ClinicalTrials.gov/show/NCT01742065"
1347,"NCT00141466","Implementation of a New Strategy to Identify HNPCC Patients","Recruiting","No Results Available","Colorectal Neoplasms|Hereditary Nonpolyposis Colorectal Cancer","Behavioral: Education for professionals|Behavioral: Distribution of educational materials|Behavioral: Feedback for professionals|Behavioral: Reminders for professionals","Radboud University|ZonMw: The Netherlands Organisation for Health Research and Development","Both","Child, Adult, Senior","","360","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind","MIPA-2005|ZonMw nr. 945-14-107","August 31, 2005","September 2005","July 2007","April 22, 2008","February 2007","No Study Results Posted","null","null","Efficacy of inclusion of eligible CRC-patients for MSI testing by pathologists.|Efficacy of referral of patients who are MSI positive to a clinical geneticist by surgeons.|Experiences with and acceptance of changed physician practice roles by patients and clinicians.|Cost efficacy of the implementation procedures.","https://ClinicalTrials.gov/show/NCT00141466"
1348,"NCT02043821","Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Capecitabine|Other: placebo","Beijing Chao Yang Hospital","Both","18 Years to 75 Years   (Adult, Senior)","","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20140116","January 21, 2014","null","null","January 23, 2014","January 2014","No Study Results Posted","null","January 2016","DDC:Duration of Disease Control|OS:Overall Survival|DCR:Disease Control Rate","https://ClinicalTrials.gov/show/NCT02043821"
1349,"NCT00215982","Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: Oxaliplatin|Drug: Irinotecan","H. Lee Moffitt Cancer Center and Research Institute|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 2","24","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-13424|XEL351","September 19, 2005","December 2004","July 2007","November 21, 2013","September 2010","No Study Results Posted","null","July 2007","response rate|time to tumor progression|toxicity and tolerability","https://ClinicalTrials.gov/show/NCT00215982"
1350,"NCT02246049","A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC","Active, not recruiting","No Results Available","Colorectal Neoplasms","Biological: Bevacizumab|Drug: 5-fluorouracil|Drug: Irinotecan hydrochloride|Drug: Leucovorin calcium|Drug: Oxaliplatin","EPS Corporation","Both","20 Years to 75 Years   (Adult, Senior)","Phase 2","65","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","QUATTRO","September 12, 2014","May 2014","February 2017","August 28, 2015","September 2014","No Study Results Posted","QUATTRO","February 2017","Progression-free survival (PFS) at 10 months|Response rate (RR) by central review.|Response rate (RR) by investigator-reported measurements.|PFS by central review according to CT image.|Overall survival (OS)|Efficacy by RAS status ; RR,PFS,OS|Incidence of adverse events|Time to treatment-failure|Completion rate in Induction treatment|Relative Dose Intensity|Treatment duration","https://ClinicalTrials.gov/show/NCT02246049"
1351,"NCT02861300","CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Colon Cancer|Rectal Cancer|Solid Tumor","Drug: CB-839|Drug: Capecitabine","Case Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","53","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE1216","August 5, 2016","August 2016","January 2020","September 9, 2016","September 2016","No Study Results Posted","null","January 2018","PHASE 1: Recommended dose for phase II study|PHASE 2: Number of patients with response to treatment|PHASE 1: proportion of patient who respond to treatment","https://ClinicalTrials.gov/show/NCT02861300"
1352,"NCT01277406","4SC-201 (Resminostat) in Advanced Colorectal Carcinoma","Completed","No Results Available","Advanced Colorectal Carcinoma","Drug: 4SC-201(Resminostat)|Drug: FOLFIRI","4SC AG","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","17","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4SC-201-3-2010","January 10, 2011","January 2011","February 2015","March 31, 2015","March 2015","No Study Results Posted","SHORE","February 2013","Phase I: MTD of 4SC-201 (Resminostat) in combination with FOLFIRI by investigating safety, tolerability and pharmacokinetics|Phase II: Progression free survival (PFS)|Phase I: Progression free survival (PFS)|Phase I: Progression free survival rate (PFSR) after 8 weeks (4 cycles) and every following 8 weeks (additional 4 cycles each)|Phase I: Time to Progression (TTP)|Phase I: Number of Objective Response (OR)|Phase I: Overall survival (OS)|Phase I: Duration of Response (DOR)|Phase II: Progression free survival rate (PFSR) after 8 weeks (4 cycles) and ever following 8 week (additional 4 cycles each)|Phase II: Time to Progression (TTP)|Phase II: Number of Objective Responses (OR)|Phase II: Duration of Response (DOR)|Phase II: Safety and tolerability data comprising vital signs, physical examinations, ECGs, clinical laboratory and adverse events|Phase II: Overall survival (OS)|Phase II: Pharmacokinetics: AUClast, AUCtau, cmax, tmax, t ½, CL/F of resminostat, Irinotecan (SN-38), 5-FU and folinic acid","https://ClinicalTrials.gov/show/NCT01277406"
1353,"NCT00981110","Standard Versus Advanced Antimicrobial Dressing Containing Ionic Silver Following Colorectal Cancer Surgery","Completed","No Results Available","Colorectal Cancer","Device: AQUAGEL Ag Hydrofiber Wound Dressing|Device: Mepore Self-adhesive absorbent dressing","European Institute of Oncology","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","IEO S402/208","August 31, 2009","June 2008","December 2010","September 10, 2012","September 2012","No Study Results Posted","AM","October 2010","The rate of patients with a Surgical site infection","https://ClinicalTrials.gov/show/NCT00981110"
1354,"NCT02758951","Perioperative Systemic Therapy in Patients Undergoing Surgery With HIPEC for Colon Cancer With Peritoneal Metastases: the CAIRO6 Study.","Not yet recruiting","No Results Available","Colorectal Neoplasms|Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Peritoneal Neoplasms|Peritoneal Diseases","Drug: FOLFOX + bevacizumab|Drug: CAPOX + bevacizumab|Drug: FOLFOX|Drug: CAPOX","Catharina Ziekenhuis Eindhoven|Hoffmann-La Roche","Male","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","340","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NL57644.100.16|2016-001865-99|ISRCTN15977568|U1111-1182-2871","April 26, 2016","January 2017","January 2026","August 29, 2016","August 2016","No Study Results Posted","CAIRO6","January 2024","Major postoperative complications (Clavien-Dindo grade III-V).|Overall survival.|Number of patients included 1 year after start of recruitment of the last participating centre.|Disease free survival.|Procedure related characteristics of cytoreductive surgery and HIPEC (i.e. blood loss, operative time).|Peritoneal Cancer Index (PCI) Score.|Completeness of Cytoreduction (CC) Score.|Severe postoperative complications (Clavien-Dindo grade III-V).|Hospital stay.|Quality of life.|Cost-effectiveness.|% of patients able to complete their full adjuvant regimen, and reason(s) for not complete and/or dose reduction (experimental arm).|Severe systemic therapy related toxicity of neoadjuvant combination chemotherapy with bevacizumab (experimental arm), determined as NCICTCAE v4.0 grade III-V|Treatment related toxicity of adjuvant combination chemotherapy (experimental arm).|• Number of patients with disease progression, stable disease, or responsive disease to neoadjuvant combination chemotherapy/bevacizumab (experimental arm).|Minor postoperative complications (Clavien-Dindo grade II).|Systemic therapy related toxicity (NCICTCAE v4.0 grade II-V)","https://ClinicalTrials.gov/show/NCT02758951"
1355,"NCT01405638","Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention","Completed","No Results Available","Blood Pressure|Colorectal Cancer","Behavioral: Motivational Interviewing|Behavioral: Patient Navigation","New York University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)","Male","50 Years and older   (Adult, Senior)","","451","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","10-00427|1R01HL096946-01A2","July 27, 2011","March 2011","June 2015","November 11, 2015","November 2015","No Study Results Posted","FAITH-CRC","June 2015","Blood Pressure|Colorectal Cancer Screening","https://ClinicalTrials.gov/show/NCT01405638"
1356,"NCT01718873","Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Bevacizumab|Drug: Oxaliplatin|Drug: levo-folinic acid|Drug: 5-fluorouracil|Drug: Capecitabine","National Cancer Institute, Naples","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","230","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OBELICS|2011-004997-27","October 29, 2012","May 2012","June 2017","November 27, 2015","November 2015","No Study Results Posted","OBELICS","June 2016","number of objective responses|progression free survival|overall survival|worst grade toxicity per patient|changes in quality of life","https://ClinicalTrials.gov/show/NCT01718873"
1357,"NCT01457287","A Longitudinal Investigation of Cognitive Function in Colorectal Cancer Patients","Completed","No Results Available","Colorectal Cancer","","University Health Network, Toronto","Both","18 Years to 70 Years   (Adult, Senior)","","300","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","COIT10","October 19, 2011","October 2003","null","October 20, 2011","October 2011","No Study Results Posted","null","null","Cognitive Function|Potential mechanisms leading to fatigue and/or cognitive decline","https://ClinicalTrials.gov/show/NCT01457287"
1358,"NCT02439580","Effect of Annona Muricata Leaves on Colorectal Cancer Patients and Colorectal Cancer Cells","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: Annona muricata extract|Dietary Supplement: Placebo","Indonesia University","Both","18 Years and older   (Adult, Senior)","Phase 0","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","406/H2.F1/ETIK/2013","April 27, 2015","October 2013","October 2014","May 12, 2015","May 2015","No Study Results Posted","null","June 2014","Nutritional Status|Cytotoxicity","https://ClinicalTrials.gov/show/NCT02439580"
1359,"NCT00601198","A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: Amifostine","University of Cincinnati|MedImmune LLC|AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","97","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ETH190-06","January 14, 2008","October 2006","February 2010","March 22, 2010","March 2010","No Study Results Posted","null","February 2010","Test drug in 28 patients. Trial will be terminated if 5 or more have grade 3 & 4 PSN. Will continue & add patients if 4 or fewer patients with grade 3 & 4 toxicity out of 28.|Addition 69 patients will be studied. If total number of cumulative PSN is > or equal to 14, drug will be rejected. If less than 14 cases of cumulative PSN, declare drug effective in reducing 3rd & 4 grade toxicity by 50%","https://ClinicalTrials.gov/show/NCT00601198"
1360,"NCT02518373","Effect of G17DT in Patients With Stage II/III Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: G17DT|Drug: Omeprazole","Cancer Advances Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","22","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CC5","August 4, 2015","April 2000","February 2001","August 5, 2015","August 2015","No Study Results Posted","CC5","February 2001","Change in plasma gastrin level.","https://ClinicalTrials.gov/show/NCT02518373"
1361,"NCT00824161","Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer","Terminated","Has Results","Advanced Colorectal Cancer","Drug: TAS-109","Taiho Pharmaceutical Co., Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 2","28","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TAS109-0403","January 14, 2009","January 2009","December 2010","April 20, 2012","April 2012","June 21, 2011","null","November 2009","Percentage of Progression Free Survival|Antitumor Activity|Overall Survival","https://ClinicalTrials.gov/show/NCT00824161"
1362,"NCT02375672","Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Pembrolizumab|Drug: mFOLFOX6","Safi Shahda, M.D.|Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCRN GI14-186","February 24, 2015","April 2015","September 2017","August 22, 2016","August 2016","No Study Results Posted","null","September 2016","Median Progression Free Survival (mPFS)|Disease Assessment for Objective Response Rate (ORR)|Disease Assessment for Disease Control Rate|Disease Assessment for Delayed Response Rate|Overall Survival (OS)|Number of Patients with Adverse Events as a Measure of Safety and Tolerability|Disease Assessment per Immune Related Response Criteria","https://ClinicalTrials.gov/show/NCT02375672"
1363,"NCT00242086","Comparison of Triphasic CT, PET and MR Tumour With Pathological Findings in Colorectal Cancer Liver Metastases","Completed","No Results Available","Liver Metastases|Colorectal Cancer","Procedure: CT, PET and MRI","University Health Network, Toronto","Both","18 Years and older   (Adult, Senior)","","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","04-0659-C","October 18, 2005","October 2004","null","May 31, 2016","May 2016","No Study Results Posted","null","March 2010","","https://ClinicalTrials.gov/show/NCT00242086"
1364,"NCT02355353","Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer","Not yet recruiting","No Results Available","Liver Metastases|Colorectal Cancer","Other: Experimental: imaging arm","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years and older   (Adult, Senior)","","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","EORTC-1423","January 27, 2015","February 2015","February 2017","January 30, 2015","January 2015","No Study Results Posted","null","September 2016","Percentage of ADC changes|Tumor regression grade (TRG)|Repeatability Coefficient|Pre-operative (post-treatment) ADC measurement|Lesion volume|Histopathological measurements of tumor tissue cellularity /density, Necrosis, Proliferation (ki-67)","https://ClinicalTrials.gov/show/NCT02355353"
1365,"NCT00786643","Study of Gamma Interfereon in Metastatic Colorectal Carcinoma","Completed","Has Results","Colorectal Cancer","Drug: 5-Fluorouracil|Drug: Leucovorin (LV)|Drug: Gamma-Interferon-1b (IFN-γ)|Drug: Bevacizumab","Accelerated Community Oncology Research Network|InterMune","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WITMMCC0301","November 3, 2008","February 2006","March 2010","February 28, 2012","February 2012","November 17, 2011","GFL","March 2010","Best Response (BR)|Early Response Rate (RR) (Stratum 1 Only)|Time to Progression","https://ClinicalTrials.gov/show/NCT00786643"
1366,"NCT01622543","Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Folfox plus Bevacizumab and reolysin|Drug: Folfox plus Bevacizumab","Canadian Cancer Trials Group|Oncolytics Biotech","Both","18 Years and older   (Adult, Senior)","Phase 2","109","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","I210","June 12, 2012","August 2012","March 2017","March 28, 2016","March 2016","No Study Results Posted","null","September 2016","Progression free survival|Changes in CEA levels|Objective response rate|Overall survival|Molecular response|Quality of Life|Tolerability and toxicity in patients","https://ClinicalTrials.gov/show/NCT01622543"
1367,"NCT01312467","A Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index","Completed","Has Results","Adenomatous Polyp|Colorectal Cancer|Obesity","Drug: metformin hydrochloride|Other: pharmacological study|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","35 Years to 80 Years   (Adult, Senior)","Phase 2","45","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","NCI-2011-01744|UCI 10-31|2010-7705|UCI09-13-01|P30CA062203|N01CN35160","March 7, 2011","March 2011","March 2014","June 3, 2015","June 2014","May 11, 2015","null","March 2014","Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235)|Effects of Metformin Hydrochloride on Colorectal Mucosa Proliferation (Ki-67, Phosphorylated IGF-1 Receptor, Phosphorylated Insulin Receptor, Phosphorylated AKT, Phosphorylated mTOR, and Phosphorylated AMP Kinase)|Effects of Metformin Hydrochloride on Serum (Fasting and 2 Hour Postprandial Insulin and Glucose, Fasting IGF-1, IGFBP-1, IGFBP-3, Leptin, Adiponectin and Metformin Levels)|Safety and Tolerability of Metformin Hydrochloride Treatment","https://ClinicalTrials.gov/show/NCT01312467"
1368,"NCT02705300","Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: Irinotecan 165 mg/m2 iv|Drug: Oxaliplatin 85 mg/m2 iv|Drug: Calcium folinate 200 mg/m2 iv|Drug: 5-fluorouracil 3200 mg/m2|Dietary Supplement: Tocotrienol|Drug: Placebo","Vejle Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FOLFOXIRI-Toco","February 26, 2016","May 2016","March 2025","May 24, 2016","May 2016","No Study Results Posted","null","August 2019","Time to first serious adverse event|Number of non-planned hospitalizations calculated from date of first treatment until 1 month after completed chemotherapy|Duration of non-planned hospitalizations calculated from date of first treatment until 1 month after completed chemotherapy|Death during treatment calculated from date of first treatment until 1 month after completed chemotherapy|Response rate|Progression free survival|Overall survival|Number of patients with treatment related adverse events as assessed by CTCAE v.4.0|Quality of life as measured by combined questionnaire consisting of EORTC QLQ-C30 and CR29|Resection rate","https://ClinicalTrials.gov/show/NCT02705300"
1369,"NCT00641615","Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: RNF43-721","Kazuhiko Yoshimatsu|Human Genome Center, Institute of Medical Science, University of Tokyo|Tokyo Women's Medical University","Both","20 Years and older   (Adult, Senior)","Phase 1","18","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TWMU1035","March 17, 2008","May 2007","July 2011","May 11, 2015","May 2015","No Study Results Posted","null","July 2011","Safety (toxicities as assessed by NCI CTCAE version 3)|Specific CTL induction in vitro, Objective rate as assessed by RECST criteria","https://ClinicalTrials.gov/show/NCT00641615"
1370,"NCT01996306","A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC","Active, not recruiting","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms","Biological: Bevacizumab|Drug: CPT-11 (Irinotecan)|Drug: 5-FU Bolus|Drug: 5-FU Infusion|Drug: l-LV (dl-LV)|Biological: bevacizumab|Drug: CPT-11 (Irinotecan)|Drug: Capecitabine","Epidemiological and Clinical Research Information Network","Both","20 Years and older   (Adult, Senior)","Phase 3","650","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AXEPT|UMIN000012263","November 22, 2013","December 2013","January 2017","February 2, 2016","February 2016","No Study Results Posted","AXEPT","January 2017","Overall survival|Progression-free survival (PFS)|Time to treatment failure (TTF)|Overall Response Rate (ORR)|Disease Control Rate (DCR)|Relative Dose Intensity|Incidence of Adverse Events (Adverse Reactions)|Correlation between UGT1A1 genotype and safety","https://ClinicalTrials.gov/show/NCT01996306"
1371,"NCT02117466","Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Dose escalation cetuximab|Drug: Standard dose cetuximab","VU University Medical Center|University Medical Center Groningen|Radboud University","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","85","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2013.265|2013-002023-41","April 8, 2014","April 2014","null","December 8, 2015","December 2015","No Study Results Posted","IMPACT-CRC","April 2017","Uptake (SUV) of 89Zr-cetuximab in extra-hepatic metastases on PET-scan|Clinical Benefit Rate|Early response evaluation with 18F-FDG PET|Tumor perfusion as early response evaluation (measured with 15O-H2O-PET)|Overall survival|Progression Free Survival|Skin toxicity and hypomagnesemia as early response marker|Quality of life (QoL) and health related QoL","https://ClinicalTrials.gov/show/NCT02117466"
1372,"NCT01741038","AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Biological: AlloStim®|Procedure: cryoablation|Other: Physician's Choice (PC)","Immunovative Therapies, Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","450","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ITL-008-INSTAVAC-CRC","November 29, 2012","December 2017","October 2020","August 7, 2016","August 2016","No Study Results Posted","null","December 2019","Overall Survival|Safety|Health-Related Quality of Life (HRQoL)","https://ClinicalTrials.gov/show/NCT01741038"
1373,"NCT00986440","Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy","Completed","No Results Available","Colorectal Cancer","Drug: CS-7017|Drug: Placebo","Daiichi Sankyo Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","86","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CS7017-A-E201","September 29, 2009","July 2009","January 2013","April 13, 2015","April 2015","No Study Results Posted","null","January 2013","Compare PFS rate of participants treated with CS-7017 versus placebo.|Compare overall PFS of participants treated with CS-7017 versus placebo.|Compare overall survival of participants treated with CS-7017 versus placebo.","https://ClinicalTrials.gov/show/NCT00986440"
1374,"NCT00353262","A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.","Completed","Has Results","Colorectal Cancer","Drug: Avastin|Drug: Oxaliplatin|Drug: capecitabine [Xeloda]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NP18587","July 17, 2006","July 2005","April 2008","February 4, 2016","February 2016","December 4, 2015","null","September 2006","Area Under The Plasma Concentration-Time Curve From Zero To Infinity (AUC0-Inf) of 5'-Deoxy-5-fluorouridine 5'-(DFUR)|AUC0-inf for Free Platinum|AUC (0-infinity) of Capecitabine and Its Metabolites (5'-DFCR, 5-FU, and FBAL)|AUC0-last of Capecitabine and Its Metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)|Maximum Plasma Concentration (Cmax) of Capecitabine and Its Metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)|Elimination Half-life Period (t1/2 Beta) of Capecitabine and Its Metabolites (5'-DFUR , 5'-DFCR, 5 FU, and FBAL)|AUC0-infinity for Total Platinum|AUC0-last of Total And Free Platinum|Cmax of Total And Free Platinum|T1/2 Beta of Total And Free Platinum|Volume of Distribution at Steady State (VSS) of Total And Free Platinum|Clearance of Total And Free Platinum|Number Of Participants With Adverse Events (AEs)|Marked Laboratory Abnormalities","https://ClinicalTrials.gov/show/NCT00353262"
1375,"NCT02656524","Stivarga Real Life Evidence in Hungary","Active, not recruiting","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)","Bayer","Both","Child, Adult, Senior","","400","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18686","December 21, 2015","May 2016","September 2016","August 18, 2016","August 2016","No Study Results Posted","null","September 2016","Length of treatment for each treatment episode|Progression Free Survival (PFS)|Overall Survival (OS)|Number of participants with treatment emergent adverse events as a measure of safety and tolerability|Resource utilization per patient","https://ClinicalTrials.gov/show/NCT02656524"
1376,"NCT00125034","Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)","Completed","Has Results","Neoplasm Metastasis|Colorectal Cancer","Biological: Cetuximab|Drug: Oxaliplatin","Merck KGaA","Both","18 Years and older   (Adult, Senior)","Phase 2","344","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62202-047","July 28, 2005","July 2005","November 2010","August 5, 2014","August 2011","August 23, 2011","OPUS","March 2007","Best Overall Response Rate - Independent Review Committee (IRC)|Best Overall Response Rate (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population)|Best Overall Response Rate (KRAS Mutant Population)|Progression-free Survival Time|Progression-free Survival Time (KRAS Wild-Type Population)|Progression-free Survival Time (KRAS Mutant Population)|Overall Survival Time|Overall Survival Time (KRAS Wild-Type Population)|Overall Survival Time (KRAS Mutant Population)|Participants With No Residual Tumor After Metastatic Surgery|Disease Control Rate (Cut Off Date 4 August 2006)|Duration of Response|Safety - Number of Patients Experiencing Any Adverse Event","https://ClinicalTrials.gov/show/NCT00125034"
1377,"NCT00630045","Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis","Recruiting","No Results Available","Colorectal Cancer|Resectable Liver Metastasis","Drug: neoadjuvant chemotherapy with oxaliplatin and capecitabine|Procedure: resection of liver metastasis","Peking University People's Hospital|Peking University|Sanofi","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","392","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OXALIC","February 26, 2008","January 2008","June 2015","March 5, 2008","February 2008","No Study Results Posted","null","June 2010","disease free survival rate|R0 resection rate|survival rate and over survival|surgery related mortality|response rate and safety of XELOX as a neoadjuvant regimen","https://ClinicalTrials.gov/show/NCT00630045"
1378,"NCT00106054","Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases","Terminated","No Results Available","Colorectal Neoplasms|Liver Neoplasms","Drug: Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","2","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A5961065","March 18, 2005","January 2006","September 2006","August 26, 2010","August 2010","No Study Results Posted","null","September 2006","To determine the rate of R0 resection or pathologically confirmed CR in patients with hepatic only metastases|oTo determine the resectable rate, defined as the number of subjects with R0 resection, pathologically staged CR, or undergoing non-surgical ablative procedures with curative intent divided by the total number of evaluable subjects following treatment","https://ClinicalTrials.gov/show/NCT00106054"
1379,"NCT01280643","Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Drug: irinotecan hydrochloride|Biological: bevacizumab|Biological: cetuximab|Drug: capecitabine|Genetic: mutation analysis|Genetic: gene expression analysis|Other: laboratory biomarker analysis|Other: immunohistochemistry staining method|Genetic: nucleic acid sequencing|Genetic: protein expression analysis|Genetic: polymerase chain reaction|Genetic: DNA analysis","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","11","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB 09-033|NCI-2011-00046","January 20, 2011","March 2010","null","September 10, 2015","September 2015","No Study Results Posted","null","December 2012","Feasibility, defined as a sufficient proportion of subjects having available tissue and an acceptable composite assay success rate among tested subjects|Best overall response via RECIST|Time to failure of treatment strategy|Progression-free survival","https://ClinicalTrials.gov/show/NCT01280643"
1380,"NCT00479752","Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFOX4 (Oxaliplatin), Cetuximab","Central European Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 2","151","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CECOG /CORE 1.2.002","May 25, 2007","January 2008","November 2015","February 17, 2016","February 2016","No Study Results Posted","CORE 2","June 2010","The primary endpoint of the trial is: • Objective response (CR/PR), as assessed by RECIST criteria|• Progression Free Survival (PFS) • Overall survival • Safety/Adverse events Safety","https://ClinicalTrials.gov/show/NCT00479752"
1381,"NCT00677612","Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer|Colon Cancer|Rectal Cancer","Biological: VEGFR1 and VEGFR2","Tokyo University|Human Genome Center, Institute of Medical Science, University of Tokyo","Both","20 Years to 85 Years   (Adult, Senior)","Phase 1|Phase 2","14","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRC-A02-I, II","May 12, 2008","May 2008","March 2009","December 28, 2009","January 2009","No Study Results Posted","null","March 2009","safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST)|To evaluate immunological responses","https://ClinicalTrials.gov/show/NCT00677612"
1382,"NCT00677287","Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer|Colon Cancer|Rectal Cancer","Biological: RNF43, TOMM34, VEGFR1 and VEGFR2","Tokyo University|Human Genome Center, Institute of Medical Science, University of Tokyo","Both","20 Years to 85 Years   (Adult, Senior)","Phase 1|Phase 2","14","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRC-A24-I, II","May 12, 2008","May 2008","March 2009","December 28, 2009","May 2008","No Study Results Posted","null","March 2009","safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST)|To evaluate immunological responses","https://ClinicalTrials.gov/show/NCT00677287"
1383,"NCT01086267","Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: BMS-908662|Drug: BMS-908662|Drug: Cetuximab","Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","17","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA206-001|2010-018944-15","March 11, 2010","July 2010","August 2011","June 23, 2016","June 2016","No Study Results Posted","null","August 2011","Toxicity will be evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3|Efficacy as determined by estimates of objective response rates and response duration|Pharmacodynamics (PD) will be assessed by evaluating markers of RAS/RAF pathway activity|Pharmacokinetics (PK) for BMS-908662 as determined by minimum observed concentrations [Cmin].|Pharmacokinetics (PK) for BMS-908662 as determined by maximum observed concentrations [Cmax].|Pharmacokinetics (PK) for BMS-908662 as determined by time of maximum observed concentration [Tmax].|Pharmacokinetics (PK) for BMS-908662 as determined by area under the concentration-curve for one dosing interval [AUC(TAU)].|Pharmacokinetics (PK) for BMS-908662 as determined by accumulation index [AI].","https://ClinicalTrials.gov/show/NCT01086267"
1384,"NCT01693848","""Cancersensor"" Metastasis Resection","Recruiting","No Results Available","Metastatic Colorectal Cancer","","Institut National de la Santé Et de la Recherche Médicale, France","Both","18 Years and older   (Adult, Senior)","","45","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","C11-58|2012-A00011-42","September 7, 2012","September 2012","December 2016","June 24, 2015","June 2015","No Study Results Posted","null","December 2016","Effect of resection of metastasis on urinary excretion of modified nucleosides|Identification of modified nucleosides as biomarkers for colorectal cancer","https://ClinicalTrials.gov/show/NCT01693848"
1385,"NCT01054924","Performance Study of the Invendo C20 Colonoscope System in Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer Screening","","Invendo Medical GmbH","Both","50 Years to 75 Years   (Adult, Senior)","","null","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","INV2009-01","January 21, 2010","November 2009","December 2009","January 21, 2010","January 2010","No Study Results Posted","null","December 2009","","https://ClinicalTrials.gov/show/NCT01054924"
1386,"NCT00349336","A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.","Completed","Has Results","Colorectal Cancer","Drug: bevacizumab [Avastin]|Drug: XELOX|Drug: bevacizumab [Avastin]|Drug: FOLFOX-4","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","64","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NO20254","July 6, 2006","August 2006","November 2008","September 12, 2012","September 2012","June 2, 2009","null","November 2008","Weekly Steady-state Exposure of Bevacizumab|Time Zero to Last Measurable Plasma Concentration of Bevacizumab|Steady-state Exposure of Bevacizumab From Time Zero to Tau|Maximum Serum Concentration of Bevacizumab at Steady State|Minimum Serum Concentration of Bevacizumab at Steady State|Serum Clearance of Bevacizumab|Time of Maximum Serum Concentration of Bevacizumab|Volume of Distribution of Bevacizumab at Steady State|Terminal Half-life of Bevacizumab","https://ClinicalTrials.gov/show/NCT00349336"
1387,"NCT02618850","PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment","Recruiting","No Results Available","Colorectal Cancer Stage IV","Procedure: PET/CT|Drug: first-line chemotherapy","National Cancer Institute, Naples","Both","18 Years and older   (Adult, Senior)","","260","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PETRA2 - CRC","April 13, 2015","April 2014","October 2016","November 27, 2015","November 2015","No Study Results Posted","PETRA2 - CRC","April 2016","change from baseline in highest value SUVmax (maximum standardized uptake values in PET/CT scan)|Change from baseline in SUVmaxsum, TLGmax and TLGmaxsum|correlation among SUVmax, SUVmaxsum, TLGmax, TLGsum with progression-free survival after first-line pharmacologic therapy|correlation among SUVmax, SUVmaxsum, TLGmax, TLGsum with objective response|prognostic value of metabolic response (SUVmax, SUVmaxsum, TLGmax, TLGsum) and recist response","https://ClinicalTrials.gov/show/NCT02618850"
1388,"NCT01349881","S0820, Adenoma and Second Primary Prevention Trial","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Eflornithine placebo & sulindac placebo|Drug: eflornithine & sulindac placebo|Drug: Eflornithine placebo & sulindac|Drug: Eflornithine plus sulindac","Southwest Oncology Group|National Cancer Institute (NCI)|Cancer Prevention Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","1340","Other|NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","S0820|U10CA037429|NCI-2012-02067","May 5, 2011","March 2013","June 2029","April 8, 2016","April 2016","No Study Results Posted","PACES","June 2024","3-year event rate after registration among Stage 0-III colon cancer patients. (An event is defined as high-risk adenoma or second primary colorectal cancer.)|Incidence of colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, polyps >/= 0.3 cm, total advanced colorectal events or total colorectal events at 3 years.|Toxicity by CTCAEv.4.0 at 3 years|Examine interaction of treatment arm and genotype expression with respect to different outcomes.|Interaction of intervention arm and baseline statin use with respect to 3-year event rate.|Evaluate SNPs associated with decreased adenoma/second primary CRC risk and AEs","https://ClinicalTrials.gov/show/NCT01349881"
1389,"NCT00035919","Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver","Withdrawn","No Results Available","Colorectal Neoplasms","Genetic: Mx-dnG1 Retroviral Vector","University of Southern California","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-01-2","May 6, 2002","November 2002","October 2003","May 20, 2014","May 2014","No Study Results Posted","null","null","dose-limiting toxicity and maximum tolerated dose|objective tumor response by CT scan or MRI","https://ClinicalTrials.gov/show/NCT00035919"
1390,"NCT01208194","Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma","Completed","No Results Available","Advanced Colorectal Carcinoma","Drug: MGN1703|Drug: Placebo","Mologen AG","Both","18 Years and older   (Adult, Senior)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MGN1703-C02|2009-017432-40","August 27, 2010","June 2010","March 2013","June 19, 2014","June 2014","No Study Results Posted","IMPACT","December 2012","Evaluation of median progression-free survival (PFS) in both treatment groups|Assessment of PFS rate|Evaluation of median overall survival (OS)|Assessment of OS proportion in both groups|Evaluation of overall response rate (ORR)|Evaluation of duration of response (complete response, partial response, stable disease) as time from initial determination of response to progressive disease measured by RECIST|Assessment of the dynamic of clinical and laboratory parameters|Evaluation of immunologic response to MGN1703|Assessment of quality of life (QOL)|Assessment of the safety profile of MGN1703","https://ClinicalTrials.gov/show/NCT01208194"
1391,"NCT02588781","Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: Pemetrexed","Samsung Medical Center","Both","20 Years and older   (Adult, Senior)","Phase 2","29","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-05-071","October 27, 2015","October 2015","July 2018","October 27, 2015","October 2015","No Study Results Posted","null","December 2017","overall response rate|overall survival|progression free survival|Number of subjects with Adverse Events as a measure of safety and Tolerability","https://ClinicalTrials.gov/show/NCT02588781"
1392,"NCT01095523","Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases","Withdrawn","No Results Available","Colorectal Carcinoma|Peritoneal Carcinomatosis","Procedure: Laparotomy+ HIPEC +/- CRS","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","0","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","100037|10-C-0037","March 27, 2010","January 2010","February 2012","March 20, 2012","February 2012","No Study Results Posted","null","February 2012","To compare the overall survival of patients at high risk for developing peritoneal carcinomatosis from colorectal cancer who undergo mandatory second look surgery + HIPEC and CRS (if applicable) vs. similar patients who receive standard of care.|To determine recurrence-free survival in both arms. To investigate selection criteria for patients who might benefit from a strategy of MSLS with CRS + HIPEC.","https://ClinicalTrials.gov/show/NCT01095523"
1393,"NCT02199223","Regorafenib + Panitumumab for Colorectal Cancers","Active, not recruiting","No Results Available","KRAS and NRAS Wild-type Colorectal Cancer","Drug: regorafenib + panitumumab","University of Utah","Both","18 Years and older   (Adult, Senior)","Phase 1","2","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCI72561","June 30, 2014","June 2014","June 2017","March 7, 2016","March 2016","No Study Results Posted","null","June 2017","Safety of regorafenib + panitumumab","https://ClinicalTrials.gov/show/NCT02199223"
1394,"NCT00192075","A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: Gemcitabine|Drug: avastin|Drug: 5FU/folinic acid|Drug: oxaliplatin","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","84","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","8142|B9E-US-S337","September 12, 2005","June 2003","November 2007","February 4, 2011","November 2009","October 30, 2008","null","null","Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)|Time to Progressive Disease|Progression-Free Survival|Overall Survival|Duration of Response","https://ClinicalTrials.gov/show/NCT00192075"
1395,"NCT02484404","Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers","Recruiting","No Results Available","Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer","Drug: Olaparib|Drug: Cediranib|Drug: MEDI4736","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","338","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","150145|15-C-0145","June 25, 2015","June 2015","December 2019","August 31, 2016","August 2016","No Study Results Posted","null","December 2018","Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of MEDI4736/olaparib (MEDI-O) and MEDI4736/cediranib (MEDI-C) in patients with advanced solid tumors|Ph II Determine overall response rate of MED-O and MEDI-C in patients with recurrent ovarian cancer","https://ClinicalTrials.gov/show/NCT02484404"
1396,"NCT01133990","FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLIRI|Drug: FOLIRI plus E7820|Drug: FOLFIRI plus Bevacizumab","Eisai Inc.|PharmaBio Development Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","5","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E7820-701|2009-016015-37","May 21, 2010","April 2010","January 2011","May 21, 2013","July 2012","No Study Results Posted","null","January 2011","Safety Parameter: Adverse Events|Safety Parameter: Concomitant Meds|Safety Parameter: Lab tests|Safety Parameter: ECGs|Efficacy Parameter","https://ClinicalTrials.gov/show/NCT01133990"
1397,"NCT02260440","A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Pembrolizumab|Drug: Azacitidine","University of Pittsburgh|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14-118","October 6, 2014","January 2015","November 2020","June 8, 2016","June 2016","No Study Results Posted","null","November 2019","objective response rate using RECIST 1.1","https://ClinicalTrials.gov/show/NCT02260440"
1398,"NCT01249521","Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: AMG386 and bevacizumab","Austin Health","Both","Child, Adult, Senior","Phase 2","40","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03501","November 29, 2010","November 2010","November 2012","November 29, 2010","November 2010","No Study Results Posted","Vengeance","November 2011","Disease control (ie non progression) at 6 months|Toxicity|Overall survival|Response rate","https://ClinicalTrials.gov/show/NCT01249521"
1399,"NCT01802684","OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Unresectable Metastatic Colorectal Cancer","Biological: aflibercept","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","49","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VELVET C12-1|2012-003521-25","February 26, 2013","May 2013","March 2016","December 10, 2015","December 2015","No Study Results Posted","VELVET","March 2016","Progression free survival at 6 months|Median Progression Free Survival|duration of disease control (DDC)|Overall Survival|tumor Response Rate (RR)|Health related Quality of life|Safety|Curative salvage surgery","https://ClinicalTrials.gov/show/NCT01802684"
1400,"NCT01895257","Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Device: HAI-90Y radioembolization (SIR-spheres injection)|Drug: systemic chemotherapy LV5FU2","Universiteit Antwerpen","Both","18 Years to 99 Years   (Adult, Senior)","Phase 3","162","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","The SIR-step trial|2012-000508-14","June 6, 2013","August 2013","December 2018","December 8, 2015","December 2015","No Study Results Posted","null","December 2017","Time to progression (TTP1 overall)|Time to global progression (TTP1 + TTP2)|PFS|Safety|R0 resection rate|Quality of life|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01895257"
1401,"NCT01126866","Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy","Terminated","No Results Available","Colorectal Carcinoma","Drug: intensified chemotherapy (FOLFOXIRI/Bevacizumab)","National Center for Tumor Diseases, Heidelberg|Roche Pharma AG|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCT-2007-11-02-1003","May 12, 2010","June 2009","June 2011","July 14, 2011","May 2011","No Study Results Posted","APRIORI","March 2011","surgically complete resectability; S-CR|Evaluate the acute and perioperative toxicity of preoperative chemotherapy according to NCI CTCAE v3.0 and all peri-and post-surgical complications|Survival rate (OS) and progression free survival (PFS)","https://ClinicalTrials.gov/show/NCT01126866"
1402,"NCT00362102","A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma","Completed","No Results Available","Colorectal Carcinoma","Drug: Cetuximab","Eli Lilly and Company","Both","20 Years to 75 Years   (Adult, Senior)","Phase 2","38","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA225-259","August 8, 2006","October 2005","July 2006","October 26, 2015","October 2015","No Study Results Posted","null","July 2006","Response according to the RECIST criteria accessed every 6 weeks|Time to progression, duration of achieved response, and the disease control rate will be accessed in all patients who received Cetuximab. The worst toxicity grades per patients will be tabulated for adverse events and laboratory measurements.","https://ClinicalTrials.gov/show/NCT00362102"
1403,"NCT01652482","Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)","Completed","No Results Available","Colorectal Cancer","Drug: 5-fluorouracil|Drug: Cetuximab|Drug: Irinotecan|Drug: Leucovorin|Drug: MEHD7945A","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","135","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GO28074|2011-005547-27","July 26, 2012","October 2012","November 2014","September 1, 2016","September 2016","No Study Results Posted","null","November 2014","Progression-free Survival (PFS) According to Modified RECIST v1.1 Criteria|Plasma Concentration of 5-Fluorouracil|Plasma Concentration of Irinotecan|Number of Participants With Anti-MEHD7945A Antibodies|Number of Participants With Objective Response According to Modified RECIST v1.1 Criteria|Duration of Objective Response According to Modified RECIST v1.1 Criteria|Overall Survival (OS)|Number of Participants With Adverse Events|Maximum Observed Serum Concentration (Cmax) of MEHD7945A|Minimum Observed Serum Concentration (Cmin) of MEHD7945A","https://ClinicalTrials.gov/show/NCT01652482"
1404,"NCT01189903","Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients","Active, not recruiting","No Results Available","Asian Colorectal Cancer Patients","Drug: Regorafenib","National University Hospital, Singapore","Both","21 Years and older   (Adult, Senior)","Phase 2|Phase 3","null","Other","Interventional","Primary Purpose: Treatment","CR01/18/10","August 25, 2010","January 2011","null","January 26, 2014","January 2014","No Study Results Posted","null","August 2013","","https://ClinicalTrials.gov/show/NCT01189903"
1405,"NCT00668863","Study Of Sunitinib With FOLFIRI In Colorectal Cancer","Completed","Has Results","Unresectable or Metastatic Colorectal Cancer","Drug: FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|Drug: Sunitinib","Pfizer","Both","20 Years and older   (Adult, Senior)","Phase 2","71","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181151","April 25, 2008","May 2008","September 2010","October 11, 2011","October 2011","September 2, 2011","null","September 2010","Progression-Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants Who Presented Objective Response: Objective Response Rate (ORR)|Duration of Response (DR)|Maximum Observed Plasma Concentration (Cmax) and Predose Concentration (Ctrough) of Sunitinib.|Time to Reach Maximum Plasma Concentration (Tmax) of Sunitinib|Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC 0-24) of Sunitinib|Apparent Oral Clearance (CL/F) of Sunitinib|Maximum Observed Plasma Concentration (Cmax) of Irinotecan|Time to Reach Maximum Plasma Concentration (Tmax) of Irinotecan|Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC Last) and Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC ∞) of Irinotecan|Terminal Phase Elimination Half-life (t1/2) of Irinotecan|Clearance of Irinotecan|Volume of Distribution at Steady State (Vss) of Irinotecan|Plasma Concentration at Steady State (Css) of 5-FU|Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Grade 3 or Higher Adverse Events According to Common Terminology Criteria (CTCAE).","https://ClinicalTrials.gov/show/NCT00668863"
1406,"NCT02414009","Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Capecitabine|Drug: Temozolomide|Drug: Irinotecan|Drug: Fluorouracil|Drug: Leucovorin","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Both","18 Years and older   (Adult, Senior)","Phase 2","82","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CAPTEM","February 5, 2015","September 2014","September 2017","April 9, 2015","April 2015","No Study Results Posted","CAPTEM","September 2017","Progression-free survival of FOLFIRI versus CAPTEM|Response rate|Overall survival of FOLFIRI versus CAPTEM|Number of Adverse events by CTCAE version 4.0|Quality of life as measured by EORTC QLQ - CR29 QLQ-C30","https://ClinicalTrials.gov/show/NCT02414009"
1407,"NCT01183494","A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFIRI, Avastin, Irinotecan","University of Chicago|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","Both","18 Years and older   (Adult, Senior)","Phase 1","45","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","09-277-B","August 12, 2010","December 2009","December 2017","October 13, 2015","October 2015","No Study Results Posted","null","December 2016","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|To evaluate the pharmacokinetic profile of irinotecan in combination with bevacizumab.","https://ClinicalTrials.gov/show/NCT01183494"
1408,"NCT02272244","Increasing Colorectal Cancer (CRC) Screening Among Hispanic Primary Care Patients","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Decision Support & Navigation|Behavioral: Standard","Thomas Jefferson University|Lehigh Valley Hospital|Fox Chase Cancer Center|Patient-Centered Outcomes Research Institute","Both","50 Years to 75 Years   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","AD-1306-01882","October 20, 2014","April 2014","March 2017","August 4, 2015","August 2015","No Study Results Posted","null","January 2017","Overall Screening Adherence|Change in Screening Decision Stage|Test Specific Screening Adherence|Screening Knowledge and Perceptions","https://ClinicalTrials.gov/show/NCT02272244"
1409,"NCT01882868","A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan","Completed","No Results Available","Colorectal Cancer Metastatic","Drug: aflibercept AVE0005","Sanofi|Regeneron Pharmaceuticals","Both","20 Years and older   (Adult, Senior)","Phase 2","62","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC11885|U1111-1120-0173","June 18, 2013","July 2013","August 2015","November 12, 2015","November 2015","No Study Results Posted","null","August 2015","Assessment of overall response rate (ORR)|Progression free survival (PFS) - Time|Overall survival (OS) - Time|Incidence of treatment emergent adverse events|Incidence of laboratory abnormalities|Assessment of the titer of anti-aflibercept antibodies as a measure of the immunogenicity of aflibercept|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - clearance (CL)|Assessment of PK parameter - distribution volume at steady state (Vss)","https://ClinicalTrials.gov/show/NCT01882868"
1410,"NCT02085005","Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer","Withdrawn","No Results Available","Colorectal Cancer Metastatic","Drug: Capecitabine|Drug: Aflibercept AVE0005|Drug: Oxaliplatin SR96669","Sanofi|Regeneron Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LPS13787|U1111-1149-0237","March 10, 2014","March 2014","August 2016","November 17, 2014","November 2014","No Study Results Posted","Drop and Go","August 2016","Progression Free Survival rate at 10 months (PFS@10m)|Progression Free Survival (PFS) - Time|Overall Survival (OS) - Time|Assessment of Objective Response Rate (ORR)|Total Score as a measure of Health Related Quality of Life|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT02085005"
1411,"NCT02292758","Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Bevacizumab|Drug: Irinotecan|Drug: Cetuximab","Academic and Community Cancer Research United","Both","18 Years and older   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","RU021302I","November 13, 2014","March 2015","null","August 23, 2016","August 2016","No Study Results Posted","null","December 2019","Progression Free Survival","https://ClinicalTrials.gov/show/NCT02292758"
1412,"NCT01374425","Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)","Completed","Has Results","Colorectal Cancer","Drug: 5-Fluorouracil|Drug: Bevacizumab|Drug: Irinotecan|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Capecitabine","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","376","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25710|2011-004755-39","June 14, 2011","August 2011","July 2015","June 30, 2016","June 2016","June 30, 2016","MAVERICC","May 2015","Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels|PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels|PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels|PFS According to RECIST Version 1.1 in Participants With High Vascular Endothelial Growth Factor (VEGF)-A Levels Versus Participants With Low VEGF-A Levels|PFS According to RECIST Version 1.1 in Participants With High ERCC-1 and High VEGF-A Levels|PFS According to RECIST Version 1.1 in Participants With High ERCC-1 and Low VEGF-A Levels|PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 and High VEGF-A Levels|PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 and Low VEGF-A Levels|Overall Survival (OS)|OS in Participants With High ERCC-1 Levels|OS in Participants With Low ERCC-1 Levels|OS in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels|Percentage of Participants With Objective Response According to RECIST Version 1.1|Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High ERCC-1 Levels|Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels|Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels|Percentage of Participants With Disease Control According to RECIST Version 1.1|Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High ERCC-1 Levels|Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels|Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels|Percentage of Participants With Liver Metastasis Resection|Percentage of Participants With Complete Liver Metastasis Resection|Percentage of Participants With Liver Metastasis Resection in Participants With High ERCC-1 Levels|Percentage of Participants With Complete Liver Metastasis Resection in Participants With High ERCC-1 Levels|Percentage of Participants With Liver Metastasis Resection in Participants With Low ERCC-1 Levels|Percentage of Participants With Complete Liver Metastasis Resection in Participants With Low ERCC-1 Levels|Percentage of Participants With Liver Metastasis Resection in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels|Percentage of Participants With Complete Liver Metastasis Resection in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels|PFS According to RECIST Version 1.1 in Participants With Wild-Type V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Versus Participants With Mutant KRAS|OS in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels|OS in Participants With Wild-Type KRAS Versus Participants With Mutant KRAS|Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels|Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With Wild-Type KRAS Versus Participants With Mutant KRAS|Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels|Percentage of Participants With Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels|Percentage of Participants With Complete Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels","https://ClinicalTrials.gov/show/NCT01374425"
1413,"NCT00671372","A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: bevacizumab|Drug: cetuximab|Drug: dulanermin|Drug: irinotecan","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","APO3583g|GO00933","April 18, 2008","July 2006","March 2012","September 1, 2016","September 2016","No Study Results Posted","null","March 2012","The safety and tolerability of dulanermin administered in combination with Camptosar and Erbitux|The safety and tolerability of dulanermin administered in combination with FOLFIRI (with or without Bevacizumab)","https://ClinicalTrials.gov/show/NCT00671372"
1414,"NCT01442649","Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Oxaliplatin|Drug: Folinic Acid|Drug: 5-fluoro-uracil|Drug: Irinotecan|Drug: Bevacizumab|Drug: Cetuximab","UNICANCER","Both","18 Years and older   (Adult, Senior)","Phase 2","132","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PRODIGE 18 / ACCORD 22/0906","September 5, 2011","December 2010","December 2018","June 17, 2016","June 2016","No Study Results Posted","null","October 2015","Progression-free survival (PFS) at 4 months|Objective response rate (OR)|Progression-free survival (PFS)|Overall survival (OS)|Overall survival from the date of the first-line chemotherapy used on the metastatic disease|Treatment tolerance|Quality of life","https://ClinicalTrials.gov/show/NCT01442649"
1415,"NCT01982227","Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.","Completed","No Results Available","Colorectal Cancer Metastatic","Drug: indocyanine green","Centre Hospitalier Universitaire de Saint Etienne","Both","18 Years to 70 Years   (Adult, Senior)","","10","Other","Observational","Time Perspective: Prospective","1208138|2012-004314-34","November 6, 2013","March 2013","December 2014","January 29, 2015","January 2015","No Study Results Posted","null","September 2014","Sensitivity (true positive) of the fluorescence ex vivo compared to histological analysis s detected by fluorescence ex vivo|Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo peritoneal cancer index (PCI) score with and without fluorescence|Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence","https://ClinicalTrials.gov/show/NCT01982227"
1416,"NCT02672774","Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers","Recruiting","No Results Available","Gastric Cancer|Colorectal Cancer|Gastrointestinal Neoplasms","Procedure: Magnification endoscopy with narrow band imaging|Device: Probe based confocal laser endomicroscopy","University of Medicine and Pharmacy Craiova","Both","18 Years to 90 Years   (Adult, Senior)","","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","PN-II-RU-TE-2014-4-2289","January 25, 2016","October 2015","September 2017","January 31, 2016","January 2016","No Study Results Posted","IM-ANG","February 2017","Real-time imaging of angiogenesis in gastric and colorectal tumors by using M-NBI and pCLE examinations|Validation of endoscopic imaging findings from immunohistochemical analysis with MVD calculations","https://ClinicalTrials.gov/show/NCT02672774"
1417,"NCT00873756","A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFOX regimen|Drug: bevacizumab|Drug: dulanermin","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","APO4565g|GO00934","March 5, 2009","May 2009","April 2014","September 1, 2016","September 2016","No Study Results Posted","null","March 2014","Incidence and nature of dose-limiting toxicities|Incidence, nature, and severity of adverse events|Change in vital signs|Change in clinical laboratory results|Incidence of anti-dulanermin antibodies","https://ClinicalTrials.gov/show/NCT00873756"
1418,"NCT02169388","Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy","Recruiting","No Results Available","Gastrointestinal Neoplasms|Colorectal Cancer|Effects of Chemotherapy|Tumor Immunity|Malnutrition","Drug: Probiotic|Drug: placebo（for probiotic）","Shandong University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Supportive Care","2014SDU-QILU-G03","June 4, 2014","June 2014","January 2015","June 24, 2014","June 2014","No Study Results Posted","null","October 2014","Composition of Microorganisms in stool after probiotic intervention|Short-chain fatty acids in feces of patients after chemotherapy|Frequency and severity of Adverse effects during Chemotherapy|The observed changes in immune status after chemotherapy|The observed changes in nutritional status after chemotherapy","https://ClinicalTrials.gov/show/NCT02169388"
1419,"NCT02350166","Short-term Effects of LASI Surgery Versus Conventional Laparotomy for Colorectal Liver Metastasis","Recruiting","No Results Available","Colorectal Cancer","Procedure: laparoscopic surgery","West China Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","sLRC-201312","January 19, 2015","November 2013","November 2016","November 15, 2015","November 2015","No Study Results Posted","null","November 2016","30-day complications|Pain score|Hospital time|C-reactive protein","https://ClinicalTrials.gov/show/NCT02350166"
1420,"NCT00851136","A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: bevacizumab|Drug: FOLFOX|Drug: PRO95780","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","APM4566g","February 23, 2009","May 2009","June 2010","June 29, 2010","June 2010","No Study Results Posted","null","null","Incidence and nature of dose-limiting toxicities|Incidence, nature, and severity of adverse events|Change in vital signs|Incidence and severity of infusion reactions|Change in clinical laboratory results|Incidence of anti-PRO95780 antibodies","https://ClinicalTrials.gov/show/NCT00851136"
1421,"NCT02613650","A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers","Recruiting","No Results Available","Advanced KRAS Positive Metastatic Colorectal Cancer","Drug: MEK162 and FOLFIRI","University of Utah|Array BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCI87144","November 12, 2015","May 2016","January 2020","August 11, 2016","August 2016","No Study Results Posted","null","January 2020","Incidence of dose limiting toxicities (DLTs) of combination MEK162 and FOLFIRI","https://ClinicalTrials.gov/show/NCT02613650"
1422,"NCT00969033","CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: CS-1008|Drug: irinotecan","Daiichi Sankyo Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","8","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CS1008-A-E203","August 28, 2009","July 2009","December 2011","January 30, 2012","January 2012","No Study Results Posted","null","December 2011","Determine the difference in progression-free survival (PFS) for CS-1008 administered in combination with irinotecan and irinotecan alone.|Determine the difference in overall survival for CS-1008 administered in combination with irinotecan and irinotecan alone.|Determine the difference in median survival for CS-1008 administered in combination with irinotecan and irinotecan alone.|Determine the difference in objective response rate (ORR) for CS-1008 administered in combination with irinotecan and irinotecan alone.|To determine the Incidence of anti- CS-1008 antibody formation.","https://ClinicalTrials.gov/show/NCT00969033"
1423,"NCT01629004","Increasing Uptake of Colorectal Cancer Screening in Ontario","Completed","No Results Available","Colorectal Disorders","Other: FOBT kit|Other: Mailed invitation","Sunnybrook Health Sciences Centre","Both","50 Years to 74 Years   (Adult, Senior)","","5155","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","308-2010","June 25, 2012","April 2011","December 2013","December 19, 2014","December 2014","No Study Results Posted","null","December 2013","Uptake of appropriate CRC screening|Uptake of lower gastrointestinal investigations","https://ClinicalTrials.gov/show/NCT01629004"
1424,"NCT02864979","Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","Not yet recruiting","No Results Available","Colorectal Neoplasms, Hereditary Nonpolyposis","Drug: Mesalamine 1600 mg QD|Drug: Mesalamine 3200 mg QD|Drug: Placebo","Rabin Medical Center","Both","30 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","MesaCapp","July 28, 2016","August 2016","July 2022","August 9, 2016","August 2016","No Study Results Posted","null","July 2022","Occurrence of a colonic neoplasm after 24 months on the study drug or placebo.|The number of neoplasms (tumor multiplicity) per patient compared between placebo and 5-ASA (low- and high-dose together)|Tumor progress after 24 months","https://ClinicalTrials.gov/show/NCT02864979"
1425,"NCT00088413","PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer","Active, not recruiting","No Results Available","Adenocarcinoma|Colorectal Cancer|Ovarian Cancer|Breast Cancer","Biological: PANVAC-V|Biological: PANVAC-F|Drug: Sargramostim (GM-CSF, Leukine)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 100 Years   (Adult, Senior)","Phase 1","51","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","040246|04-C-0246","July 23, 2004","July 2004","January 2018","August 31, 2016","March 2016","No Study Results Posted","null","January 2017","Clinical response (ovarian cancer and breast cancer arms)|Safety and tolerability (colorectal cancer and non-colorectal cancer arms)|Anti-tumor responses|Safety and tolerability (ovarian cancer and breast cancer arms)|Immune response","https://ClinicalTrials.gov/show/NCT00088413"
1426,"NCT02055560","Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients","Enrolling by invitation","No Results Available","Metastatic Colorectal Cancer|Adjuvant Colorectal Cancer|5-FU Containing Therapy Regimens","","Saladax Biomedical, Inc.","Both","18 Years and older   (Adult, Senior)","","350","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SBI-5FU-005","January 31, 2014","January 2014","September 2016","December 2, 2015","December 2015","No Study Results Posted","5-FU RECORD","June 2016","Variability of 5-FU plasma levels (exposure)|Hematological and non-hematological toxicity rates|Tumor response|Progression-free survival (PFS)|Overall survival","https://ClinicalTrials.gov/show/NCT02055560"
1427,"NCT02845973","Study of Fecal Bacteria in Early Diagnosis of Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Biological: gut microbiota","Shanghai Jiao Tong University School of Medicine|Shanghai 10th People's Hospital|Fudan University","Both","40 Years to 85 Years   (Adult, Senior)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","RJ20160701","July 17, 2016","June 2016","December 2016","July 26, 2016","July 2016","No Study Results Posted","null","September 2016","differences in abundance of gut microbiota|evidence of colorectal neoplasia","https://ClinicalTrials.gov/show/NCT02845973"
1428,"NCT02390947","Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）","Recruiting","No Results Available","Colorectal Cancer Metastatic|Colorectal Cancer Recurrent","Drug: Famitinib|Drug: Placebo","Jiangsu HengRui Medicine Co., Ltd.","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","540","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HR-FMTN-CRC-FACT","February 26, 2015","January 2015","July 2017","April 26, 2016","April 2016","No Study Results Posted","FACT","March 2017","Overall Survival(OS)|Progression Free Survival(PFS)|Objective response rate(ORR)|Disease Control Rate(DCR)|Quality of Life as measured by EORTC QLQ-C30(3.0)|The incidence of Adverse Events|The severity of Adverse Events","https://ClinicalTrials.gov/show/NCT02390947"
1429,"NCT01978249","A Randomized, Prospective, Multicenter Study for the Role of Primary Tumor Resection in Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastasis","Terminated","No Results Available","Colorectal Cancer","Procedure: Systemic chemotherapy|Procedure: primary tumor resection (PTR)","Yonsei University","Both","20 Years to 90 Years   (Adult, Senior)","Phase 3","19","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2013-0277","October 31, 2013","September 2013","November 2015","September 5, 2016","September 2016","No Study Results Posted","null","November 2015","Comparison of the overall survival between patients who underwent primary tumor resection and patients who received chemotherapy without primary tumor resection|Analysis of primary tumor related complications in the chemotherapy group and postoperative complications in the primary tumor resection followed by the chemotherapy group.","https://ClinicalTrials.gov/show/NCT01978249"
1430,"NCT01310699","Study of Flat Polyp Detection Using New Narrow Band Imaging (NBI) Compared to White Light Colonoscopy - The FIND FLAT Colonoscopy Study","Recruiting","No Results Available","Colorectal Neoplasms|Colonic Polyps|Colorectal Cancer","Device: Technically Improved High Definition NBI Colonoscopy System","VA Palo Alto Health Care System|Kansas City Veteran Affairs Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 3","600","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","FIND FLAT PA19624","March 7, 2011","January 2013","December 2020","June 11, 2014","June 2014","No Study Results Posted","NBI","June 2020","Nonpolypoid (flat and depressed) colorectal neoplasm detection.|Assess the number of missed lesions on index colonoscopy.|Stratify missed and detected lesion by morphology.|Impact on surveillance interval recommendations.|Optical Diagnosis.","https://ClinicalTrials.gov/show/NCT01310699"
1431,"NCT01318447","CyberKnife® for Hepatic Metastases From Colorectal Cancer","Terminated","No Results Available","Colorectal Liver Metastases","Radiation: CyberKnife SBRT","Accuray Incorporated|Centre Oscar Lambret","Both","18 Years and older   (Adult, Senior)","Phase 2","15","Industry|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACC-HM-001","March 16, 2011","January 2011","March 2013","April 5, 2013","April 2013","No Study Results Posted","null","March 2013","Local recurrence-free survival|Recurrence-free survival|Overall survival|Acute and long term toxicity|Quality of Life|Correlation of response as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and Positron Emission Tomography (PET) Response Criteria in Solid Tumors (PERCIST)","https://ClinicalTrials.gov/show/NCT01318447"
1432,"NCT00911170","PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study","Completed","Has Results","Cancer|Colon Cancer|Colorectal Cancer|Fever|Locally Advanced|Metastatic Colorectal Cancer|Neutropenia|Rectal Cancer","Drug: Pegfilgrastim|Drug: Placebo|Biological: Bevacizumab|Drug: Standard Chemotherapy","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 3","847","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","20080259","May 21, 2009","November 2009","January 2015","February 26, 2015","February 2015","November 19, 2013","null","September 2012","Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy|Overall Survival|Progression Free Survival|Time to Progression|Percentage of Participants With an Objective Response|Percentage of Participants With Grade 4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy|Percentage of Participants With Grade 3/4 Neutropenia Across the First 4 Cycles of Chemotherapy|Percentage of Participants With Grade 4 Neutropenia Across the First 4 Cycles of Chemotherapy|Number of Participants With Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT00911170"
1433,"NCT02089737","Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance ""Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene"" (All-patient Surveillance)","Completed","No Results Available","Advanced or Recurrent Colorectal Cancer","Drug: Panitumumab","Takeda","Both","Child, Adult, Senior","","3091","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","183-011","March 13, 2014","June 2010","July 2012","March 13, 2014","March 2014","No Study Results Posted","null","July 2012","Frequency of adverse drug reactions|Existence or non-existence of progression free survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02089737"
1434,"NCT01058655","RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Gastrointestinal Cancer","Drug: RAD001|Drug: AV-951","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Novartis|AVEO Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-276","October 29, 2009","February 2010","null","January 21, 2016","January 2016","No Study Results Posted","null","June 2016","To determine the safety, tolerability, and maximally tolerated dose of RAD001 and AV-951 administered in combination to this patient population (Phase I).|At the maximally tolerated dose, to assess progression-free survival associated with RAD001 and AV-951 in this patient population (Phase II).|To assess tumor response rate.|To assess overall survival.","https://ClinicalTrials.gov/show/NCT01058655"
1435,"NCT00473941","Life After Cancer Treatment Study","Completed","No Results Available","Colorectal Cancer","Behavioral: Expressive writing","Temple University","Both","18 Years and older   (Adult, Senior)","","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","1R21CA107428-01A2","May 15, 2007","September 2005","August 2008","August 24, 2011","September 2010","No Study Results Posted","null","August 2008","Quality of Life measurements-Behavioral Intervention","https://ClinicalTrials.gov/show/NCT00473941"
1436,"NCT00418938","SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial","Completed","Has Results","Cancer|Colon Cancer|Colorectal Cancer|Metastatic Cancer|Rectal Cancer|Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: Bevacizumab|Drug: Leucovorin|Drug: Irinotecan|Drug: 5-Fluorouracil","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","266","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20060141","January 4, 2007","November 2006","May 2013","February 13, 2014","February 2014","October 4, 2013","null","May 2012","Progression-free Survival (PFS)|Overall Survival|Objective Response Rate|Time to Response|Time to Progression|Disease Control|Duration of Response","https://ClinicalTrials.gov/show/NCT00418938"
1437,"NCT02605044","Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","2nd Line Metastatic Colorectal Cancer","Drug: Masitinib (AB1010)|Drug: FOLFIRI","AB Science","Both","18 Years and older   (Adult, Senior)","Phase 3","550","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AB12006","November 5, 2015","January 2014","June 2018","November 13, 2015","November 2015","No Study Results Posted","null","April 2018","Overall survival|Survival rate|Tumor assessment (PFS)|Tumor assessment (TTP)|Tumor assessment (Best Response)|Quality of life (ECOG)|Quality of life (analgesic intake)|Pharmacogenomic assessment (Gene typing)|Safety profile (all adverse effects)","https://ClinicalTrials.gov/show/NCT02605044"
1438,"NCT00003648","Genetic Study of Patients and Families With a History of Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Genetic: DNA stability analysis|Genetic: gene rearrangement analysis","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","1500","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NCCTG-974655|CDR0000066737","November 1, 1999","July 1998","May 2006","July 1, 2016","July 2016","No Study Results Posted","null","May 2006","frequency of defective DNA mismatch repair in individuals with familial colon cancer versus all colon cancers by using antibodies to the hMSH2 and hMLH1 protein products","https://ClinicalTrials.gov/show/NCT00003648"
1439,"NCT00960427","Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery","Withdrawn","No Results Available","Colorectal Cancer","Drug: systemic chemotherapy|Genetic: RNA analysis|Genetic: gene expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: endoscopic biopsy|Procedure: neoadjuvant therapy|Procedure: sigmoidoscopy|Radiation: radiation therapy","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000649658|WSU-2009-041","August 14, 2009","June 2009","April 2010","April 12, 2013","April 2013","No Study Results Posted","null","April 2010","Estimation of stem cell markers with stated precision|Correlation of disease-free survival with post-treatment value and change in expression of colorectal cancer stem cell markers after neoadjuvant chemoradiotherapy","https://ClinicalTrials.gov/show/NCT00960427"
1440,"NCT00988897","Colorectal Cancer RECHALLENGE","Withdrawn","No Results Available","Colorectal Neoplasms","Drug: OXALIPLATIN (SR96669)|Drug: 5-FLUOROURACIL (5-FU)|Drug: LEUCOVORIN (LV)|Drug: BEVACIZUMAB","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OXALI_L_03943","September 28, 2009","October 2009","May 2012","December 21, 2009","December 2009","No Study Results Posted","null","May 2012","Primary endpoint for the first thirteen patients according to the Simons Design: Clinical DCR (Disease Control Rate) at the end of stage I, based on Response Evaluation Criteria on Solid Tumors (RECIST) criteria.|Progression-free survival (PFS)|Duration of response|Adverse events|Overall response rate of stage I and II","https://ClinicalTrials.gov/show/NCT00988897"
1441,"NCT00014079","Genetic Markers in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Genetic: DNA stability analysis|Genetic: loss of heterozygosity analysis|Genetic: microsatellite instability analysis","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","675","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NCCTG-934655|CDR0000065549","April 10, 2001","September 1997","May 2005","July 12, 2016","July 2016","No Study Results Posted","null","July 2003","Determine the clinical and pathologic significance of unstable DNA elements|Determine the clinical and pathologic significance of loss of heterozygosity","https://ClinicalTrials.gov/show/NCT00014079"
1442,"NCT02527967","ERAS in Laparoscopic Surgery for Colorectal Cancer: Risk Factors for Delayed Recovery","Completed","No Results Available","Colonic Neoplasms|Laparoscopy|Perioperative Care","","Jagiellonian University","Both","18 Years and older   (Adult, Senior)","","143","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JagiellonianU-02","August 13, 2015","January 2013","February 2015","August 17, 2015","August 2015","No Study Results Posted","null","September 2014","Hospital length of stay (days)|Compliance with ERAS protocol (%)|Complication rate (%)|Readmission rate (%)","https://ClinicalTrials.gov/show/NCT02527967"
1443,"NCT02484833","Erbitux MEtastatic Colorectal Cancer Strategy Study","Recruiting","No Results Available","Antineoplastic Agents","Drug: Cetuximab|Drug: FOLFIRI","Carlo Barone|Catholic University of the Sacred Heart","Both","18 Years and older   (Adult, Senior)","Phase 3","600","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-004299-41","April 26, 2015","February 2015","February 2019","June 25, 2015","June 2015","No Study Results Posted","ERMES","November 2018","Progression-free survival|Incidence of grade 3-4 AEs|Response rate|Early tumor shrinkage assessed by Response rate at week 8|Overall survival|Cetuximab-related skin toxicity by CTCAE|Safety profile assessed by CTCAE|Quality of life assessed by EORT QLQ-C30 and DLQI questionnaires","https://ClinicalTrials.gov/show/NCT02484833"
1444,"NCT00004005","Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin","Completed","No Results Available","Carcinoma of Unknown Primary|Colorectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Procedure: conventional surgery|Radiation: radiation therapy","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","Both","up to 24 Years   (Child, Adult)","Phase 2","12","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000067216|P30CA021765|SJCRH-CACO5|NCI-G99-1554","November 1, 1999","September 1998","October 2005","October 3, 2011","October 2011","No Study Results Posted","null","October 2005","Response rate|Toxicity|Disease-free survival","https://ClinicalTrials.gov/show/NCT00004005"
1445,"NCT00891930","Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab","Completed","Has Results","Metastatic Colorectal Cancer","Biological: Panitumumab|Biological: Ganitumab|Drug: Irinotecan","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","76","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20070820|2008-004752-77","March 12, 2009","May 2009","July 2013","January 7, 2016","January 2016","January 7, 2016","null","July 2013","Part 1: Emergence of Mutant KRAS|Part 2: Objective Response Rate (ORR)|Part 1: Objective Response Rate|Progression-free Survival (PFS)|Overall Survival (OS)|Time to Objective Response|Duration of Response|Number of Participants Who Developed Antibodies to Panitumumab|Number of Participants Who Developed Antibodies to Ganitumab|Number of Participants With Adverse Events|Number of Subjects With Worst Post-baseline Grade 3 or Higher Laboratory Toxicities","https://ClinicalTrials.gov/show/NCT00891930"
1446,"NCT00006037","Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: oglufanide disodium","University of Southern California|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","18","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068052 (3C-99-3)|LAC-USC-3C993|NCI-G00-1812","July 5, 2000","November 1999","November 2001","May 20, 2014","May 2014","No Study Results Posted","null","November 2001","","https://ClinicalTrials.gov/show/NCT00006037"
1447,"NCT00025350","Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: gefitinib","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Treatment","CDR0000068952|E-6200","October 11, 2001","October 2001","June 2006","June 20, 2013","January 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00025350"
1448,"NCT02112747","Adherence to Colon Cancer Screening (ACCS)","Recruiting","No Results Available","Colon Cancer|Rectal Cancer","Other: Patient Navigator","Ohio State University Comprehensive Cancer Center","Both","25 Years to 75 Years   (Adult, Senior)","","12000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","OSU-12230|NCI-2013-01146","April 10, 2014","September 2013","December 2017","June 9, 2016","June 2016","No Study Results Posted","null","July 2017","Successfully following screening guidelines appropriate to the participant's risk profile|Cost effectiveness of the interventions","https://ClinicalTrials.gov/show/NCT02112747"
1449,"NCT00138060","Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: irinotecan|Drug: 5 fluorouracil","Institut de Recherche Clinique sur les Cancers et le Sang|Pfizer","Both","18 Years to 85 Years   (Adult, Senior)","Phase 4","71","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COLOGEN","August 26, 2005","June 2005","December 2008","July 19, 2010","July 2010","No Study Results Posted","null","November 2008","tumor response rate|toxicity|pharmacokinetics","https://ClinicalTrials.gov/show/NCT00138060"
1450,"NCT01490996","Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer","Active, not recruiting","No Results Available","Colonic Cancer|Metastasis","Drug: Oral complex C3 curcumin + chemotherapy|Drug: Chemotherapy only","University of Leicester","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","51","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UNOLE0225","December 7, 2011","February 2012","February 2019","May 10, 2016","May 2016","No Study Results Posted","CUFOX","February 2019","Completion of dose escalation over 2 cycles of therapy|Completion of (or withdrawal from) chemotherapy|Efficacy","https://ClinicalTrials.gov/show/NCT01490996"
1451,"NCT01950403","Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers","Active, not recruiting","No Results Available","Colorectal Cancer|Healthy, no Evidence of Disease","Drug: linaclotide acetate|Other: placebo|Other: pharmacological study|Other: laboratory biomarker analysis","Mayo Clinic|National Cancer Institute (NCI)","Both","18 Years to 65 Years   (Adult)","Phase 1","18","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science","NCI-2013-01788|HHSN2512012000042I|13-829|MAY2012-00-01|N01CN00042|P30CA015083","September 23, 2013","September 2013","null","August 25, 2016","August 2016","No Study Results Posted","null","March 2018","Dose of linaclotide acetate that produces a 60% response rate for cGMP levels in rectal tissue by radioimmunoassay (RIA)|Incidence of adverse events associated with linaclotide acetate assessed using the Common Terminology Criteria for Adverse Events version 4.0|PD effect of linaclotide acetate on cGMP levels from the transverse colon to the cecum|Change in cGMP levels between all assigned doses, analyzed sequentially from the rectum, transverse colon, and cecum|PD effect on cGMP levels (Stage II)","https://ClinicalTrials.gov/show/NCT01950403"
1452,"NCT01447199","The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)","Recruiting","No Results Available","Bladder Cancer|Colorectal Cancer|Endometrial Cancer|Kidney Cancer|Skin Cancer|Uterus Cancer","Behavioral: Health and Diet Questionnaire","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","","2000","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","DM94-060","October 4, 2011","September 1994","null","August 18, 2016","August 2016","No Study Results Posted","null","September 2017","Time to Onset for Colorectal Cancer","https://ClinicalTrials.gov/show/NCT01447199"
1453,"NCT02399943","A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|KRAS Wildtype|NRAS Wildtype|BRAF Wildtype","Drug: Trametinib|Drug: Panitumumab","University Health Network, Toronto","Both","18 Years and older   (Adult, Senior)","Phase 2","26","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MOBILITY-001","March 23, 2015","June 2015","December 2018","June 21, 2016","June 2016","No Study Results Posted","null","June 2018","Percentage of patients who experience complete response, partial response, or stable disease|Frequency and proportion of patients who experience side effects.|Proportion of subjects achieving either a complete or partial tumor response|Time period from the first dose of Trametinib and Panitumumab to the first date in which progression or death is observed|Date of first confirmed response to the first date in which progression is observed","https://ClinicalTrials.gov/show/NCT02399943"
1454,"NCT00002527","Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed","Completed","No Results Available","Colorectal Cancer","Drug: aspirin|Other: placebo","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","30 Years to 74 Years   (Adult, Senior)","Phase 3","635","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","CALGB-9270|CLB-9270|E-C9270|NCCTG-949251|NCI-P93-0048|CDR0000078380","November 1, 1999","May 1993","January 2006","July 1, 2016","July 2016","No Study Results Posted","null","March 2003","Reduction in size of tumors|Reduction in number of tumors|Disease free survival","https://ClinicalTrials.gov/show/NCT00002527"
1455,"NCT02274753","Personalizing Colorectal Cancer Medicine (ImmuCol2)","Recruiting","No Results Available","Colon Cancer","","Assistance Publique - Hôpitaux de Paris|Ministry of Health, France","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NI13017","October 20, 2014","March 2015","March 2020","September 1, 2016","August 2016","No Study Results Posted","ImmuCol2","March 2020","Relapse in relation with the immunoscore determined on a tumor section and criteria defined in the monitoring of patients|Relapse in relation with the immune component cancers beyond immunoscore|Relapse in relation with the immunoscore on biopsies","https://ClinicalTrials.gov/show/NCT02274753"
1456,"NCT00152230","A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)","Completed","No Results Available","Colorectal Cancer","Drug: UFT (uracil, tegafur)|Procedure: Surgery alone","Taiho Pharmaceutical Co., Ltd.","Both","20 Years to 75 Years   (Adult, Senior)","Phase 3","900","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","01023002","September 8, 2005","October 1996","February 2008","July 6, 2011","July 2011","No Study Results Posted","null","March 2006","Relapse-free survival and overall survival|Adverse events","https://ClinicalTrials.gov/show/NCT00152230"
1457,"NCT01606098","The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer","Recruiting","No Results Available","Colon Cancer|Primary Tumour|Rectal Cancer","Procedure: Surgery of the primary tumour|Drug: Systemic treatment","Dutch Colorectal Cancer Group|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","360","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CAIRO4","May 23, 2012","July 2012","August 2020","August 15, 2016","August 2016","No Study Results Posted","CAIRO4","August 2018","Overall survival|Progression-free survival|Response to chemotherapy|Systemic therapy related toxicity|Surgery related morbidity and mortality|Quality of life|Interval between randomization and initiation of systemic treatment|Cost-benefit analyses|Patients requiring resection of the primary tumour in the non-resection arm|Overall survival in patients in whom treatment according to protocol was initiated","https://ClinicalTrials.gov/show/NCT01606098"
1458,"NCT00096330","Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: dietary intervention|Dietary Supplement: folic acid","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","40 Years to 72 Years   (Adult, Senior)","Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CDR0000393455|P30CA016056|RUH-PHO-0514-0404|RPCI-EPR-20703|AECM-0401022E|NEMCH-6060","November 9, 2004","September 2004","March 2008","January 10, 2014","January 2014","No Study Results Posted","null","February 2007","•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints","https://ClinicalTrials.gov/show/NCT00096330"
1459,"NCT01403103","Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer","Withdrawn","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage I Colon Cancer|Stage I Rectal Cancer","Dietary Supplement: cholecalciferol|Procedure: biopsy|Genetic: protein expression analysis|Other: enzyme-linked immunosorbent assay|Other: laboratory biomarker analysis|Genetic: reverse transcriptase-polymerase chain reaction","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 0","0","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE2210|NCI-2011-01280","July 25, 2011","April 2012","January 2014","January 16, 2014","January 2014","No Study Results Posted","null","January 2014","Comparison of the expression of 15-PGDH mRNA and protein levels in tumor tissue|Comparison of the expression of 15-PGDH mRNA and protein levels in normal colorectal mucosa|Comparison of the expression of COX-1 and COX-2 mRNA in tumor tissues|Comparison of levels of PGE2 in tumor tissue|Comparison of the expression of COX-1 and COX-2 mRNA in normal colorectal mucosa|Comparison of levels of PGE2 in normal colorectal mucosa|Number of patients with grade 3 related toxicities of a single 100,000 IU dose of 25-OH-vitamin D3","https://ClinicalTrials.gov/show/NCT01403103"
1460,"NCT02395224","A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway","Recruiting","No Results Available","Neoplasms, Colorectal|Neoplasm Metastasis","Other: cancer treatment and follow-up according to current regional and national guidelines","Norwegian University of Science and Technology|Helse Midt-Norge","Both","18 Years and older   (Adult, Senior)","","700","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2013/1361","March 17, 2015","September 2014","September 2021","April 11, 2016","April 2016","No Study Results Posted","null","September 2021","survival|Nutritional status|Patient expectations|WHO performance status|Toxicity of therapy|Health related quality of life","https://ClinicalTrials.gov/show/NCT02395224"
1461,"NCT02542670","Whole Exome Sequencing in Colorectal Cancers in Delta Region","Recruiting","No Results Available","Cancer Colon","Genetic: Whole genome sequencing","Sherief Abd-Elsalam|Tanta University","Both","10 Years and older   (Child, Adult, Senior)","","50","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","Dr Said Hammad","September 2, 2015","July 2015","December 2016","April 19, 2016","April 2016","No Study Results Posted","null","December 2016","Number of cancer patients with abnormal genetic mutations .","https://ClinicalTrials.gov/show/NCT02542670"
1462,"NCT01079533","Initiation of Colon Cancer Screening in Veterans or ""Start Screening Now""","Active, not recruiting","No Results Available","Colorectal Neoplasms","Behavioral: Stepped CRCS Interventions|Behavioral: Control","The University of Texas Health Science Center, Houston|Duke University|Boston University","Both","50 Years to 64 Years   (Adult)","","1504","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","R01CA112223-01A2","February 26, 2010","July 2008","July 2015","December 2, 2014","December 2014","No Study Results Posted","SSN","July 2015","Colorectal Cancer Screening","https://ClinicalTrials.gov/show/NCT01079533"
1463,"NCT00102011","Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Procedure: annual screening|Procedure: fecal occult blood test|Procedure: screening colonoscopy|Procedure: standard follow-up care","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","40 Years to 69 Years   (Adult, Senior)","Phase 3","4952","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","00-046|MSKCC-00046A|UMN-2003NT062","January 18, 2005","May 2000","May 2017","June 1, 2016","June 2016","No Study Results Posted","00-046","May 2017","Neoplastic findings as assessed by screening colonoscopy vs annual fecal occult blood test (FOBT)-directed colonoscopy|Burden on endoscopic and clinical resources|Harms associated with screening colonoscopy vs annual FOBT-directed colonoscopy|Benefit-to-harm ration for screening colonoscopy vs annual FOBT-directed colonoscopy|Level of participation in screening with FOBT-directed colonoscopy vs a single colonoscopy","https://ClinicalTrials.gov/show/NCT00102011"
1464,"NCT02347735","Predictive Factors for Anastomotic Leakage After Colorectal Surgery","Recruiting","No Results Available","Anastomotic Leakage|Colorectal Cancer|Anastomotic Leak|Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Tumors","Other: No interventions, only data collection","Maastricht University Medical Center|Zuyderland Medical Centre|VieCuri Medical Centre","Both","18 Years and older   (Adult, Senior)","","628","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","METC142073","January 21, 2015","August 2015","December 2018","August 3, 2016","March 2016","No Study Results Posted","REVEAL","August 2018","Anastomotic leakage","https://ClinicalTrials.gov/show/NCT02347735"
1465,"NCT00084929","Computed Tomographic Colonography in Screening Healthy Participants for Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: CT Colonography","American College of Radiology Imaging Network|National Cancer Institute (NCI)","Both","50 Years and older   (Adult, Senior)","Phase 2|Phase 3","2607","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","CDR0000367101|ACRIN-6664","June 10, 2004","February 2005","null","October 7, 2013","October 2013","No Study Results Posted","ACRIN 6664","September 2008","Sensitivity|Interobserver variation in accuracy|Additional secondary outcome measures","https://ClinicalTrials.gov/show/NCT00084929"
1466,"NCT02664389","Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation","Recruiting","No Results Available","Breast Cancer|Ovarian Cancer|Colorectal Cancer|Pediatric Cancers|Multiple Primary Malignant Tumours","Genetic: Genetic analysis","University Hospital, Rouen","Both","Child, Adult, Senior","","600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2015/160/HP","January 22, 2016","February 2016","February 2017","August 16, 2016","August 2016","No Study Results Posted","PANEL","February 2017","Frequency of germline deleterious mutations","https://ClinicalTrials.gov/show/NCT02664389"
1467,"NCT01938300","Magnesium and Rotational Thromboelastometry (ROTEM) in Colorectal Cancer Surgery","Completed","No Results Available","Colorectal Cancer","Drug: Magnesium Sulfate|Drug: Normal saline","Seoul National University Bundang Hospital","Both","20 Years to 90 Years   (Adult, Senior)","","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Mg-ROTEM-colorectal ca","August 30, 2013","June 2011","October 2013","November 17, 2015","November 2013","No Study Results Posted","null","October 2013","Change of maximum clot firmness (MCF) of FIBTEM|Change of Clotting time (CT) of INTEM|Change of Clot firmness time (CFT) of INTEM|Change of Alpha angle of INTEM|Change of MCF of INTEM|Change of CT of EXTEM|Change of CFT of EXTEM|Change of Alpha angle of EXTEM|Change of MCF of EXTEM|Change of Hemoglobin|Change of Platelet count|Change of International normalized ratio of prothrombin time|Change of Activated partial thrombin time|Change of Fibrinogen","https://ClinicalTrials.gov/show/NCT01938300"
1468,"NCT00856115","Differences in Timely Cancer Diagnosis in African American and Caucasian Patients With Newly Diagnosed Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: medical chart review|Other: questionnaire administration|Other: study of socioeconomic and demographic variables|Other: survey administration","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","21 Years and older   (Adult, Senior)","Phase 1","84","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Retrospective","CASE4208|P30CA043703|CASE 4208-CC498","March 4, 2009","November 2008","January 2014","July 14, 2014","July 2014","No Study Results Posted","null","October 2010","Factors that influence appraisal and diagnostic delay","https://ClinicalTrials.gov/show/NCT00856115"
1469,"NCT00356161","HAI Via Interventionally Implanted Port Catheter Systems","Recruiting","No Results Available","Colorectal Cancer|Liver Neoplasms|Hepatocellular Carcinoma|Gallbladder Cancer|Bile Duct Cancer","Device: interventionally implanted hepatic arterial port catheter","Charite University, Berlin, Germany","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CVK-HAI 1","July 24, 2006","April 2002","April 2008","July 24, 2006","July 2006","No Study Results Posted","null","null","Comparison of evaluation and intervention group|Complication rate (device implantation)|Safety of device and regional therapy|prospective evaluation of port duration|comparison of complication and port duration with an historical collective of patients provided with a surgically implanted hepatic arterial port catheter system (liver metastases of colorectal cancer)|response|progression free and overall survival|efficacy of maintaining regional therapy combined with systemic chemotherapy in patients with extrahepatic progression while on study|quality of life","https://ClinicalTrials.gov/show/NCT00356161"
1470,"NCT01458925","Feasibility of Check-Cap's P1 Capsule System Screening","Enrolling by invitation","No Results Available","ColoRectal Cancer|Colonic Polyps","Device: The P1 Check-Cap capsule","Ceck Cap Ltd.","Both","40 Years to 75 Years   (Adult, Senior)","","100","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CL-SY-01-0091","October 21, 2011","November 2011","November 2017","May 4, 2016","May 2016","No Study Results Posted","null","November 2016","safety - transit time (less than 300 hours)|Colon Capsule correlation map (Empirical, qualitative)","https://ClinicalTrials.gov/show/NCT01458925"
1471,"NCT01198535","Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer","Terminated","No Results Available","Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Biological: Cetuximab|Drug: Gamma-Secretase Inhibitor RO4929097|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","60","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02905|VICC GI 09106|8511|N01CM00100|P30CA068485","September 9, 2010","September 2010","null","May 15, 2015","December 2012","No Study Results Posted","null","July 2012","MTD of RO4929097","https://ClinicalTrials.gov/show/NCT01198535"
1472,"NCT00385021","ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Neoplasms","Drug: 5-Fluorouracil, leucovorin, oxaliplatin, avastin","Southwestern Regional Medical Center","Both","18 Years to 86 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CTCT 06-06","October 4, 2006","October 2006","September 2007","October 31, 2007","October 2007","No Study Results Posted","null","null","The primary objective is to determine if the rate of adverse events among patients receiving chronoFOLFOX plus Avastin is acceptable compared to that in previous studies using the FOLFOX4 regimen.","https://ClinicalTrials.gov/show/NCT00385021"
1473,"NCT01252628","Phase 1 and 2 Study of PX-866 and Cetuximab","Completed","No Results Available","Incurable Metastatic Colorectal Carcinoma|Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","Drug: PX-866 (SCCHN)|Drug: Cetuximab (SCCHN)|Drug: PX-866 (CRC)|Drug: Cetuximab (CRC)","Cascadian Therapeutics Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","178","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PX-866-003","December 1, 2010","December 2010","January 2014","June 16, 2015","June 2015","No Study Results Posted","null","November 2013","The evaluation of antitumor effects of PX-866 in combination with cetuximab versus cetuximab in patients with incurable metastatic colorectal cancer and/or patients with incurable progressive, recurrent or metastatic SCC of the head and neck.","https://ClinicalTrials.gov/show/NCT01252628"
1474,"NCT00002650","High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed","Active, not recruiting","No Results Available","Colorectal Cancer","Dietary Supplement: folic acid","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","21 Years and older   (Adult, Senior)","Phase 2","80","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention","CDR0000064180|E-8292|NCI-P95-0066","November 1, 1999","April 1995","null","November 6, 2010","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002650"
1475,"NCT02100254","Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities","Recruiting","No Results Available","Colorectal Cancer|Healthy, no Evidence of Disease","Behavioral: behavioral intervention|Behavioral: behavioral intervention","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","3500","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","I 159309|NCI-2013-01707|P30CA016056","March 12, 2014","October 2009","null","August 16, 2016","August 2016","No Study Results Posted","null","September 2016","Change in likelihood of CRC screening in previously unscreened subjects|Number of negative affective responses to CRC screening per Affective Associations and Affectively-Based Risk surveys|Number of positive cognitive responses to CRC screening per Cognitively-Based Perceived Risk survey|Number of participants who had or scheduled colonoscopy|Number of participants who performed the fecal occult blood test (FOBT)/fecal immunohistochemistry test (FIT)|Number of participants who discussed CRC screening with their primary care physician|Influential factors in behavior changes, assessed using qualitative analyses of text from participant interviews, including affective associations with the program, participants' cognitive-affective influences, and predisposing influences","https://ClinicalTrials.gov/show/NCT02100254"
1476,"NCT02219893","Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial","Recruiting","No Results Available","Colorectal Neoplasms","Drug: MOC31PE Immunotoxin","Oslo University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ImmunoPeCa Trial","August 8, 2014","August 2014","August 2021","October 14, 2015","October 2015","No Study Results Posted","ImmunoPeCa","August 2016","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Cmax, Tmax|Neutralizing anti-immunotoxin antibody response|Biomarkers of disease recurrence|Overall survival|Disease free survival","https://ClinicalTrials.gov/show/NCT02219893"
1477,"NCT00235898","Clinical Trial in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colon Cancer|Rectal Cancer","Drug: CoFactor|Drug: 5-FU|Drug: Leucovorin","Mast Therapeutics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","03-CoFactor","October 6, 2005","May 2005","null","August 22, 2008","August 2008","No Study Results Posted","null","March 2008","","https://ClinicalTrials.gov/show/NCT00235898"
1478,"NCT00407654","VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer","Completed","Has Results","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: aflibercept","National Cancer Institute (NCI)","null","18 Years and older   (Adult, Senior)","Phase 2","75","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00176|PHL-050|CDR0000518293|N01CM62203","December 4, 2006","October 2006","September 2012","July 22, 2015","May 2013","March 27, 2015","null","September 2012","Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria)|Progression-free Survival (Bevacizumab- naïve Group)|Progression-free Survival (Bevacizumab-treated Group)|Overall Survival (Bevacizumab-naïve Group)|Overall Survival (Prior Bevacizumab Treated Group)|Time to Progression|Objective Stable Disease Rate|Number of Participants With Response (Bevacizumab-naïve Group)|Overall Survival (Bevacizumab-treated Group)|Number of Participants With Response (Bevacizumab-treated Group)","https://ClinicalTrials.gov/show/NCT00407654"
1479,"NCT00905918","Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: vitamin E|Other: laboratory biomarker analysis","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey","Both","18 Years and older   (Adult, Senior)","Phase 1","14","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","120901|CDR0000642446|0220090065|P30CA072720","May 20, 2009","June 2009","May 2014","September 26, 2014","September 2014","No Study Results Posted","null","June 2013","Plasma and urine levels of α-, γ-, and δ-tocopherols, and prostaglandin E2|Plasma levels of F2-isoprostane, C-reactive protein, and 3-nitrotyrosine and urinary levels of 8-hydroxy-2-deoxyguanosine (8-OHdG)|Presence in colon tissue of α-, γ-, and δ-tocopherols, cell proliferation and apoptosis indicators, β-catenin localization, RXR expression, and cyclooxygenase-2, 8-OHdG, and 3-nitrotyrosine levels","https://ClinicalTrials.gov/show/NCT00905918"
1480,"NCT00003594","Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: irinotecan|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|NCIC Clinical Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 3","1691","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N9741|CDR0000066665|CAN-NCIC-CO13","November 1, 1999","October 1998","October 2004","July 1, 2016","July 2016","No Study Results Posted","null","October 2004","time to progression|overall survival|time to treatment failure|response rate|quality of life","https://ClinicalTrials.gov/show/NCT00003594"
1481,"NCT00499395","Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Procedure: positron emission tomography|Procedure: radiofrequency ablation","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","4","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","LCCC 0513|CDR0000553137","July 10, 2007","July 2005","September 2007","April 2, 2012","April 2012","No Study Results Posted","null","September 2007","Sensitivity and specificity of fludeoxyglucose F 18 (FDG)-PET imaging in early diagnosis of residual disease|Findings on day 7 after RFA using FDG-PET imaging","https://ClinicalTrials.gov/show/NCT00499395"
1482,"NCT02614534","Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma","Recruiting","No Results Available","Colorectal Cancer","Drug: MITOMYCIN-C 40 mg","Maimónides Biomedical Research Institute of Córdoba","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","null","Other","Interventional","","FCO-HIP-2015-01","November 9, 2015","November 2015","null","September 5, 2016","September 2016","No Study Results Posted","null","October 2020","Locoregional Control (LC)","https://ClinicalTrials.gov/show/NCT02614534"
1483,"NCT00034034","Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Procedure: Acupuncture","National Center for Complementary and Integrative Health (NCCIH)","Both","18 Years and older   (Adult, Senior)","Phase 1","105","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind|Primary Purpose: Treatment","R01AT001028-01","April 19, 2002","June 2002","August 2006","January 4, 2007","January 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00034034"
1484,"NCT01380600","Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma","Completed","No Results Available","Carcinoma, Colorectal","Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)","Jennerex Biotherapeutics|Samsung Medical Center|SillaJen, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","15","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JX594-IV-CRC014","June 22, 2011","July 2010","December 2015","January 6, 2016","March 2012","No Study Results Posted","null","November 2012","Determine the maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD) of JX-594 administered by biweekly intravenous (IV) infusion|Determine the safety of JX-594 administered by biweekly IV infusion|Determine the pharmacokinetics, pharmacodynamics and immune response activity of JX-594|Determine the anti-tumoral response of JX-594","https://ClinicalTrials.gov/show/NCT01380600"
1485,"NCT02321969","Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer","Completed","No Results Available","Neoplasms, Colorectal","Dietary Supplement: GTE (green tea extract)","Seoul National University Hospital","Both","19 Years to 85 Years   (Adult, Senior)","","176","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","B-1006/103-002","December 17, 2014","August 2010","October 2015","October 26, 2015","October 2015","No Study Results Posted","null","May 2015","Recurrence/Number/Size of metachronous colorectal adenoma(s)|Recurrence/Number/Size of metachronous colorectal polyp(s) including hyperplastic polyp(s)|Change of lipid profiles after green tea extract (GTE) supplementation|Change of body weight, BMI and waist circumference|Adverse effect(s) of GTE supplementation","https://ClinicalTrials.gov/show/NCT02321969"
1486,"NCT00748449","Colonography Versus Colonoscopy in High Risk Patient","Terminated","No Results Available","Colorectal Cancer","Procedure: Colonoscopy|Procedure: CT-colonography","Assistance Publique - Hôpitaux de Paris","Both","18 Years to 80 Years   (Adult, Senior)","","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","P051074","July 31, 2008","June 2008","December 2010","September 9, 2011","August 2011","No Study Results Posted","COLO-TDM","December 2009","Percentage of patients who refuse to undergo an examination","https://ClinicalTrials.gov/show/NCT00748449"
1487,"NCT00516230","Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer","Recruiting","No Results Available","Colonic Neoplasms","","Samsung Medical Center","Both","Child, Adult, Senior","","200","Other","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","SMC-2007-04-080","August 13, 2007","January 2006","December 2011","August 13, 2007","August 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00516230"
1488,"NCT02728804","Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Southwest Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","374","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","S1417CD|NCI-2015-01885|S1417|SWOG-S1417CD|UG1CA189974","March 30, 2016","April 2016","June 2020","April 5, 2016","April 2016","No Study Results Posted","null","June 2020","Incidence of treatment-related major financial hardship, defined as one or more of the following: debt accumulation of any amount, selling or refinancing home, >= 20% income decline, borrowing money of any amount from family/friends|Accrual to a prospective-multi-site longitudinal cohort study|Caregiver participation|Changes in assets/income/wealth|Changes in health insurance|Credit history (TransUnion)|Debt and spending by credit report histories|Financial stress (patient, caregiver, or bereaved caregiver)|Health-related quality of life (HRQOL) as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) version 3.0|Out-of-pocket expenses, defined as total out-of-pocket direct medical (e.g., prescriptions, physician visits, deductibles) and non-medical (transportation, meals) expenses in the 3 months prior to each study visit|Risk factors for financial hardship","https://ClinicalTrials.gov/show/NCT02728804"
1489,"NCT00001693","Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers","Completed","No Results Available","Colorectal Neoplasm|Hereditary Nonpolyposis","Drug: Celecoxib (SC-58635)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","Child, Adult, Senior","Phase 1","20","NIH","Interventional","Endpoint Classification: Safety Study|Primary Purpose: Treatment","980087|98-C-0087","November 3, 1999","March 1998","January 2002","March 3, 2008","January 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001693"
1490,"NCT00331786","Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: nitric oxide-releasing acetylsalicylic acid derivative|Other: laboratory biomarker analysis|Procedure: biopsy","Stony Brook University|National Cancer Institute (NCI)","Both","50 Years and older   (Adult, Senior)","Phase 1","240","Other|NIH","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Prevention","CDR0000473094|SUNY-UH-20055574","May 30, 2006","July 2006","null","February 6, 2009","May 2007","No Study Results Posted","null","null","Effects of nitric oxide-releasing acetylsalicyclic acid (NCX 4016) on aberrant cryptic foci (ACF) multiplicity after the second dose at 6 months|Pharmacokinetic profile by blood, urine, and colon tissue sampling|Incidence of ACF as measured by magnification chromoendoscopy|Assessment of biomarkers expressed in colon tissue, including PGE2 (measured by immunoassay), COX-1, COX-2, NF-kB, and β-catenin (measured by immunohistochemistry) at baseline and at the final visit|Data on C-Reactive protein as a marker for inflammation|Safety and tolerability of long-term oral administration of NCX 4016 as measured by NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00331786"
1491,"NCT00265850","Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: bevacizumab|Biological: cetuximab|Drug: FOLFOX or|Drug: FOLFIRI","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Southwest Oncology Group|Bristol-Myers Squibb|Aptuit Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","2334","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB 80405|U10CA037447|CDR0000455161|NCI-2009-00434","December 14, 2005","November 2005","null","June 17, 2016","June 2016","No Study Results Posted","null","March 2013","Overall survival|Progression-free survival|Time to treatment failure|Duration of tumor response","https://ClinicalTrials.gov/show/NCT00265850"
1492,"NCT02460198","Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)","Recruiting","No Results Available","Colorectal Carcinoma","Biological: Pembrolizumab","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","120","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3475-164|2015-001852-32|153046","May 29, 2015","August 2015","May 2017","September 13, 2016","September 2016","No Study Results Posted","null","May 2017","Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST 1.1) assessed by central imaging vendor|Disease Control Rate (DCR) per RECIST 1.1 assessed by central imaging vendor|Duration of Response (DOR) per RECIST 1.1 assessed by central imaging vendor|Progression-Free Survival (PFS) per RECIST 1.1 assessed by central imaging vedor|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02460198"
1493,"NCT00034502","A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.","Completed","No Results Available","Colorectal Cancer","Drug: ALIMTA|Drug: irinotecan","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","2927|H3E-MC-JMDO","April 29, 2002","null","null","July 18, 2006","July 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00034502"
1494,"NCT00924690","Colon Cancer Prevention Study","Completed","No Results Available","Colorectal Cancer","Other: Behavioral Messages|Other: Generic Messages","University of North Carolina, Chapel Hill","Female","50 Years to 80 Years   (Adult, Senior)","","207","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UNC-CCEP","April 6, 2009","June 2009","October 2009","July 6, 2010","July 2010","No Study Results Posted","null","September 2009","Elaboration using the Elaboration Likelihood Scale|Behavioral Intention to Engage in Colorectal Cancer Screening or Physical Activity","https://ClinicalTrials.gov/show/NCT00924690"
1495,"NCT00785889","RCT of Air Insufflation Versus Water Infusion Colonoscopy","Completed","No Results Available","Colorectal Cancer","Procedure: water infusion colonoscopy","East Bay Institute for Research and Education","Both","45 Years to 75 Years   (Adult, Senior)","","56","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","EBIRE-GI-001","November 3, 2008","March 2008","October 2008","November 13, 2008","November 2008","No Study Results Posted","null","September 2008","Increments of medications used for sedation|pain scores during colonoscopy|success with cecal intubation|willingness to repeat colonoscopy","https://ClinicalTrials.gov/show/NCT00785889"
1496,"NCT00563316","Effect of Panitumumab on the Pharmacokinetics of Irinotecan","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: Irinotecan","Amgen","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","28","Industry","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20062010","November 21, 2007","March 2008","June 2010","March 14, 2016","March 2016","March 14, 2016","null","March 2009","Maximum Observed Plasma Concentration (Cmax) of Irinotecan|Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUCinf) for Irinotecan|Area Under the Plasma Concentration-time Curve From the Time of the Last Quantifiable Concentration (AUClast) for Irinotecan|Number of Participants With Clinically Significant Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT00563316"
1497,"NCT00392899","Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery","Completed","No Results Available","Colorectal Cancer","Drug: tegafur-uracil|Other: clinical observation|Procedure: adjuvant therapy","Tokyo Medical and Dental University|National Cancer Institute (NCI)","Both","20 Years to 80 Years   (Adult, Senior)","Phase 3","2000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000512573|TMDU-BRI-CC-05-01","October 25, 2006","October 2006","July 2012","December 17, 2013","July 2009","No Study Results Posted","null","June 2012","Disease-free survival|Relapse-free survival|Overall survival|Adverse events","https://ClinicalTrials.gov/show/NCT00392899"
1498,"NCT00372840","Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer","Active, not recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Malignant Mesothelioma|Prostate Cancer|Psychosocial Effects of Cancer and Its Treatment|Thymoma and Thymic Carcinoma","Other: educational intervention|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","","332","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","FCCC-FCRB-04-002-P|CDR0000464245|NCI-2009-00569|06-803","September 6, 2006","May 2006","null","March 1, 2016","March 2016","No Study Results Posted","null","November 2010","Uptake of recommended actions|Number of sections of the Facing Forward manual read with satisfaction and comprehension|Changes in psychological outcomes from baseline to 8-week follow-up","https://ClinicalTrials.gov/show/NCT00372840"
1499,"NCT01016860","OSI-906 and Irinotecan in Patients With Advanced Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: OSI-906|Drug: irinotecan","University of Colorado, Denver","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-0705.cc|NCI-2011-03204","November 18, 2009","December 2009","April 2013","October 18, 2013","October 2013","No Study Results Posted","null","April 2013","Maximum tolerated dose (MTD) and the recommend phase II dose (RP2D) for the combination of irinotecan and OSI-906 in patients with advanced cancer.","https://ClinicalTrials.gov/show/NCT01016860"
1500,"NCT01417494","1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)|Drug: Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab","Federation Francophone de Cancerologie Digestive|Roche Pharma AG","Both","75 Years to 120 Years   (Senior)","Phase 2","102","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000706869|FFCD-PRODIGE-20|EU-21120|2010-022080-34","August 13, 2011","July 2011","April 2016","May 27, 2016","May 2016","No Study Results Posted","null","September 2014","Efficacy, in terms of objective response or tumoral stability by RECIST criteria|Deterioration in the Spitzer QoL Index score of ≥ 2 points at baseline and at 4 months|Tolerance, in terms of no grade 4 arterial hypertension, grade 3-4 thromboembolic event, grade 3-4 cardiac insufficiency, and hospitalization not related to chemotherapy|Toxicity|Time to deterioration of autonomy|Survival with no deterioration of autonomy","https://ClinicalTrials.gov/show/NCT01417494"
1501,"NCT01596634","Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy","Active, not recruiting","No Results Available","Colorectal Cancer|Dysgeusia|Oral Complications of Chemotherapy","Other: questionnaire administration|Procedure: quality-of-life assessment|Other: laboratory biomarker analysis|Biological: bovine lactoferrin","Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","49","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CCCWFU 98112|NCI-2012-00279","May 9, 2012","January 2013","null","October 29, 2015","October 2015","No Study Results Posted","null","August 2016","Change in the Taste Visual Analog Scale (VAS) and taste and smell questionnaire responses|Effect of bovine lactoferrin on lipid peroxidation byproducts in saliva as measured by the TBARs assay|Malondialdehyde (MDA) concentrations before and after a ferrous iron oral rinse|Quality of life as quantified by the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) questionnaire","https://ClinicalTrials.gov/show/NCT01596634"
1502,"NCT02393755","Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer","Recruiting","No Results Available","Colon Adenocarcinoma|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: Capecitabine|Other: Laboratory Biomarker Analysis|Drug: Nintedanib|Other: Pharmacological Study","Roswell Park Cancer Institute|National Cancer Institute (NCI)|Boehringer Ingelheim|National Comprehensive Cancer Network","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","39","Other|NIH|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 265514|NCI-2015-00223|P30CA016056","March 13, 2015","May 2015","null","September 2, 2016","September 2016","No Study Results Posted","null","January 2017","Progression free survival (PFS) rate, defined as the proportion of patients who survive without disease progression via the RECIST version 1.1 (Phase II)|RP2D of nintedanib in combination with capecitabine (Phase I)|Aggregate rates of adverse events measured by CTCAE version 4.0 (Phase II)|Median OS (Phase II)|Median PFS (Phase II)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02393755"
1503,"NCT00070213","Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: capecitabine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: quality-of-life assessment","University of Leeds|Medical Research Council|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 3","460","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000330142|NCRI-FOCUS2|MRC-CR09|EU-20303","October 3, 2003","September 2003","null","September 16, 2013","June 2011","No Study Results Posted","null","null","Compare progression-free survival (PFS) in pts. treated w/ leucovorin calcium + fluorouracil (MdG) vs leucovorin calcium + fluorouracil + oxaliplatin (OxMdG) and in pts. treated w/ capecitabine (Cap) vs capecitabine + oxaliplatin (OxCap) at 1 yr|Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 14 weeks|Compare health assessment, including quality of life, in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap at baseline and 14 and 24 weeks|Compare toxicity/adverse events in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap|Compare overall failure-free survival in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap|Compare overall survival in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap|Compare health economics in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap|Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap|Compare toxicity/adverse events in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 24 weeks|Compare patients acceptability in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap|Compare PFS in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap|Compare health economics in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap","https://ClinicalTrials.gov/show/NCT00070213"
1504,"NCT02384759","Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers","Recruiting","No Results Available","Colorectal Neoplasms","Drug: aflibercept|Drug: LV5FU2","Federation Francophone de Cancerologie Digestive","Both","65 Years and older   (Adult, Senior)","Phase 2","118","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PRODIGE25","January 28, 2015","May 2015","July 2018","August 2, 2016","August 2016","No Study Results Posted","FOLFA","December 2017","Radiological progression-free survival according to the investigator|Aflibercept tolerance withe LV5FU2|Quality of life|Overall survival|Radiological progression-free survival accordint to central reading|Clinical and radiological progression-free survival according to the investigator|Best response|Curative resectability","https://ClinicalTrials.gov/show/NCT02384759"
1505,"NCT01927341","Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: MEK162|Drug: Panitumumab","Array BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","90","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","CMEK162X2116|2013-001986-18","August 2, 2013","November 2013","null","April 4, 2016","April 2016","No Study Results Posted","null","October 2015","Incidence of Dose limiting toxicities in cycle 1 (Phase Ib)|Overall Response rate (Phase II)|Safety and tolerability|Overall response rate (Phase lb)|Progression free- survival|Overall survival (Phase II)|Duration of response|Disease control rate","https://ClinicalTrials.gov/show/NCT01927341"
1506,"NCT01082757","Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients","Completed","No Results Available","Colorectal Neoplasms","","Merck KGaA|Merck Quimica Argentina S.A.I.C","Both","22 Years and older   (Adult, Senior)","","1524","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMR62202-513","March 8, 2010","June 2009","August 2013","July 30, 2014","July 2014","No Study Results Posted","null","August 2013","Mutational status of KRAS: study of codons 12 and 13 in exon 1 of KRAS gene|Subject and tumour characteristics and their association with KRAS mutational status","https://ClinicalTrials.gov/show/NCT01082757"
1507,"NCT02835924","Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 2","295","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-16-01","July 8, 2016","July 2016","January 2019","August 12, 2016","August 2016","No Study Results Posted","RE-ARRANGE","July 2018","Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria.|Percentage of total administrated dose over the planned dose accomplished in each arm.|Dose intensity during the whole treatment.|Dose intensity during first two cycles.|Disease control rate (DCR)|Progression-free survival (PFS)|Time to treatment failure (TTF)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02835924"
1508,"NCT00983580","Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer","Active, not recruiting","No Results Available","Adenomatous Polyp","Drug: Aspirin|Drug: Eflornithine|Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Telephone-Based Intervention","National Cancer Institute (NCI)","Both","40 Years and older   (Adult, Senior)","Phase 2","104","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NCI-2009-01192|09-001758|MC054A|R01CA113681|P30CA015083","September 23, 2009","August 2009","null","August 23, 2016","August 2016","No Study Results Posted","null","October 2016","Adenoma recurrence rate for the treatment arm relative to placebo|ACF characteristics vs adenoma recurrence rate|Characterization of ACF|Comparison of the percent change in ACF number across the 2 treatment arms|Effect of the study drugs and placebo with respect to biomarkers|Gene expression analysis|Safety, tolerability, and adverse events of study treatment","https://ClinicalTrials.gov/show/NCT00983580"
1509,"NCT00851084","Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Neoplasms|Neoplasm Metastasis","Drug: aflibercept|Drug: oxaliplatin|Drug: 5-FU|Drug: Folinic Acid","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","268","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC10668|EudraCT 2008-004178-41","February 24, 2009","February 2009","January 2012","May 4, 2016","May 2016","February 19, 2013","AFFIRM","April 2011","Progression Free Survival (PFS) Rate at 12 Months|Progression Free Survival (PFS)|Overall Objective Response Rate (ORR)|Overall Survival (OS)|Number of Participants With Treatment-emergent Adverse Events (TEAE)|Immunogenicity of Intravenous (IV) Aflibercept","https://ClinicalTrials.gov/show/NCT00851084"
1510,"NCT00482222","Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: cetuximab|Drug: capecitabine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Other: study of socioeconomic and demographic variables|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: quality-of-life assessment","University of Southampton|University Hospital Southampton NHS Foundation Trust.","Both","18 Years and older   (Adult, Senior)","Phase 3","340","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000549541|USCTU-4351|USCTU-EPOC|EUDRACT-2006-003121-82|ISRCTN22944367|EU-20732","June 4, 2007","February 2007","null","January 22, 2013","April 2008","No Study Results Posted","null","December 2014","Progression-free survival|Response rate before surgery as assessed by RECIST criteria|Pathological resection status|Overall survival|Toxicity|Quality of life as assessed by the EQ-5D, EORTC QLQ-C30, and EORTC QLQ-LMC21|Cost effectiveness|Safety","https://ClinicalTrials.gov/show/NCT00482222"
1511,"NCT01941173","Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy","Withdrawn","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Biological: ziv-aflibercept|Drug: leucovorin calcium|Drug: irinotecan hydrochloride|Drug: fluorouracil","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","0","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13294|NCI-2013-01727","September 9, 2013","January 2014","null","July 17, 2014","July 2014","No Study Results Posted","null","July 2014","Feasibility of a shorter infusion time, determined by rate of greater or equal to grade 2 hypersensitivity reactions as graded according to CTCAE version 4.0|Incidence of grade 3 and above toxicities, graded according to CTCAE version 4.0","https://ClinicalTrials.gov/show/NCT01941173"
1512,"NCT00007826","Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: BCG vaccine|Biological: monoclonal antibody 105AD7 anti-idiotype vaccine|Drug: alum adjuvant","Onyvax|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Industry","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000068071|ONYVAX-SGCRO01|NCI-V00-1599","January 6, 2001","April 2000","null","September 19, 2013","February 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00007826"
1513,"NCT00320320","Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer","Terminated","No Results Available","Colorectal Neoplasms|Metastases","Drug: Irinotecan","Gachon University Gil Medical Center","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","72","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GMO-GI-53","May 1, 2006","April 2005","April 2007","November 24, 2008","November 2008","No Study Results Posted","null","April 2007","Response rate after FOLFIRI reintroduction|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00320320"
1514,"NCT02052908","Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome","Recruiting","No Results Available","Lynch Syndrome","Other: Laboratory Biomarker Analysis|Drug: Naproxen|Other: Placebo","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","108","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NCI-2014-00046|MDACC IRB # 2013-0698|HHSN261201200034I|HHSN26100003; RFP B|13-585|MDACC-2013-0698|N01-CN-2012-00034|HUM00079757|2013-0698|MDA2013-01-02|N01CN00034|P30CA016672","January 30, 2014","January 2014","null","August 24, 2016","August 2016","No Study Results Posted","null","July 2017","Change in PGE2 concentration levels in normal colorectal mucosa|Incidence of toxicity graded according to National Cancer Institute Common Criteria for Adverse Events version 4.0|Minimal biologically effective dose of naproxen that induces a modulation of PGE2 levels|Change in number of polyps observed in the rectosigmoid area|Changes in gene expression mRNA profiles of the normal colorectal mucosa|Changes in the microRNA profile of the normal colorectal mucosa|Changes in the mutational rate of the normal colorectal mucosa|Naproxen concentrations in normal colorectal mucosa|Naproxen concentrations in plasma samples|PGE-M levels in urine samples","https://ClinicalTrials.gov/show/NCT02052908"
1515,"NCT00003873","Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: fluorouracil|Drug: eniluracil","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","950","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02300|E-5296|U10CA021115|CDR0000067038","November 1, 1999","April 1999","null","January 23, 2013","January 2013","No Study Results Posted","null","July 2007","Overall survival","https://ClinicalTrials.gov/show/NCT00003873"
1516,"NCT01198548","High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer","Terminated","Has Results","Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: leucovorin calcium|Biological: bevacizumab|Dietary Supplement: cholecalciferol|Drug: fluorouracil|Drug: oxaliplatin|Other: pharmacological study","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","18 Years to 79 Years   (Adult, Senior)","Phase 2","10","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 176910|NCI-2010-01783","September 8, 2010","August 2010","June 2012","June 23, 2014","June 2014","January 28, 2014","null","April 2012","Median PFS|Rate of Sufficient Cholecalciferol|RR of Patients Receiving Study Treatment|Toxicity Rates as Assessed by NCI CTCAE Version 4|OS of Patients Receiving Study Treatment|PFS of Patients Receiving Study Treatment","https://ClinicalTrials.gov/show/NCT01198548"
1517,"NCT01074385","Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care Decision-Making","Completed","No Results Available","Stage IV Colorectal Cancer","Behavioral: Dignity Therapy","Northwestern University|Robert H. Lurie Cancer Center","Both","18 Years and older   (Adult, Senior)","","24","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","NU 09CC3|STU00022908|NCI-2010-01851","February 22, 2010","April 2010","October 2012","September 13, 2013","September 2013","No Study Results Posted","null","May 2012","Impact of Dignity Therapy|Measure the impact of dignity therapy on life sustaining therapy and end-of-life goals of care.|Establish a correlation between terminal illness acknowledgement and presence of peaceful awareness with preferences for life sustaining therapy and end-of-life goals of care.","https://ClinicalTrials.gov/show/NCT01074385"
1518,"NCT00361244","SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Carcinoma","Drug: SU011248|Drug: Irinotecan|Drug: Cetuximab","Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","44","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-439","August 4, 2006","July 2006","null","December 28, 2007","December 2007","No Study Results Posted","null","December 2007","To determine the maximum tolerated dose of SU011248 when given in combination with irinotecan and cetuximab in patients with previously treated locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma|To determine the response rate of SU011248 when given in combination with irinotecan and cetuximab in this patient population.|To evaluate the toxicities of this combination of drugs in this patient population|to assess overall survival, progression-free survival, time to progression and duration of response.","https://ClinicalTrials.gov/show/NCT00361244"
1519,"NCT00606398","Combined Resection of Colorectal Metastases","Completed","No Results Available","Colorectal Cancer","Procedure: surgical resection for patients with both intra- and extra-hepatic metastases","University Health Network, Toronto|Sunnybrook Health Sciences Centre","Both","18 Years and older   (Adult, Senior)","Phase 2","56","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GIAW1","January 21, 2008","June 2007","January 2014","January 24, 2014","January 2014","No Study Results Posted","CRC","December 2007","two-year disease free survival (DFS)|Overall survival rate (OS), patterns of treatment failure, treatment efficacy (R0 resection rate), peri-operative morbidity and mortality rates, health related quality of life, hospital length of stay","https://ClinicalTrials.gov/show/NCT00606398"
1520,"NCT00597506","Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus","Completed","Has Results","Colorectal Adenocarcinoma","Drug: Bevacizumab|Drug: Everolimus","Herbert Hurwitz|Novartis Pharmaceuticals|Genentech, Inc.|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00001574","December 26, 2007","October 2007","June 2010","December 21, 2012","December 2012","July 10, 2012","BEV/EV","June 2010","Overall Response|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00597506"
1521,"NCT00695201","Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer","Active, not recruiting","No Results Available","Colon Cancer|Rectal Cancer","Drug: Floxuridine, Oxaliplatin, CPT-11|Drug: Floxuridine, Oxaliplatin, CPT-11","Memorial Sloan Kettering Cancer Center|University of Medicine and Dentistry of New Jersey|Rutgers, The State University of New Jersey|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 1","72","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","00-011","June 9, 2008","August 2000","August 2016","September 21, 2015","September 2015","No Study Results Posted","null","August 2016","Determine the MTD of hepatic arterial floxuridine (FUDR) & dexamethasone (Dex) given via implanted pump in combination w biweekly intravenous Oxaliplatin + systemic irinotecan (CPT-11) in patients w unresectable hepatic metastases from colorectal cancer.|To determine the preliminary anti-tumor activity of the aforementioned combination chemotherapy.|To procure normal and disease liver tissue for evaluation of TS, p53, p21, TOPO 1, DPD, and ERCC levels.","https://ClinicalTrials.gov/show/NCT00695201"
1522,"NCT01426490","The Effects of Vitamin B-6 Status on Homocysteine, Oxidative Stress, One-carbon Metabolism and Methylation: Cross-section, Case-control, Intervention and Follow-up Studies in Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin B6|Dietary Supplement: Folic acid|Dietary Supplement: Vitamin B6 plus folic acid","Taichung Veterans General Hospital","Both","18 Years to 85 Years   (Adult, Senior)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Prevention","S10251","August 29, 2011","August 2011","July 2015","February 17, 2014","August 2011","No Study Results Posted","null","July 2015","Antioxidant and DNA methylation","https://ClinicalTrials.gov/show/NCT01426490"
1523,"NCT00200200","Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer","Active, not recruiting","No Results Available","Hepatic Metastases|Colon Cancer|Rectal Cancer","Drug: Bevacizumab HAI plus systemic chemotherapy|Drug: HAI plus systemic chemotherapy","Memorial Sloan Kettering Cancer Center|Mount Sinai Hospital, New York|Icahn School of Medicine at Mount Sinai","Both","19 Years and older   (Adult, Senior)","Phase 2","73","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","04-086","September 12, 2005","November 2004","November 2016","November 25, 2015","November 2015","No Study Results Posted","null","November 2016","To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer|To assess toxicity|To determine survival|To assess the expression pattern of VEGFR1, VEGFR2 (angiogenesis), and VEGFR3 (lymphangiogenesis) and their cognate ligands (VEGF-A, VEGF-C, VEGF-D), and correlate with patient progression and survival following|To compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitors","https://ClinicalTrials.gov/show/NCT00200200"
1524,"NCT00193219","Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colon Cancer","Drug: Bevacizumab|Drug: Cetuximab|Drug: 5-fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin","SCRI Development Innovations, LLC|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI GI 64","September 12, 2005","July 2005","July 2010","March 6, 2013","March 2013","December 7, 2012","null","June 2008","Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment|Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease|Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death|Safety of FOLFOX6 Combined With Bevacizumab and Cetuximab","https://ClinicalTrials.gov/show/NCT00193219"
1525,"NCT00100841","Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer","Completed","Has Results","Adenocarcinoma of the Rectum|Mucinous Adenocarcinoma of the Colon|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Stage IV Colon Cancer|Stage IV Rectal Cancer","Biological: cetuximab|Biological: bevacizumab|Drug: oxaliplatin|Drug: leucovorin calcium|Drug: fluorouracil","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","66","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03006|NCI-6490|N01CM62201|N01CM62204","January 6, 2005","November 2004","July 2011","June 26, 2015","July 2013","June 26, 2015","null","July 2011","Severe Adverse Event (SAE) Rate|Progression Free Survival Rate","https://ClinicalTrials.gov/show/NCT00100841"
1526,"NCT00083720","Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy","Completed","Has Results","Colorectal Neoplasms|Metastases|Neoplasm","Biological: cetuximab","ImClone LLC|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 2","87","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CP02-0451","May 28, 2004","October 2004","April 2008","May 19, 2011","May 2011","April 16, 2009","null","April 2008","Percentage of Participants With an Overall Resonse|Number of Participants With Adverse Events|Number of Participants With Serious Adverse Events|Percentage of Participants With Disease Control (CR, PR, or SD)|Duration of Response|Time to Progression|Overall Survival","https://ClinicalTrials.gov/show/NCT00083720"
1527,"NCT02404935","Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: FOLFIRI and cetuximab","UNICANCER","Both","18 Years and older   (Adult, Senior)","Phase 2","168","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Prodige 28 - UCGI 27 (TIME)","March 23, 2015","February 2014","June 2020","June 28, 2016","June 2016","No Study Results Posted","TIME","February 2018","Evaluate whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab (Progression Free Survival)","https://ClinicalTrials.gov/show/NCT02404935"
1528,"NCT02776683","Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: BI 695502|Drug: chemotherapy","Boehringer Ingelheim","Both","18 Years and older   (Adult, Senior)","Phase 3","120","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1302.3|2015-003718-25","May 17, 2016","May 2016","August 2018","September 19, 2016","September 2016","No Study Results Posted","null","December 2017","Patients with any of the following selected Adverse Events: Infusion reactions, Thromboembolic events, GI perforations, Hypertension, Proteinuria, Hemorrhages, Wound-healing complications, Posterior Reversible Encephalopathy Syndrome, Ovarian failure|Duration of response (DOR) defined as the time from first documented complete response (CR) or partial response (PR) until time of progression as assessed by central imaging review|Time to progression (TTP) defined as the time from first administration of trial medication to the date of tumor progression, as assessed by central imaging review|Objective response according to Response Evaluation Criteria in Tumors (RECIST 1.1) as assessed by central imaging review|Overall survival (OS) defined as the time from first administration of trial medication until death from any cause|Progression-free-survival (PFS) is defined as the time from the first administration of trial medication until disease progression as assessed by central imaging review according to Response Evaluation Criteria in Tumors(RECIST 1.1) or death of any cause","https://ClinicalTrials.gov/show/NCT02776683"
1529,"NCT00860860","Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: TF2|Drug: IMP-288 labeled with In111 and Lu177","Radboud University","Both","18 Years and older   (Adult, Senior)","Phase 1","20","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RUNMC-PRIT2008","March 11, 2009","July 2009","October 2011","March 16, 2012","August 2010","No Study Results Posted","PRIT2008","October 2011","Toxicity defined by NCI Common Terminology Criteria for Adverse Events version 3.0|pharmacokinetics and biodistribution of TF2 and Lu-177-labeled IMP-288, sensitivity of pretargeted imaging with In-111-labeled IMP-288, and tumor response using RECIST criteria","https://ClinicalTrials.gov/show/NCT00860860"
1530,"NCT01701310","IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia","Recruiting","No Results Available","Anemia|Colorectal Neoplasm","Drug: Ferric carboxymaltose|Drug: Ferrous Sulphate","Nottingham University Hospitals NHS Trust|National Institute for Health Research, United Kingdom","Both","18 Years and older   (Adult, Senior)","Phase 4","116","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11GS005|2011-002185-21|PB-PG-0110-21041","March 21, 2012","April 2012","March 2015","August 19, 2013","August 2013","No Study Results Posted","IVICA","March 2015","To determine if the use of intravenous ferric carboxymaltose can reduce the need for allogeneic blood transfusion compare to oral ferrous sulphate in patients with colorectal adenocarcinoma related anaemia|To determine differences in hemoglobin and hematinic markers between the groups.|To determine differences in hepcidin levels in relation to blood profile changes in participants in the intravenous group.|To determine differences in colonic mucosal expression of iron transport proteins, C-myc and NKD1 between the groups|To determine differences in postoperative outcomes between the groups.|To determine differences in anemia symptomatology response between groups.","https://ClinicalTrials.gov/show/NCT01701310"
1531,"NCT02842580","De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer","Not yet recruiting","No Results Available","Colorectal Neoplasms","Drug: 5 FLUOROURACYL|Drug: acide folinique|Drug: irinotecan|Drug: Oxaliplatin|Drug: capécitabine|Drug: bevacizumab","Federation Francophone de Cancerologie Digestive","Both","18 Years and older   (Adult, Senior)","Phase 2","168","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PRODIGE 45","July 13, 2016","September 2016","July 2021","August 10, 2016","July 2016","No Study Results Posted","HIGH-LIGHT","November 2018","The primary objective is the percentage of patients without failure of the strategy 16 months after the randomization.|Best response rate (using RECIST version 1.1) at 16 months|Overall survival (OS) at 2 years and at 3 years|Progression free survival (PFS) at 2 years and at 3 years","https://ClinicalTrials.gov/show/NCT02842580"
1532,"NCT00940758","Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: PEP02","PharmaEngine","Both","18 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PIST-CRC-01","July 15, 2009","June 2009","June 2012","March 1, 2012","March 2012","No Study Results Posted","null","September 2011","To evaluate the DLT and the toxicity profile|To establish the MTD|To characterize the pharmacokinetics of biweekly PEP02 in patients with metastatic colorectal cancer who failed to first-line oxaliplatin-based chemotherapy|To collect data for preliminary evaluation of tumor response|To explore the association of the pharmacogenetics of PEP02 including UGT1A family - UGT1A1 and UGT1A9 with pharmacokinetic parameters and toxicity","https://ClinicalTrials.gov/show/NCT00940758"
1533,"NCT01730586","Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas","Completed","No Results Available","Colorectal Cancer|Cancer of Gastrointestinal Tract","Drug: Abraxane","M.D. Anderson Cancer Center|Celgene","Both","18 Years and older   (Adult, Senior)","Phase 2","34","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-0776|NCI-2013-00077","October 26, 2012","November 2012","August 2016","August 12, 2016","August 2016","No Study Results Posted","null","August 2016","Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma|Progression-Free Survival","https://ClinicalTrials.gov/show/NCT01730586"
1534,"NCT02235324","Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer","Withdrawn","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Biological: ziv-aflibercept|Drug: leucovorin calcium|Drug: fluorouracil|Other: laboratory biomarker analysis","University of Southern California|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-13-7|NCI-2014-01806|HS-14-00081|P30CA014089","September 4, 2014","March 2015","March 2018","May 4, 2015","May 2015","No Study Results Posted","null","March 2017","Progression‐free survival during the first phase of the study|Progression‐free survival during the second phase of the study|Overall survival (OS)|Response rate assessed using Response Evaluation Criteria in Solid Tumors 1.1|Incidence of adverse events graded according to NCI CTCAE version 4.0","https://ClinicalTrials.gov/show/NCT02235324"
1535,"NCT00839111","Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment","Recruiting","No Results Available","Colorectal Neoplasms","Drug: sorafenib|Drug: FOLFIRI","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","43","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Bay43-9006-2008005","February 6, 2009","November 2008","November 2010","September 14, 2010","September 2010","No Study Results Posted","null","November 2010","Progression-Free Survival (PFS) ,defined as the time from treatment to disease progression or death due to any cause|Secondary endpoints are disease control rate, defined as a complete response, partial response, and stable disease; Response rate and overall survival; and safety are also evaluated.","https://ClinicalTrials.gov/show/NCT00839111"
1536,"NCT00003220","Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: bryostatin 1","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066081|P30CA022453|WSU-D-1457|NCI-T97-0065","November 1, 1999","February 1998","June 2001","April 3, 2013","April 2013","No Study Results Posted","null","November 2000","","https://ClinicalTrials.gov/show/NCT00003220"
1537,"NCT01053013","Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer","Recruiting","No Results Available","Pancreatic Cancer|Colorectal Cancer","Biological: Cancer macrobead placement in abdominal cavity","The Rogosin Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0911010739","January 20, 2010","February 2010","null","May 23, 2016","February 2016","No Study Results Posted","Macrobead","August 2016","Tumor volume and number of metastases|Progression-free survival","https://ClinicalTrials.gov/show/NCT01053013"
1538,"NCT00801294","A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: BIBF 1120 and BIBW 2992","Boehringer Ingelheim","Both","19 Years and older   (Adult, Senior)","Phase 2","46","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1239.2|EudraCT 2006-000893-56","December 2, 2008","July 2006","null","October 30, 2013","October 2013","No Study Results Posted","null","November 2007","The RECIST criterion will be used to assess: objective response rate (PR + CR), and disease progression within the first 16 weeks|Progression-free survival (based on the RECIST criteria)|Overall survival|The incidence and intensity of Adverse Events with grading of Adverse Events according to the US NCI Common Terminology Criteria for Adverse Events (CTCAE version 3.0)|Changes in safety laboratory parameters|Effectiveness of dose reduction guidelines in managing adverse events","https://ClinicalTrials.gov/show/NCT00801294"
1539,"NCT01904955","Should Colorectal Cancer Patients be Followed After Five Years? Study of Recurrence in a Population Cohort","Completed","No Results Available","Colorectal Cancer","","Centre Hospitalier Universitaire Dijon","Both","Child, Adult, Senior","","598","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Faivre PHRC K 2010","July 8, 2013","September 2010","null","December 10, 2014","July 2013","No Study Results Posted","null","February 2013","data concerning evolving relapse","https://ClinicalTrials.gov/show/NCT01904955"
1540,"NCT02780700","Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]","Suspended","No Results Available","Colorectal Neoplasms","Drug: Nintedanib|Drug: Capecitabine","Boehringer Ingelheim","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1199.251","May 20, 2016","July 2016","December 2017","August 22, 2016","August 2016","No Study Results Posted","null","November 2017","Progression Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Disease Control (DC)|Percentage of patients with grade 3 or worse adverse events","https://ClinicalTrials.gov/show/NCT02780700"
1541,"NCT00006387","Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Pancreatic Cancer","Biological: QS21|Biological: ras peptide cancer vaccine","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","7","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment","FCCC-98026|NCI-T97-0051","October 4, 2000","October 2000","January 2002","July 10, 2013","July 2013","No Study Results Posted","null","January 2002","","https://ClinicalTrials.gov/show/NCT00006387"
1542,"NCT01486251","Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Carcinoma","Drug: axitinib","Gustave Roussy, Cancer Campus, Grand Paris","Both","18 Years and older   (Adult, Senior)","","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","2011-001151-37|2011/1738","October 31, 2011","September 2011","September 2014","February 9, 2016","February 2016","No Study Results Posted","AXUS","April 2013","Echography measure","https://ClinicalTrials.gov/show/NCT01486251"
1543,"NCT00143403","Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer","Completed","Has Results","Colorectal Neoplasms|Liver Neoplasms","Drug: Irinotecan + 5 FU + folinic acid|Drug: Folinic Acid + 5 FU","Pfizer","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","321","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CPT-GMA-301|A5961076","September 1, 2005","December 2001","September 2009","September 24, 2010","September 2010","February 26, 2009","null","February 2008","Disease Free Survival (DFS)|Overall Survival Rates","https://ClinicalTrials.gov/show/NCT00143403"
1544,"NCT00002997","Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Procedure: cryosurgery","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065545|ECOG-1296","November 1, 1999","August 1997","null","February 6, 2009","March 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002997"
1545,"NCT01116687","RO4929097 in Treating Patients With Metastatic Colorectal Cancer","Completed","Has Results","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","37","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02845|MCC 16221|8537|N01CM62208|P30CA076292","April 28, 2010","May 2010","March 2012","May 2, 2014","December 2012","April 13, 2012","null","May 2011","Number of Participants With Objective Radiographic Response (ORR)|Participant Overall Survival (OS) Rate|Participant Progression Free Survival (PFS) Rate|Number of Related Serious Adverse Events (SAEs)","https://ClinicalTrials.gov/show/NCT01116687"
1546,"NCT00024401","DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: DHA-paclitaxel","Theradex|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000068929|THERADEX-P01-00-01|ABCCC-010505|PROTARGA-P01-00-01","September 13, 2001","May 2001","null","July 23, 2008","June 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00024401"
1547,"NCT02256800","Prospective Analysis of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI as the First-line Setting","Recruiting","No Results Available","Metastatic Colorectal Cancer","Genetic: UGT1A1 genotyping (6,6)|Genetic: UGTIA1 genotyping (6,7)|Genetic: UGTIA1 genotyping (7,7)|Genetic: UGT1A1 non-genotyping|Drug: bevacizumab (Avastin)|Drug: irinotecan|Drug: Leucovorin|Drug: 5-FU","Jaw-Yuan Wang, MD, PhD|Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","20 Years to 80 Years   (Adult, Senior)","","320","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KMUHIRB-20130020","September 18, 2014","June 2013","null","October 3, 2014","May 2013","No Study Results Posted","null","June 2016","Progression-free survival|Objective response rates|overall survival","https://ClinicalTrials.gov/show/NCT02256800"
1548,"NCT00189683","Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy","Recruiting","No Results Available","Colorectal Cancer","Procedure: Monitoring|Procedure: Xeloda","Association Européenne de Recherche en Oncologie|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AERO-MC04","September 12, 2005","null","null","September 12, 2005","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00189683"
1549,"NCT01270438","Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer","Withdrawn","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: FOLFOX regimen|Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Biological: bevacizumab|Drug: oxaliplatin|Drug: leucovorin calcium|Drug: fluorouracil","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","0","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02571|CDR0000692198|MSKCC-10191|10-191|8467|U01CA069856|N01CM62206","January 4, 2011","December 2010","null","October 7, 2013","October 2013","No Study Results Posted","null","August 2011","Progression-free survival of patients treated with FOLFOX6 plus bevacizumab with or without gamma-secretase inhibitor RO4929097|Objective response rate (complete or partial response) as measured by RECIST|Incidence of dose-limiting and non-dose-limiting toxicities|Pharmacokinetics and pharmacodynamics of gamma-secretase inhibitor RO4929097","https://ClinicalTrials.gov/show/NCT01270438"
1550,"NCT00685568","Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis","Completed","No Results Available","Colorectal Cancer|Precancerous Condition","Drug: celecoxib|Other: placebo","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","10 Years to 14 Years   (Child)","Phase 1","22","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Prevention","ID02-090|MDA-ID-02090|CDR0000596468","May 23, 2008","December 2002","November 2006","November 16, 2012","November 2012","No Study Results Posted","null","November 2006","Toxicity|Aberrant crypt foci (ACF) and adenoma burden in the entire colorectum|Elimination of the learning curve in a phase II/III trial|Comparison of sedation strategies based on local standards|Validation of technique for scoring ACFs|Short-term (3 month) impact of celecoxib on ACF count|Adherence|Influence of polymorphisms on age of onset of phenotype or on the number of colorectal polyps|Feasibility of psychosocial questionnaires|Pharmacokinetics (plasma drug trough concentrations)","https://ClinicalTrials.gov/show/NCT00685568"
1551,"NCT00003834","Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","44","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-974651|CDR0000066991","November 1, 1999","March 1999","December 2005","July 1, 2016","July 2016","No Study Results Posted","null","December 2005","response rate|overall survival","https://ClinicalTrials.gov/show/NCT00003834"
1552,"NCT00268398","Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer|Chemotherapy","Drug: oxaliplatin, folinic acid, fluorouracil|Drug: oxaliplatin, irinotecan, folinic acid, fluorouracil","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","284","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000453815|GERCOR-C02-1|GERCOR-C02-1-MIROX|EU-20567|SANOFI-GERCOR-C02-1","December 20, 2005","July 2002","null","May 21, 2012","May 2012","No Study Results Posted","MIROX","December 2011","disease-free survival|Overall survival|Tolerability|Quality of life|Pharmacogenetics","https://ClinicalTrials.gov/show/NCT00268398"
1553,"NCT01929616","Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)","Active, not recruiting","No Results Available","Advanced Chemorefractory Colorectal Adenocarcinoma","Drug: regorafenib","Jules Bordet Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","124","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-005655-16 EUDRACT","July 28, 2013","August 2013","December 2016","February 23, 2016","May 2015","No Study Results Posted","RegARd-C","December 2016","Overall survival (OS)|Occurence of Adverse events|Evaluation of tumour response|Metabolic response assessed by FDG PET|Molecular aberrations","https://ClinicalTrials.gov/show/NCT01929616"
1554,"NCT00033371","Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis","Terminated","Has Results","Colorectal Cancer|Familial Adenomatous Polyposis","Drug: Celecoxib|Other: Placebo|Drug: eflornithine|Other: Laboratory biomarker analysis|Other: Questionnaire administration","National Cancer Institute (NCI)","Both","18 Years to 65 Years   (Adult)","Phase 2","112","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NCI-2013-00844|N01CN95040|CDR0000069278|NCI-P02-0219|ID00-109|P30CA016672|MDA-ID-00109","April 9, 2002","December 2001","December 2014","January 26, 2015","May 2013","January 26, 2015","null","April 2009","Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum|Global Duodenal Polyp Burden|Percent Change in Polyp Size in Focal Area(s) of the Colorectum|Change in Global Colorectal Polyp Burden|Percent Change in the Area of Plaque-like Duodenal Polyps","https://ClinicalTrials.gov/show/NCT00033371"
1555,"NCT01239095","Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection","Recruiting","No Results Available","Colon Cancer","Drug: Green Tea and Milk Thistle Supplements","St. Luke's-Roosevelt Hospital Center","Both","18 Years to 85 Years   (Adult, Senior)","Phase 1","30","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-089","November 9, 2010","July 2011","July 2016","November 19, 2015","November 2015","No Study Results Posted","null","June 2016","Number of patients with adverse events or complications","https://ClinicalTrials.gov/show/NCT01239095"
1556,"NCT00028626","Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: embolization therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","01-113|CDR0000069112|NCI-G01-2039","January 4, 2002","August 2001","January 2004","June 4, 2013","June 2013","No Study Results Posted","null","January 2004","","https://ClinicalTrials.gov/show/NCT00028626"
1557,"NCT00192114","Enzastaurin for Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colonic Neoplasms","Drug: Enzastaurin HCl","Eli Lilly and Company","Both","19 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9098|H6Q-MC-JCAR","September 14, 2005","August 2005","March 2008","October 5, 2009","October 2009","No Study Results Posted","null","March 2008","Progression free survival|Objective response rate|Overall survival|Duration of stable disease|Time to response|Duration of response|Safety|QTc interval|Pharmacokinetics|Evaluate carcinoembryonic antigen (CEA) response in patients receiving enzastaurin","https://ClinicalTrials.gov/show/NCT00192114"
1558,"NCT02022995","Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients","Completed","No Results Available","Colon Cancer Adenocarcinoma","","National Taiwan University Hospital","Both","20 Years to 80 Years   (Adult, Senior)","","180","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","201310053RIND","December 22, 2013","January 2014","January 2016","August 1, 2016","August 2016","No Study Results Posted","null","January 2016","evaluate the overall survival of patients with PRMT (arginine methyltransferase)|evaluate the disease-free survival of patients with PRMT (arginine methyltransferase)","https://ClinicalTrials.gov/show/NCT02022995"
1559,"NCT00860665","Case Volume and Adenoma Rate During Screening Colonoscopy","Completed","No Results Available","Colorectal Cancer","","Charite University, Berlin, Germany|Interest group of Berlin private practice gastroenterologists","Both","55 Years to 85 Years   (Adult, Senior)","","12134","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BECOP-3","March 11, 2009","October 2006","March 2009","March 11, 2009","March 2009","No Study Results Posted","null","March 2008","Correlation of adenoma detection rate with case volume of endoscopists|Patient acceptance in relation to procedural factors (e.g. sedation)","https://ClinicalTrials.gov/show/NCT00860665"
1560,"NCT01580540","Head to Head Study Epi proColon and FIT","Completed","No Results Available","Colorectal Cancer","","Epigenomics, Inc","Both","50 Years to 84 Years   (Adult, Senior)","","336","Industry","Observational","Observational Model: Case Control","Epigenomics-SPR 0022","April 17, 2012","March 2012","November 2012","August 3, 2015","July 2014","No Study Results Posted","null","November 2012","Non-inferiority of Epi proColon test result compared to FIT result using a 95% confidence interval for difference in sensitivities and differences in specificities below a strictly defined margin.","https://ClinicalTrials.gov/show/NCT01580540"
1561,"NCT00499369","Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy","Terminated","Has Results","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: fluorouracil|Biological: cetuximab|Biological: bevacizumab","National Cancer Institute (NCI)|North Central Cancer Treatment Group|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 3","72","NIH|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00784|CALGB-SWOG-S0600|SWOG-S0600|CDR0000551934|ECOG-SWOG-S0600|CAN-NCIC-SWOG-S0600|NCCTG-SWOG-S0600|S0600|U10CA032102","July 10, 2007","June 2007","November 2012","July 25, 2014","March 2014","October 22, 2013","null","November 2012","Progression-free Survival (PFS)|Overall Survival|Objective Tumor Response|Toxicity","https://ClinicalTrials.gov/show/NCT00499369"
1562,"NCT01399190","An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","68","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25523","July 20, 2011","July 2011","February 2014","June 1, 2016","June 2016","No Study Results Posted","null","February 2014","Progression-free survival (tumour assessments according to RECIST criteria)|Response rate (tumour assessments according to RECIST criteria)|Safety: Incidence of adverse events","https://ClinicalTrials.gov/show/NCT01399190"
1563,"NCT00303914","Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer","Active, not recruiting","No Results Available","Breast Cancer|Cognitive/Functional Effects|Colorectal Cancer|Lung Cancer|Pain|Prostate Cancer|Psychosocial Effects of Cancer and Its Treatment","Procedure: assessment of therapy complications|Procedure: cognitive assessment|Procedure: psychosocial assessment and care","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","2310","Other|NIH","Observational","","CDR0000462104|ECOG-E2Z02","March 15, 2006","April 2006","null","July 19, 2012","August 2009","No Study Results Posted","null","null","Prevalence, severity, and interference due to physical and psychological symptoms experienced by cancer patients as assessed by MD Anderson Symptom Inventory at baseline and days 28-35 following initial assessment|Number of symptom-related interventions related to the providers perception of symptom severity as assessed by The Revised Edmonton Staging System for cancer pain (rESS) at baseline and days 28-35 following initial assessment|Compare treatment priority based on physical or psychological symptoms|Percentage of patients who experience a significant reduction in moderate-to-severe symptoms and characterize the determinants of symptom relief|Focus and scope of interventions chosen to improve symptom control","https://ClinicalTrials.gov/show/NCT00303914"
1564,"NCT01912443","Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: bevacizumab","Sun Yat-sen University|Proswell Medical Corporation","Both","Child, Adult, Senior","","600","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML28629","July 24, 2013","August 2013","null","April 25, 2014","April 2014","No Study Results Posted","null","August 2017","Incidence, nature and severity of adverse events of special interest|Incidence, nature and severity of bevacizumab related serious adverse events|Onset time of adverse event associated with bevacizumab|Laboratory parameters|Overall survival (OS)|Overall response rate (ORR) of treatment line|Progression-free survival (PFS) of treatment line:|One-year disease-free progression rate of treatment line|One-year survival rate of treatment line|Overall survival (OS) of treatment line","https://ClinicalTrials.gov/show/NCT01912443"
1565,"NCT01697449","An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)","Completed","Has Results","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","191","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML21889","September 28, 2012","March 2009","August 2014","September 15, 2015","September 2015","September 15, 2015","null","August 2014","Percentage of Participants With At Least One Adverse Event (AE)|Percentage of Participants With Clinical Benefit of Complete Response [CR], Partial Response [PR] or Stable Disease [SD] Per Response Evaluation Criteria in Solid Tumors (RECIST)|Percentage of Participants Who Were Resectable Postbaseline Among the Participants Who Were Unresectable at Baseline|Percentage of Participants With Disease Progression or Death|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01697449"
1566,"NCT01089413","Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)","Completed","Has Results","Colorectal Cancer","Drug: bevacizumab [Avastin]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","201","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25117","March 15, 2010","January 2010","June 2013","November 13, 2015","November 2015","November 13, 2015","null","June 2013","Duration of Bevacizumab Treatment|Progression-Free Survival (PFS)|Percentage of Participants With Best Overall Response|Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status","https://ClinicalTrials.gov/show/NCT01089413"
1567,"NCT00574353","Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients","Recruiting","No Results Available","Colorectal Cancer","Radiation: Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","07-151","December 13, 2007","December 2007","December 2017","March 28, 2016","March 2016","No Study Results Posted","null","December 2017","the feasibility of a non-invasive method of detecting hypoxia, using F-FMISO-PET imaging in colorectal cancer patients.|determine volume of hypoxic tumor ROIs as a proportion of the entire tumor volume by this non-invasive imaging technique. ROIs are defined as those voxels, within the tumor volume defined on FDG PET/CT, for which the 18F-F-FMISO radioactivity concent","https://ClinicalTrials.gov/show/NCT00574353"
1568,"NCT00942266","Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment","Completed","Has Results","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: vorinostat|Other: pharmacological study","Roswell Park Cancer Institute|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","58","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","I 142808|NCI-2009-01523","July 17, 2009","July 2009","December 2011","May 22, 2014","May 2014","December 26, 2013","null","May 2011","Disease Control Rate (Stable Disease or Objective Response)|Median Progression-free Survival|Response Rate|Toxicity|Overall Survival|Vorinostat Pharmacokinetics|Fluorouracil Steady-state Pharmacokinetics","https://ClinicalTrials.gov/show/NCT00942266"
1569,"NCT00002801","Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: leucovorin calcium|Drug: tegafur-uracil|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Primary Purpose: Treatment","CDR0000064898|MSKCC-96025|BMS-MSKCC-96025|NCI-V96-0942","November 1, 1999","April 1996","December 2009","December 18, 2013","December 2009","No Study Results Posted","null","December 2003","","https://ClinicalTrials.gov/show/NCT00002801"
1570,"NCT00104689","Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: oxaliplatin","UNICANCER|National Cancer Institute (NCI)","Both","70 Years and older   (Senior)","Phase 2","60","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000416120|FRE-FNCLCC-GERICO-02/0301|EU-20500","March 3, 2005","July 2003","null","July 23, 2008","December 2006","No Study Results Posted","null","null","Efficacy in terms of stabilization or improvement by 1 point on Katz's Activities of Daily Living scale|Toxicity|Percentage of patients who receive the first 3 treatment courses at a lower dose and the percentage of patients who receive all 6 treatment courses at both lower and higher doses|Efficacy as defined in RECIST criteria|Pharmacokinetics","https://ClinicalTrials.gov/show/NCT00104689"
1571,"NCT00032110","Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer","Completed","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: erlotinib hydrochloride|Other: pharmacological study|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","30","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02459|CDR0000069258|PHL-003|NCI-5378|5378|N01CM17107","March 8, 2002","January 2002","May 2007","April 14, 2015","January 2013","No Study Results Posted","null","May 2007","Objective response or disease stabilization|Molecular changes with therapy","https://ClinicalTrials.gov/show/NCT00032110"
1572,"NCT00006479","Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","European Organisation for Research and Treatment of Cancer - EORTC|Australasian Gastro-Intestinal Trials Group|Arbeitsgruppe Lebermetastasen und Tumoren|Cancer Research UK|Fondation Francaise de Cancerologie Digestive|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068309|EORTC-40983|AGITG-EORTC-40983|ALM-CAO-EORTC-40983|CRUK-LON-EORTC-40983|FFCD-EORTC-40983|EU-20048|CRC-EORTC-40983","November 6, 2000","September 2000","null","April 15, 2011","December 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006479"
1573,"NCT00390364","Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy","Terminated","Has Results","Colorectal Cancer","Drug: everolimus|Procedure: antiangiogenesis therapy|Procedure: biopsy|Procedure: diagnostic procedure|Procedure: gene expression analysis|Procedure: immunohistochemistry staining method|Procedure: laboratory biomarker analysis|Procedure: mutation analysis|Procedure: protein tyrosine kinase inhibitor therapy|Procedure: reverse transcriptase-polymerase chain reaction","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","1","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J05107 CDR0000508071|JHOC-J05107|NOVARTIS-JHOC-J05107","October 18, 2006","October 2006","October 2007","October 7, 2014","October 2014","September 15, 2014","null","October 2007","Response Rate: The Total Number of Participants With Progression of Disease","https://ClinicalTrials.gov/show/NCT00390364"
1574,"NCT00025337","Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated","Completed","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Biological: bevacizumab|Drug: oxaliplatin|Drug: leucovorin calcium|Drug: fluorouracil","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","880","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02417|E3200|U10CA021115|CDR0000068951","October 11, 2001","September 2001","null","January 23, 2013","January 2013","No Study Results Posted","null","April 2007","Overall survival|Response defined using RECIST criteria|Progression free survival","https://ClinicalTrials.gov/show/NCT00025337"
1575,"NCT00193167","Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer","Completed","No Results Available","Colon Cancer","Drug: Topotecan","SCRI Development Innovations, LLC|GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI GI 56|104864724","September 12, 2005","January 2004","April 2006","May 2, 2011","May 2011","No Study Results Posted","null","April 2006","overall response rate|median survival|one year survival|toxicity","https://ClinicalTrials.gov/show/NCT00193167"
1576,"NCT00056030","Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: cetuximab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","73","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N014A|NCI-2012-02521|CDR0000271923","March 6, 2003","December 2004","null","August 12, 2016","August 2016","No Study Results Posted","null","March 2008","Surgical resectability rate as assessed by surgical resection of liver metastases|Response rate as measured by RECIST criteria every 6 weeks|Overall survival|Quality of life as assessed by UNISCALE and Symptom Distress Scale every 6 weeks","https://ClinicalTrials.gov/show/NCT00056030"
1577,"NCT00310076","Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer","Completed","Has Results","Carcinoma of the Appendix|Colorectal Cancer","Drug: thalidomide|Procedure: surgery","Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","29","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000466311|CCCWFU-59202|CCCWFU-BG02-406|CELGENE-CCCWFU-59202","March 29, 2006","October 2002","September 2012","October 16, 2012","October 2012","July 24, 2012","null","July 2011","Progression Free Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00310076"
1578,"NCT02369757","Patients Navigator for Organized Colorectal Cancer Screening","Completed","No Results Available","Healthy","Behavioral: Navigator intervention","Institut de Cancérologie de la Loire|Gustave Roussy, Cancer Campus, Grand Paris|University of Lyon|Centre Georges Francois Leclerc","Both","50 Years to 74 Years   (Adult, Senior)","","40774","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","2012-04","December 5, 2014","October 2012","May 2015","February 26, 2016","November 2014","No Study Results Posted","COLONAV","May 2015","Participation rates|Percentage of patients primary care peers take care of|Qualitative analysis","https://ClinicalTrials.gov/show/NCT02369757"
1579,"NCT01519895","Effectiveness of Telephone Intervention for Colorectal Cancer Caregivers","Completed","No Results Available","Psychological Stress","Behavioral: Telephone intervention","Hospital Authority, Hong Kong","Both","18 Years to 90 Years   (Adult, Senior)","Phase 2","140","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","HKCTR-1336","January 11, 2012","June 2011","December 2012","April 14, 2015","April 2015","No Study Results Posted","null","August 2012","Distress level|Burden of care|Quality of life","https://ClinicalTrials.gov/show/NCT01519895"
1580,"NCT00006050","Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver","Active, not recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: isolated perfusion|Drug: leucovorin calcium|Drug: oxaliplatin","UNICANCER|National Cancer Institute (NCI)","Both","up to 75 Years   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068072|FRE-FNCLCC-98012-PAC-ACCORD-04|EU-20017","July 5, 2000","January 1999","null","February 6, 2009","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006050"
1581,"NCT00433576","Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery","Completed","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Stage I Colon Cancer|Stage I Rectal Cancer|Stage II Colon Cancer|Stage II Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer","Drug: resveratrol|Other: pharmacological study|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","20","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00864|CDR0000528296|LRI-6930|N01CN25025|CCUM-TASK2B|N01CN25025-4|P30CA046592","February 8, 2007","December 2006","March 2009","September 12, 2014","October 2011","No Study Results Posted","null","November 2008","Pharmacodynamics of resveratrol|Concentrations of biomarkers","https://ClinicalTrials.gov/show/NCT00433576"
1582,"NCT00041340","Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer","Completed","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: imatinib mesylate|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 2","37","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02479|ID01-557|N01CM62202|CDR0000069475","July 8, 2002","May 2002","null","January 22, 2013","January 2013","No Study Results Posted","null","July 2006","Response rate","https://ClinicalTrials.gov/show/NCT00041340"
1583,"NCT00002692","Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver","Active, not recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: fluorouracil|Drug: isolated perfusion|Drug: leucovorin calcium","Medical Research Council|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 3","312","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064434|MRC-CR05|EU-95032","November 1, 1999","December 1994","null","December 18, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002692"
1584,"NCT01254591","Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer","Recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Esophageal Cancer|Head and Neck Cancer|Lung Cancer","Other: 18F-fluoromisonidazole|Other: fluorescence angiography|Other: laboratory biomarker analysis|Procedure: infrared thermography|Procedure: magnetic resonance imaging|Procedure: therapeutic conventional surgery|Radiation: [18F]-ML-10|Radiation: fludeoxyglucose F 18|Radiation: rubidium Rb-82","University College London (UCL) Cancer Institute|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","500","Other","Interventional","Primary Purpose: Diagnostic","CDR0000689973|UCL-TUMOR-ANGIOGENESIS|EU-21086","December 3, 2010","November 2006","null","August 23, 2013","December 2010","No Study Results Posted","null","August 2013","Clinical, radiological, and pathological correlation|Prognosis (6-month, 1-year, 3-year, and 5-year mortality including local/distance recurrence rates)","https://ClinicalTrials.gov/show/NCT01254591"
1585,"NCT00034619","A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.","Completed","No Results Available","Colorectal Cancer","Drug: ALIMTA|Drug: Oxaliplatin","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","5142|H3E-MC-JMEP","May 1, 2002","null","null","July 18, 2006","July 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00034619"
1586,"NCT01105377","Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer","Completed","Has Results","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: entinostat|Drug: azacitidine|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","47","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2010-02024|CDR0000670136|MC084B|8341|N01CM00099|P30CA015083|N01CM00038","April 15, 2010","April 2010","May 2014","July 30, 2014","July 2014","August 29, 2013","null","March 2012","Confirmed Tumor Response|Time to Progression","https://ClinicalTrials.gov/show/NCT01105377"
1587,"NCT01365910","Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer","Terminated","Has Results","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: linifanib","Vanderbilt-Ingram Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC GI 1058|NCI-2011-00833","June 1, 2011","June 2011","June 2013","August 24, 2014","August 2014","June 13, 2014","null","May 2012","Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15%|Progression-free Survival|Overall Survival|Number of Patients With Each Worst‐Grade Toxicity","https://ClinicalTrials.gov/show/NCT01365910"
1588,"NCT00504153","Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer","Completed","Has Results","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: dasatinib|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","19","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00223|UCCRC-NCI-7786|CDR0000557036|15431A|7786|N01CM62201|P30CA014599","July 17, 2007","July 2007","June 2011","April 30, 2014","October 2011","July 1, 2013","null","June 2011","Progression-free Survival Rate|Response Rate (RR) (Complete or Partial Responders)|Incidence of Somatic Mutations|Association Between the Incidence of Total C-src and Phosphorylated C-src Expression and Response|Change in Plasma Vascular Endothelial Growth Factor (VEGF) Levels Over 15 Days","https://ClinicalTrials.gov/show/NCT00504153"
1589,"NCT00005944","Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer|Primary Peritoneal Cavity Cancer","Drug: chemotherapy|Drug: fluorouracil|Drug: leucovorin calcium|Drug: mitomycin C|Procedure: conventional surgery|Procedure: laparoscopic surgery","UNICANCER|National Cancer Institute (NCI)","Both","up to 70 Years   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067833|FRE-FNCLCC-97018|EU-20010","July 5, 2000","November 1999","null","April 23, 2011","June 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005944"
1590,"NCT00027833","Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: ALVAC-CEA-B7.1 vaccine|Biological: tetanus toxoid|Drug: FOLFIRI regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000069082|CPMC-14534|CPMC-BB-IND-9911|FCCC-01015|APL-COL13|NCI-G01-2033","December 7, 2001","December 2001","null","January 3, 2014","September 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00027833"
1591,"NCT02651415","Phase II Study of Perindopril and Regorafenib in mCRC","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib|Drug: Perindopril","British Columbia Cancer Agency|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 2","38","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H15-02424","January 6, 2016","August 2016","null","August 11, 2016","August 2016","No Study Results Posted","PARICCA","July 2018","Proportion of Participants that have Any Grade HFSR Toxicity as Assessed by CTCAE v4.03 Criteria When Treated with a Combination of Regorafenib and Perindopril|Proportion of All Grades of Hypertension as Assessed by CTCAE v4.03 Criteria When Treated with a Combination of Regorafenib and Perindopril|Proportion of All Grade Toxicities as Assessed by CTCAE v4.03 Criteria When Treated with a Combination of Regorafenib and Perindopril|Maximal Severity of HFSR as Assessed by CTCAE v4.03 Criteria When Treated with a Combination of Regorafenib and Perindopril|Time Course to Development of Worst Grade (stage 3) HFSR as Assessed by CTCAE v4.03 Criteria When Treated with a Combination of Regorafenib and Perindopril|Progression-Free Survival","https://ClinicalTrials.gov/show/NCT02651415"
1592,"NCT00503035","Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers","Active, not recruiting","No Results Available","Familial Adenomatous Polyposis","Drug: Celecoxib|Procedure: Colonoscopy Biopsy","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","16 Years and older   (Child, Adult, Senior)","Phase 2","40","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM02-592|NCI-2012-01522|1R01CA106577-01A1","July 16, 2007","August 2003","null","November 23, 2015","November 2015","No Study Results Posted","null","August 2017","13-S-HODE, 15-LOX-1 primary product, levels (measured by ELISA assay)","https://ClinicalTrials.gov/show/NCT00503035"
1593,"NCT01867697","Nordic 8 - A Phase II Trial","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: Irinotecan|Drug: Oxaliplatin|Drug: Folinic Acid|Drug: Calcium Carbonate","Per Pfeiffer|Merck Serono International SA|Odense University Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","180","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Basic Science","Nordic 8","June 21, 2012","May 2012","null","January 20, 2015","January 2015","No Study Results Posted","null","December 2016","Response rate (RR)|Survival (Overall survival)|Frequency of secondary surgical resection (R0 + R1 + R2 resections)|Frequency of secondary micro-radical surgical resection (R0 resection)","https://ClinicalTrials.gov/show/NCT01867697"
1594,"NCT00270647","Physicians' Health Study II","Completed","No Results Available","Cancer|Prostate Cancer|Colorectal Cancer|Cardiovascular Disease|Eye Disease|Cognitive Decline","Dietary Supplement: Vitamin E|Dietary Supplement: Vitamin C|Dietary Supplement: Multivitamin|Dietary Supplement: Beta-carotene","Brigham and Women's Hospital|National Cancer Institute (NCI)","Male","50 Years and older   (Adult, Senior)","","14641","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CDR0000448630|BWH-1999-P-003315|BWH-1999-P-003318|BWH-83-00405|R01CA097193","December 27, 2005","July 1997","June 2011","July 17, 2012","July 2012","No Study Results Posted","PHS II","June 2011","Prostate cancer|Total cancer|Major cardiovascular events|Cataract|Age-related macular degeneration|Early cognitive decline|Myocardial infarction|Stroke|Colorectal cancer","https://ClinicalTrials.gov/show/NCT00270647"
1595,"NCT01164215","Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy","Completed","No Results Available","Colorectal Cancer|Diarrhea|Neutropenia","Drug: fluorouracil|Drug: leucovorin|Drug: oxaliplatin","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 1","76","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 0918|P30CA016086|CDR0000681338","July 15, 2010","February 2010","September 2013","October 7, 2015","October 2015","No Study Results Posted","null","November 2012","Achievement of targeted AUC using pharmacokinetic (PK)-guided 5 fluorouracil as part of mFOLFOX6 therapy|Toxicity differences between PK-guided therapy versus non-PK-guided therapy","https://ClinicalTrials.gov/show/NCT01164215"
1596,"NCT00684801","Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers","Completed","No Results Available","Colorectal Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer","Other: questionnaire administration|Procedure: quality-of-life assessment","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","605","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CASE6Y07|P30CA043703|CASE-6Y07-CC333","May 23, 2008","August 2007","December 2011","October 8, 2015","October 2015","No Study Results Posted","null","December 2011","Patient resource use|Symptoms|Quality of life|Proportion of patients meeting expectations regarding care and treatment|Patient spiritual well-being|Caregiver mood state|Caregiver burden|Proportion of caregivers meeting expectations regarding care and treatment|Caregiver's satisfaction with end-of-life care","https://ClinicalTrials.gov/show/NCT00684801"
1597,"NCT00026273","Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Pfizer","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","XRP 4174B-307|CDR0000069014|PFIZER-A5961053|RP-64174-V-307|EORTC-40993|PETACC-3","November 9, 2001","January 2001","null","August 6, 2012","August 2012","No Study Results Posted","null","September 2004","","https://ClinicalTrials.gov/show/NCT00026273"
1598,"NCT00544011","Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: capecitabine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Other: diagnostic laboratory biomarker analysis","Hopital Jean Minjoz|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","47","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000564118|CHRB-Folfiri-III-Avastin|INCA-RECF0432","October 13, 2007","April 2007","null","June 23, 2011","July 2009","No Study Results Posted","null","null","Objective response (complete and partial) rate|Progression-free survival|Overall survival|Tolerance|Resectability rate|Biomarkers predictive of efficacy","https://ClinicalTrials.gov/show/NCT00544011"
1599,"NCT00376909","A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women","Completed","No Results Available","Breast Cancer|Cervical Cancer|Colorectal Cancer","Other: educational intervention|Other: study of socioeconomic and demographic variables","Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)","Female","40 Years to 69 Years   (Adult, Senior)","Phase 2","2729","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","CDR0000450797|R01CA087776|DMS-15524","September 13, 2006","November 2001","null","November 26, 2014","September 2006","No Study Results Posted","null","April 2004","Follow-up patient cancer 3 months after completion of study treatment|Screening rates as measured by mammography, Pap test, hfoBT, sigmoidoscopy, barium enema and colonoscopy","https://ClinicalTrials.gov/show/NCT00376909"
1600,"NCT01383707","A Study of Bevacizumab (Avastin) and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: 5-Fluorouracil (5-FU)|Drug: Bevacizumab|Drug: Levofolinic acid|Drug: Oxaliplatin","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","77","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25625|2011-001364-22","June 27, 2011","August 2011","May 2016","July 22, 2016","July 2016","July 22, 2016","null","May 2014","Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set|Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS)|Percentage of Participants Achieving No Residual Tumor (R0)/Surgical Margin With Microscopic Residual Tumor (R1) Liver Resection|Disease-free Interval (DFI)|Progression-Free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01383707"
1601,"NCT00043004","Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer","Terminated","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: bevacizumab|Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: conventional surgery|Procedure: radiofrequency ablation","European Organisation for Research and Treatment of Cancer - EORTC|Arbeitsgruppe Lebermetastasen und Tumoren|Institute of Cancer Research, United Kingdom","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","119","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-40004|ALM-CAO-EORTC-40004|NCRI-EORTC-40004","August 5, 2002","May 2002","null","September 20, 2012","September 2012","No Study Results Posted","null","June 2007","Survival rate as measured by Kaplan Meier method at 30 months|Overall survival as measured by Logrank every 3 months for 30 months then every 6 months thereafter|Progression-free survival as measured by Logrank every 3 months for 30 months then every 6 months thereafter|Toxicity as measured by CTC version 2.0 every 3 months for 30 months then every 6 months thereafter|Quality of life as measured by Quality of Life Questionnaire Core 30 (QLQ-C30) version 3.0 at baseline, weeks 6, 12, 18, and 24, every 3 months for years 1-2 after start of treatment, then every 6 months thereafter|Response to treatment (arm II) as measured by RECIST criteria from start of treatment until disease progression","https://ClinicalTrials.gov/show/NCT00043004"
1602,"NCT02305615","An Observational Study of Continued Avastin Plus Chemotherapy Until First Progression in Patients With Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML29425","November 28, 2014","January 2015","December 2017","September 1, 2016","September 2016","No Study Results Posted","null","December 2017","Progression-free survival|Progression-free survival, calculated from the first dose of first-line therapy|1-year overall survival rate|Duration of treatment (Avastin + chemotherapy)|Overall response rate|Safety profile (composite outcome measure): incidence, nature, and severity of adverse events and serious adverse events","https://ClinicalTrials.gov/show/NCT02305615"
1603,"NCT02402036","A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer","Recruiting","No Results Available","Colon Cancer","Drug: Regorafenib","Georgetown University|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","2014-0133","February 4, 2015","February 2015","February 2018","April 6, 2016","April 2016","No Study Results Posted","null","February 2017","Serum microRNA Quantification","https://ClinicalTrials.gov/show/NCT02402036"
1604,"NCT00023868","Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: FOLFIRI regimen|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: mitomycin C","American College of Radiology Imaging Network|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068871|ACRIN-6655","September 13, 2001","November 2001","null","January 3, 2009","December 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00023868"
1605,"NCT00103311","SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer","Completed","Has Results","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: ispinesib|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","64","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02834|PHII-51|6800","February 7, 2005","January 2005","September 2010","February 13, 2015","October 2013","February 13, 2015","null","January 2010","Objective Response (CR or PR) as Determined by the RECIST Criteria|Progression-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00103311"
1606,"NCT00826540","Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","Has Results","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: sorafenib tosylate|Biological: bevacizumab","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","83","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N054C|NCI-2009-01177|U10CA025224|CDR0000632342","January 21, 2009","September 2009","null","July 1, 2016","July 2016","November 27, 2013","null","January 2010","Progression-free Survival Rate|Response Rate|Overall Survival|Feasibility of Study Treatment","https://ClinicalTrials.gov/show/NCT00826540"
1607,"NCT00623805","A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer","Completed","Has Results","Colorectal Cancer","Drug: Bevacizumab|Drug: Capecitabine|Drug: Oxaliplatin","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","123","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21440","February 18, 2008","March 2008","May 2012","July 16, 2014","July 2014","June 6, 2014","null","May 2012","Progression-free Survival|Overall Survival|Percentage of Participants With a Complete Response or a Partial Response|Time Until a Complete Response or a Partial Response|Duration of Response|Percentage of Participants With Metastatic Lesions Previously Considered Inoperable Who Became Operable and Underwent Surgery|Percentage of Participants With a R0 Resection","https://ClinicalTrials.gov/show/NCT00623805"
1608,"NCT00559858","Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Palmar-plantar Erythrodysesthesia","Dietary Supplement: pyridoxine hydrochloride|Other: placebo|Procedure: quality-of-life assessment","Cambridge University Hospitals NHS Foundation Trust|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","270","Other","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Supportive Care","CRCA-CCTC-CAPP-IT|CDR0000576453|EUDRACT-2004-000325-29|EU-20786|ISRCTN82842634|CCLG-CAPP-IT","November 15, 2007","December 2004","null","August 1, 2013","December 2008","No Study Results Posted","null","December 2009","Incidence of capecitabine dose modifications (dose delay and dose reductions) due to toxicity|Incidence of hand-foot syndrome (HFS)|Overall toxicity|Quality of life|Response to chemotherapy|Progression-free survival|Measurement of biomarkers that might predict the occurrence of HFS","https://ClinicalTrials.gov/show/NCT00559858"
1609,"NCT01189227","Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery","Terminated","Has Results","Colorectal Cancer|Metastatic Cancer","Procedure: Postoperative chemotherapy|Procedure: Perioperative chemotherapy","NSABP Foundation Inc|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","9","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP C-11|NSABP-C-11","August 25, 2010","August 2010","December 2011","May 8, 2013","May 2013","February 5, 2013","null","December 2011","Recurrence-free Survival (RFS)|RFS of Patients Event-free|Overall Survival|The Difference in R0 and Combined R0 + R1 Resection Rates Between the Two Arms.|Frequencies of Selected Postoperative Surgical Complications and Other Adverse Events Within 30 Days of Surgery|Frequencies of Adverse Events as Assessed by the NCI CTCAE v4.0","https://ClinicalTrials.gov/show/NCT01189227"
1610,"NCT01229813","Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.","Completed","No Results Available","Colorectal Cancer","Drug: bevacizumab, erlotinib|Drug: bevacizumab|Drug: bevacizumab|Drug: low dose capecitabine","Lund University Hospital|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","233","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML 25359","October 27, 2010","October 2010","December 2013","April 10, 2015","November 2013","No Study Results Posted","ACT2","December 2013","To demonstrate that maintenance treatment with bevacizumab + erlotinib following first line chemo- and anti-angiogenetic therapy results in a significant increase in progression free survival (PFS) compared to treatment with only bevacizumab.|To explore the activity of bevacizumab and low dose metronomic capecitabine in patients with KRAS mutated tumors.","https://ClinicalTrials.gov/show/NCT01229813"
1611,"NCT02738359","Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening","Not yet recruiting","No Results Available","Colon Cancer","Other: colonoscopy colon capsule and FIT","Hôpital Edouard Herriot|National Cancer Institute, France","Both","50 Years to 75 Years   (Adult, Senior)","","3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Cancer National Institute","April 11, 2016","December 2016","May 2019","August 29, 2016","April 2016","No Study Results Posted","FAMCAP","December 2016","The primary endpoint is the prevalence of advanced colorectal neoplasia (adenoma > 1 cm, adenoma with high grade dysplasia) or cancer identified by each strategy after 3 years","https://ClinicalTrials.gov/show/NCT02738359"
1612,"NCT00766142","Combination Chemotherapy and Cetuximab in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Peritoneal Cavity Cancer","Biological: cetuximab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: therapeutic conventional surgery","Institut Bergonié|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000599511|IB-COCHISE-I|IB-2007-20|EUDRACT-2006-003900|MERCK-IB-COCHISE-I","October 2, 2008","May 2007","null","July 7, 2009","July 2009","No Study Results Posted","null","December 2009","Progression-free survival at 3 years","https://ClinicalTrials.gov/show/NCT00766142"
1613,"NCT00557102","Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: cetuximab|Biological: filgrastim|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","National Cancer Institute, France|University Hospital, Grenoble","Both","18 Years and older   (Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000574153|CHUG-ERBIFORT|INCA-RECF0316|EUDRACT-2007-000357-54","November 9, 2007","September 2007","December 2010","December 10, 2012","December 2012","No Study Results Posted","ERBIFORT","December 2010","Tumor response rate|Rate of resectability|Overall and disease-free survival|Tolerability","https://ClinicalTrials.gov/show/NCT00557102"
1614,"NCT01338558","A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab","Withdrawn","No Results Available","Colorectal Cancer","Drug: bevacizumab [Avastin]|Drug: cetuximab|Drug: mFOLFOX6","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25686","April 18, 2011","June 2011","May 2015","September 1, 2016","September 2016","No Study Results Posted","null","May 2015","Progression-free survival: native versus mutated K-RAS; tumour assessments according to RECIST criteria|Overall survival|Objective response rate|Safety: Incidence of adverse events|Quality of Life: European Organisation for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C30)|Progression-free survival: comparison of the two treatment regimens in the native K-RAS arms","https://ClinicalTrials.gov/show/NCT01338558"
1615,"NCT02383810","Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)","Completed","No Results Available","Drug and/or Toxin-induced Diarrhea","Drug: Elsiglutide|Drug: Placebo","Helsinn Healthcare SA|Chiltern International Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","498","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TIDE-13-22","February 24, 2015","February 2015","February 2016","April 1, 2016","April 2016","No Study Results Posted","null","February 2016","Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the first cycle of chemotherapy in the target population|Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the first cycle of chemotherapy in the additional population|Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the second and third cycle of chemotherapy - target population|Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea over the first two cycles of chemotherapy (i.e. in at least one of the first two cycles) - target population|Proportion of patients experiencing a maximum Grade 1, Grade 2, Grade 3, Grade 4, Grade 5 and any Grade (i.e. ≥ 1) diarrhea by cycle (Cycle 1, 2 and 3) - target population|Proportion of patients experiencing an overall Grade ≥ 2 diarrhea by cycle (Cycle 1, Cycle 2 and Cycle 3) - target population|Proportion of patients experiencing an overall Grade ≥ 2 diarrhea over the first two cycles of chemotherapy (i.e. in at least one of the first two cycles) - target population|Time to onset of first event of diarrhea of any Grade (i.e. ≥ 1) and time to onset of first event of diarrhea of Grade ≥ 2 (as assessed by the Investigator) by cycle (Cycle 1, 2 and 3) - target population|Time to first day with diarrhea (as reported by patient in the eDiary) by cycle (Cycle 1, 2 and 3) - target population|Cumulative duration (days) of any Grade (i.e. ≥ 1) diarrhea events and cumulative duration of Grade ≥ 2 diarrhea events (as assessed by the Investigator) by cycle (Cycle 1, 2 and 3) - target population|Cumulative duration (days) of diarrhea events (as assessed by the Investigator) by grade (Grade 1, Grade 2, Grade 3, Grade 4, Grade 5) and by cycle (Cycle 1, 2 and 3) - target population|Number of events of diarrhea by grade (as assessed by the Investigator) by cycle (Cycle 1, 2 and 3) - target population|Number of days with presence of diarrhea (as reported by patient in the eDiary) by cycle (Cycle 1, 2 and 3) - target population|Number of days with presence of at least one bowel movement with stools of consistency 6 or 7 (according to Bristol Stool Form Scale) accompanied by urgency or by fecal incontinence by cycle (Cycle 1, 2 and 3) - target population|Number of days with presence of abdominal discomfort by cycle (Cycle 1, 2 and 3) - target population|Number of days with limitation of self-care activities due to diarrhea by cycle (Cycle 1, 2 and 3) - target population|Proportion of patients: who required i.v. fluids due to CID, who required changes to the primary therapy due to CID, who used rescue medication (i.e. medication used for treatment of diarrhea) by cycle (Cycle 1, 2 and 3) - target population|Proportion of patients having a maximum Grade ≥ 2 diarrhea - shift from Cycle 1 to Cycle 2 and from Cycle 2 to Cycle 3 - target population|Proportion of patients having a maximum Grade ≥ 1 diarrhea - shift from Cycle 1 to Cycle 2 and from Cycle 2 to Cycle 3 - target population|Proportion of patients having an overall Grade ≥ 2 diarrhea - shift from Cycle 1 to Cycle 2 and from Cycle 2 to Cycle 3 - target population|Proportion of patients having an overall Grade ≥ 1 diarrhea - shift from Cycle 1 to Cycle 2 and from Cycle 2 to Cycle 3 - target population|Time trend of the citrulline plasma concentrations in Cycles 1, 2 and 3 - target population","https://ClinicalTrials.gov/show/NCT02383810"
1616,"NCT01991080","The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy","Recruiting","No Results Available","Colon Cancer","Behavioral: biofeedback|Drug: Wheatgerm juice","Rambam Health Care Campus","Both","18 Years to 100 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","Biofeedback","October 29, 2013","December 2013","December 2017","November 19, 2015","November 2015","No Study Results Posted","null","December 2016","Primary Outcome|Secondary|secondary","https://ClinicalTrials.gov/show/NCT01991080"
1617,"NCT01206530","FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer","Recruiting","No Results Available","Rectal Cancer|Colon Cancer|Metastasis|Adenocarcinoma","Drug: Hydroxychloroquine|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-fluorouracil|Drug: 5-fluorouracil|Drug: Bevacizumab","Abramson Cancer Center of the University of Pennsylvania","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","35","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","UPCC 07210","September 16, 2010","September 2010","null","January 21, 2016","January 2016","No Study Results Posted","null","September 2016","Response Rate|Progression-free survival|Overall survival|Incidence of toxicity","https://ClinicalTrials.gov/show/NCT01206530"
1618,"NCT00569335","Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer","Completed","No Results Available","Colorectal, Cancer","Drug: S-1, Irinotecan, Bevacizumab","Taiho Pharmaceutical Co., Ltd.","Both","20 Years and older   (Adult, Senior)","Phase 2","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01023020","December 5, 2007","October 2007","March 2010","November 1, 2012","November 2012","No Study Results Posted","null","March 2010","Safety|Progression-free survival, Response rate, Overall survival, Time to treatment failure, Treatment situation","https://ClinicalTrials.gov/show/NCT00569335"
1619,"NCT01673607","Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer","Recruiting","No Results Available","Resectable Hepatic Metastases of Colorectal Cancer","Procedure: Biopsie liver","Poitiers University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","","METAHEP","February 13, 2012","null","null","April 3, 2013","April 2013","No Study Results Posted","METAHEP","April 2015","","https://ClinicalTrials.gov/show/NCT01673607"
1620,"NCT00118105","S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer","Withdrawn","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: bevacizumab|Drug: capecitabine|Drug: oxaliplatin|Procedure: conventional surgery","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000433491|S0408|U10CA032102","July 8, 2005","November 2006","April 2007","January 2, 2013","January 2013","No Study Results Posted","null","April 2007","Proportion of patients with R0 resection after treatment|Probability of nonprogression (i.e., stable disease or response [complete and partial, confirmed and unconfirmed])|Comparison of patients achieving R0 resection with literature|Overall survival|Disease-free survival|Positron emission tomography response|Correlation of clinical outcome with expression of biomarkers and telomere length","https://ClinicalTrials.gov/show/NCT00118105"
1621,"NCT01225744","Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: Irinotecan|Drug: Oxaliplatin|Drug: UFT","The Christie NHS Foundation Trust|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","47","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07_DOG03_133","October 20, 2010","April 2009","May 2013","June 10, 2014","June 2014","No Study Results Posted","eSCOUT","May 2013","Objective response rate (according to RECIST criteria)|Progression Free Survival|Overall survival (OS; all causes of death).|Toxicity|Resectability of liver, lung and pelvic disease after chemotherapy|Time to progression (TTP)","https://ClinicalTrials.gov/show/NCT01225744"
1622,"NCT02287597","An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice","Recruiting","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML29055","November 6, 2014","February 2015","December 2016","March 9, 2015","March 2015","No Study Results Posted","null","December 2016","Effectiveness: Second-line time to progression, in months|Safety (composite outcome measure): Incidence of all adverse events, adverse events of special interest (AESI) for bevacizumab and pregnancies reported in second line mCRC treatment with Avastin plus chemotherapy|Safety (composite outcome measure): Incidence, nature and severity of all serious adverse events reported in second line mCRC treatment with Avastin plus chemotherapy and information on outcome and action taken with the drug","https://ClinicalTrials.gov/show/NCT02287597"
1623,"NCT02012829","Influence of a Brief Intervention on CRC Screening","Completed","No Results Available","Colorectal Cancer","Behavioral: GPs communication skills and CRC screening","University Paris 7 - Denis Diderot","Both","Child, Adult, Senior","","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","2011/19NI","March 8, 2013","December 2011","September 2012","December 10, 2013","December 2013","No Study Results Posted","Hem-FMG","July 2012","participation rate of patients for CRC screening|GPs with a participation rate over 65%|GPs participation rate over 45%","https://ClinicalTrials.gov/show/NCT02012829"
1624,"NCT01405183","Association Between Hepatitis C Infection and Renal Cell Carcinoma","Completed","No Results Available","Hepatitis C|Renal Cell Carcinoma|Colorectal Cancer","Other: Hepatitis C testing","Henry Ford Health System|Schering-Plough","Both","18 Years and older   (Adult, Senior)","","240","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","P08406","July 28, 2011","January 2011","September 2013","September 16, 2014","September 2014","No Study Results Posted","null","August 2013","Prevalence of hepatitis C in renal cell carcinoma patients","https://ClinicalTrials.gov/show/NCT01405183"
1625,"NCT02041507","Water-aided Colonoscopy vs Air Insufflation Colonoscopy in Colorectal Cancer Screening","Completed","No Results Available","Colorectal Cancer|Colorectal Adenomas|Colorectal Polyps|Pain","Other: Air insufflation method.|Other: Water Immersion method.|Other: Water Exchange method.","Presidio Ospedaliero Santa Barbara","Both","50 Years to 70 Years   (Adult, Senior)","","1224","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)","PI.2013.2502|Delibera 1047.2013","January 18, 2014","February 2014","April 2016","April 11, 2016","April 2016","No Study Results Posted","null","March 2016","Adenoma Detection Rate.|Proximal colon Adenoma Detection Rate.|Proximal colon <10 mm Adenoma Detection Rate.|Mean adenomas resected per procedure.|Cecal intubation rate.|Cecal intubation time.|Total procedure time.|Maximum pain score recorded during insertion phase of colonoscopy.|Pain score at discharge.|Need for sedation/analgesia and its dosage","https://ClinicalTrials.gov/show/NCT02041507"
1626,"NCT01729923","A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer","Suspended","No Results Available","Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: Capecitabine|Drug: Celecoxib|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Radiation: Radiation Therapy|Radiation: Stereotactic Radiosurgery|Procedure: Therapeutic Conventional Surgery","University of Washington|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","43","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7707|NCI-2012-02137|P30CA015704","November 15, 2012","March 2013","null","July 8, 2016","July 2016","No Study Results Posted","ADAPT","March 2019","Rate of CR, assessed according to CEA and CA 19-9 measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|Adverse events defined as any condition that appears or worsens after the subject is enrolled in an investigational study, graded by numerical score according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 4.0|Best overall response rate, defined using RECIST 1.1|K-ras mutation status|Overall survival|Quality of life (QOL), assessed using the M.D. Anderson Symptom Inventory (MDASI)|Relapse free survival in patients achieving CR","https://ClinicalTrials.gov/show/NCT01729923"
1627,"NCT01726296","Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care","Recruiting","No Results Available","Adenocarcinoma of the Lung|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Squamous Cell Lung Cancer|Stage I Colon Cancer|Stage I Rectal Cancer|Stage IA Non-small Cell Lung Cancer|Stage IB Non-small Cell Lung Cancer|Stage IIA Colon Cancer|Stage IIA Non-small Cell Lung Cancer|Stage IIA Rectal Cancer|Stage IIB Colon Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIB Rectal Cancer|Stage IIC Colon Cancer|Stage IIC Rectal Cancer|Stage IIIA Colon Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer","Other: educational intervention|Other: medical chart review","Fox Chase Cancer Center","Both","18 Years and older   (Adult, Senior)","","1440","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","12-841|NCI-2012-01717","November 9, 2012","January 2013","null","March 1, 2016","March 2016","No Study Results Posted","null","July 2015","Percentage of eligible CRC and NSCLC survivors with medical record documentation of compliance with NCCN guidelines|Change in percentage of eligible survivors with documentation of compliance with NCCN survivorship guidelines after conducting the targeted educational initiative at participating sites","https://ClinicalTrials.gov/show/NCT01726296"
1628,"NCT00797485","Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","Recruiting","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: capecitabine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Southern Italy Cooperative Oncology Group|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","672","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000617983|SICOG-0803|EudraCT-2008-004890-17","November 22, 2008","July 2008","null","August 23, 2013","June 2009","No Study Results Posted","null","July 2011","Time to failure of strategy|Response according to RECIST criteria|Duration of response|Progression-free survival|Safety according to NCI CTCAE v3.0|Quality of life as assessed by EORTC QLQ-C30 questionnaire (v 3.0) at baseline, every 3 months during induction chemotherapy, and at discontinuation of treatment","https://ClinicalTrials.gov/show/NCT00797485"
1629,"NCT01710215","Comparative Effectiveness of FIT, Colonoscopy, & Usual Care Screening Strategies","Active, not recruiting","No Results Available","Colorectal Cancer","Other: FIT Screening Strategy|Other: Colon Screening Strategy","University of Texas Southwestern Medical Center|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Parkland Health & Hospital System","Both","50 Years to 64 Years   (Adult)","","5999","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Screening","102011-069|1U54CA163308-01","October 5, 2012","April 2013","September 2018","March 11, 2016","March 2016","No Study Results Posted","null","September 2016","Benefit: Proportion of patients achieving one of the effective screening ""successes.""|Harm: Rate of screening non-participation.|Cost: Cost per-patient effectively screened.|Benefit: Number of CRCs, advanced adenomas, and adenomas detected.|Benefit: Number of patients screened.|Harm: Number of CRCs diagnosed based on symptoms/signs rather than screening.|Harm: Ineffective screening.|Harm: Post-colonoscopy bleeding or perforation.|Harm: Failed colonoscopy due to incomplete bowel prep or inability to reach cecum.|Cost: Cost per patient screened.|Cost: Incremental costs for the FIT and Colo strategies relative to the Usual Care strategy.","https://ClinicalTrials.gov/show/NCT01710215"
1630,"NCT00043043","Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia","Completed","No Results Available","Colorectal Cancer","Drug: celecoxib","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","NIH","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Prevention","CDR0000069498|NCI-02-C-0194","August 5, 2002","May 2003","October 2007","June 18, 2013","November 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00043043"
1631,"NCT01469611","A Trial of JX-594 in Refractory Colorectal Carcinoma","Active, not recruiting","No Results Available","Colorectal Carcinoma","Biological: JX-594","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SMC IRB 2009-06-055","November 7, 2011","September 2010","October 2013","June 12, 2013","June 2013","No Study Results Posted","null","October 2012","Determine the maximally-tolerated dose|Determine the maximum-feasible dose","https://ClinicalTrials.gov/show/NCT01469611"
1632,"NCT01919151","Micrometastasis in Gastrointestinal Cancer","Recruiting","No Results Available","Pancreatic Adenocarcinoma|Colorectal Cancer","","Oslo University Hospital","Both","Child, Adult, Senior","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","93-08172d6.2008.540","August 7, 2013","June 2008","December 2015","August 8, 2013","August 2013","No Study Results Posted","null","December 2013","Survival","https://ClinicalTrials.gov/show/NCT01919151"
1633,"NCT01170299","Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer","Recruiting","No Results Available","Anal Cancer|Bladder Cancer|Cervical Cancer|Colorectal Cancer|Fallopian Tube Cancer|Gastrointestinal Complications|Ovarian Cancer|Radiation Toxicity|Sarcoma","Dietary Supplement: dietary intervention|Other: laboratory biomarker analysis|Procedure: gastrointestinal complications management/prevention|Procedure: management of therapy complications|Radiation: selective external radiation therapy","Royal Masonic Hospital|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","177","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Supportive Care","RM-FIBRE-STUDY|CDR0000681693|RM-CCR-3142|EU-21053","July 24, 2010","October 2009","null","August 9, 2013","July 2010","No Study Results Posted","null","April 2012","Change in IBDQ-B (Inflammatory Bowel Disease Questionnaire - Bowel Subset) score between baseline (i.e., Day 1 of radiotherapy treatment) and the nadir score during treatment|Incidence of toxicity, defined using the Bristol Stool Chart|Costs for symptom management","https://ClinicalTrials.gov/show/NCT01170299"
1634,"NCT00176761","Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine","Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: Interleukin-2 (IL-2)","University of Michigan Cancer Center|University of Michigan","Both","18 Years and older   (Adult, Senior)","Phase 2","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 9947|GCRC Protocol #1673","September 9, 2005","March 2000","May 2006","September 6, 2006","September 2006","No Study Results Posted","null","null","To assess the antitumor response of this immunotherapy regimen.|To characterize the immune response (as defined in Section VII) to the tumor-pulsed dendritic cell vaccine combined with IL-2 administration in patients with metastatic colorectal cancer.|To evaluate the toxicity of this treatment regimen.","https://ClinicalTrials.gov/show/NCT00176761"
1635,"NCT01111604","A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer","Completed","No Results Available","Colon Cancer|Rectal Cancer","Biological: IMC-1121B|Biological: IMC-18F1|Drug: mFOLFOX-6","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","157","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13942|CP20-0801|I4Y-IE-JCDB","April 8, 2010","August 2010","December 2013","April 28, 2014","April 2014","No Study Results Posted","null","December 2013","Progression-free survival (PFS)|Objective response rate (ORR)|Overall survival (OS)|Duration of response|Maximum concentration (Cmax) at Day 1|Maximum concentration (Cmax) at Day 4|Maximum concentration (Cmax) at Day 8|Maximum concentration (Cmax) at Day 15|Minimum concentration (Cmin) at Day 1|Minimum concentration (Cmin) at Day 4|Minimum concentration (Cmin) at Day 8|Minimum concentration (Cmin) at Day 15|Serum Anti-1121B Antibody Assessment|Serum Anti-IMC-18F1 Antibody Assessment|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01111604"
1636,"NCT00835679","Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery","Terminated","Has Results","Liver Metastases|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer","Biological: cetuximab|Drug: dasatinib|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 0","9","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","NCI-2013-00014|VU-VICC-GI-0838|8069|P30CA068485|081338|VICC GI 0838","February 3, 2009","December 2009","August 2011","May 7, 2014","January 2013","March 12, 2012","null","February 2011","Patients With a Biologic Response|Patients With Reduction of Biomarkers in Tumor Tissue|Number of Patients With the Given Severity of Adverse Event Within a Specified Duration|Number of Patients With the Given Severity of Post-operative Complications Within the Specified Duration","https://ClinicalTrials.gov/show/NCT00835679"
1637,"NCT00506571","Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer","Recruiting","No Results Available","Colorecal Neoplasms|Secondary","Drug: S-1, irinotecan, oxaliplatin","National Cancer Center, Korea","Both","18 Years and older   (Adult, Senior)","Phase 2","42","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-07-261","July 23, 2007","July 2007","June 2010","July 23, 2007","April 2007","No Study Results Posted","TIROX2","null","Maximal overall response rate|Progression-free survival, Overall survival, Toxicity assessment, & Pharmacokinetic characteristics and association with genetic polymorphism","https://ClinicalTrials.gov/show/NCT00506571"
1638,"NCT01455831","Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer","Recruiting","No Results Available","Adenocarcinoma of the Colon","Drug: Tinzaparin|Drug: Tinzaparin","Ottawa Hospital Research Institute","Both","18 Years and older   (Adult, Senior)","Phase 3","1075","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","221097","October 18, 2011","September 2011","December 2024","September 13, 2016","September 2016","No Study Results Posted","PERIOP-01","December 2022","Disease Free Survival|Overall Survival|Venous Thromboembolism events|Major surgical site bleeding events|Major bleeding events (not including the surgical site)|• Clinically relevant bleeding events prior to surgery and during the • Clinically relevant bleeding events|Transfusion requirements|Correlative endpoints|Other post-operative (day 0 - day 28) complications","https://ClinicalTrials.gov/show/NCT01455831"
1639,"NCT00271011","A Study of Mitomycin C, Irinotecan, and Cetuximab","Terminated","Has Results","Colorectal Cancer","Drug: Mitomycin C|Drug: Cetuximab|Drug: Irinotecan.","University of Michigan Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","13","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2005-060|HUM 00000749","December 27, 2005","December 2005","July 2009","November 4, 2015","November 2015","June 4, 2014","null","July 2008","Percentage of Patients With an Objective Response|Proportion of Patients Experiencing Hematologic and Non-hematologic Adverse Events","https://ClinicalTrials.gov/show/NCT00271011"
1640,"NCT00656838","Focusing Implementation to Bring Effective Reminders (FIBER)","Completed","No Results Available","Colorectal Cancer","Behavioral: Patients receives letter, phone call, office visit, educational materials","Kaiser Permanente|Oregon Health and Science University|Henry Ford Health System","Both","50 Years to 80 Years   (Adult, Senior)","","85289","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","R01CA132709-01","April 4, 2008","April 2008","February 2013","February 19, 2014","October 2011","No Study Results Posted","FIBER","April 2011","To determine the effectiveness and maintenance of a colon-rectal cancer screening patient reminder program.Identify patient, primary care team, and system factors important to implementation success.|Create, refine, and disseminate an implementation guide for colon-rectal cancer screening reminder programs by combining the findings from the primary aim.","https://ClinicalTrials.gov/show/NCT00656838"
1641,"NCT01801059","Patient Activation Intervention in Improving Screening Rates for Colorectal Cancer","Completed","No Results Available","Colon Cancer|Rectal Cancer","Other: educational intervention|Other: educational intervention|Other: questionnaire administration","Ohio State University Comprehensive Cancer Center","Both","50 Years and older   (Adult, Senior)","","284","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","OSU-07104|NCI-2012-01922","February 26, 2013","September 2007","December 2010","October 14, 2014","October 2014","No Study Results Posted","null","August 2010","Completion rate of CRC screening","https://ClinicalTrials.gov/show/NCT01801059"
1642,"NCT00052585","Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer","Terminated","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: irinotecan hydrochloride|Drug: gefitinib|Drug: leucovorin calcium|Drug: fluorouracil","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","50","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02505|UPCC #06202|CDR0000258548","January 24, 2003","October 2002","null","January 15, 2013","January 2013","No Study Results Posted","null","November 2004","Grade 3 or 4 toxicity, graded using the NCI CTC version 2.0|Response rate","https://ClinicalTrials.gov/show/NCT00052585"
1643,"NCT00408772","Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery","Recruiting","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: bevacizumab|Drug: capecitabine|Drug: oxaliplatin|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Procedure: radiofrequency ablation","University of California, Davis|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000517440|UCDCC-131|UCDCC-200412546-3","December 6, 2006","June 2007","null","January 27, 2010","January 2010","No Study Results Posted","null","null","Conversion rate of nonresectable disease to resectable disease|Disease-free and overall survival|Objective response rate|Duration of response","https://ClinicalTrials.gov/show/NCT00408772"
1644,"NCT00265356","Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases","Completed","No Results Available","Colorectal Cancer|Liver Metastases","Procedure: PET diagnostic imaging","Ontario Clinical Oncology Group (OCOG)|Ontario Ministry of Health and Long Term Care","Both","18 Years and older   (Adult, Senior)","Phase 3","404","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CTA-Control-098389","December 12, 2005","November 2005","April 2013","October 18, 2013","October 2013","No Study Results Posted","PETCAM","April 2010","proportion of patients who have a change in management resulting from PET|proportion of patients precluded from having a liver resection because of additional metastatic disease identified on PET|3-year overall survival of patients who undergo surgery with curative intent|3-year overall survival of all patients|sensitivity and specificity of PET in detecting other hepatic and extra-hepatic metastatic disease prior to a potentially curable liver resection for colorectal adenocarcinoma metastatic disease|economic analysis of the addition of PET in the diagnostic work-up|prognostic ability of the PET standard uptake value (SUV) in predicting 3-year overall survival","https://ClinicalTrials.gov/show/NCT00265356"
1645,"NCT02232152","CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","Recruiting","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: 6,8-bis(benzylthio)octanoic acid|Drug: fluorouracil|Other: pharmacological study|Other: laboratory biomarker analysis","Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","40","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCCWFU 59314|NCI-2014-01779|CCCWFU #59314|P30CA012197","September 2, 2014","December 2014","null","July 26, 2016","July 2016","No Study Results Posted","null","December 2018","MTD of 6,8-bis(benzylthio)octanoic acid in combination with fluorouracil based on the incidence of dose-limiting toxicities graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence of toxicity of 6,8-bis(benzylthio)octanoic acid and fluorouracil combination graded according to NCI CTCAE version 4.0|PK parameters (maximum observed concentration, area under the curve, half-life, elimination rate constant, drug clearance, and volume of distribution) of 6,8-bis(benzylthio)octanoic acid in plasma samples|Progression-free survival (PFS)|Overall response rate (ORR) (i.e., sum of complete response [CR] and partial response [PR])|Disease control rate (DCR) (i.e., sum of CR, PR, and stable disease)","https://ClinicalTrials.gov/show/NCT02232152"
1646,"NCT02894801","Multistate Relative Survival Model","Completed","No Results Available","Colorectal Cancer","","Centre Hospitalier Universitaire Dijon|Institut National de la Santé Et de la Recherche Médicale, France","Both","Child, Adult, Senior","","5194","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PIOC 2015","August 30, 2016","January 2013","null","September 5, 2016","September 2016","No Study Results Posted","MRS","December 2013","death due to cancer|death due to recurrence","https://ClinicalTrials.gov/show/NCT02894801"
1647,"NCT00316914","Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery","Completed","Has Results","Colorectal Cancer|Neurotoxicity","Drug: calcium gluconate|Drug: magnesium sulfate|Other: placebo","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|North Central Cancer Treatment Group","Both","18 Years and older   (Adult, Senior)","Phase 3","104","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","NCCTG-N04C7|CDR0000471238","April 19, 2006","January 2006","November 2012","July 11, 2016","July 2016","November 26, 2012","null","January 2008","Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event|Time to Onset of Grade 2+ Chronic Neurotoxicity|Time to Onset of Grade 3+ Chronic Neurotoxicity|Average Duration of Chronic Neuropathic Toxicity|Percentage of Patients Discontinuing Therapy for Chronic Neurotoxicity|Average Cumulative Oxaliplatin Dose|Average Duration of Oxaliplatin-containing Treatment|Percentage of Patients With Acute Neuropathic Adverse Event|Incidence of Calcium Magnesium (CaMg)-Induced Adverse Event|Percentage of Patients Experiencing Impact on Activities of Daily Living (ADL)|Change From Baseline in Fatigue Score at One Month|Change From Baseline in Quality of Life (QOL) at One Month","https://ClinicalTrials.gov/show/NCT00316914"
1648,"NCT02631564","Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver Metastasis","Recruiting","No Results Available","Colon Cancer Liver Metastasis","","Fudan University","Both","18 Years to 80 Years   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Ral-1","December 14, 2015","June 2015","December 2018","December 14, 2015","December 2015","No Study Results Posted","null","June 2017","number of adverse events|Overall survival|Time to progression","https://ClinicalTrials.gov/show/NCT02631564"
1649,"NCT02560194","Evaluation of Flexible Sigmoidoscopy Screening as an Adjunct to the National FOBT Screening Programme in Scotland","Recruiting","No Results Available","Colorectal Cancer|Colorectal Adenoma","Procedure: Flexible Sigmoidoscopy|Other: Fecal occult blood test","University of Dundee","Both","59 Years to 61 Years   (Adult)","Phase 3","6000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","2013ON22","September 3, 2015","June 2014","December 2016","September 24, 2015","September 2015","No Study Results Posted","null","May 2016","Number of colorectal cancers or adenomas diagnosed|Number of invited individuals undergoing flexible sigmoidoscopy","https://ClinicalTrials.gov/show/NCT02560194"
1650,"NCT01983098","Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment","Recruiting","No Results Available","To Compare the Monitoring of Circulating Tumor DNA With the Efficacy of Chemotherapy Evaluated by Computer Tomography Scan.","","Assistance Publique - Hôpitaux de Paris","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Time Perspective: Prospective","NI-CRC-DNAc","October 28, 2013","April 2013","October 2014","November 5, 2013","October 2013","No Study Results Posted","null","April 2014","To compare the monitoring of circulating tumor DNA with the results of computer tomography scan according the RECIST criteria|To compare the monitoring of circulating tumor DNA with the response tumor evaluated by RECIST criteria on computer tomography scan","https://ClinicalTrials.gov/show/NCT01983098"
1651,"NCT02515734","A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: Leucovorin|Drug: irinotecan|Drug: oxaliplatin|Biological: bevacizumab|Biological: cetuximab","Japan Clinical Cancer Research Organization","Both","20 Years and older   (Adult, Senior)","Phase 2","360","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JACCRO CC-13","July 12, 2015","August 2015","June 2020","August 4, 2015","August 2015","No Study Results Posted","DEEPER","December 2017","Best deepness of response|Early tumor shrinkage|Response rate|Deepness of response|Overall survival|Progression free survival|Rate of curatively resected metastatic lesion|Number of adverse events","https://ClinicalTrials.gov/show/NCT02515734"
1652,"NCT01814501","Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab","Recruiting","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer","Biological: panitumumab|Drug: irinotecan hydrochloride|Drug: fluorouracil|Drug: leucovorin calcium","Christina Wu|Amgen|Ohio State University Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","35","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-11131|NCI-2013-00432","February 25, 2013","February 2013","null","March 14, 2016","March 2016","No Study Results Posted","null","December 2017","Progression free survival(PFS)|Frequency and severity of toxicities of the regimens, graded according to the NCI CTCAE v4.0|Overall response rate, as described in RECIST v1.1 criteria|Overall survival","https://ClinicalTrials.gov/show/NCT01814501"
1653,"NCT02893540","Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC","Recruiting","No Results Available","Colorectal Cancer","Drug: Capecitabine","Ruijin Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","250","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RJH-Oncol-Metronomic","September 3, 2016","September 2016","August 2019","September 15, 2016","September 2016","No Study Results Posted","null","December 2018","PFS1|OS|QOL","https://ClinicalTrials.gov/show/NCT02893540"
1654,"NCT00500292","A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer","Active, not recruiting","Has Results","Colorectal|Cancer","Drug: Vandetanib|Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid","AstraZeneca","Both","18 Years to 120 Years   (Adult, Senior)","Phase 2","109","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4200C00047","July 3, 2007","March 2007","June 2016","April 4, 2016","March 2016","April 27, 2011","null","March 2008","Number of Patients With an Objective Disease Progression Event","https://ClinicalTrials.gov/show/NCT00500292"
1655,"NCT02046538","Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer","Not yet recruiting","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum","Drug: Leucovorin|Drug: Oxaliplatin|Drug: 5-FU|Drug: Irinotecan","Weill Medical College of Cornell University|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1309014302|2012-AFL-18","January 23, 2014","February 2014","February 2018","January 24, 2014","January 2014","No Study Results Posted","null","February 2016","Number of adverse events experienced|Number of subjects who demonstrate a response to pre-operative chemotherapy and zaltrap|Survival duration without disease progression","https://ClinicalTrials.gov/show/NCT02046538"
1656,"NCT00134069","Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer","Completed","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: sorafenib tosylate|Drug: cetuximab|Drug: irinotecan hydrochloride","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","48","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00110|07-0571|R21CA117125|U01CA070095","August 22, 2005","June 2005","December 2011","April 15, 2014","April 2014","No Study Results Posted","null","September 2010","Toxicity spectrum and dose-limiting toxicities of sorafenib in combination with cetuximab and irinotecan as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v 3.0|Recommended dose for phase II evaluation of the combination of sorafenib, cetuximab and irinotecan|Clinical activity of the combination of sorafenib, cetuximab and irinotecan in terms of radiological response|Pharmacokinetics of sorafenib, cetuximab, and irinotecan when given in combination or when given in combination with cetuximab alone and with cetuximab and irinotecan|Pharmacodynamics of the combination of irinotecan when given in combination with sorafenib and cetuximab in tumor tissues","https://ClinicalTrials.gov/show/NCT00134069"
1657,"NCT02603757","Effectiveness of High Dose Vitamin D Supplementation in Stage III Colorectal Cancer","Recruiting","No Results Available","Colon Cancer|Rectal Cancer","Dietary Supplement: cholecalciferol","Legacy Health System","Both","18 Years to 99 Years   (Adult, Senior)","","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Vitamin D & Colorectal Cancer","November 9, 2015","March 2016","December 2022","May 5, 2016","May 2016","No Study Results Posted","null","December 2022","Increase in serum Vitamin D3 level during chemotherapy in the active supplementation group compared to the control group.|Relapse-free survival (RFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02603757"
1658,"NCT00077298","Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer","Completed","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Biological: cetuximab|Biological: bevacizumab|Drug: irinotecan hydrochloride|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","70","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01445|MSKCC-03135|NCI-6444|CDR0000350086|03-135|6444|N01CM17105|N01CM17101|N01CM17103|N01CM17102","February 10, 2004","December 2003","July 2007","April 14, 2015","December 2012","No Study Results Posted","null","July 2007","Time to tumor progression|Objective response rate|Overall survival","https://ClinicalTrials.gov/show/NCT00077298"
1659,"NCT00041652","Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer","Completed","No Results Available","Colorectal Cancer|Colon Cancer|Rectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Breast Cancer|Breast Neoplasms","Drug: hMN14 (labetuzumab)","Immunomedics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IM-T-hMN14-04","July 11, 2002","February 2000","June 2003","October 21, 2005","October 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00041652"
1660,"NCT01322178","Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients","Recruiting","No Results Available","Colorectal Cancer|Liver Metastases","Drug: Cetuximab; mFOLFOX6","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","90","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62202-203","March 23, 2011","December 2010","December 2013","August 11, 2011","August 2011","No Study Results Posted","CLIME","June 2012","Resection rate (R0)|Response rate,Progression-free Survival,Overall Survival,R1 resection rate|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01322178"
1661,"NCT02851004","Special Combination of BBI608 and Pembrolizumab","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: BBI608(Napabucasin)|Drug: Pembrolizumab","Takayuki Yoshino|Sumitomo Dainippon Pharma Co., Ltd.|National Cancer Center Hospital East","Both","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","56","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EPOC1503","July 14, 2016","September 2016","March 2021","August 4, 2016","August 2016","No Study Results Posted","null","September 2020","Immune-related objective response rate determined by their Response Evaluation Criteria In Solid Tumors (RESIST)|Immune-related progression free survival rate at week 12 determined by the irRECIST|Objective response rate determined by RECIST version 1.1|Progression free survival rate at week 12 determined by the RECIST version 1.1|Progression free survival|Overall survival|Disease control rate|Incidence of adverse events|Area under the blood concentration-time curve (AUC)|Cmax","https://ClinicalTrials.gov/show/NCT02851004"
1662,"NCT00551421","Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer","Completed","Has Results","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Biological: pertuzumab|Biological: cetuximab|Drug: irinotecan hydrochloride|Other: immunohistochemistry staining method|Other: fluorescence in situ hybridization|Other: gene expression analysis|Other: mutation analysis|Other: polymerase chain reaction|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","17","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00241|07-070|U01CA062490","October 30, 2007","October 2007","June 2012","March 11, 2015","July 2014","December 17, 2014","null","November 2010","Recommended Phase II Dose of Pertuzumab When Administered in Combination With Cetuximab (Phase I)|Objective Tumor Response Rate Defined as the Proportion of Patients With a Best Overall Response of CR or PR, Per RECIST Criteria (Phase II)|Progression-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00551421"
1663,"NCT02815436","Effectiveness of Tel and SMS Reminder on Compliance With CRC Screening","Recruiting","No Results Available","Colorectal Cancer","Other: Telephone reminder|Other: SMS reminder","Chinese University of Hong Kong","Both","40 Years to 70 Years   (Adult, Senior)","","900","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","Tel Compliance Study_Protocol","June 24, 2016","April 2016","January 2017","June 27, 2016","June 2016","No Study Results Posted","null","January 2017","Rate of completion of FOBT in the year of receiving the interventions/control|Rate of return of FOBT tubes in the year of receiving the interventions/control","https://ClinicalTrials.gov/show/NCT02815436"
1664,"NCT00612586","Phase 2 Study of Enzastaurin With 5 FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Enzastaurin|Drug: Placebo|Drug: Leucovorin|Drug: 5-FU|Drug: Bevacizumab","Eli Lilly and Company|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10534|H6Q-MC-S064","January 28, 2008","February 2008","November 2011","February 17, 2012","February 2012","No Study Results Posted","null","January 2010","Progression Free Survival|Overall Survival|Safety and Adverse Events","https://ClinicalTrials.gov/show/NCT00612586"
1665,"NCT02041481","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: MEK inhibitor MEK162|Drug: leucovorin calcium|Drug: fluorouracil|Drug: oxaliplatin|Other: pharmacological study|Other: Laboratory Biomarker Analysis","City of Hope Medical Center|National Cancer Institute (NCI)|Array BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 1","34","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13355|NCI-2014-00051|CMEK162AUS09T","January 17, 2014","June 2014","null","September 2, 2016","September 2016","No Study Results Posted","null","December 2017","MTD of MEK inhibitory MEK162 on a continuous and an intermittent schedule in combination with FOLFOX assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03|DLT defined as an adverse event or abnormal laboratory value assessed as at least possibly related to the combination of MEK inhibitor MEK162 and FOLFOX graded according to NCI CTCAE v4.03|Progression-free survival|Time to failure|Survival","https://ClinicalTrials.gov/show/NCT02041481"
1666,"NCT02780284","Microbiome, Exercise Tracking Study (METS)","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Physical activity intervention","Columbia University","Both","21 Years to 69 Years   (Adult, Senior)","","20","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","AAAP1611","May 19, 2016","March 2015","June 2017","May 20, 2016","May 2016","No Study Results Posted","null","December 2016","Percentage of participants retained at the end of study|Percentage of participants with collected, processed, and analyzed stool samples","https://ClinicalTrials.gov/show/NCT02780284"
1667,"NCT00003704","Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer","Completed","No Results Available","Cancer","Drug: capecitabine|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","51","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-984652|CDR0000066811","November 1, 1999","April 1999","July 2003","July 1, 2016","July 2016","No Study Results Posted","null","July 2003","overall survival","https://ClinicalTrials.gov/show/NCT00003704"
1668,"NCT01997684","Colonic Stenting With Elective Surgery Versus Emergency Surgery in the Management of Acute Malignant Colonic Obstruction","Recruiting","No Results Available","Acute Malignant Colonic Obstruction|Colorectal Cancer|Colonic Obstruction","Procedure: Colonic Stenting with Elective Surgery|Procedure: Emergency Surgery","Nanfang Hospital of Southern Medical University|Boston Scientific Corporation","Both","18 Years and older   (Adult, Senior)","","200","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ISR-ENDO-2013-001","November 18, 2013","July 2013","December 2016","November 18, 2015","November 2015","No Study Results Posted","null","July 2016","Rates of primary colorectal anastomosis|Stoma rates|Mortality|Procedure related complication|Re-operation rates|R0 resection|Quality of life|Hospital stay and cost|Recurrence of colorectal cancer","https://ClinicalTrials.gov/show/NCT01997684"
1669,"NCT01978717","General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Procedure: epidural anesthesia|Procedure: general anesthesia","Changhong Miao|Fudan University","Both","51 Years to 65 Years   (Adult)","","53","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NO.2011-197|08431910200","November 1, 2013","September 2011","September 2012","November 1, 2013","November 2013","No Study Results Posted","null","May 2012","The changes of peripheral immune cells and cytokines","https://ClinicalTrials.gov/show/NCT01978717"
1670,"NCT00609310","Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence","Suspended","No Results Available","Colorectal Cancer","Dietary Supplement: Flavonoids","Technische Universität Dresden","Both","50 Years to 75 Years   (Adult, Senior)","Phase 2","382","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","Flav-Hoe-CCR","January 24, 2008","May 2015","December 2016","February 2, 2012","February 2012","No Study Results Posted","null","December 2016","Recurrence rate of neoplasia|Recurrence free survival, Overall survival, Serum-Flavonoid levels of patients","https://ClinicalTrials.gov/show/NCT00609310"
1671,"NCT01039506","An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in mCRC","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: CPT-11 based regimens","Daiichi Sankyo Co., Ltd.","Both","Child, Adult, Senior","","2000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TOP009-061","December 23, 2009","October 2009","March 2016","March 28, 2013","March 2013","No Study Results Posted","null","March 2015","Progression free survival|Overall survival, Time to treatment failure, response rate, disease control rate, safety","https://ClinicalTrials.gov/show/NCT01039506"
1672,"NCT00792363","Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Irinotecan|Drug: Panitumumab","Vejle Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT 2008-004923-48|S-20080104|DKMA 2612-3844","November 14, 2008","November 2008","August 2011","June 12, 2012","June 2012","No Study Results Posted","null","December 2010","Response Rate|Overall survival|Progression free survival","https://ClinicalTrials.gov/show/NCT00792363"
1673,"NCT00244348","Hepatic Artery Infusion With Oxaliplatin","Withdrawn","No Results Available","Colorectal Cancer|Metastasis|Liver Cancer","Drug: Oxaliplatin (via HAI)|Drug: 5 Fluorouracil (systemic)","Medical College of Wisconsin","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HRRC#341-05","October 25, 2005","October 2005","August 2015","August 26, 2015","August 2015","No Study Results Posted","null","August 2015","number of patients who become eligible for total resection of metastatic liver tumor|overall survival of patients resected for cure versus (vs.) resected for palliation vs. not resected.|toxicity|HAI complexity|cost","https://ClinicalTrials.gov/show/NCT00244348"
1674,"NCT00102024","Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma","Terminated","No Results Available","Colorectal Cancer|Metastases","Drug: Unconjugated IDEC-159|Drug: 111In-IDEC-159|Drug: 90Y-IDEC-159","Biogen","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","159-01","January 19, 2005","January 2005","January 2006","August 25, 2010","August 2010","No Study Results Posted","null","January 2006","To characterize the safety profile and determine the MTD of 90Y-IDEC-159 in subjects with metastatic colorectal cancer.|To evaluate activity; blood, normal organ, and tumor dosimetry; the immunogenicity and pharmacokinetics of 90Y-IDEC-159; and its effect on soluble TAG-72 (sTAG-72) levels.","https://ClinicalTrials.gov/show/NCT00102024"
1675,"NCT00138177","Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors","Completed","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: oxaliplatin|Drug: leucovorin calcium|Drug: vorinostat|Drug: fluorouracil","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","54","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00083|CDR0000439445|I 55305|6789","August 29, 2005","July 2005","null","September 27, 2013","September 2013","No Study Results Posted","null","August 2011","Maximum tolerated dose of vorinostat|Grade 3, 4, or 5 adverse events graded using the NCI CTCAE version 4.0|Response, evaluated using the new international criteria proposed by the RECIST committee|Gene expression studies for evidence of up-regulation or down-regulation, obtained from microarray testing and changes in expression patterns of TS|Pharmacokinetic analysis for vorinostat and 5-FU|DPD activity","https://ClinicalTrials.gov/show/NCT00138177"
1676,"NCT01440127","Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers","Terminated","No Results Available","Colon Cancer","Drug: Metformin","Tufts Medical Center","Both","18 Years to 79 Years   (Adult, Senior)","Phase 1","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Metformin CCSC","September 21, 2011","August 2011","October 2012","March 25, 2015","March 2015","No Study Results Posted","null","October 2012","Expression of CD133 in tumors from patients treated or not treated with metformin","https://ClinicalTrials.gov/show/NCT01440127"
1677,"NCT00199277","Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.","Not yet recruiting","No Results Available","Colorectal Neoplasm|Iron Deficiency Anemia","Drug: i.v. iron sucrose|Drug: Oral iron","J. Uriach and Company","Both","18 Years and older   (Adult, Senior)","Phase 4","150","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DM01VEN/4/03","September 16, 2005","null","null","September 16, 2005","September 2005","No Study Results Posted","null","null","Preoperative variations in hemoglobin.|Postoperative variations in hemoglobin.|Blood transfusion needs (pre, intra and postoperative)|Postoperative complications:|- Pulmonary thromboembolism|- Infections|- Reintervention|- Death|Length of hospital stay","https://ClinicalTrials.gov/show/NCT00199277"
1678,"NCT00594984","Phase I/II Combination With Irinotecan- Erbitux","Completed","No Results Available","Metastatic Colorectal Cancer (MCRC)","Drug: Cetuximab|Drug: Irinotecan|Drug: Brivanib|Drug: Brivanib|Drug: Brivanib Placebo","Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","38","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CA182-025|2007-005097-31","January 7, 2008","May 2008","December 2012","October 12, 2015","October 2015","No Study Results Posted","null","December 2012","Pharmacokinetics and markers of exploratory coagulation pathways will be conducted during this trial|Safety and tolerability of interventions will be collected|Efficacy on tumor progression and progression free survival will be collected on all enrolled subjects","https://ClinicalTrials.gov/show/NCT00594984"
1679,"NCT02198092","Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes","Recruiting","No Results Available","Familial Adenomatous Polyposis|Map Syndrome|Lynch Syndrome|Hnpcc|Colorectal Cancer","Other: Epi proColon Testing","University of Pennsylvania|Epigenomics, Inc","Both","18 Years and older   (Adult, Senior)","","46","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","816593","July 15, 2014","July 2014","August 2017","September 6, 2016","September 2016","No Study Results Posted","Septin9","August 2017","Septin9 Plasma Levels|Septin9 Plasma Levels Versus Polyps|Pre- and Post-Colectomy Colonic Epithelial Cell Numbers|Septin9 Levels Versus Circulating Colonic Epithelial Cell Numbers","https://ClinicalTrials.gov/show/NCT02198092"
1680,"NCT01918852","S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.","Active, not recruiting","No Results Available","Colorectal Cancer|Metastases","Drug: Capecitabine|Drug: Teysuno|Drug: Bevacizumab","Dutch Colorectal Cancer Group|Nordic Pharma SAS","Both","18 Years and older   (Adult, Senior)","Phase 3","160","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SALTO","June 24, 2013","December 2013","December 2016","August 15, 2016","August 2016","No Study Results Posted","SALTO","December 2015","Incidence of HFS in first line treatment|Grade 3 HFS|Progression-free survival|Overall toxicity|Overall survival|Response rate","https://ClinicalTrials.gov/show/NCT01918852"
1681,"NCT01282658","Pharmacogenomics Study of CPT-11 as the First-line Chemotherapy for mCRC","Recruiting","No Results Available","Colorectal Cancer","","Huazhong University of Science and Technology|Wuhan Union Hospital, China|Wuhan University","Both","18 Years to 75 Years   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TJCC-001","January 24, 2011","November 2010","May 2013","February 16, 2011","November 2010","No Study Results Posted","PSIFL","December 2012","","https://ClinicalTrials.gov/show/NCT01282658"
1682,"NCT01052376","Endomicrocancer: Confocal Endomicroscopy in Patients With High Risk of Colorectal Cancer","Terminated","No Results Available","Inflammatory Bowel Disease (IBD)|Familial Adenomatous Polyposis","Device: Confocal endomicroscopy","Nantes University Hospital","Both","18 Years to 75 Years   (Adult, Senior)","","73","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","BRD08/6-A","January 19, 2010","December 2008","January 2011","May 22, 2012","January 2010","No Study Results Posted","null","null","Evaluate and validate CEM in terms of its ability to diagnose neoplastic lesions and to distinguish between normal and neoplastic mucosa in vivo, based on comparison between ""optical biopsies"" and standard histology.","https://ClinicalTrials.gov/show/NCT01052376"
1683,"NCT01238965","Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy","Terminated","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: panobinostat|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: biopsy|Genetic: reverse transcriptase-polymerase chain reaction|Genetic: western blotting|Other: laboratory biomarker analysis|Genetic: gene expression analysis|Genetic: RNA analysis|Genetic: polymorphism analysis","University of Southern California|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","7","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-08-1|NCI-2010-02149","November 3, 2010","October 2010","April 2015","May 26, 2015","May 2015","No Study Results Posted","null","December 2014","To assess the safety of this regimen|Time to progression|Overall response rate|Overall survival","https://ClinicalTrials.gov/show/NCT01238965"
1684,"NCT01124630","Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: CS-1008|Drug: FOLFIRI","Daiichi Sankyo Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","21","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CS1008-A-U105","May 10, 2010","May 2010","August 2013","December 2, 2013","December 2013","No Study Results Posted","null","July 2013","Objective Response Rate|Progression Free Survival|Serum concentrations","https://ClinicalTrials.gov/show/NCT01124630"
1685,"NCT02889276","Effects of Functional Exercise on Fitness and QoL in Cancer Survivors","Not yet recruiting","No Results Available","Colorectal Cancer","Other: Functional Resistance Training|Behavioral: Unsupervised activity","University of Portsmouth|Portsmouth Hospitals NHS Trust","Both","18 Years to 90 Years   (Adult, Senior)","Phase 3","36","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","RETRACE1","August 19, 2016","September 2016","August 2017","September 2, 2016","August 2016","No Study Results Posted","RETRACE","April 2017","Change in Global Health Status/QoL (subscale of EORTC QLQ-C30, Version 3) scores in cancer survivors|Change in EORTC QLQ-C30 (Overall)|Change in 6 minute walk distance|Change in Lift and carry test performance|Change in Chair stand test performance|Change in Handgrip strength score|Change in body mass|Change in waist circumference|Change in body fat %|Change in Self-efficacy to regulate exercise scale score","https://ClinicalTrials.gov/show/NCT02889276"
1686,"NCT00166465","Stage IV Colorectal CA ALIMTA","Completed","No Results Available","Locally Advanced Unresectable or Stage IV Colorectal Cancer","Drug: ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)","Mayo Clinic","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC0248|1126-03","September 12, 2005","August 2003","June 2006","March 11, 2011","March 2011","No Study Results Posted","null","June 2006","Proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated using the exact binomial distribution.","https://ClinicalTrials.gov/show/NCT00166465"
1687,"NCT01867918","LOTCOL Study: Local Treatment of Colo-rectal Liver Met","Recruiting","No Results Available","Metastatic Colo-rectal Cancer","Procedure: Radiofrequency ablation, microwave, radiation therapy|Drug: Standard Chemotherapy","Oslo University Hospital","Both","18 Years and older   (Adult, Senior)","","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012/1392 REK South East C","May 3, 2013","May 2013","December 2019","March 30, 2016","March 2016","No Study Results Posted","LOTCOL","December 2017","Overall survival from time of randomization","https://ClinicalTrials.gov/show/NCT01867918"
1688,"NCT00051987","Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma","Completed","No Results Available","Colorectal Carcinoma","Drug: VELCADE TM (bortezomib) for Injection, or PS-341","Millennium Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","175","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M34102-049","January 21, 2003","December 2002","null","February 7, 2008","February 2008","No Study Results Posted","null","March 2004","","https://ClinicalTrials.gov/show/NCT00051987"
1689,"NCT00828620","Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project","Terminated","No Results Available","Metastatic Colorectal Cancer","Other: Imaging study","Universitaire Ziekenhuizen Leuven","Both","18 Years and older   (Adult, Senior)","","21","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","s51276 - ML5241","January 23, 2009","January 2009","June 2012","August 9, 2012","June 2012","No Study Results Posted","null","October 2011","PET response on day 7|To determine whether the PET criteria for response on day 7 correlates with the CT criteria of minimum 10% decrease in tumour size (RECIST) at week 6|To define the optimal cutoff value of SUVmax and their predictive value|To explore the test/retest reliability of PET/CT in this setting|To assess the value of PET/CT at day 7 in predicting overall survival|To asses the correlations between biomarkers and PET changes after Cetuximab","https://ClinicalTrials.gov/show/NCT00828620"
1690,"NCT00511862","TheraSphere for the Treatment of Liver Metastases","Completed","Has Results","Colorectal Cancer|Carcinoma, Neuroendocrine|Neoplasm Metastasis","Device: Yttrium 90 glass microspheres","BTG International Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","151","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","G040148","August 2, 2007","January 2007","March 2011","June 5, 2014","February 2014","October 17, 2013","null","March 2011","Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST)|Overall Survival","https://ClinicalTrials.gov/show/NCT00511862"
1691,"NCT00272324","Aspirin/Folate Prevention of Large Bowel Polyps","Completed","No Results Available","Colorectal Cancer|Polyps|Adenomas","Drug: Aspirin|Drug: Folate","Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)","Both","21 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","1121","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double-Blind|Primary Purpose: Prevention","5R01CA059005-12","January 3, 2006","February 1992","January 2007","January 3, 2006","November 2005","No Study Results Posted","null","null","colorectal adenomas during years 1-3 and years 4-8|advanced colorectal adenomas during years 1-3 and years 4-8|colorectal cancer","https://ClinicalTrials.gov/show/NCT00272324"
1692,"NCT01832467","Cetuximab Rechallenge Study","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: cetuximab-containing chemotherapy","Chinese University of Hong Kong","Both","18 Years and older   (Adult, Senior)","Phase 2","35","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COL019","April 10, 2013","April 2013","June 2018","August 11, 2016","August 2016","No Study Results Posted","null","June 2018","overall response of re-treatment with cetuximab-based chemotherapy|Adverst event and toxicity during treatment period|disease control rate|progression-free survival","https://ClinicalTrials.gov/show/NCT01832467"
1693,"NCT00874263","Confocal Probe-based Endoscopic Imaging, Colorectal Cancer, Gastrointestinal (GI) Pathologies","Completed","No Results Available","Colonic Polyps|Esophageal Diseases","","Mayo Clinic|American Society for Gastrointestinal Endoscopy","Both","18 Years and older   (Adult, Senior)","","225","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","07-007521|ASGE Grant#FNDT-1","March 31, 2009","March 2008","June 2012","June 21, 2012","June 2012","No Study Results Posted","ASGE-FNDT-1","December 2010","Endoscopic Confocal microscopy may help distinguish small adenomatous polyps with malignant potential from non-neoplastic (hyperplastic) polyps in real- time enabling immediate diagnosis and removal of only polyps with truly malignant potential.|Endoscopic Confocal microscopy has the potential to fundamentally change the way endoscopy and pathology interact by allowing near histological-quality imaging in vivo, without the need, risk, and cost of tissue removal.","https://ClinicalTrials.gov/show/NCT00874263"
1694,"NCT02287025","A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes?","Terminated","No Results Available","Physician Education","Drug: Regorafenib (Stivarga, BAY 73-4506)","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 4","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","17347","October 7, 2014","November 2014","April 2016","May 20, 2016","May 2016","No Study Results Posted","SMART","February 2016","Proportion of patients who discontinue prior to documented progression of disease (PD) or death|Duration of treatment|Dose modification|Incidence of Grade 3 Hand-foot-skin reaction （HFSR）|Incidence of Grade 3 and 4 fatigue|Incidence of Grade 3 and 4 diarrhea|Incidence of Grade 3 and 4 hypertension|Investigator comfort with the use of regorafenib and management of AEs as measured by questionnaire|Satisfaction of investigator/nurse with enhanced drug-specific information via SMART questionnaire","https://ClinicalTrials.gov/show/NCT02287025"
1695,"NCT01671592","Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)","Completed","No Results Available","Colorectal Neoplasms|Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal","Biological: DC Vaccine","Pawel Kalinski|National Cancer Institute (NCI)|University of Pittsburgh","Both","18 Years and older   (Adult, Senior)","Phase 1","6","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10-052|R01CA134633","August 20, 2012","January 2013","April 2014","December 23, 2015","December 2015","No Study Results Posted","null","April 2014","Adverse events from the labeled DC vaccine|Ability to track the labeled DC vaccine by MRI|Comparative analysis of the effectiveness of lymph node accumulation of DC vaccines injected to resting versus pre-activated nodes (DCs injected on day 1 versus day 3 of the three day-long vaccination cycle.|May assess the disease-free survival and overall survival","https://ClinicalTrials.gov/show/NCT01671592"
1696,"NCT00107861","Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases","Completed","No Results Available","Colorectal Carcinoma|Metastases","Drug: Ad.hIFN-β (BG00001, IDEC-201)","Biogen","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","44","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201-20","April 11, 2005","May 2005","September 2006","July 10, 2009","July 2009","No Study Results Posted","null","null","- Evaluate the safety of a single IV administration of Ad.hIFN-β.|Evaluate the MTD or maximum feasible dose (MFD) of Ad.hIFN-β.|Evaluate IFN-β and Ad.hIFN-β vector serum concentrations.|Evaluate immunogenicity of Ad.hIFN-β by measuring human anti adenovirus and human anti-IFN-β antibody formation.|Explore preliminary clinical activity.","https://ClinicalTrials.gov/show/NCT00107861"
1697,"NCT02296203","Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: cetuximab|Drug: irinotecan","Gruppo Oncologico del Nord-Ovest","Both","18 Years and older   (Adult, Senior)","Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GONO 10","October 15, 2014","October 2014","null","November 17, 2014","November 2014","No Study Results Posted","CRICKET","October 2016","percentage of patients achieving a decrease equal or more than 30% in the sum of the longest diameters of target lesions","https://ClinicalTrials.gov/show/NCT02296203"
1698,"NCT02053324","AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer","Recruiting","No Results Available","Liver Metastases","Radiation: AvidinOX/ST2210","sigma-tau i.f.r. S.p.A.","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","30","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AvOX/ST2210-CR-12-001|2012-005577-32","January 24, 2014","September 2013","March 2018","April 6, 2016","April 2016","No Study Results Posted","null","December 2017","Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03)|Adverse Events","https://ClinicalTrials.gov/show/NCT02053324"
1699,"NCT01966081","AGARIC Case Control Study","Recruiting","No Results Available","First Recently-diagnosed Colorectal Cancer","Other: Blood sample|Other: tissue samples from abdominal subcutaneous adipose","Centre Hospitalier Universitaire Dijon","Both","45 Years and older   (Adult, Senior)","","576","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","Bonithon hors AOI 2008","October 10, 2013","null","null","October 16, 2013","October 2013","No Study Results Posted","AGARIC","November 2014","Measure of polyunsaturated fatty acids in adipose tissue lipids.","https://ClinicalTrials.gov/show/NCT01966081"
1700,"NCT01505166","Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases","Active, not recruiting","No Results Available","Colon Cancer","Biological: Vigil™ Vaccine|Drug: Placebo","Gradalis, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CL-PTL 107","January 4, 2012","March 2012","December 2017","June 6, 2016","June 2016","No Study Results Posted","FANG-CLM","December 2016","Overall Survival Rate|Immune Response","https://ClinicalTrials.gov/show/NCT01505166"
1701,"NCT01598597","An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Non-Small Cell Lung Cancer|Glioblastoma|Renal Cell Cancer","","Genentech, Inc.|23andMe, Inc.","Both","18 Years and older   (Adult, Senior)","","276","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GO28289","May 9, 2012","March 2012","November 2014","May 7, 2015","May 2015","No Study Results Posted","null","November 2014","Percentage of subjects who complete the survey and who provide evaluable genetic information (DNA)|Clinical characteristics (current disease status/previous treatments) of subjects participating in this study|Demographic distribution (age, sex) of subjects participating in this study","https://ClinicalTrials.gov/show/NCT01598597"
1702,"NCT01290783","Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Irintoecan|Drug: HA-Irinotecan solution for Infusion","Alchemia Oncology","Both","18 Years and older   (Adult, Senior)","Phase 3","390","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACO-002","January 31, 2011","December 2011","December 2015","April 28, 2015","August 2014","No Study Results Posted","FOLF(HA)iri","October 2014","Progression Free Survival (PFS)|Safety","https://ClinicalTrials.gov/show/NCT01290783"
1703,"NCT00773097","Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma","Completed","Has Results","Risk for Colorectal Cancer","Biological: MUC1 - Poly ICLC","University of Pittsburgh|National Cancer Institute (NCI)","Both","40 Years to 70 Years   (Adult, Senior)","Phase 2","46","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","PRO07030214","October 15, 2008","October 2008","October 2012","February 12, 2014","February 2014","July 17, 2013","null","October 2011","Number of Participants With Anti Muc-1 Antibody|Number of Participants With Autoimmune Response to Muc-1 Vaccine|Number of Participants With Adverse Events Associated With the Study Agent","https://ClinicalTrials.gov/show/NCT00773097"
1704,"NCT00441337","A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies","Completed","Has Results","Carcinoma, Non-Small-Cell Lung|Colorectal Cancer|Malignant Melanoma|Renal Cancer|Prostate Cancer","Biological: MDX-1106","Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1","39","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA209-001 ST|MDX1106-01","February 27, 2007","August 2006","November 2009","February 5, 2015","February 2015","January 21, 2015","MDX1106-01","November 2009","Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting Toxicity (DLT) AE and Immune-related AEs (irAEs) in Safety Population|Geometric Mean Maximum Serum Concentration (Cmax) Observed Post-Single Dose|Median Time at Which the Maximum Serum Concentration Occurred (Tmax) Post-Single Dose|Geometric Mean Area Under the Curve (AUC) From Time of Dosing to Time of Last Observation (0-T) and Extrapolated to Infinity (INF) Observed Post-Single Dose|Mean Elimination Half-life (T-HALF) Post-Single Dose|Geometric Mean Total Body Clearance of Drug From Serum (CLT) Post-Single Dose|Mean Volume of Distribution (Vz) Post-Single Dose|Percent of Participants With Best Overall Response Rate in Safety Population and in Tumor Evaluable Population|Percent of Participants With Prostate-Specific Antigen (PSA) Response After the First Dose by Day 85 In Participants With Hormone-Refractory Prostate Adenocarcinoma (HRPC)|Number of Participants With Best Overall Response (BOR) by Category in Safety Population|Percentage of Participants With Disease Control and Major Durable Disease Control|Median Time to Tumor Response and Duration of Tumor Response|Time to Tumor Progression and Tumor Progression Free Survival|Median Time to PSA Progression in Days and Median PSA Progression Free Survival in Days in PSA Evaluable Population|Mean Change From Baseline in PSA Relative Velocity at Days 29, 57, and 85 With Cycle 1 in PSA Evaluable Population|Mean Change From Baseline in Electrocardiogram Parameters PR, QRS and QT in Safety Population|Mean Diastolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 0.3 mg Cohort - Safety Population|Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 0.3 mg Cohort - Safety Population|Mean Diastolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 1mg, 3mg, and 10 mg Cohorts - Safety Population|Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in in 1mg, 3mg, and 10 mg Cohorts - Safety Population","https://ClinicalTrials.gov/show/NCT00441337"
1705,"NCT01786538","Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines","Withdrawn","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib/FOLFOX|Drug: Placebo/FOLFOX","Asan Medical Center","Both","20 Years and older   (Adult, Senior)","Phase 3","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","Regorafenib/FOLFOX","February 4, 2013","June 2013","May 2017","March 12, 2013","March 2013","No Study Results Posted","null","May 2016","Progression-free survival|Overall survival|Response rate|Disease-control rate|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01786538"
1706,"NCT01183156","Re-invitation to Screening Colonoscopy: a Randomized Study","Recruiting","No Results Available","Colorectal Cancer|Screening|Patient Participation","Behavioral: Re-invitation letter|Behavioral: Invitation to educational meeting","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|The National Centre for Research and Development, Poland","Both","55 Years to 64 Years   (Adult)","","1000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","NR13002404","August 16, 2010","August 2010","March 2011","February 14, 2011","February 2011","No Study Results Posted","REINVITE","December 2010","Attendance to screening colonoscopy|Response rate to the re-invitation letter or invitation to the educational meeting","https://ClinicalTrials.gov/show/NCT01183156"
1707,"NCT00897429","Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581","Recruiting","No Results Available","Colorectal Cancer","Procedure: laboratory biomarker analysis","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","902","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Retrospective","CALGB-150705|CDR0000559812|NCI-2009-00452|U10CA180821","May 9, 2009","July 2007","null","August 12, 2016","August 2016","No Study Results Posted","null","July 2100","Analyses of molecular models among patients who completed the diet and lifestyle questionnaire and who provided tumor blocks for analyses (B1)|Proportion of patients who are cancer recurrence-free and alive at 4 years, approximating 4-year disease-free survival for the cohort to be 65% (B1)|Influence of energy balance on tumor with specific molecular features (B1)|Influence of medications on tumors with specific molecular features (B1)|Detection of clones associated with overall survival (OS) (B2)|Recurrence-free interval (RFI) (B3)|Clinical validation of the GHI 12-gene recurrence score (B4)|Clinical validation of the 15-gene second-generation recurrence score (B4)|Determination of whether the methylated and silenced DNA repair genes, MLH1, WRN, or MGMT, or CIMP colorectal cancers are associated with OS (B5)|Expression of newly identified prognostic biomarkers (LINE-1, PIK3CA, BRAF, FASN and VDR) on OS (B6)|Cancer-specific mortality (B6)|Detection of clones associated with disease-free survival (DFS) (B2)|Determination of whether the methylated and silenced DNA repair genes, MLH1, WRN, or MGMT, or CIMP colorectal cancers are associated with DFS (B5)studies|MRE11 status of MSI tumors genetic alterations and tumor-specific characteristics|Evaluation of up to 768 new genes for their relationship with colon cancer recurrence (B4","https://ClinicalTrials.gov/show/NCT00897429"
1708,"NCT01243762","A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027)","Terminated","No Results Available","Neoplasms Malignant","Drug: dalotuzumab + MK-2206|Drug: dalotuzumab + MK-0752|Drug: Dalotuzumab + MK-8669 (ridaforolimus)","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0646-027","November 17, 2010","November 2010","March 2013","January 29, 2015","January 2015","No Study Results Posted","null","December 2012","Number of participants with dose limiting toxicities (DLTs)|Number of participants whose best response is a partial response (PR) or complete response (CR)","https://ClinicalTrials.gov/show/NCT01243762"
1709,"NCT00005818","SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: irinotecan hydrochloride|Drug: semaxanib|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","68","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02330|ID-99-243|N01CM17003|CDR0000067823","June 2, 2000","March 2000","null","January 22, 2013","January 2013","No Study Results Posted","null","March 2003","Time to disease progression (TTP)|Overall tumor response rate (CR + PR)|Overall survival|Toxicity graded using the NCI CTC version 2.0","https://ClinicalTrials.gov/show/NCT00005818"
1710,"NCT00994526","Processed Meat and Colon Carcinogenesis","Completed","No Results Available","Colorectal Cancer","Other: Ham|Other: Ham + calcium|Other: Ham + vitamin E","Institut National de la Recherche Agronomique|Centre de Recherche en Nutrition Humaine d'Auvergne","Male","40 Years to 75 Years   (Adult, Senior)","","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Basic Science","AU794|IDRCB 2009-A00322-55|04/2009 FPIERRE","October 9, 2009","October 2009","January 2010","December 13, 2012","December 2012","No Study Results Posted","Hemcancer","December 2009","Urinary biomarker (DHN-MA:dihydroxynonene mercapturic acid), will be measured before and after every interventional period|Fecal biomarkers","https://ClinicalTrials.gov/show/NCT00994526"
1711,"NCT01479465","Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma","Completed","No Results Available","Colorectal Cancer","Drug: Simtuzumab|Drug: FOLFIRI|Drug: Placebo to match simtuzumab","Gilead Sciences","Both","18 Years and older   (Adult, Senior)","Phase 2","266","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","GS-US-295-0203|2011-003754-61","November 9, 2011","December 2011","February 2015","March 10, 2015","March 2015","No Study Results Posted","null","October 2014","Progression Free Survival|Overall survival|Objective response","https://ClinicalTrials.gov/show/NCT01479465"
1712,"NCT01365169","CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial","Active, not recruiting","No Results Available","Advanced Cancers|Colorectal Cancer|Head And Neck Cancer|Cancer Survivors","Device: Smart phone|Device: Accelerometers (Arms 1 and 2)|Device: Blood Pressure Monitor (Arms 1 and 2)|Other: Telephone Surveys|Other: Home Visit|Device: Home Health Hub and Modem (All study groups)|Device: Carbon Monoxide (CO) Monitor (Arm 4)|Device: Heat Rate Monitor (Arm 1)|Device: Global Positioning System (GPS) Device (Arm 1)|Other: Surveys","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","240","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","2010-0955|NCI-2014-02468|RC2CA148263","June 1, 2011","June 2011","null","April 19, 2016","April 2016","No Study Results Posted","null","June 2017","Study Completion as Evidenced by Completion of Final Assessment","https://ClinicalTrials.gov/show/NCT01365169"
1713,"NCT01442935","Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Oxaliplatin|Drug: Folinic Acid|Drug: 5-FU|Drug: Irinotecan|Drug: Irinotecan|Drug: Bevacizumab|Drug: Cetuximab","UNICANCER","Both","18 Years and older   (Adult, Senior)","Phase 2","256","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PRODIGE 14 / ACCORD 21/0905","August 10, 2011","February 2011","February 2019","June 17, 2016","June 2016","No Study Results Posted","null","November 2016","The main objective is to compare resection rates (R0 or R1) for hepatic metastases|The objective response rate (CR and PR) after 4 cycles of treatment|Complete remission rate (CR) 6 months after the last study treatment (hepatic surgery or last chemotherapy cycle)|Specific resection rates R0/R1/R2|Complete pathological response|Toxicity of treatment|Post operatory complications|Progression-free survival (PFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT01442935"
1714,"NCT00828984","Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer","Completed","No Results Available","Adenomatous Polyp|Colorectal Carcinoma","Drug: macrogol 3350-based oral osmotic laxative|Other: Placebo|Other: Laboratory Biomarker Analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","140","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NCI-2009-01113|NCI 06-8-01|CDR0000632553|N01CN35157|NCI06-8-01|NWU06-8-01|P30CA060553","January 23, 2009","October 2009","October 2014","March 6, 2015","February 2015","No Study Results Posted","null","October 2014","Difference A-B (After treatment minus Before treatment) of EGFR expression|Change in ACF count as measured in endoscopically normal (non-ACF) mucosal biopsies|Change in Ki-67 (proliferation) expression as measured in endoscopically normal (non-ACF) mucosal biopsies|Change in activated caspase-3 (apoptosis) expression as measured in endoscopically normal (non-ACF) mucosal biopsies|Change in SNAIL expression as measured in endoscopically normal (non-ACF) mucosal biopsies|Change in E-cadherin expression as measured in endoscopically normal (non-ACF) mucosal biopsies","https://ClinicalTrials.gov/show/NCT00828984"
1715,"NCT00264446","A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection","Completed","No Results Available","Neoplasms","Drug: ADH300004","Adherex Technologies, Inc.","Both","19 Years and older   (Adult, Senior)","Phase 1","null","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Adherex Protocol # AHX-03-101","December 12, 2005","null","null","August 3, 2007","August 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00264446"
1716,"NCT01333917","Curcumin Biomarkers","Completed","No Results Available","Colorectal Cancer","Drug: Curcumin C3 tablet","University of North Carolina, Chapel Hill","Both","40 Years to 80 Years   (Adult, Senior)","Phase 1","40","Other","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label","10-1524","April 6, 2011","November 2010","January 2013","February 6, 2013","January 2013","No Study Results Posted","null","October 2011","Gene expression|Ribonucleic acid (RNA) level|Apoptosis|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01333917"
1717,"NCT00145015","FishGastro Study: Fish Consumption and Gastro-Intestinal Health","Completed","No Results Available","Colorectal Cancer|Ulcerative Colitis|Polyps","Behavioral: Increased dietary intake of salmon or cod","Institute of Food Research|Wageningen University|University of Jena|University of East Anglia|European Commission|Food Standards Agency, United Kingdom","Both","18 Years to 80 Years   (Adult, Senior)","","270","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","IFR02/2004","September 1, 2005","December 2004","April 2008","July 29, 2008","July 2008","No Study Results Posted","null","null","Apoptosis in colonic biopsy samples|Cell proliferation|lymphocyte infiltration|circulating inflammatory markers (cytokines and prostaglandins)|tissue inflammatory markers (cytokines and prostaglandins)|faecal water cytotoxicity and genotoxicity|gene transcription","https://ClinicalTrials.gov/show/NCT00145015"
1718,"NCT02453490","Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis","Not yet recruiting","No Results Available","Colorectal Cancer|Liver Metastasis","Drug: Raltitrexed-based chemotherapy|Drug: Raltitrexed-based chemotherapy|Drug: 5-fluorouracil-based chemotherapy|Drug: 5-fluorouracil-based chemotherapy","Zhejiang University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","360","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRCLM-01","May 17, 2015","May 2015","July 2018","May 20, 2015","May 2015","No Study Results Posted","null","July 2018","Objective response rate|R0 resection rate of liver","https://ClinicalTrials.gov/show/NCT02453490"
1719,"NCT00781352","Nitrous Oxide and Risk of Cancer Recurrence After Colorectal Surgery: A Randomized, Blinded Study","Completed","No Results Available","Colorectal Cancer","Drug: nitrous oxide|Drug: nitrogen","The Cleveland Clinic","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","408","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","efno1008","October 27, 2008","November 1998","March 2007","June 28, 2016","June 2016","No Study Results Posted","null","November 2003","To determine if the risk of colorectal cancer recurrence was similar in patients who were randomly assigned to 65% nitrous oxide or nitrogen during colorectal surgery.","https://ClinicalTrials.gov/show/NCT00781352"
1720,"NCT01577511","Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer","Active, not recruiting","No Results Available","Colorectal Neoplasms","Biological: Samples and follow up","Centre Hospitalier Universitaire de Nīmes","Both","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LOCAL/2011/JFB-01|2011-A01141-40","April 12, 2012","June 2012","October 2017","April 5, 2016","April 2016","No Study Results Posted","null","October 2015","Ability to maintain the cells isolated from colorectal tumors in culture or 3D collagen matrices and then infect these cells to make them express reporter genes: yes/no.|Serology HIV|Serology Hepatitis B|Serology Hepatitis C|Location of primary tumor|Age at diagnosis|Metastases from the outset: Yes / No|Resection proposed: yes/no|Chemotherapy proposed? yes/no|Number of metastases|Resection performed: yes/no|Number of chemotherapy sessions performed|Objective tumoral response to treatment? yes/no|Tumor recurrence: yes/no|Vital status|Ability to establish tumor xenografts from injected cells: yes/no.|Ability to detect subpopulations of tumor cells expressing fluorophores by flow cytometry after isolation: yes/no|Characterization of mRNA expression profiling and micro-RNA + in vitro EMT cells|World Health Organisation Score|Tumor staging|Number of surgeries performed|Number of circulating cancer cells per ml blood","https://ClinicalTrials.gov/show/NCT01577511"
1721,"NCT02563002","Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","Recruiting","No Results Available","Colorectal Carcinoma","Drug: mFOLFOX6|Drug: FOLFIRI|Biological: pembrolizumab|Biological: bevacizumab|Biological: cetuximab","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3475-177|2015-002024-89|163238","September 28, 2015","November 2015","September 2019","September 13, 2016","September 2016","No Study Results Posted","null","August 2019","Progression-free Survival (PFS)|Overall Response Rate (ORR)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02563002"
1722,"NCT00833508","Effect of Preoperative Chemoradiotherapy on Exercise Capacity as Measured by Cardiopulmonary Exercise Testing","Completed","No Results Available","Colorectal Cancer","Other: Cardiopulmonary exercise testing","Imperial College London","Both","65 Years and older   (Adult, Senior)","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","08/H0712/117","January 30, 2009","January 2009","October 2011","February 15, 2016","February 2016","No Study Results Posted","null","October 2011","Change of Anaerobic threshold of 1.5ml/min/kg or more|Operative outcome","https://ClinicalTrials.gov/show/NCT00833508"
1723,"NCT02441998","Real-Time Characterizations of Diminutive Colorectal Polyps Using Narrow Band Imaging","Completed","No Results Available","Colorectal Cancer","Other: Education intervention: Training in Narrow Band Imaging","University of Michigan|University of Colorado, Denver","Both","Child, Adult, Senior","","26","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","131998","May 8, 2015","October 2013","December 2014","May 12, 2015","May 2015","No Study Results Posted","null","November 2014","ASGE PIVI Thresholds: >90% NPV in rectosigmoid, > 90% agreement in surveillance intervals|In vivo overall and individual performance assessed by accuracy, sensitivity, specificity, positive predictive value, negative predictive value|Ex vivo overall and individual performance assessed by accuracy, sensitivity, specificity, positive predictive value, negative predictive value","https://ClinicalTrials.gov/show/NCT02441998"
1724,"NCT01289821","First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib","Completed","Has Results","Colorectal Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Oxaliplatin|Drug: Folinic acid|Drug: 5-FU (mFOLFOX6)","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 2","54","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11728|2010-020121-41","February 3, 2011","February 2011","June 2014","August 12, 2015","August 2015","April 9, 2013","null","March 2012","Objective Response (OR)|Overall Survival (OS)|Progression-free Survival (PFS)|Disease Control (DC)|Duration of Response (DOR)|Duration of Stable Disease (DOSD)","https://ClinicalTrials.gov/show/NCT01289821"
1725,"NCT00979329","Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST","Recruiting","No Results Available","Renal Cell Cancer|Colorectal Cancer|GIST","Other: Questionnaires","Radboud University","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UMCNONCO20082","September 17, 2009","May 2008","null","October 6, 2011","October 2011","No Study Results Posted","null","December 2011","","https://ClinicalTrials.gov/show/NCT00979329"
1726,"NCT00245492","Chromocolonoscopy for the Detection of Flat Adenomas in Routine Colorectal Cancer Screening.","Completed","No Results Available","Colon Cancer|Polyp|Adenoma","Procedure: Chromocolonoscopy","Indiana University|American College of Gastroenterology|Stony Brook University|University of Chicago","Both","50 Years and older   (Adult, Senior)","","792","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","0508-64|2005ACG-100CRC","October 26, 2005","May 2006","December 2008","January 27, 2009","January 2009","No Study Results Posted","null","December 2008","Prevalence of adenomas detected by chromocolonoscopy versus standard colonoscopy.","https://ClinicalTrials.gov/show/NCT00245492"
1727,"NCT01943500","Collection of Blood Specimens for Circulating Tumor Cell Analysis","Active, not recruiting","No Results Available","Breast Cancer|Prostate Cancer|Colorectal Cancer","","Viatar LLC|Commonwealth Hematology-Oncology, P.C.","Both","18 Years and older   (Adult, Senior)","","55","Industry|Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","T30-0001","September 10, 2013","September 2013","February 2016","June 15, 2015","June 2015","No Study Results Posted","null","February 2016","The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter.","https://ClinicalTrials.gov/show/NCT01943500"
1728,"NCT02746224","Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Rectum Low Anterior Resection","Recruiting","No Results Available","Colorectal Cancer|Rectal Tumors","Procedure: Initially dissection of inferior mesenteric vein|Procedure: Initially dissection of inferior mesenteric artery|Procedure: Latero-terminal colorectal anastomosis|Procedure: Termino-terminal colorectal anastomosis","Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","Both","18 Years and older   (Adult, Senior)","","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","34502","April 13, 2016","April 2016","September 2022","April 18, 2016","April 2016","No Study Results Posted","TAHR","September 2019","Total number of resected lymph nodes|Anorectal functional outcome at 12 months assessed by COREFO questionnaire|Anorectal functional outcome at 12 months assessed by LARS scale|Intraoperative outcomes: duration of surgery|Intraoperative outcomes: surgical bleeding|Intraoperative outcomes: surgical conversion|Postoperative complications|Survival|Quality of life|Anorectal functional outcome assessed by COREFO questionnaire|Postoperative complications and anastomotic leakage|Anorectal functional outcome assessed by LARS scale|Distance to surgical margins","https://ClinicalTrials.gov/show/NCT02746224"
1729,"NCT01514786","Decision Aid to Technologically Enhance Shared Decision Making","Completed","No Results Available","Colorectal Cancer","Behavioral: Colorectal Web","University of Michigan","Both","50 Years to 75 Years   (Adult, Senior)","","568","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","HUM00044733","January 17, 2012","May 2012","April 2015","August 19, 2016","August 2016","No Study Results Posted","DATES","September 2014","The measurement of the impact of Colorectal Web on patient uptake of CRCS on patient determinants/preference/intention before the patient-physician encounter, and on SDM, concordance and patient intention during and after the patient-physician encounter.","https://ClinicalTrials.gov/show/NCT01514786"
1730,"NCT02218801","A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program","Recruiting","No Results Available","Liver Metastasis|Colorectal Carcinoma","Other: Evaluation of treatment for liver metastasis","European Organisation for Research and Treatment of Cancer - EORTC|European Society of Surgical Oncology","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EORTC-1409-GITCG","August 7, 2014","May 2015","May 2019","March 30, 2016","March 2016","No Study Results Posted","CLIMB","May 2017","Number of post-operative complications|Overall survival after 2 years of follow-up|Progression free survival at 2 years|Number of post-operative complications in the first 50 patients compared to the second 50 patients","https://ClinicalTrials.gov/show/NCT02218801"
1731,"NCT01540344","Combined Anticancer Treatment of Advanced Colon Cancer","Active, not recruiting","No Results Available","Peritoneal Carcinomatosis|Colorectal Cancer Metastatic","Procedure: CRS|Drug: HIPEC","University of Regensburg|Heinrich-Heine University, Duesseldorf","Both","18 Years to 71 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","24/06/2009|2009-014040-11","February 19, 2012","October 2010","October 2017","December 10, 2014","December 2014","No Study Results Posted","COMBATAC","July 2015","Progression-free survival (PFS)|Overall survival (OS)|Feasibility of the combined treatment concept|Quality of life (QoL)|Pathohistological regression","https://ClinicalTrials.gov/show/NCT01540344"
1732,"NCT01975077","Phase Ib Study of Fruquintinib in Patients With Metastatic Colorectal Carcinoma","Completed","No Results Available","Colorectal Cancer","Drug: fruquintinib","Hutchison Medipharma Limited|Fudan University|Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","62","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-013-00CH3","September 29, 2013","December 2012","October 2014","December 9, 2014","November 2014","No Study Results Posted","null","April 2014","safety and tolerability|efficacy (tumor assessment every 8 weeks till end of treatment)|efficacy|pharmacokinetic profiles","https://ClinicalTrials.gov/show/NCT01975077"
1733,"NCT02032953","Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia","Recruiting","No Results Available","Colorectal Cancer","Dietary Supplement: Travasol (amino acid injection)|Drug: Insulin","McGill University Health Center|Canadian Institutes of Health Research (CIHR)","Both","18 Years and older   (Adult, Senior)","Phase 4","24","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12-459-GEN","January 8, 2014","December 2013","April 2016","September 21, 2015","September 2015","No Study Results Posted","null","April 2016","Net protein balance","https://ClinicalTrials.gov/show/NCT02032953"
1734,"NCT01016639","Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer","Completed","No Results Available","Stomach Cancer|Gall Bladder Cancer|Bile Ductus Cancer|Pancreas Cancer|Colorectal Cancer","Other: oxaliplatin, capecitabine, radiotherapy","Lund University Hospital|Roche Pharma AG|Sanofi-Synthelabo","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","106","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Version1","November 18, 2009","June 2003","July 2009","October 14, 2011","October 2011","No Study Results Posted","CORGI","July 2007","","https://ClinicalTrials.gov/show/NCT01016639"
1735,"NCT00005036","Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: irinotecan hydrochloride|Drug: oxaliplatin|Drug: leucovorin calcium|Drug: fluorouracil|Procedure: quality-of-life assessment","National Cancer Institute (NCI)|Southwest Oncology Group|Eastern Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 3","560","NIH|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01847|N9841|SWOG-N9841|NCCTG-N9841|CDR0000067623|ECOG-N9841|U10CA025224","April 6, 2000","November 1999","null","May 1, 2013","May 2013","No Study Results Posted","null","December 2006","Overall survival|Time-to-tumor progression|Time-to-treatment failure|Objective tumor response rate (CR or PR) in patients with measureable disease|Toxicity and dose intensity|Quality of life","https://ClinicalTrials.gov/show/NCT00005036"
1736,"NCT00436137","Improving Followup of Abnormal Colon Cancer Screening Tests","Completed","No Results Available","Colorectal Cancer","Behavioral: Patient mailing","Harvard Vanguard Medical Associates|Brigham and Women's Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","70","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","Sequist Colorectal Cancer","February 14, 2007","June 2007","March 2008","November 5, 2008","November 2008","No Study Results Posted","null","March 2008","Performance of colonoscopy","https://ClinicalTrials.gov/show/NCT00436137"
1737,"NCT02349724","A Clinical Research of CAR T Cells Targeting CEA Positive Cancer","Recruiting","No Results Available","Lung Cancer|Colorectal Cancer|Gastric Cancer|Breast Cancer|Pancreatic Cancer","Biological: Anti-CEA-CAR T","Southwest Hospital, China","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1","75","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TMMU-BTC-002","January 25, 2015","December 2014","December 2019","March 13, 2016","March 2016","No Study Results Posted","null","December 2018","Adverse events of each patient.|Survival time of Anti-CEA CAR T cells in vivo.|Efficacy of anti-CEA CAR T cells to confirm the ability of CAR T cells to kill CEA positive cancer cells|Maximum tolerated dose (MTD) of CEA targeted CAR T cells.","https://ClinicalTrials.gov/show/NCT02349724"
1738,"NCT00625573","Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)","Completed","No Results Available","Colorectal Cancer","Drug: Abraxane","Mt. Sinai Medical Center, Miami|Celgene Corporation","Both","18 Years to 90 Years   (Adult, Senior)","Phase 2","29","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COL-01","February 19, 2008","September 2007","March 2009","September 17, 2009","September 2009","No Study Results Posted","ABX067","February 2009","To evaluate the efficacy by means of response rate of Abraxane and capecitabine in combination, in the treatment of patients with colorectal cancer in the 2nd or 3rd line metastatic setting following failure of irinotecan or oxaliplatin based therapy|To evaluate overall survival, time to progression, response duration, time to response and safety of this combination","https://ClinicalTrials.gov/show/NCT00625573"
1739,"NCT01633333","Water Exchange Versus Carbon Dioxide for Colonoscopy","Completed","No Results Available","Colorectal Cancer|Colorectal Adenomas|Colorectal Polyps|Pain","Other: Water exchange colonoscopy|Other: Carbon dioxide insufflation","Sorlandet Hospital HF|South-Eastern Norway Regional Health Authority|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Erasmus Medical Center","Both","50 Years to 80 Years   (Adult, Senior)","","473","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","WMCO2_KG","June 29, 2012","June 2012","December 2013","February 11, 2014","February 2014","No Study Results Posted","null","December 2013","Pain during colonoscopy|Cecal intubation rate|Cecal intubation time|Adenoma detection rate|Polyp detection rate|Dose of medication","https://ClinicalTrials.gov/show/NCT01633333"
1740,"NCT01505972","Time Schedules for Sending Invitations to Colonoscopy Screening","Completed","No Results Available","Colorectal Cancer","Other: Six and three time schedule|Other: Four and two time schedule","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|The National Centre for Research and Development, Poland","Both","55 Years to 64 Years   (Adult)","","1600","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","NR13002404_1","December 8, 2011","March 2011","September 2011","January 6, 2012","January 2012","No Study Results Posted","null","September 2011","Participation rate|Acceptance rate in SIX &THREE group|Acceptance rate in FOUR&TWO group|Response rate in SIX&THREE group|Response rate in FOUR&TWO group","https://ClinicalTrials.gov/show/NCT01505972"
1741,"NCT00914615","Stereotactic Body Radiation Therapy (SBRT) in Liver Metastasis (COLD 3)","Active, not recruiting","No Results Available","Liver Metastasis","Radiation: Stereotactic Body Radiation","University Health Network, Toronto","Both","18 Years and older   (Adult, Senior)","Phase 2","23","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 07-0348-C","June 4, 2009","August 2007","August 2016","February 5, 2016","February 2016","No Study Results Posted","null","August 2016","Determine one year local progression free rate, defined as lack of progression within the irradiated volume, using RECIST criteria.|Overall progression free survival|Overall survival|Quality of life|CTC3.0 toxicity|Cytokine response to radiation and association with complications","https://ClinicalTrials.gov/show/NCT00914615"
1742,"NCT02621658","Clear Liquid vs Liberalized Diet in Preparation for Colonoscopy","Not yet recruiting","No Results Available","Colorectal Cancer","Other: Clear Liquid Diet|Other: Full Liquid Diet","San Antonio Military Medical Center","Both","50 Years to 75 Years   (Adult, Senior)","","1000","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Diagnostic","Bowel Prep Protocol","November 23, 2015","January 2016","December 2016","December 1, 2015","December 2015","No Study Results Posted","null","July 2016","Quality of Bowel Preparation|Time to Cecal Intubation|Colonoscope Withdrawal time|Adenoma Detection Rate|Patient compliance|Patient satisfaction","https://ClinicalTrials.gov/show/NCT02621658"
1743,"NCT00183833","Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors","Completed","No Results Available","Colon Cancer|Colorectal Cancer","Drug: capecitabine, imatinib mesylate","University of Southern California|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","40","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-02-1","September 9, 2005","December 2002","August 2010","May 20, 2014","May 2014","No Study Results Posted","null","July 2009","To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of Gleevec in combination with a fixed dose of Xeloda po bid daily in patients with colon cancer.|To determine the time to progression, survival and response rate.|To obtain preliminary data on molecular correlates to determine clinical efficacy|Toxicity.","https://ClinicalTrials.gov/show/NCT00183833"
1744,"NCT01754896","Pilot Evaluation of Fecal Immunologic Test (FIT) in Ontario","Completed","No Results Available","Colorectal Cancer","Other: mailing of FIT kit directly to patient|Other: mailed invitation to pick up lab requisition and then kit|Other: mailing completed kits in for processing|Other: dropping completed kits at lab for processing","Sunnybrook Health Sciences Centre|Cancer Care Ontario","Both","50 Years to 74 Years   (Adult, Senior)","","28","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Health Services Research","209-2011","December 18, 2012","April 2012","April 2013","December 19, 2014","December 2014","No Study Results Posted","null","April 2013","FIT Kit uptake|Rejection rates","https://ClinicalTrials.gov/show/NCT01754896"
1745,"NCT00890305","Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: CT-011|Drug: FOLFOX","Medivation, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","171","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT-2008-01|2009-014593-18","April 28, 2009","May 2009","March 2013","June 10, 2015","June 2015","No Study Results Posted","null","May 2012","The primary endpoint will be the median progression free survival in patients treated with CT-011 plus FOLFOX compared to that of patients treated with FOLFOX alone.|Composite of safety, tolerability, pharmacokinetics and immunogenicity of CT-011.|Anti tumor activity of the antibody.|Objective response rate by RECIST.|Progression-free survival rates.|Response duration.|Overall survival.|Tumor and immunological markers.","https://ClinicalTrials.gov/show/NCT00890305"
1746,"NCT02280694","Low Dose Metronomic Poly-chemotherapy for Metastatic CRC","Recruiting","No Results Available","Colorectal Cancer","Drug: Capecitabine|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Celecoxib","HaEmek Medical Center, Israel","Both","18 Years to 85 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0035-14-EMC","October 29, 2014","January 2015","January 2018","March 30, 2016","March 2016","No Study Results Posted","LDMchemoCRC","January 2018","The median progression free survival (mPFS)","https://ClinicalTrials.gov/show/NCT02280694"
1747,"NCT02813928","Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative Treatment","Recruiting","No Results Available","Colorectal Cancer","Genetic: ccfDNA analysis","University Hospital, Limoges","Both","18 Years and older   (Adult, Senior)","","300","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","I15031","June 23, 2016","July 2016","December 2020","August 12, 2016","March 2016","No Study Results Posted","ADNCirc","July 2020","The presence of recurrences detected for patients curatively treated for a CRC stages II and III within the 3 years of follow-up.","https://ClinicalTrials.gov/show/NCT02813928"
1748,"NCT01518023","Long Term Diabetes Improvement After Cancer Gastrectomy and Colectomy","Completed","No Results Available","Diabetes Mellitus|Prediabetes|Morbid Obesity|Gastric Cancer|Colorectal Cancer","Other: Interview, questionnaire, updated biochemical tests","University of Sao Paulo","Both","18 Years and older   (Adult, Senior)","","240","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Lessdiabetes","January 20, 2012","January 2011","December 2011","January 24, 2012","January 2012","No Study Results Posted","null","December 2011","Fasting blood glucose|HbA1c","https://ClinicalTrials.gov/show/NCT01518023"
1749,"NCT01270360","Validation of an Alternative Biological Test to Increase the Detection Sensitivity of a Colon Tumour","Completed","No Results Available","Colorectal Cancer","Device: COLOHYBRITEST OR VALIHYBRITEST","Assistance Publique - Hôpitaux de Paris","Both","50 Years to 75 Years   (Adult, Senior)","","502","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AOM 09268","December 28, 2010","September 2010","December 2014","June 12, 2015","June 2015","No Study Results Posted","VATNIMAD","December 2014","To determine the performances (sensitivity, specificity and likelihood ratios) of a panel of blood and/or faecal molecular DNA markers|To estimate the cost and cost-effectiveness of adding DNA molecular tests to FOBT positive patients prior to colonoscopy|To determine the performances (sensitivity, specificity and likelihood ratios) of a panel of blood and/or faecal molecular protein markers|To create biological collections for screening purposes (asymptomatic subjects)","https://ClinicalTrials.gov/show/NCT01270360"
1750,"NCT01216930","Molecular Screening for Lynch Syndrome in Southern Denmark","Completed","No Results Available","Colorectal Cancer|Lynch Syndrome|HNPCC","Other: Observation","Vejle Hospital","Both","Child, Adult, Senior","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MS-LS-DK-01|10-5156","October 6, 2010","October 2010","September 2015","September 11, 2015","September 2015","No Study Results Posted","null","October 2012","","https://ClinicalTrials.gov/show/NCT01216930"
1751,"NCT00931840","A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: EZN-2208, Cetuximab and Irinotecan","Enzon Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","220","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EZN-2208-04","June 30, 2009","June 2009","January 2012","September 19, 2011","September 2011","No Study Results Posted","null","October 2011","Response Rate|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00931840"
1752,"NCT00986518","T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study","Completed","No Results Available","Colorectal Cancer","Biological: Adaptive autologous cell immunotherapy","Assistance Publique - Hôpitaux de Paris","Both","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","5","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P080601","September 29, 2009","October 2012","February 2013","November 21, 2013","September 2013","No Study Results Posted","STARTREK","February 2013","Tumor size of hepatic and/or lung metastases, as measured with tomodensitometry (RECIST 1.1 criteria)|MRI : Assessment of tumor necrosis, cellularity and morphological criteria RECIST 1.1 (functional criteria following injection : DCEMRI and diffusion MRI)|Sonography : assessment of vascular micro-circulation with contrast injection,|Immune cell reconstitution will be assessed through measuring rate of regulatory T-cell reconstitution,|Clinical Exam (WHO-CTC), Vital Signs, Adverse events|Laboratory test: hepatic function, immune function, haematology","https://ClinicalTrials.gov/show/NCT00986518"
1753,"NCT00866944","Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases","Completed","No Results Available","Liver Metastases|Colorectal Cancer","Drug: Adecatumumab|Drug: Adecatumumab and FOLFOX|Drug: FOLFOX 4","Amgen Research (Munich) GmbH","Both","18 Years and older   (Adult, Senior)","Phase 2","35","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MT201-204","March 20, 2009","March 2009","November 2011","November 10, 2011","November 2011","No Study Results Posted","MT201-204","July 2011","Disease free survival rate (DFS)|time to relapse|Incidence of AEs|Quality of Life","https://ClinicalTrials.gov/show/NCT00866944"
1754,"NCT00560560","Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments","Completed","Has Results","Colorectal Neoplasm","Biological: CP-751, 871","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","168","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4021006","November 15, 2007","December 2007","September 2010","May 16, 2013","May 2013","January 18, 2013","null","September 2010","Estimate of the 6 Month Survival Probability|Overall Survival|Progression-Free Survival (PFS)|Percentage of Participants With Objective Response|Descriptive Summary of Figitumumab Concentration Versus Time|Participants Reporting Positive for Total Anti-drug Antibodies (ADA)|Counts of Circulating Tumor Cells (CTCs) Expressing Positive Insulin-like Growth Factor 1 Receptor (IGF-1R)|Counts of Circulating Tumor Cells (CTCs)","https://ClinicalTrials.gov/show/NCT00560560"
1755,"NCT01904890","AANCART Research Project on Lay Health Workers and Asian Americans","Completed","No Results Available","Colorectal Cancer","Behavioral: CRC Prevention and Screening Education|Behavioral: Nutrition Education","University of California, San Francisco|University of California, Davis|University of California, Los Angeles|University of Hawaii|National Cancer Institute (NCI)","Both","50 Years to 75 Years   (Adult, Senior)","","994","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","U54CA153499-SUB7323|U54CA153499","July 10, 2013","March 2012","August 2015","December 29, 2015","December 2015","No Study Results Posted","AANCARTLHW","August 2015","Receipt of CRC Screening|Up-to-date CRC screening receipt|CRC screening Intention","https://ClinicalTrials.gov/show/NCT01904890"
1756,"NCT00259844","Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed","Completed","No Results Available","Colorectal Neoplasms","Biological: TroVax","Cancer Research UK|Oxford BioMedica","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PH2/048","November 29, 2005","June 2004","December 2006","July 17, 2006","November 2005","No Study Results Posted","null","null","To characterise and quantify the immune response to the oncofetal antigen 5T4 locally in peripheral blood, modified by vaccination with TroVax before resection of colorectal adenocarcinoma liver metastases.|To evaluate the safety, toxicity and tolerability of the TroVax vaccine in this setting.|To characterise and quantify the immune response to the oncofetal antigen 5T4 locally in tumour.|To review any further effect on immunity by TroVax vaccinations following surgery.|To monitor and collect data on clinical outcomes (time to progression/relapse/death).","https://ClinicalTrials.gov/show/NCT00259844"
1757,"NCT02122523","Sentinel Lymph Node (SLN) in Colorectal Carcinoma (CRC) With a Near-infrared (NIR)-Dye","Completed","No Results Available","Sentinel Lymph Node|Colorectal Cancer|Metastasis","Procedure: Near-Infrared (NIR) dye Indocyanin Green (ICG)","VU University Medical Center","Both","18 Years and older   (Adult, Senior)","","25","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SLN","March 19, 2014","January 2013","null","April 23, 2014","April 2014","No Study Results Posted","null","January 2014","Number of fluorescent lymph nodes|Number of Lymph nodes with metastasis","https://ClinicalTrials.gov/show/NCT02122523"
1758,"NCT01361035","Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients","Completed","No Results Available","Cervical Cancer|Breast Cancer|Colorectal Cancer","Other: Cancer risk communication skills training","Tulane University School of Medicine|Robert Wood Johnson Foundation","Both","40 Years to 75 Years   (Adult, Senior)","","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Health Services Research","RWJF-63523","May 24, 2011","June 2008","June 2012","November 13, 2014","November 2014","No Study Results Posted","null","June 2012","Change in cervical, breast and colorectal cancer screening rates|Change in standardized patient ratings of physician communication behaviors","https://ClinicalTrials.gov/show/NCT01361035"
1759,"NCT00119899","Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases","Completed","No Results Available","Colorectal Liver Metastases|Colorectal Cancer|Neoplasm Metastasis","Procedure: FDG-PET scan","Radboud University|VU University Medical Center|University Medical Center Groningen|MMC Hopsital Veldvoven (Department of Surgery)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","POLEM (ZonMW DO 945-11017)|(ZonMW DO 945-11017)","July 6, 2005","March 2002","June 2005","August 30, 2005","August 2005","No Study Results Posted","null","null","Disease Free Survival (9 months)|Economic evaluation (9 months)|Disease Free Survival|Overall Survival|Change in Clinical Management|Economic evaluation","https://ClinicalTrials.gov/show/NCT00119899"
1760,"NCT01576666","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors","Completed","No Results Available","Dose Escalation|Safety|Preliminary Efficacy|Advanced Solid Tumors|Metastatic Breast Cancer|Advanced Pancreatic Adenocarcinoma|Metastatic Colorectal Cancer|Recurrent Glioblastoma Multiforme|Gastric Cancer|Gastroesophageal Junction Cancer|Triple Negative Metastatic Breast Cancer|Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer","Drug: LDE225|Drug: BKM120","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","120","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label","CLDE225X2114|2011-005016-28","April 10, 2012","July 2012","April 2015","February 18, 2016","February 2016","No Study Results Posted","null","April 2015","Dose Limiting Toxicities|Number of Patients with Adverse Events and Serious Adverse Events|Objective response rate (ORR)|Early progression rate (EPR)|Plasma pharmacokinetics (PK) parameters","https://ClinicalTrials.gov/show/NCT01576666"
1761,"NCT02360605","Health Literacy Interventions to Overcome Disparities in CRC Screening","Recruiting","No Results Available","Colorectal Cancer","Behavioral: automated telephone reminder|Behavioral: prevention coordinator|Behavioral: Health literacy appropriate education and demonstration","Louisiana State University Health Sciences Center Shreveport|Northwestern University|Loyola University","Both","50 Years to 75 Years   (Adult, Senior)","","800","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","RSG-13-021-01 - CPPB","February 5, 2015","February 2015","December 2017","March 1, 2016","March 2016","No Study Results Posted","null","December 2017","initial CRC screening|repeat CRC screening|patients' understanding, beliefs and self-efficacy toward CRC screening over time.|effects of either strategy vary by patients' literacy","https://ClinicalTrials.gov/show/NCT02360605"
1762,"NCT02538627","Phase 1 Combination Study of MM-151 and MM-121","Recruiting","No Results Available","Colorectal Cancer|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck","Drug: MM-151|Drug: MM-121","Merrimack Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM-151-01-01-02","August 31, 2015","August 2015","null","March 23, 2016","March 2016","No Study Results Posted","null","December 2016","Phase II dose of MM-151 in combination with MM-121 based on maximum tolerated dose (MTD) in patients with heregulin-positive lung, head and neck, and colorectal cancers|Number of dose limiting toxicities (DLTs) within a cohort|Adverse event profile of MM-151 in combination with MM-121|Objective response to MM-151 in combination with MM-121 based on RECIST","https://ClinicalTrials.gov/show/NCT02538627"
1763,"NCT01056796","Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27","Recruiting","No Results Available","Colorectal Cancer","Device: CAR™ 27","Niti Medical Technologies Ltd.|University Hospital, Gasthuisberg","Both","18 Years and older   (Adult, Senior)","Phase 2","10","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Version: January 6, 2010","January 25, 2010","January 2010","May 2012","June 29, 2011","January 2010","No Study Results Posted","null","May 2012","To evaluate for the occurrence of adverse events related to the use of the CAR™ 27 device, include anastomotic leak, bleeding, ring evacuation and strictures at 6 months.|Evaluation of the creation of a functioning CAR™ 27 anastomosis in radiated patients","https://ClinicalTrials.gov/show/NCT01056796"
1764,"NCT00051688","Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Colorectal Neoplasms","Drug: tezacitabine|Drug: oxaliplatin","Chiron Corporation","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","TEZ101","January 15, 2003","June 2003","August 2004","July 10, 2006","July 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00051688"
1765,"NCT02694562","Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy","Active, not recruiting","No Results Available","Colorectal Carcinoma","Device: 40um Embozene TANDEM Microspheres","Boston Scientific Corporation","Both","19 Years and older   (Adult, Senior)","","18","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MIRACLE III","February 25, 2016","November 2013","April 2017","August 24, 2016","August 2016","No Study Results Posted","MIRACLEIII","March 2015","Rate of freedom from serious adverse events (SAEs)|Local tumor control based on the devascularization pattern from the European Association for the Study of the Liver (EASL) criteria","https://ClinicalTrials.gov/show/NCT02694562"
1766,"NCT00846482","Exploratory Study Of The ERCC-1 Gene","Recruiting","No Results Available","Colon Cancer|Rectal Cancer","Drug: Oxaliplatin","Montefiore Medical Center|Sanofi","Both","Child, Adult, Senior","","40","Other|Industry","Observational","Time Perspective: Prospective","07-10-376","February 21, 2008","February 2008","August 2010","February 17, 2009","February 2009","No Study Results Posted","null","February 2010","To see of the level of the ERCC protein will change in patients treated with oxaliplatin|Determine extent of ERCC polymorphism and its relationship to change in its level","https://ClinicalTrials.gov/show/NCT00846482"
1767,"NCT01205022","Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: fluorouracil|Biological: bevacizumab|Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Other: laboratory biomarker analysis","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","3","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10038|NCI-2010-01962","September 16, 2010","April 2011","January 2014","June 3, 2015","June 2015","No Study Results Posted","null","January 2014","Maximum tolerated dose of yttrium-90 (90Y) M5A anti-CEA antibody when given in combination with FOLFIRI chemotherapy and bevacizumab|Progression-free survival|Overall survival|Response rates|Biodistribution, clearance, and metabolism of Y-90 and In-111-M5A|Estimation of radiation doses to whole body, normal organs, and tumor through serial nuclear imaging","https://ClinicalTrials.gov/show/NCT01205022"
1768,"NCT00896896","Immunoreactivity to Cetuximab in Cancer Patients","Completed","No Results Available","Colorectal Cancer|Head and Neck Cancer","Other: immunologic technique|Other: laboratory biomarker analysis","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","","538","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","VICC HN 0668|VU-VICC-HN-0668","May 9, 2009","November 2006","October 2008","March 29, 2013","March 2013","No Study Results Posted","null","October 2008","Identification of antibodies (e.g., IgE, IgG, IgA, and IgM) against cetuximab","https://ClinicalTrials.gov/show/NCT00896896"
1769,"NCT02502760","Using Multimodal Prehabilitation to Improve Outcomes for Frail Patients Undergoing Resection of Colorectal Cancer","Enrolling by invitation","No Results Available","Colorectal Neoplasms","Behavioral: Physical Exercise Program|Dietary Supplement: Whey Protein Isolate Powder|Behavioral: Relaxation Techniques","McGill University Health Center|Sir Mortimer B. Davis - Jewish General Hospital","Both","Child, Adult, Senior","","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Supportive Care","15-131-MUHC","July 15, 2015","August 2015","null","July 29, 2015","July 2015","No Study Results Posted","null","December 2016","Post operative complications|6 Minutes Walk Test Distance|Hospital Length of Stay|Readmission rates|Anxiety and Depression|Health Related Quality of Life","https://ClinicalTrials.gov/show/NCT02502760"
1770,"NCT01030042","Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFOX-4|Drug: Irinotecan/Cetuximab","Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","110","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-006254-26","December 9, 2009","September 2009","June 2015","July 14, 2015","December 2009","No Study Results Posted","COMETS","April 2015","Overall Survival|Progression free survival","https://ClinicalTrials.gov/show/NCT01030042"
1771,"NCT00114829","Preoperative Assessment of Colon Tumor","Recruiting","No Results Available","Colorectal Cancer|Colorectal Tumor","Procedure: MR colonography with dynamic contrast uptake","Herlev Hospital|University Hospital, Gentofte, Copenhagen","Both","18 Years and older   (Adult, Senior)","Phase 4","60","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Diagnostic","KA05028-MA|KA05028","June 17, 2005","July 2005","null","March 8, 2006","May 2005","No Study Results Posted","null","null","Sensitivity in determining malignant or benign diagnose|Sensitivity/specificity of MR colonography","https://ClinicalTrials.gov/show/NCT00114829"
1772,"NCT01477866","Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer","Suspended","No Results Available","Colonic Neoplasms","Dietary Supplement: citogenex|Other: conventional therapy","University of Palermo","Both","40 Years to 60 Years   (Adult)","","250","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CITOGENEX CRC","November 18, 2011","January 2012","December 2014","October 25, 2012","October 2012","No Study Results Posted","CITOGENEX PA","June 2014","All cause mortality","https://ClinicalTrials.gov/show/NCT01477866"
1773,"NCT00313794","Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment","Completed","No Results Available","Colorectal Neoplasms","Drug: CP-675,206","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","49","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A3671014","April 10, 2006","May 2006","June 2008","June 5, 2012","June 2012","No Study Results Posted","null","June 2008","To assess the best overall response rate per RECIST (BRR) in patients with metastatic adenocarcinoma of the colon or rectum treated with CP-675,206 .|To evaluate the safety and tolerability of CP-675,206 in this population.|To identify any human anti human antibody (HAHA) response to CP-675,206 .|To identify potential relationships between polymorphisms in the Cytotoxic T lymphocyte-associated antigen 4 (CTLA4), Fcgamma receptor IIa (FcgRIIa), IgG2a genes with safety and/or immune response of patients treated with CP-675,206.|To assess additional evidence of anti-tumor activity as measured by duration of response, progression-free survival and overall survival.|To obtain pharmacokinetic (PK) data to be evaluated in a future meta analysis of CP-675,206 pharmacokinetics.","https://ClinicalTrials.gov/show/NCT00313794"
1774,"NCT00745927","Application of CO2 Insufflations in Colonoscopy Randomized Trial","Recruiting","No Results Available","Colorectal Neoplasm|Colorectal Cancer","Other: CO2 insufflations","National Taiwan University Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Screening","200802031R","August 31, 2008","June 2008","August 2012","August 13, 2012","August 2012","No Study Results Posted","null","August 2012","Degree of abdominal discomfort during and after colonoscopy|Number of neoplasm detected","https://ClinicalTrials.gov/show/NCT00745927"
1775,"NCT00697047","Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up","Active, not recruiting","No Results Available","Colorectal Cancer","Behavioral: Automated Mailing|Behavioral: Automated Mailing Plus Assisted|Behavioral: Auto Plus Assisted Plus Navigation","Group Health Cooperative|Kaiser Permanente|Fred Hutchinson Cancer Research Center|The University of Texas Health Science Center, Houston","Both","50 Years to 73 Years   (Adult, Senior)","","4653","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Screening","5R01CA121125","June 11, 2008","July 2008","June 2018","May 25, 2016","May 2016","No Study Results Posted","SOS","November 2017","Short-term adherence to CRC screening|Long-term adherence to CRC screening|Short and long-term adherence to CRC screening for those eligible for re-randomization in year 3|Impact of SOS interventions on outcomes and CRC-related costs","https://ClinicalTrials.gov/show/NCT00697047"
1776,"NCT01876511","Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors","Recruiting","No Results Available","MSI Positive Colorectal Cancer|MSI Negative Colorectal Cancer|MSI Positive Non-Colorectal Cancers","Drug: MK-3475","Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","171","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J1365|MK-3475-016|NA_00085756","June 10, 2013","September 2013","October 2020","June 28, 2016","June 2016","No Study Results Posted","null","June 2017","Immune-related progression free survival (irPFS) rate at 20 weeks in patients with MSI positive and negative colorectal adenocarcinoma using immune related response criteria (irRC)|Objective response rate (irORR) at 20 weeks in patients with MSI positive and negative colorectal adenocarcinoma using immune related response criteria (irRC)|Immune-related progression free survival (irPFS) rate in patients with MSI positive non-colorectal adenocarcinoma using immune related response criteria (irRC) at 20 weeks|Overall survival|irPFS and PFS in patients with MSI positive and negative tumors at 28 weeks using irRC and RECIST 1.1|Best overall response rate and disease control rate in patients with MSI positive and negative tumors|Number of participants experiencing immune-related toxicities (IRAEs)|Does MSI as a marker predict treatment response|Identify alternative markers of MSI status. This includes but is not limited to MLH 1, MSH 2, MSH 6, PMS2, BRAF pV600E, and TGFBR2.","https://ClinicalTrials.gov/show/NCT01876511"
1777,"NCT02195232","Cancer Associated Thrombosis and Isoquercetin (CAT IQ)","Recruiting","No Results Available","Thromboembolism of Vein VTE in Colorectal Cancer|Thromboembolism of Vein in Pancreatic Cancer|Thromboembolism of Vein in Non-small Cell Lung Cancer","Drug: Isoquercetin","Dana-Farber Cancer Institute|Quercegen Pharmaceuticals|National Heart, Lung, and Blood Institute (NHLBI)","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","618","Other|Industry|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14-114","May 13, 2014","January 2015","April 2023","August 29, 2016","August 2016","No Study Results Posted","CAT IQ","August 2018","Percentage of Participants with Reduced D-dimer values|Safety|Cumulative Incidence of VTE at 56 days","https://ClinicalTrials.gov/show/NCT02195232"
1778,"NCT00081627","Clinical Trial in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colon Cancer|Rectal Cancer","Drug: CoFactor and 5FU","Mast Therapeutics, Inc.|University of California, San Diego","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-CoFactor","April 15, 2004","April 2004","January 2007","November 26, 2007","November 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00081627"
1779,"NCT02322736","Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR","Recruiting","No Results Available","Metastatic Colorectal Cancer","","Amgen|ZeinCRO Hellas SA","Both","18 Years and older   (Adult, Senior)","","218","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20120286","December 19, 2014","November 2014","July 2018","April 20, 2016","April 2016","No Study Results Posted","VISION","July 2018","To describe the pattern of use of Vectibix® in combination with chemotherapy in 1st line or in 2nd line mCRC treatments as per approved Vectibix® indication.|To investigate the rate of objective response (ORR, defined as either a Complete Response or a Partial Response) and the rate of stable disease as best response in 1st line or in 2nd line chemotherapy regimens of mCRC including Vectibix®.","https://ClinicalTrials.gov/show/NCT02322736"
1780,"NCT00321100","Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab","Terminated","No Results Available","Colorectal Neoplasms","Drug: bevacizumab|Drug: Cetuximab|Drug: Oxaliplatin|Drug: Capecitabine","Fox Chase Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","23","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FER-GI-002","May 1, 2006","April 2006","December 2013","May 5, 2014","May 2014","No Study Results Posted","null","April 2009","Determine the objective response rate using RESIST criteria after every second cycle|Determine time to progression","https://ClinicalTrials.gov/show/NCT00321100"
1781,"NCT00026234","Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver","Completed","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Liver Metastases|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: floxuridine|Drug: dexamethasone|Drug: oxaliplatin|Drug: capecitabine","National Cancer Institute (NCI)|NSABP Foundation Inc","Both","Child, Adult, Senior","Phase 2","75","NIH|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01866|N9945|CDR0000069011|NCCTG-N9945|NSABP-CI-66|U10CA025224","November 9, 2001","February 2002","null","July 15, 2013","June 2013","No Study Results Posted","null","January 2006","Toxicity of oxaliplatin as assessed by the National Cancer Institute (NCI) Common Terminology Criteria (CTC) version 2.0|Survival rate|Survival time|Time to recurrence|Time to treatment failure|Adverse events as assessed by NCI CTC version 2.0","https://ClinicalTrials.gov/show/NCT00026234"
1782,"NCT00491140","Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab","Completed","No Results Available","Colorectal Neoplasms","Genetic: Gene mutations analysis and FISH","Istituto Clinico Humanitas","Both","18 Years and older   (Adult, Senior)","","85","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ICH n. 380","June 22, 2007","December 2006","June 2008","September 30, 2008","September 2008","No Study Results Posted","null","May 2007","Association of different biomarkers with Cetuximab sensitivity|Association of different biomarkers with time to progression and survival","https://ClinicalTrials.gov/show/NCT00491140"
1783,"NCT02624895","ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX -1st Line","Recruiting","No Results Available","Metastatic Colorectal Cancer","","Amgen","Both","18 Years and older   (Adult, Senior)","","300","Industry","Observational","Time Perspective: Prospective","20140383","November 9, 2015","December 2015","June 2018","July 6, 2016","July 2016","No Study Results Posted","SILQ","June 2018","EORTC QLQ C30 questionnaire score|QoL questionnaire DLQI questionnaire score|%of patients of enrolled subjects, experiencing a specific adverse event according to NCI CTC-AE version 4.0|Recording of number of concomitant medications, to prevent or treat dermatological adverse events|Time to onset of the dermtological toxicity|Dose reduction|""number of administered cycles""|average relative dose intensity of every drug""|Score scale on questionnaire answers|Number of cycles on treatment before and of treatment due to AE|dose delay|Questionnaire score","https://ClinicalTrials.gov/show/NCT02624895"
1784,"NCT02087475","Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin","Recruiting","No Results Available","Colorectal Neoplasms|Effects of Chemotherapy|Surgery|Metastasis|Local Neoplasm Recurrence","Drug: Irinotecan|Drug: 5-fluorouracil|Radiation: Local radiotherapy|Procedure: R0 resection","Sixth Affiliated Hospital, Sun Yat-sen University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","360","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SAH 5010 CRC","March 7, 2014","January 2011","December 2024","March 12, 2014","March 2014","No Study Results Posted","null","December 2021","Progress Free Survival|Overall Survival|R0 Resection Rate|Toxicity|Life Quality","https://ClinicalTrials.gov/show/NCT02087475"
1785,"NCT01126450","Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer","Terminated","No Results Available","Colon Cancer|Rectal Cancer","Drug: lenalidomide|Biological: cetuximab|Other: mutation analysis|Other: polymerase chain reaction|Genetic: polymorphism analysis","Case Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","3","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE8208|NCI-2010-01202","May 18, 2010","October 2009","December 2010","March 16, 2012","March 2012","No Study Results Posted","null","November 2010","Safety / Tolerability (type, frequency, severity, and relationship of adverse events to study drug)|Time to progression of disease|Tumor response according to RECIST|Lab correlatives (FCGRIIa and FCGRIIIa polymorphisms, K-Ras and B-Raf mutations)","https://ClinicalTrials.gov/show/NCT01126450"
1786,"NCT02489422","Programs To Support You During Chemotherapy","Recruiting","No Results Available","Depression|Fatigue|Stage IIA Colorectal Cancer|Stage IIB Colorectal Cancer|Stage IIC Colorectal Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration|Other: Daily Survey Administration|Behavioral: Yoga Skills Training|Behavioral: Attention Control|Other: Actigraphy Assessment","Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI)|National Center for Complementary and Integrative Health (NCCIH)","Both","21 Years and older   (Adult, Senior)","","60","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CCCWFU 01716|NCI-2015-01042|K01AT008219|P30CA068485","June 29, 2015","August 2016","null","August 24, 2016","August 2016","No Study Results Posted","PRO-YOU","December 2020","Fatigue assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS)|Circadian disruption (daily)|Circadian disruption (recalled)|Depressive symptoms assessed by PROMIS|Fatigue (daily)|Depressive symptoms (daily)|Interleukin 6 [IL-6] measured using the Mesoscale Discovery platform|Soluble tumor necrosis factor receptor 1 [sTNF-R1] measured using the Mesoscale Discovery platform|Tumor necrosis factor alpha [TNF-alpha] measured using the Mesoscale Discovery platform|Psychological stress assessed by the Perceived Stress Scale (PSS)|Psychological stress assessed by the PSS (daily)|Regulation of psychological stress assessed by the Positive and Negative Affect Schedule-Expanded Form (daily)|Regulation of psychological stress assessed using the Cancer Behavior Inventory","https://ClinicalTrials.gov/show/NCT02489422"
1787,"NCT01269060","Efficacy of Single Incision (Embryonic NOTES) Laparoscopic Colorectal Surgery","Completed","No Results Available","Colorectal Cancer","Procedure: Single Incision Laparoscopic Surgery","National Cancer Center, Korea","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","48","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-484","January 3, 2011","January 2011","August 2011","August 2, 2012","August 2012","No Study Results Posted","null","August 2011","Harvested numbers of lymph node|Postoperative mortality, morbidity","https://ClinicalTrials.gov/show/NCT01269060"
1788,"NCT01816659","An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin","Terminated","No Results Available","Colorectal Carcinoma","Drug: Metformin ER","M.D. Anderson Cancer Center","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","3","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","2012-1150|NCI-2013-00994","March 20, 2013","May 2013","August 2014","November 16, 2015","August 2014","No Study Results Posted","null","August 2014","Comparison of Ki-67 in Tumor Samples","https://ClinicalTrials.gov/show/NCT01816659"
1789,"NCT01372189","Molecular Imaging of Epidermal Growth Factor Receptor in Colorectal Neoplasia Using Confocal Laser Endomicroscopy","Completed","No Results Available","Colorectal Cancer|Colorectal Adenoma","","Shandong University","Both","18 Years to 80 Years   (Adult, Senior)","","40","Other","Observational","Time Perspective: Prospective","2011SDU-QILU-G01","January 18, 2011","January 2011","July 2011","January 30, 2012","January 2012","No Study Results Posted","null","July 2011","","https://ClinicalTrials.gov/show/NCT01372189"
1790,"NCT02485561","Evaluating Strategies to Present Colon Cancer Screening Information","Recruiting","No Results Available","Colonic Neoplasms|Colorectal Neoplasms|Colonic Diseases|Gastrointestinal Neoplasms","Behavioral: Health communication intervention|Behavioral: Education information","Washington University School of Medicine|National Cancer Institute (NCI)","Both","50 Years to 75 Years   (Adult, Senior)","","400","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","HRPO201501019|R21CA187608","June 18, 2015","June 2015","May 2017","June 25, 2015","June 2015","No Study Results Posted","null","May 2016","Intentions to get screened for colon cancer in the next 6 months will be assessed with a visual analog response scale.|Identification with the character will be assessed with perceived similarity and liking (3 items each) based on previous work by the study investigators. (McQueen & Kreuter 2010; McQueen et al., 2011)|Engagement will be assessed with an 8-item version of the Transportation Scale. (Sestir, 2010; Green & Brock, 2000)|Self-efficacy for getting screened for colon cancer will be assessed with a previously validated multi-item scale.(McQueen et al., 2008)|Affect: Items from the Positive and Negative Affect Schedule (PANAS; Crawford & Henry 2004) will measure affective responses while reading the colon cancer and screening materials.|Seven scales assessing defensive information processing will be assessed using previously validated measures.(McQueen et al., 2013, McQueen et al., 2014)|Perceived susceptibility to colon cancer will be assessed with multiple standard items assessing absolute, comparative, and feelings-of-risk of developing colon cancer. (Weinstein 2007)|Perceived prevalence of finding colon cancer during screening will be assessed with three items developed for this study.","https://ClinicalTrials.gov/show/NCT02485561"
1791,"NCT01841294","NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery","Recruiting","No Results Available","Colorectal Cancer","Drug: Intravenous Lidocaine|Drug: Normal saline infusion","Maisonneuve-Rosemont Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 4","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Basic Science","11077","February 27, 2013","January 2012","December 2013","April 25, 2013","January 2012","No Study Results Posted","null","December 2013","Dosage of NKs activity after surgery|Pain scores|Morphine consumption|Ileus time|Surgical complications|Fentanyl dose|Nausea and vomiting|Major adverses events","https://ClinicalTrials.gov/show/NCT01841294"
1792,"NCT00398333","Study to Assess the Effectiveness of a Omega-3 Enriched Supplement on Chemotherapy Tolerance in Colon Cancer Patients","Terminated","No Results Available","Colorectal Neoplasms","Dietary Supplement: Eicosapentaenoic acid enriched nutritional supplement","Hospital Clinic of Barcelona|Abbott","Both","18 Years and older   (Adult, Senior)","Phase 4","13","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","EPA-05|EPA-05/ ACA-SPAI-05-05","November 9, 2006","June 2005","March 2008","June 19, 2013","June 2013","No Study Results Posted","null","March 2008","To assess the efficacy of a nutritional intervention with supplementation enriched in EPA to improve the tolerance to the antineoplastic treatment, using the variation in quality of life changes as the tolerability index.|To assess the influence of the nutritional status over the tolerance to the antineoplastic treatment.|To assess the effect of a nutritional supplement over the nutritional status of the patient with disseminated neoplastic illness.","https://ClinicalTrials.gov/show/NCT00398333"
1793,"NCT02319928","European Polyp Surveillance Trial","Recruiting","No Results Available","""Colonic Polyps"" ""Colorectal Neoplasms""","Procedure: Colonoscopy","Asociación Española de Gastroenterología","Both","40 Years to 74 Years   (Adult, Senior)","","28000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","AEG-EPOS-1","December 15, 2014","June 2015","December 2028","November 23, 2015","November 2015","No Study Results Posted","EPoS","December 2028","Colorectal cancer incidence","https://ClinicalTrials.gov/show/NCT02319928"
1794,"NCT01356264","Multimodal Prehabilitation for Colorectal Surgery","Completed","No Results Available","Colorectal Cancer|Colorectal Cancer Stage III","Behavioral: multimodal prehabilitation|Behavioral: multimodal prehabilitation","McGill University Health Center|Society of American Gastrointestinal and Endoscopic Surgeons|Immunotec Inc.","Both","18 Years to 100 Years   (Adult, Senior)","Phase 2","89","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","GEN# 11-004","May 17, 2011","July 2011","December 2013","September 26, 2015","September 2015","No Study Results Posted","null","March 2013","six minute walk test|Health-related quality of life|physical activity level|Depression and anxiety|nutritional status|postoperative complications|Fatigue","https://ClinicalTrials.gov/show/NCT01356264"
1795,"NCT01288833","Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study","Active, not recruiting","No Results Available","Colorectal Neoplasm|Colonic Polyps","Device: Close focus HD NBI Colonoscopy System","VA Palo Alto Health Care System|Kansas City Veteran Affairs Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 3","558","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","VALID PA19624","February 1, 2011","March 2011","December 2017","June 11, 2014","June 2014","No Study Results Posted","VALID","June 2017","Compare the number of accurate high confidence polyp histology predictions by the endoscopist in the two groups.|Cost|Diagnostic characteristics|Accuracy of predicted versus actual surveillance intervals|Surveillance Colonoscopy Advanced Pathology Findings|Learning Curve","https://ClinicalTrials.gov/show/NCT01288833"
1796,"NCT01320683","Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer","Terminated","Has Results","Liver Metastases|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: oxaliplatin|Drug: leucovorin calcium|Drug: fluorouracil|Biological: bevacizumab|Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Other: laboratory biomarker analysis|Other: pharmacological study|Drug: irinotecan hydrochloride","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","1","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09053|NCI-2011-00369|P01CA043904","March 18, 2011","March 2011","December 2014","June 17, 2016","June 2016","May 11, 2016","null","December 2014","Progression-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01320683"
1797,"NCT02602938","Aspirin on CTCs of Advanced Breast and Colorectal Cancer","Recruiting","No Results Available","Epithelial-Mesenchymal Transition|Circulating Tumor Cells","Drug: Aspirin","Zhejiang Provincial People’s Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","2015KY163","November 9, 2015","November 2015","February 2017","November 12, 2015","November 2015","No Study Results Posted","ACABC","November 2016","Intervention completed|Disease progression","https://ClinicalTrials.gov/show/NCT02602938"
1798,"NCT00083785","Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases","Completed","No Results Available","Liver Metastasis|Colorectal Neoplasms|Liver Neoplasms|Neoplasm Metastasis","Drug: Talaporfin sodium (LS11)|Device: LED-based light infusion device|Device: Light emitting diodes (LED)|Procedure: Photodynamic therapy|Procedure: Phototherapy|Procedure: Chemotherapy","Light Sciences LLC","Both","18 Years and older   (Adult, Senior)","Phase 2","25","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LSC-OL003","June 2, 2004","May 2004","null","April 10, 2007","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00083785"
1799,"NCT01651832","Supportive Cancer Care Networkers (SCAN)","Recruiting","No Results Available","Colorectal Cancer|Chemotherapy","Behavioral: SCAN","Martin-Luther-Universität Halle-Wittenberg","Both","18 Years to 85 Years   (Adult, Senior)","","700","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","01GY1143","July 25, 2012","July 2012","December 2015","December 1, 2014","December 2014","No Study Results Posted","SCAN","December 2015","proportion of eligible patients undergoing adjuvant chemo therapy|disease-free survival|Health-related Quality of Life|symptom burden|Distress|supportive care needs|Quality of inpatient care","https://ClinicalTrials.gov/show/NCT01651832"
1800,"NCT00903565","A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint","Recruiting","No Results Available","Colon Cancer","","Agendia","Both","18 Years and older   (Adult, Senior)","","1200","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CP-060-CR","May 15, 2009","September 2008","December 2017","January 28, 2016","January 2016","No Study Results Posted","PARSC","December 2016","To validate the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage II colorectal cancer.|• To assess the feasibility of using the ColoPrint test in the clinical setting.|• To compare the risk assessment in stage II patients using the ColoPrint profile vs a clinical risk assessment|• To establish the proportion of low-risk and high-risk ColoPrint profiles in stage II colorectal cancer patients in various countries.|• To investigate therapy as a potential confounding factor for ColoPrint results.|• To assess the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage III colorectal cancer.|• To compare the performance of ColoPrint vs the clinical risk assessment in estimating the 5-year relapse rate.|• Assess the impact of ColoPrint on adjuvant chemotherapy treatment decisions in stage 2 colorectal cancer patients|• Compare the ColoPrint results from fresh RNARetain colorectal tumor specimens to the matched formalin-fixed paraffin-embedded tissue (FFPE) colon tumor specimens for concordance.","https://ClinicalTrials.gov/show/NCT00903565"
1801,"NCT02243735","Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia","Recruiting","No Results Available","Anemia|Colorectal Carcinoma|Surgery","Drug: Ferrous fumarate|Drug: ferric(III)carboxymaltose","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Vifor Pharma","Both","18 Years and older   (Adult, Senior)","Phase 4","198","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NL50013.018.14|2014-002827-87","September 12, 2014","November 2014","December 2016","June 17, 2015","June 2015","No Study Results Posted","FIT","June 2016","Normalization of Hb-level.|Difference in Morbidity score","https://ClinicalTrials.gov/show/NCT02243735"
1802,"NCT01693835","""Cancersensor"": Circadian Rhythms","Recruiting","No Results Available","Metastatic Colorectal Cancer","","Institut National de la Santé Et de la Recherche Médicale, France","Both","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","C11-42|2012-A00010-43","September 7, 2012","August 2012","August 2015","June 5, 2015","April 2015","No Study Results Posted","null","August 2015","Circadian rhythms in urinary excretion of modified nucleosides","https://ClinicalTrials.gov/show/NCT01693835"
1803,"NCT01693861","""Cancersensor"" Chemotherapy","Recruiting","No Results Available","Metastatic Colorectal Cancer","","Institut National de la Santé Et de la Recherche Médicale, France","Both","18 Years and older   (Adult, Senior)","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","C11-59|2012-A00168-35","September 7, 2012","October 2012","August 2015","April 24, 2015","April 2015","No Study Results Posted","null","August 2015","Effect of chemotherapy on urinary excretion of modified nucleosides","https://ClinicalTrials.gov/show/NCT01693861"
1804,"NCT00764621","Health Economic Evaluation of Primovist-enhanced Liver MRI","Completed","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis","Procedure: Primovist MRI|Procedure: Extracellular contrast media (ECCM) MRI|Procedure: Contrast-enhanced CT","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 4","360","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","91789|312041|2008-000583-16","October 1, 2008","October 2008","November 2010","November 3, 2014","November 2014","No Study Results Posted","null","September 2010","Primary variable is the proportion of patients in each of the three treatment groups for whom further imaging is required after initial imaging to come to a therapy decision.|Proportion of patients with intra-operatively modified surgical plans based on initial imaging with either Primovist-, ECCM-MRI or CE-CT","https://ClinicalTrials.gov/show/NCT00764621"
1805,"NCT00645710","Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery","Active, not recruiting","No Results Available","Liver Metastases|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: gemcitabine hydrochloride|Drug: floxuridine|Genetic: proteomic profiling|Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry|Other: liquid chromatography|Radiation: yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: pharmacological study","City of Hope Medical Center","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","28","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04122|NCI-2010-01229|CDR0000590335","March 27, 2008","February 2005","null","May 4, 2016","May 2016","No Study Results Posted","null","September 2017","Progression-free survival|Overall survival|Sites of recurrence","https://ClinicalTrials.gov/show/NCT00645710"
1806,"NCT01803282","Safety and Tolerability Study in Solid Tumors","Recruiting","No Results Available","Tumors|Pancreatic Cancer|Non-small Cell Lung Cancer|Esophagogastric Cancer|Colorectal Cancer|Breast Cancer","Drug: GS-5745|Drug: Gemcitabine|Drug: Nab-paclitaxel|Drug: Carboplatin|Drug: Pemetrexed|Drug: Leucovorin|Drug: Oxaliplatin|Drug: 5-FU|Drug: Bevacizumab|Drug: Irinotecan|Drug: Paclitaxel","Gilead Sciences","Both","18 Years and older   (Adult, Senior)","Phase 1","343","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GS-US-296-0101","February 27, 2013","March 2013","January 2019","September 9, 2016","September 2016","No Study Results Posted","null","February 2018","Safety as evaluated by incidence of AEs, assessment of clinical laboratory test findings, physical examination, 12-lead ECG, and vital signs measurements","https://ClinicalTrials.gov/show/NCT01803282"
1807,"NCT02523495","The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer","Recruiting","No Results Available","Neoplasms, Therapy-Associated","","Huazhong University of Science and Technology","Both","Child, Adult, Senior","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TJCC003-TTMCRC","August 4, 2015","June 2012","null","February 17, 2016","February 2016","No Study Results Posted","null","July 2017","overall survival","https://ClinicalTrials.gov/show/NCT02523495"
1808,"NCT01924897","Preop CPET Testing and Exercise Training in Colorectal Patients","Not yet recruiting","No Results Available","Colorectal Neoplasms","Behavioral: Exercise training","University of East Anglia|National Institute for Health Research, United Kingdom","Both","18 Years and older   (Adult, Senior)","","90","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","2013ONC11S","August 14, 2013","null","null","August 16, 2013","August 2013","No Study Results Posted","null","August 2016","postoperative morbidity|post-operative stay|mortality|Admission to HDU/ITU","https://ClinicalTrials.gov/show/NCT01924897"
1809,"NCT00339469","Effect of High-Legume Diet on Colorectal Cancer Risk","Completed","No Results Available","Inflammation|Prevention and Control|Colonic Neoplasms|Diet|Insulin","Dietary Supplement: LIFE","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Male","35 Years to 75 Years   (Adult, Senior)","Phase 0","65","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Prevention","999905215|05-C-N215","June 19, 2006","August 2005","May 2008","February 26, 2016","February 2016","No Study Results Posted","null","May 2008","Biomarkers of insulin resistance and inflammation|Weight loss","https://ClinicalTrials.gov/show/NCT00339469"
1810,"NCT02188927","Effect of an Advanced Notification Letter on Screening Colonoscopy Participation","Not yet recruiting","No Results Available","Colorectal Cancer|Adenoma|Rectal Cancer","Other: Implementation of ANL|Behavioral: No included ANL","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Medical Centre of Postgraduate Education, Poland|European Union","Both","55 Years to 64 Years   (Adult)","","6800","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","TEAM/2012-9/5","July 11, 2014","August 2014","February 2015","July 11, 2014","July 2014","No Study Results Posted","null","December 2014","Participation rate|Response rate","https://ClinicalTrials.gov/show/NCT02188927"
1811,"NCT01356706","Minimally Invasive Liver Surgery for Metastases From Colorectal Cancer: Oncologic Outcome and Prognostic Factors","Completed","No Results Available","Long-term Oncologic Outcome of MILS in Patients With CRLM and Prognostic Indicators","","University Hospital, Gasthuisberg","Both","18 Years to 90 Years   (Adult, Senior)","","274","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CRLM-MILS","May 17, 2011","October 2002","July 2012","July 1, 2012","July 2012","No Study Results Posted","null","December 2008","overall survival|prognostic variables","https://ClinicalTrials.gov/show/NCT01356706"
1812,"NCT00578838","Magnetic Resonance Study of Liver in Chemotherapy","Completed","No Results Available","Colon Cancer|Rectal Cancer","Other: Magnetic Resonance|Other: Magnetic Resonance","Memorial Sloan Kettering Cancer Center","Both","21 Years and older   (Adult, Senior)","","55","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","06-082","December 19, 2007","August 2006","May 2016","May 6, 2016","May 2016","No Study Results Posted","null","May 2016","To determine whether magnetic resonance techniques can detect changes in normal liver morphology and metabolism caused by chemotherapy in patients with colorectal cancer.","https://ClinicalTrials.gov/show/NCT00578838"
1813,"NCT00776399","Radiofrequency Ablation in Resectable Colorectal Lung Metastasis","Active, not recruiting","No Results Available","Lung Metastasis|Colorectal Cancer","Device: Lung radiofrequency ablation","Mie University","Both","20 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-993 Mie-U-IRB","October 17, 2008","October 2008","August 2017","July 28, 2015","July 2015","No Study Results Posted","null","April 2017","Primary Outcome Measures:3-year survival|Secondary Outcome measures:safety, change in respiratory function, cancer-specific survival, and local tumor progression, Radiological studies","https://ClinicalTrials.gov/show/NCT00776399"
1814,"NCT00599924","Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors","Completed","Has Results","Colorectal Neoplasms|Neoplasms","Drug: sunitinib + FOLFOX|Drug: sunitinib + FOLFOX|Drug: sunitinib + FOLFOX|Drug: sunitinib + FOLFOX|Drug: sunitinib + FOLFOX|Drug: sunitinib + FOLFOX|Drug: sunitinib + FOLFOX","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","53","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181048","January 11, 2008","September 2005","November 2008","June 22, 2015","June 2015","November 4, 2009","null","November 2008","Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Objective Response (OR)|Maximum Plasma Concentration (Cmax) of Sunitinib|Time to Cmax (Tmax) of Sunitinib|Minimum Plasma Concentration (Cmin) of Sunitinib|Clearance (CL/F) of Sunitinib|Area Under Plasma Concentration-Time Profile From Time Zero to Twenty-Four Hours Postdose (AUC24) of Sunitinib|Terminal Phase Half-Life (t1/2) of Sunitinib|Cmax of SU-012662 (Sunitinib's Metabolite)|Tmax of SU-012662 (Sunitinib's Metabolite)|Cmin of SU-012662 (Sunitinib's Metabolite)|AUC24 for SU-012662 (Sunitinib's Metabolite)|CL/F of SU-012662 (Sunitinib's Metabolite)|T1/2 of SU-012662 (Sunitinib's Metabolite)|Cmax of Free Platinum|Tmax of Free Platinum|Area Under the Plasma Concentration-Time Profile From Time Zero to Infinity (AUCinf) for Free Platinum|T1/2 for Free Platinum|Cmax of Total Platinum|Tmax of Total Platinum|Area Under the Plasma Concentration-Time Profile From Time Zero to Forty-Eight Hours (AUC48) for Total Platinum|Steady State Concentration (Css) of Fluorouracil (5-FU)|Steady State Clearance (CLss) of 5-FU|Area Under the Curve (AUC) of 5-FU|Cmax of 5-FU|T1/2 of Free Platinum, Total Platinum, and 5-FU|CL/F of Free Platinum, Total Platinum, and 5-FU|Cmin of Free Platinum, Total Platinum, and 5-FU|Volume Endothelial Transfer Constant (Ktrans) of Tumors in a Selected Group of Subjects Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI)|Initial Area Dnder the Contrast Agent Concentration-Time Curve (IAUC) of Tumors in a Selected Group of Subjects Assessed by DCE-MRI","https://ClinicalTrials.gov/show/NCT00599924"
1815,"NCT01052922","Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement","Completed","No Results Available","Colorectal Cancer Screening","Other: 3 sample g-SENSA|Other: 2 sample InSure|Other: 1 sample OC-Micron","Group Health Cooperative|Fred Hutchinson Cancer Research Center|University of Washington","Both","50 Years to 74 Years   (Adult, Senior)","Phase 2","2260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","3R01CA121125-03S1","January 19, 2010","August 2009","December 2011","May 16, 2016","May 2016","No Study Results Posted","null","December 2011","Adherence to FOBT test kit","https://ClinicalTrials.gov/show/NCT01052922"
1816,"NCT00590434","Yield and Safety of Colonoscopy in Patients Older Than 80 Years","Completed","No Results Available","Colorectal Neoplasms","","Midwest Biomedical Research Foundation|VA Office of Research and Development","Both","18 Years and older   (Adult, Senior)","","169","Other|U.S. Fed","Observational","Observational Model: Case Control|Time Perspective: Retrospective","AB0002","December 26, 2007","August 2006","December 2009","October 25, 2012","October 2012","No Study Results Posted","null","December 2009","Proportion of elderly patients (>80 yrs) with colorectal neoplasia|proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group|Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs)","https://ClinicalTrials.gov/show/NCT00590434"
1817,"NCT02482441","A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10","Recruiting","No Results Available","Advanced Relapsed Tumors|Refractory Solid Tumors","Drug: OMP-131R10|Drug: FOLFIRI","OncoMed Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","131R10-001","June 19, 2015","June 2015","May 2017","August 24, 2016","August 2016","No Study Results Posted","null","September 2016","Incidence of dose limiting toxicities (DLTs)","https://ClinicalTrials.gov/show/NCT02482441"
1818,"NCT00934882","Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI","Completed","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (BAY73-4506)","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11656|2008-007151-27","July 3, 2009","August 2009","April 2012","May 30, 2014","May 2014","No Study Results Posted","null","April 2012","Adverse Event Collection|Effect of BAY73-4506 on the pharmacokinetics of mFOLFOX6 and FOLFIRI (Cmax, AUC, through concentration of BAY73-4506 and Cmax, AUC of Platinum, Irinotecan and its metabolite SN-38, 5-Flourouracil)|Biomarker status|Pharmacodynamic parameters|Tumor response","https://ClinicalTrials.gov/show/NCT00934882"
1819,"NCT01253837","L19TNFα in Patients With Advanced Solid Tumors","Completed","No Results Available","Solid Tumors|Colorectal Cancer","Drug: L19TNFa","Philogen S.p.A.|InnoPharma Inc.|Eudax S.r.l.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","34","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PH-L19TNFα-02/07|2007-001157-26","December 2, 2010","September 2007","September 2011","September 22, 2011","September 2011","No Study Results Posted","null","May 2011","Phase I: Determination of the Maximum Tolerated Dose (MTD) and Recommended Dose (RD)|Phase II: Investigation of the anti-cancer activity of L19TNFα as measured by Objective Response Rate (ORR)|Investigation of serum concentrations of L19TNFα (pharmacokinetic properties)|Investigation of the induction of human anti-fusion protein antibody (HAFA)|Investigation of early signs of anti-tumor activity of L19TNFα","https://ClinicalTrials.gov/show/NCT01253837"
1820,"NCT01271166","Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer","Terminated","No Results Available","Advanced Colorectal Cancer","Drug: Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CSTI571BAU14","January 4, 2011","October 2007","null","January 5, 2011","January 2011","No Study Results Posted","null","August 2009","Tumour response as assessed by CT scan and RESIST","https://ClinicalTrials.gov/show/NCT01271166"
1821,"NCT01112280","Efficacy of Cap-assisted Chromoendoscopy as a Screening Test for Colorectal Neoplasm Using Web-based Research Network","Recruiting","No Results Available","Colorectal Neoplasm","Device: cap-assisted chromoendoscopy","Korean Association for the Study of Intestinal Diseases|National Cancer Center, Korea|Ministry of Health & Welfare, Korea","Both","45 Years to 75 Years   (Adult, Senior)","","2000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","KASID polyp-01|MHWFA A092230","April 26, 2010","April 2010","December 2016","February 22, 2016","February 2016","No Study Results Posted","CapACE","December 2016","Detection rate of colorectal neoplasia|3-year recurrence rate of colorectal neoplasia|Risk of colorectal adenoma according to the presence of hyperplastic polyp in distal rectum and 3 year recurrence rate|Detection and 3-year recurrence rate of hyperplastic polyp and serrated adenoma in asymptomatic people.|The association of gallbladder disease of stone or tumor and colorectal polyp|Detection rate of colorectal polyp according to Quality indices of colonoscopy","https://ClinicalTrials.gov/show/NCT01112280"
1822,"NCT01830621","BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma","Completed","No Results Available","Colorectal Carcinoma","Drug: BBI608|Drug: Placebo|Other: Best Supportive Care","NCIC Clinical Trials Group|Boston Biomedical, Inc|Canadian Cancer Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 3","282","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CO23","April 10, 2013","April 2013","May 2016","May 12, 2016","May 2016","No Study Results Posted","null","August 2015","Overall Survival|Progression Free Survival|Disease Control Rate|Number of Patients with Adverse Events|Quality of Life","https://ClinicalTrials.gov/show/NCT01830621"
1823,"NCT00386828","Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial","Completed","No Results Available","Advanced Colorectal Cancer","Drug: Bevacizumab:","British Columbia Cancer Agency","Both","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PROTOCOL NUMBER: OZM-004|A-CORRECT Study","October 11, 2006","October 2006","May 2009","November 24, 2010","November 2010","No Study Results Posted","null","May 2009","The primary endpoint is pathologic complete response (pCR) rate|Rate of Sphincter Sparing Surgery:|Complete Resection Rate|Post-Surgical Complication Rates:","https://ClinicalTrials.gov/show/NCT00386828"
1824,"NCT02870036","Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan and Simmitecan, 5-fluorouracil and Leucovorin Calcium, in Patients With Advanced Solid Tumors","Not yet recruiting","No Results Available","Advanced Solid Tumor|Advanced/Metastatic Colorectal Cancer","Drug: Simmitecan|Drug: 5-fluorouracil and Leucovorin Calcium","ShangHai HaiHe Pharmaceutical","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","158","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GV-LP-102","August 3, 2016","September 2016","October 2018","August 12, 2016","August 2016","No Study Results Posted","null","October 2018","Cmax (maximum plasma concentration)|Tmax (time to maximum plasma concentration)|AUC (area under the plasma concentration-time curve)|T½|CL (systemic clearance)|Vz (apparent volume of distribution)|Adverse events (AE)|Objective response rate (ORR)|progression free survival (PFS)|CBR (clinical benefit rate)|DCR (disease control rate)|OS (overall survival)|accumulative excretion rate","https://ClinicalTrials.gov/show/NCT02870036"
1825,"NCT01276405","An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)","Terminated","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","123","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25174","January 12, 2011","March 2010","October 2015","September 1, 2016","September 2016","No Study Results Posted","null","October 2015","Disease-free survival|Safety (Incidence of adverse events)","https://ClinicalTrials.gov/show/NCT01276405"
1826,"NCT01828918","Biomarkers for the Early Diagnosis, Prediction, Prognosis for Colorectal Cancers","Recruiting","No Results Available","Colorectal Cancers","Genetic: microRNAs","Kaohsiung Medical University Chung-Ho Memorial Hospital|Academia Sinica, Taiwan","Both","20 Years to 90 Years   (Adult, Senior)","Phase 1","300","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","KMUH-IRB-2012-03-02 (II)","January 27, 2013","June 2012","December 2016","April 10, 2013","June 2012","No Study Results Posted","null","December 2016","postoperative early recurrence","https://ClinicalTrials.gov/show/NCT01828918"
1827,"NCT02196688","Study of Fruquintinib in Patients With Metastatic Colorectal Cancer（CRC）","Completed","No Results Available","Colorectal Cancer","Drug: fruquintinib|Drug: placebo","Hutchison Medipharma Limited|Fudan University|Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","71","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012-013-00CH1","July 14, 2014","April 2014","November 2015","February 18, 2016","February 2016","No Study Results Posted","null","April 2015","Progression free survival|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Over Survival (OS)|Safety and tolerance","https://ClinicalTrials.gov/show/NCT02196688"
1828,"NCT00785122","IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)","Completed","No Results Available","Colorectal Carcinoma","Drug: Endoxana, Leukine, IMA910|Drug: Endoxana, Leukine, IMA910, Aldara","immatics Biotechnologies GmbH","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","92","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT Nr. 2007-005666-12","November 4, 2008","June 2008","May 2013","May 15, 2013","May 2013","No Study Results Posted","IMA910-101","January 2011","Disease control rate|Safety assessment|Tumour response rates and SD rate|DCR|Duration of response|Progression free survival|Cellular immunomonitoring|Biomarkers|Analysis of tumor tissue|Overall Safety|Effect of imiquimod (2nd Cohort) on immune response|Overall survival|Non-Cellular immunomonitoring","https://ClinicalTrials.gov/show/NCT00785122"
1829,"NCT00923481","A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...","Completed","Has Results","Head and Neck Neoplasms|Pheochromocytoma|Colorectal Neoplasms|Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell","Drug: Fostamatinib disodium","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","Phase 2","37","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","090138|09-C-0138","June 17, 2009","April 2009","January 2012","September 29, 2015","July 2012","July 25, 2012","null","April 2009","Response Rate|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00923481"
1830,"NCT01370928","Colonoscopy Screening Using a Novel Slim Colonoscope - a Randomized Controlled Trial","Completed","No Results Available","Colorectal Cancer|Adenomas","Device: Olympus PCF-Y0014-L|Device: Standard colonoscope","Sorlandet Hospital HF","Both","54 Years to 64 Years   (Adult)","Phase 3","190","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","PCF-Y0014-L","March 21, 2011","March 2011","August 2011","April 26, 2012","April 2012","No Study Results Posted","null","June 2011","Patients´ evaluation of pain and discomfort|Time used to reach the caecum|Need for sedation/analgesics during the colonoscopy procedure|Need to change to a different colonoscope to complete the procedure|Caecum intubation rate","https://ClinicalTrials.gov/show/NCT01370928"
1831,"NCT02179489","Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis","Recruiting","No Results Available","Malignant Neoplasm of Large Intestine TNM Staging Primary Tumor (T) T4|Metastases to Ovary|Peritoneal Carcinomatosis","Procedure: Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC","Zhejiang University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","CRCCZ-C01","June 21, 2014","October 2014","October 2023","June 25, 2016","June 2016","No Study Results Posted","null","October 2017","Disease-free survival|3 year overall survival|Peritoneal disease-free survival|5 year overall survival|Toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT02179489"
1832,"NCT02587247","ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: TF2 antibody/68Ga-IMP-288","Nantes University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","RC14_0428","October 19, 2015","March 2016","April 2018","July 6, 2016","July 2015","No Study Results Posted","iTEP Colon","April 2018","Evaluate the sensitivity of the immuno-PET PET / CT pretargeted with the bispecific anti-CEA x anti-HSG TF2 antibody and IMP-288 peptide labeled with Gallium-68|To compare the diagnostic performance of immuno-PET with morphological and functional imaging procedures currently performed in the imaging assessment (CT, ultrasound + liver MRI, FDG-PET).|To Determine the value of immuno-PET in terms of specificity and predictive value. This determination will be made at the ""patient"" and at the ""injury level.|To assess the safety of the procedure|Search for the development of a blood Immunization against the products|To study the expression of CEA intensity on surgical excision parts in surgical patients and compare it to the semi-quantitative immuno-PET|To evaluate the clinical impact (new lecture of imaging, new examens)","https://ClinicalTrials.gov/show/NCT02587247"
1833,"NCT00001568","Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities","Completed","No Results Available","Colorectal Neoplasm","Drug: 2-Fluoro-2-deoxyglucose","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","Child, Adult, Senior","Phase 2","200","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","970068|97-C-0068","November 3, 1999","February 1997","October 2002","March 3, 2008","October 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001568"
1834,"NCT00788281","A Multi-Center Randomised Controlled Study to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: laparoscopic surgery|Procedure: open surgery","Beijing Friendship Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BJLS01","November 7, 2008","April 2008","April 2016","November 12, 2008","November 2008","No Study Results Posted","null","April 2011","disease free survival rate|tumor residual rate of LRM and CRM|operation mortality|survival rate|local recurrence rate|operation time|blood lost|analgesic dosage|evacuating time|operation morbidity|transfer to open surgery|fee","https://ClinicalTrials.gov/show/NCT00788281"
1835,"NCT01416688","S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride","Recruiting","No Results Available","Colorectal Cancer|Dermatologic Complications|Lung Cancer|Therapy-related Toxicity","Procedure: assessment of therapy complications|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","Southwest Oncology Group|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","","140","Other|NIH","Observational","Time Perspective: Prospective","S1013|U10CA037429|NCI-2011-02983","August 12, 2011","November 2011","October 2017","July 8, 2016","July 2016","No Study Results Posted","null","October 2017","Psychometric properties of the FACT-EGFRI 18|Change in severity and impact of skin symptoms|Agreement between site physician ratings with the CTCAE Version 4 and patient ratings for the FACT-EGFRI 18 items|Associations between toxicity profile and treatment profiles|Feasibility as measured by accrual, time to specified accrual, time to complete forms","https://ClinicalTrials.gov/show/NCT01416688"
1836,"NCT00460837","Comparison of Bowel Preparation in Virtual Colonoscopy (VC) - Patient Experience","Withdrawn","No Results Available","Colorectal Cancer","Drug: bowel preparation: senna & gastrofin versus picolax (standard)","London North West Healthcare NHS Trust","Both","18 Years and older   (Adult, Senior)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","07.senna.SMH","March 23, 2007","November 2007","March 2009","July 23, 2010","July 2010","No Study Results Posted","null","null","Versus standard bowel preparation|Patient experience and compliance with reduced laxative tagging versus standard preparation|Comparison of per polyp specificity between the two preparation regimens","https://ClinicalTrials.gov/show/NCT00460837"
1837,"NCT01111838","Clinical and Translational Study of STA-9090","Completed","Has Results","Colon Cancer|Rectal Cancer","Drug: STA-9090","Memorial Sloan Kettering Cancer Center|Synta Pharmaceuticals Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-029","April 26, 2010","April 2010","July 2012","October 19, 2015","October 2015","October 19, 2015","null","July 2012","To Determine Overall Objective Response.","https://ClinicalTrials.gov/show/NCT01111838"
1838,"NCT02254941","Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colon Cancer","Drug: Chemotherapy|Biological: Chemotherapy plus monoclonal antibody","Grupo Espanol Multidisciplinario del Cancer Digestivo","Both","18 Years and older   (Adult, Senior)","","1950","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GEMCAD 1401","September 23, 2014","August 2014","null","August 10, 2016","August 2016","No Study Results Posted","null","September 2017","Overall survival|Validate prognostic score GEMCAD|To compare GERCOR and Köhne classification with GEMCAD classification|Evaluate Sadananda cellular phenotype classification|Study other variables to identify whether there is group of patients who may benefit from monoclonal antibodies for the treatment of first-line chemotherapy","https://ClinicalTrials.gov/show/NCT02254941"
1839,"NCT00828672","Phase II Study of Neo Adjuvant Treatment With Avastin, Xeloda and/or Eloxatin in Colorectal Cancer","Active, not recruiting","No Results Available","Advanced Colorectal Cancer","Drug: Oxaliplatin|Drug: Bevacizumab|Drug: Capecitabine|Radiation: radiotherapy","Universitaire Ziekenhuizen Leuven","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","s51104 - ML5194|2007 - 007177 - 23|MO19051","January 23, 2009","June 2009","July 2016","November 5, 2015","November 2015","No Study Results Posted","AXE BEAM","March 2014","Pathologic complete response (ypT0N0) rate|Histopathologic R0 and negative CRM resection rate|Pathologic downstaging (yp T0-2 N0) rate|Tumor regression grade|Clinical response rate|Toxicity|Loco-regional and distant recurrence rates|Progression-free and overall survival","https://ClinicalTrials.gov/show/NCT00828672"
1840,"NCT02077777","Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an ""in Vivo"" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.","Recruiting","No Results Available","Colorectal Cancer","Drug: Mesalazine","SOFAR S.p.A.","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","MES-CT 01","February 28, 2014","October 2012","June 2016","February 3, 2016","February 2016","No Study Results Posted","null","June 2016","Molecular analysis of gene expression levels of μ-protocadherin and other related proteins|Evaluation of protein expression level of μ-protocadherin, Ki-67, Caspase-3 and Histone H2AXγ, evaluation of DNA oxidative damage and intra-mucosal concentration of 5-Acetylsalicylic acid","https://ClinicalTrials.gov/show/NCT02077777"
1841,"NCT00075556","Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000346895|FRE-GERCOR-R01-01|EU-20329","January 9, 2004","January 2002","null","February 6, 2009","May 2008","No Study Results Posted","null","null","Objective tumor response rate|Tolerability|Rate of preservation of functional integrity of the anal sphincter|Comparison of the conversion rate from the effects of mutilating surgery vs surgery with sphincter preservation","https://ClinicalTrials.gov/show/NCT00075556"
1842,"NCT00336856","Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy","Completed","Has Results","Colon Cancer|Rectum Cancer","Drug: Cetuximab|Drug: Irinotecan","University of Pittsburgh|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 2","35","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-006","June 12, 2006","June 2006","June 2011","June 1, 2016","June 2016","January 12, 2016","null","June 2011","Response Rate (RR)|Time to Progression|Overall Survival","https://ClinicalTrials.gov/show/NCT00336856"
1843,"NCT01853774","Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Tailored navigation","Arizona State University|Ohio State University|Mayo Clinic","Both","50 Years to 75 Years   (Adult, Senior)","","1840","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","5R01CA162393-02","May 13, 2013","April 2012","March 2016","May 15, 2013","May 2013","No Study Results Posted","null","November 2015","Primary outcome is clinic attendance|The secondary outcome is participant completion of a CRC screening test.","https://ClinicalTrials.gov/show/NCT01853774"
1844,"NCT00003833","Genetic Study in Patients With Stage II or Stage III Colon Cancer","Completed","No Results Available","Colorectal Cancer","Genetic: DNA stability analysis|Genetic: gene mapping","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|NCIC Clinical Trials Group","Both","up to 69 Years   (Child, Adult, Senior)","","598","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NCCTG-984654|CDR0000066990|CAN-NCIC-CO9PATH","November 1, 1999","February 1999","August 2006","July 12, 2016","July 2016","No Study Results Posted","null","August 2006","overall survival","https://ClinicalTrials.gov/show/NCT00003833"
1845,"NCT02842294","Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer|Quality of Life","Drug: Bevacizumab","Centre Hospitalier Universitaire de Besancon","Both","18 Years and older   (Adult, Senior)","","320","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P/2012/151","July 20, 2016","May 2013","February 2018","July 21, 2016","July 2016","No Study Results Posted","COBEQOL","February 2017","time to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning)|time to health related quality of life score deterioration (non targeted dimensions of EORTC QLQC30 and CR 29)|INT PATSAT32|quality-adjusted life years (QALYs) using EQ5D|Overall survival|Progression Free Survival|treatment preference","https://ClinicalTrials.gov/show/NCT02842294"
1846,"NCT00165854","Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer (CRC)","Drug: E7070","Eisai Limited|Eisai Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","46","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E7070-E044-209|2004-002597-33","September 13, 2005","March 2003","null","June 26, 2014","October 2006","No Study Results Posted","null","null","To determine the recommended dose of E7070 in combination with capecitabine by dose adjustment;|to determine the safety, tolerability and efficacy (in terms of response rate and progression-free survival) of the combination in patients with metastatic CRC.|Determine the pharmacokinetic profile of capecitabine and E7070 when administered in combination;|measure duration of response and stable disease; to measure median and one year survival.","https://ClinicalTrials.gov/show/NCT00165854"
1847,"NCT01890213","Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer","Recruiting","No Results Available","Stage III Colon Cancer","Biological: AVX701","Duke University|AlphaVax, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","12","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00045976|IND13372","June 26, 2013","November 2013","November 2018","August 5, 2016","August 2016","No Study Results Posted","null","June 2017","Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01890213"
1848,"NCT01464593","Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)","Terminated","No Results Available","Colon Cancer Liver Metastasis","Drug: Lyso-Thermosensitive Liposomal Doxorubicin|Other: 5% Dextrose Solution|Drug: ThermoDox","Celsion","Both","18 Years and older   (Adult, Senior)","Phase 2","3","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","104-10-201","November 1, 2011","September 2011","June 2013","March 4, 2016","March 2016","No Study Results Posted","ABLATE","May 2013","Determine the local tumor control at 1 year post randomization|Evaluation of Safety|Time to Local Recurrence|Overall Survival","https://ClinicalTrials.gov/show/NCT01464593"
1849,"NCT01526200","Contrast-Enhanced Intraoperative Ultrasound During Liver Surgery for Colorectal Cancer Liver Metastases","Completed","No Results Available","Colon Cancer Liver Metastasis","Procedure: Contrast-enhanced intraoperative ultrasound","University of Milan","Both","29 Years to 85 Years   (Adult, Senior)","","127","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CEIOUSCLM","January 27, 2012","October 2007","December 2011","February 2, 2012","January 2012","No Study Results Posted","CEIOUSCLM","March 2011","new colorectal liver metastases detected at contrast-enhanced intraoperative ultrasonography|new colorectal liver metastases detected at intraoperative ultrasonography|new colorectal liver metastases detected during 6-month postoperative follow-up","https://ClinicalTrials.gov/show/NCT01526200"
1850,"NCT00165867","An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin","Completed","No Results Available","Colorectal Cancer","Drug: E7070","Eisai Limited|Eisai Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E7070-E044-214","September 13, 2005","April 2005","null","October 6, 2006","October 2006","No Study Results Posted","null","null","The objective response rate as defined by RECIST criteria.|Duration of response|time to progression|overall survival|safety and tolerability of the combination","https://ClinicalTrials.gov/show/NCT00165867"
1851,"NCT02475889","Hepatic RFA Increases T Cell Infiltraion and PD-L1 Expression in Primary Colorecatl Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: Hepatic RFA|Procedure: Primary tumor resection","The First People's Hospital of Changzhou","Both","32 Years to 78 Years   (Adult, Senior)","","78","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","RFAOO2","June 6, 2015","November 2007","January 2015","June 16, 2015","June 2015","No Study Results Posted","null","January 2015","Number of T cell infiltraion in primary tumor|PD-L1 expression in primary tumor","https://ClinicalTrials.gov/show/NCT02475889"
1852,"NCT01383252","Unsedated Colonoscopy for Colorectal Cancer Screening and Surveillance","Completed","No Results Available","Colon Polyp","Procedure: Water infusion in lieu of air insufflation|Procedure: Air method","VA Northern California Health Care System","Both","50 Years to 75 Years   (Adult, Senior)","","10","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","VANCHCS-GI-005","June 21, 2011","February 2010","June 2013","June 13, 2013","June 2013","No Study Results Posted","null","June 2013","Success of colonoscopy|Polyp detection","https://ClinicalTrials.gov/show/NCT01383252"
1853,"NCT01131078","A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum","Completed","Has Results","Colorectal Cancer","Drug: Bevacizumab [Avastin]|Drug: Capecitabine|Drug: Irinotecan","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","306","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18524","April 20, 2010","June 2005","November 2012","June 2, 2015","June 2015","December 19, 2014","null","November 2012","Percentage of Participants With Disease Progression or Death|Time to Progression (TTP)|Percentage of Participants Who Died|Overall Survival|Percentage of Participants With Treatment Failure|Time to Treatment Failure|Percentage of Participants With Progression Excluding Deaths|Time to Progression Excluding Deaths|Percentage of Participants With Progression Excluding Deaths Not Related to Underlying Cancer|Time to Progression Excluding Deaths Not Related to Underlying Cancer|Percentage of Participants by Best Overall Response|Percentage of Participants With a Best Overall Response of CR or PR|Percentage of Participants With Stable Disease|Percentage of Participants With Progressive Disease Within 12 Weeks From Start of Treatment|Duration of Overall Response|Duration of Stable Disease (SD)|Duration of Overall Complete Response","https://ClinicalTrials.gov/show/NCT01131078"
1854,"NCT02138617","Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer","Recruiting","No Results Available","Colon Cancer","Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Irinotecan|Drug: Bevacizumab","UNC Lineberger Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 1317","May 1, 2014","May 2014","May 2022","July 1, 2016","July 2016","No Study Results Posted","null","May 2021","Progression Free Survival|Toxicity|Overall Response|Overall Survival","https://ClinicalTrials.gov/show/NCT02138617"
1855,"NCT02891538","Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients","Not yet recruiting","No Results Available","Colon Cancer","Dietary Supplement: Epigallocatechin gallate (EGCG)","The University of Texas Health Science Center at San Antonio","Both","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CTMS 16-0085","August 31, 2016","November 2016","November 2019","September 8, 2016","September 2016","No Study Results Posted","null","November 2019","Change in methylation from baseline when compared to the control arm","https://ClinicalTrials.gov/show/NCT02891538"
1856,"NCT02280278","Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy","Recruiting","No Results Available","Stage III Colon Cancer","Procedure: Radical surgery|Drug: Adjuvant chemotherapy|Biological: Cytokine-induced killer cell immunotherapy","Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 3","550","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","5010010","October 29, 2014","October 2014","null","November 3, 2014","November 2014","No Study Results Posted","null","October 2019","Disease free survival|survival rate|toxin-side effect","https://ClinicalTrials.gov/show/NCT02280278"
1857,"NCT01675505","Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery","Recruiting","No Results Available","Adaptation, Psychological|Functional Insufficiency","","Aristotle University Of Thessaloniki","Both","18 Years to 60 Years   (Adult)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Phd Antoniadis","August 28, 2012","May 2012","null","July 9, 2013","July 2013","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01675505"
1858,"NCT01744509","PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening Program","Recruiting","No Results Available","Colon Cancer","Device: Capsule colonoscopy;","Valduce Hospital","Both","50 Years to 85 Years   (Adult, Senior)","","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Diagnostic","25-2011","December 3, 2012","March 2011","April 2013","December 5, 2012","December 2012","No Study Results Posted","null","April 2013","Sensitivity of PillCam Colon Capsule 2 (R) in identifying significant colonic polyps|to evaluate the tolerability of PCC2 as compared to optical colonoscopy (OC) and CT-colonography (CTC).","https://ClinicalTrials.gov/show/NCT01744509"
1859,"NCT00101894","Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer","Completed","No Results Available","Rectal Cancer|Colon Cancer","Drug: FOLFOX-4|Drug: AMG 706|Biological: Panitumumab (Part 1a only)|Drug: FOLFIRI","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 1","119","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20040205","January 18, 2005","December 2004","December 2011","September 13, 2012","September 2012","No Study Results Posted","null","April 2010","Part 1a - The incidence of adverse events and clinical laboratory abnormalities defined as dose-limiting toxicities|Part 1b - The incidence of adverse events and clinical laboratory abnormalities defined as dose-limiting toxicities|Part 2 - The overall objective tumor response rate (complete and partial response) in subjects treated with AMG 706 (at the dose determined in Part 1b), with either the FOLFIRI or FOLFOX-4 chemotherapy regimen|Part 1a - The PK of irinotecan (and its active metabolite SN38) when administered as a part of the FOLFIRI regimen with panitumumab and AMG 706|Part 1a - The PK of oxaliplatin when administered as a part of the FOLFOX-4 regimen with panitumumab and AMG 706|Part 1a - The objective tumor response rate (complete and partial response) throughout the study|Part 1b - The incidence of adverse events and clinical laboratory abnormalities not defined as dose-limiting toxicities|Part 1b - The PK of AMG 706 when administered with either the FOLFIRI or FOLFOX-4 chemotherapy regimen|Part 1b - The PK of 5-FU when administered as a part of the FOLFIRI or FOLFOX-4 regimen with AMG 706|Part 2 - Duration of response: (Calculated for only those subjects who respond)|Part 2 - Time-to-progression|Part 1b - The PK of irinotecan (and its active metabolite SN38) when administered as a part of the FOLFIRI regimen with AMG 706|Part 1b- The PK of oxaliplatin when administered as a part of the FOLFOX-4 regimen with AMG 706|Part 1b - The objective tumor response rate (complete and partial response) throughout the study|Part 2 - Overall survival|Part 2 - The incidence of adverse events and clinical laboratory abnormalities|Part 2 - The PK of AMG 706 when administered with either the FOLFIRI or FOLFOX-4 chemotherapy regimen (at a subset of the study centers with the capabilities to draw, ship and process PK samples)|Exploratory - Potential biomarker development based on assessment of blood cells, tumor cells, and urine and the proposed mechanism of action of study drugs, and response|Exploratory - The effects of genetic variation in drug metabolism genes, cancer genes, and drug target genes on subject response to investigational products (separate informed consent)|Part 2 - Progression-free survival time|Part 2 - Incidence of subjects undergoing resection of metastases for curative intent|Part 1a - The incidence of adverse events and clinical laboratory abnormalities not defined as dose-limiting toxicities|Part 1a - The PK of AMG 706 when administered with panitumumab and either the FOLFIRI or FOLFOX-4 chemotherapy regimen|Part 1a - The serum concentration of panitumumab when administered with AMG 706 and either the FOLFIRI or FOLFOX-4 chemotherapy regimen|Part 1a - The incidence of HAPA response following panitumumab administration|Part 1a - The PK of 5-FU when administered as a part of the FOLFIRI or FOLFOX-4 regimen with panitumumab and AMG 706","https://ClinicalTrials.gov/show/NCT00101894"
1860,"NCT02586701","Supervised Versus Non-supervised Exercise on Adherence and Functional Outcomes in Colorectal Patients","Recruiting","No Results Available","Colorectal Cancer","Other: Prehabilitation Plus","Franco Carli|McGill University Health Center","Both","45 Years to 90 Years   (Adult, Senior)","Phase 3","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","MM123","October 22, 2015","September 2013","December 2016","March 17, 2016","March 2016","No Study Results Posted","null","December 2016","Six Minute Walk Test (6MWT)","https://ClinicalTrials.gov/show/NCT02586701"
1861,"NCT00006269","Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer","Terminated","No Results Available","Colorectal Cancer|Diarrhea","Drug: irinotecan hydrochloride|Drug: octreotide acetate","Novartis","Both","18 Years and older   (Adult, Senior)","Phase 3","89","Industry","Interventional","Primary Purpose: Supportive Care","CDR0000068215|NOVARTIS-CSMS995US05","September 11, 2000","December 1999","null","May 24, 2012","May 2012","No Study Results Posted","null","December 1999","","https://ClinicalTrials.gov/show/NCT00006269"
1862,"NCT00006112","Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer","Active, not recruiting","No Results Available","Carcinoma of the Appendix|Colorectal Cancer|Primary Peritoneal Cavity Cancer","Drug: chemotherapy|Drug: fluorouracil|Drug: leucovorin calcium|Drug: mitomycin C","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068124|FRE-IGR-95/040/434-SUGAR|EU-20012","August 3, 2000","January 1996","null","April 23, 2011","May 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006112"
1863,"NCT01641458","Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients","Completed","No Results Available","Colorectal Cancer","Other: 5FU and capecitabine (Xeloda®) dosing based on DPYD genotype|Other: Therapeutic drug monitoring of 5FU","Cantonal Hospital of St. Gallen|University of Bern","Both","18 Years and older   (Adult, Senior)","Phase 4","37","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SG 343/12","July 11, 2012","October 2012","November 2015","January 31, 2016","January 2016","No Study Results Posted","FLOXTOX2","November 2015","Predefined fluoropyrimidine-related (index) toxicity|Area-under-the plasma-concentration time curve of 5-fluorouracil|Endogenous dihydrouracil/uracil ratio in plasma|Objective treatment response (best response) according to RECIST v.1.1|Progression-free survival","https://ClinicalTrials.gov/show/NCT01641458"
1864,"NCT02618356","Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer","Not yet recruiting","No Results Available","Metastatic Colon Cancer","Drug: Raltitrexed and S-1","Fudan University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","82","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","guoweijian-2015-RS","November 17, 2015","December 2015","November 2017","December 2, 2015","November 2015","No Study Results Posted","null","November 2017","Median disease progression free survival (mPFS) of Raltitrexed combined with S-1","https://ClinicalTrials.gov/show/NCT02618356"
1865,"NCT01116271","Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec","Completed","No Results Available","Colorectal Cancer","Drug: AZD6244|Drug: Irinotecan","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","32","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D9010C00009|AGICC 09CRC02","April 30, 2010","April 2010","July 2012","January 11, 2013","January 2013","No Study Results Posted","null","July 2012","Dose Finding will be calculated based upon toxicity screening and dose modification guidelines within protocol.|Objective Response Rate will be assessed by the RECIST guideline documented in the European Journal of Cancer, 2009.|Safety of combination of Selumetinib (AZD6244) with irinotecan by SAE and AE documentation|PK of Selumetinib (AZD6244), N-desmethyl Selumetinib(AZD6244) and selumetinib (AZD6244) amide in combination with irinotecan|Progression Free Survival (PFS) for patients with K-ras or B-raf mutations treated with combination of irinotecan and Selumetinib (AZD6244)","https://ClinicalTrials.gov/show/NCT01116271"
1866,"NCT01843725","Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers","Active, not recruiting","No Results Available","Metastatic Colorectal Cancers|Metastatic Gastric Cancers|Metastatic Oesophageal Cancers|Metastatic Pancreatic Cancers|Metastatic Biliary Cancers|Metastatic Breast Cancers","Drug: capecitabine|Drug: aflibercept|Drug: Capecitabine","Jules Bordet Institute","Both","18 Years and older   (Adult, Senior)","Phase 1","42","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Mom1-AD12|2012-005169-11","April 25, 2013","September 2013","December 2016","June 20, 2016","September 2015","No Study Results Posted","MOMENTUM1","October 2016","To determine the maximum tolerated dose and the recommended phase II dose of capecitabine in association with aflibercept|The secondary endpoint is preliminary data on efficacy, and this will be evaluated using CT scan or MRI using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1","https://ClinicalTrials.gov/show/NCT01843725"
1867,"NCT02319356","Does Dietary Nitrate Supplementation Improve Aerobic Performance","Not yet recruiting","No Results Available","Colorectal Cancer","Dietary Supplement: Beetroot juice|Dietary Supplement: Placebo beetroot juice","Royal Surrey County Hospital NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 0","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","163841","December 15, 2014","March 2015","June 2015","December 17, 2014","December 2014","No Study Results Posted","null","June 2015","anaerobic threshold (AT)|maximal oxygen uptake (VO2Max)","https://ClinicalTrials.gov/show/NCT02319356"
1868,"NCT00860691","Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer","Recruiting","No Results Available","Colonic Neoplasms","Procedure: Therapeutic conventional colorectal surgery|Procedure: Therapeutic laparoscopic colorectal surgery|Other: Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest","University Hospital Dubrava|Ministry of Science, Education and Sport, Republic of Croatia","Both","20 Years to 80 Years   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","198-0000000-3104","March 10, 2009","January 2008","June 2010","March 24, 2010","March 2010","No Study Results Posted","null","July 2009","Neutrophil activity before and after the open or laparoscopic surgery - Serum concentrations of sFas, sFasL and IL - 17.|Respiratory burst neutrophil production - Bursttest before and after open or laparoscopic surgery|Immunohistochemical detection of FasL in tumor and paratumor areas of colon cancer and normal colon mucosa taken at a distance of 10 cm from the tumor|Immunohistochemical detection of Fas in tumor and paratumor areas of colon cancer and normal colon mucosa taken at a distance of 10 cm from the tumor|Immunohistochemical detection of neutrophil elastase in tumor and paratumor areas of colon cancer and normal colon mucosa taken at a distance of 10 cm from the tumor|Number of leukocytes, neutrophils, lymphocytes and neutrophils/lymphocytes ratio|CRP|Fe, transferrin, ferritin|to determine neutrophil activity in patients with colon cancer and healthy volunteers|to compare the influence of laparoscopic and conventional procedures on postoperative neutrophil function|to determine functional activity of tumour infiltrating neutrophils|to determine an effect of surgery on neutrophil activity|to determine levels sFas, sFasL and IL - 17 in serum of healthy volunteers and colon cancer patients and establish its prognostic value|to eludicate the relationship between serum sFas, sFasL and IL - 17 levels and clinicopathologic features of colon cancer|to compare the influence of laparoscopic and conventional procedures on postoperative serum sFas, sFasL and IL - 17 levels in colon cancer patients|to confirm the expression of FasL protein in human colorectal cancer and elucidate the relationship between FasL expression and clinicopathologic features of the disease|to establish the prevalence of Fas in primary colon adenocarcinomas and elucidate the relationship between Fas expression and clinicopathologic features of the disease|loss of blood during the surgery, postoperative hospital stay, morbidity, and mortality within 30 days after surgery","https://ClinicalTrials.gov/show/NCT00860691"
1869,"NCT00284817","Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer","Completed","No Results Available","Cancer","Drug: MEDI-522|Drug: MEDI-522|Drug: MEDI-522|Drug: MEDI-522|Drug: MEDI-522","MedImmune LLC","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","17","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MI-CP068","January 31, 2006","July 2001","May 2005","May 27, 2008","May 2008","No Study Results Posted","null","January 2005","The recommended Phase II dose will be based on acceptable dose-limiting toxicity|Pharmacokinetic parameters may also be factored into the determination of a Phase II dose and; Tumor response","https://ClinicalTrials.gov/show/NCT00284817"
1870,"NCT01023633","OPTIMOX1 in Chinese mCRC Patients","Recruiting","No Results Available","Colorectal Cancer","Drug: Oxaliplatin, LV, 5-FU","Nanjing Medical University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Oxali04882","December 1, 2009","October 2009","July 2015","December 1, 2009","December 2009","No Study Results Posted","null","January 2014","DDC: Duration of Disease Control|OS, RR, PFS, DCR, safety,","https://ClinicalTrials.gov/show/NCT01023633"
1871,"NCT02129946","The Effect of Resistant Starch Bagels on Risk Factors of Type 2 Diabetes and Colorectal Cancer","Completed","No Results Available","Type 2 Diabetes Mellitus","Other: Resistant Starch","University of Guelph|Ontario Ministry of Agriculture, Food and Rural Affairs|Maple Leaf Foods, Canada Bread","Both","40 Years and older   (Adult, Senior)","","25","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","13MY041","April 29, 2014","January 2014","October 2014","May 26, 2015","May 2015","No Study Results Posted","null","October 2014","Fasting and postprandial blood glucose|Fasting and postprandial insulin|HbA1c|Calculated insulin sensitivity and beta-cell function|Satiety-producing effect","https://ClinicalTrials.gov/show/NCT02129946"
1872,"NCT00177307","Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer","Completed","Has Results","Cancer","Drug: Bevacizumab|Drug: Capecitabine|Drug: Oxaliplatin","University of Pittsburgh|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-118","September 12, 2005","January 2005","February 2012","June 1, 2016","June 2016","January 12, 2016","null","February 2012","Progression Free Survival (PFS)|Response Rate (RR)|Overall Survival|1-, 2-, and 3-year Overall Survival","https://ClinicalTrials.gov/show/NCT00177307"
1873,"NCT02455128","Therapeutic Listening in Patients With Colorectal Cancer","Enrolling by invitation","No Results Available","Anxiety|Fear","Other: Therapeutic listening","University of Sao Paulo","Both","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ACM 2015","May 16, 2015","August 2014","December 2015","December 6, 2015","December 2015","No Study Results Posted","null","September 2015","State-Trait Anxiety Inventory (STAI)|Blood pressure|Heart rate|Respiratory rate|Salivary cortisol|Salivary amylase|Surgical Fear Questionnaire (SFQ)","https://ClinicalTrials.gov/show/NCT02455128"
1874,"NCT00566644","Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome","Terminated","No Results Available","Endometrial Cancer|Hereditary Non-polyposis Colon Cancer (hmsh2, hmlh1, hpms1, hpms2)","Device: levonorgestrel-releasing intrauterine system|Other: questionnaire administration|Procedure: observation","St George's, University of London|National Cancer Institute (NCI)","Female","35 Years to 65 Years   (Adult)","Phase 3","600","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Prevention","CRUK-POET|CDR0000575423|EudraCT 2006-001815-30|EU-20784","November 30, 2007","July 2007","August 2009","July 9, 2013","October 2008","No Study Results Posted","null","October 2008","Rate of atypical endometrial hyperplasia or endometrial cancer during the active follow-up period of the study","https://ClinicalTrials.gov/show/NCT00566644"
1875,"NCT02574013","Randomized Controlled Trial for Retractor SPONGE Evaluation in Laparoscopic Colorectal Surgery","Recruiting","No Results Available","Colorectal Cancer|Surgery","Device: Endoractor®","St. Antonius Hospital","Both","18 Years and older   (Adult, Senior)","","188","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NL49877.100.14","September 27, 2015","November 2015","November 2017","February 23, 2016","February 2016","No Study Results Posted","SPONGE","October 2017","Length of hospital stay|Operation time (minutes)|Blood-loss (ml)|Fluid balance (L)|Postoperative body temperature|Postoperative oxygen therapy|Postoperative complications","https://ClinicalTrials.gov/show/NCT02574013"
1876,"NCT01834014","Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases","Active, not recruiting","No Results Available","Liver Metastasis|Colorectal Cancer","Drug: Bevacizumab|Drug: Cetuximab|Drug: L-OHP|Drug: l-LV|Drug: 5-FU|Drug: 5-FU","EPS Corporation","Both","20 Years to 80 Years   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ATOM Exploratory study|UMIN000010429","April 14, 2013","May 2013","null","March 27, 2016","March 2016","No Study Results Posted","ATOM ES","May 2017","To evaluate the values of angiogenesis-related growth factors in plasma with Progression-free survival (PFS)|To evaluate the correlation of values of angiogenesis-related growth factors in plasma with efficacy and adverse events|Progression-free survival among the RAS wild type subpopulation|Exploratory analysis of the relevance of tumor size and expression level of angiogenesis-related growth factors in plasma","https://ClinicalTrials.gov/show/NCT01834014"
1877,"NCT02419586","Effectiveness of Gum Chewing on Ileus in Chinese Colorectal Patients Underwent Laparoscopic Colorectal Surgery","Recruiting","No Results Available","Colorectal Cancer","Other: bubble gum","Hospital Authority, Hong Kong","Both","18 Years and older   (Adult, Senior)","","92","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","CRC03","March 4, 2015","January 2015","June 2016","April 14, 2015","April 2015","No Study Results Posted","null","December 2015","Time to first flatus|Time to first sense of hunger|Time to first bowel movement,|Length of stay","https://ClinicalTrials.gov/show/NCT02419586"
1878,"NCT02016326","I-Scan Vs High Definition White Light (Main Study)","Recruiting","No Results Available","Colorectal Cancer","Device: HD Colon|Device: I-scan 1|Device: I-Scan 2","University of Calgary","Both","18 Years to 74 Years   (Adult, Senior)","","1500","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","23474-M","November 13, 2013","November 2012","November 2014","December 13, 2013","December 2013","No Study Results Posted","null","November 2014","Adenoma Detection Rate (ADR) in the right colon using High Definition White Light Colonoscopy Versus I-Scan enhanced Colonoscopy.|Adenoma Detection Rate (ADR) in the right colon during the ""Second Look"" irrespective of imaging modality.|Adenoma Detection Rate (ADR) of High Definition White Light Colonoscopy Versus I-Scan colonoscopy through out the entire colon.","https://ClinicalTrials.gov/show/NCT02016326"
1879,"NCT02604784","Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors","Recruiting","No Results Available","Peritoneal Carcinomatosis","Drug: Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC)","Fondazione del Piemonte per l'Oncologia","Both","18 Years to 78 Years   (Adult, Senior)","Phase 2","63","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","015-IRCCS-27F-1","November 3, 2015","October 2015","October 2018","August 19, 2016","August 2016","No Study Results Posted","PI-CaP","October 2018","Overall Response Rate (ORR) according to RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC.|The overall survival (OS)|The degree of histological regression assessed by pathological review|The median time to progression (TTP) according to RECIST criteria (version 1.1) after two or three cycles of PIPAC|Measurement of clinical tumor response to therapy using FDG- Positron Emission Tomography (PET) according to PERCIST criteria (versione 1.0).|The Peritoneal Carcinomatosis Index (PCI) before and after therapy","https://ClinicalTrials.gov/show/NCT02604784"
1880,"NCT01826396","Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer","Recruiting","No Results Available","Colonic Neoplasms","Drug: Irinotecan","Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCIHeilongjiang-001","April 4, 2013","April 2013","December 2014","April 4, 2013","April 2013","No Study Results Posted","null","April 2014","R0 resection rate|disease free survival","https://ClinicalTrials.gov/show/NCT01826396"
1881,"NCT01617278","I-Scan Versus High-definition White Light","Completed","No Results Available","Colorectal Cancer","Device: I-Scan 1|Device: HD Colon|Device: I-Scan 2","University of Calgary","Both","18 Years to 74 Years   (Adult, Senior)","","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","23474-P","June 4, 2012","January 2012","July 2012","July 3, 2013","July 2013","No Study Results Posted","null","July 2012","Mean number of adenomas per colonoscopy|Number of adenomas detected in the right colon during the second look|To estimate the recruitment rate","https://ClinicalTrials.gov/show/NCT01617278"
1882,"NCT00380874","Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer","Terminated","Has Results","Chemotherapy-Induced Peripheral Neuropathy","Drug: Pregabalin|Drug: Placebo","Pfizer","Both","18 Years to 80 Years   (Adult, Senior)","Phase 4","64","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A0081124","September 25, 2006","January 2007","March 2008","October 1, 2009","October 2009","March 10, 2009","null","March 2008","Duration Adjusted Average Change (DAAC) of Paresthesia From the Onset of Chemotherapy Measured by Numeric Rating Scale (NRS)|Duration Adjusted Average Change (DAAC) of Paresthesic Symptom Score Within Each Cycle of Chemotherapy Measured by Numeric Rating Scale (NRS)|Duration Adjusted Average Change (DAAC) of Dysesthesia Symptom Score Within Each Cycle of Chemotherapy Measured by Numeric Rating Scale (NRS)|Duration Adjusted Average Change (DAAC) of Pain Symptom Score Within Each Cycle of Chemotherapy Measured by Numeric Rating Scale (NRS)|Change in Pain Scores Rated on Neuropathic Pain Symptom Inventory (NPSI) Subscales From Baseline Cycle|Number of Participants With Persistent Paresthesic, Dysesthesic, and Pain Symptoms","https://ClinicalTrials.gov/show/NCT00380874"
1883,"NCT00208260","Intensified Chemotherapy in CRC After Resection of Liver Metastases","Completed","No Results Available","Colorectal Cancer|Liver Metastases|Chemotherapy","Drug: FOLFIRI|Drug: FOLFOX-4|Drug: FOLFIRI-HD|Drug: FOLFOX-7|Drug: FOLFIRINOX","Institut du Cancer de Montpellier - Val d'Aurelle|Pfizer|Sanofi|Chugai Pharmaceutical","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","124","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","METHEP/2004/22","September 13, 2005","April 2004","August 2007","June 15, 2010","June 2010","No Study Results Posted","null","null","Response|Safety|Survival|Secondary resection","https://ClinicalTrials.gov/show/NCT00208260"
1884,"NCT00598156","Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: erlotinib (Tarceva)|Drug: bevacizumab (Avastin)","Lund University Hospital|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","249","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML19033|EUDRACT 2006-002295-18","January 9, 2008","June 2007","August 2012","April 19, 2013","April 2013","No Study Results Posted","ACT","October 2009","progression-free survival|overall survival","https://ClinicalTrials.gov/show/NCT00598156"
1885,"NCT01061515","Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer","Recruiting","No Results Available","Carcinoma","Drug: Intraperitoneal Oxaliplatin|Drug: Bevacizumab|Drug: Capecitabine","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","Phase 1","48","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10-0136 / 201107017","February 1, 2010","May 2011","January 2021","June 28, 2016","June 2016","No Study Results Posted","null","May 2017","To determine the maximum tolerated dose of IP oxaliplatin with systemic intravenous bevacizumab and oral capecitabine after surgical debulking and peritoneal scan documenting functional of intraperitoneal ports in patients with peritoneal carcinomatosis|Assess the safety and tolerability of IP oxaliplatin and intravenous (i.v.) bevacizumab and oral capecitabine after surgical debulking and functional intraperitoneal ports in patients with peritoneal carcinomatosis of appendiceal or colorectal etiology|To describe the progression rate, progression-free survival and overall survival in patients treated with this regimen.","https://ClinicalTrials.gov/show/NCT01061515"
1886,"NCT02028442","Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients","Active, not recruiting","No Results Available","Solid Tumours of Epithelial Origin|Metastatic Colorectal Cancer|Metastatic Bladder Cancer","Biological: Enadenotucirev","PsiOxus Therapeutics Ltd","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","161","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ColoAd1-1001","October 29, 2013","September 2012","April 2017","May 10, 2016","May 2016","No Study Results Posted","EVOLVE","December 2016","Phase 1 - Maximum Tolerated Dose|Phase 1b - Selection of suitable schedule for repeat cycle IV administration","https://ClinicalTrials.gov/show/NCT02028442"
1887,"NCT02373020","Enteropathogenic Escherichia Coli (EPEC): Does it Have a Role in Colorectal Tumourigenesis?","Completed","No Results Available","Enteropathogenic Escherichia Coli .|Colorectal Carcinoma","Other: colonoscopic biopsies","Mansoura University","Both","Child, Adult, Senior","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","e coli","February 16, 2015","January 2011","March 2013","April 7, 2015","February 2015","No Study Results Posted","EPEC","March 2013","virulence genes: eaeA, bfpA and stx. PCR|EPEC serogrouping:|Strains: OF E COLI","https://ClinicalTrials.gov/show/NCT02373020"
1888,"NCT01418742","SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment","Terminated","No Results Available","Colorectal Carcinoma","Drug: Panitumumab, Doxycycline/Placebo|Drug: Panitumumab","Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|ClinAssess GmbH","Both","18 Years and older   (Adult, Senior)","Phase 2","11","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","GMIHO-010/2009","August 3, 2011","August 2011","May 2013","July 11, 2014","March 2013","No Study Results Posted","null","May 2013","Time until unblinding of skin therapy allocation (basic skin treatment with or without doxycycline) due to insufficient efficacy (i.e. unbearable skin toxicity, measured by patient's allocating point 6 through 10 on a visual analogue scale)|Incidence of specific ≥ grade 2 skin toxicities over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner|Time to first occurrence of specific ≥ grade 2 skin toxicities|Most severe specific ≥ grade 3 skin toxicities of interest over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner|Time to the first most severe specific ≥ grade 3 skin toxicities|Incidence of panitumumab dose reduction due to the specific skin toxicities of interest over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner|Scores in DLQI under preemptive basic skin treatment with or without doxycycline|Incidence of doxycycline related adverse events|Type of panitumumab related adverse events|Response rate to panitumumab over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner (only if patient received at least 8 weeks of study treatment)|Type of doxycycline related adverse events|Severity of doxycycline related adverse events|Incidence of panitumumab related adverse events|Severity of panitumumab related adverse events","https://ClinicalTrials.gov/show/NCT01418742"
1889,"NCT00709462","A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Pancreatic Cancer|Bladder Cancer|Ovarian Cancer","Biological: CDX1307","Celldex Therapeutics","Both","18 Years and older   (Adult, Senior)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDX-1307-01","July 1, 2008","March 2004","June 2010","July 23, 2010","July 2010","No Study Results Posted","null","May 2010","To establish the safety and tolerability profile of CDX-1307 in patients with incurable breast, colorectal, pancreatic, ovarian or bladder cancer, alone and in combination with adjuvants.|To evaluate dose-limiting toxicities, immune response, and clinical activity (tumor response and time to progression)","https://ClinicalTrials.gov/show/NCT00709462"
1890,"NCT00507143","Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan","Recruiting","No Results Available","Colorectal Neoplasms|Secondary","Drug: irinotecan","National Cancer Center, Korea","Both","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","NCCCTS-06-206","July 23, 2007","August 2006","December 2008","July 23, 2007","July 2007","No Study Results Posted","null","null","SLCO1B1 and PXR genotypes and maximal response rate|SLCO1B1 and PXR genotypes and pharmacokinetics of SN-38|SLCO1B1 and PXR genotypes and response duration, time to progression and overall survival","https://ClinicalTrials.gov/show/NCT00507143"
1891,"NCT01249638","Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC","Recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: Capecitabine|Drug: Bevacizumab|Drug: Capecitabine|Drug: Irinotecan|Drug: Bevacizumab","Ludwig-Maximilians - University of Munich|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 3","516","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML22011","November 29, 2010","December 2010","December 2016","March 11, 2011","November 2010","No Study Results Posted","null","December 2013","TFS|ORR, OS, Quality of Life, PFS-1","https://ClinicalTrials.gov/show/NCT01249638"
1892,"NCT02386618","Endoscopic Treatment for Local Residual Neoplasia","Completed","No Results Available","Colorectal Cancer","Procedure: Standardized endoscopic treatment of local residual neoplasia","Vitkovice Hospital","Both","18 Years and older   (Adult, Senior)","","25","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DDC VN 07","September 19, 2013","October 2013","June 2015","October 4, 2015","October 2015","No Study Results Posted","null","June 2015","Efficacy of endoscopic treatment od local residual neoplasia (absence of neoplastic tissue in post-EMR scar proven by endoscopic and histologic examination)","https://ClinicalTrials.gov/show/NCT02386618"
1893,"NCT00648102","Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Pancreatic Cancer|Bladder Cancer|Ovarian Cancer","Biological: CDX-1307","Celldex Therapeutics","Both","18 Years and older   (Adult, Senior)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDX1307-02","March 28, 2008","January 2006","December 2009","July 23, 2010","July 2010","No Study Results Posted","CDX1307-02","May 2009","To establish safety and tolerability profile of CDX1307 alone and with adjuvant in patients with breast, colorectal, pancreatic, bladder and ovarian cancer|Investigate clinical activity","https://ClinicalTrials.gov/show/NCT00648102"
1894,"NCT00345696","1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Bevacizumab|Drug: Capecitabine|Drug: Oxaliplatine","Unidad Integral de Investigación en Oncología S.L.|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","32","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XELOXAVBISEMANAL","June 27, 2006","June 2006","January 2011","August 23, 2011","August 2011","No Study Results Posted","null","October 2008","Progression Free Survival|Overall Response rate|Overall survival|Toxicity of the combination of capecitabine+oxaliplatin+bevacizumab|Resection rate of hepatic or pulmonary metastases","https://ClinicalTrials.gov/show/NCT00345696"
1895,"NCT02345746","Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis","Withdrawn","No Results Available","Metastatic Colorectal Cancer","Drug: Oxaliplatin|Drug: Folinic Acid|Drug: 5-Fluorouracil","Western Regional Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-19","June 12, 2013","December 2012","December 2013","January 19, 2015","January 2015","No Study Results Posted","null","December 2013","Time to intra-hepatic progression|Time to extra-hepatic progression|Determine Response Rate","https://ClinicalTrials.gov/show/NCT02345746"
1896,"NCT00305188","Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.","Completed","No Results Available","Metastases|Colorectal Neoplasms|Colorectal Carcinoma","Drug: Xaliproden (SR57746A)|Drug: Placebo|Drug: Oxaliplatin|Drug: 5-Fluorouracil|Drug: Leucovorin","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 3","879","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","EFC5505|EUDRACT : 2005-002570-30","March 20, 2006","December 2005","October 2009","April 6, 2016","April 2016","No Study Results Posted","null","October 2009","Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment|Main: response rate using RECIST criteria|Other: nerve conduction studies|Other: progression free survival and survival","https://ClinicalTrials.gov/show/NCT00305188"
1897,"NCT02545725","Quality of Life in Colorectal (ex-)Cancer Patients, Based on the Belgian Cancer Registry.","Completed","No Results Available","Colorectal Cancer|Quality of Life","Other: Questionnaire on Quality of Life","Elizabeth Van Eycken|Flemish League Against Cancer|Belgian Cancer Registry","Both","18 Years to 90 Years   (Adult, Senior)","","1220","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","S57073","September 1, 2015","April 2015","August 2015","September 8, 2015","September 2015","No Study Results Posted","QOLColorect","August 2015","Questionnaire on Quality of Life","https://ClinicalTrials.gov/show/NCT02545725"
1898,"NCT00637091","Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions","Completed","No Results Available","Advanced Colorectal Cancer","Drug: Cetuximab, irinotecan","Asan Medical Center","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-2008-0031","March 10, 2008","March 2008","September 2011","July 17, 2014","July 2014","No Study Results Posted","null","September 2009","Response rate|Progression free survival, overall survival","https://ClinicalTrials.gov/show/NCT00637091"
1899,"NCT02081742","Comparative Study of Colon Capsule and Virtual Colonoscopy (VICOCA)","Recruiting","No Results Available","Colonic Polyps|Adenoma","","Begoña González Suárez|Norgine|Given Imaging Ltd.|Hospital Clinic of Barcelona","Both","50 Years to 69 Years   (Adult, Senior)","","374","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCV-003","September 16, 2013","February 2013","July 2016","August 25, 2015","August 2015","No Study Results Posted","VICOCA","July 2016","Percentage of colon lesions detected by virtual colonoscopy and colon capsule|number of polypoid lesions and colorectal cancer (CRC) in the intermediate risk population|Number of complications associated with each of the screening strategies|Rate of false positives and false negatives obtained with virtual colonoscopy and colon capsule|percentage of participation and adherence to the suggested screening programme in the population studied","https://ClinicalTrials.gov/show/NCT02081742"
1900,"NCT00439517","Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.","Completed","Has Results","Previously Untreated Metastatic Colorectal Cancer","Drug: UFOX + Cetuximab|Drug: FOLFOX4 + Cetuximab","Merck KGaA","Both","18 Years and older   (Adult, Senior)","Phase 2","302","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR200025-001","February 22, 2007","February 2007","May 2012","June 18, 2014","June 2014","March 31, 2011","FUTURE","June 2009","Progression-free Survival (PFS)|Best Overall Response (BOR)|Overall Survival (OS)|Quality of Life (QOL) Functional Assessment of Cancer Therapy-Colorectal (FACT-C)|QOL EuroQuol-5D (EQ-5D) Health Outcome Questionnaire|QOL Therapy Preference Questionnaire (TPQ)|Treatment Impact on Social Daily Living and Health Care Resource Utilization|Safety - Number of Patients Experiencing Any Adverse Event","https://ClinicalTrials.gov/show/NCT00439517"
1901,"NCT00910676","Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors","Completed","No Results Available","Metastatic Colorectal Cancer|Non-Small-Cell Lung Carcinoma","Drug: Diprosone","Centre Oscar Lambret|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","2007-002913-38","May 29, 2009","October 2007","March 2009","July 30, 2012","July 2012","No Study Results Posted","DIPROCOL","March 2009","To reduce by 30 % the frequency of folliculitis by a local corticotherapy beginning at the same time that the treatment by EGF-R inhibitors began|To assess the frequency of grade I, II and III folliculitis under Cetuximab and under Erlotinib|To list the cutaneous side effects of the EGF-R inhibitors|To assess the patient quality of life with the DLQI questionnaire","https://ClinicalTrials.gov/show/NCT00910676"
1902,"NCT00507351","Ambulatory Cancer Pain Management: A Feasibility Study","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer","Behavioral: Questionnaire","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2005-0841","July 24, 2007","July 2006","July 2009","July 31, 2012","July 2012","No Study Results Posted","null","July 2009","Pain and symptom data across multiple institutions","https://ClinicalTrials.gov/show/NCT00507351"
1903,"NCT02339116","Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: fluoruracil|Drug: Oxaliplatin|Drug: Irinotecan|Drug: Bevacizumab","Gruppo Oncologico del Nord-Ovest","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","654","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TRIBE2","January 12, 2015","January 2015","February 2021","March 10, 2015","March 2015","No Study Results Posted","TRIBE2","July 2019","Progression Free Survival 2 (PFS2)|Progression free survival (PFS)|2nd-Progression free survival (2nd-PFS)|Time to failure of strategy (TFS)|Overall survival (OS)|Objective Response Rate|Toxicity Rate","https://ClinicalTrials.gov/show/NCT02339116"
1904,"NCT00581724","Pain in Cancer Survivors","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Prostate Cancer|Head and Neck Cancer|Lung Cancer","Behavioral: Telephone interview or self report survey.","Memorial Sloan Kettering Cancer Center|Beth Israel Medical Center|Vanderbilt University","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","07-068","December 21, 2007","May 2007","January 2012","January 25, 2012","January 2012","No Study Results Posted","null","January 2012","Descriptive statistics will be generated to describe the prevalence of pain and its psychosocial correlates.","https://ClinicalTrials.gov/show/NCT00581724"
1905,"NCT00502502","Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients","Completed","No Results Available","Anal Cancer|Colorectal Cancer|Esophageal Cancer|Gastric Cancer|Lung Cancer","Behavioral: Questionnaire","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","205","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ANS02-495","July 16, 2007","November 2002","July 2010","July 18, 2012","July 2012","No Study Results Posted","null","July 2010","Patient Symptom Assessment (Questionnaire)","https://ClinicalTrials.gov/show/NCT00502502"
1906,"NCT01505400","Integrated Molecular Profiling in Advanced Cancers Trial","Active, not recruiting","No Results Available","Breast Cancer|Non-small Cell Lung Cancer|Colorectal Cancer|Genitourinary Cancer|Pancreatobiliary Gastrointestinal Cancer|Upper Aerodigestive Tract Cancer|Gynecological Cancers|Melanoma Cancers|Rare Cancers|Unknown Primary Cancers","","University Health Network, Toronto|Princess Margaret Hospital, Canada","Both","18 Years and older   (Adult, Senior)","","3026","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","IMPACT-001","January 4, 2012","February 2012","February 2017","August 19, 2016","August 2016","No Study Results Posted","IMPACT","February 2017","Molecular profiling data to be made available in patient's electronic medical records.|Utilization rates of molecular profiling information|Clinical trial accrual rates among patients with available molecular profiling data","https://ClinicalTrials.gov/show/NCT01505400"
1907,"NCT02473003","Physical Training and Cancer-a Multicenter Clinical Trial","Enrolling by invitation","No Results Available","Breast Cancer|Colorectal Cancer|Prostate Cancer","Behavioral: high intensity exercise|Behavioral: low/medium intensity exercise|Behavioral: Behavioral medicine strategies","Uppsala University|The Swedish Research Council|Swedish Cancer Society|Nordic Cancer Union|Linkoeping University|Lund University|University of Agder|Copenhagen University Hospital, Denmark|Norwegian School of Sport Sciences|VU University Medical Center|VU University of Amsterdam|University of Leeds","Both","18 Years and older   (Adult, Senior)","","612","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D0273401, CAN2012/631,621","October 10, 2014","March 2015","December 2025","April 12, 2016","April 2016","No Study Results Posted","Phys-Can","December 2020","Change in Fatigue|Change in Quality of Life|Change in Mood disturbance|Function in Daily life|Change in pain|Cardio respiratory fitness|Muscle strengthUpper extremities:|Health Economy|Cancer recurrence|Sleep","https://ClinicalTrials.gov/show/NCT02473003"
1908,"NCT00078897","Selenium for Prevention of Adenomatous Colorectal Polyps","Active, not recruiting","No Results Available","Colorectal Cancer|Adenomatous Colorectal Polyps|Precancerous Condition","Drug: Selenium","University of Arizona|National Cancer Institute (NCI)","Both","40 Years to 80 Years   (Adult, Senior)","Phase 3","1800","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CDR0000353185|P30CA023074|P01CA041108","March 8, 2004","January 2001","July 2016","May 18, 2016","November 2015","No Study Results Posted","null","October 2015","Recurrence of colorectal adenomatous polyps in relation to histologic type, degree of dysplasia, number, size, and location.|Tolerance and adequate adherence to long-term selenium treatment as measured by adverse events, serious adverse events, every 3-4 months during treatment, and laboratory values at the beginning of the study, 6 months and annually thereafter.|To investigate effect modification of the selenium intervention by baseline blood selenium level, by low-dose aspirin (81 mg/day), by selenoprotein genetic marker polymorphisms (GPx-1, GPx-2 and SEP15).|To investigate effect modification of low-dose aspirin (81 mg/day) by ornithine decarboxylase promoter genotype and effect modification of low-dose aspirin and its toxicity by slow-metabolizer genotypes of the cytochrome p450 2C9 and UGT1A6 loci.","https://ClinicalTrials.gov/show/NCT00078897"
1909,"NCT00453661","Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities","Active, not recruiting","No Results Available","Breast Cancer|Cervical Cancer|Prostate Cancer|Colorectal Cancer|Lung Cancer","Behavioral: Questionnaire|Behavioral: Patient Navigator (PN)","M.D. Anderson Cancer Center|Centers for Medicare and Medicaid Services","Both","40 Years and older   (Adult, Senior)","","2812","Other|U.S. Fed","Observational","Observational Model: Case Control|Time Perspective: Prospective","2006-0419|CMS-5036-N|NCI-2014-02518","March 27, 2007","March 2007","null","September 30, 2015","September 2015","No Study Results Posted","null","March 2017","Screening Rates|Compliance Rate Across 5 Cancer Types","https://ClinicalTrials.gov/show/NCT00453661"
1910,"NCT01345526","Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream","Recruiting","No Results Available","Metastatic Colorectal Cancer","Device: Reconval K1 Cream|Device: Reconval Cream","Universitätsmedizin Mannheim","Both","18 Years and older   (Adult, Senior)","Phase 2","124","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E-VITA","April 21, 2011","April 2011","December 2012","April 28, 2011","April 2011","No Study Results Posted","null","December 2012","Occurrence of acne-like skin rash grade ≥ 2 (according to the CTCAE version 4.02) during the 8 weeks of skin treatment.","https://ClinicalTrials.gov/show/NCT01345526"
1911,"NCT01791322","NovellusDx Tissue Collection Protocol","Recruiting","No Results Available","Patients That Have Been Diagnosed With Colorectal Cancer.|Patients Eligible for Tumor Biopsy.","","NovellusDx","Both","18 Years to 85 Years   (Adult, Senior)","","35","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PM 01.1","February 12, 2013","January 2014","June 2016","October 6, 2015","October 2015","No Study Results Posted","null","June 2016","Correct identification of tumor mutant genes","https://ClinicalTrials.gov/show/NCT01791322"
1912,"NCT02113683","Validation of MMS Test for Cancer Monitoring","Recruiting","No Results Available","Colo-rectal Cancer|Stomach Cancer|Melanoma","","MedInnovation GmbH|HELIOS Klinikum Berlin-Buch","Both","18 Years and older   (Adult, Senior)","","100","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MMS-tm14","April 8, 2014","May 2014","December 2017","March 15, 2016","March 2016","No Study Results Posted","MMS-TM","December 2016","active tumor growth before and after cancer therapy","https://ClinicalTrials.gov/show/NCT02113683"
1913,"NCT02239861","TAA-Specific CTLS for Solid Tumors (TACTASOM)","Recruiting","No Results Available","Bladder Cancer|Breast Cancer|Colorectal Cancer|Endometrial Cancer|Gastric Cancer|Head and Neck Cancer|HCC|Lung Cancer|Melanoma|Neuroblastoma|Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc)|Pancreatic Cancer|Prostate Cancer|Renal Cell Carcinoma|Thyroid Cancer","Biological: TAA-Specific CTLs","Baylor College of Medicine|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|Solving Kids’ Cancer|Pierce Phillips Charity","Both","2 Years to 80 Years   (Child, Adult, Senior)","Phase 1","18","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-35425, TACTASOM","September 11, 2014","April 2015","October 2018","July 18, 2016","July 2016","No Study Results Posted","null","December 2017","Number of patients with dose-limiting toxicity.|Number of patients with a disease response to the CTLs.|Persistence of the CTLs in the patient.|Expansion of the CTLs in the patient.|Epitope spreading in the patient","https://ClinicalTrials.gov/show/NCT02239861"
1914,"NCT00923052","The Natural History of Solid Organ Cancer Stem Cells (SOCSC)","Terminated","No Results Available","Hepatic Cancer|Pancreatic Ductal Cancer|Colorectal Cancer|Breast Cancer|Gastric Cancer","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","16 Years and older   (Child, Adult, Senior)","","190","NIH","Observational","Time Perspective: Prospective","090079|09-C-0079","June 17, 2009","February 2009","May 2015","May 8, 2015","May 2015","No Study Results Posted","null","null","To study and characterize both quantitatively and qualitatively SOCSC from various primary and metastatic solid organ cancers from time of surgery or other cancer directed therapy to time of recurrence or progression using an exhaustive list of ...|To determine whether SOCSC are present in the blood and/or bone marrow, and study their quantitative and/or qualitative changes over the course of the disease, from time of initial presentation to time of recurrence and/or metastasis.To sp...","https://ClinicalTrials.gov/show/NCT00923052"
1915,"NCT02568267","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)","Recruiting","No Results Available","Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Sarcomas|Salivary Gland Cancers|Adult Solid Tumor","Drug: Entrectinib","Ignyta, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","300","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RXDX-101-02","October 2, 2015","October 2015","October 2018","September 16, 2016","September 2016","No Study Results Posted","STARTRK-2","October 2017","Objective Response Rate|Duration of Response|Time to Response|Clinical Benefit Rate|Intracranial Tumor Response|CNS Progression-free Survival|Progression-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02568267"
1916,"NCT01444456","Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia","Completed","Has Results","Anemia|Breast Cancer|Cancer|Colorectal Cancer|Lung Cancer|Ovarian Cancer|Prostate Cancer|Solid Tumors|Bladder Cancer|Endometrial Cancer|Renal Cancer|Pancreatic Cancer|Esophageal Cancer|Gastric Cancer","","Amgen","Both","18 Years and older   (Adult, Senior)","","1262","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20101123","September 29, 2011","October 2011","October 2013","July 24, 2014","July 2014","July 24, 2014","null","August 2013","Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL|Percentage of Participants by Tumor Type With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL|Mean Change From Baseline in FACT-F Score for Participants With a VAS Improvement of 5 ± 3 Points|Time to First Increase in Hemoglobin|Percentage of Participants With Improvement in Patient-perceived Fatigue (PPF) at Any Time|Percentage of Participants With Increase in Hemoglobin ≥ 1 g/dL at Any Time","https://ClinicalTrials.gov/show/NCT01444456"
1917,"NCT01065441","Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer","Withdrawn","No Results Available","Solid Tumors Stage II, Stage III and Stage IV|Breast Cancer|Colorectal Cancer|Prostate Cancer|Melanoma|Ovarian Cancer|Sarcoma|Non-small Cell Lung Cancer","Biological: AlloStim|Procedure: Cryoablation|Biological: AlloStim|Biological: AlloStim|Biological: AlloStim|Biological: AlloStim|Biological: AlloStim","Immunovative Therapies, Ltd.|Hadassah Medical Organization","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Industry|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ITL-002-HMC","February 7, 2010","December 2009","July 2012","November 29, 2012","May 2011","No Study Results Posted","null","December 2011","The primary endpoint is the evaluation of any drug-related toxicity associated with AlloStimTM administration as well as the reversibility of such toxicity.|The secondary end-point is the evaluation of the anti-tumor effect of AlloStimTM administration.|The tertiary end-point is the evaluation of the immunological response to AlloStim-TM administration.","https://ClinicalTrials.gov/show/NCT01065441"
1918,"NCT01372527","Population-Based Patient-Centric Care: Comprehensive Preventive Cancer Screening Using Health IT","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Cervical Cancer","Other: TopCare: Use of provider knowledge vs. automated system","Massachusetts General Hospital","Both","21 Years to 75 Years   (Adult, Senior)","","103870","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","R18HS018161","June 10, 2011","June 2011","January 2013","October 2, 2014","October 2014","No Study Results Posted","TopCare","June 2012","Cancer completion for all eligible cancers|% of patients completing all eligible cancer screenings|Primary outcome in specified patient subgroups|TopCare system measures (intervention practices)","https://ClinicalTrials.gov/show/NCT01372527"
1919,"NCT01679756","INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for Cancer","Not yet recruiting","No Results Available","Colorectal Cancer","Procedure: Laparoscopic right hemicolectomy for cancer","Ospedale Misericordia e Dolce","Both","18 Years to 80 Years   (Adult, Senior)","","384","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","EAES 7625","September 1, 2012","March 2013","June 2014","September 1, 2012","September 2012","No Study Results Posted","INEXTREMO","March 2014","Overall surgical morbidity|Operative time|Largest incision length|Numbers of node harvested|Intraoperative complicatons|Mortality|Non surgical site complications|Bowel movement|First flatus|First stool canalization|Time to solid diet|Naso gastric tube reintroduction|Days of analgesic usage|Length of hospital stay|Readmission","https://ClinicalTrials.gov/show/NCT01679756"
1920,"NCT02713529","Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer","Recruiting","No Results Available","Pancreatic Cancer|Colorectal Cancer|Non-Small Cell Lung Cancer","Biological: AMG820 and pembrolizumab","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","197","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20150195","March 3, 2016","April 2016","July 2018","September 14, 2016","September 2016","No Study Results Posted","null","June 2018","Number of participants with treatment related adverse events as assessed by CTCAE version 4.0|Objective response rate of tumors using irRECIST criteria for total measureable tumor burden|Number of participants with treatment emergent adverse events as assessed by CTCAE version 4.0|Objective response rate of tumors using RECIST 1.1 criteria for total measurable tumor burden|Maximum observed concentration [Cmax] of AMG820|CD4, CD8, and CD68 cell numbers in pre-treatment tumor biopsy tissue|Minimum observed concentration [Cmin] of AMG 820|Area Under the Curve [AUC] of AMG820","https://ClinicalTrials.gov/show/NCT02713529"
1921,"NCT00020267","Vaccine Therapy in Treating Patients With Metastatic Cancer","Completed","No Results Available","Lung Cancer|Adult Soft Tissue Sarcoma|Colorectal Cancer|Bone Cancer|Ovarian Sarcoma|Melanoma|Colon Cancer|Rectal Cancer|Breast Cancer|Eye Cancer|Uterine Sarcoma","Drug: interleukin-2|Drug: MAGE-12 peptide vaccine|Drug: Montanide ISA-51","National Cancer Institute (NCI)","null","16 Years and older   (Child, Adult, Senior)","Phase 1","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000068173|NCI-00-C-0182|NCI-1034","March 2, 2007","July 2000","null","April 27, 2015","May 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00020267"
1922,"NCT00003046","Interleukin-12 in Treating Patients With Cancer in the Abdomen","Completed","No Results Available","Anal Cancer|Colorectal Cancer|Gallbladder Cancer|Gastric Cancer|Pancreatic Cancer","Biological: Recombinant Interleukin-12","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","29","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID97-027|P30CA016672|MDA-ID-97027|NCI-T97-0034|CDR0000065681","November 1, 1999","August 1997","October 2001","July 27, 2012","July 2012","No Study Results Posted","null","October 2001","Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12","https://ClinicalTrials.gov/show/NCT00003046"
1923,"NCT02699047","Fish Oil Supplementation in Gastrointestinal Cancer","Active, not recruiting","No Results Available","Gastrointestinal Cancer|Colorectal Cancer|Stomach Cancer","Dietary Supplement: Encapsuled fish oil|Dietary Supplement: Encapsulated Olive oil","Universidade Federal de Santa Catarina|Centro de Pesquisas Oncológicas","Both","18 Years to 70 Years   (Adult, Senior)","","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UFSC/04","February 12, 2016","March 2015","July 2017","June 29, 2016","June 2016","No Study Results Posted","null","April 2016","Change in Quality of life|Cytokines of inflammatory response|Body weight|Body Mass Index (BMI)|Weight Change|Fat mass|Lean body mass|arm circumference|tricipital skinfold|Serum C-reactive protein|Activity of Catalase|Activity of Glutathione Peroxidase|Activity of Superoxide Dismutase|Lipid Peroxidation|Evaluation of adverse events consequences|Graduation of adverse events|Tumor Markers|Survival|Serum albumin","https://ClinicalTrials.gov/show/NCT02699047"
1924,"NCT02012231","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.","Terminated","No Results Available","Melanoma|Thyroid Cancer|Colorectal Cancer|Non-small Cell Lung Cancer|Cholangiocarcinoma|Histiocytosis|Hairy Cell Leukemia","Drug: PLX8394","Plexxikon","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","5","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PLX120-01","December 5, 2013","February 2014","June 2015","May 3, 2016","May 2016","No Study Results Posted","null","September 2014","Phase 1 dose escalation: Identification of Recommended Phase 2 Dose Safety of PLX8394|Identification of Recommended Phase 2 dose (RP2D)","https://ClinicalTrials.gov/show/NCT02012231"
1925,"NCT00308516","5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer","Completed","Has Results","Rectal Cancer|Cancer of the Rectum|Colorectal Cancer","Drug: 5-Fluorouracil|Drug: Bevacizumab|Procedure: Radiation Therapy|Drug: Oxaliplatin|Drug: Leucovorin","SCRI Development Innovations, LLC|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","66","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI GI 65|AVF3105s","March 28, 2006","March 2006","February 2012","May 14, 2013","May 2013","March 26, 2013","null","April 2009","Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment|Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death","https://ClinicalTrials.gov/show/NCT00308516"
1926,"NCT02110329","Simultaneaous Detection of Quantitative Somatic Alterations Using the Qantitative Multiplex Pcr of Short Fluorescent Fragments Method (QMPSF) in Stage II-III Colon Cancer: a Prospective Study","Completed","No Results Available","Colorectal Cancer|Stage II and III","Genetic: evaluation of the recurrence rate according to molecular analysis","University Hospital, Rouen","Both","18 Years and older   (Adult, Senior)","","401","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","2007/040/HP","April 7, 2014","May 2010","November 2013","April 7, 2014","April 2014","No Study Results Posted","Code Barre","June 2013","Recurence rate according to molecular results|Survival rate according to molecular results","https://ClinicalTrials.gov/show/NCT02110329"
1927,"NCT00924092","An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...","Completed","No Results Available","Prostate Cancer|Breast Cancer|Lung Cancer|Colorectal Cancer|Head and Neck Cancer","Biological: GI-6207 [Recombinant Saccharomyces Cerevisia|Drug: (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 120 Years   (Adult, Senior)","Phase 1","25","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","090101|09-C-0101","June 17, 2009","March 2009","August 2012","August 6, 2016","May 2014","No Study Results Posted","null","null","To determine the safety and tolerability of escalating doses of a heated-killed yeast-based vaccine that targets tumors that express CEA.|To evaluate CD4 and CD8 immunologic response. To evaluate humoral immune response to yeast antigen. To evaluate evidence of clinical benefit such as PFS, OR, &amp; decreases in circulating tumor cells &amp; tumor markers.","https://ClinicalTrials.gov/show/NCT00924092"
1928,"NCT00477646","Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care","Completed","No Results Available","Breast Cancer|Cervical Cancer|Colorectal Cancer","Behavioral: Prevention Care Management","Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)|Clinical Directors Network","Female","50 Years to 64 Years   (Adult)","","2241","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","CDR0000537346|P30CA023108|DMS-20253","May 23, 2007","July 2007","February 2011","August 4, 2011","August 2011","No Study Results Posted","null","February 2011","Percentage of patients up-to-date (UTD) for colorectal cancer (CRC) screening|Percentage of patients UTD for breast and cervical cancer screening|Comparison of UTD status for CRC screening with UTD status for cervical cancer and breast cancer screening","https://ClinicalTrials.gov/show/NCT00477646"
1929,"NCT02597348","Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy","Recruiting","No Results Available","Liver Metastasis|Colorectal Cancer|Metastasis","Procedure: Liver Transplantation","Assistance Publique - Hôpitaux de Paris","Both","18 Years to 65 Years   (Adult)","Phase 3","90","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P130922","October 23, 2015","October 2015","October 2023","November 5, 2015","October 2015","No Study Results Posted","TRANSMET","October 2023","5 years overall survival (OS)|3-years overall survival (OS)|Disease free survival (DFS) (Arm LT+C) or Progression free survival (PFS) (Arm C)|Recurrence rate at 3 and 5 years|Quality of life (QOL) of patients using the European Organization for Research and Treatment of Cancer (EORTC) questionnaires.: QLQ-C30|Quality of life (QOL) of patients using the European Organization for Research and Treatment of Cancer (EORTC) questionnaires.: QLQ-LMC21|Quality of life (QOL) of patients of Group LT followed by chemotherapy, using the NIDDK questionnaire of Liver Transplantation Database","https://ClinicalTrials.gov/show/NCT02597348"
1930,"NCT02437916","Safety Study of AMG 228 to Treat Solid Tumors","Recruiting","No Results Available","Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors|Melanoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Transitional Cell Carinoma of Bladder|Colorectal Cancer","Drug: AMG 228","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 1","100","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20140131","April 3, 2015","April 2015","October 2017","June 1, 2016","June 2016","No Study Results Posted","null","October 2017","Subject incidence of dose limiting toxicities (DLT)|Subject incidence of treatment-emergent adverse events|Subject incidence of treatment-related adverse events|Subject incidence of clinically significant changes in vital signs and physical assessments|Subject incidence of clinically significant changes in ECGs|Subject incidence of clinically significant changes in clinical laboratory tests|AMG 228 maximum observed concentration (Cmax)|AMG 228 minimum observed concentration (Cmin)|AMG 228 area under the concentration-time curve (AUC)|AMG 228 half-life (t1/2)|Subject objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|Incidence of anti-AMG 228 antibody formation|Activation status and changes in numbers of T regulator cells (Treg)|Subject objective response per immune-related Response Criteria (irRC)|Activation status of cytotoxic T lymphocytes (CTL)|Changes in numbers of cytotoxic T lymphocytes (CTL)","https://ClinicalTrials.gov/show/NCT02437916"
1931,"NCT00028405","Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors","Completed","No Results Available","Liver Metastasis|Pelvic Cancer|Head and Neck Cancer|Sarcoma|Rectal Cancer|Breast Cancer|Colorectal Cancer|Mouth Cancer","Drug: LS 11(Taporfin Sodium)|Device: Lumaflex Light Delivery Catheter","Light Sciences LLC","Both","18 Years and older   (Adult, Senior)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LSC-OL001","January 4, 2002","November 2001","December 2002","June 23, 2005","March 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00028405"
1932,"NCT02422680","Colonoscopy Quality Assurance With Focus on Key Quality Indicators and Patient Satisfaction at Aalborg University Hospital","Recruiting","No Results Available","Colorectal Cancer","Procedure: No intervention, purely observational.","Aalborg Universitetshospital|Nordsim","Both","18 Years and older   (Adult, Senior)","","500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AalborgH","April 10, 2015","April 2015","July 2016","April 16, 2015","April 2015","No Study Results Posted","null","June 2015","Caecum Intubations rate and documentation|Polyps detection rate|Incidence of colorectal cancer|Patient satisfaction|Nurses perception of patients' pain","https://ClinicalTrials.gov/show/NCT02422680"
1933,"NCT01442155","An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer","Completed","Has Results","Colorectal Cancer","Drug: Capecitabine|Biological: Oxaliplatin","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","74","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25526","September 26, 2011","October 2011","April 2015","May 26, 2016","May 2016","May 26, 2016","null","April 2015","Disease-Free Survival (Time to Event)|Safety: Percentage of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT01442155"
1934,"NCT02062749","Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Oxaliplatin","M.D. Anderson Cancer Center","Both","9 Years to 21 Years   (Child, Adult)","Phase 1","1","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-0438|NCI-2014-01239","February 11, 2014","May 2014","null","August 25, 2016","August 2016","No Study Results Posted","null","May 2018","Maximum Tolerate Dose (MTD) of Oxaliplatin in Hyperthermic Intraperitoneal Chemotherapy|Differences in Genetic Aberrations in Pediatric Colon Cancer Patients and Adult Patients","https://ClinicalTrials.gov/show/NCT02062749"
1935,"NCT00706121","S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000","Completed","No Results Available","Colorectal Cancer|Precancerous Condition","Drug: Vitamin E|Drug: Selenium|Drug: Vitamin E placebo|Drug: selenium placebo","Southwest Oncology Group|National Cancer Institute (NCI)","Male","50 Years to 120 Years   (Adult, Senior)","Phase 3","8097","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CDR0000593329|S0000D|U10CA037429","June 26, 2008","June 2008","October 2015","November 16, 2015","November 2015","No Study Results Posted","ACP","October 2015","Effect of selenium on colorectal adenoma (CRA) occurrence and colorectal cancer (CRC) incidence|Effect of selenium on number, location, size, histologic type, and degree of dysplasia of CRA|Effect of vitamin E on CRA occurrence and CRC incidence|Effect modification of selenium and vitamin E by aspirin on CRA occurrence|Effect modification of selenium and vitamin E by body mass index","https://ClinicalTrials.gov/show/NCT00706121"
1936,"NCT01437007","TKM 080301 for Primary or Secondary Liver Cancer","Completed","No Results Available","Colorectal Cancer With Hepatic Metastases|Pancreas Cancer With Hepatic Metastase|Gastric Cancer With Hepatic Metastase|Breast Cancer With Hepatic Metastase|Ovarian Cancer With Hepatic Metastase","Drug: TKM-080301","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","1","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","110240|11-C-0240","September 16, 2011","August 2011","June 2012","August 6, 2016","October 2012","No Study Results Posted","null","June 2012","To evaluate feasibility of administering TKM-080301 via HAI, and establish MTD and DLT.|Characterize PK &amp; pharmacodynamics of TKM 080301|Eval biological effects of TKM-080301 on biopsies performed before &amp; after 1 cycle of tx|To evaluate the potential conversion rate from unresectable to resectable disease.","https://ClinicalTrials.gov/show/NCT01437007"
1937,"NCT00443573","Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer","Suspended","No Results Available","Colon Cancer","Drug: recombinant nematode anticoagulant protein c2 (rNAPc2)","ARCA Biopharma, Inc.","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","100","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","NAP-0601","March 2, 2007","December 2006","null","May 5, 2008","May 2008","No Study Results Posted","null","August 2007","Safety measured by major hemorrhage (NCI CTCAE v3.0 grade 3 or greater), during and up to 30 days after completion of study drug administration or, if treatment is ongoing, by 8 months after study enrollment (Stage I) or randomization (Stage II)|Safety measured by adverse events|Efficacy measured by new metastasis-free survival by 8 months|Survival by 8 months|Arterial or venous thrombosis|Tumor response rate, as assessed by RECIST criteria","https://ClinicalTrials.gov/show/NCT00443573"
1938,"NCT01787500","Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers","Recruiting","No Results Available","Advanced Cancers","Drug: Vemurafenib|Drug: Cetuximab|Drug: Irinotecan","M.D. Anderson Cancer Center|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","33","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-0748|NCI-2013-00541","February 6, 2013","February 2013","null","July 18, 2016","July 2016","No Study Results Posted","null","February 2018","Maximum Tolerated Dose (MTD)|Clinical Response","https://ClinicalTrials.gov/show/NCT01787500"
1939,"NCT00210106","Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.","Completed","No Results Available","Colorectal Cancer","Device: Ablathermy","Institut Bergonié","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","53","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IB2003-11|ARF2003","September 12, 2005","June 2003","December 2008","March 3, 2015","March 2015","No Study Results Posted","ARF2003","December 2008","Liver recurrence rate at 3 months after treatment|- overall survival at 1 year|- Disease free Survival 1 year|- Quality of live|- Morbidity of radiofrequency ablation","https://ClinicalTrials.gov/show/NCT00210106"
1940,"NCT01846650","A Bioequivalence Study of Capecitabine Tablets","Completed","No Results Available","Metastatic Breast Cancer or Metastatic Colorectal Cancer","Drug: Capecitabine tablets|Drug: XELODA","Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","KPTB-1.1","May 1, 2013","December 2012","June 2013","September 28, 2013","September 2013","No Study Results Posted","null","June 2013","Area Under Curve (AUC)","https://ClinicalTrials.gov/show/NCT01846650"
1941,"NCT00057395","A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies","Active, not recruiting","No Results Available","Esophageal Neoplasms|Hepatocellular Carcinoma|Colorectal Neoplasms|Ovarian Neoplasms|Pancreatic Neoplasms|Neoplasms","Drug: Aroplatin (Liposomal NDDP, L-NDDP)","Aronex Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C-726-04","April 1, 2003","null","null","June 23, 2005","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00057395"
1942,"NCT01523353","Prehabilitation in Liver Surgery","Completed","No Results Available","Colorectal Cancer|Colorectal Liver Metastasis|Liver Surgery|Exercise Intervention","Behavioral: Exercise Intervention","Aintree University Hospitals NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 1","37","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","11/H1005/3","January 30, 2012","July 2011","June 2013","December 16, 2013","February 2012","No Study Results Posted","null","June 2013","Anaerobic threshold prior to liver resection|Hospital Length of stay|Post operative morbidity|Quality of Life|Mortality|Attendance at exercise sessions|Serious adverse events within exercise program|other measures of cardiopulmonary function|Recovery of fitness","https://ClinicalTrials.gov/show/NCT01523353"
1943,"NCT01609361","Benefit of Rehabilitation Program in Colorectal Surgery","Completed","No Results Available","Colorectal Cancer","Other: Rehabilitation program","Assistance Publique - Hôpitaux de Paris","Both","18 Years and older   (Adult, Senior)","","270","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Supportive Care","P111006|IDRCB","April 20, 2012","November 2012","July 2016","August 18, 2016","August 2016","No Study Results Posted","REHAB","February 2016","Post operative morbidity at 30 days according to DINDO CLAVIEN classification|Mortality according to DINDO CLAVIEN classification|Hospital stay and readmissions|Intravenous perfusion stay|Global (SF36) quality of life|Specific (GIQLI) quality of life|Duration of laxation (gas and stool)","https://ClinicalTrials.gov/show/NCT01609361"
1944,"NCT01053104","Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring","Completed","No Results Available","Metastatic Colorectal Cancer|Metastatic Breast Cancer","","University of Oxford|oxBRC|Vodafone UK Foundation|Centre of Statistics and Medicine (CSM, Oxford)|Oncology Clinical Trials Office (OCTO, Oxford)","Both","18 Years and older   (Adult, Senior)","","26","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Mobile Datacap|OCTO/Oxford","January 3, 2010","November 2009","April 2011","July 24, 2012","July 2012","No Study Results Posted","DATACAP","December 2010","Toxicities (frequency at each of grades 2, 3 and 4, over all cycles)|Number of inappropriate dose adaptations and self care advice messages generated ['inappropriate' defined by nurse overriding generated advice|Frequency of patients receiving each piece of advice from the system, including recommendations on dose and on self-treating side effects.|Obtain descriptive information on amount and duration of drug delivery (stage 2 only) Number of patients who, dose reduce stay at same dose dose increase Total dose delivery Chemotherapy duration|Obtain feedback from staff on using the system Staff recommendations for changes or improvements to the system throughout the course of the study and Semi-structured interviews|Test and refine mobile phone and server software systems Frequency of occurrence of technological faults (for example, problems caused by no phone reception)|Patient Experience EvaluationPatient experience will be evaluated as detailed in Patient Experience Evaluation|Evaluate safety outcomes Total number of grade 3/4 toxicities throughout the study period Degree of toxicity experienced Number of alerts, split by severity|Dose intensity in mg/m2/week and toxicities as for stage 1","https://ClinicalTrials.gov/show/NCT01053104"
1945,"NCT00525655","Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)","Active, not recruiting","No Results Available","Familial Adenomatous Polyposis|Colorectal Cancer","Behavioral: Web-Based Multimedia Intervention|Behavioral: Questionnaire","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","13 Years to 24 Years   (Child, Adult)","","55","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2006-1037|NCI-2011-02827|1R41CA126453-01A1","September 4, 2007","August 2007","null","May 12, 2016","May 2016","No Study Results Posted","null","February 2018","Pilot Test FAP Website (Interviews)|Participant Assessment of FAP Website (Questionnaire)","https://ClinicalTrials.gov/show/NCT00525655"
1946,"NCT02882620","Enhancing Prevention Pathways Toward Tribal Colorectal Health","Not yet recruiting","No Results Available","Colorectal Neoplasm","Behavioral: High Intensity (Group 1)|Behavioral: Medium Intensity (Group 2)|Behavioral: Reference Group (Group 3)","University of New Mexico|National Cancer Institute (NCI)","Both","50 Years to 75 Years   (Adult, Senior)","","1750","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Screening","14-363|R01CA192967","August 12, 2016","October 2016","March 2021","August 24, 2016","August 2016","No Study Results Posted","null","March 2021","Annual Completion of the FIT Kit|Change in Knowledge|Change in Attitudes|Change in Perceived Control|Change in Perceived Susceptibility|Change in Perceived Severity|Change in Self-Efficacy","https://ClinicalTrials.gov/show/NCT02882620"
1947,"NCT02298907","CPET in Colorectal Surgery","Completed","No Results Available","Colorectal Cancer|Surgery","","Aintree University Hospitals NHS Foundation Trust|Medway NHS Foundation Trust|Maidstone & Tunbridge Wells NHS Trust|South Devon Healthcare NHS Foundation Trust|Plymouth Hospitals NHS Trust","Both","Child, Adult, Senior","","170","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","14/EM/1038","June 30, 2014","June 2010","August 2014","June 25, 2015","June 2015","No Study Results Posted","null","August 2014","Oxygen uptake at lactate threshold|Oxygen uptake at peak|Power output at lactate threshold and peak exercise|Ventilatory equivalents at lactate threshold and peak exercise|Number of patients with adverse post-operative outcome measures","https://ClinicalTrials.gov/show/NCT02298907"
1948,"NCT00610636","Treatment Outcomes of Hepatic Metastasis After FOLFOX-4 Therapy","Recruiting","No Results Available","Colorectal Cancer","Procedure: Hepatic resection","National Taiwan University Hospital|National Science Council, Taiwan","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","9100015204|NSC94-2314-B002-288","January 28, 2008","January 2002","December 2017","December 6, 2012","December 2012","No Study Results Posted","null","December 2017","Both groups of patients were analyzed with intention-to-treat principle. The primary end-point was time-to-progression. The secondary points were overall survival and surgical morbidity.|Surgical morbidity, Chemotherapeutic complications","https://ClinicalTrials.gov/show/NCT00610636"
1949,"NCT01879943","Capsule Versus Conventional Colonoscopy in Patient Following Colorectal Surgery","Active, not recruiting","No Results Available","Colorectal Cancer","Device: PillCam Colon 2|Procedure: Colonoscopy","IHU Strasbourg","Both","18 Years to 85 Years   (Adult, Senior)","","100","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Diagnostic","12-003|2012-A01475-38","June 14, 2013","October 2013","October 2016","August 31, 2016","March 2016","No Study Results Posted","null","October 2016","Number of patients with full colonic exploration and detection of lesions|Anastomosis visualization|Number and size of detected lesions|Quality of colic preparation|Times related to videocapsule|Adverse events related to VCC exam and colonoscopy|Patient's assessment of tolerability and acceptance|Health-economic assessment","https://ClinicalTrials.gov/show/NCT01879943"
1950,"NCT02788955","Protein Recommendation to Increase Muscle","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Dietary counselling|Other: Dietary Protein","University of Alberta|Canada Foundation for Innovation|Government of Alberta|Nestlé Health Science Spain|Olymel|Cargill","Both","45 Years to 85 Years   (Adult, Senior)","","36","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","HREBA.CC-15-0193","March 23, 2016","April 2016","April 2020","June 29, 2016","June 2016","No Study Results Posted","PRIMe","April 2018","Change/maintenance in muscle mass|Change in physical function","https://ClinicalTrials.gov/show/NCT02788955"
1951,"NCT02054923","The Effect of Routine Video-recording on Colonoscopy Quality Indicators.","Completed","No Results Available","Colorectal Cancer","Procedure: Implementation of routine videorecording|Behavioral: No routine videorecording","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Medical Centre of Postgraduate Education, Poland|Foundation for Polish Science|European Union","Both","Child, Adult, Senior","","5200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Health Services Research","REC-QUALY","January 31, 2014","March 2014","December 2014","August 3, 2015","August 2015","No Study Results Posted","null","December 2014","Change in screening centre adenoma detection rate before and after intervention|Reported and audited ceacal intubation rates|Rates of painful colonoscopy|Rates of proximal (to the splenic flexure) serrated polyps ≥10mm in size","https://ClinicalTrials.gov/show/NCT02054923"
1952,"NCT01182922","Information About a Doctor or a Possibility of Choosing Doctor's Gender and Attendance to Screening Colonoscopy","Completed","No Results Available","Colorectal Cancer|Screening","Behavioral: Invitation letter","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology","Both","55 Years to 64 Years   (Adult)","Phase 0","5100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","CO-I","August 15, 2010","August 2010","August 2011","November 17, 2011","November 2011","No Study Results Posted","null","March 2011","Percentage of invitees attending screening colonoscopy in each invitation letter group|Percentage of forms with consent for examination, sent back after invitation letter but before reminding letter. Differences in attendance between men and women depending on type of the invitation.","https://ClinicalTrials.gov/show/NCT01182922"
1953,"NCT00657371","Efficacy of the Third Eye Retroscope Auxiliary Imaging System","Completed","Has Results","Colorectal Cancer","Device: Third Eye Retroscope Auxiliary Imaging System","M.D. Anderson Cancer Center|Avantis Medical Systems","Both","50 Years to 80 Years   (Adult, Senior)","","288","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","2007-0246","April 8, 2008","March 2008","May 2010","October 11, 2013","October 2013","October 11, 2013","null","May 2010","Increase (Percent) of Polyps Detected That Would Have Been Missed Without the Third Eye Retroscope (TER)|Number Polyps Detected With the Standard Colonoscope and Third Eye Retroscope (TER)|Number Participants With Polyps Who Would Have Incorrectly Been Classified as Polyp-free Had the Third Eye Retroscope Not Been Used.","https://ClinicalTrials.gov/show/NCT00657371"
1954,"NCT00943891","A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Nasopharyngeal Cancer","Procedure: Tumor biopsies","National University Hospital, Singapore","Both","21 Years and older   (Adult, Senior)","","500","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Cross-Sectional","MC01/09/08","July 20, 2009","July 2008","December 2014","January 21, 2014","January 2014","No Study Results Posted","null","December 2014","","https://ClinicalTrials.gov/show/NCT00943891"
1955,"NCT00758186","Randomized Trial of Colonic Stents as a Bridge to Surgery","Completed","No Results Available","Colorectal Cancer|Intestinal Obstruction","Procedure: Emergency endoscopic colonic stenting|Procedure: Emergency surgery","Singapore General Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Colonic-Stenting-001","September 23, 2008","October 2004","June 2008","September 23, 2008","September 2008","No Study Results Posted","null","February 2008","The primary endpoint was postoperative complication rates.|Secondary outcomes evaluated included type of surgery performed, bowel preservation, presence of a stoma, postoperative bowel function, length of hospital stay, and hospitalization costs.","https://ClinicalTrials.gov/show/NCT00758186"
1956,"NCT01571024","BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer","Completed","No Results Available","Advanced Solid Tumors|Metastatic Colorectal Cancer|Metastatic Pancreatic Cancer","Drug: BKM120|Drug: mFOLFOX6","UNC Lineberger Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","17","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 1036","January 3, 2012","May 2012","March 2016","July 1, 2016","July 2016","No Study Results Posted","null","May 2015","Dose-limiting toxicity (DLT)|Maximum Tolerated Dose (MTD)|Number of subjects experiencing adverse events|Progression Free Survival (PFS)|Overall Survival(OS)|Biomarkers of Clinical Benefit","https://ClinicalTrials.gov/show/NCT01571024"
1957,"NCT02045680","RADOX' Reduced Abdominal Distension and Oxygen Delivery","Recruiting","No Results Available","Colorectal Cancer","","Dr Michael Scott|Royal Surrey County Hospital|Merck Sharp & Dohme Corp.|Royal Surrey County Hospital NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","30","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","13SURN0014|MISP Database 50339","December 17, 2013","March 2014","December 2014","September 4, 2014","September 2014","No Study Results Posted","RADOX","December 2014","Improved tissue oxygen delivery|Reduction in patient pain scores following surgery|Time spent in recovery until fit for discharge to the wards following surgery|Time taken for patient to first mobilise following surgery","https://ClinicalTrials.gov/show/NCT02045680"
1958,"NCT02171286","The Oncopanel Pilot (TOP) Study","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic|Advanced Non-Small Cell Lung Carcinoma|Advanced Melanoma|Gastrointestinal Stromal Tumors|Patients With Diagnosed Malignancies Being Considered for Clinical Trials","","British Columbia Cancer Agency|BC Cancer Foundation","Both","18 Years and older   (Adult, Senior)","","432","Other","Observational","","H14-01212","June 18, 2014","October 2014","October 2016","July 18, 2016","July 2016","No Study Results Posted","null","September 2016","Number of days between receipt of archival tumour tissue and generation of the OncoPanel Report|Percent of cases in which a Oncopanel report is generated on a tumour specimen that has been received","https://ClinicalTrials.gov/show/NCT02171286"
1959,"NCT01184482","Lapatinib and Cetuximab in Patients With Solid Tumors","Completed","No Results Available","Colorectal Cancer|Lung Cancer|Head and Neck Cancer","Drug: cetuximab and lapatinib","Georgetown University|GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 1","22","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","tykerb-itux 1|2010-218","August 17, 2010","June 2010","September 2013","October 29, 2013","October 2013","No Study Results Posted","TYKERB-ITUX 1","June 2013","Maximum tolerated dose|response rate|Pharmacokinetics|Genetic polymorphisms|Genetic variations and activation status for EGFR and ErbB2 pathways","https://ClinicalTrials.gov/show/NCT01184482"
1960,"NCT01587872","Double-balloon Colonoscopy to Increase Colonoscopy Completion Rate","Terminated","No Results Available","Colorectal Cancer|Colorectal Adenomas|Inflammatory Bowel Disease","Procedure: Fujinon EC-450BI5 double-balloon colonoscope","Sorlandet Hospital HF|South-Eastern Norway Regional Health Authority|Fujifilm Europa","Both","18 Years to 90 Years   (Adult, Senior)","","62","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","SSK_DBC","January 12, 2012","October 2011","April 2014","April 11, 2014","April 2012","No Study Results Posted","null","April 2014","Cecal intubation rate|Detection of additional colonic pathology","https://ClinicalTrials.gov/show/NCT01587872"
1961,"NCT01451632","A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers","Completed","Has Results","Colorectal Cancer|Squamous Cell Head and Neck Cancer|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Other Tumors With EGFR Dependence","Drug: MM-121|Drug: Irinotecan|Drug: Cetuximab","Merrimack Pharmaceuticals|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM-121-05-01-05 (TCD11696)","October 7, 2011","October 2011","June 2014","September 6, 2016","September 2016","July 12, 2016","null","November 2013","Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination|To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s) (Via Recording of Maximum Tolerated Dose (MTD)): MM-121 Doses|To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan|Objective Response Rate|Pharmacokinetics|Pharmacokinetic Parameters of MM-121|Immunogenicity","https://ClinicalTrials.gov/show/NCT01451632"
1962,"NCT00763425","Prospective Randomized Comparison of Cold Snare Polypectomy and Conventional Polypectomy","Completed","No Results Available","Colorectal Cancer","Procedure: cold polypectomy|Procedure: conventional polypectomy","Showa Inan General Hospital","Both","20 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","200888","September 29, 2008","September 2008","September 2009","November 17, 2015","November 2015","No Study Results Posted","COLD","August 2009","Complete removal rate of colorectal polyps|Complication rate","https://ClinicalTrials.gov/show/NCT00763425"
1963,"NCT00096967","A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Metastases","Drug: Avastin (bevacizumab)","Genentech, Inc.","Both","Child, Adult, Senior","Phase 3","100","Industry","Interventional","Masking: Open Label|Primary Purpose: Treatment","AVF2540g","November 17, 2004","October 2002","July 2004","March 25, 2014","March 2014","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00096967"
1964,"NCT00508846","Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients","Completed","No Results Available","Colon Cancer","Behavioral: Questionnaire","M.D. Anderson Cancer Center","Female","25 Years and older   (Adult, Senior)","","93","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ID03-0211","July 26, 2007","May 2003","March 2016","March 10, 2016","March 2016","No Study Results Posted","null","March 2016","Patient Responses to Questionnaire","https://ClinicalTrials.gov/show/NCT00508846"
1965,"NCT00332943","MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil","Completed","No Results Available","Colorectal Cancer|Polyps","Procedure: MR colonography with fecal tagging","Herlev Hospital|University Hospital, Gentofte, Copenhagen","Both","18 Years and older   (Adult, Senior)","Phase 4","20","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Diagnostic","KA-20060039 MA|KA-20060039.","June 1, 2006","December 2005","May 2006","September 19, 2007","September 2007","No Study Results Posted","null","null","Quality of fecal tagging agent|Sensitivity of VAS score vs. ReCon score","https://ClinicalTrials.gov/show/NCT00332943"
1966,"NCT00114842","Magnetic Resonance (MR) Colonography With Fecal Tagging","Completed","No Results Available","Colorectal Cancer|Polyps","Procedure: MR colonography","Herlev Hospital|University Hospital, Gentofte, Copenhagen","Both","18 Years and older   (Adult, Senior)","Phase 4","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Diagnostic","KA05029-MA|KA05029","June 17, 2005","March 2006","March 2007","September 19, 2007","September 2007","No Study Results Posted","null","null","Sensitivity/specificity for water versus air for distension of colon in MR colonography|Feasibility of MR colonography with fecal tagging|Sensitivity/specificity of MR colonography versus colonoscopy","https://ClinicalTrials.gov/show/NCT00114842"
1967,"NCT02231385","Acetic Acid Colonoscopy Enhancement Study","Not yet recruiting","No Results Available","Colorectal Cancer|Serrated Adenomas|Colon Nos Polypectomy Tubular Adenoma","Drug: Acetic Acid","Istituto Clinico Humanitas|Nuovo Regina Margherita Hospital","Both","40 Years and older   (Adult, Senior)","","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","The ""ACE"" Study","September 1, 2014","September 2014","June 2015","September 1, 2014","September 2014","No Study Results Posted","null","January 2015","Additional serrated lesions diagnosed after acetic acid spraying|- Number of new adenoma detected at second right colon examination in both studies group|Number of overall serrated and/or adenomatous lesions in the whole colon|Characteristic of lesions detected (size, morphology)|Complication rate","https://ClinicalTrials.gov/show/NCT02231385"
1968,"NCT02066064","G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate-randomized Tandem Study With Different Endoscopist","Completed","No Results Available","Colorectal Cancer|Adenoma","Procedure: Standard Colonoscopy|Procedure: G-EYE(TM) Colonoscopy","Smart Medical Systems Ltd.","Both","50 Years and older   (Adult, Senior)","","58","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Screening","G-EYE","February 10, 2014","November 2013","December 2015","February 11, 2016","February 2016","No Study Results Posted","null","December 2015","G-EYE™ colonoscopy detection rate of adenomas and serrated lesions compared to the standard colonoscopy detection rate of the same.|polyp and adenoma detection, procedure times and safety","https://ClinicalTrials.gov/show/NCT02066064"
1969,"NCT01749722","Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy","Completed","No Results Available","Colorectal Cancer|Polyp|Adenoma","Device: NaviAid™ G-Eye procedure","Smart Medical Systems Ltd.","Both","40 Years to 75 Years   (Adult, Senior)","","50","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","G-Eye 15502","November 11, 2012","November 2012","June 2013","July 29, 2013","July 2013","No Study Results Posted","null","April 2013","Number of adverse events","https://ClinicalTrials.gov/show/NCT01749722"
1970,"NCT01552200","Performance Evaluation of the NaviAid™ G-Eye System","Completed","No Results Available","Colorectal Cancer|Polyp|Adenoma","Procedure: Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Procedure: Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy","Smart Medical Systems Ltd.","Both","40 Years and older   (Adult, Senior)","","126","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","G-Eye 15501","March 6, 2012","June 2012","June 2013","April 6, 2014","April 2014","No Study Results Posted","null","June 2013","NaviAid™ G-Eye procedure adenoma detection rate compared to the standard colonoscopy procedure adenoma detection rate","https://ClinicalTrials.gov/show/NCT01552200"
1971,"NCT01895530","Impact of Probiotics in Modulation of Intestinal Microbiota","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: Saccharomyces boulardii","Maria Isabel Toulson Davisson Correia|Federal University of Minas Gerais","Both","Child, Adult, Senior","","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","ETIC 0391.0.203.000-09","June 30, 2013","July 2010","May 2012","July 5, 2013","July 2013","No Study Results Posted","null","August 2011","Difference in gene expression of citokynes|Postoperative complications","https://ClinicalTrials.gov/show/NCT01895530"
1972,"NCT01895504","ColoAssist vs. MEI","Completed","No Results Available","Colorectal Cancer|Screening","Device: ColoAssist|Device: MEI","Sorlandet Hospital HF","Both","55 Years to 66 Years   (Adult, Senior)","","475","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","ColoAssist","July 4, 2013","April 2013","July 2014","March 2, 2015","March 2015","No Study Results Posted","null","June 2014","Cecal intubation rate|Cecal intubation time|Adenoma detection rate|Polyp detection rate|Pain","https://ClinicalTrials.gov/show/NCT01895504"
1973,"NCT01547923","Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines","Recruiting","No Results Available","Colorectal Cancer|Intravenous 5 Fluorouracile","Genetic: Blood sample for phenotypic and pharmacogenetic analysis.|Genetic: Blood sample for phenotypic and pharmacogenetic analysis.","ICO Paul Papin","Both","18 Years and older   (Adult, Senior)","Phase 3","2296","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CPP-380|2008-000026-39","February 28, 2012","June 2008","December 2012","March 5, 2012","March 2012","No Study Results Posted","DPD côlon","December 2012","Number and nature of grade IV toxicity.|Number of grade III-IV toxic events.|Mortality rate.|Medical-financial study of pre-therapeutic screening.","https://ClinicalTrials.gov/show/NCT01547923"
1974,"NCT02590367","Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy","Recruiting","No Results Available","Peripheral Neuropathy","Drug: FOLFOX regimen|Drug: HD6610 Granule|Drug: HD6610 Granule placebo","Jiangsu Province Hospital of Traditional Chinese Medicine","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","64","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JiangsuPHTCM","September 14, 2015","August 2015","October 2017","November 30, 2015","November 2015","No Study Results Posted","null","October 2017","The number of patients with different degree of peripheral nerve toxicity.|EORTC（European Organization for Research and Treatment of Cancer） quality of life score|KPS（ Karnofsky Performance Status Scale） score","https://ClinicalTrials.gov/show/NCT02590367"
1975,"NCT02565017","Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System","Recruiting","No Results Available","Breast Cancer|Lung Cancer|Colorectal Cancer","Behavioral: Focus groups","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","","81","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-226","September 30, 2015","September 2015","null","April 8, 2016","April 2016","No Study Results Posted","null","September 2017","Acceptability of IBM Watson Oncology","https://ClinicalTrials.gov/show/NCT02565017"
1976,"NCT00508573","Registry for Women Who Are At Risk Or May Have Lynch Syndrome","Recruiting","No Results Available","Hereditary Nonpolyposis Colorectal Cancer|Lynch Syndrome","Behavioral: Questionnaire","M.D. Anderson Cancer Center","Female","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2006-0973","July 26, 2007","May 2007","null","May 12, 2016","May 2016","No Study Results Posted","null","May 2018","Number of Women Participating in Registry","https://ClinicalTrials.gov/show/NCT00508573"
1977,"NCT00755534","Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC","Terminated","No Results Available","Colorectal Cancer","Drug: Irinotecan|Drug: Capecitabine|Drug: Cetuximab|Drug: Oxaliplatin","Hellenic Oncology Research Group|University Hospital of Crete","Both","18 Years to 72 Years   (Adult, Senior)","Phase 2","68","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/05.31","September 18, 2008","November 2008","November 2008","February 12, 2013","February 2013","No Study Results Posted","null","November 2008","Time To Progression|Objective Response Rate|Toxicity profile|1 year Survival and Overall Survival|Correlation of the molecular characteristics of the tumor with the clinical outcome","https://ClinicalTrials.gov/show/NCT00755534"
1978,"NCT01606124","Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer","Active, not recruiting","No Results Available","Advanced Colorectal Adenomas|Adenocarcinoma of the Colon|Stage I Colon Cancer|Stage II Colon Cancer|Stage III Colon Cancer","Drug: defined green tea catechin extract|Other: placebo|Other: questionnaire administration|Other: laboratory biomarker analysis","Mayo Clinic|National Cancer Institute (NCI)","Both","40 Years and older   (Adult, Senior)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","MC084C|NCI-2012-00058","May 23, 2012","June 2012","null","April 18, 2016","January 2016","No Study Results Posted","null","January 2018","Percent change in rectal ACF, pre- and post intervention at 6 months|Tolerability as estimated using the percent dose of treatment received for each patient by dividing the total dose received by the targeted (i.e., protocol specified) total dose at 6 months","https://ClinicalTrials.gov/show/NCT01606124"
1979,"NCT00173277","Screening for CRC Using a Mixed Strategy of Sigmoidoscopy and Colonoscopy in Average-Risk Population According to Age","Recruiting","No Results Available","Colorectal Cancer","","National Taiwan University Hospital","Both","50 Years and older   (Adult, Senior)","","2500","Other","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Cross-Sectional|Time Perspective: Retrospective/Prospective","9461700610","September 12, 2005","June 2003","July 2004","September 12, 2005","June 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00173277"
1980,"NCT00958737","Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Drug: XELOX regimen|Drug: Capecitabine","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","Both","18 Years to 120 Years   (Adult, Senior)","Phase 3","2000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000647466|FRE-GERCOR-C09-1-IDEA|EUDRACT-2009-010384-16|EU-20957","August 12, 2009","April 2009","September 2017","December 10, 2015","December 2015","No Study Results Posted","IDEA","May 2016","Disease-free survival (defined as local, regional, or distant relapse; second primary colorectal cancer; or death from any cause)|Overall survival|Toxicity according to NCI CTCAE version 3.0|Total cumulative dose received vs planned dose|Incidence and timing of dose reductions and/or modifications of time","https://ClinicalTrials.gov/show/NCT00958737"
1981,"NCT01067053","Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: bevacizumab, capecitabine, oxaliplatin","Grupo Espanol Multidisciplinario del Cancer Digestivo","Both","70 Years and older   (Senior)","Phase 2","69","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEMCAD-0901","January 21, 2010","November 2009","March 2014","January 8, 2014","January 2014","No Study Results Posted","BECOX","November 2010","Time to progression|Overall survival|Objective response rate following Response Evaluation Criteria In Solid Tumors (RECIST) criteria|Overall response rate|Number of treatment cycles administered|Number of patients who have required dose reductions of either drug|Safety of treatment according to the number of adverse events reported","https://ClinicalTrials.gov/show/NCT01067053"
1982,"NCT00148226","ICIBS Trial - Improving Patient Information About Bowel Cancer Screening - a Decision Aid Trial","Completed","No Results Available","Colorectal Cancer Screening","Behavioral: Decision Aid","University of Sydney","Both","50 Years to 74 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Educational/Counseling/Training","211205","September 5, 2005","November 2003","September 2005","January 3, 2006","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00148226"
1983,"NCT00300547","Preoperative Assessment for Synchronous Carcinoma or Polyps With Magnetic Resonance (MR) Colonography","Completed","No Results Available","Obstructing Colorectal Cancer","Procedure: MR colonography","Herlev Hospital|University Hospital, Gentofte, Copenhagen","Both","18 Years and older   (Adult, Senior)","Phase 4","50","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","KA05030-MA|KA05030","March 8, 2006","March 2007","null","August 17, 2010","March 2006","No Study Results Posted","null","April 2008","Feasibility of MR colonography to diagnose possible synchronous carcinomas and polyps|Altered operative strategy due to findings on MR colonography","https://ClinicalTrials.gov/show/NCT00300547"
1984,"NCT02080650","Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)","Recruiting","No Results Available","Prostate Cancer|Renal Cell Carcinoma|Bladder Cancer|Colorectal Cancer|Gastric Cancer|Pancreatic Cancer|Non-small Cell Lung Cancer|Advanced MET Amplified Solid Tumor","Device: Mesenchymal-marker based ferrofluid (c-MET)|Device: Epithelial cell adhesion molecule (EpCAM) ferrofluid","Duke University|Prostate Cancer Foundation|Janssen Diagnostics, LLC","Both","18 Years and older   (Adult, Senior)","","85","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","Pro00052149","March 3, 2014","March 2014","null","June 27, 2016","June 2016","No Study Results Posted","null","December 2016","Feasibility|Difference in the median number of CTCs|Association of the number of detectable CTCs with baseline clinical and pathologic disease characteristics.|Kinetics of CTCs over time during treatment with c-MET targeted therapies","https://ClinicalTrials.gov/show/NCT02080650"
1985,"NCT00755118","Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc","Terminated","No Results Available","Colorectal Cancer","Drug: Oxaliplatin|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Bevacizumab|Drug: Irinotecan|Drug: Cetuximab","University Hospital of Crete","Both","18 Years to 72 Years   (Adult, Senior)","Phase 2","24","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/08.28","September 17, 2008","October 2008","August 2012","October 6, 2015","October 2015","No Study Results Posted","null","August 2012","Objective Response Rate|Time To Progression|Toxicity profile|Quality of life|Symptoms improvement|Overall Survival","https://ClinicalTrials.gov/show/NCT00755118"
1986,"NCT01483638","Axitinib as Maintenance Treatment in Patients With Metastatic CRC","Terminated","No Results Available","Colorectal Carcinoma","Drug: axitinib|Drug: placebo","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","Both","18 Years and older   (Adult, Senior)","Phase 2","84","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TTD-11-01|2011-002384-16","November 29, 2011","February 2012","September 2015","May 11, 2016","May 2016","No Study Results Posted","TTD-11-01","September 2015","progression-free survival|overall survival|overall response rate|duration of disease response|Adverse events","https://ClinicalTrials.gov/show/NCT01483638"
1987,"NCT00874224","Surgical Recovery After Left Lateral Hepatic Sectionectomy: Laparoscopic Versus Open Surgery.","Completed","No Results Available","Colorectal Cancer|Liver Metastasis|Liver Disease","Procedure: laparoscopic left lateral hepatic sectionectomy|Procedure: open left lateral hepatic sectionectomy","Maastricht University Medical Center|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|UMC Utrecht|Medisch Spectrum Twente|University Medical Center Groningen|Erasmus Medical Center|University Medical Center Nijmegen|Onze Lieve Vrouwe Gasthuis|Maxima Medical Center|Isala|San Raffaele University Hospital, Italy|University Hospital, Aachen|Deventer Ziekenhuis","Both","18 Years to 80 Years   (Adult, Senior)","","110","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","MEC 08-2-110","March 31, 2009","January 2010","July 2014","March 8, 2016","March 2016","No Study Results Posted","ORANGE II","July 2014","Time to functional Recovery|Postoperative length of hospital stay|Readmission percentage|Total morbidity|Composite endpoint of liver surgery specific morbidity|Quality of life|Body image and cosmesis|Hospital and societal costs|Incidence of incisional hernias|Reasons for delay of discharge after functional recovery","https://ClinicalTrials.gov/show/NCT00874224"
1988,"NCT00414492","Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","J06106|NA_00004883","December 20, 2006","December 2006","June 2010","September 15, 2010","September 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00414492"
1989,"NCT01117428","Sym004 in Patients With Advanced Solid Tumors","Completed","No Results Available","Metastatic Colorectal Cancer","Biological: Sym004","Symphogen A/S","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","111","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Sym004-01|2009-017119-13","April 23, 2010","March 2010","May 2015","December 23, 2015","December 2015","No Study Results Posted","null","February 2015","Adverse events|Objective tumor response according to RECIST criteria verified by imaging techniques|Duration of overall response|Progression free survival|Overall survival|Host immune response: ADA monitoring|Skin rash according to CTCAE grading|Biomarker including CEA and YKL 40|Vital signs and laboratory parameters|Pharmakokinetic profile of multiple weekly and biweekly doses of Sym004","https://ClinicalTrials.gov/show/NCT01117428"
1990,"NCT02069704","Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients","Completed","No Results Available","Metastatic Colorectal Cancer.","Drug: Bevacizumab biosimilar (BEVZ92)|Drug: Avastin® (bevacizumab, reference product)","mAbxience S.A|Laboratorio Elea S.A.C.I.F. y A.|Libbs Farmacêutica Ltda","Both","18 Years and older   (Adult, Senior)","Phase 1","142","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BEVZ92-A-01-13","February 14, 2014","October 2014","October 2015","May 19, 2016","May 2016","No Study Results Posted","null","October 2015","To compare the PK profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI|Safety, immunogenicity and efficacy profile","https://ClinicalTrials.gov/show/NCT02069704"
1991,"NCT01703585","Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples","Recruiting","No Results Available","Colorectal Cancer|Breast Cancer|Gynecological Cancer|Metastatic|Eligible for Phase I or Phase II Study|Melanoma Cancer","","University Health Network, Toronto|Ontario Institute for Cancer Research|Princess Margaret Hospital, Canada","Both","18 Years and older   (Adult, Senior)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MATCH-001","October 5, 2012","October 2012","December 2017","June 21, 2016","June 2016","No Study Results Posted","null","December 2017","Patient recruitment for paired core and fine needle biopsy greater than or equal to 50% of those screened or approached.|The rate of acceptable tumor samples from fresh core needle biopsy samples/total number of fresh core needle biopsy samples greater than or equal to 90%|The rate of acceptable tumor samples from fresh fine needle biopsy samples/total number of fresh fine needle biopsy samples greater than or equal to 50%|Successful analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 50%|Analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples from time from patient recruitment to final results, less than a defined period of time, in greater than or equal to 90%|Actionable genomic result analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 30%","https://ClinicalTrials.gov/show/NCT01703585"
1992,"NCT01286662","A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome","Completed","No Results Available","Gardner Syndrome|Colorectal Carcinoma|Desmoid Tumor","","Triemli Hospital","Both","Child, Adult, Senior","","105","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TriemliH","January 25, 2011","January 1978","December 2010","January 27, 2011","January 2011","No Study Results Posted","null","December 2010","mortality|incidence of colorectal carcinoma|Incidence of desmoid tumors","https://ClinicalTrials.gov/show/NCT01286662"
1993,"NCT00132704","An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation","Completed","No Results Available","Ovarian Neoplasms|Colorectal Neoplasms|Melanoma|Small Cell Lung Cancer|Liposarcoma","Radiation: Ionizing radiation (IR) therapy|Radiation: Ionizing radiation (IR)","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","19 Years and older   (Adult, Senior)","Phase 3","149","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","04-109","August 18, 2005","August 2004","July 2014","July 23, 2014","July 2014","No Study Results Posted","null","July 2014","apoptotic response","https://ClinicalTrials.gov/show/NCT00132704"
1994,"NCT00026117","Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer","Drug: BenFin|Other: placebo","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","88","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","NCCTG-971151|CDR0000068987|NCCAM","November 9, 2001","August 2001","September 2006","July 12, 2016","July 2016","No Study Results Posted","null","September 2006","overall survival|quality of life","https://ClinicalTrials.gov/show/NCT00026117"
1995,"NCT00905710","Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome","Completed","No Results Available","Lynch Syndrome","Procedure: Chromoendoscopy","University Medical Center Groningen|Leiden University Medical Center|Free University Medical Center|University Medical Center Nijmegen|The Netherlands Cancer Institute|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Both","20 Years to 70 Years   (Adult, Senior)","","240","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","ChromoLynch","May 18, 2009","September 2008","May 2016","May 12, 2016","May 2016","No Study Results Posted","ChromoLynch","May 2016","The primary endpoints of the study are the number of adenomas, advanced adenomas, carcinomas at baseline and the number of the number of adenomas, advanced adenomas, carcinomas and the number of patients requiring colectomy at 2-year follow-up.|The secondary endpoints of the study are the number of complications from colonoscopy at baseline and at 2-year follow-up.","https://ClinicalTrials.gov/show/NCT00905710"
1996,"NCT00468910","Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer","Active, not recruiting","No Results Available","Colon Cancer|Precancerous Condition|Rectal Cancer","Drug: acetylsalicylic acid|Drug: placebo|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","up to 75 Years   (Child, Adult, Senior)","Phase 2","115","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NCI-2009-00841|CDR0000652929|NCI 04-2-03|NWU04-2-03|N01CN35157","May 2, 2007","March 2007","null","December 6, 2013","December 2013","No Study Results Posted","null","December 2009","Change in spectral slope|Change in fractal dimension|Colonic epithelial apoptosis as measured by immunohistochemical detection of cleaved caspase 3|Colonic cell proliferation as measured by immunohistochemical detection of Ki67|Rectal prostaglandin levels as measured by ELISA|Platelet cyclooxygenase (COX) activity as measured by a peroxidase-based COX enzyme activity assay","https://ClinicalTrials.gov/show/NCT00468910"
1997,"NCT01416168","Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery","Completed","No Results Available","Colorectal Cancer","Other: McCorkle Model Intervention","H. Lee Moffitt Cancer Center and Research Institute|Tampa General Hospital|University of South Florida|Yale University","Both","60 Years and older   (Adult, Senior)","","15","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","MCC-15641","August 11, 2011","December 2008","November 2013","November 26, 2013","November 2013","No Study Results Posted","null","April 2013","Feasibility of the Intervention|Whether the Intervention is Faithful to Dr. McCorkle's Original Intervention|A Successful Collection and Testing of >=90% of the Samples Tested|Effect Size Estimates for Within-group Changes Between Baseline and 1-month","https://ClinicalTrials.gov/show/NCT01416168"
1998,"NCT00888797","β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Propranolol and Etodolac","Sheba Medical Center|Tel-Aviv Sourasky Medical Center|Rabin Medical Center","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SHEBA-09-6994-OZ-CTIL","April 26, 2009","January 2010","January 2017","July 10, 2011","July 2011","No Study Results Posted","null","January 2017","Rate of recurrent and metastatic cancer|magnitude and duration of surgically induced immune depression, as reflected in the blood samples|Early postoperative morbidity and mortality","https://ClinicalTrials.gov/show/NCT00888797"
1999,"NCT01286818","A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)","Completed","Has Results","Colorectal Carcinoma","Biological: Ramucirumab (IMC-1121B)|Drug: Irinotecan|Drug: levofolinate|Drug: 5-Fluorouracil (5-FU)","Eli Lilly and Company","Both","20 Years and older   (Adult, Senior)","Phase 1","6","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14223|CP12-1029|14T-IE-JVBY","January 25, 2011","February 2011","March 2012","October 3, 2014","October 2014","May 16, 2014","null","February 2012","Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period|Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events|Number of Participants With Serum Anti-IMC-1121B Antibodies (Immunogenicity)|Maximum Concentration (Cmax) of Ramucirumab|Area Under the Curve (AUC) of Ramucirumab|Half Life (t1/2) of Ramucirumab|Clearance (CL) of Ramucirumab|Steady State Volume of Distribution (Vss) of Ramucirumab|Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]","https://ClinicalTrials.gov/show/NCT01286818"
2000,"NCT01073358","Resection of Colorectal Liver Metastases With or Without Routine Hilar Lymphadenectomy","Enrolling by invitation","No Results Available","Hepatic Metastases|Colorectal Cancer","Procedure: Routine hilar lymphadenectomy","Heidelberg University","Both","18 Years and older   (Adult, Senior)","","166","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","NNR-5","February 22, 2010","February 2010","October 2014","February 22, 2010","February 2010","No Study Results Posted","RELY","September 2013","rate of disease recurrence","https://ClinicalTrials.gov/show/NCT01073358"
2001,"NCT00435097","Computer Assisted Early Detection of Liver Metastases From fMRI Maps","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","","Hadassah Medical Organization","Both","20 Years and older   (Adult, Senior)","","null","Other","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","colmri-HMO-CTIL","February 13, 2007","null","null","February 13, 2007","February 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00435097"
2002,"NCT01652833","European Physician Survey of EGFR Inhibitor Prescribing Patterns","Completed","No Results Available","Metastatic Colorectal Cancer","Other: Physician Survey","Amgen","Both","18 Years and older   (Adult, Senior)","","453","Industry","Observational","Time Perspective: Cross-Sectional","20101121","June 5, 2012","March 2012","November 2014","February 29, 2016","February 2016","No Study Results Posted","null","November 2014","Proportion of oncologists who are aware of the correct indication of Vectibix, with regard to tumor KRAS status and who conduct a KRAS test prior to initiation of Vectibix treatment|Proportion of oncologists who conduct a KRAS test prior to the initiation of Vectibix treatment|Proportion of oncologists who administer Vectibix in mCRC patients with mutant KRAS tumors or with KRAS status unknown|Proportion of oncologists who administer Vectibix simultaneously with oxaliplatin-containing chemotherapy in mCRC patients with mutant KRAS tumors or patients with tumor KRAS status unknown","https://ClinicalTrials.gov/show/NCT01652833"
2003,"NCT01675258","Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers","Not yet recruiting","No Results Available","Gastric Cancer|Colorectal Cancer and Pre-cancer Polyps|Pancreatic Cancer","Other: Salivary samples","Hadassah Medical Organization","Both","18 Years and older   (Adult, Senior)","","150","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","LSA003-HMO-CTIL","August 27, 2012","September 2012","null","August 27, 2012","July 2012","No Study Results Posted","null","September 2013","","https://ClinicalTrials.gov/show/NCT01675258"
2004,"NCT02205398","Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy","Active, not recruiting","No Results Available","Squamous Cell Carcinoma of Head and Neck,|Metastatic Colorectal Cancer","Drug: INC280|Drug: cetuximab","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CINC280X2104|2014-000579-20","July 25, 2014","July 2014","January 2018","September 19, 2016","September 2016","No Study Results Posted","null","January 2018","Incidence of Dose Limiting Toxicities (DLTs)|Frequency of Adverse Events (AEs)/Serious Adverse Events (SAEs)|Overall Response Rate|Overall Survival|Time versus plasma concentration profiles and basic PK parameters of INC280|Severity of Adverse Events (AEs)/Serious Adverse Events (SAEs)|Frequency of dose treatment interruptions and reductions|Progression Free Survival","https://ClinicalTrials.gov/show/NCT02205398"
2005,"NCT01341197","Fecal Screening Assay for Taiwanese Population","Completed","No Results Available","Advanced Colorectal Neoplasms|Throat Cancer|Esophageal Cancer|Gastric Cancer|Important Lower and Upper Gastrointestinal Tract Lesions","Other: Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test","National Taiwan University Hospital","Both","18 Years to 95 Years   (Adult, Senior)","","3172","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201101016RC","April 21, 2011","March 2011","November 2012","November 30, 2012","November 2012","No Study Results Posted","null","November 2012","Important Lower and Upper GI tract Lesions","https://ClinicalTrials.gov/show/NCT01341197"
2006,"NCT02346955","Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)","Recruiting","No Results Available","Non-small Cell Lung Carcinoma (NSCLC)|Melanoma|Bladder Cancer|Colorectal Cancer|Gastric Cancer|Ovarian Cancer","Biological: CM-24 (MK-6018)|Biological: Pembrolizumab (MK-3475)","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1","196","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6018-001|CB-24-01|MK-6018-001","December 9, 2014","February 2015","May 2019","September 6, 2016","September 2016","No Study Results Posted","null","May 2019","Number of participants with Adverse Events (AEs)|Number of participants discontinuing study drug due to AEs|Number of participants with a Dose Limiting Toxicity (DLT)|Maximum drug concentration in serum/plasma (Cmax)|Time to reach Cmax in serum/plasma (Tmax)|Terminal-phase elimination half-life in serum/plasma (t1/2)|Area under the plasma/serum concentration versus time curve from time zero to the last measured time (AUC 0-T)|Area under the plasma/serum concentration versus time curve from time zero to infinity (AUC 0-∞)|Objective Response Rate (ORR) defined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria|Time from ORR to disease progression or death (DOR)","https://ClinicalTrials.gov/show/NCT02346955"
2007,"NCT01351103","A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands","Suspended","No Results Available","Pancreatic Adenocarcinoma|BRAF Mutant Colorectal Cancer|Other Tumor Types With Documented Genetic Alterations Upstream in the Wnt Signaling Pathway","Drug: LGK974","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","170","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLGK974X2101|2011-000495-33","May 4, 2011","December 2011","January 2019","April 15, 2016","April 2016","No Study Results Posted","null","January 2019","Maximum Tolerated Dose or Recommended Dose for Expansion of LGK974 in patients treated|Type and category of study drug related adverse events (AE)|Absorption and plasma concentrations of LGK974|Biomarkers related to the Wnt pathway|Overall response rate of tumor","https://ClinicalTrials.gov/show/NCT01351103"
2008,"NCT02050737","Plasma Biomarkers C-RAC, ICORG 12-27, V1","Recruiting","No Results Available","Colorectal Cancer","","Cancer Trials Ireland","Both","18 Years and older   (Adult, Senior)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ICORG 12-27","January 23, 2014","October 2013","null","February 15, 2016","February 2016","No Study Results Posted","null","December 2022","Disease free survival or progression free survival|Accuracy, sensitivity, specificity and concordance index|To investigate the correlation between biomarkers identified in plasma samples with the expression of the same biomarkers at tissue level.","https://ClinicalTrials.gov/show/NCT02050737"
2009,"NCT02517554","A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services","Recruiting","No Results Available","Breast Cancer|Ovarian Cancer|Colorectal Cancer","Behavioral: Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site|Behavioral: Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site|Behavioral: Patient receives written information on how to find genetic services in their area","Abramson Cancer Center of the University of Pennsylvania","Both","18 Years and older   (Adult, Senior)","Phase 0","210","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UPCC 09115","August 5, 2015","August 2015","null","February 15, 2016","February 2016","No Study Results Posted","null","August 2018","Completion of Surveys","https://ClinicalTrials.gov/show/NCT02517554"
2010,"NCT02210260","Pain Relief After Colorectal Surgery: Spinal Combined With Painbuster® vs Painbuster® Alone.","Completed","No Results Available","Colorectal Cancer","Procedure: Spinal and infusion of local anaesthetic|Procedure: Continuous infusion of local anaesthetic|Drug: Bupivacaine|Drug: Diamorphine|Device: A Painbuster® catheter|Device: 25G Whitacre needle","York Teaching Hospitals NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","79","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SNE 2190","July 31, 2014","September 2013","February 2016","September 13, 2016","September 2016","No Study Results Posted","PROSP","February 2016","Neuroendocrine response to surgery|Length of hospital stay or fitness for discharge|Postoperative complications|Episodes of hypotension in the postoperative period|Postoperative pain|Postoperative analgesic requirement|Amount of postoperative IV fluid administered|Postoperative mobility|Return of gut function|Oxidative stress|Inflammatory pathway","https://ClinicalTrials.gov/show/NCT02210260"
2011,"NCT00869843","Study of Saline Linked Monopolar Surface Radiofrequency (RF) Ablation of Hepatic Tumors","Completed","No Results Available","Malignant Liver Tumors|Liver Metastases From Colorectal Cancer","Procedure: RF Ablation","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","Phase 1","28","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-0343","March 25, 2009","October 2002","March 2009","April 22, 2013","April 2013","No Study Results Posted","null","October 2007","Depth of coagulation which is possible in human liver tissue using the saline linked RF Surface ablation with the Tissue Link floating ball|Efficacy of the technique on surface liver tumors using saline lined RF Surface ablation.|Determine a safe (non-popping upper limit) of power per area that will permit a 1 cm depth of tissue destruction without inflow occlusion and a 2 cm depth with inflow occlusion.","https://ClinicalTrials.gov/show/NCT00869843"
2012,"NCT02473302","Preventive Strategies in Colorectal Carcinogenesis Production and Meat Processing","Completed","No Results Available","Colorectal Cancer","Other: ham|Other: ham + pomegranate extract|Other: ham + tocopherol|Other: rare sirloin steak|Other: marinated rare sirloin steak|Other: marinated cooked sirloin steak","Institut National de la Recherche Agronomique|Centre de Recherche en Nutrition Humaine d'Auvergne","Male","40 Years to 75 Years   (Adult, Senior)","","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Basic Science","Securiviande","June 12, 2015","April 2014","July 2014","June 12, 2015","June 2015","No Study Results Posted","null","July 2014","Fecal marker|NOC|cytotoxic activity of fecal water|DHN-MA|TBARs","https://ClinicalTrials.gov/show/NCT02473302"
2013,"NCT00718055","Magnetic Resonance Imaging (MRI) Using Liverspecific Oral Contrast Agent in Metastatic Colorectal Cancer Patients","Withdrawn","No Results Available","Neoplasm Metastasis|Liver|Colorectal Neoplasms|Magnetic Resonance Imaging|Contrast Media","","Copenhagen University Hospital at Herlev","Both","18 Years and older   (Adult, Senior)","Phase 4","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KA-20060096","October 4, 2006","November 2006","null","February 9, 2009","February 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00718055"
2014,"NCT00870961","Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps","Terminated","No Results Available","Colorectal Cancer|Precancerous Condition","Dietary Supplement: cholecalciferol|Other: placebo","Northwestern University|National Cancer Institute (NCI)","Both","50 Years and older   (Adult, Senior)","","22","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NU 08I3|P30CA060553|NU-08I3|STU00005964","March 26, 2009","February 2009","June 2012","September 13, 2013","September 2013","No Study Results Posted","null","June 2012","Rate of compliance as assessed at 6 months|Rate of accrual|Changes in pre- and post-treatment vitamin D levels|Correlation of vitamin D levels with vitamin D modifiers (e.g., levels of skin pigmentation, dietary vitamin D intake, and sun exposure)","https://ClinicalTrials.gov/show/NCT00870961"
2015,"NCT00215722","XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Carcinoma","Drug: Cetuximab","Grupo de Investigacao do Cancro Digestivo","Both","18 Years and older   (Adult, Senior)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GICR-P003","September 20, 2005","July 2005","July 2008","April 5, 2007","April 2007","No Study Results Posted","null","null","Determine the Efficacy of the combination treatment (cetuximab plus capecitabine and oxaliplatin) as first-line therapy based on the overall response rate (ORR) according to the RECIST criteria.|Determine the Safety parameters of combination treatment (cetuximab plus capecitabine and oxaliplatin) as first-line therapy analyzing the frequency, severity, duration and relationship of adverse events using the NCI CTCAE, version 3.0|Time to tumour progression (TTP)|Overall survival time (OS)|Evaluate the Quality of Life","https://ClinicalTrials.gov/show/NCT00215722"
2016,"NCT00023933","Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer","Completed","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: iodine I 131 monoclonal antibody CC49-deltaCH2","National Cancer Institute (NCI)","Both","19 Years and older   (Adult, Senior)","Phase 1","15","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02406|UAB 9846|CDR0000068877","September 13, 2001","October 2001","null","January 24, 2013","January 2013","No Study Results Posted","null","July 2005","Maximum tolerated dose of 131I-HuCC49^CH2 based on dose-limiting toxicities|Immune response","https://ClinicalTrials.gov/show/NCT00023933"
2017,"NCT01254617","Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer","Active, not recruiting","No Results Available","Recurrent Colon Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Recurrent Rectal Carcinoma|Recurrent Salivary Gland Carcinoma|Salivary Gland Squamous Cell Carcinoma|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary|Stage IV Hypopharyngeal Squamous Cell Carcinoma|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IVA Colon Cancer|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Verrucous Carcinoma|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVA Major Salivary Gland Carcinoma|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVA Oral Cavity Verrucous Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Verrucous Carcinoma|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVB Major Salivary Gland Carcinoma|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVB Oral Cavity Verrucous Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVB Rectal Cancer|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Verrucous Carcinoma|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVC Major Salivary Gland Carcinoma|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVC Oral Cavity Verrucous Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma|Tongue Carcinoma|Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary","Biological: Cetuximab|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","24","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02557|CDR0000690277|OSU-10112|10112|8695|P30CA016058|U01CA076576|UM1CA186712","December 3, 2010","February 2011","null","July 6, 2016","July 2016","No Study Results Posted","ADCC","January 2014","Maximum-tolerated dose of lenalidomide with cetuximab, defined as the highest dose level at which 0 or 1 patients out of 6 experiences a dose limiting toxicity graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|ADCC activity|Natural killer cell activation|Response as measured by RECIST","https://ClinicalTrials.gov/show/NCT01254617"
2018,"NCT00949312","Studying Lymph Nodes in Patients With Stage II Colon Cancer","Recruiting","No Results Available","Colorectal Cancer","Genetic: RNA marker analysis of lymph node and primary tumors|Genetic: microarray profiling of primary tumors|Genetic: reverse transcriptase-polymerase chain reaction of lymph node specimens|Other: diagnostic laboratory RNA and DNA biomarker analysis of primary tumors|Procedure: regional lymph node dissection|Other: lymph node staining for H&E and pancytokeratin IHC","John Wayne Cancer Institute|National Cancer Institute (NCI)","Both","18 Years to 85 Years   (Adult, Senior)","Phase 1","300","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDR0000649763|UCLA-0809064|BILA-UECC-0107|IRB# 08-09-064-02","July 29, 2009","May 2009","null","June 1, 2016","June 2016","No Study Results Posted","null","December 2017","Disease-free survival (time to local or distant recurrence after resection)|Overall survival (time to death from colorectal cancer)","https://ClinicalTrials.gov/show/NCT00949312"
2019,"NCT01810744","Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer|Glioblastoma|Bevacizumab|Capillaroscopy","Other: capillaroscopy|Other: blood pressure measurement","Centre Georges Francois Leclerc","Both","18 Years and older   (Adult, Senior)","","98","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","001-FANI-2012","March 12, 2013","May 2013","null","April 22, 2016","April 2016","No Study Results Posted","BEVACAPI","January 2016","change in the density of capillaries","https://ClinicalTrials.gov/show/NCT01810744"
2020,"NCT01520389","Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment","Completed","No Results Available","Advanced Solid Tumors|Colorectal Cancer|Squamous Cell Head and Neck Cancer|Non Small Cell Lung Cancer|Triple Negative Breast Cancer","Drug: MM-151|Drug: MM-151 + irinotecan","Merrimack Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","112","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM-151-01-01-01","January 13, 2012","January 2012","January 2016","March 14, 2016","March 2016","No Study Results Posted","null","December 2015","Phase II dose of MM-151 alone and in combination with irinotecan based either on the maximum tolerated dose (MTD) or maximum dose of 18 mg/kg in patients with advanced solid malignancies.|Number of dose limiting toxicities (DLTs) within a cohort|Adverse event profile of MM-151 alone and in combination with irinotecan|Objective response to MM-151 alone and in combination with irinotecan based on RECIST","https://ClinicalTrials.gov/show/NCT01520389"
2021,"NCT00003433","Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine","Duke Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066459|DUMC-2031-00-11R3|DUMC-2176-99-12R2|DUMC-97146|NCI-G98-1456","November 1, 1999","June 1998","August 2003","June 20, 2013","November 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003433"
2022,"NCT02860780","A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer","Recruiting","No Results Available","Advanced Cancer|Metastatic Cancer|Colorectal Cancer|Non-small Cell Lung Cancer","Drug: prexasertib|Drug: ralimetinib","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 1","70","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","16379|I4D-MC-JTJL|2015-005611-33","August 5, 2016","August 2016","April 2020","September 9, 2016","September 2016","No Study Results Posted","null","July 2018","Maximum Tolerated Dose (MTD) of Prexasertib and Ralimetinib|Pharmacokinetics (PK): Maximum Concentration (Cmax) of Prexasertib|PK: Area Under the Curve (AUC) of Prexasertib|PK: Cmax of Ralimetinib|PK: AUC of Ralimetinib|Best Overall Response (BOR): Percentage of Participants with Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE)|Disease Control Rate (DCR): Percentage of Participants who Exhibit SD, CR or PR|Duration of Response (DOR)|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02860780"
2023,"NCT02481219","Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure","Completed","Has Results","Colorectal Cancer Screening","Device: PillCam® COLON 2 procedure-CONTROL|Drug: Senna tablets|Drug: PEG|Drug: Metoclopramide|Drug: Erythromycin|Drug: SUPREP oral sulfate solution|Drug: Bisacodyl|Drug: SUPREP oral sulfate solution with Gastrografin","Medtronic - MITG","Both","50 Years to 75 Years   (Adult, Senior)","","122","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","MA-205","May 19, 2015","May 2015","February 2016","May 30, 2016","June 2015","March 6, 2016","null","January 2016","Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)|Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE|Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE|Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE|Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE|Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE","https://ClinicalTrials.gov/show/NCT02481219"
2024,"NCT02292641","The Role of MRI in Improving Surgical Technique and Outcomes in Exenterative Pelvic Surgery for Locally Extensive Primary or Recurrent Rectal Cancer","Recruiting","No Results Available","Neoplasms|Adenocarcinoma|Carcinoma","Procedure: New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery","Royal Marsden NHS Foundation Trust|Pelican Cancer Foundation","Both","18 Years and older   (Adult, Senior)","","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CCR 4115","May 2, 2014","October 2014","October 2019","November 12, 2014","May 2014","No Study Results Posted","Beyond TME","October 2019","Percentage of patients with R0 resection|Overall Survival and disease-free survival.|Percentage of scans showing disease by pelvic compartment|Inter-observer radiological agreement for each compartment.|SUV values in each pelvic compartment|Restriction in DWI in the seven (7) different pelvic compartments.|Proportion of patients with mutated KRAS and BRAF oncogenes|QLQ-C30 scores at baseline, 1 and 3 years. Occurrence of 30 Day Morbidity and Mortality","https://ClinicalTrials.gov/show/NCT02292641"
2025,"NCT01025960","A Comparison of Methods to Detect Polyps During Colonoscopy","Completed","No Results Available","Colorectal Cancer","Procedure: Standard Inspection Colonoscopy|Procedure: Dual Inspection Colonoscopy","The Cleveland Clinic","Both","18 Years to 80 Years   (Adult, Senior)","","768","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","09-786","December 2, 2009","November 2009","January 2012","March 26, 2012","March 2012","No Study Results Posted","null","December 2011","Adenoma detection rates for each method|Comparison of procedure times for each method|Percentage of patients with at least one adenoma detected by each method|Comparison of percentage of adenomas classified as high risk for each method","https://ClinicalTrials.gov/show/NCT01025960"
2026,"NCT02440737","Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Stage I-III Breast, Lung, Prostate, or Colorectal Cancer and Their Caregivers","Recruiting","No Results Available","Cancer Survivor|Caregiver|Stage I Colon Cancer|Stage I Lung Cancer|Stage I Prostate Cancer|Stage I Rectal Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Lung Cancer|Stage IIA Breast Cancer|Stage IIA Colon Cancer|Stage IIA Prostate Cancer|Stage IIA Rectal Cancer|Stage IIB Breast Cancer|Stage IIB Colon Cancer|Stage IIB Prostate Cancer|Stage IIB Rectal Cancer|Stage III Lung Cancer|Stage III Prostate Cancer|Stage IIIA Breast Cancer|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Breast Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer","Other: Educational Intervention|Other: Educational Intervention|Other: Follow-Up Care|Procedure: Psychosocial Assessment and Care|Other: Questionnaire Administration","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","120","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","VICC REACH 1525|NCI-2015-00470|P30CA068485","May 7, 2015","May 2015","null","December 17, 2015","December 2015","No Study Results Posted","NEST","December 2017","Patient and caregiver engagement, as measured by the PHQ, IES-R, Distress Thermometer, and Effective Consumer Scale-17|Psychosocial well-being, as measured by the Patient Health Questionnaire (PHQ), Impact of Event Scale-Revised (IES-R), and Distress Thermometer|Adherence to National Comprehensive Cancer Network (NCCN) guidelines, as measured by chart review (patients only)|Referral to subspecialists|Resource utilization, as measured by the Effectiveness in Obtaining Resources Scale and the Cancer Resource Survey|Usefulness of navigation, as measured by the Usefulness of Navigator instrument","https://ClinicalTrials.gov/show/NCT02440737"
2027,"NCT01233544","Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases","Terminated","No Results Available","Colorectal Carcinoma|Liver Metastases","Procedure: SBRT or RFA","University of Aarhus|Danish Center for Interventional Research in Radiation Oncology (CIRRO)","Both","18 Years to 90 Years   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RAS 01","November 2, 2010","September 2010","December 2014","May 11, 2016","May 2015","No Study Results Posted","RAS01","December 2014","Local progression-free survival|Toxicity|Survival|Progression (local or distant)|Quality of life","https://ClinicalTrials.gov/show/NCT01233544"
2028,"NCT00442520","Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy","Completed","No Results Available","Lung Cancer|Colorectal Cancer|Head and Neck Cancer","","University of Kansas|Paul J. Patton Trust|University of Kansas Medical Center Research Institute","Both","18 Years and older   (Adult, Senior)","","70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","10270","March 1, 2007","February 2006","September 2008","November 8, 2012","November 2012","No Study Results Posted","null","September 2008","","https://ClinicalTrials.gov/show/NCT00442520"
2029,"NCT00654160","Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer","Active, not recruiting","No Results Available","Anal Cancer|Carcinoma of the Appendix|Colorectal Cancer|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Gastrointestinal Stromal Tumor|Liver Cancer|Pancreatic Cancer|Small Intestine Cancer","Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Other: pharmacogenomic studies|Other: pharmacological study","Mayo Clinic|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","Phase 1","70","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000592931|P30CA015083|MC064G|NCI-2009-01216","April 4, 2008","June 2008","null","April 19, 2016","April 2016","No Study Results Posted","null","June 2016","Maximum tolerated dose of genotype-based dosing of FOLFIRI with or without monoclonal antibody therapy|Response rate of genotype-based dosing in the subset of patients that has colorectal cancer","https://ClinicalTrials.gov/show/NCT00654160"
2030,"NCT01390818","Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors","Completed","No Results Available","Locally Advanced Solid Tumor|Metastatic Solid Tumor|Breast Cancer|Non Small Cell Lung Cancer|Melanoma|Colorectal Cancer","Drug: MSC1936369B (pimasertib)|Drug: SAR245409 (PI3K and mTOR inhibitor)|Drug: MSC1936369B (pimasertib)|Drug: SAR245409 (PI3K and mTOR inhibitor)","EMD Serono|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 1","146","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 200066-006","April 18, 2011","May 2011","April 2015","June 3, 2015","June 2015","No Study Results Posted","null","April 2015","Number of subjects with dose limiting toxicities|Number of subjects experiencing any treatment-emergent adverse events|Pharmacokinetics parameters in plasma: Cmax, tmax, AUC (0-24), AUC (0-tau), AUC (0-infinity), t1/2, CL/f, CLss/f, Vz/f, Vss/f, Racc(AUC), and Racc(Cmax) for MSC1936369B|Pharmacokinetics parameters in plasma: Cmax, tmax, AUC (0-24), AUC (0-tau), AUC (0-infinity), t1/2, CL/f, CLss/f, Vz/f, Vss/f, Racc(AUC), and Racc(Cmax) for SAR245409|pS6 concentrations in Peripheral Blood Mononuclear Cells (PBMCs)|pERK concentrations in PBMCs|Number of subjects with complete tumor response, partial tumor response, or stable disease","https://ClinicalTrials.gov/show/NCT01390818"
2031,"NCT00003344","Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer","Completed","No Results Available","Colorectal Cancer","Drug: irinotecan hydrochloride|Radiation: radiation therapy","Medical University of South Carolina","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","49","Other","Interventional","Primary Purpose: Treatment","CDR0000066321|MUSC-7532|HCC/MUSC-GI-01|NCI-V98-1420","November 1, 1999","August 1998","January 2000","April 26, 2012","April 2012","No Study Results Posted","null","January 2000","","https://ClinicalTrials.gov/show/NCT00003344"
2032,"NCT02720926","Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer","Terminated","No Results Available","Colorectal Cancer|Gastric Cancer","Drug: Xeloda,|Drug: Oxaliplatin|Drug: TKI258","National Cancer Centre, Singapore|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","3","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC 10-03","May 14, 2012","September 2011","January 2012","March 25, 2016","March 2016","No Study Results Posted","null","January 2012","Determine the recommended phase 2 dose of TKI258 in combination with XELOX (Capecitabine and Oxaliplatin)|Describe the toxic effects of TKI258 when administered in combination with XELOX chemotherapy.|Measure the Area under the plasma concentration versus time curve (AUC) of TKI258 at specific timepoints","https://ClinicalTrials.gov/show/NCT02720926"
2033,"NCT02288078","Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)","Recruiting","No Results Available","Rectal Cancer","Other: General condition|Other: Blood pressure|Other: Patient Reported Outcome|Other: Clinical findings|Other: Hematology/blood chemistry|Other: Coagulation and fibrinolysis system|Other: Urinalysis|Other: Medication check|Other: Adverse event|Other: Thyroid function test|Other: Contrast-enhanced torso CT|Other: Brain MRI|Drug: Dexamethasone|Drug: Regorafenib|Drug: Placebo|Drug: Proton pump inhibitor","Clinical Research Support Center Kyush","Both","20 Years and older   (Adult, Senior)","Phase 2","74","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KSCC1402/HGCSG1402|UMIN000015131","October 28, 2014","October 2014","September 2016","November 11, 2014","November 2014","No Study Results Posted","null","September 2015","incidence of fatigue or malaise (CTCAE ver. 4, all grades)|brief fatigue inventory （Patient Reported Outcome）|adverse events|relative dose intensity (regorafenib)","https://ClinicalTrials.gov/show/NCT02288078"
2034,"NCT01383343","Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer","Active, not recruiting","No Results Available","Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Biological: Bevacizumab|Drug: Fluorouracil|Drug: Irinotecan Hydrochloride|Drug: Leucovorin Calcium|Drug: Sorafenib Tosylate","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","18","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02595|CDR0000702751|MC1017|8877|P30CA015083|U01CA069912|UM1CA186686","June 25, 2011","August 2011","null","September 2, 2016","September 2016","No Study Results Posted","null","January 2017","Maximum tolerated dose of sorafenib tosylate in combination with FOLFIRI and bevacizumab, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients)|Incidence of adverse events of sorafenib tosylate in combination with bevacizumab and FOLFIRI as assessed by NCI CTCAE v 4.0|Response rate in patients treated with sorafenib tosylate in combination with FOLFIRI and bevacizumab, assessed using Response Evaluation Criteria in Solid Tumors|Time to progression|Time to treatment failure|Time to until treatment related grade 3+ toxicity assessed via CTC standard toxicity grading|Time until any treatment related toxicity evaluated via the ordinal Common Toxicity Criteria (CTC) standard toxicity grading|Time until hematologic nadirs (ANC, platelets, hemoglobin)","https://ClinicalTrials.gov/show/NCT01383343"
2035,"NCT02754661","Evaluation the Efficacy of Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.","Not yet recruiting","No Results Available","Colorectal Cancer Screening","Device: COLON Capsule endoscopy|Device: Computed Tomographic Colonography","Medtronic - MITG","Both","50 Years to 75 Years   (Adult, Senior)","","320","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","COVGIC20543|MA-213","April 25, 2016","May 2016","May 2018","April 25, 2016","April 2016","No Study Results Posted","TOPAZ","November 2017","Diagnostic yield (proportion of subjects shown to have an actionable lesion, defined as any polyp or mass lesion ≥6 mm) by CCE as compared to CTC. Diagnostic yield of CCE/CTC will be calculated in relation to the confirmatory Optical colonoscopy results|Accuracy measures of CCE versus CTC in the detection of polyps ≥6 mm will be assessed in relation to the confirmatory OC results on a ""per subject"" basis: Negative predictive value (NPV), Positive predictive value (PPV); Sensitivity; Specificity","https://ClinicalTrials.gov/show/NCT02754661"
2036,"NCT02728596","S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)","Not yet recruiting","No Results Available","Febrile Neutropenia|Stage 0 Breast Cancer|Stage 0 Colorectal Cancer|Stage 0 Non-Small Cell Lung Cancer|Stage I Colorectal Cancer|Stage IA Breast Cancer|Stage IA Non-Small Cell Lung Carcinoma|Stage IB Breast Cancer|Stage IB Non-Small Cell Lung Carcinoma|Stage IIA Breast Cancer|Stage IIA Colorectal Cancer|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Breast Cancer|Stage IIB Colorectal Cancer|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIC Colorectal Cancer|Stage IIIA Breast Cancer|Stage IIIA Colorectal Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Colorectal Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IIIC Colorectal Cancer|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Other: Preventive Intervention|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Southwest Oncology Group|National Cancer Institute (NCI)|Patient-Centered Outcomes Research Institute","Both","18 Years and older   (Adult, Senior)","","3960","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","S1415CD|NCI-2016-00264|S1415|SWOG-S1415CD|UG1CA189974","March 30, 2016","October 2016","null","July 21, 2016","July 2016","No Study Results Posted","TrACER","April 2020","Change in FN-related HRQL (patient report) assessed using the Functional Assessment of Cancer Therapy -Febrile Neutropenia (FACT-N)|Change in patient knowledge of PP-CSF benefits (patient report)|Change in patient knowledge of PP-CSF indications (patient report)|Change in patient knowledge of PP-CSF out-of-pocket costs (patient report)|Change in patient knowledge of PP-CSF risks (patient report)|Incidence of febrile neutropenia (clinical) graded according to the National Cancer Institute (NCI) Common Toxicity Criteria version 4.0|Incidence of febrile neutropenia (clinical) graded according to the NCI Common Toxicity Criteria version 4.0|Overall survival (clinical)|Patient adherence to PP-CSF prescription (clinical and patient report)|Prophylactic and FN-related antibiotic use (clinical)|Proportion completing initial systemic therapy regimen: a) at planned duration and b) at planned dose intensity (clinical)|Rate of CSF prescribing as primary prophylaxis (clinical)|Rate of FN-related emergency department (ED) visits and hospitalizations (clinical)","https://ClinicalTrials.gov/show/NCT02728596"
2037,"NCT02499939","Ultrasound Therapy and Therapeutic Exercise for Chemotherapy Induced Peripheral Neuropathy (CIPN)","Recruiting","No Results Available","Colon Neoplasms|Colorectal Neoplasms","Behavioral: Standard Care|Other: Ultrasound Therapy","Margie McNeely|Cross Cancer Institute|University of Alberta","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","HREBA-CC-15-0107","July 14, 2015","December 2015","December 2016","April 4, 2016","April 2016","No Study Results Posted","ULTRA","August 2016","Functional Assessment of Cancer Therapy Gynecological Oncology Group Neurotoxicity-12 item scale|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-CIPN twenty-item scale (QLQ-CIPN20)3|Protective sensation|Temperature sensation|Vibration sensation|Reflexes|Balance Assessment","https://ClinicalTrials.gov/show/NCT02499939"
2038,"NCT01815359","ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis","Recruiting","No Results Available","Appendix Cancer|Colorectal Cancer","Procedure: Cytoreductive Surgery|Drug: HIPEC with Mitomycin-C|Drug: EPIC with FUDR and Leucovorin","Memorial Sloan Kettering Cancer Center|The Cleveland Clinic|Brigham and Women's Hospital|University of Miami|University of Pittsburgh","Both","18 Years and older   (Adult, Senior)","Phase 2","220","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-289","March 13, 2013","March 2013","March 2018","May 18, 2016","May 2016","No Study Results Posted","ICARuS","March 2018","disease-free survival|surgical toxicity grade 3 to 5|chemotherapy toxicity grade 3 to 5","https://ClinicalTrials.gov/show/NCT01815359"
2039,"NCT02308384","A Trial of the Implementation of iFOBT in General Practice","Completed","No Results Available","Colorectal Cancer","Behavioral: Intervention","University of Aarhus","Both","Child, Adult, Senior","","825","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","Randomiseret iFOBT studie","November 26, 2014","September 2015","September 2016","September 19, 2016","November 2015","No Study Results Posted","null","September 2016","Frequency of each indication used for requesting iFOBT|Frequency of iFOBT use in each municipality|The GPs' actions on positive test result (>50ng/ml)|The GPs' actions on negative test result (<49ng/ml)|Findings by colonoscopy on patients with a positive iFOBT|Standardised number of performed colonoscopies during the study period|Standardised number of CRC diagnosis|Number of CRC diagnosed in each cancer stage (1-4)|Standardised number of positive tests (>50ng/ml)|The overall Positive Predictive Values (PPV) for CRC when iFOBT is positive.|The Positive Predictive Values (PPV) for CRC in relation to cut-off","https://ClinicalTrials.gov/show/NCT02308384"
2040,"NCT01186263","Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy","Completed","No Results Available","Colorectal Cancer|Liver Metastases","Drug: MAA for diagnostic SPECT imaging|Drug: Diagnostic B20- SPECT imaging.","University of Magdeburg|Sirtex Medical","Both","18 Years to 85 Years   (Adult, Senior)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","RAD050|2008-005609-21","July 23, 2010","July 2010","August 2013","September 3, 2014","September 2014","No Study Results Posted","EXPLOSIVE","July 2011","Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy|Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m B20 scintigraphy|Pharmacokinetic parameters of the intrahepatic distribution of MAA and B20.|Adverse events as elicited upon indirect questioning.","https://ClinicalTrials.gov/show/NCT01186263"
2041,"NCT00185081","Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging","Completed","No Results Available","Colonic Neoplasms","Drug: Indium labeled IMP-205xm734","Radboud University|Immunomedics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","42","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","PRISCO","September 15, 2005","July 2005","December 2008","April 6, 2016","April 2016","No Study Results Posted","null","December 2008","Safety evaluation of intravenous injection of In-labeled IMP-205 and hMN-14xm734|Tumor targeting of In-IMP-205 in patients with colorectal carcinoma|Pharmacokinetics, biodistribution and dosimetry of In-IMP-205","https://ClinicalTrials.gov/show/NCT00185081"
2042,"NCT00032344","Long-term Follow-up Study Designed to Evaluate the Relative Risk of Two Colonoscopy Schedules for Patients With Small Polyps","Completed","No Results Available","Colorectal Cancer","Procedure: Colonoscopy","VA Office of Research and Development|Central Lab","Both","50 Years to 75 Years   (Adult, Senior)","Phase 3","3200","U.S. Fed|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","380","March 18, 2002","October 1993","February 2007","November 19, 2010","November 2010","No Study Results Posted","null","February 2007","Phase I: Risk factors include: family history; dietary; fat, fiber, calcium; alcohol history; tobacco use; physical activity; obesity; NSAID use; and, biomarkers: BRDU, PCNA|Phase II: Colonoscopy outcomes to determine recurrence rates and compare surveillance strategies|Phase III: Medical outcomes including mortality. Colonoscopy outcomes in subgroup of polyp free patient at baseline to determine long term risk.","https://ClinicalTrials.gov/show/NCT00032344"
2043,"NCT02511821","Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery","Active, not recruiting","No Results Available","Stage I Adult Liver Cancer|Stage I Colorectal Cancer|Stage IA Gastric Cancer|Stage IA Pancreatic Cancer|Stage IB Gastric Cancer|Stage IB Pancreatic Cancer|Stage II Adult Liver Cancer|Stage IIA Colorectal Cancer|Stage IIA Gastric Cancer|Stage IIA Pancreatic Cancer|Stage IIB Colorectal Cancer|Stage IIB Gastric Cancer|Stage IIB Pancreatic Cancer|Stage IIC Colorectal Cancer|Stage III Pancreatic Cancer|Stage IIIA Adult Liver Cancer|Stage IIIA Colorectal Cancer|Stage IIIA Gastric Cancer|Stage IIIB Adult Liver Cancer|Stage IIIB Colorectal Cancer|Stage IIIB Gastric Cancer|Stage IIIC Adult Liver Cancer|Stage IIIC Colorectal Cancer|Stage IIIC Gastric Cancer|Stage IV Gastric Cancer|Stage IVA Colorectal Cancer|Stage IVA Liver Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Liver Cancer|Stage IVB Pancreatic Cancer","Other: Computer-Assisted Intervention|Device: Vivofit watch|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","City of Hope Medical Center|National Cancer Institute (NCI)","Both","21 Years and older   (Adult, Senior)","","24","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","15051|NCI-2015-01061|P30CA033572","June 26, 2015","July 2015","null","May 9, 2016","May 2016","No Study Results Posted","null","December 2016","Mean time patients are able to tolerate wearing the wristband device, both before and after surgery|Mean time to complete the web based questionnaires MDASI and EQ-5D, as well as the Self Geriatric Assessment Measure|Median time patients are able to tolerate wearing the wristband device, both before and after surgery|Median time to complete the web based questionnaires MDASI and EQ-5D, as well as the Self Geriatric Assessment Measure|Percentage of patients who are able to complete the web-based questionnaires MDASI and EQ-5D|Percentage of patients who are able to wear the wristband device for at least 1 week post-operatively|Ease of use of web-based surveys and wristband device, as measured by responses from Satisfaction Tool|Feedback on items in the web-based surveys that are distressing or difficult to comprehend, as measured by responses from Satisfaction Tool|Feedback on length of surveys and timing of administration, as measured by responses from Satisfaction Tool|Mean number of missing items within each questionnaire|Percentage of patients who did not enroll in the study-composite outcome of multiple measure listed|Suggestions for items that were not covered but should be added, as measured by responses from Satisfaction Tool","https://ClinicalTrials.gov/show/NCT02511821"
2044,"NCT02399059","Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome","Completed","No Results Available","Colorectal Tumors","Procedure: Antibiotic lavage|Procedure: Normal saline lavage","Hospital General Universitario Elche","Both","Child, Adult, Senior","Phase 3","106","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","HURJ2015-01","March 23, 2015","January 2011","March 2015","March 25, 2015","March 2015","No Study Results Posted","null","March 2015","Global survival|Disease free survival","https://ClinicalTrials.gov/show/NCT02399059"
2045,"NCT02415829","Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients","Recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine plus oxaliplatin","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1501143-1","March 30, 2015","November 2014","null","April 9, 2015","April 2015","No Study Results Posted","null","January 2016","The tumor regression grade of all the patients enrolled|Number of Participants receiving complete tumor resection|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT02415829"
2046,"NCT02243267","GI SPORE Colon Biosample Protocol","Recruiting","No Results Available","Colon Cancer|Rectal Cancer","Other: sample collection","University of Michigan","Both","18 Years to 99 Years   (Adult, Senior)","","1500","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","HUM00064405","September 11, 2014","September 2014","August 2021","March 30, 2016","March 2016","No Study Results Posted","null","August 2021","New Biomarker for colon cancer detection|Response to Treatment","https://ClinicalTrials.gov/show/NCT02243267"
2047,"NCT02079740","Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors","Suspended","No Results Available","Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Solid Neoplasm|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Other: Laboratory Biomarker Analysis|Biological: Navitoclax|Other: Pharmacological Study|Drug: Trametinib","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","130","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2014-00461|13-505|9525|P30CA006516|P50CA127003|U01CA062490|UM1CA186709","March 4, 2014","March 2014","null","July 21, 2016","June 2016","No Study Results Posted","null","September 2017","Incidence of adverse events graded according to National Cancer Institute CTCAE v4.0 (Phase Ib and II)|Progression-free survival (Phase II)|Response rate (partial response [PR] + complete response [CR]) assessed according to RECIST version 1.1 (Phase II)|Percent change in levels of apoptosis markers (cleaved caspase-3) (Phase Ib and II)|Percent change in levels of proliferation markers (Ki67) (Phase Ib and II)|Percent change in levels of proteins/messenger ribonucleic acids (mRNAs) implicated in mitogen-activated protein kinase signaling (Phase Ib and II)|Percent change in levels of proteins/mRNAs implicated in B-cell lymphoma 2 family signaling (Phase Ib and II)|Pharmacokinetic parameters (observed plasma drug concentration, area under the curve, half-life) for trametinib and navitoclax when administered in combination (Phase Ib)|Response rate (PR + CR) (Phase Ib)","https://ClinicalTrials.gov/show/NCT02079740"
2048,"NCT01149304","Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity","Recruiting","No Results Available","Colorectal Cancer|Liver Metastases|Irradiation Damage|Radiation Induced Liver Disease","Drug: Pentoxifylline|Drug: Ursodeoxycholic Acid|Drug: Enoxaparin","University of Magdeburg|Sirtex Medical","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","44","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","RAD052|2008-002985-70|MD-R20080507","June 4, 2010","June 2009","null","June 22, 2010","June 2010","No Study Results Posted","ELDORADO","June 2012","HDR-brachytherapy isodose (measured in Gy) that corresponds to the metastases without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.|HDR-brachytherapy isodose (measured in Gy) that corresponds to the irradiated liver tissue without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.|Correlation between the HDR brachytherapy isodose that corresponds to damaged live tissue as defined by missing Gd-EOB-DTPA enhancement in MR imaging and liver-specific laboratory values.|Quality of live.|Safety of the study drugs.","https://ClinicalTrials.gov/show/NCT01149304"
2049,"NCT02185443","Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases","Recruiting","No Results Available","Liver Metastases|Colorectal Cancer|Anal Canal Cancer|Gastrointestinal Neuroendocrine Tumors","Radiation: SBRT","University of Sao Paulo|Instituto do Cancer do Estado de São Paulo","Both","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RT-01/2014","July 4, 2014","May 2014","May 2021","May 10, 2016","May 2016","No Study Results Posted","null","May 2021","Local Progression Free Survival|Overall Survival|Progression Free Survival|Toxicity","https://ClinicalTrials.gov/show/NCT02185443"
2050,"NCT02632448","A Study of LY2880070 in Patients With Advanced or Metastatic Cancer","Recruiting","No Results Available","Solid Tumors|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Colon Cancer|Rectal Cancer|Neoplasms","Drug: LY2880070|Drug: Gemcitabine","Esperas Pharma Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","93","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","ESPS-001","December 14, 2015","May 2016","April 2020","August 25, 2016","August 2016","No Study Results Posted","null","April 2020","Maximum Tolerated Dose|Number of dose limiting toxicities (DLTs)|Area under the plasma concentration versus time curve from time zero to 24 hours post-dose (AUC0-24)|Peak plasma concentration (Cmax)|Time to reach maximum plasma concentration (tmax)|Change from baseline in white blood cell count|Change from baseline in neutrophil count|Change from baseline in lymphocyte count|Number of participants with tumor response, as measured by the Response Evaluable Criteria in Solid Tumors (RECIST v.1.1)|Duration of response|Best response|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02632448"
2051,"NCT02215889","Partial Liver Segment 2/3 Transplantation Study","Recruiting","No Results Available","Colorectal Cancer","Procedure: Liver transplantation","Oslo University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RAPID 2014","June 24, 2014","June 2014","June 2026","March 30, 2016","March 2016","No Study Results Posted","null","June 2017","Percent of transplanted patients receiving second stage hepatectomy within 4 weeks of segment 2/3 transplantation.|Overall Survival","https://ClinicalTrials.gov/show/NCT02215889"
2052,"NCT00593073","Use of Novel Tailored Reminders in Rural Primary Care","Completed","No Results Available","Colorectal Cancer","Behavioral: Electronic tailored messaging|Behavioral: General Reminder Message","University of Kansas|National Cancer Institute (NCI)|University of Kansas Medical Center Research Institute","Both","50 Years and older   (Adult, Senior)","","707","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","10174|1R21CA121907-01","December 31, 2007","July 2005","December 2007","September 10, 2008","September 2008","No Study Results Posted","null","December 2007","Baseline assessment while waiting to see primary care physician and 90-day follow-up telephone survey.|Follow-up survey to assess participant discussion of colorectal cancer with their healthcare provider and compliance with CRC screening","https://ClinicalTrials.gov/show/NCT00593073"
2053,"NCT01934179","Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy","Terminated","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Other: cytology specimen collection procedure|Other: laboratory biomarker analysis|Other: questionnaire administration","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","70 Years and older   (Senior)","","6","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ERP-GI-049|NCI-2013-01415|13-020|GI-049|P30CA006927","August 29, 2013","October 2013","null","March 1, 2016","March 2016","No Study Results Posted","null","September 2015","TL|Incidence of chemotherapy related grade 3 or higher adverse events, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Change in TL after chemotherapy","https://ClinicalTrials.gov/show/NCT01934179"
2054,"NCT01677884","Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy","Completed","No Results Available","Colorectal Neoplasms","Drug: Bevacizumab|Drug: Capecitabine|Drug: Irinotecan","Gustave Roussy, Cancer Campus, Grand Paris","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","10","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-005559-15|CSET 2011/1827","August 30, 2012","November 2012","February 2016","June 8, 2016","June 2016","No Study Results Posted","BEVIAC","February 2016","Efficiency of treatment based on objective response rate|Treatment toxicity based on NCI-CTC v4.0|Progression Free Survival|Hepatic metastasis resection rate","https://ClinicalTrials.gov/show/NCT01677884"
2055,"NCT01300858","A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients","Terminated","No Results Available","Colorectal Cancer","Drug: EGEN-001-301","EGEN, Inc.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","4","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EGEN-001-301","February 18, 2011","June 2011","July 2014","June 15, 2015","June 2015","No Study Results Posted","null","July 2014","Progression-free survival|Overall survival|Tumor Growth Assessment by X-ray/CT|Number of study subjects with adverse events","https://ClinicalTrials.gov/show/NCT01300858"
2056,"NCT02800330","The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib","Recruiting","No Results Available","Colorectal Neoplasms|Gastrointestinal Stromal Tumors","Drug: Esomeprazole 40mg concomitantly|Drug: Esomeprazole 40mg before|Drug: Regorafenib 160mg or 120mg","Erasmus Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 4","14","Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","EMC16-165","May 25, 2016","May 2016","June 2017","June 10, 2016","June 2016","No Study Results Posted","REGORA","June 2017","As primary endpoint, AUC of regorafenib alone and AUC of regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake, respectively) will be related.|The Cmax of regorafenib alone and regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake respectively) will be related|Number of participants with treatment related adverse events as assessed by CTCAE v4.0 in absence and presence of esomeprazole|The Tmax of regorafenib alone and regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake respectively) will be related|The clearance of regorafenib alone and regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake respectively) will be related","https://ClinicalTrials.gov/show/NCT02800330"
2057,"NCT00118989","Curcumin for the Chemoprevention of Colorectal Cancer","Completed","No Results Available","Adenomatous Polyps","Drug: Curcuminoids","University of Pennsylvania|Robert Wood Johnson Foundation","Both","18 Years and older   (Adult, Senior)","Phase 2","56","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","802193","July 2, 2005","July 2005","July 2012","December 12, 2014","November 2011","No Study Results Posted","null","September 2010","Cellular proliferation and apoptosis in the colonic mucosa|COX-2 expression and activity","https://ClinicalTrials.gov/show/NCT00118989"
2058,"NCT02788279","A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma","Recruiting","No Results Available","Colorectal Cancer","Drug: Atezolizumab [TECENTRIQ]|Drug: Cobimetinib|Drug: Regorafenib","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","360","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GO30182|2016-000202-11","May 27, 2016","July 2016","April 2019","September 1, 2016","September 2016","No Study Results Posted","null","April 2019","Overall Survival (OS)|Progression-free Survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Percentage of Participants with Investigator-assessed Objective Response of Complete Response (CR) or Partial Response (PR) per RECIST Version 1.1|Duration of Response (DOR) based on RECIST Version 1.1|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 questionnaire (EORTC QLQ-C30) score","https://ClinicalTrials.gov/show/NCT02788279"
2059,"NCT01087658","Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity","Completed","No Results Available","Colorectal Neoplasms","Drug: Glutamine|Drug: Calcium and Magnesium","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 3","200","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OXALI_L_03768|U1111-1116-9494","March 15, 2010","February 2010","March 2013","June 20, 2013","June 2013","No Study Results Posted","GLUTOX","March 2013","Occurence of peripheral sensory neuropathy (PSN) grade 2, 3 and 4 assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE)|Cumulative dose of oxaliplatin and time of onset when the first PSN grade 2, 3 or 4 occurs|Dose-reduction, dose-delay and discontinuation of oxaliplatin due to PSN grade 3 or 4|Patient self-reported neurotoxicity scale for chronic peripheral neuropathy|Progression Free Survival / PFS (for metastatic patients)","https://ClinicalTrials.gov/show/NCT01087658"
2060,"NCT00272051","XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy","Completed","No Results Available","Metastases|Colorectal Neoplasms|Colorectal Carcinoma","Drug: SR57746A","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 3","620","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","EFC4972|SR57746A","January 3, 2006","July 2002","May 2004","September 11, 2006","September 2006","No Study Results Posted","null","null","Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment : Q2W ; response rate using RECIST criteria : Q8W|Safety : Q2W ; Nerve conduction studies : Baseline + cycle 12 ; Progression Free Survival : Q8W ; Survival","https://ClinicalTrials.gov/show/NCT00272051"
2061,"NCT02647671","Aquamin and Prevention of Colon Cancer","Recruiting","No Results Available","Colonic Cancer","Drug: Aquamin®|Drug: Calcium Carbonate|Drug: Placebo","James Varani|University of Michigan","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","HUM00076276","November 30, 2015","February 2016","December 2017","February 15, 2016","February 2016","No Study Results Posted","null","September 2017","Biomarkers of Risk for Colorectal Cancer|Colonic-mucosal Associated Microbial Profile.|Colonic-mucosal Associated Metabolomic Profile.|Biomarkers of bone turnover / metabolism.|Biomarkers of liver function","https://ClinicalTrials.gov/show/NCT02647671"
2062,"NCT01011478","Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery","Terminated","No Results Available","Colorectal Cancer|Precancerous Condition","Drug: rosuvastatin|Other: placebo","NSABP Foundation Inc|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","406","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NSABP-P-5|NSABP P-5|NCI-2011-09183","November 10, 2009","March 2010","February 2015","April 8, 2016","April 2016","No Study Results Posted","null","December 2014","Occurrence of ≥ 1 adenomatous polyp of the colon or rectum, metachronous colorectal carcinoma, or colon cancer recurrence (APMC+R)|Size, number, and features of colorectal adenomas, including advanced adenomas|Disease -free survival|Overall Survival: Time from randomization to death from any cause|Recurrence-free interval: Time from randomization to first recurrence of colon cancer|Second non-colorectal primary cancer-free interval|Behavioral and Health Outcomes as measured by SF-12 component scores, global quality-of-life scale, and symptom checklist|Occurrence and grade of reported toxicities|Measurements of relevant tumor and blood markers","https://ClinicalTrials.gov/show/NCT01011478"
2063,"NCT01871311","A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors","Recruiting","No Results Available","Colorectal Cancer|Head and Neck Cancer","Drug: Nilotinib + Cetuximab","Georgetown University|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","22","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-0039","June 4, 2013","May 2014","December 2016","February 11, 2016","February 2016","No Study Results Posted","null","December 2016","Maximum tolerated dose","https://ClinicalTrials.gov/show/NCT01871311"
2064,"NCT00207051","BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies","Completed","No Results Available","Colorectal Cancer","Drug: Brivanib + Cetuximab","Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1","62","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA182-003","September 12, 2005","January 2006","December 2008","January 24, 2011","March 2009","No Study Results Posted","null","December 2008","Safety assessment|dose limiting toxicity (DLT)|determination of maximum tolerated dose (MTD)|Efficacy based on duration of response and time to progression based on assessment","https://ClinicalTrials.gov/show/NCT00207051"
2065,"NCT00410579","Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers","Completed","No Results Available","Colorectal Cancer|Fatigue|Long-term Effects Secondary to Cancer Therapy in Adults|Pain|Psychosocial Effects of Cancer and Its Treatment","Other: Telephone interview","NSABP Foundation Inc|National Cancer Institute (NCI)|University of California, Los Angeles","Both","Child, Adult, Senior","","744","Other|NIH","Observational","Observational Model: Cohort","NSABP LTS-01|CDR0000494640","December 11, 2006","November 2006","February 2009","December 15, 2010","December 2010","No Study Results Posted","null","February 2009","Types of patient-reported outcomes|Degree to which patient-reported outcomes are impacted by individual characteristics, health behaviors, and when appropriate specific treatments that were received|Comparison of patient-reported outcomes prior to randomization, 1 year after completion of study treatment, and in long-term follow up > 5 years after diagnosis in patients treated in NSABP C-06 or NSABP C-07 trials","https://ClinicalTrials.gov/show/NCT00410579"
2066,"NCT00754494","Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma","Completed","Has Results","Adenomatous Polyp|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage I Colon Cancer|Stage I Rectal Cancer|Stage IIA Colon Cancer|Stage IIA Rectal Cancer|Stage IIB Colon Cancer|Stage IIB Rectal Cancer|Stage IIC Colon Cancer|Stage IIC Rectal Cancer|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer","Drug: erlotinib hydrochloride|Other: placebo|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","45","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","NCI-2012-02984|UCI06-8-01|N01CN35160|CDR0000614277","September 17, 2008","July 2008","September 2013","December 22, 2014","March 2014","April 23, 2014","null","October 2012","Change in ACF pERK Levels|Change in EGF-inducible Markers - pEGFR in Normal Mucosa|Change in EGF-inducible Markers - Total EGFR in Normal Mucosa|Change in EGF-inducible Markers - pEGFR in ACF|Change in EGF-inducible Markers - Total EGFR in ACF|ACF: Normal Mucosa pERK Ratio|Plasma Erlotinib Concentration (ng/mL)|Plasma OSI-420 Concentration (ng/mL)|Normal Mucosa Erlotinib Concentration (ng/mg)|Normal Mucosa OSI-420 Concentration (ng/mg)|Number of Participants Reported at Least 1 Side Effect During the Study|Number of Participants Reported at Least 1 Rash Side Effect During the Study|Number of Participants Reported at Least 1 Diarrhea Side Effect During the Study","https://ClinicalTrials.gov/show/NCT00754494"
2067,"NCT00005094","Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps","Completed","No Results Available","Colon Cancer|Rectal Cancer","Drug: celecoxib|Other: placebo","National Cancer Institute (NCI)","Both","30 Years and older   (Adult, Senior)","Phase 3","1170","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NCI-2012-02327|98-008|NYH-CMC-0298-108|SC-IQ4-99-02-005|CDR0000067750|NCI-P00-0141|STRANG-98-008|BWH-NO1-CN-95015|N01CN95015","April 6, 2000","March 2000","null","April 11, 2013","April 2013","No Study Results Posted","null","April 2006","Percentage of subjects with newly detected adenomas, and will be estimated using the life table method for each treatment group|Percentage of patients with adenomas, aspirin use at baseline, and covariates|The number of adenomas identified per patient|The highest histopathologic grade, largest size, and polyp burden (sum of the polyp diameters) of the colorectal adenomas|The number of advanced adenomas (adenoma of size 1.0 cm or larger, any villous histology, high grade dysplasia, or invasive cancer) detected at surveillance|Adenoma findings at year 1 colonoscopy as predictors of adenoma findings at year 3 colonoscopy|Adverse events will be coded using the MedRA dictionary|Mean number of adenomas detected at year 5, as well as the distribution of number of adenomas, and the adenoma burden based on the sum of the adenoma diameters at year 5|Adverse events coded using the MedRA dictionary","https://ClinicalTrials.gov/show/NCT00005094"
2068,"NCT02181465","Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.","Completed","No Results Available","Colorectal Cancer","Biological: G17DT","Cancer Advances Inc.","Both","18 Years to 81 Years   (Adult, Senior)","Phase 2","11","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CC1A&B","July 2, 2014","October 1993","May 1994","July 3, 2014","July 2014","No Study Results Posted","CC1A&B","May 1994","Number of participants with adverse effects|Measure serum anti gastrin-17 antibodies to determine immunological response to medication","https://ClinicalTrials.gov/show/NCT02181465"
2069,"NCT00153816","Vitamin D/Calcium Polyp Prevention Study","Active, not recruiting","Has Results","Colorectal Cancer|Polyps|Adenomas","Drug: Calcium Carbonate|Drug: Vitamin D3|Drug: placebo","Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)","Both","45 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","2813","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","5R01CA098286-03|5R01CA098286-10","September 7, 2005","July 2004","July 2016","September 21, 2015","September 2015","September 21, 2015","null","October 2013","Colorectal Adenomas|Advanced Colorectal Lesions","https://ClinicalTrials.gov/show/NCT00153816"
2070,"NCT00094809","Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer","Completed","Has Results","Colon Cancer|Colorectal Cancer|Rectal Cancer","Drug: Placebo|Drug: Pegfilgrastim","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","252","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","20020715","October 26, 2004","February 2003","July 2008","May 10, 2013","May 2013","December 16, 2010","null","July 2008","Grade 3 or 4 Neutropenia|Grade 4 Neutropenia|Dose Delay or Reduction Due to Neutropenia|Dose Delay or Reduction for Any Reason|Febrile Neutropenia|Hospitalization Due to a Neutropenia-Related Event|Progression-Free Survival|Objective Tumor Response|Survival|Antibiotic Use Due to Febrile Neutropenia","https://ClinicalTrials.gov/show/NCT00094809"
2071,"NCT02402972","A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer","Recruiting","No Results Available","Colorectal Cancer|Metastasis","Drug: FUDR +oxaliplatin|Drug: oxaliplatin+Leucovorin+5-FU","Xu jianmin|Zhejiang University|The Second Affiliated Hospital of Harbin Medical University|Ruijin Hospital|Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","700","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","IICCAC|82345432","March 20, 2015","February 2015","February 2022","March 25, 2015","January 2015","No Study Results Posted","null","February 2020","disease-free survival|overall survival|metastasis-free survival|adverse events of Chemotherapy and IPC","https://ClinicalTrials.gov/show/NCT02402972"
2072,"NCT01840280","A Non Interventional Study With Irinotecan Onkovis (Irinotecan) Utilized for the Treatment of Cancer","Recruiting","No Results Available","Carcinoma","","Onkovis GmbH|AKP Freiburg GmbH","Both","Child, Adult, Senior","","350","Industry","Observational","Time Perspective: Prospective","ONKOIRI01","April 22, 2013","May 2013","April 2018","May 17, 2016","May 2016","No Study Results Posted","null","April 2018","The Quantity of Irinotecan onkovis needed per treatment cycle|Adverse events during and after treatment","https://ClinicalTrials.gov/show/NCT01840280"
2073,"NCT00613873","Use of Screening Colonoscopy Among Minority Women and Men","Completed","No Results Available","Colorectal Screening","Procedure: Colonoscopy and Questionnaire","Memorial Sloan Kettering Cancer Center|North General Hospital, New York|Ralph Lauren Center for Cancer Care and Prevention","Both","50 Years and older   (Adult, Senior)","","611","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","03-066","January 31, 2008","July 2003","January 2009","January 14, 2009","January 2009","No Study Results Posted","null","January 2009","To determine the feasibility of using a community screening mammography center to recruit minority women form a low income community to undergo colorectal cancer screening (CRCS).|Identify individual level barriers (demographic, financial, and psychological) to CRCS among minority women who are already participating in screening for another cancer (breast or cervical)|Determine the feasibility of promoting CRCS among spouses (and other members of the household) of minority women who have undergone screening colonoscopy.","https://ClinicalTrials.gov/show/NCT00613873"
2074,"NCT02843425","The Beans to Enrich the Gut Microbiome vs. Obesity's Negative Effects (BE GONE) Trial","Recruiting","No Results Available","Colorectal Cancer Prevention","Other: Regular Diet|Other: Navy Beans (Canned)","M.D. Anderson Cancer Center","Both","30 Years to 70 Years   (Adult, Senior)","","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Prevention","2016-0365|NCI-2016-01191","July 18, 2016","July 2016","null","July 29, 2016","July 2016","No Study Results Posted","null","July 2017","Changes in Stool 16S rRNA Gene Profiles|Changes in gut microbiota profiles in serial stool samples collected over each cross-over period","https://ClinicalTrials.gov/show/NCT02843425"
2075,"NCT01761097","Endocuff Adenoma Detection Rate Pilot Study","Recruiting","No Results Available","Colorectal Adenoma|Colorectal Cancer","Device: Endocuff attachment","Cambridge University Hospitals NHS Foundation Trust","Both","Child, Adult, Senior","","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","AO92673","January 3, 2013","January 2013","December 2013","January 4, 2013","January 2013","No Study Results Posted","null","October 2013","Proportion of patients with adenomas and cancers detected|Caecal intubation time","https://ClinicalTrials.gov/show/NCT01761097"
2076,"NCT00097578","A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma","Completed","No Results Available","Colorectal Cancer","","Genentech, Inc.","Both","Child, Adult, Senior","Phase 4","1953","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AVF2941n","November 24, 2004","March 2004","July 2008","March 26, 2013","March 2013","No Study Results Posted","null","July 2008","","https://ClinicalTrials.gov/show/NCT00097578"
2077,"NCT02526264","Evaluation of Quality of Life and Period of Hospitalization by Education","Recruiting","No Results Available","Colorectal Cancer","Other: Education program","Krankenhaus Nordwest","Both","18 Years and older   (Adult, Senior)","","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","STELLA","August 10, 2015","November 2015","null","August 15, 2016","August 2016","No Study Results Posted","STELLA","November 2017","Quality of life|Quality of Life|Period of hospitalization|Complication rates","https://ClinicalTrials.gov/show/NCT02526264"
2078,"NCT01944137","Improving Care After Chemotherapy","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer|Colorectal Cancer|Breast Cancer","Other: Nursing Intervention","Massachusetts General Hospital","Both","18 Years and older   (Adult, Senior)","","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","13-258","September 12, 2013","September 2013","null","April 8, 2015","March 2015","No Study Results Posted","IMPACT","November 2014","Change from baseline (i.e. first chemotherapy administration visit) in patient-reported symptoms as measured by the Memorial Symptom Assessment Scale-Short Form.|Change from baseline (i.e. first chemotherapy administration visit) in patient-reported psychological distress as measured by the Patient Health Questionnaire-4.|Change from baseline (i.e. first chemotherapy administration visit) in patient-reported satisfaction with oncology care as measured by the Family Caregiver Satisfaction-patient scale|Frequency of urgent outpatient Cancer Center visits, emergency department visits, and hospital admissions during six months post-baseline","https://ClinicalTrials.gov/show/NCT01944137"
2079,"NCT01318239","Perfusion and Diffusion Magnetic Resonance Imaging, and Phosphorylation of Circulation Endothelial Cells to Determine Anti-anogenic Effect of Chemotherapeutic Regimens in Colorectal Liver Metastasis Patients","Completed","No Results Available","Colorectal Cancer","Procedure: DCE MRI","Yonsei University","Both","20 Years and older   (Adult, Senior)","","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","4-2010-0047","March 17, 2011","July 2010","April 2013","March 4, 2014","March 2014","No Study Results Posted","null","April 2013","MR perfusion parameter|diffusion parameter","https://ClinicalTrials.gov/show/NCT01318239"
2080,"NCT02039336","Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies","Recruiting","No Results Available","Colorectal Cancer","Drug: Dacomitinib|Drug: PD-0325901|Drug: Irinotecan|Drug: Docetaxel|Drug: Capecitabine","The Netherlands Cancer Institute|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","35","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NL45985.031.13","January 15, 2014","January 2014","null","August 5, 2014","August 2014","No Study Results Posted","M13DAP","December 2015","Incidence rate of dose-limiting toxicities|Progression free survival|Incidence and severity of adverse events|Plasma concentration|Overall response rate|Duration of response|Time to response|Overall survival","https://ClinicalTrials.gov/show/NCT02039336"
2081,"NCT01942200","A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer","Recruiting","No Results Available","Carcinoma","","Onkovis GmbH|AKP Freiburg GmbH","Both","Child, Adult, Senior","","350","Industry","Observational","Time Perspective: Prospective","ONKOOXA01","September 10, 2013","September 2013","July 2018","May 17, 2016","May 2016","No Study Results Posted","null","July 2018","The Quantity of Oxaliplatin onkovis needed per treatment cycle|Adverse events during and after treatment","https://ClinicalTrials.gov/show/NCT01942200"
2082,"NCT00905086","Psychosocial Adjustment After Radiation Therapy in Patients With Cancer","Completed","No Results Available","Breast Cancer|Cognitive/Functional Effects|Colorectal Cancer|Lung Cancer|Prostate Cancer|Psychosocial Effects of Cancer and Its Treatment","Other: questionnaire administration|Procedure: cognitive assessment|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","80","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CASE3Z08|P30CA043703","May 19, 2009","August 2008","May 2009","September 29, 2015","September 2015","No Study Results Posted","null","February 2009","Relationship between stress appraisal (as assessed by CAHS at baseline) and psychosocial adjustment (as assessed by PAIS-SR at 1 month after radiotherapy)|Relationship between stress appraisal and uncertainty, symptom distress, cancer stage, comorbidities, age, gender, race/ethnicity, and education at 2 weeks prior to completing radiotherapy|Social support (as assessed by MOS-SSS) and self-efficacy (as assessed by CBI-L v2.0) as moderators of the relationship between cognitive appraisal and adjustment","https://ClinicalTrials.gov/show/NCT00905086"
2083,"NCT01478919","Risk Factors for Residual Neoplasia After Endoscopic Mucosal Resection","Completed","No Results Available","Colorectal Cancer","","Vitkovice Hospital","Both","18 Years and older   (Adult, Senior)","","127","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DDC VN 02","November 21, 2011","January 2010","November 2011","September 19, 2013","September 2013","No Study Results Posted","null","December 2010","Occurence of Local Residual Neoplasia (LRN)|Evaluation of Selected Risk Factors for Local Residual Neoplasia (LRN)","https://ClinicalTrials.gov/show/NCT01478919"
2084,"NCT01815463","Non-Invasive Prediction of Colorectal Neoplasia","Terminated","No Results Available","Colonic Polyps|Polyposis Coli|Colorectal Cancer","","Corporal Michael J. Crescenz VA Medical Center","Both","18 Years to 85 Years   (Adult, Senior)","","2282","U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","00919|0409000159","March 18, 2013","August 2006","December 2017","April 1, 2016","November 2013","No Study Results Posted","NIPCON","November 2017","Correlation of Adnab-9 stool result with outcome of colonoscopy|Define the origin of the Adnab-9 bound antigen","https://ClinicalTrials.gov/show/NCT01815463"
2085,"NCT02678832","Momentum Project Heidelberg - Dealing Actively With a Cancerous Disease","Enrolling by invitation","No Results Available","Colorectal Cancer|Breast Cancer|Prostate Cancer|Physicians|Nurses","","Heidelberg University|German Cancer Research Center (DKFZ)|University of Heidelberg Medical Center|National Center for Tumor Diseases, Heidelberg|German Cancer Aid","Both","18 Years to 100 Years   (Adult, Senior)","","2150","Other","Observational","Time Perspective: Cross-Sectional","110512/111223","January 25, 2016","December 2015","March 2018","February 16, 2016","February 2016","No Study Results Posted","null","August 2017","Social norms and cognitions toward self-management strategies of cancer patients as assessed by the variables of the theory of planned behavior (TPB)|Physical activity as assessed with SQUASH","https://ClinicalTrials.gov/show/NCT02678832"
2086,"NCT02855385","Barriers to Care in Patients With Rectal Bleeding in Nigeria","Completed","No Results Available","Colorectal Cancer","","Obafemi Awolowo University Teaching Hospital|Memorial Sloan Kettering Cancer Center|University of Ilorin Teaching Hospital|University College Hospital, Ibadan","Both","18 Years and older   (Adult, Senior)","","134","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ERC/2013/09/01","July 28, 2016","April 2013","November 2014","August 3, 2016","August 2016","No Study Results Posted","null","November 2014","Knowledge score in relations to the demographics of patients with rectal bleeding|Colonoscopy referral triggers among General Practitioners (GP)","https://ClinicalTrials.gov/show/NCT02855385"
2087,"NCT02581059","Efficacy of Ginseng for Patients on Regorafenib","Recruiting","No Results Available","Colorectal Cancer|Palliative Medicine|Supportive Care","Drug: Regorafenib|Dietary Supplement: Ginseng","Hoosier Cancer Research Network|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 2","90","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HCRN GI14-191","October 16, 2015","April 2016","November 2017","May 2, 2016","May 2016","No Study Results Posted","null","November 2016","Subject Fatigue Assessment|Subject Compliance|Characterize Adverse Events (AE)|Subject Retention","https://ClinicalTrials.gov/show/NCT02581059"
2088,"NCT02876224","Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: Atezolizumab|Drug: Bevacizumab|Drug: Cobimetinib","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 1","33","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CO39083|2016-000584-16","August 18, 2016","September 2016","September 2018","September 1, 2016","September 2016","No Study Results Posted","null","September 2018","Percentage of Participants With Adverse Events|Plasma Maximum Concentration (Cmax) of Cobimetinib|Plasma Minimum Concentration (Cmin) of Cobimetinib|Serum Cmax of Atezolizumab|Serum Cmin of Atezolizumab|Serum Cmin of Bevacizumab|Percentage of Participants With Anti-therapeutic Antibodies (ATAs) Response to Atezolizumab","https://ClinicalTrials.gov/show/NCT02876224"
2089,"NCT01772004","Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)","Recruiting","No Results Available","Solid Tumors","Drug: Avelumab","EMD Serono|Merck KGaA","Both","18 Years and older   (Adult, Senior)","Phase 1","1700","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 100070-001|2013-002834-19","January 14, 2013","January 2013","May 2018","August 1, 2016","April 2016","No Study Results Posted","null","May 2018","Dose Limiting Toxicity|Confirmed Best Overall Response as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) for Efficacy Expansion Cohorts|Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0|Pharmacokinetic parameters: AUC (0-t), AUC (0-infinity), λz, Cmax, Tmax, T(1/2) of avelumab|Immune-related Best Overall Response (irBOR) and Best Overall Response (BOR) according to modified Immune-related response criteria (irRC) and RECIST version 1.1, respectively|Immune-related Progression-Free Survival (irPFS) time and Progression-Free Survival (PFS) Time according to modified irRC and RECIST version 1.1 , respectively|Overall Survival Time|Pharmacodynamic profile of avelumab to include serum levels of cytokines|Number of subjects with anti-avelumab antibodies|Level of PD-L1 tumor expression|Unconfirmed response according to RECIST 1.1 per investigator assessment for Primary expansion cohort|Duration of response according to modified irRC and RECIST 1.1 per investigator assessment|Progression Free Survival time according to RECIST 1.1 for Efficacy Expansion Cohorts|Duration of response according to RECIST 1.1 for Efficacy Expansion cohorts","https://ClinicalTrials.gov/show/NCT01772004"
2090,"NCT00101686","Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.","Completed","Has Results","Colorectal Neoplasms","Drug: Modified Bolus 5-FU/LV with Irinotecan|Drug: FOLFIRI + bevacizumab|Drug: miFL + bevacizumab|Drug: Infusional 5-FU/LV with Irinotecan|Drug: Oral Capecitabine with Irinotecan","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 3","547","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CPTAIV-0020-411|A5961021","January 12, 2005","February 2003","October 2008","January 4, 2010","January 2010","October 20, 2009","null","October 2008","Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL|Time to Progression: FOLFIRI, mIFL and CapeIRI|Overall Response: FOLFIRI, mIFL and CapeIRI|Survival Time: FOLFIRI, mIFL and CapeIRI|1 Year Survival: FOLFIRI, mIFL and CapeIRI|Time to Progression : Celecoxib and Placebo|Overall Response: Celecoxib and Placebo|Survival Time: Celecoxib and Placebo|Time to Progression: Bevacizumab With FOLFIRI, mIFL|Overall Response: Bevacizumab With FOLFIRI, mIFL|1 Year Survival: Bevacizumab With FOLFIRI, mIFL|Survival Time at Last Follow-Up Visit: Bevacizumab With FOLFIRI, mIFL|Dose Reduction Due to Treatment Emergent Adverse Events|Overall Relative Dose Intensity of Irinotecan","https://ClinicalTrials.gov/show/NCT00101686"
2091,"NCT01483001","Feasibility Study on Stem Cells Sensitivity Assay","Completed","No Results Available","Lung Cancer|Colorectal Cancer|Breast Cancer","Drug: Cancer Stem Cells Sensitivity Assay","Associazione Oncologia Traslazionale","Both","18 Years and older   (Adult, Senior)","Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","LIVONCO 2011/001|2011-003421-10","October 27, 2011","November 2011","December 2013","January 13, 2015","January 2015","No Study Results Posted","STELLA","September 2012","Feasibility of the project|Identification of LC, CRC and BC stem cells|Sensitivity of LC, CRC and BC stem cells to anti-tumor agents in vitro|Identification of effective drugs for a specific patient","https://ClinicalTrials.gov/show/NCT01483001"
2092,"NCT00908024","Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors","Terminated","No Results Available","Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis","Drug: BMS-754807|Drug: cetuximab (Erbitux®)","Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","54","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA191-006|EUDRACT: 2009-013766-78","May 22, 2009","October 2009","December 2012","June 17, 2013","June 2013","No Study Results Posted","null","December 2012","Maximum tolerated dose of BMS-754807 administered orally (daily schedule) in combination with cetuximab administered standard doses IV (weekly basis) will be determined by observation of dose limiting toxicities during the first 33 days of administration|To assess anti-tumor activity as measured by objective responses|To evaluate the safety and tolerability of the BMS-754807/cetuximab combination regimen|To assess the effects of the BMS-754807/cetuximab combination regimen on glucose homeostasis|Dose Expansion only: To identify biomarkers that are predictive of a response to BMS-754807/cetuximab combination therapy in advanced or metastatic CRC and SCCHN subjects with cetuximab resistance","https://ClinicalTrials.gov/show/NCT00908024"
2093,"NCT00433602","Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Gastric Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Thromboembolism","Other: clinical observation|Procedure: management of therapy complications|Procedure: ultrasound imaging","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years and older   (Adult, Senior)","","64","Other","Observational","","EORTC-90051|SANOFI-AVENTIS-EORTC-90051","February 8, 2007","November 2006","null","June 11, 2013","June 2013","No Study Results Posted","null","March 2007","Incidence of asymptomatic proximal deep vein thrombosis (DVT) of the lower limbs as assessed by bilateral compression ultrasound at baseline and at 3 months|Incidence of symptomatic, proximal and/or distal DVT of the lower limbs as assessed by clinical diagnosis and compression ultrasound within 72 hours of detection of symptoms (during the 3-month observation period)|Incidence of symptomatic pulmonary embolism as assessed by ventilation/perfusion lung scan, pulmonary angiogram, or CT lung scan within 72 hours of detection of symptoms or during autopsy (during the 3-month observation period)","https://ClinicalTrials.gov/show/NCT00433602"
2094,"NCT00088933","Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer","Terminated","No Results Available","Extensive Stage Small Cell Lung Cancer|Recurrent Colon Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Rectal Cancer|Recurrent Small Cell Lung Cancer|Stage IV Colon Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Rectal Cancer","Drug: recombinant fowlpox-CEA(6D)/TRICOM vaccine|Drug: recombinant vaccinia-CEA(6D)-TRICOM vaccine|Drug: docetaxel|Drug: sargramostim","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","60","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00049|CDR0000377574|02-452|6230|R01CA088972|P30CA051008","August 4, 2004","June 2004","null","March 28, 2014","March 2013","No Study Results Posted","null","November 2007","Anti-tumor response rate defined as the number of patients in each arm achieving a complete or partial response or stable disease divided by the total number of patients on each arm measured according to standard RECIST guidelines|Immune response defined as the numbers of patients who achieve an ELISPOT result of 1/30,000 or higher divided by the number of HLA-A2 positive individuals for each treatment arm|Number of patients experiencing each of the toxicities by grade for each treatment arm|Average quantity of circulating CEA cells determined by quantitative real time RT-PCR","https://ClinicalTrials.gov/show/NCT00088933"
2095,"NCT00488904","Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: supportan|Dietary Supplement: supportan placebo","Aalborg Universitetshospital","Both","Child, Adult, Senior","Phase 4","148","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","123omega|VN2005/35","June 19, 2007","June 2007","February 2010","April 9, 2010","April 2010","No Study Results Posted","omega3","January 2010","In previous studies a complication frequency (infectious complications) of at least 30% was found for this type of operation (14; 17) This figure has to be reduced to 10% (MIREDIF = 20%).|The secondary outcome variable is hospitalisation time and mortality. Given the material's size, it is not expected to be possible to demonstrate a significant reduction in mortality|incorporation of fatty acids in cell membranes|development in interleukins after surgery|lenght of stay in hospital","https://ClinicalTrials.gov/show/NCT00488904"
2096,"NCT01096381","Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor","Terminated","No Results Available","Breast Cancer|Cardiovascular Complications|Colorectal Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Ovarian Cancer|Peritoneal Cavity Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Other: laboratory biomarker analysis|Other: questionnaire administration","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","8","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","VICC BRE 0983|P30CA068485|VU-VICC-BRE-0983","March 30, 2010","March 2010","August 2011","February 23, 2012","February 2012","No Study Results Posted","null","July 2011","Digital-pulse amplitude (DPA) measures|Relationship between hypertension and baseline DPA|Endothelial progenitor cell levels pre- and post-bevacizumab|Correlation between physical fitness level and cardiotoxicity","https://ClinicalTrials.gov/show/NCT01096381"
2097,"NCT02827682","The Effect of IoC on Analgesia for Elderly Patients With Postoperative Effectiveness","Recruiting","No Results Available","Colorectal Cancer","Device: Angel-6000D Multiparameter Anesthesia Monitor (IoC)|Device: BIS VISTA Monitor (BIS)","First Affiliated Hospital Xi'an Jiaotong University","Both","60 Years and older   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","XJTU1AF-CRS-2016-017","June 26, 2016","July 2016","May 2018","July 11, 2016","June 2016","No Study Results Posted","null","December 2017","Duration time in PACU|Use of remifentanil|Use of propofol|length of hospital stay (LOS)","https://ClinicalTrials.gov/show/NCT02827682"
2098,"NCT00070265","Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer","Terminated","No Results Available","Liver Metastases|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: oxaliplatin|Drug: capecitabine|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 2","80","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02722|MDA-ID-02636|N01CM17003|CDR0000331853","October 3, 2003","August 2003","null","January 23, 2013","January 2013","No Study Results Posted","null","September 2004","Rate of complete resection (R0 resection)|Response rate assessed using RECIST criteria|Resectability in the subsets defined as resectable preoperatively|Improvement in survival associated with downstaging based on metastatic colorectal prognostic score|Disease-free survival|Overall survival|Positron emission tomography response rate","https://ClinicalTrials.gov/show/NCT00070265"
2099,"NCT02284139","Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects","Recruiting","No Results Available","Non-small Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer","Drug: Arm 1|Drug: Arm 2","Dong-A University Hospital","Both","20 Years and older   (Adult, Senior)","Phase 2|Phase 3","90","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DAUH-14-211","November 3, 2014","April 2015","December 2017","August 4, 2015","August 2015","No Study Results Posted","null","December 2016","To estimate the response rate of EGF ointment|Quality of Life","https://ClinicalTrials.gov/show/NCT02284139"
2100,"NCT00062348","Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases","Completed","No Results Available","Colorectal Cancer|Head and Neck Cancer|Metastatic Cancer","Drug: boronophenylalanine-fructose complex|Drug: sodium borocaptate|Procedure: conventional surgery","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years and older   (Adult, Senior)","Phase 1","27","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","EORTC-11001","June 5, 2003","April 2003","null","January 19, 2012","January 2012","No Study Results Posted","null","December 2007","Boron uptake ratio in tumor vs normal tissue|Toxicity measured by NCI-CTC v2.0 up to 28 days after injections","https://ClinicalTrials.gov/show/NCT00062348"
2101,"NCT00084643","GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors","Completed","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: GTI-2040|Drug: oxaliplatin|Drug: capecitabine|Other: pharmacological study|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","20","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03077|PHI-41|U01CA062505|CDR0000365466","June 10, 2004","May 2004","null","March 26, 2013","January 2013","No Study Results Posted","null","April 2008","MTD of the combination of GTI-2040, oxaliplatin and capecitabine based on the incidence of dose-limiting toxicity (DLT) as assessed by CTCAE version 3.0|Objective response (confirmed PR and CR) according to RECIST|Pharmacokinetics|Change in biochemical and molecular correlates","https://ClinicalTrials.gov/show/NCT00084643"
2102,"NCT01271582","Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients","Active, not recruiting","No Results Available","Stage IV Colorectal Cancer|Gastric Cancer","Drug: Irinotecan, 5FU, leucovorin","Asan Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 4","1500","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CPT_08_001","January 4, 2011","January 2009","July 2016","January 11, 2016","January 2016","No Study Results Posted","null","June 2014","Association between UGT1A1 polymorphism and grade 3/4 neutropenia after 1st cycle of FOLFIRI treatment|Association between UGT1A1 polymorphism and grade 3/4 neutropenia in all treatment duration|Association between grade 3/4 diarrhea and UGT1A1 polymorphism|Progression-free survival","https://ClinicalTrials.gov/show/NCT01271582"
2103,"NCT02299596","Physical Activity in Relation to Surgical Procedures","Recruiting","No Results Available","Colorectal Cancer|Surgery","Other: Physical activity","Sahlgrenska University Hospital, Sweden","Both","Child, Adult, Senior","","370","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","Physsurg C - the RCT","November 17, 2014","January 2015","December 2017","April 14, 2016","April 2016","No Study Results Posted","null","December 2016","Recovery measured as time back to work|Psychological recovery measured in a questionnaire, patient reported|Physical recovery measured in a questionnaire, patient reported|Complications according to Clavien-Dindo|Resumption to QoL measured in a questionnaire, patient reported|Postoperative recovery measured by SF-36|Health economic analysis of resource consumption 12 months postoperatively using EQ5D.","https://ClinicalTrials.gov/show/NCT02299596"
2104,"NCT00587756","Alternative to Two-Stage Hepatectomy","Completed","No Results Available","Colorectal Cancer|Liver Metastases","Procedure: One-stage ultrasound guided hepatectomy","University of Milan|Fondazione Humanitas per la Ricerca","Both","Child, Adult, Senior","","19","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MTX-1STAGE|MTX-CRC-1STAGE","January 3, 2008","September 2001","December 2007","January 7, 2008","December 2007","No Study Results Posted","null","May 2007","The primary outcome was the safety of the procedure. To this purpose we studied morbidity, mortality, amount of blood loss, rate of blood transfusions, and postoperative trend of liver function tests.|The secondary outcome measure was the reliability of the procedure from an oncological standpoint. For this purpose we studied the rate of true local recurrence (cut-edge) after a minimum follow-up of 6 months.","https://ClinicalTrials.gov/show/NCT00587756"
2105,"NCT01410955","Prevention of Irinotecan Induced Diarrhea by Probiotics","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: Probiotic formula|Dietary Supplement: Placebo","Monsea Ltd.|Harmonium International Inc.|Pharma Agency","Both","18 Years and older   (Adult, Senior)","Phase 3","46","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","900450001","April 26, 2011","December 2011","January 2014","January 22, 2014","January 2014","No Study Results Posted","null","December 2013","Prevention of grade 3-4 diarrhea by probiotics in patients treated by irinotecan based chemotherapy|Prevention of any grade of diarrhea|Number of patients with any grade 3 or 4 toxicity or SAE related toxicity.|Number of patients with any grade gastrointestinal symptoms","https://ClinicalTrials.gov/show/NCT01410955"
2106,"NCT01929122","Beans/Bran Enriching Nutritional Eating For Intestinal Health Trial","Active, not recruiting","No Results Available","Colorectal Cancer Control and Prevention","Dietary Supplement: Placebo-Control Meals and Snacks|Dietary Supplement: Cooked Navy Bean Powder Meals and Snacks|Dietary Supplement: Rice Bran Meals and Snacks","Colorado State University|National Cancer Institute (NCI)|Poudre Valley Health System","Both","18 Years and older   (Adult, Senior)","","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","10-1038|1R21CA161472-01A1","August 22, 2013","August 2010","null","January 27, 2016","January 2016","No Study Results Posted","BENEFIT","December 2014","Stool Microbiome Composition and Metabolome|Navy Bean or Rice Bran metabolites in stool, urine and blood.","https://ClinicalTrials.gov/show/NCT01929122"
2107,"NCT01515787","PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery","Recruiting","No Results Available","Colorectal Cancer","Drug: FOLFOX (chemotherapy)|Other: 5 FUCMT (chemoradiation)|Procedure: surgery|Procedure: magnetic resonance imaging or endorectal ultrasound","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","1060","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","N1048|CDR0000715321|NCI-2012-00234|U10CA031946","January 18, 2012","January 2012","null","June 24, 2016","June 2016","No Study Results Posted","null","July 2017","Pelvic R0 resection rate (Phase II)|DFS (Phase III)|Time to local recurrence (TLR)|Pathologic complete response|Overall survival|Adverse event (AE) profiles|Rates of receiving pre- or post-operative 5FUCMT","https://ClinicalTrials.gov/show/NCT01515787"
2108,"NCT02886897","A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors","Recruiting","No Results Available","Hepatocellular Carcinoma|Renal Cell Carcinoma|Bladder Cancer|Colorectal Cancer|Non-small-cell Lung Cancer|Breast Cancer","Biological: D-CIK and anti-PD-1 antibody","Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","B2016-036-01","August 14, 2016","July 2016","October 2019","August 26, 2016","August 2016","No Study Results Posted","null","September 2019","Progress-free survival(PFS)|Overall survival (OS)|Laboratory findings|Objective response rate|Severity of adverse events","https://ClinicalTrials.gov/show/NCT02886897"
2109,"NCT00397384","Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer","Completed","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Advanced Adult Primary Liver Cancer|Carcinoma of the Appendix|Gastrointestinal Stromal Tumor|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Small Intestine Adenocarcinoma|Small Intestine Leiomyosarcoma|Small Intestine Lymphoma|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Colon Cancer|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Gastric Cancer|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer","Drug: cetuximab|Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","43","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00107|CDR0000511880|GI 0622|6980|P30CA068485","November 8, 2006","January 2007","June 2013","September 28, 2015","February 2014","No Study Results Posted","null","June 2013","Incidence of DLT, defined as recurring grade 2 or greater non-hematological or grade 3 or greater hematological toxicities or skin rash graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE-v3)|MTD defined as the dose level at which fewer than 2 out of 6 patients experience DLT graded using CTCAE-v3|Change in molecular inhibition of the EGFR signaling pathway|OBD defined as the dose at which either a >= 75% inhibition of phosphorylation of the EGF receptor or of its downstream effectors p44/42 MAPK or Akt is observed, or Ki67 is decreased by >= 25%|Antitumor effect observed","https://ClinicalTrials.gov/show/NCT00397384"
2110,"NCT00574171","Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma","Completed","Has Results","Metastatic Colorectal Cancer","Drug: lapatinib|Drug: Capecitabine","University of Wisconsin, Madison|GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 2","29","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CO07201 (LAP109859)","December 13, 2007","September 2007","August 2009","February 19, 2016","February 2016","June 5, 2014","null","August 2009","Response Rate of Lapatinib/Capecitabine.","https://ClinicalTrials.gov/show/NCT00574171"
2111,"NCT01395459","A Sustainable Approach to Increasing Cancer Screening","Completed","No Results Available","Colorectal Cancer|Breast Cancer|Cervical Cancer","Behavioral: IVR only|Behavioral: IVR+PCC","Harvard School of Public Health|National Cancer Institute (NCI)","Both","21 Years to 86 Years   (Adult, Senior)","","13675","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","15622|R01CA126596","July 9, 2011","September 2008","October 2013","April 7, 2015","April 2015","No Study Results Posted","CATCH","March 2011","Change in population level cancer screening level at the health clinics involved.","https://ClinicalTrials.gov/show/NCT01395459"
2112,"NCT00496678","Trial of Patient Navigation-Activation","Completed","No Results Available","Breast Cancer|Colorectal Cancer","Behavioral: Navigation|Behavioral: Standard of Care","University of Rochester|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 4","900","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","RO1U01CA116924","July 3, 2007","April 2007","August 2010","August 6, 2013","December 2007","No Study Results Posted","null","June 2010","To develop, implement, and evaluate a primary care-based, patient navigation program using specially-trained community health workers. We will investigate the effect of this intervention on timing and quality of cancer-related care.|Secondary aims examine the impact of navigation on disparities in care, improvement in patient activation and total costs.","https://ClinicalTrials.gov/show/NCT00496678"
2113,"NCT01329718","Specimens for Septin 9 Performance","Completed","No Results Available","Colorectal Cancer","Other: Blood Sample","Epigenomics, Inc","Both","50 Years and older   (Adult, Senior)","Phase 0","562","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Diagnostic","Epigenomics_SPR0012","April 4, 2011","May 2011","December 2012","August 1, 2014","August 2014","No Study Results Posted","SPR0012","December 2012","Effectiveness of the Epi proColon test","https://ClinicalTrials.gov/show/NCT01329718"
2114,"NCT02844608","Feasibility of Quality of Life Assessment in Routine Clinical Oncology Practice at the University Hospital of Besancon","Recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer","Other: Quality of Life Questionnaires","Centre Hospitalier Universitaire de Besancon","Both","18 Years and older   (Adult, Senior)","","152","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","P/2015/274","July 22, 2016","March 2016","September 2017","July 22, 2016","July 2016","No Study Results Posted","QOLIBRY","May 2017","Rate of HRQOL questionnaire completion","https://ClinicalTrials.gov/show/NCT02844608"
2115,"NCT01525940","PillCam Colon Capsule and CT-colonography in the Evaluation of Patients With Incomplete Conventional Colonoscopy","Completed","No Results Available","Colorectal Cancer","Device: PillCam Colon Capsule Endoscopy (Given® Diagnostic System)","Catholic University of the Sacred Heart","Both","18 Years to 75 Years   (Adult, Senior)","","100","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CCE-CTC","January 25, 2012","November 2011","December 2013","November 9, 2015","November 2015","No Study Results Posted","null","December 2013","To evaluate the completeness of colonic exploration in patients with a previous incomplete conventional colonoscopy due to technical failure (not due to inadequate cleansing level).|To evaluate the difference in terms of accuracy and completeness between PCCE and CT-colonography","https://ClinicalTrials.gov/show/NCT01525940"
2116,"NCT01351220","Community Dissemination of an Evidence-based Colorectal Cancer (CRC) Screening Intervention","Completed","No Results Available","Colon Cancer|Rectal Cancer","Behavioral: Educational program and FOBT kits|Behavioral: Educational program and FOBT kits, and technical assistance","Jonsson Comprehensive Cancer Center|American Cancer Society, Inc.","Both","50 Years to 75 Years   (Adult, Senior)","","1100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Screening","RSGT CPPB-119384","May 6, 2011","July 2010","June 2015","July 28, 2016","February 2016","No Study Results Posted","null","June 2014","Change from Baseline in receipt of CRC screening at 6 months and 24 months|Change from Baseline in intention to obtain screening at 6 months and 24 months|Change from Baseline in CRC screening knowledge at 6 months and 24 months|Change from Baseline in frequency of patient provider communication at 6 months and 24 months","https://ClinicalTrials.gov/show/NCT01351220"
2117,"NCT01519609","Trial Comparing Moviprep and Phosphoral as Bowel Prep Before Colonoscopy","Completed","No Results Available","Colorectal Cancer","Drug: bowel prep before endoscopy","Randers Regional Hospital","Both","18 Years and older   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Randers-Moviprep","September 16, 2011","September 2011","November 2012","November 20, 2012","November 2012","No Study Results Posted","null","November 2012","Degree of bowel cleansing","https://ClinicalTrials.gov/show/NCT01519609"
2118,"NCT00619814","Is Barium Enema an Adequate Diagnostic Test for Patients With Positive FOBT?","Completed","No Results Available","Colorectal Cancer","Procedure: Double-contrast Barium enema, colonoscopy","VA Caribbean Healthcare System","Both","50 Years to 80 Years   (Adult, Senior)","","50","U.S. Fed","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Diagnostic","00171","February 8, 2008","September 2003","October 2005","February 20, 2008","February 2008","No Study Results Posted","DCBE","October 2005","","https://ClinicalTrials.gov/show/NCT00619814"
2119,"NCT00041808","Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver","Completed","No Results Available","Metastases, Neoplasm|Colorectal Neoplasms|Esophageal Neoplasms|Stomach Neoplasms|Pancreatic Neoplasms|Breast Neoplasms|Melanoma|Sarcoma|Gastrointestinal Neoplasms|Lung Neoplasms|Liver Neoplasms|Cholangiocarcinoma","Drug: MTC-DOX for Injection|Procedure: Chemotherapy","FeRx","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MTC-DOX-003","July 17, 2002","July 2001","April 2003","June 23, 2005","February 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00041808"
2120,"NCT00184782","Evaluation of Metabolic Activity of Liver Metastases by FDG-PET Scanning","Recruiting","No Results Available","Colorectal Neoplasms","Procedure: FDG-PET","Radboud University","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CP 2005","September 12, 2005","September 2003","December 2008","September 20, 2007","September 2005","No Study Results Posted","null","null","Increase in metabolic activity of liver metastases after resection of the primary tumor compared to the activity of metastases in patients without primary tumor resection","https://ClinicalTrials.gov/show/NCT00184782"
2121,"NCT01035775","Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?","Completed","No Results Available","Colorectal Cancer|Colorectal Polyps","Procedure: Inspection during insertion|Procedure: Inspection during withdrawal","Indiana University School of Medicine|Indiana University","Both","50 Years and older   (Adult, Senior)","","340","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","0909-22","December 18, 2009","December 2009","January 2011","June 22, 2011","December 2009","No Study Results Posted","null","December 2010","Adenoma detection rate|Sedation dose|Post procedural pain scores|Proportion of patients with at least one adenoma detected","https://ClinicalTrials.gov/show/NCT01035775"
2122,"NCT00310362","Use of Telehealth In-home Messaging to Improve GI (Gastrointestinal) Endoscopy Completion Rates","Completed","Has Results","Colorectal Cancer","Behavioral: Use of IVR system to improve adherene to GI appointments and prep procedures","VA Office of Research and Development","Both","Child, Adult, Senior","","3610","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Health Services Research","IIR 03-295","March 30, 2006","July 2007","February 2009","April 6, 2015","July 2014","September 16, 2014","GIVER","January 2009","Appointment Nonadherence-colonoscopy|Nonattendance-flexible Sigmoidoscopy|Preparation Nonadherence-colonoscopy|Preparation Non-adherence-flexible Sigmoidoscopy","https://ClinicalTrials.gov/show/NCT00310362"
2123,"NCT02560740","A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy","Recruiting","No Results Available","Colorectal Cancer|Advanced Gastric Cancer|Neuropathy","Dietary Supplement: PerOx Quench|Dietary Supplement: PerOx Quench Placebo","SMR Biotech Co., Ltd.","Both","18 Years to 80 Years   (Adult, Senior)","","90","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","POQ 00001","August 15, 2015","March 2016","December 2016","April 17, 2016","August 2015","No Study Results Posted","null","August 2016","Evaluation of Oxaliplatin-induced Peripheral Neuropathy incidence rate on the 35 day in 2 arms.|Evaluation of Oxaliplatin-induced Peripheral Neuropathy severity by PI on the 35 day in 2 arms.|Evaluation of Oxaliplatin-induced Peripheral Neuropathy severity by subjects on the 35 day in 2 arms.|Evaluation of subjects quality of life difference in 2 arms on the 35 day.|Evaluation of subjects Eastern Cooperation Oncology Group-Performance Score (ECOG-PS) difference in 2 arms on the 35 day.|Evaluation of the Adverse Events (AEs) incidence rate on 35 day in 2 arms.","https://ClinicalTrials.gov/show/NCT02560740"
2124,"NCT00131586","Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins","Terminated","No Results Available","Lung Cancer|Colorectal Cancer","","AHS Cancer Control Alberta","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SP-11-0033/ethics 17173","August 17, 2005","April 2003","February 2009","February 24, 2016","April 2012","No Study Results Posted","null","February 2009","","https://ClinicalTrials.gov/show/NCT00131586"
2125,"NCT02365480","Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission","Recruiting","No Results Available","Ulcerative Colitis","Drug: Berberine Chloride|Other: Laboratory Biomarker Analysis|Other: Placebo","National Cancer Institute (NCI)","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","18","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NCI-2015-00173|NCI 2014-03-01|NWU2014-03-01|N01CN00035|P30CA060553","February 17, 2015","June 2016","null","June 20, 2016","June 2016","No Study Results Posted","null","June 2017","Incidence of grade 2 systemic toxicity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4|Organ toxicity|Change in blood berberine chloride concentration measurement using high-performance liquid chromatography/mass spectrometry|Change in colorectal tissue biomarkers expression by IHC|Change in gene methylation status using methylation-specific polymerase chain reaction strategy|Change in plasma markers of inflammation via ELISA|Clinical efficacy of berberine chloride measured using the UCDAI score|Severity of histologic inflammation","https://ClinicalTrials.gov/show/NCT02365480"
2126,"NCT00454519","Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis","Recruiting","No Results Available","Stomach Neoplasms|Colorectal Neoplasms|Neoplasm Metastasis|Mesothelioma","Procedure: cytoreductive surgery|Procedure: intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin","Wuhan University|NPO Organization to Support Peritoneal Dissemination Treatment|Kishiwada Tokushukai Hospital|Kusatsu General Hopital|Ikeda Hospital","Both","20 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WUCC-0701","March 29, 2007","March 2007","null","February 12, 2009","February 2009","No Study Results Posted","IPHC","December 2009","overall survival time|perioperative morbidity and mortality","https://ClinicalTrials.gov/show/NCT00454519"
2127,"NCT01336985","Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads","Terminated","No Results Available","Neoplasm Metastases|Melanoma|Colorectal Neoplasms","Drug: Irinotecan|Procedure: Chemoembolization|Device: Drug-Eluting Beads|Procedure: Biopsy","National Institutes of Health Clinical Center (CC)","Both","18 Years to 84 Years   (Adult, Senior)","Phase 1","5","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","110131|11-CC-0131","April 14, 2011","March 2011","March 2011","August 6, 2016","November 2014","No Study Results Posted","null","null","To determine the safety of hepatic chemoembolization with drug-eluting beads containing 100mg of irinotecan|To determine the serum pharmacokinetics and tumor tissue concentrations achieved following hepatic chemoembolization with irinotecan-eluting beads","https://ClinicalTrials.gov/show/NCT01336985"
2128,"NCT01507740","Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients","Terminated","No Results Available","Hepatocellular Cancer|Non-small Cell Lung Cancer|Renal Cell Cancer|Colorectal Cancer","Drug: Avastin|Drug: Suntent|Drug: Nexavar","Medical University Innsbruck","Both","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Praemarker AAT 08","September 18, 2009","July 2009","October 2014","April 28, 2015","April 2015","No Study Results Posted","null","December 2012","Progression free survival under antiangiogenic therapy","https://ClinicalTrials.gov/show/NCT01507740"
2129,"NCT02352571","Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer","Recruiting","No Results Available","Neoplasm Metastasis|Gastric Cancer|Colorectal Cancer","Biological: GC1118","Green Cross Corporation","Both","19 Years and older   (Adult, Senior)","Phase 1","72","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GC1118_P1","January 21, 2015","January 2015","June 2017","July 4, 2016","February 2016","No Study Results Posted","null","December 2016","Occurrence of Dose Limiting Toxicity (DLT)|Frequency of Adverse Events|Changes in safety parameters, laboratory values, vital signs and physical examinations|Overall Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1|Disease Control Rate (DCR) as per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1|Progression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1 (Part B)|Time versus plasma concentration profiles and basic PK parameters of GC1118|Presence of Human Anti Drug Antibody","https://ClinicalTrials.gov/show/NCT02352571"
2130,"NCT00118365","Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps","Completed","Has Results","Precancerous Condition","Other: placebo|Drug: eflornithine|Drug: sulindac|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","40 Years to 80 Years   (Adult, Senior)","Phase 3","375","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NCI-2009-00880|UCI 97-05|R01CA088078","July 8, 2005","July 1998","August 2008","January 12, 2015","February 2014","April 18, 2014","null","August 2008","Detection of Any Adenoma at the End of the Study|Detection of Any Adenoma at the End of the Study Stratified by Baseline Prostaglandin E2 (PGE2) and Treatment|Detection of Any Adenoma at the End of the Study Stratified by Baseline Putrescine and Treatment|Detection of Any Adenoma at the End of the Study Stratified by Baseline Spermidine-to-spermine Ratio and Treatment|Detection of Any Adenoma at the End of the Study Stratified by Prostaglandin E2 (PGE2) Response and Treatment|Detection of Any Adenoma at the End of the Study Stratified by Putrescine Response and Treatment|Detection of Any Adenoma at the End of the Study Stratified by Spermidine-to-spermine Ratio Response and Treatment|Adverse Events With a Grade of 3 and Above|Baseline Putrescine by ODC Genotype|Baseline Spermidine by ODC Genotype|Baseline Spermine by ODC Genotype|At the End of the Study - Putrescine Response by ODC Genotype|At the End of the Study - Spermidine Response by ODC Genotype|At the End of the Study - Spermine Response by ODC Genotype|Number of Participants Have Adenoma Recurrence in Each ODC1 Genotytpe by Treatment Group|Biomarker in Adenoma: Apoptosis|Biomarker in Adenoma - Ki-67|Biomarker in Adenoma: CEA|Biomarker in Adenoma: Sialyl-TN (B72.3)|Biomarker in Adenoma - p53|Biomarker in Adenoma: Bcl-2","https://ClinicalTrials.gov/show/NCT00118365"
2131,"NCT01932489","The Jules Bordet Institute Molecular Profiling Program Feasibility Trial","Completed","No Results Available","Metastic Colorectal Cancer.|Metastatic Melanoma.|Metastatic Non-small Cell Lung Cancer.","Procedure: Biopsy of a metastatic lesion.","Jules Bordet Institute","Both","18 Years and older   (Adult, Senior)","","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","IJBCE2139","August 23, 2013","December 2013","October 2014","May 19, 2015","October 2014","No Study Results Posted","PRECISION-F","October 2014","Quality of the biopsies|Technical failure rate.|Percentage of patients with results within the specified turnaround time|Feasibility of a tumor sequencing board.","https://ClinicalTrials.gov/show/NCT01932489"
2132,"NCT00959127","A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer","Completed","No Results Available","Advanced Solid Tumors|Advanced or Metastatic Biliary Cancer|Metastatic Colorectal Cancer","Drug: ARRY-438162 (MEK162), MEK inhibitor; oral","Array BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 1","93","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ARRAY-162-111","August 13, 2009","August 2009","January 2013","February 12, 2013","February 2013","No Study Results Posted","null","January 2013","Establish the maximum tolerated dose (MTD) of the study drug.|Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.|Characterize the pharmacokinetics (PK) of the study drug and metabolite.|Assess the efficacy of the study drug in terms of tumor response, duration of response, duration of stable disease, progression-free survival and overall survival.|Assess possible PK/pharmacodynamic (PD) or PK/efficacy and safety correlations.","https://ClinicalTrials.gov/show/NCT00959127"
2133,"NCT02888743","Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer","Not yet recruiting","No Results Available","Recurrent Colorectal Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Biological: Durvalumab|Other: Laboratory Biomarker Analysis|Radiation: Radiation Therapy|Biological: Tremelimumab","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","180","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2016-01325|10021|P30CA006516|UM1CA186709","August 31, 2016","April 2017","null","September 8, 2016","September 2016","No Study Results Posted","null","June 2019","Overall response rate as determined by RECIST 1.1|Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events version 4.0|Local control rate and abscopal response rates|Objective response per immune-related response criteria|Overall survival (OS)|Prognostic effect of PD-L1 expression|Prognostic effect of T-cell infiltration|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02888743"
2134,"NCT00772083","Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors","Completed","No Results Available","Anemia|Colorectal Cancer","Behavioral: Educational brochure|Behavioral: Standard pamphlet","Medical College of Wisconsin|Healthier Wisconsin Partnership Program|Blood Center of Wisconsin|National Anemia Action Council","Both","18 Years and older   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","PRO00008944","October 13, 2008","November 2008","June 2009","August 10, 2010","August 2010","No Study Results Posted","null","June 2009","self-reported seeking of medical care for diagnosis of anemia found at time of blood donation","https://ClinicalTrials.gov/show/NCT00772083"
2135,"NCT02208804","Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization","Recruiting","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis|Liver Diseases|Digestive System Neoplasms","Device: Holmium-166-poly (L-lactic acid) microspheres","UMC Utrecht","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","25","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","14-287/D","July 31, 2014","November 2014","null","January 28, 2016","December 2015","No Study Results Posted","SIM","November 2016","Posttreatment tumor to non-tumor activity concentration ratio on SPECT/CT|Mean absorbed radiation doses in tumorous and healthy liver tissue on SPECT/CT|Posttreatment tumor response on CT and 18F-FDG-PET|Predictive value of the holmium-166 scout dose|Dose-response relationship between tumor absorbed doses on SPECT/CT and tumor response on CT and 18F-FDG-PET|Infusion efficiency|Overall survival|Clinical and laboratory toxicity","https://ClinicalTrials.gov/show/NCT02208804"
2136,"NCT01710293","Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis","Not yet recruiting","No Results Available","Lung Cancer|Bladder Cancer|Colorectal Cancer|Hepatocellular Carcinoma|Breast Cancer","Behavioral: Communication of Patients Lost to Follow-up to Providers","VA Office of Research and Development","Both","21 Years and older   (Adult, Senior)","","700","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Health Services Research","CRE 12-033|CIRB 15-07","October 16, 2012","October 2016","July 2018","June 23, 2016","June 2016","No Study Results Posted","PACT CREATE 3","October 2017","Median Time from Initial Follow-up Delay to Follow-up Action","https://ClinicalTrials.gov/show/NCT01710293"
2137,"NCT02754115","An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","Recruiting","No Results Available","Colorectal Cancer|Ovarian Cancer|Peritoneal Disease","Other: Hyperthermic intraperitoneal chemotherapy","Tata Memorial Centre","Both","18 Years to 70 Years   (Adult, Senior)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PN 1667","March 29, 2016","April 2016","May 2021","May 11, 2016","May 2016","No Study Results Posted","null","April 2021","Changes in invasive blood pressure in perioperative period|Changes in body temperature in perioperative period|Changes in cardiac output in perioperative period|Changes in arterial blood gas in perioperative period|Length of stay in intensive care unit|Mortality","https://ClinicalTrials.gov/show/NCT02754115"
2138,"NCT01516710","Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study","Recruiting","No Results Available","Secondary Malignant Neoplasm of Liver|Colorectal Neoplasms","Procedure: Open liver resection|Procedure: Laparoscopic liver resection","Oslo University Hospital|Helse Sor-Ost","Both","18 Years and older   (Adult, Senior)","","280","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","2011/1285/REK sør-øst B","January 13, 2012","January 2012","December 2025","June 18, 2015","April 2015","No Study Results Posted","Oslo-CoMet","December 2015","Perioperative morbidity|5 year survival|Recurrence pattern|Immediate oncologic outcome|Postoperative quality of life|Surgical trauma and activation of the immune system|Health economy|Postoperative pain|Molecular biology|Anti-tumor immunology|Imaging","https://ClinicalTrials.gov/show/NCT01516710"
2139,"NCT01341366","Fast-track Perioperative Program for Laparoscopic Colorectal Surgery","Completed","No Results Available","Colorectal Cancer","Other: Fast-track perioperative program|Other: Traditional perioperative program","Chinese University of Hong Kong","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","128","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRE-2008.552-T","April 20, 2011","November 2010","March 2013","April 29, 2013","April 2013","No Study Results Posted","null","March 2013","Duration of hospital stay|Pain scores|Morbidity and mortality|Readmission rate|Quality of life|Direct/indirect medical costs and out-of-hospital economic costs|Systemic cytokine responses|Lymphocyte subsets","https://ClinicalTrials.gov/show/NCT01341366"
2140,"NCT02266056","The Benefits of Deep Neuromuscular Block and Sugammadex in Laparoscopic Colorectal Surgery","Completed","No Results Available","Colorectal Cancer","Drug: Deep neuromuscular block using rocuronium and reversal with suggamadex|Drug: Moderate neuromuscular block using rocuronium and reversal with suggamadex","Yonsei University","Both","19 Years to 70 Years   (Adult, Senior)","","72","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)","4-2014-0559","August 26, 2014","August 2014","September 2015","October 16, 2015","October 2015","No Study Results Posted","null","September 2015","intra-abdominal pressure","https://ClinicalTrials.gov/show/NCT02266056"
2141,"NCT02350400","Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).","Recruiting","No Results Available","Colorectal Cancer Metastatic","Device: DEBIRI","Singapore General Hospital|Singhealth Foundation","Both","21 Years and older   (Adult, Senior)","Phase 1","5","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DEBIRI_TKH_01_2012","November 26, 2014","June 2014","December 2015","January 25, 2015","January 2015","No Study Results Posted","null","April 2015","Establish safety and toxicity profile of the irinotecan loaded DEBIRI beads (number of patients with adverse events according to Health Science Authority's Safety Reporting for Clinical Trials)|Tumour response (measured by mRECIST)","https://ClinicalTrials.gov/show/NCT02350400"
2142,"NCT01579357","Pharmacokinetics and Metabolic Activation of Capecitabine","Completed","No Results Available","Metastatic Colorectal Cancer","Other: blood samples","Arbeitsgemeinschaft medikamentoese Tumortherapie","Both","18 Years and older   (Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","AGMT-Capecet_PK","March 29, 2012","February 2012","December 2014","March 6, 2015","March 2015","No Study Results Posted","null","December 2014","Influence of Cetuximab on metabolic activation of Capecitabine","https://ClinicalTrials.gov/show/NCT01579357"
2143,"NCT02282722","Improving Informed Consent for Palliative Chemotherapy","Recruiting","No Results Available","Metastatic Colorectal Cancer","Other: Investigational informed consent for chemotherapy|Other: Usual, standard-of-care informed consent for chemotherapy","Dana-Farber Cancer Institute|Patient-Centered Outcomes Research Institute|Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","21 Years and older   (Adult, Senior)","","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","15-143|CE-1304-6517|1UG1CA189823-01","October 27, 2014","December 2013","November 2016","May 25, 2016","May 2016","No Study Results Posted","null","November 2016","Proportion of participants at 4 months who understand the benefits of palliative chemotherapy|Proportion of participants with core knowledge required for informed consent|Proportion of participants with decisional conflict|Proportion of patients achieving their desired role in decision-making","https://ClinicalTrials.gov/show/NCT02282722"
2144,"NCT01807117","PET-MRI in Diagnosing Patients With Colon or Rectal Cancer","Completed","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IIA Colon Cancer|Stage IIA Rectal Cancer|Stage IIB Colon Cancer|Stage IIB Rectal Cancer|Stage IIC Colon Cancer|Stage IIC Rectal Cancer|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Procedure: positron emission tomography|Procedure: computed tomography|Procedure: magnetic resonance imaging|Radiation: fludeoxyglucose F 18","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","22 Years and older   (Adult, Senior)","","15","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CASE8212|NCI-2013-00511","March 6, 2013","April 2013","November 2015","November 25, 2015","November 2015","No Study Results Posted","null","November 2015","Sensitivity for PET-CT and PET-MRI|Specificity for PET-CT and PET-MRI|Positive and negative predictive values for PET-CT and PET-MRI|Accuracy for PET-CT and PET-MRI","https://ClinicalTrials.gov/show/NCT01807117"
2145,"NCT02576665","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors","Recruiting","No Results Available","Metastatic Colorectal Cancer|Metastatic Renal Cell Carcinoma|Metastatic Melanoma|Brain Metastasis|Locally Advanced or Metastatic Pancreatic Cancer|Locally Advanced or Metastatic Breast Cancer","Biological: Toca 511|Drug: Toca FC","Tocagen Inc.","Both","18 Years to 90 Years   (Adult, Senior)","Phase 1","26","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Tg 511-15-02","October 12, 2015","July 2016","November 2019","September 9, 2016","September 2016","No Study Results Posted","Toca6","December 2016","Number of patients with vector deposition detected in the resected tumor specimens following administration of Toca 511|Number of patients who received Toca 511 and Toca FC with treatment related adverse events as assessed by CTCAE v4.0|Number of surviving patients who do not have documented tumor progression following treatment","https://ClinicalTrials.gov/show/NCT02576665"
2146,"NCT01211561","Colon Cancer Prevention Using Selenium","Not yet recruiting","No Results Available","Prevention of Colorectal Cancer","Drug: Selenium, selenomethionine|Drug: placebo","University of Illinois at Chicago","Both","50 Years and older   (Adult, Senior)","Phase 0","50","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2008-1122","September 28, 2010","December 2010","December 2016","September 28, 2010","September 2010","No Study Results Posted","null","December 2014","Reduction in ACF biomarkers","https://ClinicalTrials.gov/show/NCT01211561"
2147,"NCT01111292","Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia","Terminated","Has Results","Colon Carcinoma|Dysplasia in Crohn Disease|Low Grade Dysplasia in Ulcerative Colitis|Rectal Carcinoma","Drug: Inositol|Other: Placebo","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","5","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NCI-2011-01434|CDR0000671302|NCI09-13-02|NWU09-13-02|P30CA060553|N01CN35157","April 24, 2010","October 2010","September 2014","June 1, 2016","June 2016","January 29, 2016","null","September 2014","The Effect of Myo-inositol (Inositol) on P-β-catenin Staining in Areas of Low Grade Dysplasia in Subjects With Known Colitis-induced Low Grade Dysplasia.","https://ClinicalTrials.gov/show/NCT01111292"
2148,"NCT01694784","Understanding and Discouraging Overuse of Potentially Harmful Screening Tests","Completed","No Results Available","Preventive Screening|Prostate Cancer|Osteoporosis|Colorectal Cancer","Behavioral: Quantitative Information Sheet|Behavioral: Qualitative Information Sheet|Behavioral: Narrative Information Sheet|Behavioral: Framed Information Sheet","University of North Carolina, Chapel Hill|Agency for Healthcare Research and Quality (AHRQ)|Duke University","Both","50 Years to 85 Years   (Adult, Senior)","","775","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","12-1338","September 13, 2012","September 2012","June 2014","April 15, 2016","April 2016","No Study Results Posted","null","June 2014","Change from Baseline in Intent to Accept Screening Immediately Post-intervention|Change from Baseline in Perceived Disease Risk Immediately Post-Intervention|Change from Baseline in Perceived Disease Severity Immediately Post-Intervention|Change from Baseline in Disease Specific Knowledge Immediately Post-Intervention|Change from Baseline in Disease-Specific Screening Attitudes Immediately Post-Intervention|Change from Baseline in Decisional Balance Immediately Post-Intervention|Change from Baseline in Values Clarity Immediately Post-Intervention|Change from Baseline in General Screening Knowledge Immediately Post-Intervention|Change from Baseline in General Screening Attitudes Immediately Post-Intervention","https://ClinicalTrials.gov/show/NCT01694784"
2149,"NCT02795104","Rural Interventions for Screening Effectiveness","Not yet recruiting","No Results Available","Breast, Cervical or Colorectal Cancer Screening Needed","Behavioral: Educational Intervention via brochure|Behavioral: Educational Intervention via DVD|Behavioral: Educational Intervention-DVD & Telephone Based Navigation","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","50 Years to 74 Years   (Adult, Senior)","","1058","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","OSU-16108|NCI-2016-00774|P30CA016058|R01CA196243","June 6, 2016","July 2016","September 2020","June 9, 2016","June 2016","No Study Results Posted","RISE","July 2019","Adherence to screening guidelines|Binary adherence to all needed screening and any needed screening across the three randomized arms|Cost effectiveness of each intervention assessed by QALY (Quality Adjusted Life Year)-based cost utility|Cost of the interventions|Cost savings","https://ClinicalTrials.gov/show/NCT02795104"
2150,"NCT00255229","Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Glutamine|Other: Placebo","AHS Cancer Control Alberta|Cross Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","130","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","GI-05-0024","November 16, 2005","December 2002","January 2010","February 24, 2016","January 2012","No Study Results Posted","null","January 2010","Reduction in diarrhea.","https://ClinicalTrials.gov/show/NCT00255229"
2151,"NCT02005614","A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection","Recruiting","No Results Available","Melanoma|Renal Cell Carcinoma|Sarcoma|Breast Cancer|Lung Cancer|Colorectal Cancer|Gastrointestinal Cancers|Brain Metastases","Procedure: Gamma Knife Radiosurgery","Yale University","Both","18 Years and older   (Adult, Senior)","Phase 2","132","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1306012291","December 3, 2013","November 2013","March 2017","June 10, 2016","June 2016","No Study Results Posted","null","March 2017","Rate of Local Control Over time (RECIST Criteria)","https://ClinicalTrials.gov/show/NCT02005614"
2152,"NCT01596361","Verification of a Pharmacogenetic Approach to Customizing Chemotherapy to Asians","Recruiting","No Results Available","Colorectal Cancer","","National University Hospital, Singapore","Both","21 Years and older   (Adult, Senior)","","750","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2011/01711","April 2, 2012","August 2011","null","December 10, 2013","December 2013","No Study Results Posted","null","August 2014","Verify the differences observed in the frequency of germline pharmacogenetic variants related to chemotherapy between Asian and Caucasian CRC patients|Testing the variations in the frequency of somatic pharmacogenetic gene mutations between Asian and Caucasian CRC patients could be used to infer differences in clinical outcomes between the two ethnicities.|Characterise the deletion status of heat shock protein molecules and determine the association between heat shock protein deletion status and clinico-pathological outcomes in Asian and Caucasian patients with CRC","https://ClinicalTrials.gov/show/NCT01596361"
2153,"NCT01540435","Perioperative Treatment of Resectable Liver Metastases","Withdrawn","No Results Available","Colon Cancer Liver Metastasis","Drug: Bevacizumab","University of Regensburg|University of Halle Medical Faculty","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KKSH088|2010-023575-25","February 16, 2012","September 2012","May 2013","May 28, 2013","May 2013","No Study Results Posted","PERIMAX","May 2013","Failure-free survival (FFS@18)|Disease Free Survival (DFS)|Overall survival (OS)|Perioperative morbidity|Quality of life|Achievability of R0 resection|Overall response rate (Arm B)|Pathologic response rate","https://ClinicalTrials.gov/show/NCT01540435"
2154,"NCT01468675","Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care","Completed","No Results Available","Colorectal Cancer|Breast Cancer|Coronary Heart Disease|Diabetes","Other: risk assessment survey; decision support for providers for prevention based on risk","Brigham and Women's Hospital","Both","18 Years to 75 Years   (Adult, Senior)","","6075","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","2009P002762","November 4, 2011","February 2013","December 2014","February 5, 2015","February 2015","No Study Results Posted","null","December 2014","documentation of family history in coded fields in the patient's electronic health record","https://ClinicalTrials.gov/show/NCT01468675"
2155,"NCT01410760","PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases","Recruiting","No Results Available","Metastatic Colorectal Cancer","Other: Perfusion CT scan","University of Oxford|Oxford University Hospitals NHS Trust|University Hospitals, Leicester","Both","18 Years and older   (Adult, Senior)","Phase 0","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","10/H0505/95","August 3, 2011","April 2011","null","June 19, 2012","June 2012","No Study Results Posted","PERFORM","April 2013","Recruitment rate to this voluntary study and acquisition of sufficient data for perfusion analysis|Correlation between the tumour perfusion pattern on perfusion CT studies at baseline and shortly after the start of therapy and morphological response by RECIST criteria on CT scan 3 months post therapy in both arms of the FOXFIRE trial.","https://ClinicalTrials.gov/show/NCT01410760"
2156,"NCT00588549","Utility of PET In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases","Completed","No Results Available","Colorectal Carcinoma","","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","","204","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","98-015","December 24, 2007","July 1998","March 2009","March 18, 2009","March 2009","No Study Results Posted","null","March 2009","To assess if whole body 18F-FDG-PET enhances our ability to detect metastatic colorectal cancer restricted to liver and lung over conventional imaging such as CT and to determine the accuracy of PET in imaging extrahepatic tumors.|To determine whether PET plays a role in altering clinical management of patients undergoing evaluation for liver resection for hepatic colorectal metastases.","https://ClinicalTrials.gov/show/NCT00588549"
2157,"NCT00510627","Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases","Withdrawn","No Results Available","Metastatic Liver Cancer|Secondary Liver Cancer|Liver Neoplasm","Device: Radiofrequency Ablation (RFA)|Drug: Chemotherapy","Boston Scientific Corporation","Both","18 Years and older   (Adult, Senior)","Phase 4","682","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC-PM-032006","July 31, 2007","August 2007","December 2010","December 20, 2007","December 2007","No Study Results Posted","Prometheus","null","To evaluate Overall Survival in subjects receiving chemotherapy + RFA compared to chemotherapy alone.|To evaluate any unanticipated adverse device effects.|To determine if there are differences in the incidence or severity of adverse events in the RFA + chemotherapy arm compared to the chemotherapy only arm.","https://ClinicalTrials.gov/show/NCT00510627"
2158,"NCT02491593","Quantitative Immunochemical Fecal Occult Blood Test in Symptomatic Patients","Enrolling by invitation","No Results Available","Colorectal Neoplasms","Device: fecal occult blood test","Uppsala University","Both","18 Years and older   (Adult, Senior)","","500","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","QFecalBlood 2013/2:7","June 30, 2015","April 2014","December 2016","March 9, 2016","March 2016","No Study Results Posted","FIKA","December 2016","Number of patients with high fecal blood output in relation to colorectal cancer|Number of patients with low fecal blood output in relation to colorectal polyps","https://ClinicalTrials.gov/show/NCT02491593"
2159,"NCT02650635","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors","Recruiting","No Results Available","Colorectal Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Recurrent Breast Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Melanoma of the Skin|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Renal Cell Carcinoma|Solid Neoplasm|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma|Stage IVA Colorectal Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Pancreatic Cancer","Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: Pegfilgrastim|Other: Pharmacological Study|Drug: TLR8 Agonist VTX-2337","Mayo Clinic|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","20","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1245|NCI-2015-02150|P30CA015083","December 30, 2015","February 2016","null","June 15, 2016","February 2016","No Study Results Posted","null","May 2021","Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide|Duration of response, assessed by irDOR, defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented|Incidence of adverse events of cyclophosphamide and TLR8 agonist VTX-2337, using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Overall response rate assessed by irBORR|Overall survival (OS)|PFS as measured by serial imaging studies and assessed by irRECIST","https://ClinicalTrials.gov/show/NCT02650635"
2160,"NCT02298959","Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors","Recruiting","No Results Available","Adult Solid Neoplasm|Metastatic Melanoma|Metastatic Renal Cell Cancer|Recurrent Colorectal Carcinoma|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Renal Cell Carcinoma|Stage IV Ovarian Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Biological: Ziv-Aflibercept","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","36","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2014-01984|15-703|9676|P30CA006516|U01CA062490|UM1CA186709","November 21, 2014","March 2015","null","September 9, 2016","July 2016","No Study Results Posted","null","April 2017","Recommended combination dose of ziv-aflibercept and pembrolizumab, assessed by dose-limiting toxicities|Objective response rate (ORR)|Overall survival|Progression-free survival|Time-to-progression","https://ClinicalTrials.gov/show/NCT02298959"
2161,"NCT02439008","Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response","Recruiting","No Results Available","Carcinoma, Hepatocellular|Colorectal Neoplasms|Melanoma|Kidney Neoplasms","Procedure: Blood samples collection before radiotherapy|Procedure: Blood samples collection during radiotherapy|Procedure: Blood samples collection after radiotherapy|Radiation: Radiotherapy","Centre Oscar Lambret|Institut de Biologie de Lille","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","EarlyBio-HypoRT-WP3-1504","April 27, 2015","September 2015","June 2018","September 17, 2015","September 2015","No Study Results Posted","null","November 2016","Number of immune cells|Presence of activation markers|Number of secreted exosomes|Cell viability, determined by number of live/dead cells present|Progression-free rate|Number of Participants with Adverse Events related to radiotherapy","https://ClinicalTrials.gov/show/NCT02439008"
2162,"NCT01436656","A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma","Active, not recruiting","No Results Available","Melanoma and Metastatic Colorectal Cancer","Drug: LGX818","Array BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 1","107","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLGX818X2101|2011-000556-42","April 14, 2011","September 2011","null","February 11, 2016","February 2016","No Study Results Posted","null","October 2012","Incidence of Dose Limiting Toxicities|Number and nature of Adverse events and clinical activity|Pharmacokinetic profile of LGX818|Tumor response per RECIST|Baseline molecular status","https://ClinicalTrials.gov/show/NCT01436656"
2163,"NCT02175914","Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis","Recruiting","No Results Available","FAP-Familial Adenomatous Polyposis","Drug: Erythromycin","michal roll|Tel-Aviv Sourasky Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 4","20","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TASMC-10-RK-0519-CTIL","November 26, 2012","June 2014","June 2016","June 25, 2014","June 2014","No Study Results Posted","null","June 2015","Evaluation of changes in number and size of adenomas measured by upper endoscopy|Evaluation of changes in number and size of adenomas measured by lower endoscopy|CT and MRI imaging for desmoids","https://ClinicalTrials.gov/show/NCT02175914"
2164,"NCT00704600","Nelfinavir, a Phase I/Phase II Rectal Cancer Study","Completed","No Results Available","Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal","Drug: nelfinavir","Maastricht Radiation Oncology","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","15","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MEC 07-03-026","June 23, 2008","September 2008","July 2013","December 5, 2014","December 2014","No Study Results Posted","Nelfinavir","September 2010","phase I: Incidence of any grade 3 or higher non-hematological or grade 4 or higher hematological toxicity (CTCAE v3.0) and of grade 4 or higher postoperative toxicity within 30 days post-surgery phase II:rate of pathological complete remission","https://ClinicalTrials.gov/show/NCT00704600"
2165,"NCT01937429","Effectiveness of Instillation of Blue Water (Indigo Carmin®) for Colonoscopy","Recruiting","No Results Available","Adenoma Detection to Prevent Colorectal Cancer","Device: Colonoscopy with blue Indigo Carmin®|Device: Standard colonoscopy with insufflation of air","Hospices Civils de Lyon","Both","18 Years and older   (Adult, Senior)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2012.713","September 4, 2013","January 2013","April 2014","September 6, 2013","September 2013","No Study Results Posted","GRAND BLEU","April 2014","The rate of colonoscopy with at least one adenoma detected (or adenoma detection rate) confirmed by a histological reporting.|Measure 1: The characteristics of the lesions detected by the two types of colonoscopy (diameter, macroscopic appearance, histological nature)|Measure 2 Comparison of the time of the endoscope during the colonoscopy between the two methods|Measure 3 The comparison of the tolerance of the two colonoscopy procedures by assessing patient reported side effects.","https://ClinicalTrials.gov/show/NCT01937429"
2166,"NCT02101099","Effect of Anesthesia on Force Application During Colonoscopy","Completed","No Results Available","Outpatient Colonoscopy for Colorectal Cancer Screening or for Symptoms Suggestive of Colonic Diseases","Device: Colonoscopy Force Monitor","Artann Laboratories|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Capital Digestive Care, LLC|University of Pennsylvania|Georgetown University","Both","30 Years to 75 Years   (Adult, Senior)","","102","Industry|NIH|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CFM-04|5R44DK068936","March 28, 2014","March 2014","December 2015","July 11, 2016","July 2016","No Study Results Posted","CFM","December 2015","Peak push force is increased in patients receiving propofol as compared to conscious sedation.","https://ClinicalTrials.gov/show/NCT02101099"
2167,"NCT01593098","A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)","Recruiting","No Results Available","Adenoma|CRC","","Chinese University of Hong Kong","Both","40 Years to 70 Years   (Adult, Senior)","","600","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","AN study","May 1, 2012","May 2010","December 2019","April 13, 2016","April 2016","No Study Results Posted","AN","December 2018","Prevalence of adenoma and CRC|Rate of advanced neoplasms depending on age of index case|Rate of advanced neoplasms depending on site of neoplasm|Differences in genetic profile between siblings of patients with advanced neoplasm and controls","https://ClinicalTrials.gov/show/NCT01593098"
2168,"NCT01483443","Oophorectomy Followed by Chemotherapy Versus Chemotherapy Alone in Colorectal Cancer Patients","Completed","No Results Available","Stage IV Colon Cancer","Procedure: Oophrectomy","Gachon University Gil Medical Center","Female","55 Years to 80 Years   (Adult, Senior)","Phase 3","140","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","GIRBA2263","November 29, 2011","August 2008","August 2013","August 28, 2015","August 2015","No Study Results Posted","null","August 2012","Overall survival|Disease free survival","https://ClinicalTrials.gov/show/NCT01483443"
2169,"NCT02106858","Stivarga Regulatory Post-Marketing Surveillance Study in Korea","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Regorafenib (Stivarga,BAY73-4506)","Bayer","Both","Child, Adult, Senior","","3750","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16778|SV1314KR","April 4, 2014","June 2014","May 2019","September 8, 2016","September 2016","No Study Results Posted","StivargaPMS","May 2019","Percentage of patients with serious adverse events|Percentage of patients with adverse drug reactions (ADRs)|Overall response|Progression free survival (PFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02106858"
2170,"NCT00085163","Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon","Completed","No Results Available","Colorectal Cancer","Drug: celecoxib|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: adjuvant therapy","European Organisation for Research and Treatment of Cancer - EORTC|Dutch Colorectal Cancer Group (DCCG)|Arbeitsgemeinschaft fur Internistische Onkologie|Onkologie|EFCR - Egyptian foundation for Cancer Research|EORTC GI Group (EORTC 40023)|Federation Francophone de Cancerologie Digestive|GCCD-APIO - Grupo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação|Oncológica|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|GOCCI - Gruppo Oncologico Chirurgico Cooperativo Italiano|GOIRC - Gruppo Oncologico Italiano di Ricerca Clinica|SG - Scandinavian Group|TTD - Grupo Español para el Tratamiento de Tumores Digestivos","Both","18 Years to 120 Years   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Treatment","EORTC-40023|PETACC-5","June 10, 2004","March 2004","null","October 19, 2015","October 2015","No Study Results Posted","null","November 2005","Disease-free survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter|Overall survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter|Time occurrence of new primary colon cancer and new polyps as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter|Toxicity as measured by CTC AE version 2.0 every 3 months in year 1, every 6 months in years 2-3, and annually thereafter","https://ClinicalTrials.gov/show/NCT00085163"
2171,"NCT02148406","Programs to Support You During Chemotherapy (Pro-You)","Completed","No Results Available","Depressive Symptoms|Fatigue|Psychosocial Effects of Cancer and Its Treatment|Stage IIA Colon Cancer|Stage IIA Rectal Cancer|Stage IIB Colon Cancer|Stage IIB Rectal Cancer|Stage IIC Colon Cancer|Stage IIC Rectal Cancer|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Behavioral: Yoga Skills Training (YST)|Other: questionnaire administration|Other: fatigue and depressive symptom assessment and management|Other: psychological stress assessment|Other: laboratory biomarker analysis|Other: Attention Control","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","3","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Supportive Care","VICC GI 1416|NCI-2014-00905|P30CA068485","May 22, 2014","August 2014","April 2015","June 19, 2015","June 2015","No Study Results Posted","Pro-You","April 2015","Changes in fatigue (recalled)|Changes in depressive symptoms (recalled and daily)|Changes in daily fatigue|Changes in psychological stress (daily and recalled) as assessed by Perceived Stress Scale (PSS)|Regulation of psychological stress (daily and recalled) as assessed by Positive and Negative Affect Schedule-Expanded Form and Cancer Behavior Inventory","https://ClinicalTrials.gov/show/NCT02148406"
2172,"NCT01420874","Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)","Active, not recruiting","No Results Available","Colorectal Cancer|Cancer of Pancreas|Pancreatic Neoplasm|Malignant Neoplasm of Large Intestine|Malignant Tumor of Colon|Colon Carcinoma|Cancer of Colon|Pancreatic Cancer","Drug: FOLFOX6|Biological: EGFRBi armed ATC Infusions","Barbara Ann Karmanos Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-025","August 17, 2011","August 2011","July 2016","February 3, 2016","February 2016","No Study Results Posted","null","July 2016","Determining in a dose-escalation phase Ib trial the safety of 3 infusions of EGFR2Bi aATC, and a booster infusion after 3 months, for patients with advanced colorectal or pancreatic cancer.|Determining whether IMT enhances anti-tumor immunity;Cytokine resp., phenotypic markers, anti-tumor cytotoxicity, in vivo and in vitro specific anti-tumor antibody prod. & molecular signaling markers of T-cell activation assessed before chemo & after IMT|Determining the tumor response rate|Overall Survival","https://ClinicalTrials.gov/show/NCT01420874"
2173,"NCT02569723","Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy","Recruiting","No Results Available","Colon Adenocarcinoma","Drug: Carbon C 14 Oxaliplatin|Drug: Oxaliplatin","University of California, Davis|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","6","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCDCC#255|P30CA093373","July 27, 2015","October 2015","December 2017","April 12, 2016","April 2016","No Study Results Posted","null","September 2017","Feasibility of 14C Oxaliplatin Microdose as a clinical assay to predict oxaliplatin exposure|Duration of disease control (DDC) according to RECIST 1.1|Incidence of adverse events according to the Common Terminology Criteria for Adverse Events version 4|Response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1","https://ClinicalTrials.gov/show/NCT02569723"
2174,"NCT01703910","Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","Completed","No Results Available","Adenocarcinoma of Colon|Adenocarcinoma of Rectum|Metastatic Disease","Drug: Arm A chemotherapy|Drug: arm B chemotherapy","Centro Nacional de Investigaciones Oncologicas CARLOS III|Hospital Universitario de Fuenlabrada|Grupo Hospital de Madrid|Apices Soluciones S.L.","Both","18 Years to 76 Years   (Adult, Senior)","Phase 2","29","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CNIO-GI-01-2012","October 8, 2012","November 2012","December 2014","October 8, 2015","October 2015","No Study Results Posted","null","November 2012","Overall survival|gene expression profiles","https://ClinicalTrials.gov/show/NCT01703910"
2175,"NCT01607255","Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT)","Recruiting","No Results Available","Colorectal Neoplasms","Drug: Indigo carmine|Procedure: water (exchange) method|Procedure: water (exchange) plus dye method|Procedure: air method","VA Office of Research and Development","Both","45 Years to 75 Years   (Adult, Senior)","","480","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CLIN-10-11S","May 24, 2012","May 2013","September 2017","June 3, 2016","June 2016","No Study Results Posted","null","June 2017","Proximal diminutive (<10 mm) adenoma detection rate","https://ClinicalTrials.gov/show/NCT01607255"
2176,"NCT02876133","Narrow Band Imaging Versus White Light for Colonoscopy Serrate Lesions Detection: A Randomized Controlled Trial","Not yet recruiting","No Results Available","Colon Cancer|Colon Sessile Serrated Adenoma/Polyp","Device: narrow band imaging withdrawal|Device: white light withdrawal","Hospital Beatriz Ângelo","Both","40 Years to 80 Years   (Adult, Senior)","","987","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","176","August 18, 2016","September 2016","February 2018","August 18, 2016","August 2016","No Study Results Posted","null","December 2017","average number of serrated lesions ≥10 mm detected per colonoscopy|Serrated class lesions detection rate|Serrated lesions <10 mm detected per colonoscopy|SSL detection rate|Adenoma detection rate|Adenomas detected per colonoscopy|Advanced (malignant) adenocarcinoma detection rate|Incidence of procedure related adverse events","https://ClinicalTrials.gov/show/NCT02876133"
2177,"NCT02618811","ERAS in Colorectal Surgery Diminishes the Negative Impact of Sarcopenia on Short Term Outcomes","Completed","No Results Available","Sarcopenia|Colonic Neoplasms","","Jagiellonian University","Both","18 Years and older   (Adult, Senior)","","171","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JagiellonianU-03","November 22, 2015","January 2014","November 2015","November 28, 2015","November 2015","No Study Results Posted","null","October 2015","Complications|Hospital length of stay (days)|Compliance with ERAS protocol (%)|Tolerance of oral diet on the 1st postoperative day|Time to first flatus|Readmission rate|Mobilization on the 1st postoperative day|Need for opioid analgesia postoperatively","https://ClinicalTrials.gov/show/NCT02618811"
2178,"NCT01547130","Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation","Completed","Has Results","Colonic Neoplasms","Drug: Normal (0.9%) saline|Drug: HalfLytely","Arya, Vijaypal, M.D., P.C.","Both","21 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","133","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","WHMC-2008-35","February 26, 2012","May 2008","January 2011","February 17, 2015","February 2015","January 17, 2015","null","December 2010","Efficacy of Large Bowel Cleansing as Assessed by the Physician Performing the Colonoscopy|Palatability of Bowel Prep|Subjective Grading by Patients on Willingness to Repeat the Large Bowel Preparation.|Patient-reported Adverse Events.|Total Preparation Time","https://ClinicalTrials.gov/show/NCT01547130"
2179,"NCT02010567","Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: CRLX101|Drug: Capecitabine|Radiation: Radiotherapy|Procedure: Surgery","UNC Lineberger Comprehensive Cancer Center|Cerulean Pharma Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","71","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 1315","December 9, 2013","December 2013","December 2022","June 8, 2016","June 2016","No Study Results Posted","null","December 2021","Maximum tolerated dose (MTD)|Pathological complete response (pCR)|Pathological response rate|Number of subjects with adverse events|Disease-free survival (DFS)|Overall survival (OS)|Disease-free survival (DFS) and overall survival (OS) based on pathological complete response (pCR).","https://ClinicalTrials.gov/show/NCT02010567"
2180,"NCT01434199","Does Endoscope Position Detecting Unit Facilitate a Complete Colonoscopy Examination","Recruiting","No Results Available","Colorectal Neoplasms","Procedure: UPD guidance","Chinese University of Hong Kong","Both","18 Years and older   (Adult, Senior)","Phase 3","870","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CRE-2011.125-T","June 20, 2011","July 2011","July 2012","September 13, 2011","September 2011","No Study Results Posted","UPD-3","July 2012","caecal intubation rate|Caecal intubation time","https://ClinicalTrials.gov/show/NCT01434199"
2181,"NCT02060188","A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)","Recruiting","No Results Available","MSI Positive Colorectal Cancer|MSI Negative Colorectal Cancer","Drug: Ipilimumab|Drug: Nivolumab","Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","240","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA209-142|2013-003939-30","December 18, 2013","March 2014","December 2018","September 7, 2016","June 2016","No Study Results Posted","null","March 2017","Objective response rate (ORR) in all MSI-High subjects as determined by Investigators|ORR in all MSI-H subjects based on IRRC determination","https://ClinicalTrials.gov/show/NCT02060188"
2182,"NCT01462513","L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases","Active, not recruiting","No Results Available","Colon Carcinoma|Rectum Carcinoma","Biological: L-BLP25|Biological: Placebo","Prof. Dr. Carl Schimanski|Johannes Gutenberg University Mainz","Both","18 Years and older   (Adult, Senior)","Phase 2","122","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","LICC01","October 27, 2011","August 2011","December 2017","July 13, 2015","July 2015","No Study Results Posted","LICC","December 2017","Comparative evaluation of recurrence-free survival (RFS) time and 3 year overall survival (OS) time between the treatment groups (L-BLP25 plus cyclophosphamide versus placebo and saline infusion).|Safety / Tolerability|Recurrence-free survival time in the subgroup of MUC1 positive cancers|Overall survival time in a subgroup of MUC1 positive cancers","https://ClinicalTrials.gov/show/NCT01462513"
2183,"NCT02592603","Endocuff for Surveillance of Serrated Polyposis Syndrome","Recruiting","No Results Available","Polyposis","Device: Endocuff-assisted Colonoscopy","Hospital Clinic of Barcelona|Fundacion Clinic per a la Recerca Biomédica","Both","18 Years and older   (Adult, Senior)","","124","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","HCB/2015/0803","October 29, 2015","October 2015","June 2017","August 16, 2016","August 2016","No Study Results Posted","null","April 2017","Mean of serrated lesions per patient|Serrated lesions detection rate|Mean of relevant serrated lesions per patient|Relevant serrated lesions detection rate|Mean of total polyps per patient|Polyp detection rate|Mean of adenomas per patient|Adenoma detection rate|Withdrawal time|Total procedure time|Proportion of major adverse events|Proportion of minor adverse events","https://ClinicalTrials.gov/show/NCT02592603"
2184,"NCT01640522","Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms","Completed","No Results Available","Hepatocellular Carcinoma|Primary Liver Cancer|Bile Duct Cancer|Pancreatic Cancer|Gallbladder Cancer|Colorectal Carcinoma|Liver Metastases","Other: Collaborative Care|Other: Enhanced usual Care","University of Pittsburgh|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","261","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","PRO07050143|K07CA118576","September 16, 2010","January 2008","December 2014","December 23, 2015","July 2012","No Study Results Posted","CaSSY","December 2013","Depression|Fatigue","https://ClinicalTrials.gov/show/NCT01640522"
2185,"NCT01736072","RObotic Versus LAparoscopic Resection for Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Procedure: Standard Laparoscopic Surgery|Procedure: Robotic Assisted Laparoscopic Surgery","University of California, Irvine|University of Leeds","Both","18 Years and older   (Adult, Senior)","","520","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HS#2011-8537","November 15, 2012","December 2011","June 2018","November 30, 2015","November 2015","No Study Results Posted","ROLARR","December 2017","End of Conversion to Open Surgery|Oncological Efficacy","https://ClinicalTrials.gov/show/NCT01736072"
2186,"NCT02199912","Study of the Relationship Between Clinical and Paraclinical Markers During Situations of Cachexia and Pre-cachexia in Patients Over 70 Years With Colorectal Surgery","Recruiting","No Results Available","Colorectal Tumor","Procedure: Biopsy of adipose and muscular tissue|Other: Blood sampling|Other: Calorimetry|Other: Impedance measure|Other: Evaluation of nutritional status|Other: Evaluation of physical performance|Other: Evaluation of muscular strength|Other: Evaluation of emotional status|Other: Evaluation of functional status","Hospices Civils de Lyon","Both","70 Years and older   (Senior)","","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","2012.752|2012-A01017-36","June 26, 2014","October 2013","May 2015","July 21, 2014","May 2014","No Study Results Posted","ANC2","May 2015","biological and radiological markers|activity of the ATGL|Body composition|metabolic phenotype|loss of fat body mass and/or lean body mass","https://ClinicalTrials.gov/show/NCT02199912"
2187,"NCT01238107","A Clinical Study With MT-102 in Subjects With Cancer Cachexia","Completed","No Results Available","Cancer Cachexia","Drug: MT-102","PsiOxus Therapeutics Ltd|Veeda Oncology","Both","25 Years to 80 Years   (Adult, Senior)","Phase 2","87","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MT-102-2001","November 9, 2010","April 2011","May 2013","September 9, 2014","September 2014","No Study Results Posted","null","May 2013","Demonstrate the effect of a 10mg / bd dose of MT-102 in comparison to placebo on the rate of weight change over a sixteen week period in patients with cachexia related to underlying stage III and stage IV colorectal or non-small cell lung cancer","https://ClinicalTrials.gov/show/NCT01238107"
2188,"NCT02848079","TAS-OX for Refractory Metastatic Colon Cancer","Recruiting","No Results Available","Colorectal Neoplasms","Drug: combined TAS-102 and TAS-OX","Yale University","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","68","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1605017852","July 21, 2016","August 2016","December 2020","August 25, 2016","August 2016","No Study Results Posted","null","July 2019","Overall Response Rate measured by Response Evaluation Criteria In Solid Tumor (RECIST) 1.1 criteria|Progression Free Survival assessed according to RECIST criteria version 1.1.|Overall Survival assessed by time to death from start of study|safety and tolerability assessed with Common Terminology Criteria for Adverse Events (CTCAE)","https://ClinicalTrials.gov/show/NCT02848079"
2189,"NCT02669914","MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors","Recruiting","No Results Available","Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer|Breast Cancer|Cancer of Breast|Cancer of the Breast|Gastroesophageal Cancer|Pancreatic Cancer|Cancer of the Pancreas|Colorectal Cancer|Colorectal Carcinoma|Renal Cancer|Kidney Cancer|Cancer of the Kidney|Cancer of Kidney|Ovarian Cancer|Ovary Cancer|Cancer of the Ovary|Cancer of Ovary","Drug: MEDI4736","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","Phase 2","136","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","201602169","January 22, 2016","September 2016","December 2021","September 12, 2016","September 2016","No Study Results Posted","null","December 2019","Overall response rate of intracranial disease|Safety of MEDI4736 in advanced solid epithelial-derived tumor patients with brain metastases as measured by frequency and grade of treatment-emergent adverse events|Overall disease control rate of intracranial disease|Overall response rate of extracranial disease|Overall disease control rate of extracranial disease|Overall response rate considering both intracranial and extracranial disease|Overall disease control rate considering both intracranial and extracranial disease|Duration of response of intracranial disease|Duration of response of extracranial disease|Duration of response considering both intracranial and extracranial disease|Progression-free survival (PFS)|Overall survival (OS)|Safety of MEDI4736 in patients with intracranial epithelial-derived tumor metastases as measured by frequency and grade of treatment-emergent adverse events","https://ClinicalTrials.gov/show/NCT02669914"
2190,"NCT02222844","Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers","Recruiting","No Results Available","Cancer|Colorectal Neoplasms|Colon, Sigmoid|Magnetic Resonance Imaging|General Surgery","Other: Preoperative MRI scan","Royal Marsden NHS Foundation Trust|Pelican Cancer Foundation","Both","18 Years and older   (Adult, Senior)","Phase 2","243","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CCR 4086","August 20, 2014","August 2014","January 2021","August 26, 2014","March 2014","No Study Results Posted","IMPRESS","January 2019","To compare the proportion of patients undergoing any radical treatment in the two arms of the study|To measure the proportion of patients who underwent neoadjuvant treatment in each arm.|To compare the quality of surgery, including free resection margins, in each arm.|To compare the perioperative morbidity and mortality in each arm.|To measure and compare permanent defunctioning stoma rates in each arm.|To measure and compare radiological downstaging in each arm.|To compare quality of life at 1 year, 3 years and 5 years in each arm.","https://ClinicalTrials.gov/show/NCT02222844"
2191,"NCT02528526","Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm","Recruiting","No Results Available","Pancreatic Neoplasms|Hepatocellular Cancer|Cholangiocarcinoma|Colorectal Neoplasms","Drug: OXY111A","University of Zurich","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","69","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OXY1A_2014-0374","November 11, 2014","February 2014","December 2016","August 18, 2015","August 2015","No Study Results Posted","OXY1A","December 2016","Safety and tolerability as measured by collection of adverse effects information|Efficacy as measured by FDG-PET scan|Efficacy as measured by MRI","https://ClinicalTrials.gov/show/NCT02528526"
2192,"NCT00179348","Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer","Active, not recruiting","No Results Available","Alopecia|Anxiety|Breast Carcinoma|Cognitive Side Effects of Cancer Therapy|Colorectal Carcinoma|Depression|Fatigue|Lung Carcinoma|Nausea and Vomiting|Pain|Psychological Impact of Cancer|Sleep Disorder|Weight Change","Procedure: Quality-of-Life Assessment|Procedure: Yoga","Albert Einstein College of Medicine of Yeshiva University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","250","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CCI# 00-7|NCI-2014-01579|2000-007|NCI R03 CA88598-01A1|01-02-038|P30CA013330|R03CA088598","September 13, 2005","February 2001","null","December 9, 2015","July 2015","No Study Results Posted","null","January 2015","Change in Functional Assessment of Cancer Therapy summary score (physical, emotional, spiritual, and social QOL)|Program compliance as measured by Yoga - Daily Practice Calendar and Yoga Class Attendance Record and Yoga Evaluation Form|Program satisfaction measured by Yoga - Daily Practice Calendar and Yoga Class Attendance Record and Yoga Evaluation Form|Pain|Mood|spiritual well-being","https://ClinicalTrials.gov/show/NCT00179348"
2193,"NCT02509143","Acupuncture for Postoperative Nausea and Vomiting in Patients Undergoing Colorectal Surgery","Recruiting","No Results Available","Postoperative Nausea and Vomiting|Colorectal Neoplasms","Procedure: High-dose acupuncture with intravenous infusion of ramosetron|Device: P6 stimulation with intravenous infusion of ramosetron|Drug: Intravenous infusion of ramosetron","Pusan National University Yangsan Hospital|Korea Institute of Oriental Medicine|Korean Medicine Hospital of Pusan National University","Both","18 Years to 80 Years   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","03-2015-010","July 17, 2015","July 2015","December 2016","October 19, 2015","October 2015","No Study Results Posted","AcuPONV","December 2016","Number of patients who experience moderate or severe level nausea or vomiting|Nausea scores on a numeric rating scale|Number of vomiting|Cumulative incidence of vomiting|Number of patients who experience nausea|Cumulative number of patients who experience nausea|Number of patients who experience vomiting|Pain scores on a numeric rating scale|Patient's global assessment of recovery after surgery|Time to first flatus|Time to tolerate soft diet|Time to first defecation|Time to independent walk|Number of insertions of nasogastric tube|Time to first removal of Foley catheter|Number of reinsertions of Foley catheter|Number of clean intermittent catheterizations|Quality of life measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30|Preoperative anxiety|Patient-reported satisfaction for management of PONV|Use of medication|Postoperative complications|Serious adverse events","https://ClinicalTrials.gov/show/NCT02509143"
2194,"NCT00423150","Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)","Terminated","Has Results","Colorectal Neoplasm|Head and Neck Neoplasm|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasm","Drug: Temozolomide","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","86","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P04273","November 30, 2006","January 2007","June 2009","October 30, 2014","October 2014","May 27, 2010","null","June 2009","Tumor Responses (Complete and Partial Response)","https://ClinicalTrials.gov/show/NCT00423150"
2195,"NCT02450656","Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Colorectal, Non-small Cell Lung and Pancreatic Cancer","Recruiting","No Results Available","Colorectal Neoplasms|Gastrointestinal Neoplasms|Pancreatic Neoplasms|Carcinoma, Non-Small-Cell Lung","Drug: Afatinib|Drug: Selumetinib|Drug: Capecitabine|Drug: Irinotecan|Drug: Docetaxel","The Netherlands Cancer Institute|AstraZeneca|Boehringer Ingelheim","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","320","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","M14AFS","November 13, 2014","June 2015","December 2019","June 10, 2015","June 2015","No Study Results Posted","M14AFS","May 2019","Dose Limiting Toxicities (Phase I)|Progression Free Survival (Phase II)|Tolerability (Incidence and severity of adverse events per CTCAE v4.03)|Plasma concentrations of afatanib and selumetinib|Efficacy (Phase II) (Overall response rate (ORR), duration of response (DOR) , time to response (TTR) and overall survival (OS) per RECIST v1.1)","https://ClinicalTrials.gov/show/NCT02450656"
2196,"NCT01099111","Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders","Completed","Has Results","Irritable Bowel Syndrome|Colitis, Ulcerative|Crohn Disease|Colonic Neoplasms","","King Fahad Medical City|King AbdulAziz City for Science and Technology","Both","16 Years to 70 Years   (Child, Adult, Senior)","","225","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","09 -116|243 - 29 - AT","April 1, 2010","July 2010","March 2012","April 24, 2014","April 2014","March 22, 2014","null","January 2012","Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms","https://ClinicalTrials.gov/show/NCT01099111"
2197,"NCT02194959","Peer Patient Navigation for Colon Cancer Screening","Completed","No Results Available","Screening Colonoscopy","Behavioral: Peer PN|Behavioral: Pro PN","Icahn School of Medicine at Mount Sinai|National Institutes of Health (NIH)|National Cancer Institute (NCI)","Both","50 Years and older   (Adult, Senior)","","800","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","GCO 07-0594|5R25CA132692-05","July 17, 2014","July 2011","December 2011","July 25, 2014","July 2014","No Study Results Posted","null","October 2011","Colonoscopy completion","https://ClinicalTrials.gov/show/NCT02194959"
2198,"NCT02448693","Study of Narrow Band Imaging in the Characterization of Residual Neoplasia After Endoscopic Piecemeal Mucosal Resection","Completed","No Results Available","Colorectal Neoplasms","Device: WLE|Device: NBI","Parc de Salut Mar","Both","18 Years and older   (Adult, Senior)","","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","CROMOPIE","May 15, 2015","May 2015","May 2016","May 3, 2016","May 2016","No Study Results Posted","CROMOPIE","May 2016","Number of residual neoplastic tissue detected with both techniques (NBI versus WLE)|Number of accurate detection of residual neoplastic tissue with morphologic features in both groups (NBI and WLE) compared with histopathology|Number of missed lesions on basal colonoscopy","https://ClinicalTrials.gov/show/NCT02448693"
2199,"NCT01626963","Single-port Versus Conventional Laparoscopic Colorectal Surgery","Recruiting","No Results Available","Colorectal Cancer|Inflammatory Bowel Disease|Benign Colorectal Neoplasm|Diverticular Disease","Procedure: Single-port access surgery|Procedure: Conventional Laparoscopic Access","North Tees and Hartlepool NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","SUR-089","June 18, 2012","January 2014","December 2016","March 22, 2016","March 2016","No Study Results Posted","null","July 2016","Operative Time|Pain scores|Complication / Conversion-to-open-surgery rates|Quality of Life indicators|Cosmetic appearance|Cost comparison|LoS|IL-6|IL-8|WBCC|CRP","https://ClinicalTrials.gov/show/NCT01626963"
2200,"NCT00474097","Follow-Up Phone Calls After Colorectal Surgery","Completed","No Results Available","Colorectal Surgery|Colorectal Neoplasms|Colitis, Ulcerative|Diverticulitis|Colonic Polyps","","University Hospitals Cleveland Medical Center","Both","18 Years to 80 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","01-06-03","May 15, 2007","February 2006","December 2007","December 12, 2014","December 2014","No Study Results Posted","null","December 2007","to assess if follow-up telephone calls after surgery affects patient satisfaction, surgical outcomes and quality of life in the early post-operative phase after colorectal surgery|to track readmissions, complications and emergency room visits via telephone calls to ensure communication between the patients and the surgical office is optimal.","https://ClinicalTrials.gov/show/NCT00474097"
2201,"NCT01453257","Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients","Completed","No Results Available","Progression Free Survival","Drug: Tailored Chemotherapy","Grupo Hospital de Madrid","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","72","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C62 202-878","October 13, 2011","October 2009","October 2011","October 18, 2011","October 2011","No Study Results Posted","TT","October 2011","PFS|Complete Response Rate","https://ClinicalTrials.gov/show/NCT01453257"
2202,"NCT01879904","Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy","Completed","No Results Available","Colorectal Neoplasms|Endoscopic Submucosal Dissection","Procedure: Endoscopic submucosal dissection (ESD)","Assistance Publique - Hôpitaux de Paris","Both","18 Years to 85 Years   (Adult, Senior)","","48","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P081202","June 12, 2013","February 2010","July 2013","September 17, 2013","June 2013","No Study Results Posted","DISSECMUC","July 2013","curative resection rate (3 month)|monobloc resection rate|complication rate|complete resection predictive factors|Curative resection rate (1 year)","https://ClinicalTrials.gov/show/NCT01879904"
2203,"NCT02345889","A 4-arm Clinical Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy","Enrolling by invitation","No Results Available","Colorectal Neoplasms","Device: Colonoscopy with EndoCuff™|Device: FUSE® Colonoscopy|Device: Colonoscopy with EndoRings™|Device: Standard Colonoscopy","Indiana University","Both","50 Years and older   (Adult, Senior)","","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","1412036333","January 13, 2015","February 2015","January 2017","October 27, 2015","October 2015","No Study Results Posted","null","October 2016","Adenoma detection rate","https://ClinicalTrials.gov/show/NCT02345889"
2204,"NCT00997802","Japanese National Computed Tomographic (CT) Colonography Trial","Active, not recruiting","No Results Available","Colonic Polyps|Colonic Neoplasms","Device: CT colonography and optical colonoscopy","Japanese CT Colonography Society","Both","20 Years and older   (Adult, Senior)","","1500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","UMIN000002097|JANCT-01","October 18, 2009","October 2009","null","June 9, 2012","June 2012","No Study Results Posted","JANCT","January 2013","sensitivity in the detection of colorectal polyps and cancers in CTC|specificity and predictive values in the detection of colorectal polyps and cancers in CTC.","https://ClinicalTrials.gov/show/NCT00997802"
2205,"NCT02624115","FAZA PET as Biomarker for Hypoxia in Rectal Cancer","Recruiting","No Results Available","Colon Rectal Cancer Adenocarcinoma","","University Health Network, Toronto","Both","18 Years and older   (Adult, Senior)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-9741","November 25, 2015","May 2016","July 2017","May 12, 2016","May 2016","No Study Results Posted","null","June 2017","FAZA PET uptake in locally advanced rectal cancers prior to and after chemoradiotherapy|Correlation of FAZA-PET and blood oxygen level-dependent MRI to Pimonidazole staining in locally advanced rectal cancer","https://ClinicalTrials.gov/show/NCT02624115"
2206,"NCT02327078","A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)","Recruiting","No Results Available","Melanoma|Carcinoma, Non-Small-Cell Lung|Colorectal Neoplasms|Carcinoma, Squamous Cell of Head and Neck|Ovarian Neoplasms|B Cell NHL Including DLBCL|HL|Glioblastoma","Drug: Nivolumab + Epacadostat","Incyte Corporation|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","291","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INCB 24360-204 / ECHO-204","December 1, 2014","November 2014","October 2019","June 30, 2016","June 2016","No Study Results Posted","null","April 2019","Phase 1: Evaluation of safety and tolerability of epacadostat and nivolumab measured by number of subjects with dose limiting toxicities (DLTs)|Safety measured by the frequency of adverse events, serious adverse events, and deaths|Phase 2: Overall objective response rate (ORR) and progression free survival (PFS) per modified RECIST v1.1 criteria for select solid tumors or Cheson criteria for B cell NHL (including DLBCL) or HL, or modified RANO criteria for glioblastoma|Phase 2: Overall survival|Duration of response and duration of disease control assessed using modified RECIST v1.1 criteria for select solid tumors or Cheson criteria for B cell NHL (including DLBCL) or HL or modified RANO criteria for subjects with glioblastoma|Progression free survival (PFS) rates will be assessed based on the tumor assessments using Response Evaluation Criteria In Solid Tumors modified (RECIST) v1.1|Phase 2: Safety and tolerability measured by the frequency of adverse events, serious adverse events, and deaths","https://ClinicalTrials.gov/show/NCT02327078"
2207,"NCT00841191","A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors","Completed","No Results Available","Ovarian Neoplasms|Pancreatic Neoplasms|Colorectal Neoplasms|Head and Neck Neoplasms|Lung Neoplasms","Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody|Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody|Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody|Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody|Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody|Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody|Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody","Centocor, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","84","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR015580|CNTO328STM2001|2008-005180-33","February 9, 2009","March 2009","April 2011","May 13, 2014","May 2014","No Study Results Posted","null","April 2011","Percentage of Participants With Clinical Benefit Response (CBR)|Percentage of Participants With Overall Response|Number of Participants With Tumor Marker Response|Percentage of Participants With Hemoglobin (Hb) Response|Progression Free Survival (PFS)|Overall Survival (OS)|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-OV28) Score at Week 4 After Last Dose Administration|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf])|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC[0-t])|Minimum Observed Serum Concentration at Steady-State (Cmin,ss)|Maximum Observed Serum Concentration (Cmax)|Terminal Elimination Half Life (t1/2)|Total Systemic Clearance (CL)|Volume of Distribution at Steady State (Vss)|Percent Change From Baseline in C-Reactive Protein (CRP) Level|Percent Change From Baseline in Inflammatory Cytokines Level|Percent Change From Baseline in the Angiogenesis Related Factors Level|Percent Change From Baseline in Interleukin 6 Receptor (IL-6R) Subunits Level|Number of Participants Assessed Positive for Antibodies to Siltuximab|Percent Change From Baseline in Hepcidin Level","https://ClinicalTrials.gov/show/NCT00841191"
2208,"NCT02657044","EMR Versus ESD for Resection of Large Distal Non-pedunculated Colorectal Adenomas","Recruiting","No Results Available","Colorectal Neoplasms","Procedure: EMR|Procedure: ESD","UMC Utrecht|Comprehensive Cancer Centre The Netherlands","Both","18 Years and older   (Adult, Senior)","","212","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","15-610/D|TDM-H1/8051","January 8, 2016","April 2016","December 2020","April 4, 2016","April 2016","No Study Results Posted","MATILDA","September 2018","Recurrence rate at follow-up colonoscopy after 6 months|Long-term recurrence rate at follow-up colonoscopy after 36 months|Health care resource utilization and consts|Perceived burden and quality of life among patients|Complication rate|Surgical referral rate|R0-resection rate","https://ClinicalTrials.gov/show/NCT02657044"
2209,"NCT01466504","Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin","Terminated","No Results Available","Renal Cell Carcinoma|Hepatocellular Carcinoma|Colorectal Carcinoma","Procedure: skin punch biopsy","Dartmouth-Hitchcock Medical Center","Both","18 Years and older   (Adult, Senior)","","4","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","D11004","October 31, 2011","May 2011","April 2013","April 11, 2013","March 2013","No Study Results Posted","null","April 2013","p63 expression levels|Tumor response","https://ClinicalTrials.gov/show/NCT01466504"
2210,"NCT02805166","PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy","Completed","No Results Available","Malignant Solid Tumors","Drug: PEG-rhG-CSF","CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 4","420","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CSPC-PGC-IV-01/CSPC-PGC-IV-02","June 13, 2016","April 2013","February 2016","June 16, 2016","June 2016","No Study Results Posted","null","February 2016","The occurrence rate of adverse event during at least three consecutive cycles chemotherapy|The severity of adverse event during at least three consecutive cycles chemotherapy|the non-occurrence rate of grade IV neutropenia (ANC <0.5 x 10^9/L)during at least three consecutive cycles chemotherapy|the duration of grade IV neutropenia(ANC <0.5 x 10^9/L) during at least three consecutive cycles chemotherapy","https://ClinicalTrials.gov/show/NCT02805166"
2211,"NCT02024191","The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy","Recruiting","No Results Available","Peripheral Neuropathy","Dietary Supplement: Glutamine","Ankara Education and Research Hospital","Both","20 Years to 65 Years   (Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","031","December 25, 2013","December 2013","June 2015","December 30, 2013","December 2013","No Study Results Posted","GELUPO","January 2015","Electromyography parameters|Neurological signs and symptoms","https://ClinicalTrials.gov/show/NCT02024191"
2212,"NCT00623883","Colonoscopic Removal of Aberrant Crypt Foci: a Prospective, Randomized, Blinded Trial","Completed","No Results Available","Colorectal Neoplasms","Procedure: Surgical removal of ACF|Procedure: Colonoscopic evaluation only","National Naval Medical Center|Uniformed Services University of the Health Sciences|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","98","U.S. Fed|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","NNMC.1997.0091","February 15, 2008","January 1999","June 2007","February 15, 2008","June 2007","No Study Results Posted","null","June 2007","number, size, and location of ACF identified|complications of stain-enhanced, magnification colonoscopy","https://ClinicalTrials.gov/show/NCT00623883"
2213,"NCT02406547","Study of Narrow Band Imaging in the Characterization of Serrated Lesions","Completed","No Results Available","Serrated Polyps|Sessile Serrated Adenoma|Colorectal Neoplasms","Device: NBI|Device: WLE","Parc de Salut Mar","Both","50 Years and older   (Adult, Senior)","","41","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","CROMOSER","March 30, 2015","March 2015","April 2016","May 3, 2016","May 2016","No Study Results Posted","CROMOSER","October 2015","Number of polyps detected with both techniques (NBI versus WLE)|Number of new patients who accomplish the SPS criteria|Number of missed lesions on basal colonoscopy|Number of accurate detection of adenomas with morphologic features with both groups (NBI and WLE) compared to histopathology","https://ClinicalTrials.gov/show/NCT02406547"
2214,"NCT00188565","Celebrex With Preoperative Chemoradiation - Rectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: Celecoxib","University Health Network, Toronto|Ontario Cancer Research Network|Princess Margaret Hospital, Canada","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","39","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 02-0130-C|Ontario Cancer ResearchNetwork","September 12, 2005","March 2004","March 2009","August 12, 2010","August 2010","No Study Results Posted","null","March 2009","- To assess the safety of celecoxib at a maximum dose of 400 mg orally twice daily in combination with preop RT and continuous infusional 5-FU. Incidence of dose-limiting toxicity (DLT) will be determined.|- To determine the efficacy of celecoxib in combination with preop RT and continuous infusional 5-FU. Pathologic complete response rate (pCR) will be used as the endpoint.|Failure rate - locoregional and distant|Survival rate - disease-free and overall|Wound complication rate|Late toxicity incidence (RTOG criteria))|Sphincter preservation rate|Quality of life (FACT, EORTC)","https://ClinicalTrials.gov/show/NCT00188565"
2215,"NCT00977717","Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin","Completed","No Results Available","Curatively Resected Stage III Colon Cancer","","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2008-05-052","September 3, 2009","September 2008","April 2010","April 15, 2010","April 2010","No Study Results Posted","null","January 2010","neuropathy","https://ClinicalTrials.gov/show/NCT00977717"
2216,"NCT01882972","Strength for Health","Withdrawn","No Results Available","Colon Cancer","Behavioral: Exercise|Behavioral: Meditation","Loyola University|Hygenic Corporation","Both","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","205243","June 18, 2013","June 2013","September 2013","April 14, 2015","April 2015","No Study Results Posted","null","September 2013","Feasibility of recruitment|Retention feasibility|Pain|quality of life|Surgical Complications|Self-reported Exercise-related Injury","https://ClinicalTrials.gov/show/NCT01882972"
2217,"NCT01543451","Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea","Completed","No Results Available","Diarrhea","Drug: Elsiglutide|Drug: Placebo","Helsinn Healthcare SA","Both","18 Years and older   (Adult, Senior)","Phase 2","138","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TIDE-11-10","February 21, 2012","February 2012","October 2013","February 27, 2014","February 2014","No Study Results Posted","null","January 2013","Number of Patients experiencing Diarrhea|Safety and tolerability of the administered repeated doses of elsiglutide (ZP1846) will be evaluated|PK of elsiglutide will be evaluated","https://ClinicalTrials.gov/show/NCT01543451"
2218,"NCT01756625","PREMIUM, Observational Study","Active, not recruiting","No Results Available","First Line WT KRAS mCRC","","Dr.Laurent Mineur|Merck Serono International SA|BESPIM, CHU Nîmes (data analysis)|Institut Sainte Catherine","Both","18 Years and older   (Adult, Senior)","","500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PREMIUM","December 20, 2012","January 2010","June 2013","December 20, 2012","December 2012","No Study Results Posted","null","March 2012","To compare PFS rate at 1 year with PFS in clinical studies (ITT and subgroup analysis)|ORR at 1 year (ITT and subgroup analysis)","https://ClinicalTrials.gov/show/NCT01756625"
2219,"NCT01712958","Quantifying Micro RNA Levels of Colon","Not yet recruiting","No Results Available","Colorectal Carcinoma (CRC) Patients","","Meir Medical Center","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","0148","October 21, 2012","November 2012","November 2015","October 23, 2012","October 2012","No Study Results Posted","CRC","November 2015","identifying specific, relevant miRNAs that may serve as biomarkers to stratify CRC patients according to their clinical characteristics","https://ClinicalTrials.gov/show/NCT01712958"
2220,"NCT01707121","The Impact of Physical Activity on the Outcome of Surgery","Completed","No Results Available","Physical Activity|Breast Neoplasm|Colorectal Neoplasm|Gall Stones","","Sahlgrenska University Hospital, Sweden","Both","18 Years and older   (Adult, Senior)","","450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Physsurg","October 11, 2012","December 2012","November 2015","November 18, 2015","November 2015","No Study Results Posted","null","September 2015","Length of sick-leave/time to work|Length of hospital stay|length of sick leave/time to work|length of hospital stay|Recovery|Health economic analysis","https://ClinicalTrials.gov/show/NCT01707121"
2221,"NCT00409994","Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer","Active, not recruiting","No Results Available","Rectum Cancer","Drug: Rapamycin","Maastricht Radiation Oncology|Academisch Ziekenhuis Maastricht","Both","Child, Adult, Senior","Phase 1|Phase 2","65","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-16","December 11, 2006","September 2006","August 2019","January 27, 2016","January 2016","No Study Results Posted","null","August 2018","Phase I: Incidence of severe postoperative complications (grade IV or grade V),|assessed according to CTCv3.0|Phase II: Tumour blood flow assessed CT-PET + CTp|Phase I:Incidence of other acute toxicity, assessed according to CTCv 3.0|Activation status of mTor related and dependent molecules in the tumour|Phase II:Maximum standardised Uptake Value (SUV) of 18F-FDG, assessed bij PET-CT-scan|Phase II:Incidence of acute side effects of rapamycin, assessed according to CTCv 4.0","https://ClinicalTrials.gov/show/NCT00409994"
2222,"NCT02595645","GENESIS: Genetic Biopsy for Prediction of Surveillance Intervals After Endoscopic Resection of Colonic Polyps","Recruiting","No Results Available","Colonic Polyps","Genetic: Polypectomy and NGS","University of Ulm|Technische Universität München|Medical University of Graz|Specialized Medical Office for Gastroenterology Dornstadt|QIAGEN Gaithersburg, Inc","Both","18 Years and older   (Adult, Senior)","","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","GENESIS","October 29, 2015","August 2015","July 2016","November 2, 2015","November 2015","No Study Results Posted","GENESIS","December 2015","Genetic landscape of colonic polyps based on NGS-analysis","https://ClinicalTrials.gov/show/NCT02595645"
2223,"NCT00661102","A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).","Completed","No Results Available","Breast Cancer","Drug: Corticosteroids|Drug: Placebo|Drug: capecitabine [Xeloda]|Drug: dexpantenol [Bepantol]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","598","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21419","April 16, 2008","December 2008","April 2011","September 1, 2016","September 2016","No Study Results Posted","null","April 2011","Hand-foot syndrome onset|QoL C-30 score|Adverse events","https://ClinicalTrials.gov/show/NCT00661102"
2224,"NCT02414334","SABR-SCAN Trial for Pulmonary Oligometastases","Recruiting","No Results Available","Oligometastases","Radiation: Stereotactic Ablative Radiotherapy (SABR)","University Medical Center Groningen","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RT2015-02","March 30, 2015","June 2015","null","July 28, 2016","July 2016","No Study Results Posted","SABR-SCAN","June 2019","Progression free survival (PFS)|Relative change of tumourload expressed as volume of all tumour at one year divided by volume of all tumour at time of randomisation;|Time to failure of local strategy (TFLS): failure = death or progressive disease NOT amenable to local treatment|Progression of target lesions as measured by CT|Health-related quality of life profile|Progression of lesions other than target lesions as measured by CT","https://ClinicalTrials.gov/show/NCT02414334"
2225,"NCT01001884","The Efficacy of the Caregiver Psychoeducational Consultation Program","Recruiting","No Results Available","Depression|Sleep","Other: caregiver psychoeducational consultation program (CPCP)","National Taiwan University Hospital","Both","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Supportive Care","200902029R","October 21, 2009","February 2009","December 2010","August 12, 2010","June 2010","No Study Results Posted","null","December 2010","Short-form 12 health-related quality of life questionnaire|Caregiver reaction assessment|Experiences in close relationships scale|Moss sleeping scale|BDI-II depression scale","https://ClinicalTrials.gov/show/NCT01001884"
2226,"NCT00845039","A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of People With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab","Completed","No Results Available","Colon Cancer|Rectal Cancer","Biological: Cetuximab|Drug: Irinotecan|Biological: IMC-A12 (cixutumumab)","ImClone LLC|NSABP Foundation Inc","Both","18 Years and older   (Adult, Senior)","Phase 2","4","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13928|CP13-0708|I5A-IE-JAED|NSABP FC-4","February 10, 2009","May 2009","February 2011","February 2, 2012","July 2011","No Study Results Posted","FC-4","February 2011","Progression Free Survival|Objective Response Rate (ORR) (Complete Response plus Partial Response)|Overall Survival|Progression Free Survival (PFS) over entire duration|Resection Rate, the number of patients who had a complete resection/ablation of metastases with no evidence of disease remaining|Toxicity of the irinotecan + cetuximab + IMC-A12 regimen|Post-treatment serum levels of IMC-A12 in patients receiving IMC-A12|Change in Behavioral and Health Outcomes [BAHO] Quality of Life Questionnaire|Serum Anti-IMC-A12 Antibody Assessment","https://ClinicalTrials.gov/show/NCT00845039"
2227,"NCT01264952","Treatment of Liver Metastases With Electrochemotherapy","Completed","Has Results","Liver Metastases","Procedure: Electrochemotherapy","Institute of Oncology Ljubljana|University Medical Centre Ljubljana","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","16","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03-Z 16/KSOPKR-6","December 15, 2010","November 2008","November 2013","December 19, 2014","December 2014","December 19, 2014","ECTJ","March 2013","Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms)|Clinical Evaluation of the Patient (Pain Scale, Adverse Events, Concomitant Treatment)|Treatment Evaluation of Tumor Response - Measurements of Tumor Lesions by Contrast Enhanced Ultrasonography (US-Doppler), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Histology","https://ClinicalTrials.gov/show/NCT01264952"
2228,"NCT02009774","Accuracy of the Optical Diagnosis of Small Colonic Polyps Using the Nice Classification","Completed","No Results Available","Colon Adenoma|Colorectal Carcinoma|Hyperplastic Polyp","Procedure: NBI Function","Technische Universität München|Olympus","Both","18 Years to 90 Years   (Adult, Senior)","","380","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADOPTION","December 9, 2013","January 2014","May 2015","November 5, 2015","August 2015","No Study Results Posted","ADOPTION","April 2015","Accuracy optical biopsy|Adenoma detection rate","https://ClinicalTrials.gov/show/NCT02009774"
2229,"NCT02141152","Next pErsonalized Cancer tX With mulTi-omics and Preclinical Model","Completed","No Results Available","Metastatic Cancer","","Samsung Medical Center","Both","20 Years and older   (Adult, Senior)","","895","Other","Observational","Time Perspective: Prospective","2013-10-017","February 10, 2014","February 2015","December 2015","December 28, 2015","December 2015","No Study Results Posted","NEXT-1","December 2015","Response rate|Progression Free Survival|feasibility","https://ClinicalTrials.gov/show/NCT02141152"
2230,"NCT01590147","Supportive Intervention Programs Study","Completed","No Results Available","Fatigue|Nausea and Vomiting|Pain|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage I-IVB Colon Cancer|Stage I-IVB Rectal Cancer","Procedure: Yoga therapy|Other: questionnaire administration|Procedure: quality-of-life assessment|Other: laboratory biomarker analysis|Other: assessment of therapy complications|Procedure: management of therapy complications|Other: educational intervention","Wake Forest University|Wake Forest School of Medicine","Both","18 Years and older   (Adult, Senior)","","15","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CCCWFU 98211|NCI-2011-01093","May 1, 2012","June 2011","July 2013","July 26, 2013","July 2013","No Study Results Posted","SIPS","July 2013","Feasibility of implementing a YST among patients undergoing chemotherapy (participating rate, adherence, and retention)|Preliminary efficacy of YST, in terms of reducing fatigue|Treatment related symptoms and QOL|Mediating variables (self efficacy, response expectancies, inflammatory biomarkers) intervention effect on fatigue, treatment-related symptoms, and QOL","https://ClinicalTrials.gov/show/NCT01590147"
2231,"NCT02824835","Strigolactones and Dysplastic Colonic Lesions or Cancer","Not yet recruiting","No Results Available","Colonic Neoplasms|Colonic Polyps","Procedure: biopsy during colonoscopy","Meir Medical Center","Both","18 Years and older   (Adult, Senior)","","150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IDO123","June 27, 2016","July 2016","December 2017","July 2, 2016","July 2016","No Study Results Posted","null","December 2017","percentage of cells with reduced viability after dose-dependent exposure|percentage of cells in G2/M arrest after dose-dependent exposure","https://ClinicalTrials.gov/show/NCT02824835"
2232,"NCT02318888","Does Icodextrin Reduce the Risk of Small Bowel Obstruction?","Recruiting","No Results Available","Surgical Adhesions","Procedure: Surgery|Drug: Icodextrin","Uppsala University","Both","18 Years to 85 Years   (Adult, Senior)","","1800","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","Dnr 2009/123","December 12, 2014","December 2009","December 2022","January 7, 2015","January 2015","No Study Results Posted","null","December 2022","Surgery for small bowel obstruction|Hospitalisation for small bowel obstruction|Overall and cancer survival|Postoperative complications","https://ClinicalTrials.gov/show/NCT02318888"
2233,"NCT01415817","Endoscopic Quality Improvement Program","Completed","No Results Available","Adenomatous Polyps|Colorectal Polyps","Other: Training session","Mayo Clinic","Both","18 Years and older   (Adult, Senior)","","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","10-000433","August 8, 2011","August 2010","April 2011","August 11, 2011","August 2011","No Study Results Posted","EQUIP","December 2010","Measurement of overall adenoma detection rate|Measurement of total polypectomy rate|Measurement of colonoscopy time|Endoscopist Acceptance","https://ClinicalTrials.gov/show/NCT01415817"
2234,"NCT00044785","Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors","Terminated","No Results Available","Solid Tumors","Drug: triacetyluridine|Drug: fluorouracil|Drug: leucovorin|Drug: camptosar","Wellstat Therapeutics","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","401.02.001|GCC0121","September 4, 2002","August 2002","March 2004","June 23, 2005","May 2005","No Study Results Posted","null","null","Safety and Maximum Tolerated Dose","https://ClinicalTrials.gov/show/NCT00044785"
2235,"NCT00582426","Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea","Completed","Has Results","Chemotherapy-induced Diarrhea","Drug: Octreotide Long Acting Release|Other: Standard Treatment","Novartis Pharmaceuticals|Novartis","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","139","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CSMS995AIC04","December 21, 2007","April 2008","September 2010","April 13, 2015","April 2015","September 1, 2011","LARCID","September 2010","Percentage of Participants Developing Diarrhea (Grade 1 to 4)|Number of Episodes of Diarrhea by Patient|Number of Episodes of Diarrhea by Patient by Cycle|Percentage of Patients by Grade of Diarrhea|Percentage of Episodes by Grade|Percentage of Participants Who Need Chemotherapy Dose Reduction Due to Diarrhea|Percentage of Participants Who Need Opioids for Control of Diarrhea|Percentage of Patients Hospitalized Due to Diarrhea|Percentage of Participants Who Need Intravenous Hydration for Control of Diarrhea|Percentage of Participants With Complete or Partial Response at Response Evaluation Criteria in Solid Tumors (RECIST)|Change From Baseline in Quality of Life Measured by the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D)","https://ClinicalTrials.gov/show/NCT00582426"
2236,"NCT02792478","Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study","Recruiting","No Results Available","RAS Wild Type mCRC","","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 4","119","Industry","Observational","Time Perspective: Prospective","20140381","April 26, 2016","May 2016","September 2018","July 13, 2016","July 2016","No Study Results Posted","PERSEIDA","September 2018","Detection rate of RAS mutations in liquid biopsies in subjects with RAS wild-type mCRC at baseline.|Description of RAS mutations using liquid biopsies at the moment of disease progression|Description of the RAS mutations using liquid biopsies at 20 +/-2 weeks after starting treatment and prior to the second radiological assessment of the disease.","https://ClinicalTrials.gov/show/NCT02792478"
2237,"NCT01291420","Dendritic Cell Vaccination for Patients With Solid Tumors","Enrolling by invitation","No Results Available","Glioblastoma|Renal Cell Carcinoma|Sarcomas|Breast Cancers|Malignant Mesothelioma|Colorectal Tumors","Biological: autologous dendritic cell vaccination","University Hospital, Antwerp","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCRG 11-001","February 7, 2011","February 2011","null","July 11, 2013","July 2013","No Study Results Posted","null","February 2014","Immunogenicity of intradermal DC vaccination","https://ClinicalTrials.gov/show/NCT01291420"
2238,"NCT01022723","Clinical Validation of a Microfluidic Device for Isolation and Molecular Characterization of Circulating Tumor Cells","Recruiting","No Results Available","Cancer","","National Cancer Centre, Singapore|National Medical Research Council (NMRC), Singapore|National University, Singapore","Both","Child, Adult, Senior","","366","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CTC_ver2_081109","November 30, 2009","October 2009","December 2016","June 9, 2016","June 2016","No Study Results Posted","CTC","December 2016","The validation of the clinical use of a microfluidic device to capture circulating tumor cells (CTC) from a broad range of tumor types|Characteristics and viability of the CTC with this capture method|Clinical application of this capture method with the study of CTC titre correlation to treatment outcome|Study of predictive and pharmacodynamic biomarkers of the CTC in the context of early phase trials of novel therapeutics","https://ClinicalTrials.gov/show/NCT01022723"
2239,"NCT01166035","Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors","Recruiting","No Results Available","Solid Tumors","Drug: Lenalidomide|Drug: Cetuximab","Medical University Innsbruck|Celgene Corporation|Innsbruck - Tyrolean Working Group of Experimental Oncology (TEXO)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TEXO0309","July 19, 2010","March 2010","December 2011","July 19, 2010","May 2010","No Study Results Posted","TEXO","September 2011","Maximum tolerated dose","https://ClinicalTrials.gov/show/NCT01166035"
2240,"NCT02640365","A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer","Recruiting","No Results Available","Unresectable Advanced Cancer","Drug: MM-398|Drug: Irinotecan|Drug: Leucovorin (LV)|Drug: 5-fluorouracile (5-FU)|Drug: bevacizumab|Drug: MM-398","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Merrimack Pharmaceuticals","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","36","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DOUBLIRI C13-4","December 16, 2015","October 2015","September 2018","March 14, 2016","December 2015","No Study Results Posted","DOUBLIRI","January 2018","Adverse Event (AE)|Dose Limiting Toxicities (DLT)|Maximal tolerated dose (MTD)|Response Rate (RR)|Best overall Response (BOR)|Overall survival (OS)|Progression free survival (PFS)|Pharmacokinetic of MM-398 plus irinotecan combination therapy","https://ClinicalTrials.gov/show/NCT02640365"
2241,"NCT00625066","Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy","Recruiting","No Results Available","Colorectal Cancer|Precancerous Condition","Other: biologic sample preservation procedure|Other: cytology specimen collection procedure|Other: medical chart review|Other: questionnaire administration|Other: survey administration|Procedure: biopsy|Procedure: evaluation of cancer risk factors|Procedure: screening colonoscopy","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","40 Years to 75 Years   (Adult, Senior)","","7000","Other|NIH","Observational","","CDR0000583154|VU-VICC-GI-0294|VU-VICC-020603|VU-VICC-020531","February 27, 2008","January 2003","null","January 27, 2010","October 2008","No Study Results Posted","null","January 2011","Recruitment of 7,000 participants who are planning to undergo colonoscopy|Collection of questionnaires and medical records|Collection of biological samples, including urine, blood, buccal cells and/or saliva, rectal tissue, and colorectal polyps|Evaluation of risk factors and other differences between participants found to have polyps and those who do not have polyps","https://ClinicalTrials.gov/show/NCT00625066"
2242,"NCT00004210","Study of the Results of Education and Counseling for Persons Undergoing Genetic Testing for Hereditary Nonpolyposis Colon Cancer","Completed","No Results Available","Colorectal Cancer","Other: loss of heterozygosity analysis|Other: microsatellite instability analysis|Other: mutation analysis|Other: counseling intervention","National Human Genome Research Institute (NHGRI)|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","900","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","CDR0000067459|NCI-95-HG-0165|NCI-NMOB-9501|NHGRI-95-HG-0165","January 21, 2000","February 2000","June 2011","October 23, 2014","July 2009","No Study Results Posted","null","June 2011","Assessment of cancer risk perception, cancer screening practices, views regarding genetic services, and family communication about HNPCC / Lynch syndrome by family members","https://ClinicalTrials.gov/show/NCT00004210"
2243,"NCT01340300","Exercise and Metformin in Colorectal and Breast Cancer Survivors","Active, not recruiting","No Results Available","Colorectal Cancer|Breast Cancer","Behavioral: Exercise training|Drug: Exercise training plus metformin|Drug: Metformin|Other: Educational information","Dana-Farber Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","139","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","11-009","April 7, 2011","May 2011","null","January 20, 2016","January 2016","No Study Results Posted","null","December 2016","Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting insulin level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer.|Compare changes in other insulin-related biomarkers|Explore for an interaction effect in addition to an additive effect of exercise and metformin in reducing fasting insulin level over the 3 month intervention|Compare changes in body composition by treatment arm|Compare change in pro-inflammatory markers potentially related to insulin resistance by treatment arm|Compare self-directed change in diet quality by treatment arm","https://ClinicalTrials.gov/show/NCT01340300"
2244,"NCT00380055","Reducing Cancer Disparities for American Indians in the Rural Intermountain West","Completed","No Results Available","Prostate Cancer|Colorectal Cancer|Breast Cancer|Cervical Cancer|Lung Cancer","Behavioral: Navigation Services|Behavioral: Cancer education","University of Utah|Sletten Cancer Institute|Centers for Medicare and Medicaid Services","Both","Child, Adult, Senior","","1800","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","18388|1A0CMS300067","September 22, 2006","October 2006","December 2010","September 19, 2011","September 2011","No Study Results Posted","null","December 2010","Proportion of individuals receiving recommended screening for prostate, breast, colorectal, and cervical cancer.|Proportion of individuals receiving recommended diagnostic follow-up for prostate, breast, colorectal, and cervical cancer.|Proportion of individuals receiving recommended treatment for prostate, breast, colorectal, cervical, and lung cancer.|Cost-effectiveness of using community navigators to improve cancer care among rural Native Americans.","https://ClinicalTrials.gov/show/NCT00380055"
2245,"NCT02176746","A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer","Completed","No Results Available","Neoplasms,Colorectal","Biological: cancer stem cell vaccine","Fuda Cancer Hospital, Guangzhou|University of Michigan","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","CLC-001","June 25, 2014","June 2014","May 2015","June 1, 2015","June 2014","No Study Results Posted","CSC","May 2015","The number of participants with adverse events|The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements","https://ClinicalTrials.gov/show/NCT02176746"
2246,"NCT01613430","Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors","Active, not recruiting","No Results Available","Colorectal Cancer|Breast Cancer|Cervical Cancer","Behavioral: Coach Training (COACH)|Behavioral: Printed Educational Materials (PEM)","Johns Hopkins Bloomberg School of Public Health|National Cancer Institute (NCI)","Both","50 Years to 74 Years   (Adult, Senior)","","1106","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","U54CA153710","June 5, 2012","June 2012","September 2016","August 25, 2015","August 2015","No Study Results Posted","COACH","September 2016","Completing at least one recommended cancer screenings (colorectal, breast, cervical)|Time to completion of cancer screenings, and the effect of comorbid conditions, health literacy, patient satisfaction,and health care costs on cancer screening","https://ClinicalTrials.gov/show/NCT01613430"
2247,"NCT00132522","EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide","Completed","No Results Available","Ovarian Cancer|Colorectal Cancer|Carcinoma, Non-small-cell Lung|Prostate Cancer","Drug: EMD 273066","EMD Serono","Both","18 Years and older   (Adult, Senior)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62206-015","August 19, 2005","May 2005","April 2009","October 23, 2013","October 2013","No Study Results Posted","null","June 2008","efficacy|safety","https://ClinicalTrials.gov/show/NCT00132522"
2248,"NCT02701907","EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies","Active, not recruiting","No Results Available","Metastatic Cancers","Other: Blood sampling","UNICANCER","Both","18 Years and older   (Adult, Senior)","","264","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","UC-0105/1508","January 27, 2016","February 2016","August 2019","April 27, 2016","April 2016","No Study Results Posted","EXPRESS","February 2019","The primary endpoint is the rate of patients with tumors harboring a low level of genomic alteration (mutation, amplification or deletion) in genes (i.e. mutation, amplification, deletion) identified as causally implicated in cancer|The secondary endpoint is the rate of tumors with low level of genomic alterations between the EXPRESS cohort and control cohorts of patients.|Exploratory analyses will be performed to compare the profiles between the EXPRESS and the control cohorts of patients, to identify novel candidate somatic molecular profiles","https://ClinicalTrials.gov/show/NCT02701907"
2249,"NCT01059643","A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck","Completed","No Results Available","Ovarian Cancer|Non Small Cell Lung Cancer|Prostate Cancer|Colorectal Cancer|Gastric Cancer|Esophageal Cancer|Cancer of Head and Neck","Drug: LY2523355|Drug: pegfilgrastim","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","250","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12848|I1Y-MC-JFBF","January 11, 2010","April 2011","December 2012","April 30, 2013","February 2013","No Study Results Posted","null","December 2012","Percentage of patients with a Complete Response (CR) or Partial Response (PR)|Progression free survival|Percentage of patients who achieved a best response of CR, PR or Stable Disease (SD)|Change in tumor marker values as relevant to specific tumor types|Maximum plasma concentration (Cmax) of LY2523355 and metabolite LSN2546307|Change in tumor size at best response|Intracycle accumulation ratio of LY2523355","https://ClinicalTrials.gov/show/NCT01059643"
2250,"NCT02457143","Comparing Methods of Recall for Cancer Screening in Primary Care: a Pragmatic Clinical Trial","Recruiting","No Results Available","Early Detection of Cancer|Cancer|Socioeconomic Status","Behavioral: Letter|Behavioral: Phone call","St. Michael's Hospital, Toronto","Both","21 Years to 74 Years   (Adult, Senior)","","7000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","15-145","May 27, 2015","July 2015","July 2016","July 7, 2016","July 2016","No Study Results Posted","null","July 2016","The proportion of patients in each arm who go on to receive at least one screening test for which they are due|The proportion of patients in each arm who are due for breast, cervical and colorectal cancer screening who go on to receive those respective screening tests (female patients may be represented in the outcome calculation of more than one cancer screening","https://ClinicalTrials.gov/show/NCT02457143"
2251,"NCT00126451","A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)","Terminated","No Results Available","Breast Cancer|Colorectal Cancer|Non-small-cell Lung Carcinoma","Drug: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|Drug: Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","42","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005_014|MK0683-011","August 2, 2005","December 2004","null","May 21, 2013","May 2013","No Study Results Posted","null","October 2005","Response rate of relapsed/refractory breast, colorectal and non-small cell lung cancer to SAHA using RECIST criteria.|Positron emission tomography (PET) as an earlier indicator of the response to SAHA as assessed by RECIST criteria. To evaluate the safety and tolerability of SAHA for 14 days every 21 days.","https://ClinicalTrials.gov/show/NCT00126451"
2252,"NCT00003674","Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer|Veno-occlusive Disease","Drug: dalteparin|Drug: standard therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","141","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NCCTG-979251|CDR0000066775|NCI-P98-0139","November 1, 1999","December 1998","April 2004","July 12, 2016","July 2016","No Study Results Posted","null","April 2004","Overall survival rate|Overall quality of life|Assess the incidence of symptomatic thrombotic events such as deep venous thrombosis (DVT), pulmonary embolus (PE), and clotted catheters","https://ClinicalTrials.gov/show/NCT00003674"
2253,"NCT02811497","Study of Azacitidine and Durvalumab in Advanced Solid Tumors","Recruiting","No Results Available","Microsatellite Stable Colorectal Carcinoma|Platinum Resistant Epithelial Ovarian Cancer Type II|Estrogen Receptor Positive and HER2 Negative Breast Cancer","Drug: Azacitidine|Drug: Durvalumab","University Health Network, Toronto","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","METADUR-001","June 21, 2016","September 2016","January 2022","September 9, 2016","September 2016","No Study Results Posted","METADUR","July 2021","Overall response rate (ORR)|Disease Control Rate (DCR)|Progression-free survival (PFS)|Overall survival (OS)|Incidence of treatment-emergent adverse events (AEs)","https://ClinicalTrials.gov/show/NCT02811497"
2254,"NCT01092078","Community-based Approaches to Treating Hypertension and Colon Cancer Prevention","Completed","No Results Available","Hypertension|Colon Cancer","Behavioral: MINT|Behavioral: Patient Navigation","New York University School of Medicine|Cornell University|Wayne State University","Male","50 Years and older   (Adult, Senior)","","740","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","09-0151","March 18, 2010","May 2010","May 2014","April 20, 2015","April 2015","No Study Results Posted","MISTER-B","May 2014","Blood Pressure|Colon Cancer Screening Behavior|Medication Adherence|Physical Activity|Intrinsic Motivation to Exercise|Self-Efficacy (Exercise)|Dietary Intake|Intrinsic Motivation (Diet)|Self-efficacy (Diet)|Facilitators and Barriers to obtaining a colonoscopy|Behavioral Intention relating to colon cancer screening|Social Influence relating to colon cancer screening","https://ClinicalTrials.gov/show/NCT01092078"
2255,"NCT02191761","Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer","Suspended","No Results Available","Colorectal Cancer|Gastric Cancer|Hepatic Cancer|Pancreatic Cancer","Drug: SM04755","Samumed LLC","Both","18 Years and older   (Adult, Senior)","Phase 1","25","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SM04755-ONC-01","June 30, 2014","June 2014","July 2016","September 18, 2015","September 2015","No Study Results Posted","null","July 2016","Determine the MTD|Incidence of safety parameters including adverse events, laboratory results, vital signs, electrocardiogram (ECG) findings, Eastern Cooperative Oncology Group (ECOG) performance scores, physical and ophthalmic examination findings|Area under the plasma concentration (AUC) Versus Time Curve of SM04755|Characterize the pharmacodynamics (PD) of SM04755 by assessment of its preliminary antitumor activity determined by Response Evaluation Criteria in Solid Tumors (RECIST)|Maximum Observed Plasma Concentration (Cmax) of SM04755|Half Life of SM04755|Volume of Distribution of SM04755|Time to maximum plasma concentration|Accumulation ratio of SM04755|Total Clearance of SM04755 after oral administration","https://ClinicalTrials.gov/show/NCT02191761"
2256,"NCT00897793","Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Prostate Cancer","Procedure: venipuncture|Radiation: radiation therapy","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","25","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","VICC RAD 0576|P30CA068485|VU-VICC-RAD-0576","May 9, 2009","January 2006","July 2010","April 10, 2013","April 2013","No Study Results Posted","null","July 2010","TGF-beta levels","https://ClinicalTrials.gov/show/NCT00897793"
2257,"NCT01110798","J-Pouch Colorectal Anastomosis or Straight Colorectal Anastomosis in Treating Patients With Rectal Cancer Who Have Undergone Surgery to Remove the Tumor","Recruiting","No Results Available","Colorectal Cancer|Gastrointestinal Complications|Perioperative/Postoperative Complications","Other: intraoperative complication management/prevention|Procedure: assessment of therapy complications|Procedure: gastrointestinal complications management/prevention|Procedure: quality-of-life assessment|Procedure: therapeutic conventional surgery","Azienda Ospedaliera di Padova|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","600","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000671070|USP-1935P|EU-21032","April 23, 2010","October 2009","null","September 16, 2013","February 2011","No Study Results Posted","null","October 2011","Major anastomotic leak rate|Percentage of the colonic J-pouch reconstruction performed with respect to the total number of patients selected for the J-pouch treatment arm|Global anastomotic leak rate|Anastomotic complications rate in addition to anastomotic leak|Bowel function, fecal incontinence, and quality of life, evaluated with validated questionnaires","https://ClinicalTrials.gov/show/NCT01110798"
2258,"NCT00019773","Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer","Completed","No Results Available","Carcinoma of the Appendix|Colorectal Cancer|Small Intestine Cancer","Drug: capecitabine|Drug: oxaliplatin","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000067201|NCI-99-C-0117|MB-NAVY-99-01|NCI-T99-0011","July 11, 2001","July 1999","null","April 28, 2015","April 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00019773"
2259,"NCT01418326","Cancer Mortality Affected by the Choice of Anesthetic Drugs?","Completed","No Results Available","Breast Cancer|Colo-rectal Cancer|Skin Cancer","","Enlund|Uppsala University","Both","Child, Adult, Senior","","3284","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2008350","May 12, 2011","November 2010","October 2011","May 28, 2015","May 2015","No Study Results Posted","null","September 2011","Survival","https://ClinicalTrials.gov/show/NCT01418326"
2260,"NCT01888965","Maintenance Dovitinib for Colorectal and Pancreas Cancer","Terminated","Has Results","Colorectal Cancer|Pancreas Cancer","Drug: Dovitinib","Georgetown University|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 2","9","Other|Industry","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CTK1258AUS16T|Pro063","June 26, 2013","October 2013","October 2014","June 7, 2016","August 2015","February 8, 2016","null","August 2014","Biomarker Discovery|Progression-free Survival|Safety","https://ClinicalTrials.gov/show/NCT01888965"
2261,"NCT01874860","Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients","Recruiting","No Results Available","Colorectal Cancer|Head and Neck Cancer","Drug: Doxycycline|Drug: Hydrocortisone 1% cream|Other: Sunscreen|Other: Moisturizer|Drug: Clindamycin|Drug: Medrol-dose pack (Steroid)","James Graham Brown Cancer Center|University of Louisville","Both","18 Years and older   (Adult, Senior)","Phase 1","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BCC-OHN-GI-13","June 6, 2013","August 2013","August 2017","February 29, 2016","January 2016","No Study Results Posted","null","August 2016","Incidence of Rash|Quality of Life (QOL)|Adherence to treatment regimen|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01874860"
2262,"NCT00004879","Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer","Completed","No Results Available","Colorectal Cancer|Esophageal Cancer|Kidney Cancer|Lung Cancer|Pancreatic Cancer|Prostate Cancer","Biological: panitumumab","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000067539|UCLA-9906078|ABX-EG-9901|UCLA-9906078-04B|NCI-G00-1673","March 7, 2000","April 2000","null","January 7, 2013","January 2013","No Study Results Posted","null","July 2005","","https://ClinicalTrials.gov/show/NCT00004879"
2263,"NCT02476682","Non-invasive Risk Stratification of CR AMN/SSP","Not yet recruiting","No Results Available","Adenomatous Polyps","Other: blood or stool samples will be collected","Professor Michael Bourke|Western Sydney Local Health District","Both","18 Years and older   (Adult, Senior)","","1725","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HREC2014/9/4.4(4079)","June 10, 2015","July 2016","July 2021","December 15, 2015","December 2015","No Study Results Posted","FIT","July 2020","Demographics|Level of methylated DNA in circulation|Level of haemoglobin in stool","https://ClinicalTrials.gov/show/NCT02476682"
2264,"NCT02367001","Randomized Trial Evaluating the Effectiveness of the General Practitioner Involvement in Cancer Screening Invitations","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Cervical Cancer","Other: Normal invitation|Other: revised invitation signed by the coordinating doctor|Other: Revised invitation signed by the attending physician","University Hospital, Tours","Both","25 Years to 74 Years   (Adult, Senior)","","53978","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","INCA-P3644-KH-GPs","January 28, 2015","February 2014","September 2015","September 30, 2015","February 2015","No Study Results Posted","GPs","June 2015","Evaluate the effect on the participation (of the population) in cancer screening of an intervention involving the general practitioner (integration of signature) in the invitation letters|Evaluate the effectiveness on the participation (of the population) of the use of a simplified and more focused communication in the invitation letters : comparison of the participation rates in arm 1 (normal invitation) and arm 2 (revised invitation)|Evaluate the effectiveness on the participation (of the population) of the two types of general practitioner signature (typed versus typed + handwritten) by comparing the participation rates between two sub-groups in the arm 3.|Cost-effectiveness of different strategies for each cancer screening (breast, colorectal and cervical) as measured by cost effectiveness ratio (total costs in Euros divided by total screened people)","https://ClinicalTrials.gov/show/NCT02367001"
2265,"NCT02328664","SCar-biopsies After Malignant Colorectal Polypectomy of Uncertain RAdicality","Recruiting","No Results Available","Colorectal Cancer","Procedure: Flexible sigmoidoscopy or colonoscopy","Dr. Frank ter Borg MD PhD|Erasmus Medical Center|The Netherlands Cancer Institute|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|UMC Utrecht|Deventer Ziekenhuis","Both","18 Years and older   (Adult, Senior)","","1356","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","SCAPURA-Study","December 15, 2014","August 2015","August 2019","August 4, 2016","August 2016","No Study Results Posted","SCAPURA","August 2019","Sensitivity of biopsies for residual cancer|90-day mortality after rescue surgery|The sensitivity of biopsies for residual cancer in the bowel wall|The number of complications (defined according to GCP) after biopsies from the polypectomy scar|The sensitivity of global endoscopic assessment of polypectomy site for residual cancer at initial and follow-up endoscopy (to take scar biopsies)|The proportion of patients with residual cancer in the resected specimen if malignancy was unsuspected during the endoscopic polypectomy","https://ClinicalTrials.gov/show/NCT02328664"
2266,"NCT01450163","Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy","Enrolling by invitation","No Results Available","Pain|Neuropathic Pain|Polyneuropathy","Drug: Pregabalin, Oxaliplatin|Drug: Placebo , Oxaliplatin","University of Sao Paulo|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 3","200","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PreOx","April 26, 2010","August 2011","December 2014","May 22, 2014","May 2014","No Study Results Posted","PreOx","October 2014","Evaluate the efficacy|Safety|Quality of Life|Presence of large and small fiber injury|Cancer treatment efficacy","https://ClinicalTrials.gov/show/NCT01450163"
2267,"NCT00145769","A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum","Completed","No Results Available","Adenocarcinoma of Rectum","Drug: Short Course Adjuvent Chemotherapy|Drug: Long Course Adjuvant Chemotherapy|Radiation: Short Course Radiotherapy|Radiation: Long Course Radiotherapy|Drug: Concurrent Chemotherapy|Procedure: Initial Surgery","Trans-Tasman Radiation Oncology Group (TROG)|Australasian Gastro-Intestinal Trials Group|Colorectal Surgical Society of Australasia (CSSA)|Royal Australasian College of Surgeons (RACS)","Both","18 Years and older   (Adult, Senior)","Phase 3","326","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TROG 01.04|NHMRC 209123","September 2, 2005","July 2001","May 2011","August 7, 2013","August 2013","No Study Results Posted","null","June 2009","Local recurrence|Survival|Toxicity|Abdominoperineal resection rate. This is defined as the proportion of all patients in any arm who undergo operation by abdominalperineal resection.|Quality of life","https://ClinicalTrials.gov/show/NCT00145769"
2268,"NCT02275754","Redes III Patient Navigator Qol Study","Active, not recruiting","No Results Available","Breast Cancer|Prostate Cancer|Colorectal Cancer","Behavioral: PN+LCNC|Behavioral: PN Only","The University of Texas Health Science Center at San Antonio|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","HSC20110094H|U54CA153511","September 15, 2014","November 2010","August 2017","July 14, 2016","July 2016","No Study Results Posted","null","September 2015","General quality of life|Disease specific quality of life|Treatment Follow-up compliance","https://ClinicalTrials.gov/show/NCT02275754"
2269,"NCT01761240","Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC","Active, not recruiting","No Results Available","Breast Cancer|Pancreatic Cancer|Colorectal Cancer|Non-small-cell Lung Cancer|NSCLC|Adenocarcinoma","Drug: MORAb-066","Morphotek|SCRI Development Innovations, LLC","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","27","Industry|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MORAb-066-001","January 3, 2013","June 2013","June 2016","June 16, 2016","June 2016","No Study Results Posted","null","February 2016","Maximum Tolerated Dose","https://ClinicalTrials.gov/show/NCT01761240"
2270,"NCT02582970","A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum","Completed","No Results Available","Colorectal Cancer","Drug: 5-Fluorouracil|Drug: Bevacizumab","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 4","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18436","October 12, 2015","May 2005","April 2008","December 1, 2015","December 2015","No Study Results Posted","null","April 2008","Incidence of adverse events|Duration of survival|Time to disease progression|Direct medical cost for cancer related medical care utilization","https://ClinicalTrials.gov/show/NCT02582970"
2271,"NCT00338026","A Phase I Study of ECO-4601 in Patients With Advanced Cancer","Completed","No Results Available","Tumors|Glioma|Colorectal Cancer|Lung Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer","Drug: ECO-4601","Thallion Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ECO-4601-101","June 15, 2006","February 2006","August 2007","July 10, 2008","July 2008","No Study Results Posted","null","August 2007","Safety/tolerability of ECO-4601|Determination of MTD of ECO-4601|Determination of recommended dose for future studies of ECO-4601|Pharmacokinetics of ECO-4601|Safety of multiple cycles of administration of ECO-4601|Documentation of ECO-4601 antitumor activity as per RECIST criteria","https://ClinicalTrials.gov/show/NCT00338026"
2272,"NCT00005809","Computerized Tomographic Colonography Compared With Standard Diagnostic Procedures in Detecting Colorectal Neoplasia","Completed","No Results Available","Colorectal Cancer","Procedure: computed tomography|Procedure: diagnostic colonoscopy","American College of Radiology Imaging Network|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","null","Other|NIH","Interventional","Primary Purpose: Diagnostic","CDR0000067802|ACRIN-6656|CA80098","June 2, 2000","July 2000","January 2003","February 1, 2013","February 2013","No Study Results Posted","ACRIN 6656","October 2000","","https://ClinicalTrials.gov/show/NCT00005809"
2273,"NCT01631552","Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers","Recruiting","No Results Available","Colorectal Cancer|Gastric Adenocarcinoma|Esophageal Cancer|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Ovarian Epithelial Cancer|Carcinoma Breast Stage IV|Hormone-refractory Prostate Cancer|Pancreatic Ductal Adenocarcinoma|Head and Neck Cancers- Squamous Cell|Renal Cell Cancer|Urinary Bladder Neoplasms|Cervical Cancer|Endometrial Cancer|Follicular Thyroid Cancer|Glioblastoma Multiforme","Drug: IMMU-132","Immunomedics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","250","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IM-T-IMMU-132-01","June 26, 2012","February 2013","June 2018","September 20, 2016","September 2016","No Study Results Posted","null","June 2018","Safety|Efficacy","https://ClinicalTrials.gov/show/NCT01631552"
2274,"NCT01434342","Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients","Active, not recruiting","No Results Available","Lung Cancer|Tobacco Use Disorder|Breast Cancer|Colorectal Cancer|Prostate Cancer","Drug: Nicotine Replacement Patch","Wake Forest NCORP Research Base|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","146","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","CCCWFU 99211|U10CA081851","September 13, 2011","October 2011","January 2015","January 6, 2015","January 2015","No Study Results Posted","null","June 2014","Evaluate a smoking cessation intervention among cancer patients","https://ClinicalTrials.gov/show/NCT01434342"
2275,"NCT02804815","Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours","Recruiting","No Results Available","Cancer|Breast Cancer|Prostate Cancer|Colorectal Cancer|Gastro-oesophageal Cancer","Drug: Aspirin 100mg|Drug: Aspirin 300mg|Drug: Placebo 100mg|Drug: Placebo 300mg","University College, London","Both","16 Years and older   (Child, Adult, Senior)","Phase 3","11000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)","14/0814|2013-004398-28|120104","February 12, 2016","October 2015","October 2026","June 14, 2016","June 2016","No Study Results Posted","null","October 2026","Overall Survival|Invasive disease-free survival (IDFS)|Disease-free survival (DFS)|Overall survival|Biochemical recurrence-free survival (bRFS)|Adherence|Number of participants with serious haemorrhage (grade 3 or above) as measured by CTCAE V4.0. Data will be collected on case report forms.|Number of participants with treatment-related (active drug and placebo) cardiovascular events as assessed by CTCAE v4.0|Number of participants with second malignancies as assessed by case report form|Number of participants that show a decline in cognition and extent of decline as assessed by the Montreal Cognitive Assessment (MoCA)","https://ClinicalTrials.gov/show/NCT02804815"
2276,"NCT02040142","Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C","Enrolling by invitation","No Results Available","Peritoneal Carcinomatosis|Colorectal Cancer|Appendiceal Cancer|Peritoneal Mesothelioma|Pseudomyxoma Peritonei|Gastric Cancer","Procedure: HIPEC","Montefiore Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11-09-332","May 8, 2013","November 2011","November 2019","January 16, 2014","January 2014","No Study Results Posted","null","November 2014","Evaluate the technical parameters|Progression-free survival","https://ClinicalTrials.gov/show/NCT02040142"
2277,"NCT00080834","DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma","Completed","No Results Available","Colorectal Cancer","Drug: DJ-927","Daiichi Sankyo Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000356034|DAIICHI-927A-PRT004|MDA-2003-0749","April 7, 2004","February 2004","August 2006","May 15, 2012","May 2012","No Study Results Posted","null","August 2006","","https://ClinicalTrials.gov/show/NCT00080834"
2278,"NCT00010270","LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Esophageal Cancer|Gastric Cancer|Pancreatic Cancer","Biological: LMB-9 immunotoxin","University Hospital Freiburg|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","50","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068462|UFMC-431|UFMC-IND-7697|UFMC-NSC-691236|NCI-431|EU-20120","February 2, 2001","April 2001","null","December 18, 2013","January 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00010270"
2279,"NCT00940030","Comparison of Mechanical Bowel Preparation Versus Enema for Candidates to Colorectal Resection for Adenocarcinoma","Recruiting","No Results Available","Colorectal Cancer","Other: mechanical bowel preparation|Other: enema","European Institute of Oncology","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","440","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IEO S357/307","July 14, 2009","October 2007","December 2017","August 9, 2016","August 2016","No Study Results Posted","MBP","June 2017","Anastomotic leakage, wound infection (including deep abscess)|post surgery extra abdominal complications|patient's symptoms (through questionaire)","https://ClinicalTrials.gov/show/NCT00940030"
2280,"NCT00077233","FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum","Completed","No Results Available","Colorectal Cancer","Drug: cetuximab|Drug: 5-FU|Drug: irinotecan|Drug: leucovorin|Drug: oxaliplatin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Bristol-Myers Squibb|ImClone LLC","Both","18 Years and older   (Adult, Senior)","Phase 2","238","Other|NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB 80203|U10CA031946|CDR0000350016","February 10, 2004","December 2003","June 2010","July 1, 2016","July 2016","No Study Results Posted","null","December 2006","Overall survival|Progression-free survival|Complete response|Partial response|Proportion of patients experiencing ≥ Grade 3 diarrhea|Proportion of patients experiencing ≥ Grade 3 ANC|Percent of total dose administered|Proportion of patients experiencing ≥ Grade 4 toxicity on each cetuximab treatment arm","https://ClinicalTrials.gov/show/NCT00077233"
2281,"NCT00574977","Safety Study of Modified Vaccinia Virus to Cancer","Completed","No Results Available","Melanoma|Breast Cancer|Head and Neck Squamous Cell Cancer|Liver Cancer|Colorectal Cancer|Pancreatic Adenocarcinoma","Biological: Vaccinia virus (vvDD-CDSR)|Biological: Vaccinia virus (vvDD-CDSR)|Biological: Vaccinia virus (vvDD-CDSR)","David Bartlett|University of Pittsburgh","Both","18 Years and older   (Adult, Senior)","Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","06-041","December 13, 2007","May 2008","July 2014","December 23, 2015","December 2015","No Study Results Posted","null","January 2013","Determine the maximally tolerated dose (MTD) and/or maximum-feasible dose (MFD) and Safety of vvDD-CDSR administered by intratumoral (I.T.) injection and intravenous (I.V.) infusion.|Replication/pharmacokinetics of vvDD-CDSR|Immune response to vvDD-CDSR and to the tumor following administration|Antitumoral efficacy of vvDD-CDSR","https://ClinicalTrials.gov/show/NCT00574977"
2282,"NCT00055848","Genetic Study of Familial Factors in Patients With Colon Cancer","Completed","No Results Available","Colorectal Cancer","Genetic: cytogenetic analysis|Genetic: gene mapping|Genetic: microarray analysis","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","up to 70 Years   (Child, Adult, Senior)","","600","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CALGB-150008|CDR0000271314","March 6, 2003","December 2001","October 2010","July 12, 2016","July 2015","No Study Results Posted","null","October 2010","","https://ClinicalTrials.gov/show/NCT00055848"
2283,"NCT00379132","131-I-TM-601 Study in Adults With Solid Tumors","Completed","No Results Available","Breast Cancer|Non-Small Cell Lung Cancer|Melanoma|Colorectal Cancer|Pancreatic Cancer|Prostate Adenocarcinoma|Glioma|Primary Solid Tumors","Drug: 131-I-TM-601 (chlorotoxin)","TransMolecular","Both","18 Years and older   (Adult, Senior)","Phase 1","60","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TM601-003","September 18, 2006","August 2006","August 2008","March 30, 2009","March 2009","No Study Results Posted","null","July 2008","To evaluate whether intravenous (IV) 131-I-TM-601 provides tumor-specific localization in patients with recurrent or refractory metastatic (including brain metastases) solid tumors|To determine the distribution and dosimetry of intravenously administered 131-I-TM-601|To determine the safety and tolerability of IV administered 131-I-TM-601.","https://ClinicalTrials.gov/show/NCT00379132"
2284,"NCT01169558","A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.","Completed","No Results Available","Colorectal Cancer","Drug: bevacizumab [Avastin]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","163","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20552","July 22, 2010","May 2006","December 2009","February 1, 2016","February 2016","No Study Results Posted","null","December 2009","Safety: Serious and specific adverse events|Efficacy: Duration of survival|Efficacy: Time to disease progression","https://ClinicalTrials.gov/show/NCT01169558"
2285,"NCT02584244","Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers","Recruiting","No Results Available","Colorectal Cancer|Pancreatic Cancer|Esophageal Cancer","Drug: LUM015|Device: LUM 2.6 Imaging Device","Lumicell, Inc.|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","21","Industry|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","LUM-015/2.6-002|P50CA127003","October 16, 2015","May 2016","April 2017","May 23, 2016","May 2016","No Study Results Posted","null","April 2017","Determine optimal dose of LUM015 to be used according to tissue type based on optimal LUM015 activity in normal versus tumor tissue.|Assess toxicity in patients with gastrointestinal cancers by monitoring adverse events, including clinically significant abnormalities in CBC and serum chemistry tests from injection until first post-operative visit|Determine initial efficacy of LUM015 in labeling gastrointestinal cancers for molecular imaging by comparing imaging results with pathology.","https://ClinicalTrials.gov/show/NCT02584244"
2286,"NCT00611000","Effect of Folate on DNA in Colon Tissue and Blood Samples From Patients at Increased Risk of Developing Colorectal Neoplasia","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: folic acid|Genetic: DNA methylation analysis|Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: polymorphism analysis|Other: laboratory biomarker analysis","Rockefeller University|National Cancer Institute (NCI)","Both","40 Years to 72 Years   (Adult, Senior)","Phase 1","20","Other|NIH","Interventional","Masking: Single Blind|Primary Purpose: Prevention","CDR0000582113|RUH-PHO-0514-0306","February 7, 2008","June 2003","null","February 14, 2009","February 2008","No Study Results Posted","null","January 2006","DNA uracil incorporation in peripheral blood mononuclear cells (PBMCs)|Strand breaks in the coding region of p53 in PBMCs and rectal biopsy cells|DNA methylation (overall, p53 coding, p16 promoter, MLH1 promoter) in PBMCs and rectal biopsy cells|Differential gene expression in colonic and PBMCs by microarray analysis","https://ClinicalTrials.gov/show/NCT00611000"
2287,"NCT00577031","OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.","Completed","Has Results","Colorectal Cancer","Drug: bevacizumab [Avastin]|Drug: Oxaliplatin|Drug: Xeloda","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 4","205","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21380","December 18, 2007","February 2008","August 2011","July 21, 2015","July 2015","July 15, 2014","null","August 2011","Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death|PFS: Time to Event|Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Among Participants in the ITT Population Who Had at Least 1 Post-Baseline Assessment|Percentage of Participants With a CR or PR Among Participants in the ITT Population|Time to CR or PR Overall Response - Time to Event|Percentage of Participants With a Best Overall Response of CR or PR During First Line Treatment|Duration of Overall Response Among Participants Whose Best Response Was CR or PR During First Line Treatment - Time to Event|Percentage of Participants With a Stable Response During First Line Treatment|Duration of Stable Response|Percentage of Participants With Treatment Failure|Time to Treatment Failure|Overall Survival: Percentage of Participants That Died Due to Any Cause|Overall Survival: Time to Event|Percentage of Participants Undergoing Surgical Intervention With Residual Disease Status Post-surgery|Percentage of Participants With Best Overall Response of CR or PR by Kirsten Rat Sarcoma Viral Oncogene Homolog (K-Ras)/V-Raf Murine Sarcoma Viral Oncogene Homolog B (B-Raf) Mutation Status|European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score","https://ClinicalTrials.gov/show/NCT00577031"
2288,"NCT00397969","Improving the Frequency of Colonoscopy in Patients With a Previous Colorectal Polyp","Completed","No Results Available","Colorectal Cancer|Precancerous Condition","Other: counseling intervention|Procedure: screening colonoscopy","Harvard Medical School|National Cancer Institute (NCI)","Both","21 Years and older   (Adult, Senior)","","800","Other|NIH","Interventional","Allocation: Randomized","CDR0000492752|HMS-M11837-103|BWH-2005-P-000371/3|HPHC-1705","November 9, 2006","February 2005","June 2008","December 18, 2013","December 2006","No Study Results Posted","null","null","Successful completion of follow-up colonoscopy|Number of patients completing colonoscopy during the study period","https://ClinicalTrials.gov/show/NCT00397969"
2289,"NCT02230553","Lapatinib Plus Trametinib in KRAS Mutant Malignancies","Recruiting","No Results Available","Colorectal Cancer","Drug: Lapatinib|Drug: trametinib","The Netherlands Cancer Institute|GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NL49551.031.14","August 29, 2014","October 2014","null","November 18, 2014","November 2014","No Study Results Posted","M14LTK","December 2015","Incidence rate of dose-limiting toxicities|progression free survival|overall response rate|Incidence and severity of adveres events|Plasma concentration|Duration of response|Time to response|Overall survival","https://ClinicalTrials.gov/show/NCT02230553"
2290,"NCT02310464","Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197)in Gastric, Lung, Colorectal or Breast Cancer Subjects","Recruiting","No Results Available","Metastatic Gastric Cancer|Metastatic Breast Cancer|Metastatic Colorectal Cancer|Metastatic Lung Cancer","Drug: OBI-833/OBI-821","OBI Pharma, Inc","Both","21 Years and older   (Adult, Senior)","Phase 1","26","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OBI-833-001","December 2, 2014","December 2015","December 2018","September 9, 2016","September 2016","No Study Results Posted","null","December 2017","Safety and tolerability assessed by adverse events, changes in laboratory values, and changes in vital signs.","https://ClinicalTrials.gov/show/NCT02310464"
2291,"NCT00297128","Preoperative Chemoradiation With Capecitabine and Cetuximab","Completed","No Results Available","Rectal Cancer","Drug: Capecitabine|Drug: Cetuximab","Austrian Breast & Colorectal Cancer Study Group|Hoffmann-La Roche|Merck Gesellschaft mbH, Austria","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","31","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG R03 (96) / TAKO 06","February 27, 2006","October 2005","November 2011","December 29, 2011","December 2011","No Study Results Posted","null","August 2011","feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma|collection of response rate (T-downstaging, pCR), correlation of responsiveness with EGFR-status","https://ClinicalTrials.gov/show/NCT00297128"
2292,"NCT01434147","Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy","Completed","No Results Available","Rectal Cancer","Drug: preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine","Austrian Breast & Colorectal Cancer Study Group|Hoffmann-La Roche","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG R05|2010-024354-11","September 13, 2011","October 2011","August 2013","March 6, 2014","March 2014","No Study Results Posted","null","August 2013","termination of therapy|occurence of toxicity|collection of response rate|post-surgery morbidity","https://ClinicalTrials.gov/show/NCT01434147"
2293,"NCT00812864","Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)","Completed","No Results Available","Breast Cancer|Colorectal Cancer","Drug: Capecitabine","University Hospital, Limoges","Both","75 Years and older   (Senior)","Phase 4","20","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","I07028|N° EudraCT : 2008-001195-7","December 19, 2008","January 2009","November 2012","December 4, 2012","September 2009","No Study Results Posted","capagec","October 2011","Mean value and dispersion of the main plasmatics pharmacokinetics parameters of capécitabine, 5'DFUR, 5-FU and FBAL.|Adverse effects evaluation after every course of chemotherapy according to NCI criteria during 6 courses maximum.|Objective response comparing lesions' targets according to RECIST criteria, at course n°3 and n°6.|Quality of life.","https://ClinicalTrials.gov/show/NCT00812864"
2294,"NCT01364844","Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors","Completed","No Results Available","Solid Tumor|Colorectal Cancer|Endometrial Cancer","Drug: DS-7423","Daiichi Sankyo Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","42","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DS7423-A-U101","May 31, 2011","July 2011","November 2013","February 24, 2014","February 2014","No Study Results Posted","null","November 2013","Adverse Events|Plasma pharmacokinetics of DS-7423|Effects of DS-7423 on glucose metabolism|Pharmacodynamic effects of DS-7423 in surrogate tissues|Pharmacodynamic effects of DS-7423 in tumors|Part 2 - Objective response rate in subjects with advanced colorectal and endometrial cancer|Part 2 - Pharmacodynamic effects of DS-7423 in tumors","https://ClinicalTrials.gov/show/NCT01364844"
2295,"NCT02751723","Assessment of Disease Burden and Palliative Care Needs of Patients During the Course of Incurable Cancer Disease","Recruiting","No Results Available","Cancer Disease, Palliative Therapy","Other: validated questionnaires","Florian Lordick, MD|University of Leipzig","Both","18 Years and older   (Adult, Senior)","","500","Other","Observational","Time Perspective: Prospective","APM Project|DRKS00007536","April 14, 2016","September 2014","September 2017","April 21, 2016","April 2016","No Study Results Posted","APM-Project","September 2017","Change from Baseline Patient´s answers regarding symptom burden at 12 months|Change from Baseline physician´s report at 12 months|Change from Baseline Patient´s answers regarding symptom burden at 6 months|Change from Baseline physician´s report at 6 months|Change from Baseline Patient´s answers regarding symptom burden at 3 months|Change from Baseline physician´s report at 3 months","https://ClinicalTrials.gov/show/NCT02751723"
2296,"NCT00033319","Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps","Active, not recruiting","No Results Available","Colorectal Cancer","Dietary Supplement: folic acid|Drug: acetylsalicylic acid","Queen's Medical Centre|National Cancer Institute (NCI)","Both","up to 75 Years   (Child, Adult, Senior)","","null","Other","Interventional","Primary Purpose: Prevention","CDR0000069273|QMC-UKCAP|EU-20045","April 9, 2002","May 1997","null","September 16, 2013","December 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00033319"
2297,"NCT00046995","Combination Chemotherapy in Treating Patients With Colon Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: carboplatin|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: adjuvant therapy","Groupe Regional d'Etudes du Cancer Colorectal|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","800","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000257228|GRECCR-03|EU-20201","October 3, 2002","May 2001","null","September 19, 2013","November 2002","No Study Results Posted","null","null","Disease-free survival|Tolerability|Quality of life","https://ClinicalTrials.gov/show/NCT00046995"
2298,"NCT01440855","Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting","Completed","No Results Available","Prostate Cancer|Breast Cancer|Colorectal Cancer|Thoracic Cancer","Other: CIS (Cancer Information Service) Information Sheet|Other: Facing Forward booklet","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","340","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","IRB06803|U10CA101178-03","September 22, 2011","February 2005","October 2009","September 30, 2011","September 2011","No Study Results Posted","null","October 2009","Reported uptake of behavioral actions recommended in Facing Forward|Usability of Facing Forward","https://ClinicalTrials.gov/show/NCT01440855"
2299,"NCT00740961","Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer","Terminated","No Results Available","Breast Cancer|Cognitive/Functional Effects|Colorectal Cancer|Psychosocial Effects of Cancer and Its Treatment","Behavioral: compliance monitoring|Drug: systemic chemotherapy|Other: medical chart review|Other: study of socioeconomic and demographic variables|Other: survey administration|Procedure: cognitive assessment|Procedure: psychosocial assessment and care","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","65 Years and older   (Adult, Senior)","","63","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","CASE8Y07|P30CA043703","August 22, 2008","March 2008","September 2011","October 1, 2015","October 2015","No Study Results Posted","null","September 2011","Number of impaired domains on Comprehensive Geriatric Assessment (CGA)|Chemotherapy adherence as measured by dose reduction, dose delay, and grade 3-5 toxicities|Vulnerable Elders Survey scores|Functional decline|Time to death|Scores of individual battery of tools included in the CGA","https://ClinicalTrials.gov/show/NCT00740961"
2300,"NCT00003571","Gene Testing in Patients With Colon Cancer","Completed","No Results Available","Colorectal Cancer","Genetic: mutation analysis|Genetic: tumor replication error analysis","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","300","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CALGB-9865|U10CA031946|CLB-9865|CDR0000066637","November 1, 1999","August 1998","January 2006","July 1, 2016","July 2016","No Study Results Posted","null","January 2006","disease free survival|overall survival|tumor replication error status|determine the prognostic and predictive values for response to this therapy","https://ClinicalTrials.gov/show/NCT00003571"
2301,"NCT01601548","Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Ovarian Cancer|Uterine Cancer","Behavioral: Mindfulness Based Cancer Recovery","Masonic Cancer Center, University of Minnesota","Both","18 Years and older   (Adult, Senior)","","45","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2012NTLS014","April 24, 2012","July 2012","July 2013","January 22, 2016","January 2016","No Study Results Posted","null","July 2013","Change in Medical Outcomes Study Scores - Intervention versus Control|Change in Functional Assessment in Cancer Therapy Fatigue Scores - Intervention versus Control|Change in Pittsburgh Sleep Quality Index Scores - Intervention versus Control|Change in State-Trait Anxiety Inventory Scores - Intervention versus Control|Comparison of Sexual Functioning Scale Scores - Intervention versus Control|Change in Self-Compassion Scale Scores - Intervention versus Control|Change in Self-Collected Information - Intervention versus Control|Change in Number of Natural Killer Cells - Intervention versus Control","https://ClinicalTrials.gov/show/NCT01601548"
2302,"NCT00004604","Biological Therapy in Treating Patients With Metastatic Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Head and Neck Cancer|Liver Cancer|Lung Cancer|Metastatic Cancer|Ovarian Cancer|Pancreatic Cancer|Testicular Germ Cell Tumor","Biological: CEA RNA-pulsed DC cancer vaccine","Duke University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000065619|1817","May 2, 2000","February 1997","July 2002","February 21, 2013","February 2013","No Study Results Posted","null","June 2001","Safety|Immune response","https://ClinicalTrials.gov/show/NCT00004604"
2303,"NCT00722228","Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors","Not yet recruiting","No Results Available","Colorectal Cancer|Ovarian Cancer|Gastric Cancer|Breast Cancer|Lung Cancer","Biological: Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated","Hadassah Medical Organization","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other","Interventional","","0359-08-HMO-CTIL","July 23, 2008","null","null","July 24, 2008","July 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00722228"
2304,"NCT00019084","Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer","Completed","No Results Available","Breast Cancer|Cervical Cancer|Colorectal Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer","Biological: aldesleukin|Biological: mutant p53 peptide pulsed dendritic cell vaccine|Biological: ras peptide cancer vaccine|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000064192|NCI-95-C-0105A|NCI-T94-0096N","July 11, 2001","February 1996","May 2003","June 19, 2013","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00019084"
2305,"NCT00898781","Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer","Terminated","No Results Available","Breast Cancer|Colorectal Cancer|Ovarian Cancer|Pancreatic Cancer","","Mayo Clinic|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","80","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDR0000582085|P30CA015083|MC0744|07-006779","May 9, 2009","November 2007","April 2010","July 18, 2011","July 2011","No Study Results Posted","null","April 2010","Frequency of circulating cancer cells (CTC)|Variability in number of CTCs between patients with the same tumor type|Correlation of the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers","https://ClinicalTrials.gov/show/NCT00898781"
2306,"NCT02906943","Ontario-wide Cancer TArgeted Nucleic Acid Evaluation","Recruiting","No Results Available","Breast Cancer|Lung Cancer|Colorectal Cancer|Melanoma|Gynecological Cancer|Genitourinary Cancer|Pancreatobiliary Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Rare Cancer|Unknown Primary Cancer","","University Health Network, Toronto|Princess Margaret Hospital, Canada","Both","18 Years and older   (Adult, Senior)","","10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OCTANE","September 9, 2016","August 2016","August 2021","September 14, 2016","September 2016","No Study Results Posted","OCTANE","August 2021","Number of patients included in a province-wide registry of NGS panel-based testing results|Change in use of NGS panel-based testing in Ontario clinical genetic testing laboratories|Number of patients included in province-wide repository of genomically-characterized tumour tissue and blood samples and their utilization rates for future research|Change in rates of genomics based clinical research in Ontario|Utilization rates of province-wide genomically-characterized and clinically-annotated patient base in enrollment into specific research initiatives|Utilization rates of molecular profiling information provided to treating physicians in guiding future treatment decisions|Percentage of successful linkages between transferred study data and administrative databases|Concordance between administrative data and clinically abstracted data comparing variables using 2x2 concordance tables","https://ClinicalTrials.gov/show/NCT02906943"
2307,"NCT00436410","Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer","Completed","No Results Available","Adrenocortical Carcinoma|Breast Cancer|Colorectal Cancer|Gastrointestinal Cancer|Kidney Cancer|Liver Cancer|Melanoma (Skin)|Ovarian Cancer|Pancreatic Cancer|Sarcoma","Biological: colloidal gold-bound tumor necrosis factor|Other: electron microscopy|Other: pharmacological study|Procedure: conventional surgery","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 0","108","NIH","Interventional","Primary Purpose: Treatment","070043|07-C-0043|NCI-P6066|CYT-NCI-07-C-0043|CDR0000529849","February 15, 2007","December 2006","August 2009","May 1, 2012","May 2012","No Study Results Posted","null","null","Tumor tissue and normal tissue distribution of colloidal gold-bound tumor necrosis factor|Comparison of the impact of distribution time and histology on accumulation of treatment particles in tumor vs normal tissues|Acute antitumor activity of treatment|Long-term toxicity of treatment as assessed by CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00436410"
2308,"NCT01181609","A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum","Completed","Has Results","Colorectal Cancer","Drug: bevacizumab [Avastin]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","54","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18559","July 30, 2010","June 2005","May 2010","July 24, 2014","July 2014","June 4, 2014","null","May 2010","Percentage of Participants Achieving Overall Disease Control (ODC)|Percentage of Participants Achieving a Best Overall Response of CR or PR|Progression-Free Survival (PFS) - Percentage of Participants With an Event|PFS - Time to Event|Duration of Response|Duration of Overall Disease Control|Overall Survival (OS) - Percentage of Participants With an Event|OS - Time to Event","https://ClinicalTrials.gov/show/NCT01181609"
2309,"NCT02713984","A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer","Recruiting","No Results Available","Breast Cancer|Ovarian Cancer|Lung Cancer|Gastric Cancer|Colorectal Cancer|Glioma|Pancreatic Cancer","Biological: Anti-HER2 CAR-T","Zhi Yang|Southwest Hospital, China","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","60","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TMMU-BTC-005","March 12, 2016","March 2016","September 2019","April 1, 2016","April 2016","No Study Results Posted","null","September 2018","Determine the toxicity profile of the HER2 targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.|Survival time of Anti-HER2 CAR T cells in vivo.|Efficacy of anti-HER2 CAR T cells to confirm the ability of CAR T cells to eliminate HER2 positive cancer cells|Maximum tolerated dose (MTD) of HER2 targeted CAR T cells","https://ClinicalTrials.gov/show/NCT02713984"
2310,"NCT01588262","Early Rehabilitation of Cancer Patients","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Lymphoma|Prostate Cancer|Testicle Cancer","Other: Stressmanagement","Haukeland University Hospital|University of Bergen|Uppsala University|University of Agder","Both","18 Years to 81 Years   (Adult, Senior)","","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","REKnr 2010/1911","January 30, 2012","May 2011","August 2015","October 12, 2015","October 2015","No Study Results Posted","null","August 2015","Change in psychosocial status|Cost effectiveness of the stress-management intervention.","https://ClinicalTrials.gov/show/NCT01588262"
2311,"NCT02781935","Diffusion-Weighted MRI for Liver Metastasis","Not yet recruiting","No Results Available","Colorectal Cancer|Colon Cancer Liver Metastasis|Malignant Neoplasm of Rectum Metastatic to Liver","Procedure: DW-MRI","European Organisation for Research and Treatment of Cancer - EORTC|Japan Clinical Oncology Group|European Society of Surgical Oncology","Both","18 Years and older   (Adult, Senior)","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EORTC-1527","May 17, 2016","September 2016","September 2021","May 20, 2016","May 2016","No Study Results Posted","DREAM","September 2021","Negative Predictive Value (NPV) of the diagnostic imaging (DW-MRI)|NPV of diagnostic imaging among the group of resected confirmed DLMs|NPV of diagnostic imaging in the group of confirmed DLMs that were left in place|NPV of DW-MRI in the group of cDLMs diagnosed by central imaging review|Correlation between different types of morphologic and ADC changes and TRG to the type of conversion therapy|Correlation between findings on DW-MRI to histopathology, recurrence rate, complication rates, PFS and OS|Long term outcomes of patients who underwent surgery in terms of: - recurrence rates for 2 years after surgery - progression free survival for 2 years after surgery - overall survival for 2 years after surgery","https://ClinicalTrials.gov/show/NCT02781935"
2312,"NCT00550628","Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer","Completed","No Results Available","Colorectal Cancer|Neoplasm of Uncertain Malignant Potential","Genetic: DNA methylation analysis|Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: diagnostic laboratory biomarker analysis|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Procedure: biopsy|Procedure: therapeutic conventional surgery|Radiation: fludeoxyglucose F 18","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","15 Years and older   (Child, Adult, Senior)","","8","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","07-114|P30CA008748|MSKCC-07114","October 25, 2007","September 2007","September 2011","December 22, 2015","December 2015","No Study Results Posted","null","September 2011","Feasibility of ex-vivo imaging of colon cancer and colon polyps using fludeoxyglucose F 18 positron emission tomography (FDG PET)|Differences in molecular and genetic profiles between FDG-positive polyps and FDG-negative polyps to suggest what gene mutations and abnormal mRNA and/or protein expressions may be required for FDG avidity (""signature"" for FDG avidity)|Differences in molecular and genetic profiles between FDG-positive polyps and FDG-positive cancers to suggest what gene mutations and abnormal mRNA and/or protein expressions may be required for cancer formation (""signature"" for cancer)|Differences in molecular and genetic profiles between normal colonic mucosa, polyps, and cancer|Differences and similarities in molecular and genetic profiles between FDG-positive cancers and polyps","https://ClinicalTrials.gov/show/NCT00550628"
2313,"NCT02874885","Circulating Tumor Cells in Patients With Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: Blood Draws","M.D. Anderson Cancer Center|American Society of Colon and Rectal Surgeons Research Foundation","Both","18 Years and older   (Adult, Senior)","","520","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","PA13-0547","August 17, 2016","September 2013","null","August 17, 2016","August 2016","No Study Results Posted","null","September 2023","Change in Circulating Tumor Cell (CTC) Status","https://ClinicalTrials.gov/show/NCT02874885"
2314,"NCT00019331","Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors","Completed","No Results Available","Colorectal Cancer|Endometrial Cancer|Head and Neck Cancer|Liver Cancer|Lung Cancer|Melanoma (Skin)|Pancreatic Cancer|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific","Biological: aldesleukin|Biological: ras peptide cancer vaccine|Biological: sargramostim|Drug: DetoxPC","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000065656|NCI-97-C-0141F|NCI-T96-0078","July 11, 2001","October 1997","May 2007","June 19, 2013","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00019331"
2315,"NCT00489515","Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder","Completed","No Results Available","Colorectal Cancer|Gallbladder Cancer|Gastric Cancer|Pancreatic Cancer|Small Intestine Cancer","","Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","","115","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDR0000550095|CCCWFU-99B98|CCCWFU-BG99-047","June 20, 2007","February 1999","August 2010","October 22, 2015","October 2015","No Study Results Posted","null","June 2009","Safety, as determined by the number of adverse events resulting from procedure|Ability of surgically defined sentinel lymph nodes to predict whether other lymph nodes are involved with the tumor","https://ClinicalTrials.gov/show/NCT00489515"
2316,"NCT00613080","Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer","Active, not recruiting","Has Results","Colorectal Cancer","Drug: capecitabine|Drug: oxaliplatin|Procedure: resection|Radiation: radiation therapy|Drug: FOLFOX","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","Both","18 Years and older   (Adult, Senior)","Phase 2","79","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0822|CDR0000586277","February 9, 2008","April 2008","null","October 13, 2015","October 2015","April 12, 2013","null","January 2010","The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Critereia for Adverse Events (CTCAE) v. 3.0, Occurring Preoperatively|Intensity-modulated Radiotherapy (IMRT) Feasibility|Pathologic Complete Response Rate|All Treatment-related Adverse Events Per NCI CTCAE v3.0 Preoperative, Postoperative, and Overall|Patterns of Failure (i.e., Local, Regional, and Distant), Including Overall Survival (Death Due to Any Cause)|Rate of Anterior Posterior Resections","https://ClinicalTrials.gov/show/NCT00613080"
2317,"NCT00896753","Gene Expression Profiling in Normal Tissue and Tumor Tissue From Patients With Colon Cancer That Has Spread to the Liver, Lungs, or Peritoneum","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","","Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI)","Both","up to 120 Years   (Child, Adult, Senior)","","10","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CDR0000550060|CCCWFU-89B03|CCCWFU-BG03-403","May 9, 2009","September 2003","May 2008","September 30, 2015","September 2015","No Study Results Posted","null","September 2006","Gene expression changes that occur at each metastatic site (i.e., liver, lungs, and peritoneum)|Development of cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum","https://ClinicalTrials.gov/show/NCT00896753"
2318,"NCT02704832","Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)","Not yet recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer|Bladder Cancer|Ovarian Cancer|Lymphoma","Other: Geriatrician Intervention","Institut Bergonié|Ministry of Health, France","Both","70 Years and older   (Senior)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","IB 2015-08|ID-RCB number 2015-A01417-42","February 19, 2016","March 2016","February 2021","March 18, 2016","March 2016","No Study Results Posted","PREPARE","February 2019","Overall survival defined as the delay between randomization and death, all causes.|Health related quality of life (HR-QoL) assessed using 3 scales of European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.|Health related quality of life (hRQoL) assessed using 3 scales of EORTC QLQ-C30 questionnaire.|6-month response rates defined as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 or Cheson criteria.|Toxicity graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.|Number of unscheduled hospitalizations.|Length of unscheduled hospitalizations.|For the experimental arm only: Assessment of autonomy using Activities of Daily Living (ADL) questionnaire.|For the experimental arm only: Assessment of autonomy using Instrumental Activities of Daily Living (IADL) questionnaire.|For the experimental arm only: Assessment of depression using Geriatric Depression Scale (GDS-15) scale.|For the experimental arm only: Assessment of cognitive functions using mini mental state exam (MMSE).|For the experimental arm only: Assessment of comorbidities using Cumulative Illness Rating Scale for Geriatrics (CIRS-G) scale.|For the experimental arm only: Assessment of nutritional status using mini nutritional assessment (MNA) scale.|For the experimental arm only: Assessment of mobility using get-up and Go test.","https://ClinicalTrials.gov/show/NCT02704832"
2319,"NCT00336960","Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery","Completed","No Results Available","Colorectal Cancer","Drug: celecoxib|Drug: fluorouracil|Procedure: conventional surgery|Radiation: radiation therapy|Procedure: tumor biopsy|Other: laboratory biomarker analysis","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC GI 0173|P50CA095103|P30CA068485|VICC-GI-0173|VICC-020031","June 13, 2006","July 2002","March 2008","March 2, 2013","March 2013","No Study Results Posted","null","November 2004","Pathologic complete response rate|Complete resection rate|Patterns of failure|Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00336960"
2320,"NCT00002593","S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: levamisole hydrochloride","Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group","Both","18 Years and older   (Adult, Senior)","Phase 3","1135","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000063773|SWOG-9415|CLB-9498|INT-0153|U10CA032102","November 1, 1999","December 1994","March 2005","January 2, 2013","January 2013","No Study Results Posted","null","December 1999","Compare effectiveness of bolus 5-FU, leucovorin, levamisole vs continuous infusion 5-FU, levamisole as adjuvant therapy for patients with colon cancer, measured in overall survival|Disease free survival","https://ClinicalTrials.gov/show/NCT00002593"
2321,"NCT00900094","UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Esophageal Cancer|Liver Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer","Genetic: fluorescence in situ hybridization|Genetic: polymerase chain reaction|Genetic: protein expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: mass spectrometry","University of Michigan Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","200","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDR0000276589|U01CA084982|P30CA046592|CCUM-0003","May 9, 2009","June 2000","October 2007","February 5, 2012","February 2012","No Study Results Posted","IRB 2000-294","December 2006","Identification of tumor antigens that induce a humoral response in cancer patients|Identification of tumor-secreted proteins by special analysis in culture|Tumor-secreted protein expression in tumors and preneoplastic lesions|Potential markers for early detection of cancer","https://ClinicalTrials.gov/show/NCT00900094"
2322,"NCT00544336","Family Quality of Life Among Families With a Member Who is a Cancer Patient","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Prostate Cancer|Solid Tumor","Other: questionnaire administration|Other: survey administration|Procedure: quality-of-life assessment","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","21 Years and older   (Adult, Senior)","","366","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","VICC SUPP 0737|VU-VICC-SUPP-0737|VU-VICC-IRB-IRB-070598","October 13, 2007","August 2007","May 2009","September 7, 2012","September 2012","No Study Results Posted","null","February 2009","Preliminary validation of a family quality of life questionnaire|Generation of an initial item pool (step 1)|Reduction of the item pool based on content validity assessment (step 2)|Psychometric properties and dimensionality of the measure (step 3)","https://ClinicalTrials.gov/show/NCT00544336"
2323,"NCT00112918","Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer","Completed","Has Results","Colorectal Cancer","Biological: Bevacizumab|Drug: Capecitabine|Drug: 5-Fluorouracil (5-FU)|Drug: Leucovorin calcium|Drug: Oxaliplatin","Hoffmann-La Roche|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","3451","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000427299|P30CA016042|UCLA-0412086-01|ROCHE-BO17920A","June 2, 2005","December 2004","June 2012","June 19, 2013","June 2013","June 1, 2012","null","June 2010","Disease-free Survival in Stage III Cancer Patients - Time to Event|Disease-free Survival in Stage III Cancer Patients - Number of Events|Overall Survival in Stage III Cancer Patients - Time to Event|Overall Survival in Stage III Cancer Patients - Number of Events|Overall Survival in Stage III Cancer Patients - Time to Event: Final Analysis|Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis","https://ClinicalTrials.gov/show/NCT00112918"
2324,"NCT00004065","Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer","Completed","No Results Available","Bladder Cancer|Breast Cancer|Colorectal Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Leukemia|Lung Cancer|Melanoma (Skin)|Ovarian Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: tanespimycin","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","99-037|CDR0000067267|NCI-T99-0035|UCLA-0206019","December 10, 1999","July 1999","March 2005","June 20, 2013","June 2013","No Study Results Posted","null","March 2005","","https://ClinicalTrials.gov/show/NCT00004065"
2325,"NCT01535040","Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking","Completed","Has Results","Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer|Tobacco Use Disorder","Drug: memantine hydrochloride|Drug: placebo","Wake Forest NCORP Research Base|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","130","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","CCCWFU 99311|U10CA081851","February 14, 2012","August 2012","February 2014","July 15, 2015","July 2015","January 12, 2015","null","February 2014","Retention|Adherence|Nicotine Dependence|Smoking Withdrawal","https://ClinicalTrials.gov/show/NCT01535040"
2326,"NCT02640781","Comparison of Efficacy Between a Newly Designed Covered Stent and Uncovered Stent for Malignant Colorectal Obstruction","Not yet recruiting","No Results Available","Colorectal Cancer","Device: self-expandable metal stent insertion","Yonsei University","Both","20 Years to 85 Years   (Adult, Senior)","","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","1-2015-0046","December 10, 2015","December 2015","December 2017","December 22, 2015","December 2015","No Study Results Posted","null","December 2017","Duration of stent patency between stent insertion and recurrence of obstructive symptoms|Number of patients with technical success|Number of patients with clinical success|Number of patients with complications","https://ClinicalTrials.gov/show/NCT02640781"
2327,"NCT00003427","Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer","Completed","No Results Available","Anal Cancer|Colorectal Cancer|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Liver Cancer|Pancreatic Cancer|Small Intestine Cancer","Drug: irinotecan hydrochloride|Drug: oxaliplatin","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","36","Other|NIH","Interventional","Primary Purpose: Treatment","98-034|CDR0000066452|NCI-G98-1450","November 1, 1999","April 1998","April 2002","June 24, 2013","June 2013","No Study Results Posted","null","April 2002","","https://ClinicalTrials.gov/show/NCT00003427"
2328,"NCT00004891","PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery","Completed","No Results Available","Colorectal Cancer","Drug: chemotherapy|Procedure: computed tomography|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Procedure: positron emission tomography|Procedure: radionuclide imaging|Radiation: fludeoxyglucose F 18|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","","149","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","MSKCC-99048|CDR0000067567|NCI-G00-1695","March 7, 2000","September 1999","null","December 21, 2015","December 2015","No Study Results Posted","null","March 2007","Determine if fludeoxyglucose F 18 positron emission tomography (FDG-PET) is superior to CT scan|Determine the accuracy of FDG-PET","https://ClinicalTrials.gov/show/NCT00004891"
2329,"NCT00369109","Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Pancreatic Cancer","Other: biologic sample preservation procedure|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: biopsy","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","60","Other|NIH","Observational","","CDR0000479118|P30CA022453|WSU-2005-039|ZENECA-D1040M00003|WSU-0512003224","August 24, 2006","February 2006","June 2007","April 5, 2013","April 2013","No Study Results Posted","null","November 2006","Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors|Characterization of the method for measurement (immunohistochemistry)|Inter- and intra-patient variability for the biomarker|Dynamic time course of p-Chk1 and p-H2AX after administration of a DNA-damaging agent","https://ClinicalTrials.gov/show/NCT00369109"
2330,"NCT00075868","Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer","Completed","No Results Available","Anal Cancer|Colorectal Cancer|Drug/Agent Toxicity by Tissue/Organ|Radiation Enteritis","Drug: octreotide acetate|Other: Placebo","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","Phase 3","233","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Supportive Care","RTOG-0315|CDR0000349441","January 9, 2004","December 2003","null","November 14, 2015","November 2015","No Study Results Posted","null","August 2006","Prevention of the incidence of moderate, severe, or life-threatening diarrhea|Quality of life|Economic measures|Validity of the Functional Alterations due to Changes in Elimination-Changes in Bowel Function, the Quality of Life-Radiation Therapy Instrument, and the Expand Prostate Index Composite-Bowel questionnaires|Prevention of the incidence of severe or life-threatening (i.e., grade 3-5) diarrhea","https://ClinicalTrials.gov/show/NCT00075868"
2331,"NCT00280176","Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: bortezomib|Drug: fluorouracil|Radiation: radiation therapy","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","11","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 0209|CDR0000549844","January 18, 2006","April 2003","September 2010","February 12, 2012","February 2012","No Study Results Posted","null","November 2008","Maximum tolerated dose|Dose-limiting toxicity|Dose-effect relationship of bortezomib on NF-kappa B activation induced by chemoradiotherapy|Downstream events induced by NF-kappa B activation|Downstream events related to activation of p53 in response to treatment with chemoradiotherapy and bortezomib|Rate of complete pathologic remission|Gene expression pattern of tumors as assessed by cDNA microarray analysis pre- and post-treatment","https://ClinicalTrials.gov/show/NCT00280176"
2332,"NCT00620295","Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Sarcoma","Drug: bortezomib|Drug: gemcitabine hydrochloride","Masonic Cancer Center, University of Minnesota","Both","70 Years and older   (Senior)","Phase 1","17","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000586510|UMN-2006LS040|UMN-X05227|x464","February 20, 2008","March 2007","October 2009","November 6, 2012","November 2012","No Study Results Posted","null","February 2009","Maximum tolerated dose of bortezomib and gemcitabine|Toxicity|Disease response as measured by RECIST criteria|Characterization of gemcitabine and metabolite pharmacokinetics (as part of co-enrollment in Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors"")","https://ClinicalTrials.gov/show/NCT00620295"
2333,"NCT00003329","Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer","Genetic: gene mapping","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","4000","Other|NIH","Observational","","CDR0000066283|U10CA021115|ECOG-1Y97","November 1, 1999","January 1998","null","April 2, 2013","March 2008","No Study Results Posted","null","December 2007","","https://ClinicalTrials.gov/show/NCT00003329"
2334,"NCT00114231","Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: oxaliplatin|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","90","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACOSOG-Z6041|U10CA180821|U10CA076001|CDR0000433145","June 13, 2005","May 2006","null","July 1, 2016","July 2016","No Study Results Posted","null","October 2020","Disease-free survival|Rate of resectability as measured by the pathology report at surgery|morbidity and mortality rate|Rate of pathologic complete response of the primary tumor|Local-failure-free survival","https://ClinicalTrials.gov/show/NCT00114231"
2335,"NCT00002520","Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer","Completed","No Results Available","Bladder Cancer|Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Lymphoma|Prostate Cancer|Testicular Germ Cell Tumor|Tobacco Use Disorder|Unspecified Adult Solid Tumor, Protocol Specific","Drug: nicotine|Behavioral: Usual Care","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","19 Years to 120 Years   (Adult, Senior)","","434","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","CDR0000078281|U10CA021115|E-1Y92|NCI-P93-0042","November 1, 1999","June 1992","null","October 6, 2015","October 2015","No Study Results Posted","null","February 2002","Rate of Smoking Cessation at 6 months","https://ClinicalTrials.gov/show/NCT00002520"
2336,"NCT00081289","Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer","Completed","Has Results","Colorectal Cancer","Radiation: Radiation Therapy|Drug: Capecitabine 1650 mg/m^2/day|Drug: Capecitabine 1200 mg/m^2/day|Drug: Irinotecan|Drug: Oxaliplatin|Procedure: Surgery|Drug: Folinic Acid|Drug: Fluorouracil|Drug: Oxaliplatin","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","146","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0247|CDR0000350136","April 7, 2004","March 2004","null","November 14, 2015","November 2015","May 23, 2013","null","May 2011","Pathologic Complete Response Rate|Time to Treatment Failure and Patterns of Failure|Incidence of Hematologic and Non-hematologic Grade 3-4 Toxicity (Preoperatively, Postoperatively, and Overall)|Tumor Marker Evaluation Using Preoperative Tissue Biopsy Specimens and Surgically Resected Tissue Specimens|Quality of Life as Assessed After Completion of Chemoradiotherapy and Adjuvant Chemotherapy and Then at 2 Years","https://ClinicalTrials.gov/show/NCT00081289"
2337,"NCT02215577","ALPPS Versus PVE/PL","Recruiting","No Results Available","Colorectal Cancer|Liver Metastases","Procedure: In-situ split|Procedure: Portal embolization or ligation","Regionalt Cancercentrum Väst","Both","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","SweLiv 1-2014","August 11, 2014","June 2014","December 2018","August 12, 2014","August 2014","No Study Results Posted","LIGRO","December 2016","Surgical success rate, the rate of liver resection in each study arm|Liver growth rate","https://ClinicalTrials.gov/show/NCT02215577"
2338,"NCT00899626","Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Patients and Healthy Participants Undergoing Colonoscopy, Endoscopy, or Surgery","Recruiting","No Results Available","Colorectal Cancer|Esophageal Cancer|Gastric Cancer|Pancreatic Cancer|Precancerous Condition","Genetic: protein analysis|Genetic: proteomic profiling|Other: biologic sample preservation procedure|Other: laboratory biomarker analysis|Other: medical chart review|Procedure: diagnostic colonoscopy|Procedure: diagnostic endoscopic procedure|Procedure: diagnostic endoscopic surgery|Procedure: diagnostic surgical procedure|Procedure: endoscopic surgery|Procedure: screening colonoscopy","Vanderbilt University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","1000","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","CDR0000584214|P30CA068485|VU-VICC-GI-0283|VU-VICC-010680","May 9, 2009","June 2002","null","January 21, 2013","January 2013","No Study Results Posted","null","June 2016","Identification of new potential biomarkers of increased gastrointestinal cancer risk using tissue and biofluid samples from patients and healthy volunteers undergoing colonoscopy, endoscopy, or surgery|Development of new screening strategies based on substances found in tissue and biofluid samples","https://ClinicalTrials.gov/show/NCT00899626"
2339,"NCT01677728","Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases","Recruiting","No Results Available","Colorectal Cancer|Liver Tumor","","Xu jianmin|Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","","60","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","ZSTCC|Xjianmin","August 30, 2012","January 2007","December 2014","August 30, 2012","August 2012","No Study Results Posted","null","December 2013","","https://ClinicalTrials.gov/show/NCT01677728"
2340,"NCT00002475","Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Malignant Mesothelioma|Pancreatic Cancer","Biological: allogeneic tumor cell vaccine|Biological: autologous tumor cell vaccine|Biological: recombinant interferon alfa|Biological: recombinant interferon gamma|Biological: sargramostim|Drug: cyclophosphamide","St. Vincent Medical Center - Los Angeles|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Primary Purpose: Treatment","SVMC-ONC-222|CDR0000076913|NCI-V91-0075","November 1, 1999","April 1991","June 2009","July 9, 2013","November 2008","No Study Results Posted","null","December 2007","Clinical response (patients with evaluable disease)|Duration of response (patients with evaluable disease)|Survival (patients with evaluable disease)|Time to recurrence (patients without evaluable disease)|Survival (patients without evaluable disease)","https://ClinicalTrials.gov/show/NCT00002475"
2341,"NCT00410618","Neurological Effects of Chemotherapy and Radiation Therapy in Patients With Colon Cancer","Completed","No Results Available","Cognitive/Functional Effects|Colorectal Cancer|Long-term Effects Secondary to Cancer Therapy in Adults","Procedure: cognitive assessment|Procedure: magnetic resonance imaging|Procedure: management of therapy complications","University of Arizona|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","42","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HSCB0213|P50CA095060|P30CA023074|UARIZ-BSC-02-13","December 11, 2006","April 2003","August 2006","December 2, 2015","August 2012","No Study Results Posted","null","August 2006","Nature and long-term ramifications of CNS injury as a result of cancer treatment|Differences in cognitive measures and MRI data|Relationship between MRI measures and cognitive performance","https://ClinicalTrials.gov/show/NCT00410618"
2342,"NCT00478010","Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer|Pancreatic Cancer|Psychosocial Effects of Cancer and Its Treatment","Other: counseling intervention|Other: study of socioeconomic and demographic variables|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","200","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Health Services Research","JHOC-J0666, CDR0000530879|P30CA006973|JHOC-J0666|JHOC-NA_00003458","May 23, 2007","January 2007","null","August 5, 2010","August 2010","No Study Results Posted","null","December 2008","Participation|Decision satisfaction","https://ClinicalTrials.gov/show/NCT00478010"
2343,"NCT01016028","Chemotherapy-Induced Peripheral Neuropathy Survey","Withdrawn","No Results Available","Breast Cancer|Colorectal Cancer|Myeloma|Chemotherapy-induced Peripheral Neuropathy","Behavioral: Questionnaire|Behavioral: Sensory Tests|Behavioral: Interview","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","","0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2009-0439","November 17, 2009","November 2009","February 2013","April 29, 2016","February 2013","No Study Results Posted","null","February 2013","Assessment of Patient's Symptoms (Questionnaire)","https://ClinicalTrials.gov/show/NCT01016028"
2344,"NCT00059891","Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer","Completed","No Results Available","Anal Cancer|Colorectal Cancer|Perioperative/Postoperative Complications","Procedure: conventional surgery|Procedure: management of therapy complications","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","4","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","02-124|P30CA008748|MSKCC-02124","May 6, 2003","January 2003","October 2009","February 26, 2013","February 2013","No Study Results Posted","null","October 2009","Determine the risk of complications and feasibility of total anorectal reconstruction using the Acticon Neosphincter prosthesis after abdominoperineal resection in patients with anal or rectal cancer.|Determine continence, bowel function, and quality of life of patients treated with this surgery.","https://ClinicalTrials.gov/show/NCT00059891"
2345,"NCT00819208","Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer","Recruiting","No Results Available","Anxiety Disorder|Cognitive/Functional Effects|Colorectal Cancer|Depression|Fatigue|Psychosocial Effects of Cancer and Its Treatment|Sleep Disorders|Excercise","Behavioral: exercise intervention|Other: counseling intervention|Other: educational intervention|Other: laboratory biomarker analysis|Other: questionnaire administration|Other: study of socioeconomic and demographic variables|Procedure: fatigue assessment and management|Procedure: quality-of-life assessment|Other: Educational Intervention|Other: Fitness testing","Canadian Cancer Trials Group|Survivorship Research Group","Both","18 Years and older   (Adult, Senior)","Phase 3","962","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","CO21|CAN-NCIC-CO21|CDR0000629834","January 7, 2009","December 2008","December 2030","July 12, 2016","March 2016","No Study Results Posted","null","December 2029","Disease-free survival|Overall survival|Patient-reported outcomes, including quality of life, using SF-36, FACIT-F, PSQI, and HADS questionnaires|Objective markers of physical fitness (i.e., body mass index, hip and waist circumference, cardiovascular fitness, and physical function)|Physical activity behavior as assessed by TPAQ|Safety profile according to NCI CTCAE version 3.0|Correlative biological markers including biochemical and molecular markers associated with insulin-related growth factor and cytokines associated with the mechanisms of fatigue|Economic evaluations including cost-effective analysis and cost utility analysis|Predictors of physical activity adherence as assessed by Social Cognitive Determinants of Exercise questionnaire","https://ClinicalTrials.gov/show/NCT00819208"
2346,"NCT00002551","SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: levamisole hydrochloride|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Radiation Therapy Oncology Group|North Central Cancer Treatment Group|NCIC Clinical Trials Group|Cancer and Leukemia Group B","Both","18 Years and older   (Adult, Senior)","Phase 3","1917","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000063349|SWOG-9304|CAN-NCIC-CO11|NCCTG-934751|RTOG-9403|CLB-C9491|INT-0144|U10CA032102","November 1, 1999","March 1994","October 2008","April 3, 2013","April 2013","No Study Results Posted","null","August 2006","Survival and Relapse-free survival","https://ClinicalTrials.gov/show/NCT00002551"
2347,"NCT00128622","Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: denileukin diftitox|Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine|Biological: therapeutic autologous dendritic cells","H. Kim Lyerly|National Cancer Institute (NCI)|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000437795|DUMC-NCI-7042|NCI-7042","August 8, 2005","September 2005","May 2009","November 8, 2012","November 2012","No Study Results Posted","null","March 2007","Safety as measured by rate of adverse events during study drug treatment|Rate of immune response as measured by ELISPot at week 10","https://ClinicalTrials.gov/show/NCT00128622"
2348,"NCT00003103","Chemotherapy in Treating Patients With Solid Tumors","Completed","No Results Available","Bladder Cancer|Breast Cancer|Colorectal Cancer|Esophageal Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Ovarian Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: oblimersen sodium|Drug: docetaxel","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","57","Other","Interventional","Primary Purpose: Treatment","97-096|CDR0000065836|GENTA-G3139-97/01|NCI-G97-1337","November 1, 1999","August 1997","August 2002","July 1, 2013","July 2013","No Study Results Posted","null","August 2002","","https://ClinicalTrials.gov/show/NCT00003103"
2349,"NCT00321828","Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery","Completed","Has Results","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: leucovorin|Drug: oxaliplatin","NSABP Foundation Inc|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","90","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP C-10|U10CA012027|CDR0000463513","May 2, 2006","March 2006","December 2012","January 16, 2013","January 2013","October 31, 2012","null","November 2009","Major Morbidity Related to the Intact Primary Tumor|Local Complications as Assessed by Colonic Obstruction Requiring Hospitalization (But Not Surgery) for Medical Management, Stent Placement, Laser Treatment, or Fulguration|Local Complications as Assessed by Gastrointestinal Bleeding Requiring Transfusion But Not Requiring Surgery|Local Complications as Assessed by Fistula Formation (Self-draining Enterocutaneous Fistula and Intra-abdominal Abscess Requiring Percutaneous Drainage) Not Requiring Surgery|Local Complications as Assessed by Other Events Related to the Intact Primary Tumor Which Require Hospitalization But Not Surgery|Serious Adverse Events (Grades 3, 4, and 5) as Defined by CTCAE v3.0|Overall Survival as Measured by Death From Any Cause","https://ClinicalTrials.gov/show/NCT00321828"
2350,"NCT02217891","IFACT: Incidental Findings in Advanced Cancer Therapy","Enrolling by invitation","No Results Available","Breast Cancer|Colorectal Cancer|Bladder Cancer|Lung Cancer","Behavioral: Semi-structured interview","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","14-159","August 13, 2014","August 2014","null","January 21, 2016","January 2016","No Study Results Posted","IFACT","August 2017","qualitive data","https://ClinicalTrials.gov/show/NCT02217891"
2351,"NCT00950144","Studying Pain and Symptom Distress in Patients With Advanced Colon Cancer, Rectal Cancer, Pancreatic Cancer, or Liver Cancer","Completed","No Results Available","Colorectal Cancer|Depression|Fatigue|Liver Cancer|Pain|Pancreatic Cancer","Other: medical chart review|Other: questionnaire administration|Other: study of socioeconomic and demographic variables|Procedure: quality-of-life assessment","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","123","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","08131|P30CA033572|CHNMC-08131|CDR0000632905","July 30, 2009","December 2008","October 2010","February 28, 2011","February 2011","No Study Results Posted","null","October 2010","Illness perception as indicated in the five domains of the Common Sense Model (i.e., identity, cause, time line, consequences, controllability) and their relationship to symptom distress|Pain and other symptoms, and their relationship to overall symptom distress|Overall quality of life (QOL) and its specific summary scales|Relationship among characteristics (i.e., sociodemographic, disease, health status) associated with illness perceptions, overall symptom distress, and QOL)","https://ClinicalTrials.gov/show/NCT00950144"
2352,"NCT00873600","Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer","Withdrawn","No Results Available","Breast Cancer|Cognitive/Functional Effects|Colorectal Cancer|Psychosocial Effects of Cancer and Its Treatment","Drug: chemotherapy|Other: medical chart review|Other: questionnaire administration|Procedure: adjuvant therapy|Procedure: assessment of therapy complications|Procedure: cognitive assessment|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","65 Years and older   (Adult, Senior)","","0","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","CASE4Y07|P30CA043703","March 31, 2009","October 2007","null","March 17, 2015","March 2015","No Study Results Posted","null","null","Chemotherapy tolerability as measured by dose reduction, treatment delay, and incidence of grade 3-5 toxicities|Mean change in comprehensive geriatric assessment scores and quality-of-life scores from baseline to post-chemotherapy and from baseline to 12 months following randomization|Number of emergency room visits, acute hospitalizations, and associated Medicare costs within the first 12 months following randomization|3-year disease-free survival","https://ClinicalTrials.gov/show/NCT00873600"
2353,"NCT00027534","Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Gallbladder Cancer|Gastric Cancer|Head and Neck Cancer|Liver Cancer|Ovarian Cancer|Pancreatic Cancer|Testicular Germ Cell Tumor","Biological: TRICOM-CEA(6D)","Michael Morse, MD|National Cancer Institute (NCI)|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 1","14","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2840|1R21CA094523|CDR0000069041","December 7, 2001","January 2002","October 2007","September 4, 2014","September 2014","No Study Results Posted","null","October 2007","Safety|Immune response","https://ClinicalTrials.gov/show/NCT00027534"
2354,"NCT00335491","Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors","Completed","No Results Available","Bladder Cancer|Breast Cancer|Colorectal Cancer|Esophageal Cancer|Fatigue|Lung Cancer|Lymphoma|Ovarian Cancer|Prostate Cancer","Behavioral: exercise intervention|Procedure: complementary or alternative medicine procedure|Procedure: fatigue assessment and management|Procedure: physical therapy","University of Utah|National Cancer Institute (NCI)","Both","60 Years and older   (Adult, Senior)","","49","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Supportive Care","14551|R21CA114523|P30CA042014|UUMC-R21CA114523","June 8, 2006","March 2006","March 2010","September 28, 2011","September 2011","No Study Results Posted","null","March 2010","Patient perception and pattern of change|Structural and function changes","https://ClinicalTrials.gov/show/NCT00335491"
2355,"NCT00004910","Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction","Completed","No Results Available","Colorectal Cancer|Constipation, Impaction, and Bowel Obstruction|Extrahepatic Bile Duct Cancer|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Gastrointestinal Stromal Tumor|Pancreatic Cancer|Quality of Life|Small Intestine Cancer","Procedure: bowel obstruction management|Procedure: quality-of-life assessment","Northwestern University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Supportive Care","NU 98CC2|NU-98CC2|NCI-G00-1703","March 7, 2000","January 2000","February 2003","May 31, 2012","May 2012","No Study Results Posted","null","February 2003","","https://ClinicalTrials.gov/show/NCT00004910"
2356,"NCT01415089","Tailored Web-Based Intervention for Cancer Patients and Family Caregivers","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer","Behavioral: FOCUS-Web","University of Michigan|National Cancer Institute (NCI)|Wayne State University|Barbara Ann Karmanos Cancer Institute|Saint Joseph Mercy Health System","Both","18 Years and older   (Adult, Senior)","","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","R21CA138725","August 10, 2011","May 2009","June 2011","June 15, 2015","October 2013","No Study Results Posted","FOCUS-WEB","June 2011","Quality of life|Communication|Dyadic support|Self-efficacy|Perceived benefits of illness|Emotional distress|Satisfaction with intervention","https://ClinicalTrials.gov/show/NCT01415089"
2357,"NCT00004042","Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer","Completed","No Results Available","Colorectal Cancer","Biological: monoclonal antibody F19|Radiation: iodine I 131 monoclonal antibody F19","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Other|NIH","Interventional","Primary Purpose: Treatment","BOEH-1152.1|MSKCC-98068|CDR0000066903|LUDWIG-LUD98-002|NCI-H99-0025","December 10, 1999","November 1998","December 2009","July 17, 2013","December 2009","No Study Results Posted","null","July 2001","","https://ClinicalTrials.gov/show/NCT00004042"
2358,"NCT00859768","The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients","Completed","No Results Available","Breast Cancer|Lung Cancer|Prostate Cancer|Bladder Cancer|Cervix Cancer|Cancer of Endometrium|Cancer of Skin|Non-Hodgkin Lymphoma|Colorectal Cancer","Other: Questionnaire administration","Netherlands Open University|Dutch Cancer Society|Maastricht University Medical Center|Institute Verbeeten|Maastro Clinic, The Netherlands","Both","18 Years and older   (Adult, Senior)","","568","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","MB254|Dutch Cancer Society","March 10, 2009","April 2008","October 2010","March 7, 2011","March 2009","No Study Results Posted","null","October 2010","The primary effect outcome measurement is the number and type of referred patients with psychosocial problems to psychosocial caregivers and type of referrals with respect to psychosocial problems.|The secondary outcome measurements are patients' satisfaction with the radiotherapist-patient communication, psychosocial distress and quality of life.","https://ClinicalTrials.gov/show/NCT00859768"
2359,"NCT00628368","Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer","Recruiting","No Results Available","Colorectal Cancer|Esophageal Cancer","Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Procedure: biopsy|Procedure: endoscopic biopsy","Institut du Cancer de Montpellier - Val d'Aurelle|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","160","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Diagnostic","CDR0000574175|CLCC-EGFR-BIO|INCA-RECF0366","March 1, 2008","November 2005","null","December 13, 2009","July 2009","No Study Results Posted","null","September 2009","Role of predictive factors in the EGFR signaling pathway in response to treatment|Establishment of a tissue bank","https://ClinicalTrials.gov/show/NCT00628368"
2360,"NCT00004911","Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction","Completed","No Results Available","Colorectal Cancer|Constipation, Impaction, and Bowel Obstruction|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Gastrointestinal Stromal Tumor|Quality of Life|Small Intestine Cancer","Procedure: bowel obstruction management|Procedure: quality-of-life assessment","Northwestern University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Supportive Care","NU 98CC3|NU-98CC3|NCI-G00-1704","March 7, 2000","January 2000","February 2003","May 31, 2012","May 2012","No Study Results Posted","null","February 2003","","https://ClinicalTrials.gov/show/NCT00004911"
2361,"NCT01830647","An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum","Completed","No Results Available","Colorectal Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","35","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML28411","April 10, 2013","April 2013","April 2016","September 1, 2016","September 2016","No Study Results Posted","null","April 2016","Safety: Incidence of adverse events|Efficacy: Time to disease progression","https://ClinicalTrials.gov/show/NCT01830647"
2362,"NCT00622674","Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Pancreatic Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific","Biological: cetuximab|Drug: bortezomib","Masonic Cancer Center, University of Minnesota","Both","18 Years and older   (Adult, Senior)","Phase 1","37","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000586671|UMN-2005LS037|MILLENNIUM-X05160|UMN-0506M7030372","February 22, 2008","November 2005","February 2010","April 13, 2010","April 2010","No Study Results Posted","null","August 2009","Maximum tolerated dose (MTD) of bortezomib|Disease response as measured by RECIST criteria","https://ClinicalTrials.gov/show/NCT00622674"
2363,"NCT00608595","Celecoxib in Treating Patients With Early-Stage Rectal Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: celecoxib|Genetic: gene expression analysis|Genetic: protein expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: mass spectrometry|Procedure: biopsy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC GI 0174|VU-VICC-GI-0174","January 30, 2008","July 2002","April 2008","March 2, 2013","March 2013","No Study Results Posted","null","May 2004","Event rate of over-expression of cyclooxygenase-2|Percent change of eicosanoid level|Percent change of VEGF and prostaglandin-M levels|Change of gene and protein expression pattern from pre- to post-treatment levels","https://ClinicalTrials.gov/show/NCT00608595"
2364,"NCT00335816","Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: conventional surgery|Radiation: radiation therapy|Other: laboratory biomarker analysis|Genetic: DNA analysis|Genetic: polymerase chain reaction|Other: immunohistochemistry staining method","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","248","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","mskcc 12-201|P30CA033572|CHNMC-07182|UCSF-H44287-23127-03|UMN-2003UC036|UCSF-03451|CDR0000458059|R01CA090559","June 8, 2006","August 2008","null","October 18, 2015","October 2015","No Study Results Posted","null","December 2017","Rate of pathologic complete response|Effect of different chemoradiation-to-surgery intervals on rate of pathologic complete response and surgical difficulty.|Effect of different chemoradiation-to-surgery intervals on postoperative complications","https://ClinicalTrials.gov/show/NCT00335816"
2365,"NCT00021398","Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Procedure: conventional surgery|Radiation: radiation therapy","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","23","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068776|P30CA006927|FCCC-96071|NCI-G01-1988","July 11, 2001","July 1996","null","March 1, 2016","March 2016","No Study Results Posted","null","July 2016","Frequency of toxicity|tolerated dose of preoperative hyperfractionated radiation and concurrent chemotherapy","https://ClinicalTrials.gov/show/NCT00021398"
2366,"NCT02833753","Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI","Recruiting","No Results Available","Colorectal Cancer|Appendix Cancer|Peritoneal Carcinomatosis","Drug: Oxaliplatin","University of Massachusetts, Worcester","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","16","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H00008477","July 12, 2016","July 2016","July 2019","July 13, 2016","July 2016","No Study Results Posted","null","July 2019","Define the maximum tolerated dose (MTD) of intraperitoneal (IP) oxaliplatin given with systemic FOLFIRI in patients with peritoneal carcinomatosis (PC) of colorectal or appendiceal origin","https://ClinicalTrials.gov/show/NCT02833753"
2367,"NCT00024063","SU006668 in Treating Patients With Advanced Solid Tumors","Active, not recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Gastric Cancer|Kidney Cancer|Lung Cancer|Multiple Myeloma and Plasma Cell Neoplasm|Pancreatic Cancer|Prostate Cancer","Drug: orantinib","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068888|UCLA-0004061|SUGEN-SU6668.004|NCI-G01-2010","September 13, 2001","null","null","December 18, 2013","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00024063"
2368,"NCT00470353","Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery","Terminated","No Results Available","Colorectal Cancer","Dietary Supplement: calcium carbonate|Dietary Supplement: cholecalciferol|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","8","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","I 78706|RPCI-I-78706","May 3, 2007","September 2006","September 2009","January 31, 2013","January 2013","No Study Results Posted","null","July 2008","Change in proliferative labeling index of normal rectal mucosa as measured by Ki67 IHC staining|Changes in serum levels of 25-OH-D3, 1,25-OH-D3, 24,25-OH-D3, calcium, and parathyroid hormone|Safety of high-dose cholecalciferol supplementation as measured over 2 years|Effects of cholecalciferol on biological markers of proliferation (i.e., cyclin D1, protein kinase C, vitamin D receptor, p21, and p27) as measured by IHC at baseline and after 6 months of study treatment","https://ClinicalTrials.gov/show/NCT00470353"
2369,"NCT00942461","Inflammatory Response in Laparoscopic and Open Colectomy","Completed","No Results Available","Colorectal Cancer","Procedure: Laparoscopic colectomy|Procedure: Open colectomy","G. Hatzikosta General Hospital|University of Ioannina","Both","Child, Adult, Senior","Phase 4","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)","GH-1948-04|GHDS-12345-4","July 20, 2009","October 2008","null","July 20, 2009","July 2009","No Study Results Posted","null","June 2009","Inflammatory reaction of the patients organism in laparoscopic vs open colorectal surgery for cancer","https://ClinicalTrials.gov/show/NCT00942461"
2370,"NCT00462501","Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer","Completed","Has Results","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: conventional surgery|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","","35","Other|NIH|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-021|P30CA008748|MSKCC-07021","April 18, 2007","March 2007","February 2014","December 15, 2015","December 2015","December 15, 2015","null","February 2014","Complete Pathologic Response","https://ClinicalTrials.gov/show/NCT00462501"
2371,"NCT01212887","Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer","Terminated","No Results Available","Breast Cancer|Colorectal Cancer|Gastric Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|Biological: aldesleukin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Other: laboratory biomarker analysis|Other: pharmacological study","Cancer Research UK","Both","18 Years and older   (Adult, Senior)","Phase 1","14","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000685060|CRUK-PH1/105|CRUK-MFEz|EUDRACT-2005-004085-16|EU-21070","September 30, 2010","August 2007","April 2010","February 27, 2012","February 2012","No Study Results Posted","null","April 2010","Percentage of patients (goal is 50%) who are evaluable for MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes survival|Adverse event according to CTCAE version 3 criteria|Dose of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes that gives the highest frequency in the circulation as measured by the primary assays (recommended phase II dose)|Presence of cells with a functional chimeric immune receptor on bCEA binding assay|Partial response or complete response on CT scans at 6, 12, 24, and 52 weeks as defined by RECIST criteria|Long-term follow up for insertional mutagenesis","https://ClinicalTrials.gov/show/NCT01212887"
2372,"NCT00016133","Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery","Completed","No Results Available","Colorectal Cancer","Biological: BCG vaccine|Biological: autologous tumor cell vaccine|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: adjuvant therapy","Intracel|National Cancer Institute (NCI)","Both","21 Years to 85 Years   (Adult, Senior)","Phase 1|Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","INTRACEL-ASI-2002|CDR0000068597","May 6, 2001","March 2001","August 2004","May 29, 2013","July 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00016133"
2373,"NCT02838836","Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers","Recruiting","No Results Available","Non-small Cell Lung Cancer|Esophageal Cancer|Gastric Cancer|Pancreatic Cancer|Hepatocellular Cancer|Colorectal Cancer","Other: Blood draws, urine and tissue asservation, bone marrow aspiration","University of Missouri-Columbia","Both","18 Years and older   (Adult, Senior)","","110","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2004401","July 9, 2016","June 2016","June 2021","July 16, 2016","July 2016","No Study Results Posted","null","June 2019","CTC/DTC numbers measured in blood, urine and bone marrow samples will be correlated with patient outcome|ctDNA characteristics will be correlated with survival data","https://ClinicalTrials.gov/show/NCT02838836"
2374,"NCT00897403","Blood and Tissue Sample Collection for Future Colon Cancer Biomarker Studies in Patients Undergoing Colonoscopy","Recruiting","No Results Available","Colorectal Cancer|Health Status Unknown","Other: biologic sample preservation procedure|Procedure: diagnostic colonoscopy","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","25 Years to 75 Years   (Adult, Senior)","","3000","Other|NIH","Observational","","CDR0000546530|VU-VICC-GI-0661|VU-VICC-IRB-061096","May 9, 2009","February 2007","null","August 11, 2009","October 2008","No Study Results Posted","null","null","Collection of blood and tissue","https://ClinicalTrials.gov/show/NCT00897403"
2375,"NCT00036790","Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer","Completed","No Results Available","Breast Cancer|Chronic Myeloproliferative Disorders|Colorectal Cancer|Head and Neck Cancer|Leukemia|Lung Cancer|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic/Myeloproliferative Diseases|Prostate Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: doxorubicin hydrochloride|Drug: motexafin gadolinium","University of Wisconsin, Madison|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069322|P30CA014520|WCCC-CO-01910|PCI-PCYC-0207|NCI-G02-2061","May 13, 2002","February 2002","null","September 30, 2015","September 2015","No Study Results Posted","null","October 2005","","https://ClinicalTrials.gov/show/NCT00036790"
2376,"NCT01148758","A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer","Completed","No Results Available","Colorectal Cancer, Ovarian Cancer","Drug: RO5323441","Hoffmann-La Roche","Both","19 Years and older   (Adult, Senior)","Phase 1","7","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BP22909|2009-016014-25","May 5, 2010","May 2010","September 2010","September 1, 2016","September 2016","No Study Results Posted","null","September 2010","RO5323441 concentration - pharmacodynamic effect relationship using DCE-MRI|Feasibility of within-patient dose escalation|Additional DCE-MRI effects (time-course of DCE-MRI effects, test-retest reproducibility)|Candidate biomarkers associated with PD effect of RO5323441|Pharmacokinetics: maximum and trough concentrations of RO5323441|Safety and tolerability: Adverse events, vital signs, laboratory parameters|Efficacy: ORR, duration of response, progression-free survival according to RECIST criteria, CTI/MRI assessments","https://ClinicalTrials.gov/show/NCT01148758"
2377,"NCT00033384","CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer","Drug: CI-1040","University of Alabama at Birmingham|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069279|UAB-0152|PFIZER-1040-002-004|UAB-F011203011|NCI-G02-2052","April 9, 2002","February 2002","November 2003","April 10, 2013","December 2002","No Study Results Posted","null","November 2003","","https://ClinicalTrials.gov/show/NCT00033384"
2378,"NCT02337452","The Patient-Driven Self-Navigated Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families","Recruiting","No Results Available","Advanced Cancers|Anal Cancer|Colorectal Cancer|Gastrointestinal Cancer","Behavioral: Family History Questionnaire|Behavioral: Web-Based Family Outreach Registry","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","","10000","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","2014-0715","January 9, 2015","April 2015","null","August 22, 2016","August 2016","No Study Results Posted","null","April 2048","Web-based Family Outreach Registry","https://ClinicalTrials.gov/show/NCT02337452"
2379,"NCT00012155","Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: NV1020","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","MSKCC-00022|CDR0000068488|MGENE-NR1-001|NCI-G01-1920","March 3, 2001","October 2000","December 2009","June 25, 2013","November 2002","No Study Results Posted","null","November 2002","","https://ClinicalTrials.gov/show/NCT00012155"
2380,"NCT02318901","Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer","Recruiting","No Results Available","Advanced Cancer|Breast Cancer|Gastric Cancer|Esophageal Cancer|Colorectal Cancer","Drug: Pembrolizumab|Drug: Trastuzumab|Drug: ado-trastuzumab emtansine|Drug: Cetuximab","Western Regional Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","90","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PembroMab","December 8, 2014","October 2014","October 2017","December 7, 2015","December 2015","No Study Results Posted","PembroMab","October 2017","Determine the recommended phase 2 dose (RP2D) of monoclonal antibody therapy (Mab) in combination with pembrolizumab (pembro) in subjects with advanced cancer|Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03|Response rate by irRC and response evaluation criteria in solid tumors (RECIST) 1.1 criteria|To determine the overall survival (OS) and progression-free survival (PFS)|To characterize changes in circulating tumor DNA in patients enrolled on this study|Textural changes identified on imaging that is done per routine practice","https://ClinicalTrials.gov/show/NCT02318901"
2381,"NCT00451880","Study of XL281 in Adults With Solid Tumors","Completed","No Results Available","Cancer|Non-small-cell Lung Cancer|Colorectal Cancer|Papillary Thyroid Cancer|Melanoma","Drug: XL281|Drug: famotidine","Exelixis","Both","18 Years and older   (Adult, Senior)","Phase 1","180","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XL281-001","March 23, 2007","February 2007","October 2011","October 11, 2011","October 2011","No Study Results Posted","null","October 2011","Safety, tolerability, and maximum tolerated dose (MTD) of once daily or twice daily oral administration of XL281|To assess the pharmacokinetic/pharmacodynamic/preliminary clinical activity relationship following XL281 administration in different tumor types from subjects treated at the MTD|To determine the bioavailability of XL281 under fed and fasted conditions, and with or without the concomitant use of a single dose of famotidine in subjects with solid tumors|Plasma pharmacokinetics of once daily or twice daily oral administration of XL281","https://ClinicalTrials.gov/show/NCT00451880"
2382,"NCT02655822","Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers","Recruiting","No Results Available","Non-Small Cell Lung Cancer|Malignant Melanoma|Renal Cell Cancer|Triple Negative Breast Cancer|Head and Neck Cancer|Colorectal Cancer|Bladder Cancer","Drug: CPI-444|Drug: CPI-444|Drug: CPI-444|Drug: CPI-444 + atezolizumab","Corvus Pharmaceuticals, Inc.|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","534","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CPI-444-001","January 8, 2016","January 2016","December 2018","September 2, 2016","September 2016","No Study Results Posted","null","June 2018","Incidence of dose-limiting toxicities (DLTs) of CPI-444 as a single agent and in combination with atezolizumab|Objective response rate per RECIST v1.1 criteria of CPI-444 as a single agent and in combination with atezolizumab|Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.4.03, of CPI-444 as a single agent and in combination with atezolizumab|Mean and median Area under the curve (AUC) of CPI-444|Mean and median Maximum concentration (Cmax) of CPI-444","https://ClinicalTrials.gov/show/NCT02655822"
2383,"NCT00667641","Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Melanoma (Skin)|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: bortezomib|Drug: paclitaxel","University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000592905|P30CA072720|CINJ-050608|MILLENNIUM-CINJ-050608|CINJ-IRB-0220060270","April 25, 2008","March 2007","February 2009","May 9, 2011","May 2011","No Study Results Posted","null","February 2009","Maximum tolerated dose of paclitaxel in combination with bortezomib","https://ClinicalTrials.gov/show/NCT00667641"
2384,"NCT01263171","Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery","Completed","No Results Available","Colorectal Cancer","Drug: Leucovorin|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: radiation therapy","Cardiff University|Cancer Research UK","Both","18 Years to 120 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000691166|WCTU-COPERNICUS|2010-023083-40|C23134/A11537|CARDIFF-SPON830-10","December 17, 2010","April 2012","November 2015","September 20, 2016","September 2016","No Study Results Posted","COPERNICUS","November 2015","Proportion of patients who commence neoadjuvant chemotherapy and radiotherapy and then undergo surgical resection|Feasibility in terms of achieved dose intensity for chemotherapy and radiotherapy|Safety in terms of NCI CTCAE v 4 toxicities up to 30 days postoperatively and late toxicity at 1 year after surgery|Complete response|Efficacy in terms of down-staging rectal cancer|Local recurrence-free, distant metastasis-free, and overall survival at 1 year after surgery","https://ClinicalTrials.gov/show/NCT01263171"
2385,"NCT00006366","Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: irinotecan hydrochloride|Procedure: conventional surgery|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","RTOG-R-0012|CDR0000068239|RTOG-DEV-1030","October 4, 2000","February 2001","null","July 17, 2013","December 2002","No Study Results Posted","null","December 2003","","https://ClinicalTrials.gov/show/NCT00006366"
2386,"NCT00004095","Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors","Completed","No Results Available","Bladder Cancer|Breast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Pancreatic Cancer","Drug: gemcitabine hydrochloride|Drug: irinotecan hydrochloride","Northwestern University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 98X3|NU-98X3|P-UPJOHN-976475157|NCI-G99-1588","December 10, 1999","August 1999","October 2008","January 28, 2011","January 2011","No Study Results Posted","null","October 2008","","https://ClinicalTrials.gov/show/NCT00004095"
2387,"NCT00084773","Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: fluorouracil|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","","28","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-006|MSKCC-04006","June 10, 2004","March 2004","March 2010","December 21, 2015","December 2015","No Study Results Posted","null","January 2007","Safety profile|Activity in terms of pathological complete response rate","https://ClinicalTrials.gov/show/NCT00084773"
2388,"NCT00686166","S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer","Active, not recruiting","Has Results","Colorectal Cancer","Biological: cetuximab|Drug: capecitabine|Drug: oxaliplatin|Procedure: therapeutic surgical procedure|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","83","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S0713|U10CA032102","May 28, 2008","February 2009","July 2017","January 26, 2016","January 2016","January 26, 2016","null","July 2014","Pathologic Complete Response Rate|3-year Disease-free Survival|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to This Regimen.","https://ClinicalTrials.gov/show/NCT00686166"
2389,"NCT00387348","Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer","Terminated","Has Results","Colorectal Cancer|Depression|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Fatigue|Gallbladder Cancer|Gastric Cancer|Liver Cancer|Lung Cancer|Pancreatic Cancer","Drug: escitalopram oxalate|Drug: Placebo","Massachusetts General Hospital|National Cancer Institute (NCI)","Both","35 Years to 85 Years   (Adult, Senior)","Phase 3","24","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Supportive Care","CDR0000505774|MGH-2006-P-000299|K23CA115908","October 12, 2006","March 2006","April 2011","November 2, 2012","November 2012","July 12, 2012","null","April 2011","Depression Response Rate of Escitalopram Oxalate 10 mg Once Daily Compared to Placebo Once Daily for Major Depressive Disorder|Change in Hamilton Depression Rating Scale (HAM-D) Scores|Side Effect Burden","https://ClinicalTrials.gov/show/NCT00387348"
2390,"NCT00297141","Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma","Completed","No Results Available","Rectal Cancer","Drug: Capecitabine|Drug: Oxaliplatin","Austrian Breast & Colorectal Cancer Study Group|Sanofi-Synthelabo|Hoffmann-La Roche","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG 95 / TAKO 05|Studie R02 (95)|2004-002358-72","February 27, 2006","October 2004","December 2013","December 30, 2013","December 2013","No Study Results Posted","null","December 2013","Rate of T-downstaging (Reduction of the T-stadium)|Evaluation of the toxicity grade III and IV of the therapy scheme","https://ClinicalTrials.gov/show/NCT00297141"
2391,"NCT00084591","Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000365462|P30CA006927|FCCC-03606","June 10, 2004","December 2003","February 2007","February 11, 2010","February 2010","No Study Results Posted","null","null","Acute toxicity by CTCAE at 6 weeks following study completion|Quality of life as assessed by Quality of Life Questionnaire Core 30 Items (QLQ-C30) before and after radiotherapy and then every 6 months after surgery","https://ClinicalTrials.gov/show/NCT00084591"
2392,"NCT00726622","Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Procedure: Open laparotomy and rectal resection|Procedure: Laparoscopic-assisted rectal resection","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","486","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACOSOG-Z6051|U10CA076001|NCI-2009-00350|CDR0000601816","July 31, 2008","August 2008","null","July 1, 2016","July 2016","No Study Results Posted","null","October 2013","Circumferential margin > 1 mm|Negative distal resected margin|Completeness of total mesorectal excision (complete or nearly complete)|Patient-related benefit (length of stay, operative times and use of pain medication)|Disease-free survival|Local pelvic recurrence rates|Overall survival|Quality of life and sexual function|Bowel function|Bowel and stoma function","https://ClinicalTrials.gov/show/NCT00726622"
2393,"NCT00985400","Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery","Active, not recruiting","No Results Available","Colorectal Cancer","Behavioral: Exercise Program|Behavioral: Telephone-based intervention|Other: Counseling intervention|Other: Questionnaire administration|Behavioral: Relaxation Program","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","154","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2009-0288|MDA-2009-0288|CDR0000654446|NCI-2011-02280","September 25, 2009","November 2010","null","June 27, 2016","June 2016","No Study Results Posted","null","December 2017","Recruitment rate|Patient retention|Program and assessment implementation|Patient adherence to behavioral recommendations|Effect size of the exercise intervention on physical function|Effect size of the exercise intervention on symptoms and quality of life","https://ClinicalTrials.gov/show/NCT00985400"
2394,"NCT00005049","Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer","Completed","No Results Available","Colorectal Cancer|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Gastrointestinal Stromal Tumor|Ovarian Cancer|Peritoneal Cavity Cancer|Small Intestine Cancer","Drug: carboplatin|Drug: cisplatin|Drug: floxuridine","New York University School of Medicine|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","45","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067641|P30CA016087|NYU-9645|NCI-G00-1717","April 6, 2000","May 1997","null","April 4, 2011","April 2011","No Study Results Posted","null","November 2006","","https://ClinicalTrials.gov/show/NCT00005049"
2395,"NCT00427713","Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: standard follow-up care","Cancer Research UK|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","800","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000526299|CRUK-CHRONICLE|CRUK-BRD/05/132|EU-20679|ISRCTN59865116|CTA21106/0016/001|EUDRACT-2004-001484-21","January 25, 2007","November 2004","null","August 23, 2013","June 2007","No Study Results Posted","null","March 2008","Disease-free survival at 3 years|Overall survival at 5 years|Toxicity","https://ClinicalTrials.gov/show/NCT00427713"
2396,"NCT00836992","Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer","Active, not recruiting","No Results Available","Anal Cancer|Colorectal Cancer|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Head and Neck Cancer|Liver Cancer|Lung Cancer|Pancreatic Cancer|Small Intestine Cancer","","Mayo Clinic|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","","132","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","08-005566|P30CA015083|CDR0000629594|MCS1065","February 3, 2009","January 2009","null","April 19, 2016","April 2016","No Study Results Posted","null","September 2011","Overall quality of life (QOL) scores at baseline, weeks 1, 3, 5, and end of treatment as assessed by LASA|Component QOL domains reported on the five numerical analogue items (physical, intellectual, emotional, spiritual, and social QOL), average pain item and fatigue reported in the LASA|Frequency and severity of toxicity as assessed by NCI CTCAE at baseline, weeks 1, 3, 5, and of treatment|Scores from the IPPRS, satisfaction with the physician scale score, and global question assessment|Quantitative assessments from the post-treatment questionnaires and the qualitative data gleaned from the post-treatment interviews|Proportion of cases for which the clinical team indicates that the clinical pathways contributed positively to patient management, the number of cases which the clinicians report referrals were generated, and the qualitative data derived from the pos ...|Average physician rating of the patient-physician relationships for the two treatment groups|Average duration of the weekly on treatment visit for the two treatment groups|Percentage of patients for which physician reports indicate that availability","https://ClinicalTrials.gov/show/NCT00836992"
2397,"NCT00262808","GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer","Completed","No Results Available","Colorectal Cancer","Biological: sargramostim|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","University of Rochester","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000448633|URCC-U1203|URCC-RSRB-09956|BRLX-001-0837|DUMC-7135-05-5R0","December 6, 2005","March 2004","September 2006","October 14, 2013","October 2013","No Study Results Posted","null","September 2006","Proportion of patients with a change in tumor-associated macrophage VEGF expression|Disease-free and overall survival","https://ClinicalTrials.gov/show/NCT00262808"
2398,"NCT00019513","Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas","Completed","No Results Available","Colorectal Cancer|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer|Lung Cancer|Lymphoma|Pancreatic Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","108","NIH","Interventional","Primary Purpose: Treatment","980143|98-C-0143|CDR0000066587","July 11, 2001","August 1998","June 2004","March 21, 2012","March 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00019513"
2399,"NCT02494973","Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases","Recruiting","No Results Available","Colorectal Cancer","Drug: Oxaliplatin HAI|Drug: Oxaliplatin IV|Drug: mFOLFOX6|Drug: LV5FU2","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","220","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-005110-32|2014/2187","July 8, 2015","May 2015","May 2026","July 11, 2016","July 2016","No Study Results Posted","PACHA-01","May 2026","18-month hepatic RFS rate|3-year RFS rate","https://ClinicalTrials.gov/show/NCT02494973"
2400,"NCT00903396","Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer","Completed","No Results Available","Anal Cancer|Carcinoma of the Appendix|Colorectal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Liver Cancer|Nausea and Vomiting|Pancreatic Cancer|Primary Peritoneal Cavity Cancer|Small Intestine Cancer","Drug: palonosetron hydrochloride|Other: placebo","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","7","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","NCCTG-N08C2|NCI-2009-01109|CDR0000642449","May 15, 2009","September 2009","May 2013","August 11, 2016","August 2016","No Study Results Posted","null","January 2011","Complete response (no episodes of nausea or vomiting)|Time to treatment failure, defined as a single episode of vomiting, daily nausea score of moderate or greater, or taking ≥ 3 prochlorperazine or haloperidol tablets per day|Proportion of patients reporting treatment failure|Tolerability and adverse events as assessed by NCI CTC v 3.0|Average level of nausea reported and the proportion of patients experiencing a complete response independent of treatment arm","https://ClinicalTrials.gov/show/NCT00903396"
2401,"NCT00005858","LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer","Completed","No Results Available","Bladder Cancer|Breast Cancer|Colorectal Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer","Biological: LMB-9 immunotoxin","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","25","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067885|MSGCC-9981|MSGCC-IRB-0200123|NCI-511","June 2, 2000","April 2000","null","February 8, 2013","March 2003","No Study Results Posted","null","April 2003","","https://ClinicalTrials.gov/show/NCT00005858"
2402,"NCT00002575","Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: conventional surgery|Procedure: laparoscopic surgery","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|NCIC Clinical Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 3","810","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-934653|NCI-2012-02234|CAN-NCIC-CO12|CDR0000063648","November 1, 1999","August 1994","November 2009","July 15, 2016","July 2016","No Study Results Posted","null","May 2004","Disease-free survival|Overall survival|Morbidity|Mortality|Costs and cost effectiveness between these treatments in this patient population|Compare the differences in quality of life of patients treated with these regimens","https://ClinicalTrials.gov/show/NCT00002575"
2403,"NCT02626377","Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté","Recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Prostate Cancer|Alzheimer Disease|Age-related Macular Degeneration|Parkinson Disease|Cardiac Disease|Ischemic Stroke|Hemorrhagic Stroke","Behavioral: Support provided by social worker|Other: Information booklet receipt","Centre Hospitalier Universitaire de Besancon|Methodological and quality of life unit in oncology (CHRU de Besançon)|University of Franche-Comté|University of Burgundy|Pôle de Gérontologie Interrégional Bourgogne et Franche-Comté|CARSAT Bourgogne et Franche-Comté|CCAS of Dijon|CCAS of Besançon|CCAS of Montbéliard|Burgundy Regional Council|Franche-Comté Regional Council|The Municipality of Besançon|The Municipality of Dijon|General Council of the Doubs|General Council of the Territoire de Belfort|Collectif Inter Associatif Sur la Sante Bourgogne|Union Régionale Interfédérale des Œuvres et Organismes Privés Sanitaires Bourgogne|Association Gérontopôle Pierre Pfitzenmeyer|Pôle de compétitivité Vitagora Goût-Nutrition-Santé|Caisse Nationale d’Assurance Vieillesse des Travailleurs Salariés (CNAVTS)|Sheerbrooke Gérontopôle|France Alzheimer Côte-d’Or|Institut Régional de Vieillissement (IRV)|Novartis Pharmaceuticals|Roche Foundation|Ligue contre le cancer, France|National Cancer Institute, France|Quality of life and cancer clinical research platform","Both","60 Years and older   (Adult, Senior)","","7604","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","P/2014/231","December 1, 2015","October 2015","October 2025","July 20, 2016","July 2016","No Study Results Posted","ICE","October 2025","(Interventional Study) Comparison of caregivers' HRQoL according to the allocated intervention by randomization based on summaries score the MOS SF36|(Observational study) Changes in HRQoL of patients' caregivers using the MOS SF36 questionnaire|(Observational study) Changes in HRQoL of cancer patients' caregivers using the CarGoQoL questionnaire|(Observational study) Changes in the coping strategies of patients' caregivers using the Borteyrou, Rascle and Truchot Questionnaire|(Observational study) Changes in feelings of anxiety and depression of patients' caregivers according to the HADs questionnaire|(Observational study) Changes in social support of patients' caregivers using the SSQ6 questionnaire|(Observational study) Changes in burden of patients' caregivers using the Zarit burden inventory|(Interventional Study) Comparison of caregivers' HRQoL according to the intervention allocated by randomization based on summaries score the MOS SF36|(Interventional Study) Changes in HRQoL of patients' caregivers according to the allocated intervention using the MOS SF36 questionnaire|(Interventional Study) Changes in HRQoL of cancer patients' caregivers according to the allocated intervention using the CarGoQol questionnaire|(Interventionnal Study) Changes in the coping strategies of patients' caregivers according to the allocated intervention using the Borteyrou, Rascle and Truchot Questionnaire|(Interventional Study) Changes in feelings of anxiety and depression of patients' caregivers according to the allocated intervention using the HADs Questionnaire|(Interventional Study) Changes in social supports of patients' caregivers according to the allocated intervention using the SSQ6 questionnaire|(Interventional Study) Changes in burden of patients' caregivers according to the allocated intervention using the Zarit burden inventory|(Interventional study) Efficiency of the intervention of a social worker for caregivers using a cost-utility analysis|(Observational study) Changes in the caregivers/patients' relationship using a qualitative approach (semi-structure interview)|(Observational study) Changes in the role of caregiver due to a situation generating a rupture (entry into an institution or death, disease remission) using a qualitative approach (semi-structure interview)","https://ClinicalTrials.gov/show/NCT02626377"
2404,"NCT00647530","Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery","Completed","No Results Available","Colorectal Cancer","Biological: panitumumab|Drug: capecitabine|Drug: fluorouracil|Drug: oxaliplatin|Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: polymerase chain reaction|Genetic: proteomic profiling|Genetic: western blotting|Other: immunohistochemistry staining method|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: quality-of-life assessment|Procedure: therapeutic conventional surgery","University of Birmingham|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 3","1050","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","BCTU-FOXTROT-001|CDR0000590089|ISCRTN 87163246|EUDRACT 2007-001987-55|EU-20830|MREC-07/S0703/57|UKCRN 3771","March 28, 2008","January 2008","November 2012","August 6, 2013","November 2008","No Study Results Posted","null","January 2012","Recurrence or persistent disease (including failure of macroscopic disease clearance at primary surgery) within the first two years following randomization|Pathological down-staging as measured by depth of extramural spread among patients allocated to preoperative chemotherapy with or without panitumumab|Death from colon cancer|Overall survival|Pathological assessment of downstaging (involvement of lymph nodes, serosa, and resection margin) and quality of resection specimen|Radiological assessment of response to neoadjuvant treatment|Quality of life by EORTC QLQ C-30 and EuroQol EQ-5D|Health service costs|Surgical morbidity/mortality|Chemotherapy toxicity|Adverse events","https://ClinicalTrials.gov/show/NCT00647530"
2405,"NCT00023751","Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Procedure: conventional surgery|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","320","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-80002|U10CA031946|CLB-80002|SWOG-C80002|CDR0000068858","September 13, 2001","July 2001","April 2004","July 1, 2016","July 2016","No Study Results Posted","null","April 2004","disease-free survival|overall survival|colostomy-free survival","https://ClinicalTrials.gov/show/NCT00023751"
2406,"NCT01792882","Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples","Enrolling by invitation","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer|Hematologic Cancer","","Global BioClinical","Both","18 Years to 90 Years   (Adult, Senior)","","100","Industry","Observational","Time Perspective: Prospective","GBC PRT0008","February 6, 2013","February 2013","December 2017","September 12, 2016","September 2016","No Study Results Posted","GBCPRT0008","December 2017","Tumor genetic sequence variation|Transcription profile","https://ClinicalTrials.gov/show/NCT01792882"
2407,"NCT02327468","Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers","Recruiting","No Results Available","Breast Cancer|Lung Cancer|Pancreatic Cancer|Head and Neck Squamous Cell Cancer|Ovarian Cancer|Colorectal Cancer|Gastric Cancer|Esophageal Cancer|Hepatocellular Cancer","Biological: INO-1400|Biological: INO-9012","Inovio Pharmaceuticals|Abramson Cancer Center of the University of Pennsylvania|University of North Carolina|Thomas Jefferson University|Wayne State University","Both","18 Years and older   (Adult, Senior)","Phase 1","54","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCC 22913","December 23, 2014","December 2014","April 2018","August 3, 2016","August 2016","No Study Results Posted","null","December 2017","Adverse events graded in accordance with ""Common Terminology Criteria for Adverse Events (CTCAE)"", NCI version 4.03|Injection site reactions including, but not necessarily limited to, local skin erythema, induration, pain and tenderness at administration site [|Changes in safety laboratory parameters from baseline|Time to progression|Antigen specific cellular immune responses|Antigen specific ELISA|H&E stain; immunohistochemistry for CD45, CD3, CD8, FoxP3; and TCRbeta molecular analysis of baseline/archival tumor tissue and relapsed tumor tissue, when possible.","https://ClinicalTrials.gov/show/NCT02327468"
2408,"NCT01150045","Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: celecoxib|Drug: 5-fluorouracil|Other: placebo|Drug: oxaliplatin|Drug: leucovorin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","2500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CALGB-80702|U10CA031946|CDR0000675693","June 23, 2010","June 2010","null","June 15, 2016","June 2016","No Study Results Posted","null","December 2019","Disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01150045"
2409,"NCT00054977","Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors","Completed","No Results Available","Colorectal Cancer|Lung Cancer|Breast Cancer|Head and Neck Cancer|Prostate Cancer","Drug: GM-CT-01|Drug: 5-fluorouracil","Galectin Therapeutics Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","40","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DAVFU-001","February 14, 2003","February 2003","September 2006","March 9, 2012","March 2012","No Study Results Posted","null","April 2005","Safety|Tumor progression","https://ClinicalTrials.gov/show/NCT00054977"
2410,"NCT00972751","S9304A Study of Protein Expression in Tumor Tissue Samples From Patients With Stage II or Stage III Rectal Cancer Enrolled in Clinical Trial SWOG-9304","Completed","No Results Available","Colorectal Cancer","","Southwest Oncology Group|National Cancer Institute (NCI)","Both","18 Years to 120 Years   (Adult, Senior)","","220","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CDR0000601255|U10CA032102|SWOG-9304A-ICSC","September 4, 2009","February 2009","September 2010","September 28, 2015","September 2015","No Study Results Posted","null","September 2010","Expression of thioredoxin-1, thioredoxin-interacting protein, and hypoxia inducible factor-1 alpha|Correlation of expression of these proteins with tumor stage, disease-free survival, overall survival, and risk of recurrence","https://ClinicalTrials.gov/show/NCT00972751"
2411,"NCT01773980","CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening","Completed","No Results Available","Breast Cancer|Cervical Cancer|Colorectal Cancer","Other: Clinic Intervention|Other: Patient Intervention","OHSU Knight Cancer Institute|National Institutes of Health (NIH)","Female","50 Years to 75 Years   (Adult, Senior)","","1570","Other|NIH","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","IRB00009030","January 18, 2013","August 2013","April 2015","May 20, 2015","May 2015","No Study Results Posted","null","April 2015","Number of participants with improved cancer screening","https://ClinicalTrials.gov/show/NCT01773980"
2412,"NCT01311856","Telephone Counseling-Mailed Materials Versus Internet Interventions in Overweight Cancer Survivors","Active, not recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Prostate Cancer","Behavioral: Standard Arm (mail/telephone)|Behavioral: Internet Arm|Behavioral: Surveys and Questionnaires|Behavioral: Exercise and Diet","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2009-0504","March 4, 2011","March 2011","null","November 3, 2015","November 2015","No Study Results Posted","null","March 2017","Recruitment Rate|Drop-Out Rate","https://ClinicalTrials.gov/show/NCT01311856"
2413,"NCT00019786","Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases","Completed","No Results Available","Colorectal Cancer|Islet Cell Tumor|Liver Cancer|Metastatic Cancer|Neuroendocrine Carcinoma","Drug: isolated perfusion|Drug: melphalan|Procedure: conventional surgery","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 2","67","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","990123|99-C-0123|CDR0000067220","July 11, 2001","August 1999","January 2006","March 21, 2012","March 2012","No Study Results Posted","null","null","Response rate|Duration of response|Patterns of recurrence|Disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00019786"
2414,"NCT02903914","Arginase Inhibitor CB-1158 in Patients With Solid Tumors","Recruiting","No Results Available","Metastatic Cancer|Solid Tumors|Non-small Cell Lung Cancer|Colo-Rectal Cancer|Gastric Cancer|Renal Cell Carcinoma|Squamous-cell Carcinomas of the Head and Neck","Drug: CB-1158|Drug: Nivolumab","Calithera Biosciences, Inc","Both","18 Years and older   (Adult, Senior)","Phase 1","236","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","CX-1158-101","September 9, 2016","September 2016","May 2018","September 15, 2016","September 2016","No Study Results Posted","null","May 2018","Safety and Tolerability of CB-1158 as a single agent and in combination with nivolumab: Incidence of Adverse Events|Recommended Phase 2 Dose (RP2D) of CB-1158|RP2D of CB-1158 with Nivolumab|Maximum plasma concentration of CB-1158","https://ClinicalTrials.gov/show/NCT02903914"
2415,"NCT00967655","Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Biological: panitumumab|Drug: capecitabine|Drug: irinotecan hydrochloride|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: radiation therapy","Loma Linda Oncology Medical Group, Inc.|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","54","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000652936|LLOMGI-20050743|MALIK 012009","August 27, 2009","July 2009","null","January 9, 2014","September 2009","No Study Results Posted","null","July 2012","Pathological complete response rate|Grade 3/4 toxicity rate|Disease-free survival|Time to treatment failure|1-year survival rate|2-year survival rate","https://ClinicalTrials.gov/show/NCT00967655"
2416,"NCT00392470","Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: irinotecan hydrochloride|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","Centre Hospitalier Universitaire Vaudois|National Cancer Institute (NCI)","Both","18 Years to 74 Years   (Adult, Senior)","Phase 1","20","Other","Interventional","Primary Purpose: Treatment","CDR0000512816|CHUV-CEPO-CORCC-204-5|EU-20645|PFIZER-CHUV-CAPO-CARK-204-5|MERCK-CHUV-CAPO-CARK-204-5","October 25, 2006","August 2006","null","May 24, 2011","April 2008","No Study Results Posted","null","null","Radiological (clinical) tumor response before surgery|Pathologic response rate and histological degree of tumor regression as measured by Mandard TRG score","https://ClinicalTrials.gov/show/NCT00392470"
2417,"NCT00383695","Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: capecitabine|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 2","164","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000503948|RMNHS-RMH-CCR-2553|EU-20635|EUDRACT-2004-004707-38|CRUK-EXPERT-C|MERCK-RMNHS-RMH-CCR-2553","September 29, 2006","September 2005","null","January 12, 2010","January 2010","No Study Results Posted","EXPERT-C","null","Pathological complete response rate at time of total mesorectal excision (TME)|Radiological response rates after completion of neoadjuvant therapy|Complete resection rate (R0 resection) with microscopic clear resection margin (tumor observed > 1 mm from the resection margin), especially circumferential resection margin|Perioperative measures, including operation time, duration of in-patient stay, perioperative transfusion requirement, and mortality, within 30 days of TME|Postoperative complications, including wound infection, wound dehiscence, and fistula formation|Quality of TME as assessed by audit of photographed surgical specimens|Rate of abdominoperitoneal excision|Rate of permanent defunctioning colostomies|Clinical and radiological anastomotic leak rate|Progression-free survival and patterns of failure|Overall survival|Safety|Quality of life, including long-term bowel function","https://ClinicalTrials.gov/show/NCT00383695"
2418,"NCT01569984","Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis","Completed","No Results Available","Colorectal Cancer.","Radiation: Stereotactic body radiotherapy","Dr. Yoo-Joung Ko|Roche Pharma AG|Sunnybrook Health Sciences Centre","Both","18 Years and older   (Adult, Senior)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OZM-032","March 30, 2012","March 2012","March 2015","March 27, 2015","March 2015","No Study Results Posted","SBRT-Avastin","March 2015","Tumor perfusion|Blood flow","https://ClinicalTrials.gov/show/NCT01569984"
2419,"NCT01097265","Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery","Recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: oxaliplatin|Other: active surveillance|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: lymph node mapping|Procedure: sentinel lymph node biopsy","Jeroen Bosch Ziekenhuis|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","1500","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Diagnostic","JBZ-EnRoute+|CDR0000668525|EUDRACT-2010-018612-32|EU-21016","March 31, 2010","July 2010","null","August 9, 2013","September 2011","No Study Results Posted","null","January 2015","Accrual rate (total number of pN0 patients included in the registration study monthly/center) (stage 1)|Rate of upstaging in pN0 colon cancer patients (stage 1)|Disease-free survival (DFS) at 3 years (stage 2)|Percentage of successful sentinel lymph node mapping procedures using multivariate analysis (stage 2)|Overall survival (OS) at 3 years (stage 2)|Stratified analysis of DFS and OS according to total harvested lymph nodes per resected specimen and chemotherapy regimen (capecitabine and oxaliplatin versus capecitabine alone) (stage 2)","https://ClinicalTrials.gov/show/NCT01097265"
2420,"NCT00276861","Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer","Terminated","Has Results","Colorectal Cancer","Drug: gemcitabine hydrochloride|Drug: oxaliplatin","University of Miami Sylvester Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","UMIAMI-20030655|SCCC-2003110|WIRB-20050993","January 12, 2006","September 2005","May 2008","July 25, 2014","August 2013","January 22, 2013","null","September 2006","Response Rate as Measured by RECIST Criteria|Time to Progression as Measured by the Kaplan Meyer Curve at Completion of Study Treatment","https://ClinicalTrials.gov/show/NCT00276861"
2421,"NCT00869570","External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: sorafenib tosylate|Radiation: radiation therapy","Swiss Group for Clinical Cancer Research","Both","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","54","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 41/08|SWS-SAKK-41-08|2008-006312-38|CDR0000634955","March 25, 2009","March 2009","October 2016","September 28, 2015","September 2015","No Study Results Posted","null","May 2013","Dose-limiting toxicity of the treatment combination (Phase I)|Pathological near complete or complete tumor response (Dworak grade 3 and 4) (Phase II)|R0 and R1 resection|Postoperative complications|Time to distant failure|Disease-free survival|Adverse events as assessed by NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00869570"
2422,"NCT00004895","Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery","Completed","No Results Available","Colorectal Cancer|Constipation, Impaction, and Bowel Obstruction|Extrahepatic Bile Duct Cancer|Gastric Cancer|Gastrointestinal Stromal Tumor|Nausea and Vomiting|Ovarian Cancer|Pancreatic Cancer|Peritoneal Cavity Cancer|Small Intestine Cancer","Drug: octreotide acetate","Northwestern University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Supportive Care","NU 97X1|NU-97X1|NCI-G00-1685","March 7, 2000","October 1999","October 2002","May 31, 2012","May 2012","No Study Results Posted","null","October 2002","","https://ClinicalTrials.gov/show/NCT00004895"
2423,"NCT02335918","A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors","Recruiting","No Results Available","Non-small Cell Lung Cancer (NSCLC)|Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Ovarian Carcinoma|Colorectal Cancer (CRC)|Renal Cell Carcinoma (RCC) (Phase ll Only)|Glioblastoma (GBM) (Phase ll Only)|Melanoma (Phase 1 Only)","Drug: Combination of varlilumab and nivolumab","Celldex Therapeutics|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","190","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDX1127-02","December 18, 2014","January 2015","January 2020","July 21, 2016","July 2016","No Study Results Posted","null","December 2017","Phase I: Number of participants with treatment-related adverse events as determined by CTCAE v4.0, dose-limiting toxicities, and laboratory abnormalities in patients being treated with the combination of varlilumab and nivolumab.|Phase II: Preliminary antitumor activity of the combination of varlilumab and nivolumab as measured by objective response rate (ORR) in patients with NSCLC, CRC, ovarian cancer, RCC and SCCHN and Overall Survival-12 months (OS12) in patients with GBM.","https://ClinicalTrials.gov/show/NCT02335918"
2424,"NCT00553683","Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer","Active, not recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Gastric Cancer|Liver Cancer|Melanoma (Skin)|Metastatic Cancer|Ovarian Cancer|Pancreatic Cancer","Drug: cyclophosphamide|Drug: poly ICLC|Procedure: hepatic artery embolization|Radiation: 3-dimensional conformal radiation therapy","Rutgers, The State University of New Jersey","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000573370|UMDNJ-0120070076","November 2, 2007","October 2007","July 2014","January 11, 2014","January 2014","No Study Results Posted","null","February 2014","Overall tolerability|Progression-free survival at 6, 12, and 24 months|Overall survival at 6, 12, and 24 months","https://ClinicalTrials.gov/show/NCT00553683"
2425,"NCT00087256","Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer","Terminated","No Results Available","Colorectal Cancer","Drug: Celecoxib|Other: placebo","NSABP Foundation Inc|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","18","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NSABP P-3|NSABP-P-3","July 8, 2004","July 2004","April 2006","January 4, 2013","January 2013","No Study Results Posted","null","April 2006","To determine whether celecoxib 400 mg bid for 3 years will decrease the incidence of adenomatous polyps of the colon and rectum in participants with Stage I adenocarcinoma of the colon.|To access whether celecoxib will increase disease-free survival.|To access whether celecoxib therapy affects self-reported symptoms and health-related quality of life.|To describe the quality of life in early stage colon cancer patients.|To evaluate if the benefits from celecoxib are more pronounced in a cohort of participants whose primary colon tumors and polyps express COX-2.|To examine the expression of signaling targets such as serine/threonine kinase (AKT) extracellular signal-regulated kinase (ERK2), and endoplasmic reticulum Ca2+-ATPases in the index tumor and polyps.|To monitor the toxicity and safety of celecoxib in this population.","https://ClinicalTrials.gov/show/NCT00087256"
2426,"NCT00086931","Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: oxaliplatin|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Roswell Park Cancer Institute","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 10803|RPCI-I-10803|SANOFI-RPCI-I-10803","July 8, 2004","September 2003","May 2010","March 7, 2013","March 2013","No Study Results Posted","null","May 2007","Complete pathological response rate at time of surgery|Disease-free survival, safety, and overall survival at 5 years","https://ClinicalTrials.gov/show/NCT00086931"
2427,"NCT01087268","Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer","Recruiting","No Results Available","Bladder Cancer|Cervical Cancer|Colorectal Cancer|Endometrial Cancer|Gastrointestinal Complications|Long-term Effects Secondary to Cancer Therapy in Adults|Ovarian Cancer|Prostate Cancer|Radiation Toxicity|Sarcoma|Testicular Germ Cell Tumor|Vaginal Cancer","Other: questionnaire administration|Procedure: gastrointestinal complications management/prevention|Procedure: quality-of-life assessment","Royal Marsden NHS Foundation Trust|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","75","Other","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Supportive Care","CDR0000667367|RMH-CCR3086|EUDRACT-2008-002152-26|EU-21010|MREC-08/H0903/40","March 13, 2010","January 2009","null","July 14, 2011","March 2010","No Study Results Posted","null","December 2011","Gastrointestinal symptoms score using the IBDQ quality-of-life questionnaire|Physician assessment of adverse effects using LENT SOMA scales of radiation injury|Patient self-assessments using EORTC QLQ-C30 and Defecation Problem Subscale of QLQ-CR38|Photographic images of rectal mucosa|Physician assessment of rectal dysfunction based on the modified CTCAE grading system|Health economics data","https://ClinicalTrials.gov/show/NCT01087268"
2428,"NCT00766155","Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: oxaliplatin","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years and older   (Adult, Senior)","Phase 3","1094","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-40054-22062|EU-20880|PETACC-6|ROCHE-EORTC-40054|2006-006532-21","October 2, 2008","August 2008","null","February 19, 2015","February 2015","No Study Results Posted","PETACC-6","September 2011","Disease-free survival|Overall survival within at least the first 5 years after treatment|Loco-regional failure, defined as local or regional recurrence, inoperable disease, or R1 or R2 resection|Distant failure (i.e., distant metastasis)|Pathological down-stage (ypT0, 2N0) rate|Pathological complete remission (ypT0N0) rate|Tumor regression grade|Histopathological R0 resection rate|Sphincter preservation rate|Preoperative complication rate|Toxicity according to CTCAE v.3.0 weekly during treatment, at 4-8 weeks after surgery, at therapy completion, and every 6 months for 5 years after therapy completion","https://ClinicalTrials.gov/show/NCT00766155"
2429,"NCT00003038","Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Adrenocortical Carcinoma|Breast Cancer|Colorectal Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: doxorubicin hydrochloride|Drug: suramin","Mayo Clinic|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065661|U01CA069912|P30CA015083|960105","November 1, 1999","October 1997","January 2003","August 2, 2011","August 2011","No Study Results Posted","null","January 2003","","https://ClinicalTrials.gov/show/NCT00003038"
2430,"NCT00303875","Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Prostate Cancer","Behavioral: behavioral dietary and exercise intervention","Duke University|National Cancer Institute (NCI)","Both","65 Years and older   (Adult, Senior)","Phase 2","641","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label","Pro00012963|DUMC-5477-03-12R0ER|DUMC-5477-04-12R1ER|CDR0000460231","March 15, 2006","December 2003","May 2009","April 9, 2013","February 2013","No Study Results Posted","null","June 2008","Physical function as assessed by Short-Form Health Survey (SF-36) with physical function subscale and late effects lower body subscales at baseline and years 1 and 2 following study completion|Quality of life as assessed by SF-36 at baseline and years 1 and 2 following study completion|Physical activity as assessed by Community Healthy Activities Model Program for Seniors (CHAMPS) at baseline and years 1 and 2 following study completion|Dietary intake as assessed by 2-day dietary recalls at baseline and years 1 and 2 following study completion|Body weight status as assessed by body mass index at baseline and years 1 and 2 following study completion|Depression and/or anxiety as assessed by Hospital Anxiety Depression Scale at baseline and years 1 and 2 following study completion|Self-efficacy for exercise and dietary change assessed by self-efficacy algorithms at baseline and years 1 and 2 following study completion|Stage of readiness for exercise and dietary change as assessed by the stage of change algorithms at baseline and years 1 and 2 following study completion","https://ClinicalTrials.gov/show/NCT00303875"
2431,"NCT00058474","Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: fluorouracil|Drug: oxaliplatin|Radiation: radiation therapy","NSABP Foundation Inc|National Cancer Institute (NCI)|Cancer and Leukemia Group B","Both","18 Years and older   (Adult, Senior)","Phase 3","1608","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP R-04|NSABP-R-04|CALGB-NSABP-R-04","April 7, 2003","July 2004","May 2016","March 22, 2016","March 2016","No Study Results Posted","null","August 2013","Loco-regional disease control as assessed by evidence of tumor at 3 years|Clinical complete response as assessed by digital rectal exam and sigmoidoscopy or proctoscopy at time of definitive analysis|Pathologic complete response as assessed by gross and microscopic exam of surgical specimens at time of definitive analysis|Sphincter-saving surgery at time of definitive analysis|Survival as measured by deaths from any cause at time of definitive analysis|Disease-free survival as assessed by recurrence, second primary cancer, or death from any cause at time of definitive analysis|Tissue biomarkers as assessed by analysis of tumor tissue using current biotechnology after definitive analysis|Quality of life as assessed by FACT-C trial outcome index and EORTC CR38 after definitive analysis|Neurotoxicity as assessed by FACT-NTX scale after definitive analysis|Symptoms as assessed by fluoropyrimidine symptom scale adapted from SWOG after definitive analysis|Vitality as assessed by SF-36 vitality scale after definitive analysis|Convenience of care as assessed by NSABP C-06 convenience of care scale adapted from ECOG after definitive analysis","https://ClinicalTrials.gov/show/NCT00058474"
2432,"NCT00529984","A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies","Completed","No Results Available","Colorectal Cancer|Breast Cancer|Lung Cancer|Pancreatic Cancer|Colon Cancer","Biological: AVX701|Biological: AVX701|Biological: AVX701|Biological: AVX701|Biological: AVX701","AlphaVax, Inc.|Duke University","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","28","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AVX701|P01CA078673-04","September 12, 2007","September 2007","May 2010","July 11, 2012","July 2012","No Study Results Posted","CEA(6D)VRP","May 2010","determine the safety of immunization with CEA(6D) VRP|evaluate CEA-specific immune response to immunizations","https://ClinicalTrials.gov/show/NCT00529984"
2433,"NCT00900835","Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Fatigue|Lung Cancer|Pain|Prostate Cancer","Other: educational intervention|Other: questionnaire administration|Other: study of socioeconomic and demographic variables|Procedure: assessment of therapy complications|Procedure: fatigue assessment and management|Procedure: quality-of-life assessment|Procedure: standard follow-up care","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","470","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","04140|R01CA115323|P30CA033572|CHNMC-04140|CDR0000628799","May 12, 2009","June 2005","August 2010","March 3, 2011","March 2011","No Study Results Posted","null","September 2009","Quality of life|Pain knowledge of patients and professionals|Fatigue knowledge of patients and professionals|Adherence to algorithm by patients, professionals, and system|Satisfaction of patients and professionals","https://ClinicalTrials.gov/show/NCT00900835"
2434,"NCT00465725","A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors","Completed","No Results Available","Bladder Cancer|Breast Cancer|Colorectal Cancer|Gastrointestinal Neoplasm|Head and Neck Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer","Drug: Picoplatin","Poniard Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","0602 Oral Picoplatin","April 23, 2007","April 2007","July 2009","September 23, 2009","September 2009","No Study Results Posted","null","July 2009","MTD|Comparison of platinum levels excreted in urine from 0-8 and 8-24 hours after start of IV or oral drug","https://ClinicalTrials.gov/show/NCT00465725"
2435,"NCT01012804","Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer","Withdrawn","No Results Available","Colorectal Cancer","Genetic: western blotting|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Georgetown University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","0","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CDR0000078662|P30CA051008|GUMC-00074|NCI-G01-1992","November 12, 2009","January 2000","null","March 23, 2011","March 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01012804"
2436,"NCT01373320","Faith Moves Mountains: A Community Based Participatory Research (CBPR) Appalachian Wellness & Cancer Prevention Program","Completed","No Results Available","Lung Cancer|Cervical Cancer|Breast Cancer|Colorectal Cancer","Behavioral: Lay health advisor interactions","Nancy Schoenberg|National Institute on Minority Health and Health Disparities (NIMHD)|University of Kentucky","Both","18 Years and older   (Adult, Senior)","","1415","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Prevention","R24MD002757","June 10, 2011","March 2010","November 2012","October 21, 2013","October 2013","No Study Results Posted","null","November 2012","Proportion of participants reporting the health behavior of interest (depending on which intervention component(s) were selected)|Change in stage of readiness to change the selected health behavior(s) from baseline|Number of visits completed|Retention (i.e., number of participants who complete all planned assessment timepoints)","https://ClinicalTrials.gov/show/NCT01373320"
2437,"NCT02897375","Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors","Not yet recruiting","No Results Available","Solid Neoplasm|Stage III Pancreatic Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IVA Pancreatic Cancer|Stage IVB Pancreatic Cancer|Sarcoma|Colorectal Cancer|Head and Neck Cancer|Cancer of Unknown Primary|Bladder Cancer|Ovarian Cancer","Drug: Carboplatin|Drug: Cisplatin|Drug: Palbociclib","Emory University|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","90","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00085983|NCI-2016-01037|Winship3263-16","August 30, 2016","October 2016","February 2021","September 7, 2016","September 2016","No Study Results Posted","null","February 2019","Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Incidence of dose limiting toxicities defined as grade 3 or higher toxicity|Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin|Overall response rate (complete response + partial response) assessed by Response Evaluation Criteria in Solid Tumors 1.1 criteria|Pharmacokinetic (PK) characteristics of carboplatin including maximum concentration (Cmax)|Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax)","https://ClinicalTrials.gov/show/NCT02897375"
2438,"NCT00002525","Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed","Terminated","Has Results","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Southwest Oncology Group|Cancer and Leukemia Group B|American College of Surgeons|NSABP Foundation Inc|Eastern Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 3","859","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E1292|U10CA023318|CDR0000078337","November 1, 1999","August 1993","April 2015","July 19, 2016","July 2016","April 8, 2016","null","February 2015","5-year Overall Survival Rate in Patients With Dukes' B3/C Disease|5-year Disease-free Survival Rate in Patients With Dukes' B3/C Disease|5-year Overall Survival Rate in Patients With Dukes' B2 Disease|5-year Disease-free Survival Rate in Patients With Dukes' B2 Disease","https://ClinicalTrials.gov/show/NCT00002525"
2439,"NCT00963911","Questionnaire in Screening Older Patients With Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Lymphoma|Prostate Cancer","Other: medical chart review|Other: screening questionnaire administration|Procedure: comparison of screening methods|Procedure: quality-of-life assessment","Institut Bergonié|National Cancer Institute (NCI)","Both","70 Years and older   (Senior)","","1650","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Screening","CDR0000637122|IB-ONCODAGE|IB 2008-06|RECF0891","August 21, 2009","June 2008","null","May 12, 2011","May 2011","No Study Results Posted","null","May 2011","Validation of G8 screening tool","https://ClinicalTrials.gov/show/NCT00963911"
2440,"NCT01524978","A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers","Active, not recruiting","No Results Available","Multiple Myeloma, Neoplasms","Drug: cetuximab|Drug: vemurafenib [Zelboraf]|Drug: vemurafenib [Zelboraf]","Hoffmann-La Roche","Both","16 Years and older   (Child, Adult, Senior)","Phase 2","208","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MO28072","January 27, 2012","April 2012","September 2016","September 1, 2016","September 2016","No Study Results Posted","null","September 2016","Tumor Response Rate|Maximum tolerated dose for Zelboraf in combination with cetuximab|Dose-limiting toxicities of Zelboraf in combination with cetuximab|Safety: Incidence of adverse events|Overall Response Rate (ORR)|Clinical benefit rate|Duration of Response (DOR)|Time to Response|Time to Tumor Progression (TTP)|Progression free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01524978"
2441,"NCT00007930","Comparison of Two Types of Surgery in Treating Patients With Rectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: conventional surgery|Procedure: laparoscopic surgery","National Medical Research Council (NMRC), Singapore|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","800","Other","Interventional","Primary Purpose: Treatment","CDR0000068354|NMRC-ICR01|EU-99019","January 6, 2001","August 1999","null","August 23, 2013","December 2006","No Study Results Posted","null","null","Local recurrence at 3 years|Disease-free and overall survival at 5 years","https://ClinicalTrials.gov/show/NCT00007930"
2442,"NCT00379782","Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project","Completed","No Results Available","Breast Cancer|Cervical Cancer|Prostate Cancer|Colorectal Cancer|Lung Cancer","Other: Navigation","Queen's Medical Centre","Both","21 Years and older   (Adult, Senior)","","628","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","RA-2006-025","September 20, 2006","October 2006","March 2011","May 26, 2011","May 2011","No Study Results Posted","null","March 2011","subject satisfaction with navigation","https://ClinicalTrials.gov/show/NCT00379782"
2443,"NCT00703638","Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Mesothelioma|Pancreatic Cancer|Prostate Cancer|Sarcoma","Drug: cisplatin|Drug: pemetrexed disodium|Drug: sorafenib","Masonic Cancer Center, University of Minnesota","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007LS086|0712M22703","June 20, 2008","May 2008","November 2010","November 6, 2012","November 2012","No Study Results Posted","null","September 2010","Maximum tolerated dose of sorafenib tosylate|Disease Response|Maximum, Minimum and AUC Concentrations of Sorafenib","https://ClinicalTrials.gov/show/NCT00703638"
2444,"NCT02870920","Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: Tremelimumab|Drug: Durvalumab|Other: Best Supportive Care","Canadian Cancer Trials Group|AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","180","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CO26","August 10, 2016","August 2016","February 2019","August 12, 2016","August 2016","No Study Results Posted","null","August 2018","Overall survival|Progression-free survival defined as the time from randomization to the first objective documentation of disease progression or death due to any cause|Objective response rate defined as the proportion of patients with a documented complete response and partial response based on RECIST 1.1|Number and severity of adverse events using the NCI Common Terminology Criteria for Adverse Events.","https://ClinicalTrials.gov/show/NCT02870920"
2445,"NCT00098943","NGR-TNF in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Colorectal Cancer|Head and Neck Cancer|Kidney Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: CNGRC peptide-TNF alpha conjugate","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years and older   (Adult, Senior)","Phase 1","70","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","EORTC-16041|MOLMED-EORTC-16041|EUDRACT-2004-000950-21","December 8, 2004","September 2004","null","September 20, 2012","September 2012","No Study Results Posted","null","November 2007","Dose-limiting toxicity and maximum tolerated dose as measured by CTC v 3.0|Clinical response as measured by RECIST criteria|Mechanism of action as measured by Dynamic Imaging","https://ClinicalTrials.gov/show/NCT00098943"
2446,"NCT00002523","Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically Removed","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Procedure: conventional surgery|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","Both","up to 80 Years   (Child, Adult, Senior)","Phase 3","1011","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-22921","November 1, 1999","April 1993","January 2016","September 1, 2016","September 2016","No Study Results Posted","null","March 2003","","https://ClinicalTrials.gov/show/NCT00002523"
2447,"NCT02821793","Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer","Recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Prostate Cancer|Sarcoma|Ovarian Cancer|Lymphoma","Other: Consultation, evaluation questionnaire|Other: Geriatric consultation, evaluation questionnaire","Institut Bergonié|Fondation Université de Bordeaux|AG2R La Mondiale","Both","18 Years and older   (Adult, Senior)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IB 2015-06","June 14, 2016","January 2016","July 2019","June 29, 2016","June 2016","No Study Results Posted","PRIORITY","May 2018","Priorities of patients aged 70 and over and receiving first medical treatment for cancer.|Priorities of patients aged 70 and over and receiving first medical treatment for cancer|Intra- individual reproducibility of the prioritization grid regarding the initial measurement of priorities of the elderly.|Describe expectations of patients at initiation of treatment|Describe expectations of patients 3 months after initiation of treatment|Describe priorities and expectations of patients, at 6 months after initiation of treatment|Describe priorities and expectations of patients, at 12 months after initiation of treatment|Describe 3 months after initiation of treatment, the rate of stable patients in their priorities|Describe 6 months after initiation of treatment, the rate of stable patients in their priorities|Describe 12 months after initiation of treatment, the rate of stable patients in their priorities|Overall survival, according to priorities changing or not|Compare priorities of older subjects compared to younger patients or physician's priorities","https://ClinicalTrials.gov/show/NCT02821793"
2448,"NCT00019435","LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Bladder Cancer|Breast Cancer|Colorectal Cancer|Esophageal Cancer|Gastric Cancer|Lung Cancer|Pancreatic Cancer","Biological: LMB-9 immunotoxin","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000066180|NCI-98-C-0078A|NCI-MB-400|NCI-T98-0005","July 11, 2001","May 1998","null","April 28, 2015","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00019435"
2449,"NCT00025532","Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer","Withdrawn","No Results Available","Colorectal Cancer|Esophageal Cancer|Gastric Cancer|Pancreatic Cancer","Other: iodine I 131 monoclonal antibody CC49-deltaCH2","University of California, San Francisco|National Cancer Institute (NCI)","Both","19 Years and older   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068971|UCSF-H11156-18101-02|UCSF-00455|NCI-T97-0054","October 11, 2001","April 2001","null","September 13, 2012","September 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00025532"
2450,"NCT02374255","Improving Goals of Care Discussion in Advanced Cancer Patients","Recruiting","No Results Available","Primary Stage IV Hepatobiliary|Esophageal|Colorectal Cancer|Glioblastoma|Cancer of Stomach|Cancer of Pancreas|Melanoma|Head or Neck Cancer|Stage III|Stage IV|Lung Cancers|Pancreatic Cancers","Behavioral: GoC intervention","Icahn School of Medicine at Mount Sinai|Patient-Centered Outcomes Research Institute","Both","21 Years and older   (Adult, Senior)","Phase 2","280","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","GCO 14-0082","February 9, 2015","February 2015","April 2017","June 30, 2016","June 2016","No Study Results Posted","null","November 2016","Increased Goals of Care Discussions (measured by GoC patient survey.)|Improved Goals of Care Discussions (measured by GoC patient survey.)|Communication Skills Training (measured by a 22 item scoring sheet.)","https://ClinicalTrials.gov/show/NCT02374255"
2451,"NCT00002455","Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma","Active, not recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Melanoma (Skin)","Biological: Corynebacterium granulosum P40|Procedure: adjuvant therapy","Centro Oncologico de Excelencia|National Cancer Institute (NCI)","Both","20 Years to 80 Years   (Adult, Senior)","Phase 3","null","Other","Interventional","Primary Purpose: Treatment","ARG-CO/BR-1|CDR0000072435","November 1, 1999","April 1971","null","August 6, 2013","November 1998","No Study Results Posted","null","null","Recurrence|Response to study parameters|Survival rate","https://ClinicalTrials.gov/show/NCT00002455"
2452,"NCT00049608","Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors","Terminated","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer","Dietary Supplement: mistletoe extract|Drug: gemcitabine hydrochloride","National Center for Complementary and Integrative Health (NCCIH)|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","51","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000258130|NCCAM-02-AT-260|NCI-02-AT-0260","November 12, 2002","July 2002","August 2011","June 17, 2013","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00049608"
2453,"NCT00280761","Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy","Recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: 5-fluorouracil|Procedure: Surgical Resection|Radiation: Radiation therapy","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","60","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","LCCC 0216|P30CA016086|CDR0000561688","January 19, 2006","December 2003","December 2019","July 1, 2016","July 2016","No Study Results Posted","null","December 2018","Activation of NF-kappa B in response to treatment with external beam radiotherapy|Correlation of NF-kappa B pathway activation with therapeutic outcomes|Downstream events induced by NF-kappa B activation|Global gene expression profiles at baseline and during chemoradiotherapy|Correlation of changes in gene expression with patient outcomes|Downstream events related to activation of p53 in response to treatment with radiotherapy|Correlation of p53 pathway-mediated events with clinical outcomes","https://ClinicalTrials.gov/show/NCT00280761"
2454,"NCT00003422","Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Medical Research Council|NCIC Clinical Trials Group|National Cancer Institute (NCI)","Both","up to 75 Years   (Child, Adult, Senior)","Phase 3","1800","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066442|MRC-CR07|EU-98008|CAN-NCIC-C016|ISRCTN28785842","November 1, 1999","January 1998","June 2010","December 3, 2013","March 2007","No Study Results Posted","null","null","Local recurrence by biopsy, imaging, or imaging and carcinoembryonic antigen result|Local recurrence-free survival|Overall survival|Time to appearance of distant metastases|Disease-free survival|Morbidity|Quality of life|Economic implications","https://ClinicalTrials.gov/show/NCT00003422"
2455,"NCT02020291","Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer","Completed","No Results Available","Metastatic Breast Cancer|Colorectal Cancer|Prostate Cancer","Drug: Foxy-5","WntResearch AB","Both","18 Years and older   (Adult, Senior)","Phase 1","31","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SMR-2562","December 11, 2013","June 2013","November 2015","February 1, 2016","February 2016","No Study Results Posted","null","November 2015","Safety and tolerability of Foxy-5|Profile for the biomarker NGAL and the amount of circulating tumour cells before and after treatment with Foxy-5|Profile for the biomarker 15-PGHD and the amount of circulating tumour cells before and after treatment with Foxy-5|Maximum tolerated dose (MTD)|Area under the plasma concentration curve (AUC) of Foxy-5|Maximum observed plasma drug concentration (Cmax) of Foxy-5|Time to maximum observed plasma drug concentration (tmax) of Foxy-5|Terminal elimination half-life (t½) of Foxy-5|Total plasma clearance (CL) of Foxy-5|Volume of distribution (V) of Foxy-5|Plasma concentration at steady state (Css) of Foxy-5|Drug accumulation ratio of Foxy-5|mRNA expression and protein expression of Wnt-5a|Anti-tumour activity of Foxy-5","https://ClinicalTrials.gov/show/NCT02020291"
2456,"NCT00427570","Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery","Completed","No Results Available","Colorectal Cancer","Biological: BCG vaccine|Biological: biological therapy|Drug: fluorouracil|Drug: semustine|Drug: vincristine sulfate","NSABP Foundation Inc|National Cancer Institute (NCI)","Both","up to 79 Years   (Child, Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000071312|NSABP-C-01","January 18, 2007","September 1977","May 2006","June 21, 2013","August 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00427570"
2457,"NCT01975831","A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab","Recruiting","No Results Available","Breast Cancer|Ovarian Cancer|Colorectal Cancer|Cervical Cancer|Renal Cell Carcinoma","Drug: MEDI4736|Drug: Tremelimumab","Ludwig Institute for Cancer Research|MedImmune LLC|Cancer Research Institute, New York City","Both","18 Years and older   (Adult, Senior)","Phase 1","105","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LUD2013-003","October 29, 2013","December 2013","null","September 8, 2016","September 2016","No Study Results Posted","null","October 2017","Number of adverse events|Area under the concentration time curve, maximum concentration, clearance, half-life after administration of MEDI4736 and Tremelimumab|Number and percentage of subjects who develop detectable anti-drug antibodies (ADAs)|Tumor Response by the Immune-related Response Criteria|Tumor Response using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors|Progression-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01975831"
2458,"NCT00541112","Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery","Recruiting","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: capecitabine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","103","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000565937|FRE-FNCLCC-ACCORD-14/0604|EU-20759|EUDRACT-2006-003336-30","October 5, 2007","July 2007","null","February 19, 2009","October 2007","No Study Results Posted","null","null","Complete remission at ≥ 6 months by abdomino-pelvic-thoracic scan and a pelvic MRI|Preoperative clinical response|Progression-free survival|Overall survival|Early toxicity before surgery|Early toxicity due to surgery (mortality at 30 days, postoperative complications, surgical recovery)|Late toxicity|Late radiotherapy toxicity by CTC AE v. 3.0|Objective response of measurable metastases by RECIST|Sexual function|Downstaging and downsizing of patients with operable disease|Surgical complications|Sphincter function|Predictive biomarkers of response to cetuximab","https://ClinicalTrials.gov/show/NCT00541112"
2459,"NCT00936832","Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery","Withdrawn","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: FOLFIRI regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: sunitinib malate|Other: laboratory biomarker analysis|Other: pharmacogenomic studies|Other: pharmacological study","Federation Francophone de Cancerologie Digestive","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000637832|FFCD-0801|EUDRACT-2008-005959-19|EU-20918","July 8, 2009","April 2009","null","March 3, 2014","July 2009","No Study Results Posted","null","null","Response rate at 3 months as assessed by RECIST criteria|Rate of complete response after resection|Rate of R0 resection of metastases|Rate of local failure|Rate of local complications|Metastatic progression-free survival|Local progression-free survival|Disease-free survival|Symptom-free survival|Overall survival|Quality of life, specifically fatigue and global health score (EORTC QLQ-C30)|Time to deterioration of the final score for overall health and fatigue|Tolerance and incidence of side effects as assessed by NCI CTCAE v2|Translational research including pharmacodynamic studies of plasma and rectal tumor biopsies and histological and molecular studies","https://ClinicalTrials.gov/show/NCT00936832"
2460,"NCT01167725","Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: bevacizumab|Biological: cetuximab|Drug: FOLFIRI regimen|Drug: FOLFOX regimen|Drug: capecitabine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: mitomycin C|Drug: oxaliplatin|Procedure: therapeutic conventional surgery","Walter Reed Army Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","340","U.S. Fed|NIH","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000681540|WRAMC-8214","July 21, 2010","August 2010","null","January 21, 2012","January 2012","No Study Results Posted","null","May 2014","Overall survival (OS)|Progression-free survival (PFS)|Quality of life|Toxicity burden|Circulating tumor cells|Comparison of OS and PFS according to patients' peritoneal surface tumor genotype for the NAD(P)H","https://ClinicalTrials.gov/show/NCT01167725"
2461,"NCT00898846","Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: tegafur-uracil|Genetic: polymerase chain reaction|Genetic: reverse transcriptase-polymerase chain reaction|Other: diagnostic laboratory biomarker analysis","Tokyo Medical and Dental University|National Cancer Institute (NCI)","Both","20 Years to 80 Years   (Adult, Senior)","","1000","Other","Observational","","CDR0000551714|TMDU-BRI-CC-05-02","May 9, 2009","October 2006","null","December 17, 2013","August 2011","No Study Results Posted","null","null","Prognostic factors|Predictive factors of chemosensitivity","https://ClinicalTrials.gov/show/NCT00898846"
2462,"NCT02824484","A Guided Written Disclosure Intervention to Promote Post-traumatic Growth in Cancer Patients GUIDED WRITTEN DISCLOSURE","Recruiting","No Results Available","Breast Cancer|Colorectal Cancer","Behavioral: GWDP|Behavioral: Control","Arcispedale Santa Maria Nuova-IRCCS|European University of Rome","Both","18 Years and older   (Adult, Senior)","","250","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","2015/0024360","June 10, 2016","November 2015","December 2017","July 5, 2016","April 2016","No Study Results Posted","null","December 2017","Change in post-traumatic growth from baseline to post-intervention assessment and at 6 months follow-up. Post-Traumatic Growth Inventory (PTGI) will be used to assess this outcome|Change in constructed meaning from baseline to post-intervention assessment and at 6 monts follow-up. Constructed Meaning Scale (CMS) will be used to assess this outcome|Change in intrusive thoughts and avoidance from baseline to post-intervention assessment and at 6 months follow-up. Impact of Event Scale (IES) will be used to assess this outcome|Change in anxiety and depression from baseline to post-intervention assessment and at 6 months follow-up. Hospital Anxiety and Depression Scale (HADS) will be used to assess this outcome","https://ClinicalTrials.gov/show/NCT02824484"
2463,"NCT00900432","Immune Response in Peripheral Blood of Patients With Colon Cancer","Completed","No Results Available","Colorectal Cancer","Other: immunoenzyme technique|Other: laboratory biomarker analysis","University of Arizona|National Cancer Institute (NCI)","Both","Child, Adult, Senior","","67","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","04-0331-01|P50CA095060|P30CA023074|UARIZ-04-81","May 9, 2009","July 2004","December 2008","December 2, 2015","August 2012","No Study Results Posted","null","December 2008","Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1)","https://ClinicalTrials.gov/show/NCT00900432"
2464,"NCT01174121","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer|Metastatic Gastric Cancer|Metastatic Pancreatic Cancer|Metastatic Hepatocellular Carcinoma|Metastatic Cholangiocarcinoma","Biological: Young TIL|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Pembrolizumab","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","290","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","100166|10-C-0166","July 31, 2010","July 2010","December 2019","August 31, 2016","August 2016","No Study Results Posted","null","December 2018","To determine the rate of tumor regression in patients in cohort 3 with metastatic digestive tract, urothelial, breast, and ovarian/endometrial cancers who receive autologous, minimally cultured tumor infiltrating lymphocytes (TIL) plus aldesleuk...|To determine the toxicity of this treatment regimen.|To evaluate the safety and efficacy of pembrolizumab in combination with the TIL therapy","https://ClinicalTrials.gov/show/NCT01174121"
2465,"NCT00012246","Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract","Terminated","No Results Available","Colorectal Cancer|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Pancreatic Cancer|Small Intestine Cancer","Biological: carcinoembryonic antigen peptide 1-6D|Biological: incomplete Freund's adjuvant|Biological: sargramostim","The University of Texas Medical Branch, Galveston|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","7","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068497|UTMB-00-297|NCI-931","March 3, 2001","July 2002","July 2006","May 15, 2013","May 2013","No Study Results Posted","null","July 2006","Production of CAP 1-6D T cells|Production of cytotoxic T cells|Antitumor response|Frequency and severity of toxic effects","https://ClinicalTrials.gov/show/NCT00012246"
2466,"NCT00814619","Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: panitumumab|Drug: capecitabine|Procedure: therapeutic conventional surgery|Radiation: 3-dimensional conformal radiation therapy","Swiss Group for Clinical Cancer Research","Both","18 Years and older   (Adult, Senior)","Phase 2","68","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 41/07|SWS-SAKK-41-07|EudraCT-2008-006012-38|EU-20894|CDR0000629101","December 24, 2008","November 2008","January 2014","April 29, 2014","April 2014","No Study Results Posted","null","May 2010","Pathological complete or near-complete response (Dworak grade 3 and 4)|Pathological response|R0 or R1 resection|Postoperative complications (within 8 weeks after surgery)|Time to local relapse|Time to distant failure|Disease-free survival|Adverse events","https://ClinicalTrials.gov/show/NCT00814619"
2467,"NCT00004150","High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Procedure: adjuvant therapy","Robert Roessle Klinik|European Organisation for Research and Treatment of Cancer - EORTC|Federation Francophone de Cancerologie Digestive|Grupo Espanol Tratamiento Tumores Digestivos|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067383|PETACC-2|EORTC-40963|FFCD-PETACC-2|GETTD-PETACC-2","December 10, 1999","March 1999","April 2007","November 5, 2013","February 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004150"
2468,"NCT02586987","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours","Recruiting","No Results Available","Lung Cancer|Melanoma|Head and Neck Carcinoma|Gastroesophageal Cancer|Breast Cancer|Pancreatic Adenocarcinoma|Colorectal Cancer","Drug: Selumetinib and Medi4736","AstraZeneca","Both","18 Years to 130 Years   (Adult, Senior)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D1345C00003","September 21, 2015","December 2015","September 2017","August 16, 2016","August 2016","No Study Results Posted","null","September 2017","The number of patients with Adverse Events related to treatment|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of safety laboratory tests|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of blood pressure (BP)|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of ECG (Electrocardiogram)|Safety and tolerability of Selumetinib in Combination with MEDI4736 by assessment of physical examinations|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of ECHO (Echocardiogram)|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of pulse|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of body temperature|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of respiratory rate|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of MUGA (Multigated Acquisition)|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of Ophthalmic examination (best corrected visual acuity)|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of Ophthalmic examination (Intraocular pressure)|Safety and tolerability of Selumetinib in combination with MEDI4736 by assessment of Ophthalmic examination (slit lamp fundoscopy)|Cmax (Maximum concentration) - Pharmacokinetics of Selumetinib and Medi4736|An initial tumour response by assessment of RECIST (Response Evaluation Criteria in Solid Tumours)|ORR (Objective response rate)|Change in tumour size|BoR (Best Objective Response)|DoR (Duration of Response)|AUC (Area under the concentration-time curve) - Pharmacokinetics of Selumetinib and Medi4736","https://ClinicalTrials.gov/show/NCT02586987"
2469,"NCT00417040","Collection of Patient-Reported Symptoms and Performance Status Via the Internet","Active, not recruiting","No Results Available","Prostate Cancer|Breast Cancer|Lung Cancer|Colorectal Cancer|Leukemia|Multiple Myeloma","Other: internet-based intervention|Other: assessment of therapy complications|Other: Questionnaire Administration","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","300","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","CALGB-70501|CDR0000521898|NCI-2009-00489|UG1CA189823|U10CA037447","December 27, 2006","December 2006","null","April 15, 2016","April 2016","No Study Results Posted","null","March 2013","Willingness of approached patients to participate in this study this study|Proportion of enrolled patients who submit an online questionnaire at any given follow-up visit any given follow-up visit|Proportion of total attended visits during the study period at which a questionnaire was completed (completers:visits) which a questionnaire was completed (completers:visits)|Patient-reported CTCAE symptoms using symptom severity data|Clinician-reported CTCAE symptoms using symptom severity data clinician reporting at day 43 (when patients report before clinicians; clinicians view those reports) vs at day 22 (patients report symptoms after the clinical encounter)|Mean severity scores for patient reporting at day 43","https://ClinicalTrials.gov/show/NCT00417040"
2470,"NCT00005979","Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","UNICANCER|Federation Francophone de Cancerologie Digestive|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067967|FRE-FNCLCC-ACCORD-2|FFCD-9802|EU-20014","July 5, 2000","February 1998","null","February 3, 2009","September 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005979"
2471,"NCT00932308","Colorectal Inflammatory Response to a Western-Style Diet","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: Western-style diet (WD)|Dietary Supplement: Prudent Diet (PD)","Rockefeller University","Both","50 Years to 72 Years   (Adult, Senior)","","5","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","PHO-0588","December 11, 2008","September 2006","May 2008","February 15, 2012","February 2012","No Study Results Posted","null","May 2008","The degree of inflammation in the rectosigmoid epithelium as judged by the density and composition of the cellular infiltration.|Expression Profiles of pro- and anti-inflammatory genes in rectosigmoid biopsies as determined by microarray assay and RT-PCR.|Selected pro- and anti-inflammatory proteins in rectal biopsies|The levels of selected circulating and potential urinary inflammatory markers|The concentration of fecal calprotectin|Changes in bulk fecal and epithelial associated microbiota that may determine changes in colorectal epithelial cell biologic pathways.","https://ClinicalTrials.gov/show/NCT00932308"
2472,"NCT01099449","Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy","Completed","No Results Available","Chemotherapeutic Agent Toxicity|Colorectal Cancer|Neuropathy|Neurotoxicity","Drug: calcium gluconate|Drug: magnesium sulfate|Other: placebo|Drug: oxaliplatin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","362","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","N08CB|NCCTG-N08CB|CDR0000669660|NCI-2011-02036","April 6, 2010","June 2010","March 2013","August 11, 2016","August 2016","No Study Results Posted","null","March 2013","Oxaliplatin-induced sensory neuropathy as repeatedly measured by the EORTC QLQ-CIPN20 sensory subscale during chemotherapy|Area under the curve (AUC) of EORTC QLQ-CIPN20 motor subscale and autonomic subscale|Percentage of patients experiencing grade 2+ and grade 3+ chronic cumulative neurotoxicity (NCI CTCAE version 4.0 and oxaliplatin-specific neurotoxicity scale) during and after chemotherapy|Time to onset of grade 2+ and grade 3+ chronic cumulative neurotoxicity and the duration of the chronic cumulative neurotoxicity during and after chemotherapy|Cumulative oxaliplatin doses that can be administered without dose-limiting chronic neurotoxicity and the percentage of patients discontinuing oxaliplatin-based chemotherapy because of neurotoxicity|Percentage of acute neuropathy associated with oxaliplatin as measured by daily Side Effect Questionnaire during and after oxaliplatin-based chemotherapy (at 1, 3, 6, 12, and 18 months)|Incidence of calcium gluconate and magnesium sulfate-induced adverse events as measured by CTCAE version 4.0|AUC of patient-reported quality of life (QOL) as measured by the supplemental QOL questionnaire|Incidence and expression of GSTP1 or other gene polymorphism with early onset of oxaliplatin-induced neurotoxicity","https://ClinicalTrials.gov/show/NCT01099449"
2473,"NCT01898104","Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Radiation: preoperative radiation therapy|Drug: Valproic Acid|Drug: Capecitabine","National Cancer Institute, Naples","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","152","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","V-shoRT-R3|2012-002831-28","July 2, 2013","May 2012","December 2016","November 27, 2015","November 2015","No Study Results Posted","V-shoRT-R3","July 2016","maximum tolerated dose of capecitabine, given alone or in combination with valproic acid|number of patients with complete pathological tumor regression|overall survival|number of patients alive with disease progression|number of patients with pathologic complete response|changes in quality of life from baseline","https://ClinicalTrials.gov/show/NCT01898104"
2474,"NCT00027495","Curcumin for the Prevention of Colon Cancer","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: curcumin","University of Michigan Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Prevention","CDR0000067916|P30CA046592|CCUM-9941|NCI-P00-0144","December 7, 2001","December 2001","September 2007","December 19, 2012","December 2012","No Study Results Posted","null","February 2004","","https://ClinicalTrials.gov/show/NCT00027495"
2475,"NCT01902823","Effect of Cancer Nurse Navigators on Patient Outcomes","Terminated","No Results Available","Lung Cancer|Breast Cancer|Colorectal Cancer|Prostate Cancer","Behavioral: Services from a Nurse Navigator","University of Wisconsin, Madison|Aurora Health Care","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","16","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","11-86E","November 29, 2011","November 2011","May 2012","November 3, 2015","November 2015","No Study Results Posted","null","May 2012","Satisfaction with Care|ED/Urgent care visits|Quality of Life|Distressed mood|Symptom Distress|The Inventory of Recent Life Experiences for Cancer Patients","https://ClinicalTrials.gov/show/NCT01902823"
2476,"NCT00378716","Combination Chemotherapy in Treating Patients With Resected Colon Cancer","Completed","No Results Available","Colorectal Cancer","Drug: 5-fluorouracil|Drug: leucovorin calcium|Drug: tegafur|Drug: uracil","NSABP Foundation Inc|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 3","1608","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP C-06|U10CA012027|NSABP-C-06","September 20, 2006","February 1997","April 2009","January 8, 2010","January 2010","No Study Results Posted","null","May 2006","Compare the relative efficacy of UFT + LV with that of 5-FU + LV in prolonging disease-free survival and survival|evaluate the prognostic significants of proposed biomarkers, alone or in combination, in patients treated with 5-FU + LV or UFT + LV|Evaluate the relationships of various biomarkers to each other and to evaluate their association with patient and tumor characteristics|Compare quality of life in patients with stage II and III carcinoma of the colon treated with either 5-FU + LV or UFT + LV regimen","https://ClinicalTrials.gov/show/NCT00378716"
2477,"NCT01802645","Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases","Recruiting","No Results Available","Colorectal Cancer","Drug: Cetuximab|Drug: Bevacizumab|Drug: Irinotecan|Drug: Oxaliplatin|Drug: 5-FU|Drug: Folinic Acid","Technische Universität Dresden","Both","18 Years and older   (Adult, Senior)","Phase 2","256","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TUD-CELIM2-050|2011-003288-31","February 11, 2013","February 2013","July 2020","September 25, 2014","September 2014","No Study Results Posted","CELIM2","July 2017","Response rate|Rate of resected patients without early relaps","https://ClinicalTrials.gov/show/NCT01802645"
2478,"NCT00153998","Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)","Completed","No Results Available","Colorectal Cancer|Liver Metastases","Drug: Cetuximab|Procedure: Liver resection|Drug: Cetuximab and FOLFIRI|Drug: Cetuximab and FOLFOX","Technische Universität Dresden","Both","18 Years and older   (Adult, Senior)","Phase 2","135","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CELIM","September 8, 2005","November 2004","null","February 26, 2009","April 2007","No Study Results Posted","null","March 2008","Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population|Rate of R0 liver resection (ITT- population)|Progression free survival (ITT- population)|Disease free survival after resection (ITT- population)|Overall survival (ITT- population)|Safety (all patients that received any study drug)|Molecular predictive markers for response and toxicity","https://ClinicalTrials.gov/show/NCT00153998"
2479,"NCT01501604","BKM120 in Cancers With PIK3CA Activating Mutations","Withdrawn","No Results Available","Lung Cancer|Breast Cancer|Colorectal Cancer|Cholangiocarcinoma|Solid Tumors","Drug: BKM120","Massachusetts General Hospital|Novartis Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11-211","December 27, 2011","January 2012","August 2013","September 16, 2015","September 2015","No Study Results Posted","null","August 2013","Response Rate|Clinical Benefit Rate|Survival|Clinical Benefit","https://ClinicalTrials.gov/show/NCT01501604"
2480,"NCT00809796","A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment","Completed","No Results Available","Colorectal Cancer","Drug: pentamidine","Oncozyme Pharma Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","15","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OP-103","December 15, 2008","March 2008","June 2011","June 27, 2011","June 2011","No Study Results Posted","null","May 2011","Any severe events, tumor marker CEA, and tumor size (CT scan)","https://ClinicalTrials.gov/show/NCT00809796"
2481,"NCT02102022","Ph 1 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies","Recruiting","No Results Available","Advanced Gastrointestinal (GI) Malignancies|Hepatocellular Carcinoma|Gastric Cancer|Colorectal Cancer","Drug: ADI-PEG 20","Polaris Group","Both","18 Years and older   (Adult, Senior)","Phase 1","148","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","POLARIS2013-001","March 28, 2014","November 2014","October 2017","August 10, 2016","August 2016","No Study Results Posted","null","August 2017","Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.","https://ClinicalTrials.gov/show/NCT02102022"
2482,"NCT00016029","Comparison of Barium Enema, Computed Tomographic Colonography, and Colonoscopy in Detecting Colon Cancer","Terminated","No Results Available","Colorectal Cancer","Other: screening questionnaire administration|Procedure: barium enema injection|Procedure: computed tomography|Procedure: computed tomography colonography|Procedure: diagnostic colonoscopy|Procedure: screening colonoscopy","Duke University","Both","18 Years and older   (Adult, Senior)","","775","Other","Interventional","Primary Purpose: Diagnostic","0866|DUMC-000866-00-5R|DUMC-CA14326|NCI-V01-1655|CDR0000068587","May 6, 2001","August 2000","August 2005","March 20, 2013","September 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00016029"
2483,"NCT01284504","Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer","Withdrawn","No Results Available","Colorectal Cancer|Colon Cancer","Drug: Celecoxib","Stanford University","Both","18 Years to 75 Years   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","COL0001|SU-10182010-7110|19588","January 25, 2011","January 2011","May 2011","June 23, 2013","June 2013","No Study Results Posted","null","May 2011","Tumor sample - Analyzed for TCR Repertoire and Global Transcription Profiling|Blood samples taken before initiation of study, day of surgery, days 1 and 3 post-op, and 30 days post-op. Analyzed for 50 serum cytokines, cell-specific gene expression, and TCR Repertoire.|Surveys to evaluate patient pain, fatigue, and quality of recovery, recorded from day of surgery to 30 days post-op.","https://ClinicalTrials.gov/show/NCT01284504"
2484,"NCT00227747","Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: oxaliplatin|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","590","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000445034|FRE-FNCLCC-ACCORD-12/0405|EU-20522","September 26, 2005","July 2005","null","April 14, 2010","December 2006","No Study Results Posted","null","null","Rate of complete surgical resection|Overall survival|Disease-free survival|Sphincter preservation|Sphincter function|Biological parameters that predict tumor response and treatment-related toxicity|Acute and late toxicity","https://ClinicalTrials.gov/show/NCT00227747"
2485,"NCT00070434","S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum","Withdrawn","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin|Radiation: radiation therapy|Drug: Pyridoxine","Southwest Oncology Group|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000334469|U10CA032102|S0304","October 3, 2003","August 2004","null","June 5, 2012","June 2012","No Study Results Posted","null","February 2006","Response (confirmed and unconfirmed response, complete response, partial response)","https://ClinicalTrials.gov/show/NCT00070434"
2486,"NCT02636036","Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors","Recruiting","No Results Available","Colorectal Cancer|Bladder Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Salivary Gland Cancer","Biological: enadenotucirev|Biological: nivolumab","PsiOxus Therapeutics Ltd|INC Research","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Industry|Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ColoAd1-1003","November 20, 2015","January 2016","June 2019","September 8, 2016","September 2016","No Study Results Posted","SPICE","March 2019","Maximum Tolerated and/or Maximum Feasible Dose|to assess the blood levels of enadenotucirev following combination treatment|To examine the anti-tumor activity of combination treatment with enadenotucirev and nivolumab","https://ClinicalTrials.gov/show/NCT02636036"
2487,"NCT00091312","Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: FOLFIRI regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Procedure: adjuvant therapy","Federation Francophone de Cancerologie Digestive|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","1976","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000387797|FFCD-EORTC-40012|EORTC-40012|PETACC-4","September 7, 2004","June 2004","null","February 6, 2009","December 2006","No Study Results Posted","null","null","Disease-free survival at 5 years|Overall survival at 8 years|Tolerability|Correlation of clinical, histological, and biological prognostic factors with outcome","https://ClinicalTrials.gov/show/NCT00091312"
2488,"NCT00296608","Radiation Therapy With or Without Chemotherapy Before Surgery in Treating Patients With Stage II or Stage III Rectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Procedure: conventional surgery|Radiation: radiation therapy","Federation Francophone de Cancerologie Digestive","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","762","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000466625|FFCD-9203|EU-20600","February 24, 2006","April 1993","August 2008","May 27, 2016","May 2016","No Study Results Posted","null","August 2008","","https://ClinicalTrials.gov/show/NCT00296608"
2489,"NCT02857270","A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer","Not yet recruiting","No Results Available","Advanced Cancer|Metastatic Melanoma|Metastatic Non-small Cell Lung Cancer|Metastatic Pancreatic Ductal Adenocarcinoma|Colorectal Cancer","Drug: LY3214996|Drug: Midazolam|Drug: Abemaciclib|Drug: Nab-paclitaxel|Drug: Gemcitabine","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 1","136","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","16419|I8S-MC-JUAB|2016-001907-21","August 3, 2016","September 2016","September 2019","September 9, 2016","September 2016","No Study Results Posted","null","April 2019","Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs)|Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) of LY3214996 Administered as Monotherapy and when Administered in Combination with Nab-Paclitaxel Plus Gemcitabine, and Abemaciclib|PK: AUC of Gemcitabine when Administered with LY3214996|PK: AUC of Nab-Paclitaxel when Administered with LY3214996|PK: AUC of Abemaciclib and its Metabolites when Administered with LY3214996|PK: AUC of Midazolam and its 1'-Hydroxymidazolam Metabolite when Administered Alone and in Combination with LY3214996|Objective Response Rate (ORR): Percentage of Participants With a Complete (CR) or Partial Response (PR)|Duration of Response (DoR)|Time to First Response (TTR)|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02857270"
2490,"NCT01882946","Safety and Efficacy Study of DCVax-Direct in Solid Tumors","Active, not recruiting","No Results Available","Locally Advanced Tumor|Metastatic Solid Tissue Tumors|Liver Cancer|Colorectal Cancer|Pancreatic Cancer|Melanoma","Biological: DCVax-Direct","Northwest Biotherapeutics","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","60","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NWBio 050012","June 14, 2013","June 2013","null","October 6, 2015","October 2015","No Study Results Posted","null","December 2016","Number of patients with adverse events|Number of patients with tumor response","https://ClinicalTrials.gov/show/NCT01882946"
2491,"NCT00048971","Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy","Completed","No Results Available","Colorectal Cancer|Diarrhea|Neutropenia","Genetic: mutation analysis|Genetic: polymorphic microsatellite marker analysis","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","308","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CALGB-60102|NCCTG-CALGB-60102|CDR0000257145","November 12, 2002","April 2002","November 2006","July 1, 2016","July 2016","No Study Results Posted","null","November 2006","response","https://ClinicalTrials.gov/show/NCT00048971"
2492,"NCT02884024","Effects of Weight on Inflammation and Colon Cancer Risk","Completed","No Results Available","Colorectal Cancer","Other: no intervention","Tufts University|Tufts Medical Center","Both","40 Years to 70 Years   (Adult, Senior)","","43","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","10103","August 23, 2016","January 2011","February 2013","August 25, 2016","August 2016","No Study Results Posted","null","February 2013","colonic concentration of Tumor Necrosis Factor-alpha|colonic concentration of Interleukin-6|colonic concentration of Interleukin-1 beta|colonic concentration of Interferon-gamma","https://ClinicalTrials.gov/show/NCT02884024"
2493,"NCT02541370","Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133","Recruiting","No Results Available","Liver Cancer|Pancreatic Cancer|Brain Tumor|Breast Cancer|Ovarian Tumor|Colorectal Cancer|Acute Myeloid and Lymphoid Leukemias","Biological: anti-CD133-CAR vector-transduced T cells","Chinese PLA General Hospital","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","s2015-080-03","September 2, 2015","September 2015","October 2018","September 2, 2015","September 2015","No Study Results Posted","null","October 2017","Occurrence of study related adverse events|Anti-tumor responses to CART-133 cell infusions","https://ClinicalTrials.gov/show/NCT02541370"
2494,"NCT01662752","Lymphatic Mapping for Sentinel Node Identification and Analysis","Completed","No Results Available","Colorectal Cancer","Drug: Indocyanine green","Imperial College London|London North West Healthcare NHS Trust","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","C/32/2012","August 7, 2012","May 2013","October 2015","February 17, 2016","February 2016","No Study Results Posted","null","September 2015","The proportion of subjects in which the SLN(s) are identified|Sensitivity and specificity of tumour-bearing status of SLN(s) as a measure of lymph node status when assessed by standard techniques","https://ClinicalTrials.gov/show/NCT01662752"
2495,"NCT00425152","Fluorouracil and Leucovorin and/or Levamisole After Surgery In Treating Patients With Dukes' B Or Dukes' C Colon Cancer","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium|Drug: levamisole hydrochloride","NSABP Foundation Inc|National Cancer Institute (NCI)|Northern California Cancer Center","Both","up to 70 Years   (Child, Adult, Senior)","Phase 3","2151","Other|NIH","Interventional","Primary Purpose: Treatment","NSABP C-04|U10CA012027|NCOG-NSABP-C-04","January 18, 2007","July 1989","April 2004","February 5, 2010","February 2010","No Study Results Posted","null","June 1998","","https://ClinicalTrials.gov/show/NCT00425152"
2496,"NCT00238381","Rectal Reconstruction in Treating Patients Who Are Undergoing Surgery for Rectal Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: 5 cm colon-J-pouch|Procedure: side-to-end anastomosis|Procedure: straight coloanal anastomosis","Swiss Group for Clinical Cancer Research","Both","18 Years and older   (Adult, Senior)","Phase 3","336","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 40/04|EU-20528","October 12, 2005","July 2005","August 2016","August 11, 2016","August 2016","No Study Results Posted","null","May 2014","Composite evacuation score after total mesorectal excision|Composite evacuation score at 6, 18, and 24 months after total mesorectal excision|Composite incontinence score after total mesorectal excision|Quality of life after total mesorectal excision|Overall survival|Morbidity","https://ClinicalTrials.gov/show/NCT00238381"
2497,"NCT00820417","Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib","Completed","No Results Available","Colorectal Cancer|Head and Neck Cancer|Non Small Cell Lung Cancer (NSCLC)","Drug: Cetuximab/Gefitinib combination and/or monotherapy","Harrison Clinical Research|Merck KGaA|AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 1","63","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Masking: Open Label","C-225/ZD1839","January 9, 2009","June 2004","May 2008","January 9, 2009","January 2009","No Study Results Posted","null","September 2007","The primary objective of the study is to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of the combination intravenous Cetuximab/oral Gefitinib.|To determine the pharmacokinetic (PK) parameters of the combination Cetuximab/Gefitinib|To determine the pharmacogenomic profile of study patients and to correlate the different profiles with efficacy|To determine the possible correlation between activity and the polymorphisms of the EGFR measured in the blood and in the primary tumour|To assess the possible immune response related to cetuximab|To estimate signs of clinical activity (response rate according to the RECIST criteria)","https://ClinicalTrials.gov/show/NCT00820417"
2498,"NCT00967577","177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors","Recruiting","No Results Available","Kidney Cancer|Head and Neck Cancer|Breast Cancer|Non-small Cell Lung Cancer|Colorectal Cancer|Pancreatic Cancer|Ovarian Cancer|Esophageal Cancer|Gliomas","Drug: 177Lu-J591","Weill Medical College of Cornell University","Both","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0902010212","August 26, 2009","July 2009","December 2017","May 4, 2015","May 2015","No Study Results Posted","null","December 2016","Change in tumor perfusion as based on DCE-MRI study as well as changes in cellularity as assessed using DWI.|Progression free survival","https://ClinicalTrials.gov/show/NCT00967577"
2499,"NCT02745769","A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents","Not yet recruiting","No Results Available","Advanced Cancer|Colorectal Cancer|Mantle Cell Lymphoma","Drug: Ramucirumab|Drug: Merestinib|Drug: Abemaciclib","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","16165|I4T-MC-JVDK|2015-004381-28","April 18, 2016","September 2016","August 2019","August 30, 2016","August 2016","No Study Results Posted","null","September 2017","Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab, Merestinib and Abemaciclib|Proportion of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02745769"
2500,"NCT01227707","A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.","Completed","Has Results","Colorectal Cancer","Drug: bevacizumab [Avastin]|Drug: capecitabine [Xeloda]|Radiation: Radiation therapy|Procedure: Mesorectal excision|Drug: bevacizumab [Avastin]|Drug: 5-fluorouracil|Drug: leucovorin","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","43","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18522","October 22, 2010","November 2005","August 2010","July 21, 2015","July 2015","May 28, 2014","null","August 2010","Percentage of Participants With Pathological Complete Response (pCR)|Percentage of Participants by Primary Tumor (T), Regional Lymph Nodes (N), and Distant Metastasis (M) Clinical Stage at Baseline and at the End of Neo-Adjuvant Treatment (NAT)|Percentage of Participants Undergoing Sphincter-Saving Surgery by Type of Procedure|Percentage of Participants With Complete Response (CR) at the End of Neoadjuvant Treatment|Percentage of Participants With an Overall Response of CR at the End of Neoadjuvant Treatment|Percentage of Participants With New Lesions at the Primary Tumor Site at the End of Neoadjuvant Treatment|Percentage of Participants With Relapse During Follow-Up|Disease-Free Survival (DFS) - Percentage of Participants With an Event|DFS - Time to Event|Overall Survival (OS) - Percentage of Participants With an Event|OS - Time to Event|Time to Disease Progression (TTP) - Percentage of Participants With an Event|TTP - Time to Event","https://ClinicalTrials.gov/show/NCT01227707"
2501,"NCT00265811","Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery","Completed","No Results Available","Colorectal Cancer","Drug: Folfox + Cetuximab|Drug: Folfox","Federation Francophone de Cancerologie Digestive","Both","18 Years to 74 Years   (Adult, Senior)","Phase 3","2559","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000453839|FFCD-PETACC-8|EU-20547|2005-003463-23|PETACC-8|MERCK-FFCD-PETACC-8","December 14, 2005","November 2005","null","May 26, 2016","December 2006","No Study Results Posted","null","November 2009","Disease-free survival|3-year disease-free survival|Overall survival|5-year overall survival|Treatment compliance|Identification of prognostic factors|Safety|Markers predictive for relapse and/or treatment efficacy","https://ClinicalTrials.gov/show/NCT00265811"
2502,"NCT00819169","AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors","Terminated","No Results Available","Colorectal Cancer|Locally Advanced|Metastatic Cancer|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Sarcoma|Solid Tumors","Biological: AMG 479|Biological: AMG 655","Amgen","Both","16 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","89","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20070411","January 6, 2009","January 2009","October 2011","September 16, 2015","September 2015","No Study Results Posted","null","October 2010","Incedence of dose limiting toxicity|Objective response rate|Time to response|Duration of response|Progression free survival|To evaluate anti-AMG 655 antibody formation and anti-AMG 479 antibody formation|To evaluate the PK of AMG 655 and of AMG 479","https://ClinicalTrials.gov/show/NCT00819169"
2503,"NCT00081224","Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine|Drug: celecoxib|Radiation: radiation therapy|Procedure: surgery","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N0346|NCI-2012-02582|CDR0000360666","April 7, 2004","December 2004","November 2010","August 12, 2016","August 2016","No Study Results Posted","null","November 2010","Proportion of successes|Survival time|Time-to event analyses|Time to disease progression/recurrence|Time to recurrence|Time to first progression|Survival|Bowel function as measured by the Patient Bowel Function (Uniscale) Questionnaire, the FACT Diarrhea Subscale and the Mayo Bowel Function Questionnaire","https://ClinicalTrials.gov/show/NCT00081224"
2504,"NCT00660894","Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery","Completed","No Results Available","Colorectal Cancer","Drug: folinate calcium|Drug: tegafur-uracil|Drug: tegafur-gimeracil-oteracil potassium","Translational Research Informatics Center, Kobe, Hyogo, Japan","Both","20 Years to 80 Years   (Adult, Senior)","Phase 3","1535","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000593164|TMDU-TRICC0706","April 16, 2008","April 2008","July 2015","August 2, 2016","August 2016","No Study Results Posted","null","June 2012","Disease-free survival|Overall survival|Adverse event|Pharmaco-economics|Identification of predictive markers","https://ClinicalTrials.gov/show/NCT00660894"
2505,"NCT00918827","Study of Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery and Chemotherapy","Active, not recruiting","No Results Available","Colorectal Cancer","","Translational Research Informatics Center, Kobe, Hyogo, Japan|Tokyo Medical and Dental University","Both","Child, Adult, Senior","","2128","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDR0000642386|TMDU-TRICC0807|UMIN000002013","June 9, 2009","April 2009","null","October 15, 2015","October 2015","No Study Results Posted","null","March 2017","Relationship between expression levels of enzymes and disease-free survival, relapse-free survival, and overall survival|Relationship between expression levels of enzymes and adverse effects|Disease-free survival|Relapse-free survival","https://ClinicalTrials.gov/show/NCT00918827"
2506,"NCT00625183","Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma","Terminated","Has Results","Colorectal Cancer","Dietary Supplement: selenomethionine|Drug: capecitabine|Drug: oxaliplatin|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: radiation therapy","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","5","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 113607|RPCI-I-113607","February 26, 2008","March 2008","December 2009","January 19, 2016","January 2016","September 19, 2014","null","October 2009","Complete Pathological Response Rate|Rate of T-downstaging With Capecitabine, Oxaliplatin, Selenomethionine, and Radiotherapy|Safety and Tolerability as Assessed by NCI CTCAE Version 3.0|Dose Intensity|Local Relapse Rate|Distant Relapse Rate","https://ClinicalTrials.gov/show/NCT00625183"
2507,"NCT00154752","Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Procedure: CCRT, Pelvic lymphadenoectomy.","National Taiwan University Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","9100013841","September 8, 2005","January 1999","June 2005","November 21, 2005","January 1999","No Study Results Posted","null","null","oncologic results|functional results","https://ClinicalTrials.gov/show/NCT00154752"
2508,"NCT00427310","Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Other: Observation|Drug: sodium heparin","NSABP Foundation Inc|National Cancer Institute (NCI)|Northern California Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 3","1158","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP C-02","January 18, 2007","March 1984","February 2001","December 31, 2012","December 2012","No Study Results Posted","null","September 1989","Disease free interval|Survival","https://ClinicalTrials.gov/show/NCT00427310"
2509,"NCT02593591","Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.","Not yet recruiting","No Results Available","Colorectal Cancer","","Samsung Medical Center","Both","19 Years and older   (Adult, Senior)","","130","Other","Observational","Time Perspective: Prospective","2015-10-063","October 26, 2015","October 2015","December 2017","October 29, 2015","October 2015","No Study Results Posted","null","December 2017","Response rate|Progression Free Survival|Duration of response|overall survival","https://ClinicalTrials.gov/show/NCT02593591"
2510,"NCT02562963","Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor","Recruiting","No Results Available","Non-small Cell Lung Cancer|Gastric Cancer|Hepatocellular Carcinoma|Colorectal Cancer","Biological: natural killer T cell","Minghui Zhang|Shanghai Public Health Clinical Center|Hua Xin Hosptial First Hosptial of Tsinghua University|Tsinghua University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","120","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NKT-THU2015|SHAPHC-CA-150209|BHXH-CA-150413","September 25, 2015","November 2015","December 2018","November 3, 2015","November 2015","No Study Results Posted","null","May 2018","The incidence of adverse events following infusion of NKT cells|Objective Response Rate (ORR), confirmed by CT or MRI, or confirmed by biopsy|Hematology|Serological analysis|Overall Survival (OS)|Progression-Free Survival (PFS)|Tumor Marker","https://ClinicalTrials.gov/show/NCT02562963"
2511,"NCT00002896","Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: chemotherapy|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: conventional surgery|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","European Institute of Oncology|National Cancer Institute (NCI)","Both","up to 75 Years   (Child, Adult, Senior)","Phase 3","774","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065222|CNR-9604|EU-96047","November 1, 1999","September 1993","null","September 19, 2013","February 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002896"
2512,"NCT00003365","Sulindac and Plant Compounds in Preventing Colon Cancer","Terminated","No Results Available","Colorectal Cancer","Dietary Supplement: curcumin|Dietary Supplement: rutin|Drug: quercetin|Drug: sulindac","University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey","Both","18 Years and older   (Adult, Senior)","","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention","CDR0000066350|P30CA016056|RUH-SSH-190-0600|RUH-SSH-190-0698|NCI-V98-1425","November 1, 1999","August 1996","July 2006","January 26, 2011","January 2011","No Study Results Posted","null","July 2006","","https://ClinicalTrials.gov/show/NCT00003365"
2513,"NCT02809846","Quell Opioid Reduction and Pain Relief in Patients With Cancer","Enrolling by invitation","No Results Available","Pain|Metastatic Breast Cancer|Prostate Cancer|Colorectal Cancer","Device: Quell|Device: Sham Quell","Scripps Translational Science Institute|NeuroMetrix, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","40","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","IRB-16-6815","June 20, 2016","July 2016","December 2016","June 21, 2016","June 2016","No Study Results Posted","null","October 2016","Reduction in daily opioid use assessed as recorded by the subject in their analgesia diary.","https://ClinicalTrials.gov/show/NCT02809846"
2514,"NCT01604642","Role of Activin A (ActA) in the Human Cancer Cachexia","Active, not recruiting","No Results Available","Colorectal Cancer|Lung Cancer","Other: blood tests and muscular biopsies","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","Both","18 Years and older   (Adult, Senior)","","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","ACTICA","May 4, 2012","May 2012","null","November 18, 2014","November 2014","No Study Results Posted","null","March 2014","Circulating Activin A level|Dietary assessment measured by SNAQ score and 3-Day intake|Body mass index|Mid arm muscle circumference calculated by the triceps skinfold and the mid arm circumference|Body composition measured by bioimpedance|Muscle strength as measured by grip strength|Quality of life as assessed using the QLQ-C30","https://ClinicalTrials.gov/show/NCT01604642"
2515,"NCT00865189","A Study of Avastin (Bevacizumab) in Patients With Newly Diagnosed Locally Advanced Rectal Cancer.","Completed","No Results Available","Colorectal Cancer","Drug: bevacizumab [Avastin]|Drug: bevacizumab [Avastin]","Hoffmann-La Roche","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","91","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML19202","March 18, 2009","November 2007","March 2016","September 1, 2016","September 2016","No Study Results Posted","null","March 2016","Rate of sterilisation of tumoral specimen: YpT0-N0|Efficacy: Compliance, pathological tumor downstaging rate, recurrence rates, disease free survival, overall survival. Safety: AEs, SAEs, lab parameters, post-operative complications.","https://ClinicalTrials.gov/show/NCT00865189"
2516,"NCT02784639","Comparison of KRAS/BRAF Mutational Status With Conventional Techniques and Plasma Samples Analysis","Completed","No Results Available","Colorectal Cancer","Other: Plasma Analysis of circulating cell free DNA|Other: Tumor tissue analysis of circulating cell free DNA","Institut du Cancer de Montpellier - Val d'Aurelle","Both","18 Years and older   (Adult, Senior)","","115","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","ICM2013/08","May 24, 2016","October 2013","October 2015","August 2, 2016","May 2016","No Study Results Posted","KPLEX2","October 2015","Area under ROC curve","https://ClinicalTrials.gov/show/NCT02784639"
2517,"NCT00001823","Evaluation for NCI Surgery Branch Clinical Studies","Recruiting","No Results Available","Synovial Cell Cancer|Melanoma|Colorectal Cancer|Lung Cancer|Bladder Cancer","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","16 Years to 80 Years   (Child, Adult, Senior)","","6000","NIH","Observational","Time Perspective: Prospective","990128|99-C-0128","November 3, 1999","June 1999","null","September 10, 2016","September 2016","No Study Results Posted","null","null","To permit evaluation of patients referred to the NCI Surgery Branch in order to identify individuals who will be suitable candidates for Surgery Branch clinical research protocols.","https://ClinicalTrials.gov/show/NCT00001823"
2518,"NCT02308345","MiVideo - Video Visit Summary for Cancer Patients","Completed","No Results Available","Colorectal Cancer","Other: Pre-chemotherapy visit summary Video","University of Michigan","Both","18 Years to 80 Years   (Adult, Senior)","","58","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","HUM00090259","October 22, 2014","December 2014","March 2015","May 29, 2015","December 2014","No Study Results Posted","null","March 2015","Length of visit (minutes)|Number of patient views of their visit summary prior to chemotherapy|Number of video summary shares prior to chemotherapy|Participant-rated usefulness of video summary","https://ClinicalTrials.gov/show/NCT02308345"
2519,"NCT01972451","Feasibility of Reduction in Right Sided Bowel Cancer Through Contrast Enhanced Colonoscopy","Recruiting","No Results Available","Colorectal Cancer","Procedure: Colonoscopy with enhanced dye","Lisette Nixon|Cardiff University","Both","18 Years and older   (Adult, Senior)","Phase 2","1320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","WCTU065","October 7, 2013","November 2014","June 2016","October 13, 2015","October 2015","No Study Results Posted","CONSCOP","June 2016","Procedure time and withdrawal time|Number of people attending the screening","https://ClinicalTrials.gov/show/NCT01972451"
2520,"NCT01405430","Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab","Completed","No Results Available","Colorectal Cancer|Metastasis","Biological: Bevacizumab + blood samples","Centre Leon Berard|UMR-S Inserm 1036","Both","18 Years and older   (Adult, Senior)","","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","AVECC|ET2010-003","July 26, 2011","May 2010","May 2014","June 26, 2015","June 2015","No Study Results Posted","AVECC","May 2014","Response rate to treatment|Clinical benefit|Evaluation of progression-free survival|Evaluation of overall survival|Evaluation of tumoral markers|Evaluation of vascular toxicities","https://ClinicalTrials.gov/show/NCT01405430"
2521,"NCT02861209","Collaborative Network to Take Responsibility for Oral Anticancer Therapy","Recruiting","No Results Available","Breast Cancer|ALL|Lung Cancer|Melanoma|Colorectal Cancer|Prostate Cancer","Other: Implementation of a care pathway","Katholieke Universiteit Leuven","Both","18 Years and older   (Adult, Senior)","","228","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","LMK15022016","August 2, 2016","November 2015","November 2018","August 5, 2016","August 2016","No Study Results Posted","CONTACT","November 2018","Change in self-management skills|Change in medication Adherence|Change in patient satisfaction with treatment using the Cancer Therapy Satisfaction Questionnaire (CTSQ)|Change in patient satisfaction with care using Out-patsat 35|Health Related Quality of Life|Change in Distress using the Distress Barometer|Efficacy of treatment Using ECOG performance scale and RECIST criteria|Toxicity of treatment|Cost of care","https://ClinicalTrials.gov/show/NCT02861209"
2522,"NCT02130427","A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy","Active, not recruiting","No Results Available","Biopsy Proven Non Small Cell Lung Cancer|Head and Neck Cancer|Gastrointestinal Cancer|Colorectal Cancer|Rectal Cancers|Gynecological Malignancy Requiring Definitive Radiotherapy","Radiation: Radiation Therapy","Abramson Cancer Center of the University of Pennsylvania","Both","18 Years and older   (Adult, Senior)","","120","Other","Interventional","Primary Purpose: Diagnostic","UPCC 08909","May 1, 2014","September 2010","null","December 14, 2015","December 2015","No Study Results Posted","null","August 2014","Number of Adverse Events","https://ClinicalTrials.gov/show/NCT02130427"
2523,"NCT00973557","The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function","Completed","No Results Available","Colorectal Cancer|Lung Cancer|Breast Cancer|Glioblastoma","","Cedars-Sinai Medical Center","Both","18 Years and older   (Adult, Senior)","","6","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Pro00019830","September 8, 2009","September 2009","January 2012","February 6, 2012","February 2012","No Study Results Posted","null","September 2011","To determine whether the drug, Bevacizumab (a monoclonal anti VEGF-A antibody), which is approved to treat patients with metastatic colon cancer induces hyperprolactinemia (increased prolactin secretion) in humans with intact pituitary function.","https://ClinicalTrials.gov/show/NCT00973557"
2524,"NCT02102789","A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: mFOLFOX6|Drug: HAI","Yuhong Li|Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 3","142","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Frozen-2","March 31, 2014","March 2014","December 2024","October 28, 2015","October 2015","No Study Results Posted","null","August 2020","Complete resection rates (R0 resection rates) (defined as no macroscopic or microscopic residual tumor) of both arms|Overall response rates (ORR) of both arms|R1 resection rates (with microscopic residual tumor) of both arms|Specific R0/R1 resection plus radiofrequency ablation rates of both arms|Recurrence-free survival (RFS) of both arms|5 year cancer specific survival rate of the whole population|Progression free survival(PFS) of both arms|Overall survival (OS) of both arms|Number of participants with surgical complications, AES and SAEs as a measure of safety","https://ClinicalTrials.gov/show/NCT02102789"
2525,"NCT00003485","Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: antineoplaston A10|Drug: antineoplaston AS2-1","Burzynski Research Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Primary Purpose: Treatment","CDR0000066523|BC-CO-2","November 1, 1999","August 1998","null","July 23, 2008","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003485"
2526,"NCT02574663","TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors","Recruiting","No Results Available","Pancreatic Cancer|Colorectal Cancer|Rectal Cancer|Gastric Cancer|Esophageal Cancer|Gastrointestinal Stromal Tumor (GIST)","Drug: TGR-1202|Drug: nab-paclitaxel + gemcitabine|Drug: Oxaliplatin + Folinic acid + Fluorouracil|Drug: Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab","TG Therapeutics, Inc.|SCRI Development Innovations, LLC","Both","18 Years and older   (Adult, Senior)","Phase 1","60","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TGR-1202-102 (RM-404)","October 1, 2015","October 2015","February 2017","April 10, 2016","April 2016","No Study Results Posted","null","December 2016","Adverse events as a measure of safety and tolerability of TGR-1202 as a single agent and in combination in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.|Overall Response Rate|Duration of Response|Pharmacokinetic (PK) profile of TGR-1202. Peak Plasma Concentration (Cmax).|Pharmacokinetic (PK) profile of TGR-1202. Time to Peak Plasma Concentration (Tmax).|Pharmacokinetic (PK) profile of TGR-1202. Area under the plasma concentration versus time curve (AUC)","https://ClinicalTrials.gov/show/NCT02574663"
2527,"NCT00831181","Combination Chemotherapy in Treating Patients Undergoing Surgery for Rectal Cancer","Recruiting","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: quality-of-life assessment|Procedure: therapeutic surgical procedure","Beth Israel Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","22","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000633360|BIMCP-OX-08-006|AVENTIS-BIMCP-OX-08-006","January 27, 2009","January 2009","null","June 16, 2009","June 2009","No Study Results Posted","null","January 2012","Pathologic response and complete response rate|Toxicity|Locoregional control|Complete resectability rates|Ability of high resolution pelvic MRI to assess locoregional response and predict adequacy of the circumferential margin after total mesorectal excision (TME)|Sphincter preservation|Disease-free survival|Overall survival|Preservation of sexual, urinary, and bowel function|Patterns of disease failure, including local recurrence and distant metastasis assessed by CT scan|Quality of life at baseline and annually following TME|Comparison of preoperative stage with post-treatment pathologic stage|Comparison of preoperative staging with pelvic MRI vs endorectal ultrasound","https://ClinicalTrials.gov/show/NCT00831181"
2528,"NCT01339832","An Observational Study of Xeloda (Capecitabine) and Oxaliplatin Prior and Concurrent To Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer","Completed","Has Results","Colorectal Cancer","","Hoffmann-La Roche|Sanofi","Both","18 Years and older   (Adult, Senior)","","51","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ML21875","April 20, 2011","August 2010","December 2011","April 11, 2016","April 2016","December 29, 2015","null","December 2011","Progression-free Survival|Overall Survival|Tumor Recurrence Rate (Local and Distant)|Type of Adjuvant Chemotherapy|Length of Adjuvant Chemotherapy|Compliance to Diagnostic Procedures in Surveillance|Long Term Side Effects|Incidence of Adverse Event (AE) and Serious Adverse Event (SAE)","https://ClinicalTrials.gov/show/NCT01339832"
2529,"NCT01727570","Prehabilitation to Overcome the Stress of Surgery: the Role of Nutrition in Enhancing Postoperative Functional Capacity","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: Whey Protein (Immunocal®)","Franco Carli|Immunotec Inc.|McGill University Health Center","Both","18 Years to 85 Years   (Adult, Senior)","","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","11-240-SDR","October 31, 2012","September 2012","October 2013","November 18, 2014","November 2014","No Study Results Posted","null","October 2013","Six-Minute Walk Test (6MWT)","https://ClinicalTrials.gov/show/NCT01727570"
2530,"NCT02607826","Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors","Not yet recruiting","No Results Available","Cholangiocarcinoma|Pancreatic Ductal Adenocarcinoma|Colorectal Cancer|Gastric Cancer|Adenocarcinoma of the Esophagogastreal Junction|Esophagus Cancer","Procedure: Starvation","University Hospital Tuebingen","Both","18 Years and older   (Adult, Senior)","","298","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","Starvation Study","November 4, 2015","December 2015","March 2018","November 16, 2015","November 2015","No Study Results Posted","null","March 2018","Response to therapy on MRI or CT scancs will be measured using the RECIST criteria version 1.1.","https://ClinicalTrials.gov/show/NCT02607826"
2531,"NCT00502671","A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.","Completed","Has Results","Colorectal Cancer","Drug: capecitabine [Xeloda]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 4","228","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20592","July 17, 2007","July 2007","March 2012","August 6, 2015","August 2015","August 6, 2015","null","March 2012","Percentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE|Percentage of Participants With Early Withdrawal or Discontinuation Due to an AE","https://ClinicalTrials.gov/show/NCT00502671"
2532,"NCT00796718","A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer","Completed","Has Results","Colorectal Cancer","Radiation: Standard radiotherapy|Drug: Capecitabine [Xeloda]","Hoffmann-La Roche","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","62","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21800|2008-003980-38","November 21, 2008","October 2008","August 2010","July 14, 2016","July 2016","July 14, 2016","null","August 2010","Percentage of Participants With Pathological Complete Response|Percentage of Participants With Response to Treatment Assessed 4-6 Weeks After the Completion of Radiochemotherapy (Complete Response, Partial Remission or No Response to the Treatment)|Percentage of Participants With Response to the Treatment Assessed 1 Month After Surgery (Complete Response, Partial Remission or No Response to the Treatment)|Percentage of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00796718"
2533,"NCT00070005","J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma","Active, not recruiting","No Results Available","Colorectal Cancer|Perioperative/Postoperative Complications","Procedure: conventional surgery|Procedure: management of therapy complications","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","100","Other","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","CKTO-2002-02-POCASTER|CDR0000328269|EU-20247","October 3, 2003","June 2002","null","August 6, 2013","April 2007","No Study Results Posted","null","null","Functional outcome as measured by a validated questionnaire|Quality life as measured by a validated questionnaire|Anorectal function as assessed by anorectal manometry and barostat measurements","https://ClinicalTrials.gov/show/NCT00070005"
2534,"NCT00069121","A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer","Completed","Has Results","Colorectal Cancer","Drug: capecitabine [Xeloda]|Drug: Oxaliplatin|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5 FU","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 3","1886","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NO16968","September 15, 2003","January 2003","April 2009","August 13, 2013","August 2013","March 31, 2011","null","April 2009","Disease-free Survival (DFS) [Number of Events]|Disease-free Survival [Time to Event]|Relapse-free Survival (RFS) [Number of Events]|Relapse-free Survival (RFS) [Time to Event]|Overall Survival [Number of Events]|Overall Survival [Time to Event]|Number of Participants Assesed for Adverse Events","https://ClinicalTrials.gov/show/NCT00069121"
2535,"NCT00009737","A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer","Completed","Has Results","Colorectal Cancer","Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Capecitabine [Xeloda]","Hoffmann-La Roche","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","1987","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M66001","February 2, 2001","November 1998","April 2004","May 16, 2016","May 2016","May 16, 2016","null","April 2004","Disease-free Survival|Relapse-Free Survival|Overall Survival|Mean Change From Baseline in Global Health Status at Week 25|Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters|Number of Participants With Any Adverse Events and Serious Adverse Events","https://ClinicalTrials.gov/show/NCT00009737"
2536,"NCT02581423","A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Capecitabine","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 4","63","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18601","October 19, 2015","August 2005","March 2007","September 1, 2016","September 2016","No Study Results Posted","null","March 2007","Incidence of adverse events (AEs)|Incidence of treatment discontinuation due to AEs|Incidence of toxocity-related dose reductions","https://ClinicalTrials.gov/show/NCT02581423"
2537,"NCT00599378","Implementation Intentions to Promote Colon Cancer Screening in Rural Primary Care Practice","Completed","No Results Available","Colorectal Cancer","Behavioral: Implementation Intentions-based telephone counseling","Kimberly Engelman, PhD|National Cancer Institute (NCI)|University of Kansas Medical Center Research Institute","Both","50 Years and older   (Adult, Senior)","","373","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","11018|1R01CA121016-01A2","December 31, 2007","September 2007","June 2012","September 6, 2013","September 2013","No Study Results Posted","null","December 2011","Follow up survey to assess participant compliance with CRC screening. For those non compliant participants, randomized to either Control group or CPI2 group - active intervention with implementation intentions-based communication concepts|120 day followup survey to assess perceived barriers and screening decisional stage","https://ClinicalTrials.gov/show/NCT00599378"
2538,"NCT00559013","Peri-Strips Dry (PSD) Veritas Collagen Matrix Staple Line Reinforcement for Colorectal Surgery","Completed","Has Results","Colorectal Cancer","Device: Staple line reinforcement","Synovis Surgical Innovations","Both","18 Years and older   (Adult, Senior)","Phase 4","38","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CP1011, Rev C","November 14, 2007","March 2007","December 2008","May 23, 2012","July 2011","December 15, 2009","null","December 2008","Number of Participants With Major Colorectal Related Adverse Events: Leak, Stricture and Hemorrhage.","https://ClinicalTrials.gov/show/NCT00559013"
2539,"NCT02531620","Prehabilitation in Elective Colorectal Resection: A Pilot Study (Prehab)","Not yet recruiting","No Results Available","Colorectal Cancer","Other: Physiatry Assessment|Other: Routine Care","McMaster University","Both","18 Years and older   (Adult, Senior)","","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2015A1","August 19, 2015","September 2015","September 2016","August 21, 2015","August 2015","No Study Results Posted","Prehab","September 2016","Number of participants recruiting|Post-op complications|Mortality|Length of Stay|Number of patients with readmissions|Physical Function Assessment (6 Minute Walk Test)|Symptom Assessment (Edmonton Symptom Assessment System)|Functional Independence Assessment (UK Functional Independence Measure and Functional Assessment Measure)|Quality of Life Survey (Short Form 36 Health Survey)|Pain Assessment (Visual Analog Scale)|Bowel Function Assessment","https://ClinicalTrials.gov/show/NCT02531620"
2540,"NCT00831571","Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin","Active, not recruiting","No Results Available","Colorectal Cancer|Esophageal Cancer|Gastric Cancer|Small Bowel Cancer|Pancreatic Cancer","","Dana-Farber Cancer Institute|Sanofi","Both","18 Years and older   (Adult, Senior)","","200","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","08-140|SANOFI OX-07-008","January 27, 2009","February 2009","null","April 12, 2016","April 2016","No Study Results Posted","null","July 2016","To determine prospectively the incidence and severity of hypersensitivity reactions to oxaliplatin among patients beginning treatment with oxaliplatin during a two-year observation period.|To determine the relationship between cumulative dose of oxaliplatin and duration of therapy and development of hypersensitivity reactions.|To determine the ability of oxaliplatin skin testing to identify patients at risk for developing hypersensitivity reactions.|To determine the safety and efficacy of a rapid desensitization protocol to allow responding patients with moderate to severe hypersensitivity reactions to oxaliplatin to continue therapy with the drug.","https://ClinicalTrials.gov/show/NCT00831571"
2541,"NCT00216424","Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma","Terminated","No Results Available","Colorectal Cancer","Drug: Capecitabine (Xeloda)","James A. Haley Veterans Administration Hospital|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 4","40","U.S. Fed|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XEL372","September 21, 2005","February 2005","January 2007","November 9, 2007","November 2007","No Study Results Posted","null","null","Tumor response and resectability of tumor following treatment with radiation and capecitabine (Xeloda).","https://ClinicalTrials.gov/show/NCT00216424"
2542,"NCT00026468","Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis","Withdrawn","No Results Available","Colorectal Cancer|Small Intestine Cancer","Drug: exisulind","University of Utah|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Prevention","CDR0000069032|R01CA080852|P30CA042014|UUMC-IRB-5999-96|NCI-H01-0079","November 9, 2001","July 1999","July 1999","July 23, 2013","July 2013","No Study Results Posted","null","July 1999","","https://ClinicalTrials.gov/show/NCT00026468"
2543,"NCT02327494","Study to Evaluate Oxygen Monitoring at Different Stages of Neuromuscular Blockade in Colorectal Surgery","Not yet recruiting","No Results Available","Colorectal Cancer","Drug: neuromuscular blockade","Hospital Universitari de Bellvitge","Both","18 Years and older   (Adult, Senior)","","70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PR254/14","December 3, 2014","January 2015","January 2017","January 6, 2015","January 2015","No Study Results Posted","OXYMUBLOC","June 2016","the central venous oxygen saturation (ScvO2)|the central venous oxygen saturation (ScvO2)the regional cerebral oxygen saturation (rSO2)|the regional cerebral oxygen saturation (rSO2)|Stroke volume|Fluidotherapy and Blood components transfusion|pneumoperitoneum and abdominal pressures|postoperative outcome","https://ClinicalTrials.gov/show/NCT02327494"
2544,"NCT01667198","Randomized Study of Train the Colonoscopy Leaders Course Versus Audit and Feedback on Colonoscopy Quality Indicators","Completed","No Results Available","Colorectal Cancer","Procedure: Train the leaders course|Behavioral: Audit and feedback","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Medical Centre of Postgraduate Education, Poland|Gloucestershire Hospitals NHS Foundation Trust|University of Oslo|Erasmus Medical Center|Ministry of Science and Higher Education, Poland","Both","Child, Adult, Senior","","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","IP2010016270","August 14, 2012","July 2012","December 2012","April 15, 2014","April 2014","No Study Results Posted","null","December 2012","Screening centre leader's adenoma detection rate|Screening center's overall adenoma detection rate|Screening centre leader's proximal and distal adenoma detection rate|Screening centre's non-polypoid lesion detection rate|Overall screening centre's ceacal intubation rate|Screening centre leader's withdrawal technique","https://ClinicalTrials.gov/show/NCT01667198"
2545,"NCT02806037","Utility of Intra-operative Image Guidance System for Missing Metastases","Enrolling by invitation","No Results Available","Colorectal Cancer|Metastatic to the Liver","","Memorial Sloan Kettering Cancer Center","Both","Child, Adult, Senior","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","E15-166","June 16, 2016","November 2015","null","June 16, 2016","June 2016","No Study Results Posted","null","November 2017","localization rate of liver tumor","https://ClinicalTrials.gov/show/NCT02806037"
2546,"NCT01828047","Sublingual Microcirculation and Postoperative Ileus","Completed","No Results Available","Colorectal Cancer|Inflammatory Bowel Diseases|Gastrointestinal Dysfunction","Device: orthogonal polarization spectral (OPS) imaging","Gabriele Baldini, MD, MSc, Assistant Professor|McGill University Health Center","Female","18 Years and older   (Adult, Senior)","","34","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-214-SDR","October 31, 2012","November 2013","November 2014","March 16, 2015","March 2015","No Study Results Posted","null","November 2014","Postoperative ileus symptoms; microvascular flow index (MFI)","https://ClinicalTrials.gov/show/NCT01828047"
2547,"NCT00285701","Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study","Completed","No Results Available","Colorectal Cancer","Drug: hexaminolevulinate","Photocure|KARL STORZ Endoscopy-America, Inc.","Both","18 Years to 85 Years   (Adult, Senior)","Phase 1|Phase 2","38","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","PCCO101/05","January 31, 2006","July 2006","March 2008","January 14, 2010","January 2010","No Study Results Posted","null","November 2007","","https://ClinicalTrials.gov/show/NCT00285701"
2548,"NCT01186237","Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study","Recruiting","No Results Available","Colorectal Cancer","Procedure: Early urinary catheter removal","Stanford University","Both","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","REC0004|SU-05272010-6187|17865|NCI-2010-02350","August 9, 2010","June 2010","August 2014","February 12, 2014","February 2014","No Study Results Posted","null","August 2014","urinary retention","https://ClinicalTrials.gov/show/NCT01186237"
2549,"NCT01609660","Impact of Probiotics on the Intestinal Microbiota","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: Saccharomyces boulardii","Federal University of Minas Gerais","Both","18 Years and older   (Adult, Senior)","Phase 4","33","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CDS - APQ-01005-11","May 27, 2012","March 2010","March 2013","September 9, 2016","September 2016","No Study Results Posted","null","July 2012","Mucosal cytokine|Short chain fatty acids","https://ClinicalTrials.gov/show/NCT01609660"
2550,"NCT00033605","Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis","Completed","No Results Available","Cervical Cancer|Colorectal Cancer|Diarrhea|Endometrial Cancer|Fallopian Tube Cancer|Ovarian Cancer|Prostate Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific|Vaginal Cancer|Vulvar Cancer","Drug: octreotide acetate|Other: placebo|Radiation: radiation","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","130","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","NCCTG-N00CA|CDR0000069304|NCI-P02-0221","April 9, 2002","April 2002","July 2006","July 12, 2016","July 2016","No Study Results Posted","null","July 2006","Reduction of diarrhea as measured by NCI CTC version 2.0 weekly during pelvic radiotherapy|Reduction of patient-reported bowel dysfunction as assessed by the bowel function questionnaire weekly during radiotherapy, weekly for 4 weeks after radiotherapy, and 12 and 24 months after completion of radiotherapy|Toxicity as assessed by NCI CTC version 2.0 weekly during pelvic radiotherapy|Importance that patients attach to various measures of bowel dysfunction as assessed by questionnaire at week 4 of radiotherapy and at 12 and 24 months after completion of radiotherapy","https://ClinicalTrials.gov/show/NCT00033605"
2551,"NCT02372500","Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal Surgery","Not yet recruiting","No Results Available","Colorectal Cancer|Surgery","Dietary Supplement: Chewing gum","Countess of Chester NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","130","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","Surg050/14","February 9, 2015","March 2015","October 2016","February 20, 2015","February 2015","No Study Results Posted","null","March 2016","Bowel function (as assessed by questionnaire)|Diet (as assessed by questionnaire)|Length of stay|Post op nausea and vomiting score (as recorded by visual analogue scale)|Morbidity","https://ClinicalTrials.gov/show/NCT02372500"
2552,"NCT02433938","Role of Tibial Nerve Stimulation for Enhanced Postoperative Recovery After Colorectal Surgery","Active, not recruiting","No Results Available","Postoperative Ileus|Colorectal Cancer","Procedure: Tibial nerve stimulation|Procedure: Sham tibial nerve stimulation","University of Florence","Both","Child, Adult, Senior","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Supportive Care","jm-001","April 9, 2015","July 2015","July 2016","December 3, 2015","December 2015","No Study Results Posted","TiRex","July 2016","bowel function recovery (Time to first bowel movement or flatus)|Length of postoperative hospital stay|Post-operative vomiting (episodes of vomiting)|Use of NG Tubes (Nasogastric tube (re)insertions)","https://ClinicalTrials.gov/show/NCT02433938"
2553,"NCT01327612","Open Label Extension Study of Conatumumab and AMG 479","Active, not recruiting","No Results Available","Advanced Solid Tumors|Carcinoid|Colorectal Cancer|Locally Advanced|Lymphoma|Metastatic Cancer|Non-Small Cell Lung Cancer|Sarcoma|Solid Tumors","Drug: FOLFOX6|Biological: Conatumumab|Biological: Conatumumab|Biological: Ganitumab|Biological: Bevacizumab|Biological: Ganitumab","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20101116","March 3, 2011","March 2011","January 2017","May 6, 2016","May 2016","No Study Results Posted","null","January 2017","To evaluate the safety profile, including adverse events and serious adverse events, of conatumumab, with or without co-therapy, or AMG 479.","https://ClinicalTrials.gov/show/NCT01327612"
2554,"NCT01214512","Performance Evaluation of the Micromedic CD24 in Vitro Diagnostic Assay","Completed","No Results Available","Colorectal Cancer","Other: blood-sample based diagnostic assay","Meir Medical Center","Both","50 Years and older   (Adult, Senior)","","229","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","MMC10097/2010k-CTIL","September 14, 2010","January 2011","August 2012","March 10, 2013","March 2013","No Study Results Posted","null","August 2012","Colonoscopy and CD24 assay correlation","https://ClinicalTrials.gov/show/NCT01214512"
2555,"NCT01706822","Radial Reload Laparoscopic LAR Case Series","Terminated","Has Results","Colorectal Cancer","Device: Covidien Radial Reload Stapler with Tri-Staple Technology","Medtronic - MITG|University Hospitals Cleveland Medical Center|Duke University","Both","18 Years to 85 Years   (Adult, Senior)","Phase 4","8","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COVLARL0287","October 11, 2012","April 2013","November 2013","March 17, 2015","March 2015","February 13, 2015","null","November 2013","The Surgeon's Ability to Achieve a Staple Line at the Desired Level of the Rectum. The Reported Value Represents the Number of Participants in Whom the Criteria Was Met|The Ability to Achieve Adequate Distal Margins (Defined as >2cm [or >1cm With Clear Histologic Evaluation]) in the Low Rectum. The Reported Value Represents the Number of Participants in Whom the Criteria Was Met|Access Measured by Surgeon Usability Questionnaire. The Reported Values Represent Percentage of Cases Surgeon Agree/Strongly Agree|Visibility Measured by Surgeon Usability Questionnaire. The Reported Values Represent Percentage of Cases Surgeon Agree/Strongly Agree|Maneuverability Measured by Surgeon Usability Questionnaire. The Reported Values Represent Percentage of Cases Surgeon Agree/Strongly Agree","https://ClinicalTrials.gov/show/NCT01706822"
2556,"NCT02890069","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat","Not yet recruiting","No Results Available","Colorectal Cancer|Non-small Cell Lung Carcinoma (Adenocarcinoma)|Triple Negative Breast Cancer","Biological: PDR001|Drug: LCL161|Drug: Everolimus|Drug: Panobinostat","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","350","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CPDR001X2102","May 9, 2016","August 2016","October 2018","August 31, 2016","August 2016","No Study Results Posted","null","October 2018","Phase 1: Incidence of dose limiting toxicities (DLTs)|Frequency of dose interruptions and reductions|Frequency and severity of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)|Changes between baseline and post-baseline laboratory parameters and vital signs|Dose intensities|Quantification of Tumor Infiltrating Lymphocytes (TILs) by Hematoxylin|Changes from baseline in ECG parameters|Best overall response (BOR)|Time to reach max concentration (Tmax) for PDR001|Presence of anti-PDR001 antibodies|Progression free survival (PFS) per RECIST v1.1|Treatment Free Survival (TFS)|Maximum and minimum plasma concentrations of LCL161 (Cmax and Cmin)|Maximum and minimum Plasma concentrations of everolimus (Cmax and Cmin)|Maximum and minimum plasma concentrations of panobinostat (Cmax and Cmin)|Concentration of anti-PDR001 antibodies|Characterization of TILs and myeloid cell infiltrate by IHC (such as CD8, FoxP3 and myeloid markers as appropriate)|Quantification of Tumor Infiltrating Lymphocytes (TILs) by eosin (H&E) stain|Maximum and minimum serum concentration of PDR001 (Cmax and Cmin)|Area under the concentration-time curve calculated to the last concentration point (AUClast) for PDR001, as applicable|Progression free survival (PFS) per irRC|Area under the concentration-time curve calculated to the last concentration point (AUClast) for LCL161, as applicable|Time to reach max concentration (Tmax) for LCL161|Time to reach max concentration (Tmax) for Everolimus|Time to reach max concentration (Tmax) for Panobinostat|Area under the concentration-time curve calculated to the last concentration point (AUClast) for Everolimus, as applicable|Area under the concentration-time curve calculated to the last concentration point (AUClast) for Panobinostat, as applicable","https://ClinicalTrials.gov/show/NCT02890069"
2557,"NCT02426762","Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic Surgery","Recruiting","No Results Available","Complications of Surgical Procedures|Surgical Site Infection|Gastric Cancer|Colorectal Cancer|Gastrointestinal Stromal Tumor|Inflammatory Bowel Disease|Diverticula","Procedure: Laparoscopic surgery|Device: Skin sealant","First Affiliated Hospital, Sun Yat-Sen University","Both","16 Years to 65 Years   (Child, Adult)","Phase 2","100","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","2015[122]","April 22, 2015","February 2015","October 2015","August 11, 2015","August 2015","No Study Results Posted","null","October 2015","freedom from surgical site infection|Length of hospital stay|Pain Scores on the Visual Analog Scale","https://ClinicalTrials.gov/show/NCT02426762"
2558,"NCT01434264","Evaluating Personalized Effect of an Individualized Intervention","Completed","No Results Available","Colorectal Cancer","Procedure: Energy healing","University of Southern Denmark|University of Aarhus|The Ministry of Science, Technology and Innovation, Denmark","Both","18 Years to 80 Years   (Adult, Senior)","","247","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","09-065176/DSF","September 13, 2011","September 2011","November 2012","March 7, 2014","March 2014","No Study Results Posted","null","November 2012","Changes in personal concerns identified by the patient in the MYCaW questionnaire.|Changes in Physical Health Survey|Changes in SF-36 Physical activity|Changes in Facit-sp QoL|Changes in BDI-II depressive symptoms|Changes in POMS Mood|Changes in Daily physical performance","https://ClinicalTrials.gov/show/NCT01434264"
2559,"NCT01726309","Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4","Recruiting","No Results Available","Colorectal Cancer|Non-Small Cell Lung Cancer","","Cancer Trials Ireland","Both","18 Years and older   (Adult, Senior)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ICORG 08-40","November 9, 2012","May 2011","null","June 27, 2016","June 2016","No Study Results Posted","null","December 2019","Correlation between the type and degree of reported skin and/or eye reaction and the SNP profile of the EGFR domain III region.|Correlation between the SNP profile(s) and disease response","https://ClinicalTrials.gov/show/NCT01726309"
2560,"NCT01696630","Xenon Combined With Intraoperative Thoracic Epidural Analgesia","Completed","No Results Available","Colorectal Cancer","Drug: Xenon|Drug: Desflurane","Centre Leon Berard","Both","18 Years and older   (Adult, Senior)","Phase 2","31","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","XENON|2012-002155-41|ET2012-19","September 21, 2012","October 2012","July 2014","August 3, 2016","August 2016","No Study Results Posted","null","July 2014","Variation of intraoperative Mean Arterial Pressure (MAP)|Measure of hemodynamic parameters (Systolic Ejection Volume, Heart rate, DeltaPP)|Delay from the surgery to the discharge date|Delay between the end of surgery and Post Anesthesia Care Unit's exit (min)|Total dose requirement of Vasopressive and hypotensive agents|Volume of each product infused|Total dose of morphine|Quality of awaking|Delay to oral feeding recovery|Post-operative Adverse Events|post-operative pain|Delay to intestinal transit recovery","https://ClinicalTrials.gov/show/NCT01696630"
2561,"NCT02900664","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","Recruiting","No Results Available","Colorectal Cancer|Triple Negative Breast Cancer|Non-small Cell Lung Cancer (Adenocarcinoma)","Biological: PDR001|Biological: ACZ885|Biological: CJM112|Drug: TMT212|Drug: EGF816","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","432","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CPDR001X2103|2016-000633-49","May 17, 2016","August 2016","January 2019","September 9, 2016","September 2016","No Study Results Posted","null","January 2019","Frequency of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety|Changes between baseline and post-baseline laboratory parameters and vital signs.|Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only)|Frequency of dose interruptions|Dose intensities|Severity of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety|Frequency of dose reductions|Key secondary: Histopathology of tumor infiltrating lymphocytes (TILs)|Changes from baseline in electrocardiogram (ECG) parameters|Best overall response (BOR)|Progression free survival (PFS) per irRC and RECIST v1.1|Treatment Free Survival (TFS)|Presence and/or concentration of anti-PDR001 antibodies.|Serum concentration of PDR001, canakinumab, CJM112|Plasma concentrations of trametinib and EGF816|Key secondary: Histopathology of myeloid cell infiltrate by IHC (such as CD8, FoxP3 and myeloid markers as appropriate).|PK parameters (Eg. TMax) of EGF816|PK parameters (Eg. TMax) of trametinib|PK parameter (Eg. TMax) of PDR001|PK parameters (Eg. TMax) of canakinumab|PK parameters (Eg. TMax) of CJM112|Presence and/or concentration of anti-canakinumab antibodies.|Presence and/or concentration of anti-CJM112 antibodies.","https://ClinicalTrials.gov/show/NCT02900664"
2562,"NCT02841657","3D Laparoscopy Versus 2D Laparoscopy","Recruiting","No Results Available","Colorectal Cancer|Inflammatory Bowel Disease","","Casa di Cura Dott. Pederzoli","Both","18 Years and older   (Adult, Senior)","","350","Other","Observational","Time Perspective: Prospective","3Dvs2D","July 18, 2016","January 2016","October 2017","August 10, 2016","August 2016","No Study Results Posted","Lap3D","September 2016","Postoperative complications|Oncological radicality","https://ClinicalTrials.gov/show/NCT02841657"
2563,"NCT02836535","The Patient-Perspective of Complications After Colon and Rectum Surgery: A Qualitative Analysis","Enrolling by invitation","No Results Available","Colorectal Cancer","Behavioral: qualitative interviews","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","","50","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","16-940","July 13, 2016","July 2016","null","August 23, 2016","August 2016","No Study Results Posted","null","July 2017","Number of complications","https://ClinicalTrials.gov/show/NCT02836535"
2564,"NCT00693290","Improving Outcomes for Patients Requiring Oral Bowel Preparation for Colonoscopy","Not yet recruiting","No Results Available","Colorectal Cancer","Other: low residue diet","University of Ulster|Action Cancer|Western Health and Social Care Trust","Both","16 Years to 80 Years   (Child, Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","07/NIR03/40","June 5, 2008","June 2008","December 2008","June 6, 2008","June 2008","No Study Results Posted","null","December 2008","Clarity of the mucosa evaluated by the Ottawa Scale.|Concordance with the bowel preparation.","https://ClinicalTrials.gov/show/NCT00693290"
2565,"NCT02895464","Feasibility of Home-based Preoperative Exercise in Older People","Not yet recruiting","No Results Available","Colorectal Cancer","Other: Exercise","Karolinska Institutet|Stockholm South General Hospital","Both","70 Years and older   (Senior)","","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)","LS1311-1462","August 9, 2016","September 2016","October 2017","September 12, 2016","September 2016","No Study Results Posted","null","February 2017","Recruitment rate|Exercise compliance|Acceptability|Adverse events|Six-minute walk|Inspiratory muscle strength|Chair-stand 30-sec|Walking speed (hab/max)|Postoperative complications|Length of stay|Discharge destination","https://ClinicalTrials.gov/show/NCT02895464"
2566,"NCT01707511","The Investigation of the EtCO₂- PaCO₂ Relation During Laparoscopic Colon Surgery","Recruiting","No Results Available","Colorectal Cancer","","Diskapi Teaching and Research Hospital","Both","Child, Adult, Senior","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Diskapianesthesia-01","September 15, 2012","January 2012","December 2013","October 15, 2012","October 2012","No Study Results Posted","null","March 2012","","https://ClinicalTrials.gov/show/NCT01707511"
2567,"NCT00737828","Cardiopulmonary Exercise Testing and Preoperative Risk Stratification","Completed","No Results Available","Colorectal Cancer|Anaesthesia|Critical Illness","Other: Perioperative care pathway guided by CPX results","University College London Hospitals|University Hospital Southampton NHS Foundation Trust.","Both","18 Years and older   (Adult, Senior)","","228","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","07/0114|07/H0716/55|PB-PG-0906-11426","August 18, 2008","August 2008","May 2014","May 20, 2014","May 2014","No Study Results Posted","null","June 2013","Postoperative morbidity (presence or absence of POMS defined morbidity)|Post operative morbidity domains e.g. gastrointestinal, renal, pulmonary|Total postoperative ITU bed utilisation|Total postoperative bed utilisation|ITU re-admission|Death|SF36 (compared with SF36 at baseline)","https://ClinicalTrials.gov/show/NCT00737828"
2568,"NCT01877096","Motivational Interviewing for Colonoscopy","Completed","No Results Available","Colorectal Cancer","Behavioral: Motivational Interviewing|Behavioral: Attention Control","Icahn School of Medicine at Mount Sinai|American Cancer Society, Inc.","Both","50 Years to 75 Years   (Adult, Senior)","","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","GCO 11-1377","June 11, 2013","August 2013","February 2014","November 3, 2015","November 2015","No Study Results Posted","null","February 2014","Screening colonoscopy completion|Psychological mediators","https://ClinicalTrials.gov/show/NCT01877096"
2569,"NCT01438385","Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders","Recruiting","No Results Available","Ampullary Cancer|Duodenal Cancer|Bile Duct Cancer|Bile Duct Disorders|Gallstones|Obstructive Jaundice|Pancreatic Disorders (Noncancerous)|Colorectal Cancer|Esophageal Cancer|Barrett's Esophagus|Gastric Malignancies|Pancreatic Cancer|Pediatric Gastroenterology|Cholangiocarcinoma|Pancreatic Pseudocysts|Acute and Chronic Pancreatitis|Recurrent Pancreatitis|Cholangitis|Bile Leak|Biliary Strictures|Pancreatic Divisum|Biliary and Pancreatic Stones|Choledocholithiasis","","Weill Medical College of Cornell University","Both","18 Years and older   (Adult, Senior)","","15000","Other","Observational","Time Perspective: Prospective","1104011642","September 20, 2011","July 2011","September 2017","June 1, 2015","June 2015","No Study Results Posted","null","July 2017","Establishing a database that contains all Interventional Endoscopies","https://ClinicalTrials.gov/show/NCT01438385"
2570,"NCT00164658","Evaluating Tools for Health Promotion and Disease Prevention","Completed","No Results Available","Coronary Heart Disease|Stroke|Diabetes|Breast Cancer|Ovarian Cancer|Colorectal Cancer","Behavioral: Familial risk assessment and personalized prevention messages","Centers for Disease Control and Prevention|Case Western Reserve University|American Academy of Family Physicians National Research Network|Evanston Northwestern Healthcare Research Institute|University of Michigan","Both","35 Years to 65 Years   (Adult)","Phase 1","8400","U.S. Fed|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Prevention","CDC-OGDP-4444|U36/CCU319276-MM-0630|U50/CCU300860-TS-1216|U36/CCU319276-MM-0789","September 12, 2005","September 2005","October 2007","January 6, 2010","January 2010","No Study Results Posted","null","null","Change in stage of adoption of health behaviors and referral for additional screening and follow up for high risk participants at 6 month post evaluation|Primary care physicians' provision of preventive services in response to family medical history.","https://ClinicalTrials.gov/show/NCT00164658"
2571,"NCT02870049","Study to Increase Colorectal Screening","Enrolling by invitation","No Results Available","Colorectal Cancer","Behavioral: Inreach strategy|Behavioral: Outreach strategy|Behavioral: Both Inreach and Outreach strategies|Behavioral: Usual care","University of California, San Diego|San Diego State University","Both","50 Years to 75 Years   (Adult, Senior)","","648","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","20153270|U54132379","August 8, 2016","August 2016","December 2018","August 16, 2016","August 2016","No Study Results Posted","null","September 2018","Screening completion rate","https://ClinicalTrials.gov/show/NCT02870049"
2572,"NCT01689792","A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)","Completed","No Results Available","Colorectal Cancer","Drug: MOVIPREP|Drug: CitraFleet","Norgine","Both","40 Years to 80 Years   (Adult, Senior)","Phase 4","398","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Screening","NOR-01/2011 (PDR)","September 12, 2012","November 2011","December 2013","March 30, 2015","December 2013","No Study Results Posted","null","January 2013","Polyp detection rate|Adenoma Detection Rate (ADR)|ADR and PDR by location|Cancer detection rate|Flat lesion only detection rate|Advanced risk lesion detection rate|Colonoscopy completion rate|Colon cleansing quality|Acceptability and tolerability of medication using patient questionnaires","https://ClinicalTrials.gov/show/NCT01689792"
2573,"NCT01516489","Improving Fecal Occult Blood Test Completion Rates Among Veterans","Completed","No Results Available","Colorectal Cancer","Behavioral: Stage 1|Behavioral: Stage 2","Corporal Michael J. Crescenz VA Medical Center|VA Pittsburgh Healthcare System","Male","Child, Adult, Senior","Phase 1|Phase 2","1549","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","01334","January 19, 2012","February 2012","June 2015","October 23, 2015","October 2015","No Study Results Posted","null","October 2013","FOBT completion and return|FOBT completion rate among previously non-adherent patients and FOBT kit return time by arm","https://ClinicalTrials.gov/show/NCT01516489"
2574,"NCT00671645","Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy","Terminated","No Results Available","Rectal Cancer","Drug: capecitabine, bevacizumab","Austrian Breast & Colorectal Cancer Study Group|Hoffmann-La Roche","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","8","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG R04/TAKO 08","April 30, 2008","July 2008","March 2010","March 12, 2009","March 2009","No Study Results Posted","null","March 2010","feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma|collection of response rate (T- and M-downstaging, pathological complete remission)","https://ClinicalTrials.gov/show/NCT00671645"
2575,"NCT00425204","Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment","Completed","No Results Available","Colorectal Cancer|Non-Small Cell Lung Cancer|Prostate Cancer|Solid Tumors|Advanced Renal Cell Carcinoma","Drug: Panitumumab (ABX-EGF)","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","31","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20020375|Abgenix Protocol No. ABX-0311","January 18, 2007","March 2004","March 2008","September 11, 2008","September 2008","No Study Results Posted","null","September 2007","To provide continued, extended panitumumab treatment to subjects who appeared to have benefited from and tolerated previous panitumumab treatment in Studies 20020374 Part 2 or 20030138 and its extension study, 20040116|To assess the safety of multidose administration of panitumumab in subjects who received continued and extended panitumumab treatment","https://ClinicalTrials.gov/show/NCT00425204"
2576,"NCT00497263","End-to-End Compression Anastomosis for Left-sided Colectomy Endo-CAR Study","Completed","No Results Available","Colorectal Cancer|Diverticulitis","Device: Niti CAR","Niti Medical Technologies Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label","CLP-43-01 Rev 01","July 4, 2007","null","null","June 28, 2011","June 2011","No Study Results Posted","null","null","functioning anastomosis & no occurrence of adverse events related to device use","https://ClinicalTrials.gov/show/NCT00497263"
2577,"NCT00468416","Evaluation of NiTi Shape Memory End-to-End Compression Anastomosis Ring (CAR) for Compression Anastomosis in Anterior Resection","Recruiting","No Results Available","Colorectal Cancer","Device: Compression Anastomosis Ring (CAR)","Tel-Aviv Sourasky Medical Center|Rabin Medical Center|Kaplan Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLP-43-01-2","May 1, 2007","February 2007","February 2008","May 3, 2007","May 2007","No Study Results Posted","null","null","Functioning anastomosis and no occurrence of adverse events related to device use","https://ClinicalTrials.gov/show/NCT00468416"
2578,"NCT01923155","Safety & Effectiveness of Nurse Performed Colonoscopies Under Supervision","Completed","No Results Available","Colorectal Cancer","Procedure: Colonoscopy","Chinese University of Hong Kong","Both","18 Years and older   (Adult, Senior)","","731","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Health Services Research","NE","August 12, 2013","March 2012","June 2013","August 14, 2013","August 2013","No Study Results Posted","null","June 2013","Adenoma detection rate|Cecal intubation RATE|Withdrawal time|Complication rate|Patients pain score|Patients overall satisfactory score|Cecal intubation TIME","https://ClinicalTrials.gov/show/NCT01923155"
2579,"NCT02250196","A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods","Completed","No Results Available","Colorectal Cancer|Colon Adenoma","Drug: PEG-Asc|Drug: SPMC 2","Korea University Anam Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Supportive Care","Korea University Prep","September 8, 2014","March 2013","November 2013","September 24, 2014","September 2014","No Study Results Posted","null","September 2013","the quality of the bowel preparation using Preparation Scale|Completeness of the bowel preparation|the patient's tolerability","https://ClinicalTrials.gov/show/NCT02250196"
2580,"NCT01847599","Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib","Recruiting","No Results Available","Metastatic Breast Cancer|Colorectal Cancer","Other: Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib","Centre Jean Perrin","Both","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-A01300-39","April 5, 2013","September 2011","September 2017","June 10, 2016","June 2016","No Study Results Posted","ProMETheX","March 2017","evaluation of the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib|patient satisfaction to the educational program as determined by questionnaire|safety and tolerability as determined by adverse events frequency","https://ClinicalTrials.gov/show/NCT01847599"
2581,"NCT01651026","Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer","","National Cancer Institute, Naples","Both","18 Years and older   (Adult, Senior)","Phase 2","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CROSS-1","July 24, 2012","January 2011","May 2017","November 27, 2015","November 2015","No Study Results Posted","CROSS-1","May 2016","list of diagnostic procedures used in clinical practice, according to participating Institute","https://ClinicalTrials.gov/show/NCT01651026"
2582,"NCT00765180","Comparison of Transparent Retractable Extension Device and Narrow Band Imaging on Colorectal Adenoma Detection","Completed","No Results Available","Colorectal Cancer Screening","Device: TRE vs. NBI","Showa Inan General Hospital","Both","20 Years to 100 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Diagnostic","TRE2","October 1, 2008","January 2007","December 2010","November 17, 2015","November 2015","No Study Results Posted","null","December 2010","Colorectal adenoma detection rate|Procedure time, complication","https://ClinicalTrials.gov/show/NCT00765180"
2583,"NCT01954862","Comparison of Methods to Distend the Colon During Insertion: CO2, Air Insufflation, Water-aided Colonoscopy","Completed","No Results Available","Pain|Colorectal Adenomas|Colorectal Cancer","Other: Air Insufflation method.|Other: CO2 insufflation|Other: Water Immersion/CO2|Other: Water Exchange/CO2|Other: Water Immersion/AI|Other: Water Exchange/AI","Presidio Ospedaliero Santa Barbara","Both","18 Years to 85 Years   (Adult, Senior)","","624","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","PG. 2013/3403","September 27, 2013","October 2013","July 2014","July 30, 2014","July 2014","No Study Results Posted","null","June 2014","Maximum pain score recorded during colonoscopy.|Overall pain after the procedure.|Cecal intubation rate.|Cecal intubation time.|Total procedure time.|Adenoma detection rate.|Mean adenomas per procedure.|Advanced adenomas.","https://ClinicalTrials.gov/show/NCT01954862"
2584,"NCT01781650","A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in Diagnostic Patients","Completed","No Results Available","Pain|Colorectal Adenomas|Colorectal Cancer","Other: Air Insufflation method.|Other: Water Immersion method.|Other: Water Exchange method.","Presidio Ospedaliero Santa Barbara","Both","18 Years to 85 Years   (Adult, Senior)","","288","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","PG.2013.2470|ASL07_WW-2013","January 29, 2013","March 2013","September 2013","January 14, 2014","January 2014","No Study Results Posted","null","September 2013","Maximum pain score recorded during colonoscopy.|Need for sedation/analgesia and its dosage.|Overall pain after the procedure.|Cecal intubation rate.|Cecal intubation time.|Total procedure time.|Adenoma detection rate.|Adenoma resection rate.|Advanced adenoma.","https://ClinicalTrials.gov/show/NCT01781650"
2585,"NCT01780818","A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in CRC Screening","Completed","No Results Available","Pain|Colorectal Adenomas|Colorectal Cancer","Other: Air Insufflation method.|Other: Water Immersion method.|Other: Water Exchange method.","Presidio Ospedaliero Santa Barbara","Both","50 Years to 70 Years   (Adult, Senior)","","288","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","PG.2012.27110|ASL07_WW-2012","January 28, 2013","March 2013","November 2013","January 14, 2014","January 2014","No Study Results Posted","null","November 2013","Maximum pain score recorded during colonoscopy.|Need for sedation/analgesia and its dosage.|Overall pain after the procedure.|Cecal intubation rate.|Cecal intubation time.|Total procedure time.|Adenoma detection rate.|Adenoma resection rate.|Advanced adenoma.","https://ClinicalTrials.gov/show/NCT01780818"
2586,"NCT01610895","Split Dose Polyethylene Glycol (PEG) + Clear Fluids Versus Split Dose PEG + Low-Residue Diet","Recruiting","No Results Available","Colorectal Cancer","Other: Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions|Other: Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions","University of Calgary","Both","18 Years to 74 Years   (Adult, Senior)","","345","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)","24206","May 30, 2012","December 2011","October 2012","June 1, 2012","May 2012","No Study Results Posted","BP","August 2012","Quality of Bowel Cleanliness|Patient satisfaction with preparation","https://ClinicalTrials.gov/show/NCT01610895"
2587,"NCT01224392","Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer","Recruiting","No Results Available","Rectal Cancer","Other: Chemoradiotherapy|Radiation: Radiotherapy with boost","Universitair Ziekenhuis Brussel|Vrije Universiteit Brussel","Both","18 Years to 95 Years   (Adult, Senior)","Phase 3","156","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RectumSIB","June 28, 2010","January 2010","December 2013","April 29, 2013","April 2013","No Study Results Posted","RectumSIB","December 2013","reduction in metabolic tumor activity|histological downgrading (Dworak classification)|number of R0, R1 and R2 resections|acute and late toxicity, according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events v3.0 (CTCAE)|local control|progression free survival|survival|quality of life|cost evaluation","https://ClinicalTrials.gov/show/NCT01224392"
2588,"NCT02545699","Prospective Trial to Compare ADR of G-EYE™ Colonoscopy With Standard Colonoscopy","Recruiting","No Results Available","Adenoma|Polyps|Colorectal Cancer","Device: G-EYE™ Colonoscopy|Device: Standard Colonoscopy","Smart Medical Systems Ltd.","Both","50 Years and older   (Adult, Senior)","","350","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","G-EYE 15507","August 31, 2015","September 2015","June 2017","June 5, 2016","June 2016","No Study Results Posted","null","June 2017","G-EYE™ Colonoscopy detection rate of adenomas and serrated lesions compared to the standard colonoscopy detection rate of the same|Polyp and adenoma detection|Procedure times|Safety (number of patients with adverse events)","https://ClinicalTrials.gov/show/NCT02545699"
2589,"NCT01917513","Prospective Trial to Compare the Clinical Efficiency of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy","Recruiting","No Results Available","Adenoma|Polyps|Colorectal Cancer","Device: G-EYE™ colonoscopy|Device: Standard Colonoscopy","Smart Medical Systems Ltd.","Both","50 Years and older   (Adult, Senior)","","1000","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","G-EYE 15505","July 30, 2013","May 2014","December 2016","June 5, 2016","June 2016","No Study Results Posted","null","December 2016","G-EYE™ colonoscopy detection rate of adenomas and serrated lesions compared to the standard colonoscopy detection rate of the same.|Number of polyp and adenoma detection, procedure times and safety (number of patients with adverse events.","https://ClinicalTrials.gov/show/NCT01917513"
2590,"NCT01778192","A Randomized Prospective Trial Comparing Polyethylene Glycol and Sodium Picosulphate With Magnesium Citrate","Completed","No Results Available","Colorectal Cancer|Colon Adenoma","Drug: Polyethylene glycol|Drug: Polyethylene glycol|Drug: Sodium picosulphate with magnesium citrate|Drug: Sodium picosulphate with magnesium citrate","Korea University Anam Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Supportive Care","Korea University","January 25, 2013","July 2012","December 2012","January 29, 2013","January 2013","No Study Results Posted","null","November 2012","the quality of the bowel preparation using the Ottawa bowel preparation scale (OBPS)|Completeness of the bowel preparation|the patient's tolerability|the side effects of the sodium picosulphate and magnesium citrate","https://ClinicalTrials.gov/show/NCT01778192"
2591,"NCT02744274","Efficacy of Acupuncture in Prevention of Chemotherapy Induced Peripheral Neuropathy - a Pilot Study","Recruiting","No Results Available","Colorectal Cancer","Other: Verum acupuncture","Tzu-Liang Chen|Research Center For Chinese Medicine and Acupuncture|China Medical University Hospital","Both","20 Years to 70 Years   (Adult, Senior)","Phase 3","32","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","CMUH104-REC1-076","April 13, 2016","January 2016","December 2017","April 19, 2016","April 2016","No Study Results Posted","null","December 2017","Change from Baseline in NCV at 48weeks.|Change from Baseline in Von frey filament test at 48weeks.|Change from Baseline in questionnaire - FACT/GOG-Ntx Subscale at 48weeks.|Change from Baseline in questionnaire - FACT-G at 48weeks.|Change from Baseline in questionnaire - Brief Pain Inventory Short Form at 48weeks.","https://ClinicalTrials.gov/show/NCT02744274"
2592,"NCT02548403","Effect of Simethicone on Bowel Preparation for Colonoscopy","Completed","No Results Available","Colorectal Cancer","Drug: PEG-Asc|Drug: PEG-Asc with simethicone","Korea University Anam Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","260","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Supportive Care","Korea University Prep1","September 8, 2015","July 2014","November 2014","September 10, 2015","September 2015","No Study Results Posted","null","September 2014","the quality of the bowel preparation using Preparation Scale|Completeness of the bowel preparation|the patient's tolerability[questionnaire]|the endoscopist's tolerability[Visual Analog Score for fatigue]","https://ClinicalTrials.gov/show/NCT02548403"
2593,"NCT02534142","Colonoscopy Followup After Positive Fecal Occult Blood Test- Understanding Barriers to Adherence","Not yet recruiting","No Results Available","Colorectal Cancer","","Meuhedet. Healthcare Organization|Bar-Ilan University, Israel","Both","51 Years to 74 Years   (Adult, Senior)","","2000","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","01-20-05-15","July 28, 2015","September 2015","December 2018","August 24, 2015","August 2015","No Study Results Posted","null","December 2016","Variables related to non-completion of colonoscopy following a positive fecal occult blood test","https://ClinicalTrials.gov/show/NCT02534142"
2594,"NCT02468726","Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing","Completed","No Results Available","Colorectal Cancer","Device: NER1008 enema|Drug: Fleet","Norgine","Both","18 Years to 45 Years   (Adult)","","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Screening","NER1008-01/2011 (ENE)","June 9, 2015","November 2011","December 2012","June 10, 2015","November 2011","No Study Results Posted","null","March 2012","Success of bowel cleansing|Grade of bowel cleansing|Quality of cleansing in rectum|Quality of cleansing in sigmoid colon|Quality of cleansing in the descending colon|Depth of scope progression|Stool weight","https://ClinicalTrials.gov/show/NCT02468726"
2595,"NCT02428907","Simulation Training of Endoscopy Staff to Improve Patient Experience in Colonoscopy","Completed","No Results Available","Colorectal Cancer","Behavioral: simulation training","Aalborg Universitetshospital","Both","18 Years and older   (Adult, Senior)","","539","Other","Observational","Time Perspective: Prospective","2008-58-0028","February 18, 2015","October 2012","April 2013","April 24, 2015","April 2015","No Study Results Posted","null","February 2013","patient perception of colonoscopy|Staff perception of teamwork","https://ClinicalTrials.gov/show/NCT02428907"
2596,"NCT02425657","Fast Track Module Based Colonoscopy Training Programme for Surgical Trainees at North Jutland Surgical Departments","Not yet recruiting","No Results Available","Harm Reduction|Perforation During Colonoscopy|Colorectal Cancer","Behavioral: Training of junior doctors","Aalborg Universitetshospital|Nordsim","Both","18 Years and older   (Adult, Senior)","","10","Other","Observational","Observational Model: Cohort","AalborgH1","April 10, 2015","August 2015","July 2016","April 21, 2015","April 2015","No Study Results Posted","null","June 2016","Directly observed practical skills (DOPS) measured using JAG (joint advisory group) guidelines|Endoscopy training computer generated data - Percentage of colon visualized|Endoscopy training computer generated data - Time used for completion|Endoscopy training computer generated data - Estimated patient pain|Endoscopy training computer generated data - Total score","https://ClinicalTrials.gov/show/NCT02425657"
2597,"NCT02423174","Eval. of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery","Not yet recruiting","No Results Available","Colorectal Cancer","Procedure: Total Mesorectal Excision|Device: FMwand Surgical System","Domain Surgical, Inc.","Both","18 Years to 80 Years   (Adult, Senior)","","5","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FMW-IT-02","April 17, 2015","July 2015","December 2015","April 21, 2015","April 2015","No Study Results Posted","null","December 2015","Intraoperative Serious Adverse Events as a Measure of Safety and Feasibility|Post-operative Drainage|Onset of urinary or fecal incontinence|Duration of Procedure|Duration of TME resection|Evaluation of post-operative complications","https://ClinicalTrials.gov/show/NCT02423174"
2598,"NCT02295774","Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA","Completed","Has Results","Colorectal Cancer","Procedure: standard white light colonoscopy-equivalent to placebo|Drug: Methylene Blue MMX tablets","Cosmo Technologies Ltd","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","10","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CB-17-01/08|2013-000634-35","November 12, 2014","February 2013","December 2014","December 9, 2015","December 2015","December 9, 2015","null","December 2014","Gamma H2AX Histone Levels in Colonic Biopsy During Standard White Light Colonoscopy and Colonoscopy for Which Methylene Blue MMX Was Taken Prior to Initiating the Colonoscopy","https://ClinicalTrials.gov/show/NCT02295774"
2599,"NCT02273167","Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using a 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimens in Adults.","Completed","No Results Available","Colorectal Cancer","Drug: NER1006, 2-Day Split-Dosing|Drug: NER1006,1-Day Morning Split-Dosing|Drug: MOVIPREP, 2-Day Split-Dosing","Norgine","Both","18 Years to 85 Years   (Adult, Senior)","Phase 3","849","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Diagnostic","NER1006-02/2014 (MORA)","October 16, 2014","October 2014","August 2015","January 18, 2016","June 2015","No Study Results Posted","null","August 2015","Use of Harefield Cleansing Scale to grade bowel cleansing efficacy|Adenoma Detection Rate|Polyp Detection Rate|Use of Boston Bowel Preparation scale to evaluate bowel cleansing efficacy|BOCLIR questionnaire|Patient compliance and acceptability using the validated patient rating scale ""PRO"" (patient reported outcomes)","https://ClinicalTrials.gov/show/NCT02273167"
2600,"NCT02273141","Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using a Day Before-Only Dosing Regimen in Adults.","Completed","No Results Available","Colorectal Cancer","Drug: NER1006, Day Before-Only Dosing|Drug: SP+MS, Day Before-Only Dosing","Norgine","Both","18 Years to 85 Years   (Adult, Senior)","Phase 3","515","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Diagnostic","NER1006-03/2014 (DAYB)","October 16, 2014","November 2014","August 2015","January 18, 2016","June 2015","No Study Results Posted","null","August 2015","Use of Harefield Cleansing Scale to grade bowel cleansing efficacy|Adenoma Detection Rate|Polyp Detection Rate|Use of Boston Bowel Preparation Scale|BOCLIR questionnaire|Compliance and acceptability using the validated patient rating scale ""PRO"" (patient reported outcomes)|Number of patients with adverse events, effect on vital signs and clinical laboratory parameters","https://ClinicalTrials.gov/show/NCT02273141"
2601,"NCT02156557","Study of KCC Peptide Application in the Colon","Recruiting","No Results Available","Colon Polyps|Colorectal Cancer|Inflammatory Bowel Disease (IBD)","Biological: Colon KCC Heptapeptide","Danielle Kim Turgeon|Olympus Corporation|University of Michigan","Both","18 Years to 100 Years   (Adult, Senior)","Phase 1","120","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","HUM00086259","June 3, 2014","June 2014","null","May 10, 2016","May 2016","No Study Results Posted","KCC 1B","July 2016","Validation of binding of peptide","https://ClinicalTrials.gov/show/NCT02156557"
2602,"NCT02000180","Colonoscopic Skill Acquisition and Transfer Via Simulated Curriculum of Progressive Training","Recruiting","No Results Available","Colorectal Cancer","Behavioral: Progressive Group","St. Michael's Hospital, Toronto|The Hospital for Sick Children","Both","Child, Adult, Senior","","23","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Health Services Research","13-060","November 17, 2013","June 2013","December 2016","April 15, 2016","April 2016","No Study Results Posted","null","December 2016","Change in JAG/DOPS Expert Assessment scores|Change in Simulator Generated Metrics","https://ClinicalTrials.gov/show/NCT02000180"
2603,"NCT01991522","A Randomized Control Trial of a Simulation-based Curriculum to Enhance Skills in Colonoscopy","Completed","No Results Available","Colorectal Cancer","Behavioral: Curriculum Group|Behavioral: Self-directed learning group","St. Michael's Hospital, Toronto","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","13-197c","November 18, 2013","July 2011","June 2015","November 16, 2015","November 2015","No Study Results Posted","null","June 2015","Transfer of skills to clinical colonoscopy|Retention of clinical skills","https://ClinicalTrials.gov/show/NCT01991522"
2604,"NCT01834742","Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects","Completed","No Results Available","Colorectal Cancer","Drug: NER1006|Drug: NER1006|Drug: NER1006|Drug: Moviprep|Drug: NER1006|Drug: NER1006|Drug: NER1006|Drug: NER1006","Norgine|Pierrel Research Europe GmbH","Both","18 Years to 45 Years   (Adult)","Phase 1","161","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NER1006-01/2011 (OUT)","April 15, 2013","April 2011","December 2011","April 15, 2013","April 2013","No Study Results Posted","OUT","September 2011","Primary Variable|PEG3350 concentration|Sulphate concentration|Ascorbic acid concentration|Electrolytes concentration|Safety profile","https://ClinicalTrials.gov/show/NCT01834742"
2605,"NCT01695863","Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep","Active, not recruiting","No Results Available","Colorectal Cancer","Drug: comparing 2 drugs on their effect on the bowel preparation for colonoscopy","Rush University Medical Center","Both","18 Years to 80 Years   (Adult, Senior)","Phase 4","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Screening","11042705","August 10, 2012","February 2012","June 2013","March 20, 2013","March 2013","No Study Results Posted","null","November 2012","bowel prep efficacy|assess change in renal function pre and post bowel prep","https://ClinicalTrials.gov/show/NCT01695863"
2606,"NCT01694966","The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy","Recruiting","No Results Available","Colorectal Cancer","Drug: Methylene Blue MMX®|Drug: Placebo","Cosmo Technologies Ltd","Both","50 Years to 75 Years   (Adult, Senior)","Phase 3","1270","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Screening","CB-17-01/06|2012-003983-32","September 25, 2012","September 2013","September 2016","July 28, 2016","July 2016","No Study Results Posted","null","September 2016","To assess the detection efficacy of chromoendoscopy performed with 200mg Methylene Blue MMX® 25 mg tablets versus placebo tablets (white light endoscopy) in terms of the proportion of subjects with at least one histologically proven adenoma or carcinoma.","https://ClinicalTrials.gov/show/NCT01694966"
2607,"NCT01582178","Warm Water Versus Room Temperature Water Immersion Colonoscopy","Completed","Has Results","Colorectal Cancer","Procedure: Warm Water Immersion Colonoscopy|Procedure: Cool Water Immersion Colonoscopy","Vitkovice Hospital","Both","18 Years and older   (Adult, Senior)","","212","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","DDC VN 04","April 18, 2012","June 2012","October 2012","September 19, 2013","September 2013","June 2, 2013","null","October 2012","Cecal Intubation Time|Patient Comfort During Insertion Phase of the Colonoscopy","https://ClinicalTrials.gov/show/NCT01582178"
2608,"NCT01324882","Colonoscope Insertion Trial Protocol","Completed","Has Results","Colorectal Cancer","Device: Colonoscopy with Olympus Technically Improved Colonoscope|Device: Control with standard colonoscope Olympus CF-H180","University of Connecticut Health Center","Both","35 Years to 75 Years   (Adult, Senior)","","57","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","10-246-1|1-642-01","March 24, 2011","June 2010","December 2011","August 22, 2013","August 2013","May 8, 2013","null","December 2011","Intubation of Cecum|Time to Intubate the Cecum","https://ClinicalTrials.gov/show/NCT01324882"
2609,"NCT00911391","Randomised Trial of Doppler-Optimised Fluid Balance in Elective Colectomy","Completed","No Results Available","Colorectal Cancer|Colectomy|Surgery|Perioperative Care","Device: Oesophageal Doppler|Procedure: Intraoperative fluid restriction","University of Auckland, New Zealand|Counties Manukau Health|Waitemata District Health Board","Both","18 Years to 90 Years   (Adult, Senior)","Phase 3","85","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GDFT RCT","May 28, 2009","November 2009","October 2011","November 25, 2011","November 2011","No Study Results Posted","null","September 2011","Post-operative functional recovery|Perioperative Complications","https://ClinicalTrials.gov/show/NCT00911391"
2610,"NCT00626054","Comparison of Two Methods of Administration of a PEG Solution","Completed","No Results Available","Colorectal Cancer","Drug: PEG solution in a single dose of 3 liters|Drug: PEG solution","Rabin Medical Center","Both","18 Years to 80 Years   (Adult, Senior)","Phase 4","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","004907","February 20, 2008","March 2009","March 2012","April 12, 2016","April 2016","No Study Results Posted","PEG","December 2011","Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms|Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation","https://ClinicalTrials.gov/show/NCT00626054"
2611,"NCT00535990","Minimally Invasive Surgery (MIS) Database for the Purpose of Research","Completed","No Results Available","Morbid Obesity|Hernia|Colorectal Cancer|Laparoscopy","","University of California, San Diego","Both","18 Years and older   (Adult, Senior)","","250","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","070449|Internally funded","September 25, 2007","September 2007","November 2009","August 27, 2010","August 2010","No Study Results Posted","null","November 2009","measure patient outcomes","https://ClinicalTrials.gov/show/NCT00535990"
2612,"NCT00492193","Early Post-Op Recovery After Partial Large Bowel Resection","Completed","No Results Available","Diverticulitis|Colon Polyps|Colorectal Cancer","","University Hospitals Cleveland Medical Center|Cubist Pharmaceuticals LLC","Both","18 Years to 80 Years   (Adult, Senior)","","139","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","01-07-14|14CL401","June 25, 2007","June 2007","May 2008","December 12, 2014","August 2008","No Study Results Posted","null","May 2008","Time to upper and lower GI recovery and post-operative hospital length of stay.|Postoperative ileus related mobidity.","https://ClinicalTrials.gov/show/NCT00492193"
2613,"NCT00423345","Colon Investigation - Factors Determining Choice of Procedure","Active, not recruiting","No Results Available","Irritable Colon|Colorectal Cancer|Inflammatory Bowel Disease","","Sykehuset Telemark","Both","18 Years and older   (Adult, Senior)","","750","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","23504","January 17, 2007","October 2006","December 2014","August 24, 2012","August 2012","No Study Results Posted","null","December 2014","findings compared across investigation modes|Delayed diagnosis of CRC","https://ClinicalTrials.gov/show/NCT00423345"
2614,"NCT00229567","Intra-op Lidocaine and Ketamine Effect on Postoperative Bowel Function","Terminated","No Results Available","Colorectal Cancer","Drug: Lidocaine infusion plus ketamine injection","University of Saskatchewan|Saskatoon Health Region","Both","18 Years to 79 Years   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","Bio-REB 03-1316","September 27, 2005","September 2005","November 2006","April 18, 2007","April 2007","No Study Results Posted","null","null","Mean time after surgery to completion of the following postoperative markers:|drinking and retaining 500ml clear fluids,|presence of bowel sounds|passage of flatus, and|passage of stool.|pain after cough by VAS|narcotic usage|nausea|vomiting|infection, dehiscence and other surgical complications|time to readiness for discharge from hospital","https://ClinicalTrials.gov/show/NCT00229567"
2615,"NCT02038699","A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer","Withdrawn","No Results Available","Advanced Glioblastoma|Advanced Colorectal Cancer|Advanced Triple-negative Breast Cancer|Advanced Non-small Cell Lung Cancer","Drug: ONC201","Oncoceutics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","00001","January 14, 2014","null","null","December 18, 2015","October 2014","No Study Results Posted","null","December 2015","In Phase I, to determine the recommended phase II doses of ONC201.|In phase II, Progression-free survival of patients treated with ONC201.","https://ClinicalTrials.gov/show/NCT02038699"
2616,"NCT01226394","Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus ""in Principle"" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients","Recruiting","No Results Available","Colorectal Cancer With a Resected Minimal Synchronous PC|or Ovarian Metastases,|or Tumour Rupture in the Abdominal Cavity","Procedure: laparotomy plus HIPEC","Gustave Roussy, Cancer Campus, Grand Paris","Both","18 Years to 70 Years   (Adult, Senior)","Phase 3","130","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSET 1539-ProphyloCHIP|2009-015598-11","October 20, 2010","April 2010","June 2019","June 9, 2016","June 2016","No Study Results Posted","ProphyloCHIP","June 2019","To increase the 3-year disease-free survival|3 year overall survival|Peritoneal disease-free survival|5 year overall survival","https://ClinicalTrials.gov/show/NCT01226394"
2617,"NCT02841605","Enteric Nervous System in Alzheimer Disease","Not yet recruiting","No Results Available","Alzheimer Disease","Procedure: Rectosigmoidoscopy with colonic biopsies|Procedure: Colonoscopy with colonic biopsies","Nantes University Hospital","Both","50 Years to 80 Years   (Adult, Senior)","","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","RC15_0458","July 19, 2016","October 2016","May 2019","July 21, 2016","July 2016","No Study Results Posted","ENTEROMA","May 2019","Presence of alpha-synuclein aggregates in colonic biopsies using immunohistochemistry","https://ClinicalTrials.gov/show/NCT02841605"
2618,"NCT01705002","Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.","Recruiting","No Results Available","Cancer|Solid Tumor|Metastatic Colorectal Cancer (mCRC)","Drug: Promitil|Drug: Capecitabine","Lipomedix Pharmaceuticals Inc.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1","67","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PROMITIL-01","October 8, 2012","October 2012","September 2016","November 15, 2015","November 2015","No Study Results Posted","null","April 2016","Maximal Tolerated Dose (MTD) of PROMITIL|Dose Limiting Toxicity (DLT) of PROMITIL|Pharmacokinetic (PK) profile of PROMITIL|Anti-tumor responses to the delivered PROMITIL regimens|Toxicity profile of PROMITIL","https://ClinicalTrials.gov/show/NCT01705002"
2619,"NCT00959647","A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study","Completed","Has Results","Ovarian Cancer|Basal Cell Carcinoma|Metastatic Colorectal Cancer","Drug: Vismodegib|Drug: FOLFOX|Drug: FOLFIRI|Drug: Bevacizumab","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","19","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SHH4437g|GO01352","August 10, 2009","September 2009","January 2014","December 23, 2014","December 2014","December 23, 2014","null","January 2014","Percentage of Participants Who Experienced at Least 1 Adverse Event|Percentage of Participants Who Discontinued Treatment Due to an Adverse Event|Incidence and Severity of All Adverse Events and Serious Adverse Events|Incidence of Adverse Events Leading to GDC-0449 Discontinuation","https://ClinicalTrials.gov/show/NCT00959647"
2620,"NCT00959946","Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer","Terminated","Has Results","Advanced Breast Cancer (Parts 1 and 2)|Advanced Pancreatic Cancer (Part 1)|Advanced Colorectal Cancer (Part 1)|Advanced Cholangiocarcinoma (Part 1)|Advanced Glioblastoma Multiforme (Part 1)","Drug: Bosutinib|Drug: Capecitabine","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","32","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3160A6-2208|B1871011","August 14, 2009","September 2009","March 2011","January 18, 2013","January 2013","October 4, 2012","null","March 2011","Maximum Tolerated Dose (MTD) - Part 1|Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) - Part 1|Percentage of Participants With Objective Response - Part 2|Best Overall Response - Part 1|Progression Free Survival (PFS) - Part 2|Clinical Benefit Rate - Part 2|Duration of Response (DR) - Part 2|Maximum Observed Plasma Concentration (Cmax) - Part 2|Time to Reach Maximum Observed Plasma Concentration (Tmax) - Part 2|Apparent Volume of Distribution (Vz/F) - Part 2|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] - Part 2|Apparent Oral Clearance (CL/F) - Part 2|Terminal-Phase Disposition Rate Constant (λz) - Part 2|Plasma Decay Half-Life (t1/2) - Part 2","https://ClinicalTrials.gov/show/NCT00959946"
2621,"NCT01382407","Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab","Active, not recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: Cetuximab","Rambam Health Care Campus|Merck KGaA","Both","18 Years and older   (Adult, Senior)","","100","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","B427CTIL","June 23, 2011","July 2011","April 2017","May 11, 2015","May 2015","No Study Results Posted","null","March 2016","Relationship between acne and skin rash","https://ClinicalTrials.gov/show/NCT01382407"
2622,"NCT00767234","Permission to Collect Blood Over Time for Research","Terminated","No Results Available","Pancreatic Cancer|Gastrointestinal Neoplasms|Colon Rectal Cancer Adenocarcinoma|Esophageal Cancer|Gall Bladder Cancer|Gastric (Stomach) Cancer|Gastrooesophageal Cancer|Gastrointestinal Stromal Tumor (GIST)|Hepatobiliary Neoplasm|Liver Carcinoma|Gallbladder Carcinoma|Bile Duct Carcinoma|Carcinoma of the Large Intestine|Anal Cancer","Procedure: Observation","Stanford University","Both","18 Years and older   (Adult, Senior)","","104","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GI0003|8502","October 3, 2008","August 2008","October 2011","July 6, 2016","July 2016","No Study Results Posted","null","October 2011","Identify Biomarkers","https://ClinicalTrials.gov/show/NCT00767234"
2623,"NCT02187848","Evaluation of SAR408701 in Patients With Advanced Solid Tumors","Recruiting","No Results Available","Neoplasm Malignant","Drug: SAR408701","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","125","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TED13751|2014-001130-29|U1111-1153-3461","June 24, 2014","July 2014","August 2018","September 15, 2016","September 2016","No Study Results Posted","null","March 2018","Number of dose limiting adverse events|Assessment of overall response rate using standard imaging and RECIST 1.1 criteria|Number of treatment emergent adverse events|Maximum concentration (Cmax)|Time to reach maximum concentration (tmax)|Trough plasma concentrations (Ctrough)|Area under the plasma concentration curve versus time curve between 0 and 14 days (AUC0-14day)|Mean systemic clearance (CL)|Clearance at steady state (CLss)|Accumulation ratio (Rac) on AUC0-14day and Cmax|Detection of the development of anti-SAR408701 antibody","https://ClinicalTrials.gov/show/NCT02187848"
2624,"NCT02848807","Chemotherapy-related Toxicity, Nutritional Status and Quality of Life","Recruiting","No Results Available","Toxicity Due to Chemotherapy|Cancer Cachexia|Metastatic Colorectal Cancer|Quality of Life|Dietary Modification","Dietary Supplement: NUTRIDRINK Compact Protein","University Clinical Centre, Gdansk|Nutricia Foundation","Both","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","01/2014/UCK","July 16, 2014","September 2014","December 2016","July 25, 2016","July 2016","No Study Results Posted","null","December 2016","Chemotherapy-related toxicity during 12th week of observation|Changes in the Nutritional status / metabolic status|Changes in the Quality of life and patients well-being|Changes in the Performance status","https://ClinicalTrials.gov/show/NCT02848807"
2625,"NCT01143753","A Study of RO5212054 (PLX3603) in Patients With BRAF V600-mutated Advanced Solid Tumours","Active, not recruiting","No Results Available","Colorectal Cancer, Malignant Melanoma, Neoplasms","Drug: RO5212054","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NP25247|2010-018330-42","June 11, 2010","July 2010","October 2016","September 1, 2016","September 2016","No Study Results Posted","null","October 2016","Dose-escalation phase: Safety and tolerability, dose-limiting toxicities, maximum tolerated dose (adverse events, ECG, vital signs, dermatological evaluation, haematology, serum chemistry, urinalysis)|Pharmacokinetics: Cmax, Tmax, AUC, elimination|Overall safety profile: Adverse events, ECG, vital signs, dermatological evaluation, haematology, serum chemistry, urinalysis","https://ClinicalTrials.gov/show/NCT01143753"
2626,"NCT02387268","Evaluation of the Performance of the CleanC System-Israel","Completed","Has Results","Colorectal Cancer (CRC) Screening","Device: CleanC system","Motus GI Medical Technologies Ltd","Both","18 Years to 75 Years   (Adult, Senior)","","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","CL00005","March 2, 2015","May 2015","November 2015","February 8, 2016","February 2016","October 6, 2015","null","June 2015","Percentage Subjects With Post Procedure Cleansing Level as Measured by the Boston Bowel Preparation Scale (BBPS) Adequate Cleansing-(BBPS>1 )|Safety as Measured by Number of Serious Adverse Events and Major Complications.|Percentage of Participants in Whom the Cecum Was Reached","https://ClinicalTrials.gov/show/NCT02387268"
2627,"NCT02511756","Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)","Recruiting","No Results Available","Metastatic Colorectal Cancer","Device: Computed tomography X-ray system","Patrick Veit-Haibach|Roche Pharma AG|University of Zurich","Both","18 Years and older   (Adult, Senior)","","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Diagnostic","KEK-ZH-Nr. 2015-0084","April 29, 2015","July 2015","July 2019","June 10, 2016","June 2016","No Study Results Posted","AVA-CTP","July 2017","CTP as predictive marker for efficacy measured by progression-free survival|CTP as predictive marker for efficacy measured by overall survival|Tumor vasculature at progression|Subgroup analyses according to the RAS mutation status, BRAF mutation status and VEGF-A level|Local and distant recurrences","https://ClinicalTrials.gov/show/NCT02511756"
2628,"NCT02611661","Local Ablative Strategies After Endovascular Radioembolization (LASER)","Recruiting","No Results Available","Metastatic Colorectal Cancer","Device: PET/MRI|Radiation: Percutaneous microwave ablation|Radiation: Stereotactic body radiotherapy","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","201511087","November 18, 2015","January 2016","July 2019","August 8, 2016","August 2016","No Study Results Posted","null","February 2019","Safety and tolerability of administering hepatic locoregional therapy following radioembolization as measured by occurrences of grade 3 or higher toxicities of interest|Late toxicity associated with radioembolization followed by dosimetry-guided subsequent hepatic locoregional therapy|Local recurrence rates associated with radioembolization followed by dosimetry-guided subsequent hepatic locoregional therapy|Overall survival rates associated with radioembolization followed by dosimetry-guided subsequent hepatic locoregional therapy|Response rates associated with radioembolization followed by dosimetry-guided subsequent hepatic locoregional therapy","https://ClinicalTrials.gov/show/NCT02611661"
2629,"NCT00397878","AZD0530 in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer","Terminated","Has Results","Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer","Drug: saracatinib|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","10","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2013-00067|CDR0000512970|MDA-2005-0977|NCI-7569|P30CA016672|2005-0977|7565|N01CM62202","November 9, 2006","November 2006","November 2011","May 7, 2014","January 2013","December 17, 2013","null","November 2011","Median Progression Free Survival (PFS)|Overall Survival|Time to Progression|Pre- and Post-treatment Expression Values for Each Biological Correlate","https://ClinicalTrials.gov/show/NCT00397878"
2630,"NCT01929720","Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors","Suspended","No Results Available","Anxiety Disorder|Worry|Uncertainty|Sleep Disorders|Insomnia|Fatigue|Pain|Depression|Cognitive-behavioral Therapy|Psychological Intervention|Esophageal Cancer|Pancreatic Cancer|Leukemia|Lung Cancer|Multiple Myeloma|Ovarian Neoplasm|Stage III or IV Cervical or Uterine Cancer|Stage IIIB, IIIC, or IV Breast Cancer|Glioblastoma Multiforme|Relapsed Lymphoma|Stage III or IV Colorectal Cancer|Stage IIIC or IV Melanoma","Behavioral: Cognitive-behavioral therapy for worry, uncertainty & insomnia","Ohio State University Comprehensive Cancer Center|American Cancer Society, Inc.|Lance Armstrong Foundation","Both","18 Years and older   (Adult, Senior)","","75","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","OSU-09096|NCI-2012-02879","March 13, 2013","August 2011","null","December 22, 2015","December 2015","No Study Results Posted","FOCUS","December 2015","Changes in worry on the Penn State Worry Questionnaire|Changes in sleep efficiency on the Insomnia Severity Index|Changes in intolerance of uncertainty on the Intolerance of Uncertainty Scale|Levels of cortisol|Levels of pro and anti-inflammatory cytokines|Levels of myeloid-derived suppressor cells (MDSC)","https://ClinicalTrials.gov/show/NCT01929720"
2631,"NCT01493336","A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours","Completed","No Results Available","Breast Cancer, Colorectal Cancer","Drug: capecitabine RTD|Drug: capecitabine [Xeloda]|Drug: capecitabine [Xeloda]","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 1","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","BP27931|2011-005185-37","December 14, 2011","May 2012","October 2012","September 1, 2016","September 2016","No Study Results Posted","null","October 2012","Relative bioavailability: Area under the concentration-time curve (AUC)|Safety: Incidence of adverse events","https://ClinicalTrials.gov/show/NCT01493336"
2632,"NCT02547480","LifePearl-Iri Pharmacokinetic Study","Recruiting","No Results Available","Metastatic Colorectal Cancer|mCRC","Device: TACE with irinotecan loaded LifePearl","Terumo Europe N.V.|Federation Francophone de Cancerologie Digestive|Universitaire Ziekenhuizen Leuven","Both","18 Years and older   (Adult, Senior)","","20","Industry|Other","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T126E2","August 27, 2015","November 2015","September 2017","April 25, 2016","April 2016","No Study Results Posted","null","September 2016","Maximum Observed Plasma Concentration (Cmax)|Time to reach Cmax (Tmax)|Area Under the Curve (AUC)|Adverse Events (AE) (grade ≥3) and Serious AEs related with study treatment up to 30 days post initial treatment|Overall Survival|Progression-Free Survival|Response rate|Technical success - treatment delivery|Technical success - total dose delivered","https://ClinicalTrials.gov/show/NCT02547480"
2633,"NCT00349817","Genetics Education: Preparing Physicians for the Future","Recruiting","No Results Available","Primary Care Genetics|Hereditary Colorectal Cancer","Behavioral: web-based learning, didactic lecture and role-play","University of Toronto","Both","18 Years to 65 Years   (Adult)","","64","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Educational/Counseling/Training","University of Toronto","July 6, 2006","October 2005","January 2007","July 6, 2006","July 2006","No Study Results Posted","null","null","knowledge in approach to family medicine genetics|attitude towards family medicine genetics and genetic testing|skill in discussing these issues with patients","https://ClinicalTrials.gov/show/NCT00349817"
2634,"NCT01802320","Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery","Active, not recruiting","No Results Available","Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: Akt Inhibitor MK2206|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","54","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2013-00487|2012-0431|9340|N01CM00039|P30CA016672","February 27, 2013","March 2013","null","June 10, 2016","June 2016","No Study Results Posted","null","September 2016","Overall response rate (CR+PR) evaluated using Response Evaluation Criteria in Solid Tumors version 1.1|DR|OS|PFS|Validation of the enrichment biomarker signature in metastatic sites","https://ClinicalTrials.gov/show/NCT01802320"
2635,"NCT02110953","Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver","Recruiting","No Results Available","Liver Metastases|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Device: irinotecan-eluting beads|Procedure: hepatic artery embolization","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GI-063|NCI-2014-00706|P30CA006927","April 8, 2014","January 2016","null","January 22, 2016","January 2016","No Study Results Posted","null","April 2018","Maximum tolerated dose of irinotecan-eluting beads, determined by dose limiting toxicities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Response rate, classified using Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1|Duration of overall response|Time to progression","https://ClinicalTrials.gov/show/NCT02110953"
2636,"NCT01285102","Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer","Terminated","No Results Available","Liver Metastases|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer","Device: irinotecan-eluting beads|Procedure: hepatic artery embolization","Fox Chase Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FCCC IRB 10-002|NCI-2010-01114","January 26, 2011","October 2010","January 2013","September 10, 2015","September 2015","No Study Results Posted","null","December 2011","Time to progression|Patient tolerance and toxicity profile|Overall survival","https://ClinicalTrials.gov/show/NCT01285102"
2637,"NCT01931150","Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT","Completed","No Results Available","Cetuximab-induced Papulopustular (Acneiform) Rash Who Have|Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma","Drug: Topical Dapsone 5% Gel|Other: Moisturizer|Drug: oral antibiotics","Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 3","11","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","13-012","August 26, 2013","August 2013","September 2015","September 10, 2015","September 2015","No Study Results Posted","null","September 2015","difference in lesion counts","https://ClinicalTrials.gov/show/NCT01931150"
2638,"NCT02646748","Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors","Recruiting","No Results Available","Advanced Solid Tumors|Endometrial Cancer|Melanoma|Microsatellite Unstable (MSI) Colorectal Cancer|MMR-deficient Tumors|Non-small Cell Lung Cancer|Renal Cell Carcinoma|Head and Neck Squamous Cell Carcinoma|Triple Negative Breast Cancer|Transitional Cell Carcinoma of the Genitourinary Tract|Pancreatic Ductal Adenocarcinoma","Drug: Pembrolizumab|Drug: INCB039110|Drug: INCB050465","Incyte Corporation","Both","18 Years and older   (Adult, Senior)","Phase 1","78","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","39110-107","January 4, 2016","January 2016","December 2017","September 13, 2016","September 2016","No Study Results Posted","null","June 2017","Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse events|Objective Response Rate (ORR) as determined by radiographic disease assessments per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) v1.1 criteria|Progression Free Survival (PFS) as measured by the duration from the date of first dose until the earliest date of disease progression or death as measured by immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) v1.1|Duration of response (DOR) as measured from the time of the earliest response complete response (CR) or partial response (PR) until disease progression per irRECIST v1.1","https://ClinicalTrials.gov/show/NCT02646748"
2639,"NCT01322815","A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI","Terminated","Has Results","Colon Cancer","Drug: chemotherapy and GI-4000|Drug: GI-4000","Georgetown University|GlobeImmune","Both","18 Years and older   (Adult, Senior)","Phase 2","11","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GI-4000-05","March 23, 2011","October 2010","December 2015","July 6, 2016","February 2016","April 29, 2016","null","September 2014","Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients)","https://ClinicalTrials.gov/show/NCT01322815"
2640,"NCT00309543","Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B","Completed","No Results Available","Colon Cancer Stage II","Drug: Fluorouracil|Drug: Leucovorin","Austrian Breast & Colorectal Cancer Study Group","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","636","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG 91","March 31, 2006","November 1993","null","March 31, 2006","March 2006","No Study Results Posted","null","null","Overall survival","https://ClinicalTrials.gov/show/NCT00309543"
2641,"NCT00309530","Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C","Completed","No Results Available","Colon Cancer Stage III","Drug: 5-fluorouracil, levamisol, interferon","Austrian Breast & Colorectal Cancer Study Group","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","598","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG 90","March 31, 2006","October 1990","null","March 31, 2006","April 1999","No Study Results Posted","null","null","Recurrence-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00309530"
2642,"NCT00309517","Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C","Terminated","No Results Available","Rectal Cancer Dukes B, Dukes C","Drug: Fluourouracil|Drug: Leucovorin|Drug: MAb 17-1A","Austrian Breast & Colorectal Cancer Study Group","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABSCG 92","March 31, 2006","July 1997","null","March 31, 2006","October 2000","No Study Results Posted","null","null","Local recurrence-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00309517"
2643,"NCT01306630","A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors","Completed","No Results Available","Advanced Solid Tumors|Locally Advanced or Metastatic Breast or Colorectal Cancer","Drug: tivozanib (AV-951) and capecitabine (Xeloda®)","AVEO Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AV-951-10-114","November 3, 2010","November 2010","January 2014","January 23, 2014","January 2014","No Study Results Posted","null","January 2014","To determine the safety, tolerability, and maximum tolerated dose of tivozanib when administered in combination with capecitabine (Xeloda®) to subjects with advanced solid tumors|Evaluate the pharmacokinetics of tivozanib, and capecitabine and its metabolites by measuring the serum plasma concentrations of tivozanib and capecitabine in the blood over time.|To evaluate the antineoplastic activity of tivozanib and capecitabine, when given together, to slow the growth of or shrink tumor as measured by CT/MRI imaging assessment and according to RECIST criteria.","https://ClinicalTrials.gov/show/NCT01306630"
2644,"NCT01963117","Effectiveness of the Combined Whole Liver Irradiation (WLI) and Hyperthermia for Gastrointestinal Tract Cancer Liver Metastasis","Terminated","No Results Available","The Patients With Unresectable Chemoresistant Multiple Liver Metastasis From Colorectal Cancer","Radiation: Combined hyperthermia and radiation therapy","Samsung Medical Center","Both","20 Years and older   (Adult, Senior)","Phase 2","11","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SMC IRB 2013-06-040","September 25, 2013","October 2013","April 2015","May 18, 2015","August 2014","No Study Results Posted","null","November 2014","Time to local tumor progression after combined hyperthermia and RT|Objective response rate of combined hyperthermia and RT|Change from baseline quality of life at 3 months|Local tumor progression free survival rate after combined hyperthermia and RT|Adverse event after combined hyperthermia and RT.|Overall survival rate after combined hyperthermia and RT","https://ClinicalTrials.gov/show/NCT01963117"
2645,"NCT02497820","Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers","Not yet recruiting","No Results Available","Lynch Syndrome I (Site-specific Colonic Cancer)","Drug: Aspirin","Tel-Aviv Sourasky Medical Center|Rambam Health Care Campus|Rabin Medical Center|Soroka Medical Center|Sheba Academic Medical Center Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","1800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","0246-14-TLV","July 7, 2015","September 2016","September 2027","August 24, 2016","August 2016","No Study Results Posted","CaPP3 Israel","September 2027","cancer preventive properties of enteric coated aspirin in Lynch syndrome are dose sensitive by comparing overall cumulative Lynch syndrome cancer|Overall cumulative of new colorectal cancers incidence rates after 5 years|Overall cumulative of new endometrial cancers incidence rates after 5 years|Overall cumulative of new new cancers of all types incidence rates after 5 years|Overall cumulative of changes in the titre of frameshift peptide antibodies after 2 & 5 years|Overall cumulative of of new adenomas at five years","https://ClinicalTrials.gov/show/NCT02497820"
2646,"NCT00299299","Modelling Internal Hepatic Movement With an External Abdominal Marker","Recruiting","No Results Available","Patients With Liver Metastases From Colorectal Cancer","","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","10","Other","Observational","Time Perspective: Prospective","CCR 2736","March 3, 2006","June 2006","null","January 11, 2010","January 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00299299"
2647,"NCT02457793","A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors","Active, not recruiting","No Results Available","Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma","Drug: Cobimetinib|Drug: GD0-994","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","27","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","GO29653|2015-000092-27","May 27, 2015","June 2015","September 2018","September 1, 2016","September 2016","No Study Results Posted","null","September 2018","Percentage of patients with dose limiting toxicity (DLTs)|Percentage of patients experiencing at least one adverse event|Mean change from baseline in vital signs|Percentage of patients with at least one adverse event of special interest|Percentage of patients experiencing at least one serious adverse event|Percentage of patients experiencing laboratory abnormalities|Mean accumulation ratio|Pharmacokinetic: Serum concentration (Cmax)|Pharmacokinetic: Total exposure (AUC from time 0 to 24 hour after dose)|Pharmacokinetic: Median time to maximum concentration (t-max)|Pharmacokinetic: Mean terminal half-life (t1/2)|Pharmacodynamic: Change from baseline in fluorodeoxyglucose positron emission tomography (FDG-PET)|Pharmacodynamic: Change from baseline in tumor tissue biomarkers|Objective Response (OR) for patients with measurable disease|Progression-Free Survival (PFS)|Duration of Response (DOR)","https://ClinicalTrials.gov/show/NCT02457793"
2648,"NCT00019006","Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer","Completed","No Results Available","Recurrent Colon Cancer|Extensive Stage Small Cell Lung Cancer|Stage III Pancreatic Cancer|Stage III Rectal Cancer|Limited Stage Small Cell Lung Cancer|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Stage III Non-small Cell Lung Cancer|Stage I Pancreatic Cancer|Stage II Non-small Cell Lung Cancer|Stage IVB Pancreatic Cancer|Stage II Pancreatic Cancer|Stage III Colon Cancer|Stage IVA Pancreatic Cancer","Drug: Detox-B adjuvant|Drug: ras peptide cancer vaccine","National Cancer Institute (NCI)","null","18 Years and older   (Adult, Senior)","Phase 1","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000063475|NCI-94-C-0096D|NCI-T93-0152N","March 1, 2007","March 1995","null","April 27, 2015","May 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00019006"
2649,"NCT01823471","I-Scan For Colon Polyp Detection In HNPCC","Recruiting","No Results Available","Hereditary Non-polyposis Colon Carcinoma|HNPCC|Lynch Syndrome","Other: The use of I-scan in the detection of polyps in HNPCC","Universitaire Ziekenhuizen Leuven","Both","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","S52579","March 21, 2013","November 2010","null","March 29, 2013","September 2010","No Study Results Posted","null","June 2013","The primary endpoint of the study was the difference in adenoma detection between HD-WLE and i-scan, expressed as the miss rate for polyps for each technique.|The difference in overall adenoma detection between HD-WLE and i-scan","https://ClinicalTrials.gov/show/NCT01823471"
2650,"NCT02168777","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer","Completed","No Results Available","Neoplasms","Drug: Refametinib (BAY86-9766)|Drug: Regorafenib (Stivarga, BAY73-4506)","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","17064|2013-004861-15","June 18, 2014","June 2014","April 2016","September 2, 2016","September 2016","No Study Results Posted","null","October 2015","Number of participants with adverse events during Phase 1b as a measure of safety and tolerability|Maximum drug concentration in plasma after multiple dose (Cmax,md) for refametinib|Cmax,md for refametinib metabolite M-11|Area under the plasma concentration-time curve from 0 to 12 h after multiple dose (AUC(0-12)md) for refametinib|AUC(0-12)md for refametinib metabolite M-11|Cmax,md for regorafenib|Cmax,md for regorafenib metabolite M-2|Cmax,md for regorafenib metabolite M-5|Area under the plasma concentration-time curve from 0 to 24 h after multiple dose (AUC(0-24)md) for regorafenib|AUC(0-24)md for regorafenib metabolite M-2|AUC(0-24)md for regorafenib metabolite M-5|Number of participants with adverse events during Phase 2 as a measure of safety and tolerability|Tumor response during Phase 2 as assessed by RECIST v. 1.1|Maximum drug concentration in plasma (Cmax) for refametinib and its metabolite M-11|Time to reach maximum drug concentration in plasma after single (first) dose (tmax) for refametinib and its metabolite M-11|Area under the plasma concentration-time curve from 0 to 8 h (AUC(0-8)) for refametinib and its metabolite M-11|Time to reach maximum drug concentration in plasma after multiple dose (tmax,md) for refametinib and its metabolite M-11|Cmax for regorafenib and its metabolites M-2 and M-5|tmax for regorafenib and its metabolites M-2 and M-5|Area under the plasma concentration-time curve from 0 to 24 h (AUC(0-24)) for regorafenib and its metabolites M-2 and M-5|tmax,md for regorafenib and its metabolites M-2 and M-5|Tumor response during Phase 1b as assessed by RECIST v. 1.1|Overall survival during Phase 2|Time to progression during Phase 2|Progression-free survival during Phase 2","https://ClinicalTrials.gov/show/NCT02168777"
2651,"NCT00703976","Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer","Completed","No Results Available","Cancer","Drug: Bevacizumab|Drug: Cetuximab|Drug: Pemetrexed|Radiation: Radiation therapy","University of Pittsburgh|Eli Lilly and Company|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","UPCI 07-021","June 20, 2008","October 2008","September 2014","February 17, 2015","February 2015","No Study Results Posted","null","September 2014","Each treatment arm will be evaluated on the basis of the primary endpoint - estimated progression-free survival,to be defined as the time from initiation of treatment to the first documented progressive disease.|Secondary outcome measures include within-arm estimates of time to local progression, time to regional progression, overall survival and toxicity profiles.","https://ClinicalTrials.gov/show/NCT00703976"
2652,"NCT01015625","Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer","Active, not recruiting","No Results Available","Synchronous Metastasized Breast Cancer|Circulating Tumor Cells","Procedure: Surgery|Procedure: Surgery on Demand","Austrian Breast & Colorectal Cancer Study Group|Bayer|Amgen|Hoffmann-La Roche|AstraZeneca|Sanofi Aventis GmbH, Austria|Wyeth Lederle Pharma GmbH, Austria|GlaxoSmithKline|Merck Sharp & Dohme GmbH, Austria|Fond of the Viennese Mayor","Female","18 Years and older   (Adult, Senior)","","254","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","ABCSG 28 / POSYTIVE|ABCSG 28","November 17, 2009","October 2010","June 2021","November 17, 2015","November 2015","No Study Results Posted","POSYTIVE","June 2021","to evaluate the median survival of patients with synchronous metastasized breast cancer and the primary tumor in place comparing arm A with local therapy to the primary tumor versus arm B without local therapy|time to distant progression (TTPd)|time to local progression (TTPl)","https://ClinicalTrials.gov/show/NCT01015625"
2653,"NCT02056015","A Phase I Study of MLN6907 in Patients With Metastatic Colorectal","Recruiting","No Results Available","Imaging of Solid Gastrointestinal Tumors","Drug: [68Ga]MLN6907","Millennium Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","C35001","February 4, 2014","June 2015","September 2016","October 6, 2015","October 2015","No Study Results Posted","null","May 2016","Adverse events (AEs), serious AEs (SAEs), assessments of clinical laboratory values, and vital sign measurements|Human organ and whole body absorbed dose values from organ kinetic quantification of [68Ga]MLN6907 uptake and clearance|Expert visual rating of [68Ga]MLN6907 liver tumor uptake and quantitative measurement of tumor-to-background (normal liver, muscle, etc.) ratio for each liver tumor|Time-activity curves for each liver tumor region of interest (ROI) and kinetic curves of the ratio of each liver tumor to background (including for normal liver, muscle, and blood); determination of the time for the maximum ratio for each tumor lesion|Plasma [68Ga]MLN6907 and MLN6907 drug substance precursor PK parameters and quantification of GCC levels in liver metastases|Correlate tumor uptake of [68Ga]MLN6907 measured by PET and the level of guanylyl cyclase C (GCC) expression in tumor lesions from surgical specimens , for tumors in individual patients and for aggregated liver tumors across patients","https://ClinicalTrials.gov/show/NCT02056015"
2654,"NCT01511653","Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma","Completed","No Results Available","Colon Cancer|Rectal Cancer","","University of Michigan|Early Detection Research Network","Both","50 Years to 80 Years   (Adult, Senior)","","5230","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","GLNE010","January 6, 2012","October 2011","June 2014","June 24, 2014","June 2014","No Study Results Posted","GLNE010","June 2014","Compare biomarkers to colonoscopy as a predictor of CRC risk","https://ClinicalTrials.gov/show/NCT01511653"
2655,"NCT01324102","Yoga Cancer Rehabilitation Study: A Randomized Trial of Adaptive Yoga for Older Cancer Survivors","Completed","Has Results","Neoplasms","Behavioral: Yoga therapy","VA Office of Research and Development|Wake Forest School of Medicine","Both","18 Years to 90 Years   (Adult, Senior)","Phase 1|Phase 2","23","U.S. Fed|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D7629-P","March 4, 2011","May 2011","December 2015","December 3, 2015","December 2015","December 2, 2014","YogaCares","April 2013","Patient-Reported Outcomes Measurement System Scale, a Scale Developed by the National Institute of Health to Assess Outcomes Across Different Trials.","https://ClinicalTrials.gov/show/NCT01324102"
2656,"NCT01528878","Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases","Active, not recruiting","No Results Available","Liver Neoplasms|Colonic Neoplasms|Metastatic Cancer to Liver","Radiation: Stereotactic Radiosurgery using the CyberKnife System.","UNC Lineberger Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 0809","January 9, 2012","April 2009","April 2017","September 2, 2016","September 2016","No Study Results Posted","null","April 2016","Tolerable Doses of Radiation in Patients with Liver Cancer or Metastases to the Liver in Patients with Good vs. Compromised Liver Function.|Tumor Response to Doses of Radiation in Patients with Liver Cancer or Metastases to the Liver, in Patients with Good vs. Compromised Liver Function.","https://ClinicalTrials.gov/show/NCT01528878"
2657,"NCT02494791","Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer","Recruiting","No Results Available","Lynch Syndrome|Endometrial Neoplasms|Ovarian Neoplasms|Colorectal Neoplasms","Behavioral: Questionnaire, Educational Material","University Health Network, Toronto|Mount Sinai Hospital, Canada|Sunnybrook Health Sciences Centre|Hamilton Health Sciences Corporation|Ryerson University|University of Toronto","Both","18 Years to 70 Years   (Adult, Senior)","","915","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","14-8533CE","July 7, 2015","July 2015","July 2025","April 15, 2016","April 2016","No Study Results Posted","LS2","July 2019","Adherence to screening guidelines (colonoscopy and gynecologic risk-reducing surgery) in participants found to have Lynch Syndrome|Cost-effectiveness of universal enhanced screening strategy to identify women with Lynch Syndrome and their family members via cascade testing|Incidence of Lynch Syndrome in an unselected group of women with endometrial and non-serous ovarian cancer|Discovery of novel genetic mutations and molecular events in unexplained MMR loss (Lynch-like Syndrome)","https://ClinicalTrials.gov/show/NCT02494791"
2658,"NCT00633607","Hereditary Colorectal and Associated Tumor Registry Study","Recruiting","No Results Available","Lynch Syndrome|FAP|Hereditary Diffuse Gastric Cancer|Juvenile Polyposis Syndrome|Peutz-Jeghers Syndrome","Other: Research Registry","University of Pittsburgh","Both","8 Years to 100 Years   (Child, Adult, Senior)","","1000","Other","Observational","Observational Model: Family-Based","04-112","March 3, 2008","April 2012","December 2020","January 14, 2016","January 2016","No Study Results Posted","null","December 2020","Establish a Hereditary Colorectal Tumor Registry to facilitate development and implementation of epidemiological, clinical and cancer control research.","https://ClinicalTrials.gov/show/NCT00633607"
2659,"NCT01582841","Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting","Completed","No Results Available","Colon Cancer|Lynch Syndrome","Procedure: MSI screening test","Kaiser Permanente|Case Western Reserve University|M.D. Anderson Cancer Center|Dana-Farber Cancer Institute|Vanderbilt University","Both","18 Years and older   (Adult, Senior)","","247","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","1R01CA140377-01A2","December 15, 2011","February 2012","July 2016","August 29, 2016","August 2016","No Study Results Posted","HNPCC","July 2016","Implementation effectiveness","https://ClinicalTrials.gov/show/NCT01582841"
2660,"NCT01363843","Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)","Completed","Has Results","Colon Cancer|Rectal Cancer","Drug: FOLFOX6|Radiation: RT with concurrent chemotherapy|Procedure: Surgery","William Sikov|Memorial Hospital of Rhode Island|Rhode Island Hospital|The Miriam Hospital|Brown University","Both","18 Years and older   (Adult, Senior)","Phase 2","39","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG 224","May 26, 2011","May 2010","January 2013","July 25, 2014","July 2014","June 17, 2014","null","January 2013","Incidence of Complete Resection|Evaluate the Toxicity of Study Therapy","https://ClinicalTrials.gov/show/NCT01363843"
2661,"NCT00346099","Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum","Withdrawn","No Results Available","Rectal Cancer|Neoplasm Metastasis","Drug: Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by|Drug: Panitumumab with capecitabine and radiation","NSABP Foundation Inc|Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP FR-1","June 27, 2006","June 2006","May 2007","December 21, 2007","December 2007","No Study Results Posted","null","null","Percentage of patients with clinical complete response rate in tumor in the pelvis at 4 to 6 weeks after completion of radiation therapy|Percentage of patients with pathologic complete response rate of the primary rectal tumor and resected regional lymph nodes(tissue removed at the time of surgery)|Percentage of patients whose surgical evaluation following therapy indicates candidacy for resection|Percentage of patients who have progressive disease in the pelvis from the time of study entry to 2 years|The toxicity of panitumumab in combination with chemotherapy and in combination with chemoradiotherapy","https://ClinicalTrials.gov/show/NCT00346099"
2662,"NCT01339000","Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy","Terminated","Has Results","Breast Cancer|Colon Cancer|Bladder Cancer","Drug: Glycosylated Recombinant Human Interleukin-7|Biological: Diphtheria/Tetanus Vaccine|Biological: Polio Vaccine|Biological: Pneumococcal Vaccine|Biological: Hepatitis A Vaccine|Biological: Hepatitis B Vaccine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","60 Years to 100 Years   (Adult, Senior)","Phase 2","1","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","110146|11-C-0146","April 19, 2011","April 2011","April 2016","May 16, 2016","May 2016","May 16, 2016","null","April 2016","Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on Specific Immune Responses to Vaccines (in Particular to Neo Antigens) in Older Subjects Following Chemotherapy|Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on the T Cell Receptor Diversity in Older Subjects Following Chemotherapy|Evaluate the Effects of Interleukin-7 (CYT107) Therapy on the Quality of T Cell Specific Responses by Multiparameter Flow Cytometry|Based on the First Two Primary Objectives, Consider and Discuss the Need for Larger Studies to Evaluate the Potential Benefit of Interleukin-7 (CYT107) Administration in a Broad, Mass Protection Strategy for an Aging Population|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT01339000"
2663,"NCT01727388","Informativeness to Digital Rectal Examination","Completed","No Results Available","Colon Cancer|Upper Rectum Cancer|Diverticulitis|Rectal Bleeding|Hernia","Procedure: lateral decubitus|Procedure: supine decubitus","Centre Hospitalier Universitaire, Amiens","Male","18 Years and older   (Adult, Senior)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","PI11-PR-REGIMBEAU|2011-AO1485-36","October 22, 2012","November 2012","March 2013","November 26, 2013","November 2013","No Study Results Posted","RIFIONA","March 2013","realization of a full digital rectal examination|assessment of sphincter according to the DRESS score|missing information during the rectal examination|Conversion rate decided by the examiner|Evaluation of the position by the patient","https://ClinicalTrials.gov/show/NCT01727388"
2664,"NCT01308086","Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer","Recruiting","No Results Available","CRC","Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Oxaliplatin|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Capecitabine|Drug: Oxaliplatin|Drug: Oxaliplatin","Hellenic Oncology Research Group|University Hospital of Crete","Both","18 Years and older   (Adult, Senior)","Phase 3","2000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/09.12","March 1, 2011","October 2010","September 2016","September 25, 2015","September 2015","No Study Results Posted","null","March 2016","Relapse Free Survival|Overall Survival|Safety Profil according to NCI-CTAE v 3.0","https://ClinicalTrials.gov/show/NCT01308086"
2665,"NCT02309632","Pancreatic Cancer Screening of High-Risk Individuals in Arkansas","Recruiting","No Results Available","Pancreatic Neoplasms|Peutz-Jegher's Syndrome|BRCA1 Gene Mutation|BRCA2 Gene Mutation|Ataxia Telangiectasia|Familial Atypical Mole-Malignant Melanoma Syndrome|Colorectal Neoplasms, Hereditary Nonpolyposis|Hereditary Pancreatitis","Other: Pancreatic Cancer Screening Pathway 1|Other: Pancreatic Cancer Screening Pathway 2","University of Arkansas","Both","18 Years to 99 Years   (Adult, Senior)","","100","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","203640","December 3, 2014","November 2015","November 2025","July 20, 2016","July 2016","No Study Results Posted","null","November 2020","Detection rate of PC and precancerous lesion","https://ClinicalTrials.gov/show/NCT02309632"
2666,"NCT01183663","Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)","Completed","No Results Available","Advanced Cancers","Drug: Lenalidomide|Drug: Bevacizumab|Drug: Sorafenib|Drug: Temsirolimus|Drug: Lenalidomide|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-fluorouracil","M.D. Anderson Cancer Center|Celgene","Both","18 Years and older   (Adult, Senior)","Phase 1","180","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-0108|NCI-2012-01790","August 13, 2010","August 2010","May 2016","June 1, 2016","June 2016","No Study Results Posted","null","May 2016","Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)|Tumor Response","https://ClinicalTrials.gov/show/NCT01183663"
2667,"NCT00898768","Capsule Endoscopy to Screen for Small Bowel Neoplasia in Lynch Syndrome","Completed","No Results Available","Lynch Syndrome|Small Bowel Neoplasia","Procedure: Capsule endoscopy","University Medical Center Groningen|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Erasmus Medical Center|Leiden University Medical Center|St. Antonius Hospital|The Netherlands Cancer Institute|University Medical Center Nijmegen|Maastricht University Medical Center|Free University Medical Center|Given Imaging Ltd.","Both","35 Years to 70 Years   (Adult, Senior)","Phase 0","200","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","CELSIUS|Dutch Cancer Society 2008-4187","May 11, 2009","May 2009","December 2014","December 8, 2014","December 2014","No Study Results Posted","CELSIUS","December 2014","The main outcome measure will be the number of neoplastic small bowel lesions, with determination of size, location and histological characteristics at baseline and at follow-up after 2 years.|The secondary endpoint will be the number of complications following endoscopic procedures: rates of capsule retention and postpolypectomy bleeding and perforation.","https://ClinicalTrials.gov/show/NCT00898768"
2668,"NCT02069561","Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal Cancer","Completed","No Results Available","Ulcerative Colitis","Dietary Supplement: Eicosapentaenoic Acid","Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi","Both","18 Years to 70 Years   (Adult, Senior)","","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","EPAUC/2013","February 19, 2014","January 2014","null","September 17, 2015","September 2015","No Study Results Posted","EPAUC","August 2015","Changes of RNA profiles (gene expression and micro RNA) from baseline|Changes of DNA methylation profiles|Changes in cell proliferation|Changes of apoptosis|Changes of circulating cytokines from baseline|Changes of membrane fatty acid composition from baseline|Changes of metabolomic profiles from baseline|Change of Microbiota composition from baseline","https://ClinicalTrials.gov/show/NCT02069561"
2669,"NCT01098422","A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver","Terminated","No Results Available","Colorectal Neoplasms|Liver Neoplasms","Device: Yttrium-90 Radioactive Resin Microspheres","Tony Reid, M.D., Ph.D.|Sirtex Medical|University of California, San Diego","Both","18 Years and older   (Adult, Senior)","Phase 2","10","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","071960","April 1, 2010","January 2010","February 2015","June 4, 2015","June 2015","No Study Results Posted","null","February 2015","Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy.|Overall survival assessed at 6 months since diagnosis of progression on first-line therapy|Tumor response rate as determined by RECIST criteria using CT or Magnetic Resonance Imaging (MRI) assessment of tumor size every 3 months|Tumor response rate as determined by Position Emission Tomography (PET) scan imaging every 3 months|Tumor response rate as determined by Contrast Enhanced Ultrasound scan imaging|Time to progression, assessed by RECIST criteria using CT or MRI|Change from baseline in abnormal serum tumor marker after administration of microspheres and monthly throughout second line chemotherapy|Incidence of adverse events grade 2 or higher and dose limiting adverse events throughout microspheres treatment, second line chemotherapy and follow-up|Clinical laboratory safety results|60 day all-cause mortality rate since the start of second line chemotherapy","https://ClinicalTrials.gov/show/NCT01098422"
2670,"NCT00006392","S0000 Selenium and Vitamin E in Preventing Prostate Cancer","Completed","Has Results","Prostate Cancer","Drug: Vitamin E|Drug: Selenium|Other: Vitamin E placebo|Other: selenium placebo","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|NCIC Clinical Trials Group","Male","50 Years to 120 Years   (Adult, Senior)","Phase 3","35533","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CDR0000068277|S0000|U10CA037429","October 4, 2000","July 2001","September 2012","October 23, 2015","October 2015","June 12, 2012","SELECT","May 2011","Number of Participants With Prostate Cancer|Number of Participants With Lung Cancer|Number of Participants With Colorectal Cancer|Number of Participants With Any Diagnosis of Cancer|Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival|Number of Participants With Serious Cardiovascular Events","https://ClinicalTrials.gov/show/NCT00006392"
2671,"NCT02012244","Effects of Postoperative Pain Management on Immune Function After Laparoscopic Resection of Colorectal Cancer","Completed","No Results Available","Colorectal Surgery","Drug: fentanyl-based analgesia|Drug: local anesthetic wound infiltration-based anlagesia","Severance Hospital","Both","20 Years to 80 Years   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","4-2013-0044","December 7, 2013","January 2014","December 2015","January 10, 2016","January 2016","No Study Results Posted","null","December 2014","NK cell activity|IL-2|Complication and recurrence","https://ClinicalTrials.gov/show/NCT02012244"
2672,"NCT00582296","Multi-Organ Screening Recommendations in Patients With Lynch Syndrome","Recruiting","No Results Available","Lynch Syndrome","Behavioral: questionnaires, telephone interview, optional blood drawn|Behavioral: questionnaires, telephone interview and optional blood drawn","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Albert Einstein College of Medicine of Yeshiva University","Both","18 Years and older   (Adult, Senior)","","1000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","04-144","December 21, 2007","December 2004","December 2017","July 26, 2016","July 2016","No Study Results Posted","null","December 2017","To assess adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations in patients with Lynch Syndrome.|To evaluate predictive factors for adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations.","https://ClinicalTrials.gov/show/NCT00582296"
2673,"NCT02576431","Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Thyroid Neoplasms|Sarcoma|Colorectal Neoplasms|Salivary Gland Neoplasms|Biliary Tract Neoplasms|Brain Neoplasm, Primary|Carcinoma, Ductal, Breast|Melanoma|Solid Tumors|Glioblastoma|Bile Duct Neoplasms|Astrocytoma|Head and Neck Squamous Cell Carcinoma|Pontine Glioma","Drug: LOXO-101","Loxo Oncology, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","151","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LOXO-TRK-15002","October 12, 2015","October 2015","April 2019","September 16, 2016","September 2016","No Study Results Posted","null","April 2018","Best Overall Response of confirmed CR or PR as measured by RECIST 1.1 or RANO criteria as appropriate to tumor type|Duration of Response (DOR)|Progression Free Survival (PFS)|Overall Survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02576431"
2674,"NCT01562899","A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors","Completed","No Results Available","KRAS Mutated Colorectal Adenocarcinoma.|Metastatic Pancreatic Adenocarcinoma|BRAF Mutated Melanoma","Drug: MEK162 + AMG 479","Array BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 2","77","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CMEK162X2111|2012-000305-76","March 22, 2012","August 2012","April 2015","February 11, 2016","February 2016","No Study Results Posted","null","April 2015","Phase Ib: Estimation of Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) by measuring incidence of dose limiting toxicities|Phase II: Antitumor activity of MEK162 in combination with AMG 479 by evaluating Objective Response Rate (ORR) in colorectal carcinoma and melanoma and by evaluating Disease Control Rate (DCR) at week 10 in pancreatic carcinoma|Both Phases: Safety and tolerability of MEK162 & AMG 479 (ganitumab) in combination by evaluating the adverse events, serious adverse events, changes in hematology and chemistry values, vital signs, ECGs; dose interruptions, reductions and dose intensity|Both Phases: Determination of single and multiple dose pharmacokinetics (PK) profile of MEK162 in combination with AMG 479 (ganitumab) by measuring time vs. plasma concentrations and basic PK parameters of MEK162|Phase Ib: Preliminary anti-tumor activity of MEK162 and AMG 479 (ganitumab) in combination by evaluating the Overall Response Rate (ORR), Duration of Response (DOR) and Progression Free Survival (PFS)|Phase II: Further anti-tumor activity of MEK162 & AMG 479 (ganitumab) in combination by evaluating the DOR, PFS and OS by evaluating Disease Control Rate for colorectal carcinoma and melanoma; Overall Response Rate for pancreatic carcinoma patients","https://ClinicalTrials.gov/show/NCT01562899"
2675,"NCT00054912","An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer","Completed","No Results Available","Colonic Neoplasms|Colorectal Neoplasms","Biological: EP2101","Epimmune","Both","18 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EP2101-102","February 12, 2003","February 2003","null","April 7, 2008","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00054912"
2676,"NCT01378832","Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Postoperative Colorectal Cancer Infection in Elective Surgery","Completed","No Results Available","Surgical Site Infection","Procedure: Intra-peritoneal antibiotic lavage","Universidad Miguel Hernandez de Elche","Both","Child, Adult, Senior","Phase 3","102","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","jruiztovar","June 20, 2011","January 2010","December 2010","June 21, 2011","January 2010","No Study Results Posted","lavage","December 2010","Surgical site infection","https://ClinicalTrials.gov/show/NCT01378832"
2677,"NCT02121405","Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM","Not yet recruiting","No Results Available","Colorectal Neoplasm|Effects of Radiation Therapy|Effects of Chemotherapy|Surgery","Procedure: Rectectomy|Radiation: Radiotherapy|Drug: Capecitabine|Drug: Oxaliplatin","Zhejiang University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","350","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRCCZ-R01","April 21, 2014","December 2014","December 2022","April 22, 2014","April 2014","No Study Results Posted","PSSR","December 2020","Disease-free survival|The rate of positive circumferential resection margin|Quality of life by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C(core) 30 and QLQ-CR(colorectal) 29 forms|Overall survival","https://ClinicalTrials.gov/show/NCT02121405"
2678,"NCT02672657","Determinants of Quality Of Life in AGEd Cancer Patients","Recruiting","No Results Available","Colorectal Neoplasms|Prostatic Neoplasms","","Assistance Publique - Hôpitaux de Paris|Research Team CEpiA (Clinical Epidemiology and Ageing) EA7376, University Paris Est Créteil (UPEC)|Research Team APEMAC EA4360, University of Lorraine|Unité de Recherche Clinique Mondor, Hôpital Henri Mondor|Unité Lorraine de Coordination en Oncogériatrie (ULCOG) - Institut de Cancérologie de Lorraine|Unité de Coordination en Onco-Gériatrie (UCOG) Sud Val-de-Marne|Quality of life and cancer clinical research platform|Ligue contre le cancer, France|Conseil Régional de Lorraine, France","Both","70 Years and older   (Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2014-A00317-40","January 14, 2016","February 2016","December 2019","August 25, 2016","August 2016","No Study Results Posted","DEQOLAGE","February 2019","Changes in HRQoL of patients and their caregivers as assessed by the generic WHOQOL-BREF questionnaires|Changes in HRQoL of patients and their caregivers if aged >70 years as assessed by the WHOQOL-OLD questionnaire|Changes in HRQoL of patients as assessed by the specific EORTC-QLQ C30 questionnaire|Changes in HRQoL of patients as assessed by the specific EORTC QLQ-ELD14 questionnaire|Changes in burden of patients' caregivers as assessed by the Zarit burden inventory questionnaire|Psychometric properties of the HRQoL questionnaire WHOQOL-OLD (validity, reliability, sensitivity to change, feasibility)|Psychometric properties of the HRQoL questionnaire EORTC QLQ-ELD14 (validity, reliability, sensitivity to change, feasibility)|Prognostic value of baseline HRQoL measurements on cancer progression-free survival|Prognostic value of baseline HRQoL measurements on overall survival|Prognostic value of baseline HRQoL measurements on patient's functional decline, defined as any decrease in the ADL scale","https://ClinicalTrials.gov/show/NCT02672657"
2679,"NCT02356848","STEP UP to Avert Amputation in Diabetes","Recruiting","No Results Available","Diabetes|Foot Ulcer","Behavioral: Tailored Intervention (TI)|Behavioral: Current Practice (CP)","VA Office of Research and Development","Both","21 Years and older   (Adult, Senior)","","238","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","E1858-R","February 2, 2015","September 2015","January 2019","July 21, 2016","July 2016","No Study Results Posted","STEP UP","November 2018","Ulceration|Foot care skills|General Quality of Life|Foot health-specific quality of life|plantar pressure|step count","https://ClinicalTrials.gov/show/NCT02356848"
2680,"NCT00765869","Randomised Controlled Trial of a Literacy Sensitive Decision Aid for Bowel Cancer Screening","Recruiting","No Results Available","Colorectal Neoplasms","Other: Bowel cancer screening decision aid|Other: Bowel cancer screening decision aid|Other: Australian Government Bowel Cancer Screening booklet","University of Sydney|National Health and Medical Research Council, Australia","Both","55 Years to 64 Years   (Adult)","","555","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","HREC10403|ACTRN12608000011381","October 1, 2008","July 2008","February 2009","October 2, 2008","October 2008","No Study Results Posted","null","December 2008","Informed choice|Involvement in screening decision|Anxiety|Bowel cancer worry|Decisional conflict|Decision satisfaction|Bowel cancer screening interest|Bowel cancer screening intentions|Screening behaviour|Self reported bowel cancer symptoms|Evaluation of intervention materials|Influence of doctor on screening decision","https://ClinicalTrials.gov/show/NCT00765869"
2681,"NCT02494037","The Canadian/US Integrative Oncology Study","Recruiting","No Results Available","Breast Neoplasms|Colorectal Neoplasms|Pancreatic Neoplasms|Ovarian Neoplasms","","The Canadian College of Naturopathic Medicine|Bastyr University|Lotte & John Hecht Memorial Foundation","Both","18 Years and older   (Adult, Senior)","","400","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","3974","July 3, 2015","January 2015","January 2021","July 6, 2016","July 2016","No Study Results Posted","CUSIOS","January 2021","Survival|AIO and Conventional Oncology Treatments|Health-Related Quality of Life (HRQOL)","https://ClinicalTrials.gov/show/NCT02494037"
2682,"NCT01789229","Tumor Bank for Tissue Samples","Recruiting","No Results Available","Ovarian Neoplasms|Breast Neoplasms|Colorectal Neoplasms|Neoplasms of the Female Genitalia|Lung Neoplasms|Endocrine Gland Neoplasms","Other: Tumor tissue collection|Other: Sampling of ascites and pleural effusion|Other: Collecting urine samples|Other: Collecting saliva sample|Other: Collecting sputum|Other: Collecting stool samples|Other: Lavage/Irrigation","Medical University of Vienna","Both","18 Years and older   (Adult, Senior)","","10000","Other","Observational","Observational Model: Case Control","EK 260/2003","February 7, 2013","September 2003","January 2017","September 28, 2015","September 2015","No Study Results Posted","null","January 2017","Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.","https://ClinicalTrials.gov/show/NCT01789229"
2683,"NCT00591279","Cancer Control Following Polypectomy","Active, not recruiting","No Results Available","Colon Cancer","","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Mount Sinai Hospital, New York|Minneapolis Veterans Affairs Medical Center|Medical College of Wisconsin|St. Lukes hospital in Racine, Wiscousin|Massachusetts General Hospital|Cedars-Sinai Medical Center|Valley Presbyterian Hospital","Both","Child, Adult, Senior","","110","Other|NIH|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","81-035","December 26, 2007","February 1981","January 2017","February 2, 2016","February 2016","No Study Results Posted","null","January 2017","evaluate strategies for the surveillance of post-polypectomy patients","https://ClinicalTrials.gov/show/NCT00591279"
2684,"NCT00468455","Post-Op Quality of Life After Colorectal Surgery","Completed","No Results Available","Colorectal Neoplasms|Colitis, Ulcerative|Diverticulitis|Colonic Polyps|Crohn Disease","Procedure: Laparoscopic or open colorectal surgery","University Hospitals Cleveland Medical Center","Both","18 Years to 85 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","10-05-17","May 1, 2007","October 2005","May 2008","December 12, 2014","December 2014","No Study Results Posted","null","April 2008","Evaluate the quality of life in patients with abdominal wall hernias using a user-friendly survey that is designed specifically for this population of patients.|Evaluate the quality of life in patients with abdominal wall hernias using a user-friendly survey that is designed specifically for this population of patients","https://ClinicalTrials.gov/show/NCT00468455"
2685,"NCT01290536","Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases","Completed","Has Results","Colorectal Neoplasms|Neuroendocrine Tumors|Cholangiocarcinoma|Melanoma|Breast Cancer","Device: Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)","Nicholas Fidelman|University of California, San Francisco","Both","18 Years and older   (Adult, Senior)","Phase 2","42","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCSF-SIRT-Metastases","February 1, 2011","June 2010","October 2013","December 11, 2014","December 2014","May 10, 2014","null","October 2013","Number of Participants With Adverse Events|Radiographic Response","https://ClinicalTrials.gov/show/NCT01290536"
2686,"NCT02005965","Low Rectal Cancer Study (MERCURY II)","Active, not recruiting","No Results Available","Adenocarcinoma|Adenocarcinoma, Mucinous|Carcinoma|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|Neoplasms|Neoplasms, Cystic, Mucinous, and Serous|Colorectal Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms|Neoplasms by Site|Digestive System Diseases|Gastrointestinal Diseases|Intestinal Diseases|Rectal Diseases","","Royal Marsden NHS Foundation Trust|Pelican Cancer Foundation","Both","18 Years and older   (Adult, Senior)","","542","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCR2943","November 21, 2013","September 2007","March 2020","March 11, 2016","March 2016","No Study Results Posted","MERCURY II","March 2016","To assess the rate of CRM positivity rate in low rectal cancer.|To compare global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.|To compare patient reported outcomes in patients according to plane of surgery with or without sphincter preservation.|Analysis of the clinical and radiological factors influencing the decision by surgeons to carry out Anterior Resections, APE or extralevator APE.|Comparison of time to local recurrence, disease-free and overall survival between patients undergoing different types of surgery.|Comparison of imaging and pathology staging assessment, patient characteristics and complication rates, between different types of surgery and surgical approaches.|Investigation of potential associations between imaging and pathology assessment of radial and distal margins, neo-adjuvant chemoradiotherapy, perineal complications and sphincter preservation rates.|Investigation of potential association between length of operation with number of complications and length of post-operative ITU/HDU stay.","https://ClinicalTrials.gov/show/NCT02005965"
2687,"NCT01763125","Tumor Bank for Blood Samples","Recruiting","No Results Available","Ovarian Neoplasms|Breast Neoplasms|Colorectal Neoplasms|Neoplasms of the Female Genitalia|Lung Neoplasms|Endocrine Gland Neoplasms","Other: Blood collection","Medical University of Vienna","Both","18 Years and older   (Adult, Senior)","","10000","Other","Observational","Observational Model: Case Control","EK 366/2003","January 4, 2013","November 2003","January 2017","September 28, 2015","September 2015","No Study Results Posted","null","January 2017","Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.","https://ClinicalTrials.gov/show/NCT01763125"
2688,"NCT00506207","A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy","Active, not recruiting","No Results Available","Colorectal Neoplasm|Gastric Neoplasm|Secondary","Drug: S-1, Irinotecan, Oxaliplatin","National Cancer Center, Korea","Both","18 Years and older   (Adult, Senior)","Phase 1","23","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-06-166","July 23, 2007","September 2006","December 2009","July 23, 2007","July 2007","No Study Results Posted","TIROX","null","Toxicity measured by NCICTC v.3|Blood level of irinotecan and S-1 and their metabolites|Maximal response rate, progression-free survival, survival","https://ClinicalTrials.gov/show/NCT00506207"
2689,"NCT01086683","Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course","Completed","No Results Available","Neoplasms|Breast Neoplasms|Colorectal Neoplasms|Prostatic Neoplasms","Behavioral: Psychosocial rehabilitation course","Danish Cancer Society|University Hospital Århus, Department of Surgery|University Hospital Århus, Urology Department|Randers Regional Hospital|Regional Hospital Hørsholm, Department of Breast Surgery","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","513","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","225 06 001","March 12, 2010","May 2004","December 2009","March 12, 2010","March 2010","No Study Results Posted","null","December 2008","psychosocial well-being (as assessed by the EORTC-QLQ C30 Quality of life core questionnaire by the European Organization of Research and Treatment in Cancer (EORTC-QLQ C30) and the Profile of Mood States Short form (POMS-SF)|health behaviours: physical activity, diet, tobacco and alcohol consumption, use of health services|self-rated health|self-efficacy as measured with the General Self-Efficacy Scale (GSE)","https://ClinicalTrials.gov/show/NCT01086683"
2690,"NCT02084524","ANC1 Study Impact of a Geriatric and Nutritional Evaluation for the Malnutrition and Malnutrition Risk Screening in Patients Over 70 Years With Colorectal Surgery.","Recruiting","No Results Available","Colorectal Tumor","Procedure: Malnutrition screening and perioperative nutritional support","Hospices Civils de Lyon","Both","70 Years and older   (Senior)","","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","2011.703","November 4, 2013","June 2013","June 2016","March 11, 2014","June 2013","No Study Results Posted","ANC1","June 2013","Perioperative nutritional management|Malnutrition screening|Rate of preoperative nutritional management by immunonutrition implemented|Rate of malnourished patients|Rate of patients with cachexia|Postoperative complications|Rate of postoperative nutritional management implemented|Evolution of the activities of daily living","https://ClinicalTrials.gov/show/NCT02084524"
2691,"NCT00586053","Unprepped CT Colonography","Completed","No Results Available","Colorectal Neoplasms","","Mayo Clinic","Both","40 Years and older   (Adult, Senior)","","1255","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1221-00|CA75333-08","December 21, 2007","August 2000","December 2009","February 10, 2010","February 2010","No Study Results Posted","null","December 2008","To optimize diagnostic performance of CTC in the unprepared colon for colorectal polyp detection using electronic stool subtraction and computer-aided diagnostic techniques.|The cost-effectiveness ratio of CTC in the unprepared colon will compare favorably with other colorectal screening tests","https://ClinicalTrials.gov/show/NCT00586053"
2692,"NCT01995942","Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial","Recruiting","No Results Available","Adenocarcinoma|Rectal Diseases|Colorectal Neoplasms|Adenocarcinoma, Mucinous|Carcinoma|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|Neoplasms|Neoplasms, Cystic, Mucinous, and Serous|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms|Neoplasms by Site|Digestive System Diseases|Gastrointestinal Diseases|Intestinal Diseases","","Royal Marsden NHS Foundation Trust|Pelican Cancer Foundation","Both","18 Years and older   (Adult, Senior)","","160","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCR3873","November 21, 2013","June 2013","June 2018","November 26, 2013","July 2013","No Study Results Posted","MARVEL","June 2018","The primary endpoint will be time to relapse pertaining to the primary objective of relapse rate at 1 year and 3 years.|Response rates (in terms of mrTstage, mrN stage, involvement of CRM (circumferential resection margin) and mrTRG (tumour regression grade)) in addition to recurrence rates at 1 year and 3 years.|Measurement of the change in mrEMVI from pre to post pre-operative therapy, will be based on a new proposed EMVI-TRG classification (EMVI TRG 1-5).","https://ClinicalTrials.gov/show/NCT01995942"
2693,"NCT00962494","Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors","Completed","No Results Available","Blood Cancer|Breast Cancer|Prostatic Neoplasms|Colorectal Neoplasms|Neoplasms","Behavioral: Cancer: Thriving and Surviving Online Workshop","Stanford University|University of Hawaii Cancer Research Center","Both","19 Years and older   (Adult, Senior)","Phase 2","585","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","VAR0044|SU-07292009-3460","August 18, 2009","July 2009","December 2011","February 5, 2013","February 2013","No Study Results Posted","null","August 2011","Document patterns of health care utilization|Quality of Life|Outcome Measure: Better Interactions with Oncologists|Health Behaviors|Satisfaction with intervention","https://ClinicalTrials.gov/show/NCT00962494"
2694,"NCT00349076","Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer","Completed","No Results Available","Rectal Neoplasms","Drug: 5-FU and oxaliplatin|Drug: 5-FU","University of Erlangen-Nürnberg Medical School","Both","18 Years and older   (Adult, Senior)","Phase 3","1256","Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CAO/ARO/AIO-04|German Cancer Aid (no. 106759)","July 5, 2006","July 2006","June 2016","July 29, 2016","July 2016","No Study Results Posted","null","December 2015","Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.|Resection rate, rate of sphincter preservation, tumor regression, cumulative incidence of local and distant recurrences, overall survival, toxicity, quality of life","https://ClinicalTrials.gov/show/NCT00349076"
2695,"NCT00635596","Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer","Completed","No Results Available","Solid Tumors","Biological: MT110","Amgen Research (Munich) GmbH","Both","18 Years and older   (Adult, Senior)","Phase 1","65","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MT110-101|EUDRACT No: 2007-004437-42","March 7, 2008","March 2008","January 2015","January 12, 2015","January 2015","No Study Results Posted","MT110-101","January 2014","Overall frequency and intensity of adverse events (AEs) (clinical symptoms, laboratory abnormalities, serious adverse events [SAEs] and dose-limiting toxicities)|Pharmacokinetics of MT110; T-cell counts, kinetics, and activation status; Serum cytokine concentrations; Immunogenicity; Anti-tumor activity; Other progressive disease (PD) parameters","https://ClinicalTrials.gov/show/NCT00635596"
2696,"NCT02581709","An Intervention Programme to Reduce Cognitive Impairment Due to Cancer","Not yet recruiting","No Results Available","Breast Neoplasms|Colorectal Neoplasms","Behavioral: Countering cognitive impairment","Queen's University, Belfast|Belfast Health and Social Care Trust|Cancer Research Network","Both","18 Years and older   (Adult, Senior)","","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","STL/5086/14","October 15, 2015","November 2015","November 2016","October 19, 2015","October 2015","No Study Results Posted","null","August 2016","Feasibility of intervention implementation|Hopkins Verbal Learning Test|Reitan's Trail Making Test (TMT) A and B|Controlled oral Word Association (COWA) sub-test of the Multilingual Aphasia Examination|Digit Span sub-test of the Wechsler Adult Intelligence Scale (WAIS)|Digit Symbol sub-test of the WAIS|Functional Assessment of Cancer Therapy- Cognitive Subscale (FACT-Cog)|Short form health survey (SF-36)|Centre for Epidemiological studies Depression- Revised scale (CESD-R)|Hospital Anxiety and Depression Scale- Anxiety sub-scale (HADS-A)|Functional Assessment of Chronic Illness Therapy- Fatigue sub-scale (FACIT-F)|Pittsburgh Sleep Quality Index (PSQI)","https://ClinicalTrials.gov/show/NCT02581709"
2697,"NCT00034827","A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer","Completed","No Results Available","Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms","Drug: CI-1040","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 2","172","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1040-000-002","May 2, 2002","January 2002","May 2003","May 3, 2007","July 2006","No Study Results Posted","null","null","Overall objective response and clinical benefit response|Time to objective response, duration of response, time to progression and survival","https://ClinicalTrials.gov/show/NCT00034827"
2698,"NCT02009449","A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors","Recruiting","No Results Available","Melanoma|Prostate Cancer|Ovarian Cancer|Renal Cell Carcinoma|Colorectal Carcinoma|Pancreatic Carcinoma|Non-small Cell Lung Carcinoma|Solid Tumors|Breast Cancer","Drug: AM0010|Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Drug: gemcitabine/nab-paclitaxel|Drug: Capecitabine|Drug: Pazopanib|Drug: Pembrolizumab|Drug: Paclitaxel|Drug: nivolumab|Drug: Gemcitabine/carboplatin","ARMO BioSciences","Both","18 Years and older   (Adult, Senior)","Phase 1","300","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AM0010-001","December 2, 2013","November 2013","December 2016","January 11, 2016","January 2016","No Study Results Posted","null","December 2016","Safety and tolerability as measured by incidence of adverse events|Pharmacokinetic (PK) parameters|Change in tumor burden measured by volumetric Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) according to immune-related response criteria (irRC)|Progression in bone by bone scintigraphy according to Prostate Cancer Working Group 2 (PCWG2) for patients with metastatic castration resistant prostate cancer (CRPC)|Anti-AM0010 antibody formation","https://ClinicalTrials.gov/show/NCT02009449"
2699,"NCT02423954","Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)","Recruiting","No Results Available","Advanced Cancer|Pancreatic Cancer|Renal Cell Cancer|Non Small Cell Lung Cancer|Colorectal Carcinoma|Endometrial|Uterine","Drug: Temsirolimus|Drug: Irinotecan|Drug: Irinotecan + capecitabine|Drug: nivolumab","Western Regional Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","49","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","WG2015001","April 13, 2015","April 2015","April 2017","December 10, 2015","December 2015","No Study Results Posted","NivoPlus","April 2017","The recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer.|Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03|Response rate by irRC and response evaluation criteria in solid tumors (RECIST) 1.1 criteria1,2|The overall survival (OS) and progression-free survival (PFS)|Quantify changes in amount of blood proteins and circulating tumor DNA in patients enrolled on this study|Quantify pixel changes identified on imaging","https://ClinicalTrials.gov/show/NCT02423954"
2700,"NCT02043184","Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR","Completed","No Results Available","Prostatic Neoplasms|Breast Neoplasms|Colorectal Neoplasms|Melanoma|Leukemia","Behavioral: Interactive Voice Response (IVR) Reminders","Michigan State University|National Cancer Institute (NCI)","Both","21 Years and older   (Adult, Senior)","","246","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","1R01CA162401-01A1|1R01CA162401","January 20, 2014","March 2013","July 2016","September 19, 2016","September 2016","No Study Results Posted","null","July 2016","Medication Adherence using pill count and self report|Medication Self-Efficacy using Horne Measure|Symptom Burden is determining the overall number of symptoms on the given symptom tool|Symptom Interference is the interference with daily activities|Depression using the full Clinical Screening for depression measure|Physical Function using the Physical Function Scale|Healthcare Utilization is the use of Emergency room and Hospital admissions","https://ClinicalTrials.gov/show/NCT02043184"
2701,"NCT01915225","Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer","Recruiting","No Results Available","Colorectal Neoplasms|Gastric Neoplasms|Cholangiocarcinoma|Bile Duct Cancer|Pancreas Cancer","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 90 Years   (Adult, Senior)","","1000","NIH","Observational","Time Perspective: Prospective","130176|13-C-0176","July 31, 2013","July 2013","June 2024","August 31, 2016","April 2016","No Study Results Posted","null","June 2023","To collect biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose ofidentifying novel molecular and biologictherapeutic targets|To collect detailed history, demographic, treatment data, and perioperative findings in order to categorize and track the specific procedures and outcomes","https://ClinicalTrials.gov/show/NCT01915225"
2702,"NCT02486094","Study of PRoliferation and Apoptosis in Rectal Cancer, Predictive & Prognostic biOmarkers: Histopathology and Imaging","Recruiting","No Results Available","Neoplasms|Colorectal Neoplasms|Rectal Diseases|Gastrointestinal Neoplasms","","Royal Marsden NHS Foundation Trust|The Royal College of Surgeons of England|Croydon Health Services NHS Trust, Surrey","Both","18 Years and older   (Adult, Senior)","","45","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CCR 4324","June 22, 2015","June 2015","June 2016","June 26, 2015","June 2015","No Study Results Posted","SOPRANO","September 2015","Apoptotic index, Ki67 and Geminin in cells per mm cubed from diognostic biopsy|Apoptotic index, Ki67 and Geminin in cells per mm cubed from resected tumour|Time to local recurrence|Disease Free Survival (DFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02486094"
2703,"NCT00123760","Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer","Completed","No Results Available","Brain Neoplasms|Lung Neoplasms|Thyroid Neoplasms|Colorectal Neoplasms|Lymphoma","Procedure: Positron Emission Tomography (PET) scan","AHS Cancer Control Alberta|Cross Cancer Institute","Both","15 Years and older   (Child, Adult, Senior)","Phase 2|Phase 3","10838","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","SP-11-0035/DX-FDG-001/21221","July 22, 2005","February 2004","December 2008","February 24, 2016","March 2012","No Study Results Posted","null","December 2008","To demonstrate the safety of 18F-FDG synthesized from cyclotron produced radiofluoride in the Coincidence Technologies automated synthesis unit (ASU) in the Edmonton PET Centre facility|To confirm the diagnostic effectiveness of 18F-FDG in subjects with known or suspected oncologic disease and compare this to literature values","https://ClinicalTrials.gov/show/NCT00123760"
2704,"NCT02355262","CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers","Recruiting","No Results Available","Breast Carcinoma|Cervical Carcinoma|Colorectal Carcinoma|Health Status Unknown|Human Papillomavirus Infection|Malignant Neoplasm","Other: Informational Intervention","OHSU Knight Cancer Institute|Kaiser Foundation Hospitals, Center for Health Research|National Cancer Institute (NCI)|Oregon Community Health Information Network (OCHIN)","Both","18 Years to 64 Years   (Adult)","","200","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","9862|NCI-2014-02326|CR00024554|5219|MR00042926|MR00044877|IRB00009862|P30CA069533|R01CA181452","January 23, 2015","July 2014","June 2019","April 20, 2016","April 2016","No Study Results Posted","CATCH-UP","June 2019","Changes in the proportion of clinic patients who receive age- and gender-appropriate recommended cancer screening and preventive care (clinic-level)|Changes in the proportion of clinic patients with insurance continuity|Total number of months uninsured (total gap months)","https://ClinicalTrials.gov/show/NCT02355262"
2705,"NCT02231086","Adjuvant HIPEC in High Risk Colon Cancer","Recruiting","No Results Available","Colorectal Neoplasms|Peritoneal Neoplasms","Procedure: Adjuvant HIPEC (open/laparoscopic)|Drug: Standard adjuvant systemic chemotherapy|Procedure: Diagnostic laparoscopy","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|ZonMw: The Netherlands Organisation for Health Research and Development|Dutch Health Care Insurance Board","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","176","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","NL49960.018.14|2014-002794-11","August 22, 2014","March 2015","April 2022","September 15, 2016","September 2016","No Study Results Posted","COLOPEC","April 2019","Peritoneal recurrence free survival|Treatment related toxicity of adjuvant HIPEC, including 30-day complication rate, re-intervention rate, and re-admission rate|Hospital stay for simultaneous and staged HIPEC, either open or laparoscopic|False-negative rate of CT-scan for peritoneal metastases|Patterns of dissemination (peritoneal plus or minus distant metastases)|Disease-free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT02231086"
2706,"NCT00039793","Massage Therapy for Cancer-Related Fatigue","Completed","No Results Available","Breast Neoplasms|Ovarian Neoplasms|Prostatic Neoplasms|Colorectal Neoplasms","Procedure: Moderate-intensity and low-intensity bodywork therapy","National Center for Complementary and Integrative Health (NCCIH)","Both","18 Years and older   (Adult, Senior)","Phase 2","45","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","R21AT000348-01","June 11, 2002","March 2001","March 2004","August 17, 2006","July 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00039793"
2707,"NCT02324556","A LAparoscopic and TransAnal Total Mesorectal Excision (TME) for Rectal Cancer Trial","Recruiting","No Results Available","Colorectal Neoplasm","","Sahlgrenska University Hospital, Sweden","Both","Child, Adult, Senior","","40","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","LATA","November 27, 2014","January 2015","December 2017","April 14, 2016","April 2016","No Study Results Posted","LATA","December 2016","Number of specimens with grade I specimen according to Quirke|Conversion rate|Re-admission|Postoperative complications scored according to Clavien-Dindo within the first 12 months","https://ClinicalTrials.gov/show/NCT02324556"
2708,"NCT01919853","Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker Response","Completed","No Results Available","Fatigue","Behavioral: Mindfulness-Based Stress Reduction|Behavioral: Attention Control","Indiana University|Walther Cancer Institute|Indiana Clinical and Translational Sciences Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","107","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","01206008951|0106.01","July 30, 2013","September 2012","November 2013","December 31, 2014","December 2014","No Study Results Posted","null","November 2013","Change in cancer-related fatigue functional interference|Change in cancer-related fatigue severity|Change in vitality|Change in depression|Change in anxiety|Change in sleep disturbance|Change in pain|Change in fear of recurrence|Change in attentional function","https://ClinicalTrials.gov/show/NCT01919853"
2709,"NCT02365662","A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Colorectal Carcinoma|Glioblastoma Multiforme","Drug: ABBV-221","AbbVie","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","80","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M14-429|2014-003557-34","February 5, 2015","January 2015","February 2018","August 5, 2016","August 2016","No Study Results Posted","null","February 2018","Number of participants with adverse events|Maximum tolerated dose of ABBV-221|Recommended Phase 2 dose of ABBV-221|Maximum Plasma Concentration (Cmax) of ABBV-221|Area Under the Plasma Concentration-time Curve of ABBV-221|Area Under the Plasma Concentration-time Curve from 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-221|Assess the effect of systemic ABBV-221 administration on QT prolongation|Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT02365662"
2710,"NCT02650661","Efficacy of a Smart Management Strategy for Health (SMASH) Program for Overcoming Cancer Crisis and Growing Positively","Recruiting","No Results Available","Breast Neoplasms|Lung Neoplasms|Colorectal Neoplasms|Stomach Neoplasms","Behavioral: Online health management program|Behavioral: Health coaching|Behavioral: Workshop|Behavioral: Standard health educational booklet","Seoul National University Hospital|Samsung Medical Center|Asan Medical Center|Ewha Womans University Mokdong Hospital|National Cancer Center, Korea","Both","19 Years and older   (Adult, Senior)","","485","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","YHYun","October 1, 2015","December 2015","December 2017","January 7, 2016","January 2016","No Study Results Posted","null","February 2017","Change in percentage of patients meeting the exercise goal|Change in percentage of patients meeting the body mass index (BMI) goal|Change in percentage of patients meeting the posttraumatic growth inventory (PTGI) goal|Change in percentage of patients meeting diet goal|Change in execution level of health habits|Change in level of Hospital Anxiety Depression Scale (HADS)|Change in level of Brief Fatigue Inventory (BFI)|Change in level of Smart Management Strategy for Health Assessment Tool (SAT)|Change in level of MOS-Social Support Survey (MOS-SSS)|Change in level of McGill Quality of Life (McGill QoL)|Change in level of General health status (SF-36)|Cost effectiveness analysis","https://ClinicalTrials.gov/show/NCT02650661"
2711,"NCT02014116","A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body","Active, not recruiting","No Results Available","Neoplasms|Neoplasm Metastasis|Melanoma|Carcinoma, Non-Small-Cell Lung|Colorectal Neoplasms","Drug: LY3009120 capsule","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 1","50","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13873|I6X-MC-JBDA","December 12, 2013","November 2013","December 2016","July 25, 2016","July 2016","No Study Results Posted","null","December 2016","Maximum Tolerated Dose (MTD) of LY3009120|Number of Participants with Tumor Response|Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3009120|Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3009120","https://ClinicalTrials.gov/show/NCT02014116"
2712,"NCT02124148","A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer","Recruiting","No Results Available","Neoplasm Metastasis|Colorectal Neoplasms","Drug: Prexasertib|Drug: Cisplatin|Drug: Cetuximab|Drug: G-CSF|Drug: Pemetrexed|Drug: Fluorouracil|Drug: LY3023414|Drug: Leucovorin","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 1","185","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","15295|I4D-MC-JTJF","April 24, 2014","June 2014","April 2018","May 9, 2016","May 2016","No Study Results Posted","null","April 2018","Part A: Maximum Tolerated Dose and Schedule of Prexasertib in Combination with Cisplatin|Part B: Maximum Tolerated Dose of Prexasertib in Combination with Cetuximab|Part C: Maximum Tolerated Dose of Prexasertib in Combination with Pemetrexed|Part D: Maximum Tolerated Dose of Prexasertib in Combination with Fluorouracil (5-FU)|Part E: Maximum Tolerated Dose of Prexasertib in Combination with LY3023414|Pharmacokinetics: Maximum Concentration of Prexasertib|Pharmacokinetics: Area Under the Concentration Curve of Prexasertib|Part B Dose Expansion: Overall Response Rate|Part B Dose Expansion: Disease Control Rate|Part B Dose Expansion: Progression-Free Survival|Part B Dose Expansion: Duration of Response","https://ClinicalTrials.gov/show/NCT02124148"
2713,"NCT00257322","Cellular Immune Augmentation in Colon and Rectal Cancer","Completed","Has Results","Colon Cancer|Rectal Cancer","Drug: GM-CSF","University of California, Irvine","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 02-60|2003-2876","November 18, 2005","April 2003","July 2009","March 23, 2016","March 2016","June 26, 2009","null","July 2009","Participants Exhibiting Immune Response|Response Rates and Overall Survival.","https://ClinicalTrials.gov/show/NCT00257322"
2714,"NCT02215733","The Use of Angiotensin Receptor Blockers and the Risk of Cancer","Completed","No Results Available","Neoplasm","Drug: ARB|Drug: ACEI|Drug: Beta-blockers|Drug: Diuretics|Drug: Telmisartan","Boehringer Ingelheim","Both","Child, Adult, Senior","","1165781","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","502.599","August 12, 2014","February 2011","null","August 12, 2014","August 2014","No Study Results Posted","null","February 2012","Number of patients with occurrences of lung, colorectal, breast and prostate cancers related to use of ARBs|Determination of dose-response in terms of ARB duration of use and cumulative dose and the risk of lung, colorectal, breast and prostate cancers combined|Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of ARBs, relative to beta-blockers and diuretics|Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan, relative to beta-blockers and diuretics|Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan relative to other ARBs|Number of patients with occurrences of lung cancer related to use of ARBs alone|Number of patients with occurrences of colorectal cancer related to use of ARBs alone|Number of patients with occurrences of breast cancer related to use of ARBs alone|Number of patients with occurrences of prostate cancer related to use of ARBs alone|Number of patients with occurrences of lung cancer related to use of ARBs with ACEI|Number of patients with occurrences of colorectal cancer related to use of ARBs with ACEI|Number of patients with occurrences of breast cancer related to use of ARBs with ACEI|Number of patients with occurrences of prostate cancer related to use of ARBs with ACEI|Ratio of occurrence of lung cancer related to use of telmisartan relative to other ARBs|Ratio of occurrence of colorectal cancer related to use of telmisartan relative to other ARBs|Ratio of occurrence of breast cancer related to use of telmisartan relative to other ARBs|Ratio of occurrence of prostate cancer related to use of telmisartan relative to other ARBs","https://ClinicalTrials.gov/show/NCT02215733"
2715,"NCT02228200","Nurse-led Care Program for Cancer Patients in Chemotherapy Day Center","Completed","No Results Available","Breast Neoplasms|Colorectal Neoplasms","Behavioral: Nurse-led care|Behavioral: Routine care","The Hong Kong Polytechnic University","Both","18 Years and older   (Adult, Senior)","","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","POLYU-HSEARS20120117002","August 19, 2014","June 2012","January 2014","August 26, 2014","August 2014","No Study Results Posted","null","November 2013","Change in quality of life|Health care utilization","https://ClinicalTrials.gov/show/NCT02228200"
2716,"NCT00288444","Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer","Terminated","No Results Available","Lung Cancer|Soft Tissue Sarcoma|Colorectal Carcinoma|Breast Cancer|Prostate Cancer","Drug: Lonafarnib|Drug: Docetaxel","Emory University|Aventis Pharmaceuticals|Schering-Plough","Both","Child, Adult, Senior","Phase 1","38","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","174-2004|EU841-03","February 6, 2006","January 2006","March 2009","December 17, 2012","December 2012","No Study Results Posted","null","May 2008","Determine the molecular interaction|Determine safety and efficacy","https://ClinicalTrials.gov/show/NCT00288444"
2717,"NCT01037049","Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks","Active, not recruiting","No Results Available","Adenocarcinoma of the Rectum|Adenocarcinoma|Adenocarcinoma, Mucinous|Carcinoma|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|Neoplasms|Neoplasms, Cystic, Mucinous, and Serous|Colorectal Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms|Neoplasms by Site|Digestive System Diseases|Gastrointestinal Diseases|Intestinal Diseases|Rectal Diseases","Other: Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 2","237","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","CCR3227","December 18, 2009","October 2009","July 2019","June 22, 2015","November 2013","No Study Results Posted","null","June 2015","The primary endpoint will be the difference in the proportion of patients in each arm, downstaged according to T stage [on MRI].|Tumour response using SUV measurements [PET/CT], N downstaging and Tumour Regression Grade downstaging [on MRI].|Difference in proportion of patients in each arm undergoing sphincter saving surgery.|Morbidity, 30 day mortality and CRM (circumferential resection margin) positivity.|An analysis will also be undertaken using multivariate and linear regression analysis to evaluate the association of ypT and ypN stage as a potential independent predictors of SUV (max) baseline and after radiotherapy (pre-surgery) in the two arms.|Local and distant recurrence rates.|Radiotherapy related toxicity rates.","https://ClinicalTrials.gov/show/NCT01037049"
2718,"NCT00844064","Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2","Completed","No Results Available","Pancreatic Neoplasms|Melanoma|Colorectal Neoplasms","Drug: AP 12009","Isarna Therapeutics GmbH","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","62","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AP 12009-P001","February 12, 2009","January 2005","November 2011","November 18, 2011","November 2011","No Study Results Posted","null","November 2011","To determine the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT) of two cycles of AP 12009 administered intravenously at weekly intervals and for four days every other week.|To determine the safety and tolerability of AP 12009 administered intravenously at weekly intervals and for four days every other week.|To assess the plasma pharmacokinetic profile of AP 12009 administered intravenously at weekly intervals and for four days every other week.|To establish a suitable determination method and to assess the urine pharmacokinetic profile of AP 12009 administered intravenously for four days every other week.|To determine the effect of AP 12009 administered intravenously at weekly intervals and for four days every other week on TGF-β2 plasma concentration levels.|To determine the potential antitumor activity of AP 12009 administered intravenously at weekly intervals and for four days every other week, as assessed by the effect on tumor size and tumor markers.","https://ClinicalTrials.gov/show/NCT00844064"
2719,"NCT00145665","The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases","Terminated","No Results Available","Colorectal Neoplasms|Liver Neoplasms","Procedure: FLT-PET scan","Radboud University","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","FLT-PET CRC-LM","September 1, 2005","January 2005","December 2012","September 2, 2011","February 2007","No Study Results Posted","null","December 2011","correlation FLT-uptake in colorectal liver metastases and the histologically determined proliferation|correlation FLT and recurrence rate","https://ClinicalTrials.gov/show/NCT00145665"
2720,"NCT00207298","18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology","Recruiting","No Results Available","Brain Neoplasms|Lung Neoplasms|Lymphoma|Melanoma|Colorectal Neoplasms","Procedure: Positron Emission Tomography","British Columbia Cancer Agency","Both","19 Years to 90 Years   (Adult, Senior)","Phase 3","5000","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","R05-0076","September 13, 2005","June 2005","November 2008","November 3, 2010","November 2010","No Study Results Posted","null","null","Change in management based on PET procedure|Sensitivity of PET","https://ClinicalTrials.gov/show/NCT00207298"
2721,"NCT01778595","Colon Cancer Study of Fecal Samples in Shanghai, China","Completed","No Results Available","Colorectal Neoplasms","","National Cancer Institute (NCI)|Shanghai Center for Disease Control and Prevention|BGI|National Institutes of Health Clinical Center (CC)","Both","50 Years to 75 Years   (Adult, Senior)","","700","NIH|Other","Observational","Time Perspective: Cross-Sectional","999913068|13-C-N068","January 26, 2013","January 2013","December 2015","August 6, 2016","December 2015","No Study Results Posted","null","December 2015","Participation rate, data quality","https://ClinicalTrials.gov/show/NCT01778595"
2722,"NCT00976508","Figitumumab Combined With Pegvisomant For Advanced Solid Tumors","Terminated","Has Results","Colorectal Neoplasms|Lung Neoplasms|Breast Neoplasms|Prostatic Neoplasms|Sarcoma","Drug: figitumumab|Drug: pegvisomant","Pfizer","Both","10 Years and older   (Child, Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4021040","September 10, 2009","November 2009","October 2012","October 23, 2013","October 2013","October 23, 2013","null","September 2011","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Dose Limiting Toxicities (DLT)|Serum Circulating Insulin-like Growth Factor (IGF-1) Levels|Cycle 1: Maximum Observed Plasma Concentration (Cmax) of Figitumumab|Maximum Observed Plasma Concentration (Cmax) of Figitumumab|Cycle 1: Plasma Concentration at the Last Quantifiable Time Point (Clast) of Figitumumab|Plasma Concentration at the Last Quantifiable Time Point (Clast) of Figitumumab|Cycle 1: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Figitumumab|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)of Figitumumab|Area Under the Trough Concentrations (AUCtrough)|Mean Change in Glucose Levels Between Fasting and Post Glucose Load|Percentage of Participants Reporting Positive Anti-Drug Antibodies (ADA) Response for Figitumumab|Number of Participants With Objective Response","https://ClinicalTrials.gov/show/NCT00976508"
2723,"NCT02399410","Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis","Not yet recruiting","No Results Available","Colorectal Neoplasms","Drug: perioperative chemotherapy plus bevacizumab|Procedure: cytoreductive surgery|Drug: Intraperitoneal Oxaliplatin","University Hospital, Ghent","Both","18 Years and older   (Adult, Senior)","Phase 2","45","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UGHENT","March 9, 2015","May 2015","April 2020","March 20, 2015","March 2015","No Study Results Posted","null","August 2018","surgical morbidity and mortality|progression free survival|overall survival|treatment completion rate|chemotherapy-related toxicity|pathological gross response of peritoneal tumour deposits to neoadjuvant combination chemotherapy with bevacizumab","https://ClinicalTrials.gov/show/NCT02399410"
2724,"NCT01719926","Phase I Platinum Based Chemotherapy Plus Indomethacin","Recruiting","No Results Available","Colorectal Neoplasms|Esophageal Neoplasms|Ovarian Neoplasms","Drug: Indomethacin","UMC Utrecht","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label","NL40487.041.12","October 30, 2012","September 2012","July 2016","February 24, 2014","February 2014","No Study Results Posted","PIFA","February 2016","Number of dose limiting toxicities at each dosage cohort|Pharmacodynamics|Efficacy","https://ClinicalTrials.gov/show/NCT01719926"
2725,"NCT01542281","Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer","Recruiting","No Results Available","Colorectal Neoplasm|Biliary Tract Neoplasm|Liver Neoplasm","Dietary Supplement: Whey protein and dietary supplements|Other: prehab exercise","McGill University Health Center","Both","18 Years to 80 Years   (Adult, Senior)","","64","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","BMA-10-375","February 16, 2012","January 2012","January 2015","February 24, 2012","February 2012","No Study Results Posted","null","January 2014","Change in six minute walk test|post-operative complications|Health-related quality of life (HRQL)|Physical activity level|Depression and anxiety|Fatigue|Nutritional status","https://ClinicalTrials.gov/show/NCT01542281"
2726,"NCT02674815","Preoperative High Intensity Interval Training: The PHIIT Trial","Recruiting","No Results Available","Colorectal Neoplasms|Lung Neoplasms","Other: High Intensity Interval Training Exercise programme","University of Dublin, Trinity College","Both","18 Years and older   (Adult, Senior)","","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRFSJ0086","January 26, 2016","February 2016","December 2016","September 12, 2016","September 2016","No Study Results Posted","PHIIT","November 2016","Cost|Adherence/Compliance|Incidence of Adverse Events|Satisfaction/Acceptability|Withdrawal of participants|Protocol deviations/Adaptations|Compliance|Postoperative mortality|Changes in Aerobic Capacity|Length of stay|Postoperative complications assessed using the Postoperative Morbidity Survey|Readmission rates|ICU/HDU admission rates|ICU/HDU length of stay|Clavien-Dindo Classification Sore","https://ClinicalTrials.gov/show/NCT02674815"
2727,"NCT00385177","Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors","Completed","No Results Available","Breast Neoplasms|Colorectal Neoplasms|Pancreatic Neoplasms|Pelvic Neoplasms|Lung Neoplasms","Drug: SN2310 Injectable Emulsion","OncoGenex Technologies","Both","18 Years and older   (Adult, Senior)","Phase 1","61","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SON-2310-06-101","October 3, 2006","September 2006","May 2009","June 2, 2009","June 2009","No Study Results Posted","null","December 2008","Maximum Tolerated Dose|Dose-Limiting Toxicity|Adverse Events|Pharmacokinetic parameters for SN2310 and SN-38","https://ClinicalTrials.gov/show/NCT00385177"
2728,"NCT01521091","Comparison of Diagnostic Accuracy for Predicting Histology of Colorectal Lesions","Completed","No Results Available","Colorectal Neoplasms","","Shanghai Jiao Tong University School of Medicine","Both","18 Years to 90 Years   (Adult, Senior)","","565","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","rjxhnk01","January 24, 2012","January 2009","December 2010","January 27, 2012","January 2012","No Study Results Posted","null","December 2010","","https://ClinicalTrials.gov/show/NCT01521091"
2729,"NCT02578264","Molecular Stethoscope","Enrolling by invitation","No Results Available","Colonic Neoplasms","","Scripps Translational Science Institute|Sequenom, Inc.","Both","18 Years to 100 Years   (Adult, Senior)","","25","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15-6616","October 14, 2015","June 2015","July 2017","October 15, 2015","October 2015","No Study Results Posted","null","December 2016","Determining sensitivity of assay in known cancer patients","https://ClinicalTrials.gov/show/NCT02578264"
2730,"NCT02882659","Dendritic Killer Cell-based Immunotherapy for Solid Tumors","Active, not recruiting","No Results Available","Colorectal Neoplasms|Hepatocellular Carcinoma|Neoplasm Metastasis","Biological: Dendritic Killer Cell (DKC)","FullHope Biomedical Co., Ltd.|Taipei Veterans General Hospital, Taiwan","Both","20 Years and older   (Adult, Senior)","Phase 1","18","Industry|Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-07-026B","August 18, 2016","August 2014","December 2017","August 24, 2016","August 2016","No Study Results Posted","null","January 2016","Safety of DKC as assessed by adverse event (AE)|Safety of DKC as assessed by serious adverse event (SAE)|Safety of DKC as assessed by dose-limiting toxicity (DLT)|Safety of DKC as assessed by combining with concomitant anticancer treatment|Safety of DKC as assessed by laboratory examinations|Efficacy of DKC as assessed by tumor specific T cell response|Efficacy of DKC as assessed by change in quality of life","https://ClinicalTrials.gov/show/NCT02882659"
2731,"NCT00419627","Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas","Not yet recruiting","No Results Available","Colorectal Neoplasms|Stomach Neoplasms|Pancreatic Neoplasms|Breast Neoplasms|Ovarian Cancer","","Hillel Yaffe Medical Center|Technion, Israel Institute of Technology","Both","Child, Adult, Senior","","160","Other","Observational","Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Prospective","ProtHYMC","January 5, 2007","February 2007","null","January 5, 2007","January 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00419627"
2732,"NCT00156975","Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases","Active, not recruiting","No Results Available","Colorectal Neoplasms|Liver Metastases","Drug: Capecitabine|Drug: Oxaliplatin","Arbeitsgruppe Lebermetastasen und Tumoren","Both","18 Years and older   (Adult, Senior)","Phase 3","384","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ADHOC","September 9, 2005","November 2004","null","December 24, 2009","April 2007","No Study Results Posted","null","null","Primary outcomes:|Disease free survival|Secondary outcomes:overall survival,acute- and longtime toxicity of chemotherapy, molecular predictive markers for the risk of relapse and toxicity","https://ClinicalTrials.gov/show/NCT00156975"
2733,"NCT00661154","Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project","Completed","No Results Available","Colorectal Neoplasms|Colon Cancer|Rectal Cancer|Anal Cancer","Drug: Bevacizumab","Stanford University|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","","7","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GIIMG0001|97291|AVF3679s","April 14, 2008","February 2008","July 2010","August 8, 2012","August 2012","No Study Results Posted","null","July 2009","Determine whether[18F]-5-Fluorouracil PET/CT scanning can demonstrate a difference in [18F]-5-Fluorouracil tumor uptake before and after the administration of Avastin|Determine if [18F]-5-Fluorouracil PET/CT imaging demonstrates that there is a difference in maximal [18F]-5-Fluorouracil tumor uptake that is dependent on the time point of post-Avastin scanning","https://ClinicalTrials.gov/show/NCT00661154"
2734,"NCT02781155","Limiting Chemotherapy Side Effects by Using Moxa","Recruiting","No Results Available","Breast Neoplasms|Colorectal Neoplasms|Genital Neoplasms, Female|Toxicity Due to Chemotherapy","Other: Moxibustion","East and North Hertfordshire NHS Trust|British Acupuncture Council","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","RD2015-04","May 6, 2016","February 2016","September 2017","May 19, 2016","May 2016","No Study Results Posted","null","January 2017","Adherence to moxa regimen assessed by Daily Moxa Diary|Blood counts, specifically white blood cells, neutrophils, haemoglobin, and platelets|Variation to planned chemotherapy schedule|Chemotherapy related toxicities|Health related quality of life (HRQOL)|Patient self-management|Safety assessed by all incidents including allergies, burns, and other accidents|Incidents of additional interventions administered as prophylaxis or therapy to maintain or improve blood counts","https://ClinicalTrials.gov/show/NCT02781155"
2735,"NCT02837679","Oncogeriatric Intervention and Follow-up at Home","Recruiting","No Results Available","Neoplasms|Geriatric Assessment|Lung Neoplasms|Colorectal Neoplasms|Head and Neck Neoplasms|Gastrointestinal Neoplasms|Geriatrics|Polypharmacy|Quality of Life","Other: Comprehensive geriatric care","Aarhus University Hospital|Danish Cancer Society|University of Aarhus","Both","70 Years and older   (Senior)","","350","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","Onkogeriatri randomiseret","June 27, 2016","January 2016","January 2020","July 15, 2016","July 2016","No Study Results Posted","null","January 2019","Length of hospital stay|Success rate of admittance to initial planned oncological treatment|Quality of life (QoL)|Quality of life|90-day survival|Physical performance, Timed-up-and-go|Physical performance, chair-stand-test|Physical performance, Barthel-100|Physical performance, FAQ-IADL","https://ClinicalTrials.gov/show/NCT02837679"
2736,"NCT00168987","Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors","Completed","No Results Available","Colorectal Neoplasms|Hepatocellular Carcinoma|Cholangiocarcinoma","Drug: oral nutritional supplement rich in eicosapentanoic acid","Charite University, Berlin, Germany|Pfrimmer Nutricia GmbH, Erlangen , Germany","Both","18 Years and older   (Adult, Senior)","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EA1/174/05","September 13, 2005","January 2005","June 2007","May 5, 2008","May 2008","No Study Results Posted","null","November 2006","improvement of muscle function (hand grip strength, respiratory muscle function) at two months|improvement of cognitive function at two months|improvement of quality of life at two months|tolerance of the oral nutritional supplement|improvement of nutritional state (body weight, muscle mass, body cell mass, phase angle, serum albumin)","https://ClinicalTrials.gov/show/NCT00168987"
2737,"NCT01700062","Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery","Completed","No Results Available","Colorectal Neoplasms","Dietary Supplement: Total Parenteral Nutrition (TPN)","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","18 Years and older   (Adult, Senior)","Phase 4","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","KMUH-IRB-960022","October 2, 2012","April 2007","December 2008","October 2, 2012","October 2012","No Study Results Posted","null","November 2008","biochemistry data; Various inflammation-related cytokines ;|clinical outcome(hospital stay..)","https://ClinicalTrials.gov/show/NCT01700062"
2738,"NCT02073500","Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies","Recruiting","No Results Available","Pseudomyxoma Peritonei.|Colorectal Carcinoma.|Ovarian Carcinoma.|Mesothelioma.","Other: Observational study.","Oslo University Hospital|The Research Council of Norway","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PSM_250913","February 17, 2014","September 2009","January 2023","October 14, 2015","October 2015","No Study Results Posted","PSM","January 2017","Overall survival (OS)|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02073500"
2739,"NCT02484079","Comparative Effectiveness of Hot Versus Cold Snare Polypectomy of Small Colorectal Polyps","Enrolling by invitation","No Results Available","Colonic Polyps|Colorectal Neoplasms|Adenoma","Procedure: Polypectomy","Sorlandet Hospital HF","Both","40 Years to 75 Years   (Adult, Senior)","","800","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","SorlandetHF","April 24, 2015","August 2015","December 2022","October 29, 2015","October 2015","No Study Results Posted","HOT/COLD","December 2016","Complete resection rate|Complications|Factors explaining the primary outcome","https://ClinicalTrials.gov/show/NCT02484079"
2740,"NCT00603577","Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens","Terminated","No Results Available","Colorectal Neoplasms","Drug: Placebo|Drug: Xaliproden","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 3","102","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","XALIP_C_02090","January 17, 2008","January 2008","November 2009","April 6, 2016","April 2016","No Study Results Posted","XENON","November 2009","Neurological sensory assessment using the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE, Version 3.0)|FACT/GOG NTX-12 subscale|Hematological and biochemical testing|AE graded with NCI-CTCAE (Version 3.0) and coded using Medical Dictionary for Regulatory Activities (MedDRA, version 9.1)","https://ClinicalTrials.gov/show/NCT00603577"
2741,"NCT01479907","Synbiotics and Gastrointestinal Function Related Quality of Life After Colectomy for Cancer","Completed","No Results Available","Colorectal Neoplasms","Dietary Supplement: Synbiotics|Dietary Supplement: Placebo","University of Athens","Both","18 Years to 80 Years   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","SYNBIOTICSCOLON","November 16, 2011","November 2010","September 2015","May 11, 2016","May 2016","No Study Results Posted","null","March 2012","Assessment of gastrointestinal function-related quality of life at 1, 3 and 6 months postoperatively","https://ClinicalTrials.gov/show/NCT01479907"
2742,"NCT00606944","Fast-track Rehabilitation After Elective Colorectal and Small Bowel Resection","Completed","Has Results","Colorectal Tumor","Behavioral: fast-track rehabilitation","Seoul National University Hospital","Both","20 Years to 80 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","B-0706-046-008|SNUBH-GS-CR1","January 22, 2008","June 2007","September 2011","July 19, 2012","July 2012","July 19, 2012","null","October 2009","the Length of Hospital Stay|Pain|Quality of Life|Postoperative Complication During the First Admission|Recovery|Readmission Rate|Postoperative Complication","https://ClinicalTrials.gov/show/NCT00606944"
2743,"NCT02000089","The Cancer of the Pancreas Screening-5 CAPS5)Study","Recruiting","No Results Available","Pancreas Cancer|Peutz-Jeghers Syndrome|Gene Mutation|Germline Mutation Carrier|Lynch Syndrome","Drug: Human synthetic secretin","Johns Hopkins University|ChiRhoClin, Inc.","Both","18 Years and older   (Adult, Senior)","","2500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NA_00087754","November 26, 2013","January 2014","December 2023","September 7, 2016","September 2016","No Study Results Posted","CAPS5","October 2021","Evaluate pancreatic juice for early cancer markers.|Compare pancreas juice with pancreas cyst fluid","https://ClinicalTrials.gov/show/NCT02000089"
2744,"NCT00405587","Safety Study of PLX4032 in Patients With Solid Tumors","Active, not recruiting","No Results Available","Malignant Melanoma|Colorectal Carcinoma","Drug: PLX4032","Plexxikon|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 1","75","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PLX06-02","November 28, 2006","November 2006","September 2015","June 19, 2015","June 2015","No Study Results Posted","null","August 2015","Safety: subject incidence of adverse events, first-cycle DLTs and clinically significant changes in vital signs, ECGs and clinical laboratory tests|Pharmacodynamic activity in tumor biopsy tissue as assess by paired biopsy (Day 15 vs. Baseline) quantitation of pERK and Ki67","https://ClinicalTrials.gov/show/NCT00405587"
2745,"NCT01638533","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","Recruiting","No Results Available","Adult Mixed Glioma|Adult Pineal Gland Astrocytoma|Adult Solid Neoplasm|AIDS Related Immunoblastic Lymphoma|AIDS-Related Burkitt Lymphoma|AIDS-Related Diffuse Large Cell Lymphoma|AIDS-Related Diffuse Mixed Cell Lymphoma|AIDS-Related Diffuse Small Cleaved Cell Lymphoma|AIDS-Related Hodgkin Lymphoma|AIDS-Related Lymphoblastic Lymphoma|AIDS-Related Lymphoma|AIDS-Related Primary Central Nervous System Lymphoma|Glioma|Lymphoma|Recurrent Adult Brain Neoplasm|Recurrent Adult Soft Tissue Sarcoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Colorectal Carcinoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Head and Neck Carcinoma|Recurrent Lung Carcinoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Recurrent Melanoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Chronic Lymphocytic Leukemia|Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Other: Pharmacological Study|Drug: Romidepsin","National Cancer Institute (NCI)|Celgene Corporation","Both","18 Years and older   (Adult, Senior)","Phase 1","132","NIH|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01040|NA_00052587|NCI-2013-01545|CDR0000737061|J11105|9008|P30CA006973|U01CA132123|U01CA062505|U01CA069912|U01CA070095|UM1CA186644|UM1CA186686|UM1CA186689|UM1CA186690|UM1CA186691|UM1CA186717","July 9, 2012","June 2012","null","September 9, 2016","August 2016","No Study Results Posted","null","September 2017","Dose-limiting toxicity of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0|MTD of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0|PK profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method|Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria|Child-Pugh classification of hepatic dysfunction","https://ClinicalTrials.gov/show/NCT01638533"
2746,"NCT02839954","CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor","Recruiting","No Results Available","Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Pancreatic Carcinoma|Triple-Negative Invasive Breast Carcinoma|Malignant Glioma of Brain|Colorectal Carcinoma|Gastric Carcinoma","Biological: anti-MUC1 CAR-pNK cells","PersonGen BioTherapeutics (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei Binhu Hospital","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","10","Industry|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PG-121-001","July 14, 2016","July 2016","July 2018","July 20, 2016","July 2016","No Study Results Posted","null","July 2017","Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR-pNK cells|Phase II: Objective Response Rate","https://ClinicalTrials.gov/show/NCT02839954"
2747,"NCT00236249","Safety and Efficacy Study of Intravenous Lidocaine After Colorectal Surgery: LIDOREHAB","Completed","No Results Available","Colorectal Neoplasms","Drug: Lidocaine","Assistance Publique - Hôpitaux de Paris","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","110","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","P041008","October 10, 2005","May 2005","May 2007","February 17, 2011","March 2007","No Study Results Posted","null","May 2007","Readiness for discharge, checked twice a day|Pain every 4 hours the first day after surgery, then twice a day|Morphine consumption: dose of titration, then twice a day|Time of transit recovery|Physical rehabilitation score daily|Psychomotor test daily until reaching of preoperative values|Quality of recovery score at 1st, 3rd, and 6th day|Satisfaction score at discharge|Biological inflammation the day before the surgery, then at 1st, 3rd, and 6th day|Lidocaine concentration at the end of surgery and 24 hours forward|Clinical side effects twice a day","https://ClinicalTrials.gov/show/NCT00236249"
2748,"NCT01605344","Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI","Withdrawn","No Results Available","Advanced Adenocarcinoma of the Colon or Rectum","Drug: FOLFIRI.|Drug: Atorvastatin","UNC Lineberger Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Basic Science","LCCC 1127","May 22, 2012","April 2012","July 2014","February 26, 2014","February 2014","No Study Results Posted","null","July 2013","Area under the plasma concentration versus time curve (AUC) of irinotecan.|Area under the plasma concentration versus time curve (AUC) of SN-38.","https://ClinicalTrials.gov/show/NCT01605344"
2749,"NCT00290524","Early Alimentation Following Colorectal Surgery","Recruiting","No Results Available","Colorectal Neoplasms|Crohn Disease","Behavioral: Oral alimentation started 12 hours after colorectal surgery","Maisonneuve-Rosemont Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","800","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","QCTG-02-V5","February 9, 2006","January 2006","null","April 6, 2006","April 2006","No Study Results Posted","null","null","Hospitalisation stay measured in days|Gastro-intestinal signs and symptoms|Treatment of gastro-intestinal signs and symptoms|Post-surgery complications","https://ClinicalTrials.gov/show/NCT00290524"
2750,"NCT00378482","A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.","Active, not recruiting","No Results Available","Colorectal Neoplasms|Melanoma|Prostatic Neoplasms|Renal Cell Carcinoma|Neoplasms|Patients Who Have/Have Had Melanoma and Other Tumors","Drug: CP-675,206 (Tremelimumab)","AstraZeneca","Both","Child, Adult, Senior","Phase 2","38","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D4881C00024|A3671024","September 19, 2006","March 2008","December 2016","July 21, 2016","July 2016","No Study Results Posted","null","December 2016","Safety Endpoints: • Serious adverse events • Grade 3 or 4 CP-675,206-related adverse events • Immune-mediated adverse events • Hypersensitivity reactions to CP-675,206|Efficacy Endpoints: • Tumor status: alive with disease (AWD) or no evidence of disease (NED) • Survival","https://ClinicalTrials.gov/show/NCT00378482"
2751,"NCT02343601","Perioperative Hemodynamic Optimization Using the Photoplethysmography in Colorectal Surgery","Recruiting","No Results Available","Polyp of Large Intestine|Colorectal Neoplasms|Crohn Disease","Device: Photoplethysmography","University Hospital, Caen","Both","18 Years to 95 Years   (Adult, Senior)","Phase 3","160","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)","2014-A00870-47","June 13, 2014","December 2014","December 2016","December 3, 2015","December 2015","No Study Results Posted","PANEX3","October 2016","Incidence of patients presenting at least one complication after colorectal surgery|All complications happening after colorectal surgery|Real length of hospital stay|Perioperative mortality","https://ClinicalTrials.gov/show/NCT02343601"
2752,"NCT02552017","Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities","Recruiting","No Results Available","Colorectal Neoplasms|Colonic Polyps|Adenoma","Device: Endocuff Vision","South Tyneside NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","1772","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","039/2014|17718|1182104","September 10, 2015","November 2014","June 2016","September 15, 2015","September 2015","No Study Results Posted","ADENOMA","June 2016","Adenoma detection rate|Mean adenomas detected per procedure|Rate of cuff exchange|Effect on duration of caecal intubation rates|Patient satisfaction using validated patient comfort Bowel Cancer Screening Programme (BCSP) questionnaires|Increase in surveillance colonoscopies caused by increased adenoma detection rate|Number of proximal sessile serrated polyps by histology|Polyp location|Adenoma detection rate of BCSP and non-BCSP endoscopists|Change in adenoma detection rate of each endoscopist during the course of the trial|Adenoma detection rate of individual endoscopist before and after trial commencement","https://ClinicalTrials.gov/show/NCT02552017"
2753,"NCT01522820","Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors","Active, not recruiting","No Results Available","Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Estrogen Receptor Negative|Estrogen Receptor Positive|Glioblastoma|Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Metastatic Renal Cell Cancer|Recurrent Adult Brain Neoplasm|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Lung Carcinoma|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Uterine Corpus Carcinoma|Resectable Hepatocellular Carcinoma|Sarcoma|Stage IA Breast Cancer|Stage IA Ovarian Cancer|Stage IA Uterine Corpus Cancer|Stage IB Breast Cancer|Stage IB Ovarian Cancer|Stage IB Uterine Corpus Cancer|Stage IC Ovarian Cancer|Stage II Uterine Corpus Cancer|Stage IIA Breast Cancer|Stage IIA Lung Carcinoma|Stage IIA Ovarian Cancer|Stage IIB Breast Cancer|Stage IIB Esophageal Cancer|Stage IIB Lung Carcinoma|Stage IIB Ovarian Cancer|Stage IIB Skin Melanoma|Stage IIC Ovarian Cancer|Stage IIC Skin Melanoma|Stage IIIA Breast Cancer|Stage IIIA Esophageal Cancer|Stage IIIA Lung Carcinoma|Stage IIIA Ovarian Cancer|Stage IIIA Skin Melanoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Breast Cancer|Stage IIIB Esophageal Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Skin Melanoma|Stage IIIB Uterine Corpus Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Skin Melanoma|Stage IIIC Uterine Corpus Cancer|Stage IV Bladder Urothelial Carcinoma|Stage IV Esophageal Cancer|Stage IV Ovarian Cancer|Stage IV Prostate Cancer|Stage IV Skin Melanoma|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer","Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sirolimus","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","I 191511|NCI-2011-03568|071614|P30CA016056|R01CA158318","January 25, 2012","March 2012","null","July 25, 2016","July 2016","No Study Results Posted","null","September 2016","Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0|NY-ESO-1 specific cellular immunity|NY-ESO-1 specific humoral immunity","https://ClinicalTrials.gov/show/NCT01522820"
2754,"NCT01137162","Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors","Terminated","No Results Available","Anal, Colon, and Rectal Cancers|Head and Neck Cancer|Lung Cancer|Colon Cancer|Colonic Neoplasms|Colorectal Neoplasms|Colon/Rectal Cancer|Colon/Rectal Cancer Colon Cancer|Colon/Rectal Cancer Rectal Cancer|Colon/Rectal Cancer Anal Cancer|Head and Neck Cancers|Head and Neck Cancers Lip|Head and Neck Cancers Oral Cavity|Head and Neck Cancers Nasopharynx|Head and Neck Cancers Oropharynx|Head and Neck Cancers Hypopharynx|Head and Neck Cancers Larynx|Head and Neck Cancers Trachea|Lung Cancer Non-Small Cell Cancer (NSCLC)|Lung Cancer Small Cell Lung Cancer (SCLC)","","Stanford University","Both","18 Years and older   (Adult, Senior)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VAR0041|12418","June 1, 2010","August 2008","October 2011","July 20, 2016","July 2016","No Study Results Posted","null","October 2011","","https://ClinicalTrials.gov/show/NCT01137162"
2755,"NCT02861885","Detection and Characterization of Sessile Serrated Lesions (SSL) of the Right Colon","Active, not recruiting","No Results Available","Colorectal Neoplasm|Sessile Serrated Lesion|Neoplasms","Other: Chromoendoscopy","Hospices Civils de Lyon","Both","18 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL16_0158","August 2, 2016","October 2015","December 2018","August 9, 2016","August 2016","No Study Results Posted","Lesion SSL","December 2018","patients with sessile serrated lesions|PARIS classification|Kudo's pit pattern classification|NICE classification|Specific mean of macroscopically detected SSL|SSL histologic characterization|False positive|False negative|Detection techniques diagnosis performance","https://ClinicalTrials.gov/show/NCT02861885"
2756,"NCT01521104","The Value of Narrow Band Imaging in Stratifying Patients for Endoscopic Resection or Surgery","Completed","No Results Available","Colorectal Neoplasms","","Shanghai Jiao Tong University School of Medicine","Both","18 Years to 90 Years   (Adult, Senior)","","565","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","rjxhnk02","January 25, 2012","January 2009","December 2010","January 27, 2012","January 2012","No Study Results Posted","null","December 2010","","https://ClinicalTrials.gov/show/NCT01521104"
2757,"NCT02226107","Latino Peers as Patient Navigators for Colon Cancer Screening","Completed","No Results Available","Colon Cancer","Behavioral: Peer-PN|Behavioral: Pro-PN","Icahn School of Medicine at Mount Sinai","Both","50 Years and older   (Adult, Senior)","","85","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","GCO 11-1374","August 25, 2014","January 2014","March 2015","September 29, 2015","September 2015","No Study Results Posted","null","March 2015","Colonoscopy Completion","https://ClinicalTrials.gov/show/NCT02226107"
2758,"NCT00508690","Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics","Completed","No Results Available","Colorectal Neoplasms","Drug: cefmetazole|Drug: kanamycin/metronidazole","Japan Multinational Trial Organization","Both","20 Years and older   (Adult, Senior)","Phase 3","584","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","JMTO PREV07-01|UMIN000000776","July 27, 2007","September 2007","December 2011","September 18, 2012","September 2012","No Study Results Posted","null","December 2011","Incidence and classification of surgical site infection (SSI)|Incidence of colitis, other infectious diseases and other postoperative complications.","https://ClinicalTrials.gov/show/NCT00508690"
2759,"NCT01044732","Third Eye Retroscope Randomized Clinical Evaluation","Completed","Has Results","Colorectal Neoplasms","Device: Third Eye Retroscope","Avantis Medical Systems","Both","Child, Adult, Senior","","448","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","Avantis TER-08-06","January 6, 2010","March 2009","February 2010","July 13, 2016","July 2016","August 28, 2015","TERRACE","February 2010","Detection Rates for Adenomas and for Total Polyps|Times for Withdrawal Phase and for Complete Procedure","https://ClinicalTrials.gov/show/NCT01044732"
2760,"NCT02057471","Intravenous Iron: Measuring Response in Anemic Surgical Patients","Completed","No Results Available","Colorectal Neoplasm|Anemia","Drug: Intravenous ferric carboxymaltose","Nottingham University Hospitals NHS Trust","Both","18 Years and older   (Adult, Senior)","Phase 4","20","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09GS002|2009-011382-80","February 3, 2014","September 2009","March 2012","February 5, 2014","February 2014","No Study Results Posted","null","January 2011","Number of patients transfused allogenic red blood cells|Hemoglobin levels|Hepcidin levels|Erythropoietin levels|Transferrin saturation levels|Ferritin levels|C Reactive Protein levels","https://ClinicalTrials.gov/show/NCT02057471"
2761,"NCT02889679","Underwater Resection of Non-pedunculated Colorectal Lesions","Not yet recruiting","No Results Available","Colorectal Neoplasms","Procedure: Underwater resection|Procedure: Conventional (gas distended colon) resection|Procedure: Standard polypectomy","VA Northern California Health Care System","Both","18 Years and older   (Adult, Senior)","","600","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","16-06-00766","August 31, 2016","September 2016","June 2018","September 16, 2016","September 2016","No Study Results Posted","null","June 2018","Incomplete resection rate (histologic)","https://ClinicalTrials.gov/show/NCT02889679"
2762,"NCT02047188","Observation of Microvessels and Invasion in Early Colorectal Lesions by NBI","Completed","No Results Available","Colorectal Neoplasms","","Xiaobo Li|Shanghai Jiao Tong University School of Medicine","Both","18 Years to 90 Years   (Adult, Senior)","","418","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","12YZ036","January 25, 2014","January 2010","December 2013","January 25, 2014","January 2014","No Study Results Posted","null","May 2013","NBI prediction for lesion histology and invasion|immunohistochemical outcome of microvessel count and MMP-7","https://ClinicalTrials.gov/show/NCT02047188"
2763,"NCT01844375","A Trial of Preoperative CHO Drinks on Postoperative Walking Capacity in Colorectal Surgery","Recruiting","No Results Available","Bowel; Disease, Carbohydrate Absorption|Difficulty Walking|Colorectal Neoplasms","Dietary Supplement: Carbohydrate group|Other: Control group","Mingkwan Wongyingsinn, MD|Siriraj Hospital","Both","18 Years and older   (Adult, Senior)","","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SIRB050","April 22, 2013","May 2013","June 2017","June 1, 2016","June 2016","No Study Results Posted","null","December 2016","The walking capacity|Serum insulin and glucose concentrations|Urine urea nitrogen","https://ClinicalTrials.gov/show/NCT01844375"
2764,"NCT02216955","Nutrition and Lifestyle Study Cohort of Gastric Cancer in China","Recruiting","No Results Available","Gastric Cancer","","State Key Laboratory of Cancer Biology|Tang-Du Hospital|Tianjin Union Medical Center|Chengdu Medical College|Beihua University|Shanghai Jiao Tong University School of Medicine|Second Military Medical University|China-Japan Friendship Hospital|Chinese Academy of Medical Sciences|Beijing Cancer Hospital|Chinese PLA General Hospital|Third Military Medical University","Both","18 Years to 90 Years   (Adult, Senior)","","50000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","cdk-201002","August 13, 2014","January 2009","null","October 30, 2014","October 2014","No Study Results Posted","null","December 2016","Disease-specific survival|Overall survival","https://ClinicalTrials.gov/show/NCT02216955"
2765,"NCT02617134","CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor","Recruiting","No Results Available","Malignant Glioma of Brain|Colorectal Carcinoma|Gastric Carcinoma","Biological: anti-MUC1 CAR-T cells","PersonGen BioTherapeutics (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei Binhu Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","20","Industry|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PG-021-002","November 26, 2015","November 2015","November 2018","July 11, 2016","July 2016","No Study Results Posted","null","November 2017","Adverse events attributed to the administration of the anti-MUC1 CAR-T cells|Objective Response Rate","https://ClinicalTrials.gov/show/NCT02617134"
2766,"NCT01913223","Endoscopic Sub-mucosal Dissection With the Nestis® Jet Injector System With a Bi-functional Catheter: First Prospective Trial","Completed","No Results Available","Barrett's Esophagus|Intestinal Dysplasia|Esophageal Dysplasia|Colorectal Neoplasms","Device: Nestis® jet injector system with a bi-functional catheter","Hospices Civils de Lyon","Both","18 Years and older   (Adult, Senior)","","17","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011.709","July 30, 2013","June 2012","July 2014","August 26, 2014","August 2014","No Study Results Posted","NESTIS","December 2013","Safety outcome|Effectiveness of the procedure in terms of complete neoplasia resections","https://ClinicalTrials.gov/show/NCT01913223"
2767,"NCT00582660","Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib","Completed","Has Results","Colorectal Adenoma|Colorectal Carcinoma","Drug: Celecoxib|Drug: Placebo","University of Alabama at Birmingham|Pfizer|Pharmacia","Both","19 Years to 90 Years   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","F001228004|NQ8-00-02-008","December 20, 2007","December 2001","June 2008","July 15, 2014","July 2014","February 2, 2011","UAB0040","June 2008","Number of Subjects Witha Change (IMPROVEMENT) in Colo-rectal Adenocarcinoma as Measured by Cyclooxygenase-2 Activity After 7 Days of Celecoxib|Subjects With Positive Response 72 Hours After Administration of Study Treatment as Measured by Immunoblot","https://ClinicalTrials.gov/show/NCT00582660"
2768,"NCT02758977","Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)","Not yet recruiting","No Results Available","Colon Cancer Liver Metastases|Liver Neoplasms|Liver Diseases|Secondary Malignant Neoplasm of Liver|Malignant Neoplasm of Large Intestine Metastatic to Liver|Hepatectomy|Surgery","Procedure: ALPPS|Procedure: TWO STAGE HEPATECTOMY","University of Zurich","Both","18 Years and older   (Adult, Senior)","","214","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","2015-0024","April 5, 2016","May 2016","null","April 28, 2016","April 2016","No Study Results Posted","ALPPSforCRLM","April 2019","1 Year Disease-free Survival|Procedure-associated Mortality|Procedure-associated Complications|Percentage of patients in which complete curative two-staged surgery was possible.|Complete (R0) vs. incomplete (R1/2) resection (oncological outcome)|Overall survival (oncological outcome)|Quality of Life (QoL)|Radiographic liver volumetric changes|Incidence of posthepatectomy liver failure|Incidence of posthepatectomy renal failure","https://ClinicalTrials.gov/show/NCT02758977"
2769,"NCT01880918","A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing","Recruiting","No Results Available","Diverticulum, Colon|Colorectal Neoplasms|Crohn Disease|Colitis, Ulcerative|Colostomy|Ileostomy - Stoma|Rectal Prolapse|Intestinal Polyposis|Lymphoma|Endometriosis|Intestinal Volvulus","","novoGI","Both","18 Years and older   (Adult, Senior)","","200","Industry","Observational","Time Perspective: Retrospective","RETROPRESS, CLPR-43-11-01","June 16, 2013","October 2012","July 2013","June 16, 2013","June 2013","No Study Results Posted","null","June 2013","The rate of anastomotic leakage.|Rate of other device related complications and measures during hospitalization and post procedure.","https://ClinicalTrials.gov/show/NCT01880918"
2770,"NCT01301417","Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis","Completed","No Results Available","Diverticulum, Colon|Colorectal Neoplasms|Crohn Disease|Colitis, Ulcerative|Colostomy|Ileostomy - Stoma|Rectal Prolapse|Intestinal Polyposis|Lymphoma|Endometriosis|Intestinal Volvulus","Device: ColonRing™","novoGI","Both","18 Years and older   (Adult, Senior)","","171","Industry","Observational","Time Perspective: Retrospective","RETROPRESS","February 20, 2011","February 2011","August 2011","June 4, 2013","June 2013","No Study Results Posted","RETROPRESS","August 2011","Rate of anastomotic leakage|Rate of other device related complications and measures during hospitalization and post procedure:","https://ClinicalTrials.gov/show/NCT01301417"
2771,"NCT00677781","Impact of Microparticles on Postoperative Complications in Surgical Patients","Completed","No Results Available","Neoplasm, Hepatic|Pancreatic Neoplasms|Colorectal Neoplasms","","University of Bern","Both","18 Years and older   (Adult, Senior)","","108","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KEK251_07","May 8, 2008","February 2008","January 2010","September 5, 2011","September 2011","No Study Results Posted","null","December 2008","Postoperative morbidity|Hospital stay|Mortality","https://ClinicalTrials.gov/show/NCT00677781"
2772,"NCT00295646","Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid","Active, not recruiting","No Results Available","Breast Cancer","Drug: tamoxifen|Drug: anastrozole|Drug: zoledronic acid","Austrian Breast & Colorectal Cancer Study Group|AstraZeneca|Novartis Pharmaceuticals","Female","19 Years to 59 Years   (Adult)","Phase 3","1803","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG-12|CZOL 446 1B 01|Zol-A-01","February 23, 2006","June 1999","June 2016","August 3, 2015","August 2015","No Study Results Posted","null","December 2015","Comparison of tamoxifen with anastrozole in premenopausal patients with non-metastatic breast cancer and comparison of a subgroup additionally treated with zoledronate to a control subgroup without receiving zoledronate according to DFS.|For the assessment of the recurrence free survival (RFS) patients receiving tamoxifen will be compared to patients receiving anastrozole and patients receiving zoledronate will be compared to controls, respectively.|For the assessment of the overall survival (OS) patients receiving tamoxifen will be compared to patients receiving anastrozole and patients receiving zoledronate will be compared to controls, respectively.|The objective is to assess whether zoledronate added to standard adjuvant therapy can decrease or even prevent bone loss in patients treated with hormonal blockade combined with an anti-estrogen or aromatase inhibitor (AI).|Adverse and severe adverse events will be listed for all therapy subgroups ""anastrozole / zoledronate"" (AZ), ""anastrozole / zoledronate control"" (AC), ""tamoxifen / zoledronate"" (TZ), ""tamoxifen / zoledronate control"" (TC).","https://ClinicalTrials.gov/show/NCT00295646"
2773,"NCT01367028","A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Trastuzumab, Docetaxel|Drug: Trastuzumab, Docetaxel, Bevacizumab|Drug: Trastuzumab+Docetaxel+NPLD|Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab","Austrian Breast & Colorectal Cancer Study Group|Hoffmann-La Roche|Cephalon","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG 32|2010-023324-25","May 31, 2011","June 2011","April 2014","May 12, 2014","May 2014","No Study Results Posted","ABCSG 32","April 2014","Cardiac toxicity|Pathological complete response (ypCR)|Total pathological complete response (ytpCR)|Overall clinical response rate (cORR)|Safety evaluation according to patients numbers of AEs, SAEs, lab test abnormalities, cardiac assessment, clinical evaluation","https://ClinicalTrials.gov/show/NCT01367028"
2774,"NCT01694238","A Randomized Trial on the Technical Aspects of Stoma Construction.","Recruiting","No Results Available","Colostomy|Colorectal Neoplasm|Diverticulitis","Procedure: Cruciate incision|Procedure: Circular incision|Other: Mesh enforced cruciate incision","Sahlgrenska University Hospital, Sweden|The Swedish Society of Medicine|The Swedish agreement concerning research and education of doctors","Both","Child, Adult, Senior","","240","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Stoma-Const","September 24, 2012","June 2013","September 2017","August 19, 2015","August 2015","No Study Results Posted","null","September 2016","Stoma hernia frequency at 12 months|Readmission|Postoperative infections|Total hospital stay|Other complications|30 day mortality","https://ClinicalTrials.gov/show/NCT01694238"
2775,"NCT01310985","A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer","Completed","No Results Available","Colon Rectal Cancer Duke Stage Stageval","Drug: Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)","King Faisal Specialist Hospital & Research Center","Both","14 Years to 85 Years   (Child, Adult, Senior)","","15","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","RAC# 2071-051","March 6, 2011","March 2008","August 2014","February 24, 2016","December 2011","No Study Results Posted","null","August 2014","Evaluate the safety of pre-operative concurrent chemotherapy with capacitabine (Xeloda), weekly cetuximab (Erbitux), and external beam radiation.|Evaluate efficacy of sphincter preserving surgery rate, local recurrence rate and the disease free and overall survival in patients.","https://ClinicalTrials.gov/show/NCT01310985"
2776,"NCT00309556","Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Epirubicin|Drug: Docetaxel|Drug: Capecitabine|Drug: Trastuzumab","Austrian Breast & Colorectal Cancer Study Group|Amgen|Ebewe Pharma GmbH|Hoffmann-La Roche|Sanofi","Female","19 Years to 80 Years   (Adult, Senior)","Phase 3","536","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG-24|Ro 09-1978","March 31, 2006","February 2005","November 2011","December 29, 2011","December 2011","No Study Results Posted","null","November 2009","Rate of pathological complete remissions|Rates of axillary lymph node involvement and breast-conserving procedures","https://ClinicalTrials.gov/show/NCT00309556"
2777,"NCT02065037","The Impact of Warmed Carbon Dioxide Insufflation During Colonoscopy on Polyp Detection","Terminated","No Results Available","Colonic Polyps|Colonic Neoplasms","Device: room temperature air insufflation|Device: warmed carbon dioxide insufflation","Queen's University","Both","40 Years and older   (Adult, Senior)","Phase 4","229","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","6011440|DMED-1658-13","February 10, 2014","June 2014","September 2015","March 30, 2016","March 2016","No Study Results Posted","null","September 2015","Polyp Detection Rate|adenoma detection rate|advanced lesion per patient detection rate","https://ClinicalTrials.gov/show/NCT02065037"
2778,"NCT00291798","Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane","Completed","No Results Available","Breast Cancer","Procedure: rate of remission","Austrian Breast & Colorectal Cancer Study Group|Pharmacia Austria GmbH","Female","59 Years and older   (Adult, Senior)","Phase 2","98","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG-17","February 14, 2006","September 2000","March 2009","September 18, 2006","February 2006","No Study Results Posted","null","null","rate of remission|Toxicity (WHO-grading)|rate of mastectomy|response of tumor subject to HER2-status|collection of disease free survival and overall survival","https://ClinicalTrials.gov/show/NCT00291798"
2779,"NCT02254486","Phase III Study Comparing Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 With Trisulfate Bowel Cleansing Solution Using a 2-Day Split-Dosing Regimen in Adults","Completed","No Results Available","Colon Cancer|Colorectal Carcinoma","Drug: NER1006|Drug: Trisulfate solution","Norgine","Both","18 Years to 85 Years   (Adult, Senior)","Phase 3","621","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Screening","NER1006-01/2014 (NOCT)|29672","October 1, 2014","August 2014","June 2015","January 18, 2016","June 2015","No Study Results Posted","null","June 2015","Use of Harefield Cleansing Scale to grade bowel cleansing efficacy|Adenoma detection rate|Polyp detection rate","https://ClinicalTrials.gov/show/NCT02254486"
2780,"NCT00309569","Randomized Study Comparing Pre- and Postoperative Vs. Conventional Adjuvant Treatment in Receptor-Negative Patients","Completed","No Results Available","Early Stage Breast Cancer","Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Fluorouracil|Drug: Epirubicine","Austrian Breast & Colorectal Cancer Study Group","Female","18 Years to 80 Years   (Adult, Senior)","Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG-7","March 31, 2006","October 1991","null","March 31, 2006","October 1999","No Study Results Posted","null","null","Overall survival|Recurrence-free survival|Rate of breast-conserving procedures","https://ClinicalTrials.gov/show/NCT00309569"
2781,"NCT02062788","Evaluation of Preoperative Oral Rehydration Solution in Colectomy","Not yet recruiting","No Results Available","Insulin Resistance|Postoperative Complication","Dietary Supplement: Oral rehydration solution","Seoul National University Hospital|Seoul National University Bundang Hospital","Both","19 Years to 75 Years   (Adult, Senior)","Phase 3","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ORS-colectomy|B-1310/224-007","January 20, 2014","February 2014","December 2014","February 12, 2014","February 2014","No Study Results Posted","null","October 2014","Changes in HOMA-IR levels|Changes in Insulin levels|Changes in glucose level|Changes in cortisol level|Assessment of patient pain via Visual Analogue Scale|Reduction of postoperative complications|Changes in triglyceride level","https://ClinicalTrials.gov/show/NCT02062788"
2782,"NCT01731379","Optical Detection of Peripheral Nerve Bundles During Surgery","Completed","No Results Available","Malignant Lymphoma of Lymph Nodes of Inguinal Region|Malignant Lymphoma of Lymph Nodes of Axillary|Malignant Lymphoma of Lymph Nodes of the Cervix|Carcinoma of Parotid Gland|Colon Rectal Cancer Tubulovillous Adenocarcinoma|Tumor of Soft Tissue of Head, Face and Neck","Procedure: Surgical resection","Philips Healthcare|Philips Research","Both","18 Years and older   (Adult, Senior)","","35","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","NL 40893.031.12","November 16, 2012","December 2012","October 2015","November 2, 2015","November 2015","No Study Results Posted","NerveSpect","January 2014","Differentiation between nerve tissue and its surrounding tissue","https://ClinicalTrials.gov/show/NCT01731379"
2783,"NCT02510911","Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy?","Recruiting","No Results Available","Postoperative Ileus|Laparoscopic Colectomy Without Stoma Formation|Colorectal Neoplasm|Diverticulitis","Drug: Caffeine (100 mg)|Drug: Caffeine (200 mg)|Drug: corn starch (250 mg approx.)|Other: Radiopaque marker","Thomas Steffen|Gottfried und Julia Bangerter-Rhyner Foundation, Switzerland|Cantonal Hospital of St. Gallen","Both","18 Years and older   (Adult, Senior)","","180","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CaCo, Chir201401","July 27, 2015","August 2015","July 2020","April 6, 2016","April 2016","No Study Results Posted","CaCo","May 2020","Time to first bowel movement|Time to first flatus|Time to tolerance of solid food|Postoperative vomiting events|Colonic passage time|Actual postoperative hospital stay|Theoretical postoperative hospital stay|Daily doses of analgetics|Postoperative pain|Postoperative mobilization|Overall fluid intake|Blood pressure|Pulse|Intensive care|Well-being|Sleep behaviour|Sleeping habits|Satisfaction with surgery|Consumption of sleep inducing drugs","https://ClinicalTrials.gov/show/NCT02510911"
2784,"NCT01417611","The Usefulness of I-scan in Screening Colonoscopy","Completed","No Results Available","Colorectal Neoplasm","Procedure: i-scan CE, SE, TE mode","Konkuk University Hospital","Both","40 Years to 75 Years   (Adult, Senior)","","389","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","KUMCHSN02","July 27, 2010","September 2010","June 2011","August 15, 2011","August 2011","No Study Results Posted","null","May 2011","polyp/adenoma detection rate (per-polyp/adenoma analysis and per-patient analysis)|characterization of polyp","https://ClinicalTrials.gov/show/NCT01417611"
2785,"NCT02599103","The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects","Completed","No Results Available","Colorectal Neoplasms","Other: Fat-free milkshake|Other: Olive oil|Other: Soybean oil|Other: Fried soybean oil|Other: Palm oil|Other: Fried palm oil|Other: Camellia oil|Other: Fried camellia oil|Other: Tallow|Other: Fried tallow","Academia Sinica, Taiwan","Male","20 Years to 50 Years   (Adult)","","17","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Basic Science","AS-IRB02-102083","September 15, 2015","September 2013","September 2015","November 5, 2015","October 2015","No Study Results Posted","null","September 2015","The changs of metabolomics profile between before and after oil consumption","https://ClinicalTrials.gov/show/NCT02599103"
2786,"NCT02504411","Outcomes of Disposable Distal Attachment Device (Endocuff and Transparent Plastic Cap) Assisted Colonoscopy","Not yet recruiting","No Results Available","Colorectal Neoplasms","Device: Device Assisted Colonoscopy|Device: Standard Colonoscopy","The University of Texas Health Science Center, Houston","Both","18 Years and older   (Adult, Senior)","","640","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","HSC-MS-12-0587","July 20, 2015","July 2015","null","July 20, 2015","July 2015","No Study Results Posted","null","July 2018","Adenoma detection rate (ADR) as determined by Colonoscopy|Complete adenoma resection rate (CARE) for adenoma > 10 mm in diameter as determined by Colonoscopy|Cecal Intubation Rate (CIR)","https://ClinicalTrials.gov/show/NCT02504411"
2787,"NCT02368977","Third Eye Panoramic Device Feasibility Evaluation","Enrolling by invitation","No Results Available","Colorectal Neoplasms","Device: Third Eye Panoramic device","Avantis Medical Systems","Both","up to 75 Years   (Child, Adult, Senior)","","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","Avantis TEP 13-01","February 11, 2015","November 2013","October 2016","July 13, 2016","July 2016","No Study Results Posted","null","October 2016","Device usability factors|Device video factors|Patient safety assessed by number of subjects with adverse events as a measure of safety and tolerability","https://ClinicalTrials.gov/show/NCT02368977"
2788,"NCT01897584","Effect Inverse Ratio Ventilation on Arterial Oxygenation and Respiratory Mechanics During lapaLAR","Completed","No Results Available","Colorectal Neoplasms","Other: inverse IE","Gachon University Gil Medical Center","Both","20 Years to 70 Years   (Adult, Senior)","","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","GBIRB2013-127","June 26, 2013","July 2013","December 2014","August 30, 2015","August 2015","No Study Results Posted","null","December 2014","arterial oxygenation (PaO2)|cerebral perfusion pressure","https://ClinicalTrials.gov/show/NCT01897584"
2789,"NCT01790139","Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles","Completed","No Results Available","Colorectal Neoplasms","Drug: Oral simethicone","Asan Medical Center|GE Healthcare","Both","20 Years and older   (Adult, Senior)","","84","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","2012-0584","February 7, 2013","February 2013","January 2014","March 24, 2014","March 2014","No Study Results Posted","null","November 2013","Colonic bubble-related image quality|Overall image quality|diagnostic performance","https://ClinicalTrials.gov/show/NCT01790139"
2790,"NCT01276795","Whey Protein-based Enteral Nutrition Support to Improve Protein Economy in Surgical Patients","Completed","No Results Available","Protein Metabolism|Colorectal Neoplasms","Dietary Supplement: Oral Nutrition Support","McGill University Health Center|McGill University","Both","18 Years to 90 Years   (Adult, Senior)","","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","09-053-SDR","January 12, 2011","January 2010","August 2010","January 12, 2011","July 2010","No Study Results Posted","null","August 2010","Protein balance","https://ClinicalTrials.gov/show/NCT01276795"
2791,"NCT00140036","Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).","Completed","No Results Available","Colorectal Neoplasms","Procedure: Blood draw","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 4","137","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CPTAIV-0020-366|A5961020","August 29, 2005","September 2002","August 2005","February 28, 2008","February 2008","No Study Results Posted","null","null","Correlation of genotype with safety and efficacy measures.","https://ClinicalTrials.gov/show/NCT00140036"
2792,"NCT00309491","Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients","Completed","No Results Available","Early-stage Breast Cancer","Drug: Tamoxifen alone|Drug: Tamoxifen + Aminoglutethimide","Austrian Breast & Colorectal Cancer Study Group","Female","50 Years to 80 Years   (Adult, Senior)","Phase 3","2020","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG-6","March 31, 2006","December 1990","null","April 8, 2016","April 2016","No Study Results Posted","null","null","Overall survival|Recurrence-free survival|Side-effect profiles","https://ClinicalTrials.gov/show/NCT00309491"
2793,"NCT00309478","Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-Positive Patients","Completed","No Results Available","Early-Stage Breast Cancer","Drug: cyclophosphamide|Drug: Methotrexate|Drug: Fluorouracil|Drug: Goserelin|Drug: Tamoxifen","Austrian Breast & Colorectal Cancer Study Group","Female","19 Years and older   (Adult, Senior)","Phase 3","1099","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG-5","March 31, 2006","December 1990","null","May 18, 2006","June 1999","No Study Results Posted","null","null","Disease-free survival|Overall survival|Toxicities","https://ClinicalTrials.gov/show/NCT00309478"
2794,"NCT02820948","Effect of Vitamin E Ointment on Incisional SSI in Colorectal Surgery","Completed","No Results Available","Surgical Site Infection","Drug: Vitamin E ointment application","Hospital General Universitario Elche","Both","Child, Adult, Senior","Phase 3","108","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","HRJC 16-6","June 29, 2016","January 2015","March 2016","June 30, 2016","June 2016","No Study Results Posted","null","March 2016","Surgical site infection","https://ClinicalTrials.gov/show/NCT02820948"
2795,"NCT01175317","Improvement of Fluid Balance in Patients Undergoing Surgery of the Colon and Rectum","Completed","Has Results","Colorectal Carcinoma","Procedure: Goal-directed fluid optimization|Other: Regimen based on expertise anaesthesist","Maastricht University Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 4","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","MEC 09-2-089","July 29, 2010","April 2010","October 2013","May 19, 2014","May 2014","November 5, 2013","HOC","October 2013","Peak Value of I-FABP|Average Intraoperative CO2 Gap","https://ClinicalTrials.gov/show/NCT01175317"
2796,"NCT02269631","Legume Diet Satiety Pilot Study","Recruiting","No Results Available","Obesity|Colorectal Carcinoma","Behavioral: Legume diet group|Behavioral: Control diet group|Device: Smartpill|Other: legumes","Emory University","Male","40 Years to 70 Years   (Adult, Senior)","","12","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","IRB00075830","October 17, 2014","December 2014","December 2016","June 13, 2016","June 2016","No Study Results Posted","null","September 2016","Change in weight|Gastric emptying time|Biomarkers and self-report of appetite regulation|Energy intake|Satiety","https://ClinicalTrials.gov/show/NCT02269631"
2797,"NCT01324284","Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy","Completed","No Results Available","Colorectal Carcinoma","Drug: Lubiprostone","Asian Institute of Gastroenterology, India","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","442","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","AIG-GI2011-01","March 22, 2011","March 2011","June 2011","April 4, 2013","April 2013","No Study Results Posted","Lubiprostone","June 2011","Quality of bowel preparation in Same day Low volume PEG with placebo versus same day low volume PEG with Lubiprostone","https://ClinicalTrials.gov/show/NCT01324284"
2798,"NCT01991847","Tertiary Prevention by Exercise in Colon Cancer Therapy","Recruiting","No Results Available","Colon Cancer","Behavioral: Physical activity","Technische Universität München|German Cancer Aid","Both","40 Years to 80 Years   (Adult, Senior)","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","F-PROTECT","November 18, 2013","November 2013","December 2015","December 1, 2014","November 2014","No Study Results Posted","F-PROTECT","October 2015","Target sample size|Physical activity|Peak oxygen consumption|Patient satisfaction|Cancer related fatigue|Anxiety and depression|Cancer related quality of life|Quality of life in colorectal cancer|Adverse and serious adverse events","https://ClinicalTrials.gov/show/NCT01991847"
2799,"NCT01023737","Hydroxychloroquine + Vorinostat in Advanced Solid Tumors","Recruiting","No Results Available","Malignant Solid Tumour","Drug: Hydroxychloroquine|Drug: Vorinostat","Devalingam Mahalingam|Merck Sharp & Dohme Corp.|The University of Texas Health Science Center at San Antonio","Both","16 Years and older   (Child, Adult, Senior)","Phase 1","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IDD 08-52","July 22, 2009","November 2009","January 2016","November 4, 2015","November 2015","No Study Results Posted","null","January 2016","Maximum tolerated dose (MTD) of Hydroxychloroquine (HCQ) in combination with Vorinostat in patients with advanced solid tumors|To evaluate the safety and tolerability of HCQ in combination with Vorinostat in this patient population as determined by toxicity profile, incidence and rating according to NCI/CTC v3.0 criteria.|To evaluate the antitumor activity of HCQ in combination with Vorinostat as determined by response rate and progression free survival (exploratory)","https://ClinicalTrials.gov/show/NCT01023737"
2800,"NCT02057562","Impact of Diverticular Disease on the Detection of Colon Adenomas","Recruiting","No Results Available","Colon Adenoma|Diverticulosis","","Technische Universität München","Both","18 Years to 90 Years   (Adult, Senior)","","1891","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DECADE","February 5, 2014","February 2014","December 2016","November 5, 2015","November 2015","No Study Results Posted","DECADE","September 2016","Adenoma detection rate|Polyp detection rate|Frequency of colon diverticulosis","https://ClinicalTrials.gov/show/NCT02057562"
2801,"NCT01769222","Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer","Suspended","No Results Available","Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Colon Cancer|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Melanoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Rectal Cancer|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia","Biological: ipilimumab|Radiation: radiation therapy|Other: laboratory biomarker analysis","Stanford University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","69","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VAR0090|NCI-2012-02988","January 14, 2013","February 2013","null","November 19, 2013","November 2013","No Study Results Posted","null","March 2015","Safety as the percentage of patients experiencing dose limiting toxicities (DLTs) or serious adverse events using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Immune response (Phase II)|Response rate (complete response [CR], partial response [PR], stable disease [SD]) calculated based on the Response Evaluation Criteria in Solid Tumors (RECIST)/RECIST Immunotherapy and Cheson criteria (Phase II)|Overall survival (Phase II)|Duration of response (Phase II)","https://ClinicalTrials.gov/show/NCT01769222"
2802,"NCT01135849","B-Receptor Signaling in Cardiomyopathy","Completed","No Results Available","Carcinomas|Amyloidosis|Anal Cancer|Anemia|Cholangiocarcinoma of the Extrahepatic Bile Duct|Transitional Cell Carcinoma of Bladder|Bone Marrow Transplant Failure|Bone Cancer|Cancer of Brain and Nervous System|Breast Cancer|Carcinoma of the Large Intestine|Endocrine Cancer|Esophageal Cancer|Eye Cancer|Gall Bladder Cancer|Gastric (Stomach) Cancer|Gastrooesophageal Cancer|Gastrointestinal Stromal Tumor (GIST)|Gynecologic Cancers|Head and Neck Cancers|Hepatobiliary Neoplasm|Kidney (Renal Cell) Cancer|Leukemia|Lung Cancer|Hodgkin Disease|Lymphoma, Non-Hodgkin|Mesothelioma|Multiple Myeloma|Myelodysplastic Syndromes (MDS)|Neuroendocrine Tumors|Myeloproliferative Disorders|Pancreatic Cancer|Prostate Cancer|Skin Cancer|Soft Tissue Sarcoma|Testicular Cancer|Thymus Cancer|Thyroid Cancer","","Daniel Bernstein|Stanford University","Both","up to 40 Years   (Child, Adult)","","99","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PEDSVAR0038|SU-11172008-1345","June 1, 2010","November 2008","October 2010","November 16, 2015","November 2015","No Study Results Posted","null","October 2010","Development of cardiomyopathy","https://ClinicalTrials.gov/show/NCT01135849"
2803,"NCT00499850","Phase I FOLFOX Combination","Completed","No Results Available","Advanced Colorectal Carcinoma","Drug: ZD6474 (vandetanib)|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin","Genzyme, a Sanofi Company|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D4200C00037","July 10, 2007","August 2005","April 2008","August 24, 2016","August 2016","No Study Results Posted","null","June 2006","Safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin","https://ClinicalTrials.gov/show/NCT00499850"
2804,"NCT00470782","Aerobic Capacity and Body Composition in Colon Cancer Patients","Completed","No Results Available","Colonic Neoplasms","","AHS Cancer Control Alberta","Both","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Case-Only","GI-5-0064 / ethics 23429","May 7, 2007","October 2007","October 2009","February 24, 2016","April 2012","No Study Results Posted","null","October 2009","","https://ClinicalTrials.gov/show/NCT00470782"
2805,"NCT00798447","Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery","Completed","No Results Available","GI Cancer","Drug: MLF 541|Drug: Lipofundin MCT","B. Braun Melsungen AG|B.Braun Taiwan Co., Ltd.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","100","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HC-G-H-0603","November 25, 2008","November 2008","October 2010","June 8, 2011","June 2011","No Study Results Posted","null","October 2010","reduction of pro inflammatory activity","https://ClinicalTrials.gov/show/NCT00798447"
2806,"NCT02363049","Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer","Recruiting","No Results Available","Malignant Neoplasm of Large Intestine|Colon Cancer Liver Metastasis","Procedure: Colectomy|Drug: Chemotherapy","Assistance Publique - Hôpitaux de Paris|UNICANCER|Federation Francophone de Cancerologie Digestive|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","278","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-A00685-40","February 9, 2015","July 2014","July 2018","September 4, 2015","September 2015","No Study Results Posted","CLIMAT","July 2018","overall survival|quality of life|Post-operative complications|Progression free survival (PFS)|Time to metastatic progression (TTP)|Rate of secondary curative resection (R0)","https://ClinicalTrials.gov/show/NCT02363049"
2807,"NCT01320891","Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators","Recruiting","No Results Available","Carcinoma of the Large Intestine","Behavioral: balanced solutions|Behavioral: not balanced","Università degli Studi di Ferrara|B. Braun Melsungen AG","Both","18 Years to 90 Years   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HC-I-H-0909","March 8, 2011","February 2010","null","March 22, 2011","March 2011","No Study Results Posted","null","December 2011","acid/base disorder|pro/antiinflammatory cytokine","https://ClinicalTrials.gov/show/NCT01320891"
2808,"NCT01912586","Early Intervention for Erectile Dysfunction After Laparoscopic Resection for Rectal Cancer","Completed","No Results Available","Rectal Tumors|Erectile Dysfunction","Other: vacuum erection device","Nanfang Hospital of Southern Medical University","Male","18 Years to 70 Years   (Adult, Senior)","Phase 4","90","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","NanFang2013035","July 29, 2013","May 2013","June 2015","June 17, 2015","February 2014","No Study Results Posted","null","December 2014","Changes in sexual function based on the (IIEF)-5 score and NPT|Compliance and overall patient satisfaction based on the self reported compliance diary and IIEF-5 score and NPT","https://ClinicalTrials.gov/show/NCT01912586"
2809,"NCT02789709","Metabolomic Phenotyping After Surgery for Colon Cancer: Study of Novel Predictive Biomarkers","Recruiting","No Results Available","Colon Cancer","Procedure: Surgery","Parc de Salut Mar|University of Barcelona","Both","18 Years and older   (Adult, Senior)","","130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PI15/00458","May 30, 2016","January 2016","December 2019","May 30, 2016","May 2016","No Study Results Posted","null","December 2018","Disease-free survival|Disease-specific survival|Local recurrence|Systemic recurrence|Postoperative intra-abdominal sepsis|Postoperative mortality","https://ClinicalTrials.gov/show/NCT02789709"
2810,"NCT00253812","Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy","Recruiting","No Results Available","Familial Adenomatous Polyposis","Procedure: flexible sigmoidoscopy","London North West Healthcare NHS Trust","Both","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind|Primary Purpose: Diagnostic","05ADR-88","November 11, 2005","November 2005","null","September 21, 2007","September 2007","No Study Results Posted","null","null","The primary outcome measure will be the mean number of adenomas detected on the blinded video review for each endoscopy|Adenoma detection rate for each of the modalities compared with each other.|Primary endoscopist adenoma count for each modality.","https://ClinicalTrials.gov/show/NCT00253812"
2811,"NCT02136277","Vascular Changes During Colorectal Surgery","Recruiting","No Results Available","Patients Undergoing Open Resection of Colorectal Tumours","Drug: Hartmann's solution","University of Nottingham","Both","18 Years to 80 Years   (Adult, Senior)","","32","Other","Observational","Time Perspective: Prospective","13115","May 8, 2014","January 2015","June 2016","January 25, 2015","January 2015","No Study Results Posted","MaMiFlo","January 2016","Changes in microvascular blood flow during colorectal surgery","https://ClinicalTrials.gov/show/NCT02136277"
2812,"NCT02595021","Total/Subtotal Colectomy in Ovarian Cancer","Recruiting","No Results Available","Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Secondary Malignant Neoplasm of Large Intestine","Procedure: Total or Subtotal Colectomy|Procedure: Other Bowel Resection","Shanghai Gynecologic Oncology Group|Shanghai Zhongshan Hospital","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","zsfud-obgyn-004","September 18, 2015","July 2015","December 2018","July 23, 2016","July 2016","No Study Results Posted","null","December 2017","Postoperative complications|The rate of 12- month- disease non-progression|Initiation of the first cycle chemotherapy|Hospitalization expenses|Hospitalization days","https://ClinicalTrials.gov/show/NCT02595021"
2813,"NCT00155415","A Prospective Single-Blinded Randomized Trial Comparing Colonoscopic Preparation at Different Time","Completed","No Results Available","Colonoscopy|Colon Neoplasm","Behavioral: Different timing of taking polyethylene glycol(PEG)","National Taiwan University Hospital","Both","20 Years to 85 Years   (Adult, Senior)","","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Diagnostic","9461700305","September 8, 2005","April 2005","September 2005","December 1, 2008","September 2005","No Study Results Posted","null","September 2005","Cleansing level of colon and detected lesion number during colonoscopy","https://ClinicalTrials.gov/show/NCT00155415"
2814,"NCT02838186","Backwards Examination of the Right Colon: A Back-to-back Study","Completed","No Results Available","Colon Neoplasms","Procedure: retroflexion|Procedure: forward view","Attikon Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","674","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","Retro-2013","June 19, 2013","May 2013","February 2014","July 16, 2016","July 2016","No Study Results Posted","null","December 2013","number of additional identified polyps with right colon scope retroflexion|Change in colorectal cancer (CRC) surveillance intervals among screening-surveillance patients|Rate of retroflexion-related adverse events.","https://ClinicalTrials.gov/show/NCT02838186"
2815,"NCT00773981","Transrectal Vacuum Assisted Drainage: A New Method of Treating Anastomotic Leakage After Rectal Resection","Recruiting","No Results Available","Colorectal Surgery","Procedure: Transrectal vacuum assisted drainage","Hvidovre University Hospital|Braun Aesculap","Both","18 Years and older   (Adult, Senior)","Phase 3","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H-B-2007-061","October 15, 2008","October 2008","October 2011","November 3, 2008","October 2008","No Study Results Posted","null","October 2011","Healing time of the anastomotic leakage|Salvage surgery (abdominal reoperation with debridement of anastomosis)|Duration of fever and antibiotic treatment|Duration of hospital stay|Number of visits in the outpatient clinic / number of sponge changes|Functional result, defined as +/- closure of temporary ileostomy|Functional result evaluated by examination of the anal physiology in a smaller patient population (supplementary trial protocol)","https://ClinicalTrials.gov/show/NCT00773981"
2816,"NCT01127698","Swedish Mammography Cohort","Completed","No Results Available","Cancers|Cardiovascular Diseases|Cataract|Gastrointestinal Diseases|Osteoporosis|Fractures","","Karolinska Institutet|Harvard School of Public Health","Female","40 Years to 74 Years   (Adult, Senior)","","61433","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1706/2010-631-1","May 20, 2010","March 1987","null","February 27, 2014","February 2014","No Study Results Posted","SMC","December 1990","Breast cancer|Colorectal cancer|Endometrial Cancer|Ovarian cancer|Pancreatic cancer|Stomach cancer|Kidney cancer|Bladder cancer|Cardiovascular diseases|Mortality|Cataract|Fractures, hip fractures","https://ClinicalTrials.gov/show/NCT01127698"
2817,"NCT02860234","Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment","Not yet recruiting","No Results Available","Rectal Cancer","Drug: Oxaliplatin|Drug: Capecitabine|Radiation: intensity modulated radiotherapy|Procedure: DRE-Endoscopy-MRI-CEA|Procedure: Nonoperative Management|Procedure: Local Excision|Procedure: Total Mesorectal Excision|Behavioral: Quality of Life Questionnaires","Beijing Cancer Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","72","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PKUCH-R01","August 4, 2016","August 2016","April 2023","August 15, 2016","August 2016","No Study Results Posted","null","August 2022","Organ preservation rate|Rate of non-regrowth disease-free survival (NR-DFS)|Stoma-free survival|Major adverse events|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29)","https://ClinicalTrials.gov/show/NCT02860234"
2818,"NCT02864849","Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer","Not yet recruiting","No Results Available","Rectal Cancer","Drug: Oxaliplatin|Drug: Capecitabine|Radiation: Intensity modulated radiotherapy|Procedure: Total mesorectal excision","Beijing Cancer Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","75","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PKUCH-R02","August 4, 2016","August 2016","April 2023","August 15, 2016","August 2016","No Study Results Posted","null","August 2022","Major adverse events|Disease-free survival (DFS)|Pathological downstaging rate|Compliance rate with neoadjuvant treatment schedule|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29)","https://ClinicalTrials.gov/show/NCT02864849"
2819,"NCT01127711","Cohort of Swedish Men","Completed","No Results Available","Cancers|Cardiovascular Diseases|Cataract|Gastrointestinal Diseases|Osteoporosis|Fractures","","Karolinska Institutet","Male","45 Years to 79 Years   (Adult, Senior)","","48850","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1706/2010-631-2","May 20, 2010","September 1997","null","February 27, 2014","February 2014","No Study Results Posted","COSM","December 1997","Prostate cancer|Pancreatic cancer|Stomach cancer|Cataract|LUTS (Lower urinary tract symptom)|Cardiovascular Diseases|Mortality|Colorectal Cancer|Bladder cancer|Fractures, hip fractures","https://ClinicalTrials.gov/show/NCT01127711"
2820,"NCT02371135","Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes","Recruiting","No Results Available","Lynch Syndrome|Hereditary Colonic Polyposis Syndromes","Genetic: colonic biopsies|Genetic: questionnaires","Memorial Sloan Kettering Cancer Center|Harvard University|Broad Institute","Both","18 Years and older   (Adult, Senior)","","75","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-016","February 19, 2015","February 2015","null","July 25, 2016","July 2016","No Study Results Posted","null","February 2017","association of the gut microbiome and dietary factors (To validate said associations, individual questions from the Brief Diet and Lifestyle Questionnaire will be primarily used in the overall analyses)","https://ClinicalTrials.gov/show/NCT02371135"
2821,"NCT02710812","Rectal Sparing Approach After Preoperative Radio and/or Chemotherapy in Patients With Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms","Procedure: Local Excision or Wait-and-See","University of Padova|Istituto Oncologico Veneto IRCCS|Centro di Riferimento Oncologico - Aviano|Istituto Nazionale per lo Studio e la Cura dei Tumori|Policlinico Universitario Agostino Gemelli|Azienda Ospedaliero, Universitaria Ospedali Riuniti","Both","18 Years and older   (Adult, Senior)","","164","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","3554/AO/15","March 4, 2016","January 2016","August 2021","March 18, 2016","March 2016","No Study Results Posted","ReSARCh","January 2021","Rate of organ preservation|Rate of overall survival (OS)|Rate of disease-free survival (DFS)|Rate of relapse-free local recurrence|Rate of patients without stoma|Rate of pCR|Morbidity|Mortality|Rate of patients undergoing conservative treatment|Memorial Sloan-Kettering Cancer Center Bowel Function Instrument|Fecal Incontinence Quality of Life Scale|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29","https://ClinicalTrials.gov/show/NCT02710812"
2822,"NCT01704820","Right Sided Colon Polyp Miss Rate: Impact Of Retroflexion In The Right Colon","Recruiting","No Results Available","Colon Polyps|Colon Cancer Screening","Procedure: Retroflexion in the right colon","Washington University School of Medicine|Medical College of Wisconsin","Both","18 Years and older   (Adult, Senior)","","1020","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","Retro-View","October 8, 2012","September 2012","November 2014","May 29, 2013","May 2013","No Study Results Posted","null","September 2014","Per patient adenoma detection rate (average # adenomas detected/ patient in each arm of the study).|Evaluate the success rate of retroflexion in the proximal colon.|Identify risk factors for missing polyps on first examination of right colon|Access whether duration of exam is different in the retroflexion vs. forward view arms of the study.|Evaluate endoscopist comfort with performing retroflexion in the proximal colon.","https://ClinicalTrials.gov/show/NCT01704820"
2823,"NCT01443377","Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer","Completed","No Results Available","Rectal Cancer","Biological: Panitumumab","National Center for Tumor Diseases, Heidelberg","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCT-0001021","August 23, 2011","July 2011","September 2013","May 6, 2015","April 2012","No Study Results Posted","NEOREC-1","September 2012","Histopathological complete response rate (pCR)|Objective tumor response rate assessed by MRI of the pelvis (incl. RECIST)|Metabolic tumor response rate assessed by means of changes in the standardized uptake values (SUV) using FDG-PET-CT (incl. RECIST)|Pathological tumor regression grades will be classified according to Becker|Quality of Life (QoL) will be assessed using the EORTC QLQ-C30 in combination with the colorectal cancer-specific quality of life questionaire module (QLQ-CR29)|distant metastases-free survival|relapse-free survival|overall survival","https://ClinicalTrials.gov/show/NCT01443377"
2824,"NCT02081547","IPC Status as a Surgical Quality Marker in Rectal Cancer Surgery","Recruiting","No Results Available","Rectal Cancer","","Uppsala University","Both","18 Years and older   (Adult, Senior)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IPC","October 11, 2012","April 2012","September 2014","March 5, 2014","March 2014","No Study Results Posted","null","March 2014","IPC status|TME quality|local recurrence|Survival","https://ClinicalTrials.gov/show/NCT02081547"
2825,"NCT01569672","Ohio Patient Navigator Research Program","Active, not recruiting","No Results Available","Breast Cancer|Cervical Cancer|Colon Cancer|Rectal Cancer|Abnormal Breast Cancer Screening Tests|Abnormal Cervical Cancer Screening Tests|Abnormal Colon Cancer Screening Tests","Behavioral: Patient Navigator matched with subject|Behavioral: Subjects are mailed informational/educational materials","Ohio State University Comprehensive Cancer Center|American Cancer Society, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 4","941","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Health Services Research","OPNRP|SIRG-05-253-01|NCI-2012-00205|OSU-6100","March 19, 2012","November 2006","null","October 14, 2015","October 2015","No Study Results Posted","OPNRP","December 2010","Amount of time from abnormal evaluation of the breast, cervix, and colon or rectum to needed tests and treatment|Number of barriers and effect of barriers on receiving needed tests and treatment","https://ClinicalTrials.gov/show/NCT01569672"
2826,"NCT01389830","End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer","Active, not recruiting","No Results Available","Advanced Cancers","Behavioral: Telephone Survey","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","230","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","2011-0436|7K01CA151785-02","July 6, 2011","June 2011","null","July 19, 2016","July 2016","No Study Results Posted","null","June 2018","End of Life Treatment Preferences of Older Latinos With and Without Cancer (Survey Responses)","https://ClinicalTrials.gov/show/NCT01389830"
2827,"NCT02151123","Metabiomics Colon Cancer Clinical Research Study","Not yet recruiting","No Results Available","Colonic Neoplasms","","Metabiomics Corp","Both","18 Years to 95 Years   (Adult, Senior)","","100","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","MB-02_CU","May 27, 2014","August 2016","December 2018","March 29, 2016","March 2016","No Study Results Posted","null","December 2017","False negative rate of test for colon cancer","https://ClinicalTrials.gov/show/NCT02151123"
2828,"NCT01411826","Online Programs to Promote Colon Cancer Screening","Completed","No Results Available","Colon Cancer Screening","Behavioral: Information + Narratives + Support Group|Behavioral: Information Only","The University of Texas Health Science Center, Houston","Both","50 Years to 75 Years   (Adult, Senior)","","306","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","HSC-MS-11-0305","August 4, 2011","July 2011","May 2012","November 7, 2012","November 2012","No Study Results Posted","null","May 2012","Feasibility|Colon cancer screening attitudes","https://ClinicalTrials.gov/show/NCT01411826"
2829,"NCT00248404","NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)","Completed","No Results Available","Tumors","Drug: NB1011","Kiadis Pharma","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","155","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR-TSC-001","November 3, 2005","September 2005","null","September 26, 2012","January 2008","No Study Results Posted","null","null","Safety/tolerability of NB1011 infusions|Determination of maximum tolerated dose (MTD)|Pharmacokinetics of NB1011 and its metabolite|Clinical activity as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria|Assessment of TS overexpression","https://ClinicalTrials.gov/show/NCT00248404"
2830,"NCT02602327","Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases","Not yet recruiting","No Results Available","Colon Cancer|Rectal Cancer|Liver Metastases","Drug: Tas-102|Device: SIR-Sphere","University of California, San Francisco","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Tas-102 with Radioembolization","November 9, 2015","September 2016","September 2020","November 10, 2015","November 2015","No Study Results Posted","null","September 2019","Safety (adverse events)|Radiographic response|Progression-free survival (PFS)|Hepatic progression-free survival (HPFS)|Extrahepatic progression free survival (EHPFS)|Overall survival (OS)|Biomarker response","https://ClinicalTrials.gov/show/NCT02602327"
2831,"NCT02167087","Sentinel Node Mapping With Indocyanine Green in Colon Cancer: a Feasibility Trial and a Descriptive Serie.","Completed","No Results Available","Colon Cancer|Lymphatic Metastasis","Procedure: Sentinel node mapping","Ismail Gögenür|Herlev Hospital","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","SENSE2014","June 6, 2014","March 2015","February 2016","February 15, 2016","February 2016","No Study Results Posted","SENSE","February 2016","Number of procedures with successful identification of sentinel nodes|Number of sentinel nodes identified during surgery and their localization|Number of sentinel nodes identified by ex vivo sentinel node mapping|Malignant status of the sentinel node(s)|Malignant status of the lymph nodes|Number of cases with negative sentinel node, but positive non-sentinel node|Localization of sentinel nodes with metastasis|Localization of lymph nodes with metastasis according to D1, D2 and D3 resection lines and if they are within 1 cm from a sentinel node|Number of cases where the sentinel node procedure has changed the clinical course of the patient|Number of procedures where the procedure is stopped due to technical reasons|Registration of possible side effects occurring due to the use of indocyanine green|Number of sentinel nodes identified by only one of the sentinel node mapping techniques|Total number of lymph nodes|Localization of the identified sentinel nodes, and whether or not they are included within the normal resection lines","https://ClinicalTrials.gov/show/NCT02167087"
2832,"NCT00622999","Effects of Malnutrition on Colon Cancer Patients With Abdominal Surgery","Completed","No Results Available","Malnutrition|Colon Cancer","","University Hospital Inselspital, Berne","Both","18 Years and older   (Adult, Senior)","","186","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Malnutr_Colon_CH_2007|Study ID: 2000/049","February 14, 2008","January 2003","January 2005","March 10, 2011","March 2011","No Study Results Posted","null","January 2005","Complication rate|Mortality","https://ClinicalTrials.gov/show/NCT00622999"
2833,"NCT01524094","Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis","Completed","No Results Available","Colorectal Peritoneal Carcinomatosis","Drug: Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Procedure: Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)","Uppsala University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","49","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SPS-1","January 18, 2012","June 2003","January 2012","January 31, 2012","January 2012","No Study Results Posted","null","December 2010","Overall survival|progression free survival|Time to secondary treatment|Radical resectability|Quality of life|Health costs|Side effects of treatment","https://ClinicalTrials.gov/show/NCT01524094"
2834,"NCT01437826","Antioxidant Supplement and Reduction of Metachronous Adenomas of the Large Bowel: a Double Blind Randomized Trial","Terminated","No Results Available","Colorectal Adenomas","Drug: antioxidants|Drug: placebo","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|LILT (Italian league against cancer)","Both","25 Years to 75 Years   (Adult, Senior)","Phase 3","411","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","IST-1988","September 14, 2011","March 1988","June 1996","September 19, 2011","September 2011","No Study Results Posted","null","June 1996","occurrence of metachronous adenomas or cancer detected during endoscopic follow up examinations","https://ClinicalTrials.gov/show/NCT01437826"
2835,"NCT00932438","Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6","Completed","No Results Available","Colon Cancer With Metastases to the Liver","Device: LC bead loaded with Irinotecan|Drug: FOLFOX6 and Avastin","University of Louisville|Biocompatibles UK Ltd","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","70","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DEBIRI # 09.0034|UL2008.1","July 1, 2009","June 2009","December 2012","April 17, 2013","November 2011","No Study Results Posted","DEBIRI","December 2012","Tumor Response","https://ClinicalTrials.gov/show/NCT00932438"
2836,"NCT01647776","Screening and Risk Factors of Colon Neoplasia","Recruiting","No Results Available","Colon Cancer","Other: Stool DNA Test|Procedure: biopsies of rectal and colon mucosa|Other: Questionnaires","Case Comprehensive Cancer Center","Both","30 Years to 80 Years   (Adult, Senior)","","1600","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","CASE1207|SPORE 2|10-04-12","July 5, 2012","April 2012","null","June 15, 2016","June 2016","No Study Results Posted","null","December 2016","Stool DNA (sDNA) Feasibility and Compliance|Efficacy of sDNA testing for the detection of advanced adenomas|Concordance/discordance between tissue and stool DNA aberrant methylation markers|Persistence of positive sDNA testing after removal of advanced adenomas|Assess the frequency of missed or occult colonic and upper gastrointestinal neoplasia in patients with initially normal colonoscopies and persistently positive sDNA testing.|Insulin Resistance Syndrome|Analyses stratified by ethnicity (Caucasians versus African Americans), and gender.|Examine the impact of candidate gene variants in the insulin-GH-IGF-IRS axis on colon polyps.|Evaluate the association of dietary patterns, glycemic index (GI) and glycemic load (GL) with colon polyps.|Synthesize the information on candidate genes and diet by looking at their joint effects on colon polyps|To investigate the association of activated (phosphorylated) IRS1, AKT and mTOR with colon adenomas.","https://ClinicalTrials.gov/show/NCT01647776"
2837,"NCT01685632","Intra Peritoneal Chemo Hyperthermia (IPCH) : Cellular and Metabolic Consequences","Terminated","No Results Available","Peritoneal Carcinomatosis From Colorectal or Ovarian Origin","Procedure: Surgery with IPCH|Procedure: Without surgery and without IPCH","Centre Hospitalier Universitaire de Nice","Both","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","11-PP-01","September 12, 2012","September 2012","July 2014","October 16, 2015","October 2015","No Study Results Posted","CHIP","June 2014","heat shock protein expression (blood/cell ratio)compared to baseline values","https://ClinicalTrials.gov/show/NCT01685632"
2838,"NCT01591798","Efficacy Study of Robotic Surgery for Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasm","Procedure: Robotic surgery|Procedure: Laparoscopic surgery","National Cancer Center, Korea","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","146","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC-CTS603","March 16, 2012","March 2012","December 2017","May 3, 2012","May 2012","No Study Results Posted","null","December 2014","Quality of mesorectal excision|Short-term postoperative outcome|Sexual and urinary function, Quality of life, Anorectal function|Long-term outcome","https://ClinicalTrials.gov/show/NCT01591798"
2839,"NCT00709176","Outcomes of Triaged Family Care in Advanced Cancer","Completed","No Results Available","Advanced Cancer","Behavioral: Brief FOCUS Program|Behavioral: Extensive FOCUS Program","University of Michigan|Wayne State University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","484","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","R01CA107383|UMCC 2003-094|IRBMED No. 2004-0129","July 1, 2008","June 2005","May 2010","February 10, 2014","October 2013","No Study Results Posted","FOCUS-Triage","May 2010","Change in Quality of Life|Risk for Distress|Change in Emotional Distress|Change in Appraisal of Illness/Caregiving|Change in Uncertainty|Change in Hopelessness|Change in Self-efficacy|Change in Benefits of Illness|Change in Family Communication|Change in Support|Change in Depression|Change in Coping|Change in Health Care Resource Utilization|Change in Caregiver Burden","https://ClinicalTrials.gov/show/NCT00709176"
2840,"NCT00861107","In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation","Completed","No Results Available","Metastatic Cancer","Biological: AlloStim-7|Procedure: percutaneous tumor cryoablation|Biological: AlloStim-7|Biological: AlloStim8 or AlloStim-9","Immunovative Therapies, Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ITL-002-CRYO","March 12, 2009","August 2009","May 2011","June 6, 2011","June 2011","No Study Results Posted","null","March 2011","evaluation of any drug-related toxicity associated with AlloStim administration as well as the reversibility of such toxicity.|evaluation of the anti-tumor effect of AlloStim administration|evaluation of the immunological response to AlloStim administration","https://ClinicalTrials.gov/show/NCT00861107"
2841,"NCT01037790","PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER","Recruiting","No Results Available","Adult Solid Tumor|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Adult Central Nervous System Germ Cell Tumor|Adult Teratoma|Benign Teratoma|Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|Familial Testicular Germ Cell Tumor|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Male Breast Cancer|Ovarian Immature Teratoma|Ovarian Mature Teratoma|Ovarian Monodermal and Highly Specialized Teratoma|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Extragonadal Germ Cell Tumor|Recurrent Extragonadal Non-seminomatous Germ Cell Tumor|Recurrent Extragonadal Seminoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Melanoma|Recurrent Ovarian Germ Cell Tumor|Recurrent Rectal Cancer|Stage III Extragonadal Non-seminomatous Germ Cell Tumor|Stage III Extragonadal Seminoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Ovarian Germ Cell Tumor|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Extragonadal Non-seminomatous Germ Cell Tumor|Stage IV Extragonadal Seminoma|Stage IV Melanoma|Stage IV Ovarian Germ Cell Tumor|Stage IV Rectal Cancer|Testicular Immature Teratoma|Testicular Mature Teratoma","Drug: PD-0332991|Other: pharmacological study","Abramson Cancer Center of the University of Pennsylvania","Both","18 Years and older   (Adult, Senior)","Phase 2","205","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCC 03909|NCI-2009-01467","December 10, 2009","October 2009","null","August 24, 2016","July 2016","No Study Results Posted","null","October 2016","Response rates|Safety and tolerability|Pharmacodynamic effects on tumor and non-tumor tissue|Relationship between selected biomarkers, pharmacokinetics, and/or efficacy and safety outcomes|Population pharmacokinetic for PD 0332991 and correlation with efficacy outcomes","https://ClinicalTrials.gov/show/NCT01037790"
2842,"NCT01786200","Physiological Effects of Altering Cancer-related Inflammation","Not yet recruiting","No Results Available","Colon Cancer","Drug: Aspirin|Drug: Ibuprofen","NHS Greater Glasgow and Clyde|Academy of Medical Sciences|Wellcome Trust","Both","18 Years to 75 Years   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","GN12SU401|12736","January 29, 2013","February 2013","null","February 5, 2013","February 2013","No Study Results Posted","null","December 2014","Klintrup-Makinen immune score|Systemic inflammatory response|Assessment of gene inflammatory profile|Local inflammatory response","https://ClinicalTrials.gov/show/NCT01786200"
2843,"NCT01770353","Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent","Recruiting","No Results Available","Solid Tumors|ER/PR Positive Breast Cancer|Triple Negative Breast Cancer|Metastatic Breast Cancer With Active Brain Metastasis","Drug: Ferumoxytol followed by MM-398","Merrimack Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label","MM-398-01-01-02","December 19, 2012","November 2012","October 2017","July 7, 2016","July 2016","No Study Results Posted","null","June 2017","Measure tumor levels of irinotecan and SN-38 (in ng/mL)|Safety profile of MM-398 in the presence of ferumoxytol (number and type of Adverse Events compared with histological control)|Tumor response Rate measured by RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 guidelines|Half-life of the drug (t 1/2) in number of hours|Maximum concentration of drug in plasma (Cmax) in ng/mL|Measure of drug availability in the plasma (AUC) in ng/mL x hours","https://ClinicalTrials.gov/show/NCT01770353"
2844,"NCT01681472","PK/PD Investigation of Modufolin® in Plasma, Tumor and Adjacent Mucosa in Patients With Colon Cancer","Completed","Has Results","Colonic Neoplasms","Drug: [6R] 5,10-methylenetetrahydrofolate|Drug: Levoleucovorin","Isofol Medical AB","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","32","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","ISO-CC-002|2012-000522-22","September 5, 2012","September 2012","August 2013","April 20, 2016","April 2016","May 21, 2015","null","August 2013","Comparison of Folate Concentration in Tumor Tissue and Adjacent Mucosa Between Treatment Arms.","https://ClinicalTrials.gov/show/NCT01681472"
2845,"NCT01399710","Impact of Computer-Aided Detection (CAD) as Second Reader in CT Colonography","Completed","No Results Available","Individuals With Suspected Colorectal Disease","Procedure: CT colonography|Procedure: colonoscopy|Device: CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy","im3D S.p.A.|Candiolo Cancer Institute|Bicocca Universiy of Milano, Milan, Italy|Fondazione Salvatore Maugeri|Catholic University, Italy|Valduce Hospital|University of Turin, Italy|University of Roma La Sapienza|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Nuovo Regina Margherita Hospital|University of Pisa|University of Florence|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","Both","18 Years and older   (Adult, Senior)","Phase 3","651","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CAD COLON 001","July 15, 2011","July 2007","March 2010","July 21, 2011","July 2011","No Study Results Posted","CAD-IMPACT","May 2009","Sensitivity of CT colonography with unassisted and CAD-assisted reading in detecting individuals with lesions 6 to 9 mm|Specificity of CT colonography with unassisted and CAD-assisted reading in detecting individuals with no clinical relevant lesions|Sensitivity of CT colonography with unassisted and CAD-assisted reading in detecting individuals with lesions 10 mm or larger|Sensitivity of CT colonography with unassisted and CAD-assisted reading in detecting lesions 6 mm or larger","https://ClinicalTrials.gov/show/NCT01399710"
2846,"NCT02490709","Local Excision of Clinical T3 Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy","Recruiting","No Results Available","Rectal Cancer","Procedure: Local excision","National Cancer Center, Korea","Both","20 Years and older   (Adult, Senior)","Phase 2","86","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC-LE","July 2, 2015","April 2015","April 2020","July 2, 2015","July 2015","No Study Results Posted","null","April 2020","3-year disease free survival|Complete response rate|Overall survival rate","https://ClinicalTrials.gov/show/NCT02490709"
2847,"NCT02003417","Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy","Active, not recruiting","No Results Available","Prostate Cancer","","UNC Lineberger Comprehensive Cancer Center|Radiation Therapy Oncology Group","Male","18 Years and older   (Adult, Senior)","","101","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LCCC 1218","November 18, 2013","June 2012","December 2017","May 10, 2016","May 2016","No Study Results Posted","null","July 2016","Proportion of prostate cancer patients with controlled blood sugars, blood pressure, and cholesterol profile.|Proportion of prostate cancer patients with guideline-recommended cardiovascular preventive care (glucose testing, cholesterol testing, and blood pressure measurement).|Proportion of prostate cancer patients who receive other (non-cardiovascular) guideline-recommended primary and preventive care (flu vaccination, colorectal cancer screening, and healthy lifestyle counseling).|Patient-reported quality of life.|Patient-reported coordination of care.|Patient-reported satisfaction with care.","https://ClinicalTrials.gov/show/NCT02003417"
2848,"NCT02262455","Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors","Recruiting","No Results Available","Ovarian Cancer|Fallopian Tube Cancer|Endometrial Cancer|Solid Tumors","Drug: STM 434|Drug: Liposomal doxorubicin","Santa Maria Biotherapeutics","Both","18 Years and older   (Adult, Senior)","Phase 1","81","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","STM-434-001","September 29, 2014","October 2014","July 2017","July 14, 2016","July 2016","No Study Results Posted","null","July 2017","Maximum Tolerated Dose (MTD)|Recommended Phase 2 dose (RP2D)|Radiographic response rate|Muscle function and body composition","https://ClinicalTrials.gov/show/NCT02262455"
2849,"NCT00120939","Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer","Completed","No Results Available","Breast Neoplasms|Ovarian Neoplasms|Prostatic Neoplasms|Lung Neoplasms|Gastrointestinal Neoplasms","Drug: Motexafin Gadolinium","Pharmacyclics","Both","18 Years and older   (Adult, Senior)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PCYC-0212","July 12, 2005","null","null","April 2, 2009","May 2007","No Study Results Posted","null","null","Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.|Tumor response rate 8, 16 and 24 weeks, and common PK parameters at 24 weeks","https://ClinicalTrials.gov/show/NCT00120939"
2850,"NCT01378013","SurgicAl Metabolic Phenotyping Longitudinal Evaluation Study","Completed","No Results Available","Colon Cancer|Breast Cancer|Trauma|Inflammatory Bowel Disease|Hernia","","Imperial College London","Both","18 Years and older   (Adult, Senior)","","50","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","11/L0/686|NIHR BRC","June 20, 2011","August 2011","March 2015","March 24, 2015","July 2011","No Study Results Posted","SaMPLE","January 2015","Sepsis|Oncological resection margins|Local and distant recurrence|Organ failure|Mortality","https://ClinicalTrials.gov/show/NCT01378013"
2851,"NCT02685631","Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Registry","Recruiting","No Results Available","Localized Non-Resectable Adult Liver Carcinoma","Other: Yttrium-90 Resin Microspheres","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","400","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","VICC GI 1523|NCI-2015-01837|P30CA068485","December 19, 2015","July 2015","August 2021","August 16, 2016","August 2016","No Study Results Posted","RESIN","August 2020","Response to treatment with Y90 microspheres either as mono therapy or as part of multidisciplinary management of their specific disease|Treatment related toxicity assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4) measures|Overall Survival|Time to Progression","https://ClinicalTrials.gov/show/NCT02685631"
2852,"NCT02079389","The Value of Laparoscopic Ultrasound in Patients Undergoing Laparoscopic Resection for Cancer of the Colon or Rectum","Completed","No Results Available","Colon Cancer|Rectum Cancer|Liver Metastases","Device: Lap+Lus","Odense University Hospital|Svendborg Hospital|Sygehus Lillebaelt|Sydvestjysk Hospital","Both","18 Years and older   (Adult, Senior)","","280","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","20110135","February 10, 2014","May 2013","April 2015","May 4, 2015","May 2013","No Study Results Posted","null","December 2014","A change in the stage of Tumor, lymph Node and metastases (TNM-stage)|A change in the postoperative treatment strategy","https://ClinicalTrials.gov/show/NCT02079389"
2853,"NCT01259284","Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer","Terminated","Has Results","Advanced Cancers","Drug: Atorvastatin|Dietary Supplement: Fish Oil Supplement|Other: Placebo","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","2","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","2009-0591","December 10, 2010","January 2011","September 2011","July 31, 2012","July 2012","April 24, 2012","null","September 2011","Incidences of Atrial Fibrillation During First 4 Days After Lung Resection","https://ClinicalTrials.gov/show/NCT01259284"
2854,"NCT02817633","A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors","Recruiting","No Results Available","Advanced or Metastatic Solid Tumors","Drug: TSR-022|Drug: anti PD-1 antibody","Tesaro, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","402","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4020-01-001","June 22, 2016","July 2016","June 2020","August 26, 2016","August 2016","No Study Results Posted","null","December 2019","Safety and tolerability of TSR-022 using Common Terminology Criteria for Adverse Events (CTCAE v.4.03) in patients with advanced solid tumors|Anti-tumor activity of TSR-022 in patients with solid tumors, in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1|Recommended Phase 2 dose (RP2D) and schedule as monotherapy and in combination with an anti-PD-1 antibody|Safety and tolerability of TSR-022 using CTCAE v.4.03|Overall Response Rate (ORR) by RECIST v. 1.1 (Part 1)|ORR by immune-related RECIST (irRECIST)|Duration of response (DOR) by RECIST v 1.1|Disease control rate (DCR) by RECIST v 1.1 and by irRECIST|Progression-free survival (PFS) by RECIST v 1.1 and by irRECIST|Overall survival (OS)|PK Parameter: AUC, 0-last assessment|PK Parameter: AUC, 0 to infinity|PK Parameter: AUC at steady state|PK Parameter: Minimum Concentration (Cmin)|PK Parameter: Maximum Concentration (Cmax)|PK Parameter: Clearance (CL)|PK Parameter: Cmin at steady state (Cmin,ss)|PK Parameter: Cmax at steady state (Cmax, ss)|PK Parameter: Volume of Distribution (Vz)|PK Parameter: terminal half-life (t1/2)|Pharmacodynamic profile as assessed by receptor occupancy|Immunogenicity as assessed by the presence of anti-drug antibodies","https://ClinicalTrials.gov/show/NCT02817633"
2855,"NCT01397305","An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: [6R] 5,10-methylenetetrahydrofolate|Drug: Pemetrexed","Isofol Medical AB","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ISO-MC-091","May 25, 2011","April 2011","null","April 19, 2016","April 2016","No Study Results Posted","null","November 2014","Feasibility of Pemetrexed Prior to Surgery|Pathological Complete Response (pCR)|Number of Participants Receiving Sphincter Saving Surgery|Evaluation of qualitative and quantitative toxicities|[6R] 5,10-methylenetetrahydrofolate tissue concentration determination|Correlation between 5,10-methylenetetrahydrofolate and HCy levels in blood|Correlation of folate gene polymorphisms and gene signature profiling with clinical outcome and toxicity profiles.|Pharmacokinetic parameters of [6R] 5,10-mTHF, 5-formyl-THF, 5-methyl-THF and THF calculated from plasma","https://ClinicalTrials.gov/show/NCT01397305"
2856,"NCT01495663","Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned","Completed","No Results Available","Cancer","Drug: I-131-CLR1404","Cellectar Biosciences, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","12","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DCL-10-001","December 16, 2011","December 2011","January 2014","February 25, 2015","February 2015","No Study Results Posted","null","November 2013","Determination of the recommended dose of I-131-CLR1404 in treating subjects with relapsed or refractory advanced solid malignancies|Expansion of the safety profile of I-131-CLR1404|Expansion of the pharmacokinetic profile of I-131-CLR1404|Preliminary antitumor activity of I-131-CLR1404|Tumor dosimetry of I-131-CLR1404 in a subset of subjects with non-hepatic lesions measuring at least 2 cm in one dimension","https://ClinicalTrials.gov/show/NCT01495663"
2857,"NCT00496860","Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies","Completed","Has Results","Progressive Metastatic Malignancies","Biological: ALT-801","Altor Bioscience Corporation","Both","18 Years and older   (Adult, Senior)","Phase 1","26","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA-ALT-801-01-06","July 3, 2007","May 2007","October 2009","July 17, 2013","July 2013","April 2, 2013","null","October 2009","The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies|The Maximum-tolerated Dose (MTD) of ALT-801|Clinical Antitumor Response to ALT-801|ALT-801 Induced Cell-mediated Immune Responses|Immunogenicity of ALT-801","https://ClinicalTrials.gov/show/NCT00496860"
2858,"NCT02613260","Mailed FIT Outreach to Improve Colon Cancer Screening in the Safety-net System","Recruiting","No Results Available","Colonic Neoplasms","Behavioral: FIT Outreach","University of California, San Francisco|Stanford University|San Francisco Department of Public Health","Both","50 Years to 75 Years   (Adult, Senior)","","9500","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","14-14861","November 20, 2015","November 2015","November 2019","November 20, 2015","November 2015","No Study Results Posted","null","November 2018","Completion of FIT- one year|Incomplete FIT- 28 days|FIT Positive|Completed Colonoscopy|Colonoscopy Findings|Cost","https://ClinicalTrials.gov/show/NCT02613260"
2859,"NCT00413075","Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma","Completed","No Results Available","Solid Tumor|Lymphoma","Drug: oral belinostat","Onxeo|Spectrum Pharmaceuticals, Inc","Both","18 Years and older   (Adult, Senior)","Phase 1","121","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PXD101-CLN-9","December 18, 2006","June 2006","August 2011","July 7, 2015","July 2015","No Study Results Posted","null","August 2011","Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort|Determine the pharmacokinetics of oral PXD101 when dosed once or twice daily at various dose levels|Explore anti-tumor activity|Determine the safety, tolerability, and anti-tumor activity of orally administered PXD101 to patients with lymphoma","https://ClinicalTrials.gov/show/NCT00413075"
2860,"NCT00641147","Curcumin in Treating Patients With Familial Adenomatous Polyposis","Active, not recruiting","No Results Available","Familial Adenomatous Polyposis","Drug: Curcumin|Other: Laboratory Biomarker Analysis|Other: Placebo","National Cancer Institute (NCI)","Both","18 Years to 85 Years   (Adult, Senior)","Phase 2","50","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NCI-2013-00536|CDR0000592794|NA_00011821|00011821|1R01CA134620|R01CA134620|P30CA006973","March 17, 2008","October 2010","null","July 20, 2016","July 2016","No Study Results Posted","null","August 2016","Change in activation of NFKB pathway|Change in Akt phosphorylation levels|Change in apoptosis index levels|Change in Ki-67 anti-proliferative cell nuclear antibody index levels|Change in mucosa and adenoma histology assessed by light microscopy|Change in mucosal DNA methylation levels|Change in mucosal leukotriene levels|Change in mucosal prostaglandin levels|Change in ODC activity levels expressed as nmol of activity/mg of musosal tissue/hr|Change in polyamines levels expressed pg/mg protein|Change in vascular density|Incidence of grade >= 2 adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0|Mean polyp size in mm (mean size of the 5 largest polyps)|Medication compliance|Number of patients failing study|Side effects of curcumin treatment|Total number of polyps","https://ClinicalTrials.gov/show/NCT00641147"
2861,"NCT00475722","Healthy Eating for Colon Cancer Prevention","Completed","Has Results","Colon Cancer","Behavioral: 1 Healthy Eating|Behavioral: 2 Mediterranean","University of Michigan","Both","21 Years and older   (Adult, Senior)","","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","HUM00007622","May 17, 2007","May 2007","December 2011","August 4, 2015","August 2015","May 26, 2015","null","November 2010","Adherence to Dietary Goals","https://ClinicalTrials.gov/show/NCT00475722"
2862,"NCT02150148","Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors","Completed","No Results Available","Cancer","Behavioral: Experimental: Mentored Gardening Intervention","University of Alabama at Birmingham|National Cancer Institute (NCI)","Both","60 Years and older   (Adult, Senior)","","46","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","CA182508|R21CA182508-01","May 24, 2014","April 2014","December 2015","February 5, 2016","November 2015","No Study Results Posted","null","December 2015","feasibility|physical function|diet quality|physical activity|quality of life|biomarkers of successful aging","https://ClinicalTrials.gov/show/NCT02150148"
2863,"NCT00094003","Study of NS-9 in Patients With Liver Metastases","Completed","No Results Available","Liver Neoplasms|Neoplasm Metastasis|Local Neoplasm Recurrences","Drug: NS-9 [Poly I: Poly C]","NS Pharma, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NS9001","October 8, 2004","September 2002","null","November 9, 2005","November 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00094003"
2864,"NCT01269567","Drainage After Rectal Excision for Rectal Cancer","Completed","No Results Available","Rectal Cancer Surgery|Randomized Clinical Trial|Multicenter Study|Pelvic Drainage","Procedure: Laying and management of the drain (strictly randomized arm with drainage)|Procedure: No pelvic drainage","University Hospital, Bordeaux","Both","18 Years and older   (Adult, Senior)","Phase 3","494","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CHUBX 2010/24","January 3, 2011","January 2011","January 2015","July 22, 2015","July 2015","No Study Results Posted","GRECCAR 5","January 2015","Pelvic sepsis|Overall sepsis|Peri-operative mortality|Surgical morbidity according to Dindo classification|Re-surgery during the hospitalization|Rate of closure of stoma","https://ClinicalTrials.gov/show/NCT01269567"
2865,"NCT00413322","Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors","Completed","No Results Available","Tumor","Drug: belinostat|Drug: 5-Fluorouracil (5-FU)","Onxeo","Both","18 Years and older   (Adult, Senior)","Phase 1","35","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PXD101-CLN-4","December 18, 2006","September 2005","June 2008","July 7, 2015","July 2015","No Study Results Posted","null","March 2008","to determine the maximum tolerated dose of PXD101 administered in combination with 5-FU|to determine whether PXD101 alone can down-regulate thymidylate synthase in patient tumors","https://ClinicalTrials.gov/show/NCT00413322"
2866,"NCT00248053","Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients","Withdrawn","No Results Available","Familial Adenomatous Polyposis","Drug: curcumin","Johns Hopkins University","Both","18 Years to 85 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label","05-04-12-04","November 1, 2005","November 2005","null","September 18, 2012","September 2012","No Study Results Posted","null","June 2008","polyp number and size|side effects and medication compliance","https://ClinicalTrials.gov/show/NCT00248053"
2867,"NCT00090727","Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma","Active, not recruiting","No Results Available","Solid Malignancies|Non-Hodgkin's Lymphoma","Drug: AQ4N","Novacea","Both","18 Years and older   (Adult, Senior)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","021-001","September 2, 2004","August 2004","null","October 31, 2006","April 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00090727"
2868,"NCT00603356","Phase I Study of OSI-930 and Erlotinib in Cancer Tumors","Completed","No Results Available","Advanced Solid Tumors","Drug: OSI-930 and erlotinib","Astellas Pharma Inc|OSI Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","60","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSI-930-103","December 26, 2007","November 2007","July 2010","September 26, 2011","September 2011","No Study Results Posted","null","April 2010","Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles|Safety, evaluate pharmacodynamic relationships","https://ClinicalTrials.gov/show/NCT00603356"
2869,"NCT00601549","A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT)","Recruiting","No Results Available","Rectal Cancer","Procedure: Laparoscopic surgery|Procedure: Traditional open surgery","National Taiwan University Hospital|National Science Council, Taiwan","Both","18 Years to 85 Years   (Adult, Senior)","Phase 3","600","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","941007|NSC96-2314-B-002-146","January 15, 2008","January 2000","December 2017","December 5, 2012","December 2012","No Study Results Posted","null","December 2017","Oncologic Results|Functional recovery of patients","https://ClinicalTrials.gov/show/NCT00601549"
2870,"NCT02659631","PF-06671008 Dose Escalation Study in Advanced Solid Tumors","Recruiting","No Results Available","Neoplasms","Drug: PF-06671008|Drug: PF-06671008","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","110","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","B7831001","January 15, 2016","May 2016","June 2019","September 12, 2016","September 2016","No Study Results Posted","null","June 2019","Number of participants with Dose-Limiting Toxicities (DLT) [Part 1]|Number of participants with objective response|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Plasma Decay Half-Life (t1/2)|Area Under the Curve from Time Zero to End of Dosing Interval (AUCtacu)|Area Under the Curve from time zero to infinity (AUCinf)|Systemic Clearance|Number of participants with objective response (Part 1)|Number of participants with PFS (Part 2)|Number of participants with OS (Part 2)","https://ClinicalTrials.gov/show/NCT02659631"
2871,"NCT01552967","Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma","Recruiting","No Results Available","Colorectal Adenocarcinoma","Drug: Capecitabine","Sixth Affiliated Hospital, Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAHMO-01","March 5, 2012","March 2012","February 2014","March 27, 2012","March 2012","No Study Results Posted","mXELOX","August 2013","Overall response rate according to RECIST 1.1|Time to progression|overall survival|Safety data of this regimen","https://ClinicalTrials.gov/show/NCT01552967"
2872,"NCT00646607","FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer","Completed","No Results Available","Colon Cancer","Drug: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|Drug: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)","Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|Mario Negri Institute for Pharmacological Research","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","3756","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-000354-31","March 17, 2008","June 2007","November 2014","November 25, 2014","December 2009","No Study Results Posted","TOSCA","April 2013","disease free survival (DFS)|overall Survival (OS), Toxicity and incidence of adverse events","https://ClinicalTrials.gov/show/NCT00646607"
2873,"NCT00467844","Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.","Completed","Has Results","Cachexia","Drug: GTx-024|Drug: GTx-024|Drug: Placebo","GTx","Both","Child, Adult, Senior","Phase 2","159","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","G200502","April 30, 2007","May 2007","September 2008","June 26, 2014","June 2014","January 18, 2013","null","September 2008","The Efficacy of GTx-024 on Total Body Lean Mass.|To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.","https://ClinicalTrials.gov/show/NCT00467844"
2874,"NCT00513851","Phase 1 Study of OSI-930 in Cancer Patients","Completed","No Results Available","Advanced Solid Tumors","Drug: OSI-930|Drug: OSI-930","Astellas Pharma Inc|OSI Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","60","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSI-930-102","August 7, 2007","April 2006","September 2009","September 26, 2011","September 2011","No Study Results Posted","null","July 2009","Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of OSI-930|Safety, Pharmacokinetic profile, Pharmacodynamic relationships, Preliminary antitumor activity","https://ClinicalTrials.gov/show/NCT00513851"
2875,"NCT02554812","A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)","Recruiting","No Results Available","Advanced Cancer","Drug: Avelumab|Drug: PF-05082566|Drug: PF-04518600|Drug: PF-04518600","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","317","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","B9991004|2015-002552-27|JAVELIN MEDLEY","September 16, 2015","November 2015","June 2018","September 12, 2016","September 2016","No Study Results Posted","null","June 2018","Number of participants with Dose-Limiting Toxicities (DLT)|Objective Response - Number of Participants With Objective Response|Cmax of avelumab (MSB0010718C)|Cmax of PF-05082566|Ctrough of avelumab (MSB0010718C)|Ctrough of PF-05082566|Anti-Drug Antibody (ADA) levels of avelumab (MSB0010718C)|Anti-Drug Antibody (ADA) levels of PF-05082566|Time to Tumor Response (TTR)|Duration of Response (DR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Tumor tissue biomarkers|Cmax of PF-04518600|Anti-Drug Antibody (ADA) levels of PF-04518600|Ctrough of PF-04518600","https://ClinicalTrials.gov/show/NCT02554812"
2876,"NCT00375245","Rapamycin With Grapefruit Juice for Advanced Malignancies","Completed","No Results Available","Tumors|Neoplasm Metastasis","Drug: Rapamycin (sirolimus)|Other: Grapefruit Juice","University of Chicago","Both","18 Years and older   (Adult, Senior)","Phase 1","41","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14435B","September 11, 2006","September 2006","May 2012","January 16, 2014","January 2014","No Study Results Posted","null","May 2009","Pharmacokinetic interaction","https://ClinicalTrials.gov/show/NCT00375245"
2877,"NCT02711137","A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies","Recruiting","No Results Available","Advanced Cancer","Drug: INCB057643","Incyte Corporation","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","155","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INCB 57643-101","March 9, 2016","May 2016","July 2018","June 8, 2016","June 2016","No Study Results Posted","null","June 2018","Safety and tolerability of INCB057643 as assessed by clinical laboratory assessments, physical examinations, 12 lead ECGs, and adverse events (AEs)|Plasma and urine concentrations of INCB057643 when administered in the fasted state|Plasma concentrations of INCB057643 plasma when administered in the fed state|Measurement of cellular myc protein concentrations before and after administration of INCB057643|Efficacy assessed by objective response rate (ORR) per disease-specific response criteria|Efficacy assessed by progression-free survival (PFS) per disease-specific response criteria|Efficacy assessed by duration of response per disease-specific response criteria|Efficacy assessed by overall survival per disease-specific response criteria","https://ClinicalTrials.gov/show/NCT02711137"
2878,"NCT00710697","Cardiac Safety Assessment Study of Picoplatin in Solid Tumors","Active, not recruiting","No Results Available","Solid Tumors","Drug: Picoplatin","Poniard Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","40","Industry","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0701","July 2, 2008","June 2008","July 2009","September 23, 2009","September 2009","No Study Results Posted","null","March 2009","ECG interval change|Safety/Efficacy","https://ClinicalTrials.gov/show/NCT00710697"
2879,"NCT01375842","A Phase 1 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors","Recruiting","No Results Available","Solid Cancers","Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","604","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PCD4989g|2011-001422-23|GO27831","June 16, 2011","June 2011","April 2019","January 14, 2016","January 2016","No Study Results Posted","null","September 2017","Incidence of dose limiting toxicities (DLTs)|Nature of dose limiting toxicities (DLTs)|Incidence of adverse events graded according to NCI CTCAE v4.0|Nature of adverse events graded according to NCI CTCAE v4.0|Severity of adverse events graded according to NCI CTCAE v4.0","https://ClinicalTrials.gov/show/NCT01375842"
2880,"NCT02431260","An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies","Recruiting","No Results Available","Advanced Cancer","Drug: INCB054329 Monotherapy","Incyte Corporation","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","155","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INCB 54329-101","April 27, 2015","May 2015","February 2018","August 8, 2016","August 2016","No Study Results Posted","null","October 2017","Number of Participants With Adverse Events (AE)|Plasma concentrations of INCB054329 will be determined by the use of validated assays|Objective Response Rate|Duration of Response|Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02431260"
2881,"NCT01762254","Prospective Randomized Trial of Incisionless Versus Conventional Laparoscopic Colectomy for Left-sided Colonic Tumors","Completed","No Results Available","Pain,|Postoperative Wound Complication","Procedure: incisionless laparoscopic colectomy|Procedure: conventional laparoscopic colectomy","Pamela Youde Nethersole Eastern Hospital","Both","18 Years and older   (Adult, Senior)","","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","HKEC-2009-023","November 29, 2012","June 2009","June 2012","January 4, 2013","January 2013","No Study Results Posted","null","March 2012","pain score|wound complication","https://ClinicalTrials.gov/show/NCT01762254"
2882,"NCT01474187","Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: Irinotecan|Drug: Capecitabine|Radiation: Radiotherapy","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","60","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FDRT-003","November 11, 2011","November 2011","December 2012","November 15, 2011","November 2011","No Study Results Posted","null","November 2011","toxicity|pathological complete response (pCR)","https://ClinicalTrials.gov/show/NCT01474187"
2883,"NCT01946074","Study of ABT-165 in Subjects With Advanced Solid Tumors","Recruiting","No Results Available","Advanced Solid Tumors","Drug: ABT-165|Drug: paclitaxel|Drug: FOLFIRI","AbbVie","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","90","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M14-006","September 17, 2013","August 2013","April 2017","August 2, 2016","August 2016","No Study Results Posted","null","April 2017","Number of participants with Adverse Events|Vital signs|Physical exam|Clinical lab testing|Cardiac assessment|Maximum observed serum concentration (Cmax) of ABT-165|The terminal elimination half life of ABT-165|Area under the curve (AUC) form time zero to the last measurable concentration AUC (0-t)|Objective response rate (ORR)|Progression free survival (PFS)|Duration of overall response (DOR)","https://ClinicalTrials.gov/show/NCT01946074"
2884,"NCT02442414","A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors","Recruiting","No Results Available","Advanced Solid Tumors","Drug: KBP-5209","Sihuan Pharmaceutical Holdings Group Ltd.|Covance|XuanZhu Pharma Co., Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Industry|Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","5209-CPK-1001","April 29, 2015","April 2015","December 2016","May 8, 2015","April 2015","No Study Results Posted","null","August 2016","Outcome Measure: safety and tolerability, based on the rate of dose-limiting toxicities, toxicity grade, and reversibility of toxicity.|Dose-dependency of toxicity based on: dose limiting toxicities; frequency, type, grade, and seriousness, and causality of treatment-emergent adverse events, and laboratory assessments.","https://ClinicalTrials.gov/show/NCT02442414"
2885,"NCT01723306","Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas","Suspended","No Results Available","Metastatic Cancers","Genetic: Gene Modified T Cells","Roger Williams Medical Center","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","48","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","306-04","November 1, 2012","October 2012","August 2017","June 10, 2016","June 2016","No Study Results Posted","null","October 2016","Efficacy|Safety","https://ClinicalTrials.gov/show/NCT01723306"
2886,"NCT02416466","CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases","Recruiting","No Results Available","Liver Metastases","Biological: anti-CEA CAR-T cells|Device: Sir-Spheres","Roger Williams Medical Center|Sirtex Medical","Both","18 Years and older   (Adult, Senior)","Phase 1","6","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","383-74","March 30, 2015","April 2015","December 2016","March 31, 2016","March 2016","No Study Results Posted","HITM-SIR","September 2016","Safety of CAR-T cell hepatic artery infusions in combination with Sir-Spheres as Measured by Number of Participants with Adverse Events|Treatment response (Liver tumor response by MRI, PET, CEA level, and biopsy)|Serum cytokine levels|CAR-T detection in liver tumors, normal liver, and extrahepatic sites","https://ClinicalTrials.gov/show/NCT02416466"
2887,"NCT02217085","Colorectal Polyp Resection Adequacy","Recruiting","No Results Available","Polyp Resection Adequacy.","","Rush University Medical Center","Both","40 Years to 80 Years   (Adult, Senior)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RSA-RTSC 2014","July 14, 2014","May 2014","December 2016","October 26, 2015","October 2015","No Study Results Posted","null","August 2016","The incomplete resection rates in polyps from Group 1 (clear margins) versus Group 2 (positive margins).","https://ClinicalTrials.gov/show/NCT02217085"
2888,"NCT00739453","A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)","Completed","No Results Available","Advanced Solid Tumors","Drug: OSI-906|Drug: erlotinib","Astellas Pharma Inc","Both","18 Years and older   (Adult, Senior)","Phase 1","95","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSI-906-103|2008-001743-20","August 19, 2008","October 2008","December 2011","December 21, 2011","December 2011","No Study Results Posted","null","August 2011","Determine the maximum tolerated dose (MTD) and recommended phase 2 dose of OSI-906 and erlotinib|Safety profile, Pharmacokinetic profile, pharmacodynamic activity, Preliminary antitumor activity","https://ClinicalTrials.gov/show/NCT00739453"
2889,"NCT00514306","Study of Intermittent OSI-906 Dosing","Completed","No Results Available","Advanced Solid Tumors","Drug: OSI-906","Astellas Pharma Inc","Both","18 Years and older   (Adult, Senior)","Phase 1","79","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSI-906-102|2006-005938-20","August 7, 2007","June 2007","December 2010","September 12, 2011","September 2011","No Study Results Posted","null","December 2010","Determine the maximum tolerated dose (MTD) for each of 3 intermittent schedules and establish a recommended phase 2 dose of OSI-906|Safety profile, Pharmacokinetic profile, Pharmacodynamic relationships Preliminary antitumor activity","https://ClinicalTrials.gov/show/NCT00514306"
2890,"NCT00514007","Study of Continuous OSI-906 Dosing","Completed","No Results Available","Advanced Solid Tumors","Drug: OSI-906","Astellas Pharma Inc","Both","18 Years and older   (Adult, Senior)","Phase 1","95","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSI-906-101|2006-005937-39","August 7, 2007","December 2006","March 2012","April 16, 2012","April 2012","No Study Results Posted","null","March 2012","Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of oral OSI-906|Safety profile; Pharmacokinetic (PK) profile; Pharmacodynamic relationships and preliminary antitumor activity","https://ClinicalTrials.gov/show/NCT00514007"
2891,"NCT02850536","CAR-T Hepatic Artery Infusions for CEA-Expressing Liver Metastases","Not yet recruiting","No Results Available","Liver Metastases","Biological: anti-CEA CAR-T cells","Roger Williams Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1","5","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","350-74","July 14, 2016","August 2016","August 2017","July 29, 2016","July 2016","No Study Results Posted","HITM-SURE","August 2017","Safety of CAR-T cell hepatic artery infusions delivered using the Surefire Infusion System (SIS) as Measured by Number of Participants with Adverse Events|Radiographic treatment response by MRI|Radiographic treatment response by PET|CAR-T detection in liver tumors|CAR-T detection in normal liver tissue|CAR-T detection in extrahepatic sites|Serum Cytokine Levels|CEA level|Tumor biopsy","https://ClinicalTrials.gov/show/NCT02850536"
2892,"NCT00833131","The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Radiation: Short course of radiotherapy|Radiation: Radiochemotherapy","Polish Colorectal Cancer Study Group|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Cracow|Poznan University of Medical Sciences|Medical University of Lublin","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","540","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PGBRJG0109","January 29, 2009","November 2008","November 2015","April 14, 2010","April 2010","No Study Results Posted","null","November 2012","The rate of patients with R0 resection|Overall long-term survival|Progression-free long-term survival|The rate of local failures|The rate of distant metastases|The rate of early toxicity of neoadjuvant treatment according to the NCI CTCAE (version 3.0)|The rate of postoperative complications|The rate of late toxicity according to the RTOG/EORTC scale|The rate of complete pathological response","https://ClinicalTrials.gov/show/NCT00833131"
2893,"NCT00738790","Preoperative Radiotherapy and Local Excision in Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Radiation: Short course of radiotherapy|Radiation: Radiochemotherapy","Polish Colorectal Cancer Study Group|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Poznan University of Medical Sciences|Medical University of Lublin","Both","18 Years and older   (Adult, Senior)","Phase 3","102","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PGBRJG0108|KBN0655/P05/2005/28","August 19, 2008","November 2003","November 2013","April 14, 2010","April 2010","No Study Results Posted","null","November 2010","The rate of patients with downstaging after radiotherapy to pathological complete response or ypT1 disease with negative margins.|The rate of local control, overall survival and disease-free survival and toxicity.","https://ClinicalTrials.gov/show/NCT00738790"
2894,"NCT01607827","Colorectal Polypectomy Upon Insertion And Withdrawal Or Upon Withdrawal Only?","Completed","No Results Available","Colorectal Polyps","Procedure: Polyp removal upon insertion and withdrawal|Procedure: Polyp removal upon withdrawal only","University of Zurich","Both","18 Years and older   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","EK-1066","May 24, 2012","April 2004","April 2007","June 18, 2012","June 2012","No Study Results Posted","null","March 2007","Polyp detection","https://ClinicalTrials.gov/show/NCT01607827"
2895,"NCT01938027","The Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision","Completed","No Results Available","Rectal Cancer","Procedure: Transanal total mesorectal excision","National Cancer Center, Korea","Both","20 Years to 80 Years   (Adult, Senior)","","12","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC-TAME|NCC-1210170","September 4, 2013","September 2013","August 2014","March 25, 2015","March 2015","No Study Results Posted","null","August 2014","Total Mesorectal Excision(TME) quality|30-day postoperative complications, No. of harvested LN","https://ClinicalTrials.gov/show/NCT01938027"
2896,"NCT02714374","Safety and Effect of GL-ONC1 Administered IV With or Without Eculizumab Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery","Recruiting","No Results Available","Solid Organ Cancers","Biological: GL-ONC1|Biological: Eculizumab","Kaitlyn Kelly, MD|Genelux Corporation|University of California, San Diego","Both","18 Years and older   (Adult, Senior)","Phase 1","36","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","151060","March 2, 2016","March 2016","March 2020","June 17, 2016","May 2016","No Study Results Posted","null","March 2018","Number of participants with treatment-related adverse events as defined by CTCAE v4.03.|The presence of GL-ONC1 within malignant tumors by examination of the resected surgical specimen.|The maximum concentration (Cmax) of GL-ONC1 in blood after administration|Level of anti-vaccinia neutralizing antibodies in serum|Amount of lymphocyte infiltration in pre-treatment biopsy and post-treatment resected tumor tissue","https://ClinicalTrials.gov/show/NCT02714374"
2897,"NCT01781403","Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer","Active, not recruiting","Has Results","Rectal Cancer","Drug: Temozolomide","Asan Medical Center","Both","20 Years and older   (Adult, Senior)","Phase 1","22","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML28381","January 21, 2013","May 2013","March 2017","June 30, 2016","June 2016","May 17, 2016","null","December 2016","Maximum Tolerated Dose (MTD)|Recommended Dose (RD)|Pathological Complete Response","https://ClinicalTrials.gov/show/NCT01781403"
2898,"NCT01181739","Computed Tomography (CT) Colonography Versus Optical Colonoscopy","Recruiting","No Results Available","Colonic Neoplasia","","University of British Columbia|Canadian Society of Intestinal Research","Both","19 Years to 65 Years   (Adult)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","H08-00776","August 11, 2010","October 2008","December 2013","April 9, 2013","April 2013","No Study Results Posted","null","December 2013","CT colonography","https://ClinicalTrials.gov/show/NCT01181739"
2899,"NCT00050635","STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea","Completed","No Results Available","Neoplasms|Diarrhea","Drug: Sandostatin LAR Depot","Novartis Pharmaceuticals|Quintiles, Inc.|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 4","150","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CSMS995AUS38|STOP Trial","December 17, 2002","December 2002","July 2003","November 18, 2009","November 2009","No Study Results Posted","null","null","Change from baseline and at 6 months in the proportion of patients with NCI Grades 3 and/or 4 diarrhea during chemotherapy","https://ClinicalTrials.gov/show/NCT00050635"
2900,"NCT00295035","Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer","Not yet recruiting","No Results Available","Colon Neoplasm","Drug: CELECOXIB|Drug: CURCUMIN","Tel-Aviv Sourasky Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 3","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment","tasmc-05-na-05160-ctil","February 21, 2006","March 2006","March 2007","February 21, 2006","February 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00295035"
2901,"NCT01926444","A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy","Completed","No Results Available","Pain|Cancer|Colonic Diseases","Drug: GIC-1001","gicare Pharma Inc.|JSS Medical Research Inc.|Algorithme Pharma Inc","Both","40 Years to 70 Years   (Adult, Senior)","Phase 2","308","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GIC13-01","August 8, 2013","July 2013","March 2014","August 8, 2016","August 2016","No Study Results Posted","null","March 2014","Measurements of visceral pain, using a 100-mm Visual Analog Scale (VAS)|Time to Caecum|Colonoscopy completion rate (%)|Safety","https://ClinicalTrials.gov/show/NCT01926444"
2902,"NCT02859415","Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases","Recruiting","No Results Available","Esophageal Neoplasms|Lung Neoplasms|Mesothelioma|Thymus Neoplasms|Neoplasms, Germ Cell and Embryonal","Drug: Mithramycin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 100 Years   (Adult, Senior)","Phase 1|Phase 2","100","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","160152|16-C-0152","August 6, 2016","July 2016","August 2028","August 31, 2016","July 2016","No Study Results Posted","null","August 2028","Maximum tolerated dose|Overall response rate","https://ClinicalTrials.gov/show/NCT02859415"
2903,"NCT00888771","Discard:Characterisation of Colonic Polyps in Vivo","Completed","No Results Available","Colorectal Polyps","","Imperial College London","Both","18 Years and older   (Adult, Senior)","","130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","05/Q0405/121/1","April 27, 2009","August 2008","June 2009","February 11, 2016","July 2010","No Study Results Posted","DISCARD","February 2009","Accuracy of polyp characterisation|Change in surveillance interval after formal histopathology","https://ClinicalTrials.gov/show/NCT00888771"
2904,"NCT00201331","Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer","Recruiting","No Results Available","Colonic Diseases|Adenocarcinoma","Drug: leucovorin+5-FU","National Health Research Institutes, Taiwan|Chang Gung Memorial Hospital|Changhua Christian Hospital|China Medical University Hospital|Mackay Memorial Hospital|Chi Mei Medical Hospital|Kaohsiung Veterans General Hospital.|National Cheng-Kung University Hospital|Taichung Veterans General Hospital","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","162","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T1202","September 13, 2005","April 2002","October 2012","December 15, 2005","December 2005","No Study Results Posted","null","null","To compare the DFS and OS of HDFL vs. weekly bolus 5-FU plus high dose LV as adjuvant chemotherapy for N2 colon cancer|1. To evaluate safety and toxicity of both arm|2. To assess the impact of TS overexpression on patients with resectable N2 colon carcinoma.|3. To assess the disease-free survival of patients with high or low TS level of N2 colon cancer, when adjuvant chemotherapy of 5-FU was administered by bolus or continuous infusion .","https://ClinicalTrials.gov/show/NCT00201331"
2905,"NCT02788669","LRP1 and Colon Cancer","Recruiting","No Results Available","Colon Cancer|Adenocarcinoma","","CHU de Reims","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PO15124","May 20, 2016","November 2015","May 2017","June 1, 2016","May 2016","No Study Results Posted","null","May 2017","LRP1 molecular expression","https://ClinicalTrials.gov/show/NCT02788669"
2906,"NCT00126867","Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment","Recruiting","No Results Available","Colon Cancer","","AHS Cancer Control Alberta","Both","18 Years and older   (Adult, Senior)","","104","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GI-05-0049 / 21882","August 3, 2005","May 2005","March 2015","October 2, 2014","October 2014","No Study Results Posted","null","March 2015","","https://ClinicalTrials.gov/show/NCT00126867"
2907,"NCT02261844","Resveratrol and Human Hepatocyte Function in Cancer","Withdrawn","No Results Available","Liver Cancer","Dietary Supplement: Resveratrol|Drug: Placebo","University of Louisville","Both","21 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Basic Science","ResveraCA","May 20, 2014","December 2015","June 2016","June 13, 2016","June 2016","No Study Results Posted","null","June 2016","Improved metabolic profile of liver cells|Decreased cell growth and proliferation|Decreased hepatic inflammation","https://ClinicalTrials.gov/show/NCT02261844"
2908,"NCT02530593","QoLiCOL - Quality of Life in Colon Cancer","Recruiting","No Results Available","Colonic Neoplasm","Behavioral: There is no intervention, only observation","Sahlgrenska University Hospital, Sweden","Both","18 Years and older   (Adult, Senior)","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","QoLiCOL","August 19, 2015","June 2015","June 2020","April 14, 2016","April 2016","No Study Results Posted","QoLiCOL","June 2017","QoL in colon cancer patients|Generate basic descriptive data of the patient population, such as demography, socioeconomic data, disease stage at diagnosis, type of treatment, recurrence and survival|Compare differences in QoL between patients with different tumour levels|Detect differences in QoL in patients over time after colon cancer treatment|Evaluate the effect of complications after colon cancer surgery on the patients socioeconomic situation|Evaluate the effect of coping strategies on QoL after initiated treatment|Describe patient expectations at diagnosis of colon cancer|Identify differences in QoL between patients in different groups regarding gender, age and education level|Analyse how clinical factors like oncologic result of operation, morbidity, recurrence and survival influence QoL|Identify areas of improvement in treatment and patient care|Enable initiation interventional studies when appropriate|Analyse health economy aspects of QoL and morbidity in the patient population","https://ClinicalTrials.gov/show/NCT02530593"
2909,"NCT00601172","A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.","Completed","No Results Available","Nausea and Vomiting|Nausea and Vomiting, Chemotherapy-Induced","Drug: Casopitant|Drug: Dexamethasone and Ondansetron|Drug: Placebo","GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 3","710","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","NKV110721","January 15, 2008","March 2008","April 2009","January 4, 2013","March 2011","No Study Results Posted","null","April 2009","Complete response (no vomiting and no use of rescue medication) assessed via subject diary completed during cycle 1, that records vomiting and the use of rescue medication.|Complete response during cycle 2.|The proportion of subjects who achieve a complete response in the acute and delayed phases of Cycle 1.|Assessed in the overall, acute and delayed phases of Cycle 1:|Maximum nausea score, assessed by a Visual Analogue Scale (VAS). • The proportion of subjects who receive rescue medication. • The proportion of subjects who vomit/retch.|The proportion of subjects reporting significant nausea, defined as a maximum nausea score ≥ 25 mm on the VAS. • The proportion of subjects reporting nausea, defined as a maximum nausea score ≥ 5 mm on the VAS.|The proportion of subjects achieving complete protection, defined as complete responders who had no significant nausea.|The proportion of subjects achieving total control, defined as complete responders who had no nausea. • Time to first anti-emetic rescue medication. • Time to first emetic event.|Time to event is defined as the time elapsed from the start of the oxaliplatin infusion to the first event.|If a subject withdraws prematurely or dies during the first 120 hours, then the time of withdrawal or death will be considered to be their time to first event, and will be censored.|Health Outcomes Endpoints assessed in Cycle 1: • The impact on subjects' daily life activities in the overall phase, as assessed by the FLIE questionnaire.|Severity of nausea in the overall, acute, and delayed phases assessed by a categorical scale.|PK Endpoints assessed in Cycle 1 (subset of subjects only)|Single-dose pharmacokinetic parameters: AUC(0-∞), AUC(0-t), Cmax, tmax, t1/2 for casopitant and metabolites GSK525060, GSK517142 and GSK631832; and CL and Vdss for casopitant only.","https://ClinicalTrials.gov/show/NCT00601172"
2910,"NCT02377232","Simultaneous Improvement in Colon Cancer Screening Rates and Patient-Centered Care","Recruiting","No Results Available","Colon Cancer","Behavioral: Decision Aid for Colon Cancer Screening|Behavioral: Usual Care Outreach for Colon Cancer Screening","University of Colorado, Denver","Both","50 Years to 75 Years   (Adult, Senior)","","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","14-1976","February 25, 2015","February 2015","null","March 18, 2016","March 2016","No Study Results Posted","CRCSreening","November 2016","Colon Cancer Screening Intent|Colon Cancer Screening Completed","https://ClinicalTrials.gov/show/NCT02377232"
2911,"NCT00942383","Freehand Ultrasound Elasticity Imaging in Liver Surgery","Recruiting","No Results Available","Liver Tumors","Device: IOUS - Siemens Anteras","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","","40","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","J0765|NA_00011327","July 17, 2009","September 2007","September 2013","August 5, 2011","August 2011","No Study Results Posted","IOUS","September 2011","Comparison of transverse ablation diameter between intraoperative ultrasound elasticity imaging (USEI) and postoperative cross-sectional imaging (CT or MRI).|Comparison of ablation volume between ultrasound elasticity imaging (USEI) and CT/MRI.|Correlation between ""in vivo"" versus phantom tumor size to validate the development of guidance systems combined with appropriate visualization and planning software for ablative therapy.|Feasibility of image acquisition using Siemens Anteras clinical free-hand system.|Feasibility of image processing and image segmentation using this clinical free-hand system.","https://ClinicalTrials.gov/show/NCT00942383"
2912,"NCT02786602","LRP1 Methylation and Colon Cancer","Withdrawn","No Results Available","Colon Cancer","Genetic: pyrosequencing","CHU de Reims","Both","18 Years and older   (Adult, Senior)","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PA16046","May 26, 2016","May 2016","null","June 2, 2016","May 2016","No Study Results Posted","null","November 2016","Clinical characteristics (age, sex, tumor location) compared between LRP1 high and low methylation groups.","https://ClinicalTrials.gov/show/NCT02786602"
2913,"NCT01522677","A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer","Recruiting","No Results Available","Colon Cancer","Drug: PDT with 5-ALA radiosensitization","Holcombe, Randall F., M.D.|University of California, Irvine|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","42","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","108643|1R21CA153594","January 26, 2012","January 2012","December 2013","January 31, 2012","January 2012","No Study Results Posted","null","December 2013","Efficacy|Safety|Quality of Life|Sustained immunity","https://ClinicalTrials.gov/show/NCT01522677"
2914,"NCT00978107","Trial of TG4023 Combined With Flucytosine in Liver Tumors","Completed","No Results Available","Hepatocellular Carcinoma","Biological: MVA-FCU1, flucytosine","Transgene","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TG4023.01|Eudra CT 2008-005024-90","September 15, 2009","September 2009","September 2011","July 15, 2014","July 2014","No Study Results Posted","null","September 2011","Maximal tolerated dose|Tumor response of injected and non-injected lesions Viral dissemination Proof of concept: 5-FU concentration in plasma and in tumors","https://ClinicalTrials.gov/show/NCT00978107"
2915,"NCT00131599","Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer","Active, not recruiting","No Results Available","Colon Cancer","Drug: 5FU/LV","AHS Cancer Control Alberta","Both","18 Years and older   (Adult, Senior)","","104","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GI-05-0021","August 17, 2005","August 2002","August 2015","October 1, 2014","October 2014","No Study Results Posted","null","August 2015","","https://ClinicalTrials.gov/show/NCT00131599"
2916,"NCT01990040","A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome","Recruiting","No Results Available","Short Bowel Syndrome","","Shire","Both","Child, Adult, Senior","","1310","Industry","Observational","Time Perspective: Prospective","TED-R13-002","November 11, 2013","June 2014","December 2029","May 9, 2016","May 2016","No Study Results Posted","null","December 2028","Occurrence of colorectal cancer in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting|Occurrence of other malignancy in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting|Actual volume change in parenteral support in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting|Occurrence of benign neoplasia of the gastrointestinal tract, hepatobiliary system, and pancreas in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting|Occurrence of colorectal polyps in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting|Occurrence of intestinal obstruction in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting|Occurrence of pancreatic and biliary disease in patients with short bowel syndrome who who are treated with teduglutide in a routine clinical setting|Occurrence of heart failure and other manifestations of volume overload in patients with short bowel syndrome who who are treated with teduglutide in a routine clinical setting|Occurrence of allergic/hypersensitivity reaction to teduglutide in patients with short bowel syndrome who who are treated with teduglutide in a routine clinical setting|Percentage volume change in parenteral support in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting|Occurrence of other long-term safety outcomes in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting","https://ClinicalTrials.gov/show/NCT01990040"
2917,"NCT01688557","Trial on Innovative Technologies in Colonoscopy","Recruiting","No Results Available","Polyps|Neoplasms|Inflammatory Bowel Disease","Device: Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|Device: Conventional colonoscopy (Olympus CF-H180DL)","Jagiellonian University|Specialist Diagnostic and Therapeutic Center MEDICINA","Both","40 Years to 65 Years   (Adult)","","600","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","Innovations in colonoscopy","September 16, 2012","September 2012","December 2016","July 31, 2016","July 2016","No Study Results Posted","RCT-IC","December 2016","Diagnostic accuracy of innovative colonoscopy|Total examination time|Coecal intubation time|Pain intensity (VAS scale)","https://ClinicalTrials.gov/show/NCT01688557"
2918,"NCT02460822","Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management","Completed","No Results Available","Colon Cancer|Rectal Cancer","Device: MyChemoCare iPad application","University of Michigan|McKesson Foundation","Both","18 Years to 80 Years   (Adult, Senior)","","16","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","12-PAF07680","October 22, 2014","October 2014","November 2015","December 22, 2015","December 2015","No Study Results Posted","null","November 2015","Patient retention and engagement with the MyChemoCare application|Patient satisfaction and usability of the MyChemoCare application|Physician compliance to study protocol|Mastery of cancer and chemotherapy symptoms|Symptom burden|Quality of Life","https://ClinicalTrials.gov/show/NCT02460822"
2919,"NCT02906969","Colonoscopy Educational Video Upon Inner City Population","Completed","No Results Available","Other Surgical Procedures","Other: Colonoscopy Educational Video|Other: Placebo Educational Video","Drexel University","Both","18 Years to 65 Years   (Adult)","","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)","1203000992","June 13, 2016","March 2012","March 2013","September 15, 2016","September 2016","No Study Results Posted","null","March 2013","Primary outcome improvement in adequate bowel preparations|Comprehension of colonoscopy/colorectal cancer screening","https://ClinicalTrials.gov/show/NCT02906969"
2920,"NCT00927485","Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)","Recruiting","No Results Available","Familial Adenomatous Polyposis","Drug: Calcumin (Curcumin)|Other: Risk Factor Questionnaire|Other: Blood samples|Other: Biopsies (Sigmoidoscopy)|Other: Biopsies (Upper endoscopy)","University of Puerto Rico","Both","21 Years to 85 Years   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","Protocol A2210108-UPR","June 24, 2009","November 2007","June 2017","May 10, 2016","May 2016","No Study Results Posted","null","May 2017","To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in patients with FAP.","https://ClinicalTrials.gov/show/NCT00927485"
2921,"NCT01507103","Tecemotide (L-BLP25) in Rectal Cancer","Completed","Has Results","Rectal Cancer","Biological: Tecemotide (L-BLP25)|Drug: cyclophosphamide (CPA)|Other: Chemoradiotherapy","Merck KGaA","Both","18 Years and older   (Adult, Senior)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR063325-013|2011-000847-25","January 6, 2012","February 2012","June 2014","April 26, 2016","April 2016","September 21, 2015","SPRINT","June 2014","Change From Baseline in Tumor Immune Response Evaluated by Immunohistochemical (IHC) Analysis of Tumor Infiltrating Lymphocytes (TILs) at Week 14 (Post-surgery)|Immunological Response to Treatment in Relation to Microsatellite Instability (MSI) Status: Number of Subjects Per MSI Category|Change From Baseline in Interferon (IFN)-Gamma Secretion of Mononuclear Cells in Response to MUC1 by Enzyme-linked Immunosorbent Spot (ELISpot) at Post-baseline|Change From Baseline in IFN-gamma Secretion of Mononuclear Cells in Response to Carcinoembryonic Antigen (CEA) by ELISpot at Post-baseline|Change From Baseline in Peritumoral Immune Response at Week 14 (Post-surgery)|Change From Baseline in Immunological Response in Peripheral Blood at Week 18 (Follow-up / end-of Trial)","https://ClinicalTrials.gov/show/NCT01507103"
2922,"NCT00282386","A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)","Completed","No Results Available","Colorectal Adenoma","Drug: MK0966; Rofecoxib / Duration of Treatment: 156 weeks|Drug: Placebo/ Duration of Treatment: 156 weeks","Merck Sharp & Dohme Corp.","Both","40 Years and older   (Adult, Senior)","Phase 3","2586","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","0966-122|2006_005","January 24, 2006","December 1999","September 2004","September 15, 2015","September 2015","No Study Results Posted","null","September 2004","Cumulative colorectal adenoma recurrence during treatment in patients with an increased risk to develop colorectal cancer.|Cumulative colorectal adenoma recurrence during treatment in patients with a history of colorectal adenoma|Cumulative colorectal adenoma recurrence during treatment in all patients|To evaluate safety & tolerability of rofecoxib","https://ClinicalTrials.gov/show/NCT00282386"
2923,"NCT00302718","Financial Incentives to Translate ALLHAT Into Practice: A Randomized Trial","Completed","Has Results","Hypertension","Behavioral: Physician-level financial incentives|Behavioral: Practice-level financial incentives|Behavioral: Physician- and practice-level financial incentives","VA Office of Research and Development|National Heart, Lung, and Blood Institute (NHLBI)","Both","Child, Adult, Senior","","83","U.S. Fed|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","IIR 04-349|R01HL079173","March 10, 2006","February 2007","September 2012","April 6, 2015","October 2014","November 21, 2014","null","October 2011","Proportion of the Physicians' Patients With Blood Pressure Control or Appropriate Response to Uncontrolled Blood Pressure|Proportion of Physicians' Patients With Blood Pressure Control or Appropriate Response to Uncontrolled Blood Pressure|Proportion of Physicians' Patients Prescribed Guideline-recommended Antihypertensive Medications|Colorectal Cancer (CRC) Screening, Low-density Lipoprotein (LDL) Cholesterol Levels, Hemoglobin (Hb) A1c Levels, and Beta Blocker Use","https://ClinicalTrials.gov/show/NCT00302718"
2924,"NCT02137356","Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms","Radiation: standard dose pelvic radiation therapy|Drug: standard dose capecitabine|Drug: dose-escalated selinexor treatment","Sheba Medical Center|Karyopharm Therapeutics, Inc","Both","18 Years and older   (Adult, Senior)","Phase 1","28","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SHEBA-14-1061-YL-CTIL","May 1, 2014","December 2014","September 2017","September 2, 2015","September 2015","No Study Results Posted","null","June 2017","Number of patients with adverse events|Number of patients whose tumors demonstrate pathological complete response at resection","https://ClinicalTrials.gov/show/NCT02137356"
2925,"NCT01919541","Mechanistic Prehabilitation","Not yet recruiting","No Results Available","Colon Cancer|Rectal Cancer","Other: Prehabilitation|Device: hyperinsulinemic euglycemic isoaminoacid clamp|Device: hyperinsulinemic euglycemic hyperaminoacid clamp|Dietary Supplement: whey protein supplementation|Other: Prehabilitation","Franco Carli|McGill University Health Center","Both","65 Years and older   (Adult, Senior)","","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","13-127-GEN","July 31, 2013","December 2016","December 2016","September 21, 2015","September 2015","No Study Results Posted","null","December 2016","Protein Synthesis","https://ClinicalTrials.gov/show/NCT01919541"
2926,"NCT02354560","Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version","Not yet recruiting","No Results Available","FAP-Familial Adenomatous Polyposis","Drug: Erythromycin","michal roll|Tel-Aviv Sourasky Medical Center","Both","10 Years to 17 Years   (Child)","Phase 4","15","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0377-14-TLV","January 21, 2015","June 2015","December 2017","January 29, 2015","January 2015","No Study Results Posted","null","December 2017","Evaluation of changes in number of adenomas measured by upper endoscopy|Evaluation of changes in size of adenomas measured by lower endoscopy|Evaluation of changes in size of desmoid tumors","https://ClinicalTrials.gov/show/NCT02354560"
2927,"NCT00611858","Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer","Terminated","No Results Available","Rectal Cancer","Drug: Cetuximab|Drug: 5-Fluorouracil|Radiation: External Beam Pelvis Radiation Therapy","Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 2","13","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-297|BMS CA225302","January 29, 2008","January 2008","July 2016","January 20, 2016","January 2016","No Study Results Posted","null","July 2016","Determine the pathological complete response rate of cetuximab with standard 5-FU and radiation as neoadjuvant therapy in patients with stage II/III rectal cancer.|Determine complete resection rate, local recurrence rate, distance recurrence rate, disease free survival and overall survival in this patient population with this treatment.|Characterize toxicity profile of neoadjuvant therapy with cetuximab, 5-FU and radiation in this patient population.","https://ClinicalTrials.gov/show/NCT00611858"
2928,"NCT01929499","Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer","Not yet recruiting","No Results Available","Colonic Neoplasms","Biological: cytokine-induced killer cells","Yanjuan Zhu|Guangdong Provincial Hospital of Traditional Chinese Medicine","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","210","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CIKCC","August 20, 2013","September 2013","August 2019","August 27, 2013","August 2013","No Study Results Posted","CIKCC","August 2016","DFS (Disease free survival)|OS (overall survival)|Side effect|T lymphocyte subset|QoL (quality of life)","https://ClinicalTrials.gov/show/NCT01929499"
2929,"NCT01675934","Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes","Withdrawn","No Results Available","Colonic Neoplasms","Procedure: Retroflexion with the adult colonoscope.|Procedure: Retroflexion with the pediatric colonoscope.","Medical College of Wisconsin","Both","18 Years to 100 Years   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","PRO00017208","August 28, 2012","February 2012","May 2013","January 6, 2016","January 2016","No Study Results Posted","null","May 2013","Percentage of cases in which right-sided retroflexion is successful with the adult and pediatric colonoscopes.|Adenoma detection rate in forward and retroflexed views.|Reasons for failure of retroflexion.","https://ClinicalTrials.gov/show/NCT01675934"
2930,"NCT00216086","Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer","Terminated","Has Results","Rectal Cancer","Drug: Capecitabine|Drug: Irinotecan|Procedure: EUS|Drug: Neoadjuvant Chemotherapy|Procedure: Preoperative Radiation|Procedure: Surgery|Procedure: Adjuvant Chemotherapy","Gabi Chiorean, MD|Pfizer|Roche Pharma AG|Walther Cancer Institute|Hoosier Cancer Research Network","Both","18 Years and older   (Adult, Senior)","Phase 2","22","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HOG GI03-53","September 9, 2005","May 2005","May 2008","April 27, 2016","April 2016","January 5, 2016","null","May 2008","Pathological Complete Response (pCR) Rate|Local and Distant Disease Recurrence Rates|Rate of Clinical Response|Disease-Free Survival","https://ClinicalTrials.gov/show/NCT00216086"
2931,"NCT02371304","Rectal Preserving Treatment for Early Rectal Cancer. A Multi-centred Randomised Trial of Radical Surgery Versus Adjuvant Chemoradiotherapy After Local Excision for Early Rectal Cancers","Not yet recruiting","No Results Available","Rectal Cancer","Radiation: Adjuvant chemoradiotherapy|Procedure: Additional TME surgery|Drug: capecitabine","VU University Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 3","302","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","NL50364.029","February 18, 2015","August 2015","January 2022","February 24, 2015","February 2015","No Study Results Posted","TESAR","June 2020","Recurrence free at 3 year follow-up|Treatment related morbidity","https://ClinicalTrials.gov/show/NCT02371304"
2932,"NCT00113230","Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer","Completed","Has Results","Rectal Cancer","Drug: Avastin (Bevacizumab, RHUMAB VEGF)|Drug: Capecitabine|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0832","June 6, 2005","February 2005","January 2009","July 31, 2012","July 2012","April 17, 2009","null","January 2009","Pathologic Local Tumor Response","https://ClinicalTrials.gov/show/NCT00113230"
2933,"NCT01077596","Carcinogenicity Study of Bupropion","Completed","Has Results","Depressive Disorder|Cancer","Drug: Regular bupropion use|Drug: Regular SSRI (Selective serotonin reuptake inhibitors) use|Drug: Regular TCA (Tricyclic antidepressants) use|Drug: Regular use of any other antidepressant","GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","","50430","Industry","Observational","Observational Model: Case Control|Time Perspective: Retrospective","111982|EPI40463|WEUKSTV1113","February 25, 2010","June 2008","March 2010","June 2, 2011","June 2011","January 21, 2011","null","March 2010","Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant|Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant|Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant|Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant|Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant|Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant|Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant","https://ClinicalTrials.gov/show/NCT01077596"
2934,"NCT00195260","Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors","Completed","Has Results","Neoplasms","Drug: bosutinib|Drug: bosutinib|Drug: bosutinib|Drug: bosutinib","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","151","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3160A1-100|B1871012","September 12, 2005","October 2004","November 2007","January 3, 2013","January 2013","October 4, 2012","null","November 2007","Number of Participants With Dose-limiting Toxicities (DLT) in Part 1|Number of Participants With Adverse Events (AEs) by Seriousness|Duration of Most Frequently Observed Adverse Events (AEs)|Number of Participants With Best Overall Response (BOR) in Part 1|Number of Participants With Best Overall Response (BOR) in Part 2|Maximum Tolerated Dose (MTD) in Part 1|Maximum Tolerated Dose (MTD) for Prolonged Use|Number of Participants With Change From Baseline in Laboratory Test Results|Number of Participants With Change From Baseline in Electrocardiogram (ECG) and Chest X-ray|Concomitant Medications Used for Management of Adverse Events (AEs)|Change From Baseline in Karnofsky Performance Score|Number of Participants With Change From Baseline in Physical Examination|Number of Participants With Change From Baseline in Opthalmologic Examination|Overall Survival (OS) in Part 2|Progression Free Survival (PFS) in Part 2|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Plasma Decay Half-Life (t1/2)|Area Under the Concentration-Time Curve (AUC)","https://ClinicalTrials.gov/show/NCT00195260"
2935,"NCT01094795","Safety Study of Abatacept in Sweden","Active, not recruiting","No Results Available","Rheumatoid Arthritis","","Bristol-Myers Squibb|Karolinska Institutet","Both","Child, Adult, Senior","","100000","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IM101-125","March 24, 2010","March 2011","October 2019","January 26, 2016","January 2016","No Study Results Posted","null","October 2017","Hospitalized infection|Malignancy (total, lymphoma, lung cancer, breast cancer, colorectal cancer, prostate cancer)|Total mortality|Autoimmune disorders (lupus, psoriasis, multiple sclerosis)","https://ClinicalTrials.gov/show/NCT01094795"
2936,"NCT02584400","Tumor Hypoxia With HX4 PET in Several Diseases","Recruiting","No Results Available","Prostatic Neoplasms|Esophageal Neoplasms|Neoplasm Metastases, Brain|Rectal Neoplasms|Brain Neoplasm, Primary","Drug: Injection with the hypoxia tracer [18F]HX4,","Maastricht Radiation Oncology","Both","18 Years and older   (Adult, Senior)","Phase 2","120","Other","Interventional","Endpoint Classification: Bio-availability Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","NL50833.068","October 7, 2015","May 2016","June 2020","May 23, 2016","May 2016","No Study Results Posted","HX4 SD","December 2019","Visualization of tumor hypoxia with [18F] HX4 PET imaging, valuated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT|Quantification of tumor hypoxia with [18F] HX4 PET imaging, evaluated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT|Time between [18F] HX4 uptake with local and locoregional tumor recurrence and survival|Correlation of hypoxia imaging with blood hypoxia markers will be measured by the Pearson or Spearman correlation coefficient|Correlation of hypoxia imaging with tumor tissue biomarkers will be measured by the Pearson or Spearman correlation coefficient|Evaluation of tumor hypoxia changes during treatment by comparison of the PET uptake values in the tumor, measured before and during treatment|Spatial correlation of [18F] HX4-PET with imaging pre-treatment using a correlation coefficient|Spatial correlation of [18F] HX4-PET with imaging three months after treatment using a correlation coefficient","https://ClinicalTrials.gov/show/NCT02584400"
2937,"NCT02243917","A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors","Recruiting","No Results Available","Advanced Solid Tumors","Drug: CB-5083","Cleave Biosciences, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","150","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLC-101","September 15, 2014","October 2014","null","July 20, 2016","May 2016","No Study Results Posted","null","December 2018","Dose Escalation Stage - the dose limiting toxicities (DLTs), using NCI CTCAE v4.0, of oral CB-5083 in subjects with advanced tumors|Dose Escalation Stage - the pharmacokinetic profile (PK) of oral CB-5083 in subjects with advanced solid tumors; parameters include AUC, Cmax, Tmax and T1/2|Dose Expansion Stage - safety and tolerability of oral CB-5083 administered to subjects with RAS mutated metastatic colorectal cancer (mCRC) at the RP2D, using NCI CTCAE v4.0|Dose Expansion Stage - safety and tolerability of CB-5083 in subjects with advanced renal-cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNET) or solid tumors with RAS-MAPK mutations, if such arms are opened per Sponsor, using NCI CTCAE v4.0|Dose Escalation Stage - the pharmacodynamic (PD)effects of CB-5083 through the measurement of polyubiquitin accumulation (PUA) in peripheral blood mononuclear cells (PBMCs)|Dose Expansion Stage - PK and PD profiles of CB-5083; PK parameters to include AUC, Cmax, Tmax and T1/2; PD effects through the measurement of PUA in PBMCs|Dose Expansion Stage - anti tumor activity in certain subjects, using the Response Evaluation Criteria in Solid Tumors (RECIST), v1.1","https://ClinicalTrials.gov/show/NCT02243917"
2938,"NCT01972373","Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent Tracer","Recruiting","No Results Available","Rectal Cancer","Drug: Bevacizumab-IRDye800CW|Device: NIR fluorescence endoscopy","University Medical Center Groningen|Dutch Cancer Society","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","NL43407.042.13|2013-000333-12","October 21, 2013","October 2013","December 2015","December 3, 2014","December 2014","No Study Results Posted","RAPIDO-TRACT","December 2015","Sensitivity of the marker bevacizumab-IRDye800CW|Correlation between bevacizumab-IRDye800CW uptake and pathological response (pCR)|In vivo quantification of the NIR fluorescent signal of bevacizumab-IRDye800CW using the NIR fluorescence endoscope vs. ex vivo VEGF levels in biopsies|To Perform correlate pathways analyses using RNA/DNA/protein analyses to NIR fluorescence data|The ability of optoacoustic endoscopy to detect bevacizumab-IRDye800CW in deeper areas of the tumor|Collection of safety regarding administration of Bevacizumab-IRDye800CW","https://ClinicalTrials.gov/show/NCT01972373"
2939,"NCT01458509","Feasibility and Psychometric Properties of Paper vs. Web vs. Automated Telephone Administration of Patient Reported Outcome Surveys","Active, not recruiting","No Results Available","Colon Cancer|Rectal Cancer","Behavioral: surveys|Behavioral: surveys|Behavioral: surveys|Behavioral: Surveys","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","","328","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","11-101","October 18, 2011","October 2011","October 2016","September 25, 2015","September 2015","No Study Results Posted","null","October 2016","clinically useful to collect patient-reported data|feasibility of electronic PRO assessment|psychometric equivalence|problems people experience","https://ClinicalTrials.gov/show/NCT01458509"
2940,"NCT00339950","Colorectal Neoplasia Screening With Colonoscopy in Asymptomatic Women at Regional Navy/Army Medical Centers: The CONCeRN Trial","Completed","No Results Available","Colorectal Adenoma","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","40 Years to 79 Years   (Adult, Senior)","","1500","NIH","Observational","Time Perspective: Retrospective","999900010|OH00-C-N010","June 19, 2006","February 2000","null","August 27, 2016","August 2016","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00339950"
2941,"NCT01902953","Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)","Active, not recruiting","No Results Available","Colon Cancer|Rectal Cancer","Drug: Lymphoseek and VBD Sln dissection","Maimonides Medical Center","Both","18 Years to 85 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2013-02-05","May 29, 2013","March 2013","June 2016","August 12, 2015","August 2015","No Study Results Posted","null","June 2016","Efficacy|Localization rates, time to localization","https://ClinicalTrials.gov/show/NCT01902953"
2942,"NCT02352259","Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II","Recruiting","No Results Available","Liver Metastases","Procedure: Electrochemotherapy|Device: Cliniporator Vitae®|Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP)","Institute of Oncology Ljubljana|University Medical Centre Ljubljana|University Medical Centre Maribor|University of Ljubljana","Both","18 Years and older   (Adult, Senior)","Phase 2","15","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03-Z/KESOPKR-28","December 17, 2014","September 2013","December 2016","January 27, 2015","January 2015","No Study Results Posted","null","June 2016","Evaluation of safety related to electrochemotherapy (according to CATCE criteria)|Changes is clinical response- Number of Adverse events|Response to treatment (determined by Modified RECIST criteria).|Changes in quality of life","https://ClinicalTrials.gov/show/NCT02352259"
2943,"NCT02534389","Fish Oil Supplement in Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms","Dietary Supplement: omega-3 fish oil","AC Camargo Cancer Center|University of Sao Paulo","Both","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1818/2013","August 17, 2015","January 2015","July 2017","August 25, 2015","August 2015","No Study Results Posted","null","July 2016","Check effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on Glasgow Prognostic Score (GPS).|Check effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on body weight and body composition with regard to skeletal muscle mass, and adipose tissue.|Check for effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on muscle function.|Check for effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on quality of life (QOL).|Check for effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on inflammatory cytokines (IL-6, IL-1, TNF-alpha).|Check for effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on pathological response.","https://ClinicalTrials.gov/show/NCT02534389"
2944,"NCT02856425","Trial Of Pembrolizumab And Nintedanib","Recruiting","No Results Available","Patients With Any Advanced Solid Tumors.","Drug: Nintedanib|Drug: Pembrolizumab","Gustave Roussy, Cancer Campus, Grand Paris","Both","18 Years and older   (Adult, Senior)","Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-004511-21|2015/2329","August 2, 2016","July 2016","July 2021","August 4, 2016","August 2016","No Study Results Posted","PEMBIB","July 2021","MTD of Nintedanib","https://ClinicalTrials.gov/show/NCT02856425"
2945,"NCT02324023","Endoscopic Ultrasound and Contrast Enhancement for Staging and Evaluation of Angiogenesis of Left Sided Colon Cancers","Recruiting","No Results Available","Colonic Neoplasms","Device: Endoscopic ultrasound","Roskilde County Hospital|Herlev Hospital","Both","18 Years and older   (Adult, Senior)","","74","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","H-4-2014-075","November 24, 2014","November 2014","November 2017","December 23, 2014","December 2014","No Study Results Posted","null","November 2016","T-stage in left sided colonic cancer determined by endoscopic ultrasound compared to histological stage|Perfusion in left sided colonic cancer determined by contrast enhanced endoscopic ultrasound compared to histological vascular immunostaining","https://ClinicalTrials.gov/show/NCT02324023"
2946,"NCT02890667","Evaluation of Algorithms to Identify Incident Cancer Cases by Using French Health Administrative Databases","Completed","No Results Available","All Cancer Incidence","Other: Incident cancer","Assistance Publique - Hôpitaux de Paris","Both","up to 90 Years   (Child, Adult, Senior)","","447694","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PHRC-K 14-158","September 1, 2016","May 2015","August 2016","September 6, 2016","August 2016","No Study Results Posted","null","August 2016","All Cancer incidence|Prostate cancer incidence|Breast cancer incidence|Lung cancer incidence|Colorectal cancer incidence","https://ClinicalTrials.gov/show/NCT02890667"
2947,"NCT00845247","The Effect of Case Management in Complex Cancer Pathways","Completed","No Results Available","Colonic Neoplasms|Rectal Neoplasms","Other: Nurse case management","University of Aarhus|Research Unit for General Practice, Aarhus University|Forskningsrådet for Sundhed og Sygdom|Danish Cancer Society|Novo Nordisk A/S|Kvalitets- og efteruddannelsesudvalget for Region Midtjylland","Both","Child, Adult, Senior","","280","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Health Services Research","477 980 567|Datatilsyn J.nr. 2008-41-2932","February 13, 2009","March 2009","January 2012","August 30, 2012","August 2012","No Study Results Posted","null","January 2011","Patient satisfaction with care pathways(questionnaire)|Quality of Life measures(questionnaire)|Use of health care services during ""the secondary care treatment period"", i.e. GPs, emergency department, planned and emergency admission, total length of hospitalisation|GPs' evaluations of continuity of care (questionnaire).|Care process measures in terms of monitoring of data from the National Patient Registry","https://ClinicalTrials.gov/show/NCT00845247"
2948,"NCT02077296","The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer","Completed","No Results Available","Rectal Cancer","","St. Antonius Hospital","Both","18 Years and older   (Adult, Senior)","","34","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL46983.100.13/R13.044","February 26, 2014","March 2014","August 2016","September 8, 2016","September 2016","No Study Results Posted","CYTORECT","August 2016","Plasma and tissue cytokine levels","https://ClinicalTrials.gov/show/NCT02077296"
2949,"NCT02022553","Procedure RACHEL in Complex Treatment of Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer T3-4N0-2M0","Procedure: usual rectal cancer surgery|Procedure: RACHEL","Voronezh N.N. Burdenko State Medical Academy|Voronesh Regional Clinical Hospital #1","Both","15 Years to 75 Years   (Child, Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NNKOR2013","December 19, 2013","February 2006","null","December 27, 2013","December 2013","No Study Results Posted","RACHEL","December 2013","tumor reduction","https://ClinicalTrials.gov/show/NCT02022553"
2950,"NCT01026480","Ileal Pouch-Anal Anastomosis Registry","Recruiting","No Results Available","Ileal Pouch-Anal Anastomosis","","Boston Medical Center","Both","Child, Adult, Senior","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-28518","November 25, 2009","November 2009","December 2050","March 28, 2016","March 2016","No Study Results Posted","IPAA","December 2050","Pouch status: functional pouch or non-functional pouch (diverted or excised)|Quality of life|Health status","https://ClinicalTrials.gov/show/NCT01026480"
2951,"NCT01904968","Impact of Methylation Alterations in Colon Cancer: Epidemiology and Prognosis","Withdrawn","No Results Available","Colon Cancer","","Centre Hospitalier Universitaire Dijon","Both","Child, Adult, Senior","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Piard PHRC K 2011","June 26, 2013","December 2011","null","July 17, 2013","July 2013","No Study Results Posted","null","December 2015","Quality control DNA|Assessment of methylation level|MSI Phenotype evaluation|Mutational status evaluation of BRAF, KRAS and PI3KCA :","https://ClinicalTrials.gov/show/NCT01904968"
2952,"NCT02871960","Surgical Stress and Colorectal Surgery","Active, not recruiting","No Results Available","Surgical Stress and Immune Function","Procedure: Robotic and Laparoscopic Colectomy","Federico II University","Both","50 Years to 90 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RoboticUnina2016","July 21, 2016","July 2016","September 2017","August 15, 2016","August 2016","No Study Results Posted","ESSIMIC","July 2017","interleukin 1|interleukin 6|Tumor necrosis factor alpha|C-reactive protein|fibrinogen|prolactin|cortisol|insulin|glucagon|Adrenocorticotropic hormone|Growth hormone|human leukocyte antigen","https://ClinicalTrials.gov/show/NCT02871960"
2953,"NCT01755585","Irradiation Modulates the Pharmacokinetics of Anticancer Drugs","Enrolling by invitation","No Results Available","Rectal Cancer|Cervical Cancer","","Far Eastern Memorial Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","40","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","FEMH No. 099148-F","December 19, 2012","July 2011","null","January 19, 2014","January 2014","No Study Results Posted","null","December 2015","all cause mortality","https://ClinicalTrials.gov/show/NCT01755585"
2954,"NCT00512993","Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy","Completed","No Results Available","Breast Cancer","Drug: Zoledronic acid","German Breast Group|Austrian Breast & Colorectal Cancer Study Group|Novartis Pharmaceuticals","Female","18 Years and older   (Adult, Senior)","Phase 3","654","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 36|NATAN|ABCSG 29","August 3, 2007","December 2004","November 2013","March 4, 2015","March 2015","No Study Results Posted","NATAN","November 2013","The event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with ""chemo-insensitive"" breast cancer (ypT1-4 and/or ypN1-3) after preoperative anthracycline/taxane containing chemotherapy.|The overall survival in both treatment arms.|The EFS with respect to the interval between surgery and randomization.|The bone-metastasis free-survival in both arms.|The toxicity of and compliance to zoledronic acid.|The predictive value of primary breast tumor response on the effect of postoperative treatment.|The prognostic impact of chemotherapy induced amenorrhea in premenopausal patients.","https://ClinicalTrials.gov/show/NCT00512993"
2955,"NCT02850783","SLN in Colon Cancer Using a Multimodal Tracer","Completed","No Results Available","Sentinel Lymph Node","Procedure: 89Zr-nanocoll and Indocyanine Green","VU University of Amsterdam","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","10","Other","Interventional","Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment","NL47648.029.14","July 22, 2016","March 2015","null","July 29, 2016","July 2016","No Study Results Posted","null","January 2016","Identification rate of SLNM with preoperative PET/CT imaging and intraoperative NIR fluorescence imaging in patients with colon carcinoma.","https://ClinicalTrials.gov/show/NCT02850783"
2956,"NCT01224444","Complete Histologic Resection of Adenomatous Polyps?","Completed","Has Results","Adenomatous Polyps","Other: standard polypectomy snare","White River Junction VAMC|Dartmouth-Hitchcock Medical Center","Both","40 Years to 85 Years   (Adult, Senior)","","269","U.S. Fed|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","DMS-21237","October 19, 2010","May 2008","January 2013","December 30, 2014","December 2014","December 16, 2013","CARE","December 2011","Percent of Incompletely Resected Adenomatous Polyps|Incomplete Adenoma Resection of Small and Large Adenomas","https://ClinicalTrials.gov/show/NCT01224444"
2957,"NCT02134925","Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps","Recruiting","No Results Available","Colorectal Adenoma|Colorectal Adenoma With Severe Dysplasia|Colorectal Tubulovillous Adenoma","Other: Laboratory Biomarker Analysis|Biological: MUC1 Peptide-Poly-ICLC Vaccine|Other: Quality-of-Life Assessment|Other: Saline","National Cancer Institute (NCI)","Both","40 Years to 70 Years   (Adult, Senior)","Phase 2","120","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NCI-2014-01080|HHSN261201200042I|N01-CN-2012-00042|MAY2013-01-01|N01CN00042|P30CA015083","May 7, 2014","June 2014","null","September 20, 2016","September 2016","No Study Results Posted","null","February 2017","Change in anti-MUC1 immunoglobulin G (IgG) levels as determined by enzyme-linked immunosorbent assay (ELISA)|Adenoma recurrence rate assessed using surveillance exams|Booster response|Incidence of adverse events as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Incidence of participant-reported injection site reaction collected using the participant completed Vaccine Report Card|Proportion of patients with at least a 2‐fold increase in the IgG ratio","https://ClinicalTrials.gov/show/NCT02134925"
2958,"NCT01928459","Phase 1b Trial of BGJ398/BYL719 in Solid Tumors","Active, not recruiting","No Results Available","Advanced Solid Tumors,|Metastatic Solid Tumors","Drug: BGJ398|Drug: BYL719","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","61","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CBGJ398X2102","August 21, 2013","October 2013","August 2016","August 16, 2016","August 2016","No Study Results Posted","null","August 2016","Incidence rate of dose limiting toxicities (DLTs) of the combination of BGJ398 with BYL719|Safety and tolerability of BGJ398/BYL719 combination at the recommended dose for expansion (RDE)|Overall response rate|Progression free survival|Time vs. concentration profile of BGJ398 and BYL719","https://ClinicalTrials.gov/show/NCT01928459"
2959,"NCT02505750","Phase III Study Comparing, Efficacy and Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma","Recruiting","No Results Available","Rectal Neoplasms","Radiation: 3D conformal EBRT|Device: Contact X-ray brachytherapy 50 kV|Drug: Capecitabine","Centre Antoine Lacassagne|Centre de Haute Energie|Centre Azuréen de Cancérologie|Hôpital de la Croix-Rousse|Institut Paoli-Calmettes|Hôpital de la Timone|Centre de radiothérapie Bayard|Centre Oncologie Radiothérapie de Mâcon|Centre Leon Berard|Hospices Civils de Lyon|Clinique Charcot|Institut de Cancérologie Lucien Neuwirth|The Clatterbridge Cancer Centre NHS Foundation Trust|Spire Hull and East Riding Hospital|Nottingham University Hospitals NHS Trust|Royal Surrey County Hospital|Uppsala University Hospital|Karolinska Institutet|Aarhus University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","236","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014/14|ID-RCB: 2014-A01851-46","April 21, 2015","March 2015","March 2021","February 2, 2016","February 2016","No Study Results Posted","OPERA","March 2021","Rate of rectum preservation either with local excision or watch and wait strategy after neoadjuvant treatment without non salvageable locally progressive disease at 3 years post treatment, or permanent stoma.|Clinical Complete Response (assessed by digital rectal examination, endoscopy with photos and MRI)|Overall Survival|Disease-free survival|Tumour regression score on the operative specimen","https://ClinicalTrials.gov/show/NCT02505750"
2960,"NCT01124266","Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy","Completed","No Results Available","Polyp|Adenomatous Polyp|Colonoscopy","Procedure: standard of care colonoscopy|Procedure: standard of care colonoscopy","Soon Chun Hyang University|Kangbuk Samsung Hospital|Hanyang University|Dankook University|Incheon St.Mary's Hospital|Kyung Hee University Hospital at Gangdong","Both","50 Years and older   (Adult, Senior)","Phase 4","844","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2010-15","May 14, 2010","May 2010","January 2011","February 16, 2011","May 2010","No Study Results Posted","null","January 2011","adenoma detection rate|subjects with at least one polyp|Subjects with at least one adenoma|total number of polyp|total number of adenoma|Subjects with at least one advanced adenoma or cancer|total number of advanced adenoma or cancer|polyp and adenoma detection rate according to the endoscopists or nurse experience","https://ClinicalTrials.gov/show/NCT01124266"
2961,"NCT00073112","A Study of ABT-751 in Patients With Renal Cell Cancer","Completed","No Results Available","Renal Cell Cancer","Drug: ABT-751","Abbott","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M02-416","November 17, 2003","August 2003","September 2006","November 28, 2007","November 2007","No Study Results Posted","null","null","Objective Response Rate in subjects with RCC|Time to Tumor Progression (TTP)|Survival|Toxicities associated with treatment administration","https://ClinicalTrials.gov/show/NCT00073112"
2962,"NCT01138904","FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)","Completed","No Results Available","Gastric Cancer","Drug: irinotecan, oxaliplatin|Drug: oxaliplatin, irinotecan","Dong-A University Hospital|Pusan National University Yangsan Hospital","Both","20 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","DAUH-AGC-10-1","June 4, 2010","September 2009","September 2013","November 2, 2014","November 2014","No Study Results Posted","null","September 2013","Response rate by RECIST|progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT01138904"
2963,"NCT02829788","Study Comparing the Role of the Laparoscopy Surgical Staging in the Peritoneal Carcinomatosis to Laparotomic Approach","Recruiting","No Results Available","Colorectal Peritoneal Carcinomatosis","Other: Non interventional","Hospices Civils de Lyon","Both","Child, Adult, Senior","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL16_0433","July 6, 2016","November 2015","December 2017","July 11, 2016","July 2016","No Study Results Posted","COELIOCHIP","June 2017","Peritoneal carcinomatosis staging","https://ClinicalTrials.gov/show/NCT02829788"
2964,"NCT02051465","Effectiveness and Safety of the Endoscopic Removal of Large and Flat Colonic Polyps With LumenR RetractorTM","Recruiting","No Results Available","Colonic Adenomatous Polyps","Device: LumenR Retractor|Device: Removal without overtube","Mercy Medical Center","Both","17 Years to 90 Years   (Child, Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MMC 2012-64","January 26, 2014","May 2013","December 2016","September 13, 2016","September 2016","No Study Results Posted","null","December 2016","Percentage of successful en block removal of polyps|Length of time required to remove large and flat colonic polyps|Amount of carbon dioxide (CO2) gas for colonic insufflation used during procedure|Amount of solution used for submucosal injection to lift the polyp|Presence of residual polypoid tissue at the site of polypectomy|Safety assessment based on the number of delayed adverse events and complications|Rate of bleeding during polypectomy|Rate of perforation during polypectomy","https://ClinicalTrials.gov/show/NCT02051465"
2965,"NCT01040832","EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","Completed","Has Results","Squamous Cell Carcinoma of the Head and Neck Cancer","Drug: Cetuximab|Drug: EMD 1201081","EMD Serono","Both","18 Years and older   (Adult, Senior)","Phase 2","107","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 200068-006","December 29, 2009","December 2009","null","July 28, 2014","July 2014","June 24, 2014","null","January 2012","Progression-free Survival (PFS) Time: Independent Read Assessments|Percentage of Participants With Objective Response: Independent Read Assessments|Percentage of Participants With Disease Control: Independent Read Assessments|Overall Survival (OS) Time|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs","https://ClinicalTrials.gov/show/NCT01040832"
2966,"NCT00237276","Experience and Enhancement: Improving Colonoscopic Polyp Detection","Recruiting","No Results Available","Polyps","Procedure: colonoscopy","London North West Healthcare NHS Trust","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","05/CL05/70","October 10, 2005","October 2005","null","September 21, 2007","September 2007","No Study Results Posted","null","null","The difference in adenoma detection rate on video between consultants endoscopist vs. trainee endoscopists who have performed more than 200 endoscopies vs. trainee endospopists who have performed less than 200 endoscopies|For each technique:|differences in adenoma detection rate between endoscopist of varying abilities with and without techniques to highlight polyps. Differences in adenoma detection rate in terms of esperience.","https://ClinicalTrials.gov/show/NCT00237276"
2967,"NCT02651532","Confocal Endomicroscopy Utility (p-CLE) in Irritable Bowel Syndrome","Recruiting","No Results Available","Irritable Bowel Syndrome (IBS)","Device: Confocal Laser Endomicroscopy","Instituto Ecuatoriano de Enfermedades Digestivas","Both","18 Years to 80 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","ENE12016","January 7, 2016","January 2016","January 2018","May 1, 2016","May 2016","No Study Results Posted","null","January 2018","Confocal Laser Endomicroscopy (CLE) utility for diagnosing microscopic inflammation of the mucosa in patients with irritable bowel syndrome (IBS)|Relationship between microscopic inflammation and sex, age and the subtypes of IBS.","https://ClinicalTrials.gov/show/NCT02651532"
2968,"NCT02355379","Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over","Recruiting","No Results Available","Colonic Adenocarcinoma","Drug: LV5FU2 or capectitabine|Drug: FOLFOX4 or XELOX|Other: Observation|Drug: LV5FU2 or capecitabine","Federation Francophone de Cancerologie Digestive","Both","75 Years and older   (Senior)","Phase 3","774","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PRODIGE34-ADAGE","January 26, 2015","January 2015","August 2025","August 2, 2016","August 2016","No Study Results Posted","ADAGE","August 2023","The 3-year disease-free survival|Overal survival|safety: all observed toxicities, graded according to NCI-CTC v4 and the SAE|Determination of geriatric predictive factor","https://ClinicalTrials.gov/show/NCT02355379"
2969,"NCT01330810","Curcumin Pharmacokinetics","Completed","No Results Available","Comparative Multidose Pharmacokinetics","Drug: curcumin","University of North Carolina, Chapel Hill","Both","18 Years to 65 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","10-2243","April 4, 2011","March 2011","April 2012","February 6, 2013","December 2011","No Study Results Posted","null","December 2011","AUC|Cmax|Tmax|Ke|T1/2|Vd|Test of bioequivalence|bioequivalence of tissue curcumin concentration","https://ClinicalTrials.gov/show/NCT01330810"
2970,"NCT00514332","Comparison Between Colorectal Stents and Primary Surgery in Obstructive Colonic Cancer. A Randomized, Controlled Study","Terminated","No Results Available","Colorectal Obstruction|Left Colonic Adenocarcinoma","Procedure: stent","University Hospital, Montpellier|University Hospital, Rouen|University Hospital, Toulouse|University Hospital, Grenoble|Rennes University Hospital|University Hospital, Lille|University Hospital, Angers|University Hospital, Bordeaux","Both","18 Years and older   (Adult, Senior)","","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UF7683","August 8, 2007","December 2002","October 2006","August 8, 2007","August 2007","No Study Results Posted","null","null","number of stoma in each group|mortality in each group|complications|number of procedures|length of stay","https://ClinicalTrials.gov/show/NCT00514332"
2971,"NCT01266187","Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study)","Terminated","No Results Available","Liver Metastasis","Procedure: adjuvant surgery + FOLFOX + cetuximab|Procedure: perioperative/Folfox + cetuximab","RWTH Aachen University","Both","18 Years and older   (Adult, Senior)","","16","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTC-A10-005","December 20, 2010","July 2011","September 2015","September 21, 2015","September 2015","No Study Results Posted","null","September 2015","Clavien score (> grade 1)|Disease free survival|Secondary objectives","https://ClinicalTrials.gov/show/NCT01266187"
2972,"NCT02226185","Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence","Recruiting","No Results Available","Colorectal Adenoma","Drug: Berberine hydrochloride","Shanghai Jiao Tong University School of Medicine","Both","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RJ2014BH","August 23, 2014","December 2014","December 2018","May 26, 2015","May 2015","No Study Results Posted","null","December 2017","The primary objective of this study is to investigate recurrence rates of colorectal adenoma (CRA) after Berberine hydrochloride or placebo intervention.|The incidences of advanced colorectal adenoma or colorectal cancer after Berberine hydrochloride or placebo intervention","https://ClinicalTrials.gov/show/NCT02226185"
2973,"NCT02326727","Influence of Epidural Analgesia on Natural Killer Cell (NK) Activity After Colonic Cancer Surgery","Not yet recruiting","No Results Available","Colonic Neoplasms","Drug: Ropivacaine|Drug: Fentanyl|Drug: Propofol|Drug: Isoflurane|Drug: Nitrous Oxide","Hillel Yaffe Medical Center","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","0095-14-HYMC","December 10, 2014","April 2015","May 2017","December 22, 2014","December 2014","No Study Results Posted","null","April 2017","Count of live and dead target erythroleukemic cells|Plasma concentration of cytokines","https://ClinicalTrials.gov/show/NCT02326727"
2974,"NCT00534053","Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial","Recruiting","No Results Available","Colon Cancer","Other: Mailed Educational Reminder","University of California, San Diego","Both","50 Years and older   (Adult, Senior)","","800","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Screening","070504","September 20, 2007","June 2007","October 2007","September 20, 2007","September 2007","No Study Results Posted","null","null","Our primary outcome is FOBT card return rate|Predictors of Non-compliance to fecal occult blood testing","https://ClinicalTrials.gov/show/NCT00534053"
2975,"NCT01933958","Regorafenib Post-marketing Surveillance in Japan","Recruiting","No Results Available","Gastrointestinal Stromal Tumors","Drug: Regorafenib (Stivarga, BAY73-4506)","Bayer","Both","Child, Adult, Senior","","135","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16732|STIVARGA-GIST-01","August 29, 2013","September 2013","September 2017","September 5, 2016","September 2016","No Study Results Posted","null","September 2017","Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib.|Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.|Number of Patients with serious adverse drug reactions (SADRs) from the first administration of Regorafenib|overall survival (OS)|time to treatment failure (TTF)|tumour response|Integration analysis for safety in drug use investigations (DUIs) for both colorectal cancer and gastrointestinal stromal tumor.","https://ClinicalTrials.gov/show/NCT01933958"
2976,"NCT02193646","Endoscopic Size Assessment of Advanced Adenomatous Polyps","Recruiting","No Results Available","Adenoma Detection Rate Improvement in Screening Colonoscopy","","Rush University Medical Center","Both","40 Years to 80 Years   (Adult, Senior)","","1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","ESA-2014","July 14, 2014","November 2010","September 2016","October 26, 2015","October 2015","No Study Results Posted","null","August 2016","Adenomatous Polyp Detection Rate|Endoscopic Size Assessment Versus Pathological Size Assessment|Retroflexion as an indication of adenoma detection rate in colorectal cancer screening","https://ClinicalTrials.gov/show/NCT02193646"
2977,"NCT02788006","Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .","Recruiting","No Results Available","Colorectal Adenocarcinoma","Drug: Regorafenib 160 mg","Federation Francophone de Cancerologie Digestive","Both","70 Years and older   (Senior)","Phase 2","42","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FFCD 1404 - REGOLD","May 20, 2016","January 2016","May 2018","August 10, 2016","May 2016","No Study Results Posted","REGOLD","December 2017","Tumor control rate","https://ClinicalTrials.gov/show/NCT02788006"
2978,"NCT02221713","The Gut Microbiome in Diverticulitis and Diverticulosis","Not yet recruiting","No Results Available","Diverticulitis|Diverticulosis|Diverticular Disease","","King's College Hospital NHS Trust","Both","18 Years to 90 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","IRAS 163084","August 19, 2014","December 2015","May 2016","September 10, 2015","September 2015","No Study Results Posted","null","April 2016","assessment of gut microbiome","https://ClinicalTrials.gov/show/NCT02221713"
2979,"NCT00684229","Regional Anesthesia in Colon Rectal Surgery","Withdrawn","No Results Available","Colon Cancer","Procedure: Regional anesthesia and analgesia|Drug: general anesthesia followed by opioid analgesia","The Cleveland Clinic","Both","18 Years to 85 Years   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","07-933","May 22, 2008","December 2007","November 2013","September 13, 2016","September 2016","No Study Results Posted","null","November 2013","cancer recurrence|length of post operative hospitalization","https://ClinicalTrials.gov/show/NCT00684229"
2980,"NCT01662284","Study of 124I-NM404 in Advanced Solid Malignancies","Terminated","No Results Available","Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer","Drug: 124I-NM404","University of Wisconsin, Madison|Cellectar Biosciences, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","12","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CO12901|2012-0230","August 3, 2012","July 2012","May 2016","May 16, 2016","May 2016","No Study Results Posted","null","May 2016","Optimal Imaging Parameters|Adverse events|PET comparison","https://ClinicalTrials.gov/show/NCT01662284"
2981,"NCT01639131","Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma","Recruiting","No Results Available","Metastatic Colorectal Adenocarcinoma","Drug: Gemcitabine|Drug: Docetaxel|Drug: Filgrastim or Pegfilgrastim","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1214|Nilo Azad, MD|NA_00069666","July 9, 2012","August 2012","null","May 23, 2016","May 2016","No Study Results Posted","null","August 2018","Response|Progression free survival|Overall survival|CHFR methylation|CHFR methylation II|Global methylation|Quality of life","https://ClinicalTrials.gov/show/NCT01639131"
2982,"NCT00848510","EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases","Completed","Has Results","Colorectal and Ovarian Cancer Patients With Liver Metastases","Biological: EMD 525797","Merck KGaA","Both","18 Years and older   (Adult, Senior)","Phase 1","41","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62242-003|2008-001820-30","February 19, 2009","February 2009","November 2013","November 9, 2015","November 2015","July 24, 2015","null","November 2013","Number of Subjects With Dose Limiting Toxicities (DLTs)|Volume Transfer Coefficient of Contrast Agent Across the Capillary Walls|Blood Plasma Volume and Extravascular/Extracellular Volume|Initial Area Under the DCE-MRI Contrast Agent Concentration Time Curve After 60 Seconds (IAUC60)|Whole Tumor Volume and Enhancing Tumor Volume|Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death|Number of Subjects With Best Overall Response, Tumor Response and Clinical Benefit|Number of Subjects With Worsened Post Baseline Shift in ECOG Performance Status Score|Number of Subjects With Positive Binding Abituzumab Antibodies|Progression-Free Survival (PFS) Time","https://ClinicalTrials.gov/show/NCT00848510"
2983,"NCT02090816","Combined Liver and Right Lung Resection for Colorectal Metastases by Means of J-shaped Thoracophrenolaparotomy","Completed","No Results Available","Colon Cancer Liver Metastasis|Multiple Pulmonary Nodules","Procedure: Surgery of liver and lung","University of Milan","Both","18 Years and older   (Adult, Senior)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Liver-lung-001","February 4, 2014","September 2004","December 2013","March 14, 2014","March 2014","No Study Results Posted","null","April 2013","Number of metastases removed|Number of patients that received interventional treatments after surgery|Number of re-operated patients","https://ClinicalTrials.gov/show/NCT02090816"
2984,"NCT02410720","The Effectiveness of a Customized Mobile Application in Colonoscopy Preparation","Completed","No Results Available","Colonoscopy Preparation","Other: Instruction leaflet|Other: Mobile App|Other: Explanation of paper and application instructions|Other: Picoprep solution","American University of Beirut Medical Center","Both","18 Years and older   (Adult, Senior)","","160","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","IM.AS1.35","July 10, 2013","June 2013","July 2015","December 28, 2015","December 2015","No Study Results Posted","null","March 2015","Quality of the preparation using the modified Aronshick scale|Questionnaire for adherence to the assigned diet|Questionnaire for compliance with the prep protocol|Patient satisfaction with the written instructions and mobile application using a visual analogue scale|Questionnaire for ease of use of the mobile App|Questionnaire for patient willingness to take the same preparation in the future if needed","https://ClinicalTrials.gov/show/NCT02410720"
2985,"NCT01646775","The Effect of Epidural Fentanyl on Immune Function","Recruiting","No Results Available","Malignancy","Drug: epidural fentanyl","McGill University Health Center","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","11-186-SDR","July 11, 2012","July 2012","December 2014","June 20, 2014","June 2014","No Study Results Posted","null","October 2014","Natural Killer cell activity.|Visual analogue pain scores|opioid side effects|incidence of infections","https://ClinicalTrials.gov/show/NCT01646775"
2986,"NCT00208793","Calcium and Vitamin D vs Markers of Adenomatous Polyps","Completed","No Results Available","Colorectal Adenomatous Polyps","Dietary Supplement: Calcium and vitamin D3 combined|Drug: Placebo|Dietary Supplement: Calcium|Dietary Supplement: Vitamin D3","Emory University|National Institutes of Health (NIH)|National Cancer Institute (NCI)","Both","30 Years to 74 Years   (Adult, Senior)","Phase 2","92","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","0126-2004|R01CA104637","September 13, 2005","May 2005","February 2013","November 22, 2013","November 2013","No Study Results Posted","CaDvMAP","September 2006","Biomarkers of Risk for Colorectal Neoplasms|Vitamin D metabolites|Circulating inflammation markers","https://ClinicalTrials.gov/show/NCT00208793"
2987,"NCT02812303","Implementation of a Population Health Chronic Disease Management Program","Completed","No Results Available","Diabetes Mellitus|Cardiovascular Diseases|Hypertension","Other: Centralized support for population health management activities","Massachusetts General Hospital","Both","18 Years and older   (Adult, Senior)","","108000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2009P002079","June 20, 2016","July 2014","December 2014","June 21, 2016","June 2016","No Study Results Posted","null","December 2014","Difference in differences in Low density lipoprotein (LDL) goal achievement over the follow-up period comparing PHC to non-PHC practices|Difference in differences in Hemoglobin A1c (HbA1c) goal achievement over the follow-up period comparing PHC and non-PHC practices|Difference in differences in Blood pressure (BP) goal achievement over the follow-up period comparing PHC and non-PHC practices|Difference in differences in proportion of patients completing breast cancer screening over the follow-up period comparing PHC and non-PHC practices|Difference in differences in proportion of patients completing cervical cancer screening over the follow-up period comparing PHC and non-PHC practices|Difference in differences in proportion of patients completing colorectal cancer screening over the follow-up period comparing PHC and non-PHC practices","https://ClinicalTrials.gov/show/NCT02812303"
2988,"NCT01549418","The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin","Not yet recruiting","No Results Available","Gastrointestinal Hemorrhage","Drug: Aspirin (ASA)|Drug: Placebo","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Medical Centre of Postgraduate Education, Poland","Both","40 Years and older   (Adult, Senior)","Phase 4","760","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","ASAPOL","March 6, 2012","September 2012","September 2015","March 8, 2012","March 2012","No Study Results Posted","ASAPOL","September 2015","Clinically significant bleeding after colorectal polypectomy|Proportion of composite cardiovascular events, ending unplanned hospitalization in both groups aspirin and placebo|Proportion of clinically significant delayed bleeding in both groups","https://ClinicalTrials.gov/show/NCT01549418"
2989,"NCT02885142","Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery?","Not yet recruiting","No Results Available","Anal Cancer","Procedure: Local excision for early rectal cancer","Assistance Publique Hopitaux De Marseille","Both","18 Years and older   (Adult, Senior)","","400","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","2016-33|2016-A01363-48","August 26, 2016","November 2016","November 2020","August 26, 2016","August 2016","No Study Results Posted","MUCEM","November 2019","Number of complete excision for TEM compare to number of complete excision for ESD in rectal carcinomas staged usT1N0 and rectal adenomas.","https://ClinicalTrials.gov/show/NCT02885142"
2990,"NCT01881386","Lactate Imaging as a Tumour Biomarker","Recruiting","No Results Available","Cancer","Device: Magnetic Resonance Imaging (MRI)","Institute of Cancer Research, United Kingdom|Cancer Research UK","Both","18 Years to 80 Years   (Adult, Senior)","","90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","13/LO/0536 CCR3939","June 17, 2013","September 2013","null","August 30, 2016","August 2016","No Study Results Posted","null","September 2017","Correlation between changes in MRS lactate measurements at two time points after treatment and clinical response|Reproducibility of MRS lactate measurement","https://ClinicalTrials.gov/show/NCT01881386"
2991,"NCT01483040","PeerScope B System™ Clinical Protocol","Completed","No Results Available","Colon Cancer|Colon Diseases|Colon Polyps|Colon Adenomas","Device: colonoscopy system (PeerScope B System™)","PeerMedical Ltd.","Both","18 Years to 70 Years   (Adult, Senior)","","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","CD-1130","November 22, 2011","September 2011","November 2011","November 7, 2012","November 2012","No Study Results Posted","null","November 2011","The primary endpoint is reaching the cecum of the colon with PeerScope B S","https://ClinicalTrials.gov/show/NCT01483040"
2992,"NCT01503372","FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer","Recruiting","No Results Available","Advanced Gastric Cancer","Drug: Pazopanib|Drug: 5-FU, Oxaliplatin, Leukovorin (FLO)","Charite University, Berlin, Germany","Both","18 Years and older   (Adult, Senior)","Phase 2","75","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PaFLO|2010-024379-15","December 22, 2011","November 2011","May 2015","January 10, 2012","January 2012","No Study Results Posted","PaFLO","May 2014","progression-free survival rate at 6 months|progression-free survival rate at 9 and 12 months|median progression-free survival|response rate|duration of response|toxicity|tolerability|overall survival|time to treatment failure|evaluation of the predictive and prognostic relevance of biomarkers","https://ClinicalTrials.gov/show/NCT01503372"
2993,"NCT00454701","Assessment and Tracking of Long-term Alefacept Safety","Terminated","No Results Available","Psoriasis","Drug: Alefacept exposure","Astellas Pharma Inc","Both","18 Years and older   (Adult, Senior)","Phase 4","1897","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","0485-CL-0001|C-736","March 29, 2007","June 2003","February 2012","December 10, 2013","December 2013","No Study Results Posted","ATLAS","February 2012","To measure the rates of non-Hodgkin's lymphoma (NHL) and infections that require hospitalization occurring in psoriasis patients treated with alefacept|To estimate the rates of lung cancer, breast cancer (female), prostate cancer, colorectal cancer, melanoma and active tuberculosis within a population of patients with psoriasis treated with alefacept.","https://ClinicalTrials.gov/show/NCT00454701"
2994,"NCT02674360","RCT Regarding SDM Online Training and Face-to-face SDM Training","Not yet recruiting","No Results Available","Doctor-Patient-Communication","Behavioral: SDM Training","University Hospital Heidelberg|Universitätsklinikum Hamburg-Eppendorf","Both","18 Years and older   (Adult, Senior)","","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","DKH109956, DKH110010","January 25, 2016","May 2016","November 2017","February 1, 2016","February 2016","No Study Results Posted","null","May 2017","Change from baseline in SDM competence measured by an objective Rating (OPTION)|Change from baseline in SDM competence by subjective standardized patient rating (Dyadic Option)|Change from baseline in SDM competence by subjective standardized patient rating (Patient Perception Scale)|Change from baseline in SDM competence by subjective standardized patient rating (SDM-Q-9)|Change from baseline in SDM competence by subjective physician rating (Dyadic Option)|Change from baseline in SDM competence by subjective physician rating (Physician-Perception-Scale)|Change from baseline in SDM competence by subjective physician rating (SDM-Q-9)|Change from baseline in quality of doctor-patient-interaction by subjective Patient rating (Questionnaire on the Quality of physician-patient interaction)|Change from baseline in quality of doctor-patient-interaction by subjective Physician rating (Questionnaire on the Quality of physician-patient interaction)","https://ClinicalTrials.gov/show/NCT02674360"
2995,"NCT00224679","APACC Study:Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence","Terminated","No Results Available","Colon Adenomas","Drug: Aspirin","Assistance Publique - Hôpitaux de Paris|Société Nationale Française de Gastroentérologie|Ministry of Health, France|Sanofi-Synthelabo","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","300","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","AOM 95176|P951202|RAF 95176","September 19, 2005","March 1997","March 1999","June 4, 2012","September 2006","No Study Results Posted","null","null","Is daily soluble aspirin associated with a reduction in the risk for recurrent adenomas at 1 and 4 years after starting treatment.","https://ClinicalTrials.gov/show/NCT00224679"
2996,"NCT02139579","Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer","Active, not recruiting","No Results Available","Lung, Carcinoma","Drug: Bevacizumab","Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University|Second Affiliated Hospital, Sun Yat-Sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","24","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-FXY-032","May 11, 2014","May 2014","null","May 13, 2014","May 2014","No Study Results Posted","null","December 2015","Response Evaluation Criteria in Solid Tumors(RECIST) 1.1","https://ClinicalTrials.gov/show/NCT02139579"
2997,"NCT02387593","Usefulness of Endocuff in the Adenoma Detection Rate. Comparative Study","Recruiting","No Results Available","Colorectal Canceer","Device: ENDOCUFF","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Both","18 Years and older   (Adult, Senior)","","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","END-1302-14/15-1","March 9, 2015","September 2014","null","March 12, 2015","September 2014","No Study Results Posted","null","April 2015","Adenoma detection rate|Measurement of the polyp detection rate|Cecal intubation rate|ileal intubation rate|Difficulty performing polypectomy|Complications during colonoscopy","https://ClinicalTrials.gov/show/NCT02387593"
2998,"NCT00611507","A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer","Completed","No Results Available","Stomach Neoplasms","Drug: Oxaliplatin, 5-Fluorouracil","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","L_8107","January 28, 2008","November 2002","April 2004","March 24, 2008","March 2008","No Study Results Posted","null","null","Response rate - RECIST criteria (unidimensional)|Progression-free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00611507"
2999,"NCT00723996","Preventive Health Behavior in Women","Active, not recruiting","No Results Available","Colon Cancer","Behavioral: Behavioral Study in Women","University of Michigan","Female","50 Years to 75 Years   (Adult, Senior)","","254","Other","Observational","Time Perspective: Prospective","HUM00048680","July 24, 2008","September 2003","September 2016","May 31, 2016","May 2016","No Study Results Posted","null","September 2016","The primary outcome will be determined through review of medical records or a telephone follow-up 6 months after enrollment","https://ClinicalTrials.gov/show/NCT00723996"
3000,"NCT00034281","Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2","Completed","No Results Available","Breast Neoplasm|Pancreatic Neoplasm|Lung Neoplasm|Ovarian Neoplasm|Renal Neoplasm","Drug: TAK-165","Takeda","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-01-TL-165-001|U1111-1127-6123","April 24, 2002","June 2002","September 2003","January 31, 2012","January 2012","No Study Results Posted","null","September 2003","Dose Limiting Toxicity|Maximum Tolerated Dose|Optimal Dosing for Phase II Studies.|Clinical Pharmacokinetic Profile of TAK-165|Response Evaluation Criteria in Solid Tumors Documentation of Objective Tumor Response.","https://ClinicalTrials.gov/show/NCT00034281"
3001,"NCT01280201","Pazopanib as Single Agent in Advanced NETs","Completed","No Results Available","Advanced/Metastatic Neuroendocrine Tumors","Drug: Pazopanib","Grupo Espanol de Tumores Neuroendocrinos","Both","18 Years and older   (Adult, Senior)","Phase 2","44","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GETNE-1002|2010-020749-28","January 19, 2011","December 2010","November 2015","August 17, 2016","August 2016","No Study Results Posted","null","April 2013","Clinical Benefit Rate at six months|Progression-Free Survival|Radiological Objective Response Rate|Duration of Response (DR)|Time to Tumor Response (TTR)|Safety assessment criteria|Biomarkers assessment","https://ClinicalTrials.gov/show/NCT01280201"
3002,"NCT01855607","Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy","Recruiting","No Results Available","Breast Cancer|Colon Cancer","Other: topical menthol|Other: placebo cream","Columbia University","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","AAAL2664","May 14, 2013","August 2013","July 2016","June 30, 2015","June 2015","No Study Results Posted","null","July 2015","Prevalence of decrease in neuropathic pain|Change in sensory and motor function","https://ClinicalTrials.gov/show/NCT01855607"
3003,"NCT01186601","Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer","Completed","No Results Available","Neoplasms","Drug: PET tracer (BAY94-9392)","Piramal Imaging SA","Both","18 Years to 90 Years   (Adult, Senior)","Phase 1","30","Industry","Interventional","Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","15329","August 20, 2010","December 2010","October 2011","November 11, 2014","November 2014","No Study Results Posted","null","October 2011","Evaluation of the accumulation of BAY94-9392 in primary cancer lesions confirmed by histology.|Evaluation of the accumulation of BAY94-9392 in known or suspected local and/or systemic recurrent cancer lesions and/or lymph node metastasis or distant metastasis.|Standardized uptake value (SUV)|Standardized uptake value ratio (SUVR)|Vital Signs|Laboratory Findings|Electrocardiograms (ECGs)|Adverse Event Collection","https://ClinicalTrials.gov/show/NCT01186601"
3004,"NCT00753415","A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)","Completed","Has Results","Non-Small Cell Lung Carcinoma|Breast Cancer|Melanoma|Upper GI Tract Carcinoma|Colon Carcinoma|Renal Cell Carcinoma|Bladder Carcinoma|Prostate Cancer","Biological: V935|Biological: V934-EP","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1","37","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","V934-002|2008_541","September 15, 2008","August 2008","April 2011","February 26, 2015","February 2015","March 19, 2014","null","April 2011","Number of Participants With Dose-Limiting Toxicity (DLT)|Number of Participants With Adverse Events (AEs)|Number of Participants With Immunologic Response to V934/V935 (Immunologic Response Rate)","https://ClinicalTrials.gov/show/NCT00753415"
3005,"NCT01763307","A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI","Not yet recruiting","No Results Available","Rash Due to Epidermal Growth Factor Receptor Inhibitors","Drug: RECONVAL CREAM|Drug: PLACEBO","Hadassah Medical Organization","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","EGFRI-MER-1a-HMO-CTIL","December 24, 2012","January 2013","December 2014","January 7, 2013","December 2012","No Study Results Posted","EGFRI","January 2014","Potential reduction in skin toxicity by Vitamin K1 cream in metastatic colorectal patients treated with EGFRI","https://ClinicalTrials.gov/show/NCT01763307"
3006,"NCT00658671","A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer","Completed","No Results Available","Advanced Cancer","Drug: ENMD-2076","CASI Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","67","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2076-CL-001","April 11, 2008","April 2008","June 2012","January 26, 2016","January 2016","No Study Results Posted","null","December 2010","Safety and tolerability of ENMD-2076|Plasma PK|Evidence of benefit (tumor response, clinical benefit, or tumor marker improvement, if appropriate)","https://ClinicalTrials.gov/show/NCT00658671"
3007,"NCT01177007","Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors","Active, not recruiting","No Results Available","Liver Neoplasms","Device: TheraSphere, Yttrium-90 glass Microspheres","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J09150, NA_00035790|J09150","August 2, 2010","September 2010","August 2014","August 6, 2014","August 2014","No Study Results Posted","null","August 2014","Time to progression (TTP) of the treated lesion(s) according to RECIST criteria|Time to progression (TTP) of the treated lesion(s) according to EASL criteria|Overall Survival (OS)|Safety as graded by CTCAE version 3.0","https://ClinicalTrials.gov/show/NCT01177007"
3008,"NCT02279433","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b","Recruiting","No Results Available","Solid Tumors","Drug: DS6051b","Daiichi Sankyo Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","70","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DS6051-A-U101","October 15, 2014","September 2014","December 2017","April 20, 2016","April 2016","No Study Results Posted","null","August 2017","Part 1: Number of participants with dose-limiting toxicities|Part 2: tumor response|Composite of plasma exposure parameters of DS-6051a|Changes in QTc interval","https://ClinicalTrials.gov/show/NCT02279433"
3009,"NCT01099527","A Trial of RAD001/Capecitabine in Refractory Gastric Cancer","Completed","No Results Available","Metastatic Gastric Cancer","Drug: Everolimus (RAD001)|Drug: Capecitabine","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","59","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-02-041","April 6, 2010","October 2009","December 2013","December 28, 2015","December 2015","No Study Results Posted","null","August 2013","To determine maximum tolerated dose (MTD) in phase I|To assess response rate in phase II","https://ClinicalTrials.gov/show/NCT01099527"
3010,"NCT02303756","Colonic Capsule Endoscopy (CCE) for Screening of Neoplasm's A Pilot Study","Recruiting","No Results Available","Rectal Bleeding","Device: Pillcam® COLON Capsule","Odense University Hospital","Both","50 Years and older   (Adult, Senior)","","250","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","S-20140141","November 24, 2014","November 2014","September 2015","April 30, 2015","April 2015","No Study Results Posted","null","July 2015","Number of patients with neoplasia","https://ClinicalTrials.gov/show/NCT02303756"
3011,"NCT02466724","Study on the Impact of Education Website on the Quality of Outpatient Bowel Preparation for Colonoscopy","Active, not recruiting","No Results Available","Colon Cancer","Device: Aiddly (Web Site)","University of British Columbia","Both","19 Years and older   (Adult, Senior)","","450","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Health Services Research","H14-02390","May 13, 2015","February 2015","December 2016","June 14, 2016","June 2016","No Study Results Posted","null","May 2016","Patients with Excelent Colonoscopy preparation|Benefit and satisfaction to patients of this method of patient education.|Bowel preparation tolerability with this method of patient education.|Use of web-based educational platform","https://ClinicalTrials.gov/show/NCT02466724"
3012,"NCT01025349","Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Drug: Bevacizumab, docetaxel, cisplatin","Taipei Medical University Hospital","Female","18 Years to 65 Years   (Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TMUH-01-09-09","December 1, 2009","January 2005","September 2009","December 2, 2009","December 2009","No Study Results Posted","null","September 2009","Response Rate|Time to Progression(TTP), Progression free survival, overall survival, safety, Quality of Life","https://ClinicalTrials.gov/show/NCT01025349"
3013,"NCT00403130","Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer|Metastatic Breast Cancer","Drug: Gemcitabine|Drug: Paclitaxel|Drug: Bevacizumab","George Albert Fisher|Genentech, Inc.|Eli Lilly and Company|Stanford University","Female","18 Years and older   (Adult, Senior)","Phase 2","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13761|96052|BRSMTS0007","November 22, 2006","February 2006","December 2010","February 28, 2014","February 2014","No Study Results Posted","null","December 2010","Time to progression will be the primary outcome measure for this trial.|Overall survival and response rates will be secondary outcome measures.|toxicity data will be collected for a comprehensive safety analysis of this regimen in this patient population.","https://ClinicalTrials.gov/show/NCT00403130"
3014,"NCT02313012","Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors","Terminated","No Results Available","Neoplasm Metastasis","Drug: CC-90003","Celgene Corporation","Both","18 Years and older   (Adult, Senior)","Phase 1","19","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CC-90003-ST-001","December 5, 2014","January 2015","May 2016","August 18, 2016","August 2016","No Study Results Posted","null","May 2016","Summary of the adverse events (type, severity, and incidence) related to CC-|Dose Limiting Toxicities of CC-90003|Maximum Tolerated Dose (MTD) of CC-90003|Pharmacokinetics (PK) observed maximum concentration (Cmax)|PK-Area under the plasma concentration time curve (AUC)|PK-Time to maximal plasma concentration (Tmax)|PK- terminal half-life; t1/2|PK-Apparent total body clearance (CL/F)|PK- Apparent Total Volume of Distribution (Vz/F)|Accumulation index of CC-90003|Response Rate based on RECIST 1.1|Duration of Response|Disease Control|Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02313012"
3015,"NCT01123811","Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer","Completed","No Results Available","Adenocarcinoma of Stomach or Esophagogastric Junction","Drug: Cetuximab IF","Johannes Gutenberg University Mainz|AIO-Studien-gGmbH","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GC-CIF-2005","May 7, 2010","May 2006","May 2010","May 12, 2010","March 2006","No Study Results Posted","GC-CIF-2005","May 2010","objective response rate|Progression-free survival","https://ClinicalTrials.gov/show/NCT01123811"
3016,"NCT00512850","Folic Acid in Preventing Colorectal Polyps in Patients With Previous Colorectal Polyps","Active, not recruiting","No Results Available","Adenoma of Large Intestine","Dietary Supplement: Folic acid|Other: Placebo","Brigham and Women's Hospital|National Cancer Institute (NCI)|Dana-Farber/Brigham and Women's Cancer Center","Both","up to 75 Years   (Child, Adult, Senior)","","672","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","BWH-1999-P-001674/10|CDR0000559650|BWH-94-06819|R01CA067883","August 6, 2007","May 1996","January 2020","July 21, 2015","July 2015","No Study Results Posted","null","March 2004","Recurrent colorectal adenoma|recurrent adenoma by location, size, stage, number,","https://ClinicalTrials.gov/show/NCT00512850"
3017,"NCT00398320","Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors","Completed","Has Results","Neuroendocrine Tumors","Drug: Capecitabine|Drug: Oxaliplatin|Drug: Bevacizumab","Pamela L. Kunz|Stanford University","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","END0002|97273","October 31, 2006","November 2006","October 2012","October 15, 2013","October 2013","October 15, 2013","null","October 2012","12-month Progression Free Survival (PFS)|Toxicity by CTCAE Version 3.0|Response Rates|Overall Survival|Biochemical Markers","https://ClinicalTrials.gov/show/NCT00398320"
3018,"NCT01587703","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers","Recruiting","No Results Available","Carcinoma, Midline","Drug: GSK525762","GlaxoSmithKline","Both","16 Years and older   (Child, Adult, Senior)","Phase 1","225","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","115521","April 3, 2012","March 2012","May 2020","September 8, 2016","September 2016","No Study Results Posted","null","May 2018","Overall response rate (RR) by response evaluation criteria in solid tumors (RECIST) 1.1.|Adverse event (AEs), serious adverse event s(SAEs), dose reductions or delays, withdrawals due to toxicities and changes in safety assessments (e.g., laboratory parameters, vital signs, electrocardiograms, cardiotoxicity, gastrointestinal, etc).|Composite of pharmacokinetic (PK) parameters following single oral administration of GSK525762 as amorphous free-base or besylate tablet.|Cmax (maximum observed concentrations) (0, 2, 4, 8, 12, 24, 48 hours post dose), 7 timepoints up to 9 weeks.|AUC (area under concentration-time curve) (0-48 hours post dose); AUC (0-infinity for single dose); AUC (0-tau at steady state).|Changes in cardiac safety including QT interval corrected by Fridericia formula (QTcF) following single and repeat-dose oral administration of GSK525762.|Progression free survival (PFS), time to response, duration of response, overall survival (OS).|Antitumor response assessed by various imaging modalities.","https://ClinicalTrials.gov/show/NCT01587703"
3019,"NCT02901132","Association Between Different Parameters of Nutritional Assessment and Clinical Outcomes in Cancer Patients","Active, not recruiting","No Results Available","Cancer|Postoperative Complications|Sarcopenia","","Federal University of Minas Gerais","Both","18 Years and older   (Adult, Senior)","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FUMinas Gerais","September 6, 2016","March 2013","March 2017","September 9, 2016","September 2016","No Study Results Posted","null","July 2016","Postoperative complications|Survival","https://ClinicalTrials.gov/show/NCT02901132"
3020,"NCT02364895","ColonCancerCheck Mailed Invitations: An Evaluation","Completed","No Results Available","Colorectal Disorders","Other: Males control group: Deferred letter|Other: Males Group 1: Current CCC invitation letter|Other: Males Group 2: New letter with neutral gender content|Other: Males Group 3: New letter with male-specific content|Other: Females control group: Deferred letter|Other: Females Group 1: Current CCC invitation letter|Other: Females Group 2: New letter with neutral gender content","Sunnybrook Health Sciences Centre|Cancer Care Ontario","Both","55 Years to 74 Years   (Adult, Senior)","","75317","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Screening","375-2013","December 19, 2014","November 2013","December 2014","February 10, 2015","February 2015","No Study Results Posted","null","May 2014","fecal occult blood test (FOBT) uptake|FOBT or colonoscopy uptake|Intermediate outcomes","https://ClinicalTrials.gov/show/NCT02364895"
3021,"NCT00407186","Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)","Recruiting","No Results Available","Gastric Cancer","Drug: cisplatin+capecitabine|Radiation: radiotherapy|Drug: epirubicin+cisplatin+capecitabine","Dutch Colorectal Cancer Group|The Netherlands Cancer Institute|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 3","788","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRITICS","December 1, 2006","December 2006","December 2013","August 27, 2011","August 2011","No Study Results Posted","null","June 2013","overall survival|disease-free survival|toxicity|health-related quality of life","https://ClinicalTrials.gov/show/NCT00407186"
3022,"NCT01458093","Large Overuse of Post-polypectomy Surveillance Colonoscopy","Completed","No Results Available","Colonic Polyps|Surveillance|Colonoscopy","Other: colonoscopy","Valduce Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","7081","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SURV_2011","October 18, 2011","July 2010","January 2011","October 20, 2011","October 2011","No Study Results Posted","null","January 2011","Adherence to post-polypectomy surveillance guidelines|Factors associated to surveillance appropriateness","https://ClinicalTrials.gov/show/NCT01458093"
3023,"NCT01182142","Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients","Completed","No Results Available","Metastatic Renal Cell Carcinoma","Drug: Capecitabine","Kidney Cancer Research Bureau","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","51","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRT-06.CAP","August 11, 2010","September 2007","August 2010","August 22, 2010","August 2010","No Study Results Posted","null","September 2009","Overall response rate|Overall survival Progression-free survival","https://ClinicalTrials.gov/show/NCT01182142"
3024,"NCT02863471","Open-label Pilot Phase I / II Study on Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Macroscopically","Recruiting","No Results Available","Adenocarcinomas of the Pancreas","Drug: Gemcitabine","University Hospital Tuebingen","Both","18 Years to 100 Years   (Adult, Senior)","Phase 1|Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PanHIPEC","August 8, 2016","January 2016","October 2017","August 11, 2016","August 2016","No Study Results Posted","PanHIPEC","July 2017","30 days mortality after macroscopically complete Resection ( R0 / R1 ) of an adenocarcinoma of the pancreas in combined with hyperthermic intraperitoneal chemotherapy (HIPEC)|Nausea|Vomiting|Diarrhea|Stomatitis|Hair loss|Neutrophilia|Thrombocytopenia","https://ClinicalTrials.gov/show/NCT02863471"
3025,"NCT02245854","Efficacy and Safety of a New Polypectomy Snare for Cold-polypectomy for Small Colorectal Polyps","Completed","No Results Available","Polyp of Large Intestine|Colonic Polyps|Colon Nos Polypectomy Tubular Adenoma|Complications|Bleeding","Device: Exacto™","Istituto Clinico Humanitas|San Gerardo Hospital|Azienda Ospedaliero Universitaria Maggiore della Carita","Both","18 Years and older   (Adult, Senior)","","250","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E-Scope","September 1, 2014","September 2013","August 2014","September 19, 2014","September 2014","No Study Results Posted","null","April 2014","Percentage of complete polyp removal|Clinical success according to size|Post-polypectomy bleeding rates","https://ClinicalTrials.gov/show/NCT02245854"
3026,"NCT02301286","A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients","Recruiting","No Results Available","Colon Cancer|Adjuvant Therapy","Drug: Acetylsalicylic acid|Drug: Placebo Acetylsalicylic acid","Leiden University Medical Center|Stichting voor Patienten met Kanker aan het Spijsverteringskanaal (SPKS)|Dutch Colorectal Cancer Group|Stichting Geriatrische Oncologie Nederland (GeriOnNe)|Fonds NutsOhra|Innovatiefonds Zorgverzekeraars|Anticancer Fund, Belgium","Both","45 Years and older   (Adult, Senior)","Phase 3","1588","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P14.152","November 7, 2014","September 2014","September 2022","March 16, 2016","March 2016","No Study Results Posted","ASPIRIN","September 2022","5 year overall survival|Disease Free Survival|Time to Treatment Failure","https://ClinicalTrials.gov/show/NCT02301286"
3027,"NCT02439723","Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients","Not yet recruiting","No Results Available","Metastatic Solid Malignancies|Locally Advanced Solid Malignancies","Drug: Regorafenib","AHS Cancer Control Alberta|Cross Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 1","40","Other","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Regorafenib 1.0","May 7, 2015","March 2016","December 2017","December 31, 2015","December 2015","No Study Results Posted","null","June 2017","Peak plasma concentration of regorafenib|The area under the concentration-time curve (AUC) for regorafenib","https://ClinicalTrials.gov/show/NCT02439723"
3028,"NCT02885987","Use of Endocuff During Average Risk Screening Colonoscopy to Increase Adenoma Detection Rate","Not yet recruiting","No Results Available","Colonic Polyps","Device: Endocuff","Loma Linda University","Both","50 Years and older   (Adult, Senior)","","370","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","16057","July 8, 2016","September 2016","September 2021","August 31, 2016","August 2016","No Study Results Posted","null","September 2021","Difference in adenoma detection rate (ADR), with and without use of Endocuff.|ADR will be differentiated according to morphology|ADR will be differentiated according to final pathology|ADR will be differentiated according to location|Advanced ADR|Mean total number of polyps detected|ADR-plus|APP (adenomas per positive participant)|APC (adenomas per colonoscopy)|Quality metrics: time of colonoscopy|Quality metrics: prep quality|Sedative Medications used","https://ClinicalTrials.gov/show/NCT02885987"
3029,"NCT00728650","A Retrospective Review of Malignant Liver Tumors","Completed","No Results Available","Liver Cancer","","University of Oklahoma","Both","20 Years to 90 Years   (Adult, Senior)","","228","Other","Observational","Time Perspective: Retrospective","TAB11119","August 1, 2008","October 2003","June 2011","February 6, 2012","February 2012","No Study Results Posted","null","October 2010","Survival|Efficacy","https://ClinicalTrials.gov/show/NCT00728650"
3030,"NCT02288910","Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver","Recruiting","No Results Available","Hepatocellular Carcinoma|Metastatic Carcinoma to the Liver","","Rush University Medical Center","Both","18 Years and older   (Adult, Senior)","","25","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","14030305","November 5, 2014","November 2014","July 2018","April 21, 2016","April 2016","No Study Results Posted","null","July 2017","Diagnostic accuracy of PBV maps|Relationship between blood volume values and patient treatment response|PBV blood volume value accuracy","https://ClinicalTrials.gov/show/NCT02288910"
3031,"NCT00600522","Alternative Surgical Policy for Central Liver Tumors","Completed","No Results Available","Colorectal Liver Metastases|Hepatocellular Carcinoma","Procedure: Ultrasound-guided hepatectomy","University of Milan","Both","Child, Adult, Senior","","15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HEP-MHV|NEWHEP-2","January 14, 2008","January 2004","May 2007","January 14, 2008","January 2008","No Study Results Posted","null","January 2007","The primary outcome measure was the rate of failure of conservative resection, i.e. the rate of patients who received TSs or MHs despite they fitted in the eligibility criteria.|The secondary outcome measure was the safety of the procedure. For that, we studied morbidity, mortality, amount of blood loss, rate of blood transfusions, and postoperative trend of liver function tests.","https://ClinicalTrials.gov/show/NCT00600522"
3032,"NCT00644254","The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma","Completed","No Results Available","Pancreatic Neoplasms|Pancreatic Adenocarcinoma","Procedure: Pancreatic resection","Katholieke Universiteit Leuven|Agentschap voor Innovatie door Wetenschap en Technologie","Both","Child, Adult, Senior","","145","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ECLNI DPAC","March 20, 2008","October 2007","March 2008","July 6, 2009","July 2009","No Study Results Posted","ECLNI DPAC","November 2007","Overall cancer-specific survival|Disease-free survival (DFS)& Correlation of ECLNI with other pathological variables","https://ClinicalTrials.gov/show/NCT00644254"
3033,"NCT02215720","Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors","Recruiting","No Results Available","Patients With Advanced or Metastatic Solid Tumors","Drug: Cetuximab|Drug: Temsirolimus","Gustave Roussy, Cancer Campus, Grand Paris","Both","18 Years and older   (Adult, Senior)","Phase 1","42","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-012275-88|2010/1626","August 8, 2014","April 2011","October 2016","February 9, 2016","February 2016","No Study Results Posted","TORERO","October 2016","Safety|Efficacy","https://ClinicalTrials.gov/show/NCT02215720"
3034,"NCT02835833","Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors","Recruiting","No Results Available","Renal Cell Carcinoma|Colorectal Adenocarcinoma|Non-squamous Non-small Cell Lung Cancer|Platinum-refractory Ovarian Carcinoma|Cervical Carcinoma","Drug: Nintedanib|Drug: Bevacizumab","University of Alabama at Birmingham|Boehringer Ingelheim","Both","19 Years and older   (Adult, Senior)","Phase 1","8","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","F160202011 (UAB 15108)","July 7, 2016","June 2016","null","July 13, 2016","July 2016","No Study Results Posted","null","December 2019","Number of participants with adverse events as a measure of safety and tolerability|Maximum tolerable dose of Nintedanib|Objective tumor response rate|Progression-free survival|Plasma level of vascular endothelial growth factor (VEGF)|Plasma level of platelet-derived growth factor (PDGF)|Plasma level of vascular endothelial growth factor and receptor (VEGF-R)|Plasma level of phosphatidylinositol-glycan biosynthesis class F protein (PIGF)|Plasma level of fibroblast growth factor (FGF)","https://ClinicalTrials.gov/show/NCT02835833"
3035,"NCT00755729","The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway","Completed","No Results Available","Colorectal Disease","Dietary Supplement: Preoperative Oral Carbohydrate|Dietary Supplement: Preoperative Oral Carbohydrate","Shanghai Changzheng Hospital","Both","25 Years to 75 Years   (Adult, Senior)","Phase 4","32","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Basic Science","SCZH-0809-110","September 18, 2008","November 2006","March 2007","September 18, 2008","September 2008","No Study Results Posted","null","March 2007","PTK activity and PI3K, PKB, GLUT4 expression in rectus abdominis muscle samples by the end of operation|Preoperative general well-beings and the insulin resistance before and immediately after surgery assessed with the visual analogue scale (VAS) and the homeostasis model assessment (HOMA) respectively","https://ClinicalTrials.gov/show/NCT00755729"
3036,"NCT01737567","Comparison Between White Light Endoscopy and Bright Narrow Band Imaging in Diagnosis Colonic Adenomas.","Recruiting","No Results Available","Colonic Adenomas","Other: Bright Narrow Band Imaging.|Other: White Light Endoscopy","Professor Michael Bourke|Western Sydney Local Health District","Both","50 Years to 99 Years   (Adult, Senior)","","1000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","HREC/11/WMEAD/223|HREC2011/12/4.9 (3395)","November 27, 2012","February 2014","June 2017","December 15, 2015","December 2015","No Study Results Posted","WLEvB-NBI","June 2016","Improvement in detection of colorectal adenomas.|Improvement of histological prediction","https://ClinicalTrials.gov/show/NCT01737567"
3037,"NCT02269332","Vitamin D and Screening Colonoscopy or Polyp Surveillance","Completed","No Results Available","Colon Cancer","Other: Screening Colonoscopy","Mike O'Callaghan Federal Hospital","Both","18 Years and older   (Adult, Senior)","","298","U.S. Fed","Observational","Observational Model: Case Control|Time Perspective: Prospective","FWH20140085H","October 14, 2014","August 2014","November 2015","February 1, 2016","February 2016","No Study Results Posted","VitDColon","November 2015","Serum Vitamin D","https://ClinicalTrials.gov/show/NCT02269332"
3038,"NCT01936948","Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.","Recruiting","No Results Available","Colon Polyps","Procedure: Clip closure","White River Junction VAMC|Center for Bioinformatics at Geisel School of Medicine at Dartmouth|Boston Scientific Corporation","Both","18 Years to 89 Years   (Adult, Senior)","","1020","U.S. Fed|Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CPHS-23578","September 3, 2013","April 2013","December 2021","December 9, 2015","December 2015","No Study Results Posted","null","December 2020","Delayed bleeding complications|Overall complications|Complete polyp resection|Polyp recurrence|Clip complications","https://ClinicalTrials.gov/show/NCT01936948"
3039,"NCT02283359","Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus","Terminated","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: Selinexor|Drug: Irinotecan","H. Lee Moffitt Cancer Center and Research Institute","Both","18 Years and older   (Adult, Senior)","Phase 1","3","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-17919","November 3, 2014","December 2014","January 2016","January 14, 2016","January 2016","No Study Results Posted","null","December 2015","Maximum Tolerated Dose (MTD)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Best Overall Response|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02283359"
3040,"NCT01685307","Impact of Cooking Process on Meat Protein Digestion and Metabolism","Recruiting","No Results Available","Physiology|Digestive Tract|Heating Process","Dietary Supplement: Test meal","Institut National de la Recherche Agronomique|National Research Agency, France","Both","18 Years to 45 Years   (Adult)","","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","PRONUTRIAL","March 21, 2012","February 2012","null","September 11, 2012","September 2012","No Study Results Posted","null","September 2012","protein digestibility|nitrogen metabolism","https://ClinicalTrials.gov/show/NCT01685307"
3041,"NCT00076609","Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma","Completed","No Results Available","Hepatocellular Carcinoma|Liver Cancer","Drug: PHY906|Drug: capecitabine","PhytoCeutica","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","31","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PHY906-2002-1","January 27, 2004","October 2003","null","March 27, 2007","March 2007","No Study Results Posted","null","null","Tumor imaging and evaluation every 6 weeks|Alphafetoprotein measurements every 3 weeks for first 3 courses, then every 6 weeks thereafter|QoL assessment every 3 weeks|Survival follow-up every 2 months","https://ClinicalTrials.gov/show/NCT00076609"
3042,"NCT00557232","Intraocular Bevacizumab (Avastin) for Rubeosis Iridis","Completed","No Results Available","Glaucoma|Rubeosis Iridis","Drug: bevacizumab","Instituto de Olhos de Goiania","Both","18 Years to 65 Years   (Adult)","Phase 4","25","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JN-01-2007-ARVO","November 8, 2007","November 2006","November 2011","November 25, 2011","November 2011","No Study Results Posted","null","October 2011","Intraocular Bevacizumab (Avastin) for Rubeosis Iridis","https://ClinicalTrials.gov/show/NCT00557232"
3043,"NCT00001587","A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver","Completed","No Results Available","Liver Neoplasms|Neoplasm Metastasis","Procedure: Isolated hepatic portal and arterial perfusion|Drug: Melphalan","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","Child, Adult, Senior","Phase 1","30","NIH","Interventional","Endpoint Classification: Safety Study|Primary Purpose: Treatment","970200|97-C-0200","November 3, 1999","September 1997","March 2001","March 3, 2008","April 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001587"
3044,"NCT02723370","Implementation of Evidence Based Practices for Colonoscopy: The Strategies to Improve Colonoscopy Study","Enrolling by invitation","No Results Available","Colonoscopy","Behavioral: Staff multi-component implementation strategy","Washington University School of Medicine|National Cancer Institute (NCI)|BJC HealthCare","Both","18 Years and older   (Adult, Senior)","","46184","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","201401089|R21CA184282","March 15, 2016","May 2013","August 2016","March 23, 2016","March 2016","No Study Results Posted","STIC","May 2016","Percent of patients with adequate of bowel preparation as indicated by a Boston Bowel Preparation Scale (BBPS) score > 6 or an Aronchick scale score of fair or better.|Adoption of Evidence Based Practices","https://ClinicalTrials.gov/show/NCT02723370"
3045,"NCT00792649","Comparison Between HD+ Endoscopy and Standard Videoendoscopy in Screening Colonoscopy","Enrolling by invitation","No Results Available","Polyps|Neoplasia","","Johannes Gutenberg University Mainz","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","837.386.07","November 17, 2008","February 2008","null","November 17, 2008","February 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00792649"
3046,"NCT01775280","Response of Hepatic Tumors to Radioembolization","Withdrawn","No Results Available","Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma|Liver Metastasis","Radiation: Injection of Ytttrium-90 microspheres into the hepatic artery","University of Zurich","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","USZ-ZH-VIS-RESRAD","January 22, 2013","October 2012","October 2015","June 8, 2015","June 2015","No Study Results Posted","RESRAD","October 2015","Primary endpoint ist the percentage of patients that can be downstaged to resectability|Histologic response to radioembolization|Immunological response to radioembolization","https://ClinicalTrials.gov/show/NCT01775280"
3047,"NCT02553538","Improving Comprehensive Cancer Screening Among Vulnerable Patients Using Patient Navigation","Completed","No Results Available","Patient Compliance","Behavioral: Patient Navigation","Massachusetts General Hospital","Both","21 Years to 75 Years   (Adult, Senior)","","1612","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","2013P000473","September 16, 2015","April 2014","December 2014","September 16, 2015","September 2015","No Study Results Posted","null","December 2014","Cancer Screening Test Completion Rate","https://ClinicalTrials.gov/show/NCT02553538"
3048,"NCT00409565","A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer","Completed","Has Results","Head and Neck Cancer|Squamous Cell Carcinoma","Drug: Cetuximab|Drug: Bevacizumab","University of Pittsburgh|National Cancer Institute (NCI)","Both","18 Years to 98 Years   (Adult, Senior)","Phase 2","48","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-087|NCI / CTEP Protocol # 7440","December 7, 2006","September 2006","February 2012","June 1, 2016","May 2016","February 12, 2014","null","February 2012","To Determine the Objective Response Rate (Primary Endpoint) With the Combination of Cetuximab Plus Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.|To Determine the Progression-free Survival and Overall Survival of Patients With Recurrent or Metastatic Head and Neck Cancer Treated With Cetuximab Plus Bevacizumab.","https://ClinicalTrials.gov/show/NCT00409565"
3049,"NCT00866450","Effects of a Western-type Diet on Colorectal Inflammation","Completed","No Results Available","Colorectal Inflammation","Dietary Supplement: Western style diet (high fat and low in calcium)|Dietary Supplement: Prudent-style diet (low fat and high in calcium)","Rockefeller University","Both","50 Years to 72 Years   (Adult, Senior)","Phase 0","5","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Basic Science","SWP-0658","March 19, 2009","February 2009","February 2010","January 10, 2012","January 2012","No Study Results Posted","null","February 2010","Inflammation in the rectosigmoid epithelium|Circulating endotoxin levels|Expression profiles of pro- and anti-inflammatory genes in rectosigmoid biopsies|Gut permeability|Inflammatory cytokines in the colorectal mucosa and serum|Luminal and adherent gut microbiota|Fecal calprotectin levels in the stool samples","https://ClinicalTrials.gov/show/NCT00866450"
3050,"NCT02228356","Non-interventional Observational Study of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Cancer","Recruiting","No Results Available","Neoplasm Metastasis","Radiation: Stereotactic Body Radiation Therapy","Universitair Ziekenhuis Brussel","Both","18 Years to 100 Years   (Adult, Senior)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BUN143201215117","August 22, 2014","June 2012","null","May 10, 2016","May 2016","No Study Results Posted","null","June 2017","One year local control|Acute toxicity|Survival|Progression Free Survival|Late toxicity","https://ClinicalTrials.gov/show/NCT02228356"
3051,"NCT01511146","Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor","Recruiting","No Results Available","Liver Metastasis","Drug: Oxaliplatin|Drug: Mitomycin + Gemcitabine","Copenhagen University Hospital at Herlev","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AA-1023","August 4, 2011","July 2011","July 2016","January 18, 2012","January 2012","No Study Results Posted","null","July 2015","tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.|Progression free survival, adverse events","https://ClinicalTrials.gov/show/NCT01511146"
3052,"NCT02551198","Comparison of Polyethylene Glycol With Ascorbic Acid and Oral Sulfate Solution for Bowel Preparation","Recruiting","No Results Available","Healthy","Drug: HAPREP®|Drug: SUCLEAR®","National Cancer Center, Korea|Daehang Hospital","Both","20 Years to 75 Years   (Adult, Senior)","Phase 3","184","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","NCC2015-0210","September 11, 2015","November 2015","September 2016","November 25, 2015","November 2015","No Study Results Posted","null","March 2016","Adequacy of bowel preparation|5-point scale symptom questionnaire for drug tolerability|Number of Participants with Adverse Events|colonoscopy insertion time|adenoma detection rate","https://ClinicalTrials.gov/show/NCT02551198"
3053,"NCT02053948","Pursestring Wound Closure vs ""Gunsight"" Skin Incision and Closure Technique to Reverse Stoma","Recruiting","No Results Available","Colostomy","Procedure: Pursestring Wound Closure|Procedure: Gunsight Skin Incision and Closure Technique","Beijing Chao Yang Hospital","Both","Child, Adult, Senior","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","GSICT1126","November 26, 2013","November 2013","December 2014","February 3, 2014","February 2014","No Study Results Posted","GSICT1126","December 2014","superficial wound infection of stoma site|Healing time after stoma reversal","https://ClinicalTrials.gov/show/NCT02053948"
3054,"NCT01178775","Development and Validation of Perceived Fatigue Meaning Scale on Walking Program","Recruiting","No Results Available","Gastric Cancer","Behavioral: walking","National Taiwan University Hospital|National Science Council, Taiwan","Both","20 Years and older   (Adult, Senior)","","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","200807050R","April 11, 2010","September 2008","December 2011","August 9, 2010","August 2010","No Study Results Posted","PFMS","March 2010","Fatigue Symptom Inventory","https://ClinicalTrials.gov/show/NCT01178775"
3055,"NCT01638091","Practice-Based Learning to Predict Polyp Histology at Colonoscopy","Completed","No Results Available","Colonic Polyps|Adenomatous Polyps","Behavioral: Ex vivo module|Behavioral: In vivo practice-base learning phase","Stanford University","Both","Child, Adult, Senior","","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","HSR-10-1167|IRB-20373","July 6, 2012","March 2011","null","July 10, 2012","July 2012","No Study Results Posted","null","March 2012","Proportion of participants achieving 90% accuracy|Learning curves|Surveillance recommendations","https://ClinicalTrials.gov/show/NCT01638091"
3056,"NCT00398879","Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients","Completed","No Results Available","Colon Cancer","Drug: Perifosine in combination with capecitabine","AEterna Zentaris","Both","18 Years and older   (Adult, Senior)","Phase 2","381","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","Perifosine 211","November 6, 2006","August 2005","October 2011","March 4, 2013","February 2012","No Study Results Posted","null","December 2010","To determine the time to tumor progression.|To determine the toxicity of single agent chemotherapy in combination with perifosine|To compare the time to progression of chemotherapy in combination with placebo to historical experience","https://ClinicalTrials.gov/show/NCT00398879"
3057,"NCT02072733","Suitability of an Organization With an Onco-geriatric Team to a Whole Region (Region Midt) of Denmark","Completed","No Results Available","Elderly|Cancer","Other: Comprehensive geriatric assessment","University of Aarhus|Danish Cancer Society","Both","70 Years to 130 Years   (Senior)","","320","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","Oncogeriatric feasibility","February 19, 2014","January 2015","December 2015","May 29, 2016","December 2015","No Study Results Posted","null","December 2015","Feasibility|frailty status","https://ClinicalTrials.gov/show/NCT02072733"
3058,"NCT02419495","Phase IB of Selinexor in Combination With Standard Chemotherapy in Patients With Advanced Malignancies","Recruiting","No Results Available","Advanced Cancers","Drug: Selinexor|Drug: Carboplatin|Drug: Paclitaxel|Drug: Eribulin|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Pemetrexed|Drug: Topotecan|Drug: Irinotecan|Drug: 5-FU|Drug: Capecitabine|Drug: Oxaliplatin|Drug: Olaparib|Drug: Pembrolizumab","M.D. Anderson Cancer Center|Karyopharm Therapeutics, Inc","Both","18 Years and older   (Adult, Senior)","Phase 1","470","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-0640|NCI-2015-00693","April 14, 2015","June 2015","null","August 11, 2016","August 2016","No Study Results Posted","null","June 2018","Maximum Tolerated Dose (MTD)|Disease Control","https://ClinicalTrials.gov/show/NCT02419495"
3059,"NCT02875457","Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin","Not yet recruiting","No Results Available","Small Cell Lung Cancer","Drug: apatinib;etoposide and cisplatin|Drug: placebo;etoposide and cisplatin","Third Military Medical University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AEP-ES-SCLC","June 11, 2016","September 2016","September 2023","August 23, 2016","August 2016","No Study Results Posted","null","September 2018","Progression-free survival|Overall survival|Tumor response rate|Treatment-related adverse events|Performance Status","https://ClinicalTrials.gov/show/NCT02875457"
3060,"NCT02007395","Prospective Study on Polypectomy Complications: SPoC.","Completed","No Results Available","Endoscopic Polypectomy","","Valduce Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","5170","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","5/2013","December 5, 2013","June 2013","December 2013","December 5, 2013","December 2013","No Study Results Posted","null","September 2013","complications of endoscopic polypectomy","https://ClinicalTrials.gov/show/NCT02007395"
3061,"NCT01049776","GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line","Terminated","Has Results","Non Small Cell Lung Cancer","Drug: Pazopanib (GW786034)","Illinois CancerCare, P.C.","Both","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ILCC #2 IllinoisCancerCare #2","January 12, 2010","January 2010","null","September 16, 2014","September 2014","August 11, 2014","null","March 2014","Proportion of Non Small Cell Lung Cancer Participants With Disease Control (Complete Response+Partial Response+Stable Disease) Based on RECIST 1.0 Measured by CT or MRI|To Describe the Clinical Toxicity Profile of Pazopanib in This Particular Patient Population","https://ClinicalTrials.gov/show/NCT01049776"
3062,"NCT01691144","Follow-up of Gynecological Cancer Patients, Their Needs and Expectations, A Cooperation Project","Completed","No Results Available","Endometrial Cancer|Ovarian Cancer|Cervical Cancer","","University of Oslo","Female","19 Years and older   (Adult, Senior)","","239","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2012/355B","August 15, 2012","September 2012","December 2015","May 11, 2016","May 2016","No Study Results Posted","null","December 2015","Patient expectation questionnaire|Patient satisfaction questionnaire","https://ClinicalTrials.gov/show/NCT01691144"
3063,"NCT02826967","Feasibility and Effectiveness of Colonic Irrigation","Recruiting","No Results Available","Colonic Irrigation","Procedure: Colonic Irrigation","New York University School of Medicine","Both","50 Years to 84 Years   (Adult, Senior)","","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","16-00578","July 6, 2016","June 2016","December 2016","July 6, 2016","July 2016","No Study Results Posted","null","December 2016","Overall quality of bowel cleansing for each of the three segments of the colon (ascending, transverse, and descending) as measured by the Boston Bowel Preparation Score (BBPS)|Patient satisfaction, as measured by a questionnaire administered by a study investigator via follow-up phone call after completion of the colonic irrigation and subsequent colonoscopy.","https://ClinicalTrials.gov/show/NCT02826967"
3064,"NCT02251353","Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer|Metastasis","Procedure: intervention|Drug: systemic treatment","Federation of Breast Diseases Societies","Female","18 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMET","September 25, 2014","June 2014","June 2022","March 5, 2015","September 2014","No Study Results Posted","IMET","June 2019","Overall survival (OS)|Progression free survival (PFS)|Morbidity due to treatment modality","https://ClinicalTrials.gov/show/NCT02251353"
3065,"NCT02097810","Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.","Recruiting","No Results Available","Locally Advanced Solid Tumors|Metastatic Solid Tumors","Drug: Entrectinib","Ignyta, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","175","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RXDX-101-01","March 21, 2014","June 2014","June 2017","April 7, 2016","April 2016","No Study Results Posted","STARTRK-1","June 2017","Dose-Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Recommended Phase 2 Dose (RP2D)|Plasma concentrations of entrectinib|Disease Control|Duration of Response","https://ClinicalTrials.gov/show/NCT02097810"
3066,"NCT00366457","Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer|Adenocarcinoma of the Pancreas","Drug: Bevacizumab|Drug: Erlotinib|Drug: Gemcitabine","Massachusetts General Hospital|Genentech, Inc.|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","32","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-234","August 17, 2006","August 2006","July 2011","April 25, 2012","April 2012","No Study Results Posted","null","August 2008","Determine the time to tumor progression on the combination of gemcitabine with bevacizumab and erlotinib.|Determine the response rate and toxicity profile|determine the median survival, 1 year survival, progression free survival and duration of response.","https://ClinicalTrials.gov/show/NCT00366457"
3067,"NCT02859714","Detection of Colorectal Adenomas in Côte-d'Or","Not yet recruiting","No Results Available","Colorectal Adenoma","Other: screening data","Centre Hospitalier Universitaire Dijon","Both","50 Years to 74 Years   (Adult, Senior)","","11600","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COTTET PARI 2015","August 1, 2016","null","null","August 4, 2016","July 2016","No Study Results Posted","DACCOR","January 2017","Detection rates for colorectal adenomas","https://ClinicalTrials.gov/show/NCT02859714"
3068,"NCT01337765","Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific|Solid Tumor","Drug: BEZ235 + MEK162","Array BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 1","29","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CMEK162X2103|2011-000421-74","April 2, 2011","July 2011","March 2013","February 11, 2016","February 2016","No Study Results Posted","null","March 2013","Incidence of Dose Limiting Toxicities|Number of participants with adverse events and serious adverse events|Overall response rate, duration of response, time to response and progression free survival|Time versus plasma concentration profiles of BEZ235 and MEK162|Treatment-induced PI3K and MEK/ERK pathway signaling inhibition and evidence of biological activity in tumor","https://ClinicalTrials.gov/show/NCT01337765"
3069,"NCT02761486","Effect of Aspirin on Gut Microbiome","Not yet recruiting","No Results Available","Healthy","Drug: Aspirin|Drug: Placebo","University of Minnesota - Clinical and Translational Science Institute","Both","50 Years to 75 Years   (Adult, Senior)","Phase 1","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","1604M86161|2016NTLS049","April 29, 2016","August 2016","August 2017","June 15, 2016","June 2016","No Study Results Posted","ASMIC","August 2017","Composition of the gut microbiome|Urinary and blood inflammatory biomarkers","https://ClinicalTrials.gov/show/NCT02761486"
3070,"NCT01470235","Hypodontia and Ovarian Cancer","Recruiting","No Results Available","Ovarian Cancer|Hypodontia|Breast Cancer|Colon Cancer","","University of Aarhus|Danish Cancer Society|Arvid-Nilsson Foundation","Female","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","Hypodontovariancancer2011","November 9, 2011","September 2011","August 2015","October 31, 2013","October 2013","No Study Results Posted","null","September 2014","Prevalence rates of hypodontia in women with ovarian cancer|Genetic causes for hypodontia and ovarian cancer|Prevalence rates of hypodontia in patients with a known risk for epithelial cancer","https://ClinicalTrials.gov/show/NCT01470235"
3071,"NCT01869166","Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)","Recruiting","No Results Available","Advanced EGFR-positive Solid Tumors","Biological: CART-EGFR","Chinese PLA General Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","60","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CHN-PLAGH-BT-007","June 1, 2013","May 2013","December 2017","September 27, 2015","September 2015","No Study Results Posted","CART-EGFR","December 2016","Occurrence of study related adverse events|Anti-tumor responses to CART-EGFR cell infusions","https://ClinicalTrials.gov/show/NCT01869166"
3072,"NCT01363232","Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients","Active, not recruiting","No Results Available","Advanced Solid Tumors,|Selected Solid Tumors","Drug: BKM120 + MEK162","Array BioPharma","Both","18 Years and older   (Adult, Senior)","Phase 1","89","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CMEK162X2101|2011-001083-22","May 24, 2011","August 2011","null","May 12, 2016","May 2016","No Study Results Posted","null","March 2014","Incidence of Dose Limiting Toxicities|Number of participants with adverse events and serious adverse events.|Overall response rate, duration of response, time to response and progression free survival|Time versus plasma concentration profiles of BKM120 and MEK162|Treatment -induced PI3K and MEK/ERK pathway signaling inhibition and evidence of biological activity in tumor.","https://ClinicalTrials.gov/show/NCT01363232"
3073,"NCT01775449","Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet","Recruiting","No Results Available","Neuropathy|Digestive Cancer System","Behavioral: Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines","University Hospital, Clermont-Ferrand|Fondation Apicil|Ligue contre le cancer – Auvergne","Both","18 Years to 70 Years   (Adult, Senior)","Phase 3","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","CHU-0137|2011-A00911-40","January 7, 2013","February 2013","December 2016","July 28, 2016","July 2016","No Study Results Posted","NEUROXAPOL","December 2016","Cold pain thresholds|Heat pain thresholds|DN4 (Douleur Neuropathique en 4 Questions) scores|HADS (Hospital Anxiety and Depression Scale) score|Adverse drug reactions (CTCAE (Common Terminology Criteria for Adverse Events))|Cancer response|Oxaliplatin dose intensity|Erythrocyte polyamine levels|NPSI ( Neuropathic Pain Symptom Inventory)scores|QLQ-C30 (Quality of Life questionnaire C30)scores","https://ClinicalTrials.gov/show/NCT01775449"
3074,"NCT00398593","Methods of Improvement Adherence With Therapy in Ulcerative Colitis.","Active, not recruiting","No Results Available","Ulcerative Colitis","Behavioral: Range of electronic pill dispensers with alarms","University Hospitals, Leicester","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","UHL 09788|REC 06/Q2502/100","November 13, 2006","December 2007","April 2009","February 13, 2009","February 2009","No Study Results Posted","null","April 2008","Levels of patient adherence to therapy will be assessed in two ways:|through pill counts and measurement of salicylate levels in urine samples.|Quantitative data will be collected through feedback from patients.","https://ClinicalTrials.gov/show/NCT00398593"
3075,"NCT00137241","Veterans as Leaders in Understanding and Education (VALUE)","Completed","No Results Available","Cancer","","VA Office of Research and Development","Both","Child, Adult, Senior","","1850","U.S. Fed","Observational","","CRI 03-153","August 25, 2005","July 2004","November 2005","April 6, 2015","October 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00137241"
3076,"NCT02573974","Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer","Recruiting","No Results Available","Undernutrition|Gastrointestinal Cancer","Other: Samples","University Hospital, Tours","Both","18 Years to 80 Years   (Adult, Senior)","","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","PHAO14-TL/METERMUCADIG|2015-A00683-46|2015-R25|150963B-12","October 7, 2015","January 2016","December 2017","February 1, 2016","February 2016","No Study Results Posted","METERMUCADIG","December 2017","Measurement of muscle mitochondrial bioenergetics|Quantification of muscle lipid droplets|Analysis of the expression of target genes and proteins|Determination of body composition (fat mass / lean mass)|Determining the isotopic composition of nitrogen hair","https://ClinicalTrials.gov/show/NCT02573974"
3077,"NCT00997360","Study of PKI-179 Administered Orally to Subjects With Solid Tumors","Terminated","No Results Available","Advanced Malignant Solid Tumors","Drug: PKI-179","Wyeth is now a wholly owned subsidiary of Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","80","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3266A1-1002","October 16, 2009","February 2010","February 2012","December 1, 2009","December 2009","No Study Results Posted","null","February 2012","Safety as measured by physical examinations, electrocardiograms, laboratory assessments, vital signs, adverse events and serious adverse events|Tumor assessments, blood samples to look at how the drug enters your body and what the body does with it.","https://ClinicalTrials.gov/show/NCT00997360"
3078,"NCT02694120","Study on Complications, EfficAcy and Costs of Large Polypectomy","Not yet recruiting","No Results Available","Polypectomy","","Valduce Hospital","Both","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2016.2","January 29, 2016","February 2016","null","February 23, 2016","February 2016","No Study Results Posted","SCALP","July 2016","complications of large polypectomy|costs of large polypectomy|efficacy of large polypectomy","https://ClinicalTrials.gov/show/NCT02694120"
3079,"NCT01749332","A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections","Recruiting","No Results Available","Liver Cancer","Other: Perihepatic Phlebotomy","Memorial Sloan Kettering Cancer Center|University of Michigan","Both","Child, Adult, Senior","","145","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","12-236","December 11, 2012","December 2012","December 2017","June 20, 2016","June 2016","No Study Results Posted","null","December 2017","ctDNA differences|collect preliminary data","https://ClinicalTrials.gov/show/NCT01749332"
3080,"NCT01358331","A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)","Terminated","No Results Available","Tumor, Solid","Drug: MK-8353","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P06203|2012-002696-33","May 19, 2011","November 2011","May 2014","June 5, 2015","June 2015","No Study Results Posted","null","May 2014","Number of participants with dose-limiting toxicities (DLTs)|Number of participants with complete response (CR) or partial response (PR)","https://ClinicalTrials.gov/show/NCT01358331"
3081,"NCT01672411","Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer","Completed","No Results Available","Prostate Cancer","","University Of Perugia","Male","18 Years to 75 Years   (Adult, Senior)","","250","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","propsa12","August 21, 2012","April 2012","December 2012","February 23, 2013","February 2013","No Study Results Posted","null","December 2012","diagnosis of prostate cancer|prognosis of prostate cancer","https://ClinicalTrials.gov/show/NCT01672411"
3082,"NCT02701829","Taxi METERS: Measuring Effectiveness of Technology, Education, Referrals and Support","Enrolling by invitation","No Results Available","Improving Blood Pressure Control","Other: CONTROL- Usual & Customary Health Fair Follow-up|Other: Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring]|Other: Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)","Memorial Sloan Kettering Cancer Center","Male","21 Years and older   (Adult, Senior)","","144","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","16-038","March 2, 2016","February 2016","null","September 15, 2016","September 2016","No Study Results Posted","null","February 2018","decrease in blood pressure levels","https://ClinicalTrials.gov/show/NCT02701829"
3083,"NCT02395068","Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors","Active, not recruiting","No Results Available","Solid Tumors","Drug: Nimotuzumab|Drug: irinotecan","Biotech Pharmaceutical Co., Ltd.","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BT-PK-001","February 28, 2015","November 2012","December 2015","August 17, 2015","October 2012","No Study Results Posted","null","November 2014","Pharmacokinetics of Nimotuzumab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors: Single dose：Tmax，Cmax， AUC，Vc，t1/2α，t1/2β，CL. Multiple dose：Tmax，Css-min，Css-max，Css-a，t1/2β，CL，AUCss，DF.|Safety - AE measured by NCI CTCAE v 3.0|ORR（Objective Response Rate）|DCR（Disease Control Rate）|PFS（Progression Free Survival）","https://ClinicalTrials.gov/show/NCT02395068"
3084,"NCT01465425","Extracolonic Findings on Computed Tomography (CT) Colonography","Enrolling by invitation","No Results Available","Solitary Pulmonary Nodules|Multiple Pulmonary Nodules|Renal Neoplasms|Adrenal Gland Neoplasms|Aortic Aneurysm, Abdominal|Liver Neoplasms|Adnexal and Skin Appendage Neoplasms|Lymphadenopathy|Pancreatic Neoplasms","","American College of Radiology Imaging Network","Both","50 Years and older   (Adult, Senior)","","520","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","ACRIN 7151|A7151","October 31, 2011","September 2011","April 2014","January 25, 2013","January 2013","No Study Results Posted","ACRIN 7151","December 2013","Rates of Follow Up Imaging, Hospitalization, Intervention|Characterize Outcomes|Estimate Relative Risk|Determine Potential Predictors|Estimate Differences in Cost","https://ClinicalTrials.gov/show/NCT01465425"
3085,"NCT00317200","A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer","Completed","No Results Available","Small Cell Lung Cancer","Drug: Paclitaxel|Drug: Bevacizumab","Hoosier Cancer Research Network|Genentech, Inc.|Walther Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","34","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HOG LUN05-99","April 20, 2006","April 2006","November 2007","April 28, 2011","April 2011","No Study Results Posted","null","November 2007","To determine progression free survival(PFS) of this regimen in patients with chemosensitive relapsed small cell lung cancer (SCLC).|To determine the response rate of the combination of paclitaxel and bevacizumab with chemosensitive SCLC.|To determine the toxicity of the combination of paclitaxel and bevacizumab in patients with SCLC.|To determine overall survival.|To assess VEGF polymorphisms in the study population.","https://ClinicalTrials.gov/show/NCT00317200"
3086,"NCT00234650","Adenoma Detection Rate With Position Change at Colonoscopy","Completed","No Results Available","Polyps","Procedure: Colonoscopy","London North West Healthcare NHS Trust","Both","50 Years to 80 Years   (Adult, Senior)","","130","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single Blind|Primary Purpose: Diagnostic","05/CO05/15","October 5, 2005","October 2005","September 2007","April 1, 2009","December 2008","No Study Results Posted","null","null","adenoma detection rate for position 1 compared to position 2|percentage of adenomas detected in all the participants for each position","https://ClinicalTrials.gov/show/NCT00234650"
3087,"NCT02827916","Exploration of Neuropathic Pain Induced by Oxaliplatin Electrophysiological Approach","Recruiting","No Results Available","Peripheric Neuropathy|Chemo-induced Neuropathy","Device: Assessment of neuropathic pain with theThermotest device|Device: Assessment of neuropathic pain with SUDOSCAN device|Device: Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.","Groupe Hospitalier Paris Saint Joseph","Both","18 Years and older   (Adult, Senior)","","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CANALOXA","June 29, 2016","May 2016","May 2017","July 8, 2016","July 2016","No Study Results Posted","CANALOXA","May 2017","Evaluation of neuropathy by electrophysiological methods using SUDOSCAN|Evaluation of neuropathy by devices for quantitative measurement of neuropathic pain|NPSI ange of Characterization of pain neuropathy","https://ClinicalTrials.gov/show/NCT02827916"
3088,"NCT02235441","Effects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies","Active, not recruiting","No Results Available","Pathologically Proven Gastrointestinal Malignancy|Plan of Care Must Include Chemoradiation","Other: Cardiopulmonary Exercise Test (CPET)","Duke University","Both","18 Years and older   (Adult, Senior)","","25","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","Pro00055718","August 29, 2014","November 2014","October 2017","December 7, 2015","December 2015","No Study Results Posted","null","October 2017","Feasibility Composite Score","https://ClinicalTrials.gov/show/NCT02235441"
3089,"NCT01533324","S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)","Recruiting","No Results Available","Carcinoma|Liver Diseases|Hepatocellular Carcinoma","Drug: S-1 combined with Leucovorin","Second Military Medical University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","32","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCC-SL-2W","February 10, 2012","November 2011","December 2016","February 14, 2012","February 2012","No Study Results Posted","null","November 2016","DCR|TTP ( time to progression)|OS ( overall survival)|safety","https://ClinicalTrials.gov/show/NCT01533324"
3090,"NCT02866903","Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis","Not yet recruiting","No Results Available","Peritoneal Carcinosis","Drug: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Drug: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Drug: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy","Hospices Civils de Lyon","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","47","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","69HCL16_0134","August 4, 2016","October 2016","March 2019","August 10, 2016","August 2016","No Study Results Posted","IPOXA","March 2019","Adverse events (NCI CTCAE v4.0)|Dose Limiting Toxicities, DLT|Overall response rate according to RECIST|Peritoneal Cancer Index (PCI)","https://ClinicalTrials.gov/show/NCT02866903"
3091,"NCT00546156","Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Bevacizumab","Ian E. Krop, MD, PhD|Genentech, Inc.|Massachusetts General Hospital|Brigham and Women's Hospital|New Hampshire Oncology-Hematology PA|Dana-Farber Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","104","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-130","October 17, 2007","October 2007","December 2012","March 22, 2013","March 2013","March 22, 2013","null","October 2011","Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population.|Decrease in Interstitial Fluid Pressure.","https://ClinicalTrials.gov/show/NCT00546156"
3092,"NCT00940498","Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors","Completed","No Results Available","Neoplasms","Drug: PF-05212384 (also known as PKI-587)","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","78","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","B2151001|3265K1-1002","July 14, 2009","January 2010","October 2012","November 8, 2012","November 2012","No Study Results Posted","B2151001","August 2011","Assessment of Dose Limiting Toxicities (DLTs), Adverse Events (AEs) and Serious Adverse Events (SAEs)|Assess safety and tolerability at the MTD|Assess how the study drug enters the body and what the body does with it|Assess how well the study drug works|Assess the effect of the study drug on tumors and other tissues","https://ClinicalTrials.gov/show/NCT00940498"
3093,"NCT02172638","Postoperatory Recovery in Advanced Ovarian Cancer, Fast-Track Protocol vs. Classical Management","Recruiting","No Results Available","Median Length of Stay|Readmission Rate|Surgery Related Complications Rate|Cost Per Patient Rate","Procedure: Fast-Track Protocol|Procedure: Usual management","Hospital Universitari Vall d'Hebron Research Institute","Female","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","PR(AMI)136/2014","June 13, 2014","June 2014","null","September 11, 2014","September 2014","No Study Results Posted","PROFAST","June 2017","median length of stay|Number of readmissions related to postoperative complications.|Number of surgery related complications|Cost per patient","https://ClinicalTrials.gov/show/NCT02172638"
3094,"NCT02076958","Implementation of Evidence-Based Cancer Early Detection in Black Churches","Active, not recruiting","No Results Available","Information Dissemination|Evidence-Based Public Health","Behavioral: Community Health Advisor education","University of Maryland","Both","40 Years to 75 Years   (Adult, Senior)","","574","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","R01CA147313","February 27, 2014","March 2011","February 2017","May 10, 2016","May 2016","No Study Results Posted","Project HEAL","February 2017","Adherence to program delivery protocol - Implementation of the 3-workshop series.|Number of training events (workshops)|Number of CHA trainees|Completion of CHA training|Self-report of modifications or problems with program delivery|Number of booster CHA training sessions over two-year period|Change in number of survey completion from baseline to 12-month to 24-month|Number of educational sessions participants attended|Change in knowledge of cancer early detection from workshop 1 to workshop 3|Change in perceived benefits of screening|Change in perceived barriers to screening|Change in self-efficacy for screening|Change in self-report of screening from baseline to 12-month to 24-month|Ratings of program|Percent of eligible congregation that enrolled in the project|Number of participants that attended educational sessions|Enrollment of churches|Number of additional training cycles completed over two year period|Amount of supplemental funding church receives for additional health education over two years|Number of continued health education activities including cancer education over two year period","https://ClinicalTrials.gov/show/NCT02076958"
3095,"NCT01787006","Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer","Recruiting","No Results Available","Esophageal Cancer","Drug: Cetuximab|Drug: Cisplatin, 5-FU|Radiation: Radiotherapy","University of Schleswig-Holstein","Both","18 Years and older   (Adult, Senior)","Phase 2","134","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LEOPARD II|2010-023427-18","February 5, 2013","September 2011","null","December 19, 2014","December 2014","No Study Results Posted","null","September 2016","2-year survival|1-year survival|Progression free Survival|Overall incidence of patients with adverse events|Metastasis free survival|Response rate|Rate of local tumor control|Quality of Life","https://ClinicalTrials.gov/show/NCT01787006"
3096,"NCT01170754","Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy","Completed","Has Results","Colon Cancer","Drug: PEG-3350 and Gatorade|Drug: Golytely 4 liters","Temple University","Both","40 Years to 75 Years   (Adult, Senior)","Phase 4","136","Other","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","PEG-3350","July 22, 2010","April 2010","July 2011","May 6, 2016","May 2016","April 16, 2015","null","July 2011","Comparison of the Efficacy, of the Standard Bowel Preparation Golytely With Miralax.|Safety of Two Competing PEG Preparations","https://ClinicalTrials.gov/show/NCT01170754"
3097,"NCT01650311","Investigating Serotonin Signalling in IBD Patients","Active, not recruiting","No Results Available","Inflammatory Bowel Disease","","McMaster University","Both","19 Years to 85 Years   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-239","June 17, 2012","July 2012","May 2016","April 1, 2016","April 2016","No Study Results Posted","IBD","May 2016","Colonic 5-HT levels|Receptor expressions|Colonic cytokine levels","https://ClinicalTrials.gov/show/NCT01650311"
3098,"NCT02736305","Use of Regorafenib in Recurrent Epithelial Ovarian Cancer","Recruiting","No Results Available","Ovarian Neoplasms","Drug: Regorafenib","National Cancer Centre, Singapore","Female","21 Years to 99 Years   (Adult, Senior)","Phase 2","34","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC OV-01","October 13, 2015","February 2016","June 2018","April 13, 2016","April 2016","No Study Results Posted","null","December 2017","Investigator assessed progression free survival (PFS)|Overall survival (OS)|Overall tumour response rate (ORR) as per Gynecological Cancer Intergroup (GCIG) and RECIST v1.1 criteria|Treatment Emergent Adverse Events","https://ClinicalTrials.gov/show/NCT02736305"
3099,"NCT01506869","Risk Evaluation of cAncers in Chinese diabeTic Individuals: a lONgitudinal Study","Recruiting","No Results Available","Cancer","","Shanghai Jiao Tong University School of Medicine|Chinese Society of Endocrinology","Both","40 Years to 75 Years   (Adult, Senior)","","200000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCEMD010","January 5, 2012","May 2011","June 2015","January 9, 2012","January 2012","No Study Results Posted","REACTION","December 2014","number of participants who develop cancer during follow-up","https://ClinicalTrials.gov/show/NCT01506869"
3100,"NCT00815113","Screening for Gastric Cancer in High-risk Population","Recruiting","No Results Available","Gastric Cancer","","Rabin Medical Center","Both","18 Years to 60 Years   (Adult)","","450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RMC080000CTIL","December 25, 2008","October 2009","December 2014","December 2, 2012","December 2012","No Study Results Posted","Stomach","October 2013","Characterization of the high-rik individual for gastric cancer - ""Gastric Cancer Phenotype""|Establish a screen plan for high-risk population for gastric cancer","https://ClinicalTrials.gov/show/NCT00815113"
3101,"NCT02263365","Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies","Recruiting","No Results Available","Dehydration, Diverting Ileostomy, Loperamide","Drug: Loperamide","Cedars-Sinai Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 3","220","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","Loperamide Dehydration","October 8, 2014","October 2014","December 2016","July 27, 2016","July 2016","No Study Results Posted","null","November 2016","Incidence of 30 day readmission (severe dehydration)|Moderate dehydration resulting in outpatient visits or ER intervention that is =/<24hrs that did not require hospital admission|Mild dehydration - subjective report of difficulty in managing fluid balances and stoma care","https://ClinicalTrials.gov/show/NCT02263365"
3102,"NCT02025504","Carolina-ColoWrap® in Colonoscopy Performance and Outcomes Study","Completed","No Results Available","Performance and Tolerance of Colonoscopy","Device: ColoWrap","ColoWrap, LLC|University of North Carolina, Chapel Hill","Both","40 Years to 80 Years   (Adult, Senior)","","350","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Prevention","ColoWrap-002","December 28, 2013","April 2014","March 2015","March 31, 2015","March 2015","No Study Results Posted","C3PO","March 2015","Mean colonoscopic insertion time|Frequency of use of ancillary maneuvers|Frequency of prolonged, difficult cases|Drug and Dosage Required to Complete Procedure|Colonoscopy Completion Rate|Time to patient discharge|Operator perception of patient discomfort|Patient Pain, Bloating, and Satisfaction at Discharge|Operator's Assessment of Procedural Difficultly|Assistant/Technician's Assessment of Musculoskeletal Pain Following Procedure","https://ClinicalTrials.gov/show/NCT02025504"
3103,"NCT00721266","A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.","Completed","No Results Available","Neoplasms","Drug: RO5083945","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 1","102","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BO21495|2007-005939-28","July 4, 2008","June 2008","June 2011","September 1, 2016","September 2016","No Study Results Posted","null","June 2011","Pharmacokinetic parameters, and maximum tolerated dose (Part 1)|Tumor growth control rate (CR, PR, SD) (Part 2)|AEs and laboratory parameters, pharmacodynamic parameters (Parts 1 and 2)|Anti-tumor activity (ORR, DR, PFS) (Part 2)","https://ClinicalTrials.gov/show/NCT00721266"
3104,"NCT01471210","Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","Completed","No Results Available","Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma","Drug: Urelumab (BMS-663513)","Bristol-Myers Squibb","Both","18 Years and older   (Adult, Senior)","Phase 1","124","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA186-011|2012-000170-28","November 10, 2011","February 2012","April 2016","September 7, 2016","August 2016","No Study Results Posted","null","April 2016","Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests|Dose-limiting toxicity and maximum tolerated dose of Urelumab (BMS-663513) as determined by the incidence of dose-limiting toxicities|Maximum observed serum concentrations (Cmax) of Urelumab (BMS-663513)|Minimum observed serum concentrations (Cmin) of Urelumab (BMS-663513)|Time of maximum observed serum concentration (Tmax) of Urelumab (BMS-663513)|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of Urelumab (BMS-663513)|Plasma half-life (T-HALF) of Urelumab (BMS-663513)|Total body clearance (CLT) of Urelumab (BMS-663513)|Volume of distribution at steady-state (Vss) of Urelumab (BMS-663513)|Human Anti-human Antibodies|Tumor response and progression as determined by proportion of patients with best overall response (BOR), progression-free survival (PFS), objective response rate (ORR), time to response, and duration of response","https://ClinicalTrials.gov/show/NCT01471210"
3105,"NCT00887497","Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery","Terminated","No Results Available","Colon Rectal Resection","Procedure: Angioembolization","University of California, Irvine","Both","18 Years and older   (Adult, Senior)","Phase 4","10","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-6618","April 22, 2009","April 2009","June 2011","September 26, 2011","September 2011","No Study Results Posted","null","June 2011","Any adverse even (safety study)","https://ClinicalTrials.gov/show/NCT00887497"
3106,"NCT00463203","Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy","Completed","No Results Available","Brain Neoplasms|Glioma","Drug: Bevacizumab|Drug: Irinotecan","Rigshospitalet, Denmark","Both","18 Years and older   (Adult, Senior)","Phase 2","54","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BI-Brain-01","April 18, 2007","March 2007","June 2011","June 27, 2011","June 2011","No Study Results Posted","null","March 2011","progression-free survival|Response rate - Response according to MacDonald criteria|Adverse event according to CTCAE 3.0","https://ClinicalTrials.gov/show/NCT00463203"
3107,"NCT00859222","LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma","Active, not recruiting","No Results Available","Malignant Glioma","Drug: LBH589|Drug: bevacizumab","Patrick Y. Wen, MD|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Northwestern University|University of Virginia|Genentech, Inc.|Novartis|Dana-Farber Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","48","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-342|CLBH589BUS42T","March 9, 2009","March 2009","December 2014","June 30, 2014","June 2014","No Study Results Posted","null","September 2013","Phase I: To determine the maximum tolerated dose of LBH589 in combination with bevacizumab in this patient population.|Phase II: To determine the efficacy of LBH589 in combination with bevacizumab in this patient population as measured by 6-month progression-free survival.|Phase I: To define the safety of LBH589 and bevacizumab in this patient population.|Phase I: To characterize the pharmacokinetics of LBH589 in this population.|Phase II: To determine the efficacy of LBH589 in combination with bevacizumab in this patient population by overall survival, time-to-tumor progression and objective tumor response.|Phase II: To further evaluate the safety profile of LBH589 and bevacizumab in this population.","https://ClinicalTrials.gov/show/NCT00859222"
3108,"NCT00123786","Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma","Terminated","No Results Available","Sarcoma","Procedure: Positron Emission Tomography","AHS Cancer Control Alberta|Cross Cancer Institute","Both","15 Years and older   (Child, Adult, Senior)","Phase 2","4","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","MS-12-0009/DX-FDG-005/21933","July 22, 2005","August 2005","March 2008","February 24, 2016","March 2012","No Study Results Posted","null","March 2008","establish the general utility, value and clinical relevance of FDG-PET imaging in patients with known or suspected soft tissue sarcoma|demonstrate the safety of FDG-PET by documentation of adverse events|determine whether the number of subjects available for study at the Cross Cancer Institute (CCI) is sufficient to achieve statistically significant results|determine the feasibility of extending this study to a larger multicenter design","https://ClinicalTrials.gov/show/NCT00123786"
3109,"NCT02091895","Validation of Clinical Efficacy and Development of New Diagnostic Algorithm of Probe-based Confocal Laser Endomicroscopy in Patients With Lower Gastrointestinal Disorder","Recruiting","No Results Available","Lower Gastrointestinal Disorders","Procedure: probe-based confocal laser endomicroscopy","Yonsei University","Both","20 Years and older   (Adult, Senior)","","311","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","4-2013-0942","March 16, 2014","March 2014","March 2016","January 7, 2015","January 2015","No Study Results Posted","null","March 2016","Sensitivity of pCLE diagnosis|Specificity of pCLE diagnosis|Accuracy of pCLE diagnosis|amphoteric predict of pCLE diagnosis","https://ClinicalTrials.gov/show/NCT02091895"
3110,"NCT02042144","Safety and Effectiveness of Regorafenib","Recruiting","No Results Available","Neoplasms","Drug: Stivarga (Regorafenib, BAY73-4506)","Bayer","Both","18 Years and older   (Adult, Senior)","Phase 4","1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16821|SV1302","January 20, 2014","April 2014","December 2017","August 22, 2016","August 2016","No Study Results Posted","Correlate","September 2017","Incidence of all treatment-emergent adverse events (TEAE) - Patients will be monitored for TEAE using the NCI-CTCAE Version 4.3|Overall Survival (OS), OS is defined as the time interval from the start of regorafenib therapy to death, due to any cause.|Progression free survival (PFS) is defined as the time interval measured from the day of start with regorafenib treatment to (radiological or clinical) progression or death, whichever comes first.|Disease control rate (DCR) - DCR is defined as percentage of patients, whose best response was not progressive disease (i.e. CR, PR or SD). Stable disease must be at least 6 weeks in duration.|Quality of Life - HRQoL using PRO questionnaire EQ-5D (8) in applicable countries|Healthcare resource utilization","https://ClinicalTrials.gov/show/NCT02042144"
3111,"NCT01880606","Endomicroscopy in Primary Sclerosing Cholangitis Related Inflammatory Bowel Disease Surveillance","Completed","No Results Available","Primary Sclerosing Cholangitis|Inflammatory Bowel Disease","Procedure: colonoscopy with endomicroscopy","Karolinska University Hospital","Both","18 Years to 75 Years   (Adult, Senior)","","69","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PSC-IBD2012","June 12, 2013","August 2011","June 2014","April 24, 2015","April 2015","No Study Results Posted","pCLE-PSC-IBD","December 2013","Sensitivity and specificity of endomicroscopy versus white light endoscopy in detection of dysplastic lesions in colon using histological assesment as a gold standard.|measurement of number of dysplastic lesions discovered by adding pCLE to white-light endoscopy","https://ClinicalTrials.gov/show/NCT01880606"
3112,"NCT01075828","Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea","Completed","No Results Available","Head and Neck Cancer","Drug: Cetuximab","Merck KGaA","Both","Child, Adult, Senior","","221","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","EMR62241-508 (EMR 62202-551)","February 24, 2010","March 2009","July 2014","August 28, 2014","August 2014","No Study Results Posted","null","July 2014","Frequency of Adverse Events|Clinical efficacy","https://ClinicalTrials.gov/show/NCT01075828"
3113,"NCT01216111","Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer","Available","No Results Available","Triple Negative Breast Cancer","Drug: Paclitaxel Cisplatin","Fudan University|Chinese Anti-Cancer Association","Female","18 Years to 65 Years   (Adult)","","null","Other","Expanded Access","","Fudan TNBC Adjuvant CT","October 6, 2010","null","null","October 6, 2010","June 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01216111"
3114,"NCT02362750","Evaluating Cancer Survivorship Care Models","Completed","No Results Available","Quality of Life|Cancer","Other: Organizational Interview|Other: Organizational Survey|Other: Survivor Survey (1): Pre-Visit Baseline|Other: Survivor Survey (2): Post-Visit|Other: Survivor Survey (3): 3 Month Post-Visit|Other: Survivor Survey (4): 6 Month Post-Visit|Other: Clinician Survey","George Washington University","Both","18 Years and older   (Adult, Senior)","","992","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IH-12-11-5255","January 21, 2015","July 2013","April 2016","June 20, 2016","June 2016","No Study Results Posted","null","April 2016","Patient-centered outcomes for cancer survivors","https://ClinicalTrials.gov/show/NCT02362750"
3115,"NCT02453607","The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease","Recruiting","No Results Available","Inflammatory Bowel Disease|Crohn's Disease","Drug: Infliximab|Drug: thiopurine","Ernest Seidman|University of Toronto|University of Calgary|University of Alberta|McGill University Health Center","Both","18 Years to 70 Years   (Adult, Senior)","","225","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-158-GEN","May 21, 2015","May 2015","null","May 22, 2015","May 2015","No Study Results Posted","null","June 2017","Correlation of 6-TGN serum levels with IFX serum trough levels","https://ClinicalTrials.gov/show/NCT02453607"
3116,"NCT00256269","Weekly Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal Carcinoma","Completed","No Results Available","Esophageal Cancer|Gastroesophageal Cancer","Drug: Oxaliplatin|Drug: Irinotecan","University of California, Irvine","Both","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 04-09|2004-3849","November 17, 2005","June 2005","April 2011","August 15, 2011","August 2011","No Study Results Posted","null","February 2008","To assess the overall response rate|To assess the frequency and severity of toxicities","https://ClinicalTrials.gov/show/NCT00256269"
3117,"NCT01877525","Resect and Discard Approach to Diminutive Colonic Polyps","Completed","No Results Available","Benign Polyps of Large Intestine","Procedure: Colonoscopy","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","","618","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201105473","June 11, 2013","October 2011","October 2012","June 11, 2013","June 2013","No Study Results Posted","RD","October 2012","concordance of recommended surveillance intervals|diagnostic performance","https://ClinicalTrials.gov/show/NCT01877525"
3118,"NCT01813994","Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer","Recruiting","No Results Available","Early Gastric Cancer or Gastric Adenoma","Drug: Arm1: Statin|Drug: Arm2: Placebo","Yonsei University","Both","20 Years to 70 Years   (Adult, Senior)","","110","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","4-2012-0889","March 7, 2013","February 2013","May 2016","May 26, 2014","February 2014","No Study Results Posted","null","December 2015","Proportion of the patients with high-risk (III/IV) OLGA stages","https://ClinicalTrials.gov/show/NCT01813994"
3119,"NCT00691691","Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors","Recruiting","No Results Available","Liver Tumors","Radiation: Stereotactic Body Radiation Therapy","Alberta Health Services|AHS Cancer Control Alberta","Both","18 Years and older   (Adult, Senior)","Phase 2","71","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","18740","June 3, 2008","November 2007","null","January 18, 2012","August 2011","No Study Results Posted","null","null","Response rate to SBRT|Treatment Related Toxicity","https://ClinicalTrials.gov/show/NCT00691691"
3120,"NCT01140802","Gut Microbiota in the Healthy Population, Inflammatory Bowel Disease Patients, and Their Relatives","Recruiting","No Results Available","Inflammatory Bowel Disease","","Chinese University of Hong Kong","Both","18 Years and older   (Adult, Senior)","","72","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IBD Microbe","June 8, 2010","March 2010","June 2016","February 2, 2015","February 2015","No Study Results Posted","null","June 2016","To identify specific gut microbiota in IBD patients|To identify environmental risk factors|To identify genetic differences among IBD patients, their relatives and the control subjects|To identify disease characteristics among IBD patients","https://ClinicalTrials.gov/show/NCT01140802"
3121,"NCT00797914","Evaluation of Handheld Colonoscopy Force Monitor by Expert Endoscopists in the Performance of Colonoscopy","Completed","No Results Available","Identify Characteristics of Colonoscopists During Endoscopy","","Artann Laboratories|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Capital Digestive Care, LLC|Mayo Clinic|Sansum Clinic|Georgetown University","Both","30 Years to 75 Years   (Adult, Senior)","","150","Industry|NIH|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CFM-01|5R44DK068936","November 23, 2008","July 2008","June 2016","July 11, 2016","July 2016","No Study Results Posted","null","June 2016","CFM can continuously record forces applied to colonoscope by different expert endoscopists during routine outpatient colonoscopy.|CFM can characterize differences in force patterns for different patients and different endoscopists","https://ClinicalTrials.gov/show/NCT00797914"
3122,"NCT00463073","Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas","Completed","No Results Available","Malignant Gliomas","Drug: Cetuximab|Drug: Bevacizumab|Drug: Irinotecan","Rigshospitalet, Denmark|Aalborg Universitetshospital|Odense University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","CBI-GBM-01","April 19, 2007","August 2006","December 2008","December 10, 2008","December 2008","No Study Results Posted","null","December 2008","","https://ClinicalTrials.gov/show/NCT00463073"
3123,"NCT01522989","PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies","Recruiting","No Results Available","Advanced Solid Tumor Malignancies","Drug: PD-0332991|Drug: 5-FU|Drug: Oxaliplatin","Georgetown University|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","37","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-219|WS1877559","December 20, 2011","December 2011","December 2016","August 17, 2016","August 2016","No Study Results Posted","null","December 2016","Recommended Phase 2 dose and schedule|Toxicity|Pharmacodynamics|Response rate|Disease control rate|Trough level of PD-0332991 on Day 1 of Cycles 1-4","https://ClinicalTrials.gov/show/NCT01522989"
3124,"NCT00745095","Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage","Completed","Has Results","Spinal Cord Injury","Drug: Neostigmine","VA Office of Research and Development","Both","18 Years and older   (Adult, Senior)","Phase 4","360","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Diagnostic","A6428-R|KOR-09-10","September 2, 2008","March 2009","May 2013","July 2, 2014","May 2014","April 18, 2014","null","March 2013","Quality of Bowel Preparation|Polyp Detection","https://ClinicalTrials.gov/show/NCT00745095"
3125,"NCT02887599","Assessment of the Cytotoxic Immune Status of Pancreatic Cancer Patients and the Severity of the Cancer Using Measurement of Natural Killer Cell Activities","Recruiting","No Results Available","Pancreatic Cancer","Procedure: Blood collection","Yonsei University","Both","19 Years to 84 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","4-2016-0015","August 22, 2016","August 2016","February 2017","August 29, 2016","August 2016","No Study Results Posted","null","February 2017","Difference of the cytotoxic immune status|Difference of the severity of the pancreatic cancer|Correlation of the cytotoxic immune status","https://ClinicalTrials.gov/show/NCT02887599"
3126,"NCT02728973","ERAS Protocol on the Incidence of Postoperative Complications Following Intestinal Surgery","Recruiting","No Results Available","Postoperative Complications","Other: ERAS program","First Affiliated Hospital of Chongqing Medical University","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","ERASCQ2016","March 27, 2016","February 2016","March 2017","March 31, 2016","March 2016","No Study Results Posted","null","December 2016","The difference in postoperative morbidity rate|length of hospital stay|mortality","https://ClinicalTrials.gov/show/NCT02728973"
3127,"NCT00583323","Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET","Completed","No Results Available","Lymphoma","Drug: Lomotil|Other: Normal saline","Mayo Clinic","Both","18 Years and older   (Adult, Senior)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Diagnostic","2051-02","December 20, 2007","February 2003","September 2005","August 20, 2014","August 2014","No Study Results Posted","null","September 2005","Reduction of bowel activity|Reduction of stomach activity","https://ClinicalTrials.gov/show/NCT00583323"
3128,"NCT02860481","FSH-R : Diagnostic Application for Localized Tumors in Cancerology","Recruiting","No Results Available","Cancer","Procedure: blood sample for FSHR analysis|Procedure: blood sample for FSHR analysis","Institut Curie","Both","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","IC 2012-09","July 28, 2016","November 2013","null","August 8, 2016","July 2016","No Study Results Posted","FRACTal","November 2016","sensitivity of blood FSH R detection in cancer patients|variability of blood FSH-R in the same tumoral type and between different tumoral types|comparison of blood FSH-R with blood from healthy donor","https://ClinicalTrials.gov/show/NCT02860481"
3129,"NCT02681692","Effect of Magnetic Endoscopic Imaging on Patient Pain During Colonoscopy","Recruiting","No Results Available","Colonic Diseases","Device: Magnetic endoscopic imaging system","Shanghai Jiao Tong University School of Medicine","Both","18 Years to 75 Years   (Adult, Senior)","","570","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","rj（2015）086k","February 10, 2016","April 2016","January 2017","August 7, 2016","August 2016","No Study Results Posted","null","December 2016","patients over pain experience|Maximum target colon loop force|number of attempts of abdominal hand pressure|number of patient reposition|endoscopist perception of ease of procedure|patient's intention to attend unsedated colonoscopy again|caecal intubation rate|caecal intubation time|ime for the colonoscopist to advance to splenic flexure of colon","https://ClinicalTrials.gov/show/NCT02681692"
3130,"NCT01747551","FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer","Active, not recruiting","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: Oxaliplatin|Drug: Folinic Acid|Drug: 5-Fluorouracil|Drug: Ziv-aflibercept|Drug: Ziv-aflibercept Placebo","Dana-Farber Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","64","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","12-401","December 5, 2012","September 2013","null","May 9, 2016","May 2016","No Study Results Posted","null","September 2016","Estimate efficacy of Ziv-aflibercept+mFOLFOX6 in esophagogastric adenocarcinomas, as measured by progression-free survival (PFS).|Evaluate safety and tolerability of Ziv-aflibercept+mFOLFOX6 by evaluating toxicity and the number of adverse events.|Evaluate response rate using RECIST 1.1.|Estimate duration of objective response","https://ClinicalTrials.gov/show/NCT01747551"
3131,"NCT01216124","Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients","Available","No Results Available","Triple Negative Local Advanced Breast Cancer","Drug: docetaxel oxaliplatin","Fudan University|Chinese Anti-Cancer Association","Female","18 Years to 65 Years   (Adult)","","null","Other","Expanded Access","","Fudan TNBC Neo CT","October 6, 2010","null","null","October 6, 2010","September 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01216124"
3132,"NCT01360320","Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-","Recruiting","No Results Available","Colorectal Serrated Adenomas|Colorectal Tubular Adenomas|Colorectal Villous Adenomas|Colorectal Tubulovillous Adenomas","Dietary Supplement: Green tea extract of Camellia Sinensis|Dietary Supplement: Green tea extract of Camellia Sinensis followed by placebo","Martin-Luther-Universität Halle-Wittenberg|University of Ulm|KKS Netzwerk|Deutsche Krebshilfe e.V., Bonn (Germany)","Both","50 Years to 80 Years   (Adult, Senior)","Phase 2","2941","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MIRACLE","May 23, 2011","November 2011","March 2018","April 5, 2012","April 2012","No Study Results Posted","MIRACLE","March 2018","Incidence of metachronous colorectal adenomas (tubulovillous, tubular, villous and serrated lesions) at the 3 year follow-up colonoscopy|Occurrences of colorectal adenomas or mucosal lesions|Number of colorectal adenomas or mucosal lesions|Size of colorectal adenomas or mucosal lesions|Localization of colorectal adenomas or mucosal lesions|Histological subtypes of colorectal adenomas or mucosal lesions|Invasive growth of colorectal adenomas or mucosal lesions|Incidence of colorectal carcinoma|Translational research|Toxicity and feasibility","https://ClinicalTrials.gov/show/NCT01360320"
3133,"NCT02712073","Predictive Score of the Bowel Preparation Quality Based on a Self-administered Questionnaire","Recruiting","No Results Available","Colonoscopy","Other: Questionnaire","University Hospital, Angers","Both","18 Years and older   (Adult, Senior)","","1260","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DRCI V11 01/01/2015","March 14, 2016","May 2015","September 2017","April 12, 2016","April 2016","No Study Results Posted","PREPA-CO","September 2017","Score performance|acceptability of questionnaire|Adenoma detection","https://ClinicalTrials.gov/show/NCT02712073"
3134,"NCT02138318","High Definition Versus Chromoendoscopy for Dysplasia Detection in Ulcerative Colitis (UC)","Recruiting","No Results Available","Ulcerative Colitis","Other: High definition (HD) endoscopy|Other: chromoendoscopy","The Leeds Teaching Hospitals NHS Trust","Both","18 Years and older   (Adult, Senior)","","152","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GA12/10210","April 1, 2014","May 2012","null","May 13, 2014","May 2014","No Study Results Posted","null","May 2015","number of lesions","https://ClinicalTrials.gov/show/NCT02138318"
3135,"NCT00182234","SONICS - Effectiveness of Specialist Oncology Nursing","Completed","No Results Available","Continuity of Care|Quality of Life","Behavioral: Community Interlink Program","McMaster University|Canadian Institutes of Health Research (CIHR)|Ontario Ministry of Health and Long Term Care","Both","18 Years and older   (Adult, Senior)","Phase 3","183","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","74867|CIHR - 74867|MOHLTC - 04171","September 13, 2005","December 2005","March 2009","June 17, 2009","June 2009","No Study Results Posted","null","March 2009","Difference in unmet supportive care needs between intervention and control group|Difference in continuity of care between intervention and control group|Difference in quality of life between intervention and control group|Difference in uncertainty in illness between intervention and control group|Difference in use of resources between intervention and control group|Acute stress following surgery","https://ClinicalTrials.gov/show/NCT00182234"
3136,"NCT02356757","Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy","Recruiting","No Results Available","Diabetes|Foot Ulcer","Behavioral: Personalized Behavioral Intervention|Behavioral: Current Best Practice","VA Office of Research and Development","Both","21 Years and older   (Adult, Senior)","","404","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","IIR 14-009","February 2, 2015","August 2015","January 2019","July 21, 2016","July 2016","No Study Results Posted","PATRIOT","October 2018","Ulcerative and non-ulcerative Foot lesions|Foot care skills|Foot-care education|Medication adherence|Diet|Physical activity|A1c|Systolic blood pressure|LDL|Health-related quality of life|Cost-effectiveness","https://ClinicalTrials.gov/show/NCT02356757"
3137,"NCT00393094","Bevacizumab and Irinotecan to Treat Brain Tumors","Terminated","Has Results","High-Grade Gliomas","Biological: Bevacizumab|Drug: Irinotecan hydrochloride","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","Phase 2","31","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","060250|06-C-0250","October 25, 2006","September 2006","March 2010","July 6, 2012","July 2012","March 27, 2012","null","January 2010","Radiographic Response Rate (Malignant Glioma Participants)|Number of Participants With Toxicity as Measured by The National Cancer Institute (NCI) Common Toxicity Criteria v. 3.0.|Radiographic Response Rate (Anaplastic Glioma Participants)|Radiographic Response Rate (Glioblastoma Multiforme Participants)","https://ClinicalTrials.gov/show/NCT00393094"
3138,"NCT00127920","Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients","Completed","No Results Available","Ovarian Neoplasms","Drug: Avastin","Gynecologic Oncology Associates|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AV53206s","August 5, 2005","August 2004","October 2012","March 9, 2015","March 2015","No Study Results Posted","null","August 2006","time to tumor progression|response rate|safety|survival","https://ClinicalTrials.gov/show/NCT00127920"
3139,"NCT02456714","Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma","Recruiting","No Results Available","Cholangiocarcinoma","Drug: FOLFIRINOX","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","volgt","March 10, 2015","December 2015","January 2018","February 11, 2016","February 2016","No Study Results Posted","4CC","January 2018","pilot study: toxicity|phase II: the response rate|pilot study: the response rate|pilot study: time to progression.|pilot study: the overall survival|pilot study: quality of life|phase II: toxicity during the treatment period and 30 days after the treatment.|phase II: time to progression.|phase II: the overall survival.|phase II: quality of life","https://ClinicalTrials.gov/show/NCT02456714"
3140,"NCT02083224","Familial Cancer Registry and DNA Bank","Recruiting","No Results Available","Cancer","","National University Hospital, Singapore","Both","13 Years and older   (Child, Adult, Senior)","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2000/00511","March 4, 2014","January 2000","null","March 6, 2014","March 2014","No Study Results Posted","null","December 2018","Change in genetics testing method","https://ClinicalTrials.gov/show/NCT02083224"
3141,"NCT01807572","Relation of Consummatory and Anticipatory Food Reward to Obesity","Completed","No Results Available","Weight Gain|Food Habits","","Oregon Research Institute|National Institutes of Health (NIH)","Both","14 Years to 16 Years   (Child)","","162","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","DK080760-01","February 7, 2013","June 2009","July 2015","September 29, 2015","September 2015","No Study Results Posted","null","May 2015","Test whether high-risk youth show abnormalities in consummatory and anticipatory food reward relative to low-risk youth|Test the hypothesis that individuals showing abnormalities in anticipatory and consummatory food reward are at increased risk for future weight gain and obesity onset over a 3-year follow-up","https://ClinicalTrials.gov/show/NCT01807572"
3142,"NCT01619020","FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health","Recruiting","No Results Available","Healthy","Dietary Supplement: Flaxseed Lignans","Fred Hutchinson Cancer Research Center|Texas A&M University|National Cancer Institute (NCI)","Both","20 Years to 45 Years   (Adult)","","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)","FHCRC IR 7532","April 16, 2012","October 2012","August 2017","August 9, 2016","August 2016","No Study Results Posted","FlaxFx","May 2017","mRNA expression in colonic mucosal tissue (stroma and epithelial) and exfoliated cells in individuals with low- or high-ENL excretion.","https://ClinicalTrials.gov/show/NCT01619020"
3143,"NCT02084836","Relation of Consummatory & Anticipatory Food Reward to Obesity","Active, not recruiting","No Results Available","Obesity","Other: Functional Magnetic Resonance Imaging","Oregon Research Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","14 Years to 17 Years   (Child)","","162","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","DK080760|R01DK080760","March 10, 2014","June 2009","July 2014","March 11, 2014","March 2014","No Study Results Posted","null","July 2014","increases in BMI|(anticipated) reward from food intake","https://ClinicalTrials.gov/show/NCT02084836"
3144,"NCT02031029","Character Traits and Stress in Suspected Prostate Cancer","Terminated","No Results Available","Prostatic Diseases","","Helse Stavanger HF|University Hospital, Akershus","Male","18 Years to 75 Years   (Adult, Senior)","","51","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2013/113","October 9, 2013","December 2013","December 2018","April 4, 2016","April 2016","No Study Results Posted","null","December 2016","MGRSS questionnaire|Testosterone|Cholesterol|Vitamin D, Folic acid, White Blood Cells, C-reactive protein (CRP)|coffee and green tea consumption","https://ClinicalTrials.gov/show/NCT02031029"
3145,"NCT00418678","A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting","Terminated","No Results Available","Nausea and Vomiting","Drug: Cesamet","Veeda Oncology|Valeant Pharmaceuticals International, Inc.","Both","18 Years to 65 Years   (Adult)","Phase 4","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I-05-017","January 3, 2007","August 2006","December 2007","November 30, 2010","August 2008","No Study Results Posted","null","December 2007","To demonstrate incremental improvement with Cesamet in control of chemotherapy induced nausea and vomiting in patients who have failed to respond adequately to standard antiemetic regimens.|To determine whether the addition of Cesamet to standard antiemetic regimens leads to incremental benefit in the secondary outcomes of:|The percent of patients with no emetic episodes, the percentage of patients with no nausea, the percentage of patients with no significant nausea|time to first emetic episode, decrease in pain over the 5 day study period, decrease in analgesic use over the 5 day study period,Improvement in global quality of life as compared to without cannabinoid use|the mean (or median) change in VAS score for nausea and pain","https://ClinicalTrials.gov/show/NCT00418678"
3146,"NCT00979277","Transcriptomal and Molecular Characterization of Tumor Associated Monocytes/Macrophages in Human Cancers","Recruiting","No Results Available","Tumor|Cancer","","National University Hospital, Singapore","Both","21 Years and older   (Adult, Senior)","","null","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MC03/17/07","September 15, 2009","null","null","January 8, 2014","January 2014","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00979277"
3147,"NCT00656786","Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash","Active, not recruiting","No Results Available","EGFR Inhibitor-associated Rash","Drug: Menadione Topical Lotion|Drug: Menadione Topical Lotion","Spectrum Pharmaceuticals, Inc","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HBS701","April 7, 2008","April 2008","December 2015","June 2, 2015","June 2015","No Study Results Posted","null","December 2015","To evaluate safety, tolerability and systemic absorption of Menadione Topical Lotion as an emergent and pre-emergent treatment for EGFR inhibitor-associated rash|To evaluate skin rash status as an emergent and pre-emergent treatment for EGFR inhibitor-associated rash","https://ClinicalTrials.gov/show/NCT00656786"
3148,"NCT01902745","Fatigue Reduction Diet","Completed","No Results Available","Chronic Fatigue","Behavioral: Social Cognitive Theory","University of Michigan|University of Michigan Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HUM00075741","July 2, 2013","November 2013","September 2015","June 30, 2016","June 2016","No Study Results Posted","FRD","September 2015","Fatigue in Breast Cancer Survivors|Tolerability, Goals, Beliefs and Expectations of Participants","https://ClinicalTrials.gov/show/NCT01902745"
3149,"NCT01609114","Irradiation Modulates the Pharmacokinetics of Anticancer Drugs for Head and Neck Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","","Far Eastern Memorial Hospital","Both","20 Years to 80 Years   (Adult, Senior)","","30","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","FEMH No.:100163-F","April 27, 2012","April 2012","null","May 8, 2013","May 2013","No Study Results Posted","null","July 2016","Area under the plasma concentration versus time curve (AUC) of'chemo-drugs""","https://ClinicalTrials.gov/show/NCT01609114"
3150,"NCT00342966","Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation","Completed","No Results Available","Cancer","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","20 Years to 60 Years   (Adult)","","34","NIH","Observational","","999999032|OH99-C-N032","June 19, 2006","June 1999","July 2010","July 24, 2010","July 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00342966"
3151,"NCT01337102","Computer-Generated Quality of Life Assessment Program for Advanced Non-Small Cell Lung Cancer Patients (LUNL2)","Completed","No Results Available","Non Small Cell Lung Cancer","Procedure: Physician Receives QoL results|Procedure: Physician Does not receive the results","University Health Network, Toronto|Mount Sinai Hospital, Canada","Both","18 Years and older   (Adult, Senior)","","103","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Supportive Care","04-0349-CE","April 5, 2011","November 2004","November 2011","December 13, 2011","December 2011","No Study Results Posted","LUNL2","October 2011","Number of Palliative care Referrals.|Number of palliative first-line chemotherapy cycles administered.|Use of supportive treatments.|Number of imaging tests ordered.|Differences between study arm scores","https://ClinicalTrials.gov/show/NCT01337102"
3152,"NCT01509976","Triclosan, Triclocarban, and the Microbiota","Recruiting","No Results Available","Triclosan Effects on Microbial Flora.","Other: triclosan/triclocarban-containing personal care products","Stanford University","Both","18 Years and older   (Adult, Senior)","","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","AVOCET","January 6, 2012","July 2011","December 2012","January 12, 2012","January 2012","No Study Results Posted","null","October 2012","Changes in microbial flora|Microbial resistance|Time to alteration in flora.","https://ClinicalTrials.gov/show/NCT01509976"
3153,"NCT01492673","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma","Active, not recruiting","No Results Available","Neuroblastoma|Sarcoma","Drug: Cyclophosphamide, Topotecan, and Bevacizumab","Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Children's Mercy Hospital Kansas City|Penn State University|University of Colorado, Denver|Sidney Kimmel Comprehensive Cancer Center|Phoenix Children's Hospital Center for Cancer & Blood Disorders|Alberta Children's Hospital|MD Anderson Cancer Center Orlando|M.D. Anderson Cancer Center","Both","up to 21 Years   (Child, Adult)","Phase 2","9","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11-183","December 12, 2011","December 2011","December 2017","April 25, 2016","April 2016","No Study Results Posted","null","December 2017","efficacy|safety","https://ClinicalTrials.gov/show/NCT01492673"
3154,"NCT02002468","Follow-up of Abnormal and Inadequate Smear-test Results","Active, not recruiting","No Results Available","Carcinoma in Situ of Uterine Cervix","Other: Test result sent by letter|Other: Test result conveyed by general practitioners","University of Aarhus","Female","23 Years and older   (Adult, Senior)","","125000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","Cervix cancer screening","November 29, 2013","October 2012","February 2017","September 14, 2016","December 2015","No Study Results Posted","null","October 2014","Proportion of women with timely follow-up|Frequency of general practitioner contacts (consultations/telephone calls /e-mails) regarding conveying the smear test result.","https://ClinicalTrials.gov/show/NCT02002468"
3155,"NCT00271609","Bevacizumab for Recurrent Malignant Glioma","Completed","Has Results","Recurrent High-Grade Gliomas|Malignant Gliomas","Drug: Bevacizumab","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","Phase 2","88","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","060064|06-C-0064","December 31, 2005","December 2005","February 2014","April 13, 2014","April 2014","April 30, 2012","null","March 2011","Percentage of Participants With Progression Free Survival at 6 Months.|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00271609"
3156,"NCT00511212","Intravenous Immunoglobulin in Combination Therapy With Antibacterial Agents for SSI of the Lower Digestive Tract","Withdrawn","No Results Available","Peritonitis|Postoperative Complications","Drug: intravenous immunoglobulin","Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group","Both","20 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MCSGO-0701","August 1, 2007","August 2007","June 2009","July 20, 2011","August 2007","No Study Results Posted","null","null","clinical efficacy|clinical efficacy, recurrence rate, mortality, time between drug administration and defervescence, defervescence rate,time between drug administration and disappearance of clinical symptoms, improvement rate on clinical symptoms","https://ClinicalTrials.gov/show/NCT00511212"
3157,"NCT02874053","The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk Tradeoffs","Not yet recruiting","No Results Available","Cancer","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","","600","NIH","Observational","Time Perspective: Cross-Sectional","999916161|16-C-N161","August 17, 2016","August 2016","November 2016","September 13, 2016","September 2016","No Study Results Posted","null","November 2016","willingness to take hypothetical pill","https://ClinicalTrials.gov/show/NCT02874053"
3158,"NCT01782443","Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors","Recruiting","No Results Available","Carcinoid Tumor","Drug: Ziv-aflibercept","Dana-Farber Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-456","January 31, 2013","February 2013","null","July 13, 2016","July 2016","No Study Results Posted","null","June 2017","Progression Free Survival|Safety and Tolerability of Ziv-aflibercept|Evaluation of Disease Response|Evaluation of Biochemical Response","https://ClinicalTrials.gov/show/NCT01782443"
3159,"NCT01010958","Adjuvant Valproate for High Grade Sarcomas","Terminated","No Results Available","High Grade Sarcoma","Drug: Valproic Acid","Columbia University","Both","18 Years and older   (Adult, Senior)","Phase 1","7","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAD4523","November 6, 2009","October 2009","February 2014","May 20, 2015","May 2015","No Study Results Posted","null","February 2014","Recurrence rate of lower grade sarcoma|Relapse free survival rate|Time to local failure|Time to distant failure","https://ClinicalTrials.gov/show/NCT01010958"
3160,"NCT02820857","Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer","Not yet recruiting","No Results Available","Neuroendocrine Carcinomas","Drug: Folfiri-bevacizumab|Drug: Folfiri","Hospices Civils de Lyon","Both","18 Years and older   (Adult, Senior)","Phase 2","124","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","69HCL14_0442","June 29, 2016","January 2017","January 2020","June 29, 2016","June 2016","No Study Results Posted","BEVANEC","June 2019","Proportion of patients alive","https://ClinicalTrials.gov/show/NCT02820857"
3161,"NCT02812875","A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas","Recruiting","No Results Available","Advanced Solid Tumors or Lymphomas","Drug: CA-170","Curis, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","150","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA-170-101","June 14, 2016","May 2016","January 2020","June 22, 2016","June 2016","No Study Results Posted","null","January 2019","The number of patients with a dose-limiting toxicity (DLT) in the first treatment cycle|Maximum tolerated dose (MTD) of CA-170|Recommended Phase 2 Dose (RP2D) of CA-170|Maximum Concentration (Cmax)|Area Under the Curve (AUC)|Exploratory Outcome Measure: Preliminary clinical efficacy based on RECIST|Exploratory Outcome Measure: Preliminary clinical efficacy based on irRECIST|Exploratory Outcome Measure: Preliminary clinical efficacy based on Cheson","https://ClinicalTrials.gov/show/NCT02812875"
3162,"NCT01775501","Sorafenib + mFOLFOX for Hepatocellular Carcinoma","Recruiting","No Results Available","Hepatocellular Cancer","Drug: Leucovorin|Drug: Fluorouracil|Drug: Oxaliplatin|Drug: Sorafenib","Massachusetts General Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-218","January 18, 2013","January 2013","December 2017","October 30, 2014","October 2014","No Study Results Posted","null","December 2015","Time to Progression|Number of patients experiencing Adverse Events|Overall response rate|Median progression free survival|Median Overall survival|Duration of response","https://ClinicalTrials.gov/show/NCT01775501"
3163,"NCT02310139","Failed/Difficult Colonoscopy Outcomes","Recruiting","No Results Available","Colonoscopy","Procedure: Colonoscopy","Professor Michael Bourke|Western Sydney Local Health District","Both","18 Years to 99 Years   (Adult, Senior)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HREC2014/9/4.7(4082)","December 3, 2014","May 2015","May 2021","December 15, 2015","December 2015","No Study Results Posted","FoDCO","May 2020","Description of reasons for failure of colonoscopy.","https://ClinicalTrials.gov/show/NCT02310139"
3164,"NCT01129154","Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)","Recruiting","No Results Available","Carcinoma, Squamous Cell","Drug: infusions of Panitumumab","Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Cliniques Universitaires UCL de Mont-Godinne, Dr Joseph Kerger|Cliniques Saint-Pierre Ottignies, Dr Lionel Duck","Both","18 Years and older   (Adult, Senior)","Phase 2","17","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Luc 09-002","May 21, 2010","August 2010","July 2012","August 27, 2010","August 2010","No Study Results Posted","PASCE","July 2012","Overall Response Rate (ORR)|To assess the safety profile of panitumumab in SCC|Time to treatment failure (TTF)and Time to treatment progression TTP|To measure the duration of response.|To explore the gene expression profiles in SCC under panitumumab treatment (i.e CCL27, EGFR,…).","https://ClinicalTrials.gov/show/NCT01129154"
3165,"NCT01990716","Lipid Mediators in Colonic Biopsies as Biomarkers of Disease Activity of Inflammatory Bowel Diseases","Active, not recruiting","No Results Available","Inflammatory Bowel Diseases|Colitis, Ulcerative|Crohn Disease","Other: Colonic Biopsy","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France","Both","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","12 393 02|AOL 2012","November 15, 2013","February 2013","December 2015","August 24, 2015","August 2015","No Study Results Posted","MICILIP","December 2015","Measure of 5,6-EET quantity in a colonic biopsy|Nature and quantity of Lipid metabolites as a function of the patient clinical profile (mapping)","https://ClinicalTrials.gov/show/NCT01990716"
3166,"NCT01796028","Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer","Active, not recruiting","No Results Available","Prostatic Neoplasms","Drug: METFORMIN|Drug: Placebo|Drug: TAXOTERE®","Centre Antoine Lacassagne","Male","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012-000530-19|2010/35","November 12, 2012","January 2013","December 2017","July 25, 2016","June 2016","No Study Results Posted","TAXOMET","December 2015","PSA response rate|Biochemical and clinical progression-free survival","https://ClinicalTrials.gov/show/NCT01796028"
3167,"NCT02845999","Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab","Completed","No Results Available","Gastrointestinal Metastatic Cancer","Biological: allogenic immunotherapy based on Natural Killer cells adoptive transfer|Biological: cetuximab|Drug: Cyclophosphamide|Drug: fludarabine|Drug: interleukin-2","Centre Hospitalier Universitaire de Besancon|National Cancer Institute, France","Both","18 Years to 65 Years   (Adult)","Phase 1","9","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","N2005/48-A","December 1, 2011","November 2009","null","July 22, 2016","March 2016","No Study Results Posted","NK-EGFR01","January 2013","number of patients with clinical or biological grade 3 or 4 treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02845999"
3168,"NCT02760381","Acetic Acid for Optical Characterization of Colonic Polyps","Not yet recruiting","No Results Available","Colonic Polyps","Device: NBI + Acetic Acid (AA)","Technische Universität München","Both","18 Years to 99 Years   (Adult, Senior)","","55","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","ATOMIC I","April 23, 2016","May 2016","October 2016","April 29, 2016","April 2016","No Study Results Posted","ATOMIC I","July 2016","Diagnostic test: Optical characterization of colon polyps","https://ClinicalTrials.gov/show/NCT02760381"
3169,"NCT01482741","Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging","Completed","No Results Available","Breast Cancer|Colon Cancer|Lung Cancer|Neuroblastoma|Testicular Cancer","Behavioral: Focus Group Sessions|Behavioral: Focus Group Sessions|Behavioral: Focus Group Sessions|Behavioral: Focus Group Sessions|Behavioral: Focus Group Sessions|Behavioral: Focus Group Sessions","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","11-185","November 28, 2011","November 2011","June 2015","June 24, 2015","June 2015","No Study Results Posted","null","June 2015","characterize participant knowledge, attitudes","https://ClinicalTrials.gov/show/NCT01482741"
3170,"NCT01871948","Effective Communication for Preventing and Responding to Oncology Adverse Events","Completed","No Results Available","Cancer","Other: ""We Want to Know"" campaign, Patient survey at 2 time points","University of Massachusetts, Worcester|National Cancer Institute (NCI)","Both","21 Years to 80 Years   (Adult, Senior)","","500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Health Services Research","1184|P20CA137219","May 22, 2013","October 2008","August 2013","December 12, 2013","December 2013","No Study Results Posted","CanComm","August 2013","Calculate differences in satisfaction with cancer care communication, using a summary score from patient surveys, between intervention and control groups.","https://ClinicalTrials.gov/show/NCT01871948"
3171,"NCT01336452","Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: MR Perfusion, Contrast Enhanced Ultrasound and Biomarkers","Recruiting","No Results Available","Advanced Adult Hepatocellular Carcinoma","Radiation: DCE MRI","Yonsei University","Both","20 Years and older   (Adult, Senior)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","4-2010-0566","April 13, 2011","April 2011","December 2013","June 1, 2013","June 2013","No Study Results Posted","null","December 2013","characteristic of Perfusion MR","https://ClinicalTrials.gov/show/NCT01336452"
3172,"NCT00687622","Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma","Completed","No Results Available","Solid Tumours","Drug: GSK1120212","GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 1","94","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MEK111054","May 28, 2008","July 2008","November 2011","June 8, 2015","June 2015","No Study Results Posted","null","June 2011","- To determine the maximum tolerated dose of GSK1120212|- To characterize the PK of GSK1120212 after single and repeat-dose administration|- To evaluate the pharmacodynamic response in tumors after treatment with GSK1120212|- To explore relationships between GSK1120212 PK, MAPK signalling inhibition and clinical endpoints|- To explore the clinical tumor response after treatment with GSK1120212|- To determine the association of clinical and PK endpoints with genetic and protein profiles from tumor tissue","https://ClinicalTrials.gov/show/NCT00687622"
3173,"NCT01627119","The Functional and Clinicopathological Roles and Therapeutic Implication of Connective Tissue Growth Factor in Peritoneal Metastasis of Gastric Cancer","Recruiting","No Results Available","Gastric Cancer","","National Taiwan University Hospital","Both","25 Years to 90 Years   (Adult, Senior)","","120","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","200906054R","June 21, 2012","July 2009","June 2012","June 22, 2012","June 2012","No Study Results Posted","CTGF","June 2012","To measure the expression level of CTGF in patient blood and tissue|To determine the survival probability of gastric cancer patients after surgery","https://ClinicalTrials.gov/show/NCT01627119"
3174,"NCT00590681","Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Glioblastoma Multiforme","Drug: Bevacizumab and Temozolomide","University of Chicago|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","62","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","15149A","December 26, 2007","February 2007","September 2014","September 2, 2015","September 2015","No Study Results Posted","null","September 2014","Determine estimates of the objective response and PFS in subjects wtih newly diagnosed GBM who are treated with radiotherapy and daily temozolomide/monthly cycles of temozolomide and Avastin until either disease progression or unacceptable toxicities|Determination of the safety of Avastin in combination with temozolomide in this study population/duration of response/determination of overall survival and changes in relative cerebral blood volume (rCBV) of tumors after (2 infusions) of Avastin","https://ClinicalTrials.gov/show/NCT00590681"
3175,"NCT01617915","Tumor Specific Plasma DNA","Recruiting","No Results Available","Breast Cancer|Lung Cancer","","Dartmouth-Hitchcock Medical Center","Both","18 Years and older   (Adult, Senior)","","6","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","D12127","June 10, 2012","October 2012","December 2016","April 26, 2016","September 2013","No Study Results Posted","null","December 2016","Circulating tumor levels correlation to response|Circulating tumor DNA following surgery|To determine optimal timing for detection of circulating tumor DNA|Circulating tumor DNA detection following surgery|Circulating tumor DNA correlation with pathologic complete response|Circulating tumor DNA correlation with clinical evidence of disease recurrence or progression","https://ClinicalTrials.gov/show/NCT01617915"
3176,"NCT02864836","Study of Copper Isotope in Head and Neck Cancer","Not yet recruiting","No Results Available","Head and Neck Tumors","Procedure: Samples collection","Lille Catholic University|Ecole Normale Supérieure de Lyon","Both","18 Years and older   (Adult, Senior)","","60","Other","Observational","Time Perspective: Prospective","RT-14","August 9, 2016","November 2016","November 2021","August 16, 2016","August 2016","No Study Results Posted","ISOTOPE","November 2018","Ratio of the different stable isotopes of copper in the various samples and groups|Patient survival rate|mRNA expression level of proteins involved in copper metabolism assessed by Polymerase chain reaction (PCR)","https://ClinicalTrials.gov/show/NCT02864836"
3177,"NCT02094456","Prophylactic Elective Clipping of Colonic Diverticula","Recruiting","No Results Available","Diverticular Disease","Procedure: Endoscopic clipping of diverticula|Procedure: Follow-up colonoscopy","King's College Hospital NHS Trust","Both","18 Years and older   (Adult, Senior)","","24","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","14/LO/0032","March 20, 2014","March 2016","May 2018","April 7, 2016","April 2016","No Study Results Posted","null","May 2017","The primary outcome will be episodes of recurrent bleeding requiring hospitalization.","https://ClinicalTrials.gov/show/NCT02094456"
3178,"NCT02266017","Mobile Pain Coping Skills Training for Cancer Pain","Recruiting","No Results Available","Mobile Pain Coping Skills Training|In Person Pain Coping Skills Training","Behavioral: Pain Coping Skills Training","Duke University","Both","18 Years and older   (Adult, Senior)","","180","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00054792|Research Scholars Grant","September 2, 2014","October 2014","June 2017","March 30, 2016","February 2016","No Study Results Posted","null","June 2017","Change in Pain","https://ClinicalTrials.gov/show/NCT02266017"
3179,"NCT00340743","Diet and Genetic Damage","Completed","No Results Available","Diet","","National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 45 Years   (Adult)","","16","NIH","Observational","Time Perspective: Prospective","999904169|04-E-N169","June 19, 2006","April 2004","null","May 11, 2016","October 2015","No Study Results Posted","null","null","to determine if eating certain foods and other dietary constituents will ameliorate the short-term damaging effects associated with fried meat consumption.","https://ClinicalTrials.gov/show/NCT00340743"
3180,"NCT02463162","Trial of Advance Care Planning (ACP) & Goals of Care Designations (GCD) Discussions","Active, not recruiting","No Results Available","Advance Care Planning|Goals of Care","Other: Conversations Matter videos","University of Alberta|University of Calgary","Both","19 Years and older   (Adult, Senior)","","240","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Health Services Research","Pro00054953","May 28, 2015","June 2015","August 2017","September 16, 2016","September 2016","No Study Results Posted","null","November 2016","Video effectiveness measured by change from baseline in number of participants who have had a conversation with a health care provider about ACP or GCD to 1 month, 2 months and 3 months|Economic impact of Videos measured by comparing change from 12 months prior to baseline in health care costs to baseline, 1 month, 2 months, 3 months and 12 months after baseline between two groups","https://ClinicalTrials.gov/show/NCT02463162"
3181,"NCT02638870","Colonoscopy-related Pain Predicts the Treatment Response of Amitriptyline in Patients With Irritable Bowel Syndrome","Not yet recruiting","No Results Available","Irritable Bowel Syndrome","Drug: Amitriptyline","Samsung Medical Center","Both","18 Years to 75 Years   (Adult, Senior)","","118","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2015-08-109","December 20, 2015","January 2016","October 2016","December 23, 2015","December 2015","No Study Results Posted","null","August 2016","treatment response of abdominal pain/discomfort|treatment responses of urgency of defecation|treatment responses of bloating|treatment responses of overall IBS symptoms scores","https://ClinicalTrials.gov/show/NCT02638870"
3182,"NCT01094444","Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis","Completed","No Results Available","Folliculitis","Other: Vitamin K3","Per Pfeiffer|Odense University Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","09.15","February 22, 2010","May 2010","November 2014","January 20, 2015","January 2015","No Study Results Posted","null","December 2013","Potential reduction in skin toxicity by vitamin K3 lotion|Potential toxicity of vitamin K3 lotion","https://ClinicalTrials.gov/show/NCT01094444"
3183,"NCT02157987","Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose","Recruiting","No Results Available","Telangiectasia, Hereditary Hemorrhagic","Drug: bevacuzimab spray","University Hospital, Caen","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Treatment","2013-004390-27","June 4, 2014","December 2014","January 2017","January 26, 2015","January 2015","No Study Results Posted","EROSB","December 2016","decrease of at least 50% of number of epistaxis in a month compared to the month before inclusion.","https://ClinicalTrials.gov/show/NCT02157987"
3184,"NCT01498276","Family Genetics Health Education and Healthy Behaviors","Recruiting","No Results Available","Diabetes|Cancer|Heart Disease","","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","","335","NIH","Observational","Time Perspective: Prospective","120023|12-HG-0023","December 21, 2011","December 2011","null","August 31, 2016","July 2016","No Study Results Posted","null","null","Participants comprehension of an intervention tool outlining family health history and risk assessment to be used in a subsequent intervention study.|Efficacy of utilizing mothers to educate family members of disease risk and motivate healthy behaviors.","https://ClinicalTrials.gov/show/NCT01498276"
3185,"NCT01365975","Follow-up Study of Late Effects of Periconceptional Folic Acid in Mothers and Offspring in the Community Intervention Program Population: The Chinese Children and Families Study","Completed","No Results Available","Pediatric Leukemia|Other Pediatric Cancers","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","15 Years to 60 Years   (Child, Adult)","","1500","NIH","Observational","Time Perspective: Retrospective","999911165|11-C-N165","June 1, 2011","May 2011","null","May 11, 2016","February 2016","No Study Results Posted","null","null","Evaluation of long term health effects","https://ClinicalTrials.gov/show/NCT01365975"
3186,"NCT02481336","To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity","Recruiting","No Results Available","Neurotoxicity Syndromes","Other: Questionnaires|Procedure: Peripheral nervous system examination|Genetic: Whole Genome Sequence","National Cheng-Kung University Hospital","Both","20 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","A-ER-103-395","June 9, 2015","March 2015","March 2020","April 1, 2016","April 2016","No Study Results Posted","null","March 2017","Adverse events occurring after chemotherapy based on genomic profiling|Changes in quality-of-life measured by EORTC CIPN20|Changes in quality-of-life measured by EQ-5D-3L|Change from Baseline in nerve conduction velocity (NCV)|Change from Baseline in quantitative sensory test (QST)|Change from Baseline in nerve excitability test (NET)|Relapse-free survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02481336"
3187,"NCT02012699","Cancer Research Repository for Individuals With Cancer Diagnosis and High Risk Individuals.","Recruiting","No Results Available","Pancreatic Cancer|Thyroid Cancer|Lung Cancer|Esophageal Cancer|Thymus Cancer|Colon Cancer|Rectal Cancer|GIST|Anal Cancer|Bile Duct Cancer|Duodenal Cancer|Gallbladder Cancer|Gastric Cancer|Liver Cancer|Small Intestine Cancer|Peritoneal Surface Malignancies|Familial Adenomatous Polyposis|Lynch Syndrome|Bladder Cancer|Kidney Cancer|Penile Cancer|Prostate Cancer|Testicular Cancer|Ureter Cancer|Urethral Cancer|Hypopharyngeal Cancer|Laryngeal Cancer|Lip Cancer|Oral Cavity Cancer|Nasopharyngeal Cancer|Oropharyngeal Cancer|Paranasal Sinus Cancer|Nasal Cavity Cancer|Salivary Gland Cancer|Skin Cancer|CNS Tumor|CNS Cancer|Mesothelioma","","University of Nebraska","Both","19 Years and older   (Adult, Senior)","","9999","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UNMC 253-13","December 2, 2013","November 2013","December 2099","December 12, 2014","December 2014","No Study Results Posted","iCaRe2","December 2099","Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC)|Procurement and banking of excess biological material for future analysis","https://ClinicalTrials.gov/show/NCT02012699"
3188,"NCT02060396","Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action","Completed","No Results Available","Healthy Volunteers","Drug: Acetylsalicylic acid","Aragon Institute of Health Sciences","Both","18 Years to 45 Years   (Adult)","Phase 1","24","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","D12-01|2012-004425-25","February 6, 2014","April 2013","December 2013","March 17, 2014","March 2014","No Study Results Posted","null","June 2013","Assessment of the extenet of acetylation at serine-529 of platelet COX-1 during 1 week|Change from baseline in quantification acetylation COX-1 in the circulating platelets during 1 week|Change from baseline in urinary levels of 11-dehydro-TXB2 (TX-M) during 1 week|Change from baseline in whole blood platelet aggregation during 1 week|Change from baseline in plasma levels of aspirin and salicylate during 1 week.","https://ClinicalTrials.gov/show/NCT02060396"
3189,"NCT02206360","Pancreatic Cancer Early Detection Program","Recruiting","No Results Available","Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma|Familial Pancreatic Cancer|BRCA 1/2|HNPCC|Lynch Syndrome|Hereditary Pancreatitis|FAMMM|Familial Atypical Multiple Mole Melanoma|Peutz Jeghers Syndrome","Procedure: Endoscopic Ultrasound|Procedure: Magnetic Resonance Imaging (MRI)","White Plains Hospital","Both","18 Years and older   (Adult, Senior)","","50","Other","Observational","Time Perspective: Prospective","WPH 1401","July 29, 2014","April 2014","March 2020","July 30, 2014","July 2014","No Study Results Posted","PCEDP","March 2019","Premalignant or malignant pancreatic conditions found with alternating EUS and MRI testing.|Clinical outcomes which occur as a result of this Protocol|Complications of any interventions as a result of this Protocol|Non-Pancreatic cancers diagnosed while on this protocol","https://ClinicalTrials.gov/show/NCT02206360"
3190,"NCT01199250","Biomarkers in Samples From Patients With Endometrial Cancer","Not yet recruiting","No Results Available","Lynch Syndrome|Recurrent Uterine Corpus Carcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer","Other: Laboratory Biomarker Analysis","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","","3600","Other|NIH","Observational","Time Perspective: Retrospective","GOG-8020|NCI-2011-02868|CDR0000684553|P50CA134254|R01CA071754|R21CA133295|U10CA027469|U10CA037517","September 9, 2010","January 2100","null","May 27, 2015","May 2015","No Study Results Posted","null","January 2100","Clinical sensitivity and specificity of epigenetic biomarkers in a cohort of blind samples (Project 2)|Confirmation of CpG island loci frequently hypermethylated in EECs exhibiting recurrence (Project 2)|Development of a molecular screening regimen to compliment family history risk assessment for the detection of Lynch syndrome (Project 3)|Expression of candidate ERK1/2 substrates in the normal endometrium, primary endometrial cancers and endometrial cancer cell lines dependence of substrate phosphorylation on ERK (Project 4)|Frequency of Lynch syndrome-related endometrial cancer and relationships between inherited and acquired DNA mismatch repair defects and clinicopathologic variables (Project 3)|GSK3β inhibition as a therapeutic treatment of endometrial cancer and role of inhibiting other ERK substrates in endometrial cancer cell lines (Project 4)|Identification of cognate FGF ligands and receptors expressed in normal endometrium and endometrial cancers (Project 1)|Identification of profiles of CpG island hypermethylation for stratifying subtypes of EECs (Project 2)|Predictive and prognostic accuracy of a panel of SNPs alone and with informative clinical, surgical, and pathologic variables in a cohort of Caucasian women with stage IB or IC vs IIIC endometrioid endometrial cancer from WUSM and GOG-0210 (Project 5)|Relationship between ERK substrate phosphorylation status and upstream ERK signaling pathway activation in primary endometrial cancers and clinicopathologic significance of ERK substrate expression(Project 4)|Relationship between inherited variation in the MLH1 DNA repair gene and somatic (acquired) inactivation of MLH1 in sporadic endometrial cancer (Project 3)|Role of FGFR2 mutations in low, intermediate and high risk endometrial cancers (Project 1)","https://ClinicalTrials.gov/show/NCT01199250"
3191,"NCT01596452","Enumeration of Circulating Tumour Cells (CTCs) in Patients With Advanced Solid Malignancy Using Complementary Metal Oxide Semiconductor (CMOS) Technology","Recruiting","No Results Available","Non Small Cell Lung Cancer","","National University Hospital, Singapore","Both","18 Years and older   (Adult, Senior)","","31","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Version 1","April 2, 2012","June 2012","null","December 8, 2013","December 2013","No Study Results Posted","null","May 2015","Establish whether CTCs are detectable using novel CMOS technology in patients with metastatic cancer.|Compare CTC counts as determined by CMOS technology with CTC counts as determined by immunomagnetic capture with the CellSearch platform (Veridex, NJ).|Determine the relationship between baseline CTC number as determined by CMOS technology and clinical outcome.","https://ClinicalTrials.gov/show/NCT01596452"
3192,"NCT00217737","Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","Active, not recruiting","No Results Available","Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Lynch Syndrome|Stage IIA Colon Cancer|Stage IIB Colon Cancer|Stage IIC Colon Cancer","Biological: Bevacizumab|Drug: Fluorouracil|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Oxaliplatin","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","3610","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00562|ECOG-E5202|E5202|CDR0000443410|U10CA180820|U10CA021115","September 20, 2005","August 2005","null","September 20, 2016","September 2016","No Study Results Posted","null","December 2016","Disease-free survival|Impact of tumor biologic characteristics and their relationship to overall survival|Incidence of adverse events graded by NCI CTCAE 4.0|Overall survival","https://ClinicalTrials.gov/show/NCT00217737"
3193,"NCT02396472","Mental Health Pathways in Internet Support Groups","Not yet recruiting","No Results Available","Depression|Stress|Anxiety","Behavioral: Order by time and topic|Behavioral: Order by information relevance|Behavioral: Order by social relationship|Behavioral: Order by help giving|Behavioral: Order by self-disclosure","Carnegie Mellon University|University of Pittsburgh|National Institute of Mental Health (NIMH)|American Cancer Society, Inc.","Both","18 Years and older   (Adult, Senior)","","200","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Supportive Care","CarnegieMU","January 15, 2015","April 2015","May 2017","March 23, 2015","January 2015","No Study Results Posted","null","May 2017","Read message (Does the user read the message they were exposed to?)|Interaction satisfaction (Self-report measure of satisfaction 3-item survey)|Reply to message (How long does it take the users to reply to a message they were exposed to, if they reply at all.)","https://ClinicalTrials.gov/show/NCT02396472"
3194,"NCT00609505","Telemedicine vs. Face-to-Face Cancer Genetic Counseling","Completed","No Results Available","Hereditary Breast and Ovarian Cancer Syndrome|Lynch Syndrome","Other: Telemedicine|Other: Face-to-Face","Duke University|Susan G. Komen Breast Cancer Foundation","Both","18 Years and older   (Adult, Senior)","","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","Pro00001547|DISP0707781","January 25, 2008","August 2008","April 2011","February 21, 2012","February 2012","No Study Results Posted","null","March 2011","Patient satisfaction|Cost-effectiveness","https://ClinicalTrials.gov/show/NCT00609505"
3195,"NCT02849158","Fibroblast Before and After Neoadjuvant Chemo-radiotherapy in Patient With Locally Advanced Rectal Adenocarcinoma","Not yet recruiting","No Results Available","Rectum Adenocarcinoma","Other: Biopsy","Institut Curie","Both","18 Years and older   (Adult, Senior)","","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","IC 2015-12","July 13, 2016","September 2016","September 2021","July 28, 2016","July 2016","No Study Results Posted","FibroRect","September 2021","Proteomic level evaluation in intra-tumor fibroblast|Study of fibroblast impact on colorectal tumor cells (in vitro)","https://ClinicalTrials.gov/show/NCT02849158"
3196,"NCT01599039","Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema","Active, not recruiting","No Results Available","Lymphedema|Breast Cancer Stage II|Early Disease Onset","","Nij Smellinghe Hosptial","Both","18 Years and older   (Adult, Senior)","","75","Other","Observational","Time Perspective: Prospective","NS3NL","May 13, 2012","May 2012","January 2016","November 1, 2015","November 2015","No Study Results Posted","null","January 2014","Bio impedance spectometry|body Mass Index (BMI)|quality of life measurement with the "" LAST"" meter","https://ClinicalTrials.gov/show/NCT01599039"
3197,"NCT02053805","Prostate Cancer Screening Among Men With High Risk Genetic Predisposition","Recruiting","No Results Available","BRCA1 Syndrome|BRCA2 Syndrome|Lynch Syndrome","Other: PSA|Other: IPSS questionnaire|Other: DRE (Digital Rectal Examination )|Other: urine flow and residual|Procedure: a multiparametric prostate MRI|Procedure: trans-rectal ultra-sound guided prostate biopsy","Rabin Medical Center","Male","40 Years to 70 Years   (Adult, Senior)","","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","0582_13_RMC","January 30, 2014","February 2014","June 2019","April 21, 2016","March 2016","No Study Results Posted","null","June 2018","Prevalence, stage and pathology of screen-detected prostate cancer in BRCA1/BRCA2 founder mutation carriers and Lynch mutation carriers|Accuracy of different screening tests (PSA, free to total PSA, prostate MRI) in detecting prostate cancer among men with genetic predispositions.","https://ClinicalTrials.gov/show/NCT02053805"
3198,"NCT01276886","Italian Study Group on Complicated Diverticulosis","Completed","No Results Available","Diverticulitis","Drug: antibiotic|Procedure: Colonic resection with or without stoma","Gruppo Italiano per lo Studio della Diverticolite Complicata","Both","Child, Adult, Senior","","null","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GISDIC-1","January 12, 2011","January 1996","December 1999","January 21, 2011","December 2010","No Study Results Posted","GISDIC","December 1999","to assess the rate of recurrence of acute diverticulitis requiring hospitalization during the follow-up period|to assess the risks of emergency surgery, stoma and disease-related mortality during the follow up","https://ClinicalTrials.gov/show/NCT01276886"
3199,"NCT01720966","Adhesions After Open Versus Laparoscopic Resection of Colorectal Malignancies Detected During Liver Resection","Completed","No Results Available","Adhesions","Procedure: Liver resection","Radboud University","Both","18 Years to 100 Years   (Adult, Senior)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RU-RTB-0004","October 24, 2012","January 2013","October 2015","November 9, 2015","November 2015","No Study Results Posted","ALIVE","October 2015","Incidence of adhesion to ventral abdominal wall|Incidence of adhesions|Extent of adhesions|Adhesion Score|Adhesiolysis|Duration of adhesiolysis|Inadvertent bowel injury|Postoperative mobidity","https://ClinicalTrials.gov/show/NCT01720966"
3200,"NCT00033358","Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer","Completed","No Results Available","Endometrial Cancer","Drug: medroxyprogesterone|Drug: ethinyl estradiol|Drug: norgestrel|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Female","25 Years to 50 Years   (Adult)","Phase 2","52","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","NCI-2013-00466|ID01-340|CDR0000069277|NCI-P02-0218|MDA-ID-01340|N01CN05127","April 9, 2002","February 2002","null","May 2, 2013","April 2013","No Study Results Posted","null","October 2007","Change in potential SEBs relevant to endometrial carcinogenesis.|Changes in histology and ultrasound appearance of the endometrium in women with HNPCC","https://ClinicalTrials.gov/show/NCT00033358"
3201,"NCT02822352","RCT: HDWL vs Virtual Chromoendoscopy in the Detection of Intraepithelial Neoplasia in Longstanding Colitis","Recruiting","No Results Available","Ulcerative Colitis|Crohn's Colitis","Other: Chromoendoscopy","Portsmouth Hospitals NHS Trust","Both","18 Years and older   (Adult, Senior)","","204","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","PHT/2016/02","June 29, 2016","August 2016","November 2017","August 18, 2016","August 2016","No Study Results Posted","VIRTUOSO","September 2017","To compare the rates of neoplasia detection using virtual chromoendoscopy compared to high definition white light (HDWL) endoscopy","https://ClinicalTrials.gov/show/NCT02822352"
3202,"NCT00611728","Ph I SU011248 + Irinotecan in Treatment of Pts w MG","Completed","No Results Available","Glioblastoma","Drug: SU011248 & Irinotecan","Duke University|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","25","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00000931","January 29, 2008","March 2008","September 2010","July 18, 2014","December 2011","No Study Results Posted","null","June 2010","Determine MTD & DLT of SU011248 + Irinotecan in pts w RMG not on EIAEDs|Demographic & baseline characteristics|Efficacy observations & measurements|Safety observations & measurements|PK measurements","https://ClinicalTrials.gov/show/NCT00611728"
3203,"NCT02668198","Assessing a Endoscopic Mucosal Resection Site Using Different Endoscopic Imaging Methods","Recruiting","No Results Available","Post-endoscopic Mucosal Resection of Colon Polyps","Device: Olympus CF190 Colonoscope High definition white light|Device: Olympus CF190 Colonoscope White light with near focus|Device: Olympus CF190 Colonoscope Narrow band imaging|Device: Olympus CF190 Colonoscope Narrow band imaging with near focus","Michael Wallace|Olympus America, Inc.|Mayo Clinic","Both","18 Years and older   (Adult, Senior)","","200","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","15-007241","January 23, 2016","January 2016","January 2017","January 26, 2016","January 2016","No Study Results Posted","null","January 2017","Paris Endoscopic Classification|Kudo's Pit Pattern Classification for colorectal neoplasm","https://ClinicalTrials.gov/show/NCT02668198"
3204,"NCT02813824","Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome","Not yet recruiting","No Results Available","Lynch Syndrome","Drug: Acetylsalicylic acid lysinate 300 mg|Drug: Placebo (for Aspirin 300)|Drug: Acetylsalicylic acid lysinate 100 mg|Drug: Placebo 100 (for Aspirin 100)","Assistance Publique - Hôpitaux de Paris","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","852","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","P130937","June 23, 2016","January 2017","January 2025","June 23, 2016","June 2016","No Study Results Posted","AAS-Lynch","January 2024","Number of patients with at least one adenoma seen on chromo-endoscopy 48 months after complete withdrawal of polyps and initiation of treatment (aspirin or placebo)|Delay between the onset of 1 adenoma after complete resection of polyps and date of start of treatment (aspirin vs placebo)|Number of patients who presented an adenoma during follow-up based on the gene reached (MLH1, MSH2, MSH6, PMS2, or without other identified anomalies)|Load serrated polyps after 24 and 48 months of treatment","https://ClinicalTrials.gov/show/NCT02813824"
3205,"NCT02196402","Narrow Band Imaging in the Prediction of Surveillance Intervals After Polypectomy in Community Practice: Ready for (a European) Prime Time","Completed","No Results Available","Resect and Discard Strategies for Colonoscopy","","Valduce Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","280","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","5/2014","July 16, 2014","October 2013","February 2014","July 18, 2014","July 2014","No Study Results Posted","null","February 2014","proportion of cases in which the accordance between the endoscopy-directed and histology-directed surveillance strategies by applying the resect and discard strategy for diminutive polyps according to the PIVI statements was observed","https://ClinicalTrials.gov/show/NCT02196402"
3206,"NCT00341575","Psychosocial Aspects of Genetic Testing for Hereditary Nonpolyposis Colon Cancer","Completed","No Results Available","HNPCC|Hereditary Nonpolyposis Colon Cancer","","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 82 Years   (Adult, Senior)","","80","NIH","Observational","","999905249|05-HG-N249","June 19, 2006","September 2005","August 2010","August 3, 2010","August 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00341575"
3207,"NCT00545870","Bevacizumab Versus Ranibizumab for Diabetic Retinopathy","Completed","No Results Available","Diabetic Retinopathy|Diabetic Macular Edema|Proliferative Diabetic Retinopathy","Drug: bevacizumab|Drug: Ranibizumab","Ursula Schmidt-Erfurth, M.D.|Medical University of Vienna","Both","18 Years and older   (Adult, Senior)","Phase 3","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","238/2006","October 16, 2007","June 2008","April 2013","April 14, 2015","April 2015","No Study Results Posted","null","March 2013","To investigate the change in macular edema and the absolute change in visual acuity. To investigate the change of neovascularisation.","https://ClinicalTrials.gov/show/NCT00545870"
3208,"NCT01646112","Uncertain Genetic Test Results for Lynch Syndrome","Completed","No Results Available","HNPCC","","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 100 Years   (Adult, Senior)","","34","NIH","Observational","Time Perspective: Retrospective","999912126|12-HG-N126","July 18, 2012","April 2012","February 2016","August 31, 2016","February 2016","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01646112"
3209,"NCT02570516","NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome","Recruiting","No Results Available","Lynch Syndrome","Procedure: Colonoscopy","Assistance Publique - Hôpitaux de Paris|ARC Foundation for Cancer Research","Both","18 Years to 80 Years   (Adult, Senior)","","140","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","P140108|2015-A00552-47","September 30, 2015","November 2015","December 2017","March 16, 2016","March 2016","No Study Results Posted","LYNCH-CHROMO","October 2017","Number of adenomas and / or adenocarcinoma detected during each procedure (NBI vs Indigo carmine)|All neoplastic lesions detected during colonoscopy|Cost of each procedure (NBI vs Indigo carmine)|Duration of each procedure (NBI vs Indigo carmine)|Number of subject with adverse events as mesure of safety.","https://ClinicalTrials.gov/show/NCT02570516"
3210,"NCT01864746","A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery","Recruiting","No Results Available","Breast Cancer|Hormonreceptor Positive|Her2-normal|Postneoadjuvant Treatment With CDK 4/6 Inhibitor|CPS-EG Score","Drug: Palbociclib PD-0332991|Drug: Placebo","German Breast Group|Pfizer|AGO Study Group|NSABP Foundation Inc|Breast International Group","Female","18 Years and older   (Adult, Senior)","Phase 3","1100","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GBG78/BIG 1-13/NSABP-B-54-I|2013-001040-62","May 14, 2013","November 2013","November 2023","August 17, 2016","August 2016","No Study Results Posted","PENELOPE-B","December 2020","Invasive disease free survival (iDFS) for palbociclib vs. placebo in patients with high CPS-EG score after neoadjuvant chemotherapy receiving standard adjuvant endocrine therapy for HR-positive/HER2-normal primary breast cancer.|iDFS excluding second non-breast cancers|distant disease free survival (DDFS)|overall survival (OS)|iDFS per treatment group in patients with luminal-B tumors (as determined by e.g. PAM50 or any other commercially available test at the time of analysis)|compliance and safety according to NCI-CTCAE Version 4.0|patients reported outcomes EORTC QLQ C30, • EORTC QLQ BR-23, • EORTC QLQ FA-13 Fatigue, • GAD7 patient self-rating mood scale|quality-adjusted life years (QALY), health economic outcomes EQ-5D|Area under the Curve (AUC), Cmax|correlations between exposure and efficacy and/or safety findings","https://ClinicalTrials.gov/show/NCT01864746"
3211,"NCT00315185","Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Cetuximab","Fox Chase Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","53","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OPN-TH-017","April 14, 2006","December 2004","June 2008","September 22, 2010","September 2010","No Study Results Posted","null","June 2007","To determine the response rate and stable disease rate with this combination regimen|To determine the clinical benefit (complete response [CR] + partial response [PR] + static disease [SD])|Time to progression|Survival rate|As well as toxicity evaluation","https://ClinicalTrials.gov/show/NCT00315185"
3212,"NCT01220661","Safety and Efficacy of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery","Completed","No Results Available","Colorectal Surgery","Drug: Cefotetan","National Cancer Center, Korea","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","312","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-10-485","October 12, 2010","October 2010","December 2011","December 11, 2011","December 2011","No Study Results Posted","null","December 2011","Surgical site infection|Overall infection","https://ClinicalTrials.gov/show/NCT01220661"
3213,"NCT02023333","Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma","Recruiting","No Results Available","Metastatic Colorectal Adenocarcinoma","Device: Regorafenib","Memorial Sloan Kettering Cancer Center|Bayer|State University of New York - Downstate Medical Center|Queens Cancer Center of Queens Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","12","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13-211","December 23, 2013","December 2013","null","March 29, 2016","March 2016","No Study Results Posted","null","December 2017","progression free survival|overall survival|disease control rate|duration of stable disease|toxicity","https://ClinicalTrials.gov/show/NCT02023333"
3214,"NCT02082782","Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases","Recruiting","No Results Available","Colorectal Liver Metastases","Procedure: Irreversible electroporation (IRE)","VU University Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","29","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COLDFIRE-2 study","March 6, 2014","May 2014","May 2018","April 28, 2016","April 2016","No Study Results Posted","COLDFIRE-2","May 2017","Efficacy","https://ClinicalTrials.gov/show/NCT02082782"
3215,"NCT01075646","Local Anesthesia Versus Saline Serum in Surgical Incision of Colorectal or Hepatic Surgery","Completed","No Results Available","Postoperative Pain|Major Abdominal Surgery|Postoperative Outcome","Drug: ropivacaine|Drug: placebo","Hospital Universitari de Bellvitge","Both","18 Years to 80 Years   (Adult, Senior)","Phase 4","225","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","ANESTHESIA SERVICE HUB","January 11, 2010","March 2009","June 2014","March 17, 2015","March 2015","No Study Results Posted","CATROP-2007","June 2014","Mg of morphine consumption during 48 hours administered by patient controlled analgesia system|Intensity of pain measured by verbal pain scale.|Sitting in a chair, Deambulation, solid ingestion.|secondary effects due to morphine: nausea and vomiting, itching, sedation and respiratory depression.|Local reaction in the wound and insertion point of the catheter (inflammation signs and infection)|contamination of the catheter (microbiologist analysis)","https://ClinicalTrials.gov/show/NCT01075646"
3216,"NCT01578018","Tumor Markers in Lung Cancer: DCAMLK-1LK-1","Completed","No Results Available","Lung Cancer|Smoking","Other: Measure DCAM levels in blood|Other: DCAM levels in blood","University of Oklahoma","Both","45 Years and older   (Adult, Senior)","","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","16249","April 11, 2012","December 2011","July 2012","August 8, 2012","August 2012","No Study Results Posted","null","July 2012","Tumor Markers in Lung Cancer:","https://ClinicalTrials.gov/show/NCT01578018"
3217,"NCT01097642","Neo-Adjuvant Study in Triple Negative Breast Cancer Patients","Active, not recruiting","No Results Available","Breast Cancer","Drug: Cetuximab|Drug: Ixabepilone","Jenny C. Chang, MD|Bristol-Myers Squibb|Houston Methodist Research Institute|The Methodist Hospital System","Female","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00002243|0908-0265","March 29, 2010","October 2008","December 2016","September 12, 2016","September 2016","No Study Results Posted","ICE","December 2016","Complete Response Rate|Overall Objective Response Rate|Safety and toxicity of both treatment regimens","https://ClinicalTrials.gov/show/NCT01097642"
3218,"NCT00403026","Intravitreal Bevacizumab for Retinal Disorders","Recruiting","No Results Available","Wet AMD|Macular Oedema|Proliferative Diabetic Retinopathy","Drug: Bevacizumab ( Avastin)","Narayana Nethralaya","Both","18 Years and older   (Adult, Senior)","","150","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NN-002/2006","November 22, 2006","August 2006","November 2006","November 22, 2006","November 2006","No Study Results Posted","null","null","Vision change|Anatomical changes (Regression of NVE, CNVM, reduction in macular thickness)|Electrophysiological changes (ERG, VEP)|Ocular side effects (infection, RD, IOP rise, cataract)","https://ClinicalTrials.gov/show/NCT00403026"
3219,"NCT02362126","Endoscopic Full Thickness Resection in the Lower GI Tract With the ""Full Thickness Resection Device""","Recruiting","No Results Available","Colorectal Adenomas|Submucosal Tumors","Device: Endoscopic full thickness resection (EFTR)","Kliniken Ludwigsburg-Bietigheim gGmbH|Ovesco Endoscopy, Tübingen, Germany","Both","18 Years and older   (Adult, Senior)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WALL-RESECT","February 7, 2015","February 2015","February 2017","February 11, 2015","February 2015","No Study Results Posted","WALL-RESECT","February 2017","Technical success|R0-Resection|Histologically confirmed full thickness resection|Procedure-associated complications|Procedure time|Necessity of surgical treatment|Residual or recurrent adenoma/carcinoma at endoscopic follow up","https://ClinicalTrials.gov/show/NCT02362126"
3220,"NCT01254435","Positioning During Colonoscopy","Completed","No Results Available","Colonic Polyps","Procedure: Colonoscopy","Sheffield Teaching Hospitals NHS Foundation Trust|Sheffield Teaching Hospitals NHS Foundations Trust","Both","18 Years and older   (Adult, Senior)","Phase 0","41","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","STH14709","December 3, 2010","May 2009","September 2010","December 3, 2010","March 2009","No Study Results Posted","null","August 2009","Mucosal visualisation|Luminal distension","https://ClinicalTrials.gov/show/NCT01254435"
3221,"NCT00291759","ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.","Completed","No Results Available","Breast Cancer","Drug: Tamoxifen|Drug: Anastrozole","AstraZeneca","Female","up to 80 Years   (Child, Adult, Senior)","Phase 3","3858","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1033AU/0002|ABCSG 8","February 13, 2006","January 1996","June 2009","January 29, 2013","January 2013","No Study Results Posted","null","June 2009","To assess the difference in event free survival and overall survival (subject to stand-alone or combined/meta-analysis) between postmenopausal women with HR +ve early BC who switched from tamoxifen to anastrozole and those who continued on tamoxifen.|To assess the difference in event free survival & overall survival (subject to stand-alone or combined/meta-analysis) plus side effects between postmenopausal women with HR+ve early BC who switched from tam to anastrozole and those who continued on tam.","https://ClinicalTrials.gov/show/NCT00291759"
3222,"NCT01422577","Diagnosis of Colonic Adenomas by Bright Narrow Band Imaging (B-NBI)","Completed","No Results Available","Colonic Adenomas","Device: Bright Narrow Band Imaging|Device: White light Endoscopy","Chinese University of Hong Kong","Both","40 Years and older   (Adult, Senior)","","1006","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","B-NBI","August 2, 2011","October 2010","March 2014","August 10, 2015","August 2015","No Study Results Posted","null","September 2012","Colorectal adenoma detection rate|1. Rate in the detection of advanced neoplasms (defined by adenomas >10 mm in size, with high grade dysplasia or with >25% villous features).|2. Sensitivity and specificity of either image modality in the diagnosis of malignant adenomas using pathology","https://ClinicalTrials.gov/show/NCT01422577"
3223,"NCT00749502","A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)","Completed","No Results Available","Solid Tumors|Chronic Lymphocytic Leukemia|T-cell-prolymphocytic Leukemia","Drug: MK-4827","Tesaro, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","113","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MK-4827-001|2008_501","September 5, 2008","September 2008","June 2013","July 23, 2013","July 2013","No Study Results Posted","null","September 2011","Number of participants with dose limiting toxicities (DLTs)|Percent inhibition of peripheral blood mononuclear cell PARP enzyme activity (Part A, B, and C)","https://ClinicalTrials.gov/show/NCT00749502"
3224,"NCT02336789","Proposal to Examine the Effect of Fecal Transplantation on Obesity","Recruiting","No Results Available","Disorientation as to People, Time and Place","Other: fecal material|Other: normal saline","Kaplan Medical Center","Both","40 Years and older   (Adult, Senior)","","20","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","0088-14-KMC","January 8, 2015","December 2014","December 2016","January 12, 2015","December 2014","No Study Results Posted","null","December 2015","weight loss","https://ClinicalTrials.gov/show/NCT02336789"
3225,"NCT01180452","Endoscopic Detection of Dysplasia in Crohn 's Disease Patient","Completed","No Results Available","Crohn Disease Located in Jejunum or Ileum","Procedure: enteroscopy","Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","Both","18 Years and older   (Adult, Senior)","Phase 4","107","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","GETAID 2008-4","March 31, 2010","January 2010","June 2014","June 21, 2015","June 2015","No Study Results Posted","DYDJI","June 2014","Frequency of dysplasia and adenocarcinoma|Success of endoscopic detection","https://ClinicalTrials.gov/show/NCT01180452"
3226,"NCT01224990","Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Gastro-intestinal Tumors","Active, not recruiting","No Results Available","Gastro-intestinal Tumor|Accurate Staging|Whole-body Diffusion Weighted MRI|Non-invasive","Procedure: Whole body diffusion MRI","Universitaire Ziekenhuizen Leuven","Both","Child, Adult, Senior","","150","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","s51240","October 19, 2010","November 2010","December 2015","April 9, 2015","April 2015","No Study Results Posted","s51240","November 2014","The aim of the study is to asses whole body diffusion weighted imaging (WB-DWI) in patients with proven gastro-intestinal tumors and to evaluate this non-invasive method for staging and therapy monitoring.","https://ClinicalTrials.gov/show/NCT01224990"
3227,"NCT01788826","Prophylactic Mesh to Reduce The Incidence of Ventral Hernia","Active, not recruiting","No Results Available","Ventral Hernia","Procedure: Prophylactic mesh|Procedure: No prophylactic mesh closure","Henares University Hospital","Both","18 Years and older   (Adult, Senior)","","112","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","HH01","February 7, 2013","June 2009","September 2013","February 8, 2013","February 2013","No Study Results Posted","null","September 2011","Compare the incidence of ventral hernia between the 2 groups|Incidence of superficial surgical site infection|Incidence of deep surgical site infection|Seroma|Postoperative complications","https://ClinicalTrials.gov/show/NCT01788826"
3228,"NCT02865707","Ulcerative Colitis Relapse Prevention by Prebiotics","Not yet recruiting","No Results Available","Ulcerative Colitis","Dietary Supplement: Synergy-1|Dietary Supplement: Maltodextrin","University of Alberta|University of British Columbia","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","Pro00041938","July 12, 2016","August 2016","October 2018","August 9, 2016","August 2016","No Study Results Posted","null","May 2018","Prevention of relapse|Time to relapse|Patient compliance|Patient tolerability|Changes in endoscopic disease activity inflammation|Changes in fecal calprotectin|Changes in Mayo score|Changes in microscopic score in colonic biopsies","https://ClinicalTrials.gov/show/NCT02865707"
3229,"NCT02712736","Quality of Life in Patients With Primary Sclerosing Cholangitis","Not yet recruiting","No Results Available","Primary Sclerosing Cholangitis","Other: quality of life survey","Duke University","Both","18 Years and older   (Adult, Senior)","","250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","Pro00069683","March 11, 2016","March 2016","null","March 30, 2016","March 2016","No Study Results Posted","QOL in PSC","December 2016","Impaired quality of life as measured by questionnaire","https://ClinicalTrials.gov/show/NCT02712736"
3230,"NCT00798070","Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","Active, not recruiting","No Results Available","Breast Cancer","Drug: dtEC→dtT|Drug: FEC→T","Karolinska University Hospital|Swedish Breast Cancer Group|Austrian Breast & Colorectal Cancer Study Group|German Breast Group","Female","18 Years to 65 Years   (Adult)","Phase 3","2017","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PANTHER SBG2004-1|2007-002061-12|ISRCTN39017665|ABCSG25|GBG53","November 24, 2008","February 2007","January 2022","June 8, 2015","June 2015","No Study Results Posted","PANTHER","December 2021","Breast cancer relapse-free survival|Distant disease-free survival|Event-free survival|Overall survival|Health-related quality of life and toxicity analyses according to CTC|Outcome in relation to tumour biological factors and polymorphism patterns|BCRFS in arm A in relation to given dose levels","https://ClinicalTrials.gov/show/NCT00798070"
3231,"NCT02513394","PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Palbociclib|Drug: Standard Adjuvant Endocrine Therapy","Alliance Foundation Trials, LLC.|Austrian Breast & Colorectal Cancer Study Group|NSABP Foundation Inc|PrECOG, LLC.|Breast International Group|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 3","4600","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AFT-05|ABCSG 42|BIG 14-03|2014-005181-30","July 29, 2015","August 2015","September 2025","July 22, 2016","July 2016","No Study Results Posted","PALLAS","September 2020","Invasive Disease Free Survival (iDFS)|To compare the safety of 2 years of palbociclib with adjuvant endocrine therapy versus adjuvant endocrine therapy alone. (distant recurrence-free survival (DRFS), locoregional recurrences-free survival (LRRFS), and overall survival (OS)","https://ClinicalTrials.gov/show/NCT02513394"
3232,"NCT02273973","A Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)","Recruiting","No Results Available","Breast Cancer","Drug: GDC-0032|Drug: Letrozole|Other: Placebo","Genentech, Inc.|SOLTI Breast Cancer Research Group|Breast International Group|Austrian Breast and Colorectal Cancer Group","Female","18 Years and older   (Adult, Senior)","Phase 2","330","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","GO28888|2013-000568-28","October 22, 2014","November 2014","July 2017","September 9, 2015","September 2015","No Study Results Posted","null","July 2017","Objective Reponse Rate (ORR)|Pathologic complete response (pCR) rate in breast and axilla (total pCR)|Change in Ki67 levels|Preoperative endocrine prognostic index (PEPI) scroe|Change in tumor volume|Incidence of adverse events|Health-related quality of life measured by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30/BR23","https://ClinicalTrials.gov/show/NCT02273973"
3233,"NCT00556374","Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy","Active, not recruiting","Has Results","Breast Cancer","Drug: Placebo|Drug: Denosumab|Drug: Non-steroidal aromatase inhibitor therapy","Amgen|Austrian Breast and Colorectal Cancer Study Group","Female","45 Years to 100 Years   (Adult, Senior)","Phase 3","3420","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20050209|ABCSG-18|2005-005275-15","November 8, 2007","December 2006","October 2019","June 27, 2016","June 2016","October 6, 2015","null","March 2014","Time to First Clinical Fracture|Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites|Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites|Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites|Number of Participants With New Vertebral Fractures|Number of Participants With New or Worsening Vertebral Fractures|Disease-free Survival|Bone Metastases-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00556374"
3234,"NCT02324374","Endocytoscopy and Colorectal Neoplasia","Completed","No Results Available","Colon Cancer","Procedure: Endocystoscopy During Colonoscopy|Device: Endocytoscope","University of Pennsylvania","Both","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","813061","December 18, 2014","June 2011","December 2015","September 7, 2016","September 2016","No Study Results Posted","null","December 2015","Unblinded Analysis of Endocytoscopic Images of Colorectal Lesions (Technical quality of the images will be compared to histology and rated on a scale of 1-5 (1-worst, 3- acceptable, 5-being equal to histology)","https://ClinicalTrials.gov/show/NCT02324374"
3235,"NCT01741636","Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer","Completed","No Results Available","Stage I Colon Cancer|Stage I Rectal Cancer|Stage IA Non-small Cell Lung Cancer|Stage IB Non-small Cell Lung Cancer|Stage IIA Colon Cancer|Stage IIA Non-small Cell Lung Cancer|Stage IIA Rectal Cancer|Stage IIB Colon Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIB Rectal Cancer|Stage IIC Colon Cancer|Stage IIC Rectal Cancer|Stage IIIA Colon Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer","Other: educational intervention|Other: questionnaire administration|Procedure: quality-of-life assessment","City of Hope Medical Center|National Cancer Institute (NCI)","Both","21 Years and older   (Adult, Senior)","","30","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","12342|NCI-2012-02783","December 3, 2012","January 2013","December 2013","December 16, 2013","December 2013","No Study Results Posted","null","December 2013","Percentage of attrition based on number of patients who failed to complete the two-month study|Total retention across the two month follow-up|Percentage of those who are qualified and agree to participate|Data collection protocols including who will administer the survey, timing of surveys, telephone interviews vs. face to face administration|Cost implications including hiring and training of the research staff, development of study manuals and patient education materials, research staff time, intervention supplies, and other miscellaneous costs|Satisfaction with the timing, content, and delivery of the intervention","https://ClinicalTrials.gov/show/NCT01741636"
3236,"NCT00335504","Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia","Completed","Has Results","Colon Cancer|Precancerous Condition|Rectal Cancer","Drug: oligofructose-enriched inulin|Drug: sulindac|Drug: placebo|Drug: atorvastatin calcium|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","40 Years and older   (Adult, Senior)","Phase 2","85","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","NCI-2009-00837|CDR0000467755|MAY03-1-03|N01CN35000|P30CA015083","June 8, 2006","March 2006","April 2009","April 23, 2014","April 2013","November 26, 2012","null","April 2009","Percent Change in Number of Rectal Aberrant Cryptic Foci (ACF) as Measured by Magnification Chromoendoscopy|Effects on Proliferation (Ki67 Expression).|Effects on Apoptosis (Caspase-3 Expression).|Adverse Events.","https://ClinicalTrials.gov/show/NCT00335504"
3237,"NCT01836926","Short Term Outcomes of Laparoscopic Intersphincteric Resection for Low Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Procedure: Open intersphincteric resection|Device: laparoscopic intersphincteric resection","Osama Mohammad Ali ElDamshety|Mansoura University|University of Roma La Sapienza","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","106","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Mansoura oncology centre","April 4, 2013","December 2012","June 2016","October 6, 2015","October 2015","No Study Results Posted","ISR","December 2015","Hospital stay.|Duration of the intervention|Amount of blood loss and rate of blood transfusion|The onset of intestinal motility.|Pain score|Postoperative complications|30 days follow up for readmission in the postoperative period|Clinical functional outcome of intersphincteric resection|Local recurrence within 2 years|Distant metastasis within 2 years|conversion rate for laparoscopic ISR","https://ClinicalTrials.gov/show/NCT01836926"
3238,"NCT01196494","Study of Intraoperative Colonic Irrigation Versus Stent Placement in Obstructive Left-Sided Colonic Cancer","Terminated","No Results Available","Colon Neoplasm|Colorectal Surgery|Intestinal Obstruction","Procedure: intraoperative colon lavage with primary anastomosis","Corporacion Parc Tauli","Both","18 Years and older   (Adult, Senior)","","null","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","STENTCSPT01","September 7, 2010","null","null","September 7, 2010","January 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01196494"
3239,"NCT00537901","First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study","Completed","No Results Available","Colonic Neoplasms|Rectal Neoplasms","Radiation: First-Line Bevacizumab and Chemotherapy|Drug: Bevacizumab","King Faisal Specialist Hospital & Research Center","Both","Child, Adult, Senior","","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RAC #2041-082","October 1, 2007","October 2007","October 2013","December 16, 2015","December 2015","No Study Results Posted","null","October 2013","Effectiveness|Quality of life","https://ClinicalTrials.gov/show/NCT00537901"
3240,"NCT01940237","A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer","Suspended","No Results Available","Depression|Pancreatic Cancer|Lung Cancer|Colon Cancer|Prostate Cancer","Behavioral: Psychotherapy","New York State Psychiatric Institute","Both","18 Years to 75 Years   (Adult, Senior)","","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6397","August 28, 2013","April 2012","August 2016","September 2, 2014","September 2014","No Study Results Posted","null","August 2016","Change in Hamilton Depression Scale (HAMD-17)","https://ClinicalTrials.gov/show/NCT01940237"
3241,"NCT00663819","Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses","Terminated","Has Results","Rectal Cancer|Ulcerative Colitis|Familial Adenomatous Polyposis|Diverticulitis","Device: GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement|Procedure: Staple line without reinforcement","W.L.Gore & Associates","Both","18 Years and older   (Adult, Senior)","","258","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-109|CS150","April 18, 2008","April 2008","October 2012","September 2, 2014","September 2014","August 21, 2014","null","October 2012","Proportion of Subjects Who Experience a Clinical and/or Radiologic Anastomotic Leak|Identify and Compare the Rate of Anastomotic Stenosis Associated With Circular Stapled Anastomoses Constructed With and Without CBSG.|Determine the Rate of Significant Staple Line Hemorrhage With and Without the Use of CBSG in Circular Stapled Anastomoses|Provide a Cost/Benefit Analysis With Regard to the Use of CBSG in Stapled Circular Anastomoses|Determine the Efficacy and Further Substantiate Safety of CBSG Used in Conjunction With Circular Staplers When Performing High-risk Colorectal, Coloanal, and Ileoanal Anastomoses.","https://ClinicalTrials.gov/show/NCT00663819"
3242,"NCT01656746","Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease","Completed","No Results Available","Adenomatous Polyp|Crohn Disease|Familial Adenomatous Polyposis|Hereditary Intestinal Polyposis Syndrome|Recurrent Colon Cancer|Stage I Colon Cancer|Stage IIA Colon Cancer|Stage IIB Colon Cancer|Stage IIC Colon Cancer|Stage IIIA Colon Cancer|Stage IIIB Colon Cancer|Stage IIIC Colon Cancer","Procedure: therapeutic laparoscopic surgery","Ohio State University Comprehensive Cancer Center","Both","18 Years to 80 Years   (Adult, Senior)","","10","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-09123|NCI-2012-00604","August 1, 2012","May 2010","October 2013","November 4, 2013","November 2013","No Study Results Posted","null","October 2013","Operative time|Length of skin and fascial incisions|Estimated blood loss|Oncologic sample including size of specimen removed, number of lymph nodes (LN) removed, pathological type and staging, lymph node, vessel or perineural invasion, and status of margins|Quality of life measured using the short form (SF)-12 health related quality of life scale (HQRL) scored using quality metric licensed software|Quality of life measured using the SF-12 HQRL scored using quality metric licensed software|Visual analogue pain scale scored on the scale from 0 to 10 where 0 is no pain, and 10 is the maximum pain|Visual analogue cosmesis scale scored on the scale from 0 to 10 where 0 is ""worst scar"", and 10 is the ""best scar""","https://ClinicalTrials.gov/show/NCT01656746"
3243,"NCT01191684","Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer","Completed","No Results Available","Recurrent Colon Cancer|Recurrent Gastric Cancer|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Gastric Cancer|Stage III Pancreatic Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Gastric Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer","Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay|Other: flow cytometry|Other: immunoenzyme technique|Biological: modified vaccinia virus ankara vaccine expressing p53","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10105|NCI-2010-01859","August 27, 2010","October 2011","August 2013","August 21, 2013","August 2013","No Study Results Posted","null","August 2013","Safety and tolerance of modified vaccinia virus ankara vaccine expressing p53 assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4 toxicity scale|Immunogenicity","https://ClinicalTrials.gov/show/NCT01191684"
3244,"NCT00101348","Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer","Completed","No Results Available","Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Basal Cell Carcinoma of the Lip|Stage III Colon Cancer|Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Lymphoepithelioma of the Oropharynx|Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Pancreatic Cancer|Stage III Rectal Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Colon Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Untreated Metastatic Squamous Neck Cancer With Occult Primary","Drug: erlotinib hydrochloride|Biological: cetuximab|Biological: bevacizumab|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","66","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02639|CDR0000401514|NCI-6588|CTRC-IDD-0332|6588|U01CA069853|P30CA054174","January 7, 2005","January 2005","May 2008","June 10, 2014","December 2012","No Study Results Posted","null","October 2007","Maximum tolerated dose (MTD) of erlotinib hydrochloride combined with cetuximab determined by dose-limiting toxicities (DLT) graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3 (Part I)|MTD of bevacizumab combined with cetuximab and erlotinib hydrochloride determined by DLT graded according to the CTCAE version 3 (Part II)|Antitumor activity defined as the number and extent (complete or partial) objective responses as well as objective stable disease as measured by RECIST criteria|Median time to progression|Progression-free survival","https://ClinicalTrials.gov/show/NCT00101348"
3245,"NCT01006577","Side-to-end Anastomosis Versus Colon J Pouch for Reconstruction After Low Anterior Resection for Rectal Cancer (SAVE)","Not yet recruiting","No Results Available","Rectal Cancer","Procedure: side-to-end anastomosis|Procedure: colon j pouch","Charite University, Berlin, Germany|ChirNet","Both","18 Years to 80 Years   (Adult, Senior)","","306","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","EA4/105/08","October 19, 2009","June 2010","October 2015","November 2, 2009","November 2009","No Study Results Posted","SAVE","July 2015","Side-to-end anastomosis is not inferior not colon J pouch in terms of fecal incontinence. fecal incontinence (Wexner score)|anorectal function|quality of life|postoperative complications|sexual function|urinary function|operation time|institutional costs|local recurrence|cancer related deaths","https://ClinicalTrials.gov/show/NCT01006577"
3246,"NCT00423254","Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.","Completed","No Results Available","Ovarian|Melanoma|Renal|Prostate|Colorectal|Endometrial Carcinoma|Cervical Carcinoma|Testicular Cancer|Thyroid Cancer|Small Cell Lung Carcinoma|Mesothelioma|Breast Carcinoma|Esophageal Carcinoma|Gastric Cancer|Pancreatic Carcinoma|Neuroendocrine Cancer|Liver Cancer|Gallbladder Cancer|Biliary Tract Cancer|Anal Carcinoma|Bone Sarcomas|Soft Tissue Sarcomas|Carcinoma of Unknown Origin, Primary","Biological: PSMA/PRAME|Biological: PSMA/PRAME","Mannkind Corporation","Both","18 Years and older   (Adult, Senior)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MKC1106-PP-001","January 12, 2007","February 2007","November 2009","August 2, 2010","August 2010","No Study Results Posted","null","September 2009","To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP|to determine the blood plasmid levels by PCR analysis|measure cytokine levels|to describe any objective tumor responses to the treatment with MKC1106-PP","https://ClinicalTrials.gov/show/NCT00423254"
3247,"NCT01797770","Trial on Mechanical Bowel Preparation in Laparoscopic Colorectal Surgery","Recruiting","No Results Available","Rectal Cancer|Colon Cancer","Drug: polyethylene glycol|Other: No Preparation","PVS Memorial Hospital","Both","25 Years to 75 Years   (Adult, Senior)","Phase 4","90","Other","Observational","Time Perspective: Prospective","PVS2","September 16, 2012","January 2012","February 2014","February 21, 2013","February 2013","No Study Results Posted","MBP","January 2014","anastomotic leak|surgical site infection|Intraoperative parameters assessment|bowel recovery|drain removal|Re-exploration|Hospital stay|Readmission","https://ClinicalTrials.gov/show/NCT01797770"
3248,"NCT00668161","Effect of Exercise on Biomarkers of Colon Cancer Risk","Completed","No Results Available","Colon Cancer Prevention","Behavioral: Exercise","Fred Hutchinson Cancer Research Center","Both","40 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","202","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","APPEAL CA77572-01|FHCRC-4838, R01 CA77572-01","April 24, 2008","January 2001","February 2005","November 26, 2012","November 2012","No Study Results Posted","APPEAL","December 2004","Proliferation rate in the upper part of colon and rectal mucosa crypts.|expression of apoptosis-related proteins (bax/bcl-2 ratio) in colon and rectal mucosal biopsies|rectal mucosal prostaglandin levels|fasting serum/plasma insulin, glucose, triglycerides, insulin-like growth factor 1(IGF-1), and IGF binding protein-3 (IGFPB-3)|body fat mass and distribution (body mass index, waist and hip circumferences, bioelectrical impedance, DEXA scan)and subcutaneous abdominal and intra-abdominal fat mass (measured by one-slice CT scan at the L4 level)|quality of life (measured by standardized self-report instruments) and sleep quality","https://ClinicalTrials.gov/show/NCT00668161"
3249,"NCT01182116","Quality of Life in Patients That Undergo J Pouch or Side to End Coloanal Anastomosis for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: J Pouch","The Cleveland Clinic","Both","18 Years to 75 Years   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","IRB 08-178","May 25, 2010","March 2009","December 2013","July 29, 2013","July 2013","No Study Results Posted","null","December 2013","Improved function and capacity of the neorectum.","https://ClinicalTrials.gov/show/NCT01182116"
3250,"NCT02280811","T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers","Completed","No Results Available","Vaginal Cancer|Cervical Cancer|Anal Cancer|Penile Cancer|Oropharyngeal Cancer","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: E6 TCR|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","12","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","150005|15-C-0005","October 30, 2014","October 2014","June 2016","August 31, 2016","June 2016","No Study Results Posted","null","June 2016","To determine the objective tumor response rate and duration in patients with metastatic or recurrent/refractory HPV-16+ cancers treated with autologous T cells expressing the E6 TCR plus aldesleukin following a lymphocyte-depleting preparative r...","https://ClinicalTrials.gov/show/NCT02280811"
3251,"NCT00712751","The Sexual Health of Rectal Cancer Patients","Active, not recruiting","No Results Available","Rectal Cancer|Rectum","Behavioral: questionnaires|Behavioral: CSI-SH- Cancer Survivorship Intervention","Memorial Sloan Kettering Cancer Center|Albert Einstein College of Medicine of Yeshiva University|Icahn School of Medicine at Mount Sinai|M.D. Anderson Cancer Center|National Institutes of Health (NIH)","Both","21 Years and older   (Adult, Senior)","","192","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","08-073","July 7, 2008","June 2008","June 2016","October 18, 2015","October 2015","No Study Results Posted","null","June 2016","To investigate the feasibility, tolerability, acceptability (including adherence) and efficacy of CSI-SH, a psycho-educational intervention, on the primary outcome of sexual functioning among RC survivors.|To investigate the impact of CSI-SH on secondary outcomes: sexual self-schema, cancer specific distress, general distress symptoms, and Quality of Life for all participants, as well as sexual bother for men only.|To explore baseline variables that may influence the effectiveness of CSI-SH (i.e., moderators such as socio-demographic and medical variables).","https://ClinicalTrials.gov/show/NCT00712751"
3252,"NCT00973440","Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies","Completed","No Results Available","Rectal Cancer|Breast Cancer|Lung Cancer","","Dana-Farber Cancer Institute|American Society of Clinical Oncology","Both","70 Years and older   (Senior)","","59","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","09-035","September 8, 2009","March 2009","October 2013","October 21, 2013","October 2013","No Study Results Posted","null","July 2011","To determine the feasibility and added clinical utility of a self-administered computer-based version of an abbreviated comprehensive geriatric assessment tool.","https://ClinicalTrials.gov/show/NCT00973440"
3253,"NCT00250835","Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer","Terminated","Has Results","Rectal Cancer","Other: Chemotherapy, Celecoxib, and Radiation","New Mexico Cancer Care Alliance","Both","18 Years and older   (Adult, Senior)","Phase 2","38","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3304C|NCI-2011-02685","November 4, 2005","April 2005","May 2015","August 3, 2015","August 2015","June 19, 2015","null","December 2012","Pathologic Complete Response (PCR)|Toxicity|Progression-free Survival (PFS)|Incidence of Sphincter-sparing Surgery|Surgical Downstaging Rate|Pelvic Local Control Rate","https://ClinicalTrials.gov/show/NCT00250835"
3254,"NCT02907385","Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing","Not yet recruiting","No Results Available","Rectal Cancer|Anastomotic Leak","Device: LifeSeal™ Kit","LifeBond Ltd.","Both","21 Years and older   (Adult, Senior)","Phase 3","736","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CLP-LS-0131","September 15, 2016","September 2016","September 2020","September 19, 2016","September 2016","No Study Results Posted","null","March 2018","Incidence of overall anastomotic leak|Incidence of post operative anastomotic leaks","https://ClinicalTrials.gov/show/NCT02907385"
3255,"NCT02488707","Minimally Invasive Sphincter Sparing Total Mesorectal Excision for Ultra-low Rectal Cancer After Initial Chemo-radiotherapy (MISS-TRICR).","Enrolling by invitation","No Results Available","Rectal Cancer","Procedure: laparoscopic intersphincteric resection (LISR group)|Procedure: Transanal minimally invasive Total mesorectal excision (TAMIS group)","Mansoura University","Both","18 Years and older   (Adult, Senior)","Phase 2","250","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","MISS-TRICR","June 27, 2015","February 2014","April 2016","July 1, 2015","July 2015","No Study Results Posted","MISS-TRICR","February 2016","Percent of Intraoperative and postoperative morbidity within 30 days starting from the time of the operation|Hospital stay","https://ClinicalTrials.gov/show/NCT02488707"
3256,"NCT02598414","The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak in Robotic Colorectal Surgery","Recruiting","No Results Available","Colon Neoplasms|Rectal Neoplasms|Inflammatory Bowel Disease|Diverticular Disease","Procedure: Near-infrared ICG fluorescence imaging|Procedure: Traditional bowel anastomosis|Device: FireFly™","Acibadem University|Acibadem Atakent University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","102","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","ICG-COLORECTAL","November 2, 2015","November 2015","December 2017","November 22, 2015","November 2015","No Study Results Posted","null","December 2017","Anastomotic leak rate|Complication rate|Mortality","https://ClinicalTrials.gov/show/NCT02598414"
3257,"NCT00973193","Preoperative Panitumumab and Radiotherapy in Rectal Cancer","Terminated","No Results Available","Rectal Cancer","Drug: panitumumab","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL-ONCO 09-001|Academic study","September 7, 2009","September 2009","December 2012","April 19, 2016","April 2016","No Study Results Posted","PrePaRad","September 2011","Pathological Complete Response (pCR)|Safety, pathologic R0 resection, negative Circumferential Resection Margin, pathologic downstaging, tumor regression grade, quality of mesorectal excision, rate of sphincter-preservation, Disease-Free Survival, local control rate, translational research","https://ClinicalTrials.gov/show/NCT00973193"
3258,"NCT01661829","An RCT for the Effect of Biofeedback Therapy the Prevention of AR Syndrome in Rectal Cancer Patients","Completed","No Results Available","Rectal Cancer","","The Catholic University of Korea","Both","18 Years and older   (Adult, Senior)","","56","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KSVHCRC trial-01|Colorectal disease","August 5, 2012","March 2012","February 2015","February 2, 2015","February 2015","No Study Results Posted","null","February 2015","Incidence of anterior resection syndrome after stoma closure","https://ClinicalTrials.gov/show/NCT01661829"
3259,"NCT00910143","Introduction and Influence of Total Mesorectal Excision (TME) in the Treatment of Rectal Cancer","Completed","No Results Available","Rectal Cancer","Procedure: conventional rectal surgery|Procedure: total mesorectal excision","University Hospital Inselspital, Berne","Both","16 Years and older   (Child, Adult, Senior)","","194","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KEK 08-05-09","May 28, 2009","January 1993","December 2001","May 28, 2009","May 2009","No Study Results Posted","null","December 2001","Local recurrence, recurrence-free survival, overall survival|Surgical complications|quality of life|Percentage of patients undergoing transcatheter arterial embolisation","https://ClinicalTrials.gov/show/NCT00910143"
3260,"NCT00988936","Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug","Completed","No Results Available","Metastatic Breast Cancer|Metastatic Colon/Rectum Cancer|Non-squamous Non-small Cell Lung Cancer","Drug: [F-18]RGD-K5","Siemens Molecular Imaging","Both","18 Years and older   (Adult, Senior)","Phase 2","35","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","K5-101","October 1, 2009","September 2009","May 2012","August 21, 2012","August 2012","No Study Results Posted","K5-101","March 2012","To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response to Avastin® (the anti-angiogenesis drug) plus chemotherapy treatment before the full course of treatment is completed.|To continue safety evaluation by collection of safety data from all patients.|To gain experience with [F-18]RGD-K5 PET/CT in order to improve the study design and conduct of future studies.","https://ClinicalTrials.gov/show/NCT00988936"
3261,"NCT02751736","The Effect Of Probiotics On Bowel Function Restoration After Ileostomy Closure In Patients With Rectal Cancer","Enrolling by invitation","No Results Available","Rectal Cancer","Dietary Supplement: CJLP243|Dietary Supplement: Placebo","Seoul National University Hospital|CJ HealthCare Corporation","Both","20 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","40","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","B-1603-339-003","April 7, 2016","April 2016","December 2017","June 30, 2016","June 2016","No Study Results Posted","null","December 2016","Memorial Sloan Kettering Cancer Center bowel function index|Low Anterior Resection Syndrome score|Change of bowel functions index|EORTC C30|EORTC CR (Colorectal) 29|Postoperative complication","https://ClinicalTrials.gov/show/NCT02751736"
3262,"NCT02017509","Immunoscore in Rectal Cancer","Recruiting","No Results Available","Cancer of the Rectum|Neoplasms, Rectal|Rectal Cancer|Rectal Tumors|Rectal Adenocarcinoma|Melanoma|Breast Cancer|Renal Cell Cancer|Lung Cancer|Bladder Cancer|Head and Neck Cancer|Ovarian Cancer|Thyroid Cancer","Procedure: Diagnostic Biopsy and Surgical Procedure|Procedure: Intravoxel incoherent motion MRI (IVIM)|Procedure: Dynamic Contrast Enhanced MRI (DCE-MRI)|Genetic: RNA gene expression analysis","Providence Health & Services|Oregon Health and Science University","Both","18 Years and older   (Adult, Senior)","","86","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","13-107A","December 9, 2013","September 2013","September 2025","March 28, 2016","March 2016","No Study Results Posted","null","September 2025","Correlation of the number of infiltrating leukocytes within a biopsy sample with pathologic response","https://ClinicalTrials.gov/show/NCT02017509"
3263,"NCT02849717","Pre-Habilitation Exercise Intervention","Recruiting","No Results Available","Inflammatory Bowel Diseases|Colon Cancer|Rectal Cancer|Diverticular Disease","Behavioral: Exercise for Cancer Patients","University of Rochester","Both","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","59142","July 19, 2016","March 2016","null","July 26, 2016","July 2016","No Study Results Posted","null","March 2018","The primary outcome measure for this study is fatigue assessed by the FACIT-F fatigue subscale..|Aerobic Capacity via VO2 maximum testing|Skeletal Muscle Mass will be assessed using bio-electrical impedance assessment of muscle mass|Skeletal Muscle Mass will be assessed using CT assessment of muscle mass|Circulating Levels of Pro-Inflammatory Cytokines will be measured by standard Complete Blood Count (CBC) differential procedures.|Post-operative Complications will be extracted from patient charts and will be classified for severity using the Clavien-Dindo classification of surgical complications.|Quality of Life (QOL) on self reported psychological distress questionnaires: Profile of Mood States (POMS).|Quality of Life (QOL) on self reported psychological distress questionnaires: Spielberg State/Trait Anxiety Inventory (STAI Form Y-1).","https://ClinicalTrials.gov/show/NCT02849717"
3264,"NCT02591407","Trial Comparing Transversus Abdominis Plane Block Versus Epidural Anesthesia for Pain Management in Colorectal Surgery","Enrolling by invitation","No Results Available","Colon Cancer|Rectal Cancer|Colonic Diverticulosis","Procedure: TAP Block|Procedure: Continuous Epidural Analgesia","Saint Joseph Mercy Health System","Both","18 Years and older   (Adult, Senior)","","176","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","HSR 15-1618","October 7, 2015","October 2015","October 2018","October 28, 2015","October 2015","No Study Results Posted","TAP","October 2017","Post-operative pain control day 1 using the numeric pain scale|Post-operative pain control day 2 using the numeric pain scale|Post-operative pain control day 3 using the numeric pain scale|Overall benefits of analgesia treatment post-operative day 1|Overall benefits of analgesia treatment post-operative day 2|Overall benefits of analgesia treatment post-operative day 3","https://ClinicalTrials.gov/show/NCT02591407"
3265,"NCT02550769","Study of NOTES-TME Versus L-LAR in Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: TRANSANAL TOTAL MESORECTAL EXCISION|Procedure: Laparoscopic-LAR","Corporacion Parc Tauli","Both","18 Years and older   (Adult, Senior)","Phase 4","116","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NOTES-LRAB_TAU-2015","August 31, 2015","April 2015","April 2019","September 14, 2015","September 2015","No Study Results Posted","NOTESvsL-LAR","September 2018","Evaluate the effectiveness of the T-TME versus L-LAR with the Dindo-Claviens classification in patients with rectal cancer.|Evaluate the effectiveness of the T-TME versus L-LAR with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) CR-30 score in patients with rectal cancer.|Evaluate the effectiveness of the T-TME versus L-LAR with the EORTC QLQ-CR29 score in patients with rectal cancer.|Evaluate the effectiveness of the T-TME versus L-LAR with the LARS score in patients with rectal cancer.","https://ClinicalTrials.gov/show/NCT02550769"
3266,"NCT00467922","An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy","Completed","No Results Available","Crohn's Disease|Ulcerative Colitis|Rectal Cancer|Colon Cancer|Colon Polyps|Rectal Polyps|Diverticulitis","Drug: Hextend|Drug: Lactated Ringers","Spectrum Health Hospitals|Deltex Medical, Inc.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","69","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2007-109","April 27, 2007","May 2007","October 2009","October 20, 2009","October 2009","No Study Results Posted","null","September 2009","Determine the relative effects of a standard, colloid or crystalloid based strategy for hand-assisted laparoscopic colectomy surgery on decreasing length of stay|1. Determine the effects of the three fluid management strategies on post-operative fluid requirements in colorectal surgery. on the incidence and severity of post-operative complications. on return of gastrointestinal function.","https://ClinicalTrials.gov/show/NCT00467922"
3267,"NCT01424293","Fluorescent Evaluation of Colorectal Anastamoses","Active, not recruiting","No Results Available","Rectal Neoplasms|Colon Neoplasms|Diverticulitis","Device: Indocyanine Green|Device: The SPY® Intraoperative Imaging System","Maimonides Medical Center","Both","18 Years to 65 Years   (Adult)","","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","1004va09","September 29, 2010","May 2010","September 2016","August 6, 2015","August 2015","No Study Results Posted","null","September 2016","Evaluate the vascular supply to bowel anastomoses","https://ClinicalTrials.gov/show/NCT01424293"
3268,"NCT00254683","Use of Positron Emission Tomography/Computed Tomography (PET/CT) to Assess Tumor Response to Neoadjuvant Treatment for Distal Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Device: PET/CT with FDG","University of Sao Paulo","Both","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","717/05","November 15, 2005","September 2005","September 2015","April 13, 2009","April 2009","No Study Results Posted","null","August 2010","PET/CT specificity and sensitivity for tumor response|Correlation between PET/CT and complete clinical Response","https://ClinicalTrials.gov/show/NCT00254683"
3269,"NCT00808743","Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis","Completed","No Results Available","Familial Adenomatous Polyposis|Duodenal Neoplasms|Duodenal Polyps","Drug: Celecoxib|Drug: Ursodeoxycholic acid|Drug: Placebo","Radboud University|Dutch Cancer Society","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","37","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","RUN 2008-4198|ABR nr.: NL23569.091.08|CMO: 2008/148|EudraCT: 2008-003696-43","December 15, 2008","May 2009","January 2013","May 15, 2013","August 2010","No Study Results Posted","PreDuoFAP","July 2011","Change in number and size of duodenal adenomas (assessed directly and by evaluation of video and photographic material from endoscopic procedures)|Cell proliferation, in normal mucosa and adenomas (if present)|Biliary acid profile (if present)","https://ClinicalTrials.gov/show/NCT00808743"
3270,"NCT01891552","Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab","Completed","No Results Available","Colon Cancer Liver Metastasis","","International Group of Endovascular Oncology","Both","18 Years to 70 Years   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TACETUX01","June 26, 2013","May 2013","May 2015","May 12, 2015","May 2015","No Study Results Posted","TACETUX","May 2015","time to progression|number of adverse events","https://ClinicalTrials.gov/show/NCT01891552"
3271,"NCT01345175","Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Drug: Rifaximin|Drug: Placebo","Memorial Sloan Kettering Cancer Center","Both","21 Years and older   (Adult, Senior)","Phase 3","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","11-045","April 28, 2011","April 2011","April 2017","March 28, 2016","March 2016","No Study Results Posted","null","April 2017","To compare the efficacy of rifaximin and placebo in the treatment of bowel dysfunction as measured by MSKCC Bowel Function Instrument (BFI score) in patients following Anterior Resection (AR) or Sphincter Preserving Surgery (SPS) for rectal cancer.|To determine if reduction in intestinal bacterial quantity correlates with improvement in bowel symptoms (BFI score).|To explore the bacterial composition of stool before and after antibiotic treatment.|To identify dynamic changes in bowel function during and after antibiotic treatment using a bowel function log.|efficacy of metronidazole","https://ClinicalTrials.gov/show/NCT01345175"
3272,"NCT02514278","Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy","Recruiting","No Results Available","Rectal Cancer","Drug: Neoadjuvant chemotherapy Folfirinox, 4 cycles|Radiation: 50 Gy, 2 Gy/session; 25 fractions|Procedure: Local excision in good responders|Procedure: Rectal excision in bad responders|Drug: Capecitabine","University Hospital, Bordeaux","Both","18 Years and older   (Adult, Senior)","Phase 3","218","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CHUBX 2014/33","July 6, 2015","January 2016","March 2022","August 18, 2016","August 2016","No Study Results Posted","GRECCAR 12","January 2020","Rate of organ preservation and absence of stoma|Compliance to treatment|Tolerance to treatment|Rate of clinical complete response|Rate of radiological response|Rate of complete pathologic response|Correlation between radiological and clinical response|Correlation between radiological and pathologic response|Rate of curative surgery|Surgical morbidity|Quality of life|Local recurrence|Overall survival|Disease-free survival","https://ClinicalTrials.gov/show/NCT02514278"
3273,"NCT01187901","A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients","Completed","Has Results","Adenomatous Polyposis Coli","Drug: Erlotinib|Drug: Sulindac|Drug: Placebo A|Drug: Placebo B","University of Utah|National Cancer Institute (NCI)","Both","18 Years to 69 Years   (Adult, Senior)","Phase 2","92","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","00039278|P01CA073992","August 3, 2010","April 2010","July 2014","May 10, 2016","May 2016","May 10, 2016","FAPEST","June 2014","Change in Duodenal Polyp Burden From Baseline to 6 Months|Change in Duodenal Polyp Burden From Baseline to 6 Months in Classic Familial Adenomatous Polyposis (FAP) Participants|Change in Duodenal Polyp Burden From Baseline to 6 Months in Attenuated FAP Participants|Change in Number of Duodenal Polyps From Baseline to 6 Months|Change in Number of Duodenal Polyps From Baseline to 6 Months in Classic FAP Participants|Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants","https://ClinicalTrials.gov/show/NCT01187901"
3274,"NCT02279771","Transanal Reinforcement of Low Rectal Anastomosis in Rectal Cancer Surgery","Not yet recruiting","No Results Available","Rectal Cancer","Procedure: transanal anastomotic reinforcement|Procedure: protective ileostomy group|Device: a circular anal dilator (CAD)","Donato F Altomare|Societa Italiana di Chirurgia ColoRettale","Both","30 Years to 80 Years   (Adult, Senior)","","140","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Siccr/2014","October 29, 2014","January 2015","June 2016","October 30, 2014","October 2014","No Study Results Posted","LessStoReS","December 2015","anastomotic leak|duration of the two operations|Number of overall postoperative complications","https://ClinicalTrials.gov/show/NCT02279771"
3275,"NCT01995396","Hartmanns Procedure or Abdominoperineal Excision With Intersphincteric Dissection in Rectal Cancer: a Randomized Study","Recruiting","No Results Available","Rectal Cancer.|Sphincter Ani Incontinence|Other Diagnoses, Comorbidities, and Complications","Procedure: APE with intersphincteric dissection|Procedure: Hartmann´s procedure","Landstinget Västmanland","Both","18 Years and older   (Adult, Senior)","","340","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LTV-398121","November 21, 2013","February 2014","February 2019","March 4, 2016","March 2016","No Study Results Posted","HAPIrect","February 2018","Rates ot postoperative surgical complications within 30 days.|Peroperative data|The rate of intraoperative perforations|Resection margins|Rate of local recurrence|Survival after 3 and 5 years follow-up|Postoperative actions|Other postop complications","https://ClinicalTrials.gov/show/NCT01995396"
3276,"NCT01980238","Defunctioning Cannula Ileostomy After Lower Anterior Resection of Rectal Cancer","Active, not recruiting","No Results Available","Rectal Neoplasms","Device: cannula ileostomy|Device: loop ileostomy|Device: LAR","First Affiliated Hospital of Zhejiang University","Both","Child, Adult, Senior","","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","cannula ileostomy","October 23, 2013","January 2011","December 2014","November 16, 2013","November 2013","No Study Results Posted","null","December 2013","anastomotic leakage, reoperation and mortality rate|ileus rate","https://ClinicalTrials.gov/show/NCT01980238"
3277,"NCT00782457","Prospective Randomised Study Comparing Laparoscopic Versus Open Surgery in Patients With Rectal Cancer","Completed","No Results Available","RECTAL CANCER","Procedure: RECTAL CANCER RESECTION","Hospital Universitario Virgen de la Arrixaca","Both","Child, Adult, Senior","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D-08-00770","October 29, 2008","January 2002","December 2010","March 17, 2015","October 2008","No Study Results Posted","null","February 2007","Lymph nodes isolated, circumferential margin involved, rate of complications and length of stay","https://ClinicalTrials.gov/show/NCT00782457"
3278,"NCT02701088","Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life","Recruiting","No Results Available","Locally Advanced Anal Canal Cancer","Drug: 5Fluorouracile and Mitomycin-C|Radiation: Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy","Centre Francois Baclesse|Accuray Incorporated","Both","18 Years and older   (Adult, Senior)","Phase 2","66","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CANAL-IMRT-01","December 23, 2015","December 2015","December 2017","March 2, 2016","February 2016","No Study Results Posted","CANAL-IMRT-01","December 2017","Efficacy: The 3-month locoregional control rate|Tolerance profile: Proportion of patients with no significant toxicities responsible for irradiation breaks|Quality of life measured by the EORTC QLQ-C30 (version 3.0)|The acute and late toxicities assessed according to NCI CTCAE v4.03|The 6- and 12-month locoregional control rates defined by the proportion of patients with no local disease progression at 6 and 12 months after the end of radiotherapy|Duration of response defined by the time elapsed from first objective response to progression or death from any cause|Quality of life measured by the additional colorectal module QLQ-CR 29|Quality of life measured by the Vaizey incontinence scale|The acute and late toxicities assessed according the SOMA/LENT scale","https://ClinicalTrials.gov/show/NCT02701088"
3279,"NCT02724397","Linked Color Imaging/Magnifying Blue Laser Imaging vs. White Light for Adenomas and Serrated Lesions in Proximal Colon","Not yet recruiting","No Results Available","Colon Cancer","Device: LCI/BLI then white endoscopy|Device: White endoscopy and then LCI/BLI","Affiliated Hospital to Academy of Military Medical Sciences","Both","50 Years to 85 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","307-LCI/BLI-002","March 18, 2016","April 2016","January 2017","March 31, 2016","March 2016","No Study Results Posted","null","October 2016","Number of Proximal Serrated lesions and colorectal adenomas in proximal colon|Improvement of histological diagnosis for serrated lesions and colorectal adenomas using LCI/BLI by comparing with that under white endoscopy","https://ClinicalTrials.gov/show/NCT02724397"
3280,"NCT00509444","Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial","Active, not recruiting","No Results Available","Breast Cancer|Colon Cancer|Rectum Cancer|Cervix Cancer|Prostate Cancer|Lung Cancer","Behavioral: Educational materials|Behavioral: educational materials, plus patient navigation","Johns Hopkins Bloomberg School of Public Health|Centers for Medicare and Medicaid Services","Both","65 Years and older   (Adult, Senior)","Phase 3","200","Other|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00063","July 27, 2007","October 2006","December 2012","June 18, 2012","June 2012","No Study Results Posted","CPTD","December 2010","The primary outcome variable will be difference between the two intervention groups in the time to initiation of therapy, beginning on the date of randomization.|The time in days to the first treatment-related visit (with a medical, radiation oncologist, or surgical oncologist) beginning on the date of randomization.|The rate of completion of recommended courses of chemo and/or radiation therapy.|The proportion completing recommended surgical treatment.|The proportion receiving recommended screenings for breast, cervix, colon/rectum and prostate cancer.","https://ClinicalTrials.gov/show/NCT00509444"
3281,"NCT01861678","Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Anterior Resection","Active, not recruiting","No Results Available","Rectal Cancer|Colon Rectal Resection","Procedure: High tie of IMA|Procedure: Low tie of IMA","Shoichi Fujii, MD, PhD|Yokohama City University Medical Center","Both","20 Years and older   (Adult, Senior)","Phase 3","331","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","YCUMC-D1108013|YokohamaCUMC424","May 21, 2013","July 2006","September 2017","August 4, 2013","August 2013","No Study Results Posted","null","September 2012","Anastomotic leakage rate|Overall survival|Operation time|Amount of blood loss","https://ClinicalTrials.gov/show/NCT01861678"
3282,"NCT02052921","Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy","Recruiting","No Results Available","Rectal Cancer","Procedure: Rectal resection|Other: Observation","Instituto do Cancer do Estado de São Paulo","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NP172/11","January 31, 2014","November 2011","February 2019","May 31, 2016","May 2016","No Study Results Posted","null","December 2016","Disease-free survival (DFS)|Operative complication rate","https://ClinicalTrials.gov/show/NCT02052921"
3283,"NCT00535652","Concentration of Ertapenem in Colorectal Tissue","Completed","No Results Available","Diverticulosis, Colonic|Rectal Neoplasms|Colonic Neoplasms","Drug: Ertapenem","University of Ulm","Both","18 Years to 90 Years   (Adult, Senior)","Phase 4","23","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-07","September 24, 2007","September 2007","December 2009","April 5, 2010","February 2009","No Study Results Posted","null","December 2009","Concentration of ertapenem in colorectal tissue in mg/kg 3 to 6 hours after a single dose of 1 gram ertapenem I.V..|safety assessment","https://ClinicalTrials.gov/show/NCT00535652"
3284,"NCT02441153","Timing of Rectal Cancer Resection After Preoperative Chemoradiotherapy","Not yet recruiting","No Results Available","Rectal Neoplasms","Other: Extended Timing","Health Sciences North Research Institute|Northern Ontario Academic Medical Association","Both","18 Years and older   (Adult, Senior)","","80","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","T4RC North","May 8, 2015","June 2015","June 2018","May 8, 2015","May 2015","No Study Results Posted","T4RC","June 2017","Disease-free survival","https://ClinicalTrials.gov/show/NCT02441153"
3285,"NCT02205307","A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection","Recruiting","No Results Available","Rectal Cancer|Rectosigmoid Cancer","Device: PINPOINT|Device: SPY Elite","Novadaq Technologies Inc.","Both","18 Years and older   (Adult, Senior)","","1000","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PP PLR 03","July 29, 2014","January 2015","June 2017","February 25, 2016","February 2016","No Study Results Posted","PILLAR III","February 2017","Anastomotic Leak Rate|Evaluate the ability of PINPOINT or SPY Elite to provide sufficient visualization for assessment of blood flow and related tissue perfusion during the procedure|Rate of postoperative abscess requiring surgical management","https://ClinicalTrials.gov/show/NCT02205307"
3286,"NCT02538913","Exercise Training for Rectal Cancer Patients","Recruiting","No Results Available","Rectal Neoplasms","Behavioral: Exercise training|Procedure: Usual care","Norwegian University of Science and Technology|St. Olavs Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","2014/2284","August 26, 2015","September 2015","August 2023","September 14, 2016","September 2016","No Study Results Posted","null","August 2018","Anal incontinence|Urinary incontinence|Bowel dysfunction|Physiology of the anal sphincter|Sexual dysfunction|Quality of life|Maximal oxygen uptake (VO2max)|Postoperative complications|Physical activity level|In-hospital time","https://ClinicalTrials.gov/show/NCT02538913"
3287,"NCT01101672","Trial for Single Port Versus Conventional Laparoscopic Colectomy","Recruiting","No Results Available","Colonic Polyps|Colonic Cancers","Procedure: Single port laparoscopic colectomy|Procedure: Conventional laparoscopic colectomy","The University of Hong Kong","Both","18 Years to 89 Years   (Adult, Senior)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","UW09-341","April 8, 2010","November 2009","October 2011","April 9, 2010","April 2010","No Study Results Posted","null","July 2011","Post-operative pain on coughing|Operative blood loss and transfusion|Operative morbidities and 30 days mortality|Length of hospital stay|Recurrence and survival for cancer patient","https://ClinicalTrials.gov/show/NCT01101672"
3288,"NCT01031056","Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers","Withdrawn","No Results Available","Gastrointestinal Neoplasms|Gynecologic Cancers|Gynecologic Cancers Cervical Cancer|Gastric (Stomach) Cancer|Gastro-Esophageal(GE) Junction Cancer|Gastrointenstinal Stromal Tumor (GIST)|Colon/Rectal Cancer|Colon/Rectal Cancer Colon Cancer|Colon/Rectal Cancer Rectal Cancer|Colon/Rectal Cancer Anal Cancer|Anal Cancer|Hepatobiliary Cancers|Hepatobiliary Cancers Liver|Pancreatic Cancer","Procedure: Blood Draw|Procedure: Frozen Tumor Specimens","Stanford University|Caring for Carcinoid Foundation|GI Cancer Research Gift Fund","Both","18 Years and older   (Adult, Senior)","","0","Other","Observational","Time Perspective: Prospective","SU-09092009-3840|GI0004","December 10, 2009","January 2010","January 2099","May 24, 2012","May 2012","No Study Results Posted","null","January 2099","None: Biospecimen will be collected for future research.","https://ClinicalTrials.gov/show/NCT01031056"
3289,"NCT01844908","Electroacupuncture for Postoperative Ileus After Laparoscopic Rectal Cancer Surgery","Recruiting","No Results Available","Postoperative Ileus","Procedure: Electroacupuncture","Chinese University of Hong Kong","Both","18 Years to 80 Years   (Adult, Senior)","","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRE-2013.032","April 24, 2013","May 2013","May 2014","February 10, 2014","February 2014","No Study Results Posted","null","May 2014","Incidence of prolonged ileus|Time of first passing flatus reported by the patients|Time to first defecation|Time that the patients tolerated solid diet|Duration of hospital stay|Pain scores on visual analog scale|Postoperative analgesic requirement|Overall complication rate|30-day mortality rate","https://ClinicalTrials.gov/show/NCT01844908"
3290,"NCT00622557","General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)","Recruiting","No Results Available","Colon Cancer|Diverticulitis|Colorectal Polyps|Crohn's Disease|Ulcerative Colitis|Rectal Cancer","","University Hospitals Cleveland Medical Center","Both","14 Years to 95 Years   (Child, Adult, Senior)","","200000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","04-07-18","February 11, 2008","May 2007","December 2015","December 11, 2013","December 2013","No Study Results Posted","SOCRATES","December 2015","","https://ClinicalTrials.gov/show/NCT00622557"
3291,"NCT02012023","Use of One Kind of Controllable Tube Ileostomy in the Low Rectal Cancer","Completed","No Results Available","Rectal Neoplasms|Low Anterior Resection","Device: Low anterior resection|Device: tube ileostomy|Device: loop ileostomy|Device: accept reversal operation|Device: remove the tube ileostomy","First Affiliated Hospital of Zhejiang University","Both","Child, Adult, Senior","","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","Controllable tube ileostomy","December 4, 2013","January 2014","August 2016","August 21, 2016","July 2016","No Study Results Posted","CTI","August 2016","anastomotic leakage|reoperation rate|mortality|ileus rate|operation data","https://ClinicalTrials.gov/show/NCT02012023"
3292,"NCT01163526","Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies","Active, not recruiting","No Results Available","Neuroendocrine Tumors|Brain (Nervous System) Cancers|Colon/Rectal Cancer|Colon Cancer|Hepatobiliary Cancers|Hepatocellular Carcinoma (Hepatoma)|Liver","Procedure: CT perfusion","Stanford University|Siemens Corporation, Corporate Technology|GE Healthcare","Both","18 Years and older   (Adult, Senior)","","13","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HEP0031|SU-07092010-6491","July 14, 2010","September 2010","July 2017","June 22, 2016","June 2016","No Study Results Posted","null","July 2016","Predict RECIST response to treatment|Characterize CT perfusion longitudinally in both responders and nonresponders|Predict disease progression","https://ClinicalTrials.gov/show/NCT01163526"
3293,"NCT01056913","NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery","Completed","Has Results","Colonic Neoplasms|Rectal Neoplasms|Diverticulitis|Inflammatory Bowel Diseases|Rectal Prolapse","Device: Compression Anastomosis Device|Other: follow-up colonoscopy","St John of God Hospital, Vienna","Both","18 Years to 90 Years   (Adult, Senior)","Phase 4","62","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT2","January 24, 2010","October 2008","September 2010","December 11, 2013","December 2013","December 11, 2013","null","September 2010","Anastomotic Leakage|Clinical Relevant Stenosis","https://ClinicalTrials.gov/show/NCT01056913"
3294,"NCT01113736","Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy","Completed","No Results Available","Colon Cancer|Rectal Cancer","Biological: AlloMEM™","Conor Delaney, MD, PhD|Proxy Biomedical Limited|University Hospitals Cleveland Medical Center","Both","18 Years and older   (Adult, Senior)","","10","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","09-09-23","April 12, 2010","January 2010","July 2012","December 12, 2014","December 2014","No Study Results Posted","AlloMem","July 2012","If there is a decrease on adhesion formation of AlloMEM™ used in formation of a temporary loop ileostomy.|Decrease in operative time and a promotion of peritoneal remodeling","https://ClinicalTrials.gov/show/NCT01113736"
3295,"NCT00226941","Safety Study of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer","Completed","No Results Available","Rectal Cancer|Colon/Rectal Cancer Rectal Cancer|Colon/Rectal Cancer","Drug: Oxaliplatin|Drug: Capecitabine|Drug: Cetuximab","George Albert Fisher|Bristol-Myers Squibb|Stanford University","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COR0001|95054","September 8, 2005","June 2004","February 2009","November 6, 2012","July 2010","No Study Results Posted","null","March 2008","To determine the MTD and DLTs of oxaliplatin and capecitabine when combined with C225 and radiotherapy (Phase I)|o determine the pathologic response rate, at the time of surgical resection, of C225 in combination with this neoadjuvant cytotoxic regimen (Phase II).|To determine the effect of EGFR inhibition on immunohistochemical markers of downstream pathways|To determine additional efficacy endpoints including downstaging, local relapse rate and survival, and time-to-progression in patients treated with the treatment regimen|To determine the toxicity associated with this treatment and to document perioperative morbidity.","https://ClinicalTrials.gov/show/NCT00226941"
3296,"NCT01127425","Length of Hospital Stay, Nursing Hours and Recovery After Laparoscopic Versus Open Colon Resection Without Fast Track","Terminated","No Results Available","Sigmoid Neoplasms","Procedure: laparoscopic colonic resection|Procedure: laparoscopic sigmoid resection","University Hospital, Gentofte, Copenhagen","Both","40 Years to 90 Years   (Adult, Senior)","","18","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","KA-20060067","February 17, 2010","July 2006","December 2008","June 4, 2010","June 2006","No Study Results Posted","null","December 2008","primary: Length of stay|secondary: Nursing hours, pain and recovery","https://ClinicalTrials.gov/show/NCT01127425"
3297,"NCT02231203","Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function","Active, not recruiting","No Results Available","Colon Cancer","Drug: Omegaven|Drug: Placebo","Medical Center Alkmaar","Both","60 Years to 80 Years   (Adult, Senior)","Phase 4","44","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NL46230.029.13","July 29, 2014","October 2014","July 2016","April 25, 2016","April 2016","No Study Results Posted","EMPIRE","June 2016","Change in ex vivo production of pro-inflammatory cytokine IL-6 in LPS stimulated whole blood|Change in ex vivo production of TNF-α and IL-10 in LPS stimulated whole blood|Change in erythrocyte function|Change in in vivo systemic inflammatory response parameters","https://ClinicalTrials.gov/show/NCT02231203"
3298,"NCT00635466","Phase II Trial to Evaluate Laparoscopic Surgery for Stage 0/I Rectal Carcinoma","Active, not recruiting","No Results Available","Rectal Cancer","Procedure: laparoscopic surgery for rectal carcinoma","Japan Society of Laparoscopic Colorectal Surgery","Both","20 Years to 75 Years   (Adult, Senior)","Phase 2","495","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Lap RC|NCCHCT19-49","March 6, 2008","February 2008","September 2015","June 15, 2011","June 2011","No Study Results Posted","Lap RC","September 2015","overall survival|anastomotic leakage rate","https://ClinicalTrials.gov/show/NCT00635466"
3299,"NCT02585271","Transanal Decompression Tube Versus Stent for Acute Malignant Left-sided Colonic and Rectal Obstruction","Enrolling by invitation","No Results Available","Colonic Cancer|Rectal Cancer","Device: Transanal decompression tube|Device: Stent","Xuzhou Central Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","66","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","46650455-0","October 21, 2015","October 2015","December 2018","August 5, 2016","November 2015","No Study Results Posted","null","June 2018","Creation of stoma|Transanal decompression tube/stent-related complications|Surgery-related complications|Overall survival","https://ClinicalTrials.gov/show/NCT02585271"
3300,"NCT01987726","Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors","Recruiting","No Results Available","Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Breast Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Other: cytology specimen collection procedure|Other: laboratory biomarker analysis","Ohio State University Comprehensive Cancer Center|Foundation Medicine","Both","18 Years and older   (Adult, Senior)","","200","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","OSU-12067|NCI-2013-00872","November 13, 2013","September 2013","null","March 7, 2016","March 2016","No Study Results Posted","null","December 2016","Feasibility of NGS on metastatic solid tumor tissue, in terms of number of patients screened, FMI test attempted, FMI test successful, and FMI tests results released to physicians|Feasibility of NGS result-based non-FDA-approved treatment plan, measured by reasons for ability or inability to receive an anti-cancer agent|Availability of recommended experimental regimens via clinical trials|Proportion of patients who have one recommended therapy|Proportion of patients who have multiple options recommended|Presence of any oncogene or tumor suppressor gene mutations or amplifications identified by NGS on tumor tissue in each cohort","https://ClinicalTrials.gov/show/NCT01987726"
3301,"NCT00585312","Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)","Terminated","Has Results","Adenomatous Polyposis Coli","Drug: Celecoxib|Drug: Placebo","Pfizer","Both","10 Years to 17 Years   (Child)","Phase 3","106","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","A3191193","January 1, 2008","September 2006","October 2013","October 28, 2014","October 2014","October 28, 2014","CHIP","October 2013","Time to Disease Progression|Time to Treatment Failure|Total Number of Colorectal Polyps|Colorectal Polyp Burden","https://ClinicalTrials.gov/show/NCT00585312"
3302,"NCT02164149","Length of Tumour Feeding Artery After Colon Cancer Surgery","Recruiting","No Results Available","Colon Cancer","Other: Patients with primary colon cancer","University of Aarhus","Both","18 Years and older   (Adult, Senior)","","65","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CT121177","June 2, 2014","May 2014","November 2015","June 12, 2014","June 2014","No Study Results Posted","ColonCT","November 2014","CT scan after colon cancer surgery. The length of the tumour feeding artery will be measured on the images.","https://ClinicalTrials.gov/show/NCT02164149"
3303,"NCT01740648","Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer","Recruiting","No Results Available","Recurrent Rectal Cancer|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer","Drug: trametinib|Drug: fluorouracil|Radiation: radiation therapy","Evan Wuthrick|National Comprehensive Cancer Network|Novartis Pharmaceuticals|Ohio State University Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-12054|NCI-2012-02158","November 30, 2012","November 2012","null","May 23, 2016","May 2016","No Study Results Posted","null","December 2016","Identify the maximally tolerated dose of Trametinib to be used in combination with 5FU and radiation in patients with rectal cancers.|Frequency of dose-limiting toxicities, assessed according to the NCI CTCAE version 4|Local failure rate|Progression free survival|Overall survival|Pathological response rate, defined as extent of tumor in the resected specimen that is classified by tumor, lymph node, metastasis (TNM) staging of the AJCC/International Union Against Cancer (UICC)|Frequency of patients undergoing sphincter preserving surgery","https://ClinicalTrials.gov/show/NCT01740648"
3304,"NCT01236053","Cancer in Patients With Gabapentin (GPRD)","Completed","Has Results","Pain, Neuropathic|Epilepsy|Renal Pelvis Cancer|Pancreatic Cancer|Breast Cancer|Nervous System Cancer|Chronic Pancreatitis|Stomach Cancer|Renal Cell Carcinoma|Diabetes|Bladder Cancer|Bone and Joint Cancer|Penis Cancer|Anal Cancer|Cancer|Renal Cancer","Drug: Gabapentin prescriptions","GlaxoSmithKline","Both","Child, Adult, Senior","","2323608","Industry","Observational","Observational Model: Case Control|Time Perspective: Retrospective","114790|WEUSRTP4931","October 14, 2010","June 2010","September 2010","February 2, 2012","January 2012","July 1, 2011","null","September 2010","Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin|Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin|Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin|Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin|Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin|Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin|Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin|Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin|Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin|Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin|Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin|Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions|Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin|Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin|Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","https://ClinicalTrials.gov/show/NCT01236053"
3305,"NCT01725321","Narrow Band Imaging for Diagnosis of Proximal Serrated Polyps","Completed","No Results Available","Colonic Neoplasm","Other: Narrow band imaging","The University of Hong Kong","Both","40 Years and older   (Adult, Senior)","","360","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NBI_1","November 8, 2012","October 2012","October 2013","May 28, 2015","May 2015","No Study Results Posted","null","September 2013","Detection rate of proximal serrated polyp|Missed rate for proximal serrated polyps","https://ClinicalTrials.gov/show/NCT01725321"
3306,"NCT01923987","Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis","Recruiting","No Results Available","Rectal Cancer|Liver Metastasis|Lung Metastasis","Radiation: Short Course Radiotherapy|Drug: Chemotherapy|Procedure: Delayed Surgery","Korea Cancer Center Hospital|Kyung Hee University Hospital at Gangdong|Gachon University Gil Medical Center|Catholic University of Korea, Yeouido St. Mary`s Hospital|Pusan National University Yangsan Hospital|Gangnam Severance Hospital|Severance Hospital|Wonju Severance Christian Hospital|Chungnam National University Hospital|Dongtan Sacred Heart Hospital|The Koreran Society of Coloproctology|Catholic University of Korea, Seoul St. Mary`s Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","39","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","K-1208-001-002|KCT0000525","August 7, 2013","August 2012","August 2019","April 21, 2016","April 2016","No Study Results Posted","null","August 2017","R0 resection rate|Overall survival rate|Progression free survival rate|Tumor regression grade|Toxicity","https://ClinicalTrials.gov/show/NCT01923987"
3307,"NCT00774839","Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients","Completed","No Results Available","Colon Cancer","Behavioral: Patient Interview","Memorial Sloan Kettering Cancer Center|National Institutes of Health (NIH)|State University of New York - Downstate Medical Center|Ralph Lauren Center for Cancer Care and Prevention|Albert Einstein College of Medicine of Yeshiva University","Both","65 Years and older   (Adult, Senior)","","62","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","08-124","October 16, 2008","October 2008","August 2016","August 9, 2016","August 2016","No Study Results Posted","null","August 2016","Self-reported expenses associated with colon cancer treatment and living with this illness.|The perceived impact of cancer on patients' overall financial and social well-being.|The awareness of cancer support organizations and their utilization of informal and formal supports during treatment.|The patients' unmet resource and service needs during treatment.|Identify the medical, social and economic risk factors that are most closely associated with perceived adverse impact on financial and social well-being and unmet resource and service needs.","https://ClinicalTrials.gov/show/NCT00774839"
3308,"NCT00354705","Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients","Active, not recruiting","No Results Available","Colon Cancer","Behavioral: Questionnaire","M.D. Anderson Cancer Center","Both","14 Years and older   (Child, Adult, Senior)","","200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2005-0383","July 18, 2006","January 2006","null","October 22, 2015","October 2015","No Study Results Posted","null","January 2017","Occurence of Recurrent Colon Cancer","https://ClinicalTrials.gov/show/NCT00354705"
3309,"NCT01149434","Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers","Terminated","Has Results","Cancer|Neuroendocrine|Ovarian Cancer|Colon Cancer","Drug: JI-101|Drug: Everolimus","University of Utah|Jubilant Innovation Ltd.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","19","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HCI43102","June 22, 2010","September 2010","August 2012","September 24, 2014","September 2014","September 8, 2014","null","August 2012","Effect of JI 101 on Pharmacokinetics Area Under Curve (AUC) (0-inf) of RAD001|Effect of RAD001 on Pharmacokinetics AUC(0-inf) of JI-101|Progression Free-Survival in the Ovarian Cancer Cohort|Tumor Response in the Ovarian Cancer Cohort|Safety and Tolerability of JI-101|Tumor Response","https://ClinicalTrials.gov/show/NCT01149434"
3310,"NCT02107105","Quality of Life (QOL) Following Surgical Treatment for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Behavioral: Questionnaires","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","","330","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2013-0631","April 4, 2014","May 2014","null","August 9, 2016","August 2016","No Study Results Posted","null","May 2019","Health state Utilities Among Patients with Rectal Cancer","https://ClinicalTrials.gov/show/NCT02107105"
3311,"NCT01863420","The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy to GI Cancer","Recruiting","No Results Available","Rectal Cancer|Gastric Cancer|Bone Marrow Toxicity|Adverse Effect of Radiation Therapy","Radiation: Bone Marrow-sparing Intensity-Modulated Radiotherapy","Chinese Academy of Medical Sciences","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","58","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LC2012B22","May 26, 2013","November 2012","October 2015","May 28, 2013","May 2013","No Study Results Posted","IMRT","October 2014","Hematologic toxicity|Low dose volume|Conformity and Homogeneity of IMRT plan","https://ClinicalTrials.gov/show/NCT01863420"
3312,"NCT02852915","Laparoscopic Surgery for T4 Tumor of the Colon Cancer","Not yet recruiting","No Results Available","Colonic Neoplasms","Procedure: Laparoscopic surgery","LI XIN-XIANG|Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","1960","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LapT4","July 21, 2016","October 2016","October 2024","August 3, 2016","August 2016","No Study Results Posted","null","October 2019","Disease free survival|Overall survival|Adverse events (mortality and morbidity)","https://ClinicalTrials.gov/show/NCT02852915"
3313,"NCT00321685","Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer","Active, not recruiting","Has Results","Rectal Adenocarcinoma|Stage II Rectal Cancer|Stage III Rectal Cancer","Biological: Bevacizumab|Drug: Capecitabine|Drug: Fluorouracil|Drug: Leucovorin Calcium|Drug: Oxaliplatin|Radiation: Radiation Therapy|Procedure: Therapeutic Conventional Surgery","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","57","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-01081|CDR0000471148|ECOG-E3204|E3204|U10CA180820|U10CA021115","May 2, 2006","July 2006","May 2020","July 1, 2016","June 2016","April 21, 2015","null","August 2013","Pathologic Complete Response Rate|Resection Rate for T3 Rectal Cancers|Resection Rate for T4 Rectal Cancers|5-year Overall Survival Rate|5-year Recurrence-free Survival Rate","https://ClinicalTrials.gov/show/NCT00321685"
3314,"NCT01152164","Quality of Life in Patients After Combined Modality Treatment of Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Behavioral: questionnaires","Institute of Oncology Ljubljana","Both","18 Years to 85 Years   (Adult, Senior)","","167","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","125/08","June 25, 2010","January 2008","September 2012","March 23, 2012","March 2012","No Study Results Posted","null","September 2012","To prospectively evaluate the quality of life of patients one year after rectal cancer resection|To prospectively evaluate the quality of life of patients at baseline|To prospectively evaluate the quality of life of patients two years after rectal cancer resection","https://ClinicalTrials.gov/show/NCT01152164"
3315,"NCT01671891","Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Radiation: radiation therapy|Drug: capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SCRC-NM-1001","July 19, 2012","February 2012","February 2013","August 21, 2012","August 2012","No Study Results Posted","null","null","circulating tumor cells level changes after radiotherapy|overall survival|disease-free survival|serum carcinoembryonic antigen (CEA) level|pathological response (tumor regression grade)if surgery|RECIST-based tumor response at 10 week after radiotherapy","https://ClinicalTrials.gov/show/NCT01671891"
3316,"NCT02579278","Circulating Tumour DNA (ctDNA) Rectal Cancer and the Relationship to Extramural Venous Invasion","Not yet recruiting","No Results Available","Cancer|Rectal Cancer","Other: Blood sample","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCR 4121","October 6, 2015","November 2015","November 2017","October 16, 2015","October 2015","No Study Results Posted","ctDNA","November 2017","To measure the presence or absence of ctDNA post CRT in EMVI-positive rectal cancer.|To document the % mutation frequency|Comparison of levels of measured ctDNA intraoperatively between mrEMVI positive and mrEMVI negative tumours.|Comparison of % mutation frequency of ctDNA intraoperatively between mrEMVI negative and mrEMVI positive tumours.","https://ClinicalTrials.gov/show/NCT02579278"
3317,"NCT02445456","Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer","Not yet recruiting","No Results Available","Rectal Cancer","Drug: Sienna+ injection|Other: MRI scan|Procedure: Surgery to excise rectal cancer|Device: Sentimag probe","Oxford University Hospitals NHS Trust|University of Leeds|Endomagnetics Limited","Both","18 Years to 90 Years   (Adult, Senior)","","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","R37025/CN339","May 1, 2015","May 2015","May 2016","May 15, 2015","May 2015","No Study Results Posted","SentiRect","April 2016","Number of participants experiencing of adverse or hypersensitivity reaction|Number of operations where effects of tracer injection can be detected by surgeon during surgery|Qualitative assessment of surgical difficulty due to tracer injection using 5-point visual analogue scale and content analysis of surgeon's free-text comments|Correlation between histopathology and Sentimag probe findings for lymph node number and location|Composite map of distribution and spread of tracer through mesorectum|Accuracy of magnetic tracer system in identifying the 'sentinel' lymph node (as determined by histopathology)|High resolution MRI composite map of drainage pattern of Sienna+ tracer in mesorectum|Number of TEM operations where the sentinel lymph node can be identified and removed during transanal endoscopic microsurgery (TEM)","https://ClinicalTrials.gov/show/NCT02445456"
3318,"NCT01181557","A Questionnaire to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma","Completed","No Results Available","Rectal Cancer","","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Both","18 Years and older   (Adult, Senior)","","236","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","INT-D176768","April 1, 2010","September 2008","December 2009","August 12, 2010","July 2008","No Study Results Posted","null","August 2009","Questionnaire number 1, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma|Questionnaire number 2, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma|Questionnaire number 3, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma","https://ClinicalTrials.gov/show/NCT01181557"
3319,"NCT01775514","A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics","Completed","No Results Available","Cancer","","Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","32277","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML28579","January 18, 2013","October 2012","October 2015","September 1, 2016","September 2016","No Study Results Posted","null","October 2015","Number of Participants with Malignant Melanoma (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region|Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate), Defined as New Cases Recorded in the Region in 1 Year Divided by (/) Population of the Region|Number of Participants with Colon Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region|Number of Participants with Breast Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region|Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region|Percentage of Participants Categorized by Tumor Size|Percentage of Participants Categorized by Histopathology Diagnosis|Percentage of Participants Categorized by the Staging System|Percentage of Participants Categorized by Surgery Type|Percentage of Participants Categorized by Type of Treatments Administered (ie, Adjuvant and Neoadjuvant Treatments)|Percentage of Participants With Metastasis Categorized by Treatment Regimens Used (ie, First-line, Second-line, Third-line, or Forth-line Chemotherapy)|Overall Survival (OS)|Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)|Percentage of Participants With Family History of Cancer and Other Conditions|Percentage of Participants With History of Another Primary Cancer|Percentage of Participants Categorized by Diagnostic Methods|Percentage of Participants With Metastasis|Percentage of Participants Categorized by Tumor Localization","https://ClinicalTrials.gov/show/NCT01775514"
3320,"NCT01477229","Quality of Life in RECTal Cancer - a Prospective Multicenter Cohort Study","Active, not recruiting","No Results Available","Rectal Cancer|Quality of Life|Surgery","","Sahlgrenska University Hospital, Sweden|Swedish Cancer Foundation|The Swedish Society of Medicine|Assar Gabrielsson Foundation|The Gothenburg Medical Society","Both","18 Years and older   (Adult, Senior)","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","QoLiRECT","November 15, 2011","February 2012","September 2020","October 3, 2015","October 2015","No Study Results Posted","QoLiRECT","September 2015","To describe QoL, symptoms and functional impairments in an unselected population of rectal cancer patients|To explore potential differences in QoL, symptoms and functional impairments between subgroups of the population|To identify symptoms and functional impairments and other risk factors that have great impact on QoL|To identify patient and environmental factors with an impact on QoL|To analyse how clinical factors like oncologic result of operation, morbidity, recurrence and survival influence QoL|To initiate interventional studies when appropriate|To generate basic descriptive data of the rectal cancer patient population: demography, socioeconomic data, disease stage at diagnosis, fashion of treatment, recurrence, survival|To analyse health economy aspects of QoL and morbidity in the patient population|To explore the presence and impact of intrusive thoughts on QoL|QoL in an unselected population of rectal cancer patients","https://ClinicalTrials.gov/show/NCT01477229"
3321,"NCT01339273","Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection","Completed","No Results Available","Colonic Cancer|Rectal Cancer|Colonic Diverticulum|Ulcerative Colitis","Procedure: Ultrasound guided Transversus Abdominis Plane (TAP) bock|Procedure: Local anaesthetic infiltration of laparoscopic port sites","Oxford University Hospitals NHS Trust","Both","18 Years and older   (Adult, Senior)","","72","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","Sponsorship review number:113","April 18, 2011","September 2011","December 2013","December 5, 2013","December 2013","No Study Results Posted","null","December 2013","Morphine consumption in the first 48hours after the operation|Numerical rating pain scores at emergence, 6, 12, 24, 48 & 72 hours postoperatively|Nausea score at emergence,6, 12, 24, 48 & 72 hours postoperatively|Time to first request for rescue analgesia|Time to mobilisation|Time to successful intake of fluids|Time to resumption of normal diet|Time to first bowel motion|Time to first flatus|Time to medically fit to discharge","https://ClinicalTrials.gov/show/NCT01339273"
3322,"NCT00031681","7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)","Completed","No Results Available","Advanced Adult Primary Liver Cancer|Carcinoma of the Appendix|Estrogen Receptor-negative Breast Cancer|Extensive Stage Small Cell Lung Cancer|Gastrointestinal Stromal Tumor|HER2-negative Breast Cancer|Metastatic Gastrointestinal Carcinoid Tumor|Ovarian Sarcoma|Ovarian Stromal Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Cell Lung Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Small Intestine Adenocarcinoma|Small Intestine Leiomyosarcoma|Small Intestine Lymphoma|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Gastric Cancer|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer|Triple-negative Breast Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Metastatic Squamous Neck Cancer With Occult Primary","Drug: 7-hydroxystaurosporine|Drug: irinotecan hydrochloride|Other: diagnostic laboratory biomarker analysis","National Cancer Institute (NCI)|Washington University Siteman Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","41","NIH|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00019|NCI-5582|WUSM-SCC-0102|CDR0000069215|UVACC-SCC-0102|SCC 01-02|5582|P30CA044579","March 8, 2002","December 2001","null","September 27, 2013","September 2013","No Study Results Posted","null","January 2011","MTD of irinotecan hydrochloride in combination with 7-hydroxystaurosporine in patients with resistant solid tumor malignancies (Part I)|DLT of irinotecan hydrochloride in combination with 7-hydroxystaurosporine in patients with resistant solid tumor malignancies (Part I)|Toxicities associated with irinotecan hydrochloride in combination with 7-hydroxystaurosporine in patients with resistant solid tumor malignancies (Part I)|Anti-tumor activity of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in ER-negative, PgR-negative, HER-2 not-amplified (triple negative) recurrent breast cancer (Part II)|Side effect profile of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in triple negative recurrent breast cancer (Part II)|Anti-tumor activity of the combination of irinotecan hydrochloride and 7-hydroxystaurosporine in treatment of patients with resistant solid tumor malignancies|Pharmacokinetics of irinotecan hydrochloride and 7-hydroxystaurosporine when administered in combination|Serum alpha-acid glycoprotein and correlate this level with free 7-hydroxystaurosporine concentrations|In vivo mechanistic basis for 7-hydroxystaurosporine activity","https://ClinicalTrials.gov/show/NCT00031681"
3323,"NCT00826579","Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer","Completed","No Results Available","Colonic Neoplasms","Procedure: Sentinel lymph node procedure|Procedure: Bone marrow aspiration","University Hospital, Basel, Switzerland","Both","Child, Adult, Senior","Phase 1|Phase 2","192","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","Rhein4031","January 13, 2009","May 2000","January 2009","March 11, 2015","March 2015","No Study Results Posted","null","January 2009","To assess the extent of upstaging due to the SLN procedure for colon cancer.|To evaluate the accuracy of the SLN procedure for colon cancer. To identify factors influencing the success of the procedure. To correlate SLN results with the presence of colon cancer cell in bone marrow aspirates. To assess OS and DFS.","https://ClinicalTrials.gov/show/NCT00826579"
3324,"NCT01313026","Treatment of ""Low Anterior Resection Syndrome"" by Percutaneous Nerve Evaluation and Transanal Irrigation","Recruiting","No Results Available","Rectal Cancer","Procedure: Percutaneous nerve evaluation","University of Aarhus","Both","18 Years and older   (Adult, Senior)","","20","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","LARS 001","January 7, 2011","January 2011","December 2018","December 4, 2015","December 2015","No Study Results Posted","null","December 2017","changes in LARS score|Sexual function|Bladder function|Incontinence|Patient Satisfaction","https://ClinicalTrials.gov/show/NCT01313026"
3325,"NCT01567722","Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies","Recruiting","No Results Available","Anal Cancer|Cervical Cancer|Lung Cancer|Lymphoma","Genetic: DNA analysis|Genetic: RNA analysis|Genetic: gene expression analysis|Genetic: polymorphism analysis|Other: biologic sample preservation procedure|Other: flow cytometry|Other: laboratory biomarker analysis|Other: medical chart review","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|AIDS and Cancer Specimen Resource|University of Arkansas","Both","18 Years and older   (Adult, Senior)","","300","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AMC-083|CDR0000729843|U01CA121947","March 29, 2012","July 2012","June 2020","September 1, 2016","September 2016","No Study Results Posted","null","June 2020","Mutational spectrum of each type of HIV-1 associated malignancy","https://ClinicalTrials.gov/show/NCT01567722"
3326,"NCT01045200","Nurse-or Surgeon-led Follow-up After Rectal Cancer","Completed","No Results Available","Rectal Cancer","Other: Comparison of follow-up","Centrallasarettet Västerås","Both","19 Years and older   (Adult, Senior)","","110","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DNR 01-498","January 6, 2010","January 2002","September 2009","January 7, 2010","January 2002","No Study Results Posted","null","October 2004","Patient satisfaction|Resource utilisation","https://ClinicalTrials.gov/show/NCT01045200"
3327,"NCT00510796","Combined Colon and Endometrial Cancer Screening in Women With HNPCC","Completed","No Results Available","Colon Cancer","Behavioral: Interview","M.D. Anderson Cancer Center","Female","18 Years and older   (Adult, Senior)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ID01-694","July 31, 2007","March 2002","December 2015","February 15, 2016","February 2016","No Study Results Posted","null","December 2015","Feasibility to perform both colon and endometrial cancer screening at the time of colonoscopy in women at high risk for colon and endometrial cancer.","https://ClinicalTrials.gov/show/NCT00510796"
3328,"NCT02575508","Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer","Withdrawn","No Results Available","Colon Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Rectal Adenocarcinoma|Stage III Pancreatic Cancer|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IV Pancreatic Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: Fluorouracil|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Oxaliplatin|Drug: pan FGFR Kinase Inhibitor BGJ398|Other: Pharmacological Study","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 265214|NCI-2015-01597|P30CA016056","October 6, 2015","null","null","May 19, 2016","May 2016","No Study Results Posted","null","May 2020","Incidence of dose-limiting toxicity (DLT) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase Ib)|Maximum tolerated dose (MTD) and recommended phase II dose of BGJ398 in combination with mFOLFIRINOX, defined as the dose with a probability of DLT of 0.30 graded according to the NCI CTCAE version 4.0 (Phase Ib)|Overall survival (Phase II)|Changes in CA19-9 expression levels (Phase II)|Incidence of adverse events graded according to the NCI CTCAE version 4.0|Objective tumor response (Phase II)|Progression free survival (Phase II)|Potential associations between response rate and tumor biomarkers (Phase II)","https://ClinicalTrials.gov/show/NCT02575508"
3329,"NCT01292369","Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study","Recruiting","No Results Available","Breast Cancer|Colon Cancer","","Rambam Health Care Campus|Technion, Israel Institute of Technology","Both","50 Years to 90 Years   (Adult, Senior)","","560","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","RMB-0566.CTIL","February 6, 2011","February 2011","December 2011","August 17, 2011","August 2011","No Study Results Posted","null","October 2011","System performance","https://ClinicalTrials.gov/show/NCT01292369"
3330,"NCT00842686","Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study","Active, not recruiting","No Results Available","Locally Advanced Rectal Cancer","Drug: bevacizumab, capecitabine","Institute of Oncology Ljubljana","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21901","February 11, 2009","January 2009","August 2014","March 23, 2012","March 2012","No Study Results Posted","CRAB","August 2010","Pathological complete remission rate (pCR)|Pathological response rate|Rate of sphincter sparing surgical procedure|Histopathological R0 resection rate|Acute and late toxicity|Loco-regional failure rate|Disease-free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT00842686"
3331,"NCT01648894","Influence of Lengthening the Interval Between Radiochemotherapy and Surgery on Complete Pathological Response in Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Procedure: Surgery after 11 weeks of delay after chemoradiotherapy.|Procedure: Surgery after 7 weeks of delay after chemoradiotherapy","Assistance Publique - Hôpitaux de Paris","Both","18 Years and older   (Adult, Senior)","Phase 3","265","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P 110125|AOM 11304","July 20, 2012","October 2012","April 2020","January 22, 2016","January 2016","No Study Results Posted","GRECCAR6","April 2015","Percentage of pathological complete response after pathological examination of surgical specimen defined by the absence of persistent tumor cell invasion and lymph node (ypT0N0) in group 7 weeks versus 11 weeks in the group|Rates of clinical response to radio-chemotherapy before surgery, comparison between the two groups (7 versus 11 weeks)|Rate of tumor regression, comparison between the two groups (7 versus 11 weeks)|Rates of operative mortality and morbidity at 90 days, comparison between the two groups (7 versus 11 weeks)|Quality of mesorectum resection, comparison between the two groups (7 versus 11 weeks)|Rate of sphincter preservation, comparison between the two groups (7 versus 11 weeks)|Local and distant recurrence rates, comparison between the two groups (7 versus 11 weeks)|Overall survival and disease-free survival rates, comparison between the two groups (7 versus 11 weeks)","https://ClinicalTrials.gov/show/NCT01648894"
3332,"NCT00579579","Functional Outcomes and Quality of Life in Patients Undergoing Surgery for Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Behavioral: Questionaires","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","","229","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","06-151","December 20, 2007","November 2006","December 2017","August 12, 2016","August 2016","No Study Results Posted","null","December 2017","To prospectively evaluate bowel, sexual and bladder function in patients who undergo resection for stage I-III rectal cancer.|To assess the impact of bowel, bladder and sexual function on quality of life over time in patients undergoing resection for stage I-III rectal cancer and to compare QOL in patients with and without a stoma.|To evaluate the expectations, informational needs and satisfaction with the surgical consent process in patients undergoing resection for stage I-III rectal cancer.","https://ClinicalTrials.gov/show/NCT00579579"
3333,"NCT00087191","EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer","Terminated","No Results Available","Advanced Adult Primary Liver Cancer|Carcinoma of the Appendix|Fallopian Tube Cancer|Gastrointestinal Stromal Tumor|Localized Extrahepatic Bile Duct Cancer|Localized Gallbladder Cancer|Localized Gastrointestinal Carcinoid Tumor|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Metastatic Gastrointestinal Carcinoid Tumor|Ovarian Sarcoma|Ovarian Stromal Cancer|Primary Peritoneal Cavity Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Adult Soft Tissue Sarcoma|Recurrent Colon Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Recurrent Small Intestine Cancer|Recurrent Uterine Sarcoma|Regional Gastrointestinal Carcinoid Tumor|Small Intestine Adenocarcinoma|Small Intestine Leiomyosarcoma|Small Intestine Lymphoma|Stage 0 Non-small Cell Lung Cancer|Stage I Adult Soft Tissue Sarcoma|Stage I Colon Cancer|Stage I Gastric Cancer|Stage I Non-small Cell Lung Cancer|Stage I Ovarian Epithelial Cancer|Stage I Ovarian Germ Cell Tumor|Stage I Pancreatic Cancer|Stage I Rectal Cancer|Stage I Uterine Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage II Colon Cancer|Stage II Gastric Cancer|Stage II Non-small Cell Lung Cancer|Stage II Ovarian Epithelial Cancer|Stage II Ovarian Germ Cell Tumor|Stage II Pancreatic Cancer|Stage II Rectal Cancer|Stage II Uterine Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage III Colon Cancer|Stage III Gastric Cancer|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage III Pancreatic Cancer|Stage III Rectal Cancer|Stage III Uterine Sarcoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adult Soft Tissue Sarcoma|Stage IV Colon Cancer|Stage IV Gastric Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Uterine Sarcoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer","Drug: EF5|Drug: motexafin lutetium|Other: pharmacological study","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","30","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","NCI-2012-02607|UPCC# 04204|P01CA087971|CDR0000373812","July 8, 2004","May 2004","null","January 15, 2013","January 2013","No Study Results Posted","null","January 2006","Motexafin lutetium uptake in tumors and normal tissues|Tumor to normal tissue ration (TNTR) of motexafin lutetium for any tumor and normal tissue|Pattern and presence of EF5 binding|Toxicity as assessed by NCI Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 3.0","https://ClinicalTrials.gov/show/NCT00087191"
3334,"NCT02546973","Quality of Life in Patients With Anal Cancer","Recruiting","No Results Available","Anal Cancer","","Sahlgrenska University Hospital, Sweden","Both","Child, Adult, Senior","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ANCA","August 26, 2015","September 2015","September 2022","April 14, 2016","April 2016","No Study Results Posted","ANCA","September 2021","HRQL in patient's with anal cancer 3 years after diagnosis|HRQL in patient's with anal cancer 6 years after diagnosis Functional aspects and symptoms|Comorbidity in the cohort prior to the diagnosis anal cancer|Post-treatment morbidity in patients treated for anal cancer|Type and number of surgical procedures in the patient population treated for anal cancer|Accumulated length of hospital stay|Differences in morbidity related to different treatments regimes|Complete health economic analysis of resource consumption|Mortality after anal cancer treatment|Patient related personal factors that may affect HRQL measured by questionnaires|Effect of complications on the patient's socioeconomic situation|HRQL (measured by questionnaires) differences between patient groups such as age, gender and educational level","https://ClinicalTrials.gov/show/NCT02546973"
3335,"NCT02569645","Rosuvastatin in the Treatment of Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: Rosuvastatin","AHS Cancer Control Alberta|Ozmosis Research Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OZM-064","September 24, 2015","November 2015","May 2021","September 19, 2016","August 2016","No Study Results Posted","null","November 2018","To determine the pathological complete response rate in patients with high-risk locally advanced rectal cancer treated with standard neo-adjuvant chemotherapy and radiation in combination with rosuvastatin.|To determine the Ro resection rate|To determine the pathological near-complete or complete tumour response rate|To determine the sphincter preservation rate|To determine the down staging rate|To determine 3-year disease free survival|To determine 3-year overall survival|To determine the neoadjuvant rectal cancer (NAR) score|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.|To identify the genetic biomarkers that may be both prognostic and predictive of response and toxicity to treatment.|To identify serological biomarkers that may be both prognostic and predictive of response and toxicity to treatment.|To identify pathological biomarkers that may be both prognostic and predictive of response and toxicity to treatment.|Tmax will be collected as pharmacokinetic data|Cmax will be collected as pharmacokinetic data|T1/2 will be collected as pharmacokinetic data|Dose normalized Cmax will be collected as pharmacokinetic data|Area under the curve (AUC) will be collected as pharmacokinetic data|Dose normalized AUC will be collected as pharmacokinetic data","https://ClinicalTrials.gov/show/NCT02569645"
3336,"NCT00949273","Safety and Efficacy Study of Cylindrical Abdominoperineal Resection to Treat Rectal Cancer","Recruiting","No Results Available","Rectal Cancer|Treatment|Postoperative Complications|Neoplasm Recurrence, Local|Survival Rate","Procedure: cylindrical abdominoperineal resection","Beijing Chao Yang Hospital|Shandong Provincial Hospital|Shandong Cancer Hospital and Institute|The First Affiliated Hospital of Zhengzhou University|Wuhan University|Shenyang Anorectal Hospital|Beijing Luhe Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","300","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","CAPR0668","July 29, 2009","July 2009","November 2013","November 26, 2013","November 2013","No Study Results Posted","null","November 2013","postoperative complications|3-years overall survival","https://ClinicalTrials.gov/show/NCT00949273"
3337,"NCT00826800","Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer","Terminated","Has Results","Colon Cancer","Drug: FOLFOX and bevacizumab","Memorial Sloan Kettering Cancer Center|Genentech, Inc.","Both","18 Years to 90 Years   (Adult, Senior)","","2","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-162","January 20, 2009","February 2009","January 2011","April 3, 2015","April 2015","April 3, 2015","null","January 2011","To Determine the Pathologic Complete Response (Path CR) Rate in Patients With Locally Advanced (Stage II or III) Colon Cancer to FOLFOX-bevacizumab Administered as Neoadjuvant.","https://ClinicalTrials.gov/show/NCT00826800"
3338,"NCT01023529","Symptoms and Quality of Life (QoL) After Palliative Pelvic Radiation of Prostate and Rectal Cancers","Completed","No Results Available","Prostatic Neoplasms|Rectal Neoplasms","Radiation: Palliative pelvic soft-tissue radiation (external beam)","Sorlandet Hospital HF|Oslo University Hospital|Sykehuset Innlandet HF|Nordlandssykehuset HF|University Hospital of North Norway|Helse Stavanger HF|Alesund Hospital|Trondheim University Hospital","Both","18 Years and older   (Adult, Senior)","","98","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2009-1684(REK)","November 30, 2009","November 2009","July 2015","November 17, 2015","November 2015","No Study Results Posted","PallRad1","July 2015","Effect on patient's target symptom.|Effect on patient's QoL.|Time to improvement in patient's symptoms and QoL.","https://ClinicalTrials.gov/show/NCT01023529"
3339,"NCT00996710","Genomic Structural Variation in Cancer Susceptibility","Enrolling by invitation","No Results Available","Breast Cancer|Colon Cancer|Germ Cell Cancer|Neuroblastoma|Rectal Cancer|Sarcoma","","Memorial Sloan Kettering Cancer Center|Cold Spring Harbor Laboratory|Coriell Institute|Weill Medical College of Cornell University|University of Washington Center for Mendelian Genomics","Both","Child, Adult, Senior","","1250","Other","Observational","Observational Model: Family-Based","09-068","October 15, 2009","October 2009","October 2017","August 15, 2016","August 2016","No Study Results Posted","null","October 2017","To determine the frequency of de novo germline copy number variants (CNVs) in cancer affected probands using an ascertainment of ""trios"" consisting of cancer patients and their unaffected biologic parents|To explore the role of germline homozygosity in cancer susceptibility by determining the frequency and length of autozygous regions in patients with cancer","https://ClinicalTrials.gov/show/NCT00996710"
3340,"NCT00579163","Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers","Recruiting","No Results Available","Breast Neoplasms|Ovarian Neoplasms|Colonic Neoplasms|Prostatic Neoplasms|Uterine Cervical Neoplasms|Leukemia|Lymphoma, Non-Hodgkin","","Memorial Sloan Kettering Cancer Center","Both","Child, Adult, Senior","Phase 1|Phase 2","1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","93-102","December 19, 2007","December 1994","December 2017","September 6, 2016","September 2016","No Study Results Posted","null","December 2017","To establish a bank of DNA and frozen lymphoblastoid cell lines for the purpose of facilitating genetic epidemiology investigations of familial cancers.|A related goal is to provide patients with cancer and their living relatives the opportunity to preserve DNA samples so that they may be used for future genetic counseling regarding inherited cancer risk.","https://ClinicalTrials.gov/show/NCT00579163"
3341,"NCT01585428","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers","Completed","No Results Available","Cervical Cancer|Oropharyngeal Cancer|Vaginal Cancer|Anal Cancer|Penile Cancer","Drug: Fludarabine|Drug: Cycolphosphamide|Biological: Young TIL|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","29","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","120116|12-C-0116","April 24, 2012","April 2012","August 2016","September 16, 2016","September 2016","No Study Results Posted","null","April 2016","To determine if autologous Young TIL infused in conjunction with high dose aldesleukin following a non-myeloablative lymphodepleting preparative regimen can mediate tumor regression in patients with metastatic or locally advanced refractory/recu...","https://ClinicalTrials.gov/show/NCT01585428"
3342,"NCT02858310","E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers","Recruiting","No Results Available","Cervical Cancer|Vaginal Cancer|Anal Cancer|Penile Cancer|Oropharyngeal Cancer","Biological: E7 TCR cells|Drug: pembrolizumab|Drug: aldesleukin|Drug: fludarabine|Drug: cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 66 Years   (Adult, Senior)","Phase 1","40","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","160154|16-C-0154","August 4, 2016","July 2016","January 2026","August 31, 2016","August 2016","No Study Results Posted","null","December 2020","Determine a safe dose for E7 TCR cells plus aldesleukin with or without pembrolizumab","https://ClinicalTrials.gov/show/NCT02858310"
3343,"NCT00019110","Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer","Completed","No Results Available","Anal Cancer|Cervical Cancer|Esophageal Cancer|Head and Neck Cancer|Penile Cancer|Vulvar Cancer","Biological: human papillomavirus 16 E7 peptide|Biological: synthetic human papillomavirus 16 E6 peptide","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000064330|NCI-95-C-0154|NCI-T94-0134N","July 11, 2001","November 1995","null","April 28, 2015","November 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00019110"
3344,"NCT01853059","Functional Outcomes Following Anal Cancer Treatment","Not yet recruiting","No Results Available","Anal Cancer","","Cambridge University Hospitals NHS Foundation Trust|The Christie NHS Foundation Trust|Bowel Disease Research Foundation","Both","18 Years and older   (Adult, Senior)","","176","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","A092896","May 10, 2013","October 2013","October 2017","May 13, 2013","May 2013","No Study Results Posted","FOFACT","October 2017","Functional quality of life after chemoradiotherapy for anal cancer|Patient-reported treatment-related toxicity after chemoradiotherapy for anal cancer","https://ClinicalTrials.gov/show/NCT01853059"
3345,"NCT01075399","Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors","Completed","Has Results","Head and Neck Cancer|Lung Cancer|Liver Cancer|Rectal Cancer|Cervical Cancer","Drug: [F 18]HX4","Siemens Molecular Imaging","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","HX4-200","February 23, 2010","February 2010","February 2012","July 26, 2013","July 2013","February 14, 2013","HX4-200","May 2011","Reproducibility of [F18]HX4 PET Imaging in Measuring Hypoxia in Tumors","https://ClinicalTrials.gov/show/NCT01075399"
3346,"NCT02132858","Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation","Recruiting","No Results Available","Mucinous Adenocarcinoma of the Rectum|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Rectum|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer","Other: cytology specimen collection procedure|Other: laboratory biomarker analysis","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","40","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CGI-066|NCI-2014-00719|P30CA006927","May 6, 2014","July 2014","null","September 3, 2015","September 2015","No Study Results Posted","null","May 2016","Proportion of the randomly chosen samples that are successfully sequenced|Tumor response measured using the tumor regression grading system|Tumor heterogeneity in patients with partial response to radiation","https://ClinicalTrials.gov/show/NCT02132858"
3347,"NCT00004547","Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy","Completed","Has Results","Abdominal Neoplasm|Colonic Neoplasm|Mesothelioma|Peritoneal Neoplasm","Procedure: Surgery|Procedure: Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|Drug: Postoperative dwell with paclitaxel and 5-FU","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","Phase 2","188","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","000069|00-C-0069","February 3, 2000","January 2000","August 2009","October 19, 2015","September 2015","August 30, 2011","null","August 2009","Number of Participants With Disease-free Survival|Number of Participants With a Response|Number of Participants With Adverse Events|Percentage of Participants Who Had Paclitaxel and 5-fluorouracil (5-FU) Analysis Performed|Quality of Life Questionnaire Score|Signal Transduction Pathways in Tumor Tissue Versus Normal Tissue","https://ClinicalTrials.gov/show/NCT00004547"
3348,"NCT00576654","Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery","Recruiting","No Results Available","Adult Hodgkin Lymphoma|Adult Non-Hodgkin Lymphoma|Breast Carcinoma|Colon Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Lung Carcinoma|Metastatic Malignant Neoplasm|Ovarian Carcinoma|Pancreatic Carcinoma|Progesterone Receptor Negative|Solid Neoplasm|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Breast Cancer|Stage IIIA Colon Cancer|Stage IIIA Ovarian Cancer|Stage IIIB Breast Cancer|Stage IIIB Colon Cancer|Stage IIIB Ovarian Cancer|Stage IIIC Breast Cancer|Stage IIIC Colon Cancer|Stage IIIC Ovarian Cancer|Stage IV Breast Cancer|Stage IV Lung Cancer|Stage IV Ovarian Cancer|Stage IVA Colon Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colon Cancer|Stage IVB Pancreatic Cancer|Triple-Negative Breast Carcinoma|Unresectable Malignant Neoplasm","Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Veliparib","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","48","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-01057|HIC 1410014852|2007-014|HIC1410014852|CDR0000579642|7977|P30CA016359|R21CA135572|U01CA062487|U01CA062490|UM1CA186689|UM1CA186709","December 18, 2007","December 2007","null","July 27, 2016","July 2016","No Study Results Posted","null","February 2017","Maximum administered dose of study drugs, defined as the dose level at which at least 2 of 6 patients develop dose-limiting toxicity (DLT) as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|MTD of study drugs, defined as the dose at which no more than 1 patient of 6 develops DLT as graded by the NCI CTCAE version 4.0|OBD defined as the dose level at which no greater inhibition of PAR levels in tumor cells is identified, relative to the next lower dose|RP2D of study drugs, defined as the MTD if DLTs are observed before achieving the OBD, or the OBD if DLTs are not observed before reaching the OBD as graded by the NCI CTCAE version 4.0|Incidence of AEs, graded using the NCI CTCAE version 4.0|Tumor response, evaluated using RECIST version 1.1","https://ClinicalTrials.gov/show/NCT00576654"
3349,"NCT02287727","Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment","Recruiting","No Results Available","Rectal Adenocarcinoma|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer","Other: Laboratory Biomarker Analysis|Drug: Regorafenib","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 246813|NCI-2014-02202|ONC-2013-036|BAY ONC-3012-036|P30CA016056","November 6, 2014","March 2015","null","August 17, 2016","August 2016","No Study Results Posted","null","September 2016","Disease free survival (DFS)|Biomarkers associated with anti-cancer effects of regorafenib maintenance therapy|Distant recurrence|Frequency of toxicity, graded according to National Cancer Institute CTCAE version 4.0|Local recurrence|Overall survival","https://ClinicalTrials.gov/show/NCT02287727"
3350,"NCT02526953","Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients","Not yet recruiting","No Results Available","Anus Neoplasms|Carcinoma, Squamous Cell|Anus Diseases|Neoplasms|Neoplasms, Squamous Cell|Carcinoma","Drug: Paclitaxel|Drug: Capecitabine|Drug: Capecitabine|Drug: Mitomycins|Drug: Mitomycins|Radiation: Radiotherapy","Blokhin's Russian Cancer Research Center","Both","18 Years to 70 Years   (Adult, Senior)","Phase 3","314","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SCAC-001","August 15, 2015","October 2015","October 2021","August 17, 2015","August 2015","No Study Results Posted","null","October 2021","3-year disease-free survival|Complete response at 26 weeks|3-year colostomy-free survival|3-year cancer-specific survival|3-year overall survival|Acute toxicity measured according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.4.0|Late toxicity measured according to Radiation Therapy Oncology Group (RTOG) criteria","https://ClinicalTrials.gov/show/NCT02526953"
3351,"NCT01379872","Assessment of New Radiation Oncology Technologies and Treatments","Completed","No Results Available","Prostate Cancer (Post Prostatectomy)|Anal Cancer|Nasopharyngeal Cancer|Intermediate Risk Prostate Cancer","Other: Non-Interventional Study","Trans-Tasman Radiation Oncology Group (TROG)","Both","18 Years to 80 Years   (Adult, Senior)","","138","Other","Observational","Time Perspective: Retrospective","TRP.11A","June 8, 2011","June 2011","June 2012","February 12, 2013","June 2011","No Study Results Posted","ANROTAT","May 2012","Comparison of dosimetry between treatment plans prepared using IMRT/IGRT vs 3DCRT/Non IGRT as a surrogate for effectiveness and safety.|Obtain Data on the impact of disease and treatment on QoL|Compare the resource usage associated with the planning and delivery of the new technologies compared to the conventional standard approaches|Synthesise the data obtained for objectives 1-3 together with information from previous studies and expert opinion to estimate the safety, clinical efficacy and cost-effectiveness of new technologies compared to conventional standards","https://ClinicalTrials.gov/show/NCT01379872"
3352,"NCT01005225","Genetic Investigation of Solid Tumors Cohort","Completed","No Results Available","Prostate Cancer|Colon Cancer","","Scripps Translational Science Institute","Both","18 Years and older   (Adult, Senior)","","25","Other","Observational","Observational Model: Cohort","HSC# 004835","October 28, 2009","February 2008","May 2014","June 10, 2014","June 2014","No Study Results Posted","null","May 2014","Solid tumor biological insights","https://ClinicalTrials.gov/show/NCT01005225"
3353,"NCT01483144","Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)","Active, not recruiting","No Results Available","Familial Adenomatous Polyposis","Drug: Eflornithine plus Sulindac|Drug: Eflornithine and Placebo|Drug: Sulindac and Placebo","Cancer Prevention Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","171","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CPP-FAP-310","November 21, 2011","October 2013","June 2018","April 11, 2016","April 2016","No Study Results Posted","null","April 2018","Delaying time to the 1st occurrence of any FAP-related event.|presence or absence of an ODC polymorphism|excretion of 4 urinary polyamines","https://ClinicalTrials.gov/show/NCT01483144"
3354,"NCT01133340","A Feasibility Study to Compare the Benefits of Endoscopic Tumor Clip Placement and 3T-MRI Simulation for Accurate Target Volume Definition for Rectal Cancer Patients Undergoing Pre-operative Chemoradiation","Completed","No Results Available","Rectal Cancer","Radiation: Radiation","AHS Cancer Control Alberta|IGAR Image guided adaptive radiotherapy","Both","18 Years and older   (Adult, Senior)","","10","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RECTAL MRI SIM 25409","May 27, 2010","June 2010","November 2013","October 1, 2014","October 2014","No Study Results Posted","null","November 2013","To define the usefulness of Endoscopic clip placement and 3T-MRI imaging for accurate target volume definition in rectal cancer patients undergoing pre-operative chemoradiation.|To assess the differences in pelvic lymph node (CTV) volume definition between Ct and MRI images.","https://ClinicalTrials.gov/show/NCT01133340"
3355,"NCT01164722","Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia","Completed","No Results Available","Anal Cancer|Neoplasm of Uncertain Malignant Potential|Nonneoplastic Condition|Precancerous Condition","Other: clinical observation|Device: infrared photocoagulation therapy","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas","Both","27 Years and older   (Adult, Senior)","Phase 3","121","Other|NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Prevention","AMC-076|U01CA121947","July 16, 2010","April 2011","July 2016","August 16, 2016","August 2016","No Study Results Posted","null","July 2015","Complete response at 3 months and 1 year|Tolerability and safety of infrared coagulator ablation|Proportion of patients with high-grade anal intraepithelial neoplasia at 1 year|Recurrence rate at 1 year|Incidence of metachronous lesions","https://ClinicalTrials.gov/show/NCT01164722"
3356,"NCT02172651","Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.","Recruiting","No Results Available","Stage, Colon Cancer|Stage I-III Colon Cancer|Stage IV Colon Cancer With Resectable Liver Metastases","Drug: Vitamin D3","Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Pharmavite","Both","18 Years and older   (Adult, Senior)","Phase 0","12","Other|NIH|Industry","Interventional","Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","14-091|P50CA127003-06A1","June 17, 2014","July 2014","May 2020","August 4, 2016","August 2016","No Study Results Posted","null","September 2017","VDR Binding Sites|RNA transcriptome|Number of Participants with Serious and Non-Serious Adverse Events","https://ClinicalTrials.gov/show/NCT02172651"
3357,"NCT02639403","Palliative Short-Course Radiotherapy in Rectal Cancer","Completed","No Results Available","Rectal Neoplasms","Radiation: Conformal three-dimensional Radiotherapy","Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi","Both","Child, Adult, Senior","Phase 2","18","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","001","December 18, 2015","October 2003","November 2012","December 21, 2015","December 2015","No Study Results Posted","null","November 2012","Change of the obstructive symptoms|Change of the overall symptoms|Change of the tumor mass volume|Number of participants with treatment-related adverse events as assessed by National Cancer Institute Common Toxicity Criteria v4.0|Overall survival|Obstruction/colostomy-free survival","https://ClinicalTrials.gov/show/NCT02639403"
3358,"NCT00576563","Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer","Completed","No Results Available","Rectum Cancer","Drug: FDG","Maastricht Radiation Oncology","Both","18 Years and older   (Adult, Senior)","","103","Other","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-02","December 18, 2007","March 2007","December 2015","April 20, 2016","April 2016","No Study Results Posted","null","January 2015","The metabolic tumour response by PET scan will be determined according to the EORTC criteria (appendix 1)61. The pathological tumour response will be determined according to Dworak and Wheeler.62,63|Clinical examination(weight, performance status including the CTCv3.0 scale for acute and late reactions)","https://ClinicalTrials.gov/show/NCT00576563"
3359,"NCT01444495","Randomized Clinical Trial on Preoperative Radiotherapy 25 Gy in Rectal Cancer","Completed","No Results Available","Rectal Cancer","Radiation: Preoperative radiotherapy|Procedure: Surgery","Jagiellonian University","Both","18 Years and older   (Adult, Senior)","Phase 3","154","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Cracow Rectal Cancer Trial","September 29, 2011","January 1999","December 2010","June 15, 2014","June 2014","No Study Results Posted","null","June 2008","local and systemic recurrence rate|radical resections rate (R0)|sphincter saving (sparing) procedures|overall survival|downstaging of rectal cancer","https://ClinicalTrials.gov/show/NCT01444495"
3360,"NCT02163785","Abdominoperineal Extra-Elevators Rectal Resection for Cancer: Prone Position vs. Supine Position","Recruiting","No Results Available","Rectal Cancer|Abdominoperineal Resection","Procedure: Abdominoperineal extra-elevators rectal resection for low lying rectal cancer","Hospital Universitario La Fe|Fundacion Para La Investigacion Hospital La Fe|Instituto de Salud Carlos III","Both","18 Years and older   (Adult, Senior)","","320","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","APPRO","June 12, 2014","June 2014","June 2019","February 21, 2016","February 2016","No Study Results Posted","APPRO","June 2017","Assessment of the circumferential resection margin|Histopathological quality of surgical specimen","https://ClinicalTrials.gov/show/NCT02163785"
3361,"NCT01637194","Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer","Completed","No Results Available","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Colon Cancer|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Colon Cancer|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Tongue Cancer","Drug: everolimus|Biological: cetuximab|Other: pharmacological study|Other: laboratory biomarker analysis","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB 06-043|NCI-2011-02971","October 20, 2011","November 2008","July 2011","July 6, 2012","July 2012","No Study Results Posted","null","July 2011","Number of patients with dose limiting toxicity|Composite Pharmacokinetic (PK) Analysis|Preliminary clinical evidence of anti-tumor activity by time to progression and RECIST criteria with this regimen|Association between clinical outcomes and biologic markers that may predict sensitivity of a tumor in patients treated with this regimen|Pharmacodynamic effects of this regimen on post-therapy tumor and/or skin specimens","https://ClinicalTrials.gov/show/NCT01637194"
3362,"NCT02724202","Curcumin in Combination With 5FU for Colon Cancer","Recruiting","No Results Available","Metastatic Colon Cancer","Drug: Curcumin|Drug: 5-flurorouracil","Baylor Research Institute","Both","18 Years and older   (Adult, Senior)","Phase 0","14","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","014-143","March 16, 2016","March 2016","March 2018","March 31, 2016","March 2016","No Study Results Posted","null","March 2018","Determine the safety using curcumin in patients with metastatic colon cancer; where toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.|Overall Response|Evidence of altered biomarker status (circulating DNA methylation status, miRNA profile) at 8 weeks post-treatment according to RECIST version 1.1 and survival criteria.|Duration of response|Duration of progression free survival|Duration of overall survival|Duration of Quality of Life","https://ClinicalTrials.gov/show/NCT02724202"
3363,"NCT02195141","Trial of Using SIB-IMRT in Preoperative Radiotherapy for Locally Advanced Rectum Cancer","Recruiting","No Results Available","Rectal Cancer","Radiation: conventional fraction|Radiation: SIB","Chinese Academy of Medical Sciences","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","104","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC2014-ST02","July 11, 2014","January 2014","December 2015","February 2, 2015","February 2015","No Study Results Posted","null","December 2015","• Pathological complete remission rate (pCR)|Number of participants with adverse events (according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","https://ClinicalTrials.gov/show/NCT02195141"
3364,"NCT01133132","Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors","Active, not recruiting","No Results Available","Colon Cancer","Behavioral: Survivorship CHESS|Other: Control","University of Wisconsin, Madison|University of North Carolina, Chapel Hill|M.D. Anderson Cancer Center|Hartford Hospital","Both","21 Years and older   (Adult, Senior)","","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Supportive Care","M-2009-1127|XP08218","May 26, 2010","February 2010","June 2017","June 8, 2016","June 2016","No Study Results Posted","null","June 2013","Change in level of physical activity","https://ClinicalTrials.gov/show/NCT01133132"
3365,"NCT00923520","A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies","Completed","No Results Available","Renal Cell Carcinoma|Breast Cancer|Colon Cancer|Lung Cancer|Non-Hodgkin Lymphoma","Drug: dimethane sulfonate (DMS612, NSC 281612)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","31","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","090111|09-C-0111","June 17, 2009","March 2009","May 2016","August 31, 2016","May 2016","No Study Results Posted","null","May 2016","Determine the Maximum Tolerated Dose|Evaluate non-dose limiting toxicity|PK|Anti-tumor Effects","https://ClinicalTrials.gov/show/NCT00923520"
3366,"NCT02834052","Pembrolizumab + Poly-ICLC in MRP Colon Cancer","Not yet recruiting","No Results Available","Metastatic Colon Cancer|Solid Tumor","Drug: pembrolizumab|Drug: Poly-ICLC","Samir N. Khleif|Oncovir, Inc.|Merck Sharp & Dohme Corp.|Augusta University","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","42","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GCC-16047","June 15, 2016","July 2016","December 2019","July 12, 2016","July 2016","No Study Results Posted","null","December 2018","Phase 1: Determine the maximum tolerated dose of poly-ICLC that can be combined with pembrolizumab|Phase 1 and 2: Determine the response rate of metastatic MRP colon cancer (that has progressed following two lines of therapy in the metastatic setting) to the combination of pembrolizumab and poly-ICLC|Determine the adverse event profile and dose limiting toxicities of the combination of pembrolizumab and poly-ICLC|Determine the progression free survival rate of recurrent metastatic MRP colon cancer to the combination of pembrolizumab and poly-ICLC|Determine the 20-week progression free survival rate of recurrent metastatic MRP colon cancer to the combination of pembrolizumab and poly-ICLC|Determine the overall survival rate for recurrent metastatic MRP colon cancer response to the combination of pembrolizumab and poly-ICLC|Determine the duration of response of recurrent metastatic MRP colon cancer to the combination of pembrolizumab and poly-ICLC","https://ClinicalTrials.gov/show/NCT02834052"
3367,"NCT01671488","A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer","Active, not recruiting","No Results Available","Anal Cancer","Biological: Advaxis","Brown University|Rhode Island Hospital|The Miriam Hospital","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG 276","August 7, 2012","April 2013","May 2018","June 16, 2016","June 2016","No Study Results Posted","276","December 2017","To evaluate number of adverse events with the addition of ADXS11-001 to standard chemoradiation for patients with anal cancer.|To evaluate the 6-month clinical complete response rate for patients with anal cancer treated with ADXS11-001 mitomycin, 5-FU and IMRT.|To evaluate progression-free and overall survival for patients with anal cancer treated with ADXS11-001, mitomycin, 5-FU and IMRT.|To assess peripheral and histologic markers of immune response including measuring immunohistochemistry of biopsies for T cell infiltration, following ADXS11-001 in patients","https://ClinicalTrials.gov/show/NCT01671488"
3368,"NCT01863862","Organ Preservation in Elderly Patients With Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Radiation: Radiochemotherapy or radiotherapy","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology","Both","70 Years and older   (Senior)","","90","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PGBRJG0113","May 14, 2013","August 2012","January 2016","May 23, 2013","May 2013","No Study Results Posted","null","January 2014","The final three-year rate of local and distant recurrences taking into consideration results of rescue surgery for pelvic recurrence.|The rate of local recurrence at one year without taking into consideration results of rescue surgery.|The rate of local and distant recurrences after rescue surgery of pelvic recurrence.|Overall survival at three years.|Disease-free survival at three years|Cancer specific survival at three years.|Evaluation of anorectal function by using self-administered questionnaire in patients without local recurrence.|Multivariable analysis of prognostic factors associated with clinical complete response.","https://ClinicalTrials.gov/show/NCT01863862"
3369,"NCT02425059","Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms","Recruiting","No Results Available","Rectal Neoplasms","Procedure: Irreversible electroporation (IRE)|Device: NanoKnife","Fuda Cancer Hospital, Guangzhou","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Rectal cancer-IRE-01","April 15, 2015","January 2015","January 2020","March 27, 2016","March 2016","No Study Results Posted","null","January 2017","Number of participants with Adverse events|Percentage of lesions that show no sign of recurrence 12 months after IRE","https://ClinicalTrials.gov/show/NCT02425059"
3370,"NCT00543842","Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: Bevacizumab|Drug: Capecitabine|Drug: Erlotinib|Radiation: Radiation Therapy|Procedure: Surgery","M.D. Anderson Cancer Center|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","19","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-0080","October 11, 2007","December 2007","December 2013","February 24, 2015","February 2015","No Study Results Posted","null","December 2013","Maximal tolerated dose (MTD)","https://ClinicalTrials.gov/show/NCT00543842"
3371,"NCT01226979","Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Radiation: High-dose endorectal brachytherapy","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years to 100 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0977|NA_00029263","September 21, 2010","September 2010","September 2020","August 11, 2016","August 2016","No Study Results Posted","HDRBT","September 2020","Evaluate the pathological response rates associated with HDRBT","https://ClinicalTrials.gov/show/NCT01226979"
3372,"NCT02865135","Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer","Not yet recruiting","No Results Available","Cancer of Head and Neck|Cancer of Cervix|Cancer of Anus","Drug: DPX-E7 vaccine|Drug: Cyclophosphamide","Dana-Farber Cancer Institute|Stand Up To Cancer","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","44","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-578","July 14, 2016","September 2016","May 2023","August 10, 2016","August 2016","No Study Results Posted","null","May 2019","Number of Participants Experiencing Adverse Events Related to Treatment|Overall Response Rate|Overall Survival Rate|Progression Free Survival Rate","https://ClinicalTrials.gov/show/NCT02865135"
3373,"NCT01053923","MRI for Tumor During Chemoradiation for Anal Canal and Perianal Cancer","Withdrawn","No Results Available","Anal Cancer Patients|Perianal Patients","Other: Magnetic Resonance Imaging (MRI)","University Health Network, Toronto|Princess Margaret Hospital, Canada","Both","19 Years and older   (Adult, Senior)","","0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UHN REB 09-0695-CE","January 21, 2010","December 2009","March 2013","June 11, 2013","June 2013","No Study Results Posted","null","March 2013","Primary tumor dimensions at simulation and during week 3 and last week of fractionated radiotherapy from MRI|Primary tumor perfusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI|Primary tumor apparent diffusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI|Change with time from start of radiotherapy course in primary tumor dimensions from MRI|Change with time from start of radiotherapy course in primary tumor perfusion coefficient from MRI|Change with time from start of radiotherapy course in primary tumor apparent diffusion coefficient from MRI","https://ClinicalTrials.gov/show/NCT01053923"
3374,"NCT02697084","Individual Following in Anal Cancer With PET/CT","Recruiting","No Results Available","Anal Cancer","Other: anal cancer","Centre Antoine Lacassagne","Both","18 Years and older   (Adult, Senior)","","110","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2014/54","February 22, 2016","November 2014","June 2018","February 26, 2016","February 2016","No Study Results Posted","IFACT","May 2018","time of disease-free survival|best metabolic response measurement variable: SUVmax|best metabolic response measurement variable: SUVmean|best metabolic response measurement variable: SUL peak|best metabolic response measurement variable: Metabolic Total Volume (MTV)|best metabolic response measurement variable: Total Lesion Glycolysis (TLG)|best treatment response criterion: SUV or metabolic volume threshold|best treatment response criterion: ratio (SUV or metabolic volume)|best treatment response criterion: complete or partial metabolic response according to EORTC or PERCIST criteria","https://ClinicalTrials.gov/show/NCT02697084"
3375,"NCT00597610","Evaluating The Response to Pre-Operative Chemotherapy and/or Radiation Therapy For Rectal Cancer Using Three-Dimension Transrectal Ultrasound","Completed","No Results Available","Rectal Cancer","Other: Transrectal ultrasound 3-D (TRUS)","Memorial Sloan Kettering Cancer Center","Both","Child, Adult, Senior","","84","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","03-127","January 9, 2008","November 2003","September 2012","September 26, 2012","September 2012","No Study Results Posted","null","September 2012","To measure the response of primary rectal cancer to neoadjuvant chemotherapy and/or radiation therapy using 3-D TRUS|To correlate these findings with post-operative pathologic examination","https://ClinicalTrials.gov/show/NCT00597610"
3376,"NCT02314182","GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis","Recruiting","No Results Available","Rectal Adenocarcinoma","Procedure: Primary tumor resection + chemotherapy|Drug: Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab","Hospices Civils de Lyon","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","290","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","2014.847","November 12, 2014","November 2014","November 2019","December 10, 2014","November 2014","No Study Results Posted","GRECCAR8","November 2019","Overall survival|Progression free survival|Quality of life|Toxicity of chemotherapy (Common Toxicity Criteria for Adverse Events (NCI-CTC-AE V4.0)|Response of the metastatic disease to systemic chemotherapy (RECIST 1.1 criteria)|Time to disease progression|Post-operative morbidity","https://ClinicalTrials.gov/show/NCT02314182"
3377,"NCT02718729","Anastomotic Leakage Following Laparoscopic Resection for Rectal Cancer","Recruiting","No Results Available","Anastomotic Leakage","Procedure: Laparoscopic resection for rectal cancer","Mansoura University|University of Rome Tor Vergata","Both","Child, Adult, Senior","","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","MD 84","March 12, 2016","January 2014","January 2017","March 31, 2016","March 2016","No Study Results Posted","null","May 2016","Incidence of anastomotic leakage|Role of diversion in prevention of anastomotic leakage.|Management of anastomotic leakage|Oncological outcomes of anastomotic leakage|30 days postoperative morbidity and mortality","https://ClinicalTrials.gov/show/NCT02718729"
3378,"NCT00256334","Resveratrol for Patients With Colon Cancer","Completed","No Results Available","Colon Cancer|Cancer","Drug: Resveratrol","University of California, Irvine|University of California, Los Angeles","Both","18 Years and older   (Adult, Senior)","Phase 1","11","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 05-20|2005-4333","November 17, 2005","July 2005","April 2009","June 18, 2014","June 2014","No Study Results Posted","null","December 2008","Test the hypothesis that resveratrol modulates Wnt signaling in vivo in colon cancer and normal colonic mucosa","https://ClinicalTrials.gov/show/NCT00256334"
3379,"NCT02113384","Locally Advanced Rectal Cancer - Exfoliated Peritoneal Tumor Cells","Recruiting","No Results Available","Rectal Cancer","Other: Observational study.","Oslo University Hospital|The Research Council of Norway","Both","18 Years and older   (Adult, Senior)","","160","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Larc-Ex_09/2012","April 8, 2014","September 2012","January 2028","October 14, 2015","October 2015","No Study Results Posted","LARC-EX","January 2017","Overall survival|Disease-free survival","https://ClinicalTrials.gov/show/NCT02113384"
3380,"NCT01249443","Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection","Recruiting","No Results Available","HIV Infection|Recurrent Anal Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Anal Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Unspecified Adult Solid Tumor, Protocol Specific","Drug: vorinostat|Other: diagnostic laboratory biomarker analysis|Other: pharmacological study|Drug: carboplatin|Drug: paclitaxel","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas","Both","18 Years and older   (Adult, Senior)","Phase 1","26","Other|NIH|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-078|NCI-2011-02511|CDR0000689900|U01CA121947","November 25, 2010","November 2013","January 2021","August 3, 2016","August 2016","No Study Results Posted","null","July 2017","Incidence of adverse events during paclitaxel and carboplatin treatment according to dose-limiting toxicities (DLTs), graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)|Response rates in patients with lung, head and neck, and esophageal cancers assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1|Effects of therapy on HIV viral load and CD4 cell count","https://ClinicalTrials.gov/show/NCT01249443"
3381,"NCT00303628","Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer","Terminated","Has Results","Adenocarcinoma of the Rectum|Stage II Rectal Cancer|Stage III Rectal Cancer","Drug: oxaliplatin|Drug: fluorouracil|Drug: leucovorin calcium|Drug: bevacizumab","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 3","355","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E5204|NCI-2009-00563|CDR0000467561|U10CA021115","March 15, 2006","February 2006","April 2019","July 13, 2016","July 2016","January 28, 2016","null","April 2015","5-year Overall Survival Rate|5-year Disease-free Survival Rate|Patterns of Failure|Proportion of Patients Who Completed 12 Cycles of Treatment","https://ClinicalTrials.gov/show/NCT00303628"
3382,"NCT02363374","Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms|Rectal Cancer Stage II|Rectal Cancer Stage III","Drug: Induction Chemotherapy arm A|Radiation: Radiation arm A|Radiation: Radiation arm B|Drug: Chemotherapy arm B|Procedure: Surgery","Prof. Dr. med. Claus Rödel|Johann Wolfgang Goethe University Hospital|Goethe University","Both","18 Years and older   (Adult, Senior)","Phase 2","304","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JWGUniversity","February 3, 2015","February 2015","May 2022","June 16, 2016","June 2016","No Study Results Posted","CAOAROAIO-12","May 2017","Number of patients with pathological complete response (pCR), i.e. ypT0N0.|Safety of the respective combination sequences by Toxicity assessment according to NCI CTCAE V.4.0|Surgical morbidity|Surgical complications|Pathological staging|Tumor downstaging assessed by ypTNM (neoadjuvant pathological staging tumor nodes metastasis) findings in relation to initial cTNM (clinical stage tumor nodes metastasis)|Tumor regression grading according to Dworak|R0 resection rate; negative circumferential resection rate|Rate of sphincter-sparing surgery|Relapse-free survival (local / distant / overall)|Overall survival","https://ClinicalTrials.gov/show/NCT02363374"
3383,"NCT02560298","Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer","Recruiting","No Results Available","Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Squamous Cell Carcinoma|Metastatic Anal Canal Carcinoma|Recurrent Anal Canal Carcinoma|Stage IIIB Anal Canal Cancer|Stage IV Anal Canal Cancer","Drug: Capecitabine|Drug: Carboplatin|Drug: Cisplatin|Drug: Fluorouracil|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Quality-of-Life Assessment","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EA2133|NCI-2015-00771|13/LO/1463|CCR 3847|2013-001949-13|InterAACT CCR 3847|3847|U10CA180820","September 24, 2015","January 2016","null","March 22, 2016","March 2016","No Study Results Posted","InterAACT","August 2018","Best ORR defined as the percentage of patients achieving confirmed partial (PR) or complete responses (CR) as per RECIST v1.1|Anti-tumor activity and magnitude of response|Best ORR of non-irradiated lesions defined as the percentage of patients achieving confirmed PR or CR as per RECIST v1.1 of non-irradiated sites of disease|Changes in QOL|DCR defined as CR, PR, or SD assessed according to RECIST criteria v1.1|DCR defined as CR, PR, or stable disease (SD) assessed according to RECIST criteria v1.1|Feasibility in terms of proportion of centers that successfully recruit at least one patient|Feasibility in terms of recruitment rate|OS|PFS|Proportion of patients experiencing grade 3-5 toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Sensitivity analysis of ORR","https://ClinicalTrials.gov/show/NCT02560298"
3384,"NCT01379612","Ultrasound Elastography in Patients With Rectal Cancer","Completed","No Results Available","Rectal Cancer","Other: Ultrasonic Elastography","Vejle Hospital","Both","18 Years and older   (Adult, Senior)","","31","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","S-20100028","June 8, 2011","May 2010","December 2012","June 14, 2013","June 2013","No Study Results Posted","null","June 2012","Tumor regression grade","https://ClinicalTrials.gov/show/NCT01379612"
3385,"NCT01197664","Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery","Terminated","No Results Available","Mucinous Adenocarcinoma of the Rectum|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer","Drug: paricalcitol|Radiation: radiation therapy|Other: laboratory biomarker analysis|Drug: fluorouracil","Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","2","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CCCWFU 54110|NCI-2011-02409","September 2, 2010","August 2010","April 2014","July 21, 2014","July 2014","No Study Results Posted","null","July 2012","Toxicity and tolerability of the paricalcitol regimen, as measured by calcium levels|Biologic effects of oral paricalcitol with oral fluorouracil chemoradiation on vitamin D receptor staining, MIB-1, caspase 3, p 21, and bax protein expression|Patterns of gene expression in tumor samples of patients who receive chemoradiation with and without paricalcitol","https://ClinicalTrials.gov/show/NCT01197664"
3386,"NCT00714077","Adjuvant Treatment of Concurrent RT and CAPOX or Capecitabine Alone for Stage II and III Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms","","Chinese Academy of Medical Sciences|Zhejiang Cancer Hospital|Cancer Hospital of Guizhou Province|Shandong Cancer Hospital and Institute|Hebei Medical University Fourth Hospital|Peking University Third Hospital|General Hospital of Chinese Armed Police Forces|Beijing Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","570","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAMS_rectal cancer_01","July 9, 2008","April 2008","June 2018","February 15, 2016","February 2016","No Study Results Posted","null","January 2018","3-year disease free survival rate|overall survival rate|cumulative incidence of local recurrence|cumulative incidence of distant metastasis|compliance|safety","https://ClinicalTrials.gov/show/NCT00714077"
3387,"NCT01189877","Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins","Completed","No Results Available","Rectal Cancer","Procedure: Eppendorf hypoximeter","Memorial Sloan Kettering Cancer Center","Both","18 Years to 89 Years   (Adult, Senior)","","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","10-121","August 25, 2010","August 2010","October 2012","October 10, 2012","October 2012","No Study Results Posted","null","October 2012","Measure pO2 in rectal cancers|Correlate immunohistochemical analysis of endogenous markers of hypoxia","https://ClinicalTrials.gov/show/NCT01189877"
3388,"NCT01544452","Total Preoperative MR Diagnostic Evaluation Versus Standard Diagnostic Evaluation in Patients With Rectal Cancer","Terminated","No Results Available","Rectal Cancer|Liver Metastasis","Procedure: MR colonography and MR of the liver|Procedure: Standard diagnostic evaluation","Herlev Hospital","Both","18 Years and older   (Adult, Senior)","","75","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","H-1-2009-094","November 7, 2011","August 2010","February 2013","November 26, 2014","November 2014","No Study Results Posted","null","February 2013","Synchronous colon cancers and liver metastasis|sensitivity/specificity of CT versus MR versus Peroperative ultrasonography of the liver","https://ClinicalTrials.gov/show/NCT01544452"
3389,"NCT01147965","Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA","Completed","No Results Available","Colon Cancer|Lung Cancer|Breast Cancer","Biological: AD5 CEA Vaccine","Etubics Corporation|Duke University","Both","21 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","35","Industry|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ETBX-011","June 15, 2010","June 2010","March 2013","March 21, 2013","March 2013","No Study Results Posted","null","March 2013","The primary objective of this protocol is to determine the safety of immunization with Ad5 [E1-, E2B-]-CEA(6D), in patients with advanced or metastatic CEA-expressing malignancies, including Maximum Tolerated Dose (MTD).|The secondary objectives of this protocol are to evaluate CEA-specific immune responses to the immunizations and to obtain preliminary data on clinical response rate.","https://ClinicalTrials.gov/show/NCT01147965"
3390,"NCT02199236","Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management","Recruiting","No Results Available","Rectal or Anal Cancer","Radiation: endorectal brachytherapy|Drug: concurrent capecitabine or 5-FU|Behavioral: Questionnaires","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14-104","July 22, 2014","July 2014","null","July 11, 2016","July 2016","No Study Results Posted","null","July 2017","maximum tolerated dose (MTD)|tumor response","https://ClinicalTrials.gov/show/NCT02199236"
3391,"NCT00182130","Quality Initiative in Rectal Cancer (QIRC) Trial","Active, not recruiting","No Results Available","Rectal Cancer","Procedure: Quality Initiative in Rectal Cancer (QIRC) strategy","Hamilton Health Sciences Corporation|Canadian Institutes of Health Research (CIHR)|McMaster University","Both","Child, Adult, Senior","","691","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Educational/Counseling/Training","MCT-50013","September 10, 2005","May 2002","June 2007","September 10, 2005","July 2005","No Study Results Posted","null","null","Hospital rate of permanent colostomy|Hospital rate of local recurrence|Bowel, bladder and sexual function|Quality of life","https://ClinicalTrials.gov/show/NCT00182130"
3392,"NCT00294476","IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma","Recruiting","No Results Available","Cancer of Colon|Malignant Melanoma|Urologic Cancer","Drug: IVIG|Procedure: Biological Therapy","GammaCan","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GCan-01","February 19, 2006","July 2005","null","October 11, 2006","September 2006","No Study Results Posted","null","null","1. Tumor response is measured at baseline and evaluated every 3 treatment cycles (9 weeks) by RECIST(CT or MRI measurements), Time to Progression|and Serum tumor markers as appropriate CEA, PSA. Additionally, ECOG performance status is evaluated before each treatment cycle|Secondary efficacy measurements: Overall survival, Karnofsky Performance Status is evaluated at baseline and before each treatment cycle and Quality of life questionnaires is completed and evaluated at baseline and every 3 treatment cycles (9 weeks)|Safety assessments include Adverse events and laboratory values which are measured and evaluated before every treatment cycle","https://ClinicalTrials.gov/show/NCT00294476"
3393,"NCT00745134","Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Drug: Curcumin|Drug: Placebo|Radiation: Radiotherapy|Drug: Capecitabine","M.D. Anderson Cancer Center|Gateway for Cancer Research","Both","18 Years and older   (Adult, Senior)","Phase 2","45","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","2006-0644|P07010|NCI-2012-01676","September 2, 2008","August 2008","null","March 30, 2016","March 2016","No Study Results Posted","null","July 2017","Pathologic Complete Response (pCR) Rate","https://ClinicalTrials.gov/show/NCT00745134"
3394,"NCT00394602","Chemoradiation-Induced Nausea and Emesis: Quality of Life","Recruiting","No Results Available","Gastric Cancer|Pancreatic Cancer|Cervical Cancer|Vulvar Cancer|Endometrial Cancer|Anal Cancer","Behavioral: Interview|Other: Questionnaire","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","","200","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","2003-0529","October 30, 2006","April 2004","null","July 8, 2016","July 2016","No Study Results Posted","null","April 2018","Longitudinal Quality of Life + Symptom Assessment Data","https://ClinicalTrials.gov/show/NCT00394602"
3395,"NCT02217020","Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Drug: FOLFOXIRI","Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","84","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GIHSYSU07","August 10, 2014","August 2014","August 2017","August 27, 2016","August 2016","No Study Results Posted","FORTUNE","August 2016","The ratio of tumor downstaging to stage 0 and stage I|Average neoadjuvant rectal cancer score|the local Recurrence rate|Recurrence free survival|Reported Adverse events","https://ClinicalTrials.gov/show/NCT02217020"
3396,"NCT01816607","Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness","Recruiting","No Results Available","Rectal Diseases|Rectal Neoplasms|Gastrointestinal Diseases|Gastrointestinal Neoplasms","Procedure: new functional magnetic resonance imaging (MRI) protocols","University Hospital, Akershus|Oslo University Hospital|University of Oslo","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REK-2013/152","March 20, 2013","October 2013","June 2016","June 22, 2015","June 2015","No Study Results Posted","OxyTarget","June 2016","Presence of metastatic disease 5 years after rectal cancer treatment|Histomorphological response to preoperative chemoradiotherapy","https://ClinicalTrials.gov/show/NCT01816607"
3397,"NCT02437851","Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection","Recruiting","No Results Available","Anal Squamous Cell Carcinoma|HIV Infection|Stage 0 Anal Canal Cancer|Stage I Anal Canal Cancer","Procedure: Therapeutic Conventional Surgery","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation","Both","Child, Adult, Senior","Phase 2","56","Other|NIH|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-092|NCI-2014-02056|U01CA121947","January 14, 2015","April 2015","July 2020","September 6, 2016","September 2016","No Study Results Posted","null","July 2019","The proportion of participants with treatment failure at 2 years will be estimated with the binomial proportion and exact one-sided 95% confidence intervals.|The proportion of participants with incident SISCCA or anal squamous cancers at sites other than the index SISCCA will be estimated using the binomial proportion and its two-sided exact 95% confidence interval.|The cumulative proportion of study participants who have experienced treatment failure by 3 years will be estimated using the product-limit estimate and its 95% confidence interval using Greenwood's formula.|The rate of treatment related adverse events including non-healing ulcer, fissure, persistent pain and bleeding, stricture, incontinence, and colostomy 6 months after excision of SISCCA.","https://ClinicalTrials.gov/show/NCT02437851"
3398,"NCT00324415","Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer","Completed","Has Results","Anal Cancer","Biological: cetuximab|Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation","Both","18 Years to 120 Years   (Adult, Senior)","Phase 2","45","Other|NIH|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-045|U01CA070019|CDR0000440065","May 10, 2006","September 2006","May 2016","June 14, 2016","June 2016","July 22, 2015","null","April 2014","Local Failure Rate at 3 Years|Progression-free Survival|Relapse-free Survival|Colostomy-free Survival at 1 Year|Overall Survival|Quality of Life|Toxicity|Changes in CD4 Counts During and for 1 Year After Completion of Study Treatment|Incidence of Opportunistic Illnesses|Anogenital Human Papilloma Virus (HPV) Infection and Anal Cytology|Objective Response Rate (Complete and Partial)","https://ClinicalTrials.gov/show/NCT00324415"
3399,"NCT02735941","Study on Cannabinoid Receptor Expression in Gastrointestinal Diseases","Not yet recruiting","No Results Available","Ulcerative Colitis|Crohn's Disease|Colon Cancer","","Medical University of Graz","Both","18 Years and older   (Adult, Senior)","","90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KLI 521-B31","February 1, 2016","April 2016","April 2020","April 6, 2016","March 2016","No Study Results Posted","null","April 2020","Analysis of cannabinoid receptors in blood leukocytes and biopsies from patients with IBD and colon cancer|Assessment of endoscopic activity scores (Mayo, Harvey Bradshaw index) in IBD patients.|Assessment of malignancy of colon cancer by tumor staging","https://ClinicalTrials.gov/show/NCT02735941"
3400,"NCT01835925","Rectal Cancer Consortium","Completed","No Results Available","Rectal Cancer","Genetic: Tissue specimen","Brown University","Both","18 Years and older   (Adult, Senior)","","12","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","285","April 9, 2013","July 2013","April 2014","April 30, 2014","April 2014","No Study Results Posted","null","April 2014","Tumor tissue to predict likelihood of achieving pathologic complete response post standard treatment.|Tumor tissue results with clinical outcome post standard treatment. .","https://ClinicalTrials.gov/show/NCT01835925"
3401,"NCT01323166","Quality of Life After Abdominoperineal Resection for Rectal Cancer, Comparing Two Surgical Techniques","Completed","No Results Available","Rectal Cancer","Procedure: Excision of the levator muscle","Sahlgrenska University Hospital, Sweden|Swedish Cancer Foundation","Both","Child, Adult, Senior","","75","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","QoL after APR at SU","March 24, 2011","March 2011","October 2011","September 3, 2015","September 2015","No Study Results Posted","APR","October 2011","Health Related Quality of life after rectal cancer surgery - possible differences due to choice of procedure|Impact of rectal cancer surgery on household finances in a long-term perspective|Impact of rectal cancer surgery and the level of intrusive thoughts","https://ClinicalTrials.gov/show/NCT01323166"
3402,"NCT01609504","ELRR by TEM Versus Laparoscopic TME in iT2N0M0 SMALL LOW RECTAL CANCER","Completed","No Results Available","Rectal Cancer","Procedure: ELRR BY TEM|Procedure: LTME","University of Roma La Sapienza|Università Politecnica delle Marche","Both","Child, Adult, Senior","Phase 3","283","Other","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","URBINO-LEZ-1995","September 15, 2011","April 1997","April 2004","May 29, 2012","May 2012","No Study Results Posted","ELRRvsLTME","April 2004","oncological result in term of local and/or systematic recurrence|Morbidity|operative time|blood loss|analgesic use|30 day mortality|hospital stay|cancer-related mortality","https://ClinicalTrials.gov/show/NCT01609504"
3403,"NCT00808379","Concurrent Chemo-Radiotherapy Versus Radiotherapy With Boost in Locally Advanced Unresectable Rectal Cancers","Active, not recruiting","No Results Available","Rectal Cancer","Drug: Chemoradiation|Radiation: Additional Radiation boost to the primary tumor volume","Tata Memorial Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","260","December 12, 2008","May 2006","July 2009","December 12, 2008","December 2008","No Study Results Posted","null","February 2009","Comparison of resectability rate of in the two groups at 6-8 weeks following radiotherapy.|Side effects and other adverse effects in the two groups during radiotherapy and up to 2 years post radiotherapy.|Comparison of pathological downstaging between the two groups who undergo surgery.","https://ClinicalTrials.gov/show/NCT00808379"
3404,"NCT01012362","Study of Pazopanib and Ixabepilone in Patients With Solid Tumors","Terminated","No Results Available","Breast Cancer|Lung Cancer|Colon Cancer|Pancreatic Cancer|Head and Neck Cancer|Kidney Cancer|Sarcoma|Hepatocellular Cancer","Drug: Pazopanib|Drug: Ixabepilone","Masonic Cancer Center, University of Minnesota|GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 1","31","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","2009LS001|0906M68402|NCI-2009-01444","November 12, 2009","December 2009","February 2013","January 22, 2016","January 2016","No Study Results Posted","null","February 2013","To determine the optimal tolerated regimen (OTR) of pazopanib and ixabepilone when used in combination by evaluation of toxicity and tolerability|To obtain preliminary toxicity and tolerability of this drug regimen.","https://ClinicalTrials.gov/show/NCT01012362"
3405,"NCT01579721","Prospective Randomized Study of SILS Versus CLS for Rectal Cancer","Completed","No Results Available","Rectal Cancer|Adenocarcinoma","Procedure: Single Incision Laparoscopic Surgery","Hvidovre University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 4","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SILS rectal cancer","April 16, 2012","September 2011","October 2012","February 3, 2013","February 2013","No Study Results Posted","null","October 2012","morbidity|immunology|postoperative outcome|oncology","https://ClinicalTrials.gov/show/NCT01579721"
3406,"NCT01489332","Induction Chemotherapy,Radiochemotherapy, Consolidation Chemotherapy in Preoperative Treatment of Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: intensified preoperative chemotherapy","Institute of Oncology Ljubljana","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","163/06/11","November 11, 2011","October 2011","April 2018","December 7, 2011","December 2011","No Study Results Posted","null","April 2013","Pathological complete remission rate (pCR)|Toxicity|Histopathological R0 resection rate|Loco-regional failure rate|Disease-free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT01489332"
3407,"NCT02614157","Lateral Lymph Node Dissection After Neoadjuvant Chemo-radiation in Advanced Low Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: LLND|Device: labeled line","West China Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","212","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","pLNR-201501","November 23, 2015","May 2016","May 2022","June 11, 2016","June 2016","No Study Results Posted","null","May 2019","3-year local recurrence|overall survival|disease free survival|Incidence of sexual and urinary dysfunction|postoperative complications","https://ClinicalTrials.gov/show/NCT02614157"
3408,"NCT01187641","Comparison of the Diagnostic Accuracy of 3D Volume Acquisition MRI With CT in Staging Colonic Cancer","Recruiting","No Results Available","Colon Cancer","","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","62","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CCR3370","August 23, 2010","August 2010","September 2011","August 26, 2010","August 2010","No Study Results Posted","null","September 2011","The primary endpoint will be the accuracy of MRI and CT in determining T stage using histology as the gold standard, on a per patient basis.|Secondary endpoints will be the accuracy of CT and MRI in determining N stage, depth of invasion beyond the muscularis propria, and EMVI.|We will also compare the accuracy of 1.5T against 3.0T MRI scans, and T2 weighted against T1 weighted images","https://ClinicalTrials.gov/show/NCT01187641"
3409,"NCT01621217","Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0","Active, not recruiting","No Results Available","Locally Advanced Cancer in the Anal Region.","Drug: Cetuximab|Drug: Mitomycin C|Drug: 5-Fluoruracil|Radiation: Radiotherapy","Lund University Hospital|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1","21","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NOAC8.Version1","June 14, 2012","June 2012","null","September 13, 2016","September 2016","No Study Results Posted","NOAC8","July 2017","To establish maximum tolerable dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab and radiotherapy in patients with locally advanced cancer in the anal region","https://ClinicalTrials.gov/show/NCT01621217"
3410,"NCT00093379","Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer","Completed","Has Results","Anal Cancer","Drug: Capecitabine|Drug: Oxaliplatin|Radiation: Radiation Therapy (XRT)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","16 Years and older   (Child, Adult, Senior)","Phase 2","20","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0874|P30CA016672|MDA-2003-0874|SANOFI-MDA-2003-0874|CDR0000380771","October 6, 2004","April 2004","July 2012","March 12, 2014","March 2014","October 15, 2013","null","July 2012","2 Year Failure Free Survival|Number of Participants With Complete Response at 2 Years|Number of Participants With 2-year Colostomy-Free Survival|2-year Local Regional Control|2-Year Median Overall Survival|Number of Participants With Progression-Free Survival at 2-Year","https://ClinicalTrials.gov/show/NCT00093379"
3411,"NCT01775254","The Inland Northwest Colon Cancer Survivor's Study","Recruiting","No Results Available","Colon Cancer","","Washington State University|American Cancer Society, Inc.","Both","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DSCN-11-194-01","January 23, 2013","January 2013","June 2015","January 31, 2013","January 2013","No Study Results Posted","null","January 2015","Quality of Life|Peripheral Neuropathy|Changes in Sexual Function|Demands of Illness|Patient Education and Support","https://ClinicalTrials.gov/show/NCT01775254"
3412,"NCT02673177","Trial of Robotic Versus Laparoscopic-assisted Radical Resection for Rectal Cancer","Not yet recruiting","No Results Available","Rectal Neoplasms","Procedure: robot-assisted total mesorectal excision|Procedure: laparoscopic total mesorectal excision","Southwest Hospital, China","Both","18 Years to 70 Years   (Adult, Senior)","","225","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015(43)","January 27, 2016","February 2016","May 2019","February 2, 2016","February 2016","No Study Results Posted","TRVL","May 2018","Incidence of sexual and urinary dysfunction|disease-free survival(DFS )|Anus preservation rate","https://ClinicalTrials.gov/show/NCT02673177"
3413,"NCT00423293","Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer","Active, not recruiting","Has Results","Anal Cancer","Drug: fluorouracil|Drug: mitomycin C|Radiation: Intensity-modulated radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","Both","18 Years and older   (Adult, Senior)","Phase 2","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0529|CDR0000524057","January 16, 2007","December 2006","null","March 26, 2015","March 2015","April 11, 2013","null","February 2009","Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for Adverse Events)|Reproducibility of the Intensity-modulated Radiation Therapy Technique|Adverse Event Rates as Defined by CTCAE v 3.0 Within 90 Days From the Start of Study Treatment|Clinical Complete Response Rate|Radiotherapy Treatment Time|Efficacy of Treatment, in Terms of Locoregional Failure, Disease-free Survival, Time to Colostomy, Colostomy-free Survival, and Overall Survival","https://ClinicalTrials.gov/show/NCT00423293"
3414,"NCT01744340","A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer","Completed","Has Results","Head and Neck Cancer|Colon Cancer","Drug: Head and neck|Drug: Colon- Closed as of May 2014","howard safran|Fatima Memorial Hospital|Montefiore Medical Center|Rhode Island Hospital|The Miriam Hospital|Brown University","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","23","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG 254","February 23, 2012","May 2012","July 2015","March 11, 2016","March 2016","January 12, 2016","null","March 2015","If Eribulin Mesylate, up to a Maximum Dose of 1.4 mg/m2 Day 1 and 8 of a 21 Day Cycle, Can be Safely Combined With Full Dose Cetuximab for Patients With Advanced Head and Neck Cancer and Colon Cancer.|Response Rate (Whether Patient's Disease is Progressing or Being Controlled) of Patients With Head and Neck Cancer Treated With Eribulin Mesylate and Cetuximab.","https://ClinicalTrials.gov/show/NCT01744340"
3415,"NCT00025090","Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer","Completed","No Results Available","Anal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: mitomycin C|Radiation: radiation therapy","University College London (UCL) Cancer Institute|National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 3","600","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000068911|NCRI-ACT-II|EU-20056|UKCCCR-ACT-II|ISRCTN26715889","October 11, 2001","March 2001","August 2007","August 23, 2013","March 2007","No Study Results Posted","null","null","Complete response rate at 6 months|Acute toxicity as measured up to 4 weeks after chemoradiation|Recurrence-free survival|Colostomy rate|In field recurrence rate as measured by confirmed disease within radiation therapy field|Cause-specific and overall survival","https://ClinicalTrials.gov/show/NCT00025090"
3416,"NCT01013805","Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer","Completed","No Results Available","Rectal Cancer","Radiation: External Beam Radiotherapy|Drug: Oxaliplatin|Drug: Fluorouracil|Drug: Leucovorin|Procedure: Surgical Resection","Trans-Tasman Radiation Oncology Group (TROG)","Both","18 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TROG 09.01|ACTRN12610000175077","October 8, 2009","November 2009","December 2012","January 27, 2016","January 2016","No Study Results Posted","PROArCT","December 2012","Tolerability Rate of patients treated with integrated pre-operative radiotherapy with FOLFOX chemotherapy regimen|Complete pathologic response rate following the completion of treatment|Treatment Related Toxicity rates|Dose Intensity of the treatment drug","https://ClinicalTrials.gov/show/NCT01013805"
3417,"NCT02293954","Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer","Recruiting","No Results Available","Breast Cancer|Colon Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastrointestinal Cancer|Liver and Intrahepatic Biliary Tract Cancer|Lung Cancer|Metastatic Cancer|Pancreatic Cancer|Rectal Cancer|Thyroid Gland Medullary Carcinoma|Unspecified Adult Solid Tumor, Protocol Specific","Procedure: radionuclide imaging|Procedure: positron emission tomography|Other: laboratory biomarker analysis|Other: pharmacological study|Drug: Cu 64 anti-CEA monoclonal antibody M5A IV","City of Hope Medical Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","20","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","14238|NCI-2014-02079","October 9, 2014","June 2015","null","September 12, 2016","September 2016","No Study Results Posted","null","June 2018","Efficacy of each modality in locating cancer in each of four regions (primary, hepatic, extra-hepatic abdominal, and extra-abdominal) using lesion analysis|Efficacy of each modality in locating cancer in each of four regions (primary, hepatic, extra-hepatic abdominal, and extra-abdominal) using region analysis|Pharmacokinetic parameters of copper Cu 64 anti-CEA monoclonal antibody M5A|Immunogenicity properties of copper Cu 64 anti-CEA monoclonal antibody M5A|Incidence of adverse events graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03","https://ClinicalTrials.gov/show/NCT02293954"
3418,"NCT02129218","Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer","Recruiting","No Results Available","Stage I Colon Cancer|Stage II Colon Cancer|Stage III Colon Cancer|Stage I Rectal Cancer|Stage II Rectal Cancer|Stage III Rectal Cancer","Other: questionnaire administration|Other: laboratory biomarker analysis|Behavioral: Standard Dietary Intervention|Behavioral: Intensified Dietary Intervention|Behavioral: Low glycemic load|Behavioral: Medium Glycemic Load","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","72","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CASE7213|NCI-2014-00831|P30CA043703","April 17, 2014","February 2015","February 2017","August 11, 2016","August 2016","No Study Results Posted","null","February 2017","Individual patient compliance, defined by following assigned target glycemic load index >= 75% of the time between weeks 4 and 12|Food acceptability score|Hours of nutritionist time per week","https://ClinicalTrials.gov/show/NCT02129218"
3419,"NCT01887509","Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology","Active, not recruiting","No Results Available","Rectal Cancer|Rectal Adenocarcinoma","Device: Probe-based confocal laser endomicroscopy|Procedure: Rectoscopy|Procedure: EUS|Procedure: Biopsy and resection","IHU Strasbourg","Both","18 Years and older   (Adult, Senior)","","21","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","12-005|2013-A00406-39","June 20, 2013","November 2013","October 2016","August 31, 2016","August 2016","No Study Results Posted","TRaMA","October 2016","Concordance in identification of lower pole of tumor|Identification of tissue characteristics|Concordance of techniques (pCLE and histopathology)|Comparison of pCLE results to EUS (echoendoscopy) results|Creation of an image bank|Assessment of predictive value of interpretation criteria","https://ClinicalTrials.gov/show/NCT01887509"
3420,"NCT02009631","A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors","Completed","No Results Available","Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors","Drug: Veliparib (ABT-888)|Drug: Placebo","AbbVie","Both","18 Years and older   (Adult, Senior)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","M12-020|2013-002028-18","December 9, 2013","November 2013","December 2014","December 11, 2014","December 2014","No Study Results Posted","null","December 2014","To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF)|Pharmacokinetic sampling maximum observed plasma concentration (Cmax)|Pharmacokinetic sampling - time to maximum observed plasma concentration (Tmax)|Pharmacokinetic sampling - the area under the plasma concentration-time curve (AUC) from time 0-24 hours (AUC 0-24)|The number of subjects with adverse events|Vital Signs|Clinical Laboratory Tests|Tumor Assessment","https://ClinicalTrials.gov/show/NCT02009631"
3421,"NCT01233505","Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors","Terminated","No Results Available","Adenocarcinoma of the Pancreas|Adenocarcinoma of the Stomach|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ovarian Mucinous Cystadenocarcinoma|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Gastric Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Gastric Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: veliparib|Drug: capecitabine|Drug: oxaliplatin|Other: pharmacological study|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","16","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02543|CDR0000687938|C010903|8604|P30CA014520|U01CA062491","November 2, 2010","October 2010","null","April 1, 2014","October 2013","No Study Results Posted","null","October 2013","Maximum-tolerated (MTD) dose of veliparib in combination with oxaliplatin and capecitabine as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Dose-limiting toxicities of veliparib in combination with oxaliplatin and capecitabine as assessed by NCI CTCAE version 4.0|Pharmacokinetics of veliparib administered concomitantly with oxaliplatin and capecitabine|Safety and tolerability as assessed by NCI CTCAE version 4.0|Anti-tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST)","https://ClinicalTrials.gov/show/NCT01233505"
3422,"NCT02314871","Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery","Recruiting","No Results Available","Colon Cancer|Minimal Residual Disease","Other: Epidural analgesia|Drug: Piritramide|Drug: Morphine","The Institute of Molecular and Translational Medicine, Czech Republic|Brno University Hospital|T. Bata Regional Hospital Zlin, Czech Republic","Both","18 Years and older   (Adult, Senior)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CAREC-1","December 1, 2014","January 2015","December 2017","March 17, 2016","March 2016","No Study Results Posted","null","October 2017","Change from baseline number of circulating cancer cells at 3 weeks after surgery|Pain intensity assessment","https://ClinicalTrials.gov/show/NCT02314871"
3423,"NCT01871571","Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer","Recruiting","No Results Available","Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Rectum|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer","Biological: bevacizumab|Drug: oxaliplatin|Drug: leucovorin calcium|Drug: fluorouracil|Other: laboratory biomarker analysis","University of Southern California|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","43","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3R-12-2|NCI-2013-01069|ML28263|P30CA014089","June 4, 2013","July 2013","July 2017","October 24, 2015","October 2015","No Study Results Posted","null","July 2016","Rate of CPR in the pathology specimen|Tumor regression on mesorectal margins (pathologic stage lower than clinical stage)|Rate of locoregional recurrence|Incidence and nature of adverse events (AEs) according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 ( v4)|Incidence and nature of serious AEs (SAEs) according to NCI CTCAE v4.0|Incidence and nature of AEs of special interest for bevacizumab (grades) according to NCI CTCAE v4.0","https://ClinicalTrials.gov/show/NCT01871571"
3424,"NCT02381561","Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy","Recruiting","No Results Available","Bile Duct Carcinoma|Stage III Pancreatic Cancer|Stage IIIA Colon Cancer|Stage IIIA Gastric Cancer|Stage IIIA Rectal Cancer|Stage IIIA Small Intestinal Cancer|Stage IIIB Colon Cancer|Stage IIIB Gastric Cancer|Stage IIIB Rectal Cancer|Stage IIIB Small Intestinal Cancer|Stage IIIC Colon Cancer|Stage IIIC Gastric Cancer|Stage IIIC Rectal Cancer|Stage IV Gastric Cancer|Stage IV Pancreatic Cancer|Stage IV Small Intestinal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Ropidoxuridine","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","30","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2015-00258|BRUOG 265|9882","March 5, 2015","February 2016","null","June 17, 2016","June 2016","No Study Results Posted","null","July 2017","MTD defined as the dose below which 2 or more of 6 patients experience dose-limiting toxicity|%IUdR-DNA incorporation in peripheral (circulating) granulocytes|%IUdR-DNA incorporation in tumor biopsies|PK incorporation in peripheral (circulating) granulocytes|PK incorporation in tumor biopsies|Tumor response relationship to the %IUdR-DNA incorporation using RECIST criteria based on HPLC and flow cytometry measurements","https://ClinicalTrials.gov/show/NCT02381561"
3425,"NCT01308190","Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: Capecitabine (Xeloda)|Radiation: 50.4 Gy|Procedure: Transanal Endoscopic Microsurgery|Procedure: Total Mesorectal Excision","Corporacion Parc Tauli|Fundación Olga Torres","Both","18 Years and older   (Adult, Senior)","Phase 3","173","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAU-TEM-2009-01","March 3, 2011","August 2010","December 2018","September 9, 2015","September 2015","No Study Results Posted","null","December 2017","Local recurrence","https://ClinicalTrials.gov/show/NCT01308190"
3426,"NCT00003596","Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer","Completed","No Results Available","Anal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: mitomycin C|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Southwest Oncology Group|North Central Cancer Treatment Group","Both","18 Years and older   (Adult, Senior)","Phase 3","650","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","RTOG-9811|CDR0000066667|CALGB-89808|ECOG-R9811|NCCTG-R9811|SWOG-R9811|GUMC-00125","November 1, 1999","October 1998","null","November 18, 2013","November 2013","No Study Results Posted","null","October 2005","","https://ClinicalTrials.gov/show/NCT00003596"
3427,"NCT01814969","Preoperative Hyperfractionated Radiotherapy or Radiochemotherapy in Locally Advanced Rectal Cancer.","Recruiting","No Results Available","Rectal Cancer","Radiation: Hyperfractionated Radiochemotherapy|Radiation: Hyperfractionated Radiotherapy","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","260","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PHRT-COI-01","March 18, 2013","March 2014","December 2018","May 4, 2015","May 2015","No Study Results Posted","null","December 2016","• The rate of patients with downstaging after radiotherapy or radiochemotherapy to pathological response or disease with negative margins|The rate of local failures|Progression-free long-term survival|The rate of distant metastases|Overall long-term survival|The rate of late toxicity according to the RTOG/EORTC scale|The rate of postoperative complications|The rate of early toxicity of neoadjuvant treatment according to the NCI CTCAE (version 4.0)","https://ClinicalTrials.gov/show/NCT01814969"
3428,"NCT02688712","ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer","Not yet recruiting","No Results Available","Rectal Adenocarcinoma","Drug: LY2157299|Drug: Capecitabine|Drug: Fluorouracil|Procedure: Tumor specific mesorectal excision","Providence Health & Services|Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-050A","January 25, 2016","June 2016","June 2022","June 23, 2016","June 2016","No Study Results Posted","null","December 2021","Evaluation of pathologic response|Immunoscore (utilizing tumor tissue)|MRI Parameters|Immunologic monitoring parameters","https://ClinicalTrials.gov/show/NCT02688712"
3429,"NCT02140021","Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer","Recruiting","No Results Available","Malignant Female Reproductive System Neoplasm","Procedure: Anal Pap Test|Procedure: Anoscopy","M.D. Anderson Cancer Center","Female","18 Years and older   (Adult, Senior)","","500","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2014-0021","May 14, 2014","October 2014","null","July 1, 2016","July 2016","No Study Results Posted","null","October 2020","Prevalence of Invasive Squamous Cell Carcinoma of the Anus in Women with Cervical, Vaginal and Vulvar Dysplasia and Cancer","https://ClinicalTrials.gov/show/NCT02140021"
3430,"NCT01386502","CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors","Withdrawn","No Results Available","Breast Cancer|Colon Cancer|Pancreatic Cancer|Sarcoma|Ovarian Cancer","Biological: p53: 264-272 peptide|Drug: CT-011","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","Phase 1","0","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","110198|11-C-0198","June 30, 2011","June 2011","October 2011","December 30, 2011","October 2011","No Study Results Posted","null","null","To determine the safety and tolerability of escalating doses of anti PD1 antibody (CT-011) in combination with subcutaneous p53 vaccine.|To determine the immune response to wt p53 (264-272) peptide.|To determine the clinical efficacy of this combination.","https://ClinicalTrials.gov/show/NCT01386502"
3431,"NCT01097239","Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer","Recruiting","No Results Available","Rectal Cancer|Ovarian Cancer|Endometrial Cancer|Vaginal Cancer|Cervical Cancer","Device: Sonablate 500 (High Intensity Focused Ultrasound (HIFU))","Imperial College London|Imperial College Healthcare NHS Trust","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","09/H0808/43","March 31, 2010","November 2009","null","September 15, 2016","September 2016","No Study Results Posted","null","December 2017","Quality of life scores (EORTC QLQ−C30 and/or EORTC QLQ−CR38, EORTC QLQ-CX24, EORTC QLQ-EN24 or EORTC QLQ-OV24)|Pain relief visual analogue scale|Tumour marker changes (CEA and CA19.9)","https://ClinicalTrials.gov/show/NCT01097239"
3432,"NCT02017704","Chemoradiation or Brachytherapy for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Radiation: Endo-HDR (if randomized to this arm)|Drug: capecitabine and IMRT (if randomized to this arm)|Radiation: IMRT (intensity modulated radiation therapy)|Drug: FOLFOX6|Procedure: Surgery","Sidney Kimmel Comprehensive Cancer Center|Nucletron","Both","18 Years to 100 Years   (Adult, Senior)","Phase 2","138","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","J1360|NA_00082167","December 5, 2013","October 2013","null","August 22, 2016","August 2016","No Study Results Posted","CORRECT","October 2018","Pathologic complete response rate|Number of participants with adverse events|Quality of Life Comparison|Time to death|Time to distant metastases free survival|Time to progression free survival|Time to local disease recurrence","https://ClinicalTrials.gov/show/NCT02017704"
3433,"NCT00068744","Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer","Terminated","No Results Available","Anal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: mitomycin C|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","88","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-22011-40014|EORTC-22011|EORTC-40014","September 10, 2003","July 2003","null","September 20, 2012","September 2012","No Study Results Posted","null","November 2007","Response as measured by RECIST at 8 weeks after completion of study treatment (Phase II)|Event-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter (Phase III)|Acute toxicity and compliance to treatment as measured by CTC v 2.0 at completion of study treatment (Phase II)|Colostomy-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter (Phase III)|Overall survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter|Disease-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter|Local control as measured by Gray at 12 and 26 weeks, then every 6 months thereafter|Late toxicity as measured by RTOG and EROTC every 6 months after week 26|Quality of life as measured by EORTC Quality of Life Questionnaire-C30 and ASCT at 12 and 26 weeks, then every 6 months for 2 years after entry","https://ClinicalTrials.gov/show/NCT00068744"
3434,"NCT02747862","Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program","Recruiting","No Results Available","Attenuated Familial Adenomatous Polyposis|Deleterious Familial Adenomatous Polyposis","Other: Chart Review","M.D. Anderson Cancer Center","Both","Child, Adult, Senior","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DR08-0006","April 14, 2016","February 2008","null","April 21, 2016","April 2016","No Study Results Posted","null","February 2020","Chart Review of Outcomes of Participants with Attenuated Familial Adenomatous Polyposis (AFAP) and Deleterious Familial Adenomatous Polyposis (FAP) Undergoing Endoscopic Surveillance","https://ClinicalTrials.gov/show/NCT02747862"
3435,"NCT00909558","Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer","Suspended","No Results Available","Breast Cancer|Glioma|Hepatocellular Cancer|Squamous Cell Lung Cancer|Pancreatic Cancer|Colon Cancer|Prostate Cancer","Biological: Autologous Natural Killer / Natural Killer T Cell Immunotherapy","Envita Medical Center, Inc.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1","24","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E001-08","May 27, 2009","May 2009","null","February 23, 2010","February 2010","No Study Results Posted","null","June 2010","Is there any measurable effect upon the underlying cancer as assessed by an increase or decrease in the tumor as measured from baseline using established criteria?|Are the dosages administered during the study safe, as measured by the number of unexpected and serious adverse events associated with the study drug, as defined by FDA regulations and as measured by established criteria?","https://ClinicalTrials.gov/show/NCT00909558"
3436,"NCT02554448","Detection of CTCs in Stage III Rectal Cancer Patients Undergoing Neoadjuvant Therapy","Recruiting","No Results Available","Rectal Neoplasms|Circulating Tumor Cells","Other: ISET system","Sixth Affiliated Hospital, Sun Yat-sen University","Both","18 Years and older   (Adult, Senior)","","80","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","CTC-1","September 17, 2015","January 2016","December 2016","May 28, 2016","April 2016","No Study Results Posted","null","October 2016","The number of Circulating Tumor Cells (CTCs)","https://ClinicalTrials.gov/show/NCT02554448"
3437,"NCT02869152","Sentinel Lymph Node Mapping in Rectal Cancer","Not yet recruiting","No Results Available","Rectal Neoplasms","Other: Endoscopic injection of 99mTc-sulfur colloid|Other: Endoscopic injection of ICG|Other: Endoscopic injection of Spot|Procedure: Flexible sigmoidoscopy|Procedure: Endoscopic NIR imaging and gamma probe|Procedure: Dissection of sentinel lymph node(s)","University of Virginia","Both","18 Years and older   (Adult, Senior)","","26","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","19120","July 14, 2016","August 2016","null","August 17, 2016","August 2016","No Study Results Posted","null","March 2019","1st Phase: Detection rate of sentinel lymph node in first 6 patients|2nd Phase: Detection rate of refined protocol in identifying SLN|Size of the SLN according to pathologic analysis|Location of the SLN according to pathologic analysis|Time required for completion of the protocol|Number of protocol modifications for procedural and/or technical issues|Ergonomic optimization of the protocol as measured by operative time|Ergonomic optimization of the protocol as measured by surgeon satisfaction","https://ClinicalTrials.gov/show/NCT02869152"
3438,"NCT00636948","Rectal Cancer Trial On Defunctioning Stoma","Completed","No Results Available","Rectal Cancer","","Rectal Cancer Trial on Defunctioning Stoma Study Group","Both","18 Years and older   (Adult, Senior)","","234","Other","Observational","Time Perspective: Prospective","Dnr 99039","February 11, 2008","December 1999","null","March 10, 2008","March 2008","No Study Results Posted","RECTODES","June 2005","Symptomatic anastomotic leakage following low anterior resection of the rectum for cancer with and without a defunctioning stoma. Anorectal function after one and five years without defunctioning stoma.|Reoperation within 30 days of initial surgery.","https://ClinicalTrials.gov/show/NCT00636948"
3439,"NCT00600496","A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)","Active, not recruiting","No Results Available","Breast Cancer|Breast Neoplasms|Colon Cancer|Colonic Cancer|Colon Neoplasms|Lung Cancer|Melanoma|Kidney Cancer","Drug: AZD6244|Drug: Dacarbazine|Drug: Erlotinib|Drug: Docetaxel|Drug: Temsirolimus","AstraZeneca","Both","18 Years to 130 Years   (Adult, Senior)","Phase 1","211","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D1532C00004","January 15, 2008","December 2007","December 2016","July 6, 2016","July 2016","No Study Results Posted","null","August 2010","Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies.|PK of AZD6244 and selected chemotherapies.|Define highest tolerated dose of AZD6244 when in combination with selected chemotherapies.|Tumor response.","https://ClinicalTrials.gov/show/NCT00600496"
3440,"NCT01650428","Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery","Active, not recruiting","No Results Available","Rectal Cancer","Biological: Bevacizumab|Drug: Irinotecan|Drug: Oxaliplatin|Drug: 5-Fluorouracil","University College, London|Cancer Research UK|Hoffmann-La Roche","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL/09/0176","July 16, 2012","April 2013","December 2017","September 9, 2015","May 2015","No Study Results Posted","BACCHUS","October 2017","Pathological Complete Response (PCR)|RECIST Response Rate|CRM Negative Resection Rate|T and N stage downstaging|Progression Free Survival|Disease Free Survival|Overall Survival|Local Control|1 year Colostomy Rate|Frequency and severity of Adverse Events|Compliance of Chemotherapy|Tumour Regression Grade (TRG)|Tumour Cell Density","https://ClinicalTrials.gov/show/NCT01650428"
3441,"NCT02233374","Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET","Recruiting","No Results Available","Rectal Neoplasms","Other: Early MRI and PET/CT - 2 weeks after commencing chemo/RT|Other: Late MRI and PET/CT 6 weeks post chemo/RT","Royal North Shore Hospital","Both","18 Years and older   (Adult, Senior)","","44","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)","14-NSCCRO-P001","August 13, 2014","September 2014","December 2019","July 12, 2015","July 2015","No Study Results Posted","PRISM","December 2016","Predictive value of PET/CT and MRI 2 weeks into chemo-irradiation for developing a pathologic complete response at surgery.|Feasibility of conducting additional PET and MRI scans at 6 weeks post-treatment.|Utility of adding PET scan to the baseline staging of patients|Pathologic response according to Tumour Regression Grade (TRG)|Impact of pCR rates on long term disease control","https://ClinicalTrials.gov/show/NCT02233374"
3442,"NCT02033551","A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors","Active, not recruiting","No Results Available","Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors","Drug: Veliparib|Drug: Carboplatin|Drug: Paclitaxel|Drug: FOLFIRI","AbbVie","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M14-144|2013-003137-16","January 8, 2014","December 2013","November 2016","August 4, 2016","August 2016","No Study Results Posted","null","November 2016","Number of subjects with adverse events|Objective Response Rate (ORR)|Overall Survival (OS)|Time to Disease Progression (TTP)|Progression Free Survival (PFS)|Clinical Laboratory Tests|Electrocardiogram|Tumor Assessment","https://ClinicalTrials.gov/show/NCT02033551"
3443,"NCT02526836","Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer","Recruiting","No Results Available","Colon Cancer","Procedure: Conventional Surgery|Procedure: Complete mesocolic excision with central vascular ligation","Mansoura University","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","Complete Mesocolic Excision","August 11, 2015","September 2014","January 2018","August 14, 2016","August 2016","No Study Results Posted","null","September 2017","Lymph nodes harvest|Oncologic outcome|Operative outcome|Postoperative outcome|Survival outcome","https://ClinicalTrials.gov/show/NCT02526836"
3444,"NCT01526486","Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer","Completed","No Results Available","Melanoma|Merkel Cell Carcinoma|Squamous Cell Carcinoma|Penile Carcinoma|Urethral Carcinoma|Extramammary Paget's Disease|Scrotal Carcinoma|Anal Cancer|Vulvar Cancer|Skin Cancer|Lymphadenopathy","Procedure: Videoscopic procedure|Procedure: Open, traditional approach","Emory University","Both","18 Years to 80 Years   (Adult, Senior)","","29","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00012329|WCI1585-08","January 28, 2012","June 2009","February 2013","May 4, 2015","May 2015","No Study Results Posted","null","February 2013","Complication profile|Length of stay|Lymphedema|Nodal yield|Readmission|Oncologic outcomes--survival","https://ClinicalTrials.gov/show/NCT01526486"
3445,"NCT01899118","Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer","Recruiting","No Results Available","Locally Advanced Rectal Cancer","Radiation: Preoperative irradiation|Drug: Nimotuzumab|Drug: Oxaliplatin|Drug: Capecitabine","Zhejiang Cancer Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZhejiangCH-ARO2013","July 10, 2013","April 2013","null","July 12, 2013","July 2013","No Study Results Posted","null","April 2016","Pathology complete remission rate|tumor regression rate|local recurrence rate|overall survival|sphincter preservation rate|Incidence of Adverse Events","https://ClinicalTrials.gov/show/NCT01899118"
3446,"NCT02510378","Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases","Recruiting","No Results Available","Stage IV Rectal Cancer, Liver Metastasis, Resectable","Radiation: Short course radiotherapy","Chinese Academy of Medical Sciences","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","47","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-072","July 12, 2015","January 2014","December 2022","July 27, 2015","July 2015","No Study Results Posted","null","December 2020","percentage of patients undergo R0 surgery during the follow-up|The rate of early toxicity of radiotherapy according to the NCI Common Toxicity Criteria for Adverse Effects (version 3.0)","https://ClinicalTrials.gov/show/NCT02510378"
3447,"NCT00127036","Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)","Terminated","Has Results","Adenocarcinoma|Colon Cancer","Drug: XELOX|Drug: XELIRI|Drug: Bevacizumab","H. Lee Moffitt Cancer Center and Research Institute|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 2","65","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-13449|R21 CA10135|XEL390|2005-0729","August 3, 2005","October 2003","December 2010","November 21, 2013","December 2011","January 5, 2012","null","December 2010","Number of Participants Per Treatment Arm, Per Tumor Tissue Response Classifier|Number of Participants Per Treatment Arm, With Overall Survival (OS)|Number of Participants With Serious Adverse Events (SAEs)","https://ClinicalTrials.gov/show/NCT00127036"
3448,"NCT02353858","Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer","Recruiting","No Results Available","Rectal Cancer|Locally Advanced Rectal Cancer|Hyperthermia|Hyperthermic Radiochemotherapy|Hyperthermic Chemoradiotherapy|Deep Regional Hyperthermia","Other: Deep regional hyperthermia|Radiation: Radiotherapy|Drug: Chemotherapy (5-Fluorouracil)","University Hospital Tuebingen","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","78","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HT01","December 2, 2014","August 2012","August 2016","December 4, 2015","December 2015","No Study Results Posted","HT01","August 2016","Pathological complete response rate|Locoregional progression free survival|Disease free survival|Distant metastases free survival|Overall survival|Number of hyperthermia treatments|Acute and chronic treatment related toxicity, according to CTC criteria|post operative morbidity","https://ClinicalTrials.gov/show/NCT02353858"
3449,"NCT02129049","Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children","Completed","No Results Available","Breast Cancer|Cervical Cancer|Colon Cancer|Leukemia|Lymphoma|Malignant Neoplasm|Melanoma|Rectal Cancer","Other: educational intervention|Behavioral: telephone-based intervention|Other: questionnaire administration","University of Washington|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","35","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","9095|NCI-2014-00928|R03CA178488|P30CA015704","April 30, 2014","April 2014","null","March 8, 2016","March 2016","No Study Results Posted","null","July 2015","Recruitment and retention, monitored by tracking detailed recruitment spreadsheets|Dosage and fidelity, monitored for each intervention session using Performance Checklists|Acceptability of the program, assessed from interview data obtained from the Exit interview and the Swanson Caring Professional Scale|Rate of receipt of mailed materials both to participants and from participants|Duration of phone intervention sessions|Rate of success in scheduling and completing intervention sessions by telephone|Quality of data on baseline and post-intervention measures|Short-term impact of the program, evaluated by comparing the change in pre- and post-test scores on the standardized questionnaires|Impact of the telephone-delivered compared to the in-person delivered program","https://ClinicalTrials.gov/show/NCT02129049"
3450,"NCT00176787","Radiation Therapy With Capecitabine in Rectal Cancer","Terminated","No Results Available","Rectal Cancer","Drug: Capecitabine|Procedure: Radiation|Procedure: Surgery","University of Michigan Cancer Center|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 0046","September 12, 2005","October 2000","June 2007","December 28, 2007","December 2007","No Study Results Posted","null","May 2005","Objectives:|In patients with locally advanced rectal cancer treated with preoperative radiation and capecitabine chemotherapy to estimate:|a. the pathologic complete response rate|b. the clinical response rate|c. the proportion of patients converted to sphincter sparing surgery|clinical response rate|d. The quantitative and qualitative toxicities of the treatment approach|e. The relationship of intratumoral levels of thymidylate synthase, dipyrimidine dehydrogenase and thymidine phosphorylase determined immunohistochemically to response","https://ClinicalTrials.gov/show/NCT00176787"
3451,"NCT00052559","Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer","Completed","No Results Available","Adenocarcinoma of the Rectum|Stage II Rectal Cancer|Stage III Rectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Radiation: external beam radiation therapy|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","32","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02908|6042-05-7R1|CDR0000258532|U01CA099118|U01CA062490","January 24, 2003","August 2002","null","June 4, 2013","June 2013","No Study Results Posted","null","April 2003","Maximum tolerated dose of bevacizumab when administered concurrently with 5-fluorouracil (5-FU) and external beam radiation therapy (EBRT) in patients with cT3 and T4 rectal cancer prior to surgery|Pathological response rate after preoperative bevacizumab, 5-FU, EBRT, and surgery|Progression-free survival|Local control|Overall survival","https://ClinicalTrials.gov/show/NCT00052559"
3452,"NCT01519817","Cancer Vaccine Targeting Brachyury Protein in Tumors","Active, not recruiting","No Results Available","Neoplasms|Malignant Solid Tumors|Colon Neoplasms|Adenocarcinoma","Biological: GI-6301 (Yeast Brachyury Vaccine)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 100 Years   (Adult, Senior)","Phase 1","34","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","120056|12-C-0056","January 12, 2012","January 2012","January 2018","August 31, 2016","March 2016","No Study Results Posted","null","January 2017","Change in T cell precursors|Adverse events of escalating doses of GI- 6301 vaccine|Clinical benefit|General immune activation","https://ClinicalTrials.gov/show/NCT01519817"
3453,"NCT02905968","Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Device: transanual tube placement","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","520","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTPLAR","September 8, 2016","January 2016","December 2018","September 14, 2016","September 2016","No Study Results Posted","null","December 2018","anastomotic leak rate|Time Frame: Reoperation rate after anastomotic leak","https://ClinicalTrials.gov/show/NCT02905968"
3454,"NCT02252250","Transanal Minimal Invasive Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms","Procedure: conventional laparoscopic total mesentery excision|Procedure: transanal hybrid-laparoscopic total mesentery excision","Third Military Medical University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20141056","September 23, 2014","October 2014","October 2021","February 22, 2016","February 2016","No Study Results Posted","null","November 2018","Adequacy of the total mesorectal excision(TME) based on standard guidelines on pathologic evaluation of TME specimens.|Incidence of 30-day perioperative complications including intraoperative, and postoperative complications|Incidence of long-term complications|Oncologic outcomes in subjects receiving transanal hybrid-laparoscopic total mesentery excision.","https://ClinicalTrials.gov/show/NCT02252250"
3455,"NCT00190541","Mesorectal Excision (ME) Versus ME With Lateral Node Dissection for Stage II, III Lower Rectal Cancer (JCOG0212)","Recruiting","No Results Available","Rectal Neoplasms","Procedure: Mesorectal excision with lateral lymph node dissection|Procedure: Mesorectal excision without lateral lymph node excision","Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan","Both","21 Years to 74 Years   (Adult, Senior)","Phase 3","700","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG0212|C000000034","September 13, 2005","June 2003","June 2015","June 13, 2010","June 2010","No Study Results Posted","null","June 2015","Relapse-free survival|Overall survival|Local-recurrence-free survival|Incidence of adverse events|Incidence of major adverse events|Operative time|Blood loss|Incidence of sexual and urinary dysfunction","https://ClinicalTrials.gov/show/NCT00190541"
3456,"NCT00066430","Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia","Completed","No Results Available","Anal Cancer|Precancerous Condition","Procedure: infrared photocoagulation therapy|Device: Infrared Coagulator","AIDS Malignancy Consortium|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","18","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-032|CDR0000316109","August 6, 2003","September 2003","April 2006","September 16, 2014","September 2014","No Study Results Posted","null","September 2004","","https://ClinicalTrials.gov/show/NCT00066430"
3457,"NCT02665299","Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy","Recruiting","No Results Available","Colon Cancer|Colon Adenomas|Colon Polyps","","Pathway Genomics","Both","18 Years and older   (Adult, Senior)","","200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pathway Genomics 005","January 22, 2016","January 2016","December 2020","January 26, 2016","January 2016","No Study Results Posted","null","December 2016","Utility of plasma ctDNA measurements to detect colon cancer or precancerous conditions.|Determination of incident rate of new colon or other cancers in patients who underwent initial measurement of ctDNA","https://ClinicalTrials.gov/show/NCT02665299"
3458,"NCT00963352","Colon Cancer Prognosis After Radical Surgery","Recruiting","No Results Available","Colon Cancer","","Haraldsplass Deaconess Hospital","Both","Child, Adult, Senior","","300","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","Knut2009","August 19, 2009","January 2007","December 2010","August 26, 2010","August 2010","No Study Results Posted","null","August 2009","3-year disease free survival (DFS)|5-year overall survival (OS)","https://ClinicalTrials.gov/show/NCT00963352"
3459,"NCT02728427","Multicenter Study on Suprapubic Catheterization Versus Transurethral Catheterization in Laparoscopic Surgery for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer|Surgery","Device: Suprapubic catheterization using central venous catheter(CVC-2 7F)|Device: Transurethral catheterization using Foley catheter","Nanfang Hospital of Southern Medical University|Fujian Cancer Hospital|Fujian Provincial Hospital","Male","18 Years and older   (Adult, Senior)","","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","SPCCVC-TUC","March 22, 2016","April 2016","April 2017","April 12, 2016","April 2016","No Study Results Posted","MSSPC","April 2017","Catherization time|Number of catheterization|Catheter-Associated Urinary Tract Infection|Pain score|International Prostatic Symptom Score|Time to first ambulation|Duration of hospital stay|Urinary extravasation|Hematuria|Catheter obstruction","https://ClinicalTrials.gov/show/NCT02728427"
3460,"NCT01675999","Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer","Recruiting","No Results Available","Colon Cancer|Locally Advanced Malignant Neoplasm","Other: Perioperative simplified FOLFOX-4 chemotherapy|Other: Perioperative FOLFOX4+Cetuximab chemotherapy|Other: Surgery followed by FOLFOX4 chemotherapy","Assistance Publique - Hôpitaux de Paris|Federation Francophone de Cancerologie Digestive|UNICANCER|Association de Recherche Experimentale et Clinique en Chirurgie Digestive|Association Européenne de Recherche en Oncologie|Merck Serono S.A., Geneva","Both","18 Years to 76 Years   (Adult, Senior)","Phase 2","186","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P100131","February 2, 2012","May 2012","February 2021","January 14, 2016","January 2012","No Study Results Posted","ECKINOXE","May 2012","Histological tumor response in the primary tumor according to the simplified Tumor Regression Grade (TRG) of Ryan|Safety and tolerability and efficacy of the neoadjuvant chemotherapy|•Disease free survival and regression free survival at 3 years|•Overall survival at 6 and 7 years|•Quality of life (EORTC QLQ-C30, QLQ-CR29)|•Quality and radicality of the surgical excision|•Accuracy of pre-treatment CT scan staging and evaluation of radiological response to chemotherapy|•Correlation between radiological and histological response|•Evaluation of another histopathological grade","https://ClinicalTrials.gov/show/NCT01675999"
3461,"NCT02438839","Curative Chemoradiation of Low Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","","Vejle Hospital","Both","18 Years and older   (Adult, Senior)","","105","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","WW2","May 5, 2015","April 2015","null","May 11, 2016","May 2016","No Study Results Posted","WW2","December 2019","Proportion of patients with locoregional tumor control with chemoradiation alone two years after end of treatment|Cumulative incidence of local recurrence after surgery|Rate of distant metastases|Response and tumor control on MRI scans compared to clinical observations, including rectoscopic examination","https://ClinicalTrials.gov/show/NCT02438839"
3462,"NCT01525056","Rectal Cancer: Local Staging, Re-staging and Assessment of Lymph Nodes Using Pet-Ct, CT-Perfusion and 3T MRI","Completed","No Results Available","Rectal Cancer","Radiation: ct and mri scans|Radiation: ct, mri and pet scan|Radiation: ct, mri and pet scans","London Health Sciences Centre","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","LRCP01","January 25, 2012","March 2012","September 2014","September 8, 2014","September 2014","No Study Results Posted","null","September 2014","efficacy of PET, CT-perfusion and MRI to stage patients with rectal cancer","https://ClinicalTrials.gov/show/NCT01525056"
3463,"NCT00896467","Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy","Terminated","No Results Available","Anal Cancer|Anxiety Disorder|Breast Cancer|Depression|Esophageal Cancer|Gallbladder Cancer|Gastric Cancer|Kidney Cancer|Liver Cancer|Lung Cancer|Pancreatic Cancer|Small Intestine Cancer","Other: questionnaire administration|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","Centre Oscar Lambret|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","","COL-0701|CDR0000626737|COL-IPSY|COL-RCB 2007-A00223-50|INCA-RECF0480","May 8, 2009","September 2007","November 2010","July 9, 2013","July 2009","No Study Results Posted","null","September 2010","Quality of life as assessed by the QLQ-30 questionnaire|Symptoms of anxiety and depression as assessed by the HADS questionnaire|Adjustment strategies and emotional regulation as assessed by the WCC and ERQ questionnaires","https://ClinicalTrials.gov/show/NCT00896467"
3464,"NCT02664077","A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer","Recruiting","No Results Available","Stage III (IIIB or IIIC) Colon Cancer","Drug: Regorafenib|Drug: Placebo","NSABP Foundation Inc|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 3","1118","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NSABP C-13|17808","December 4, 2015","June 2016","January 2025","August 31, 2016","August 2016","No Study Results Posted","ARGO","November 2023","Disease-free survival (DFS) - time from randomization until first colon cancer recurrence, second primary colon cancer, or death due to any cause.|Overall Survival (OS) - time from randomization until death from any cause.|Toxicity - frequency and severity of adverse events categorized using the NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)|Compliance - Time to discontinuation of study therapy.|Correlative Science - Biomarker evaluations|Correlative Science - Pharmacokinetics - Plasma regorafenib concentrations|Correlative Science - Pharmacodynamics|Compare the symptoms experienced by patients receiving regorafenib to patients receiving placebo during treatment as measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","https://ClinicalTrials.gov/show/NCT02664077"
3465,"NCT02467582","Adjuvant Aspirin for Colon Cancer","Recruiting","No Results Available","Colon Cancer","Drug: Aspirin|Drug: Placebo","Swiss Group for Clinical Cancer Research","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","185","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","SAKK 41/13 - Aspirin|SNCTP000001339|2015-001482-57","June 5, 2015","July 2015","December 2028","May 24, 2016","May 2016","No Study Results Posted","null","December 2018","Disease-free survival (DFS)|Time to recurrence (TTR)|Overall survival (OS)|Cancer-specific survival (CSS)|Adverse events (AEs)","https://ClinicalTrials.gov/show/NCT02467582"
3466,"NCT01131234","Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Solid Neoplasm|Male Breast Carcinoma|Recurrent Adult Brain Neoplasm|Recurrent Breast Carcinoma|Recurrent Colon Carcinoma|Recurrent Melanoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Carcinoma|Recurrent Rectal Carcinoma|Recurrent Renal Cell Carcinoma|Stage III Pancreatic Cancer|Stage III Renal Cell Cancer|Stage IIIA Colon Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Ovarian Germ Cell Tumor|Stage IIIA Rectal Cancer|Stage IIIA Skin Melanoma|Stage IIIB Breast Cancer|Stage IIIB Colon Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Ovarian Germ Cell Tumor|Stage IIIB Rectal Cancer|Stage IIIB Skin Melanoma|Stage IIIC Breast Cancer|Stage IIIC Colon Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Ovarian Germ Cell Tumor|Stage IIIC Rectal Cancer|Stage IIIC Skin Melanoma|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer","Drug: Gamma-Secretase Inhibitor RO4929097|Drug: Cediranib Maleate|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","20","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-01428|CDR0000673867|PJC-004|8503|U01CA132123","May 25, 2010","May 2010","September 2014","December 22, 2014","November 2014","No Study Results Posted","null","September 2014","Recommended phase II dose of gamma-secretase inhibitor RO4929097 defined as the dose level at which < 1/6 patients experience dose-limiting toxicity as graded by the National Cancer Institute (NCI) CTCAE version 4.0|Incidence of adverse events as graded by the NCI CTCAE version 4.0|PK profiles for both drugs|PD effects of gamma-secretase inhibitor RO4929097 when administered alone and in combined with cediranib maleate|Preliminary antitumor efficacy","https://ClinicalTrials.gov/show/NCT01131234"
3467,"NCT02448173","A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer","Recruiting","No Results Available","Stage II Colon Cancer","Biological: OncoVAX and Surgery|Procedure: Surgery","Vaccinogen Inc","Both","18 Years and older   (Adult, Senior)","Phase 3","550","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ASI-2005-04","May 6, 2015","May 2015","July 2022","July 24, 2015","July 2015","No Study Results Posted","null","July 2020","Disease-Free Survival|Overall Survival|Recurrence-Free Interval","https://ClinicalTrials.gov/show/NCT02448173"
3468,"NCT02135419","Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions","Recruiting","No Results Available","Anal Cancer|High-grade Squamous Intraepithelial Lesion|HIV Infection|Human Papilloma Virus Infection","Drug: imiquimod|Drug: fluorouracil|Procedure: infrared photocoagulation therapy|Procedure: thermal ablation therapy|Procedure: laser therapy|Other: clinical observation|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California, San Francisco","Both","35 Years and older   (Adult, Senior)","Phase 3","5058","Other|NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","AMC-A01|NCI-2014-00636|U01CA121947","May 8, 2014","September 2014","June 2022","July 15, 2016","July 2016","No Study Results Posted","ANCHOR","June 2022","Time to anal cancer|Incidence of adverse events for each treatment|Quality of life assessed using the Functional Assessment of Incontinence Therapy - Fecal (FAIT-F) questionnaire","https://ClinicalTrials.gov/show/NCT02135419"
3469,"NCT02250053","Exercise and Colon Cancer","Active, not recruiting","No Results Available","Stage II Colon Cancer|Stage III Colon Cancer","Other: Exercise","Abramson Cancer Center of the University of Pennsylvania","Both","18 Years and older   (Adult, Senior)","Phase 0","39","Other","Interventional","Primary Purpose: Treatment","UPCC 10214","September 22, 2014","December 2015","null","August 31, 2016","August 2016","No Study Results Posted","null","January 2016","1. The biological efficacy of aerobic exercise on soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular adhesion molecule-1 (sVCAM-1) prognostic biomarkers.|Exercise adherence, quantified as the percentage of total dose completed relative to the total dose prescribed during the six-month study;|Visceral adipose tissue and anthropometric measures at baseline and six-months;|Fasting insulin measured at baseline and six-months;|Circulating tumor cells measured at baseline and six-months.","https://ClinicalTrials.gov/show/NCT02250053"
3470,"NCT02648386","Stem Cell Therapy Combined With NeuroRegen Scaffold™ in Patients With Erectile Dysfunction After Rectal Cancer Surgery","Recruiting","No Results Available","Rectal Cancer|Erectile Dysfunction","Procedure: Laparoscopic surgery|Device: NeuroRegen scaffold transplantation|Biological: NeuroRegen scaffold/BMMCs transplantation|Biological: NeuroRegen scaffold/HUC-MSCs transplantation","Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","Male","20 Years to 65 Years   (Adult)","Phase 1|Phase 2","34","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","CAS-XDA-ED-IGDB","January 5, 2016","January 2016","December 2018","April 14, 2016","December 2015","No Study Results Posted","null","December 2018","Safety and Tolerability assessed by Adverse Events|IIEF-5 (International Index of Erectile Function)|Mean scores of the Sexual Encounter Profile (SEP) Question 2, 3|Penile cavernosal artery peak systolic velocity (PSV)|Nocturnal penile tumescence (NPT)|The change of results of Nerve electrophysiological examination|Maximum Flow Rate (Qmax)","https://ClinicalTrials.gov/show/NCT02648386"
3471,"NCT02649647","Proximally Extended Resection for Rectal Cancer After Neoadjuvant Chemoradiotherapy","Recruiting","No Results Available","Rectal Cancer","Procedure: Conventional resection|Procedure: Proximally extended resection","Sixth Affiliated Hospital, Sun Yat-sen University|Shanghai Changzheng Hospital","Both","18 Years to 75 Years   (Adult, Senior)","","420","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PERN2015019","January 5, 2016","February 2016","February 2026","February 17, 2016","January 2016","No Study Results Posted","PERN","February 2022","Incidence of major bowel dysfunction|Incidence of anastomotic leakage|Incidence of anastomotic stenosis|Incidence of anastomotic haemorrhage|Incidence of intraoperative complication|Postoperative morbidity|Postoperative mortality|Quality of life","https://ClinicalTrials.gov/show/NCT02649647"
3472,"NCT01724775","Efficacy and Safety Study of Complete Mesocolic Excision for Colon Cancer","Recruiting","No Results Available","Colon Cancer|Surgery","","Shan Wang|Peking University People's Hospital","Both","18 Years and older   (Adult, Senior)","","450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PKPH-CME|Z121100005312015|TG-2015-002|20130001120064","November 4, 2012","November 2012","December 2017","August 17, 2016","August 2016","No Study Results Posted","ESCME","November 2017","Prognosis assessment of postoperative patients|Safety assessment of the patients in perioperation period","https://ClinicalTrials.gov/show/NCT01724775"
3473,"NCT01217450","Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors","Completed","No Results Available","Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: selumetinib|Biological: cetuximab|Other: laboratory biomarker analysis|Other: pharmacological study","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","33","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02915|CDR0000686619|CO10901|8627|P30CA014520|U01CA062491","October 7, 2010","October 2012","May 2014","May 28, 2014","December 2013","No Study Results Posted","null","December 2012","MTD of selumetinib combined with cetuximab|Tumor response, as evaluated by the RECIST|Toxicities graded using the NCI Common Toxicity Criteria","https://ClinicalTrials.gov/show/NCT01217450"
3474,"NCT01207895","Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer","Completed","No Results Available","Rectal Cancer","Device: PET imaging with [18F]-FLT","Vanderbilt-Ingram Cancer Center","Both","18 Years and older   (Adult, Senior)","","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","VICC GI 0993","September 17, 2010","March 2010","July 2013","May 9, 2016","May 2016","No Study Results Posted","null","December 2012","Utility of [18F]-FLT PET to assess cellular proliferation in neoadjuvant trials of patients with rectal cancer|Correlative biology","https://ClinicalTrials.gov/show/NCT01207895"
3475,"NCT00427375","Local Excision in Downstaged Rectal Cancer","Active, not recruiting","No Results Available","Rectal Neoplasms","Procedure: local rectal excision|Procedure: total mesorectal excision","University Hospital, Bordeaux|Sanofi|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 3","148","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CHUBX 2006/03|2005-025","January 26, 2007","March 2007","December 2017","August 19, 2016","August 2016","No Study Results Posted","GRECCAR 2","December 2014","Compare the proportion of patients presenting at least 1 component of the composite outcome (4 components: death, recurrence, major morbidity and severe after effects) at 2 years after|Compare the incidence at 2 years of each component separately: death, recurrence, major morbidity and severe after effect|5-year survival.|Quality of life (QLQ C30 - CR38)","https://ClinicalTrials.gov/show/NCT00427375"
3476,"NCT00904813","The Stockholm III Trial on Different Preoperative Radiotherapy Regimens in Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Radiation: Preoperative radiotherapy|Radiation: Preoperative radiotherapy|Radiation: Preoperative radiotherapy","Karolinska Institutet|Swedish Cancer Society|The Swedish Research Council","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","840","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","98/240","May 19, 2009","November 1998","January 2018","September 8, 2016","September 2016","No Study Results Posted","Stockholm III","January 2017","time to recurrence|acute and late toxicity","https://ClinicalTrials.gov/show/NCT00904813"
3477,"NCT00789893","Study of Vaginal Dilator Use After Pelvic Radiotherapy","Completed","No Results Available","Cervical Cancer|Endometrial Cancer|Rectal Cancer|Anal Cancer","Device: Vaginal Dilator","Memorial Sloan Kettering Cancer Center","Female","21 Years to 85 Years   (Adult, Senior)","","115","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","08-127","November 12, 2008","November 2008","June 2015","June 10, 2015","June 2015","No Study Results Posted","null","June 2015","To measure compliance with vaginal dilator use.|To examine the effect of dilator use in minimizing vaginal stenosis so that patients are able to use the pre-radiation baseline dilator size 6 months after starting dilator use.|To measure vaginal symptoms related to vaginal stenosis during vaginal dilation over 6 months after starting dilator use.|To explore reasons for non-compliance with use of dilators.|To explore patient-reported self-efficacy as it relates to the use of the vaginal dilator.","https://ClinicalTrials.gov/show/NCT00789893"
3478,"NCT01643499","Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies","Recruiting","No Results Available","Acinar Cell Adenocarcinoma of the Pancreas|Adenocarcinoma of the Gallbladder|Adenocarcinoma of Unknown Primary|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Cholangiocarcinoma of the Gallbladder|Diffuse Adenocarcinoma of the Stomach|Duct Cell Adenocarcinoma of the Pancreas|Intestinal Adenocarcinoma of the Stomach|Localized Unresectable Adult Primary Liver Cancer|Metastatic Carcinoma of Unknown Primary|Metastatic Extrahepatic Bile Duct Cancer|Mixed Adenocarcinoma of the Stomach|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Newly Diagnosed Carcinoma of Unknown Primary|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage III Pancreatic Cancer|Stage IIIA Colon Cancer|Stage IIIA Gallbladder Cancer|Stage IIIA Gastric Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Gallbladder Cancer|Stage IIIB Gastric Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Gastric Cancer|Stage IIIC Rectal Cancer|Stage IV Gastric Cancer|Stage IV Pancreatic Cancer|Stage IVA Colon Cancer|Stage IVA Gallbladder Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Gallbladder Cancer|Stage IVB Rectal Cancer|Unresectable Extrahepatic Bile Duct Cancer","Drug: oxaliplatin|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: fluorouracil|Other: laboratory biomarker analysis","University of Chicago|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","45","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-0033|NCI-2012-00585","July 16, 2012","March 2012","March 2017","July 20, 2016","July 2016","No Study Results Posted","null","March 2017","DLT rate in course 1 for each of the two most common genotype groups (*1*1 and *1*28)|Response rates (by RECIST 1.1) for patients with each different type of gastrointestinal malignancy|Cumulative dose intensity of irinotecan hydrochloride","https://ClinicalTrials.gov/show/NCT01643499"
3479,"NCT01558921","Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial","Active, not recruiting","No Results Available","Rectal Cancer","Other: M1 scheme|Other: standard long course chemoradiotherapy","University Medical Center Groningen|Karolinska University Hospital|Leiden University Medical Center|Uppsala University Hospital|Dutch Cancer Society","Both","18 Years and older   (Adult, Senior)","Phase 3","920","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NL36315.042.11|2010-023957-12","March 18, 2012","June 2011","December 2019","June 2, 2016","June 2016","No Study Results Posted","RAPIDO","January 2017","Time to disease related treatment failure (TdrTF)|Overall survival|CRM negative (margin > 1 mm) rate|Pathological complete response (pCR) rate|Short and long-term toxicity|Surgical complications|Quality of life","https://ClinicalTrials.gov/show/NCT01558921"
3480,"NCT01330186","Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy","Recruiting","No Results Available","Anal Cancer","Other: FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)","Copenhagen University Hospital at Herlev","Both","18 Years and older   (Adult, Senior)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GI 1026","April 5, 2011","February 2011","May 2012","April 11, 2011","April 2011","No Study Results Posted","null","February 2012","Tumor response","https://ClinicalTrials.gov/show/NCT01330186"
3481,"NCT00470951","Randomized Prospective Trial for Laparoscopic vs Open Resection for Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Procedure: open rectal resection|Procedure: laparoscopic rectal resection","National Cancer Center, Korea","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","340","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-06-179","May 7, 2007","April 2006","August 2014","August 16, 2012","August 2012","No Study Results Posted","CTS-179","August 2012","Disease free survival|Anorectal function|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT00470951"
3482,"NCT01324141","Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer","Terminated","No Results Available","Anal Cancer","Drug: Tempol|Drug: 5-Fluorouracil|Drug: Mitomycin-C|Procedure: Radiation Therapy","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 90 Years   (Adult, Senior)","Phase 1","6","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","110129|11-C-0129","March 25, 2011","March 2011","April 2015","August 6, 2016","April 2015","No Study Results Posted","null","April 2015","To determine the safety and tolerability of topical MTS-01 on a daily basis prior to irradiation in the groin and gluteal cleft of patients receiving combined therapy with MMC, 5-FU, and RT for carcinoma of the anal canal.|To describe the rates and severity of skin toxicity in patients treated with this regimen|To describe the need for toxicity related treatment breaks with this regimen|To describe the opiate requirements in patients treated with this regimen|To describe 12-month progression-free survival, disease-free survival, and overall survival in patients treated with concurrent chemotherapy, radiation therapy, MTS-01|Evaluate the effects of antiretroviral therapy, 5-fluorouracil, mitomycin C, and radiation on low level persistent HIV viremia and HIV genetic diversity|To evaluate the feasibility of collecting HIV RNA and mononuclear cells from rectal associated lymphoid tissue for correlative studies|Collect and store anal cytology and core needle biopsies of tumor for future HPV and tumor based analyses","https://ClinicalTrials.gov/show/NCT01324141"
3483,"NCT01068483","Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients","Completed","No Results Available","Breast Cancer|Colon Cancer|Ovarian Cancer|Endometrium Cancer","Drug: BKM120","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","107","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CBKM120X2101|2008-002652-17","February 11, 2010","November 2008","August 2012","April 9, 2013","April 2013","No Study Results Posted","null","September 2011","Maximum Tolerated Dose (MTD) of BKM120|Safety and tolerability of BKM120|Pharmacokinetics of BKM120|Changes in tumor metabolic activity|Pharmacodynamics of BKM120|Clinical tumor response in patients with tumors that show PI3K pathway activation","https://ClinicalTrials.gov/show/NCT01068483"
3484,"NCT00914537","Anal Cancer Screening Study","Completed","No Results Available","Anal Cancer","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 110 Years   (Adult, Senior)","","1000","NIH","Observational","Time Perspective: Prospective","999909158|09-C-N158","June 4, 2009","May 2009","null","August 27, 2016","August 2016","No Study Results Posted","null","null","High resolution anoscopy|Natural History of Anal HPV in HIV-positive men","https://ClinicalTrials.gov/show/NCT00914537"
3485,"NCT00955240","Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer","Active, not recruiting","No Results Available","Anal Cancer","Biological: cetuximab|Drug: cisplatin|Drug: fluorouracil|Other: laboratory biomarker analysis|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","77","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000642638|FRE-FNCLCC-ACCORD-16-0708|EU-20941|EUDRACT-2007-0 07029-38","August 7, 2009","March 2009","null","July 8, 2011","July 2011","No Study Results Posted","null","null","Objective response (complete and partial) according to RECIST criteria at 8 weeks after completion of study treatment|Survival rate at 3 and 5 years|Colostomy-free survival at 3 and 5 years|Duration of objective response","https://ClinicalTrials.gov/show/NCT00955240"
3486,"NCT01346280","Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs","Completed","No Results Available","Non-Small Cell Lung Cancer (Stage III)|Colon Cancer (Stage II &Amp; III)|Rectal Cancer (Stage III)","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 99 Years   (Adult, Senior)","","1695","NIH","Observational","","999911145|11-C-N145","April 29, 2011","April 2011","October 2015","August 6, 2016","October 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01346280"
3487,"NCT02031939","Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer","Recruiting","No Results Available","Advanced Rectal Cancer","Drug: Induction and gap chemotherapy (Capecitabine combine with oxaliplatin)|Radiation: standard chemoradiotherapy","Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 3","556","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2013013|SYSU5010Fund","December 30, 2013","January 2014","January 2023","November 18, 2015","November 2015","No Study Results Posted","null","January 2018","overall survival|disease free survival|Disease free survival|Respond rate","https://ClinicalTrials.gov/show/NCT02031939"
3488,"NCT02465593","A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Unresectable Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: PEP503|Drug: 5-fluorouracil|Drug: capecitabine|Procedure: surgical resection|Radiation: Radiotherapy","PharmaEngine","Both","20 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","42","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PEP503-RC-1001","June 1, 2015","June 2015","December 2017","June 4, 2015","June 2015","No Study Results Posted","null","December 2017","safety profile /the Dose Limiting Toxicity (DLT)|the recommended volume (dose)|anti-tumor activity","https://ClinicalTrials.gov/show/NCT02465593"
3489,"NCT00036400","Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery","Completed","No Results Available","Stomach Neoplasms|Rectal Neoplasms","Drug: epoetin alfa","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho Biotech Products, L.P.","Both","18 Years and older   (Adult, Senior)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","CR002365","May 9, 2002","December 2001","December 2003","June 8, 2011","April 2010","No Study Results Posted","null","null","Number of red blood cell transfusions|Hemoglobin levels during preoperative chemoradiation; effect on quality of life measured by patient self-reported Linear Analog Scale Assessment, Functional Assessment of Cancer Therapy-Anemia, and Brief Fatigue Inventory; tumor response; safety","https://ClinicalTrials.gov/show/NCT00036400"
3490,"NCT02647398","Study Comparing Two Strategies of Exercise in Breast and Colon Cancer Survivors and Their Impact on Fatigue","Recruiting","No Results Available","Neoplasms|Fatigue","Behavioral: Vigorous aerobic training","Puerta de Hierro University Hospital|Universidad Europea de Madrid","Both","18 Years to 65 Years   (Adult)","Phase 2","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","PH-UEM-04","January 3, 2016","January 2016","April 2017","June 17, 2016","June 2016","No Study Results Posted","null","November 2016","Improvement in cancer related-fatigue|Changes in cardiorespiratory fitness|Changes in quality of life|adherence to the program|adherence to international recommendations|Changes in body composition|Employment status","https://ClinicalTrials.gov/show/NCT02647398"
3491,"NCT00316888","Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer","Active, not recruiting","Has Results","Anal Cancer","Biological: cetuximab|Drug: cisplatin|Drug: fluorouracil|Radiation: radiotherapy","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 2","63","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E3205|U10CA023318|CDR0000470269","April 19, 2006","January 2007","May 2022","July 18, 2016","July 2016","July 18, 2016","null","November 2015","Local Failure Rate at 3 Years|3-year Overall Survival Rate|3-year Progression-free Survival Rate|Objective Response Rate|3-year Colostomy-free Survival Rate","https://ClinicalTrials.gov/show/NCT00316888"
3492,"NCT00414232","Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy","Completed","No Results Available","Rectal Cancer","","Sidney Kimmel Comprehensive Cancer Center|University of Michigan","Both","18 Years and older   (Adult, Senior)","","13","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","J-06109|NA_00004324","December 20, 2006","November 2006","null","January 7, 2013","January 2013","No Study Results Posted","null","October 2010","Quality of Life (QoL)","https://ClinicalTrials.gov/show/NCT00414232"
3493,"NCT01152710","Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer","Completed","No Results Available","Resectable Rectal Cancer Clinical Stage II and III","Drug: Capecitabine","Institute of Oncology Ljubljana","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","57","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","139/03/06","June 25, 2010","June 2004","April 2010","June 28, 2010","June 2010","No Study Results Posted","null","March 2006","complete pathological remission rate|the rate of sphincter preservation in low-sited tumours|toxicity of combined modality treatment (Number of Participants with Adverse Events)|overall downstaging rate|overall survival|local control|relapse-free survival|long-term rectal and urogenital morbidity","https://ClinicalTrials.gov/show/NCT01152710"
3494,"NCT02685046","Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy","Recruiting","No Results Available","Colonic Neoplasms","Drug: Imatinib","UMC Utrecht|Meander Medical Center|Erasmus Medical Center|Hubrecht Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","27","Other","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CC-TT-IMA-14|NL50620.041.15|2014-003965-11","February 9, 2016","April 2016","December 2018","April 20, 2016","April 2016","No Study Results Posted","ImPACCT","March 2018","Effects of treatment on the mesenchymal gene expression profile|Extent of targeted inhibition of PDGFR and KIT phosphorylation in cancer cells|Correlation between plasma imatinib trough levels on day 14 and intratumoural concentration of imatinib in the resection specimen|Correlation between the extent of PDGFR and cKIT inhibition and systemic and intratumoural imatinib and CGP74588 concentration|Change in plasma CEA-concentrations|Change in plasma levels of circulating tumor DNA|Effects of imatinib on the ability of cancer cells to form in vitro 3D cell cultures (organoids)|Number of participants with treatment-related adverse events as assessed by CTCAEv4.02","https://ClinicalTrials.gov/show/NCT02685046"
3495,"NCT01157806","Palliative Radiochemotherapy Against Palliative Surgery in Stage IV Rectal Cancer With Unresectable Metastases","Recruiting","No Results Available","Rectal Cancer","Radiation: short course of palliative radiotherapy","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology","Both","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0109","July 6, 2010","January 2010","June 2012","February 14, 2011","February 2011","No Study Results Posted","null","December 2010","percentage of patients not requiring palliative surgery during the follow-up|The rate of early toxicity of radiotherapy according to the NCI CTCAE (version 3.0)|Palliative effect of radiotherapy|Time from palliative radiotherapy to delayed palliative surgery|Determination of prognostic factors indicating the need for immediate palliative surgery.","https://ClinicalTrials.gov/show/NCT01157806"
3496,"NCT00506844","Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer","Active, not recruiting","No Results Available","Rectal Neoplasms|Neoadjuvant Treatment","Drug: Cetuximab, Irinotecan, Capecitabine","National Cancer Center, Korea","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-06-165","July 23, 2007","May 2006","May 2010","July 23, 2007","July 2007","No Study Results Posted","ERBIRIX","null","Pathologic stage Tumor regression grade|Toxicity measured by NCICTC v3|Disease-free survival","https://ClinicalTrials.gov/show/NCT00506844"
3497,"NCT00506623","Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer","Active, not recruiting","No Results Available","Rectal Neoplasm|Neoadjuvant Therapy","Drug: Capecitabine, Irinotecan","National Cancer Center, Korea","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","48","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS 04-088","July 23, 2007","July 2004","December 2008","July 23, 2007","July 2007","No Study Results Posted","null","null","Pathologic stage Tumor regression grade|Toxicity","https://ClinicalTrials.gov/show/NCT00506623"
3498,"NCT00931203","Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer","Completed","No Results Available","Locally Advanced Rectal Cancer","Drug: Celecoxib","National Health Research Institutes, Taiwan|Taipei Veterans General Hospital, Taiwan|Changhua Christian Hospital|Chi Mei Medical Hospital|Taichung Veterans General Hospital|National Cheng-Kung University Hospital|Chang Gung Memorial Hospital|Mackay Memorial Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","55","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T2207","July 1, 2009","July 2008","April 2013","May 3, 2016","July 2009","No Study Results Posted","null","June 2012","The primary objective is to determine the pathological complete response (pCR) of combining preoperative tegafur-uracil, folinate, radiation and celecoxib for locally advanced rectal cancer.|1.Toxicity profile of combining celecoxib, tegafur-uracil, folinate and preoperative radiation for locally advanced rectal cancer.|Negative resection margins (circumferential resection margin) rate.|Downstaging rate.|Sphincter preservation rate.","https://ClinicalTrials.gov/show/NCT00931203"
3499,"NCT02532803","Mri IN STaging REctal Polyp Planes","Recruiting","No Results Available","Rectal Cancer|Rectal Neoplasms|Colonic Polyps","Other: Pelvic MRI scan","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCR4346","August 18, 2015","August 2015","August 2022","August 21, 2015","August 2015","No Study Results Posted","MINSTREL","August 2017","Measurement of the accuracy of a novel MRI assessment tool to accurately stage Early Rectal Cancers and Polyps|Measurement of Inter-observer Kappa agreement for stage of tumour|Measurement of the Sensitivity and specificity of MRI for lymph node metastasis","https://ClinicalTrials.gov/show/NCT02532803"
3500,"NCT02751606","Nano MRI on 7 Tesla in Rectal and Breast Cancer","Recruiting","No Results Available","Rectal Neoplasms|Breast Neoplasms","Drug: ferumoxtran-10|Device: 7 Tesla MRI|Device: 3 Tesla MRI","Radboud University","Both","18 Years and older   (Adult, Senior)","Phase 3","30","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","7TNANO1","November 28, 2014","June 2015","null","April 21, 2016","April 2016","No Study Results Posted","null","September 2016","Sensitivity and specificity of 7 Tesla MRI in combination with ferumoxtran-10 on nodal level.|Comparison of 7 Tesla and 3 Tesla MRI","https://ClinicalTrials.gov/show/NCT02751606"
3501,"NCT00590278","A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer","Completed","No Results Available","Inoperable or Recurrent Rectal Cancer","Drug: Tomudex|Procedure: Radiotherapy|Procedure: Haematology|Procedure: Biochemistry","AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 2","49","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1694TR/01","December 26, 2007","August 2002","null","January 23, 2008","January 2008","No Study Results Posted","TOMUDEX","null","This study will evaluate the value of TOMUDEX in combination with a 'standard' course of pelvic radiotherapy for inoperable/recurrent rectal cancer, in terms of response rate and increasing the resectability rate","https://ClinicalTrials.gov/show/NCT00590278"
3502,"NCT01431599","Short-course Preoperative Chemoradiotherapy for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Radiation: short-course radiation","Seoul St. Mary's Hospital|Seoul National University Hospital|Samsung Medical Center|National Cancer Center, Korea","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KROG 11-02","September 6, 2011","September 2011","October 2017","December 10, 2015","December 2015","No Study Results Posted","KROG 11-02","October 2012","downstaging effect of tumor|bladder and small bowel toxicity after chemoradiation","https://ClinicalTrials.gov/show/NCT01431599"
3503,"NCT02830633","Trial to Evaluate Laparoscopy-assisted Nerve-preserved Total Mesorectal Excision (LNTME) Versus Open TME for Rectal Cancer","Not yet recruiting","No Results Available","Rectal Cancer","Procedure: LNTME|Procedure: OTME","Anhui Medical University","Male","18 Years to 60 Years   (Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LNTME-01","June 12, 2016","July 2016","July 2020","July 9, 2016","July 2016","No Study Results Posted","null","July 2016","Postoperative complications including bleeding, anastomotic leakage, postoperative infection, organ dysfunctions.|The postoperative sexual function assessed by IIEF questionnaire|The postoperative voiding function assessed by IPSS questionnaire.|Operative time|Postoperative deaths|The length postoperative hospital stay|C-reactive protein","https://ClinicalTrials.gov/show/NCT02830633"
3504,"NCT00909987","Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum","Completed","No Results Available","Rectum Cancer","Drug: Capecitabine|Drug: Oxaliplatin|Drug: Bevacizumab|Radiation: Radiotherapy|Drug: Capecitabine during all Radiotherapy period|Procedure: Total Mesorectal Excision (TME)","Grupo Espanol Multidisciplinario del Cancer Digestivo|Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEMCAD-0801","March 23, 2009","March 2009","June 2013","October 10, 2013","September 2013","No Study Results Posted","null","January 2013","Efficacy of XELOX/BVZ neoadjuvant therapy with selective radiotherapy use in patients with locally advanced tumors of the rectum, measured in terms of the proportion of responders (PCR + CCR), according to RECIST criteria|Study treatment,which selectively omits neoadjuvant irradiation,can achieve a R0= 90%|Rate of local and systemic recurrence|Toxicity of treatment|Rate of surgical complications during postoperative|Profile of gene expression before neoadjuvant treatment|Complete Phatologic Response (pCR)","https://ClinicalTrials.gov/show/NCT00909987"
3505,"NCT01659424","Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy and FOLFOX Chemotherapy for Rectal Cancer","Withdrawn","No Results Available","Rectal Cancer","Radiation: High Dose Rate Endorectal Brachytherapy (HDR-ERBT)","Beth Israel Medical Center|St. Luke's-Roosevelt Hospital Center","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HDRBT for Rectal cancer","April 24, 2012","June 2011","November 2014","December 17, 2014","December 2014","No Study Results Posted","HDRBT","November 2014","Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy (BT) Improve Compliance|Locoregional failure|Distant Metastasis|Toxicity|4) Quality of Life","https://ClinicalTrials.gov/show/NCT01659424"
3506,"NCT00068692","Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery","Terminated","No Results Available","Mucinous Adenocarcinoma of the Rectum|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Rectum|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer|Stage IVA Rectal Cancer|Stage IVB Rectal Cancer","Drug: capecitabine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: irinotecan hydrochloride|Drug: oxaliplatin|Radiation: external beam radiation therapy|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","3000","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02959|E3201|U10CA021115|CDR0000327815","September 10, 2003","October 2003","null","February 26, 2013","February 2013","No Study Results Posted","null","January 2100","Overall survival|Sphincter preservation|Tolerance of treatment|Patterns of failure","https://ClinicalTrials.gov/show/NCT00068692"
3507,"NCT02112240","Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients","Withdrawn","No Results Available","Rectal Cancer","Other: Intraoperative Mobile Gamma Camera imaging|Drug: Endoscopic injection of 99mTc-sulfur colloid|Other: Endoscopic injections of Spot|Procedure: Preoperative flexible sigmoidoscopy|Radiation: SPECT/CT","University of Virginia|American Cancer Society, Inc.","Both","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","16746","March 20, 2014","May 2013","null","July 14, 2016","July 2016","No Study Results Posted","null","February 2017","Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.|Feasibility","https://ClinicalTrials.gov/show/NCT02112240"
3508,"NCT01985698","A Trial of Robotic-assisted Versus Laparoscopic Versus Open Abdominoperineal Resection for Treating Low Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: Robotic-assisted resection.|Procedure: Laparoscopic resection|Procedure: Open surgery","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","","450","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RLOAPR","November 9, 2013","November 2013","October 2019","August 20, 2016","August 2016","No Study Results Posted","RLOAPR","October 2017","operative complications|operative mortality|disease-free survival|overall survival|locoregional recurrence rate","https://ClinicalTrials.gov/show/NCT01985698"
3509,"NCT02127645","Neoadjuvant Radiotherapy Followed by Transanal Endoscopic Microsurgery for T1-T2 Extraperitoneal Rectal Cancer","Active, not recruiting","No Results Available","RECTAL CANCER","Procedure: SRT-TEM|Procedure: LRT-TEM|Procedure: Transanal Endoscopic Microsurgery (TEM)|Procedure: Total Mesorectal Excision (TME)","European Association for Endoscopic Surgery","Both","18 Years to 90 Years   (Adult, Senior)","Phase 3","25","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EAES-4","April 26, 2014","June 2011","May 2017","January 20, 2016","January 2016","No Study Results Posted","NERATEM","May 2014","incidence of local and distant recurrence|morbidity, subdivided into major (requiring surgery) and minor (requiring endoscopic or medical intervention)|disease specific and general quality of life|anorectal function","https://ClinicalTrials.gov/show/NCT02127645"
3510,"NCT02439086","Prediction of Response to Neoadjuvant Therapy in Rectal Cancer","Not yet recruiting","No Results Available","Rectal Neoplasms","Device: PET-CT Scan","Colchester General Hospital|Anglia Ruskin University","Both","Child, Adult, Senior","","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Diagnostic","TBA (ethics)","April 23, 2015","September 2015","September 2017","May 8, 2015","May 2015","No Study Results Posted","PRENT-LARC","September 2017","Accuracy of Texture analysis PET-CT|Correlation between tumour response parameters to survival.|Accuracy of Texture analysis MRI","https://ClinicalTrials.gov/show/NCT02439086"
3511,"NCT00393822","A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer","Completed","No Results Available","Colon Cancer","Drug: palifermin|Drug: placebo","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","100","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20040122","October 26, 2006","August 2005","March 2014","July 14, 2014","July 2014","No Study Results Posted","null","December 2007","Incidence of Grade ≥ 2 (WHO scale) oral mucositis|Incidence of chemotherapy (5-FU) dose reductions and dose delays|Average mouth and throat soreness (MTS) score|Duration of grade ≥ 2 (WHO scale) oral mucositis|Incidence and severity of adverse events|Changes in laboratory values|Incidence of serum anti-palifermin antibody formation|Progressive disease rate|Incidence of secondary primary tumors|Incidence of other malignancies|Progression-free survival (PFS)|Overall survival (OS)|Incidence of grade ≥ 2 (WHO scale) oral mucositis","https://ClinicalTrials.gov/show/NCT00393822"
3512,"NCT02603302","Radiation Dose Escalation in Locally Advanced Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Radiation: Dose Escalation Radiotherapy|Procedure: Delayed surgery","University of Brasilia","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","48","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01","November 6, 2015","January 2016","December 2018","June 11, 2016","June 2016","No Study Results Posted","RaDE","December 2017","Pathologic complete response|Disease free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02603302"
3513,"NCT00587964","Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases","Completed","Has Results","Brain Metastasis|Bladder Cancer|Breast Cancer|Cervical Cancer|Colon Cancer|HEENT Cancer|Lung Cancer|Melanoma|Pancreatic Cancer|Prostate Cancer|Rectal Cancer|Sarcoma|Testicular Cancer","Radiation: Stereotactic Radiosurgery","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","51","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-061","December 26, 2007","June 2004","January 2009","January 22, 2016","January 2016","December 14, 2015","null","January 2009","Local Control","https://ClinicalTrials.gov/show/NCT00587964"
3514,"NCT00003835","Combination Chemotherapy in Treating Patients With Stage III Colon Cancer","Completed","No Results Available","Adenocarcinoma of the Colon|Stage III Colon Cancer","Drug: leucovorin calcium|Drug: fluorouracil|Drug: irinotecan hydrochloride|Other: laboratory biomarker analysis","National Cancer Institute (NCI)|Southwest Oncology Group|North Central Cancer Treatment Group|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group","Both","18 Years and older   (Adult, Senior)","Phase 3","1260","NIH|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01844|SWOG-C89803|NCCTG-C89803|CDR0000066992|CAN-NCIC-CO15|E-89803|CALGB 89803|C89803|U10CA031946","November 1, 1999","May 1999","null","October 7, 2013","October 2013","No Study Results Posted","null","August 2007","Time to recurrence|Survival","https://ClinicalTrials.gov/show/NCT00003835"
3515,"NCT02387307","A Study of rSIFN-co in Subjects With Advanced Solid Tumors","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell|Melanoma|Carcinoma, Hepatocellular|Colon Cancer","Drug: rSIFN-co","Sichuan Huiyang Life Science and Technology Corporation","Both","21 Years and older   (Adult, Senior)","Phase 1","42","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","rSIFN-01","February 6, 2015","May 2013","December 2017","December 10, 2015","December 2015","No Study Results Posted","rSIFN-01","December 2016","To determine the safety and tolerability of rSIFN-co|To determine the RD of rSIFN-co for solid tumors|To evaluate extended safety and antitumor efficacy (Disease Control Rate) of rSIFN-co at the RD|To determine the objective response rate (ORR), progression-free survival (PFS), and time to progression (TTP) on rSIFN-co|To determine the FDG-PET response before and after administration of rSIFN-co","https://ClinicalTrials.gov/show/NCT02387307"
3516,"NCT02873741","New Strategies to Assess Anal Cancer Risk In Women","Recruiting","No Results Available","Human Immunodeficiency Virus (HIV)|Human Papillomavirus (HPV)","Procedure: Perianal and Digital Anorectal Exam|Procedure: Cervical Swabs|Procedure: Anal Swabs|Procedure: High Resolution Anoscopy (HRA)","Emory University","Female","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","IRB00083800","August 17, 2016","July 2016","October 2019","August 18, 2016","August 2016","No Study Results Posted","ANCAR-WIHS","October 2019","Anal Cancer Risk Index Score|Presence of Anal hr-HPV","https://ClinicalTrials.gov/show/NCT02873741"
3517,"NCT00079274","Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer","Completed","Has Results","Adenocarcinoma of the Colon|Stage III Colon Cancer","Drug: irinotecan hydrochloride|Drug: oxaliplatin|Drug: leucovorin calcium|Drug: fluorouracil|Biological: cetuximab|Drug: Locally Directed Therapy","National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 3","3397","NIH|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00639|N0147|U10CA025224|CDR0000355132","March 8, 2004","February 2004","November 2012","January 23, 2015","October 2014","December 5, 2013","null","November 2012","Disease-free Survival (Arms A and D: Wild-type KRAS Patients)|Disease-free Survival (Arms A and D: Mutant KRAS Patients)|Disease-free Survival|Overall Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00079274"
3518,"NCT01772407","Laparoscopic Surgery Equivalent to Open Surgery in Right Colon Cancer Surgery?","Recruiting","No Results Available","Colon Cancer","","Assistance Publique - Hôpitaux de Paris","Both","18 Years to 80 Years   (Adult, Senior)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STIC ICO711","January 17, 2013","September 2009","September 2016","May 20, 2016","May 2016","No Study Results Posted","CHIRCOL","August 2016","Cost during the 2 postoperative years|Mortality, morbidity and quality of life during the 2 postoperative years","https://ClinicalTrials.gov/show/NCT01772407"
3519,"NCT01092481","Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy","Recruiting","No Results Available","Colon Cancer","Drug: oxaliplatin","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 3","2660","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-11-008","November 22, 2009","January 2010","December 2016","June 12, 2013","June 2013","No Study Results Posted","null","December 2014","disease-free survival|overall survival|quality of life|safety profiles","https://ClinicalTrials.gov/show/NCT01092481"
3520,"NCT00503932","Proton Therapy With Capecitabine for Rectal Cancer","Withdrawn","No Results Available","Rectal Cancer","Procedure: Proton Therapy|Drug: Capecitabine","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0657","July 17, 2007","July 2007","April 2008","March 21, 2012","March 2012","No Study Results Posted","null","April 2008","Maximum Tolerated Dose (MTD)","https://ClinicalTrials.gov/show/NCT00503932"
3521,"NCT00813540","The Effects of Exercise Training on the Health-related Fitness of Colon Cancer Survivors","Completed","No Results Available","Colonic Neoplasms","Behavioral: Exercise Training|Other: Usual Care","AHS Cancer Control Alberta","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","52","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","G1-23950","December 19, 2008","March 2009","May 2012","March 10, 2016","April 2012","No Study Results Posted","null","May 2012","Safety (Monitoring for Adverse Events)|Change in Aerobic Capacity|Change in body composition|Feasibility (Adherence to the exercise training program)","https://ClinicalTrials.gov/show/NCT00813540"
3522,"NCT02882269","Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer","Not yet recruiting","No Results Available","Colon Cancer","Drug: Postoperative chemotherapy|Drug: Neoadjuvant chemotherapy","The First Affiliated Hospital with Nanjing Medical University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRSYM201608","August 24, 2016","December 2016","December 2021","August 28, 2016","August 2016","No Study Results Posted","null","December 2021","disease-free survival|overall survival|recurrence-free survival|local recurrence rate|length of postoperative hospital stay|early complication rate|operative time|number of lymph nodes retrieved","https://ClinicalTrials.gov/show/NCT02882269"
3523,"NCT00006094","Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum","Completed","No Results Available","Adenocarcinoma of the Rectum|Stage II Rectal Cancer|Stage III Rectal Cancer","Drug: oxaliplatin|Drug: fluorouracil|Radiation: external beam radiation therapy","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02357|CALGB-89901|U10CA031946|CDR0000068099","August 3, 2000","July 2000","null","January 15, 2013","January 2013","No Study Results Posted","null","October 2006","The maximum tolerated dose of oxaliplatin when delivered concurrently with 5-FU and external beam radiation in patients with locally advanced rectal adenocarcinomas|Progression-free survival|Pathological complete response rate|Latent toxicities graded using the Common Toxicity Criteria (CTC) version 2.0","https://ClinicalTrials.gov/show/NCT00006094"
3524,"NCT02178644","Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: Chemo with concomitant Capecitabine and KD018","Yale University","Both","18 Years and older   (Adult, Senior)","","24","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1404013708","June 26, 2014","July 2014","January 2018","June 24, 2016","June 2016","No Study Results Posted","null","July 2017","Grade 3-4 Toxicity Rate|pCR Rate","https://ClinicalTrials.gov/show/NCT02178644"
3525,"NCT01129700","Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer","Completed","No Results Available","Rectal Cancer","Radiation: Radiation: short-course preoperative chemoradiotherapy","National Cancer Center, Korea","Both","18 Years and older   (Adult, Senior)","Phase 2","73","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-10-458","May 13, 2010","February 2010","February 2012","April 25, 2012","April 2012","No Study Results Posted","null","February 2012","To evaluate the pathologic response|Tumor regression grade & MR volumetry|Acute/ late toxicities","https://ClinicalTrials.gov/show/NCT01129700"
3526,"NCT02765620","PERCIST Criteria for Response Evaluation With Solid Tumors","Recruiting","No Results Available","Lung Neoplasms|Breast Neoplasms|Colonic Neoplasms|Lymphoma","Other: drug&radiation","Tianjin Medical University Cancer Institute and Hospital|Shengjing Hospital|First Affiliated Hospital of Jinan University|Harbin Medical University|Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Both","30 Years to 80 Years   (Adult, Senior)","","150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ED12345","April 11, 2016","April 2016","April 2018","May 4, 2016","March 2016","No Study Results Posted","null","January 2018","Evaluate treatment response by PERCIST to RECIST 1.1 criteria in early stage of treatment|Evaluate treatment response by PERCIST to RECIST 1.1 criteria after the whole treatment process|PFS","https://ClinicalTrials.gov/show/NCT02765620"
3527,"NCT00030498","Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction","Completed","No Results Available","Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Primary Hepatocellular Carcinoma|Adult Subependymoma|Advanced Adult Primary Liver Cancer|Advanced Malignant Mesothelioma|Male Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Brain Tumor|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Malignant Mesothelioma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage II Esophageal Cancer|Stage II Pancreatic Cancer|Stage III Esophageal Cancer|Stage III Pancreatic Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Metastatic Squamous Neck Cancer With Occult Primary","Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","75","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01868|CALGB-60101|U10CA031946|CDR0000069170","February 14, 2002","December 2001","null","January 15, 2013","January 2013","No Study Results Posted","null","July 2007","Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities","https://ClinicalTrials.gov/show/NCT00030498"
3528,"NCT01995591","Indocyanine Green (ICG) in the ex Vivo Detection of Sentinel Lymph Node (SLN)in Colon Cancer","Completed","No Results Available","Colon Cancer|Colon Surgery","","Jules Bordet Institute","Both","18 Years and older   (Adult, Senior)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2068","November 20, 2013","January 2013","February 2015","January 11, 2016","June 2015","No Study Results Posted","2068","February 2013","number of sentinel lymph nodes identified in pieces of colectomy from patients with colon cancer with Indocyanine Green","https://ClinicalTrials.gov/show/NCT01995591"
3529,"NCT02510118","Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients","Recruiting","No Results Available","Colon Cancer","Drug: mFOLFOX6|Drug: XELOX|Drug: Placebo ChangTai Keli|Drug: ChangTai Keli","Nanjing NingQi Medicine Science and Technology Co., Ltd.|Jiangsu Province Hospital of Traditional Chinese Medicine","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","360","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BL2014099-Y0103|Y0103","July 12, 2015","June 2015","June 2018","July 30, 2015","July 2015","No Study Results Posted","null","June 2016","Number of Participants With Adverse Event (AE)|Quality of life|symptom|Investigator-assessed Progression-Free Survival (PFS)|Progression-free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02510118"
3530,"NCT00689702","Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Drug: cetuximab, capecitabine","Institute of Oncology Ljubljana","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","43","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62202-688","May 30, 2008","February 2007","May 2013","March 23, 2012","March 2012","No Study Results Posted","XERT","April 2009","Complete pathological remission rate|Rate of sphincter sparing surgical procedure Toxicity/safety","https://ClinicalTrials.gov/show/NCT00689702"
3531,"NCT01745874","Diagnostic Value of Whole-Body MRI for Rectal Cancer Preoperative Staging","Recruiting","No Results Available","Rectal Cancer","","University of Lausanne Hospitals","Both","18 Years to 95 Years   (Adult, Senior)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","247/12","December 2, 2012","October 2012","October 2013","December 7, 2012","December 2012","No Study Results Posted","null","October 2013","Evaluate the diagnostic accuracy of whole-body MRI for the staging of rectal cancer before and after neoadjuvant treatment|Tumoral regression after neoadjuvant treatment","https://ClinicalTrials.gov/show/NCT01745874"
3532,"NCT01843218","Erectile Rating During the Treatment of Rectal Cancers Localized","Terminated","No Results Available","Rectal Cancer Stage I","Other: Evaluation of erectile dysfunction","Institut Bergonié","Male","18 Years and older   (Adult, Senior)","","12","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","IB2008-07","November 6, 2012","March 2008","December 2015","March 3, 2016","March 2016","No Study Results Posted","METEORR","December 2014","assess erectile dysfunction|Evaluate objectively the presence of erectile dysfunction before and 12 months after the medico-surgical treatment of rectal cancer","https://ClinicalTrials.gov/show/NCT01843218"
3533,"NCT01876901","Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)","Recruiting","No Results Available","Medium and Lower Rectal Cancer","Procedure: Delayed coloanal anastomosis (ACAD)|Procedure: ACAI Group (coloanal anastomosis Immediate)","Institut Bergonié","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","116","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IB2010-08","November 5, 2012","May 2010","May 2017","May 25, 2016","May 2016","No Study Results Posted","CASCADOR","May 2017","Main objective is to evaluate effectiveness of delayed coloanal anastomosis (ACAD) in the medium and lower rectal cancer treatment,|The number of stomata bypass (preventive or therapeutic) will be evaluated.|Morbidity will be assessed|Postoperative mortality will be assessed during the first 30 days of the date of surgery.|Progression-free survival will be assessed at 1 and 2 years|A functional evaluation will be conducted in the month before the surgery as well as 6 months, 1 year and 2 years after surgery","https://ClinicalTrials.gov/show/NCT01876901"
3534,"NCT02723253","Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer","Completed","No Results Available","Rectal Neoplasms","Radiation: Radiotherapy|Drug: Tom-OX","Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi","Both","18 Years and older   (Adult, Senior)","Phase 2","18","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TOMOX Rectal Study","March 19, 2016","January 2005","February 2012","March 29, 2016","March 2016","No Study Results Posted","null","January 2008","Number of patients defined as good responders (G1 or G2) according to the Mandard regression grading system.|Number of patients in which a surgical resection was feasible|Number of participants with treatment-related adverse events as assessed by CTCAE v3.0|The number of patients without disease (i.e. rectal cancer) during the follow-up.|The number of patients still alive at the end of follow-up","https://ClinicalTrials.gov/show/NCT02723253"
3535,"NCT02586610","Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer","Not yet recruiting","No Results Available","Rectal Cancer|Rectal Neoplasm","Drug: Pembrolizumab|Drug: Capecitabine|Radiation: Radiation Therapy","Osama Rahma, MD|Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","53","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCRN GI15-213","October 22, 2015","September 2016","December 2020","August 22, 2016","August 2016","No Study Results Posted","null","June 2018","Pathological Complete Response (pCR) Rate|Density of CD8(+) Tumor-Infiltrating Lymphocytes (TIL)|Response Rate (RR)|Disease Free Survival (DFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02586610"
3536,"NCT02529007","Endo-cuff Assisted Vs. Standard Colonoscopy for Polyp Detection in Bowel Cancer Screening","Completed","No Results Available","Colonic Polyps|Colonic Neoplasms","Device: Endo-cuff|Other: Standard colonoscopy","Portsmouth Hospitals NHS Trust","Both","60 Years to 75 Years   (Adult, Senior)","","534","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","PHT/2013/71","July 17, 2015","September 2014","September 2015","May 27, 2016","July 2015","No Study Results Posted","E-CAP","September 2015","Number of polyps detected per patient|Cancer detection rate|Polyp detection rate|Adenomas per patient|Adenoma detection rate|Caecal intubation rate|Total procedure time - from scope insertion to removal|Time taken to reach caecum|Time taken to withdraw scope (from caecum to removal of scope)|Patient comfort score","https://ClinicalTrials.gov/show/NCT02529007"
3537,"NCT00351572","Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients","Completed","No Results Available","Colon Cancer","Procedure: Cell Search Assay","Alberta Health Services|AHS Cancer Control Alberta","Both","18 Years and older   (Adult, Senior)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GI-5-0055","July 11, 2006","July 2006","null","April 15, 2011","April 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00351572"
3538,"NCT01582750","Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy","Recruiting","No Results Available","Rectal Cancer","","Chinese Academy of Medical Sciences","Both","18 Years to 75 Years   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CH-RO-GI-eus","April 19, 2012","October 2010","December 2015","September 17, 2013","September 2013","No Study Results Posted","null","September 2014","Endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values","https://ClinicalTrials.gov/show/NCT01582750"
3539,"NCT00089362","Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors","Completed","No Results Available","Male Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Gastric Cancer|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Melanoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Ovarian Epithelial Cancer|Recurrent Prostate Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Basal Cell Carcinoma of the Lip|Stage III Colon Cancer|Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage III Gastric Cancer|Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Lymphoepithelioma of the Oropharynx|Stage III Melanoma|Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Gastric Cancer|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Melanoma|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Ovarian Epithelial Cancer|Stage IV Prostate Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Metastatic Squamous Neck Cancer With Occult Primary","Drug: alvespimycin hydrochloride|Other: laboratory biomarker analysis|Other: pharmacological study","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","30","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01455|04-053|MSKCC-04053|NCI-6542|CDR0000378288|U01CA069856","August 4, 2004","July 2004","null","April 9, 2013","April 2013","No Study Results Posted","null","January 2008","MTD, defined as the dose level where the observed DLT incidence in no more than one out of six patients treated at a particular dose level","https://ClinicalTrials.gov/show/NCT00089362"
3540,"NCT00003652","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer","Active, not recruiting","No Results Available","Anal Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: neoadjuvant therapy|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","Both","up to 80 Years   (Child, Adult, Senior)","Phase 3","350","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066744|FNCLCC-FFCD-SFRO-ACCORD-3|EU-98050","November 1, 1999","January 1999","null","February 6, 2009","May 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003652"
3541,"NCT02379039","Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer","Recruiting","No Results Available","Squamous Carcinoma|Head and Neck Cancer|Anal Cancer|Lung Cancer|Esophageal Cancer|Cervix Cancer","","Umeå University|Lund University","Both","18 Years and older   (Adult, Senior)","","412","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MORRIS_1","February 26, 2015","May 2015","May 2020","May 13, 2016","May 2016","No Study Results Posted","MORRIS","May 2018","Loco regional control|Loco regional tumour control (response)|Patterns of failure|Overall survival|Changes in imaging and metabolic data|Site specific toxicity","https://ClinicalTrials.gov/show/NCT02379039"
3542,"NCT00003486","Antineoplaston Therapy in Treating Patients With Colon Cancer","Withdrawn","No Results Available","Stage IV Colon Cancer|Recurrent Colon Cancer|Adenocarcinoma of the Colon","Drug: antineoplaston A10|Drug: antineoplaston AS2-1|Procedure: alternative product therapy|Procedure: biological therapy|Procedure: biologically based therapies|Procedure: cancer prevention intervention|Procedure: complementary and alternative therapy|Procedure: differentiation therapy","Burzynski Research Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Primary Purpose: Treatment","BC-CO-3|CDR0000066524","November 1, 1999","null","null","July 9, 2013","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003486"
3543,"NCT01481545","Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Radiation: Radiation therapy|Drug: Oxaliplatin|Drug: Raltitrexed|Drug: levofolinic acid|Drug: 5-fluorouracil|Drug: Bevacizumab","National Cancer Institute, Naples","Both","18 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRANCH|2008-003989-26","November 11, 2011","December 2006","March 2017","November 27, 2015","November 2015","No Study Results Posted","BRANCH","March 2016","complete tumor regression rate (TRG1)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|sphincter saving procedure rate|disease free survival|overall survival|clinical response rate|number of patients with metastaticlymph nodes at pathology exam after surgery","https://ClinicalTrials.gov/show/NCT01481545"
3544,"NCT02785263","Shared Decision Making With Anal Cancer Patients on Radiation Dose","Recruiting","No Results Available","Anal Cancer","Radiation: 2.15 gray and 1.8 gray. Max. 6 weeks.|Radiation: 2.15 gray and 1.8 gray. Max. 5 weeks.","Vejle Hospital","Both","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PC-Anal-01","May 9, 2016","April 2016","September 2023","May 27, 2016","May 2016","No Study Results Posted","PC-Anal-01","March 2019","The fraction of enrolled patients wanting to take part in the decision making on radiation dose level|The fraction of enrolled patients choosing the lower radiation dose|Number of patients with a V45Gy of less than 300 cc for the small bowel calculated on the basis of dose plans|Number of patients with a V35Gy of less than 75% for the bladder calculated on the basis of dose plans|Number of patients with treatment related adverse events as assessed by healthcare staff based on the common toxicity criteria (CTCAE v.4.0)|Quality of life as assessed by combined questionnaires EORTC QLQ CR30 and CR29|Subjective symptoms as assessed by LARS score (low anterior resection syndrome)|Rate of complete response|Number of patients with loco-regional recurrence 60 months after end of treatment|Number of patients with distant metastases at 5 years|Colostomy free survival|Disease free survival|Overall survival|Number of patients with HPV at time of enrollment|Response evaluation assessed by diffusion weighted imaging","https://ClinicalTrials.gov/show/NCT02785263"
3545,"NCT00052897","SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia","Completed","No Results Available","Anal Cancer","Biological: HspE7","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","18","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","NCI-2012-02507|AMC-035|CDR0000258786","January 24, 2003","December 2002","null","February 8, 2013","April 2004","No Study Results Posted","null","July 2005","","https://ClinicalTrials.gov/show/NCT00052897"
3546,"NCT01995084","In Vivo Assessment of Hypoxia in Gastro-intestinal Cancer Using 18F-HX4-PET: an Optimization and Reproducibility Study","Completed","No Results Available","Pancreatic Cancer|Esophageal Cancer|Rectal Cancer","Drug: [F-18]HX4","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Both","18 Years and older   (Adult, Senior)","","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","NL40274.018.12","November 21, 2013","May 2012","June 2014","January 13, 2015","January 2015","No Study Results Posted","HYPE","June 2014","Reproducibility of SUV measured with 18F-HX4 PET|Optimal time frame between administration of 18F-HX4 and PET scan","https://ClinicalTrials.gov/show/NCT01995084"
3547,"NCT01952951","Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer","Active, not recruiting","No Results Available","Rectal Neoplasms|Adenocarcinoma","Drug: Capecitabine Oxaliplatin|Radiation: pelvic radiation capecitabine 5-fluorouracil","National Cancer Center, Korea|Korean Cancer Study Group","Both","20 Years and older   (Adult, Senior)","Phase 2","110","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KCSG CO14-03","September 11, 2013","June 2014","December 2019","April 20, 2016","April 2016","No Study Results Posted","PREPARE","December 2016","downstaging rate|pathologic response|radiologic response rate|toxicity profile|pattern of failure|local control rate|relapse-free survival|Disease-free survival|overall survival|quality of life","https://ClinicalTrials.gov/show/NCT01952951"
3548,"NCT01296984","Oncological and Functional Result of AbdominoPerineal Extra Levator Resection for Distal Rectal Cancer","Completed","No Results Available","Rectal Cancer","","Sahlgrenska University Hospital, Sweden|Swedish Cancer Foundation","Both","18 Years and older   (Adult, Senior)","","1319","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","SSORG APER","February 15, 2011","February 2011","June 2014","November 17, 2014","November 2014","No Study Results Posted","APER","March 2014","3-year local recurrence|Postoperative complications|Reoperation, readmittance and mortality|Late morbidity|Quality of Life|Health economy|Stoma function","https://ClinicalTrials.gov/show/NCT01296984"
3549,"NCT01273051","Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer","Recruiting","No Results Available","Rectal Tumour","Drug: Capecitabine|Radiation: radiotherapy|Procedure: TME resection|Procedure: TEM surgery","Radboud University","Both","18 Years and older   (Adult, Senior)","Phase 2","55","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CMO 2010_121","November 22, 2010","November 2010","null","April 10, 2012","April 2012","No Study Results Posted","CARTS","July 2013","Response|Quality of life|Local Recurrence|Toxicity|Number of positive lymph nodes in patient who have been treated with classical surgery|The number of sphincter saving procedures","https://ClinicalTrials.gov/show/NCT01273051"
3550,"NCT01245816","A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)","Withdrawn","No Results Available","Familial Adenomatous Polyposis","Drug: Eflornithine plus Sulindac|Drug: Eflornithine plus Placebo|Drug: Sulindac plus Placebo","Cancer Prevention Pharmaceuticals, Inc.","Both","18 Years to 65 Years   (Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CPP FAP-301","November 19, 2010","March 2011","June 2013","April 23, 2015","April 2015","No Study Results Posted","null","May 2013","Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment.|Change in number of polyps 2 mm or greater in the distal 10 cm of rectum or pouch.|Qualitative change in overall colon/rectum/pouch polyp burden (number and size).|Presence of high grade dysplasia or villous adenoma in any polyp resected.","https://ClinicalTrials.gov/show/NCT01245816"
3551,"NCT02537340","PET/CT for Staging Rectal Cancer Patients With and Without EMVI-MR","Active, not recruiting","No Results Available","Rectal Neoplasms","","Instituto do Cancer do Estado de São Paulo|GE Healthcare","Both","18 Years and older   (Adult, Senior)","","106","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NP796/15","August 30, 2015","August 2015","September 2018","August 30, 2015","August 2015","No Study Results Posted","null","September 2016","Detection rate|Clinical Impact|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02537340"
3552,"NCT01158274","RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors","Completed","No Results Available","Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|HER2-negative Breast Cancer|HIV-associated Hodgkin Lymphoma|Intraocular Lymphoma|Male Breast Cancer|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Rectal Cancer|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Colon Cancer|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Rectal Cancer|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Rectal Cancer|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia","Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Drug: capecitabine|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","30","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02918|CDR0000680610|CO09907|8515|U01CA062491|U01CA132123|P30CA014520","July 7, 2010","June 2010","null","November 6, 2014","June 2014","No Study Results Posted","null","August 2012","MTD of RO4929097 and capecitabine, defined as that dose level at which less than one-third of patients experience a dose-limiting toxicity (DLT) graded according to NCI CTCAE version 4.0 (Part 1)|Incidence of adverse events graded according to NCI CTCAE version 4.0 (Part 1)|Incidence of adverse events graded according to NCI CTCAE version 4.0 (Parts 2a and 2b)|Confirmed anti-tumor response rate validated by the RECIST (Part 1)|Changes in the expression of Notch1 signaling pathway members (Part 1)|Pharmacokinetics of the combination of RO4929097 and capecitabine, including Cmax, Tmax, AUC, t1/2, and CL (Part 1)|PFS (Parts 2a and 2b)|OS (Part 2a and 2b)|Overall response rate (Parts 2a and 2b)","https://ClinicalTrials.gov/show/NCT01158274"
3553,"NCT00379743","Partnership for Healthy Seniors","Active, not recruiting","No Results Available","Breast Cancer|Colon Cancer|Rectum Cancer|Cervix Cancer|Prostate Cancer","Behavioral: Health coordinator (or patient navigator)|Behavioral: Educational materials only","Johns Hopkins Bloomberg School of Public Health|Centers for Medicare and Medicaid Services","Both","65 Years and older   (Adult, Senior)","Phase 3","2874","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","IRB00000063","September 20, 2006","October 2006","December 2012","June 18, 2012","June 2012","No Study Results Posted","null","December 2010","Difference between the two intervention groups in the proportion of participants who complete at least one of the recommended screenings.|Adherence to maintenance screening.|Timely notification of abnormal screening results.|Timely follow up with specialist following abnormal screening result.|Timely diagnosis following abnormal result.|Timely treatment start-up.|Improved utilization of Medicare-covered preventive services.|Stage at diagnosis.","https://ClinicalTrials.gov/show/NCT00379743"
3554,"NCT02900248","MED-C Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice","Not yet recruiting","No Results Available","Neoplasms|Lung Neoplasms|Colon Neoplasms|Breast Neoplasms|Pancreatic Neoplasms|Prostate Neoplasms|Kidney Neoplasms|Liver Neoplasms|Rectal Neoplasms|Hematologic Neoplasms|Multiple Myeloma|Myelodysplastic Syndromes|Ovarian Neoplasms|Bladder Neoplasms|Testicular Neoplasms|Endometrial Neoplasms|Brain Neoplasms|Biliary Tract Neoplasms|Head and Neck Neoplasms|Uterine Cervical Neoplasms|Skin Neoplasms|Melanoma|Gastric Neoplasms|Anal Neoplasms|Sarcoma","Other: Provider determined","Molecular Evidence Development Consortium Inc.","Both","18 Years and older   (Adult, Senior)","","150000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MED-C N1OR","June 18, 2015","October 2016","October 2024","September 8, 2016","September 2016","No Study Results Posted","N1","October 2021","Overall Survival|Time to Treatment Failure|Time to Treatment Progression|Best Overall Response|NGS Biomarker Detection compared to Companion Diagnostic","https://ClinicalTrials.gov/show/NCT02900248"
3555,"NCT02236884","The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer|Surgery","Procedure: no-scar transanal total mesorectal excision(TME)","Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GIHSYSU08|D2014002","September 4, 2014","September 2014","September 2017","September 9, 2014","September 2014","No Study Results Posted","null","September 2015","Composite mesure of prioperative feasibility and safety|composite measure of life quality|Composite mesure of postoperative outcome|Composite mesure of oncological outcome","https://ClinicalTrials.gov/show/NCT02236884"
3556,"NCT00963794","Diagnosis of Rectal Cancer by Electromagnetic Device","Completed","No Results Available","Rectal Cancer","Other: Electromagnetic measurement","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Both","18 Years to 95 Years   (Adult, Senior)","","442","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","INT-D176767","August 20, 2009","January 2008","December 2008","August 21, 2009","August 2009","No Study Results Posted","null","December 2008","Electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.","https://ClinicalTrials.gov/show/NCT00963794"
3557,"NCT00122291","A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer|Neoplasm Metastasis","Drug: Capecitabine|Procedure: Pelvic radiation","Alberta Health Services|AHS Cancer Control Alberta","Both","17 Years and older   (Child, Adult, Senior)","Phase 2","66","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","16080|Capecitabine Phase 2","July 20, 2005","January 2002","null","January 18, 2012","August 2011","No Study Results Posted","null","null","safety|response","https://ClinicalTrials.gov/show/NCT00122291"
3558,"NCT02292914","Prospective Analysis of Robot-Assisted Surgery","Recruiting","No Results Available","Esophageal Cancer|Gastric Cancer|Pancreatic Cancer|Rectal Cancer|Bladder Cancer|Prostate Cancer|Renal Cancer|Uterus Cancer|Head and Neck Cancer|Lung Cancer","Procedure: Robot-assisted surgery|Procedure: Conventional Surgery","Instituto do Cancer do Estado de São Paulo","Both","18 Years to 75 Years   (Adult, Senior)","","1120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NP433/13","September 3, 2014","March 2014","November 2017","February 23, 2016","February 2016","No Study Results Posted","null","November 2016","Postoperative Complications|ICU and hospital length of stay","https://ClinicalTrials.gov/show/NCT02292914"
3559,"NCT01865071","Early Closure of Temporary Loop Ileostomy After Rectal Resection for Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: loop ileostomi","Odense University Hospital","Both","18 Years and older   (Adult, Senior)","","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S-20110026","October 11, 2012","September 2011","October 2015","February 4, 2014","February 2014","No Study Results Posted","null","October 2015","Mortality","https://ClinicalTrials.gov/show/NCT01865071"
3560,"NCT00994864","Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer","Recruiting","No Results Available","Colon Cancer","Drug: FOLFOX","Jules Bordet Institute","Both","18 Years and older   (Adult, Senior)","","205","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PEPITA 001|EudraCT number: 2009-011445-13","October 13, 2009","November 2009","December 2016","February 23, 2016","February 2016","No Study Results Posted","PePiTA","December 2016","Examine the predictive value of PET-assessed tumour FDG uptake response after one course of preoperative chemotherapy on the outcome of adjuvant therapy, measured by 3-year DFS.|Examine the predictive value of PET-assessed tumour FDG uptake changes after one course of preoperative chemotherapy on OS|Evaluate the best cut-off value for relative delta SUV in assessment of preoperative chemotherapy response by FDG-PET/CT imaging.|Analyze the cost-effectiveness of preoperative chemo-sensitivity testing|Assess the predictive value of circulating tumour cells on disease-free survival|Assess the predictive value of SNPs on toxicity- and drug target-related genes on DFS|Create a frozen tumour bank for future studies","https://ClinicalTrials.gov/show/NCT00994864"
3561,"NCT00969657","Validation of a Predictive Model After Complete Response in Rectal Cancer","Completed","No Results Available","Rectal Cancer","","Maastricht Radiation Oncology","Both","18 Years and older   (Adult, Senior)","","80","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","6050|09-03-023","August 31, 2009","August 2009","December 2014","January 12, 2015","January 2015","No Study Results Posted","Thunder","October 2011","Pathological complete response (ypT0N0)|Several extra outcomes are registered for research: Local relapse at 2 years, metastases free survival, survival and relapse free survival","https://ClinicalTrials.gov/show/NCT00969657"
3562,"NCT02051868","International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel","Recruiting","No Results Available","Squamous Cell Carcinoma of the Anus","Drug: Cisplatin|Drug: 5-Fluorouracil (5-FU)|Drug: Carboplatin|Drug: Paclitaxel","Royal Marsden NHS Foundation Trust|Cancer Research UK|Australasian Gastro-Intestinal Trials Group|ECOG-ACRIN Cancer Research Group|European Organisation for Research and Treatment of Cancer - EORTC|International Rare Cancers Initiative (IRCI ) This study is indorsed by IRCI","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CCR 3847 InterAACT|2013-001949-13","January 13, 2014","December 2013","February 2018","November 3, 2015","November 2015","No Study Results Posted","InterAACT","August 2017","Best overall response rate by 24 weeks post treatment|Feasibility of conducting a multicentre, international study on squamous cell carcinoma of the anus and recruiting within a reasonable time frame.|Toxicity|Progression-free survival|Overall survival|Disease control rate|Best overall response rate of non-irradiated lesions|Anti-tumour activity and magnitude of tumour response|Quality of Life|Identification of potential tumour biomarker","https://ClinicalTrials.gov/show/NCT02051868"
3563,"NCT02686567","Use of the TDT for Prevention of Anastomotic Leakage After Laparoscopic Anterior Resection for Rectal Cancer","Recruiting","No Results Available","Anastomotic Leakage|Rectal Neoplasms","Procedure: with TDT|Procedure: without TDT","Third Military Medical University","Both","18 Years to 80 Years   (Adult, Senior)","","600","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TDT20160214","February 15, 2016","February 2016","December 2019","April 26, 2016","April 2016","No Study Results Posted","null","February 2016","the rate of anastomotic leakage after laparoscopic anterior resection for rectal cancer","https://ClinicalTrials.gov/show/NCT02686567"
3564,"NCT02533271","Optimization of Preoperative Treatment in Locally Advanced Rectal Cancer","Recruiting","No Results Available","Cancer, Rectum","Radiation: Short-course radiotherapy with neoadjuvant chemotherapy|Radiation: Long-term chemoradiotherapy","Chinese Academy of Medical Sciences","Both","18 Years to 70 Years   (Adult, Senior)","Phase 3","552","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XT2015-03","August 21, 2015","August 2015","August 2025","August 22, 2015","August 2015","No Study Results Posted","STELLAR","August 2023","disease-free survival rate|overall survival rate|incidence of surgical complications|incidence of acute toxicities during radiation or chemotherapy","https://ClinicalTrials.gov/show/NCT02533271"
3565,"NCT01347697","Collagen Implant Compared to Gluteus Maximus Flap for Reconstruction of Pelvic Floor After ELAPE/EAPE in Rectal Cancer","Recruiting","No Results Available","Rectal Cancer|Defect of Floor of Lesser Pelvis","Procedure: Reconstruction with an acellular porcine collagen implant|Procedure: Reconstruction with a gluteus maximus myocutaneous flap","Umeå University|The Swedish Society of Medicine|Västerbotten County Council, Sweden","Both","18 Years and older   (Adult, Senior)","Phase 3","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NEAPE-2010-335-31M","May 3, 2011","May 2011","May 2018","June 2, 2016","May 2016","No Study Results Posted","NEAPE","November 2017","Performance in Timed-Stands Test|Change in physical performance|Primary wound healing assessed with the Southampton Wound Assessment Scale|Complications according to classification by Dindo-Clavien|Proportion of persistent perineal sinus or fistula|Ability to sit|Change of pain and discomfort in gluteal region measured with VAS|Change of quality of life measured with EQ-5D and EORTC forms C30 and CR29|Quality of life spot measures|Length of hospital stay, costs of surgical treatments and QALYs gained","https://ClinicalTrials.gov/show/NCT01347697"
3566,"NCT02665026","Effectiveness and Safety Study on Different Timing of Preventive Ileostomy Closure After Surgery for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: stoma closure at different times","Huashan Hospital","Both","18 Years to 70 Years   (Adult, Senior)","","250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KY2015-276","January 23, 2016","January 2016","December 2021","August 23, 2016","August 2016","No Study Results Posted","null","December 2021","Postoperative complication|Postoperative quality of life|survival rate|Disease-free survival","https://ClinicalTrials.gov/show/NCT02665026"
3567,"NCT02437656","Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer (METCAP).","Recruiting","No Results Available","Rectal Cancer","Drug: Metformin","Centre Oscar Lambret","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","METCAP-1404|2014-003687-20","May 5, 2015","April 2015","May 2017","July 28, 2016","July 2016","No Study Results Posted","null","December 2016","The efficacy will be assessed on the operative specimen by the complete histological response rate (absence of tumor cells : pCR).|Toxicity will be assessed according to NCI-CTCAE v4.0. Grades ≥ 3 related to metformin will be collected by the clinician.|Sphincter preservation rate and downstaging rate","https://ClinicalTrials.gov/show/NCT02437656"
3568,"NCT02270606","Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer","Enrolling by invitation","No Results Available","Mucinous Adenocarcinoma of the Rectum|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Rectum|Rectal Adenocarcinoma|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer","Radiation: intensity-modulated radiation therapy|Drug: fluorouracil|Drug: oxaliplatin|Drug: leucovorin calcium|Procedure: therapeutic conventional surgery","Virginia Commonwealth University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","20","Other|NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-14-10491|NCI-2014-02089","October 16, 2014","December 2014","February 2017","September 19, 2016","September 2016","No Study Results Posted","null","February 2017","Dose limiting toxicity for continuous infusional 5-Fluorouracil given concurrently with short course pelvic radiation","https://ClinicalTrials.gov/show/NCT02270606"
3569,"NCT02022852","Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: Capecitabine|Drug: XELOX","Harbin Medical University","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HarbinMU-BCui-001","December 9, 2013","July 2013","January 2018","December 23, 2013","December 2013","No Study Results Posted","null","July 2015","Disease free survival|Local recurrence rate|Safety: Number of Participants with Adverse Events|R0 resection rate|Pathologic complete response","https://ClinicalTrials.gov/show/NCT02022852"
3570,"NCT01294072","Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue","Recruiting","No Results Available","Colon Cancer","Dietary Supplement: curcumin|Dietary Supplement: Curcumin conjugated with plant exosomes|Other: No intervention","James Graham Brown Cancer Center|University of Louisville","Both","20 Years and older   (Adult, Senior)","Phase 1","35","Other","Interventional","Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","BCC-GI-10 Curcumin","February 3, 2011","January 2011","December 2015","May 28, 2014","May 2014","No Study Results Posted","null","January 2015","Concentration of curcumin in normal and cancerous tissue|safety and tolerability of curcumin alone as determined by adverse events|effects of curcumin on normal and cancerous colon cells by measuring the biomarkers using histochemical staining|the immune system response to curcumin, measured by serum cytokine levels|immune response in ex vivo cell cultures of colon cancer cells treated with curcumin and Exo-cur, to be evaluated by using histochemical staining|measurement of curcumin alone on metabolic characteristics of normal colon mucosa and colon tumors|safety and tolerability of curcumin with plant exosomes as determined by adverse events|measurement of curcumin mixed with plant exosomes on metabolic characteristics of normal colon mucosa and colon tumors","https://ClinicalTrials.gov/show/NCT01294072"
3571,"NCT00091182","Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment","Completed","No Results Available","Childhood Central Nervous System Germ Cell Tumor|Childhood Extragonadal Germ Cell Tumor|Childhood Hepatoblastoma|Childhood Hepatocellular Carcinoma|Childhood High-grade Cerebral Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Malignant Ovarian Germ Cell Tumor|Childhood Malignant Testicular Germ Cell Tumor|Childhood Teratoma|Recurrent Adrenocortical Carcinoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Recurrent Colon Cancer|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Nasopharyngeal Cancer|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer","Drug: oxaliplatin","National Cancer Institute (NCI)","Both","up to 21 Years   (Child, Adult)","Phase 2","180","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01815|ADVL0421|COG-ADVL0421|CDR0000384560|U10CA098543","September 7, 2004","October 2004","null","June 4, 2013","June 2013","No Study Results Posted","null","February 2006","Response rate","https://ClinicalTrials.gov/show/NCT00091182"
3572,"NCT00158886","Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer","Terminated","No Results Available","Rectal Cancer","Drug: Hycamtin","GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","104864/517","September 8, 2005","November 2001","null","May 21, 2009","May 2009","No Study Results Posted","null","null","To determine the MTD of oral topotecan in combination with pelvic radiation|To evaluate the toxicity and potential efficacy of oral topotecan and concurrent pelvic radiation for the treatment of rectal cancer. To determine pathologic response to treatment and assessment of sphincter preservation.","https://ClinicalTrials.gov/show/NCT00158886"
3573,"NCT00003799","Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer","Completed","No Results Available","Adenocarcinoma of the Rectum|Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Rectum|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer","Drug: fluorouracil|Drug: oxaliplatin|Radiation: radiation therapy|Drug: leucovorin calcium|Procedure: therapeutic conventional surgery","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","20","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03145|E1297|U10CA021115|CDR0000066943","November 1, 1999","May 1999","null","January 9, 2013","January 2013","No Study Results Posted","null","September 2003","MTD of oxaliplatin when combined with radiation therapy and fluorouracil based on the incidence of DLT as assessed by CTC version 2.0","https://ClinicalTrials.gov/show/NCT00003799"
3574,"NCT02312284","Observational Study on the Patients With Rectal Cancer","Completed","No Results Available","Rectal Cancer|Adjuvant Chemoradiotherapy|Neoadjuvant Chemoradiotherapy|Adjuvant Chemotherapy|Surgery","","Chinese Academy of Medical Sciences","Both","18 Years and older   (Adult, Senior)","","3995","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CAMS 14-122/912","December 4, 2014","January 2011","November 2014","January 14, 2016","January 2016","No Study Results Posted","null","November 2014","Overall survival|Cancer-specific survival|Locoregional recurrence free survival|Distant metastasis free survival|Chemotherapy/Radiotherapy/Chemoradiotherapy toxicities|Surgery complication","https://ClinicalTrials.gov/show/NCT02312284"
3575,"NCT02887365","A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer","Recruiting","No Results Available","MSI-L/MSS|Stage II Colon Cancer","Drug: tegafur-uracil","National Taiwan University Hospital","Both","20 Years to 80 Years   (Adult, Senior)","Phase 4","300","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","201407054MINC","August 1, 2016","September 2014","August 2017","September 5, 2016","September 2016","No Study Results Posted","null","August 2017","3-year disease-free survival Safety profile of tegafur-uracil|5-year overall survival","https://ClinicalTrials.gov/show/NCT02887365"
3576,"NCT02036112","Conventional Versus Individual Extralvator Abdominoperineal Excision for Advanced Lower Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: conventional ELAPE|Procedure: Individual ELAPE","Beijing Chao Yang Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IELAPE1127","November 26, 2013","August 2013","August 2016","January 12, 2014","January 2014","No Study Results Posted","ELAPE","August 2016","The perioperative morbidity|Three years survival postoperatively","https://ClinicalTrials.gov/show/NCT02036112"
3577,"NCT01064999","A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: Oxaliplatin|Drug: Capecitabine|Radiation: Radiotherapy|Procedure: Surgery","Fudan University|Zhejiang Cancer Hospital|First Affiliated Hospital of Zhejiang University|RenJi Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","240","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FDRT-002","February 5, 2010","March 2010","December 2014","March 12, 2012","March 2012","No Study Results Posted","null","March 2012","the rate of pathological complete response (pCR)|toxicity|local recurrence|disease-free survival|overall survival","https://ClinicalTrials.gov/show/NCT01064999"
3578,"NCT00028496","Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer","Completed","No Results Available","Adenocarcinoma of the Colon|Adenocarcinoma of the Gallbladder|Adenocarcinoma of the Pancreas|Adenocarcinoma of the Rectum|Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Gallbladder|Diffuse Adenocarcinoma of the Stomach|Intestinal Adenocarcinoma of the Stomach|Male Breast Cancer|Mixed Adenocarcinoma of the Stomach|Ovarian Endometrioid Adenocarcinoma|Paget Disease of the Breast With Intraductal Carcinoma|Paget Disease of the Breast With Invasive Ductal Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Salivary Gland Adenocarcinoma|Stage II Malignant Testicular Germ Cell Tumor|Stage II Pancreatic Cancer|Stage III Colon Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Pancreatic Cancer|Stage III Rectal Cancer|Stage III Salivary Gland Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Gastric Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Thyroid Gland Medullary Carcinoma|Unresectable Gallbladder Cancer","Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine|Biological: sargramostim|Biological: recombinant fowlpox GM-CSF vaccine adjuvant","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","48","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02433|FCCC-01016|CDR0000069093","January 4, 2002","November 2001","null","January 24, 2013","January 2013","No Study Results Posted","null","November 2005","Maximum tolerated dose of recombinant fowlpox-CEA(6D)/TRICOM vaccine determined by dose-limiting toxicities graded according to NCI Common Toxicity Criteria, version 2.0","https://ClinicalTrials.gov/show/NCT00028496"
3579,"NCT01130233","Randomized Trial on Robotic Assisted Resection for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer|Adenocarcinoma","Procedure: robotic assisted rectal resection|Procedure: laparoscopic rectal resection","The University of Hong Kong","Both","18 Years and older   (Adult, Senior)","Phase 3","98","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UW 09-132","May 24, 2010","June 2009","December 2014","May 24, 2010","May 2010","No Study Results Posted","null","June 2014","Bladder function|tumor status|Quality of life","https://ClinicalTrials.gov/show/NCT01130233"
3580,"NCT02473094","Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms|Adenocarcinoma|Carcinoma","Drug: Capecitabine|Drug: Metformin|Radiation: Radiotherapy|Drug: Placebo","University of Campinas, Brazil","Both","18 Years and older   (Adult, Senior)","Phase 2","98","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NEOMETRE201501","June 13, 2015","July 2015","May 2018","May 16, 2016","May 2016","No Study Results Posted","NEOMETRE","January 2018","Pathological Complete Response|Overall Response Rate|Sphincter Preservation Rate|Toxicity will be assessed using National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) v4.03|Local Recurrence Rate|Local Recurrence Free Survival|Disease Free Survival|Overall Survival|Quality of Life","https://ClinicalTrials.gov/show/NCT02473094"
3581,"NCT01749956","5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer","Completed","No Results Available","Rectal Cancer","Radiation: Radiation|Drug: Aflibercept|Procedure: Surgery|Drug: FOLFOX6","SCRI Development Innovations, LLC|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI GI 168","December 12, 2012","January 2013","September 2015","April 1, 2016","April 2016","No Study Results Posted","null","September 2015","Pathologic Complete Response Rate|Frequency of adverse events and serious adverse events as a measure of safety.|Overall Survival|Disease-Free Survival","https://ClinicalTrials.gov/show/NCT01749956"
3582,"NCT01927497","Biological Mesh Closure of the Pelvic Floor After Extralevator Abdomino Perineal Resection for Rectal Cancer","Completed","No Results Available","Rectal Cancer","Procedure: Biological mesh assisted perineal closure|Procedure: Primary perineal closure","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|LifeCell","Both","18 Years and older   (Adult, Senior)","Phase 3","104","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","METC 2012_360|NTR3717","August 19, 2013","March 2013","November 2015","November 23, 2015","November 2015","No Study Results Posted","BIOPEX","September 2014","The primary endpoint is the percentage of uncomplicated perineal wound healing|Perineal wound healing according to the Southampton wound grading|Incidence of persistent perineal or presacral sinuses, both clinically and by imaging|Need for re-intervention or re-admission related to pre-sacral abscess or other perineal wound problems|Length of hospital stay|Need for nursing home admission|Need for home nursing wound care: frequency per week and total period of time|Use of wound care material and devices like vacuum assisted closure|Incidence of symptomatic and asymptomatic perineal hernia|Quality of life|Costs","https://ClinicalTrials.gov/show/NCT01927497"
3583,"NCT02687009","A Study of Niclosamide in Patients With Resectable Colon Cancer","Not yet recruiting","No Results Available","Colon Cancer","Drug: Niclosamide","Michael Morse, MD|Duke University","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","18","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label","Pro00066964","February 10, 2016","July 2016","July 2022","May 12, 2016","May 2016","No Study Results Posted","null","July 2020","Dose limiting toxicity|Niclosamide blood levels","https://ClinicalTrials.gov/show/NCT02687009"
3584,"NCT00307736","Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer","Completed","No Results Available","Rectal Cancer|Adenocarcinoma of the Rectum","Drug: 5-fluorouracil|Drug: bevacizumab|Drug: erlotinib|Procedure: External beam radiation therapy (EBRT)","Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","32","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-345","March 24, 2006","May 2006","July 2011","April 25, 2012","April 2012","No Study Results Posted","null","April 2010","Determine the dose-limiting toxicity and the maximum tolerated dose of 5-FU, bevacizumab, and erlotinib when administered in combination with external beam radiation therapy|determine pathological response.|Determine toxicity profile|determine survival, local control, progression free survival and duration of response|determine the surgical morbidity after resection of rectal cancers following preoperative 5-FU, bevacizumab, erlotinib, and external beam radiation therapy.","https://ClinicalTrials.gov/show/NCT00307736"
3585,"NCT01861691","Randomized Controlled Trial Between Laparoscopic and Open Surgery in Transverse and Descending Colon Cancer Patients","Active, not recruiting","No Results Available","Malignant Neoplasm of Transverse Colon|Malignant Neoplasm of Descending Colon","Procedure: Open surgery|Procedure: Laparoscopic surgery","Shoichi Fujii, MD, PhD|Yokohama City University Medical Center","Both","20 Years and older   (Adult, Senior)","Phase 2","66","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","YCUMC-D1108014|YokohamaCUMC33","May 21, 2013","August 2008","October 2017","November 24, 2013","November 2013","No Study Results Posted","null","October 2012","Early complication rate|Recurrence-free survival|Overall survival|Length of postoperative hospital stay|Health-related QOL score","https://ClinicalTrials.gov/show/NCT01861691"
3586,"NCT02887313","FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Single Arm Phase II Study","Recruiting","No Results Available","Rectal Cancer","Drug: mFOLFOX6 with radiation","Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GIHSYSU11","August 27, 2016","July 2016","November 2019","August 29, 2016","August 2016","No Study Results Posted","FOTAC","July 2018","pathologic complete response (pCR) rate|The ratio of tumor downstaging to stage 0 and stage I|Recurrence free survival","https://ClinicalTrials.gov/show/NCT02887313"
3587,"NCT02777437","Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer","Not yet recruiting","No Results Available","Colonic Neoplasms","Drug: XELOX or FOLFOX chemotherapy","Fudan University|Shanghai Jiao Tong University School of Medicine|Zhejiang University|Tongji University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","1960","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FuDanLapT4","May 2, 2016","October 2016","October 2021","May 17, 2016","May 2016","No Study Results Posted","null","October 2019","Disease free survival|Overall survival|Adverse events (mortality and morbidity)|The proportion of completion of laparoscopic surgery","https://ClinicalTrials.gov/show/NCT02777437"
3588,"NCT02466906","RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer","Recruiting","No Results Available","Colon Cancer","Drug: rhGM-CSF|Drug: placebo","The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","L-15-01","June 5, 2015","June 2015","July 2020","January 18, 2016","December 2015","No Study Results Posted","null","June 2020","Disease-free survival（DFS）|Immune anti-tumor effect: DC cells, CD4+ cells, CD8+ cells, Treg cells|Overall survival (OS)|Incidence of liver metastasis|Adverse effects (AE)","https://ClinicalTrials.gov/show/NCT02466906"
3589,"NCT02008656","Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management","Recruiting","No Results Available","Rectal Cancer","Drug: Oxaliplatin (OXAL)|Drug: 5-Fluorouracil (5-FU)|Drug: Leucovorin|Drug: Capecitabine (Xeloda®)|Radiation: intensity modulated radiotherapy (IMRT)|Behavioral: Quality of Life Questionnaires|Procedure: DRE-Endoscopy","Memorial Sloan Kettering Cancer Center|Colon and Rectal Surgery Inc.|The Cleveland Clinic|John Muir Health|Oregon Health and Science University|St. Joseph Hospital of Orange|University of Calgary|University of California, Irvine|University of California, San Francisco|University of Chicago|University of South Florida|University of Vermont|University of Washington|Washington Hospital Center|Washington University School of Medicine|Bergan Mercy Medical Centere|The Methodist Hospital System|University of Rochester|University of Virginia|St. Paul's Hospital|St. Joseph, Florida|Cleveland Clinic Florida|University of Colorado, Aurora|University of Michigan","Both","18 Years and older   (Adult, Senior)","Phase 2","222","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13-213","November 27, 2013","November 2013","null","June 28, 2016","June 2016","No Study Results Posted","null","November 2017","disease-free survival (DFS)|major adverse events","https://ClinicalTrials.gov/show/NCT02008656"
3590,"NCT01340508","Preoperative Concurrent Chemotherapy and Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Rectal Cancer","Recruiting","No Results Available","Rectal Cancers.","Radiation: Intensity Modulated Radiotherapy","National University Hospital, Singapore|Tan Tock Seng Hospital","Both","21 Years to 90 Years   (Adult, Senior)","Phase 2","63","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","B/09/377","April 18, 2011","January 2011","January 2013","April 20, 2011","April 2011","No Study Results Posted","null","January 2013","Pathological complete response rates|Toxicity|Disease Free survival|Downstaging rates|Sphincter Preservation rates","https://ClinicalTrials.gov/show/NCT01340508"
3591,"NCT00819559","Preoperative Chemoradiotheray for Rectal Cancer","Not yet recruiting","No Results Available","Rectal Neoplasm","Radiation: PCRT","Korean Rectal Cancer Study Group","Both","18 Years to 70 Years   (Adult, Senior)","","1160","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KRCSG1","January 7, 2009","March 2009","December 2016","January 8, 2009","January 2009","No Study Results Posted","null","February 2011","Disease-free survival|Overall survival Local recurrence Early or late complication associated with preoperative radiotherapy Quality of life Accuracy of clinical staging Difference of surgical outcome between laparoscopic and open surgery","https://ClinicalTrials.gov/show/NCT00819559"
3592,"NCT00422864","A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: oxaliplatin|Drug: fluorouracil|Drug: leucovorin|Procedure: External beam radiotherapy","Peter MacCallum Cancer Centre, Australia","Both","18 Years and older   (Adult, Senior)","Phase 2","26","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06/35","January 15, 2007","October 2006","January 2011","December 14, 2011","September 2011","No Study Results Posted","null","June 2009","Tolerability rate|Toxicity rates|Pelvic response rate|Distant response rate","https://ClinicalTrials.gov/show/NCT00422864"
3593,"NCT01460641","Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","","Stanford University","Both","18 Years and older   (Adult, Senior)","","21","Other","Observational","Time Perspective: Prospective","REC0006|SU-10202011-8538|19224","October 21, 2011","November 2011","July 2018","July 6, 2016","July 2016","No Study Results Posted","null","July 2016","Tumor stage change from Computed Tomography (CT) perfusion measurement|Tumor perfusion as measured by perfusion CT.","https://ClinicalTrials.gov/show/NCT01460641"
3594,"NCT01325961","Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers","Active, not recruiting","No Results Available","Prostate Cancer|Cervical Cancer|Anal Canal Cancers","Radiation: Intensity-Modulated Radiation Therapy","Institut Cancerologie de l'Ouest","Both","18 Years and older   (Adult, Senior)","","220","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","BRD 10/12-O","March 28, 2011","March 2011","February 2020","September 2, 2016","August 2016","No Study Results Posted","RCMI PELVIS","May 2015","Medico-economic study : medical cost differential between 3 ways of Radiotherapy by IMRT (helical tomotherapy and dynamic arc therapy : RapidArc and VMAT).|Others economic criteria|clinical response and safety of the treatment by radiotherapy","https://ClinicalTrials.gov/show/NCT01325961"
3595,"NCT00297791","COLOR II: Laparoscopic Versus Open Rectal Cancer Removal","Active, not recruiting","No Results Available","Rectal Cancer","Procedure: surgery","Jaap Bonjer|Nova Scotia Health Authority","Both","18 Years and older   (Adult, Senior)","Phase 3","1100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDHA007","February 27, 2006","June 2004","October 2017","July 29, 2013","July 2013","No Study Results Posted","COLORII","April 2013","locoregional recurrence rate|survival free of cancer recurrence|overall survival|port-site and wound-site recurrences|distant metastases rate|operative mortality and morbidity|macroscopic evaluation of the resected specimen|duration of in-hospital stay|duration of absence of work|postoperative health related quality of life,including standardized questionnaires on sexual and bladder function|in-hospital direct and indirect costs|out-of-hospital postoperative costs","https://ClinicalTrials.gov/show/NCT00297791"
3596,"NCT00969046","Dose-Escalation Study in Advanced Colon Cancer Patients","Completed","No Results Available","Colon Cancer","Drug: EPO906 (patupilone)","Novartis Pharmaceuticals|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CEPO906A2117","August 10, 2009","November 2003","November 2006","April 20, 2016","April 2016","No Study Results Posted","null","November 2006","To identifymaximum tolerated dose (MTD)|To characterize the safety and tolerability of patupilone by assessing adverse events (AEs) and serious adverse events (SAEs), hematology and biochemistry labs, vital signs, performance status, and by physical/neurological exams|To evaluate preliminary anti-tumor activity of patupilone using standard imaging technologies (e.g. best overall response rate and time to progression according to Response Evaluation Criteria in Solid Tumors [RECIST])|To evaluate the blood concentrations profile (pharmacokinetics [PK]) of patupilone by multiple blood sampling before, during and after drug administration","https://ClinicalTrials.gov/show/NCT00969046"
3597,"NCT00972881","Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Biological: cetuximab|Drug: capecitabine|Drug: irinotecan hydrochloride|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: radiation therapy","University College, London","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","80","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000648171|CRUK-UCL-EXCITE|EUDRACT-2007-006701-25|EU-20964","September 5, 2009","April 2009","December 2014","December 5, 2014","December 2014","No Study Results Posted","EXCITE","December 2011","Histologically confirmed R0 resection rate|Radiotherapy compliance|Grade 3 or 4 toxicity as assessed by NCI CTCAE v3.0|Pathological complete response|Post-operative morbidity|Long-term morbidity|Disease-free survival|Local failure-free survival","https://ClinicalTrials.gov/show/NCT00972881"
3598,"NCT01586416","Intervention to Increase Chemotherapy Tolerance in Elderly Cancer Patients","Active, not recruiting","No Results Available","Colonic Neoplasms","Behavioral: Behavioral Intervention","Massachusetts General Hospital|National Cancer Institute (NCI)","Both","60 Years and older   (Adult, Senior)","Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","1R03CA157200-01A1","April 24, 2012","December 2012","December 2015","September 21, 2015","September 2015","No Study Results Posted","null","September 2014","Participant satisfaction with intervention structure, timing and content|Number of participants who withdraw from study after enrollment|Change from baseline in the Hospital Anxiety and Depression Scale|Change from baseline in the Symptom Distress Scale|Proportion of each chemotherapy component administered during the treatment regimen relative to the total planned amount","https://ClinicalTrials.gov/show/NCT01586416"
3599,"NCT01043484","Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Drug: Bevacizumab + Capecitabine + Radiotherapy|Drug: Capecitabine + Radiotherapy","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","90","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-08-05|EudraCT: 2009-010192-24","December 30, 2009","December 2009","September 2016","August 12, 2016","June 2016","No Study Results Posted","AVAXEL","January 2013","Rate complete pathologic responses|Disease free survival at 3 and 5 years|Rate of local and distant recurrence at 3 and 5 years|Overall survival at 3 and 5 years|R0 resection rate.|Adverse events|Rate of surgery complications|Molecular predictive markers: changes in angiogenic parameters, vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptors, microvessel quantification and angiopoietin-2 (Ang-2)|Rate of sphincter preservation","https://ClinicalTrials.gov/show/NCT01043484"
3600,"NCT00140894","A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)","Terminated","No Results Available","Adenomatous Polyposis Coli","Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks|Drug: Comparator: placebo / Duration of Treatment: 24 weeks","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 4","62","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","2005_052","August 30, 2005","March 2003","null","November 30, 2006","November 2006","No Study Results Posted","null","null","Number and average size of rectal polyps|Safety and tolerability|Number and average size of duodenal polyps|Proportions of patients with improved overall colon rating","https://ClinicalTrials.gov/show/NCT00140894"
3601,"NCT02767986","Where Culture Meets Genetics: Exploring Latinas Causal Attributions of Breast and Colon Cancer and Models of Disease Inheritance","Recruiting","No Results Available","Colon Cancer|Breast Cancer","","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","Female","18 Years to 75 Years   (Adult, Senior)","","75","NIH","Observational","Time Perspective: Cross-Sectional","999916106|16-HG-N106","May 10, 2016","May 2016","December 2016","August 11, 2016","August 2016","No Study Results Posted","null","November 2016","Participant's responses to qualitative interview questions","https://ClinicalTrials.gov/show/NCT02767986"
3602,"NCT01493206","A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer","Completed","No Results Available","Malignant Rectal Neoplasm|Recurrent Tumor","Radiation: intraoperative radiotherapy","Peter MacCallum Cancer Centre, Australia","Both","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PMCC04/16","December 13, 2011","July 2004","August 2011","December 14, 2011","December 2011","No Study Results Posted","null","August 2011","clinical outcomes|toxicities","https://ClinicalTrials.gov/show/NCT01493206"
3603,"NCT01946139","Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV","Active, not recruiting","No Results Available","Anal Cancer|HIV Infection|Human Papilloma Virus Infection","Procedure: comparison of screening methods|Other: laboratory biomarker analysis|Other: questionnaire administration|Procedure: quality-of-life assessment","AIDS Malignancy Consortium|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","276","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","AMC-084|NCI-2013-01637|R01CA163103|U01CA121947","September 17, 2013","December 2013","June 2019","June 8, 2016","April 2016","No Study Results Posted","null","May 2018","Sensitivity of each of the methods of HSIL detection (anal cytology APTIMA, HC2 and OncoHealth HPVE6/E7 oncoprotein)|Specificity of each other methods of HSIL detection (anal cytology, APTIMA, HC2, and OncoHealth HPVE6/7)|Prevalence of HSIL|Incidence of HSIL among women who were HRA negative for HSIL at study entry|Incidence of anal HPV among women who were negative for anal HPV at study entry|Acceptability of anal cancer screening among HIV-infected women based on survey responses regarding patient satisfaction and phone call surveys","https://ClinicalTrials.gov/show/NCT01946139"
3604,"NCT01871363","Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer","Recruiting","No Results Available","Locally Advanced Malignant Neoplasm","Radiation: chemoradiation","Chinese Academy of Medical Sciences","Both","18 Years to 65 Years   (Adult)","Phase 2","35","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-027","May 19, 2013","October 2012","null","June 3, 2013","June 2013","No Study Results Posted","null","October 2015","Pathological complete remission rate (pCR)|Acute and late toxicity","https://ClinicalTrials.gov/show/NCT01871363"
3605,"NCT02066259","OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol","Recruiting","No Results Available","Colon Cancer","","Eventus Diagnostics Ltd","Both","18 Years and older   (Adult, Senior)","","1080","Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","OctavaColon_001","February 9, 2014","August 2014","March 2018","August 4, 2014","August 2014","No Study Results Posted","null","March 2016","Number of participants in each of the clinicaly defined groups (0,1 and 2).","https://ClinicalTrials.gov/show/NCT02066259"
3606,"NCT01951521","RECTAL BOOST Study","Recruiting","No Results Available","Rectal Cancer","Radiation: Boost","UMC Utrecht","Both","18 Years and older   (Adult, Senior)","","94","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NL46051.041.13","September 18, 2013","September 2014","December 2016","May 16, 2016","May 2016","No Study Results Posted","RECTAL BOOST","December 2016","pathological complete response rate|Acute toxicity in common toxicity criteria for adverse events (CTCAE).|Patient reported quality of life|Tumor response on Magnetic resonance imaging (MRI)|Patient reported workability|Surgical complication|(disease-free) survival","https://ClinicalTrials.gov/show/NCT01951521"
3607,"NCT00267787","Molecular Genetic and Pathological Studies of Anal Tumors","Recruiting","No Results Available","Rectal Cancer|Colon Cancer|Colonic Neoplasms|Anal Cancer","Other: genetic analysis","Stanford University","Both","18 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ANAL0001|95340","December 19, 2005","September 2004","December 2013","July 5, 2012","July 2012","No Study Results Posted","null","December 2012","Genetic analysis of blood sample as well as tissues , will provide us with any possible tumor marker for a better prognostic indicator.","https://ClinicalTrials.gov/show/NCT00267787"
3608,"NCT01636674","18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer","Active, not recruiting","No Results Available","Colon Cancer","Other: 18F-fluordeoxyglucose positron emission tomography/ computed tomography","Naestved Hospital|University of Copenhagen|Rigshospitalet, Denmark|Region Zealand","Both","18 Years and older   (Adult, Senior)","","66","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","SJ-82","July 6, 2012","July 2009","March 2013","July 9, 2012","July 2012","No Study Results Posted","COLOPET1","March 2013","time to recurrence","https://ClinicalTrials.gov/show/NCT01636674"
3609,"NCT01108107","Neoadjuvant Treatment of Colon Cancer","Completed","No Results Available","Colon Cancer","Drug: Oxaliplatin|Drug: Capecitabine|Drug: Oxaliplatin|Drug: Capecitabine|Biological: Panitumumab","Vejle Hospital|Herlev Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","76","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","S-20100014","April 14, 2010","April 2010","March 2015","May 20, 2015","March 2014","No Study Results Posted","null","September 2013","The frequency of patients requiring adjuvant chemotherapy based on the histological evaluation of the preparation from the operation.|Recurrence free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01108107"
3610,"NCT01464918","Safety and Efficacy of Using MASTER to Perform Endoscopic Submucosal Dissection in Human","Not yet recruiting","No Results Available","Gastric Cancer|Colon Cancer","Device: Endoscopic submucosal dissection (ESD) using device, MASTER","National University Hospital, Singapore|Prince of Wales Hospital, Shatin, Hong Kong|Apollo Gleneagles Hospitals, Kolkata","Both","21 Years to 65 Years   (Adult)","","7","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E11/058","October 30, 2011","November 2011","December 2012","November 1, 2011","October 2011","No Study Results Posted","null","December 2012","Total time taken to complete the ESD procedure|Measure of ease of performing the ESD procedure|Safety","https://ClinicalTrials.gov/show/NCT01464918"
3611,"NCT02468362","Long Term Outcomes After Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer.","Enrolling by invitation","No Results Available","Low Rectal Cancer","Procedure: laparoscopic intersphincteric resection|Procedure: open intersphincteric resection","Mansoura University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","112","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","ISR-TME","June 7, 2015","April 2014","October 2019","June 9, 2015","June 2015","No Study Results Posted","ISR-TME","April 2019","Disease Free survival|Local recurrence|Distant metstasis|5 year survival","https://ClinicalTrials.gov/show/NCT02468362"
3612,"NCT01830582","Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Procedure: Advanced MR Imaging","Memorial Sloan Kettering Cancer Center","Both","21 Years and older   (Adult, Senior)","","28","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","13-019","April 10, 2013","April 2013","April 2017","July 11, 2016","July 2016","No Study Results Posted","null","April 2017","determine the best MR imaging schedule|Determine if the best imaging schedule for DCE is the same as for DWI","https://ClinicalTrials.gov/show/NCT01830582"
3613,"NCT00578396","Phase I Biomarker Study of Dietary Grape-Derived Low Dose Resveratrol for Colon Cancer Prevention","Active, not recruiting","No Results Available","Colon Cancer","Dietary Supplement: grapes|Dietary Supplement: grapes|Dietary Supplement: grapes","University of California, Irvine|Gateway for Cancer Research","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","OCRT07046|Foundation grant","December 18, 2007","January 2008","January 2010","May 4, 2009","May 2009","No Study Results Posted","null","May 2009","Expression and cellular localization of beta-catenin in intestinal mucosa: localization of β-catenin. Expression of Wnt pathway target genes in intestinal mucosa: Wnt target gene expression|Define whether grape supplemented diet affects colonic mucosa cell proliferation. Ki67 staining method will be utilized on the pre- and post-resveratrol biopsy specimens.|Define any side-effects associated with the resveratrol-rich dietary program. Laboratory testing is performed at specified timepoints in this protocol, along with history & physical, for the purposes of toxicity monitoring.|Monitor resveratrol content of grapes throughout the course of the study. Grapes will be obtained from the same source as participants monthly throughout the study and the content of resveratrol will be measured.","https://ClinicalTrials.gov/show/NCT00578396"
3614,"NCT02698293","A Phase I Study of Photodynamic Therapy (PDT) for High-grade Anal Dysplasia and Microinvasive Anal Cancer","Not yet recruiting","No Results Available","Anal Cancer","Drug: Gliolan","Abramson Cancer Center of the University of Pennsylvania","Both","18 Years and older   (Adult, Senior)","Phase 1","12","Other","Interventional","Primary Purpose: Treatment","UPCC 08216","March 1, 2016","null","null","May 5, 2016","March 2016","No Study Results Posted","null","April 2018","Number of adverse events","https://ClinicalTrials.gov/show/NCT02698293"
3615,"NCT01554969","Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: capecitabine + ganetespib","Emory University|Synta Pharmaceuticals Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1","16","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00054181|STA 9090","March 13, 2012","May 2012","June 2015","February 19, 2016","February 2016","No Study Results Posted","null","March 2015","Tumor response and disease progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST).","https://ClinicalTrials.gov/show/NCT01554969"
3616,"NCT01426074","DCE-MRI PET Bevacizumab Study in Rectal Cancer","Completed","No Results Available","Rectal Cancer Patients","Drug: Bevacizumab 5 mg/kg","Abramson Cancer Center of the University of Pennsylvania","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Primary Purpose: Treatment","UPCC 05209","August 29, 2011","August 2011","August 2014","October 10, 2014","October 2014","No Study Results Posted","null","August 2014","Pathologic Complete Response (pCR)","https://ClinicalTrials.gov/show/NCT01426074"
3617,"NCT01437514","Effective Study of Preoperative Short-course Radiotherapy for the Advanced Resectable Rectal Cancer","Terminated","No Results Available","Rectal Neoplasms","Radiation: preoperative short-course radiotherapy","West China Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","410","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","pSRT-201106","September 14, 2011","August 2011","July 2018","September 6, 2016","September 2016","No Study Results Posted","null","December 2015","local recurrence|disease free survival|metastatic rate|quality of life|overall survival|short-term complication of the surgery","https://ClinicalTrials.gov/show/NCT01437514"
3618,"NCT01268943","Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients","Completed","Has Results","Rectal Neoplasms","Drug: Capecitabine|Drug: Capecitabine|Drug: Capecitabine|Drug: Capecitabine","Chinese Academy of Medical Sciences","Both","71 Years and older   (Senior)","Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-013","December 28, 2010","November 2010","January 2014","March 17, 2015","March 2015","March 5, 2015","null","January 2014","Dose Related Toxicity","https://ClinicalTrials.gov/show/NCT01268943"
3619,"NCT02702089","Hartmann's Versus Intersphincetric APE: A Prospective, Multicentre Study","Not yet recruiting","No Results Available","Rectal Cancer","Procedure: Rectal cancer surgery","Countess of Chester NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Surg05/15","March 3, 2016","March 2016","March 2019","March 3, 2016","March 2016","No Study Results Posted","HiP","March 2018","morbidity|Quality of life|Length of stay|Readmission rate|Time to chemotherapy|Reintervention rate","https://ClinicalTrials.gov/show/NCT02702089"
3620,"NCT01716949","Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Radiation: Radiotherapy|Procedure: Hyperthermia|Drug: 5-Fluorouracil|Drug: Capecitabine|Drug: Oxaliplatin","University of Erlangen-Nürnberg Medical School","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","59","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ESHO201107/001","October 5, 2012","September 2012","June 2023","July 29, 2016","July 2016","No Study Results Posted","HyRec","June 2022","Feasibility rate (i.e. rate of patients not experiencing dose-limiting toxicity [DLT])|Number of hyperthermia applications by patient|Local progression-free survival|Distant metastasis-free survival|Overall survival|Response rate|Rate of R0-resections|Rate of acute and late toxicity","https://ClinicalTrials.gov/show/NCT01716949"
3621,"NCT02288195","Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients","Recruiting","No Results Available","Rectal Neoplasms","Drug: Oxaliplatin|Drug: capecitabine|Radiation: Radiation","Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","648","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","","February 24, 2014","August 2014","June 2024","November 6, 2014","November 2014","No Study Results Posted","null","July 2018","Time to local recurrence|Disease free survival|Pathologic complete response and tumor regression grade|Pelvic R0 resection rate|Overall survival|Adverse event (AE) profiles|Rates of receiving pre-operative or post-operative chemoradiation","https://ClinicalTrials.gov/show/NCT02288195"
3622,"NCT02873845","Role of the Spouse/Partner of Persons Treated With Chemotherapy for Colon Cancer","Recruiting","No Results Available","Colon Cancer","Other: Preliminary validation of the COBQoL questionnaire","Centre Hospitalier Universitaire Dijon","Both","Child, Adult, Senior","","12","Other","Observational","Time Perspective: Prospective","LEJEUNE LaLigue 2014","August 4, 2016","May 2014","null","August 16, 2016","July 2016","No Study Results Posted","APPACH","December 2020","Objective burden score in the dimensions of the COBQoL questionnaire with good psychometric properties","https://ClinicalTrials.gov/show/NCT02873845"
3623,"NCT01042743","Laparoscopic Surgery Versus Robot Surgery for Right-side Colon Cancer: Short-term Outcome of a Randomised Clinical Trial","Completed","No Results Available","Colon Cancer","Procedure: robot-assisted surgery|Procedure: laparoscopic right-hemicolectomy","Kyungpook National University","Both","20 Years to 80 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","KNUHCRC001","January 5, 2010","January 2010","December 2011","December 18, 2011","December 2011","No Study Results Posted","null","December 2011","surgical quality based on pathological examination|complication","https://ClinicalTrials.gov/show/NCT01042743"
3624,"NCT00687570","Bowel Preparation Before Rectal Cancer Surgery","Completed","No Results Available","Rectal Cancer","Dietary Supplement: Fresubin Energy Drink|Drug: Laxabon®","Karolinska Institutet","Both","18 Years to 90 Years   (Adult, Senior)","","32","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Open Label","2008/332-31","May 28, 2008","July 2008","July 2014","February 19, 2015","February 2015","No Study Results Posted","null","July 2014","Bowel purity degree|Nutritional status|Complications|physiological function","https://ClinicalTrials.gov/show/NCT00687570"
3625,"NCT00807911","Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Drug: Adjuvant FL|Drug: Adjuvant FOLFOX","Asan Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","320","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-0256","December 11, 2008","November 2008","December 2016","January 11, 2016","January 2016","No Study Results Posted","null","July 2014","disease-free survival|overall survival, pattern of failure,safety, quality of life","https://ClinicalTrials.gov/show/NCT00807911"
3626,"NCT01479894","Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer","Completed","No Results Available","Colon Cancer","","University of Arkansas|Genomic Health","Both","18 Years and older   (Adult, Senior)","","44","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","133972","November 17, 2011","November 2011","January 2015","February 18, 2015","February 2015","No Study Results Posted","null","January 2015","Compare the prognosis of colon cancer patients compared to gene expression.","https://ClinicalTrials.gov/show/NCT01479894"
3627,"NCT02379520","HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA","Recruiting","No Results Available","Human Papillomavirus-Related Carcinoma|Human Papillomavirus Positive Oropharyngeal Carcinoma|Human Papillomavirus Positive Cervical Carcinoma|Human Papillomavirus Positive Anal Carcinoma|Human Papillomavirus Positive Vulvar Carcinoma|Human Papillomavirus Positive Penile Carcinoma","Genetic: HPV Specific T Cells","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-36021 HESTIA","February 25, 2015","September 2015","October 2033","August 10, 2016","August 2016","No Study Results Posted","HESTIA","October 2018","Number of Patients with DLT|Number of HPVST cells in Blood|Number of Patients with Tumor Response|Number of HPVSTs in the blood that have been transduced with a dominant-negative receptor for TGFβ","https://ClinicalTrials.gov/show/NCT02379520"
3628,"NCT01282502","Midostaurin (PKC412) for Locally Advanced Rectal Cancer","Recruiting","No Results Available","Adenocarcinoma of the Rectum","Drug: Midostaurin","Massachusetts General Hospital","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-457","January 21, 2011","August 2011","null","September 12, 2016","September 2016","No Study Results Posted","null","June 2017","To determine Maximum Tolerated Dose (MTD) of midostaurin in combination with standard 5-FU chemoradiation|To determine the rate of Dworak Tumor Regression Grade 3/4 for locally advanced rectal cancer treated with study combination at the MTD, stratified by KRAS status (mutant vs. wild type)|To determine surgical complication rate in patients who received preoperative radiation therapy|Perform an exploratory analysis of the impact of selected mutations in APC, PTEN, BRAF, NRAS, and PIK3CA, among other genes|To evaluate proteomic markers of response and resistance to midostaurin-based chemoradiation","https://ClinicalTrials.gov/show/NCT01282502"
3629,"NCT02589483","Reinforcement of Rectal Anastomosis-RORA","Not yet recruiting","No Results Available","Rectal Cancer","Procedure: The rectal anastomosis will be reinforced with HemoPatch.|Device: Hemopatch","Capio Sankt Görans Hospital","Both","Child, Adult, Senior","","10","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","Baxter","October 21, 2015","February 2016","December 2016","October 27, 2015","October 2015","No Study Results Posted","null","December 2016","Evidence of clinical anastomotic leak( elevated C reactive protein and white blood corpuscles, fever, nausea). Suspicion of a leak will be investigated with a Ct scan.","https://ClinicalTrials.gov/show/NCT02589483"
3630,"NCT01060501","Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer","Completed","No Results Available","Rectal Cancer","Drug: Folinic Acid, interferon-alpha","University of Ulm|Medac GmbH (Hamburg, Germany)|Roche (Grenzach-Wyhlen, Germany)","Both","18 Years and older   (Adult, Senior)","Phase 3","796","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FOGT1","February 1, 2010","July 1992","July 2009","February 1, 2010","July 1991","No Study Results Posted","FOGT1","July 2009","overall survival|recurrence-free survival|Toxicity (WHO)","https://ClinicalTrials.gov/show/NCT01060501"
3631,"NCT01333709","Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma","Completed","No Results Available","Locally Advanced Malignant Neoplasm|Rectal Carcinoma","Drug: Induction trichemotherapy - FOLFIRINOX regimen|Other: Early tumor response evaluation by MRI volumetry|Radiation: Radiochemotherapy Cap 50|Radiation: Radiochemotherapy Cap 60|Procedure: Radical proctectomy with total mesorectal excision","Institut du Cancer de Montpellier - Val d'Aurelle","Both","18 Years and older   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GRECCAR 4|2010-023546-73","April 8, 2011","May 2011","September 2014","March 2, 2015","March 2015","No Study Results Posted","GRECCAR4","September 2014","Ro resection rate|Efficiency of MRI for prognosis|Compliance rate with neoadjuvant treatment schedule|Acute and late toxicity of neoadjuvant treatments|Pathological complete response rate|Tumor regression grade (TRG)|Perioperative and postoperative morbidity|Sphincter-saving surgery rate|Functional outcome|Quality of life|Local recurrence rate|Incidence of metastases","https://ClinicalTrials.gov/show/NCT01333709"
3632,"NCT00002968","Edrecolomab in Treating Patients With Stage II Colon Cancer","Completed","No Results Available","Mucinous Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Colon|Stage IIA Colon Cancer|Stage IIB Colon Cancer|Stage IIC Colon Cancer","Biological: edrecolomab|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","2100","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02826|NCIC CTG CO.14|CLB-9581|CDR0000065473|C9581|CAN-NCIC-CO14|U10CA031946","November 1, 1999","May 1997","null","June 4, 2013","June 2013","No Study Results Posted","null","July 2003","Survival|Disease-free intervals|Disease-free survival","https://ClinicalTrials.gov/show/NCT00002968"
3633,"NCT02640586","Predicting Neoadjuvant Therapy Response of Rectal Cancer With MRI","Not yet recruiting","No Results Available","Rectal Neoplasms","Device: three MR examination","Sun Ying-Shi|Beijing Cancer Hospital","Both","18 Years and older   (Adult, Senior)","","500","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","PNTRRC-MRI","December 17, 2015","October 2016","December 2020","July 24, 2016","July 2016","No Study Results Posted","null","February 2018","Predictive value of eary MRI (14-16 days MRI) for assessing pathological complete response(pCR) at surgery|Predictive value of eary MRI (14-16 days after initiation of preoperative radio-chemotherapy) for assessing pathological response according to Tumour Regression Grade (TRG)|Feasibility of conducting MRI scans at 7-9 weeks after preoperative radio-chemotherapy|MRI-predicted pCR and MRI-predicted response on long-term disease control and survival","https://ClinicalTrials.gov/show/NCT02640586"
3634,"NCT00188292","Screening for HIV-Associated Anal Cancer","Completed","No Results Available","HIV Infections|Anal Cancer|Anal Dysplasia|Papillomavirus Infections","","University Health Network, Toronto|Ontario HIV Treatment Network|Canadian Foundation for AIDS Research (CANFAR)","Male","18 Years and older   (Adult, Senior)","","401","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REB #02-0325-B|#016005","September 9, 2005","August 2002","June 2012","March 4, 2016","March 2016","No Study Results Posted","TRACE","June 2012","","https://ClinicalTrials.gov/show/NCT00188292"
3635,"NCT01671683","Additional Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer","Completed","No Results Available","Rectal Cancer","","Chungnam National University","Both","20 Years to 90 Years   (Adult, Senior)","","44","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CNUH 10","August 21, 2012","July 2010","September 2011","August 21, 2012","August 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01671683"
3636,"NCT00585728","CT Virtual Proctoscopy for Staging and Volume Assessment for Rectal Cancer","Completed","No Results Available","Rectal Cancer","Procedure: CT Virtual Proctoscopy (CTVP)","University of Wisconsin, Madison","Both","18 Years and older   (Adult, Senior)","","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2007-0134 (CC07206)","December 21, 2007","September 2007","August 2011","August 26, 2011","August 2011","No Study Results Posted","null","August 2011","The utility of CT virtual proctoscopy (CTVP) for evaluation of rectal cancer.","https://ClinicalTrials.gov/show/NCT00585728"
3637,"NCT02163187","Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation","Active, not recruiting","No Results Available","Rectal Cancer|for Bowel Dysfunction Following Surgery for Rectal Cancers","Device: Implantation of the InterStimTM|Behavioral: MSK BFI questionnaires|Behavioral: The Low Anterior Resection Score (LARS) questionnaires|Behavioral: The EuroQOL5D questionnaires|Behavioral: The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires","Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","4","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","14-100","June 11, 2014","June 2014","null","September 6, 2016","September 2016","No Study Results Posted","null","June 2017","change in bowel function|Quality of life","https://ClinicalTrials.gov/show/NCT02163187"
3638,"NCT00207831","Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma","Terminated","No Results Available","Rectal Cancer|Stage II/III|T3 or T4 (Only Anal Extension) Rectal Cancer|N0-2|M0","Drug: Tegafur and Uracil","ICO Paul Papin|Merck Sharp & Dohme Corp.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","219","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CPP276","September 13, 2005","July 2004","February 2008","July 20, 2010","July 2010","No Study Results Posted","UFT RT Phase 3","June 2007","Compare the rate of pathologic complete response of the primary tumor in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone|Compare endoscopic ultrasonographic response in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone.|Compare quality of life (Quality of Life Questionnaire Core 30 Items [QLQ-C 30])|Compare the rate of sphincter conservation alone.|Compare the safety of the chemoradiotherapy regimen to radiotherapy alone|Compare the rate of resectability with negative resection margins in patients treated with this two regimen.|Compare recurrence free survival and disease free survival|Compare overall survival","https://ClinicalTrials.gov/show/NCT00207831"
3639,"NCT02619942","Investigate the Radical Extent of Lymphadenectomy of LAparoscopic Right Colectomy for Colon Cancer(RELARC).","Recruiting","No Results Available","Colon Cancer","Procedure: D2 radical operation|Procedure: Complete mesocolic excision (CME)","Peking Union Medical College Hospital|Chinese PLA General Hospital|West China Hospital|Sixth Affiliated Hospital, Sun Yat-sen University|Peking University Third Hospital|Beijing Cancer Hospital|Beijing Friendship Hospital|Xuanwu Hospital, Beijing|Beijing Chao Yang Hospital|Ruijin Hospital|Shanghai Zhongshan Hospital|First Hospital of Jilin University|Nanfang Hospital of Southern Medical University|Fujian Medical University|Peking Union Medical College","Both","18 Years to 75 Years   (Adult, Senior)","","1072","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","RELARC","November 29, 2015","December 2015","January 2021","January 22, 2016","January 2016","No Study Results Posted","RELARC","January 2018","Disease-free survival|Postoperative complications|Postoperative mortality|3 years overall survival|Metastasis rate of central lymph node (3rd station)","https://ClinicalTrials.gov/show/NCT02619942"
3640,"NCT00937482","Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer","Terminated","No Results Available","Male Breast Cancer|Stage IV Breast Cancer|Stage IV Melanoma|Stage IV Non-small Cell Lung Cancer|Stage IV Renal Cell Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer|Tumors Metastatic to Brain","Drug: cediranib maleate|Radiation: whole-brain radiation therapy","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","18","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2013-00575|09-089|U01CA062490","July 9, 2009","August 2009","null","March 7, 2013","March 2013","No Study Results Posted","null","March 2011","MTD defined as the dose at which no patients develop treatment-related grade 5 toxicity and less than 30% of patients develop acute dose limiting toxicities (DLT) assessed using NCI CTCAE version 4.0|Objective response in the CNS|Neurologic progression-free survival|Overall survival|Cause of death|Vascular MRI studies","https://ClinicalTrials.gov/show/NCT00937482"
3641,"NCT01999478","Novel Biophotonics Methodology for Colon Cancer Screening","Completed","No Results Available","Colon Cancer","","Boston Medical Center","Both","18 Years and older   (Adult, Senior)","","4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01CA128641","November 26, 2013","February 2008","February 2015","June 9, 2016","June 2016","No Study Results Posted","BRP","February 2015","Early cancer changes in the colon","https://ClinicalTrials.gov/show/NCT01999478"
3642,"NCT00719641","Experimental Device to Improve Colonoscopy","Recruiting","No Results Available","Colonoscopy|Looping|Prevent Looping|Colon Cancer Screening|Segmental Stiffening Wire","Procedure: Colonoscopy|Procedure: Colon Cancer Screening|Device: Segmental Stiffening Wire","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","40 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","103","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind|Primary Purpose: Treatment","080173|08-DK-0173","July 19, 2008","July 2008","February 2017","August 31, 2016","October 2015","No Study Results Posted","null","February 2017","The use of SSW will prevent re-looping of the colonoscope.|Reduction of colonoscope looping will improve operator and procedural efficiency and patient tolerability of colonoscopy.","https://ClinicalTrials.gov/show/NCT00719641"
3643,"NCT01237665","IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Drug: IXO regimen","Ottawa Hospital Research Institute|Ottawa Regional Cancer Foundation|Sanofi|Hoffmann-La Roche","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","15","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OTT 09-02","August 25, 2010","September 2010","December 2017","October 12, 2012","October 2012","No Study Results Posted","IXOr","December 2012","Pathological complete response (pCR)|Objective Response|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Recurrence|RFS, PFS, TTR|Quality of life|Surgical morbidity and mortality|Rate of post-operative sphincter preservation|OS","https://ClinicalTrials.gov/show/NCT01237665"
3644,"NCT02651701","Rectal Cancer Staging Using Whole Body MR-PET","Recruiting","No Results Available","Rectal Cancer","Procedure: MR-PET","Seoul National University Hospital|Bayer","Both","18 Years and older   (Adult, Senior)","","71","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","MRPET-CRC","January 5, 2016","January 2016","December 2017","July 6, 2016","July 2016","No Study Results Posted","null","June 2017","the concordance rate between rectal cancer staging performed by WB MR-PET and the current standard of care (chest/abdominopelvic CT and rectal MRI|incidence of recommendation for further workup after examination|concordance rate of clinical staging between standard of care and that obtained by combination of WB MR-PET and chest CT.|concordance rate of clinical stagings and true M staging obtained by biopsy or follow-up","https://ClinicalTrials.gov/show/NCT02651701"
3645,"NCT01717391","[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers","Active, not recruiting","No Results Available","Uterine Cervical Neoplasms|Endometrial Neoplasms|Anus Neoplasms|Rectal Neoplasms|Prostatic Neoplasms","Radiation: Bone marrow sparing IMRT radiation therapy","University of Iowa|National Institutes of Health (NIH)|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201204712|R01CA169336","October 18, 2012","October 2012","December 2018","July 5, 2016","July 2016","No Study Results Posted","null","February 2016","Changes in FLT uptake as measured by PET/CT scanning|Adverse event frequency|Blood Cell Counts|Chemotherapy compliance","https://ClinicalTrials.gov/show/NCT01717391"
3646,"NCT01148056","Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer","Terminated","No Results Available","Rectal Cancer","Radiation: Intensity Modulated Radiation Therapy","Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|National Institutes of Health (NIH)","Both","18 Years and older   (Adult, Senior)","Phase 2","2","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-157","June 18, 2010","March 2010","April 2014","April 10, 2014","April 2014","No Study Results Posted","null","April 2014","Bowel Quality of Life|Pelvic Control Rate|Surgical Complication Rate|Tissue Microarray|Quantity of Circulating Tumor Cells|Accuracy","https://ClinicalTrials.gov/show/NCT01148056"
3647,"NCT01423214","A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: robot-assisted surgery|Procedure: Laparoscopic surgery","Kyungpook National University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","540","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KNUHCRC003","August 1, 2011","June 2013","December 2018","March 9, 2015","March 2015","No Study Results Posted","COLRAR","December 2018","Surgical quality based on pathological examination|Postoperative morbidity|Pelvic autonomic nerve preservation (intraoperative confirmation of pelvic nerve preservation)|Change from Baseline in QLQ 30, IIEF-5(5-item Version of the International Index of Erectile Function), IPSS(International Prostate Symptom Score), FSFI(Female Sexual Function Index), and Wexner's scoring|5-year overall survival rate|5-year disease-free survival rate","https://ClinicalTrials.gov/show/NCT01423214"
3648,"NCT01656044","Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer","Active, not recruiting","No Results Available","Colon Cancer|Pancreatic Cancer|Perioperative/Postoperative Complications|Primary Peritoneal Cavity Cancer|Rectal Cancer","Procedure: wound care management|Procedure: wound care management","Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","264","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CCCWFU 99212|NCI-2012-00624","July 31, 2012","June 2012","null","July 1, 2016","July 2016","No Study Results Posted","null","July 2016","Rate of incisional surgical site infection (SSI), which includes superficial incisional SSIs and deep incisional SSIs as defined by the Center of Disease Control and Prevention|Rates of organ/space SSIs, seromas, hematomas, incisional cellulitis, and wound opening for any reason|The cost of NPT and SSD, as well as estimate additional costs associated with incisional SSIs in affected patients","https://ClinicalTrials.gov/show/NCT01656044"
3649,"NCT02641691","Five Fractions of Radiotherapy Followed by FOLFOX Chemotherapy as Organ-Sparing Treatment for Low Risk Rectal Cancer","Recruiting","No Results Available","Cancer of Rectum|Cancer of the Rectum|Neoplasm, Rectum|Rectal Cancer|Rectum Cancer|Rectum Neoplasms|Adenocarcinoma of the Rectum","Radiation: Radiation|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","Phase 0","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201512140","December 23, 2015","May 2016","July 2019","June 2, 2016","June 2016","No Study Results Posted","null","July 2019","Clinical response rate|Prospective patient reported outcomes as measured by FACT-C questionnaire|Incidence of any grade 3 or higher toxicities|Incidence of post chemotherapy grade 3 or higher toxicities|Quality of anorectal function as measured by the FACT-C questionnaire","https://ClinicalTrials.gov/show/NCT02641691"
3650,"NCT00381173","A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing","Completed","No Results Available","Breast Cancer|Ovarian Cancer|Prostate Cancer|Colon Cancer|Renal Cancer","Drug: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)","Eisai Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZYC3-002","September 26, 2006","November 2006","October 2008","May 13, 2013","July 2011","No Study Results Posted","null","October 2008","Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.|Assess the effect of cyclophosphamide on T reg number and function. Assess the generation of CYP1B1-specific immun. as a result of vac. regimen. Assess the effect of vac. regimen on tumor response, if any, in pat. pop.","https://ClinicalTrials.gov/show/NCT00381173"
3651,"NCT02694718","A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: Capecitabine|Drug: Oxaliplatin","Hoffmann-La Roche|Sanofi-Synthélabo (Schweiz) AG","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Industry|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18280","February 25, 2016","March 2005","November 2006","February 25, 2016","February 2016","No Study Results Posted","null","August 2006","Percentage of participants with pathological complete response|Percentage of participants with sphincter-preservation|Number of participants with marked laboratory abnormalities|Percentage of participants with Resection (R0) in participants with T4 rectal cancer|Percentage of participants with downstaging of primary tumor and/or lymph nodes|Percentage of participants with pathological incomplete tumor response|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT02694718"
3652,"NCT01643070","Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases","Active, not recruiting","No Results Available","Rectal Cancer|Liver Metastases","Drug: Capecitabine, Oxaliplatin|Radiation: Radiotherapy","Asan Medical Center","Both","20 Years to 75 Years   (Adult, Senior)","Phase 2","38","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","XELOX-RT","November 1, 2011","January 2010","December 2016","January 11, 2016","January 2016","No Study Results Posted","null","September 2014","R0 resection rate after simultaneous surgery of the rectum and the liver","https://ClinicalTrials.gov/show/NCT01643070"
3653,"NCT01212627","Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer","Terminated","Has Results","Non-Small Cell Lung Cancer","Drug: Ridaforolimus|Drug: Ridaforolimus","Angela Taber MD|Rhode Island Hospital|The Miriam Hospital|Memorial Hospital of Rhode Island|Roger Williams Medical Center|Brown University","Both","18 Years and older   (Adult, Senior)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG-Phase 1-233","September 29, 2010","September 2010","April 2013","June 24, 2015","June 2015","May 20, 2015","null","December 2012","Determine Maximum Tolerated Dose (MTD) of Ridaforolimus With Given With Cetuximab|Check the Tolerability, and Maximum Tolerated Dose (MTD) of Several Dosing Schedules of Oral Ridaforolimus.","https://ClinicalTrials.gov/show/NCT01212627"
3654,"NCT01818973","Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: Xeloda|Drug: Oxaliplatin|Drug: Bevacizumab|Radiation: Radiation|Procedure: surgery","Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6901061","March 23, 2013","March 2013","March 2020","June 3, 2015","June 2015","No Study Results Posted","null","June 2015","The pathologic tumor regression grade (TRG)|5-y overall survival|Occurence of toxicity|5-y local relapse free survival","https://ClinicalTrials.gov/show/NCT01818973"
3655,"NCT00501306","Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men","Completed","No Results Available","Anal Cancer","","Laser Surgery Care|Merck Sharp & Dohme Corp.","Male","18 Years to 85 Years   (Adult, Senior)","","195","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","07-0337-2|32873","July 12, 2007","June 2007","May 2008","June 21, 2011","June 2011","No Study Results Posted","null","May 2008","","https://ClinicalTrials.gov/show/NCT00501306"
3656,"NCT02278653","Functional Outcome of Organ Preservation After Neo-adjuvant Chemo Radiation for Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms","Other: Questionnaires for the evaluation of Quality of Life|Other: Manometry","Maastricht University Medical Center|Dutch Cancer Society","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL49171.068.14","October 6, 2014","September 2014","September 2022","March 15, 2016","March 2016","No Study Results Posted","null","September 2017","Functional outcome|Cumulative risk of local failure|Cumulative risks of disease-free, distant-metastasis free and overall survival|The percentage of patients that choose the alternative strategies instead of traditional strategies and the motivation for their choice|The compliance to the intensive follow-up schedule|Early detection of local failure (standard surgery still possible)","https://ClinicalTrials.gov/show/NCT02278653"
3657,"NCT01310972","Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX","Completed","No Results Available","Colon Cancer","Other: Registry","King Faisal Specialist Hospital & Research Center","Both","14 Years to 85 Years   (Child, Adult, Senior)","","6","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RAC# 2071-027","March 6, 2011","September 2007","September 2007","February 24, 2016","December 2011","No Study Results Posted","null","September 2007","OS, PFS, DFS","https://ClinicalTrials.gov/show/NCT01310972"
3658,"NCT01674309","First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis","Active, not recruiting","No Results Available","Adenocarcinoma of Rectum","Drug: FOLFORINOX","Federation Francophone de Cancerologie Digestive","Both","18 Years and older   (Adult, Senior)","Phase 2","65","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FFCD 1102","April 2, 2012","April 2012","October 2016","August 2, 2016","August 2016","No Study Results Posted","null","January 2016","Tumor control rate of the primary tumor and metastasis|Toxicity of the treatment|rate of local failure and local complication (occlusion, important bleedings, resistant pains with morphinic treatment, perforation)|survival without local failure (radiological or clinical progression of the rectal cancer or local complication)|rectal tumor response rate (CT scan, MRI and endocopy)|metastasis response rate","https://ClinicalTrials.gov/show/NCT01674309"
3659,"NCT01047969","Avoiding Surgery in Rectal Cancer After Pre-Operative Therapy","Active, not recruiting","No Results Available","Rectal Adenocarcinoma","Drug: Adjuvant Chemotherapy|Procedure: Surgery","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 2","99","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2759","January 12, 2010","September 2006","June 2019","May 27, 2016","May 2016","No Study Results Posted","null","June 2019","To estimate the percentage of patients who can safely omit surgery, defined as the percentage of patients at two years after end of CRT who have not had surgery and who are in CR (no detectable local disease)|To prove the safety of deferred surgery, as measured by the percentage of patients who have local failure at two years, where local failure is defined as positive margin status of resected tumour or surgically unsalvageable disease.|Time to distant disease|Time to maximal tumour response after CRT|Time to local re-growth|Percentages of positive margins, and sphincter-preservation rates in patients who have had surgery|Progression-free and overall survival|Quality of Life including long-term bowel, urinary and sexual function|To correlate the expression of biological markers which may predict for pathological complete response with progression free survival","https://ClinicalTrials.gov/show/NCT01047969"
3660,"NCT01211210","Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Drug: fluorouracil|Drug: fluorouracil, oxaliplatin|Drug: fluorouracil, oxaliplatin","Sun Yat-sen University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","495","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GIHSYSU01","September 28, 2010","June 2010","June 2020","May 21, 2015","November 2013","No Study Results Posted","FOWARC","June 2017","3-year disease free survival|pathologic complete response rate|local recurrence rate|overall survival|sphincter-saving surgery rate|R0 resection rate|predictive biomarkers|quality of life","https://ClinicalTrials.gov/show/NCT01211210"
3661,"NCT00651677","Hand Assisted Versus ""Pure"" Laparoscopic Assisted Proctectomy for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: HAL proctectomy|Procedure: ""straight"" laparoscopic proctectomy|Procedure: Hand-assisted laparoscopic proctectomy|Procedure: SL Proctectomy","Weill Medical College of Cornell University","Both","18 Years and older   (Adult, Senior)","","128","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MITT02","March 31, 2008","April 2011","December 2012","April 18, 2011","April 2011","No Study Results Posted","null","November 2012","operative time|Adequacy of resection margins|In-hospital mortality and morbidity|urinary and sexual function","https://ClinicalTrials.gov/show/NCT00651677"
3662,"NCT00375024","Patient Navigator Project","Completed","No Results Available","Breast Cancer|Colon Cancer","Procedure: Patient Navigation|Procedure: Clinic Staff","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","1267","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","MCC-14718","September 11, 2006","May 2007","November 2012","November 2, 2012","November 2012","No Study Results Posted","null","September 2012","Questionnaire Results Regarding Time to Diagnosis|Patient Satisfaction Questionaire Results|Questionnaire Results Regarding Patient Navigators","https://ClinicalTrials.gov/show/NCT00375024"
3663,"NCT01460589","Early Commencement of Adjuvant Chemotherapy for Colon Cancer","Recruiting","No Results Available","Colon Cancer","Procedure: timing to initiate the adjuvant chemotherapy","Kyungpook National University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","198","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KNUHCRC004","October 25, 2011","November 2011","December 2018","September 11, 2015","September 2015","No Study Results Posted","ECTX","October 2018","3-year disease free survival rate|short-term cumulative surgery-related complications during chemotherapy|side effects of chemotherapy","https://ClinicalTrials.gov/show/NCT01460589"
3664,"NCT00648635","Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations","Recruiting","No Results Available","Rectal Cancer","Behavioral: Questionnaire","M.D. Anderson Cancer Center","Both","Child, Adult, Senior","","164","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2007-0322","March 27, 2008","March 2008","null","September 12, 2016","September 2016","No Study Results Posted","null","March 2018","Quality of Life (QOL) Survey Responses","https://ClinicalTrials.gov/show/NCT00648635"
3665,"NCT01115790","A Phase 1 Study in Participants With Advanced Cancer","Completed","No Results Available","Advanced Cancer|Squamous Cell Carcinoma|Carcinoma, Squamous Cell of Head and Neck|Lung Squamous Cell Carcinoma Stage IV|Anal Squamous Cell Carcinoma|Carcinoma, Non-Small-Cell Lung","Drug: Prexasertib","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 1","150","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13129|I4D-MC-JTJA","April 28, 2010","February 2010","January 2016","May 9, 2016","May 2016","No Study Results Posted","null","January 2016","Determination of a Recommended Phase 2 Dosing Regimen: Maximum Tolerated Dose (Parts A and B)|Determination of Clinically Significant Safety Effects (Parts A and B)|Percentage of Participants With a Complete or Partial Response (Overall Response Rate) (Part C)|Percentage of Participants with Complete Response, Partial Response, or Stable Disease (Disease Control Rate) (Parts A, B, and C)|Progression Free Survival (Parts B and C)|Duration of Response (Parts B and C)|Preliminary Pharmacokinetics of Prexasertib (Cmax) (Parts A, B, and C)|Preliminary Pharmacokinetics of Prexasertib (AUC) (Parts A, B, and C)","https://ClinicalTrials.gov/show/NCT01115790"
3666,"NCT02774512","Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer","Not yet recruiting","No Results Available","Colon Cancer","Drug: Nilotinib","Institut Bergonié|Novartis Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 0","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","IB 2015-03","April 27, 2016","May 2016","November 2017","May 12, 2016","May 2016","No Study Results Posted","ZAK-0","November 2017","ZAK expression level by immunohistochemistry on frozen material (surgical specimen) by Western blot and on paraffinembedded tissues section using an immunohistochemistry approach|Efficacy of the 7day nilotinib treatment based on histological response as measured with tumour regression grade|Efficacy of the 7day nilotinib treatment based on histological response as measured with the proportion of tumour necrosis|Efficacy of the 7day nilotinib treatment based on histological response as measured with the type of tumour necrosis|Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v4.0 as assessed by CTCAE v4.0|Postoperative complications as assessed by Dindo and Clavien classification|Maximum Plasma Concentration [Cmax] of nilotinib .|Half-life of nilotinib","https://ClinicalTrials.gov/show/NCT02774512"
3667,"NCT00532987","Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer","Terminated","No Results Available","Rectal Cancer|Colon Cancer|Anal Cancer","Behavioral: Questionnaire","Stanford University","Both","30 Years and older   (Adult, Senior)","","22","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REC0003|79517","September 20, 2007","December 2003","September 2009","February 24, 2012","February 2012","No Study Results Posted","null","September 2009","","https://ClinicalTrials.gov/show/NCT00532987"
3668,"NCT00654342","Comparison Between ex Vivo and in Vivo Injection of Blue Dye in Sentinel Lymph Node Mapping for Colon Cancer","Recruiting","No Results Available","Sentinel Lymph Node Biopsy|Colon Cancer","Procedure: Intraoperative injection (in vivo)|Procedure: Postoperative injection (ex vivo)","Chung-Ang University","Both","18 Years to 80 Years   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)","caugs_01","April 2, 2008","October 2007","null","April 2, 2008","April 2008","No Study Results Posted","null","February 2009","Accuracy & sensitivity of sentinel lymph node mapping","https://ClinicalTrials.gov/show/NCT00654342"
3669,"NCT00554892","Rectal Cancer Surgery Without Mechanical Bowel Preparation","Completed","No Results Available","Patients With Rectal Cancer","Procedure: bowel preparation|Procedure: no preparation bowel","Assistance Publique - Hôpitaux de Paris","Both","18 Years and older   (Adult, Senior)","","186","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P060233|AOM 06086|IDRCB 2007-A00471","November 6, 2007","September 2007","August 2009","June 29, 2010","June 2010","No Study Results Posted","PREPACOL","February 2009","Overall morbidity including infectious and non infectious complications|- peri operative mortality - non infectious morbidity - anastomotic leakage - hospital stay - per operative evaluation of bowel preparation - clinical evaluation of bowel preparation|Evaluate the postoperative complications classified according to the DINDO classification.","https://ClinicalTrials.gov/show/NCT00554892"
3670,"NCT01048580","Study of Perifosine + Capecitabine for Colon Cancer Patients","Completed","No Results Available","Colon Cancer","Drug: Perifosine + Capecitabine","AEterna Zentaris|SCRI Development Innovations, LLC","Both","18 Years and older   (Adult, Senior)","Phase 1","10","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Perifosine 141","January 9, 2010","October 2009","October 2011","February 14, 2014","November 2011","No Study Results Posted","null","May 2011","Safety. Determination of maximum tolerated dose.","https://ClinicalTrials.gov/show/NCT01048580"
3671,"NCT02745639","Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer","Completed","No Results Available","Rectal Neoplasms","Radiation: VMAT-SIB|Drug: XELOX","Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi","Both","18 Years and older   (Adult, Senior)","Phase 2","18","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GRACE-RECTUM-1","April 17, 2016","February 2010","November 2015","April 17, 2016","April 2016","No Study Results Posted","GRACE","November 2013","Pathological response rate|Acute Toxicity","https://ClinicalTrials.gov/show/NCT02745639"
3672,"NCT01628250","Laparoscopic Complete Mesocolic Excision on Colon Cancer","Completed","Has Results","Operation Finding|Complications|Pathology|Quality of Life|Neoplasms Recurrence","Procedure: laparoscopic complete mesocolic excision|Procedure: D3-laparoscopic colectomy","Bo Feng|Ruijin Hospital","Both","18 Years to 79 Years   (Adult, Senior)","","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SH-MIS","June 20, 2012","June 2012","October 2015","May 21, 2016","May 2016","November 7, 2015","LCME","October 2015","Histopathological Outcomes Obtained Through the Surgeries|Survival Rate","https://ClinicalTrials.gov/show/NCT01628250"
3673,"NCT01269229","A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis","Completed","No Results Available","Rectal Cancer","Drug: folfox|Radiation: short course Radiotherapy","Yonsei University","Both","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2009-0522","January 3, 2011","January 2010","April 2015","September 5, 2016","September 2016","No Study Results Posted","null","April 2015","complete resection (R0) rate for rectal and liver lesions.|Response rate (RECIST V1.0)|Overall survival rate|Progression free survival time|Toxicity profile","https://ClinicalTrials.gov/show/NCT01269229"
3674,"NCT01500993","Capecitabine in the Perioperative Treatment of Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: Capecitabine|Drug: 5-FU","Universitätsmedizin Mannheim","Both","18 Years and older   (Adult, Senior)","Phase 3","401","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Rektum III","December 21, 2011","March 2002","March 2011","December 26, 2011","December 2011","No Study Results Posted","Rektum-III","March 2011","Overall survival|disease-free survival (DFS)|Local recurrence rate","https://ClinicalTrials.gov/show/NCT01500993"
3675,"NCT01975064","Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia","Recruiting","No Results Available","Breast Neoplasms|Colonic Neoplasms|Rectal Neoplasms","Drug: Propofol|Drug: Sevoflurane","Uppsala University|Region Örebro County|University Hospital, Linkoeping|Lund University Hospital|Kalmar County Hospital|Skellefteå lasarett|Wroclaw Medical University","Both","18 Years and older   (Adult, Senior)","Phase 4","8000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","CAN/CKF-11115|2013-002380-25","October 28, 2013","November 2013","December 2022","December 3, 2015","December 2015","No Study Results Posted","CAN","December 2017","Over all survival","https://ClinicalTrials.gov/show/NCT01975064"
3676,"NCT00575640","Hydralazine as a Demethylating Agent in Rectal Cancer","Withdrawn","No Results Available","Rectal Cancer","Drug: Hydralazine","University of Arkansas","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","2004-03","December 14, 2007","November 2004","null","March 3, 2015","March 2015","No Study Results Posted","null","May 2008","The study design calls for an initial phase of dose-escalation in cohorts of 3 patients. There are no intra-patient changes in dose.|Subsequent to this Phase I scheme, the study will continue with the selected dose-level (on toxicity and tolerability grounds) to accrue patients in a phase II scheme.","https://ClinicalTrials.gov/show/NCT00575640"
3677,"NCT01806675","18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy","Recruiting","No Results Available","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Male Breast Cancer|Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Brain Tumor|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Hypopharyngeal Cancer|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Laryngeal Cancer|Recurrent Lip and Oral Cavity Cancer|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Nasopharyngeal Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Oropharyngeal Cancer|Recurrent Pancreatic Cancer|Recurrent Paranasal Sinus and Nasal Cavity Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVA Salivary Gland Cancer|Stage IVB Colon Cancer|Stage IVB Salivary Gland Cancer|Stage IVC Salivary Gland Cancer|Tongue Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Radiation: fludeoxyglucose F 18|Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide|Procedure: positron emission tomography|Procedure: computed tomography|Procedure: positron emission tomography|Procedure: computed tomography|Other: laboratory biomarker analysis","Sanjiv Sam Gambhir|National Cancer Institute (NCI)|Stanford University","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","150","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","VARIMG0002|NCI-2013-00535","March 5, 2013","March 2013","March 2019","November 16, 2015","November 2015","No Study Results Posted","null","March 2018","Change in maximum standard uptake values (SUVmax) on 18F FPPRGD2 and 18F FDG PET|Progression-free survival","https://ClinicalTrials.gov/show/NCT01806675"
3678,"NCT00457327","Pilot Study for Evaluation of the Need for Protective Ileostomy After Low Anterior Resection Due to Rectal Cancer","Terminated","No Results Available","Rectal Cancer","Procedure: protective ileostomy","Heidelberg University","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","433/2005","April 4, 2007","July 2006","March 2007","June 4, 2008","June 2008","No Study Results Posted","null","March 2007","Morbidity and mortality until day 30 postoperative|Quality of life|Ranking of factors influencing quality of life","https://ClinicalTrials.gov/show/NCT00457327"
3679,"NCT02113202","Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW","Completed","No Results Available","Adenomatous Polyposis Coli","Drug: Bevacizumab-IRDye800CW|Device: Near infrared fluorescence endoscopy platform","University Medical Center Groningen","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","17","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","NL45148.042.13|2013-002490-22","April 2, 2014","March 2014","October 2015","January 8, 2016","January 2016","No Study Results Posted","FLUOFAP","October 2015","Number of fluorescent adenomatous polyps during surveillance endoscopy using the near-infrared fluorescence endoscopy platform in patients with Familial Adenomatous Polyposis (FAP), after administration of the fluorescent tracer bevacizumab-IRDye800CW.|Meassure the mean fluorescent intensity of the polyps during fluorescence endoscopy, resect the polyps and score VEGF intensity after immunohistochemistry for VEGF.|Number of participants with Serious Adverse Events as a measure of safety and Tolerability.|Measure the mean fluorescent intensity of adenomas and compare this between the three different dosing groups to determine the best tracer dose for the fluorescence endoscopy procedure.","https://ClinicalTrials.gov/show/NCT02113202"
3680,"NCT02399631","Enhanced Recovery Program After Laparoscopic Colon Cancer Surgery","Recruiting","No Results Available","Colon Cancer","Other: Enhanced recovery program","Kyungpook National University","Both","20 Years to 80 Years   (Adult, Senior)","","248","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KNUHCRC005","March 9, 2015","January 2012","December 2017","March 21, 2015","March 2015","No Study Results Posted","null","December 2015","Length of hospital stay|Actual hospital stay|Readmission rate|30-day morbidity|30-day mortality|Quality of life|Nutritional status","https://ClinicalTrials.gov/show/NCT02399631"
3681,"NCT02277158","Phase I Study of CCRT as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.","Recruiting","No Results Available","Rectal Cancer","Drug: Chemoradiotherapy","Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","18","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DP03182014","October 22, 2014","November 2014","December 2015","November 30, 2014","November 2014","No Study Results Posted","null","June 2015","Maximum Tolerated Dose (MTD)|Dose Limiting Toxicities (DLTs)|Quality of Life","https://ClinicalTrials.gov/show/NCT02277158"
3682,"NCT00249301","A Study of MLN8054 in Patients With Advanced Solid Tumors","Terminated","No Results Available","Breast Neoplasm|Colon Neoplasm|Pancreatic Neoplasm|Bladder Neoplasm","Drug: MLN8054","Millennium Pharmaceuticals, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","63","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C10001","November 4, 2005","October 2005","null","March 28, 2008","March 2008","No Study Results Posted","null","January 2008","The safety of MLN8054 will be based on the continuous monitoring and observation of patients and the collection and evaluation of adverse events and serious adverse events and the assessment of their potential relationship to the study medication.","https://ClinicalTrials.gov/show/NCT00249301"
3683,"NCT01882660","Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study","Recruiting","No Results Available","Colon Cancer","Drug: Decitabine","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Both","18 Years and older   (Adult, Senior)","","88","Other","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label","NL44048.018.13","May 24, 2013","July 2013","July 2017","July 26, 2016","July 2016","No Study Results Posted","DECO","July 2017","Wnt target gene expression (APCDD1, AXIN2, DKK1, LGR5 and ASCL2)|Wnt target methylation.|CIMP gene methylation|Beta-catenin localisation|Proliferation (Ki-67)|Apoptose (TNEL en M30 assay)|Tumor differentiation","https://ClinicalTrials.gov/show/NCT01882660"
3684,"NCT02861430","Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular Biology","Recruiting","No Results Available","Colon Cancer|Lymph Node|Sentinel Node","Procedure: Immunochemistry and molecular biology on sentinel lymph node specimen","Centre Hospitalier Universitaire de Besancon","Both","18 Years and older   (Adult, Senior)","","388","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Besancon Unmask","August 2, 2016","April 2014","March 2020","August 5, 2016","August 2016","No Study Results Posted","UNMASK","April 2017","Concordance between immunochemistry and molecular biology|Disease-free survival","https://ClinicalTrials.gov/show/NCT02861430"
3685,"NCT01941641","Colon Neoadjuvant FOLFOXIRI Study","Recruiting","No Results Available","Rectal Cancer","Drug: neoadjuvant FOLFOXIRI|Drug: Capecitabine","Chinese University of Hong Kong","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COL021","September 3, 2013","October 2013","October 2018","July 7, 2016","July 2016","No Study Results Posted","null","December 2016","Objective tumour response rate|Tumour regression grade|pathologic complete response|Rate of circumferential resection margin (CRM) clearance|Rate of tumour downstaging|Number of Participants with Adverse Events|Overall survival|disease-free survival, relapse-free survival|Time to local (and distant) recurrence|Number of patients with 30-day post-operative mortality|Compliance to study treatment|Number of response to neoadjuvant therapy","https://ClinicalTrials.gov/show/NCT01941641"
3686,"NCT00967148","Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer","Completed","No Results Available","Deep Vein Thrombosis|Pulmonary Embolism|Cancer","Drug: Tinzaparin","Ottawa Hospital Research Institute|LEO Pharma","Both","18 Years and older   (Adult, Senior)","","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","2009121-01H","July 8, 2009","June 2009","September 2010","October 21, 2014","October 2014","No Study Results Posted","PERI-OP","September 2010","Recruitment rate|Refusal rate|Rate of non-compliance and lost to follow-up|Expression of sialylated fucosylated glycans (including CA19-9, sialyl Lewis X and CD24) in primary tumor specimens by immunohistochemistry (IHC).|Expression of TF. VEGF and microvessel density in primary tumor specimens by IHC.|Serum soluble TF and TFPI levels pre and postoperatively (postoperative day 0, 1, 4, 7±1, and 28±4) measured by enzyme linked immunosorbent assay (ELISA).|Platelet count and serum soluble P-selectin levels pre and postoperatively (postoperative day 0, 1, 4, 7±1, and 28±4) measured by hemocytometer and ELISA.|Serum VEGF levels pre and postoperatively (postoperative day 0, 1, 4, 7±1, and 28±4) measured by ELISA|Quantification and characterization of VPC pre and postoperatively (postoperative day 0, 1, 4, 7±1, and 28±4) measured by VPC cell culture assay and flow cytometry.","https://ClinicalTrials.gov/show/NCT00967148"
3687,"NCT01257035","Predictive Value of 18F-FAZA in Rectum Cancer","Terminated","No Results Available","Locally Advanced Rectum Cancer","Other: 18F-FAZA-PET/CT","Vejle Hospital|Aarhus University Hospital","Both","18 Years and older   (Adult, Senior)","","21","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","S-20100054","December 8, 2010","November 2010","August 2012","June 14, 2013","June 2013","No Study Results Posted","FAZA","February 2012","Response to chemoradiotherapy measured by TRG|Recurrence free survival|Survival","https://ClinicalTrials.gov/show/NCT01257035"
3688,"NCT02753465","A Prospective Clinical Study for Laparoscopic D3 Dissection With Preservation of Left Colic Artery in Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms","Procedure: left colic artery|Procedure: High ligation","Fudan University","Both","18 Years to 80 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FUDANLCA","April 3, 2016","April 2016","December 2019","May 10, 2016","May 2016","No Study Results Posted","null","December 2019","anastomotic leak rate|Number of lymph node dissection|Overall survival rate|disease-free survival rate|30-day mortality rate","https://ClinicalTrials.gov/show/NCT02753465"
3689,"NCT02792842","Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer","Recruiting","No Results Available","Postoperative Stage II/III Colon Cancer","Drug: ART-123 (High Frequency)|Drug: ART-123 (Low Frequency)|Drug: Placebo","Asahi Kasei Pharma Corporation","Both","20 Years to 79 Years   (Adult, Senior)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","ART-123-201","May 28, 2016","July 2016","February 2018","July 12, 2016","July 2016","No Study Results Posted","null","February 2018","NCI-CTCAE|FACT-G: Functional Assessment of Cancer Therapy - General|Discontinuation/ suspension/dose reduction of chemotherapeutic agents","https://ClinicalTrials.gov/show/NCT02792842"
3690,"NCT01972737","Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer","Active, not recruiting","No Results Available","Colon Cancer","Biological: Ad5-hGCC-PADRE vaccine","Thomas Jefferson University","Both","18 Years and older   (Adult, Senior)","Phase 1","10","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","13S.462|SAP #4100051723","October 24, 2013","October 2013","December 2018","January 8, 2016","January 2016","No Study Results Posted","null","June 2014","Adverse events|Antibody responses|T cell responses|Persistent immunological responses","https://ClinicalTrials.gov/show/NCT01972737"
3691,"NCT01872104","Safety and Efficiency of Photodynamic Therapy for Rectal Cancer","Suspended","No Results Available","Advanced Rectal Cancer","Procedure: Photodynamic therapy","li xiong|Central South University","Both","25 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PDT-R-01","June 5, 2013","August 2013","August 2016","June 5, 2013","June 2013","No Study Results Posted","PDT-R-01","August 2015","Survival rate|Progression-free survival","https://ClinicalTrials.gov/show/NCT01872104"
3692,"NCT01196000","Laparoscopic Surgery or Robotic-Assisted Laparoscopic Surgery in Treating Patients With Rectal Cancer That Can Be Removed By Surgery","Withdrawn","No Results Available","Recurrent Rectal Cancer|Stage I Rectal Cancer|Stage II Rectal Cancer|Stage III Rectal Cancer","Procedure: conventional laparoscopic surgery|Procedure: robotic-assisted laparoscopic surgery|Procedure: quality-of-life assessment|Other: questionnaire administration","City of Hope Medical Center","Both","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07158|NCI-2010-01427","September 3, 2010","December 2011","null","April 16, 2012","April 2012","No Study Results Posted","null","July 2013","Rate of conversion to open surgery as an indicator of surgical technical difficulty|Circumferential resection margin positivity rate|Local recurrence rate|Intra-operative and post-operative complications|Operative mortality|Self reported bladder and sexual function|Health related quality of life|Disease free and overall survival|Intra-operative laparoscopic skills (randomly selected cases only) as assessed by the global assessment tool for evaluation of intra-operative laparoscopic skills (GOALS)|Quality of the plane of surgery as assessed by central review of photographs|Health economics","https://ClinicalTrials.gov/show/NCT01196000"
3693,"NCT01914068","The Effects of a 9 Week Exercise Programme on Fitness and Quality of Life in Rectal Cancer Patients After Chemoradiotherapy and Before Surgery","Recruiting","No Results Available","Rectal Cancer","Other: Supervised exercise in hospital","University Hospital Southampton NHS Foundation Trust.|AintreeNHSTrust","Both","18 Years to 85 Years   (Adult, Senior)","","46","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Health Services Research","PB-PG-0711-25093","June 7, 2013","August 2013","December 2015","August 27, 2013","August 2013","No Study Results Posted","SRETP","February 2015","Change in physical fitness measured by CPET (ml/kg/min)|Quality of life|Physical activity","https://ClinicalTrials.gov/show/NCT01914068"
3694,"NCT01186081","Comparison of Preoperative and Postoperative Radiotherapy and Capecitabine in Locally Advanced Rectal Cancer","Completed","No Results Available","Rectal Cancer","Radiation: Preoperative chemoradiotherapy|Radiation: Postoperative chemoradiotherapy","Asan Medical Center","Both","19 Years to 75 Years   (Adult, Senior)","Phase 3","240","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC Rectal Pre Vs Post 2004","August 18, 2010","March 2004","August 2009","August 20, 2010","August 2010","No Study Results Posted","null","April 2009","Disease-free survival|Overall survival|Local relapse-free survival|Sphincter preservation rate|Treatment related toxicities","https://ClinicalTrials.gov/show/NCT01186081"
3695,"NCT02280070","RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).","Recruiting","No Results Available","Rectal Cancer","Other: Laboratory test|Other: Medical history and physical examination|Other: BW and height|Other: Performance status|Other: Creatinine clearance|Other: Biomarker|Radiation: Contrasting CT|Other: Adverse event|Other: HBs antigen and HCV antibody|Other: Endoscopy|Other: HBs antibody and HBc antibody|Drug: S-1|Drug: L-OHP (130mg/m2)|Drug: L-OHP (85 mg/m2)|Drug: l-LV|Drug: 5-FU","Clinical Research Support Center Kyush","Both","20 Years and older   (Adult, Senior)","Phase 2","110","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KSCC1301","October 16, 2014","September 2013","August 2020","October 29, 2014","October 2014","No Study Results Posted","null","August 2018","3-years Disease Free Survival rate|Pathological Effect|R0 resection rate|Completion rate of each modality (neoadjuvant chemotherapy, operation and adjuvant chemotherapy)|Overall survival (OS)|Disease Free survival (DFS)|OS in patients with R0 resection|DFS in patients with R0 resection|Transition rate to Operation|local recurrence rate (per operated population)|Safety|Pattern of first recurrence","https://ClinicalTrials.gov/show/NCT02280070"
3696,"NCT00952926","Watchful Waiting. An Observational Study of Patients With Rectal Cancer After Concomitant Radiation and Chemotherapy","Active, not recruiting","No Results Available","Rectal Cancer","","Vejle Hospital","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","S-20090063","August 3, 2009","September 2009","December 2018","May 24, 2016","May 2016","No Study Results Posted","null","January 2014","Frequency of local recurrence|Frequency of cumulative local recurrence|Frequency of distant metastases verified by planned PET/CT scans|Overall survival","https://ClinicalTrials.gov/show/NCT00952926"
3697,"NCT02408861","Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors","Recruiting","No Results Available","Anal Carcinoma|HIV Infection|Kaposi Sarcoma|Lung Carcinoma|Solid Neoplasm","Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab","National Cancer Institute (NCI)","Both","19 Years and older   (Adult, Senior)","Phase 1","42","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2015-00461|PAMC-095_R03PAPP01|AMC-095|U01CA121947","April 3, 2015","August 2015","null","August 31, 2016","August 2016","No Study Results Posted","null","December 2020","Maximum tolerated dose of nivolumab defined as the starting dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT|Change in HIV viral load|Change in immune status|Immune function|Objective response rate","https://ClinicalTrials.gov/show/NCT02408861"
3698,"NCT00964457","Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients","Not yet recruiting","No Results Available","Rectum Cancer","Drug: cetuximab","Copenhagen University Hospital at Herlev","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GI0905","August 21, 2009","August 2009","July 2017","August 24, 2009","August 2009","No Study Results Posted","null","July 2012","response rate","https://ClinicalTrials.gov/show/NCT00964457"
3699,"NCT02843191","Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy","Not yet recruiting","No Results Available","Rectal Cancer","Drug: Chemotherapy","Kyung Hee University Hospital at Gangdong|Korean Society of ColoProctology","Both","20 Years to 75 Years   (Adult, Senior)","Phase 3","316","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KSCP2016","July 19, 2016","October 2016","September 2021","September 13, 2016","September 2016","No Study Results Posted","null","September 2021","Disease-free survival|Pathologic complete response|Radiotherapy-related complications|R0 resection|Postoperative complications|Peripheral neuropathy","https://ClinicalTrials.gov/show/NCT02843191"
3700,"NCT00254436","A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients","Terminated","No Results Available","Gastrointestinal Cancer|Rectal Cancer","Drug: Procrit (epoetin alfa)","M.D. Anderson Cancer Center|Ortho Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 3","50","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","ID00-264","November 14, 2005","December 2002","June 2004","July 27, 2012","July 2012","No Study Results Posted","null","June 2004","Number of Patients with Reduction in Red Blood Cell Transfusions|Patient Iron Levels","https://ClinicalTrials.gov/show/NCT00254436"
3701,"NCT02165800","Multicenter Study on Laparoscopic Versus Open PANP-TME for Male Mid-low Rectal Cancer Patients","Recruiting","No Results Available","Rectum Neoplasms","Procedure: L-PANP-TME|Procedure: O-PANP-TME","Third Affiliated Hospital, Sun Yat-Sen University|First Affiliated Hospital, Sun Yat-Sen University|Sixth Affiliated Hospital, Sun Yat-sen University|Nanfang Hospital of Southern Medical University|Southern Medical University, China","Male","20 Years to 60 Years   (Adult)","","667","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CUSTOMER-001","June 10, 2014","January 2014","December 2023","November 7, 2015","November 2015","No Study Results Posted","null","December 2019","3-year disease free survival rate|Urinary function|Sexual function|5-year disease free survival rate|Morbidity|3-year overall survival rate|Mortality|5-year overall survival rate","https://ClinicalTrials.gov/show/NCT02165800"
3702,"NCT02550743","BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study","Recruiting","No Results Available","Rectal Cancer","Drug: BYL719|Drug: Capecitabine|Radiation: Radiation","howard safran|Brown University|Lifespan|Novartis Pharmaceuticals Corporation (Financial supporter)","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG 302","September 11, 2015","June 2016","June 2018","June 3, 2016","June 2016","No Study Results Posted","null","December 2017","Maximum tolerated dose of BYL719|Pathologic complete response for patients with rectal cancer","https://ClinicalTrials.gov/show/NCT02550743"
3703,"NCT00001805","A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab","Completed","No Results Available","Breast Neoplasms|Colonic Neoplasms|Lung Neoplasms|Pancreatic Neoplasms|Stomach Neoplasms","Drug: Rituximab","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","Child, Adult, Senior","Phase 2","20","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","990071|99-C-0071","November 3, 1999","March 1999","June 2000","March 3, 2008","March 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001805"
3704,"NCT02704520","Magnetic Resonance Tumour Regression Grade as Biomarker for Stratified Management of Rectal Cancer Patients","Recruiting","No Results Available","Rectal Cancer","Drug: Capecitabine|Drug: Oxaliplatin|Drug: 5-fluorouracil|Drug: Folinic Acid","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","90","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CCR4326","February 5, 2016","March 2016","December 2021","August 17, 2016","August 2016","No Study Results Posted","TRIGGER","December 2016","Patient recruitment rate|pathology circumferential resection margin (pCRM) involvement rate|Drug toxicity|Surgical morbidity|Quality of surgery|Strength of agreement of reported mrTRG between site and central radiologists","https://ClinicalTrials.gov/show/NCT02704520"
3705,"NCT02682589","Open Versus Laparoscopic Complete Mesocolic Excision for Locally Advanced Colon Cancer","Recruiting","No Results Available","Colon Cancer","Procedure: Open surgery|Procedure: Laparoscopic surgery","The First Affiliated Hospital with Nanjing Medical University|West China Hospital|Changhai Hospital|Chinese PLA General Hospital|Peking Union Medical College Hospital|Ruijin Hospital|RenJi Hospital|Shanghai Changzheng Hospital|Wuhan Union Hospital, China|Fujian Medical University|First Affiliated Hospital of Chongqing Medical University","Both","18 Years and older   (Adult, Senior)","Phase 3","1080","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRSYM201602","February 4, 2016","April 2016","April 2023","July 3, 2016","July 2016","No Study Results Posted","OLCMECC","April 2023","disease-free survival|overall survival|recurrence-free survival|local recurrence rate|length of postoperative hospital stay|early complication rate|operative time|completeness of the mesocolon of the specimen|number of lymph nodes retrieved|postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire","https://ClinicalTrials.gov/show/NCT02682589"
3706,"NCT02164136","Laparoscopic Versus Open PANP-TME for Male Mid-low Rectal Cancer Patients","Recruiting","No Results Available","Rectum Neoplasms","Procedure: L-PANP-TME|Procedure: O-PANP-TME","Third Affiliated Hospital, Sun Yat-Sen University","Male","20 Years to 60 Years   (Adult)","","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CUSTOMER-01","June 11, 2014","June 2014","June 2023","November 7, 2015","November 2015","No Study Results Posted","null","June 2019","3-year disease free survival rate|Urinary function|Sexual function|5-year disease free survival rate|Morbidity|3-year overall survival rate|3-year recurrence pattern|Mortality|5-year overall survival rate|5-year recurrence pattern","https://ClinicalTrials.gov/show/NCT02164136"
3707,"NCT02151019","Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer","Recruiting","No Results Available","Locally Advanced Rectal Cancer","Radiation: IMRT","Cancer Trials Ireland","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","268","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ICORG 12-38","May 27, 2014","August 2014","July 2030","June 27, 2016","June 2016","No Study Results Posted","TRI-LARC","August 2020","Reduction in incidence of grade 2 or higher GI toxicity|Compare incidence of acute grade > 2 GU toxicity|Evaluate incidence of late GI and GU toxicity|Rate of loco-regional control|Assess quality of life|Rate of disease free survival|Estimate overall survival","https://ClinicalTrials.gov/show/NCT02151019"
3708,"NCT01804790","Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer","Recruiting","No Results Available","Cancer of the Rectum","Drug: mFolfirinox|Radiation: Radiotherapy 50Gy|Drug: Capecitabine|Procedure: TME surgery|Drug: mFolfox6 or capecitabine","UNICANCER","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","460","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PRODIGE 23 - UCGI 23","March 1, 2013","January 2012","January 2022","June 16, 2016","June 2016","No Study Results Posted","Néofirinox","June 2017","disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01804790"
3709,"NCT00597311","Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer","Recruiting","No Results Available","Primary Rectal Cancer","Radiation: radiotherapy","Kaunas University of Medicine","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BE-2-48|137/2006","January 9, 2008","January 2007","January 2012","January 9, 2008","January 2008","No Study Results Posted","null","January 2012","5 years overall and disease free survival|recurrence rate|pathological ""complete response"" and downstaging rates|Impact on sphincter sparing operation rates|morbidity and mortality rates|Impact on quality of surgical resection","https://ClinicalTrials.gov/show/NCT00597311"
3710,"NCT01918527","Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer","Recruiting","No Results Available","Colon Cancer","Drug: Capecitabine|Drug: Oxaliplatin","Vejle Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","250","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NeoCol","August 6, 2013","September 2013","August 2019","August 3, 2016","August 2016","No Study Results Posted","null","August 2018","Two-year disease free survival|Rate of patients fulfilling the criteria for adjuvant chemotherapy","https://ClinicalTrials.gov/show/NCT01918527"
3711,"NCT02546596","The Effect of Electro-Hyperthermia in Preoperative Radiotherapy for Locally Advanced Rectal Cancer","Recruiting","No Results Available","Rectal Cancer|Hyperthermia","Device: Electro-hyperthermia","Yonsei Hyperthermia Study Group","Both","19 Years to 85 Years   (Adult, Senior)","Phase 2","72","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","YURO-H1","September 6, 2015","April 2014","February 2022","July 11, 2016","July 2016","No Study Results Posted","null","March 2017","T stage (0 - 4), N (0 - 3) stage, tumor regression grade (0 - 4)|Survival (months)|Treatment toxicity (grade 0 - 5)","https://ClinicalTrials.gov/show/NCT02546596"
3712,"NCT01436617","Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab","Completed","No Results Available","Colon Cancer|Head and Neck Cancer|Allergic Reaction","Other: blood sample","Centre Francois Baclesse|University Hospital, Caen","Both","18 Years and older   (Adult, Senior)","Phase 2","303","Other","Observational","Time Perspective: Prospective","IgES","September 14, 2011","January 2010","March 2013","March 7, 2013","March 2013","No Study Results Posted","IgES","March 2013","Validate the utility of an IgE anti-cetuximab test in the treatment strategy","https://ClinicalTrials.gov/show/NCT01436617"
3713,"NCT00004074","Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu","Completed","No Results Available","Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage III Bladder Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IVA Cervical Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome","Biological: recombinant interleukin-12|Biological: ABI-007/carboplatin/trastuzumab","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","15","NIH","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01398|99H0185|U01CA076576|CDR0000067282","December 10, 1999","August 1999","null","February 27, 2013","February 2013","No Study Results Posted","null","February 2009","Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 2.0 (CTCAE v2.0)","https://ClinicalTrials.gov/show/NCT00004074"
3714,"NCT02727153","""Ultra"" Enhanced Recovery After Surgery (E.R.A.S.) in Laparoscopic Colectomy for Cancer","Completed","No Results Available","Colonic Cancer","Other: ""Ultra"" E.R.A.S.|Other: Classic E.R.A.S.","AUSL Romagna Rimini","Both","18 Years to 90 Years   (Adult, Senior)","Phase 3","765","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AUSLR","March 10, 2016","January 2008","December 2015","April 2, 2016","March 2016","No Study Results Posted","null","December 2015","Mortality|Morbidity|Reoperation rate|Readmission rate","https://ClinicalTrials.gov/show/NCT02727153"
3715,"NCT02301338","Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing","Terminated","No Results Available","Colon Cancer","Other: Usual care|Other: Videoconferencing|Device: IPad","Memorial Sloan Kettering Cancer Center","Both","65 Years and older   (Adult, Senior)","","2","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","14-213","November 21, 2014","November 2014","null","April 26, 2016","April 2016","No Study Results Posted","null","April 2016","acute healthcare utilization (AHCU) rates","https://ClinicalTrials.gov/show/NCT02301338"
3716,"NCT02572141","FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)","Recruiting","No Results Available","Colon Cancer","Drug: Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|Drug: Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens","Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 3","738","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GIHSYSU10|C01","October 1, 2015","October 2015","October 2022","December 29, 2015","October 2015","No Study Results Posted","OPTICAL","October 2020","Disease-free survival|Curative resection rate|Overall survival (OS)|Relapse-free survival (RFS)|Down-staging of primary tumors|Toxicity assessed using the NCI common toxicity criteria, version 4.0.|Postoperative complications","https://ClinicalTrials.gov/show/NCT02572141"
3717,"NCT01589419","A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer","Completed","No Results Available","Locally Advanced Rectal Cancer","Drug: veliparib|Drug: capecitabine|Radiation: radiation","AbbVie (prior sponsor, Abbott)|AbbVie","Both","18 Years and older   (Adult, Senior)","Phase 1","32","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M12-950","April 30, 2012","June 2012","January 2015","January 20, 2015","January 2015","No Study Results Posted","null","January 2015","Determine the maximum tolerated dose (MTD) and/or establish the recommended phase two dose (RPTD)|Assess the safety (number of participants with adverse events and types of adverse events observed)|Assess the tolerability (number of participants with adverse events and types of adverse events observed)|Assess the pharmacokinetic profile by area under the curve vs. dose of veliparib","https://ClinicalTrials.gov/show/NCT01589419"
3718,"NCT00107679","A Study of Anal Cancer Development in HIV Infected People","Completed","No Results Available","HIV Infections|Anus Neoplasms","","National Institute of Allergy and Infectious Diseases (NIAID)","Both","13 Years and older   (Child, Adult, Senior)","","560","NIH","Observational","Time Perspective: Prospective","CPCRA 065G|SMART|10117","April 6, 2005","February 2005","March 2006","April 15, 2014","April 2014","No Study Results Posted","null","March 2006","Time to high-grade anal dysplasia or anal cancer|Time to anal cancer|time to low-grade or high-grade anal dysplasia|time to anal HPV infection|time to anal HPV infection with a specific strain, for types 16, 18, or 31|time to cervical HPV infection|time to cervical HPV infection with a specific strain, for types 16, 18, or 31|time to high-grade anal dysplasia|time from low-grade anal dysplasia to normal","https://ClinicalTrials.gov/show/NCT00107679"
3719,"NCT00979680","Sphincter-preserving Surgery After Preoperative Treatment of Ultra-low Rectal Carcinoma","Completed","No Results Available","Rectal Cancer","Radiation: High-Dose radiotherapy|Radiation: Chemo-radiotherapy","Institut du Cancer de Montpellier - Val d'Aurelle","Both","18 Years and older   (Adult, Senior)","Phase 3","207","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KBR-2001","September 17, 2009","April 2001","September 2007","September 18, 2009","September 2009","No Study Results Posted","GRECCAR1","null","Sphincter preservation rate|Tumor response according to rectal endo-echography|operative mortality and morbidity|anatomopathology margins (lateral and inferior)|Functional results (stoma closure, continence, manometry)|Local recurrence|Disease-free survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00979680"
3720,"NCT01347645","Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer","Active, not recruiting","No Results Available","Colon Cancer|Rectal Cancer","Drug: FOLFIRI|Drug: E7820","Eisai Inc.|PharmaBio Development Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","95","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E7820-702|2011-001762-18","April 28, 2011","October 2011","September 2014","July 17, 2014","July 2014","No Study Results Posted","null","September 2014","Safety parameter: adverse events|Safety Parameter: Concomitant medications|Safety parameter: lab tests|Safety parameter: ECGs|Efficacy parameter: Time to progression (TTP)|Efficacy parameter: Overall survival (OS|Efficacy parameter: Overall response rate (ORR)","https://ClinicalTrials.gov/show/NCT01347645"
3721,"NCT00795301","A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab","Active, not recruiting","No Results Available","Rectal Cancer","Drug: Capecitabine, Cetuximab, Oxaliplatin","National University Hospital, Singapore","Both","21 Years and older   (Adult, Senior)","Phase 2","74","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Primary Purpose: Treatment","CR02/06/07","November 20, 2008","July 2008","null","January 13, 2014","January 2014","No Study Results Posted","null","December 2014","","https://ClinicalTrials.gov/show/NCT00795301"
3722,"NCT02551471","Benchmarking Trial Between France and Australia Comparing Management of Primary Rectal Cancer Beyond TME (Total Mesorectum Excision) and Locally Recurrent Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Other: Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|Other: MDT (Multidisciplinary team) meeting observation|Other: Semi-structured exploratory interviews and focus group with MDT health professional attendees","University Hospital, Bordeaux","Both","18 Years and older   (Adult, Senior)","","240","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUBX 2014/37","August 31, 2015","May 2015","March 2018","June 27, 2016","June 2016","No Study Results Posted","PELVICARE","December 2017","Clinical resection rates in both countries|Concordance rate of operative decisions between France and Australia|R0 resection rate|Disease Free Survival|Overall Survival|Post-operative morbidity and mortality rates|Quality of life questionnaire|Stress level score|Analyses of semi-structured interviews","https://ClinicalTrials.gov/show/NCT02551471"
3723,"NCT01613469","Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms","Drug: 5FU/Leucovorin|Radiation: external beam photon radiation","Marks, John, M.D.","Both","18 Years and older   (Adult, Senior)","Phase 2","35","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","R12-3092L","June 5, 2012","August 2011","August 2017","April 1, 2015","April 2015","No Study Results Posted","null","August 2017","To assess the complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer.|The proportion of subjects with complete pathological response at surgical resection","https://ClinicalTrials.gov/show/NCT01613469"
3724,"NCT01421940","The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: Placebo drug|Drug: Udenafil","Kyungpook National University","Male","20 Years to 65 Years   (Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","KNUHCRC002","August 1, 2011","October 2009","October 2013","March 9, 2015","March 2015","No Study Results Posted","null","December 2011","Change from baseline in International Index of Erectile Function (5-item Version) at 12 and 24 week|Change from baseline in SEP Q2,Q3 and GEQ|Number of patients with adverse events during 24 weeks of the study","https://ClinicalTrials.gov/show/NCT01421940"
3725,"NCT02528175","Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer","Recruiting","No Results Available","Recurrent Rectal Cancer","Device: Magnetic resonance-guided focused ultrasound|Radiation: Standard Radiation|Drug: Chemotherapy","Dr. William Chu|Philips Medical Systems|Sunnybrook Health Sciences Centre","Both","18 Years and older   (Adult, Senior)","","20","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","273-2011|226861","June 9, 2015","April 2015","April 2020","April 13, 2016","April 2016","No Study Results Posted","null","April 2017","Acute toxicities|Late toxicities|The efficacy of MRg-FU in reducing pain|Patient quality of life|Assessment of radiologic response following treatment.","https://ClinicalTrials.gov/show/NCT02528175"
3726,"NCT00263029","Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer","Completed","No Results Available","Rectal Neoplasms","Drug: Oxaliplatin|Drug: Capecitabine|Radiation: Radiotherapy","Sanofi","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","L_8479","December 6, 2005","June 2002","null","September 17, 2009","September 2008","No Study Results Posted","PROCTFUL","March 2007","Response rate (both clinical and pathological) of the primary rectal cancer observed after the chemoradiotherapy. Histologically confirmed complete resection rate (R0 rate).|Adverse events collection","https://ClinicalTrials.gov/show/NCT00263029"
3727,"NCT00275210","MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer","Completed","No Results Available","Colonic Neoplasms","Drug: Oxaliplatin (SR96669)","Sanofi","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","2246","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC3313","January 3, 2006","October 1998","April 2003","April 17, 2009","April 2009","No Study Results Posted","null","April 2003","To to detect occurrence of relapse the following examinations have to be performed for 5 years:|Every 6 months for ultrasound or abdominopelvic CT scan and CEA determination,|Every year for chest X-ray and colonoscopy for non polyp free patient,|Every 3 years colonoscopy for polyp free patient|Every 2 weeks clinical and laboratory tests (hematological, creatinine and liver tests) for safety evaluation during treatment then every 6 months neurological examination Date of death for OS","https://ClinicalTrials.gov/show/NCT00275210"
3728,"NCT00607282","Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer","Completed","No Results Available","Erectile Dysfunction|Sigmoid Colon Cancer|Rectal Cancer","Drug: Udenafil","Seoul National University Hospital","Male","19 Years to 70 Years   (Adult, Senior)","Phase 2","46","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","B-0610-038-004|SNUBH-GS-CR2","January 22, 2008","March 2009","January 2012","September 2, 2012","September 2012","No Study Results Posted","null","January 2012","Improvement of erectile function using IIEF-5 (International Index of Erectile Function-5), SEP Q2, Q3 (Sexual Encounter Profile Q2,Q3), and GEQ (Global efficacy Question)|Improvement of erectile function using IIEF-5, SEP Q2,Q3, and GEQ","https://ClinicalTrials.gov/show/NCT00607282"
3729,"NCT02157246","RHYTHM-I: Investigating Hypoxia in Rectal Tumours","Active, not recruiting","No Results Available","Hypoxia in Rectal Cancer","Other: Pimonidazole|Other: F-MISO scan","University of Oxford","Both","18 Years and older   (Adult, Senior)","Phase 0","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","OCTO_043","October 10, 2013","October 2013","December 2016","August 18, 2016","August 2016","No Study Results Posted","RHYTHM-I","December 2016","Group A FMISO-PET derived hypoxic volumes|Group B Percentage change in FMISO-PET SUVmax and uptake volume|Hypoxia gene microarray read outs from biopsies|FMISO-PET SUVmax|pCT derived blood flow parameters|Comparison of changes in T1/T2* MRI","https://ClinicalTrials.gov/show/NCT02157246"
3730,"NCT01209325","Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males","Active, not recruiting","No Results Available","Anal Cancer|Nonneoplastic Condition|Penile Cancer|Precancerous Condition","Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Other: laboratory biomarker analysis","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas","Male","13 Years to 26 Years   (Child, Adult)","Phase 2","149","Other|NIH|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","AMC-072|U01CA121947|CDR0000685816","September 24, 2010","June 2011","December 2018","December 23, 2015","December 2015","No Study Results Posted","null","December 2017","Any incident of AIN or anal/perianal condyloma associated with HPV 16, 18, 6, or 11 DNA|Diagnosis of HGAIN related to vaccine HPV types at any time during the study|Any persistent anogenital infection with HPV 16, 18, 6, or 11 DNA|Occurrence of grade ≥ 3 AEs that are possibly, probably, or definitely related to the vaccine|Longitudinal changes in plasma HIV-1 RNA and CD4+ cell count from baseline|Level of HPV antibodies to types 6, 11, 16, and 18 at baseline; one month after the completion of HPV vaccination series; and at weeks 52, 76, and 104|Level of HPV DNA before and after vaccination|Type and level of HPV DNA in the oral cavity|HPV strain variation before and after receipt of the quadrivalent HPV vaccine|Baseline prevalence and incidence of penile gonorrhea and Chlamydia infection|Change in young men's risk perceptions, sexual behaviors, and STI diagnosis after HPV vaccination","https://ClinicalTrials.gov/show/NCT01209325"
3731,"NCT02374931","18F-FES PET/CT in Imaging Patients With Desmoid Tumors","Recruiting","No Results Available","Deep Fibromatosis/Desmoid Tumor|Familial Adenomatous Polyposis","Radiation: F-18 16 Alpha-Fluoroestradiol|Procedure: Positron Emission Tomography|Procedure: Computed Tomography|Other: Laboratory Biomarker Analysis","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","10","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","VICC SAR 1458|NCI-2015-00081|P30CA068485","February 16, 2015","April 2015","December 2018","June 17, 2016","June 2016","No Study Results Posted","null","December 2018","Standard uptake value (SUV) measured as percent injected dose per cc|IHC staining intensity in tissue samples","https://ClinicalTrials.gov/show/NCT02374931"
3732,"NCT02656134","Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)","Recruiting","No Results Available","Familial Adenomatous Polyposis","Procedure: Duodenoscopy and enteroscopy|Genetic: Molecular analysis.","University of Sao Paulo","Both","15 Years to 65 Years   (Child, Adult)","","55","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Small bowel profile in FAP","January 2, 2016","March 2015","December 2016","January 12, 2016","January 2016","No Study Results Posted","null","September 2016","Genetic profile in FAP patients","https://ClinicalTrials.gov/show/NCT02656134"
3733,"NCT01846520","Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers","Recruiting","No Results Available","Healthy, no Evidence of Disease|Localized Transitional Cell Cancer of the Renal Pelvis and Ureter|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Psychosocial Effects of Cancer and Its Treatment|Recurrent Bladder Cancer|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Gastric Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Uterine Sarcoma|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Stage II Bladder Cancer|Stage II Renal Cell Cancer|Stage II Urethral Cancer|Stage IIA Cervical Cancer|Stage IIA Colon Cancer|Stage IIA Gastric Cancer|Stage IIA Ovarian Epithelial Cancer|Stage IIA Ovarian Germ Cell Tumor|Stage IIA Pancreatic Cancer|Stage IIA Rectal Cancer|Stage IIA Uterine Sarcoma|Stage IIB Cervical Cancer|Stage IIB Colon Cancer|Stage IIB Gastric Cancer|Stage IIB Ovarian Epithelial Cancer|Stage IIB Ovarian Germ Cell Tumor|Stage IIB Pancreatic Cancer|Stage IIB Rectal Cancer|Stage IIB Uterine Sarcoma|Stage IIC Colon Cancer|Stage IIC Ovarian Epithelial Cancer|Stage IIC Ovarian Germ Cell Tumor|Stage IIC Rectal Cancer|Stage III Bladder Cancer|Stage III Pancreatic Cancer|Stage III Renal Cell Cancer|Stage III Urethral Cancer|Stage IIIA Cervical Cancer|Stage IIIA Colon Cancer|Stage IIIA Gastric Cancer|Stage IIIA Ovarian Epithelial Cancer|Stage IIIA Ovarian Germ Cell Tumor|Stage IIIA Rectal Cancer|Stage IIIA Uterine Sarcoma|Stage IIIB Cervical Cancer|Stage IIIB Colon Cancer|Stage IIIB Gastric Cancer|Stage IIIB Ovarian Epithelial Cancer|Stage IIIB Ovarian Germ Cell Tumor|Stage IIIB Rectal Cancer|Stage IIIB Uterine Sarcoma|Stage IIIC Colon Cancer|Stage IIIC Gastric Cancer|Stage IIIC Ovarian Epithelial Cancer|Stage IIIC Ovarian Germ Cell Tumor|Stage IIIC Rectal Cancer|Stage IIIC Uterine Sarcoma|Stage IV Bladder Cancer|Stage IV Gastric Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Stage IV Urethral Cancer|Stage IVA Cervical Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVA Uterine Sarcoma|Stage IVB Cervical Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer|Stage IVB Uterine Sarcoma|Ureter Cancer","Other: educational intervention|Behavioral: telephone-based intervention|Procedure: quality-of-life assessment|Other: questionnaire administration","City of Hope Medical Center|National Cancer Institute (NCI)|American Cancer Society (ACS) National Office","Both","18 Years and older   (Adult, Senior)","","200","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","08176|NCI-2013-00839","May 1, 2013","October 2013","null","July 12, 2016","July 2016","No Study Results Posted","null","October 2023","Effects of Family Caregiver Palliative Care Intervention (FCPCI) on caregiver burden|Effects of FCPCI on caregiving skills preparedness|Effects of FCPCI on Quality Of Life (QOL)|Effects of FCPCI on psychological distress|Caregiver's self-care behavior|Caregivers' resource use|Identification of subgroups of family caregivers who benefit most from the FCPCI in relation to sociodemographic, health status, and patient characteristics|Family caregivers' satisfaction with the FCPCI|Caregiver out-of-pocket costs","https://ClinicalTrials.gov/show/NCT01846520"
3734,"NCT02498353","Comparing Preoperative Short-course Radiotherapy With or Without Local Boost for Rectal Cancer","Not yet recruiting","No Results Available","Rectal Cancer","Radiation: preoperative short-course radiotherapy with local boost|Radiation: preoperative short-course radiotherapy without local boost|Procedure: TME surgery","Zhongnan Hospital","Both","18 Years to 70 Years   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","ZNHCR","June 28, 2015","July 2015","May 2020","July 10, 2015","July 2015","No Study Results Posted","null","May 2020","pathological complete remission rate|disease free survival|sphincter retention rate|toxicity of radiotherapy based on the CTCAE v3.0 (common terminology criteria for adverse events，CTCAE v3.0)","https://ClinicalTrials.gov/show/NCT02498353"
3735,"NCT02314169","Nivolumab in Treating Patients With Refractory Metastatic Anal Canal Cancer","Active, not recruiting","No Results Available","Anal Canal Squamous Cell Carcinoma|Metastatic Anal Canal Carcinoma|Recurrent Anal Canal Carcinoma","Other: Laboratory Biomarker Analysis|Biological: Nivolumab","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 2","37","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2014-02420|NCI9673|P9673_R03PAPPHOLD01|9673|N01CM00100|N01CM00032|N01CM00038|N01CM00039|N01CM00071|N01CM00099|P30CA016672|UM1CA186704","December 10, 2014","May 2015","null","July 12, 2016","July 2016","No Study Results Posted","null","September 2016","Overall response rate|Incidence of toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT02314169"
3736,"NCT00572143","Follow-up After Surgery for Colon Cancer. General Practice vs. Surgical-based Follow-up?","Completed","No Results Available","Colon Cancer","Other: ca coli follow-up by GP","University Hospital of North Norway","Both","20 Years to 75 Years   (Adult, Senior)","","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","P-REK NORD 79/2006","December 11, 2007","June 2007","June 2013","January 26, 2016","January 2016","No Study Results Posted","ONKOLINK","December 2012","Quality of life; EORTC-QLQ-C30 and EQ 5D|Cost-effectiveness Serious clinical events","https://ClinicalTrials.gov/show/NCT00572143"
3737,"NCT02291744","A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients","Recruiting","No Results Available","Metastatic Colon Cancer","Procedure: resection of primary lesion|Drug: XELOX","Fudan University","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","130","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","guoweijian-2014-XELOX","November 4, 2014","October 2014","October 2017","November 10, 2015","November 2015","No Study Results Posted","null","October 2017","TFS time of failure of strategy (the second progression time after induction therapy, or time to the use of second line strategy (if no reapplication of induction therapy) or time to no further treatment)","https://ClinicalTrials.gov/show/NCT02291744"
3738,"NCT00581815","Spectroscopy With Surface Coils and Decoupling","Completed","No Results Available","Adrenal Cortical Cancer|Brain Cancer|Breast Cancer|CNS Cancer|Colon Cancer|HEENT Cancer|Hodgkin's Disease|Kaposi's Sarcoma|Liver Cancer|Lung Cancer|Non-Hodgkin's Lymphoma|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Rectal Cancer|Renal Cancer|Sarcoma|Squamous Cell Carcinoma|Thyroid Cancer","Device: Proton-decoupled 31P MRS at 1.5T|Device: 1H Spectroscopy at 1.5T and 3T","Memorial Sloan Kettering Cancer Center|Columbia University|University of Pennsylvania|St. George's Hospital, London|Royal Marsden NHS Foundation Trust|University Medical Center Nijmegen|Weill Medical College of Cornell University","Both","18 Years and older   (Adult, Senior)","Phase 1","582","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","97-014","December 20, 2007","February 1997","February 2014","December 23, 2015","December 2015","No Study Results Posted","null","February 2014","To obtain high resolution spectra from tumors using surface coils to improve sensitivity.|In some of these studies, to enhance our spectral resolution and obtain additional metabolic information, we propose to use decoupling, which will increase both signal quality (the signal to noise ratio) and spectral resolution.","https://ClinicalTrials.gov/show/NCT00581815"
3739,"NCT02340949","Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Drug: Aflibercept|Drug: 5-Fluoruracil|Drug: Oxaliplatin|Drug: Leucovorin","Grupo Espanol Multidisciplinario del Cancer Digestivo|Pivotal S.L.","Both","18 Years to 69 Years   (Adult, Senior)","Phase 2","180","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEMCAD-1402","January 9, 2015","January 2015","March 2020","February 10, 2015","February 2015","No Study Results Posted","RIA","March 2017","To evaluate the efficacy (number of patients achieving pCR) of induction therapy with mFOLFOX6 +/- aflibercept followed by CT/RT in terms of pathologic complete response (pCR).|To evaluate pathological parameters of efficacy: R0 resection, TRG, and positive or negative CRM rate|To evaluate the relationship between MRI changes with outcome. (T Downstaging: defined as a lower pathologic T stage compared to pre-treatment mrT stage)|To further characterize the safety and tolerability of mFOLFOX6 +/- aflibercept followed chemoradiation (assessed by means of AEs and changes in laboratory data. AEs will be coded and evaluated using the NCI-CTCAE v4.0 toxicity criteria)|To determine the rate of 30 days surgical complications (assessed by means of AEs reported)|To evaluate the 3 years local recurrence and DFS|To determine the levels of tumor biomarkers expression at baseline and correlate them with response to treatment with mFOLFOX6 + aflibercept.","https://ClinicalTrials.gov/show/NCT02340949"
3740,"NCT02130492","A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)","Recruiting","No Results Available","Radiosensitive Stage IV Solid and Hematological Tumors With High FDG Uptake Not Responding to Standard of Care|Lung Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Pancreatic Cancer, Colon Cancer, Lymphomas, Sarcomas, Etc","Radiation: FDG","Northwell Health","Both","21 Years and older   (Adult, Senior)","Phase 1","6","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB# 13-382A","May 1, 2014","May 2014","July 2017","August 18, 2016","August 2016","No Study Results Posted","null","July 2017","Number of Participants with Serious and Non-Serious Adverse Events and Type of Serious and Non-Serious Adverse Events|Efficacy Outcome Measure","https://ClinicalTrials.gov/show/NCT02130492"
3741,"NCT01941966","A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.","Completed","No Results Available","Anal Canal Cancer.","Drug: Capecitabine|Drug: Mitomycins|Radiation: Radiotherapy","Instituto do Cancer do Estado de São Paulo","Both","18 Years and older   (Adult, Senior)","Phase 2","51","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NP 84/2010","September 5, 2013","November 2010","null","March 26, 2014","March 2014","No Study Results Posted","null","November 2013","The primary endpoint will be local control rate after 6 months of the end of radiotherapy and chemotherapy, defined by the rate of radiological and clinical neoplasia.|Treatment Toxicity|Complete Response|Overall survival|Progression-free survival|Colostomy rate","https://ClinicalTrials.gov/show/NCT01941966"
3742,"NCT01721785","Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer","Suspended","No Results Available","Rectal Neoplasms|Magnetic Resonance Imaging|Neoplasms Staging","Drug: Gadofosveset trisodium","Maastricht University Medical Center|Dutch Cancer Society","Both","18 Years and older   (Adult, Senior)","","450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-2-051|2012-002935-27","November 1, 2012","October 2012","July 2016","March 15, 2016","November 2014","No Study Results Posted","null","July 2016","Diagnostic performance of the techniques under investigation|To determine the inter-observer agreement for the imaging techniques under investigation","https://ClinicalTrials.gov/show/NCT01721785"
3743,"NCT02629315","Carnoy`s Solution Versus Formalin in Rectal Cancer Specimens Following Neoadjuvant Chemoradiation: a Randomized Trial","Completed","No Results Available","Rectal Cancer","Other: Carnoy's solution|Other: 10% neutral buffered formaldehyde","Instituto do Cancer do Estado de São Paulo","Both","Child, Adult, Senior","","130","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Diagnostic","NP458/13","December 10, 2015","May 2012","March 2015","December 11, 2015","December 2015","No Study Results Posted","null","March 2015","Lymph node yield|Dissection duration","https://ClinicalTrials.gov/show/NCT02629315"
3744,"NCT01461525","Comparison of Sphincter Preservation Surgery and Abdominoperineal Resection (APR): Prospective Clinical Trial","Recruiting","No Results Available","Rectal Cancer","Procedure: Abdominoperineal resection|Procedure: Sphincter preservation surgery","Seoul National University Hospital|Seoul National University Bundang Hospital|National Cancer Center, Korea|Seoul National University Boramae Hospital|Hallym University Medical Center|Daehang Hospital","Both","20 Years to 80 Years   (Adult, Senior)","","294","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","APR-SPS trial","October 20, 2011","October 2011","June 2016","July 21, 2015","July 2015","No Study Results Posted","null","December 2015","Quality of life|Oncologic outcomes|Bladder function|Sexual function|Anal function","https://ClinicalTrials.gov/show/NCT01461525"
3745,"NCT02148731","MOST: Mediterranean Oncology Senior Tests","Active, not recruiting","No Results Available","Colon Cancer Patients Receiving Chemotherapy in the Adjuvant or Metastatic Setting|Aged 70 or Older","Other: Frailty markers","Association Sud pour la Recherche en Oncogériatrie","Both","70 Years and older   (Senior)","","180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ASRO101","May 23, 2014","January 2010","December 2015","May 27, 2014","May 2014","No Study Results Posted","MOST","December 2014","Occurrence of Adverse Events|Performance of the brief screening tool","https://ClinicalTrials.gov/show/NCT02148731"
3746,"NCT00531297","Endoscopic Posterior Mesorectal Resection in T1 Rectal Cancer","Recruiting","No Results Available","Rectal Neoplasms","Procedure: endoscopic posterior mesorectal resection","Cantonal Hospital of St. Gallen|Heidelberg University|University of Basel|University of Krakau, Department of Visceral surgery","Both","18 Years and older   (Adult, Senior)","Phase 3","96","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EKSG 05/072/2B","September 17, 2007","December 2005","December 2020","January 23, 2013","January 2013","No Study Results Posted","null","December 2020","Recurrence rate|Morbidity (>= CTCAE grade 3)|Perioperative mortality","https://ClinicalTrials.gov/show/NCT00531297"
3747,"NCT00096278","Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer","Completed","Has Results","Adenocarcinoma of the Colon|Stage IIA Colon Cancer|Stage IIB Colon Cancer|Stage IIC Colon Cancer|Stage IIIA Colon Cancer|Stage IIIB Colon Cancer|Stage IIIC Colon Cancer","Drug: oxaliplatin|Drug: leucovorin calcium|Drug: fluorouracil|Biological: bevacizumab","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 3","2710","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NCI-2012-03017|NSABP-C-08|U10CA012027","November 9, 2004","September 2004","December 2012","May 16, 2014","July 2013","October 31, 2012","null","March 2009","Disease-free Survival|Survival as Assessed by Death From Any Cause|Proteinuria After Completion of Bevacizumab|Proteinuria With Clinical Sequelae|The Risk Factors for Development of Proteinuria|As Measured by Blood Pressure and Antihypertensive Medication Hypertension|Delayed Vascular Events Such as Myocardial Infarction, Central Nervous System (CNS) Ischemia, and Thrombosis in Patients Receiving Chemotherapy + Bevacizumab|Ovarian Function in Premenopausal Women as Measured by Serum Ovarian Function Test|Bevacizumab Immunogenicity and Post-treatment Serum Levels of Bevacizumab in Patients Receiving Bevacizumab","https://ClinicalTrials.gov/show/NCT00096278"
3748,"NCT00654212","Endo-Laparoscopic Approach Versus Conventional Open Surgery in Obstructing Left-sided Colon Cancer: RCT","Completed","No Results Available","Colonic Neoplasms","Procedure: endo-laparoscopic approach|Procedure: open approach","Pamela Youde Nethersole Eastern Hospital","Both","18 Years and older   (Adult, Senior)","Phase 4","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","Shan","April 2, 2008","January 2002","December 2007","May 3, 2015","May 2015","No Study Results Posted","null","May 2005","successful one-stage operation|cumulative operative time, cumulative blood loss, conversion rate, post-operative pain, cumulative length of hospital stay, operative mortality, post-operative complications, ates of permanent stoma creation,disease recurrence, survival","https://ClinicalTrials.gov/show/NCT00654212"
3749,"NCT01171300","Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients","Active, not recruiting","No Results Available","Adenocarcinoma|Rectal Neoplasms","Other: 18F- FDG PET scans|Other: DW-MRI scans","Universitaire Ziekenhuizen Leuven","Both","18 Years and older   (Adult, Senior)","","94","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","S52399","July 13, 2010","October 2010","December 2016","December 3, 2015","December 2015","No Study Results Posted","null","December 2015","Pathologic complete response (ypT0N0) rate|Pathologic downstaging (ypT0-2N0) rate and Tumour Regression Grade (TRG); according to Dworak et al. Response rate at time of surgery (RECIST criteria based on MRI);|Quality of mesorectal excision.","https://ClinicalTrials.gov/show/NCT01171300"
3750,"NCT02488577","Outcomes of TAMIS-Total Mesorectal Excision Versus Transanal Loco-regional Excision for T2 Low Rectal Cancer","Enrolling by invitation","No Results Available","Low Rectal Cancer","Procedure: Transanal minimally invasive total mesorectal excision|Procedure: transanal minimally invasive locoregional resection","Osama Mohammad Ali ElDamshety|Mansoura University","Both","Child, Adult, Senior","Phase 1|Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","MISS-TRICKR2","June 30, 2015","June 2015","October 2018","July 1, 2015","July 2015","No Study Results Posted","TAMIS","June 2018","Overall percent of postoperative complications.|Hospital stay|Recurrence.","https://ClinicalTrials.gov/show/NCT02488577"
3751,"NCT00330915","A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.","Completed","Has Results","Rectal Neoplasms","Drug: pemetrexed","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 2","37","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9732|H3E-MC-S077","May 26, 2006","June 2006","June 2008","June 3, 2009","June 2009","June 3, 2009","null","June 2008","Feasibility of Pemetrexed Prior to Surgery|Pathological Complete Response (pCR)|Number of Participants With Complete Tumor Resection|Number of Participants Receiving Sphincter Saving Surgery","https://ClinicalTrials.gov/show/NCT00330915"
3752,"NCT00693173","Radiation Dosimetry Study Comparing 2 Different Patient Setups in Anal/Rectal Cancer Patients","Completed","No Results Available","Anal Cancer","","The University of Texas Medical Branch, Galveston","Male","18 Years to 80 Years   (Adult, Senior)","","14","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","07-049","June 4, 2008","July 2007","June 2009","February 11, 2013","February 2013","No Study Results Posted","null","June 2009","The Genital Drop Technique (IMRT-GD) decreased the radiation dose to the testicles scrotal skin and penile shaft compared to standard prone technique.|Dosimetry comparison details.","https://ClinicalTrials.gov/show/NCT00693173"
3753,"NCT02466113","A 6 microRNA Tool for Stratifying Stage II Colon Cancer of Receiving Adjuvant Chemotherapy","Not yet recruiting","No Results Available","Colonic Neoplasms|Effects of Chemotherapy","Other: A 6 microRNA stratified tool|Other: A classic stratified tool","First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-sen University|Third Affiliated Hospital, Sun Yat-Sen University|Sixth Affiliated Hospital, Sun Yat-sen University","Both","18 Years to 65 Years   (Adult)","","430","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","2015[28]","April 30, 2015","January 2016","January 2026","June 8, 2015","June 2015","No Study Results Posted","null","January 2026","Disease free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02466113"
3754,"NCT01376453","Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: Sorafenib|Drug: 5-Fluorouracil (5-FU)|Radiation: Radiation","H. Lee Moffitt Cancer Center and Research Institute|Bayer","Both","18 Years and older   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-16475|IST 000575","June 16, 2011","June 2011","March 2016","September 9, 2016","April 2016","No Study Results Posted","null","November 2014","Maximum Tolerated Dose (MTD)|Number of Participants With Pathologic Response|Number of Participants With Serious Adverse Events (SAEs)","https://ClinicalTrials.gov/show/NCT01376453"
3755,"NCT02431676","Survivorship Promotion In Reducing IGF-1 Trial","Recruiting","No Results Available","Breast Cancer|Prostate Cancer|Lung Cancer|Colon Cancer|Melanoma of Skin|Endometrial Cancer|Liver Cancer|Pancreatic Cancer|Rectal Cancer|Kidney Cancer|Other Solid Malignant Tumors","Drug: Metformin|Behavioral: Coach Directed Behavioral Weight Loss|Behavioral: Self-control weight loss","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","J14148|IRB00035653","April 21, 2015","May 2015","June 2018","August 12, 2016","August 2016","No Study Results Posted","SPIRIT","September 2017","IGF-1 levels|IGF-1 levels :IGFBP3 levels (Ratio)","https://ClinicalTrials.gov/show/NCT02431676"
3756,"NCT02774447","Day-Case Closure of Loop Ileostomy in Rectal Cancer","Recruiting","No Results Available","Ileostomy Closure in Rectal Cancer","Procedure: ileostoma closure","Uppsala University","Both","18 Years to 80 Years   (Adult, Senior)","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Dnr 2014/363","September 28, 2015","August 2015","August 2016","May 12, 2016","May 2016","No Study Results Posted","null","August 2016","Number of patients with complications|Number of patients re-admitted|Number of patients re-operated|Number of patients who were able to return home after day-case closure of loop-ileostomy","https://ClinicalTrials.gov/show/NCT02774447"
3757,"NCT00147550","MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.","Terminated","No Results Available","Melanoma|Colonic Neoplasms|Breast Neoplasms","Drug: PD-0325901","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","79","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4581001","September 2, 2005","February 2004","July 2013","September 11, 2013","September 2013","No Study Results Posted","null","May 2007","Objective Response Rate, Safety.|Time to progression, overall survival, patient reported outcomes.","https://ClinicalTrials.gov/show/NCT00147550"
3758,"NCT00394615","Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA","Terminated","No Results Available","Rectal Cancer","Procedure: Metabolic Imaging","Stanford University|Stanford Cancer Council","Both","18 Years and older   (Adult, Senior)","","15","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","REC0001","July 5, 2006","October 2003","October 2005","March 25, 2010","March 2010","No Study Results Posted","null","October 2005","To learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy.","https://ClinicalTrials.gov/show/NCT00394615"
3759,"NCT01325649","Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma","Recruiting","No Results Available","Rectal Cancer Stage II|Rectal Cancer Stage III","Procedure: total mesorectal excision / long course radiochemotherapy|Radiation: long course 5-FU bases radiochemotherapy","Johannes Gutenberg University Mainz","Both","18 Years and older   (Adult, Senior)","","782","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","Ocumstudy 19.08.2009","March 28, 2011","February 2009","July 2016","March 3, 2016","March 2016","No Study Results Posted","OCUM","June 2016","Locoregional recurrence rate|Rate of involvement of circumferential resection margin (pCRM positive of resected specimens","https://ClinicalTrials.gov/show/NCT01325649"
3760,"NCT01528683","Phase I/II Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Recurrent Rectal Cancer","Recruiting","No Results Available","Recurrent Rectal Cancer","Radiation: Carbon Ion Radiotherapy","University Hospital Heidelberg","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","45","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PANDORA","December 31, 2011","December 2012","December 2015","February 18, 2013","February 2013","No Study Results Posted","PANDORA","December 2015","Safety and Efficacy","https://ClinicalTrials.gov/show/NCT01528683"
3761,"NCT00137878","TNFerade™ Plus Chemo/Radiation/Surgery for Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: TNFerade™","GenVec","Both","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Randomized|Primary Purpose: Treatment","GV-001.007","August 26, 2005","null","null","February 22, 2012","May 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00137878"
3762,"NCT00910494","Intraoperative Radiotherapy for Rectal Cancer Using the Photon Radiosurgery System","Recruiting","No Results Available","Rectal Neoplasm","Radiation: Photon Radiosurgery System IORT|Radiation: Photon Radiosurgery System IORT","University of Dundee","Both","18 Years and older   (Adult, Senior)","Phase 1","25","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EB/JK/LET/LN1277","May 28, 2009","January 2010","January 2017","June 24, 2010","June 2010","No Study Results Posted","null","January 2012","surgical complication rate|survival|local control","https://ClinicalTrials.gov/show/NCT00910494"
3763,"NCT02584985","Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: ETAP|Procedure: Standard Transabdominal Laparoscopic Proctectomy","Institut Paoli-Calmettes","Both","18 Years and older   (Adult, Senior)","Phase 3","226","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ETAP-GRECCAR 11-IPC 2015-005","October 15, 2015","January 2016","January 2022","September 15, 2016","April 2016","No Study Results Posted","ETAP","January 2019","R1 resection rate|Failure rate (conversion to open)|Disease-free survival at 3 years","https://ClinicalTrials.gov/show/NCT02584985"
3764,"NCT01091558","Study of Effects of L-Arginine in Colitis and Colon Cancer","Active, not recruiting","No Results Available","Ulcerative Colitis|Colon Cancer","","Vanderbilt University|National Institutes of Health (NIH)|National Center for Complementary and Integrative Health (NCCIH)","Both","18 Years and older   (Adult, Senior)","","200","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","090943|3R01AT004821-02S1","March 18, 2010","September 2009","December 2016","December 17, 2015","December 2015","No Study Results Posted","null","September 2011","L-Arginine (L-Arg) availability in ulcerative colitis (UC) patients and normal control subjects, and correlate with disease activity|L-Arg intake in the diet of UC patients and control subjects","https://ClinicalTrials.gov/show/NCT01091558"
3765,"NCT00202111","Comparative Study of Laparoscopic Versus Open Operations for Colon Cancer","Active, not recruiting","No Results Available","Colonic Neoplasms","Procedure: Laparoscopic-assisted colectomy|Procedure: Conventional open colectomy","The Queen Elizabeth Hospital|National Health and Medical Research Council, Australia|Health Research Council, New Zealand|Ethicon Endo-Surgery","Both","18 Years and older   (Adult, Senior)","","600","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","83449871|NH&MRC ID 207815|NH&MRC ID 349381","September 12, 2005","January 1998","March 2010","October 16, 2006","February 2006","No Study Results Posted","null","null","Disease-free interval|Three-year survival|Five-year survival|30-day mortality|Postoperative pain|Paralytic ileus|Early morbidity|Late morbidity|Recovery|Transfusion requirement|Cost effectiveness|Quality of Life outcomes","https://ClinicalTrials.gov/show/NCT00202111"
3766,"NCT02268006","IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment","Recruiting","No Results Available","Rectal Carcinoma","Radiation: IMRT-SIB|Drug: Capecitabine|Procedure: Surgery","Institute of Oncology Ljubljana","Both","18 Years to 90 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","41/12/13","February 2, 2014","January 2014","December 2020","October 15, 2014","September 2014","No Study Results Posted","BISER","December 2015","Pathological complete remission rate (pCR)|Toxicity|Histopathological R0 resection rate|Tumor down-staging rate|Rate of sphincter sparing surgical procedure|Loco-regional failure rate|Disease-free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT02268006"
3767,"NCT01459328","Resource-Sparing Curative Treatment for Rectal Cancer","Recruiting","No Results Available","Rectal Carcinoma","Radiation: Radiotherapy|Radiation: Radiotherapy","International Atomic Energy Agency|Centre Anti Cancer Hopital Frantz Fanon|Hospital A.C. Camargo|Credit Valley Hospital|Instituto Nacional de Cancerologia, Columbia|University Hospital ""Sestre milosrdnice""|Minesterio de Cienca, Tecnologia y Medio Ambiente|V.N. Cancer Center GKNM Hospital|Tata Memorial Hospital|Dr Cipto Mangunkusumo General Hospital|National Cancer Center, Bratislava|University of Cape Town|Catholic University of the Sacred Heart","Both","18 Years and older   (Adult, Senior)","Phase 3","350","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E33034","October 10, 2011","September 2009","null","October 24, 2011","October 2011","No Study Results Posted","null","September 2013","Overall Survival|Biological Effect and Tumour Biology|Quality of Life|Health-related Economics","https://ClinicalTrials.gov/show/NCT01459328"
3768,"NCT02140723","p53 and Response to Preoperative Radiotherapy for T2 and T3","Recruiting","No Results Available","Rectal Cancer","Radiation: preoperative short course radiation","Medical University of Vienna","Both","18 Years to 99 Years   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PART1","April 30, 2014","August 2011","June 2018","March 17, 2016","March 2016","No Study Results Posted","PART1","December 2017","Interaction between the status of the biomarker TP53 and response to treatment|pCR rate|complete resection rate|relapse|overall survival","https://ClinicalTrials.gov/show/NCT02140723"
3769,"NCT01095432","Partial Wave Spectroscopic Detection of Colon Cancer Risk","Completed","No Results Available","Ulcerative Colitis|Colon Cancer","Procedure: PWS Testing","University of Chicago|Northwestern University","Both","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","10-066-B","March 24, 2010","March 2010","November 2015","May 20, 2016","May 2016","No Study Results Posted","Brushings","November 2015","Study samples of rectal mucosa (the moist lining of the rectum) using PWS.","https://ClinicalTrials.gov/show/NCT01095432"
3770,"NCT01261962","Modulation of Immune Response by Oral Zinc Supplementation in Chemotherapy for Colon Cancer","Not yet recruiting","No Results Available","Adjuvant Chemotherapy|Colon Cancer|Immunity","Dietary Supplement: zinc|Other: Placebo","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","Both","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","FAPESP:2010/08787-1","December 16, 2010","February 2011","August 2013","December 16, 2010","December 2010","No Study Results Posted","null","December 2011","Gene expression|Humoral immunity and neutrophil function","https://ClinicalTrials.gov/show/NCT01261962"
3771,"NCT00387842","COlon Cancer Laparoscopic or Open Resection","Active, not recruiting","No Results Available","Colonic Neoplasms","Procedure: Laparoscopic surgery|Procedure: Conventional surgery","Erasmus Medical Center|Ethicon Endo-Surgery","Both","18 Years and older   (Adult, Senior)","Phase 3","1200","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COLOR I","October 12, 2006","March 1997","March 2008","October 12, 2006","October 2006","No Study Results Posted","null","null","Primary endpoint is cancer free survival at three years.|Secondary endpoints are overall survival at three and five years, 28 day mortality and morbidity, quality of life, costs, location and rates of recurrences and pathologic anatomic characteristics of the resected specimen.","https://ClinicalTrials.gov/show/NCT00387842"
3772,"NCT00215956","A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma","Completed","No Results Available","Rectal Neoplasms","Drug: topotecan|Procedure: radiation|Procedure: surgery","H. Lee Moffitt Cancer Center and Research Institute|GlaxoSmithKline","Both","18 Years and older   (Adult, Senior)","Phase 1","31","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-12349|USFIRB#5881","September 19, 2005","November 2001","January 2008","December 20, 2013","January 2009","No Study Results Posted","null","January 2008","Maximum Tolerated Dose (MTD) of Topotecan|Side Effect Profile of Topotecan|Response Rate","https://ClinicalTrials.gov/show/NCT00215956"
3773,"NCT00956241","J-pouch Versus Side-to-end Coloanal Anastomosis After Preoperative Radiotherapy and Total Mesorectal Excision for Rectal Cancer","Completed","No Results Available","Rectal Cancer","Procedure: j-pouch coloanal anastomosis|Procedure: side-to-end coloanal anastomosis","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Dutch Digestive Diseases Foundation|Commission of Applied Clinical Research (Commissie voor Klinisch Toegepast Onderzoek: CKTO).","Both","Child, Adult, Senior","","127","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","WS 01-62","August 10, 2009","April 2002","January 2007","August 10, 2009","August 2009","No Study Results Posted","null","January 2007","Primary endpoint was the function of the neo-rectum as assessed by a validated functional outcome questionnaire at 4 months.|Function of the neo-rectum as assessed by the functional outcome questionnaire|Surgical results|Quality of life","https://ClinicalTrials.gov/show/NCT00956241"
3774,"NCT01937780","Anal Cancer Radiotherapy Study","Recruiting","No Results Available","Anal Cancer","","Oslo University Hospital","Both","18 Years and older   (Adult, Senior)","","75","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2012/2274","August 28, 2013","August 2013","null","September 4, 2013","September 2013","No Study Results Posted","ANCARAD","September 2021","Disease-free survival|Prediction of local recurrence|Biomarker ability to predict local recurrence rate|Improvement of faecal incontinence|Pain relief of palliative radiotherapy","https://ClinicalTrials.gov/show/NCT01937780"
3775,"NCT00640913","Early Reversal of Defunctioning Stoma Trial","Recruiting","No Results Available","Rectal Cancer","Procedure: Reversal of defunctioning stoma","Rectal Cancer Trial on Defunctioning Stoma Study Group","Both","18 Years to 85 Years   (Adult, Senior)","","20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Ö 109-07","March 10, 2008","February 2008","November 2009","March 19, 2008","March 2008","No Study Results Posted","ELSOR","April 2009","Reversal of defunctioning loop stoma on postoperative day 14 following low anterior resection of the rectum for cancer with or without preoperative adjuvant treatment|Postoperative 30 day morbidity. Postoperative ano-rectal function at 1 and 6 months.","https://ClinicalTrials.gov/show/NCT00640913"
3776,"NCT02309931","ISOperistaltic Versus ANTIperistaltic Anastomosis After Laparoscopic Right Colectomy for Cancer","Recruiting","No Results Available","Primary Malignant Neoplasm of Ascending Colon","Procedure: antiperistaltic side-to-side ileocecal anastomosis|Procedure: isoperistaltic side-to-side ileocecal anastomosis","Hospital Universitario Virgen de la Arrixaca","Both","18 Years and older   (Adult, Senior)","","108","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","CCR-HCUVA-2014-01","November 28, 2014","June 2014","December 2017","December 3, 2014","December 2014","No Study Results Posted","ISOVANTI","July 2016","postoperative complications|Operating time|Anastomosis time|Hospital length of say|first tolerance day|first flatus day|first faeces day|Orocecal transit|Gastrointestinal life quality","https://ClinicalTrials.gov/show/NCT02309931"
3777,"NCT01216189","Sexual Function and Wellbeing in Females Diagnosed With Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","","Karolinska Institutet|Swedish Cancer Society","Female","18 Years and older   (Adult, Senior)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2008/247-31/3","October 4, 2010","April 2010","December 2016","February 25, 2016","February 2016","No Study Results Posted","null","December 2016","Hormone levels","https://ClinicalTrials.gov/show/NCT01216189"
3778,"NCT01216202","Sexual Function and Wellbeing in Males Diagnosed With Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","","Karolinska Institutet|Swedish Cancer Society","Male","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2009/1860-31/2","October 4, 2010","April 2010","December 2016","February 25, 2016","February 2016","No Study Results Posted","null","December 2016","Sexual function|Hormone levels","https://ClinicalTrials.gov/show/NCT01216202"
3779,"NCT00939666","Minimal Invasive Strategies for Good and Complete Response to Chemoradiation in Rectal Cancer","Recruiting","No Results Available","Locally Advanced Rectal Cancer","Procedure: Omission of surgery or transanal endoscopic microsurgery, combined with intensive follow-up","Maastricht University Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 2","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MEC 09-2-034","July 14, 2009","July 2009","null","July 21, 2011","July 2011","No Study Results Posted","null","December 2013","Local recurrence|Overall survival|Disease-free survival|Distant metastasis-free survival|Quality of life|Compliance|Percentage of patients that chooses the minimal invasive strategies over standard surgery","https://ClinicalTrials.gov/show/NCT00939666"
3780,"NCT02233595","Evaluation of Rectal Cancer Treatment Response Using PET/MRI","Recruiting","No Results Available","Rectal Adenocarcinoma","Radiation: Chemoradiation","University of California, San Francisco","Both","18 Years and older   (Adult, Senior)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Rectal-PETMRI-1","September 3, 2014","October 2014","null","May 12, 2016","May 2016","No Study Results Posted","Rectal PET/MRI","December 2016","change in SUVmax|tumor volume","https://ClinicalTrials.gov/show/NCT02233595"
3781,"NCT01766661","Prospective Multicenter Randomized Controlled Trial On Two-Stage Turnbull-Cutait Coloanal Anastomosis For Rectal","Recruiting","No Results Available","Rectal Neoplasm","Procedure: Hand-sewn coloanal anastomosis|Procedure: Two staged Turnbull-Cutait procedure|Procedure: Ultralow anterior rectal resection with total mesorectal excision","Hospital Universitari de Bellvitge","Both","18 Years to 74 Years   (Adult, Senior)","","92","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","TURNBULL-BCN-01|PR174/11","January 10, 2013","January 2013","null","March 23, 2016","March 2016","No Study Results Posted","TURNBULL-BCN","June 2016","post-operative morbidity|quality of life|Fecal incontinence|local and/or distant recurrence of neoplasm","https://ClinicalTrials.gov/show/NCT01766661"
3782,"NCT00319007","Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis","Recruiting","No Results Available","Adenomatous Polyposis Coli","Drug: Sulindac (drug)|Drug: VSL#3 (probiotic)|Drug: Inulin (probiotic)","Radboud University|Dutch Cancer Society","Both","16 Years and older   (Child, Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Prevention","23266|KUN 2003-2911","April 27, 2006","April 2006","December 2006","August 9, 2007","August 2007","No Study Results Posted","null","null","Pouch mucosal proliferation index at 0, 1 and 2 months|Pouch mucosal apoptosis index at 0, 1 and 2 months|Pouch mucosal Glutathione S transferases activity and isoenzyme levels at 0, 1 and 2 months|Faecal genotoxicity at 0, 1 and 2 months|Faecal cytotoxicity at 0, 1 and 2 months","https://ClinicalTrials.gov/show/NCT00319007"
3783,"NCT00937248","Cone Beam Computed Tomography (CT) (CBCT) With and Without a Customized Vacuum Immobilization Device (CVID)","Active, not recruiting","No Results Available","Rectal Cancer","Device: prone pillow and simple ankle fixation device|Device: Customized Vacuum Immobilization Device (CVID)","University Health Network, Toronto","Both","18 Years and older   (Adult, Senior)","","20","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 09-0086-CE","July 8, 2009","April 2009","February 2017","May 31, 2016","May 2016","No Study Results Posted","null","February 2017","Comparing the use of a prone pillow and simple ankle fixation device vs. the use of a CVID for immobilization rectal patients during the course of preoperative radiation therapy using KV CBCT for IGRT.|quantify interfractional set-up displacements using either of the two devices;determine a standard planning target volume margin; evaluate the role of soft-tissue image matching for IGRT using CBCT.","https://ClinicalTrials.gov/show/NCT00937248"
3784,"NCT01376505","Vaccine Therapy in Treating Patients With Metastatic Solid Tumors","Recruiting","No Results Available","Malignant Solid Tumour|Breast Cancer|Malignant Tumor of Colon|GIST|Ovarian Cancer","Biological: HER-2 vaccine","Pravin Kaumaya|Ohio State University Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","36","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-09138|NCI-2011-00920","June 9, 2011","June 2011","null","March 1, 2016","March 2016","No Study Results Posted","null","December 2016","Type and duration of immune response measured over time to repeat vaccine administration|Clinical benefit will be assessed|Evaluation of safety and toxicity at regular intervals by NCI common toxicity criteria (CTCAE v 4.0)","https://ClinicalTrials.gov/show/NCT01376505"
3785,"NCT00419978","The Significance of Sentinel Node Analysis in Colon Cancer","Terminated","No Results Available","Colon Cancer","Procedure: Colectomy","Legacy Health System","Both","18 Years to 85 Years   (Adult, Senior)","","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","750040399","January 5, 2007","June 2004","May 2008","June 27, 2008","June 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00419978"
3786,"NCT01584544","Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer","Completed","Has Results","Rectal Neoplasms","Drug: capecitabine|Drug: Capecitabine|Drug: Capecitabine|Drug: Capecitabine|Drug: Capecitabine","Chinese Academy of Medical Sciences","Both","75 Years and older   (Senior)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-024","April 20, 2012","January 2011","May 2014","April 17, 2015","April 2015","April 7, 2015","null","May 2014","Number of Participants Experienced Dose Limited Toxicity","https://ClinicalTrials.gov/show/NCT01584544"
3787,"NCT01160926","Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial","Terminated","No Results Available","Rectal Cancer","Drug: AZD6244|Drug: Cediranib (AZD2171)","The Christie NHS Foundation Trust|Cancer Research UK|AstraZeneca","Both","18 Years and older   (Adult, Senior)","Phase 1","31","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09_DOG03_184|2009-016524-31","July 7, 2010","July 2010","September 2016","January 26, 2016","January 2016","No Study Results Posted","DREAMtherapy","October 2013","To determine the MTD (maximum tolerated dose) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.|Grade 3 or 4 toxicity|Radiotherapy compliance|MRI (Magnetic Resonance Imaging)Response Rate|Histologically confirmed R0 resection rate|Pathological Complete Response (pCR)|Morbidity - post operative and long term|To explore biological and radiological markers of response or toxicity","https://ClinicalTrials.gov/show/NCT01160926"
3788,"NCT00494611","A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients","Terminated","No Results Available","Colon Cancer","Drug: Peri operative Cetuximab.","St. Luke's-Roosevelt Hospital Center|Bristol-Myers Squibb","Both","18 Years to 90 Years   (Adult, Senior)","Phase 1","25","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAC3683","June 28, 2007","September 2007","November 2010","May 18, 2011","June 2010","No Study Results Posted","null","November 2010","Safety of peri operative Cetuximab.","https://ClinicalTrials.gov/show/NCT00494611"
3789,"NCT00770991","Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)","Completed","Has Results","Familial Adenomatous Polyposis","Drug: Black raspberry (BRB) Slurry|Drug: Black Raspberry (BRB) Suppositories|Drug: Black Raspberry (BRB) Placebo Slurry","The Cleveland Clinic|Ohio State University Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","34","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","2003-34501-13965","October 9, 2008","December 2005","December 2008","February 11, 2016","February 2016","February 11, 2016","null","September 2008","Change From Baseline to End of Study in Number of Rectal Polyps|Change in Burden of Rectal Polyps|Apoptosis and Cell Proliferation Measured by Percent Difference in Staining.","https://ClinicalTrials.gov/show/NCT00770991"
3790,"NCT00955591","Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men","Active, not recruiting","No Results Available","Anal Cancer|Nonneoplastic Condition|Precancerous Condition","Other: Papanicolaou test","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Senior)","","48","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","CDR0000643881|P30CA016042|UCLA-0901062|IRB# 09-01-062-02","August 7, 2009","March 2009","January 2017","September 30, 2015","September 2015","No Study Results Posted","null","December 2011","Comparison of anal cytology screening outcome derived from specimens collected by a flocked nylon swab vs a Dacron swab","https://ClinicalTrials.gov/show/NCT00955591"
3791,"NCT00550589","Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus","Completed","Has Results","Anal Cancer|Precancerous Condition","Drug: cidofovir|Genetic: DNA methylation analysis|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Procedure: biopsy|Procedure: histopathologic examination","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation","Both","18 Years to 120 Years   (Adult, Senior)","Phase 2","33","Other|NIH|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-046|U01CA121947|CDR0000570720","October 26, 2007","September 2007","February 2010","November 17, 2015","November 2015","May 24, 2011","null","February 2010","Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL)|Safety and Tolerability of Topical Cidofovir as Assessed by NCI CTCAE v3.0|Human Papilloma Virus (HPV) DNA Type in Perianal HSIL and Normal Perianal Tissue|Correlation of Clinical Regression of Perianal HSIL With Clearance of HPV DNA|Identification of HPV-DNA Types Present in the Anus|Identification of Abnormally Methylated Genes in Perianal Dysplasia|Distribution of Abnormally Methylated Genes Among HSIL, Low-grade Squamous Intraepithelial Lesions, and Normal Perianal Skin|Changes in Gene Expression in Perianal HSIL After Exposure to Cidofovir as Assessed by RNA Microarray Analysis","https://ClinicalTrials.gov/show/NCT00550589"
3792,"NCT02421432","Evaluation of the Safety and the Efficacy of Transanal TME in Difficult Cases","Recruiting","No Results Available","Rectal Cancer","Procedure: Transanal total mesorectal excision","National Cancer Center, Korea","Both","20 Years to 80 Years   (Adult, Senior)","Phase 1","12","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC2015-0050","April 5, 2015","April 2015","April 2020","November 25, 2015","November 2015","No Study Results Posted","null","April 2016","TME quality & circumferential resection margin (CRM)|30-day postoperative complications|Number of harvested Lymph Nodes","https://ClinicalTrials.gov/show/NCT02421432"
3793,"NCT00004931","Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer","Completed","No Results Available","Stage II Colon Cancer|Stage III Colon Cancer","Drug: leucovorin calcium|Drug: fluorouracil|Drug: oxaliplatin|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Both","Child, Adult, Senior","Phase 3","2472","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03165|NSABP-C-07|U10CA012027","March 7, 2000","February 2000","null","January 10, 2013","January 2013","No Study Results Posted","null","September 2005","DFS rate|Survival rate","https://ClinicalTrials.gov/show/NCT00004931"
3794,"NCT02567942","Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Colon Cancer","Recruiting","No Results Available","Colon Cancer","Drug: propofol group|Drug: sevoflurane group","Konkuk University Medical Center","Both","20 Years and older   (Adult, Senior)","","300","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Basic Science","KUH1160089","September 2, 2015","July 2015","July 2020","February 26, 2016","February 2016","No Study Results Posted","null","July 2020","natural killer cell activity|helper T cell activity","https://ClinicalTrials.gov/show/NCT02567942"
3795,"NCT00527111","Pre-op Rectal ChemoRad +/- Cetuximab","Completed","No Results Available","Rectal Cancer","Drug: Cetuximab|Drug: 5-fluorouracil|Radiation: Pelvic irradiation","US Oncology Research|Bristol-Myers Squibb|ImClone LLC","Both","18 Years and older   (Adult, Senior)","Phase 2","139","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","05102|CA225269","September 7, 2007","February 2007","January 2015","November 7, 2015","November 2015","No Study Results Posted","null","January 2015","The primary objective of this study is to determine the pathologic response rate, using tumor regression grading, to treatment with preoperative chemoradiotherapy (pelvic radiotherapy with concurrent 5-FU) with and without concurrent ERBITUX.|To determine response rate based on RECIST; the toxicity rates in patients who receive preoperative chemoradiotherapy with or without ERBITUX; local recurrence-free survival in these patient groups; overall and recurrence-free survival in these cohorts.","https://ClinicalTrials.gov/show/NCT00527111"
3796,"NCT00835055","Expression of Molecular Markers Before and After Neo-adjuvant Chemoradiotherapy in Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","","St. Claraspital AG","Both","Child, Adult, Senior","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","43/05","February 2, 2009","April 2005","null","September 21, 2009","September 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00835055"
3797,"NCT02167321","Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision","Recruiting","No Results Available","Locally Advanced Rectal Cancer","Drug: Arm A : standard neoadjuvant chemoradiotherapy group|Drug: Arm B : adjuvant FOLFOX group","Yonsei University","Both","19 Years to 80 Years   (Adult, Senior)","Phase 3","580","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2014-0239","June 11, 2014","December 2014","May 2021","July 12, 2016","July 2016","No Study Results Posted","null","May 2018","Disease free survival (DFS)|Quality of life|Overall survival (OS)|Local recurrence rate|Systemic recurrence rate|Total score for function of urination (IPSS) and defecation (Wexner's score)|Evaluation for rate of various events after surgery","https://ClinicalTrials.gov/show/NCT02167321"
3798,"NCT00411112","Sentinel Node in Colon Cancer","Recruiting","No Results Available","Colon Cancer","Procedure: blue and isotopic detection of sentinel lymph nodes","University Hospital, Strasbourg, France","Both","18 Years and older   (Adult, Senior)","","140","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","3737","December 12, 2006","March 2007","null","January 9, 2009","January 2009","No Study Results Posted","null","March 2013","Survival without recurrence after 3 years","https://ClinicalTrials.gov/show/NCT00411112"
3799,"NCT00847119","Xeloda and Bevacizumab to Treat Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Biological: Bevacizumab|Drug: capecitabine (Xeloda)|Radiation: Rectal Radiotherapy","Institut Català d'Oncologia|Hoffmann-La Roche","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","43","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML 20006. XEBERECTO/ICO/005|EudraCT number:2007-000456-13","February 18, 2009","September 2007","September 2013","June 19, 2013","June 2013","No Study Results Posted","xeberecto","June 2011","Pathologic complete response rate. % patients with pathologic complete response (absence of tumoral cells in the resected piece)|Overall clinical response|To determine the downstaging caused by treatment|relapse free survival|Quantify the local control grade: R0 resections in surgery|Local relapse and distant relapse rates|To determine the security profile of this neoadjuvant treatment (radio- chemotherapy)|Surgery complication rate|To determine the angiogenic profile changes in tumour.","https://ClinicalTrials.gov/show/NCT00847119"
3800,"NCT02290574","Efficacy of Neoadjuvant Thermo-Radio-chemotherapy for Locally Advanced Rectal Cancer Before Laparoscopic Total Mesorectal Excision: Prospective Phase II Trial","Recruiting","No Results Available","Locally Advanced Rectal Cancer","Radiation: Hyperthermia with concurrent chemo-radiation therapy","Samsung Medical Center","Both","20 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-10-019","November 6, 2014","November 2014","null","November 10, 2014","November 2014","No Study Results Posted","NEO TREAT","October 2015","Curative resection rate of laparoscopic TME|Pathologic response of thermo-radio-chemotherapy|Adverse event of laparoscopic TME and hyperthermia with CCRT|Rate of open TME|Pathologic complete response of hyperthermia with CCRT|Quality of life assessment by Tablet","https://ClinicalTrials.gov/show/NCT02290574"
3801,"NCT02812628","Conventional Laparoscopic APR Versus Laparoscopic APR With Transabdominal Individualized Levator Transection","Recruiting","No Results Available","Rectal Cancer","Procedure: LAPR|Procedure: LAPR-TILT","Ruijin Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","528","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","MISC-APR","June 10, 2016","December 2012","June 2022","June 21, 2016","June 2016","No Study Results Posted","null","June 2020","3-year local recurrence|3-year overall survival|3-year disease-free survival","https://ClinicalTrials.gov/show/NCT02812628"
3802,"NCT01340755","Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer","Active, not recruiting","No Results Available","Adenocarcinoma of the Rectum","Procedure: Transanal endoscopic surgery","Massachusetts General Hospital","Both","18 Years and older   (Adult, Senior)","Phase 1","5","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-409","April 21, 2011","March 2011","May 2017","June 27, 2016","June 2016","No Study Results Posted","null","May 2012","Adequacy of the total mesorectal excision based on standard guidelines on pathologic evaluation of TME specimens.|Incidence of 30-day perioperative complications including intraoperative, surgical postoperative, and medical postoperative complications.|Incidence of long-term complications|Oncologic outcomes in subjects receiving transanal endoscopic rectosigmoid resection","https://ClinicalTrials.gov/show/NCT01340755"
3803,"NCT02311803","Preservation Versus Excision of Denonvilliers Fascia in L-PANP Surgery","Recruiting","No Results Available","Rectal Cancer","Procedure: Preservation of Denonvilliers Fascia|Procedure: Excision of Denonvilliers Fascia","Third Affiliated Hospital, Sun Yat-Sen University","Male","20 Years to 60 Years   (Adult)","","172","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PED-PANP001","December 4, 2014","February 2015","null","November 7, 2015","November 2015","No Study Results Posted","null","February 2017","Urinary function|Sexual function|3-year disease free survival rate|5-year disease free survival rate|Morbidity|3-year overall survival rate|3-year recurrence pattern|Mortality|5-year overall survival rate|5-year recurrence pattern","https://ClinicalTrials.gov/show/NCT02311803"
3804,"NCT01326065","Implementation of Laparoscopy-assisted Surgery for Colon Cancer","Terminated","No Results Available","Colon Cancer","","Helse Stavanger HF","Both","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SUH424503","February 27, 2011","February 2011","February 2017","November 17, 2014","November 2014","No Study Results Posted","null","March 2012","Long term outcome|Complications related to the surgical procedure|Quality of life|Quality of the surgical specimen","https://ClinicalTrials.gov/show/NCT01326065"
3805,"NCT00000764","Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.","Completed","No Results Available","HIV Infections|Anus Neoplasms","Drug: Isotretinoin|Drug: Interferon alfa-2a","National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 1","98","NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Primary Purpose: Treatment","ACTG 216|11193","November 2, 1999","null","July 1996","March 30, 2012","March 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00000764"
3806,"NCT02572362","Secondary Cancer Risk After Radiation Therapy for Rectal Cancer","Recruiting","No Results Available","Neoplasms, Second Primary","Other: No intervention in this retrospective study","Kantonsspital Graubuenden|Klinik Hirslanden, Zurich","Both","18 Years to 100 Years   (Adult, Senior)","","25","Other","Observational","Time Perspective: Retrospective","KEK-ZH-Nr. 2014-0255","October 4, 2015","August 2015","July 2016","October 7, 2015","October 2015","No Study Results Posted","null","July 2016","Calculation of the organ-specific excess lifetime attributable risk (LAR) (%)","https://ClinicalTrials.gov/show/NCT02572362"
3807,"NCT01859442","The Effect of Cancer Therapies and Exercise on Mitochondrial Energetics and Fitness","Completed","No Results Available","Locally Advanced Rectal Cancer","Procedure: Structured responsive interval exercise training programme|Other: Sham group","Michelle Mossa|University of Liverpool|Aintree University Hospitals NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 0","12","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","11/H1002/12c","May 13, 2013","January 2012","October 2013","May 5, 2014","September 2013","No Study Results Posted","null","July 2013","Exponential rate constant of post-chemoradiotherapy and post-exercise phosphocreatine recovery.|Alterations in mitochondrial energetics post-chemoradiotherapy and exercise","https://ClinicalTrials.gov/show/NCT01859442"
3808,"NCT01142713","The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II Study","Not yet recruiting","No Results Available","Rectal Cancer","Radiation: Patient Position During Radiotherapy","Tel-Aviv Sourasky Medical Center","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TASMC-10-EG-0681-09-TLV-CTIL","June 10, 2010","August 2010","December 2011","June 10, 2010","February 2010","No Study Results Posted","null","December 2010","Dose and irradiated volume of small bowel and urinary bladder","https://ClinicalTrials.gov/show/NCT01142713"
3809,"NCT00701012","Comparison of Low and High Ligation in the Rectal Cancer","Completed","No Results Available","Rectal Cancer","Procedure: preservation of nerve fibers around IMA|Procedure: resection of nerve fibers around IMA","Wakayama Medical University","Both","Child, Adult, Senior","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WMU512","June 17, 2008","January 2008","December 2011","December 17, 2013","December 2013","No Study Results Posted","null","January 2008","Assessment of bowel function|comparison of leakage rate","https://ClinicalTrials.gov/show/NCT00701012"
3810,"NCT02423226","Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer","Completed","No Results Available","Rectum Cancer","Procedure: Computed tomography guided radioactive seeds implant|Drug: Systemic chemotherapy (FOLFIRI)","The First People's Hospital of Changzhou","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","56","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CZ-I125-001","April 16, 2015","October 2008","April 2015","April 21, 2015","April 2015","No Study Results Posted","null","December 2014","Progression free survival|Treatment related adverse events","https://ClinicalTrials.gov/show/NCT02423226"
3811,"NCT01125111","The Clinical Study of Making the Evidence With Application of Da Vinci-Robot Assisted Low Anterior Resection in Rectal Cancer","Completed","No Results Available","Rectal Cancer","Procedure: surgery(robot versus laparoscopy)","Yonsei University","Both","45 Years to 75 Years   (Adult, Senior)","","69","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","4-2009-0210","May 10, 2010","June 2009","March 2010","May 17, 2010","May 2010","No Study Results Posted","null","March 2010","The difference in 1 month between two surgical methods in terms of Bladder function.|The difference in 3 months between two surgical methods in tems of Sexual function.|The serial change of Bladder and sexual function according to times, in each operation method.","https://ClinicalTrials.gov/show/NCT01125111"
3812,"NCT00671996","Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C","Completed","No Results Available","Chemotherapy|Colon Cancer","Drug: Mangafodipir|Drug: Placebo treatment (0.9% NaCl)","PledPharma AB","Both","18 Years and older   (Adult, Senior)","Phase 2","14","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","PP 01-07","May 4, 2008","June 2008","April 2010","May 3, 2010","May 2010","No Study Results Posted","MANFOL","April 2010","Neutropenia|Quality of Life","https://ClinicalTrials.gov/show/NCT00671996"
3813,"NCT01407107","Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer","Active, not recruiting","No Results Available","Rectal Cancer","Drug: nitroglycerin","University of Texas Southwestern Medical Center|VA Office of Research and Development","Both","18 Years to 90 Years   (Adult, Senior)","Phase 1","24","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","STU 122010-172","July 29, 2011","January 2011","March 2017","May 31, 2016","May 2016","No Study Results Posted","null","March 2017","Maximum tolerated dose (MTD)|Pathological complete response (pCR)","https://ClinicalTrials.gov/show/NCT01407107"
3814,"NCT02625272","A Randomized Controlled Trial of a Novel HALS Technique Versus Laparoscopic Technique for Right Hemicolectomy","Recruiting","No Results Available","Colon Neoplasms","Procedure: HALS-CME with no touch isolation","West China Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HALS-CME 201512","December 1, 2015","June 2015","April 2020","December 8, 2015","December 2015","No Study Results Posted","null","April 2017","3-year local recurrence|postoperative complications|overall survival|disease free survival","https://ClinicalTrials.gov/show/NCT02625272"
3815,"NCT00403624","Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer","Completed","No Results Available","Rectal Neoplasms","Drug: OXALIPLATIN","Sanofi","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","38","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","L_8128","November 23, 2006","July 2001","November 2005","August 26, 2010","April 2008","No Study Results Posted","null","November 2005","Tumour response|Disease free and Overall survival ; Adverse events","https://ClinicalTrials.gov/show/NCT00403624"
3816,"NCT00628147","Clinical Evaluation of Narrow Band Imaging Colonoscope","Completed","No Results Available","Colonic Neoplasms","Device: Narrow band imaging colonoscope (CF-H180AL, CF-Q180AL, Evis Exera II CV-180)","VA Palo Alto Health Care System","Both","18 Years and older   (Adult, Senior)","Phase 4","284","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","SOE0011","February 25, 2008","January 2006","March 2007","March 3, 2008","February 2008","No Study Results Posted","null","February 2007","neoplasm miss rate|neoplasm detection rates|completion of examinations|procedure complications","https://ClinicalTrials.gov/show/NCT00628147"
3817,"NCT02730702","Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure","Not yet recruiting","No Results Available","Colon Cancer","Device: LEBS - Low coherence enhanced backscattering","American BioOptics, LLC","Both","50 Years and older   (Adult, Senior)","","600","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ABO 2016-01","March 28, 2016","September 2016","September 2020","April 5, 2016","April 2016","No Study Results Posted","null","September 2020","Whether rectal LEBS readings can predict the presence of advanced adenomas in the colon.","https://ClinicalTrials.gov/show/NCT02730702"
3818,"NCT02526134","Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum","Active, not recruiting","No Results Available","Oesophageal Cancer|Rectal Cancer","Device: radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)","Institut Paoli-Calmettes|Cook medical laboratory","Female","18 Years and older   (Adult, Senior)","Phase 2","29","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FIDUCOR-IPC 2013-008","June 25, 2015","April 2014","January 2017","February 25, 2016","February 2016","No Study Results Posted","FIDUCOR","January 2017","Patients rate in which a significant variation in the area to be irradiated will be observed between before evaluation and evaluation after laying the trustees.|Number of trustees (2 up 6 maximum) and set up their positions estimated success rate of implementation and the evaluation of the safety and toxicity (complications) associated with the establishment trustees (composite measure)","https://ClinicalTrials.gov/show/NCT02526134"
3819,"NCT00220051","A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: Oxaliplatin, Capecitabine|Procedure: Pre operative radiotherapy|Procedure: Surgical Resection","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","Phase 2","109","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1973","September 19, 2005","November 2001","null","May 30, 2013","May 2013","No Study Results Posted","null","null","Pathological complete response rate.|Acute toxicity has been evaluated in previous phase I studies and should occur to a similar extent.|Progression-free survival|Treatment related toxicity|Overall survival|Radiological response rate|Proportion of patients achieving pathological down staging compared with the pre-treatment MRI scan|Surgical complications|Bowel function and quality of life","https://ClinicalTrials.gov/show/NCT00220051"
3820,"NCT02512263","Assessment of Adherence and Efficiency of a Home-based Training Program on Muscular Strength, Endurance and Qol for Colon Cancer Patients","Recruiting","No Results Available","Colon Cancer","Procedure: Home-based training program","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","Both","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","HBTPCoCa","July 27, 2015","July 2015","July 2017","July 28, 2015","July 2015","No Study Results Posted","null","October 2015","Muscular strength measured by Microfet|Quality of life measured by questionnaire|Fatigue measured by questionnaire|Physical activity measured by questionnaire|Anxiety measured by questionnaire|Exercise tolerance measured by Six minute walking test|Depression measured by questionnaire","https://ClinicalTrials.gov/show/NCT02512263"
3821,"NCT01585727","Intraoperative Monitoring of the Pelvic Autonomic Nerves","Recruiting","No Results Available","Rectal Cancer","Procedure: TME|Procedure: TME|Procedure: Neuromonitoring","Johannes Gutenberg University Mainz","Both","18 Years to 90 Years   (Adult, Senior)","","188","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","2007-012|KN 930/1-1","April 25, 2012","June 2012","December 2017","August 29, 2016","August 2016","No Study Results Posted","NEUROS","June 2017","Urogenital function|Sexual function (females)|Sexual function (males)|Adverse events|Oncological safety|Quality of mesorectal excision|Fecal incontinence","https://ClinicalTrials.gov/show/NCT01585727"
3822,"NCT00195585","Study Evaluating Isovorin in Colon Cancer","Completed","No Results Available","Colon Cancer","Drug: Isovorin|Drug: UFT","Wyeth is now a wholly owned subsidiary of Pfizer","Both","20 Years to 75 Years   (Adult, Senior)","Phase 3","650","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ISO/5FU-11","September 12, 2005","October 2002","February 2006","August 12, 2009","August 2009","No Study Results Posted","null","February 2006","Relapse-free survival time|Disease-free survival time, survival time, safety","https://ClinicalTrials.gov/show/NCT00195585"
3823,"NCT01271192","Efficacy and Safety Study of Neoadjuvant in Treating Patients With Resectable Local Recurrent Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Procedure: surgical resection and adjuvant therapy|Procedure: Neoadjuvant followed by operation","Sun Yat-sen University|Guangdong General Hospital|Second Military Medical University","Both","18 Years to 80 Years   (Adult, Senior)","","360","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GIHSYSU02","January 5, 2011","December 2010","December 2020","January 5, 2011","December 2010","No Study Results Posted","NARC","December 2015","5-year disease free survival|Side effect of chemo radiotherapy, postoperative complications, recurrent rate, distant metastatic rate,biomarkers, quality of life, toxic profile, convenience","https://ClinicalTrials.gov/show/NCT01271192"
3824,"NCT01831245","Right-sided Colon Tumor, Laparoscopic Versus Open Surgery, in an ERAS Protocol","Completed","No Results Available","Colon Tumor","","Karolinska Institutet|Danderyd Hospital|Region Örebro County|Ersta Hospital, Sweden","Both","18 Years and older   (Adult, Senior)","","125","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2012/2105-31/2","February 25, 2013","January 2011","July 2014","February 19, 2015","February 2015","No Study Results Posted","null","July 2014","Pathological Anatomic diagnosis (PAD) on a tumor biopsy|Length of hospital stay, days|C - reactive protein","https://ClinicalTrials.gov/show/NCT01831245"
3825,"NCT02228668","Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma","Enrolling by invitation","No Results Available","Colon Cancer Treated With Bevacizumab After Colon Surgery","","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","","3451","Other|Industry","Observational","Observational Model: Cohort","S-AVANT C13-1","August 8, 2014","March 2015","January 2019","May 10, 2016","November 2015","No Study Results Posted","null","March 2018","Overall Survival (OS) up to 8 and 10 years median follow-up of the stage III population randomized in the AVANT study.|Overall Survival (OS) in stage III patients at 8 years median follow-up in the subgroup of alive patients not lost to follow-up after the AVANT trial ending.|Disease-Free Survival (DFS) in stage III patients at 8 and 10 years median follow-up.|Relapse Free Survival (RFS) in patients with stage II and stage III colon cancer.|Cancer Specific Survival (CSS) in patients with stage II and stage III colon cancer.","https://ClinicalTrials.gov/show/NCT02228668"
3826,"NCT02161822","Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients","Recruiting","No Results Available","Adenocarcinoma of Rectum","Drug: simvastatin","Samsung Medical Center","Both","20 Years and older   (Adult, Senior)","Phase 2","86","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-03-056","May 30, 2014","December 2014","April 2018","May 3, 2015","March 2014","No Study Results Posted","null","December 2015","pathologic complete response rate|rate of sphincter-sparing surgical procedure|rate of R0 resection|disease-free survival|overall survival|pattern of failure|safety and toxicity|lipid lowering effect of simvastatin","https://ClinicalTrials.gov/show/NCT02161822"
3827,"NCT01274962","A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer","Recruiting","No Results Available","Operable T2-3N+M0 Rectal Cancer (Stage III)","Drug: FOLFOX|Radiation: high dose rate endorectal brachytherapy","Sir Mortimer B. Davis - Jewish General Hospital|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","180","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KIR 009","January 11, 2011","November 2009","December 2020","September 1, 2016","September 2016","No Study Results Posted","null","December 2017","Compliance to chemotherapy - patients receiving at least 85% of planned full-dose of chemotherapy prescribed at each cycle for the 12 cycles|Disease free survival rate (local recurrence and metastases)|Overall survival rate","https://ClinicalTrials.gov/show/NCT01274962"
3828,"NCT00799474","Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination","Completed","Has Results","Anus Neoplasms","","University of North Carolina, Chapel Hill|Merck Sharp & Dohme Corp.","Male","18 Years to 59 Years   (Adult)","","609","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Merck-558377","November 26, 2008","December 2008","January 2009","February 25, 2016","January 2010","December 7, 2009","null","January 2009","Willingness to Receive the Human Papillomavirus (HPV) Vaccine|Awareness of HPV Vaccine|Knowledge of HPV","https://ClinicalTrials.gov/show/NCT00799474"
3829,"NCT02576184","Mesh Reinforcement During Temporary Stoma Closure After Sphincter-Saving Rectal Cancer Surgery","Recruiting","No Results Available","Incisional Hernia After Diverting Stoma Closure","Device: Biologic Mesh|Device: Synthetic Mesh","Assistance Publique - Hôpitaux de Paris","Both","18 Years and older   (Adult, Senior)","Phase 3","381","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","P140312|2015-A00410-49","October 5, 2015","December 2015","December 2018","April 21, 2016","April 2016","No Study Results Posted","MEMBO","December 2018","radiological incisional hernia rate|Postoperative morbidity|Postoperative pain|Postoperative rehospitalization|Postoperative reintervention|Quality of life|Clinical incisional hernia rate","https://ClinicalTrials.gov/show/NCT02576184"
3830,"NCT02145416","ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy","Recruiting","No Results Available","Anal Cancer","","University of Oxford|Oxford University Hospitals NHS Trust","Both","18 Years and older   (Adult, Senior)","","26","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OCTO-051","May 20, 2014","October 2014","January 2018","August 31, 2016","August 2016","No Study Results Posted","ART","December 2017","Changes on DW MRI during CRT in anal cancer.|Changes on DCE MRI, Perfusion CT, T2* MRI, FDG PET|Correlation of findings on different functional images.|Correlation of baseline functional images with outcome of CRT|Correlation of the change in functional images over CRT with outcome of CRT","https://ClinicalTrials.gov/show/NCT02145416"
3831,"NCT02153853","Does Obesity Increase the Risk of Conversion and Short Term Complications in Laparoscopic Rectal Surgery?","Enrolling by invitation","No Results Available","Rectal Cancer|Obesity","","Hvidovre University Hospital","Both","Child, Adult, Senior","","335","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BMIandRectalCancer","May 29, 2014","June 2014","July 2015","January 22, 2015","January 2015","No Study Results Posted","null","July 2015","Conversion rate|Peroperative Bleeding|Length of Hospital Stay|Short term complications|Readmission within 30 days after surgery|30-day mortality|Duration of surgery","https://ClinicalTrials.gov/show/NCT02153853"
3832,"NCT02484040","Two-week Course Versus Conventionally Fractionated Chemoradiotherapy in Rectal Cancer","Recruiting","No Results Available","Response to Toxin|Toxicity|Recurrence","Radiation: Two-week course of radiation|Drug: Two-week course of radiation","Seoul St. Mary's Hospital","Both","20 Years to 80 Years   (Adult, Senior)","Phase 3","370","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TwoArc trial","June 17, 2015","December 2015","July 2021","April 27, 2016","April 2016","No Study Results Posted","null","July 2019","Tumor response from stage II-III to stage 0-I|Toxicity (acute and chronic)|Recurrence and survival","https://ClinicalTrials.gov/show/NCT02484040"
3833,"NCT00867464","Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls","Active, not recruiting","No Results Available","Cervical Cancer|Human Papillomavirus|Anal Cancer|Oral Cancer","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","24 Years to 32 Years   (Adult)","","10000","NIH","Observational","Time Perspective: Prospective","999909106|09-C-N106","March 20, 2009","March 2009","null","May 28, 2016","May 2016","No Study Results Posted","null","null","10-year global impact of HPV-16/18 vaccination of young adultwomen|Determinants of the immune response to HPV and the vaccine, andmarkers of long-term protection|The natural history of HPV and cervical disease in vaccinated andunvaccinated populations","https://ClinicalTrials.gov/show/NCT00867464"
3834,"NCT01104181","Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test","Completed","No Results Available","Anal Canal HPV Infection Diagnosis|Anal Dysplasia Diagnosis|Anal Cancer","Device: HC2 collection kit with a swab or brush","Laser Surgery Care|QIAGEN Gaithersburg, Inc","Both","18 Years to 90 Years   (Adult, Senior)","","300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","R09-HPV-001","March 25, 2010","March 2010","March 2011","June 21, 2011","June 2011","No Study Results Posted","null","December 2010","HC2 can accurately test for oncogenic HPV in anal specimens|Sensitivity and specificity of cytology with HC2","https://ClinicalTrials.gov/show/NCT01104181"
3835,"NCT00232453","Preoperative Combined Radiation and Chemotherapy - Rectal Cancer","Completed","No Results Available","Rectal Neoplasms","Procedure: Combined Radiation and Chemotherapy","University Health Network, Toronto|Princess Margaret Hospital, Canada","Both","18 Years and older   (Adult, Senior)","Phase 2","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 01-0024-C","October 3, 2005","March 2001","December 2004","February 11, 2011","February 2011","No Study Results Posted","null","December 2004","Assess acute toxicity and complete remission rate of combined preoperative radiation and chemotherapy","https://ClinicalTrials.gov/show/NCT00232453"
3836,"NCT01403883","Psychological and Enterostomal Therapy Care","Recruiting","No Results Available","Cancer of Rectum","Behavioral: Standard Care|Behavioral: Optimal care (Psychological and enterostomal therapy clinics)","Association de Recherche Experimentale et Clinique en Chirurgie Digestive","Both","18 Years to 75 Years   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","UK10005","November 30, 2010","October 2011","February 2015","January 15, 2015","January 2015","No Study Results Posted","PROSPER","February 2015","Evolution of Global Quality of life (SF36)|Evolution of Psychological anxiety score (STAI/Beck)|Evolution of Specific stoma score and stoma care learning|Hospital stay|Overall morbidity|Specific stoma related morbidity","https://ClinicalTrials.gov/show/NCT01403883"
3837,"NCT01401309","PET Respiratory Gating to Detect Hepatic Metastasis in Patients With Colon Cancer","Completed","No Results Available","Colon Cancer","","Southwestern Regional Medical Center","Both","18 Years and older   (Adult, Senior)","","81","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","SRMC 10-07","January 24, 2011","January 2011","March 2013","February 20, 2014","February 2014","No Study Results Posted","null","November 2011","Detecting","https://ClinicalTrials.gov/show/NCT01401309"
3838,"NCT01257360","Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)","Active, not recruiting","No Results Available","Rectal Cancer","Drug: Panitumumab|Radiation: Radiation of the pelvis","WiSP Wissenschaftlicher Service Pharma GmbH|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH","Both","18 Years and older   (Adult, Senior)","Phase 2","59","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","WISP_AG52|2009-016782-28|GMIHO 009/2009","December 1, 2010","December 2010","July 2016","January 12, 2016","January 2016","No Study Results Posted","NEO-RIT","January 2016","Rate of pathological complete remissions|Toxicity according to NCI CTCAE|Frequency of surgical morbidity and complications|pTNM findings in relation to initial cTNM staging|Regression grading according to Dworak|Clinical response rates (CR/PR/SD/PD) after neoadjuvant treatment|Correlative biomarker analyses","https://ClinicalTrials.gov/show/NCT01257360"
3839,"NCT01717014","Radial Reload Open LAR Case Series","Terminated","Has Results","Low Anterior Resection|Proctosigmoid Resection|Rectal Cancer","Device: Covidien Radial Reload Stapler with Tri-Staple Technology","Medtronic - MITG|Duke University|Providence Medical Research Center|University of South Florida","Both","18 Years to 85 Years   (Adult, Senior)","","8","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COVLARO0286","October 26, 2012","May 2013","November 2013","February 13, 2015","February 2015","February 13, 2015","null","November 2013","Staple Line|Distal Margins|Usability: Visibility|Usability: Access|Usability: Manueverability","https://ClinicalTrials.gov/show/NCT01717014"
3840,"NCT00399009","Comparative Study of Circular Stapling Instruments","Terminated","No Results Available","Anastomotic Leak|Rectal Cancer","Device: AutoSuture Premium Plus CEEA/Ethicon Proximate ILS","Uppsala University Hospital","Both","18 Years and older   (Adult, Senior)","","880","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Ups03-130","November 13, 2006","January 2004","November 2007","June 5, 2008","June 2008","No Study Results Posted","null","November 2007","Clinical anastomotic leak","https://ClinicalTrials.gov/show/NCT00399009"
3841,"NCT02190656","Anterior Resection Syndrome Following Sphincter-preserving Surgery","Completed","No Results Available","Rectal Cancer","","Queen Mary University of London|The Royal College of Surgeons of England","Both","18 Years and older   (Adult, Senior)","","1197","Other","Observational","Time Perspective: Cross-Sectional","009515","March 12, 2014","May 2014","September 2015","April 4, 2016","April 2016","No Study Results Posted","null","June 2015","Number of participants with no LARS; minor LARS and major LARS|Correlation between LARS score and EORTC QLQ-C30 questionnaire score","https://ClinicalTrials.gov/show/NCT02190656"
3842,"NCT02112162","Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery","Active, not recruiting","No Results Available","Rectal Neoplasms","Radiation: fludeoxyglucose F 18|Device: positron emission tomography|Device: magnetic resonance imaging|Other: laboratory biomarker analysis","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","","2","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","201401064","April 9, 2014","June 2014","September 2016","June 9, 2016","June 2016","No Study Results Posted","null","September 2016","Change in FDG-PET/MR SUVmax|Change in FDG-PET/MR SUVmean|Change in ADCmean|Radiosensitivity index","https://ClinicalTrials.gov/show/NCT02112162"
3843,"NCT02519140","Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections","Recruiting","No Results Available","Gastric Cancer|Colon Cancer","Drug: Cook Medical EMR Gel","Maimonides Medical Center","Both","18 Years to 65 Years   (Adult)","Phase 3","32","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-05-06","August 17, 2014","August 2014","September 2016","February 21, 2016","February 2016","No Study Results Posted","null","September 2016","Lift Efficacy|Dissection Adequacy","https://ClinicalTrials.gov/show/NCT02519140"
3844,"NCT00428285","Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men","Completed","No Results Available","Anus Neoplasms|HIV Infections","Procedure: Argon Plasma Coagulation","Centre hospitalier de l'Université de Montréal (CHUM)|McGill University Health Center|CIHR Canadian HIV Trials Network","Male","18 Years to 65 Years   (Adult)","Phase 2","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CTN-216|SL06-0.11 (CHUM)","January 25, 2007","February 2007","July 2016","July 29, 2016","July 2016","No Study Results Posted","null","February 2010","High grade dysplasia (AIN 2/3)|Anal human papilloma virus (HPV)|Tolerability and safety of the treatment","https://ClinicalTrials.gov/show/NCT00428285"
3845,"NCT00263055","MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV","Completed","No Results Available","Colonic Neoplasms","Drug: oxaliplatin","Sanofi","Both","18 Years to 75 Years   (Adult, Senior)","Phase 4","null","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","R_9262","December 6, 2005","August 2004","null","September 14, 2009","September 2009","No Study Results Posted","null","June 2005","Occurrence of dose-limiting toxicity|Occurrence of one or more adverse event in a patient|Overall distribution of intensity of adverse events|Occurrence of particular adverse events and their intensities|Percent of patients completing study treatment|Percent of patients with grade 1, 2 and 3 neuropathy|Percent of intended dose delivered for 5-FU/LV and Oxaliplatin|Delays in scheduled dosing|Dose intensity, as expressed as the amount of 5-FU/LV and Oxaliplatin administered divided by the duration of treatment|•Survival Analysis •Laboratory assay and vital signs ECOG and KPS|Long term toxicity","https://ClinicalTrials.gov/show/NCT00263055"
3846,"NCT02401100","Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow","Recruiting","No Results Available","Anastomotic Leak","","Umeå University","Both","Child, Adult, Senior","","90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UmU-AL-01","March 24, 2015","May 2015","September 2018","June 28, 2016","June 2016","No Study Results Posted","null","May 2018","Blood flow measurements|Anastomotic leakage","https://ClinicalTrials.gov/show/NCT02401100"
3847,"NCT01653301","Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study","Recruiting","No Results Available","Rectal Cancer","Drug: XELAC RT|Drug: XELOX RT","Catholic University of the Sacred Heart","Both","18 Years and older   (Adult, Senior)","Phase 3","616","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","515(A1144)/2005","April 30, 2012","October 2005","null","July 26, 2012","July 2012","No Study Results Posted","INTERACT","December 2012","Pathological major downstaging|Tumor downstaging|sphincter saving surgery|local control|survival","https://ClinicalTrials.gov/show/NCT01653301"
3848,"NCT02630056","Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer","Not yet recruiting","No Results Available","Rectal Neoplasm","","Sixth Affiliated Hospital, Sun Yat-sen University","Both","Child, Adult, Senior","","90","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SASYSU","November 27, 2015","December 2015","December 2017","December 14, 2015","November 2015","No Study Results Posted","null","August 2017","the grade of acute hematologic toxicity","https://ClinicalTrials.gov/show/NCT02630056"
3849,"NCT01320267","Single Port Laparoscopic Colectomy","Withdrawn","No Results Available","Colon Cancer","Procedure: Single port laparoscopic right hemicolectomy","University of British Columbia|Tyco Healthcare Group","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H10-00969","March 1, 2011","December 2011","May 2012","March 14, 2014","March 2014","No Study Results Posted","SILS","May 2012","Successful completion of the right hemicolectomy|Use of additional ports and reason|Conversion to an open procedure and reason|Duration of surgery|Operative complications|Total Length of surgical incision (cm)|Postoperative analgesia requirements (total opioid used)|30 Day Mortality|Length of postoperative hospital stay|Pathological Cancer stage (TNM)|Pathology: Resection margin clearance|Number of lymph nodes assessed|Total Number of Surgical Incisions|Wound Infection|Postoperative complications: Requirement of Re-operation|Postoperative complications: Reason for reoperation|Postop Complications: Wound Dehiscence|Postoperative Complications: Others|30 Day Re-admission|Postoperative Measure of Pain","https://ClinicalTrials.gov/show/NCT01320267"
3850,"NCT01497457","Interest of Saline MR Peritoneography for Pre-operative Assessment of Rectal Cancer","Completed","No Results Available","Rectal Adenocarcinoma","Procedure: MR saline peritoneography","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","Both","18 Years and older   (Adult, Senior)","","17","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","B403201112604","December 14, 2011","December 2011","September 2013","May 19, 2015","May 2015","No Study Results Posted","null","September 2013","Determination of the distance between a rectal tumor and the pouch of Douglas","https://ClinicalTrials.gov/show/NCT01497457"
3851,"NCT02399813","Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum","Recruiting","No Results Available","Anal Cancer|Rectal Cancer","Drug: ADXS11-001","Advaxis, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","55","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ADXS001-06","March 23, 2015","September 2015","null","August 16, 2016","August 2016","No Study Results Posted","null","March 2017","Number of subjects with adverse events|Overall response rate for all subjects","https://ClinicalTrials.gov/show/NCT02399813"
3852,"NCT01751516","PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study","Active, not recruiting","No Results Available","Rectal Carcinoma","","UNC Lineberger Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","","8","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","LCCC1225","December 13, 2012","October 2012","October 2018","October 13, 2015","October 2015","No Study Results Posted","null","August 2014","Negative post-chemoradiation PET/MRI scan, as correlated with surgical pathology|Recurrence-free survival|Disease-specific survival|Overall survival","https://ClinicalTrials.gov/show/NCT01751516"
3853,"NCT02407561","Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays","Terminated","No Results Available","Rectal Adenocarcinoma|Anal Adenocarcinoma|Anal Squamous Cell Carcinoma","","Castle Biosciences Incorporated","Both","18 Years and older   (Adult, Senior)","","3","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Protocol_CBI_RC_PVS","March 26, 2015","February 2015","December 2030","July 29, 2016","July 2016","No Study Results Posted","null","December 2020","Validate the proprietary rectal and anal carcinoma immunohistochemistry protocols under CLIA compliant SOPs, in order to predict response to pre-operative chemoradiation treatment for patients with rectal/ anal carcinoma.|Gene expression profiling will be undertaken to determine if RNA is a superior biomarker to protein","https://ClinicalTrials.gov/show/NCT02407561"
3854,"NCT01126346","Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","Completed","No Results Available","Advanced Malignant Mesothelioma|Carcinoma of the Appendix|Ovarian Sarcoma|Ovarian Stromal Cancer|Pseudomyxoma Peritonei|Recurrent Colon Cancer|Recurrent Malignant Mesothelioma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Stage III Colon Cancer|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage IV Colon Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Unspecified Childhood Solid Tumor, Protocol Specific","Behavioral: HIPEC Orientation|Behavioral: Consultation with Survivorship Navigator|Other: Questionnaires","Comprehensive Cancer Center of Wake Forest University","Both","Child, Adult, Senior","","10","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CCCWFU 97110|NCI-2010-00980","May 13, 2010","May 2010","October 2013","July 21, 2014","July 2014","No Study Results Posted","HOPE","April 2011","Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population|Reduce pre-treatment distress and anxiety|Improve pre-treatment self-efficacy|Provide educational material delivered by the SRB|Improve overall post-operative QOL ratings at 3 months, relative to discharge","https://ClinicalTrials.gov/show/NCT01126346"
3855,"NCT01604564","Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients","Recruiting","No Results Available","Colitis,Ulcerative|Adenomatous Polyposis Coli|Reservoir, Ileoanal","","Universitaire Ziekenhuizen Leuven","Both","Child, Adult, Senior","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","S-54228","May 21, 2012","May 2012","December 2019","July 28, 2016","July 2016","No Study Results Posted","KOPOF","December 2018","Evaluation of postoperatieve recovery","https://ClinicalTrials.gov/show/NCT01604564"
3856,"NCT00510692","Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA","Completed","Has Results","Familial Adenomatous Polyposis Coli|FAP","Drug: Eicosapentanoic Acid (EPA)|Procedure: Endoscopy|Procedure: Biopsies taken|Drug: Placebo","S.L.A. Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","58","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EPA/POL/03","July 30, 2007","November 2006","April 2008","August 6, 2014","August 2014","July 7, 2014","null","April 2008","Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum.|Percentage Change in the Number of Polyps Measured in the Defined Focal Area of the Rectum.|Change in Global Rectal Polyp Burden.|Relative EPA Concentration of Total Free Fatty Acids in the Rectal Mucosa.|Number of Subjects With Adverse Events.","https://ClinicalTrials.gov/show/NCT00510692"
3857,"NCT00151476","Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients","Terminated","Has Results","Familial Adenomatous Polyposis (FAP)","Drug: Celecoxib|Other: Routine Medical Care","Pfizer","Both","12 Years and older   (Child, Adult, Senior)","Phase 4","68","Industry","Observational","Observational Model: Cohort","NQ4-00-02-012|A3191167","September 7, 2005","November 2004","November 2008","March 4, 2010","March 2010","November 19, 2009","null","November 2008","Time From Ileorectal Anastomosis (IRA) to Time of First Excisional Polypectomy of a Rectal Polyp Post IRA|Time From Start of Study Follow-up to the Time of First Excisional Polypectomy of a Rectal Polyp Post IRA|Time From Ileopouch Anal Anastomosis (IPAA) to Time of First Excisional Polypectomy of a Rectal Polyp Post IPAA|Time From Start of Study Follow-up to Time of First Excisional Polypectomy of a Rectal Polyp Post IPAA|Time From Most Recent Prior FAP-related Surgical Event or Onset of FAP Phenotype to Time of First Excisional or Ablational Event for Rectal, Colonic, Pouch, or Duodenal Adenomas (Duodenal Adenomatous Polyps)|Time From Start of Study Follow-up to Time of First Excisional or Ablational Event for Rectal, Colonic, Pouch, or Duodenal Adenomas|Time From Most Recent Prior FAP-related Surgical Event or Onset of FAP Phenotype to Time of First FAP-related Adverse Event|Time From Start of Study Follow-up to Time of First FAP-related Adverse Event|Time From Post IRA to Time of Conversion From IRA to IPAA|Time From Start of Study Follow-up to Time of Conversion From IRA to IPAA|Duodenal Adenoma Burden as Measured by Spigelman Stage|Rectal or Pouch Adenoma Burden Based on Polyp Counts","https://ClinicalTrials.gov/show/NCT00151476"
3858,"NCT00134758","Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients","Active, not recruiting","No Results Available","Adenomatous Polyposis Coli, Familial","Drug: Ursodeoxycholic acid|Drug: Placebo","Assistance Publique - Hôpitaux de Paris|Axcan Pharma","Both","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","90","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","P030419|AOM 03041","August 23, 2005","October 2004","October 2009","July 28, 2009","July 2009","No Study Results Posted","null","June 2009","SPIGELMAN severity score of duodenal lesion after 2 years of follow-up|Cellular proliferation (Ki 67 and PCNA)|Biliary acid profile|Compliance to the treatment","https://ClinicalTrials.gov/show/NCT00134758"
3859,"NCT02784262","Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis","Not yet recruiting","No Results Available","Chronic Disease|Nasal Polyposis|Rhinitis","Drug: botox injection Multiguide","Norwegian University of Science and Technology|St. Olavs Hospital","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","10","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","011015-01|2015-004377-33","May 24, 2016","September 2016","January 2017","May 26, 2016","May 2016","No Study Results Posted","null","January 2017","adverse events|change in symptom index on a visual analog scale nasal obstruction/running nose|change in sinonasal quality of life assessed with the sino-nasal outcome test 22 (SNOT-22)|change in nose-sinus related quality of life assessed with a visual analog scale (VAS)|change in the geometrics of the nose assessed by acoustic rhinometry|change in air flow in the nose measured by peak nasal inspiratory flow (PNIF)|change in polyp mass assessed by magnetic resonance imaging (MRI)|change in polyp mass assessed by computer tomography (CT)|change in quality of life expressed by Patients' Global Impression of Change (PGIC)","https://ClinicalTrials.gov/show/NCT02784262"
3860,"NCT02734849","Study to Evaluate Multiple Doses in Patients With Nasal Polyposis","Recruiting","No Results Available","Nasal Polyposis","Drug: AK001 low dose|Drug: AK001 high dose|Drug: Placebo","Allakos, Inc.","Both","18 Years to 65 Years   (Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AK001-002","March 24, 2016","April 2016","July 2017","April 11, 2016","April 2016","No Study Results Posted","null","June 2017","Evaluation of AK001 in combination with an intranasal steroid versus intranasal steroid alone in the reduction of nasal polyp size.|Size of polyps as evaluated by Lund-Mackay score at selected sites by computed tomography (CT) scan","https://ClinicalTrials.gov/show/NCT02734849"
3861,"NCT02562924","The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery","Recruiting","No Results Available","Chronic Sinusitis|Nasal Polyposis","Device: MEDIHONEY®|Drug: Budesonide|Drug: Normal saline sinus rinse|Drug: Prednisone|Procedure: Endoscopic sinus surgery|Drug: nasal saline spray","University of Vermont Medical Center","Both","18 Years and older   (Adult, Senior)","","36","Other","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHRMS 15-010","April 21, 2015","November 2015","November 2017","May 23, 2016","May 2016","No Study Results Posted","null","November 2017","Lund-Kennedy endoscopic scores|Nasal drainage cultures|SNOT-22 questionnaire|Symptom scores","https://ClinicalTrials.gov/show/NCT02562924"
3862,"NCT01946711","Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi","Recruiting","No Results Available","Rhinosinusitis|Chronic Polyposis","Drug: Budesonide|Drug: Budesonide","Pari Pharma GmbH","Both","18 Years and older   (Adult, Senior)","Phase 3","20","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12082.101","September 4, 2013","April 2014","March 2017","March 30, 2016","March 2016","No Study Results Posted","null","December 2016","Change of inflammation of the nasal mucosa and paranasal sinus|Safety assessment","https://ClinicalTrials.gov/show/NCT01946711"
3863,"NCT01624662","Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety","Completed","No Results Available","Bilateral Nasal Polyposis","Drug: fluticasone propionate|Drug: fluticasone propionate","Optinose US Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","323","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","OPN-FLU-NP-3102","June 13, 2012","October 2013","October 2015","February 2, 2016","February 2016","No Study Results Posted","null","August 2015","reduction of nasal congestion/obstruction symptoms|reduction in total polyp grade (sum of scores from both nasal cavities) over the 16 weeks of the double-blind treatment phase as determined by a nasal polyp grading scale score measured by nasoendoscopy","https://ClinicalTrials.gov/show/NCT01624662"
3864,"NCT01622569","Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety","Completed","No Results Available","Bilateral Nasal Polyposis","Drug: fluticasone propionate|Drug: fluticasone propionate","Optinose US Inc.","Both","18 Years and older   (Adult, Senior)","Phase 3","323","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","OPN-FLU-NP-3101","June 13, 2012","October 2013","December 2015","February 2, 2016","February 2016","No Study Results Posted","null","October 2015","• reduction of nasal congestion/obstruction symptoms|reduction in total polyp grade (sum of scores from both nasal cavities) over the 16 weeks of the double-blind treatment phase as determined by a nasal polyp grading scale score measured by nasoendoscopy","https://ClinicalTrials.gov/show/NCT01622569"
3865,"NCT01393340","Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma","Completed","No Results Available","Nasal Polyposis|Asthma","Drug: Omalizumab|Drug: Placebo","University Hospital, Ghent|Novartis Pharma AG, Switzerland","Both","18 Years and older   (Adult, Senior)","Phase 2","23","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","2006/240","July 7, 2011","December 2006","December 2009","July 11, 2011","July 2011","No Study Results Posted","null","October 2008","Effect of Omalizumab on nasal polyp size and evolution of nasal polyps|Effect of Omalizumab on rhinosinusitis symptoms:nasal discharge, nasal congestion, postnasal drip scores: Subject's Diary|Effect of Omalizumab on asthma symptom scores including cough, wheeze, dyspnoea: Subject's Diary.|Effect of Omalizumab on sinus computed tomography (CT)-scan score : Sinus CT-scan evaluation|Effect of Omalizumab on smell: UPSIT (University of Pennsylvania Smell Identification Test)|Effect of Omalizumab on Rhinitis specific Quality of Life: Rhinosinusitis Outcome Measure (RSOM-31)|Effect of Omalizumab on asthma related Quality of life: Asthma Quality of Life Questionnaire (AQLQ)|Effect of Omalizumab on overall Quality of Life: The Short Form (36) Health Survey (SF-36)|Effect of Omalizumab on peak nasal inspiratory flow|Effect of Omalizumab and Forced Expiratory Volume in 1 second (FEV1): spirometry|Effect of Omalizumab on diverse inflammatory mediators in serum, in nasal fluid (eosinophilic cationic protein (ECP), Interleukin-2 receptor (IL-2R), Sol Interleukin-5 receptor, soluble Cluster of differentiation 23 (sCD23), tryptase)|Evaluation of adverse events, directly or by general physical examination, blood sampling , review of concomitant medication or symptom scores.","https://ClinicalTrials.gov/show/NCT01393340"
3866,"NCT01197612","Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis","Recruiting","No Results Available","Chronic|Sinusitis|Polyposis","Drug: pulmicort","University of Michigan|American Rhinologic Society","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Primary Purpose: Treatment","HUM00029273","August 30, 2010","September 2010","null","September 8, 2010","August 2010","No Study Results Posted","null","null","olfaction|Sinonasal health|Olfaction","https://ClinicalTrials.gov/show/NCT01197612"
3867,"NCT00480298","Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis","Completed","No Results Available","Nasal Polyposis","Drug: Administration of oral methylprednisolone","University Hospital, Ghent","Both","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment","2002/067","May 25, 2007","November 2002","July 2006","December 19, 2007","December 2007","No Study Results Posted","null","null","endoscopic evaluation of the nasal polyp size compared to baseline|Nasal Polyp score: endoscopic evaluation of the nasal polyp size compared to baseline. Nasal polyposis signs and symptoms including nasal discharge, nasal congestion, postnasal drip, sense of smell,olfactory test (sites Gent, Stockholm and Huddinge) and","https://ClinicalTrials.gov/show/NCT00480298"
3868,"NCT01977053","Impact of a Telephonic Monitoring During Inter-treatment Intervals on Emotional State, Quality of Life and Toxicities, on Neo Adjuvant or Adjuvant Chemotherapy-treated Patients","Recruiting","No Results Available","Non-metastatic Patients With Breast Cancer|Non-metastatic Patients With Colon Cancer|Non-metastatic Patients With Rectal Cancer|Patients Undergoing Adjuvant Chemotherapy","Other: Clinical and psychosocial phone calls","Centre Antoine Lacassagne","Both","18 Years and older   (Adult, Senior)","","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","2012/04|2013-A00506-39","October 22, 2013","September 2013","June 2017","February 2, 2016","February 2016","No Study Results Posted","EMOTION","December 2016","emotional state (anxiety, depression, confusion, angry, fatigue, force and interpersonal relation)|Evolution of emotional states scores|toxicities|quality of life|anxiety|caregiver mood states|patient satisfaction|relationship between psychosocial criteria and anxiety","https://ClinicalTrials.gov/show/NCT01977053"
3869,"NCT00220181","Prospective Study in Pelvic Radiotherapy Patients","Completed","No Results Available","Gynaecological, Urological or Rectal Cancer","","Royal Marsden NHS Foundation Trust","Both","Child, Adult, Senior","","100","Other","Observational","Observational Model: Case Control|Observational Model: Natural History|Time Perspective: Cross-Sectional|Time Perspective: Prospective","CCR2240","September 21, 2005","April 2003","September 2005","September 21, 2005","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00220181"
3870,"NCT02816879","Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men","Recruiting","No Results Available","Anal Carcinoma|HIV Infection|Human Papillomavirus Infection","Procedure: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Senior)","","375","Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","RCA169508A|NCI-2014-01292|JCCCID370|P30CA016042|R01CA169508|13-000997","May 23, 2016","September 2013","June 2018","July 5, 2016","June 2016","No Study Results Posted","null","June 2017","Accuracy of cytology specimens for Dacron swab compared to flocked nylon (NF) swab in predicting histology outcome|Ability of APTIMA-HPV to predict risk for HG-AIN|Ability of Hybrid-capture 2 to predict risk for HG-AIN|Cost effectiveness analysis evaluating differences in survival, the cost of out-patient procedures & in-patient hospitalizations for invasive anal cancer.","https://ClinicalTrials.gov/show/NCT02816879"
3871,"NCT00271986","Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection (LAR) for Recto-sigmoid Cancer","Completed","No Results Available","Cancer of Rectum","","Odense University Hospital","Both","Child, Adult, Senior","","60","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","VF20050008","January 3, 2006","January 2006","January 2008","July 20, 2011","May 2008","No Study Results Posted","null","November 2007","anastomotic leakage","https://ClinicalTrials.gov/show/NCT00271986"
3872,"NCT00353457","Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma","Terminated","No Results Available","Rectal Cancer","Drug: Capecitabine, Oxaliplatin and Cetuximab|Radiation: Radiation","University of Pennsylvania|Bristol-Myers Squibb|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","803437|UPCC 09204","July 14, 2006","February 2006","null","September 29, 2010","September 2010","No Study Results Posted","null","February 2010","Pathologic complete response|Sphincter function|Type of surgery|Disease free survival","https://ClinicalTrials.gov/show/NCT00353457"
3873,"NCT01979029","Study of the Preservation of the Left Colic Artery on Rectum Cancer Surgery","Completed","Has Results","Rectum Cancer","Procedure: preserving the left colic artery|Procedure: not preserving the left colic artery","Jian Suo|First Hospital of Jilin University","Both","18 Years to 85 Years   (Adult, Senior)","","57","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","Left Colic Artery","October 25, 2013","February 2013","October 2014","April 28, 2016","April 2016","March 2, 2016","POTLCAORCS","September 2014","The Blood Pressure of the Arterial Arcade|Distal Colon Length","https://ClinicalTrials.gov/show/NCT01979029"
3874,"NCT01269216","A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer","Completed","No Results Available","Rectal Cancer","Drug: 5-FU with leucovorin|Drug: TS-1 with Irinotecan","Yonsei University","Both","18 Years and older   (Adult, Senior)","Phase 2","136","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2008-0361","January 3, 2011","October 2008","September 2014","January 26, 2015","January 2015","No Study Results Posted","null","September 2014","pathologic complete response rate","https://ClinicalTrials.gov/show/NCT01269216"
3875,"NCT02857608","A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus","Not yet recruiting","No Results Available","Anal Cancer","Drug: Lymphoseek","Navidea Biopharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 2","10","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","NAV3-20","August 2, 2016","September 2016","August 2017","August 4, 2016","August 2016","No Study Results Posted","null","August 2017","Concordance (the proportion of the number of subjects with lymph nodes identified by Lymphoseek and standard of care methods compared to the number of subjects with lymph nodes identified by standard of care methods)|Reverse Concordance (the proportion of the number of subjects with lymph nodes identified by Lymphoseek and standard of care methods compared to the number of subjects with lymph nodes identified by Lymphoseek)|Nodal Concordance (the proportion of the number lymph nodes identified by Lymphoseek and standard of care methods compared to the number of lymph nodes identified by standard of care methods)|Reverse Nodal Concordance (the proportion of the number lymph nodes identified by Lymphoseek and standard of care methods compared to the number of lymph nodes identified by Lymphoseek)|Incidence of Adverse Events","https://ClinicalTrials.gov/show/NCT02857608"
3876,"NCT02406118","Phase II Clinical Trial for the Evaluation of the Efficacy of Transanal TME","Recruiting","No Results Available","Rectal Cancer","Procedure: Transanal total mesorectal excision","National Cancer Center, Korea","Both","20 Years to 80 Years   (Adult, Senior)","Phase 2","49","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC2015-0033","March 25, 2015","March 2015","December 2020","November 25, 2015","November 2015","No Study Results Posted","null","December 2018","TME quality & circumferential resection margin (CRM)|30-day postoperative complications|Number of harvested Lymph Nodes","https://ClinicalTrials.gov/show/NCT02406118"
3877,"NCT02592304","Preoperative Assessment of Mesorectal Lymph Nodes by Dual Energy CT. PUMK-DECT","Recruiting","No Results Available","Rectal Cancer","Device: Dual energy computed tomography","Odense University Hospital","Both","18 Years and older   (Adult, Senior)","","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","SvG2-4-13-07","October 7, 2015","September 2014","September 2017","October 29, 2015","October 2015","No Study Results Posted","null","September 2016","the detection of lymph nodes by DECT in specimens from rectal resection for cancer.|sensitivity and specificity for the detection of malignant lymph nodes in vitro RC specimens compared with histopathology|sensitivity, specificity, positive- ognegative predictive values, accuracy of DECT and standard MRI.|DECT as imaging tool for diagnosing response to chemo radiotherapy of malignant lymph nodes, and tumors.","https://ClinicalTrials.gov/show/NCT02592304"
3878,"NCT01285778","Vectibix for the Treatment of Anal Cancer","Active, not recruiting","No Results Available","Anal Squamous Cell Carcinoma","Drug: panitumumab, mytomicin C, 5-FU, radiation","Grupo Espanol Multidisciplinario del Cancer Digestivo|Amgen|Trial Form Support S.L.","Both","18 Years and older   (Adult, Senior)","Phase 2","58","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEMCAD-0902","January 20, 2011","October 2010","December 2016","March 10, 2015","September 2013","No Study Results Posted","VITAL","December 2015","Three-year disease-free survival rate|Disease free survival rate|Three-year free local-regional failure rate|Overall survival|Colostomy-free survival rate|Complete response rate|Safety profile|Predictive potential of different biomarkers","https://ClinicalTrials.gov/show/NCT01285778"
3879,"NCT02817126","Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer","Recruiting","No Results Available","Rectal Carcinoma","Procedure: Robot-assisted resection|Procedure: Laparoscopic resection","Fudan University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","680","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","REAL","March 7, 2016","October 2015","October 2023","June 25, 2016","June 2016","No Study Results Posted","REAL","October 2021","disease-free survival|overall survival|operative complications|operative mortality|locoregional recurrence rate","https://ClinicalTrials.gov/show/NCT02817126"
3880,"NCT00855946","Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy","Completed","No Results Available","Rectal Adenocarcinoma","","University Hospital, Bordeaux","Both","18 Years to 80 Years   (Adult, Senior)","","46","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUBX - 2008/25","March 4, 2009","May 2009","May 2012","May 7, 2013","May 2013","No Study Results Posted","PROTEORECTUM","May 2012","differential expression of early seric biomarkers between good and bad responders.|modifications of isolated biomarkers within presurgical period","https://ClinicalTrials.gov/show/NCT00855946"
3881,"NCT02177084","Percutaneous Tibial Nerve Stimulation in the Treatment of Anterior Resection Syndrome After Rectal Cancer Surgery","Not yet recruiting","No Results Available","Rectal Cancer|Low Anterior Resection Syndrome","Device: PTNS","St. Orsola Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","12","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PTNS BO-01","June 25, 2014","July 2014","null","June 26, 2014","June 2014","No Study Results Posted","null","December 2016","LARS score|EORTC QLQ-CR38|EORTC QLQ-C30|FISI|FIQL|ODS SCORE|CRQoL|functional outcome|morbidity","https://ClinicalTrials.gov/show/NCT02177084"
3882,"NCT01073384","A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer","Completed","No Results Available","Enteritis","Drug: SGX201 (delayed release beclomethasone 17,21-dipropionate)","Soligenix|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","16","Industry|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","BDP-ENT-01|1R43CA141968-01","February 19, 2010","December 2009","November 2012","December 12, 2012","December 2012","No Study Results Posted","null","January 2012","Preliminary Efficacy","https://ClinicalTrials.gov/show/NCT01073384"
3883,"NCT01476631","Step Down Colon Cancer Risk","Terminated","No Results Available","Adenomatous Polyps","Behavioral: Walking","Washington University School of Medicine","Both","50 Years to 80 Years   (Adult, Senior)","","17","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","201105308","November 9, 2011","November 2008","April 2010","August 2, 2013","August 2013","No Study Results Posted","null","April 2010","Exercise will decrease serum markers (insulin, C-peptide, IL-6 and PGE-2) in a dose response manner.|Participants in the 60 minute intervention will have significantly higher physical activity levels (measured by pedometer and accelerometer) than those in the 30 minute intervention at three months.","https://ClinicalTrials.gov/show/NCT01476631"
3884,"NCT02503111","The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men","Enrolling by invitation","No Results Available","Anal Dysplasia|Human Papillomavirus|Anal Cancer","Device: The Hyfrecator ® 2000 Electrosurgical System|Other: Observation Alone","University Health Network, Toronto|Canadian Institutes of Health Research (CIHR)|Ontario HIV Treatment Network|CIHR Canadian HIV Trials Network|Merck Sharp & Dohme Corp.","Male","18 Years and older   (Adult, Senior)","","3000","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","HPV-SAVE","July 10, 2015","November 2015","December 2020","September 13, 2016","September 2016","No Study Results Posted","HPV-SAVE","November 2020","Anal dysplasia treatment on a per-patient basis|Resolution of high-grade AIN at 3 and 6 months on a per-lesion basis|Acceptance rate of participants recruited into the study|Recurrence rates of high-grade AIN|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT02503111"
3885,"NCT01458353","Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer","Not yet recruiting","No Results Available","Peritoneal Contamination After Ileocolonic Anastomosis|Wound Infection|Intra-abdominal Abscess","Procedure: Stapled anastomosis|Procedure: Handsewn anastomosis","Hospital General Universitario Elche","Both","Child, Adult, Senior","Phase 3","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","HGUElche1","October 19, 2011","November 2011","December 2012","October 21, 2011","October 2011","No Study Results Posted","null","December 2012","Peritoneal contamination after finishing the ileocolonic anastomosis","https://ClinicalTrials.gov/show/NCT01458353"
3886,"NCT00259363","Oxaliplatin in Rectal Cancer","Terminated","No Results Available","Rectal Neoplasms","Drug: Oxaliplatin","Sanofi","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","46","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","L_8330","November 28, 2005","October 2002","null","December 4, 2009","December 2009","No Study Results Posted","null","June 2006","Phase I : Maximum Tolerated Dose & Recommended Dose|Phase II : Response and resectability rate.","https://ClinicalTrials.gov/show/NCT00259363"
3887,"NCT01910974","Multicentric Study an Endoscopic Treatment of Digestive Neoplasia by Submucosal Dissection Evaluation of a New Water Jet System","Completed","No Results Available","Stomach Neoplasm|Intestinal Neoplasm|Rectal Neoplasm","Procedure: endoscopic sub-mucosal dissection","Hôpital Edouard Herriot","Both","18 Years to 90 Years   (Adult, Senior)","","80","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TRESTIS 2013-A00133-42|TRESTIS","July 15, 2013","July 2012","February 2014","August 29, 2016","July 2012","No Study Results Posted","null","February 2014","SAFETY THAT IS TO SAY PERFORATION RATE AND delayed BLEEDING ONE","https://ClinicalTrials.gov/show/NCT01910974"
3888,"NCT02216149","Effects of S-1 and Capecitabine on Coronary Artery Blood Flow","Recruiting","No Results Available","Esophagus Cancer|Stomach Cancer|Small Bowel Cancer|Colon Cancer|Rectum Cancer","Drug: S-1|Drug: Capecitabine","Heikki Joensuu|Helsinki University Central Hospital","Both","18 Years to 100 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","HUS-01/2013|2013-003976-11","August 7, 2014","January 2015","August 2019","March 4, 2016","March 2016","No Study Results Posted","FluoHeart","August 2018","Frequency of coronary artery dysfunction|Coronary artery blood flow rate|Cardiac arrythmias during 24-hour electrocardiogram registration|Adverse events between the allocation groups|Response to chemotherapy","https://ClinicalTrials.gov/show/NCT02216149"
3889,"NCT01560377","Perfusion Assessment in Laparoscopic Left Anterior Resection","Completed","No Results Available","Rectal Cancer|Colon Cancer|Crohn's Disease|Polyp|Procidentia|Diverticulitis","Device: PINPOINT Endoscopic Fluorescence Imaging System","Novadaq Technologies Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","147","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","Version 1","March 19, 2012","May 2012","November 2013","June 30, 2014","June 2014","No Study Results Posted","PILLAR II","October 2013","Incidence of use of PINPOINT System to aid in surgical colectomies decision making.|Incidence of all other operative complications","https://ClinicalTrials.gov/show/NCT01560377"
3890,"NCT02635087","microRNAs Tool for Stratifying Stage II Colon Cancer","Recruiting","No Results Available","Colonic Neoplasms|Effects of Chemotherapy","Device: miRNA tool","First Affiliated Hospital, Sun Yat-Sen University","Both","20 Years to 75 Years   (Adult, Senior)","","630","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2015[112]","December 16, 2015","December 2015","July 2025","December 29, 2015","December 2015","No Study Results Posted","null","July 2020","DFS|OS","https://ClinicalTrials.gov/show/NCT02635087"
3891,"NCT01382745","Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers","Terminated","No Results Available","Squamous Cell Carcinoma of Anal Canal","Drug: Nimotuzumab|Radiation: Intensity Modulated Radiation Therapy (IMRT)","Dr. Te Vuong|YM BioSciences|Sir Mortimer B. Davis - Jewish General Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","1","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11-044","June 24, 2011","January 2012","January 2022","January 25, 2013","January 2013","No Study Results Posted","null","September 2021","Toxicity|Local tumor response rate|Overall cancer-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01382745"
3892,"NCT01060007","Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer","Completed","Has Results","Rectal Neoplasms","Radiation: External beam radiation|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-FU|Drug: Capecitabine","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-0696 / 201106272","January 28, 2010","November 2009","September 2014","January 23, 2015","December 2014","January 23, 2015","null","April 2013","Rate of T Stage Downstaging|Preoperative Gastrointestinal Morbidity|Incidence of Any Late Grade 3 or Higher Morbidity|Incidence of Post Chemoradiotherapy Grade 3 or Higher Morbidity|Local Control|Rate of Overall Control|Rate of Locoregional Control|Freedom From Disease Relapse|Determine Quality of Anorectal Function","https://ClinicalTrials.gov/show/NCT01060007"
3893,"NCT00302094","Image Fusion PET, CT and 3D-ultrasound Examinations","Completed","No Results Available","Anal Cancer","","Rigshospitalet, Denmark","Both","18 Years and older   (Adult, Senior)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","(KF) 11-107/03","March 10, 2006","June 2006","April 2009","November 29, 2012","November 2012","No Study Results Posted","null","April 2009","Program to fuse 3D ultrasound and PET/CT data","https://ClinicalTrials.gov/show/NCT00302094"
3894,"NCT02532478","Fortune of Temporary Ileostomies in Patients After Rectal Cancer Surgery","Completed","No Results Available","Loop Ileostomy","","Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi","Both","Child, Adult, Senior","","160","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DrLutfi","August 19, 2015","February 2007","February 2014","August 21, 2015","August 2015","No Study Results Posted","null","February 2014","Stoma closure rate","https://ClinicalTrials.gov/show/NCT02532478"
3895,"NCT01609231","A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)","Completed","No Results Available","Rectal Neoplasms","Drug: Dalotuzumab|Drug: Irinotecan|Drug: Cetuximab","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 2","11","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0646-025|2012-000317-36","May 29, 2012","July 2012","December 2014","January 6, 2015","January 2015","No Study Results Posted","null","December 2014","Progression-Free Survival (PFS)|Objective Response Rate","https://ClinicalTrials.gov/show/NCT01609231"
3896,"NCT02435758","Multicenter Study on Preservation Versus Excision of Denonvilliers Fascia in L-PANP Surgery","Recruiting","No Results Available","Rectal Cancer","Procedure: Preservation of Denonvilliers Fascia during L-PANP surgery","Third Affiliated Hospital, Sun Yat-Sen University|Sixth Affiliated Hospital, Sun Yat-sen University|Nanfang Hospital of Southern Medical University","Male","20 Years to 60 Years   (Adult)","","264","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PED-PANP01","April 26, 2015","April 2015","null","November 7, 2015","November 2015","No Study Results Posted","null","December 2017","Urinary function|Sexual function|3-year disease free survival rate|5-year disease free survival rate|Morbidity|3-year overall survival rate|3-year recurrence pattern|Mortality|5-year overall survival rate|5-year recurrence pattern","https://ClinicalTrials.gov/show/NCT02435758"
3897,"NCT00421824","Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer","Completed","No Results Available","Rectal Neoplasms","Drug: Oxaliplatin, capecitabine|Drug: Oxaliplatin, capecitabine","Sanofi","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","108","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PM_L_0098|EudraCT # : 2005-005149-20","January 11, 2007","May 2006","November 2010","January 3, 2011","January 2011","No Study Results Posted","null","November 2010","Response rate|Relative dose intensity|Disease free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00421824"
3898,"NCT00568425","QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT","Terminated","No Results Available","Anal Cancer","","Stanford University","Both","30 Years to 70 Years   (Adult, Senior)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ANAL0002-|96405|SU-11062007-812","December 4, 2007","September 2005","September 2009","November 29, 2012","November 2012","No Study Results Posted","null","September 2009","Evaluate the late effects of radiation treatment","https://ClinicalTrials.gov/show/NCT00568425"
3899,"NCT02724306","Physical Activity Intervention With People at Increased Risk of Developing Colon Cancer","Completed","No Results Available","Colon Polyps|Colon Adenomas","Behavioral: Active Lifestyle Programme","University of East Anglia","Both","60 Years and older   (Adult, Senior)","","31","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","12/EE/0106","February 12, 2016","March 2011","September 2014","March 24, 2016","March 2016","No Study Results Posted","PARC","September 2014","Change in DNA methylation in genes associated with inflammation and colon carcinogenesis|Compliance to intervention|Change in minutes spent in moderate and vigorous intensity physical activity measure with the International Physical Activity Questionnaire long version|Change in minutes spent in moderate and vigorous intensity leisure activity assessed with the Godin Leisure-Time Exercise Questionnaire|Change in behavioural regulation measure with the Behavioural Regulation in Exercise Questionnaire version 2|Change in Quality of life measure with the SF-36 questionnaire|Changes in anthropometric measures (height, weight, BMI)|Change in physical fitness|Change in intention to exercise|Change in barriers to exercise|Change in minutes of physical activity measured with objective measure (accelerometer, Actigraph)|Changes in body composition (% body fat) assessed with bioelectrical impedance analysis|Change in antropometric measures (waist circumference, hip circumference)","https://ClinicalTrials.gov/show/NCT02724306"
3900,"NCT00000611","Women's Health Initiative (WHI)","Completed","No Results Available","Bone Diseases|Breast Neoplasms|Cardiovascular Diseases|Colonic Neoplasms|Coronary Disease|Heart Diseases|Myocardial Ischemia|Osteoporosis|Postmenopause","Drug: hormone replacement therapy|Drug: estrogens|Drug: progestins|Drug: estrogen replacement therapy|Behavioral: diet, fat-restricted|Drug: calcium|Drug: vitamin D|Behavioral: dietary supplements","National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Cancer Institute (NCI)|National Institute on Aging (NIA)","Female","50 Years to 79 Years   (Adult, Senior)","Phase 3","null","NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention","114","October 27, 1999","null","null","April 14, 2016","January 2006","No Study Results Posted","null","March 2005","","https://ClinicalTrials.gov/show/NCT00000611"
3901,"NCT01203969","Safety and Efficacy of Single Port Laparoscopic Surgery in Colon Cancer","Completed","No Results Available","Colon Cancer","Procedure: Single port laparoscopic surgery|Procedure: Conventional laparoscopic surgery","Kyunghee University Medical Center","Both","up to 85 Years   (Child, Adult, Senior)","Phase 1","62","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KHNMC IRB 2010-007","September 15, 2010","June 2010","April 2012","February 2, 2016","February 2016","No Study Results Posted","null","April 2011","rate of intraoperative complication|rate of 30 day morbidity and mortality|operation time|degree of postoperative pain|amount of postoperative analgesics usage|postoperative functional recovery|Duration of postoperative hospital stay","https://ClinicalTrials.gov/show/NCT01203969"
3902,"NCT02605265","Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1","Recruiting","No Results Available","Locally Advanced Rectal Cancer","Radiation: Radiation|Drug: Capecitabine|Drug: Irinotecan|Drug: Oxaliplatin","Fudan University|The First Affiliated Hospital with Nanjing Medical University|Hubei Cancer Hospital|First Affiliated Hospital of Chongqing Medical University|Ruijin Hospital","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","360","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FDRT-R005","November 9, 2015","October 2015","null","December 24, 2015","December 2015","No Study Results Posted","CinClare","December 2017","Pathologic Complete Response|Overall Survival|Disease-free Survival|Local Control rate|Number of participants with chemoradiation-related adverse events as assessed by CTCAE v4.0|Surgical complications","https://ClinicalTrials.gov/show/NCT02605265"
3903,"NCT02162641","Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer","Withdrawn","No Results Available","Squamous Cell Carcinoma of the Anus","Procedure: Sentinel lymph node biopsy","The Christie NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","13_DOG03_261|CFTSp081","June 11, 2014","September 2014","May 2015","June 2, 2015","June 2015","No Study Results Posted","R-SeNSAR","May 2015","The proportion of nodes detected will be expressed per inguinal nodal basin and per number of patients|Micro-metastatic disease within sentinel nodes|Surgical complications|Delays in receiving radiotherapy treatment","https://ClinicalTrials.gov/show/NCT02162641"
3904,"NCT00189657","5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer","Recruiting","No Results Available","Cancer of the Rectum","Procedure: 5FU/LV Mayo Clinic or LV5FU2|Procedure: LV5FU2 + irinotecan","Association Européenne de Recherche en Oncologie|Aventis Pharmaceuticals|Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 3","null","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AERO-R98","September 12, 2005","null","null","September 12, 2005","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00189657"
3905,"NCT01472601","A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile","Recruiting","No Results Available","Colon Cancer","","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","","2660","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2011-04-098","November 13, 2011","June 2011","April 2017","June 12, 2013","June 2013","No Study Results Posted","null","June 2013","disease-free survival","https://ClinicalTrials.gov/show/NCT01472601"
3906,"NCT01134601","A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum","Terminated","No Results Available","Non-Metastatic Adenocarcinoma of the Rectum","Procedure: Radiation Therapy|Drug: Capecitabine|Drug: AZD6244","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","18 Years and older   (Adult, Senior)","Phase 1","1","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","100132|10-C-0132","May 28, 2010","May 2010","October 2012","February 19, 2014","October 2012","No Study Results Posted","null","October 2012","To define the maximum tolerable dose and toxicity profile of AZD6244 Hyd-Sulfate delivered BID, 7 days per week, in combination with radiation therapy (RT) and Capecitabine in patients with locally advanced adenocarcinoma of the rectum.|To evaluate the pharmacokinetics. To obtain exploratory information regarding the pathologic response rate. To determine changes in phosphorylated ERK (pERK) in peripheral blood mononuclear cells.","https://ClinicalTrials.gov/show/NCT01134601"
3907,"NCT02627729","J-Pouch vs Side-to-End Anastomosis After Hand-Assisted Laparoscopic Low Anterior Resection for Rectal Cancer","Completed","No Results Available","Quality of Life|Fecal Incontinence|Postoperative Complications","Device: Linear cutter-Circular stapler|Device: Circular stapler","Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi","Both","Child, Adult, Senior","","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Treatment","DrLutfi2","December 7, 2015","June 2009","February 2014","December 9, 2015","December 2015","No Study Results Posted","null","April 2012","Short Form 36 Quality of life Questionnaire|Postoperative complications|Functional outcome measured with Fecal Incontinence Severity Index|Functional outcome measured with Sexual Health Inventory|Functional outcome measured with Overactive Bladder validated 8 scale","https://ClinicalTrials.gov/show/NCT02627729"
3908,"NCT00469339","Risk Communication Within Mexican-American Families","Completed","No Results Available","Diabetes|Colon Cancer|Cardiovascular Disease","Behavioral: Family Health History","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 70 Years   (Adult, Senior)","","560","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Prevention","999907140|07-HG-N140","May 3, 2007","April 2007","December 2010","August 11, 2016","August 2016","No Study Results Posted","null","December 2010","Family Communication about Risk|Illness representations, Cooperative strategies to screen and adopt healthy behaviors","https://ClinicalTrials.gov/show/NCT00469339"
3909,"NCT01877135","Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients","Recruiting","No Results Available","Anal AIN3|Anal Carcinoma","","French Society of Coloproctology|Société Nationale Française de Gastroentérologie","Both","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Observational Model: Cohort","11-LAZ-001","June 11, 2013","August 2013","June 2019","March 4, 2015","September 2013","No Study Results Posted","AIN3","June 2016","at least one anal cancer|Observance|patient's feelings about his therapeutic care and impact on his emotional life","https://ClinicalTrials.gov/show/NCT01877135"
3910,"NCT02682485","Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing","Not yet recruiting","No Results Available","Anastomotic Leak|Rectal Cancer","Drug: Cipro, metronidazole, neomycin combo|Procedure: Serial Endoscopic Surveillance|Drug: Saline","University of Chicago","Both","18 Years and older   (Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB15-0971","February 8, 2016","January 2017","July 2020","March 22, 2016","March 2016","No Study Results Posted","SES-DTA","December 2019","Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18)","https://ClinicalTrials.gov/show/NCT02682485"
3911,"NCT00606983","Prevention of Acute Voiding Difficulty After Radical Proctectomy","Completed","No Results Available","Rectal Cancer|Urinary Retention","Drug: Tamsulosin","Seoul National University Hospital","Both","20 Years to 80 Years   (Adult, Senior)","Phase 3","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","B-0702-042-006|SNUBH-GS-CR3","January 22, 2008","May 2007","September 2010","July 18, 2011","July 2011","No Study Results Posted","null","September 2010","Re-insertion rate of urinary catheter after removal|Scores of IPSS (International Prostatic Symptom Score) and the results of uroflowmetry","https://ClinicalTrials.gov/show/NCT00606983"
3912,"NCT02836977","Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection","Active, not recruiting","No Results Available","Stage III Colon Cancer","Drug: tegafur-uracil","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","20 Years to 80 Years   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KMUHIRB-F(I)-20160016","July 10, 2016","March 2016","null","July 18, 2016","June 2016","No Study Results Posted","null","March 2017","Disease free survival","https://ClinicalTrials.gov/show/NCT02836977"
3913,"NCT01395667","Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX","Recruiting","No Results Available","Rectal Cancer","Other: CCRT","National Taiwan University Hospital","Both","20 Years to 70 Years   (Adult, Senior)","Phase 1","15","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201103126MB","July 14, 2011","June 2011","December 2014","April 15, 2014","April 2014","No Study Results Posted","null","December 2014","Maximally tolerated dose|Improved rate","https://ClinicalTrials.gov/show/NCT01395667"
3914,"NCT01287637","Early Closure of Temporary Ileostomy","Completed","No Results Available","Rectal Cancer","Procedure: Early reversal of temporary ileostomy|Procedure: Standard reversal of temporary ileostomy","Herlev Hospital","Both","18 Years and older   (Adult, Senior)","","89","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AKD03","January 28, 2011","February 2011","December 2015","January 16, 2016","January 2016","No Study Results Posted","EASY","November 2015","Postsurgical morbidity|Postsurgical morbidity.|Quality of life|Socio-economic effect of early reversal of temporary ileostomy","https://ClinicalTrials.gov/show/NCT01287637"
3915,"NCT00938210","Rehabilitation Following Laparoscopic Colonic Surgery","Completed","No Results Available","Colonic Cancer|Postoperative Care|Fatigue","Procedure: Laparoscopic colonic surgery","Aarhus University Hospital","Both","Child, Adult, Senior","","50","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MBJ-1","July 10, 2009","May 2009","August 2012","August 7, 2012","August 2012","No Study Results Posted","null","November 2011","Fatigue|Muscular strength|Change in work capacity (pulse rate)|Balance (sway)|Pain at rest and when moving|Quality of life (Short Form 36 - SF-36)|Body weight|Body composition (fat mass and fat free mass estimated by bio-impedance)|Social support","https://ClinicalTrials.gov/show/NCT00938210"
3916,"NCT01589471","The Value of Botox-A for Management of Low Anterior Resection Syndrome","Active, not recruiting","No Results Available","Low Anterior Resection Syndrome|Rectal Cancer","Drug: intra-rectal Botulinum toxin A injection","Centre hospitalier de l'Université de Montréal (CHUM)|Allergan","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","23","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CE 11.088","April 27, 2012","May 2012","November 2015","May 7, 2015","May 2015","No Study Results Posted","null","October 2015","Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score|Efficacy of intra-rectal Botox-A injection on anorectal function as documented with a visual scale for tenesmus and completeness of stool evacuation|Efficacy of intra-rectal Botox-A injection on quality of life as documented with EORTC-QlQ standardized questionnaires|Efficacy of intra-rectal Botox-A injection as documented with a patient medicine calender|Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized anorectal manometry readings|Long term efficacy of intra-rectal Botox-A injection on anorectal function as documented with Wexner score, EORTC-QLQ questionnaire and visual scale|Safety of intra-rectal Botox-A injections as documented with adverse events monitoring","https://ClinicalTrials.gov/show/NCT01589471"
3917,"NCT01127867","A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women","Completed","No Results Available","Breast Cancer|Rectal Cancer|Colon Cancer|Obesity","Dietary Supplement: dietary intervention","Rockefeller University","Female","40 Years to 70 Years   (Adult, Senior)","","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","PHO-0702","May 19, 2010","May 2010","April 2013","May 16, 2013","May 2013","No Study Results Posted","null","April 2013","Reduced subcutaneous fat|multiplex bead assay/immunoassay","https://ClinicalTrials.gov/show/NCT01127867"
3918,"NCT01366118","Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients","Completed","No Results Available","Rectal Cancer","Drug: Therapeutic target tailored chemotherapy","Grupo Hospital de Madrid","Both","18 Years and older   (Adult, Senior)","","16","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","62 202-878","May 31, 2011","October 2009","April 2011","June 2, 2011","October 2009","No Study Results Posted","TT","April 2011","ypTN|Feasibility","https://ClinicalTrials.gov/show/NCT01366118"
3919,"NCT00975247","Impact of a Novel Patient Educational Booklet on Colonoscopy Quality","Completed","No Results Available","Colon Cancer|Colonoscopy","Other: Receiving an educational booklet","VA Greater Los Angeles Healthcare System","Both","18 Years and older   (Adult, Senior)","","500","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","IIR 08-310|Project Number 0013","September 10, 2009","April 2008","September 2012","December 9, 2014","December 2014","No Study Results Posted","null","September 2012","Bowel preparation quality, as measured by the Ottawa scale.|Adenomatous Polyp Detection|Advanced Adenomatous Polyp Detection|Cecal Intubation|Withdrawal Time","https://ClinicalTrials.gov/show/NCT00975247"
3920,"NCT02626728","A Prospective Feasibility Study for TAMIS","Recruiting","No Results Available","Rectal Cancer","Procedure: laparoscopic assisted transanal surgery (TAMIS)","Hvidovre University Hospital","Both","18 Years to 99 Years   (Adult, Senior)","","25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","123-TAMIS","December 8, 2015","September 2015","April 2017","August 15, 2016","August 2016","No Study Results Posted","TAMIS","March 2017","morbidity|mortality|short-term oncological result","https://ClinicalTrials.gov/show/NCT02626728"
3921,"NCT01488045","Compare Propofol to Fentanyl and Midazolam for Colonoscopy","Active, not recruiting","No Results Available","Colon Cancer|Rectal Cancer|Colonic Diverticulosis","Drug: Fentanyl|Drug: Propofol|Drug: Midazolam","Saint Joseph Mercy Health System","Both","18 Years and older   (Adult, Senior)","","290","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","RCCS 262","December 1, 2011","June 2011","June 2016","December 19, 2014","December 2014","No Study Results Posted","null","January 2016","Patient satisfaction|Patient discomfort","https://ClinicalTrials.gov/show/NCT01488045"
3922,"NCT01807546","Oral Rigosertib for Squamous Cell Carcinoma","Completed","No Results Available","Head and Neck Squamous Cell Carcinoma|Anal Squamous Cell Carcinoma|Lung Squamous Cell Carcinoma|Cervical Squamous Cell Carcinoma|Esophageal Squamous Cell Carcinoma|Skin Squamous Cell Carcinoma|Penile Squamous Cell Carcinoma","Drug: rigosertib","Onconova Therapeutics, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","64","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Onconova 09-09|COMIRB 13-0116","March 4, 2013","March 2013","April 2016","May 18, 2016","May 2016","No Study Results Posted","null","March 2015","Overall response rate|Overall survival (OS)|Progression free survival (PFS),|Concentration of rigosertib in plasma|Levels of Biomarkers|Number of Adverse Events","https://ClinicalTrials.gov/show/NCT01807546"
3923,"NCT00580073","Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum","Completed","No Results Available","Rectal Cancer","Drug: FOLFOX4|Drug: Cetuximab","University of Wisconsin, Madison|Sanofi|Bristol-Myers Squibb|ImClone LLC","Both","18 Years and older   (Adult, Senior)","Phase 2","6","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-0197 (CO06207)","December 17, 2007","December 2007","November 2009","October 15, 2010","October 2010","No Study Results Posted","null","November 2009","response to therapy","https://ClinicalTrials.gov/show/NCT00580073"
3924,"NCT01302613","Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma","Terminated","No Results Available","Stage II Rectal Cancer|Stage III Rectal Cancer","Drug: Capecitabine|Drug: 5-FU|Drug: Leucovorin|Drug: Oxaliplatin|Radiation: radiation|Procedure: total mesorectal excision","University of Texas Southwestern Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","2","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","STU 082010-335","February 21, 2011","March 2011","March 2016","May 29, 2015","October 2012","No Study Results Posted","null","March 2016","The primary study endpoint for the phase I portion of this study is to assess surgical complications through the Clavien grading system.|The primary endpoint of the phase II portion of the study is complete pathologic response.","https://ClinicalTrials.gov/show/NCT01302613"
3925,"NCT01941979","A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment.","Recruiting","No Results Available","Rectal Cancer","Drug: 5-FU, Capecitabine, Oxaliplatin, Leucovorin.","Instituto do Cancer do Estado de São Paulo","Both","18 Years to 75 Years   (Adult, Senior)","Phase 3","309","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NP-113/2011","September 4, 2013","September 2011","September 2016","October 29, 2014","October 2014","No Study Results Posted","null","September 2015","Disease free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01941979"
3926,"NCT02320123","End-of-Life Care for African Americans","Active, not recruiting","No Results Available","Colonic Neoplasms|Breast Neoplasms|Lung Neoplasms","Behavioral: Educational DVD","University of Texas Southwestern Medical Center|Agency for Healthcare Research and Quality (AHRQ)","Both","21 Years and older   (Adult, Senior)","","116","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research","STU 032013-051","December 15, 2014","September 2013","August 2018","December 23, 2014","December 2014","No Study Results Posted","null","August 2018","Feasibility and Acceptability of the Intervention. (number and rates of patients/caregivers who complete the intervention and follow-up interviews)|Intent to Discuss EOL Care Options (based on the Transtheoretical Stages of Change Model)|Knowledge of Prognosis and EOL Care (revised version of the Coping with Cancer II interview guide)|Decisional Conflict (Decisional Conflict Scale)|Quality of Life|Health Care Utilization (measured by outpatient visits, ER visits, hospitalizations, use of hospice services, etc.)","https://ClinicalTrials.gov/show/NCT02320123"
3927,"NCT00827580","Eniluracil Hand Foot Syndrome","Completed","No Results Available","Breast Cancer|Colon Cancer","Drug: Eniluracil|Drug: Capecitabine","West Virginia University|Investigator initiated study","Both","18 Years and older   (Adult, Senior)","Phase 1","35","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment","HS20667","January 22, 2009","January 2009","null","August 27, 2009","August 2009","No Study Results Posted","null","null","the frequency of HFS; evaluation of eniluracil dose response; and assessment of any toxicity related to the topical product.","https://ClinicalTrials.gov/show/NCT00827580"
3928,"NCT01586117","A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity","Recruiting","No Results Available","Rectal Cancer","Drug: Amifostine","Chinese Academy of Medical Sciences","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CH-GI-022","April 22, 2012","February 2012","December 2014","August 14, 2013","August 2013","No Study Results Posted","null","December 2013","Acute radiation-induced toxicity: daily diarrhea frequency","https://ClinicalTrials.gov/show/NCT01586117"
3929,"NCT00682786","Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma","Completed","Has Results","Rectal Carcinoma","Drug: 5FU|Radiation: Radiation|Procedure: Surgery of resectable lesions|Drug: Irinotecan","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","Phase 2","135","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","02-0561","April 11, 2008","October 2002","August 2010","September 5, 2014","September 2014","July 14, 2014","null","December 2008","Rate of Tumor Downstaging Compared With Historical Controls.|Complete Response Rates|Define Patient Quality of Life Prior to and Following Neoadjuvant Chemoradiation.|Determine Patient Fears and Expectations of Pharmacogenetics.","https://ClinicalTrials.gov/show/NCT00682786"
3930,"NCT01344330","Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients","Recruiting","No Results Available","Colon Cancer","","Texas A&M University|Oregon Health and Science University|National Cancer Institute (NCI)","Both","50 Years to 75 Years   (Adult, Senior)","","150","Other|NIH","Observational","Time Perspective: Prospective","P01CA090890","April 27, 2011","January 2012","April 2017","May 6, 2016","May 2016","No Study Results Posted","null","April 2017","Cruciferous vegetable intake correlated with SFN and I3C urinary metabolites|Cruciferous vegetable intake and p21 expression (qRT-PCR, ChIP in PBMCs)|Cruciferous vegetable intake correlated with acetylated histone expression (PBMCs, colon tissue),|Cruciferous vegetable intake correlated with HDAC activity (in PBMCs)","https://ClinicalTrials.gov/show/NCT01344330"
3931,"NCT01408407","Alkagin Paste in the Prevention of Radiation Dermatitis","Terminated","No Results Available","Anus Neoplasms|Rectal Neoplasms|Urogenital Neoplasms","Other: Aveeno cream|Other: Alkagin paste","Dr. Te Vuong|Avario Healthcare Inc.|Sir Mortimer B. Davis - Jewish General Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","2","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","11-052","August 2, 2011","December 2011","null","May 22, 2015","May 2015","No Study Results Posted","null","May 2014","Maximum skin toxicity","https://ClinicalTrials.gov/show/NCT01408407"
3932,"NCT01438645","ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy","Completed","No Results Available","Colonic Neoplasms|Iron Deficiency Anemia|Diarrhea","Device: Olympus ScopeGuide","Christopher Teshima|University of Alberta","Both","18 Years and older   (Adult, Senior)","","250","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","ScopeGuide 01","September 14, 2011","September 2011","December 2012","January 16, 2013","January 2013","No Study Results Posted","null","October 2012","Sedation Score|Patient comfort|Time-to-cecum|Cecal intubation rate|Ancillary maneuvers to facilitate procedure","https://ClinicalTrials.gov/show/NCT01438645"
3933,"NCT01480128","Multicenter Single-port Colectomy RCT","Enrolling by invitation","No Results Available","Colon Neoplasms","Procedure: Single-port|Procedure: Multi-port","The Catholic University of Korea|Kyung Hee University|Chonnam National University","Both","20 Years to 85 Years   (Adult, Senior)","Phase 3","388","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SPA-2011","November 23, 2011","July 2011","December 2017","October 5, 2015","October 2015","No Study Results Posted","SIMPLE","December 2016","postoperative complications|oncologic outcomes","https://ClinicalTrials.gov/show/NCT01480128"
3934,"NCT01579591","VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer","Recruiting","No Results Available","Rectal Cancer","Other: VSL#3|Other: Placebo","Catholic University of the Sacred Heart","Both","18 Years and older   (Adult, Senior)","Phase 3","160","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A.1459/2011","April 12, 2012","March 2012","June 2013","April 17, 2012","April 2012","No Study Results Posted","null","March 2013","The impact of the probiotic preparation on increasing the TRG1-2 rate.|Determine whether VSL#3® can have an impact on reduction of acute bowel toxicity|pathological complete response (pCR)|impact on reduction of sphincter saving surgery (SSS)|disease free survival (DFS) at 36 months|Determine whether VSL#3® can have an impact on reduction of late toxicity at 12 and 36 months.","https://ClinicalTrials.gov/show/NCT01579591"
3935,"NCT01706809","Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum Cancer","Recruiting","No Results Available","Rectal Cancer","Other: blood sampels from vena rectalis superior and vena cubiti","Odense University Hospital","Both","18 Years and older   (Adult, Senior)","","30","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","S-20100006","October 11, 2012","September 2011","December 2015","February 4, 2014","February 2014","No Study Results Posted","null","September 2015","The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival.","https://ClinicalTrials.gov/show/NCT01706809"
3936,"NCT02770911","Laparoscopic Anterior Resection With or Without ""Dog Ear"" Double-stapled Anastomosis for Rectal Cancer","Not yet recruiting","No Results Available","Rectal Carcinoma|Laparoscopy|Anastomotic Leak","Procedure: without ""Dog Ear"" group|Procedure: with ""Dog Ear"" group","Fujian Medical University","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","250","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FJMU-20160424","May 8, 2016","June 2016","June 2018","May 11, 2016","May 2016","No Study Results Posted","null","June 2017","anastomotic leakage rate|Intra-operative and post-operative complications|post-operative Mortality|re-operation rate|QLQ 30|Wexner's scoring","https://ClinicalTrials.gov/show/NCT02770911"
3937,"NCT00895388","Effects of Structured Rehabilitation Program on Quality of Life in Rectal Cancer Patients- a Randomized Controlled Trial","Recruiting","No Results Available","Quality of Life|Sexual Function|Urinary Incontinence|Anal Incontinence","Behavioral: Structured Rehabilitation program","University Hospital of North Norway|Helse Nord","Both","18 Years to 75 Years   (Adult, Senior)","","64","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P REK NORD 105/2007","May 7, 2009","May 2009","November 2013","November 2, 2011","November 2011","No Study Results Posted","null","November 2011","Quality of Life (EORTC QLQ-C30, EORTC QLQ-CR38)|Quality of LIfe (EQ 5D)|St Marks incontinence|ICIQ sexual function|ICIQ Urinary function Short form","https://ClinicalTrials.gov/show/NCT00895388"
3938,"NCT00280332","A Follow-up Colonoscopy Examination in Patients Who Had Previously Undergone Screening Colonoscopy","Completed","No Results Available","Colonic Cancer","Procedure: colonoscopy","Chinese University of Hong Kong","Both","50 Years to 75 Years   (Adult, Senior)","","560","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","FUC","January 20, 2006","March 2006","November 2007","May 9, 2008","May 2008","No Study Results Posted","null","November 2007","The prevalence of advanced colonic adenoma in the re-screening population|The time to adenoma adenoma development according to different baseline characteristics of patients and colonoscopy findings","https://ClinicalTrials.gov/show/NCT00280332"
3939,"NCT00849394","Evaluation of Protein in the Urine in Patients Receiving Bevacizumab","Completed","No Results Available","Colon Cancer|Rectal Cancer","","North Texas Veterans Healthcare System|University of Texas Southwestern Medical Center","Both","18 Years and older   (Adult, Senior)","","106","U.S. Fed|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","07-097|122007-001;|A07-3423","February 20, 2009","November 2007","June 2012","October 31, 2012","February 2009","No Study Results Posted","null","June 2012","To evaluate the effect of shortened infusions (0.5 mg/kg/min) of bevacizumab on the incidence of proteinuria.|To evaluate the time (number of days) to the incidence of proteinuria with shortened infusions of bevacizumab AND to evaluate the effect of controlled versus uncontrolled hypertension and the incidence of proteinuria.","https://ClinicalTrials.gov/show/NCT00849394"
3940,"NCT00515853","The Role of Biofeedback in Improving Continence After Anterior Resection","Recruiting","No Results Available","Rectal Neoplasms|Fecal Incontinence|Aged","Behavioral: Biofeedback","University of Southampton","Both","18 Years and older   (Adult, Senior)","","110","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","RHM GSU 0132","August 10, 2007","November 2006","null","June 3, 2008","June 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00515853"
3941,"NCT01554059","Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients","Completed","No Results Available","Rectal Adenocarcinoma","Drug: Bevacizumab|Drug: Oxaliplatin|Drug: 5-FU|Radiation: Radiotherapy","Sixth Affiliated Hospital, Sun Yat-sen University","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAHMO-03","March 11, 2012","March 2012","August 2014","November 7, 2014","November 2014","No Study Results Posted","New Beat","May 2013","Pathological complete response rate|Time to progression|Time to relapse|Overall survival|Safety data of this regimen","https://ClinicalTrials.gov/show/NCT01554059"
3942,"NCT01146769","Early Pelvic Floor Muscle Training Improves Pelvic Floor Muscle Strength in Patient After Low Anterior Resection","Recruiting","No Results Available","Cancer of Rectum","Other: Pelvic floor exercise","Kwong Wah Hospital","Both","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMTIMS-01","June 15, 2010","April 2010","April 2012","June 17, 2010","April 2010","No Study Results Posted","null","October 2011","Maximum Squeeze Pressure|Functional Outcomes","https://ClinicalTrials.gov/show/NCT01146769"
3943,"NCT01211132","Cap Assisted Colonoscopy for the Detection of Colon Polyps","Recruiting","No Results Available","Adenoma|Colon Polyps|Colon Cancer","Device: Cap - Transparent retractable extension device.|Device: Standard","American Society for Gastrointestinal Endoscopy|Midwest Biomedical Research Foundation|Kansas City Veteran Affairs Medical Center","Both","21 Years to 85 Years   (Adult, Senior)","","462","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","AR0006","September 28, 2010","September 2009","November 2010","September 28, 2010","September 2010","No Study Results Posted","null","October 2010","The primary outcome is the prevalence of adenomas in the two groups.|The secondary outcomes are the number of adenomas detected per subject, cecal intubation rate, insertion times, withdrawal times and complication rates in the two arms.","https://ClinicalTrials.gov/show/NCT01211132"
3944,"NCT00533975","A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy","Not yet recruiting","No Results Available","Colon Cancer","","University of California, San Diego","Both","18 Years and older   (Adult, Senior)","","500","Other","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","071015","September 20, 2007","September 2007","December 2008","September 20, 2007","June 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00533975"
3945,"NCT00894725","Laparoscopic Versus Open Left Colonic Resection","Completed","No Results Available","Colon Cancer|Benign Disease","Procedure: laparoscopic left colonic resection|Procedure: open left colonic resection","Università Vita-Salute San Raffaele","Both","18 Years and older   (Adult, Senior)","Phase 3","268","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","hmsxLPS09","May 6, 2009","February 2000","December 2008","May 6, 2009","May 2009","No Study Results Posted","null","December 2004","short-term morbidity rate|long-term outcome","https://ClinicalTrials.gov/show/NCT00894725"
3946,"NCT02371655","Different Bowel Preparations in CT Colonography: is Diet Necessary? A Randomized Controlled Trial","Recruiting","No Results Available","Cathartic Colon|Colonic Neoplasms","Procedure: Diet|Drug: Faecal Tagging|Drug: Bowel cleansing|Procedure: CT colonography","University of Roma La Sapienza","Both","40 Years and older   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","URomLSDBAL1","February 19, 2015","October 2015","September 2016","May 10, 2016","May 2016","No Study Results Posted","DIETSAN","June 2016","overall quality of bowel preparation using a 0-3 scale for each parameter (Homogeneity of solid-fluid fecal tagging, volume of residual fluid, colon distension).|compliance of patients","https://ClinicalTrials.gov/show/NCT02371655"
3947,"NCT01572428","Narrow-Band Imaging Versus Standard White Light for the Detection of Serrated Lesions in the Proximal Colon","Active, not recruiting","No Results Available","Colon Cancer","Procedure: Inspection with Narrow-Band Imaging(NBI)|Procedure: Standard White Light","Indiana University|Olympus","Both","50 Years to 85 Years   (Adult, Senior)","","950","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","1012-17","July 11, 2011","April 2011","January 2017","October 27, 2015","October 2015","No Study Results Posted","null","January 2017","Number of Proximal Serrated lesions","https://ClinicalTrials.gov/show/NCT01572428"
3948,"NCT01023984","Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas","Recruiting","No Results Available","RECTAL NEOPLASMS","Procedure: TEM - Transanal Endoscopic Microsurgery|Procedure: ESD - Endoscopic Submucosal Dissection","European Association for Endoscopic Surgery","Both","18 Years and older   (Adult, Senior)","Phase 4","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EAES-2","December 1, 2009","January 2012","December 2019","August 4, 2016","August 2016","No Study Results Posted","TEMENDO","December 2019","Incidence of recurrence at 12 months|Morbidity, subdivided into major (requiring surgery) and minor (requiring endoscopic or medical intervention)|Anorectal function|Disease specific and general quality of life|Number of days not spent in hospital from initial treatment until 2 years afterwards","https://ClinicalTrials.gov/show/NCT01023984"
3949,"NCT01581840","Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus","Recruiting","No Results Available","Epidermoid Carcinoma|Anus","Drug: radiochemotherapy|Drug: Panitumumab","Federation Francophone de Cancerologie Digestive","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","45","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FFCD 0904","April 6, 2012","June 2012","June 2020","August 2, 2016","August 2016","No Study Results Posted","null","June 2017","Phase I = determination the maximum tolerated dose 5FU and panitumumab in combination with radiotherapy and mitomycin, and thereby to deduce the maximum tolerated dose in patient with localised epidermoid carcinoma of the anus|Phase II = Complete response of the tumor rectal examination and morphological exams|Phase II = Partial response rate, stable disease and progression|Phase II = Colostomy-free survival|Phase II = Recurrence-free survival at 3 years|Phase II = Overall survival|Phase II = Quality of life (EORTC QLQ-C30 + Wexner questionnaire)","https://ClinicalTrials.gov/show/NCT01581840"
3950,"NCT01702116","Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma","Recruiting","No Results Available","Rectal Adenocarcinoma","Procedure: extralevator APR|Procedure: APR","Stony Brook University","Both","18 Years and older   (Adult, Senior)","","34","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","APR2011","August 11, 2011","July 2011","July 2013","April 23, 2013","April 2013","No Study Results Posted","null","July 2013","measurement of circumferential resection margin|operative time|hospital stay|estimated blood loss","https://ClinicalTrials.gov/show/NCT01702116"
3951,"NCT00622440","Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream","Completed","Has Results","Anus Neoplasms","Drug: AIJP (Arnebia Indigo Jade Pearl)|Drug: Placebo","University of California, San Francisco","Both","18 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CCRC 5031|CC # 07501|CTRF Grant # P-07-020","February 13, 2008","March 2008","December 2012","August 11, 2014","August 2014","July 17, 2014","AIJP","December 2012","Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL)|Treatment Adherence|Estimate Effect Size for Phase 3 Trial|Response With >50% Adherence|Response With >75% Adherence","https://ClinicalTrials.gov/show/NCT00622440"
3952,"NCT02308631","Endoscopically Assisted Colostomy With Colopexy for Critically Ill Patients Without General Anesthesia or Laparotomy","Completed","No Results Available","Colonic Neoplasms|Rectal Neoplasms|Fecal Incontinence","Procedure: ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY","University of Sao Paulo|LEONARDO ALFONSO BUSTAMANTE L|MARIANNY NAZARETH SULBARAN N|PAULO SAKAI|EDUARDO MOURA|CRISTIANO SAKAI|CAIO SERGIO NAHAS|CARLOS FREDERICO MARQUES|IVAN CECONELLO|SERGIO CARLOS NAHAS","Female","Child, Adult, Senior","Phase 1","5","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12267","September 24, 2014","February 2014","September 2014","December 1, 2014","October 2014","No Study Results Posted","EACC","August 2014","Safety and Tolerability of the procedure|Number of animals with Adverse Events in the colostomy.","https://ClinicalTrials.gov/show/NCT02308631"
3953,"NCT02665741","Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments","Recruiting","No Results Available","Colon Cancer Screening|Colon Polyps|Colon Adenomas|Water Exchange Colonoscopy","Device: Distal colonscope attachments (Olympus transparent cap, Medivators Endocuff)","University of California, Davis","Both","50 Years and older   (Adult, Senior)","","126","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","797109-3","January 25, 2016","January 2016","March 2017","February 23, 2016","February 2016","No Study Results Posted","null","January 2017","Adenoma detection rate|Proximal adenoma detection rate|Polyp detection rate|Cecal intubation rate|Withdrawal time|Major complications (perforation, bleeding requiring transfusion)","https://ClinicalTrials.gov/show/NCT02665741"
3954,"NCT01725490","The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study","Recruiting","No Results Available","Familial Adenomatous Polyposis","Drug: metformin","Yonsei University","Both","20 Years to 65 Years   (Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","4-2012-0491","October 31, 2012","November 2012","September 2015","July 8, 2013","July 2013","No Study Results Posted","null","September 2015","the mean percentage change of the number and size of polyps in colon and/or duodenum.","https://ClinicalTrials.gov/show/NCT01725490"
3955,"NCT02384005","The Feasibility of Self or Partner-assisted Digital Anal Exam Screening","Completed","No Results Available","Anus Neoplasms","Other: Self-anal exam arm","The University of Texas Health Science Center, Houston|National Cancer Institute (NCI)|Baylor College of Medicine","Male","27 Years to 80 Years   (Adult, Senior)","","201","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","HSC-SPH-13-0671|1R21CA181901-01A1","March 3, 2015","February 2015","April 2016","May 10, 2016","May 2016","No Study Results Posted","null","April 2016","Kappa agreement will be calculated between lay person and nurse practitioner on the anal exam results.|Odds ratios will be calculated for the association between partnership status and concordance between participant and clinician.|Odds ratios will be calculated for the association between age and concordance between participant and clinician.|Odds ratios will be calculated for the association between waist circumference and concordance between participant and clinician.|Odds ratios will be calculated for the association between race and concordance between participant and clinician.|Odds ratios will be calculated for the association between ethnicity and concordance between participant and clinician.|Number of persons who state that a self-DAE is an acceptable procedure.|Number of persons with adverse events after conducting a self-DAE.|Number of persons who state they have the ability to conduct a self-DAE.|Number of persons who state they intend to seek subsequent care in the event of an abnormal result to a self-DAE.","https://ClinicalTrials.gov/show/NCT02384005"
3956,"NCT00174616","CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision","Completed","No Results Available","Rectal Neoplasms","Drug: Oxaliplatin, capecitabine, radiotherapy","Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","87","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C_8601","September 9, 2005","July 2003","November 2007","December 4, 2009","December 2009","No Study Results Posted","null","November 2007","MRI staging and TME surgery|Measure safety - NCI-CTC version 2","https://ClinicalTrials.gov/show/NCT00174616"
3957,"NCT02402842","Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma","Recruiting","No Results Available","Anal Canal Carcinoma","Drug: Docetaxel, Cisplatin and 5-Fluorouracil","Centre Hospitalier Universitaire de Besancon","Both","18 Years and older   (Adult, Senior)","Phase 2","66","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Epitopes-HPV02|2014-001789-81","November 27, 2014","September 2014","September 2021","February 23, 2016","January 2016","No Study Results Posted","Epitopes-HPV02","September 2018","Progression-free survival rate|Overall survival|Progression free survival|response rate|Tolerance of the DCF regimen ( Common Terminology Criteria for Adverse Events version 4.03)|quality of life related to health|HPV-specific T cell responses measured by ELISPOT assay before and after DCF treatment","https://ClinicalTrials.gov/show/NCT02402842"
3958,"NCT00922688","Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients","Recruiting","No Results Available","Colon Carcinoma","Drug: Dipeptide Alanyl-Glutamine|Drug: Placebo|Drug: Dipeptide Alanyl-Glutamine","Medical Center Alkmaar","Male","18 Years to 75 Years   (Adult, Senior)","","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","AIRCo05.02.2009/2","June 16, 2009","December 2010","May 2013","July 20, 2011","November 2010","No Study Results Posted","AIRCo","December 2012","The effect of intravenously and enterally administered dipeptide alanyl-glutamine preoperatively on postoperative insulin resistance in colon cancer patients.given, on postoperative insulin resistance in colon cancer patients.|The effect of the dipeptide alanyl-glutamine on components of the insulin signalling cascade in muscle tissue.|The effect of the dipeptide alanyl-glutamine on the systemic inflammatory response as well as on inflammatory pathways in muscle.|The effect of the dipeptide alanyl-glutamine on the amino acid concentration in muscle tissue.|The effect of the dipeptide alanyl-glutamine on antioxidant/oxidant parameters in the circulating compartment.|The effect of dipeptide alanyl-glutamine on the inflammatory response in the liver|The effect of dipeptide alanyl-glutamine on lipolysis.|The effect of dipeptide alanyl-glutamine on key enzymes involved in glucose production.","https://ClinicalTrials.gov/show/NCT00922688"
3959,"NCT00278694","Oxaliplatin and 5-FU Based Preoperative Chemoradiation","Active, not recruiting","No Results Available","Rectal Cancer","Drug: Oxaliplatin and 5-FU based preoperative chemoradiation|Drug: Chemoradiation","Oslo University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S-05059|Eudractnr 2005-000024-16","January 16, 2006","September 2005","May 2018","November 4, 2014","November 2014","No Study Results Posted","LARC-RRP","December 2016","Safety profile|Number of patients obtaining pCR|Clinical, radiological and molecular response to treatment","https://ClinicalTrials.gov/show/NCT00278694"
3960,"NCT01033682","Evaluation of Bladder Volumes in Patients Receiving Radiotherapy to the Rectum, Using Kilovoltage Cone-beam Imaging","Recruiting","No Results Available","Rectal Cancer","","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCR3175","December 15, 2009","May 2009","February 2010","December 15, 2009","December 2009","No Study Results Posted","FILL","February 2010","The percentage of patients who are able to achieve a bladder volume within +/- 30% of planning volume, on all treatment CBCT (cone beam computed tomography) scans|The per-patient standard deviation of bladder volume throughout the course of radiotherapy|The percentage of patients who are unable to follow the bladder filling protocol at any point during their treatment.|The correlation between bladder volume and small bowel volume planning target volume","https://ClinicalTrials.gov/show/NCT01033682"
3961,"NCT01634685","A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma","Active, not recruiting","No Results Available","Rectal Adenocarcinoma","Radiation: Radiation|Drug: Bavituximab|Drug: Capecitabine","University of Texas Southwestern Medical Center","Both","18 Years to 99 Years   (Adult, Senior)","Phase 1","18","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","STU 032012-025","June 28, 2012","August 2012","June 2017","February 29, 2016","February 2016","No Study Results Posted","null","June 2017","dose-limiting toxicities (DLT)|adverse events|MR imaging and histopathological response|tumor-vasculature parameters|maximally tolerated dose (MTD)","https://ClinicalTrials.gov/show/NCT01634685"
3962,"NCT02378337","Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality","Completed","No Results Available","Malignant Neoplasm of Breast.|Hodgkin's Disease.|Non-Hodgkin Lymphoma, Follicular (Nodular).|Malignant Neoplasm of Bronchus and Lung.|Malignant Neoplasm of Colon.|Secondary Neoplasm Malignant and Unspecified Lymph Nodes.|Malignant Melanoma of the Skin.|Malignant Neoplasm of Small Intestine.","Other: Image quantify","Hospital Sao Rafael","Both","18 Years and older   (Adult, Senior)","","335","Other","Observational","Observational Model: Cohort","27558714.4.0000.0048","February 13, 2015","September 2014","null","August 19, 2015","August 2015","No Study Results Posted","pet-ct","August 2015","Correlation of body weight with the variation coefficient (image noise).|Correlation of dose-regimen with the variation coefficient (image noise).|Correlation of acquisition protocol time with the variation coefficient (image noise).","https://ClinicalTrials.gov/show/NCT02378337"
3963,"NCT02000050","Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)","Recruiting","No Results Available","Rectal Carcinoma","Drug: FOLFOX4|Radiation: Tomotherapy|Procedure: TME (Total Mesorectal Excision)","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRST 154.01|2013-000770-30","November 26, 2013","July 2013","July 2018","December 31, 2015","December 2015","No Study Results Posted","COLORE","July 2018","Toxicity events|The Simon optimal two-stage design (Richard Simon, Controlled Clinical Trials 1989)|Complete pathological response (pCR)|Objective tumor response rate (ORR)|Pathological Downstaging Rate|Disease-free survival time (DFS)|Overall survival time (OS)|Intention-to-treat (ITT) population","https://ClinicalTrials.gov/show/NCT02000050"
3964,"NCT02565667","A Prospective Clinical Study for Transanal Double Purse-string Rectal Anastomosis Preformed With KOL Stapler","Recruiting","No Results Available","Rectal Neoplasms","Device: KOL|Device: traditional staple","Fudan University","Both","18 Years to 70 Years   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FudanKOL","September 29, 2015","September 2015","December 2018","March 24, 2016","March 2016","No Study Results Posted","null","December 2018","anastomotic leak rate|post-operative anal function|30-day mortality rate","https://ClinicalTrials.gov/show/NCT02565667"
3965,"NCT01930942","Genetic Profile on Predicting Sensibility of Preoperative Chemoradiotherapy on Locally Advanced Rectal Carcinoma","Recruiting","No Results Available","Rectal Neoplasms","Radiation: preoperative concurrent chemoradiation","Chinese Academy of Medical Sciences","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","150","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D0905001040531","August 14, 2013","January 2006","December 2017","January 4, 2016","January 2016","No Study Results Posted","null","December 2017","gene expression in different response groups|overall survival, disease free survival and local-regional free survival","https://ClinicalTrials.gov/show/NCT01930942"
3966,"NCT01552226","Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery","Active, not recruiting","No Results Available","Colon Cancer|Rectal Cancer|Colonic Diverticulosis","Device: Continuous Preperitoneal Analgesia|Device: Continuous Epidural Analgesia","Saint Joseph Mercy Health System","Both","18 Years and older   (Adult, Senior)","","137","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","RCNM 114","February 28, 2012","January 2010","March 2015","July 22, 2014","July 2014","No Study Results Posted","null","March 2015","Post-operative pain control day 1|Post-operative pain control day 2|Post-operative pain control day 3|Post-operative pain control day 4|Post-operative pain control day 5|Patient use of supplemental narcotic analgesia day 1|Patient use of supplemental narcotic analgesia day 2|Patient use of supplemental narcotic analgesia day 3|Patient use of supplemental narcotic analgesia day 4|Patient use of supplemental narcotic analgesia day 5","https://ClinicalTrials.gov/show/NCT01552226"
3967,"NCT00867724","Clinical Study-evaluate Performance&Safety ""Aer-O-Scope"" in Colon of Low Risk Patients","Recruiting","No Results Available","Colon Cancer|Rectal Cancer","Device: aeroscopy (aer-o-scope)","GI View Ltd.","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","100","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","190-CLD-AOS","March 23, 2009","September 2009","March 2012","June 9, 2011","June 2011","No Study Results Posted","null","December 2011","Ability to screen the entire length of the colon to the cecum.|Safety endpoints to include incidence of bowel perforation, Colonic bleeding, Damage to colon, rectum and anus mucosa or any other Adverse events","https://ClinicalTrials.gov/show/NCT00867724"
3968,"NCT01648504","Johns Hopkins Interactive eGuide to Colonoscopy and Ipad Office Education to Improve Colonoscopy","Completed","No Results Available","Colon Cancer Screening|Colon Cancer Surveillance","Other: eGuide to Colonoscopy and in office ipad education","Johns Hopkins University|Krames Staywell Corporation","Both","18 Years to 90 Years   (Adult, Senior)","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","NA_00070166","July 17, 2012","June 2012","September 2013","March 26, 2014","March 2014","No Study Results Posted","null","September 2013","Completion rate of colonoscopy procedure|preparation quality|adenoma detection rate by provider|Patient satisfaction","https://ClinicalTrials.gov/show/NCT01648504"
3969,"NCT00959738","Diverting Loop Ileostomy: With or Without Rod","Terminated","No Results Available","Ileostomy|Rectal Neoplasms","Procedure: Diverting loop ileostomy with rod|Procedure: diverting loop ileostomy without rod","University Hospital Inselspital, Berne","Both","18 Years and older   (Adult, Senior)","","121","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","061/08","August 14, 2009","August 2008","November 2014","November 13, 2014","November 2014","No Study Results Posted","ROLLI","July 2014","Severe stoma specific morbidity rate|Rate of patients reaching self-sufficient stoma care|Time used by the stoma nurses for instructing and assisting patients|Quality of life (QoL) by a stoma quality of life scale|Predictive factors for stomal complications","https://ClinicalTrials.gov/show/NCT00959738"
3970,"NCT01651949","Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)","Completed","Has Results","Genital Warts|Anal Cancer|Anal Intraepithelial Neoplasia","Biological: 9vHPV Vaccine","Merck Sharp & Dohme Corp.","Both","16 Years to 26 Years   (Child, Adult)","Phase 3","2520","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","V503-003|2012-002758-22","July 25, 2012","October 2012","August 2014","August 4, 2015","August 2015","February 24, 2015","null","August 2014","Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine|Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card|Percentage of Participants With Elevated Oral Body Temperature (>=37.8° C, >=100° F)|Percentage of Participants With an Adverse Event|Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event|Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine","https://ClinicalTrials.gov/show/NCT01651949"
3971,"NCT00549276","Randomized Comparison of Curved Cutter Stapler and Linear Stapler","Completed","No Results Available","Rectal Neoplasm|Surgical Stapler","","Samsung Medical Center","Both","20 Years and older   (Adult, Senior)","","null","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Samsung Medical Center","October 23, 2007","May 2006","November 2006","October 23, 2007","May 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00549276"
3972,"NCT02669992","Loop Ileostomy Closure:Stapled or Hand-sewn Anastomoses? Suture or Mesh Closure of the Stoma Site?","Recruiting","No Results Available","Rectal Neoplasm","Procedure: Stapled or Hand-sewn anastomosis|Procedure: Mesh or suture stoma site closure","Karolinska University Hospital","Both","Child, Adult, Senior","","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","2015/321-31/1","December 8, 2015","April 2015","April 2017","January 27, 2016","January 2016","No Study Results Posted","LISTO","April 2017","Number of participants with postoperative bowel obstruction|Number of participants with postoperative stoma site hernia|Number of participants with postoperative complications|Postoperative Hospital stay","https://ClinicalTrials.gov/show/NCT02669992"
3973,"NCT02117674","Full Spectrum vs. Standard Forward-viewing Colonoscopy","Completed","No Results Available","Colon Neoplasms","Procedure: standard forward-viewing colonoscopy|Procedure: full-spectrum colonoscopy|Procedure: right colon retroflexion","Attikon Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","246","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","FUSE-001","April 14, 2014","April 2014","August 2015","December 30, 2015","December 2015","No Study Results Posted","null","July 2015","polyp detection rate|colonoscopy completion|procedure time|adverse events|endoscopist's satisfaction|feasibility of the retroflexion in the right colon by trainee|feasibility of retroflexion in the right colon by the consultant|patients' satisfaction","https://ClinicalTrials.gov/show/NCT02117674"
3974,"NCT02340065","Endocuff-assisted vs. Standard Colonoscopy","Completed","No Results Available","Colon Neoplasms","Procedure: standard colonoscopy|Procedure: Endocuff-assisted colonoscopy","Attikon Hospital","Both","18 Years to 80 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","ENDOCUFF-001","January 13, 2015","January 2015","April 2016","July 13, 2016","July 2016","No Study Results Posted","null","March 2016","number and rate of missed adenomas|number of adenomas and adenoma detection rate in the entire colon|number of adenomas and adenoma detection rate in the right colon|number of polyps and polyp detection rate in the entire colon|number of polyps and polyp detection rate in the right colon|colonoscopy completion (colonoscopy completion rate, reason for incomplete colonoscopy)|intubation and withdrawal time|adverse events|endoscopist's satisfaction (quantified using a scale from 0 (not satisfied) to 10 (completely satisfied)|mean number of adenomas per procedure","https://ClinicalTrials.gov/show/NCT02340065"
3975,"NCT02890758","Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803","Not yet recruiting","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|Non Hodgkin Lymphoma|Hodgkin Lymphoma|Myeloproliferative Syndromes|Plasma Cell Myeloma|Colon Carcinoma|Adenocarcinoma of Rectum|Soft Tissue Sarcoma|Ewing's Sarcoma|Rhabdomyosarcoma","Biological: Natural Killer (NK) Cells|Biological: ALT803","David Wald|Case Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 1","27","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE2Z16","September 1, 2016","October 2016","August 2019","September 1, 2016","September 2016","No Study Results Posted","null","August 2019","Number of patients without Graft Versus Host Disease (GVHD)|Number of patients with hematological response|Patients response for radiographically measurable lesions|Patients with malignant lymphoma response|Patients response for Waldenstrom's macroglobulinemia (WM)|Patients response for cutaneous lymphomas|Patients response for multiple myeloma|Patients response for chronic myeloid leukemia (CML)|Patients response for metastatic colon/rectal carcinoma and soft tissue sarcomas|Average duration of response|Average duration of Overall Survival|Average duration of relapse free survival|in vivo Natural Killer (NK) levels","https://ClinicalTrials.gov/show/NCT02890758"
3976,"NCT00534131","Anterior Perineal Plane for Ultra Low Anterior Resection of the Rectum","Recruiting","No Results Available","Rectal Neoplasms|Colitis, Ischemic|Colitis, Ulcerative","Procedure: Standard abdominal approach for rectal excision|Procedure: APPEAR Procedure|Procedure: Proctectomy","Queen Mary University of London","Both","16 Years and older   (Child, Adult, Senior)","","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09/H0704/30","September 21, 2007","April 2004","March 2012","July 27, 2010","June 2008","No Study Results Posted","APPEAR","January 2012","Yield (within each arm of study)|Functional assessment (faecal continence)|Surgical Safety Assessment|Oncological safety assessment - where appropriate","https://ClinicalTrials.gov/show/NCT00534131"
3977,"NCT01384097","An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery","Completed","No Results Available","Fracture of Surgical Neck of Humerus|Colonic Tumor|Stage IIIB Ovarian Carcinoma|Neoplasm of Head of Pancreas","","Charite University, Berlin, Germany","Both","18 Years and older   (Adult, Senior)","","774","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ERAS_feasibility","June 27, 2011","September 2007","June 2011","September 7, 2011","September 2011","No Study Results Posted","ERAS_feasi","February 2011","hospital length of stay|need for ventilator therapy|monetary reimbursement for prolonged hospital stay","https://ClinicalTrials.gov/show/NCT01384097"
3978,"NCT00730808","Effectiveness and Tolerability of an Oral Nutritional Supplement (PreOP Booster) Given Before Surgery","Completed","No Results Available","Rectal Tumors","Dietary Supplement: PreOP Booster (food for special medical purposes)","Fresenius Kabi","Both","18 Years to 75 Years   (Adult, Senior)","","20","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","N-POB-04-NL","August 5, 2008","December 2008","November 2009","May 18, 2010","May 2010","No Study Results Posted","null","November 2009","Immunoinflammatory parameters|Antioxidant / oxidant parameters|Ischemia / reperfusion injury parameters|pre-and postoperative discomfort (well-being)|hand grip strength|GI tolerance|Safety","https://ClinicalTrials.gov/show/NCT00730808"
3979,"NCT01843452","Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal","Terminated","No Results Available","Carcinoma of Anal Canal","Radiation: RADIOTHERAPY|Biological: PANITUMUMAB|Drug: MITOMYCIN|Drug: CAPECITABINE","Centre Hospitalier Universitaire Vaudois","Both","18 Years and older   (Adult, Senior)","Phase 2","8","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CHUV 20080214","April 26, 2013","December 2012","May 2016","May 18, 2016","May 2016","No Study Results Posted","null","May 2016","Efficacy|Complete response (CR) rate|Colostomy-free survival|Functional colostomy-free survival|Overall survival (OS)|Progression-free survival (PFS)|Tolerability and safety profile of this regimen.|Role of PET for staging and outcome prediction.","https://ClinicalTrials.gov/show/NCT01843452"
3980,"NCT02752360","Biodegradable Stenting Anastomoses Versus Double-layer Hand Sutures for Reconstruction in Intestinal Anastomosis","Recruiting","No Results Available","Colonic Neoplasms|Diverticulosis, Colonic|Crohn Disease","Procedure: Biodegradable Stenting Anastomoses|Procedure: Double-layer Hand Sutures","Beijing Friendship Hospital|Peking University Third Hospital|Zhejiang Cancer Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1","288","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","BjFH20160410-1","April 19, 2016","April 2016","December 2017","April 22, 2016","April 2016","No Study Results Posted","null","May 2017","Anastomotic Leakage Rate|Anastomotic Hemorrhage Rate|Anastomotic Stenosis Rate|Number of participant with abnormal laboratory values|Severe adverse events (SAEs)|Whether the Biodegradable Stenting Anastomoses be eliminated or not|The time of reconstruction in the surgery of Intestinal Anastomosis","https://ClinicalTrials.gov/show/NCT02752360"
3981,"NCT00666107","Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men","Active, not recruiting","No Results Available","Anal Cancer|HIV Infections","Biological: Gardasil","Southern California Institute for Research and Education|Merck Sharp & Dohme Corp.","Male","18 Years and older   (Adult, Senior)","","150","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","#33245","April 22, 2008","June 2008","June 2012","March 12, 2012","November 2010","No Study Results Posted","MIRB #862","June 2012","Determine Geometric Mean Titers of anti-HPV 16 and anti-HPV 18 antibodies|Determine percentage of subjects who seroconverted or mounted a significant serologic response to each of the 2 antigens 16 and 18|Determine how many patients, if any, develop evidence of anal HPV infection, as measured by development of a positive HPV test.|Determine if vaccinations will activate the subject's immune systems sufficiently that the HIV-1 viral load either increases from the baseline value, or becomes detectable and stays detectable after being undetectable at the baseline visit","https://ClinicalTrials.gov/show/NCT00666107"
3982,"NCT02609451","Closure of Protective Ileostomy 2 vs. 12 Weeks After TME","Terminated","No Results Available","Rectal Cancer","Procedure: Ileostomy closure","Kantonsspital Liestal","Both","18 Years and older   (Adult, Senior)","","71","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EKBB-REF-NR-266/07_Ileostomy","September 24, 2015","November 2007","March 2016","February 23, 2016","November 2015","No Study Results Posted","Closure2vs12","March 2014","Quality Of Life (GQLI - Questionnaire)|Feasibility (via Visual Analogue Scale)|Safety as assessed by Morbidity, Mortality|Quality Of Life (EORTC - Questionnaire)","https://ClinicalTrials.gov/show/NCT02609451"
3983,"NCT02266849","Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study","Recruiting","No Results Available","Rectal Cancer|Ulcerative Colitis|Short Bowel Syndrome","Drug: Loperamide|Drug: Placebo","Odense University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 3","42","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","s-20140081","October 8, 2014","October 2014","August 2015","April 30, 2015","April 2015","No Study Results Posted","null","June 2015","Output weight|Gastrointestinal transit time","https://ClinicalTrials.gov/show/NCT02266849"
3984,"NCT02046278","LifeSeal™ Pilot Study in Subjects Undergoing Circular Stapled Anastomosis Created Within 10 cm of the Anal Verge","Completed","No Results Available","Rectal Cancer","Device: LifeSeal™ Kit","LifeBond Ltd.","Both","18 Years to 90 Years   (Adult, Senior)","","70","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLP-LS-0110","January 23, 2014","January 2014","August 2016","August 29, 2016","August 2016","No Study Results Posted","null","August 2014","Assessment of the overall Subject safety by incidence of pre specified procedure related Adverse Events.|Performance Rate of anastomotic leak (both radiological and clinical leaks)","https://ClinicalTrials.gov/show/NCT02046278"
3985,"NCT01999634","Monitoring by Microdialysis of Postoperative Complications After Proctectomy","Recruiting","No Results Available","Rectal Cancer","Device: cma microdialysis catheter placement","Centre Hospitalier Universitaire, Amiens","Both","18 Years and older   (Adult, Senior)","Phase 3","30","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","PI2012_843_0024|2013-A00261-44","November 26, 2013","November 2013","December 2016","April 25, 2016","April 2016","No Study Results Posted","MTM-COLON-II","November 2016","anastomotic leaks rate|superficial surgical site infection rate|functional success of microdialysis","https://ClinicalTrials.gov/show/NCT01999634"
3986,"NCT01790230","LifeSeal™ Preliminary Study in Subjects Undergoing Low Anterior Resection","Completed","No Results Available","Rectal Cancer","Device: LifeSeal™ Kit","LifeBond Ltd.","Both","18 Years and older   (Adult, Senior)","","10","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLP-LS-0105","January 31, 2013","January 2013","August 2013","September 1, 2013","September 2013","No Study Results Posted","null","August 2013","Assessment of subject's safety by incidence of related Adverse Events|Assessment of the device's application technique","https://ClinicalTrials.gov/show/NCT01790230"
3987,"NCT01786694","Feasibility of Microdialysis by Laparoscopy","Completed","No Results Available","Rectal Cancer","Device: cma microdialysis catheter placement","Centre Hospitalier Universitaire, Amiens","Both","18 Years and older   (Adult, Senior)","Phase 3","11","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","PI2012_843_0022|2012-A01218-35","February 1, 2013","October 2013","November 2014","July 28, 2015","July 2015","No Study Results Posted","MTM-COLON-I","October 2014","functional success of microdialysis|anastomotic leaks rate|superficial surgical site infection rate|the mortality rate|the quality of life after the surgery","https://ClinicalTrials.gov/show/NCT01786694"
3988,"NCT01670851","Perineal Reconstruction Following eLAPE and Simultaneous Stoma Sublay Reinforcement","Completed","No Results Available","Rectal Cancer","Device: Strattice","University Hospitals, Leicester|Karolinska University Hospital|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Slagelse Hospital","Both","18 Years and older   (Adult, Senior)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ISIS.11.01.06.BS/SC","August 19, 2012","March 2013","September 2015","December 7, 2015","December 2015","No Study Results Posted","PRESSUR","September 2015","Perineal wound healing|Incidence of perineal herniation|Incidence of parastomal hernia","https://ClinicalTrials.gov/show/NCT01670851"
3989,"NCT00427492","Effect of Postoperative Laxative on Bowel Function After Colonic Surgery","Completed","No Results Available","Colonic Cancer","Drug: Magnesia|Drug: Placebo","Hvidovre University Hospital","Both","18 Years and older   (Adult, Senior)","Phase 4","56","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","02 290964","January 26, 2007","January 2007","January 2009","February 10, 2009","February 2009","No Study Results Posted","null","January 2009","Time to defecation after colonic resection","https://ClinicalTrials.gov/show/NCT00427492"
3990,"NCT01373021","The Effect of Dexmedetomidine on Postoperative Analgesia","Completed","No Results Available","Colon Cancer, Rectal Cancer","Drug: Fentanyl|Drug: Dexmedetomidine","Seoul National University Hospital|Pharmbio Korea Co., Ltd.","Both","20 Years to 74 Years   (Adult, Senior)","Phase 4","95","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Health Services Research","sunrud1129","June 13, 2011","June 2011","February 2012","March 6, 2012","March 2012","No Study Results Posted","null","February 2012","total amount of administered fentanyl","https://ClinicalTrials.gov/show/NCT01373021"
3991,"NCT01227239","Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting","Active, not recruiting","No Results Available","Rectal Carcinoma","Drug: S-1|Drug: Oxaliplatin|Radiation: Radiation","Japan Clinical Cancer Research Organization|Taiho Pharmaceutical Co., Ltd.","Both","20 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","45","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JACCRO CC-04","October 18, 2010","September 2010","August 2016","November 26, 2012","November 2012","No Study Results Posted","null","August 2013","Phase I: Determine the Recommended dose (RD)|Phase II: pathological complete response rate|R0 resection rate|down staging rate|local reccurence rate|desease free survuval|safety","https://ClinicalTrials.gov/show/NCT01227239"
3992,"NCT00557713","XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma","Recruiting","No Results Available","Rectal Neoplasms|Locally Advanced Rectal Adenocarcinoma","Drug: bevacizumab","Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","44","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AVACROSS","November 13, 2007","February 2007","October 2013","November 13, 2007","November 2007","No Study Results Posted","null","null","Pathologic Complete Response Rate|Complete Resection (R0) Rate|Disease Free Survival|Time to Failure Treatment|Metastatic or Local Recurrence|Toxicity Evaluation|Surgical Morbility","https://ClinicalTrials.gov/show/NCT00557713"
3993,"NCT01699399","Comparing Water Exchange, Water Immersion and Air Insufflation Methods During Colonoscopy With the Option of on Demand Sedation","Recruiting","No Results Available","Colon Neoplasm","Procedure: water immersion|Procedure: water exchange|Procedure: air insufflation","Dalin Tzu Chi General Hospital","Both","20 Years to 80 Years   (Adult, Senior)","","225","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Diagnostic","DTCRD101(2)-E-03","September 30, 2012","August 2012","September 2015","July 29, 2014","July 2014","No Study Results Posted","null","September 2015","Proportions of patients requiring sedation|patient pain during insertion","https://ClinicalTrials.gov/show/NCT01699399"
3994,"NCT01535326","Comparing Water Immersion and Water Exchange Methods During Minimally Sedated Colonoscopy","Completed","Has Results","Colon Neoplasm|Pain","Procedure: air insufflation|Procedure: water immersion|Procedure: water exchange","Dalin Tzu Chi General Hospital","Both","20 Years to 80 Years   (Adult, Senior)","","270","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Diagnostic","DalinTCGH-hsieh-01","February 11, 2012","February 2012","March 2013","July 28, 2014","July 2014","March 16, 2014","null","March 2013","Proportion of Patients Without Pain|Patient Pain Score|Patient Satisfaction Score|Number of Participants With at Least One Adenoma","https://ClinicalTrials.gov/show/NCT01535326"
3995,"NCT00832299","Neo-Adjuvant FOLFOX for Rectal Carcinoma","Terminated","Has Results","Rectal Neoplasms","Drug: FOLFOX|Procedure: total mesorectal excision (TME)","Beth Israel Medical Center|St. Luke's-Roosevelt Hospital Center","Both","18 Years to 70 Years   (Adult, Senior)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","156-08|OX-08-006","January 27, 2009","January 2009","August 2011","March 7, 2013","March 2013","February 25, 2013","null","August 2011","Pathologic Complete Response|Observation of Overall Pathologic Response Rate, Correlation of Pathologic Staging With Pre-op Ultrasound and Pelvic MRI Staging Observed Toxicities Patterns of Disease Relapse Disease-free Survival Overall Survival","https://ClinicalTrials.gov/show/NCT00832299"
3996,"NCT00535041","Pilot Trial of Pre-operative Chemo/RT Using Xeloda and External Beam RT Followed by Definite Surgery in Patients With Localized Rectal CA","Completed","No Results Available","Rectal Neoplasms","Drug: Chemotherapy, radiation therapy & surgery","King Faisal Specialist Hospital & Research Center","Both","Child, Adult, Senior","","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RAC#2011-031","September 21, 2007","September 2007","September 2015","January 4, 2016","January 2016","No Study Results Posted","null","September 2015","safety","https://ClinicalTrials.gov/show/NCT00535041"
3997,"NCT02385552","Development of Quality Indicators and Quality Improvement Plan of Colonoscopy in Experienced Endoscopist","Recruiting","No Results Available","Colonic Polyps|Colonic Neoplasms","Behavioral: Feedback","Seoul National University Hospital","Both","18 Years and older   (Adult, Senior)","","17","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-1502-003-644","March 1, 2015","March 2011","December 2019","April 14, 2016","April 2016","No Study Results Posted","null","March 2019","Adenoma detection rate|Colonoscopy performance indicators|Colonoscopy quality indicators","https://ClinicalTrials.gov/show/NCT02385552"
3998,"NCT01959087","Single Port Colic Laparoscopic Surgery","Recruiting","No Results Available","Colonic Neoplasms|Crohn's Disease|Diverticulitis","Procedure: single port surgery|Procedure: Multiport surgery","Assistance Publique - Hôpitaux de Paris|Fondation de l'Avenir","Both","18 Years and older   (Adult, Senior)","Phase 3","128","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","P111112","October 7, 2013","January 2014","February 2017","August 18, 2016","August 2016","No Study Results Posted","TRUE","February 2017","Length of postoperative hospital stay|Operative mortality|Post-operative morbidity|Conversion rates|Pathologic results|Postoperative recovery|Postoperative pain|Aesthetic results|Costs|Lenght of true hospitalization stay|Technical feasability|Post-operative quality of life","https://ClinicalTrials.gov/show/NCT01959087"
3999,"NCT00643682","Improving Bowel Preparation for Colonoscopy With a Simple Educational Card","Completed","Has Results","Colonic Polyps|Colonic Neoplasms","Other: Educational card","Boston Medical Center","Both","18 Years and older   (Adult, Senior)","","2000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","BMC-GI-1","March 20, 2008","February 2006","October 2009","August 29, 2012","August 2012","July 9, 2012","null","June 2008","Boston Bowel Preparation Scale Score|Time to Advance Colonoscope From Anus to Tip of Cecum.|Time to Withdraw Colonoscope From Tip of Cecum to Anus.|Number of Repeat Procedures Recommended Due to Inadequate Bowel Preparation.","https://ClinicalTrials.gov/show/NCT00643682"
4000,"NCT01619696","Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas","Terminated","No Results Available","Rectal Adenocarcinoma","Procedure: Pelvic MRI and F MISO TEP","University Hospital, Toulouse|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","3","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","0932103","June 12, 2012","March 2011","December 2012","January 22, 2013","January 2013","No Study Results Posted","null","December 2012","acceptation rate of the entire sequence by eligible patients|radiological changes while on chimiotherapy, to tumour regression, and prognosis","https://ClinicalTrials.gov/show/NCT01619696"
4001,"NCT02551237","Neoadjuvant Treatment for Advanced Rectal Carcinoma","Recruiting","No Results Available","Rectal Carcinoma","Radiation: 50 Gy|Drug: Capecitabine|Radiation: 25 Gy","UNICANCER","Both","75 Years and older   (Senior)","Phase 3","420","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PRODIGE 42 GERICO12/UCGI|2015-A01365-44|UC-0103/1503","August 31, 2015","December 2015","March 2030","March 17, 2016","March 2016","No Study Results Posted","NACRE","March 2020","R0 resection rate|IADL (Instrumental Activities of Daily Living) Score|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.03|Post-operative complications|Death rate|Overall survival (OS)|Specific survival|Disease free survival|Loco-regional disease free survival|Rate of stoma|Instrumental Activities of Daily Living (IADL)|Activities of Daily Living (ADL)|Questionnaire G8|Mini-Mental Score Examination (MMSE)|Walking gate|Geriatric Depression Scale (GDS15)|Charlson score|Mini Nutritional Assessment (MNA)|EORTC QLQ-C30 + EDL14","https://ClinicalTrials.gov/show/NCT02551237"
4002,"NCT02369939","Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy","Recruiting","No Results Available","Anal Carcinoma","Radiation: Irradiation|Drug: Mitomycin C|Drug: 5-Fluorouracil|Procedure: Hyperthermia","University of Erlangen-Nürnberg Medical School","Both","18 Years and older   (Adult, Senior)","Phase 3","118","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HYCAN","January 7, 2015","December 2014","April 2021","July 29, 2016","July 2016","No Study Results Posted","HYCAN","December 2017","Improvement of complete remission|Colostomy-free survival|locoregional relapse-free survival|Overall relapse-free survival|Overall survival|Response rate|Rate of acute and late toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT02369939"
4003,"NCT02319304","Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma","Recruiting","No Results Available","Rectal Adenocarcinoma","Drug: FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|Radiation: Low dose fractionated radiation therapy (LDFRT)","University of Maryland","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HP-00060641","December 10, 2014","March 2015","December 2021","June 10, 2016","June 2016","No Study Results Posted","GCC 1314","December 2018","Primary Outcome Measure (Overall survival rate)|Secondary Outcome Measure (Number of adverse events)","https://ClinicalTrials.gov/show/NCT02319304"
4004,"NCT01396928","Study of Two Techniques of Rectal Reservoir in Low Anterior Resection of Rectum","Completed","No Results Available","Low Rectal Adenocarcinoma","Procedure: Colonic reservoir","Hospital Universitari de Bellvitge","Both","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","106","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CGD-01/2000","July 18, 2011","November 2000","July 2010","October 1, 2012","November 2000","No Study Results Posted","null","December 2005","Quality of life|Morbidity and cost-effectiveness","https://ClinicalTrials.gov/show/NCT01396928"
4005,"NCT01173250","Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?","Completed","No Results Available","Ulcerative Colitis|Familial Adenomatous Polyposis","Procedure: adding diverting ileostomy|Procedure: omitting diverting ileostomy","Mansoura University","Both","Child, Adult, Senior","","null","Other","Interventional","","251068","July 30, 2010","null","null","August 13, 2010","October 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01173250"
4006,"NCT01002287","An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery","Terminated","Has Results","Ulcerative Colitis|Familial Polyposis","Device: SprayShield Adhesion Barrier System|Procedure: Good Surgical Technique Alone","Integra LifeSciences Corporation","Both","18 Years and older   (Adult, Senior)","","11","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","ABD-08-001","October 26, 2009","October 2009","May 2011","November 7, 2014","November 2014","June 21, 2012","null","October 2010","The Incidence of Adhesions, Defined as the Proportion of Subjects Presenting at the Follow-up Surgery (10-12 Weeks) With One or More Adhesions to the Midline Incision, Regardless of Extent and/or Severity.|Severity of Adhesions|Adhesion Involvement Along the Midline Incision (Percentage)|Mobilization Time","https://ClinicalTrials.gov/show/NCT01002287"
4007,"NCT01767870","Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia","Recruiting","No Results Available","Colorectal Adenoma","Procedure: FIT-sigmoidoscopy|Procedure: Colonoscopy","Yonsei University","Both","45 Years to 75 Years   (Adult, Senior)","Phase 4","5282","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CR312033","December 19, 2012","August 2012","August 2015","January 10, 2013","January 2013","No Study Results Posted","FITS","August 2015","Advanced colorectal adenoma detection rate between two groups|Sensitivity of fecal immunochemical test for advanced colorectal adenoma|Sensitivity of sigmoidoscopy for right advanced colorectal adenoma and right colon cancer|Sensitivity of fecal immunochemical test with sigmoidoscopy for right advanced colorectal adenoma and right colon cancer|positive predictive valueof fecal immunochemical test for advanced colorectal adenoma|specificity of fecal immunochemical test for advanced colorectal adenoma|negative predictive value of fecal immunochemical test for advanced colorectal adenoma|specificity of sigmoidoscopy for right advanced colorectal adenoma and right colon cancer|positive predictive value of sigmoidoscopy for right advanced colorectal adenoma and right colon cancer|negative predictive value of sigmoidoscopy for right advanced colorectal adenoma and right colon cancer|specificityof fecal immunochemical test with sigmoidoscopy for right advanced colorectal adenoma and right colon cancer|positive predictive value of fecal immunochemical test with sigmoidoscopy for right advanced colorectal adenoma and right colon cancer|negative predictive value of fecal immunochemical test with sigmoidoscopy for right advanced colorectal adenoma and right colon cancer","https://ClinicalTrials.gov/show/NCT01767870"
4008,"NCT02908451","A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer","Not yet recruiting","No Results Available","Gastric, Colorectal, and Pancreatic Adenocarcinoma","Biological: AbGn-107","AbGenomics B.V Taiwan Branch","Both","18 Years and older   (Adult, Senior)","Phase 1","54","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2016.006.01","September 6, 2016","December 2016","March 2019","September 16, 2016","September 2016","No Study Results Posted","null","December 2018","Adverse events (AEs) graded according to CTCAE v4.03.|Cmax (maximum measured concentration of the analyte in plasma)|Tmax (time from dosing to maximum measured concentration)|T1/2 (half-life of the analyte)|Immunogenicity evaluation based on anti-drug antibodies titer|Overall Response Rate Evaluated by Response Evaluation Criteria in Solid Tumor (RECIST)","https://ClinicalTrials.gov/show/NCT02908451"
4009,"NCT01191632","Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases","Recruiting","No Results Available","Colorectal Liver Metastases","Radiation: one time radiation|Radiation: No Radiation","Heidelberg University","Both","50 Years to 90 Years   (Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S081/2008","August 20, 2010","March 2010","March 2012","October 21, 2010","October 2010","No Study Results Posted","null","March 2012","Purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumor activity|To determine local control and recurrence patterns of colorectal liver metastases in a CT|To determine the progression-free survival in patients treated with low dose photon beam radiation therapy|• To determine the surgical morbidity in patients undergoing liver resection who received this protocol treatment|• To determine 30-day post-operative mortality after liver resection in patients who received this protocol treatment|• To determine the T-cell activity in the resected liver tissue|• To determine quality of life according to the EORTC QoL questionnaire after 6 months.|To determine the number of regulatory T-cells in the resected liver tissue|To determine the frequencies of tumor-reactive T-cells in the blood and bone marrow of the patients|To determine quality of life according to the EORTC QoL questionnaire after 12 months.|To determine the number of patients with adverse events as a measure of safety and tolerability according to CTCAE, Version 4.0 criteria","https://ClinicalTrials.gov/show/NCT01191632"
4010,"NCT01460134","A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers","Active, not recruiting","No Results Available","CD27 Expressing B-cell Malignancies, (for Example: Hodgkin's Lymphoma,|Chronic Lymphocytic Leukemia, Burkett's Lymphoma,|Mantle Cell Lymphoma, Primary Lymphoma of the Central Nervous System,|Marginal Zone B Cell Lymphoma);|Any T-cell Malignancy;|Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma,|Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer|Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)","Drug: CDX-1127|Drug: CDX-1127|Drug: CDX-1127","Celldex Therapeutics","Both","18 Years and older   (Adult, Senior)","Phase 1","90","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDX1127-01","October 12, 2011","October 2011","December 2016","April 5, 2016","April 2016","No Study Results Posted","null","December 2015","Characterize the adverse events associated with CDX-1127 administration|Levels of anti-CD27 antibodies in circulating blood.|Levels of CDX-1127 in circulating blood.|Activity Evaluations|Immune system effects (eg: lymphoid cell populations and serum cytokine levels)","https://ClinicalTrials.gov/show/NCT01460134"
4011,"NCT02886104","Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis","Recruiting","No Results Available","Secondary Malignant Neoplasm of Liver","Procedure: CRLM resection group|Device: CRLM ablation group","Sixth Affiliated Hospital, Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University|Second Affiliated Hospital, Sun Yat-Sen University","Both","18 Years to 80 Years   (Adult, Senior)","","548","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E2016026","August 24, 2016","August 2016","July 2026","August 28, 2016","August 2016","No Study Results Posted","HELARC","July 2021","Overall survival|R0 resection rate in both primary and secondary tumor in CRLM|Death rate during hospitalization or within 30 days after surgery/ablation|Rate of patients with at least one postoperative severe complication within 30 days after surgery/ablation|Disease-free survival and 1, 2 and 3-years disease-free survival rate|Complete ablation rate in CRLM","https://ClinicalTrials.gov/show/NCT02886104"
4012,"NCT01048216","Partial Liver Radiotherapy for Unresectable Liver Metastases","Recruiting","No Results Available","Metastatic Colorectal Liver Cancer","Radiation: radiation therapy","Royal Marsden NHS Foundation Trust","Both","18 Years and older   (Adult, Senior)","","18","Other","Interventional","Primary Purpose: Treatment","CCR2772","January 12, 2010","November 2006","June 2008","January 12, 2010","January 2010","No Study Results Posted","null","June 2008","To evaluate feasibility of conformal radiation therapy in patients with metastatic colorectal liver cancer and determine its safety|To evaluate local control rate within irradiated fields|To assess failure patterns and survival of patients treated with conformal liver radiation|Set up verification with cone-beam CT (OBI on Boar Imager)","https://ClinicalTrials.gov/show/NCT01048216"
4013,"NCT01255007","Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases","Completed","No Results Available","Colorectal Liver Metastases","Other: MR imaging","University Health Network, Toronto|Bayer","Both","18 Years and older   (Adult, Senior)","","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","UHN100405CE2010","December 3, 2010","September 2010","December 2014","January 6, 2015","January 2015","No Study Results Posted","null","July 2014","To establish superiority of Primovist-enhanced liver MRI and DWI to MDCT in the preoperative detection of colorectal liver metastases in patients who have received prior chemotherapy by comparison against pathology or Intra-operative ultrasound.|To compare diagnostic performance of MDCT, Diffusion Weighted MR and Primovist-enhanced MRI in the differentiation of viable from non-viable metastatic tumour compared to reference standard of pathology.|To investigate in the cohort of patients who have pre and post-chemotherapy MRI the role of DWI in predicting treatment response by baseline pretreatment Apparent Diffusion Coefficient (ADC) values.|To assess performance of Primovist-enhanced MRI, DW-MRI and MDCT in assessment of treatment response following chemotherapy in the cohort of patients who have pre and post-chemotherapy MRI.|To compare accuracies of Primovist-enhanced MRI and DWI to MDCT in the characterization of non-metastatic liver lesions against histopathology or intra-operative ultrasound.","https://ClinicalTrials.gov/show/NCT01255007"
4014,"NCT01696994","Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)","Active, not recruiting","Has Results","Ovarian Carcinoma|Ovarian Germ Cell Tumor","Other: Laboratory Biomarker Analysis|Other: Screening Questionnaire Administration|Procedure: Ultrasonography","National Cancer Institute (NCI)","Female","55 Years to 74 Years   (Adult, Senior)","","78216","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Screening","NCI-2012-01758|PLCO-1|CDR0000078532|NCI-P93-0050|PLCO-Ovarian","September 28, 2012","November 1993","null","July 5, 2016","July 2016","August 30, 2013","null","May 2012","Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)|Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)|Deaths From All Causes|Death Rates From All Causes|Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers)|Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).|Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test|T0 (Baseline) CA-125 Screening Results|T0 (Baseline) TVU Screening Results|T1 CA-125 Screening Results|T1 TVU Screening Results|T2 CA-125 Screening Results|T2 TVU Screening Results|T3 CA-125 Screening Results|T3 TVU Screening Results|T4 CA-125 Screening Results|T5 CA-125 Screening Results","https://ClinicalTrials.gov/show/NCT01696994"
4015,"NCT00942292","The Effect of Fish Oils on Human Hepatic Colorectal Metastases","Completed","No Results Available","Colorectal Liver Metastases","Dietary Supplement: Lipidem- fish oil emulsion BBraun UK|Procedure: Digital Contrast MRI scan","University Hospitals, Leicester|B. Braun Melsungen AG","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","10097|REC reference: 06/Q2501/160|EudraCT number: 2006-000044-71","July 16, 2009","May 2007","October 2010","June 24, 2013","June 2013","No Study Results Posted","null","December 2009","Change in gadolinium chelate enhancement on DCE-MRI between study entry and exit, as determined by calculating the bi-directional transfer co-efficient.(Changes in tumour angiogenesis after treatment with fish oils or control TPN)|Changes in biomarkers of inflammation and angiogenesis in the patient's blood and resected tumour samples","https://ClinicalTrials.gov/show/NCT00942292"
4016,"NCT01471756","Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia","Completed","No Results Available","Neoplasms|Gastric Cancer","Procedure: Standard of Care Procedure as described in ARM","Mayo Clinic|US Endoscopy","Both","18 Years and older   (Adult, Senior)","Phase 4","66","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","10-008104","September 29, 2011","October 2011","May 2014","September 5, 2014","September 2014","No Study Results Posted","null","July 2013","Efficacy of Two Devices used in EMR|Compare the Use of Two Injectates","https://ClinicalTrials.gov/show/NCT01471756"
4017,"NCT02461550","Irreversible Electroporation Ablation for Colorectal Metastases to the Lung","Recruiting","No Results Available","Colorectal Metastases to the Lung","Device: Irreversible Electroporation Ablation","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","","10","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-001","June 1, 2015","June 2015","null","August 12, 2016","August 2016","No Study Results Posted","null","December 2017","The frequency of adverse events","https://ClinicalTrials.gov/show/NCT02461550"
4018,"NCT02399995","Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time","Recruiting","No Results Available","Colorectal Liver Metastasis","Behavioral: HRQoL questionnaires.","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-057","March 23, 2015","March 2015","null","May 9, 2016","May 2016","No Study Results Posted","null","March 2018","changes in the quality of life (QoL)","https://ClinicalTrials.gov/show/NCT02399995"
4019,"NCT01765790","Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors","Completed","No Results Available","Metastatic Adenocarcinoma of the Colon or Rectum|Malignant Solid Tumors","Biological: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Biological: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody","Baxalta US Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","68","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","391101|2013-002870-31","January 9, 2013","June 2012","July 2016","September 13, 2016","September 2016","No Study Results Posted","null","July 2016","Number of participants experiencing serious adverse events (SAEs) and/or adverse events (AEs) regardless of causality|Plasma pharmacokinetic parameters|Tumor response|Levels of free active MIF and free total MIF in plasma and tumor tissue (where applicable)|Change in levels of tumor-associated biomarkers, if applicable based on cancer type, following treatment with anti-MIF antibody|Number of serious adverse events (SAEs) and/or adverse events (AEs), regardless of causality|Number of participants experiencing related serious adverse events (SAEs) and/or adverse events (AEs)|Number of related serious adverse events (SAEs) and/or adverse events (AEs)|Number of dose limiting toxicities (DLTs)|Number of participants experiencing dose limiting toxicity (DLT)|Number of participants who develop binding and/or neutralizing anti-anti-macrophage migration inhibitory factor (anti-MIF) antibodies following treatment with anti-MIF|Anti-MIF antibody in tumor tissues, bound and/or unbound to active MIF (where applicable)|Levels of other potential biomarkers in tumor tissue (where applicable)","https://ClinicalTrials.gov/show/NCT01765790"
4020,"NCT01880554","Ultrasound Liver Intraoperative Imaging With SonoVue®","Recruiting","No Results Available","Liver Metastases From Colorectal Primary Cancer","Device: Contrast-enhanced intraoperative ultrasound","Institut Bergonié","Both","18 Years and older   (Adult, Senior)","Phase 2","57","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","IB2010-29","November 5, 2012","June 2011","December 2022","May 25, 2016","May 2016","No Study Results Posted","ULIIS","December 2017","The clinical utility will be evaluated in terms of the proposed amendment justified after ultrasound surgery of Intraoperative contrast, compared to the planned following surgery a conventional intraoperative ultrasonography|evaluation of the clinical utility of contrast echocardiography|Assessment of tumor perfusion quantification|Performance Evaluation of intraoperative ultrasound contrast per lesion|Description of technical arrangements for the CEUS Intraoperative and description of the specific toxicity of intraoperative use of SonoVue ®,|Survival rate","https://ClinicalTrials.gov/show/NCT01880554"
4021,"NCT00557557","Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases","Completed","No Results Available","Colorectal Liver Metastases","Drug: Drug: 5-FU|Drug: Drug: Oxaliplatin","David Bartlett|National Institutes of Health (NIH)|National Cancer Institute (NCI)|University of Pittsburgh","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1","14","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-096|1R21CA115059-01A1","November 13, 2007","July 2007","August 2014","December 23, 2015","December 2015","No Study Results Posted","null","March 2012","Primary endpoint is to determine the maximum tolerated dose and dose limiting toxicity of 5-FU delivered with 40mg/m² of Oxaliplatin via IHP.|Secondary endpoints will be to determine the response rate and survival after IHP with 5-FU and Oxaliplatin.","https://ClinicalTrials.gov/show/NCT00557557"
4022,"NCT02879370","Transanal Inspection and Management of Low ColoRectal Anastomosis Performed With a New Technique","Recruiting","No Results Available","Anastomotic Leak","Procedure: Transanal Inspection and management of low ColoRectal Anastomosis","University of Rome Tor Vergata|San Giuseppe Moscati Hospital|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Casa di Cura San Pio X, Milano, Italy|Policlinico Abano Terme|Ospedale Maggiore, Bologna Italy","Both","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","65/14","November 24, 2014","January 2013","December 2016","August 20, 2016","August 2016","No Study Results Posted","TICRANT","September 2016","Incidence of anastomotic leakage after intervention|Safety margin after tumor resection|Postoperative morbidities and moralities","https://ClinicalTrials.gov/show/NCT02879370"
4023,"NCT02284802","Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy","Recruiting","No Results Available","Barrett Esophagus|Gastric Antrectomy Partial|Biliary Duct Stricture|Pancreatic Duct Stricture|Colorectal Polyps|Esophageal Epidermoid Cancer in Pts With Head and Neck Cancer","Procedure: Confocal endomicroscopy","Fauze Maluf Filho|Instituto do Cancer do Estado de São Paulo","Both","18 Years and older   (Adult, Senior)","","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","NP354/13","November 2, 2014","September 2014","February 2017","November 26, 2015","September 2015","No Study Results Posted","null","September 2016","Diagnostic accuracy of confocal endomicroscopy for the early detection of tumors of the digestive tract","https://ClinicalTrials.gov/show/NCT02284802"
4024,"NCT01683357","Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases","Completed","No Results Available","Liver Metastases","Procedure: Hepatectomy","University of Milan","Both","Child, Adult, Senior","","58","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MTX-1STAGE LONG-TERM","September 4, 2012","September 2001","July 2012","September 6, 2012","September 2012","No Study Results Posted","null","March 2012","feasibility on an intention-to-treat basis|safety of the procedure","https://ClinicalTrials.gov/show/NCT01683357"
4025,"NCT02820194","A Trial on SBRT Versus MWA for Inoperable Colorectal Liver Metastases (CLM)","Recruiting","No Results Available","Secondary Malignant Neoplasm of Liver","Radiation: Stereotactic Body Radiation Therapy|Procedure: Microwave Ablation","Istituto Clinico Humanitas","Both","18 Years and older   (Adult, Senior)","Phase 3","250","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1559","June 24, 2016","June 2016","February 2021","June 28, 2016","June 2016","No Study Results Posted","null","February 2021","Control of local disease|Progression free-survival of treated patients|Overall survival of treated patients|Incidence of acute and late complications","https://ClinicalTrials.gov/show/NCT02820194"
4026,"NCT00508872","Folfox-B Study for Patients With Colorectal Liver Metastases","Terminated","Has Results","Colorectal Liver Metastases","Drug: 5-Fluorouracil|Drug: Bevacizumab|Drug: Leucovorin|Drug: Oxaliplatin","M.D. Anderson Cancer Center|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 2","2","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0816","July 27, 2007","November 2005","June 2009","July 27, 2012","July 2012","October 8, 2010","null","June 2009","Complete Gross Resection Rate","https://ClinicalTrials.gov/show/NCT00508872"
4027,"NCT01271959","A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study","Terminated","No Results Available","Solid Organ Tumors","","Precision Therapeutics","Both","18 Years and older   (Adult, Senior)","","167","Industry","Observational","Time Perspective: Retrospective","PT-207","January 5, 2011","November 2010","October 2012","October 4, 2012","October 2012","No Study Results Posted","null","October 2012","To determine physicians' rate of compliance with ChemoFx assay results in the treatment of subjects with solid tumors.|To investigate the association between the results of Precision's ChemoFx assay results and overall survival in subjects with solid tumors.","https://ClinicalTrials.gov/show/NCT01271959"
4028,"NCT01799044","Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases","Completed","No Results Available","Colorectal Liver Metastases|Metastatic Liver Disease","Device: Irreversible electroporation (IRE)","Dr. M.R. Meijerink|VU University Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1","10","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NL 41089.029.12 COLDFIRE","February 20, 2013","November 2012","September 2013","September 3, 2013","September 2013","No Study Results Posted","IRE","September 2013","Safety|Efficacy","https://ClinicalTrials.gov/show/NCT01799044"
4029,"NCT02268825","Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers","Recruiting","No Results Available","Advanced GI Cancer","Drug: MK-3475","University of Utah|Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","128","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCI76239","October 15, 2014","January 2015","January 2020","April 25, 2016","April 2016","No Study Results Posted","MK-3475 GI","January 2020","Safety of combination mFOLFOX and MK-3475","https://ClinicalTrials.gov/show/NCT02268825"
4030,"NCT01696968","Screening for Lung Cancer in Older Patients (PLCO Screening Trial)","Active, not recruiting","Has Results","Lung Carcinoma","Procedure: Radiography|Other: Screening Questionnaire Administration","National Cancer Institute (NCI)","Both","55 Years to 74 Years   (Adult, Senior)","","154901","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Screening","NCI-2012-01756|PLCO-1|CDR0000078532|NCI-P93-0050|PLCO-Lung","September 28, 2012","November 1993","null","July 11, 2016","July 2016","August 30, 2013","null","May 2012","Lung Cancer Deaths|Lung Cancer Death Rates|Deaths From All Causes|Death Rates From All Causes|Lung Cancer Incidence|Lung Cancer Incidence Rates|Complications of Diagnostic Evaluation Following a Positive Screening Test|T0 (Baseline) CXR Screening Results|T1 CXR Screening Results|T2 CXR Screening Results|T3 CXR Screening Results","https://ClinicalTrials.gov/show/NCT01696968"
4031,"NCT00002540","Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)","Active, not recruiting","Has Results","Prostate Carcinoma","Other: Laboratory Biomarker Analysis|Procedure: Medical Examination|Other: Screening Questionnaire Administration","National Cancer Institute (NCI)","Male","55 Years to 74 Years   (Adult, Senior)","","76685","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Screening","NCI-2012-01755|PLCO-1|CDR0000078532|PLCO-Prostate|NCI-P93-0050","November 1, 1999","November 1993","null","July 6, 2016","July 2016","August 30, 2013","null","May 2012","Prostate Cancer Deaths|Prostate Cancer Death Rates|Deaths From All Causes|Death Rates From All Causes|Prostate Cancer Incidence|Prostate Cancer Incidence Rates|Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test|T0 (Baseline) PSA Screening Results|T0 (Baseline) DRE Screening Results|T1 PSA Screening Results|T1 DRE Screening Results|T2 PSA Screening Results|T2 DRE Screening Results|T3 PSA Screening Results|T3 DRE Screening Results|T4 PSA Screening Result|T5 PSA Screening Results","https://ClinicalTrials.gov/show/NCT00002540"
4032,"NCT02730104","Community-based Neuroendocrine Tumor (NET) Research Study","Recruiting","No Results Available","Gastroenteropancreatic Neuroendocrine Tumors","","Ipsen","Both","18 Years and older   (Adult, Senior)","","100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","A-US-52030-340","April 1, 2016","November 2015","December 2019","June 30, 2016","June 2016","No Study Results Posted","null","December 2019","Time to disease progression|Overall survival|Adverse events|Change in flushing and diarrhea|Patient satisfaction with treatment","https://ClinicalTrials.gov/show/NCT02730104"
4033,"NCT01447732","Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors","Completed","No Results Available","Solid Tumour|Adenocarcinoma of the Colorectal|Adenocarcinoma of the Pancreas","Drug: CEP-37250/KHK2804","Kyowa Hakko Kirin Pharma, Inc.|Teva Pharma|Kyowa Kirin Pharmaceutical Development, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","71","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CEP-37250/KHK2804-001","September 30, 2011","October 2011","January 2015","March 17, 2015","March 2015","No Study Results Posted","null","January 2015","Adverse Event collection and assessment will be done for all 74 potentially treated subjects.|To assess PK parameters which include: area under the plasma concentration versus time curve (AUC), peak plasma concentration (Cmax), t 1/2 and CL of CEP-37250/KHK2804.|To screen for the development of antibodies against CEP-37250/KHK2804 (immunogenicity)|To evaluate preliminary efficacy (overall response (Objective response rate(ORR; Complete Response(CR)+Partial Response(PR) and clinical benefit rate(CR+PR+stable disease(SD)).","https://ClinicalTrials.gov/show/NCT01447732"
4034,"NCT00168155","Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma","Completed","No Results Available","Colorectal Adenocarcinoma|Liver Metastases","Drug: perioperative chemotherapy","Alberta Health Services|Pfizer|AHS Cancer Control Alberta","Both","18 Years and older   (Adult, Senior)","Phase 2","70","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CPTAIV-0020-357","September 13, 2005","January 2002","May 2009","January 18, 2012","September 2011","No Study Results Posted","null","May 2009","disease free survival","https://ClinicalTrials.gov/show/NCT00168155"
4035,"NCT01457599","Computertomography-guided Wire Marking of the Liver","Completed","No Results Available","Secondary Malignant Neoplasm of Liver","Procedure: Computertomography-guided marking of colorectal liver metastases","Medical University of Graz","Both","18 Years and older   (Adult, Senior)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","INS-621000-0274-002","October 18, 2011","July 2011","August 2016","August 15, 2016","August 2016","No Study Results Posted","null","August 2016","Sensitivity","https://ClinicalTrials.gov/show/NCT01457599"
4036,"NCT00339495","Early Marker and Etiologic Studies in the PLCO Trial","Active, not recruiting","No Results Available","Cancer|Death","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","55 Years to 74 Years   (Adult, Senior)","","156000","NIH","Observational","Time Perspective: Prospective","999997041|OH97-C-N041","June 19, 2006","July 1997","null","May 26, 2016","May 2016","No Study Results Posted","null","null","Death|Cancer incidence","https://ClinicalTrials.gov/show/NCT00339495"
4037,"NCT02349958","Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy","Recruiting","No Results Available","Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Uterine Cancer|Mesotheliomas|Gastrointestinal Cancers|Cervical Cancer","Device: HIPEC: MMC 30mg @ T0, 10mg @ T45min|Device: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Device: HIPEC: CDDP 75 mg/m2 @T0|Device: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0","Bay Area Gynecology Oncology","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HIPEC","December 22, 2014","September 2006","September 2016","January 26, 2015","January 2015","No Study Results Posted","HIPEC/IPHC","September 2016","measure treatment response to HIPEC and tumor debulking","https://ClinicalTrials.gov/show/NCT02349958"
4038,"NCT00994903","Simvastatin in Colorectal Surgery","Completed","No Results Available","Intestinal Neoplasm|Perioperative Care","Drug: Simvastatin|Drug: Placebo","University of Auckland, New Zealand|Counties Manukau Health|Waitemata District Health Board|Auckland District Health Board","Both","18 Years to 90 Years   (Adult, Senior)","Phase 3","132","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","StatCol","October 13, 2009","October 2011","September 2013","November 27, 2013","November 2013","No Study Results Posted","StatCol","September 2013","Total complications|Peritoneal Cytokines|Serum cytokines|Change in serum C-reactive protein (CRP)|Change in functional recovery","https://ClinicalTrials.gov/show/NCT00994903"
4039,"NCT00720785","Natural Killer Cells and Bortezomib to Treat Cancer","Recruiting","No Results Available","Lung or Prostatic Neoplasms|Colorectal or Kidney Neoplasms|Pancreatic Neoplasms|Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive|Melanoma|CLL","Drug: NK cells +CliniMACs CD3 and CD56 systems","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","61","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","080186|08-H-0186","July 22, 2008","July 2008","January 2018","August 31, 2016","July 2016","No Study Results Posted","null","January 2018","Safety of escalating NK cell doses|The anti-neoplastic effects of this treatment regimen (assessed using standard disease specific response criteria) and the toxicity profile associated with extended cycles of protocol therapy.","https://ClinicalTrials.gov/show/NCT00720785"
4040,"NCT02756780","Tenovus Cancer Choirs Study: the Benefits of Singing for Those Affected by Cancer","Recruiting","No Results Available","Cancer","Other: Tenovus Cancer Choir","Royal Marsden NHS Foundation Trust|London Cancer Alliance|Royal College of Music|Tenovus Cancer Care","Both","18 Years and older   (Adult, Senior)","","420","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","SWU2016","April 28, 2016","April 2016","April 2018","April 28, 2016","April 2016","No Study Results Posted","null","December 2017","Anxiety & Depression|Social Support|Wellbeing|Self-efficacy|Self-esteem|General Health|Stress hormones|Immune proteins","https://ClinicalTrials.gov/show/NCT02756780"
4041,"NCT02599324","A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors","Recruiting","No Results Available","Renal Cell Carcinoma (RCC)|Urothelial Carcinoma|Gastric Adenocarcinoma|Colorectal Adenocarcinoma (CRC)","Drug: ibrutinib|Drug: everolimus|Drug: docetaxel|Drug: paclitaxel|Drug: cetuximab","Pharmacyclics","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","261","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PCYC-1128-CA","November 4, 2015","November 2015","June 2019","September 19, 2016","September 2016","No Study Results Posted","null","February 2019","Phase 1b: Determination of the recommended Phase 2 dose (RP2D) of ibrutinib in combination with everolimus in RCC, paclitaxel in urothelial carcinoma, docetaxel in gastric adenocarcinoma and cetuximab in CRC.|Phase 2: Progression-free survival (PFS) of ibrutinib combination therapy in RCC and urothelial carcinoma|Phase 2: ORR of ibrutinib combination therapy in gastric adenocarcinoma and CRC|Phase 2: PFS of ibrutinib combination therapy in gastric adenocarcinoma and CRC|Phase 2: ORR of ibrutinib combination therapy in RCC and urothelial carcinoma|Phase 2: DCR of ibrutinib combination therapy in each cohort","https://ClinicalTrials.gov/show/NCT02599324"
4042,"NCT01114256","FNA Tumor Sampling for CD137 Modulation: A Pilot Study","Recruiting","No Results Available","Head and Neck Cancer|Breast Cancer|Head and Neck Cancers|Non-Hodgkin Lymphoma|Colorectal Adenocarcinoma","Procedure: FNA Biopsy","Stanford University","Both","21 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VAR0053|SU-04072010-5602","April 23, 2010","March 2010","null","August 5, 2015","August 2015","No Study Results Posted","null","February 2016","evaluation of change in CD137 positive NK cells in blood & tumors in response to therapeutic moAbs|Evaluation of activation status of CD137 positive NK cells","https://ClinicalTrials.gov/show/NCT01114256"
4043,"NCT02331641","Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.","Completed","No Results Available","Colorectal Liver Metastases|Colon Cancer","Procedure: Hepatectomy","University of Milan|University of Bologna","Both","18 Years and older   (Adult, Senior)","","554","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","MajorVsMinorHepatectomy","December 29, 2014","January 2005","December 2014","January 5, 2015","January 2015","No Study Results Posted","null","November 2014","Number of postoperative complications after MH or MMH, graded based on the Dindo's classification (Dindo et al. Ann Surg 2004;240:205-13)|Long-term outcome (overall and disease-free survival)","https://ClinicalTrials.gov/show/NCT02331641"
4044,"NCT00292708","Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery","Completed","No Results Available","Colorectal Surgery","Drug: Cefmetazole (drug)","National Cancer Center, Japan","Both","20 Years to 80 Years   (Adult, Senior)","Phase 3","500","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C000000069","February 15, 2006","May 2004","July 2005","February 15, 2006","February 2006","No Study Results Posted","null","null","Incidence of incisional surgical site infection (SSI)|Incidences of organ/space SSI and other infectious diseases. Other postoperative complications and postoperative hospital stay","https://ClinicalTrials.gov/show/NCT00292708"
4045,"NCT02834013","Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","Not yet recruiting","No Results Available","Acinar Cell Carcinoma|Adrenal Cortex Carcinoma|Adrenal Gland Pheochromocytoma|Anal Canal Neuroendocrine Carcinoma|Anal Canal Undifferentiated Carcinoma|Appendix Mucinous Adenocarcinoma|Bladder Adenocarcinoma|Bronchioloalveolar Carcinoma|Cervical Adenocarcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Cholangiocarcinoma|Chordoma|Colorectal Squamous Cell Carcinoma|Endometrial Adenocarcinoma|Endometrioid Adenocarcinoma|Esophageal Neuroendocrine Carcinoma|Esophageal Undifferentiated Carcinoma|Extrahepatic Bile Duct Carcinoma|Fallopian Tube Adenocarcinoma|Fibromyxoid Tumor|Gastric Neuroendocrine Carcinoma|Gastric Squamous Cell Carcinoma|Giant Cell Carcinoma|Intestinal Neuroendocrine Carcinoma|Intrahepatic Cholangiocarcinoma|Lung Carcinoid Tumor|Lung Sarcomatoid Carcinoma|Major Salivary Gland Carcinoma|Malignant Odontogenic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Skin Neoplasm|Malignant Testicular Sex Cord-Stromal Tumor|Metastatic Malignant Neoplasm of Unknown Primary Origin|Mixed Mesodermal (Mullerian) Tumor|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Nasal Cavity Adenocarcinoma|Nasal Cavity Carcinoma|Nasopharyngeal Carcinoma|Nasopharyngeal Papillary Adenocarcinoma|Nasopharyngeal Undifferentiated Carcinoma|Oral Cavity Carcinoma|Oropharyngeal Undifferentiated Carcinoma|Ovarian Adenocarcinoma|Ovarian Germ Cell Tumor|Ovarian Mucinous Adenocarcinoma|Ovarian Squamous Cell Carcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Neuroendocrine Carcinoma|Paraganglioma|Paranasal Sinus Adenocarcinoma|Paranasal Sinus Carcinoma|Parathyroid Gland Carcinoma|Pituitary Gland Carcinoma|Placental Choriocarcinoma|Placental-Site Gestational Trophoblastic Tumor|Primary Peritoneal High Grade Serous Adenocarcinoma|Pseudomyxoma Peritonei|Scrotal Squamous Cell Carcinoma|Seminal Vesicle Adenocarcinoma|Seminoma|Serous Cystadenocarcinoma|Small Intestinal Adenocarcinoma|Small Intestinal Squamous Cell Carcinoma|Spindle Cell Neoplasm|Squamous Cell Carcinoma of the Penis|Teratoma With Malignant Transformation|Testicular Non-Seminomatous Germ Cell Tumor|Thyroid Gland Carcinoma|Tracheal Carcinoma|Transitional Cell Carcinoma|Undifferentiated Gastric Carcinoma|Ureter Adenocarcinoma|Ureter Squamous Cell Carcinoma|Urethral Adenocarcinoma|Urethral Squamous Cell Carcinoma|Vaginal Adenocarcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified|Vulvar Adenocarcinoma|Vulvar Squamous Cell Carcinoma","Procedure: Biospecimen Collection|Biological: Ipilimumab|Biological: Nivolumab","National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","334","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2016-01041|S1609|U10CA180888","July 13, 2016","June 2017","null","August 24, 2016","July 2016","No Study Results Posted","null","August 2020","ORR defined as confirmed and unconfirmed complete and partial response, assessed by RECIST 1.1|Best response calculated from the sequence of RECIST 1.1 and immune-related response criteria (irRC) objectives|Clinical benefit rate defined as complete response, partial response, or stable disease, estimated using both RECIST and irRC|Incidence of adverse events graded by NCI CTCAE version 4.0|OS, estimated using both RECIST and irRC|PFS, estimated using both RECIST and irRC","https://ClinicalTrials.gov/show/NCT02834013"
4046,"NCT02238938","Piecemeal Versus En Bloc Resection of Large Rectal Adenomas","Recruiting","No Results Available","Colorectal Adenoma With Mild Dysplasia|Colorectal Adenoma With Severe Dysplasia|Colorectal Adenomatous Polyp|Colorectal Low Grade Intraepithelial Neoplasia|Colorectal High Grade Intraepithelial Neoplasia","Procedure: en-bloc resection|Procedure: piecemeal resection","Universitätsklinikum Hamburg-Eppendorf","Both","18 Years and older   (Adult, Senior)","","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PERLA|PV 4580","September 4, 2014","April 2014","June 2019","May 10, 2016","May 2016","No Study Results Posted","PERLA","April 2019","success rate of complete resection|en-bloc group: rate of R0 resections|recurrence rate after complete adenoma resection|progress of therapy in patients with incomplete resection and recurrences|differences in the subgroups of adenomas|required time for the initial procedure|complications including success of complication management|complications through patient sedation|resolution of tumor board for post resections and outcomes of patients with carcinoma histology","https://ClinicalTrials.gov/show/NCT02238938"
4047,"NCT00849979","Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy","Completed","No Results Available","Gastrointestinal Cancer","Behavioral: Questionnaire|Other: Interview","M.D. Anderson Cancer Center","Both","18 Years and older   (Adult, Senior)","","184","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","2007-0228","February 23, 2009","July 2008","January 2010","July 26, 2012","July 2012","No Study Results Posted","null","January 2010","Validation of M. D. Anderson Symptom Inventory - Gastrointestinal (MDASI-GI) Questionnaire (Response)","https://ClinicalTrials.gov/show/NCT00849979"
4048,"NCT01405391","Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks","Completed","No Results Available","Major Advanced Solid Tumors Other Than Colorectal","Drug: PM01183","PharmaMar","Both","18 Years and older   (Adult, Senior)","Phase 1","42","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PM1183-A-005-11","July 26, 2011","November 2011","January 2016","January 14, 2016","January 2016","No Study Results Posted","null","January 2016","Recommended dose (RD)|Pharmacokinetics (PK): The dose-exposure relationships for Cmax and area under the curve (AUC) will be evaluated.|Antitumor activity measured clinically and/or radiologically according to RECIST or by evaluation of tumor markers|Pharmacogenomics (PGx) analysis: Number of tumour patient samples with identified and validated putative molecular markers associated with the clinical outcome of non-CRC patients treated with PM01183.","https://ClinicalTrials.gov/show/NCT01405391"
4049,"NCT02638909","Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies","Recruiting","No Results Available","Colorectal Adenocarcinoma|Cholangiocarcinoma|Pancreatic Adenocarcinoma|Hepatocellular Adenocarcinoma|Gastric Adenocarcinoma|Esophageal Adenocarcinoma","Drug: ceritinib","Criterium, Inc.|University of Colorado, Denver|Novartis","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Industry|Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NOV-ALK-01","December 15, 2015","December 2015","August 2017","March 24, 2016","March 2016","No Study Results Posted","null","August 2017","Clinical Benefit Rate (CBR) of ceritinib, as defined as the percentage of patients who have achieved complete response, partial response, and stable disease at 2 months per RECIST 1.1) to ceritinib by investigator assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Objective tumor response based on computed tomography scans (or magnetic resonance imaging if patients are allergic to iodinated contrast) per RECIST 1.1 criteria","https://ClinicalTrials.gov/show/NCT02638909"
4050,"NCT00797251","Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression","Active, not recruiting","No Results Available","Colorectal Liver Metastases|Hepatocellular Carcinoma|Liver Malignancies","Procedure: Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.","University of Milan","Both","18 Years to 85 Years   (Adult, Senior)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IOUS-Compression","November 24, 2008","September 2007","January 2009","November 24, 2008","November 2008","No Study Results Posted","null","January 2009","The primary outcome is the safety of the anatomical right posterior sectionectomy performed IOUS-guided finger compression.|The secondary outcome is the efficacy of the anatomical right posterior sectionectomy performed by IOUS-guided finger compression.","https://ClinicalTrials.gov/show/NCT00797251"
4051,"NCT00555295","Laparoscopic Colorectal Surgery For Cancer- Long Term Survival","Not yet recruiting","No Results Available","Colon Cancer","","Tel-Aviv Sourasky Medical Center","Both","Child, Adult, Senior","","200","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","TASMC-07-AS-389-CTIL","October 27, 2007","December 2007","February 2008","November 7, 2007","June 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00555295"
4052,"NCT02391207","Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence","Completed","No Results Available","Secondary Malignant Neoplasm of Liver","Procedure: Hepatic vein-sparing hepatectomy","University of Milan","Both","28 Years to 79 Years   (Adult, Senior)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HV-SparingHx","March 7, 2015","January 2009","December 2014","March 17, 2015","March 2015","No Study Results Posted","null","December 2012","the safety of HV-sparing surgery in terms of operative mortality and morbidity","https://ClinicalTrials.gov/show/NCT02391207"
4053,"NCT02143869","Evolution of Corporeal Composition in the PeriOperative Period","Active, not recruiting","No Results Available","Gastrointestinal Cancer (Esophagus, Gastric, Pancreatic, Hepatic, Colorectal and Anal)|Lung Cancer","Device: Bioelectrical Impedance Analysis","Hôpital Européen Marseille","Both","18 Years and older   (Adult, Senior)","","374","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2013-A01346-39","May 18, 2014","December 2013","December 2018","September 7, 2016","September 2016","No Study Results Posted","ECCOP","December 2016","body composition|perioperative complications","https://ClinicalTrials.gov/show/NCT02143869"
4054,"NCT02642185","Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases","Recruiting","No Results Available","Neoplasm Metastasis","Procedure: Microwave ablation|Procedure: Resection","Karolinska Institutet","Both","18 Years to 90 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAVERRIC","October 30, 2015","December 2015","December 2028","August 29, 2016","August 2016","No Study Results Posted","MAVERRIC","December 2021","Overall survival|Complications to treatment|Disease free survival|Overall cost of treatment as measured in euros|Local recurrence rates|Accuracy of placement of ablative device measured as mm from needle target location|Analysis of ablation volumes measured as length and radius of ovoid ablation zone.|Need for further liver specific treatment as assessed by number of sessions with ablation or resections","https://ClinicalTrials.gov/show/NCT02642185"
4055,"NCT00954148","Defining the Utility of PET/CT in the Follow-up of Patients With Solid Tumors","Terminated","No Results Available","Cancer Recurrence|Solid Tumors","Procedure: PET/CT|Procedure: NCCN recommendations for solid tumor post treatment","Dallas VA Medical Center","Both","18 Years to 90 Years   (Adult, Senior)","","53","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Diagnostic","09-017","August 5, 2009","September 2009","June 2010","June 29, 2010","May 2010","No Study Results Posted","null","May 2010","ThatPET/CT will be superior (15% improvement) to conventional methods of follow-up in terms of 5 year survival, cost and time to identification of new disease|Improvement in patient/caregiver compliance in keeping their appointments and completing their tests","https://ClinicalTrials.gov/show/NCT00954148"
4056,"NCT00597805","Quality of Life in Patients Undergoing Total Pelvic Exenteration","Recruiting","No Results Available","Total Exenteration,|Anterior or Posterior Pelvic Exenteration|Gynecologic Malignancies|Colorectal Malignancies|Urologic Malignancies","Behavioral: questionnaires/interviews","Memorial Sloan Kettering Cancer Center|H. Lee Moffitt Cancer Center and Research Institute","Both","18 Years and older   (Adult, Senior)","","136","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","05-001","January 9, 2008","January 2005","January 2017","March 31, 2016","March 2016","No Study Results Posted","null","January 2017","To characterize the extent of physical and psychological stress, and overall quality of life in patients undergoing total, anterior or posterior pelvic exenteration.|To determine how patients ratings of the specific QOL domains predict response to surgery, (ie; QOL, level of stress, function and symptoms).","https://ClinicalTrials.gov/show/NCT00597805"
4057,"NCT01948661","Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma","Recruiting","No Results Available","Colorectal Adenoma|Risk Reduction","Dietary Supplement: Mirtoselect® + Meriva®","Ente Ospedaliero Ospedali Galliera|Fondazione Umberto Veronesi|Indena S.p.A","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GAL 02","January 18, 2013","March 2014","September 2015","August 3, 2015","August 2015","No Study Results Posted","MIRACOL","August 2015","Change of immunohistochemical expression of beta catenin in normal and adenomatous colonic tissue|Change of IHC Nuclear Factor-Kβ (NFKβ), Ki-67 Labeling Index and P53 in normal and adenomatous mucosa.","https://ClinicalTrials.gov/show/NCT01948661"
4058,"NCT00399607","Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention","Active, not recruiting","No Results Available","Colorectal Adenomatous Polyps","Procedure: Rectal biopsy during colonoscopy|Procedure: Rectal biopsy at randomization|Procedure: Rectal biopsy at 1 year|Procedure: Rectal biopsy prior to colonoscopy|Procedure: Biopsies during colonoscopy","Emory University|National Cancer Institute (NCI)","Both","45 Years to 75 Years   (Adult, Senior)","","264","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00000357|R01CA114456|0975-2005","November 13, 2006","June 2006","August 2016","February 29, 2016","February 2016","No Study Results Posted","PPS4B","February 2016","COX-2 Levels|APC Protein Levels|β-catenin Levels|E-cadherin Levels|MLH1 Protein Levels|Bax Levels|hTERT Levels|Bcl-2 Levels|TGFα Levels|TGFβ1 Levels","https://ClinicalTrials.gov/show/NCT00399607"
4059,"NCT01730365","Optical Detection of Malignancy During Percutaneous Interventions","Completed","No Results Available","Pulmonary Coin Lesion|Colon Cancer Liver Metastasis|Breast Cancer","Procedure: Core biopsy procedure","Philips Healthcare","Both","18 Years and older   (Adult, Senior)","","104","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","NL40578.031.12","October 4, 2012","October 2012","December 2015","April 8, 2016","April 2016","No Study Results Posted","null","December 2015","Differentiation between normal and malignant tissue","https://ClinicalTrials.gov/show/NCT01730365"
4060,"NCT02743637","A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors","Recruiting","No Results Available","Advanced Malignancy|Advanced Solid Tumors|Neoplasm|Metastasis","Drug: SDX-7320","SynDevRx, Inc.","Both","21 Years to 85 Years   (Adult, Senior)","Phase 1","30","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SDX-0101","April 7, 2016","February 2016","null","August 1, 2016","August 2016","No Study Results Posted","SDX-0101","March 2017","Number of participants with adverse events as a measure of safety and tolerability of SDX-7320 to find the recommended Phase II dose|Anti-tumor activity","https://ClinicalTrials.gov/show/NCT02743637"
4061,"NCT02102074","Intra-peritoneal Environmental Changes Following Surgery","Recruiting","No Results Available","Tumor Cells and Tumor Markers in Peritoneal Cavity","","Meir Medical Center","Both","18 Years and older   (Adult, Senior)","","70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0036","February 7, 2013","May 2012","May 2015","December 9, 2014","February 2013","No Study Results Posted","CRC","December 2014","tumor cells and tumor markers|Cytokine levels in the abdomen","https://ClinicalTrials.gov/show/NCT02102074"
4062,"NCT01927965","Study of Minnelide™ in Patients With Advanced GI Tumors","Active, not recruiting","No Results Available","Advanced Gastrointestinal Tumors","Drug: Minnelide™ 001","Minneamrita Therapeutics LLC","Both","18 Years and older   (Adult, Senior)","Phase 1","54","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Minnelide™ 001","August 19, 2013","August 2013","December 2016","April 19, 2016","April 2016","No Study Results Posted","null","October 2016","To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of Minnelide™|To establish the dose of Minnelide™ recommended for future phase 2 protocol|To determine the pharmacokinetics of Minnelide™|To observe patients for any evidence of antitumor activity of Minnelide™ per RECIST criteria|To determine pharmacodynamic effect of Minnelide™ on HSP70 levels. And to explore pharmacodynamics effect of Minnelide™ on PET Scans and using Choi criteria on the CT scans.","https://ClinicalTrials.gov/show/NCT01927965"
4063,"NCT02727179","Open vs Laparoscopic Liver Surgery for Colorectal Liver Metastases","Recruiting","No Results Available","Colorectal Liver Metastasis|Laparoscopic Liver Resection","Procedure: Liver resection","Hospital Universitario Virgen de la Arrixaca","Both","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HUVA-0515","March 14, 2016","February 2005","June 2016","March 29, 2016","March 2016","No Study Results Posted","LapOpHuva","June 2016","Overall survival|Surgical operative time|Blood losses|Transfusion|Hospital stay|Time between surgery and adjuvant chemotherapy|Mortality|Morbidity","https://ClinicalTrials.gov/show/NCT02727179"
4064,"NCT01887158","Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection","Completed","No Results Available","Intestinal Cancer","Drug: Polyethylene glycol|Drug: Bisacodyl","Ospedale Santa Maria delle Croci","Both","18 Years and older   (Adult, Senior)","Phase 4","116","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Treatment","PEGOP0613","June 11, 2013","July 2013","June 2014","June 15, 2014","June 2014","No Study Results Posted","PEGOP","June 2014","quality of bowel preparation rated according to a modified Ottawa bowel preparation scale|Tolerability to the preparation (specific questionaire)|safety (adverse event rate)|Lesion detection (type and lesion detection rate/patient)","https://ClinicalTrials.gov/show/NCT01887158"
4065,"NCT01285037","A Study of LY2801653 in Advanced Cancer","Recruiting","No Results Available","Cancer","Drug: LY2801653|Drug: Cetuximab|Drug: Cisplatin|Drug: Gemcitabine|Drug: Ramucirumab","Eli Lilly and Company","Both","18 Years and older   (Adult, Senior)","Phase 1","190","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13008|I3O-MC-JSBA","January 26, 2011","November 2009","November 2017","September 7, 2016","September 2016","No Study Results Posted","null","November 2017","Recommended dose for phase 2 studies: Maximum tolerated dose|Number of participants with tumor response|Clinical benefit rate (CBR)|Progression free survival (PFS)|Duration of response|Number of participants with clinically significant effects|Pharmacokinetics: Area under the concentration/time curve (AUC)|Pharmacokinetics: Maximum plasma concentration (Cmax)|Maximum tolerated dose (MTD) of LY2801653 in combination with cetuximab for phase 2 studies in HNSCC|Maximum tolerated dose (MTD) of LY2801653 in combination with cisplatin for phase 2 studies in cholangiocarcinoma|Maximum tolerated dose (MTD) of LY2801653 in combination with gemcitabine plus cisplatin for phase 2 studies in cholangiocarcinoma|Maximum tolerated dose (MTD) of LY2801653 in combination with ramucirumab for phase 2 studies in gastric carcinoma","https://ClinicalTrials.gov/show/NCT01285037"
4066,"NCT00018551","Chemoprevention With Folic Acid","Completed","No Results Available","Colon Cancer|Adenoma|Colonic Polyps","Drug: Folic Acid","VA Office of Research and Development","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","null","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Masking: Double-Blind|Primary Purpose: Prevention","ONCO-021-98S","July 3, 2001","October 1998","September 2003","January 20, 2009","December 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00018551"
4067,"NCT02595424","Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery","Recruiting","No Results Available","Colorectal Large Cell Neuroendocrine Carcinoma|Esophageal Large Cell Neuroendocrine Carcinoma|Gallbladder Large Cell Neuroendocrine Carcinoma|Gastric Large Cell Neuroendocrine Carcinoma|Pancreatic Large Cell Neuroendocrine Carcinoma|Small Intestinal Large Cell Neuroendocrine Carcinoma","Drug: Capecitabine|Drug: Cisplatin|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Temozolomide","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Both","18 Years and older   (Adult, Senior)","Phase 2","126","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EA2142|NCI-2015-00547|NCI-2015-00505|U10CA180820","November 2, 2015","November 2015","null","January 5, 2016","January 2016","No Study Results Posted","null","January 2018","PFS|Incidence of toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|OS|Response rate (complete response or partial response) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1","https://ClinicalTrials.gov/show/NCT02595424"
4068,"NCT01522209","Detection Rate of Liver Metastases With Contrast Enhanced Intraoperative Ultrasound Compared to Regular Imaging","Completed","No Results Available","Colon Cancer Liver Metastasis|Contrast Enhances Intraoperative Ultrasound|Imaging for Liver Cancer|Imaging for Liver Metastasis","Procedure: Liver Surgery|Device: Contrast Enhanced Ultrasound|Radiation: CT Scan (standard)|Radiation: Primovist MRI (3 Tesla)","Asklepios Kliniken Hamburg GmbH","Both","18 Years and older   (Adult, Senior)","","59","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","Asklepios","January 3, 2012","December 2011","January 2015","January 14, 2015","January 2015","No Study Results Posted","CEIOUS-Liver","December 2014","Detection of Liver Metastasis during Operation|Comparison of Detection Rate for Liver Metastases of all imaging modalities|Comparison of Sensitivity of all imaging modalities|Comparison of Specicivity of all imaging modalities","https://ClinicalTrials.gov/show/NCT01522209"
4069,"NCT01174368","Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T","Recruiting","No Results Available","Prostate Cancer","Biological: Cancer Macrobead placement in abdominal cavity","The Rogosin Institute","Male","18 Years and older   (Adult, Senior)","Phase 2","38","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1003010955","August 1, 2010","June 2010","December 2017","May 23, 2016","February 2016","No Study Results Posted","null","December 2016","Tumor volume|Number of metastases|Progression-free survival","https://ClinicalTrials.gov/show/NCT01174368"
4070,"NCT01104129","Stool Testing for Pancreatic Cancer","Active, not recruiting","No Results Available","Pancreatic Cancer","","Columbia University|Mayo Clinic","Both","18 Years to 85 Years   (Adult, Senior)","","200","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","AAAD8007","April 13, 2010","July 2009","July 2017","June 10, 2016","June 2016","No Study Results Posted","null","December 2016","Positive mutation rate in tumors/IPMN lesions vs. control|Percentage of patients with genetic abnormalities correctly detected in stool samples","https://ClinicalTrials.gov/show/NCT01104129"
4071,"NCT01042691","Isolated Liver Perfusion With Oxaliplatin","Completed","No Results Available","Unresectable Colorectal Liver Metastases","Drug: Oxaliplatin","David Bartlett|The Pittsburgh Foundation|Sanofi|University of Pittsburgh","Both","18 Years and older   (Adult, Senior)","Phase 1","10","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-135","January 4, 2010","May 2003","November 2011","December 23, 2015","December 2015","No Study Results Posted","null","November 2011","To determine the maximum tolerated dose and dose limiting toxicity of oxaliplatin delivered via isolated hepatic perfusion (IHP).|To determine if isolated hepatic perfusion with oxaliplatin can increase the response rate, duration of response and survival of patients being treated with standard HAI with FUDR when compared to historical controls.|To determine the tissue absorption of oxaliplatin in normal liver versus tumor during IHP.","https://ClinicalTrials.gov/show/NCT01042691"
4072,"NCT02293811","Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa","Not yet recruiting","No Results Available","Crohn Disease-Associated Colorectal Adenocarcinoma","Other: Analysis","Centre Hospitalier Universitaire de Nice","Both","18 Years and older   (Adult, Senior)","","180","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","14-AOI-04","November 14, 2014","December 2014","June 2016","November 14, 2014","November 2014","No Study Results Posted","P2RX7","December 2015","Analysis of expression of P2RX7|Five isoforms of the P2RX7 protein","https://ClinicalTrials.gov/show/NCT02293811"
4073,"NCT02615665","Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases","Completed","No Results Available","Colorectal Liver Metastases","Procedure: Hepatic resection","University of Milan","Both","18 Years and older   (Adult, Senior)","","121","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NKTCellsInCLM","November 18, 2015","January 2013","August 2015","November 24, 2015","November 2015","No Study Results Posted","null","August 2015","Overall survival","https://ClinicalTrials.gov/show/NCT02615665"
4074,"NCT02756468","Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study","Recruiting","No Results Available","Pancreatic Cancer","Other: pts operated for pancreatic cancer","University of Roma La Sapienza","Both","18 Years to 100 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PREDIPS","April 18, 2016","January 2015","December 2016","April 28, 2016","April 2016","No Study Results Posted","PREDIPS","June 2016","Sensitivity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery|Specificity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery|PCT and CRP cuts-off in 3rd POD with a good NPV for AL|PCT and CRP cuts-off in 5th POD with a good NPV for AL","https://ClinicalTrials.gov/show/NCT02756468"
4075,"NCT01515514","Confocal Endomicroscopy for GI Neoplasia Study","Completed","No Results Available","Colorectal Polyps","","Mayo Clinic|Bankhead-Coley","Both","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","11-006327","January 10, 2012","August 2012","November 2012","May 15, 2013","May 2013","No Study Results Posted","null","November 2012","Quality of the confocal image","https://ClinicalTrials.gov/show/NCT01515514"
4076,"NCT02675946","Study of CGX1321 in Subjects With Advanced Solid Tumors","Recruiting","No Results Available","Solid Tumors|Colorectal Adenocarcinoma|Gastric Adenocarcinoma|Pancreatic Adenocarcinoma|Bile Duct Carcinoma|Hepatocellular Carcinoma|Esophageal Carcinoma","Drug: CGX1321","Curegenix Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","86","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CGX1321-101","January 22, 2016","February 2016","June 2018","July 25, 2016","February 2016","No Study Results Posted","null","June 2018","Number of participants with adverse events and/or abnormal laboratory values that are related to treatment|CGX1321 area under the curve|CGX1321 maximum or peak concentration|CGX1321 minimum or trough concentration|CGX1321 time to maximum concentration|CGX1321 half-life","https://ClinicalTrials.gov/show/NCT02675946"
4077,"NCT01795404","A Randomized Controlled Trial of Inquiry Based Stress Reduction (IBSR) Program for Cancer Survivors.","Not yet recruiting","No Results Available","Cancer","Behavioral: Inquiry Based Stress Reduction (IBSR)","Tel-Aviv Sourasky Medical Center","Both","18 Years to 90 Years   (Adult, Senior)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","TASMC-13-NA-549-CTIL","February 17, 2013","June 2013","December 2016","February 17, 2013","February 2013","No Study Results Posted","IBSR","June 2016","Quality of Life (QoL)","https://ClinicalTrials.gov/show/NCT01795404"
4078,"NCT02756455","Procalcitonin Reveals Early Dehiscence in Gastric Surgery: the PREDIGS Study","Recruiting","No Results Available","Gastric Cancer","Other: gastric cancer pts undergoing surgery","University of Roma La Sapienza","Both","18 Years to 100 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PREDIGS","April 18, 2016","January 2015","December 2016","April 28, 2016","April 2016","No Study Results Posted","null","June 2016","% of patients with leaks after gastric surgery correctly identified by the biomarkers (PCT and CRP)|% of patients without leaks after gastric surgery correctly identified by PCT and CRP|PCT cut-off that gives good negative predictive (NPV) value for leak after gastric surgery in 3rd POD|PCT cut-off that gives good negative predictive value for leak after gastric surgery in 5th POD","https://ClinicalTrials.gov/show/NCT02756455"
4079,"NCT00055705","PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer","Completed","No Results Available","Cancer","Biological: PV701","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000270801|MSKCC-02080|NCI-1617","March 6, 2003","January 2003","null","April 23, 2011","August 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00055705"
4080,"NCT02794493","Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer","Not yet recruiting","No Results Available","Hand Foot Syndrome","Drug: Traditional Chinese Medicine Formula LC09|Other: Placebo","China-Japan Friendship Hospital","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","156","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2015BAI04B07","May 26, 2016","June 2016","null","June 4, 2016","January 2016","No Study Results Posted","null","December 2017","Grade of hand foot syndrome over time as measured by NCI CTCAE version 4.03 PPE syndrome criteria|Assessment of patient reported pain using a 1-10 score.|Instrumental Activities of Daily Living Scale|Dermatology Life Quality Index (DLQI) Total Score|Chemotherapy completion rate|Incidence of reduced dosage of capecitabine thereby|Incidence of cessation of capecitabine thereby","https://ClinicalTrials.gov/show/NCT02794493"
4081,"NCT01633970","A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors","Recruiting","No Results Available","Cancer","Drug: 5-FU|Drug: Atezolizumab|Drug: Bevacizumab|Drug: Carboplatin|Drug: Leucovorin|Drug: Nab-paclitaxel|Drug: Oxaliplatin|Drug: Paclitaxel|Drug: Pemetrexed","Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 1","225","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GP28328|2012-001422-10","June 22, 2012","July 2012","September 2017","April 2, 2016","February 2016","No Study Results Posted","null","September 2017","Maximum tolerated atezolizumab dose|Percentage of participants with adverse events|Percentage of participants with dose-limiting toxicities|Pharmacokinetics: Maximum serum concentration (Cmax) of atezolizumab|Pharmacokinetics: Minimum serum concentration (Cmin) of atezolizumab|Pharmacokinetics: Clearance of atezolizumab|Pharmacokinetics: Volume of distribution of atezolizumab|Pharmacokinetics: Accumulation ratio of atezolizumab|Pharmacokinetics: Half-life of atezolizumab|Pharmacokinetics: Area under the concentration-time curve of atezolizumab|Percentage of participants with best overall response according to RECIST criteria|Percentage of participants with objective response (complete response + partial response) according to RECIST criteria|Duration of objective response according to RECIST criteria|Progression-free survival","https://ClinicalTrials.gov/show/NCT01633970"
4082,"NCT00591695","Enteral Stents for Colonic Obstruction","Active, not recruiting","No Results Available","Malignant Colorectal Obstruction","Procedure: Stent bridge to surgery + elective surgery|Procedure: Emergency Surgery","European Association for Endoscopic Surgery","Both","Child, Adult, Senior","Phase 4","144","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EAES-1","December 29, 2007","January 2008","July 2018","January 20, 2016","January 2016","No Study Results Posted","ESCO","July 2015","incidence of postoperative complications|postoperative mortality|success percentage of stent positioning in emergency|percentage of complications related to stent positioning|length of hospital stay|quality of life and survival|cost differences|oncological results (local and distant recurrence rate)","https://ClinicalTrials.gov/show/NCT00591695"
4083,"NCT01716468","Ketogenic Diet in Advanced Cancer","Completed","Has Results","Cancer","Other: Ketogenic Diet","VA Pittsburgh Healthcare System","Both","18 Years and older   (Adult, Senior)","","17","U.S. Fed","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label","PRO00000367","September 18, 2012","October 2012","December 2015","April 9, 2016","April 2016","February 9, 2016","null","January 2015","To Determine the Safety and Tolerability of a Modified Low Carbohydrate Diet in People With Advanced Cancer Across Different Tumor Types.","https://ClinicalTrials.gov/show/NCT01716468"
4084,"NCT01265953","Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation","Recruiting","No Results Available","Prostate Cancer Prevention","Drug: sulforaphane glucosinolate capsules|Dietary Supplement: Gelatin capsule containing cellulose and magnesium stearate","Portland VA Medical Center|National Cancer Institute (NCI)|Oregon State University|OHSU Knight Cancer Institute","Male","21 Years and older   (Adult, Senior)","","100","U.S. Fed|NIH|Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","Portland VA-09-0607|2096|6232|2P01CA090890-06A2","December 16, 2010","July 2011","null","April 25, 2013","April 2013","No Study Results Posted","null","April 2015","Identify distribution of SFN (sulforaphane) and its metabolites and HDAC (histone deacetylase) inhibition following SFN supplementation|Investigate the effects (biomarkers of disease progression) of broccoli sprout supplementation on DNA methylation status and proliferation markers in a pre-biopsy setting.","https://ClinicalTrials.gov/show/NCT01265953"
4085,"NCT00212433","Optimisation and Performance of Reduced Preparation CT Colography","Completed","No Results Available","Patients With Potential Colorectal Neoplasia","Drug: Tagitol V, Lo So, Readi-Cat 2","London North West Healthcare NHS Trust|St Mark's Foundation","Both","50 Years and older   (Adult, Senior)","Phase 4","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","04/Q0405/CT2","September 12, 2005","July 2004","February 2006","July 20, 2006","December 2005","No Study Results Posted","null","null","Which of four combinations of low residue diet, reduced laxative dose and oral contrast agent is best tolerated by patients and optimally prepares the colon prior ro CT colonography|to compare the diagnostic performance of CT colonography after reduced bowel preparation and faecal tagging with conventional colonoscopy in patients undergoing both procedures","https://ClinicalTrials.gov/show/NCT00212433"
4086,"NCT01347866","Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer","Terminated","No Results Available","Advanced Cancer","Drug: PF-05212384|Drug: PD-0325901|Drug: PF-05212384|Drug: irinotecan","Pfizer","Both","18 Years and older   (Adult, Senior)","Phase 1","105","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","B1271002|2011-001671-39","May 2, 2011","October 2011","December 2015","January 13, 2016","January 2016","No Study Results Posted","null","December 2015","First cycle Dose Limiting Toxicities (DLTs)|Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE v.4.0), timing , seriousness and relationship to study therapy|Area under the plasma concentration versus time curve (AUC) of PF-04691502, PF-05212384 and PD-0325901|Objective Tumor Response Rate (ORR)|Expression and/or phosphorylation in biopsied tumor tissue of PI3K pathway proteins and markers of cell cycle and survival|Gene and/or protein expression in biopsied tumor tissue relating to PI3K and/or MAPK pathway signaling","https://ClinicalTrials.gov/show/NCT01347866"
4087,"NCT02437760","The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring","Recruiting","No Results Available","Lung Cancer","Other: serum and pleural effusion CA-125 level","E-DA Hospital","Both","20 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","EMRP49103N","April 18, 2015","February 2015","February 2018","May 5, 2015","May 2015","No Study Results Posted","null","February 2017","The diagnostic Value of the cancer antigen-125 in lung cancer|The prognostic value of the cancer antigen-125 in lung cancer","https://ClinicalTrials.gov/show/NCT02437760"
4088,"NCT01895673","PET-MRI After Radiofrequency Ablation (RFA) or Microwave Ablation (MWA)","Recruiting","No Results Available","Liver Neoplasms|Local Neoplasm Recurrence","Other: Gadolinium","dr. M.P. van den Tol MD PhD|VU University Medical Center","Both","18 Years and older   (Adult, Senior)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL43058.000.13","June 20, 2013","June 2013","January 2015","September 30, 2013","September 2013","No Study Results Posted","null","January 2015","Local site recurrence (LSR) detection|Detection new intrahepatic lesions|inter-observer variability|Influence on decision making|Patients experience with PET-CT and PET-MRI","https://ClinicalTrials.gov/show/NCT01895673"
4089,"NCT00340015","A Prospective Study of Diet and Cancer in Members of the American Association of Retired Persons","Completed","No Results Available","Death|Cancer","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","50 Years to 69 Years   (Adult, Senior)","","566401","NIH","Observational","Time Perspective: Prospective","999995025|OH95-C-N025","June 19, 2006","October 1995","null","September 20, 2016","September 2016","No Study Results Posted","null","null","Cancer incidence|All cause and diases specific mortality|Chronic diseases|Parkinson's disease","https://ClinicalTrials.gov/show/NCT00340015"
4090,"NCT00414271","Neo-Adjuvant Chemotherapy in Locally Advanced Gastric Cancer","Active, not recruiting","No Results Available","Stage T3-4NxM0 Gastric Cancer","Drug: Capecitabine, doxcetaxol","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JS 0420|05-09-01-04","December 20, 2006","January 2006","null","December 16, 2008","December 2008","No Study Results Posted","null","null","Rate of complete pathological response|Correlation of clinical outcomes such as time to recurrence, overall survival, and complete pathological response with RUNX-3 methylation status and Thymidylate synthetase in the tumor tissue.|Feasibility and safety of pre-operative chemotherapy in locally advanced gastric cancer|Correlation of CGH and gene expression profile and their changes after chemotherapy with the same clinical outcomes","https://ClinicalTrials.gov/show/NCT00414271"
4091,"NCT02464007","Study of rSIFN-co for Patients With Advanced Solid Tumors","Recruiting","No Results Available","Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor","Biological: rSIFN-co","Sichuan Huiyang Life Science and Technology Corporation|Medelis Inc.","Both","18 Years to 80 Years   (Adult, Senior)","Phase 1","36","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","STM-04","June 3, 2015","January 2016","December 2016","February 25, 2016","February 2016","No Study Results Posted","null","December 2016","Maximum Tolerated Dose","https://ClinicalTrials.gov/show/NCT02464007"
4092,"NCT01104077","Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)","Recruiting","No Results Available","Pancreatic Cancer|Neoplasm","","Columbia University","Both","18 Years to 85 Years   (Adult, Senior)","","400","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","AAAD6106","April 13, 2010","November 2008","July 2017","June 10, 2016","June 2016","No Study Results Posted","null","December 2016","Percentage of IPMN patients with relatives with pancreatic cancer or IPMN|Percentage of IPMN patients exhibiting higher malignant potential or recurrence following surgical resection","https://ClinicalTrials.gov/show/NCT01104077"
4093,"NCT02602067","131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients","Active, not recruiting","No Results Available","Breast Neoplasm|Head and Neck Neoplasm|Skin Neoplasm|Respiratory Tract Neoplasm|Urogenital Neoplasm|Digestive System Neoplasm|Pancreatic Neoplasm|Connective and Soft Tissue Neoplasm|Lymphoma, Non-Hodgkin","Radiation: 131I-Tenatumomab","sigma-tau i.f.r. S.p.A.|Medpace, Inc.","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","36","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TENATUMOMAB/ST2146-CR-14-001|2014-003832-38","November 9, 2015","November 2015","June 2017","November 9, 2015","November 2015","No Study Results Posted","Tenatumomab","June 2017","Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03)|Adverse Events","https://ClinicalTrials.gov/show/NCT02602067"
4094,"NCT00140868","Outcome of Palliative Management of Malignant Large Bowel Obstruction w/Colorectal Stents or Surgery","Completed","No Results Available","Large Bowel Obstruction","Device: Luminal stents|Procedure: Minimally Invasive Surgical Bowel Diversion","Memorial Sloan Kettering Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","02-125","August 30, 2005","December 2002","October 2006","December 6, 2007","December 2007","No Study Results Posted","null","null","Primary objective: compare the effect on quality of life of minimally invasive surgical bowel diversion and endoscopic stent placement in the treatment of malignant large bowel obstruction.|Secondary objectives:the symptom response and complication rate of treatment of malignant large bowel obstruction with endoscopic stent placement or minimally invasive surgical bowel diversion","https://ClinicalTrials.gov/show/NCT00140868"
4095,"NCT00716209","Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers","Active, not recruiting","No Results Available","Gastrointestinal Cancer","","Haematology-Oncology|National University Hospital, Singapore","Both","18 Years and older   (Adult, Senior)","","null","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NUSIRB 04-116","July 14, 2008","September 2012","null","March 3, 2014","March 2014","No Study Results Posted","null","December 2014","","https://ClinicalTrials.gov/show/NCT00716209"
4096,"NCT00925652","Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: Bevacizumab|Drug: Cyclophosphamide|Drug: Methotrexate|Behavioral: Diet Intervention|Behavioral: Diet and Exercise Intervention","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Translational Breast Cancer Research Consortium|Genentech, Inc.","Both","18 Years and older   (Adult, Senior)","Phase 2","55","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","09-134|AVF 4571s; TBCRC 012","June 19, 2009","September 2010","September 2017","October 20, 2015","October 2015","No Study Results Posted","ABCDE","September 2017","Recurrence-free survival|Feasibility of bevacizumab and metronomic chemotherapy administration.|To characterize the side effects and tolerability of bevacizumab and metronomic chemotherapy|Overall survival","https://ClinicalTrials.gov/show/NCT00925652"
4097,"NCT01777061","Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan","Available","No Results Available","Prostate Cancer","Drug: [11C]Acetate","Reginald Dusing, MD|University of Kansas Medical Center|University of Kansas Medical Center Research Institute","Male","45 Years to 80 Years   (Adult, Senior)","Phase 3","null","Other","Expanded Access","","13429","January 17, 2013","January 2013","December 2017","September 8, 2016","September 2016","No Study Results Posted","null","January 2016","","https://ClinicalTrials.gov/show/NCT01777061"
4098,"NCT01705184","Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic|Nonsquamous Nonsmall Cell Neoplasm of Lung","Drug: Cisplatin|Drug: Bevacizumab|Drug: Pemetrexed","Intergroupe Francophone de Cancerologie Thoracique","Both","18 Years and older   (Adult, Senior)","Phase 2","118","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IFCT-1102|2012-002647-18","October 5, 2012","December 2012","December 2016","March 9, 2016","March 2016","No Study Results Posted","BUCiL","January 2016","Feasibility|Control rate after the 2nd sequence|Response rate after the 1st sequence|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT01705184"
4099,"NCT02608853","Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants","Completed","No Results Available","Diabetes|Diabetes Mellitus, Type 2","Other: No treatment given","Novo Nordisk A/S","Both","Child, Adult, Senior","","9999","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NN2211-4259|U1111-1173-7000","October 1, 2015","January 2015","January 2015","November 17, 2015","November 2015","No Study Results Posted","null","January 2015","Incidence of all malignant neoplasms|Incidence of specific malignant neoplasms - Breast (women only)|Incidence of specific malignant neoplasms - Colorectal|Incidence of specific malignant neoplasms - Pancreatic|Incidence of specific malignant neoplasms - Thyroid|Incidence of specific malignant neoplasms - Medullary Thyroid|Incidence of acute pancreatitis","https://ClinicalTrials.gov/show/NCT02608853"
4100,"NCT00954512","Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)","Terminated","Has Results","Neoplasms","Drug: Carboplatin|Drug: Epirubicin|Biological: Trastuzumab|Drug: Everolimus|Drug: Gemcitabine|Biological: Robatumumab|Biological: Cetuximab|Drug: Paclitaxel|Drug: Cisplatin|Drug: 5-FU|Drug: Erlotinib|Drug: Irinotecan|Drug: Folinic Acid","Merck Sharp & Dohme Corp.","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P04722|MK-7454-004|2009-011101-16","July 23, 2009","September 2009","June 2011","January 11, 2016","January 2016","November 18, 2015","null","June 2011","Part 2: Number of Participants With Each Type of Response Evaluation Criteria in Solid Tumors (RECIST)-Determined Overall Best Response|Part 1: Number of Participants Who Experienced One or More Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT00954512"
4101,"NCT00220012","Effect of Folate on Colon and Blood Cells","Completed","No Results Available","Subjects Will Have a Pre-cancerous Colorectal Polyp|Family Member Has History of Colorectal Adenoma of Adenocarcinoma","Procedure: Folate depletion and supplementation","Rockefeller University","Both","40 Years to 72 Years   (Adult, Senior)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind|Primary Purpose: Prevention","PHO-0514|N01CN35111","September 15, 2005","June 2003","September 2008","November 14, 2013","November 2013","No Study Results Posted","null","null","Measurements of established folate-related endpoints in DNA from blood mononuclear cells and rectal cells:|Luracil incorporation in blood mononuclear cells|Strand breaks in the coding region of p53 in blood cells and rectal biopsy cells|DNA methylation (overall, p53, coding, p16 promotor. MLH1 promotor) in blood cells and rectal biopsy cells|Measurements of differential gene expression in colonic and blood cells by microarray analysis, further defining folate's action in modifying cell cycle activity, cell maturation, signal transduction and oncogene expression.","https://ClinicalTrials.gov/show/NCT00220012"
4102,"NCT01489787","Study to Evaluate a High Intensity Focused Ultrasound (HIFU) Procedure in Patient With Liver Metastases","Recruiting","No Results Available","Neoplasm Metastasis","Procedure: HIFU|Procedure: HIFU|Procedure: HIFU","Centre Leon Berard|National Cancer Institute, France|Cancéropôle Lyon Auvergne Rhône-Alpes","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","38","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HIFU|ET2009-068","November 24, 2011","March 2010","June 2016","August 13, 2014","August 2014","No Study Results Posted","HIFU","December 2015","First step: Ability to shoot and supplementary duration of intervention, to use the medical device following requested asepsis procedures and no evidence of hurt on peripheral tissues and to keep vital signs stable|Phase IIa - First step: accuracy of shootings on a precise area|Phase IIb: possibility of ≤ 15 shootings, safety margin ≥ 5 mm in healthy liver.|Phase IIa - Second step: accuracy of shootings on a zone to be spared|Phase I: adjust the probe position to different liver segments and patient physical structure.|Phase I: Possibility to set a stationary mark, at given depth, echographically detectable|Phase I: Possibility to spot echographically a previously Patent Blue or Methylene blue marked vessel|Phase I: Mean duration to achieve each step expressed in minutes(initialization, conditioning, targeting, shooting)|Phase I: description of outline during perioperative echography|Phase I: description of limits during anatomopathological analysis|Phase I: distance between the mark / marked vessel and the hurt limits during anatomopathological analysis|Phase II: safety of the device|Phase II: assessment of vital signs during shooting phase|Phase IIa: correlation between hurt perioperative echographic and postoperative macroscopic, measures","https://ClinicalTrials.gov/show/NCT01489787"
4103,"NCT02709811","Safety and Feasibility of Electrochemotherapy in Unresectable Colorectal Adenocarninoma Liver Metastases","Terminated","No Results Available","Colorectal Adenocarcinoma","Drug: Electrochemotherapy","IGEA","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","5","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PECTL1","November 24, 2014","August 2012","January 2015","March 10, 2016","March 2016","No Study Results Posted","null","January 2015","Safety and feasibility evaluation of Electrochemotherapy treatment of liver metastasesSafety and feasibility evaluation of Electrochemotherapy treatment of liver metastases as meaured by unexpected intraoperative adverse events|Overall survival|Disease free survival|Quality of Life (Karnofsky performance status)|Objective response evaluation of treated liver metastases following RECIST criteria|Toxicity of Electrochemotherapy treatment of liver metastases as meaured by unexpected postoperative complications related to treatment","https://ClinicalTrials.gov/show/NCT02709811"
4104,"NCT00908960","Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles","Completed","Has Results","Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer","Drug: Enoxaparin","Beth Israel Deaconess Medical Center|Massachusetts General Hospital|North Shore Medical Center|University of Southern California|VA Boston Healthcare System|Sanofi|Dana-Farber Cancer Institute","Both","18 Years and older   (Adult, Senior)","Phase 2","70","Other|U.S. Fed|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","08-378","May 26, 2009","May 2009","October 2012","October 22, 2013","October 2013","July 22, 2013","MicroTEC","April 2012","The Cumulative Incidence of VTE at 2 Months.|To Investigate the Safety of Prophylactic Enoxaparin in Cancer Patients (Major Bleeding Episodes).|To Assess the Impact of Enoxaparin on Overall Survival.","https://ClinicalTrials.gov/show/NCT00908960"
4105,"NCT00771290","Comparision of Air Versus CO2 for Distention During Sigmoidoscopy","Terminated","No Results Available","Colorectal Surgery","Procedure: Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)","Columbia University","Both","18 Years and older   (Adult, Senior)","","54","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","AAAB6097","October 10, 2008","March 2008","March 2009","November 13, 2012","November 2012","No Study Results Posted","null","January 2009","diameter of colon/rectal wall at surgery","https://ClinicalTrials.gov/show/NCT00771290"
4106,"NCT00744159","Prospective Comparison of Immunological Benefit of Laparoscopic Colectomy","Completed","No Results Available","Immunity","","Samsung Medical Center","Both","20 Years to 80 Years   (Adult, Senior)","","84","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IRB 2005-08-041|#CRS-106-14-1","August 27, 2008","January 2006","November 2007","August 28, 2008","August 2008","No Study Results Posted","null","November 2007","Immune factors|Post-operative complications","https://ClinicalTrials.gov/show/NCT00744159"
4107,"NCT01688687","Conventional Biopsies vs pCLE for Diagnosis of Superficial Gastric Neoplasia","Completed","No Results Available","Early Gastric Cancer|Gastric Dysplasia","Procedure: Endoscopic submucosal dissection","Soonchunhyang University Hospital","Both","18 Years to 85 Years   (Adult, Senior)","","63","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MD-2012-01","September 6, 2012","February 2012","null","September 19, 2012","September 2012","No Study Results Posted","pCLE","September 2012","The accuracy of pCLE compared to conventional forceps biopsy|Comparison of ""real time"" in-vivo pCLE diagnosis with that of blinded ""off-line"" pCLE diagnosis.|Off-line pCLE interobserver agreement","https://ClinicalTrials.gov/show/NCT01688687"
4108,"NCT02288169","Patient Outcomes of a Self-care Management Approach to Cancer Symptoms: A Clinical Trial","Recruiting","No Results Available","Cancer","Behavioral: COPE|Behavioral: Support/Attention Control","University of South Florida|Patient-Centered Outcomes Research Institute","Both","18 Years and older   (Adult, Senior)","","450","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","USflorida","November 6, 2014","September 2013","September 2016","May 10, 2016","May 2016","No Study Results Posted","null","July 2016","Quality of Life (The Multidimensional Quality of Life scale)|Anxiety (State-Trait Anxiety Inventory)|Depression (The Centers for Epidemiologic Study - Depression)|Health Services Utilization (The Health Services Utilization Index)","https://ClinicalTrials.gov/show/NCT02288169"
4109,"NCT00289445","Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)","Completed","No Results Available","Gastrointestinal Neoplasms|Neoplasm Metastasis","Drug: Mitomycin C|Drug: 5-FU|Drug: Folinic acid","University Hospital Tuebingen","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","jth_003","February 8, 2006","September 1999","March 2006","January 25, 2013","January 2013","No Study Results Posted","null","March 2006","maximum tolerated dose (MTD) of bolus mitomycin C (MMC) in combination with 24 h-continuous infusion of 5-fluorouracil (FU) plus folinic acid|toxicity|activity","https://ClinicalTrials.gov/show/NCT00289445"
4110,"NCT01222208","Oral Versus Parenteral Nutrition Support to Improve Protein Balance in Colorectal Surgical Patients","Completed","No Results Available","Colon Cancer","Dietary Supplement: Oral Nutrition with dextrose and pressurized whey protein|Dietary Supplement: Peripheral Parenteral Nutrition","McGill University Health Center|Montreal General Hospital|McGill University","Both","18 Years to 85 Years   (Adult, Senior)","","20","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","10-106-GEN","October 14, 2010","March 2011","November 2011","February 3, 2012","February 2012","No Study Results Posted","null","November 2011","Whole body protein balance|Synthesis rates of hepatic secretory proteins","https://ClinicalTrials.gov/show/NCT01222208"
4111,"NCT02509507","Safety Study of Talimogene Laheraprepvec Injected Into Hepatocellular Carcinoma and Metastatic Liver Tumors","Recruiting","No Results Available","Hepatocellular Carcinoma|Liver Metastases","Drug: Talimogene Laherparepvec","Amgen","Both","18 Years and older   (Adult, Senior)","Phase 1","100","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20140318|2014-005386-67","July 10, 2015","February 2016","April 2020","September 13, 2016","August 2016","No Study Results Posted","null","April 2018","Subject incidence of Dose-Limiting Toxicities in dose-escalation cohorts to determine the Maximum Tolerated Dose.|Safety: To evaluate the safety of intrahepatic injection of talimogene laherparepvec into liver tumors as assessed by subject incidence of treatment-emergent and treatment-related adverse events|Safety: To estimate the incidence of detectable talimogene laherparepvec DNA in blood and urine|Safety: To estimate the incidence of clearance of talimogene laherparepvec DNA from blood and urine|Safety: To estimate the rate of detection and incidence of talimogene laherparepvec DNA and virus at the surface of talimogene laherparepvec injection site, the exterior of the occlusive dressing, and the oral mucosa|Safety: To estimate the incidence of talimogene laherparepvec DNA detection in lesions suspected to be herpetic in origin","https://ClinicalTrials.gov/show/NCT02509507"
4112,"NCT00402961","Trial of Acupuncture for Reduction of Post-Colectomy Ileus","Completed","No Results Available","Postoperative Ileus|Colon Cancer|Pain, Postoperative|Postoperative Nausea and Vomiting","Other: Acupuncture|Other: Sham Acupuncture","Memorial Sloan Kettering Cancer Center|National Institutes of Health (NIH)","Both","18 Years and older   (Adult, Senior)","Phase 2","90","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-145","November 22, 2006","October 2006","February 2013","October 9, 2015","October 2015","No Study Results Posted","null","February 2013","To determine whether a Phase III trial of acupuncture for postoperative recovery after colorectal surgery is warranted as defined by evidence of reduction of postoperative ileus when compared to sham acupuncture|To explore whether acupuncture improves patient satisfaction with the hospital experience by ameliorating other postoperative symptoms such as pain and nausea and vomiting|To determine the feasibility of a Phase III trial in terms of sample size, accrual rate, attrition rate and data completion|GI-2, (also representing time to recovery of gastrointestinal [GI] function)|GI contractions measured with a multifunctional stethoscope|Daily pain score|Opioid consumption (total dose of morphine equivalent during hospitalization and average dose per day)|Number of emetic episodes during hospital stay","https://ClinicalTrials.gov/show/NCT00402961"
4113,"NCT02063919","Association Between Confocal Laser Endomicroscopic (CLE) Features and Colorectal Mucosal Microbiome","Completed","No Results Available","Colorectal Neoplasia|Colorectal Inflammation|Hyperplasia|Mucosal Microbiome","Other: the mucosal microbiome in the biopsy specimen was analysed","Shandong University","Both","18 Years to 80 Years   (Adult, Senior)","","45","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","2014SDU-QILU-G01","January 29, 2014","November 2013","June 2014","June 27, 2015","June 2015","No Study Results Posted","null","April 2014","The operational taxonomy unit in the colorectal mucosal microbiome.","https://ClinicalTrials.gov/show/NCT02063919"
4114,"NCT00951574","Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)","Completed","No Results Available","Advanced Cancer|Metastatic Cancer","Drug: Nadroparin calcium|Drug: saline solution (placebo)","Italfarmaco","Both","18 Years and older   (Adult, Senior)","Phase 3","1166","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DS/02/SELE/01","July 31, 2009","October 2003","July 2008","January 31, 2012","January 2012","No Study Results Posted","null","May 2007","Cumulative incidence of symptomatic venous and arterial thromboembolism, in patients with metastatic or locally advanced solid tumors undergoing chemotherapy|Survival, at the end of study treatment|Response to chemotherapy|For patients with central venous catheters (CVC), complications of possible thrombotic origin, such as malfunction or requirement of CVC removal|Superficial thrombophlebitis of lower limbs|Asymptomatic thromboembolic events diagnosed during tests performed for other purposes|Safety (major bleeding, minor bleeding, other adverse events)","https://ClinicalTrials.gov/show/NCT00951574"
4115,"NCT00152906","Stereotactic Radiotherapy (SRT) Liver (COLD 1)","Active, not recruiting","No Results Available","Liver Neoplasms|Neoplasm Metastases","Procedure: Stereotactic radiotherapy (SRT) or highly conformal (CRT)","University Health Network, Toronto|American Society of Clinical Oncology","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","140","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 03-0295-C|ASCO Clinical Research Grant","September 8, 2005","July 2003","July 2016","January 28, 2016","January 2016","No Study Results Posted","null","July 2016","Phase I: To evaluate feasibility and maximally tolerated dose of SRT|Phase II: To determine with more confidence the rate and spectrum of all toxicities that occur at the maximally tolerated dose of radiation.|To evaluate local control, progression-free survival and survival of patients with unresectable primary hepatobiliary cancer and metastatic liver cancer treated with SRT.|To evaluate the quality of life.|To evaluate changes in liver function following SRT.|To evaluate patterns of breathing at and during RT.|To develop more confidence in a revised normal tissue complication probability (NTCP) model for radiation induced liver toxicity and collect preliminary data to determine how the liver responds to radiation.|To determine whether serum cytokines and P-III-P can help predict RILD.","https://ClinicalTrials.gov/show/NCT00152906"
4116,"NCT01226732","A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors","Completed","Has Results","Metastatic or Unresectable Solid Tumor Malignancy","Drug: Capecitabine|Drug: Hsp90 Inhibitor AUY 922","SCRI Development Innovations, LLC|Novartis Pharmaceuticals","Both","18 Years and older   (Adult, Senior)","Phase 1","23","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI GI 143","October 18, 2010","November 2010","June 2014","January 6, 2015","January 2015","January 6, 2015","null","July 2013","Dose Determination|Safety|Preliminary Efficacy Assessment: Response Rate (RR)","https://ClinicalTrials.gov/show/NCT01226732"
4117,"NCT02662179","Are the Fried Criteria Predictive of a Functional Decline in Older People With Solid Malignant Tumors?","Recruiting","No Results Available","Elderly Patients With a Solid Tumor","Other: Quality of life evaluation|Other: Functional decline assessment|Other: Physical decline assessment|Other: Cognitive decline assessment","Brugmann University Hospital","Both","70 Years and older   (Senior)","","30","Other","Observational","Time Perspective: Prospective","CHUB-Fried","November 27, 2015","November 2015","January 2018","July 14, 2016","July 2016","No Study Results Posted","null","January 2018","Functional decline - Katz (ADL)|Functional decline - Lawton (IADL)|Physical decline - walking speed|Physical decline - prehension force|Cognitive decline - MMSE 30|Quality of life - SF 36|Quality of life - SF36|Switch in oncologic treatment decision","https://ClinicalTrials.gov/show/NCT02662179"
4118,"NCT02785783","Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection","Recruiting","No Results Available","Colorectal Neoplasia|Intestinal Neoplasms|Digestive Neoplasms|Digestive System Disease|Intestinal Disease|Gastrointestinal Disease|Gastrointestinal Neoplasm","Device: Standard colonoscopy|Device: EndoRings™","Portsmouth Hospitals NHS Trust|University of Portsmouth","Both","55 Years and older   (Adult, Senior)","","554","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","PHT/2015/101","May 25, 2016","May 2016","November 2017","May 27, 2016","May 2016","No Study Results Posted","Erings™","July 2017","Number of polyps per patient","https://ClinicalTrials.gov/show/NCT02785783"
4119,"NCT00885950","Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants","Completed","No Results Available","Sinusoidal Obstruction Syndrome|Colorectal Liver Metastases","","Maastricht University Medical Center","Both","18 Years and older   (Adult, Senior)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","08-4-076","April 21, 2009","January 2008","June 2010","February 3, 2014","February 2014","No Study Results Posted","null","December 2009","Histologically proven hepatic sinusoidal injury|90-day morbidity and mortality","https://ClinicalTrials.gov/show/NCT00885950"
4120,"NCT01062035","Study of a Screening Blood Test to Determine Patients' Potential Risk of Adenomatous or Advanced Colon Polyps (ACPs)","Completed","No Results Available","Colonic Polyp","","Mayo Clinic","Both","50 Years to 60 Years   (Adult)","","72","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","09-000131","February 2, 2010","January 2010","September 2013","June 24, 2014","June 2014","No Study Results Posted","null","September 2013","Telomere length are shorter in individuals with colon polyps.","https://ClinicalTrials.gov/show/NCT01062035"
4121,"NCT01982149","Incorporation of Genetic Expression of Airway Epithelium With CT Screening for Lung Cancer","Active, not recruiting","No Results Available","Chronic Obstructive Pulmonary Disease|COPD","Genetic: Group 1|Genetic: Group 2|Genetic: Group 3","Weill Medical College of Cornell University","Both","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","1305013973|Weill Cornell Medical College","October 25, 2013","September 2011","August 2016","May 6, 2016","May 2016","No Study Results Posted","null","August 2016","Measure the correlation among gene expression levels between nasal and bronchial epithelium on an individual gene and multivariate basis","https://ClinicalTrials.gov/show/NCT01982149"
4122,"NCT00184834","Quality of Life and Liver Metastases","Completed","No Results Available","Colorectal Liver Metastases|Quality of Life","Behavioral: quality of life","Radboud University","Both","Child, Adult, Senior","","100","Other","Observational","Observational Model: Defined Population|Time Perspective: Longitudinal|Time Perspective: Prospective","qol1","September 12, 2005","June 1999","November 2002","September 12, 2005","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00184834"
4123,"NCT01711580","Re-irradiation of High Grade Gliomas: a Quality of Life Study","Withdrawn","No Results Available","Anaplastic Astrocytoma|Glioblastoma Multiforme|Anaplastic Oligoastrocytoma","Other: EORTC QLQ-C30|Other: EORTC QLQ-BN20|Other: Hopkins Verbal Learning Test-Revised (HVLT-R)|Other: Stroop color-word test|Other: Controlled oral word association test (COWA)|Other: Jamar hand dynamometer|Other: EORTC QLQ- FA13|Other: Trail Making Test (TMT)","Maastricht Radiation Oncology","Both","18 Years and older   (Adult, Senior)","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-01-25/01-intern-6810","October 12, 2012","March 2013","September 2015","May 11, 2015","May 2015","No Study Results Posted","null","March 2015","Change from baseline in the palliative effect of re-irradiation in patients with a high grade glioma, defined by quality-of-life parameters|Overall survival of patients with glioblastoma and anaplastic glioma after re-irradiation|Progression free survival of patients with glioblastoma and anaplastic glioma after re-irradiation","https://ClinicalTrials.gov/show/NCT01711580"
4124,"NCT01929915","Analgesia and Pancreatic Cancer Surgery","Recruiting","No Results Available","Pancreatic Neoplasms","Procedure: Epidural patient controlled analgesia|Drug: Intravenous patient controlled analgesia","National Taiwan University Hospital","Both","20 Years to 85 Years   (Adult, Senior)","","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","201203094RIC","July 18, 2013","August 2012","August 2015","July 14, 2015","July 2015","No Study Results Posted","null","August 2015","Perioperative immunoprofile|survival rate","https://ClinicalTrials.gov/show/NCT01929915"
4125,"NCT02741401","COMplementary Hand-foot Massage to Improve Experience of illneSs Trial","Enrolling by invitation","No Results Available","Gastrointestinal Cancer","Other: Usual post-operative care|Other: Hand-foot massage","Zuyderland Medisch Centrum","Both","18 Years and older   (Adult, Senior)","","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","COMMIS","April 4, 2016","March 2016","December 2016","April 21, 2016","April 2016","No Study Results Posted","COMMIS","September 2016","Change from baseline in quality of life as assessed by EuroQol-5D-L3 (EQ-5D-L3) questionnaire|Change from baseline in anxiety and depression as assessed by Hospital Anxiety and Depression Scale (HADS) questionnaire|Patient satisfaction about the received hospital care and hand-foot massage (if applicable) as assessed by questionnaire|Patients' opinion and need about hand-foot massage's utility as assessed by questionnaire","https://ClinicalTrials.gov/show/NCT02741401"
4126,"NCT00336609","TRIAD Burden of Illness Mucositis Study","Recruiting","No Results Available","Gastrointestinal Mucositis (Defined as Mucositis Involving the Mouth, Esophagus, or Small Intestine)","","TRIAD Burden of Illness","Both","18 Years and older   (Adult, Senior)","","1600","Other","Observational","Observational Model: Defined Population|Time Perspective: Longitudinal|Time Perspective: Prospective","No. 200509024","June 12, 2006","November 2005","May 2007","April 19, 2007","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00336609"
4127,"NCT02000011","Interest of a Geriatric Intervention Plan Associated to a Comprehensive Geriatric Assessment on Autonomy, Quality of Life and Survival of Patients Aged 70 Years Old and More Surgically Treated for a Resectable Cancer (Thoracic, Digestive or Urologic). Randomized Multicentric Study","Recruiting","No Results Available","Cancer","Other: comprehensive geriatric assessment (CGA)|Other: Geriatric intervention plan (GIP)","Assistance Publique Hopitaux De Marseille","Both","70 Years and older   (Senior)","","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2013-A01038-37|2013-33","November 26, 2013","December 2013","May 2018","July 6, 2016","July 2016","No Study Results Posted","epigac","November 2017","the 6-month autonomy after surgery|12-month autonomy","https://ClinicalTrials.gov/show/NCT02000011"
4128,"NCT00667550","Lower Urinary Tract and Sexual Function in Women Following Surgery for Colorectal Disorders","Completed","No Results Available","Lower Urinary Tract Symptoms|Colorectal Disorders","","University of California, Irvine","Female","18 Years and older   (Adult, Senior)","","34","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2007-5995","April 24, 2008","March 2008","March 2010","July 13, 2010","July 2010","No Study Results Posted","null","March 2010","","https://ClinicalTrials.gov/show/NCT00667550"
4129,"NCT01563991","Impact of Perioperative Intravenous Fluid Utilization on Postoperative Outcomes","Active, not recruiting","No Results Available","Benign Neoplasm of Intestinal Tract|Primary Malignant Neoplasm of Intestinal Tract|Secondary Malignant Neoplasm of Intestinal Tract","Procedure: Normal fluid volume|Procedure: Reduced fluid volume","The Cleveland Clinic","Both","18 Years and older   (Adult, Senior)","","186","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07-016","March 24, 2012","February 2007","null","February 12, 2013","February 2013","No Study Results Posted","null","June 2013","Morbidity","https://ClinicalTrials.gov/show/NCT01563991"
4130,"NCT00994370","Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT","Completed","No Results Available","Liver Cancer","","Rutgers, The State University of New Jersey|Sirtex Medical","Both","18 Years to 85 Years   (Adult, Senior)","","36","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","0220080303","October 13, 2009","April 2009","January 2013","March 18, 2014","March 2014","No Study Results Posted","null","January 2013","Cellular and peptide pro-angiogenic markers in patients with hepatic malignancy before and after SIRT|Imaging based predictors","https://ClinicalTrials.gov/show/NCT00994370"
4131,"NCT01789515","Defunctioning Stoma and Postoperative Morbidity","Completed","No Results Available","Loopileostomy|Fast Track Program,(Enhanced Recovery After Surgery (ERAS))","","Karolinska Institutet|Ersta Hospital, Sweden","Both","18 Years to 90 Years   (Adult, Senior)","","287","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2012/538-31/1","September 28, 2012","May 2012","December 2013","March 11, 2014","March 2014","No Study Results Posted","null","December 2013","Clinical anastomotic leakage|Permanent stoma","https://ClinicalTrials.gov/show/NCT01789515"
4132,"NCT00539877","Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding","Completed","No Results Available","Stomach Neoplasms","Drug: irinotecan","Samsung Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1","17","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-05-017","October 3, 2007","October 2004","August 2007","June 22, 2010","June 2010","No Study Results Posted","null","December 2006","The objectives of this study are to assess the feasibility, to determine the maximum tolerated dose, and to assess the toxicities of intraperitoneally administered CPT-11 in gastric cancer patients with peritoneal seeding.","https://ClinicalTrials.gov/show/NCT00539877"
4133,"NCT00875147","Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases","Completed","No Results Available","Colorectal Liver Metastases","Drug: bevacizumab","University of Zurich","Both","18 Years to 90 Years   (Adult, Senior)","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","StV 12-2009","April 2, 2009","April 2009","September 2009","January 22, 2010","January 2010","No Study Results Posted","null","August 2009","Overall complications|specific complications such as liver insufficiency, length of hospital stay","https://ClinicalTrials.gov/show/NCT00875147"
4134,"NCT01596374","Clinical Relevance of ROS (V-ros UR2 Sarcoma Virus Oncogene Homolog) Aberrations in Solid Tumours","Recruiting","No Results Available","Cancer","","National University Hospital, Singapore","Both","21 Years and older   (Adult, Senior)","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2011/01714","April 2, 2012","August 2011","null","December 10, 2013","December 2013","No Study Results Posted","null","July 2014","Characterize the frequency of ROS gene fusion, ROS protein overexpression and ROS gene mutations in cell lines and tumors|Identify novel ROS gene variants in human solid tumors harboring ROS aberrations using next generation sequencing (NGS)|Determine the functional relevance of novel ROS gene variants identified with NGS|Characterize the sensitivity of cells with functionally relevant ROS aberrations using ROS tyrosine kinase inhibitors","https://ClinicalTrials.gov/show/NCT01596374"
4135,"NCT00162669","Bevacizumab in Advanced Hepatocellular Carcinoma","Recruiting","No Results Available","Hepatocellular Carcinoma","Drug: bevacizumab","Gustave Roussy, Cancer Campus, Grand Paris|Hoffmann-La Roche","Both","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IGR 1123|HCC-Avastin","September 8, 2005","May 2005","null","September 7, 2006","September 2006","No Study Results Posted","null","null","The main response parameter will be the disease control rate, defined by the objective response and stable disease rate (Response Evaluation Criteria in Solid Tumors [RECIST criteria]) after two consecutive tumor evaluations during treatment.|Overall survival, progression-free survival, toxicity (National Cancer Institute-Common Toxicity Criteria Version 3 [NCI-CTC V3])|Evaluation of vascular changes will be performed using Doppler ultrasound with injection of sonographic contrast agent","https://ClinicalTrials.gov/show/NCT00162669"
4136,"NCT01980134","The MORDIS Study Clinical Investigational Plan","Recruiting","No Results Available","Adenoma","","SpectraScience|Azienda Ospedaliera Universitaria Policlinico|European Institute of Oncology|Institut des Maladies de l’Appareil digestif|European Georges Pompidou Hospital|Katholieke Universiteit Leuven|Innere Medizin I Interdisziplinäre Endoskopie Universitätsklinikum Tübingen|University of Erlangen-Nürnberg|Copenhagen University Hospital at Herlev|Skane University Hospital|Institute for Clinical and Experimental Medicine","Both","18 Years and older   (Adult, Senior)","","1200","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","MORDIS Study 010044-002","November 1, 2013","December 2013","November 2016","April 12, 2016","April 2016","No Study Results Posted","MORDIS","August 2016","To demonstrate potential of the WavSTAT4 Optical Biopsy System to predict adenomatous histology with a NPV > = 90% for diminutive colorectal lesions.|Improved determination of post-polypectomy surveillance intervals","https://ClinicalTrials.gov/show/NCT01980134"
4137,"NCT02356081","eSMART Trial to Evaluate ASyMS","Recruiting","No Results Available","Cancer","Other: ASyMS intervention Group","University of Surrey|University College Dublin|King's College London|University of California, San Francisco|University of Athens|Medical University of Vienna|University of Oslo|University of Dundee|European Cancer Patient Coalition (ECPC)|Docobo Ltd","Both","18 Years and older   (Adult, Senior)","","1108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","CRC331","January 26, 2015","February 2015","null","May 11, 2016","January 2015","No Study Results Posted","null","February 2019","Memorial Symptom Assessment Scale (MSAS)","https://ClinicalTrials.gov/show/NCT02356081"
4138,"NCT01770301","Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)","Recruiting","No Results Available","Ovarian Sex-cord Stromal Tumor","Drug: Paclitaxel|Drug: Bevacizumab","ARCAGY/ GINECO GROUP|Roche Pharma AG","Female","18 Years and older   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ALIENOR (GINECO-OV222)","January 15, 2013","February 2013","January 2021","June 20, 2016","June 2016","No Study Results Posted","ALIENOR","June 2016","clinical benefit of combining bevacizumab treatment to weekly paclitaxel","https://ClinicalTrials.gov/show/NCT01770301"
4139,"NCT02865889","Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications","Completed","No Results Available","UTERINE CERVICAL NEOPLASMS|ENDOMETRIAL NEOPLASMS","Procedure: Laparoscopy in Gynecologic Oncologic Indications|Procedure: Conventional surgery (abdominal radical surgery)","Institut Paoli-Calmettes","Female","18 Years and older   (Adult, Senior)","","343","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STIC COELCO","August 5, 2016","September 2008","null","August 9, 2016","August 2016","No Study Results Posted","null","March 2013","Cost comparison between Conventional vs Robotic-Assisted Laparoscopy|Comparison of the effectiveness of procedures (Conventional vs Robotic-Assisted Laparoscopy)","https://ClinicalTrials.gov/show/NCT02865889"
4140,"NCT01243775","BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Belotaxel|Drug: Belloxa","Chonnam National University Hospital|Chong Kun Dang Pharmaceutical","Both","18 Years and older   (Adult, Senior)","Phase 2","33","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","m601NSC10B","November 15, 2010","November 2010","January 2013","July 20, 2015","July 2015","July 19, 2015","BELOXAN","January 2013","Response Rate|Progression Free Survival|Overall Survival|Neutropenia Grade 3-4","https://ClinicalTrials.gov/show/NCT01243775"
4141,"NCT00587236","Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis","Completed","No Results Available","Colitis, Ulcerative|Cholangitis, Sclerosing","","Mayo Clinic","Both","18 Years to 75 Years   (Adult, Senior)","","65","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","5-06","December 21, 2007","March 2006","August 2010","January 13, 2016","January 2016","No Study Results Posted","null","August 2010","Compare the dysplasia detection rate between scope modalities and biopsy type; surveillance or targeted biopsies in CUC patients with concurrent PSC.|Assess the impact of patient related factors on the difference in dysplasia detection rate between while light colonoscopy and the AFI and NBI techniques in patients with CUC and concurrent PSC.","https://ClinicalTrials.gov/show/NCT00587236"
4142,"NCT01155440","Bowel Function After Laparoscopic Colon Surgery: Effect of IV Lidocaine","Completed","No Results Available","Colon Cancer|Inflammatory Bowel Diseases|Diverticulitis","Drug: Lidocaine|Procedure: Thoracic epidural block","McGill University Health Center","Both","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","GEN-06-023(1)","June 30, 2010","June 2009","October 2011","November 24, 2011","November 2011","No Study Results Posted","null","October 2011","Restoration of bowel function|Pain intensity","https://ClinicalTrials.gov/show/NCT01155440"
4143,"NCT00779272","Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases","Completed","No Results Available","Colorectal Liver Metastases","","University of Zurich","Both","Child, Adult, Senior","","184","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","StV 29-2008","October 23, 2008","September 2008","October 2008","October 23, 2008","October 2008","No Study Results Posted","null","October 2008","Postoperative Complications and liver regeneration","https://ClinicalTrials.gov/show/NCT00779272"
4144,"NCT02260349","Interest of Indocyanine Green in Neoplastic Prostatic Tissue","Withdrawn","No Results Available","Prostatic Neoplasms","Drug: indocyanine green infusion","Centre Hospitalier Universitaire de Saint Etienne","Male","18 Years and older   (Adult, Senior)","Phase 3","0","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","1308190|2014-000218-67","September 25, 2014","April 2014","February 2016","March 9, 2016","March 2016","No Study Results Posted","null","February 2016","Sensitivity of indocyanine green|Specificity of indocyanine green","https://ClinicalTrials.gov/show/NCT02260349"
4145,"NCT02253303","Evaluation of the Extraction-site, - Midline Incision vs Off-midline Incision-","Not yet recruiting","No Results Available","Colon Cancer","Other: midline incision or off-midline incision","Hiroki Yamaue|Katsunari Takifuji|Wakayama Medical University","Both","Child, Adult, Senior","","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","WMU1398","September 24, 2014","October 2014","September 2017","September 26, 2014","September 2014","No Study Results Posted","null","September 2017","cosmetic effect|Quality of life","https://ClinicalTrials.gov/show/NCT02253303"
4146,"NCT00298545","Effect of Vitamin D and Calcium on Genes in the Colon","Completed","No Results Available","Colorectal Polyps|Colorectal Adenoma|Adenocarcinoma","Drug: placebo and Calcitriol|Drug: Calcium and Calcitriol","Rockefeller University","Both","48 Years to 72 Years   (Adult, Senior)","Phase 1","10","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","RUH IRB # PHO-0554","March 1, 2006","November 2005","May 2009","November 17, 2011","November 2011","No Study Results Posted","null","May 2009","Gene expression related to proliferation, apoptosis, and differentiation of human rectal mucosal cells|Expression of additional genes involved in the cell properties noted above","https://ClinicalTrials.gov/show/NCT00298545"
4147,"NCT01159678","Online Psychoeducation for Sexual Dysfunction in Cancer Survivors","Completed","No Results Available","Sexual Dysfunction","Behavioral: online psychoeducation","University of British Columbia|Canadian Institutes of Health Research (CIHR)","Both","19 Years to 70 Years   (Adult, Senior)","","112","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H10-01032","June 22, 2010","October 2010","April 2014","June 11, 2015","June 2015","No Study Results Posted","OPES","October 2013","Sexual distress|Sexual function","https://ClinicalTrials.gov/show/NCT01159678"
4148,"NCT02407925","Implementation of Optical Diagnosis for Diminutive Polyps Amongst Endoscopists: Training and Long-term Quality Assurance","Recruiting","No Results Available","Colonoscopy|Colonic Polyps","Behavioral: Feedback","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Dutch Digestive Diseases Foundation","Both","55 Years to 75 Years   (Adult, Senior)","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","W14_099|NTR4635|FP 13","March 19, 2015","January 2015","January 2017","March 31, 2015","March 2015","No Study Results Posted","DISCOUNT2","August 2016","the number of training rounds needed until endoscopists reach a clinical acceptable accuracy of predicting histology of subcentimetric (1-9 mm) colorectal lesions using NBI|the number of qualified endoscopists that are able to maintain a clinical acceptable accuracy of predicting histology of subcentimetric (1-9 mm) colorectal lesions using NBI over a year, either with and without regular interim feedback.|the number of the accredited endoscopists that is able to reach a negative predictive value of at least 90% for predicting neoplastic diminutive (1-5mm) and small (6-9mm) colorectal lesions in the rectosigmoid|the number of diminutive (1-5mm) and small (6-9mm) lesions that are correctly predicted with high confidence|the number of patients in whom a surveillance interval (according to the Dutch surveillance guideline) can be advised directly after colonoscopy, based on the endoscopic diagnosis|the number of patients in whom the surveillance interval (according to the Dutch surveillance guideline) is correctly predicted based on endoscopic diagnosis|the number of correctly diagnosed sessile serrated adenoma/polyps in diminutive (1-5mm) and small (6-9mm) polyps|the sensitivity for predicting neoplastic histology per endoscopist, time frame and feedback or no feedback group|the costs in euros that would have been saved by multiplying the amount of high confidence predicted diminutive and small polyps with the histopathology costs per lesion","https://ClinicalTrials.gov/show/NCT02407925"
4149,"NCT01575730","Cytoreduction Followed by Normothermic Versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion (HIPEC): a Study in Peritoneal Carcinomatosis","Recruiting","No Results Available","Peritoneal Carcinomatosis","Procedure: Hyperthermic intraoperative Peritoneal Chemoperfusion|Procedure: Hyperthermic intraoperative Peritoneal Chemoperfusion|Drug: Hyperthermic intraoperative Peritoneal Chemoperfusion","University Hospital, Ghent|University Ghent","Both","18 Years to 75 Years   (Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012/237|2012-000701-77","April 6, 2012","June 2012","July 2015","December 4, 2014","December 2014","No Study Results Posted","null","July 2015","Morbidity|Mortality|Area under the perfusate concentration versus time curve (AUC) of platinum|Area under the plasma concentration versus time curve (AUC) of platinum|Tissue Concentration (Cmax) of Platinum","https://ClinicalTrials.gov/show/NCT01575730"
4150,"NCT00411762","A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma","Completed","Has Results","Pancreatic Cancer","Drug: Capecitabine|Drug: PHY906","Yale University|PhytoCeutica|National Comprehensive Cancer Network|Roche Pharma AG","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","25","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0512000905","December 13, 2006","December 2006","December 2009","March 19, 2015","March 2015","March 10, 2015","null","December 2009","Median Progression Free Survival|Median Overall Survival","https://ClinicalTrials.gov/show/NCT00411762"
4151,"NCT02516501","Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition","Recruiting","No Results Available","Neoplasms","Dietary Supplement: Ketogenic breakfast|Dietary Supplement: Ketogenic diet|Radiation: Radio(chemo)therapy","MVZ Leopoldina GmbH|dr. reinwald healthcare gmbh+co. kg|Vitaflo International, Ltd","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1","85","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","15025","July 31, 2015","June 2015","null","March 21, 2016","March 2016","No Study Results Posted","KETOCOMP","June 2018","Dropout rate|Body composition|Phase angle|Quality of life|Blood parameters|Regression grade (TNM classification)|Normal tissue toxicity after RT","https://ClinicalTrials.gov/show/NCT02516501"
4152,"NCT01431703","The Learning Curve of NBI With Magnification in the Diagnosis of Colorectal Lesions","Completed","No Results Available","Colorectal Lesion","","Zhizheng Ge|Shanghai Jiao Tong University School of Medicine","Both","16 Years to 85 Years   (Child, Adult, Senior)","","10050956","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","rjyyxhk0923","September 8, 2011","May 2010","April 2011","September 8, 2011","September 2011","No Study Results Posted","null","April 2011","","https://ClinicalTrials.gov/show/NCT01431703"
4153,"NCT00932490","Tailored Intervention Protocol for Oral Chemotherapy Adherence","Completed","No Results Available","Cancer","Behavioral: Nurse Coaching","Duke University|National Cancer Institute (NCI)","Both","18 Years and older   (Adult, Senior)","","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","Pro00015563|1R15CA139398-01|3031779","July 2, 2009","August 2009","February 2012","July 14, 2014","November 2012","No Study Results Posted","null","February 2012","Adherence to Oral Chemotherapy Medication","https://ClinicalTrials.gov/show/NCT00932490"
4154,"NCT02168426","Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus","Completed","No Results Available","Patient Under Going Colorectal and Stomach Cancer Surgery","Procedure: Guardix|Procedure: Seprafilm","Gachon University Gil Medical Center","Both","25 Years to 90 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","GDIRB2013-15","June 18, 2014","August 2013","February 2015","August 28, 2015","August 2015","No Study Results Posted","null","December 2014","ileus rate|adverse effect rate","https://ClinicalTrials.gov/show/NCT02168426"
4155,"NCT00613769","Orally Administered Trimethoprim-sulfamethoxazole and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery","Completed","No Results Available","Infection Prophylaxis in Colo Rectal Surgery","Drug: trimethoprim-sulfamethoxazole + metronidazole|Drug: cefuroxime and metronidazole","Halmstad County Hospital","Both","18 Years and older   (Adult, Senior)","Phase 4","1073","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TSM|EudraCT number 2006-006575-20","January 31, 2008","September 2007","May 2012","September 27, 2012","September 2012","No Study Results Posted","null","December 2011","Cutaneous-,subcutaneous and intraabdominal infections|Non infectious wound complications|Complications to the anastomosis|Adverse reaction of given drug|Other post operative infections|Septicaemia","https://ClinicalTrials.gov/show/NCT00613769"
4156,"NCT02192216","The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy","Terminated","No Results Available","Neoplasms","Behavioral: Exercise","Department of Public Health, Denmark|Aarhus University Hospital","Both","18 Years and older   (Adult, Senior)","","16","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","SKDM2014|41408","July 4, 2014","February 2014","December 2016","September 1, 2015","September 2015","No Study Results Posted","null","September 2015","Changes in body composition|Changes in underlying biological mechanisms associated with changes in muscle mass|Changes in dynamic muscle strength|Changes in aerobic performance|Changes in cancer related fatigue and quality of life|Changes in functional performance","https://ClinicalTrials.gov/show/NCT02192216"
4157,"NCT01587976","Health Related Quality of Life After Surgery and Oncological Treatment of Colorectal Liver Metastases","Recruiting","No Results Available","Metastasis|Quality of Life","","Haukeland University Hospital|Helse Stavanger HF","Both","Child, Adult, Senior","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2011/570","February 27, 2012","June 2011","December 2015","March 27, 2015","September 2013","No Study Results Posted","HQOL","November 2015","Health related quality of life after liver resection in combination with chemotherapy|Identifying possible clinical parameters influencing the HQoL after liver resection.","https://ClinicalTrials.gov/show/NCT01587976"
4158,"NCT01617382","Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed","Recruiting","No Results Available","Peritoneal Carcinomatosis|Pseudomyxoma Peritonei|Peritoneal Mesothelioma","","Universitaire Ziekenhuizen Leuven","Both","Child, Adult, Senior","","125","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","S-54350","June 8, 2012","May 2012","June 2019","July 28, 2016","July 2016","No Study Results Posted","HIPEC","June 2018","To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.","https://ClinicalTrials.gov/show/NCT01617382"
4159,"NCT01816438","A French Non Interventional Multicentric Cohort Study in Patients With Colorectal Dysplasia","Recruiting","No Results Available","Hyperplasia|Dysplasia","","Hôpital Edouard Herriot","Both","18 Years to 80 Years   (Adult, Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SFED N°100","March 20, 2013","July 2013","July 2017","August 29, 2016","August 2016","No Study Results Posted","null","July 2017","endoscopies results","https://ClinicalTrials.gov/show/NCT01816438"
4160,"NCT01737515","Investigation of Waist Circumference and Waist/Hip Ratio as a Predictive Risk Factor for Morbidity and Mortality After Colorectal Surgery","Completed","No Results Available","Obesity","Other: Abdominal waist and hip circumference","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","Both","18 Years and older   (Adult, Senior)","","1415","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AbdoWaistHip","November 27, 2012","November 2008","June 2010","November 27, 2012","November 2012","No Study Results Posted","null","December 2009","Morbidity after colorectal surgery|Mortality after colorectal surgery","https://ClinicalTrials.gov/show/NCT01737515"
4161,"NCT02239536","Hot Snare Versus Hot Snare Polypectomy With Saline Injection for Colorectal Polyps","Enrolling by invitation","No Results Available","Polyp of Large Intestine","Procedure: removal of eligible polyps using hot snare polypectomy technique|Procedure: removal of eligible polyps using hot snare polypectomy after saline injection technique","Seoul St. Mary's Hospital|St. Vincent's Medical Center|Incheon St.Mary's Hospital","Both","30 Years to 85 Years   (Adult, Senior)","Phase 4","310","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CMC-0039","September 10, 2014","June 2014","June 2016","September 10, 2014","September 2014","No Study Results Posted","HSP vs HSPASI","June 2016","Complete histologic polyp eradication rate|Time taken for polypectomy|Rates of adverse events","https://ClinicalTrials.gov/show/NCT02239536"
4162,"NCT02687412","Fast-track Surgery After Gynecological Oncology Surgery","Not yet recruiting","No Results Available","Length of Stay|Postoperative Complications","Procedure: pre-operative assessment, counseling and education|Procedure: Preoperative nutritional drink up to 4 h prior to surgery|Procedure: only oral intestinal cleaner 12 h pre-operation|Procedure: preoperative treatment with carbohydrates|Procedure: fast solid|Procedure: avoiding hypothermia|Procedure: Postoperative glycaemic control|Procedure: postoperative nausea and vomiting (PONV) control;|Procedure: early postoperative diet|Procedure: pre-operative fasting at least 8h|Procedure: Oral bowel preparations|Procedure: intra-operative lowtemperature at 34.7 ±0.6 degree centigrade|Procedure: began to take solid diet after anal exhaust","Ling Cui|Sichuan Cancer Hospital and Research Institute","Female","18 Years to 70 Years   (Adult, Senior)","","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SichuanCHRI","February 2, 2016","April 2016","December 2017","February 23, 2016","February 2016","No Study Results Posted","null","April 2017","Length of hospitalization post-operation|Complications|infection,|postoperative nausea and vomiting (PONV)|ileus|Postoperative haemorrhage|Postoperative thrombosis|APACHE II score","https://ClinicalTrials.gov/show/NCT02687412"
4163,"NCT01835119","Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies","Recruiting","No Results Available","Postoperative Ileus","Drug: gum","Erzincan Military Hospital","Female","Child, Adult, Senior","Phase 4","152","Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","gungorduk14","April 10, 2013","January 2012","April 2013","April 17, 2013","April 2013","No Study Results Posted","null","April 2013","postoperative flatus pass time|duration of hospital stay|gastrointestinal disturbance|time to first bowel movement|Time to first defaecation","https://ClinicalTrials.gov/show/NCT01835119"
4164,"NCT02059603","Electroacupuncture Versus Fast-track Perioperative Program for Laparoscopic Colorectal Surgery","Recruiting","No Results Available","Postoperative Ileus","Procedure: Electroacupuncture|Procedure: Fast-track program","Chinese University of Hong Kong","Both","18 Years to 80 Years   (Adult, Senior)","Phase 3","164","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRE-2013.009","February 10, 2014","January 2014","December 2015","February 10, 2014","February 2014","No Study Results Posted","null","December 2015","Time to defecation|Total postoperative hospital stay|Time of first passing flatus reported by the patients|Time that the patients tolerated solid diet|Time to walk independently|Pain scores on visual analog scale|Morbidity|Mortality|Readmission rate|Quality of life","https://ClinicalTrials.gov/show/NCT02059603"
4165,"NCT02461979","The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis","Recruiting","No Results Available","Liver Cancer","Other: The VDR genotype","Sherief Abd-Elsalam|Tanta University","Both","Child, Adult, Senior","","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","liver cancer","May 31, 2015","February 2015","December 2016","March 9, 2016","March 2016","No Study Results Posted","null","December 2016","number of HCC patients with abnormal (APAL) VDR polymorphism","https://ClinicalTrials.gov/show/NCT02461979"
4166,"NCT00522509","Preoperative Hepatic Arterial Infusion Chemotherapy","Active, not recruiting","No Results Available","Colorectal Liver Metastases","Drug: Floxuridine FUDR","IRCCS San Raffaele","Both","18 Years to 90 Years   (Adult, Senior)","","null","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","Neoadjuvant HAIC","August 28, 2007","December 1995","null","August 28, 2007","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00522509"
4167,"NCT02056405","Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery","Recruiting","No Results Available","Postoperative Ileus","Drug: Mosapride|Drug: Placebo","Hospital Italiano de Buenos Aires","Both","18 Years to 85 Years   (Adult, Senior)","Phase 4","90","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","2104","January 31, 2014","December 2015","December 2017","December 16, 2015","December 2015","No Study Results Posted","ILEUS","December 2016","Number of days after Surgery until the recovery of bowel movement|Number of patients to develop adverse reactions to Mosapride","https://ClinicalTrials.gov/show/NCT02056405"
4168,"NCT02678663","Injection-Assisted Cold Snare Polypectomy Versus Endoscopic Mucosal Resection for Small Colorectal Polyps","Recruiting","No Results Available","Colonic Polyps","Procedure: Injection-assisted Cold Snare Polypectomy|Procedure: Endoscopic Mucosal Resection","Benizelion General Hospital","Both","18 Years and older   (Adult, Senior)","","162","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","1513/3.2.2016","February 3, 2016","January 2016","November 2016","February 5, 2016","February 2016","No Study Results Posted","null","November 2016","Complete Resection Rate|Incidence of complications (intraprocedural bleeding, postprocedural bleeding, post-polypectomy syndrome, perforation).|Necessity of hemostasis (due to intraprocedural or postprocedural bleeding)|Polyp retrieval rate","https://ClinicalTrials.gov/show/NCT02678663"
4169,"NCT01646242","Cold Snare Versus Double Biopsy Polypectomy Technique for Removal of Diminutive Colorectal Polyps","Completed","No Results Available","Polyp of Large Intestine","Procedure: removal of eligible polyps using cold snare polypectomy technique|Procedure: removal of eligible polyps using double biopsy technique","Kyunghee University Medical Center","Both","20 Years and older   (Adult, Senior)","Phase 4","54","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CPP2012","July 16, 2012","July 2012","June 2013","October 13, 2014","October 2014","No Study Results Posted","null","June 2013","Complete histologic polyp eradication rate|Time taken for polypectomy (complete visual eradication of each polyp)|Successful tissue retrieval rate of removed tissues|Rates of adverse events|Complete visual polyp eradication rate","https://ClinicalTrials.gov/show/NCT01646242"
4170,"NCT00747292","Peri-Operative Management of Patients Undergoing Laparoscopic Colorectal Surgery","Recruiting","No Results Available","Neoplasm|Diverticular Disease|Analgesia","Procedure: epidural|Procedure: PCA|Procedure: Spinal","Minimal Access Therapy Training Unit","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","99","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07/H1111/70","September 4, 2008","December 2007","October 2009","September 4, 2008","September 2008","No Study Results Posted","null","October 2009","Length of hospital stay|Pain, time till flatus, time till bowels open, incidence of nausea and vomiting, quality of life","https://ClinicalTrials.gov/show/NCT00747292"
4171,"NCT02042794","Pringle Manoeuvre Versus Portal Vein Clamping for Liver Resection","Recruiting","No Results Available","Liver Metastasis","","The Leeds Teaching Hospitals NHS Trust","Both","18 Years and older   (Adult, Senior)","","80","Other","Observational","Time Perspective: Prospective","PB-PG-0711-25080","January 16, 2014","June 2013","null","February 20, 2015","February 2015","No Study Results Posted","null","December 2015","The ability to recruit and randomise patients into the study","https://ClinicalTrials.gov/show/NCT02042794"
4172,"NCT01839292","ComVi and D-type Stent in Malignant GOO","Completed","No Results Available","Gastric Outlet Obstruction","Device: uncovered D-type stent insertion|Device: double-layered ComVi stent insertion","Ajou University School of Medicine|National Cancer Center, Korea|Kyungpook National University|Hallym University|The Catholic University of Korea|Seoul National University|DongGuk University","Both","18 Years and older   (Adult, Senior)","","89","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","AJIRB-DEV-DE4-10-009","April 18, 2013","April 2010","null","April 22, 2013","April 2013","No Study Results Posted","null","August 2012","the stent patency time from stent insertion to restenosis due to stent malfunction or death|stent malfunction (e.g., stent migration or occlusion due to tumor ingrowth/overgrowth) and the reintervention rate","https://ClinicalTrials.gov/show/NCT01839292"
4173,"NCT00124163","Evaluation of Stool Tagging for Improved Patient Compliance","Recruiting","No Results Available","Colon Cancer|Polyps","Procedure: Imaging procedure of CT colonography","Center for Diagnostic Imaging","Both","45 Years to 80 Years   (Adult, Senior)","Phase 1","60","Other","Observational","Allocation: Random Sample|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","633","July 25, 2005","July 2005","null","January 31, 2006","January 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00124163"
4174,"NCT02086123","Randomized Study Comparing the Use of Epidural Analgesia to Intravenous Narcotics for Laparoscopic Colorectal Resection.","Active, not recruiting","No Results Available","Pain, Postoperative","Procedure: Epidural Analgesia|Procedure: Parenteral Analgesia (Intravenous)","University of California, Irvine","Both","18 Years and older   (Adult, Senior)","Phase 2","87","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","HS#2011-8564","November 20, 2013","May 2012","April 2015","November 6, 2014","November 2014","No Study Results Posted","null","February 2015","Length of Hospital Stay|Return of bowel function","https://ClinicalTrials.gov/show/NCT02086123"
4175,"NCT00681499","Quality of Life After Liver Resection","Completed","No Results Available","Liver Diseases|Liver Neoplasms","","University of Bern","Both","18 Years and older   (Adult, Senior)","","198","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KEK 18/08","May 19, 2008","February 2008","January 2014","November 12, 2015","November 2015","No Study Results Posted","null","January 2014","Quality of Life","https://ClinicalTrials.gov/show/NCT00681499"
4176,"NCT02645864","Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: Apatinib|Drug: Irinotecan","Peking University|Jiangsu HengRui Medicine Co., Ltd.","Both","18 Years to 70 Years   (Adult, Senior)","Phase 1","9","Other|Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AHEAD-HBE001","December 23, 2015","January 2016","December 2017","March 22, 2016","March 2016","No Study Results Posted","null","December 2016","Dose limiting toxicity|Maximum tolerance dose|Objective response rate|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02645864"
4177,"NCT02353533","Endoscopic Full-thickness REsection of Residual Colorectal Lesions - The FiRE Study","Recruiting","No Results Available","Adenoma","Device: over- the- scope full- thickness resection device (FTRD)|Device: EMR","Technische Universität München","Both","18 Years and older   (Adult, Senior)","","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FiRE","January 23, 2015","January 2015","January 2017","November 5, 2015","November 2015","No Study Results Posted","FiRE","November 2016","Success of resection|Duration of procedure","https://ClinicalTrials.gov/show/NCT02353533"
4178,"NCT01112514","Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract","Completed","Has Results","High Risk Polyposis Syndrome|Distal Colonic Lesions|Colorectal Polyps","Drug: indocyanine green","Massachusetts General Hospital|Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Damon Runyon Cancer Research Foundation","Both","18 Years and older   (Adult, Senior)","","4","Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","09-398","April 27, 2010","February 2010","April 2013","January 8, 2014","January 2014","August 6, 2013","null","December 2010","Number of Neoplastic Lesions Detected","https://ClinicalTrials.gov/show/NCT01112514"
4179,"NCT00531739","SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery","Completed","No Results Available","Adhesions|Colectomy","Other: Polylactic Acid Sheet","Cytori Therapeutics","Both","18 Years and older   (Adult, Senior)","Phase 4","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","SURGIWRAP(TM)","September 18, 2007","March 2006","July 2009","October 5, 2010","October 2010","No Study Results Posted","null","null","Assess the efficacy of SurgiWrapTM in the prevention/reduction of Grade 2 or higher soft tissue attachments under the abdominal incision made during colorectal surgery|Clinical and radiographic evidence of bowel obstruction|The incidence and extent of soft tissue attachments under the abdominal incision and on the pelvic floor after colorectal surgery","https://ClinicalTrials.gov/show/NCT00531739"
4180,"NCT02696811","The Effects of Foods on Cell Damage Study","Recruiting","No Results Available","DNA Damage|Inflammation","Dietary Supplement: White carrots|Dietary Supplement: Oat biscuits","Newcastle University","Both","45 Years and older   (Adult, Senior)","","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","VEG_01","February 17, 2016","October 2015","December 2016","February 25, 2016","February 2016","No Study Results Posted","null","May 2016","Change in lymphocyte DNA damage from baseline after 6 weeks of carrot or oat supplementation in the diet, and after 6 weeks wash out (no carrots or oats).|Change in inflammation from baseline after 6 weeks of carrot or oat supplementation in the diet, and after 6 weeks wash out.|Analysis of faecal water from baseline after 6 weeks of carrot or oat supplementation in the diet, and after 6 weeks wash out to determine toxicity to colon epithelial cells.","https://ClinicalTrials.gov/show/NCT02696811"
4181,"NCT01367418","Effects of Anesthetic Technique on Immune and Inflammatory Systems Following Radical Prostatectomy","Completed","No Results Available","Prostate Cancer","Drug: Patient controlled analgesia (PCA)|Drug: Thoracic Epidural Analgesia (TEA)","Örebro University, Sweden","Male","50 Years to 78 Years   (Adult, Senior)","Phase 3","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","20110601","May 26, 2011","September 2010","March 2012","March 16, 2012","March 2012","No Study Results Posted","AIMS","March 2012","Natural Killer Cell activity|IL-2|IL-6|TNF alpha|Serum cortisol","https://ClinicalTrials.gov/show/NCT01367418"
4182,"NCT02650427","A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection","Recruiting","No Results Available","Hepato Carcinoma","Drug: Sitagliptin","Institut National de la Santé Et de la Recherche Médicale, France","Both","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C15-41|2015-002968-17","December 22, 2015","February 2016","July 2018","February 11, 2016","February 2016","No Study Results Posted","HCC-DPPIV","November 2017","Safety (Number of adverse events. Toxicity grade > 3)|DPPIV Activity|CXCL10 truncation|Immune cells trafficking|Infiltration of leucocytes in tumor tissue","https://ClinicalTrials.gov/show/NCT02650427"
4183,"NCT02569905","Effect of Parecoxib Sodium and Flurbiprofen Injection on Postoperative Shivering","Completed","No Results Available","Postoperative Shivering","Drug: parecoxib sodium|Drug: flurbiprofen|Drug: saline","Guangxi Medical University","Both","21 Years to 62 Years   (Adult)","Phase 4","166","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","2014032605","October 1, 2015","April 2014","April 2015","October 23, 2015","October 2015","No Study Results Posted","null","April 2015","shivering|visual analogue score|sedation scores|incidence of postoperative nausea and vomiting","https://ClinicalTrials.gov/show/NCT02569905"
4184,"NCT02052557","The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery","Completed","No Results Available","Post-operative Pain|Colon Cancer|Diverticulitis","Drug: Bupivacaine|Drug: Bupivacaine liposome suspension","Des Moines University|Mercy Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 4","56","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Supportive Care","MMC2013-09","January 24, 2014","February 2013","December 2013","January 30, 2014","January 2014","No Study Results Posted","null","December 2013","PCA (patient controlled analgesia) usage|Oral Pain Medications|Total IV (intravenous) narcotic used|Total Oral narcotic used|Length of Stay|return of bowel function|Readmission|Toradol Use|Ofirmev|Nausea Medication|Foley catheter removal|Postoperative pain|Post operative Satisfaction|Home oral narcotic use","https://ClinicalTrials.gov/show/NCT02052557"
4185,"NCT00141193","Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)","Completed","No Results Available","Colorectal Adenoma","Drug: Celecoxib","Pfizer","Both","30 Years and older   (Adult, Senior)","Phase 3","1561","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","EQ4-00-02-018|A3191107","August 30, 2005","February 2001","May 2007","August 5, 2008","August 2008","No Study Results Posted","PRESAP","May 2007","To evaluate the effects of celecoxib in reducing the proportion of subjects with new colorectal adenomas post baseline polypectomy after Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.|The number of colorectal adenomas in study subjects|the histopathologic grade of colorectal adenomas|the size of colorectal adenomas measured after one year and three years of study drug use.","https://ClinicalTrials.gov/show/NCT00141193"
4186,"NCT02143505","Study of Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence","Recruiting","No Results Available","Colorectal Adenoma","Drug: Ca plus vit D","Shanghai Jiao Tong University School of Medicine|Ministry of Science and Technology of the People´s Republic of China","Both","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","900","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2014BAI09B05","May 17, 2014","March 2014","February 2019","May 17, 2014","May 2014","No Study Results Posted","null","February 2017","The primary objective of this study is to investigate recurrence rates of colorectal adenoma (CRA) after calcium plus vitamin D intervention.|The recurrence rates of advanced colorectal adenoma (A-CRA) after calcium plus vitamin D intervention.","https://ClinicalTrials.gov/show/NCT02143505"
4187,"NCT00486512","Chemoprevention of Colorectal Adenomas","Terminated","No Results Available","Adenomatous Polyps","Drug: aspirin, 1,25-dihydroxycholecalciferol, calcium|Drug: placebo","Colotech A/S","Both","40 Years to 75 Years   (Adult, Senior)","Phase 3","1000","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","COLO CP-01-US","June 12, 2007","June 2007","June 2012","February 4, 2011","February 2011","No Study Results Posted","null","June 2012","cumulative frequency of recurrence of colorectal adenomas|number and size of colorectal adenomas measured after three years of using the study drug|durability of treatment effect for two years post-treatment","https://ClinicalTrials.gov/show/NCT00486512"
4188,"NCT00227526","Enhancing Outcomes After Colon Surgery","Completed","No Results Available","Colorectal Surgery","Behavioral: Prehabilitation","McGill University|Canadian Anesthesiologists' Society","Both","18 Years and older   (Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","REC02-053","September 27, 2005","February 2005","December 2008","September 2, 2010","September 2010","No Study Results Posted","null","December 2008","6 Minute Walk Test|V02 max and submax|SF-36 - Short form 36|CHAMPS - Community Healthy Activities Model Program for Seniors|Hospital Anxiety Depression Scale - HADS|Fatigue and Pain VAS|Visual Analogue Mood States (VAMS)|2Minute Walk Test|Complications: infection (wound, sepsis, urinary, lung); bleeding; wound dehiscence; technical complications (ileus, anastomotic leakage); stroke, MI, DVT/PE, delirium, fall w/wo injury; malnutrition; urinary retention; respiratory failure|Charges for bed day: surgical procedure; surgeon/anaesthesiologist; pre, post and follow-up tests and procedures; visits; follow-up medications","https://ClinicalTrials.gov/show/NCT00227526"
4189,"NCT01894685","Mesalazine Effects in Sporadic Colorectal Adenoma Patients","Completed","No Results Available","Sporadic Colorectal Adenoma","Drug: Mesalazine|Drug: Placebo","UMC Utrecht","Both","50 Years to 75 Years   (Adult, Senior)","Phase 2","74","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NL36557.041.11","July 3, 2013","July 2012","June 2015","December 6, 2015","December 2015","No Study Results Posted","null","June 2015","Apoptotic index|Proliferation index|Expression of β-catenin signaling pathway","https://ClinicalTrials.gov/show/NCT01894685"
4190,"NCT01388257","Anal Crohn Fistula Surgery","Recruiting","No Results Available","Crohn Disease|Fistula|Anoperineal Fistula|Anal Fistula","Procedure: All types of surgery procedures|Procedure: Simple seton drain removal","French Society of Coloproctology","Both","18 Years and older   (Adult, Senior)","","180","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SNFCP-001","July 4, 2011","October 2011","March 2017","June 6, 2012","June 2012","No Study Results Posted","FACC","March 2016","Percentage of patients having a clinical healing of their anoperineal fistulas in Crohn disease|Proportion of patients having more than half of their fistulas healed|Change in Crohn disease activity assessed by Crohn's Disease Activity Index (CDAI) and Perianal Disease Activity Index (PDAI)|Change in anal continence assessed by Wexner and Vaizey scores|Crohn's Disease Endoscopic Index of Severity (CDEIS)|Change in patients' quality of life, assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)|Change in fistula activity assessed by magnetic resonance imaging (MRI)|Change in discomfort and impact assessed by the patient using a visual analog scale (VAS)","https://ClinicalTrials.gov/show/NCT01388257"
4191,"NCT01844076","Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma","Recruiting","No Results Available","Colorectal Adenocarcinoma","Drug: Phase I (Quinacrine)|Drug: Capecitabine","Milton S. Hershey Medical Center","Both","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PSHCI 11-099","March 4, 2013","March 2014","April 2016","April 24, 2014","April 2014","No Study Results Posted","null","April 2015","Phase I - Tolerability and Safety|Phase II - Rate of Response","https://ClinicalTrials.gov/show/NCT01844076"
4192,"NCT02073552","Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid.","Completed","No Results Available","Colonoscopy Preparation","Drug: Polyethylene glycol 4000|Drug: Macrogol 3350 plus ascorbic acid","Fundación Canaria Rafael Clavijo para la Investigación Biomédica","Both","Child, Adult, Senior","Phase 4","472","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Diagnostic","REPREP1|2013-002506-31","February 25, 2014","May 2014","May 2016","June 24, 2016","September 2015","No Study Results Posted","REPREP1","December 2015","Colon cleansing|Tolerance of bowel preparation|Detection of colorectal neoplasia","https://ClinicalTrials.gov/show/NCT02073552"
4193,"NCT02448056","MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma","Not yet recruiting","No Results Available","Carcinoma, Hepatocellular|Marker, Biological","","National Taiwan University Hospital|Far Eastern Memorial Hospital","Both","20 Years and older   (Adult, Senior)","","150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","201504020RINC","May 10, 2015","June 2015","May 2025","May 14, 2015","May 2015","No Study Results Posted","null","May 2017","Patient survival","https://ClinicalTrials.gov/show/NCT02448056"
4194,"NCT00507091","Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination","Completed","No Results Available","Metastatic|Colorectal|Adenocarcinoma","Drug: ZD6474 (vandetanib) 100mg|Drug: Irinotecan|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: ZD6474 (vandetanib) 300mg","Genzyme, a Sanofi Company|Sanofi","Both","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D4200C00038","July 10, 2007","August 2005","June 2008","August 24, 2016","August 2016","No Study Results Posted","null","May 2006","Establish the safety & efficacy of ZD6474 w/5-fluorouracil,leucovorin & oxaliplatin to patients with advanced colorectal adenocarcinoma, by assessment of AEs, vital signs, clinical chemistry, hematology, urinalysis, ECG and physical examinations","https://ClinicalTrials.gov/show/NCT00507091"
4195,"NCT00969124","Impact of Experience on Results With the Third Eye Retroscope","Completed","No Results Available","Colorectal Neoplasia","Device: Third Eye Retroscope","Avantis Medical Systems","Both","Child, Adult, Senior","","328","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","Avantis TER 08-07","August 27, 2009","January 2009","October 2009","January 22, 2013","January 2013","No Study Results Posted","null","October 2009","Detection rates for adenomas and for all polyps by the Third Eye Retroscope in comparison to the standard colonoscope alone|Time spent during the withdrawal phase and total procedure time for colonoscopy using the Third Eye Retroscope","https://ClinicalTrials.gov/show/NCT00969124"
4196,"NCT02626091","Perfusion Evaluation by Real-time Fluorescence-based Enhanced Reality of Anastomosis","Recruiting","No Results Available","Sigmoid Diverticulosis|Sigmoid Diverticulitis|Colorectal Malignancy","Procedure: Left-sided colonic resection","IHU Strasbourg","Both","18 Years and older   (Adult, Senior)","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","15-005","December 3, 2015","January 2016","January 2018","August 31, 2016","August 2016","No Study Results Posted","PERFECT","January 2018","Correlation between the perfusion evaluated by the ICG fluorescence-based enhanced reality and the metabolic state of the intestine|Correlation between the intraoperative intestinal perfusion and the rate of anastomosis leakage|Distance between the resection site based on the surgeon's appreciation and the resection site based on the digital analysis and the peri-operative samplings","https://ClinicalTrials.gov/show/NCT02626091"
4197,"NCT00034190","Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma","Completed","No Results Available","Colorectal Adenocarcinoma","Drug: S-8184 Paclitaxel Injectable Emulsion","OncoGenex Technologies","Both","18 Years and older   (Adult, Senior)","Phase 2","28","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SON-8184-1066","April 23, 2002","March 2002","September 2007","June 2, 2009","June 2009","No Study Results Posted","null","September 2007","Determine the Objective Response Rate|To determine time to disease progression","https://ClinicalTrials.gov/show/NCT00034190"
4198,"NCT02859870","Evaluation of the Colonoscope With Vision to 330 ° (Full Spectrum Endoscopy) in the Detection of Colorectal Adenomas","Recruiting","No Results Available","Colorectal Adenoma","Device: FUSE-TM colonoscope","Institut Paoli-Calmettes","Both","18 Years and older   (Adult, Senior)","","131","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FUSE-TM-Colon-IPC 2015-002","August 2, 2016","March 2015","null","August 4, 2016","July 2016","No Study Results Posted","FUSETM-Colon","March 2016","Efficacy|Toxicity","https://ClinicalTrials.gov/show/NCT02859870"
4199,"NCT01663558","Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV","Withdrawn","No Results Available","Anal Dysplasia|Human Papilloma Virus|HIV","Drug: imiquimod|Procedure: ablative","United States Naval Medical Center, San Diego","Male","18 Years and older   (Adult, Senior)","Phase 4","0","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","23592103","August 9, 2012","May 2015","May 2016","August 18, 2016","August 2016","No Study Results Posted","null","December 2015","cytologic grade|HPV","https://ClinicalTrials.gov/show/NCT01663558"
4200,"NCT00487409","Random Comparison of LigaSure and Disposable Staples for Laparoscopic Surgery","Completed","No Results Available","Colonic Diseases|Rectal Diseases","Procedure: Bipolar electrosurgical generator and instruments|Procedure: Disposable stapling instruments","University Hospitals Cleveland Medical Center|Tyco Healthcare Group","Both","18 Years to 80 Years   (Adult, Senior)","","100","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","10-06-33","June 15, 2007","December 2006","November 2010","December 12, 2014","December 2014","No Study Results Posted","null","November 2010","this study will evaluate the surgical approach using the Ligasure device at six weeks post operative.|Will evaluate the surgical approach using electrocautery with surgical clips and staples","https://ClinicalTrials.gov/show/NCT00487409"
4201,"NCT01866436","Educational Study of Multimedia in Surgical Skills Training in Colorectal Surgery","Completed","No Results Available","Focus of Study: Cognitive Surgical Skill Acquisition","Other: Multimedia group|Other: Study Day Group","University of Sheffield|Ethicon Endo-Surgery|HCA International Limited|Digimed","Both","Child, Adult, Senior","","59","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)","SMBRER186","May 14, 2013","October 2011","January 2012","May 30, 2013","May 2013","No Study Results Posted","null","December 2011","Improvement in assessment scores following implementation of the teaching modality (Multimedia and Study day).|The association between change in scores and level of training and acceptability of multimedia as an educational resource.","https://ClinicalTrials.gov/show/NCT01866436"
4202,"NCT00356031","Bevacizumab and Radiation Therapy for Sarcomas","Recruiting","No Results Available","Soft Tissue Sarcoma|Fibrous Histiocytoma|Liposarcoma|Leiomyosarcoma|Fibrosarcoma|Synovial Sarcoma","Drug: Bevacizumab|Procedure: Radiation Therapy","Massachusetts General Hospital|National Institutes of Health (NIH)","Both","18 Years and older   (Adult, Senior)","Phase 2","28","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-090|1R21CA117128-01A1","July 21, 2006","July 2006","March 2010","April 27, 2010","April 2010","No Study Results Posted","null","March 2010","To determine the objective response rate for neoadjuvant bevacizumab combined with radiation therapy for intermediate and high-risk soft tissue sarcomas.|To analyze the biologic effects of this regimen on tumor vasculature, blood flow, and oxygenation|to obtain preliminary data regarding local control, distant control, disease-free survival, and overall survival with this regimen.","https://ClinicalTrials.gov/show/NCT00356031"
4203,"NCT01900717","Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)","Completed","No Results Available","Metastatic Colorectal Adenocarcinoma","Drug: LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified|Drug: LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks","Centre Hospitalier Universitaire Dijon","Both","75 Years and older   (Senior)","Phase 2","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","Bedenne PHRC K 2010.|2010-022080-34","July 12, 2013","April 2011","null","May 12, 2014","July 2013","No Study Results Posted","Prodige20","July 2013","Initial examination","https://ClinicalTrials.gov/show/NCT01900717"
4204,"NCT02109991","Safety, Tolerability and Performance Profile of the Cologuard Device CG-100 in Patients Undergoing Colorectal Surgery","Recruiting","No Results Available","Gastrointestinal Anastomosis","Device: CG-100 device","Cologuard Ltd.","Both","18 Years and older   (Adult, Senior)","","20","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLD-001","April 8, 2014","March 2014","null","January 28, 2016","January 2016","No Study Results Posted","null","December 2016","Rate of adverse events, and device related complications|Occurrence of anastomotic leakage when the CG-100 is used|Position of the device (internal sheath)|Assessment of the device's application technique ease of placement and extraction of the device performance|Determine subject tolerability of the device","https://ClinicalTrials.gov/show/NCT02109991"
4205,"NCT02865382","Detection of Colorectal Adenoma by Optical Enhancement Technology vs. High-Definition Colonoscopy","Not yet recruiting","No Results Available","Colonic Polyps","Procedure: white light was used for colonoscopy withdrawal|Procedure: OE mode was used for colonoscopy withdrawal","Yanqing Li|Shandong University","Both","18 Years to 80 Years   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","2016SDU-QILU-11","August 2, 2016","September 2016","March 2017","August 9, 2016","August 2016","No Study Results Posted","null","February 2017","adenoma detection rate","https://ClinicalTrials.gov/show/NCT02865382"
4206,"NCT01451008","Compression Anastomosis Using the Compression Anastomotic Ring-locking Procedure (CARP)","Completed","No Results Available","Cancer|Polyp","Device: Compression anastomotic ring-locking procedure (CARP)","Region Skane|Carponovum AB","Both","18 Years to 90 Years   (Adult, Senior)","Phase 1","25","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CARP-002","September 26, 2011","June 2009","September 2012","July 5, 2013","July 2013","No Study Results Posted","null","September 2012","Complications, including anastomotic leakage, problems with ring evacuation|Time to evacuation of the CARP device","https://ClinicalTrials.gov/show/NCT01451008"
4207,"NCT02399605","Subcutaneous Electrical Stimulation in the Prevention of Postoperative Ileus","Active, not recruiting","No Results Available","Ileus","Other: Stimulation","Hospital General Universitario Elche","Both","18 Years and older   (Adult, Senior)","","500","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","Cirugia1","March 10, 2015","March 2015","June 2015","March 21, 2015","March 2015","No Study Results Posted","SESPI","March 2015","Time to first flatus","https://ClinicalTrials.gov/show/NCT02399605"
4208,"NCT02217956","Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma","Completed","No Results Available","Ovarian Adenocarcinoma|Fallopian Tube Adenocarcinoma|Primary Peritoneal Carcinoma","Drug: Cisplatin|Drug: Bevacizumab","Gustave Roussy, Cancer Campus, Grand Paris","Female","18 Years to 65 Years   (Adult)","Phase 1","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-024361-51|2010/1699","August 14, 2014","June 2011","June 2015","January 25, 2016","January 2016","No Study Results Posted","CHIPASTIN","June 2015","Toxicity|Progression Free Survival","https://ClinicalTrials.gov/show/NCT02217956"
4209,"NCT00443040","Asimadoline for the Treatment of Post-Operative Ileus","Terminated","Has Results","Post-Operative Ileus","Drug: Asimadoline|Drug: Placebo","Tioga Pharmaceuticals|RTI Health Solutions","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","35","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASMP2004","February 27, 2007","January 2007","February 2008","November 30, 2011","November 2011","October 14, 2011","null","February 2008","Time to Return of Upper and Lower GI Function|Time to Tolerating Solid Food|Time to First Passage of Flatus|Time to First Bowel Movement|Time to Writing of Hospital Discharge Order|Nausea Score|Vomiting Score|Pain Score|Nasogastric Tube Re-insertion|Post-operative Analgesic Use|Adverse Events|Laboratory Values","https://ClinicalTrials.gov/show/NCT00443040"
4210,"NCT02693886","Effect of Single Colonoscopy on Colorectal Adenomas Detection","Not yet recruiting","No Results Available","Colonic Polyps","Other: doctor experience","Wuxi People's Hospital","Both","40 Years to 80 Years   (Adult, Senior)","","10000","Other","Observational","Observational Model: Case-Only","WX0302-B010507-150031-PB","January 27, 2016","April 2016","December 2017","February 26, 2016","January 2016","No Study Results Posted","null","December 2017","Detection rate of polyps in different withdraw time|Detection rate of polyps in different experiment levels of examiners","https://ClinicalTrials.gov/show/NCT02693886"
4211,"NCT02372331","The Effect of ERAS on Pancreaticoduodenectomy","Recruiting","No Results Available","Periampullary Tumor","Other: ERAS perioperative management","Asan Medical Center","Both","18 Years to 80 Years   (Adult, Senior)","","276","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ERAS","February 12, 2015","March 2015","February 2017","July 13, 2016","July 2016","No Study Results Posted","ERAS","October 2016","Morbidity|Mortality|length of stay|nutritional status","https://ClinicalTrials.gov/show/NCT02372331"
4212,"NCT02263144","Resect and Discard Extension to FICE of NIcE Classification","Recruiting","No Results Available","Hyperplastic Polyps|Adenomatous Polyps","Procedure: virtual chromo-endoscopy using FICE Fujifilm Technology","Istituto Clinico Humanitas|Universitaire Ziekenhuizen Leuven|Royal Alexandra Hospital|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Nuovo Regina Margherita Hospital|University of Erlangen-Nürnberg Medical School|University Hospital Regensburg|Hôpital Edouard Herriot","Both","Child, Adult, Senior","","110","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","REDEFINE","September 25, 2014","May 2014","December 2014","October 8, 2014","October 2014","No Study Results Posted","FICE;NICE","December 2014","accuracy of the NICE criteria using FICE technology for differentiating between the non-neoplastic and neoplastic histotypes in diagnoses with high-confidence on a video-library of 110 polyps reviewed by 7 experts.|Inter-observer agreement among the 7 experts","https://ClinicalTrials.gov/show/NCT02263144"
4213,"NCT01919463","Intubation Techniques on Colonoscopy Quality (SINOCOLO2013)","Recruiting","No Results Available","Colorectal Adenoma|Colorectal Polyp","Behavioral: Abdominal Compression|Device: Guidance of Magnetic Endoscopic Imaging (MEI) System","Changhai Hospital","Both","18 Years and older   (Adult, Senior)","","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","SINOCOLO2013","August 6, 2013","March 2015","February 2016","March 2, 2015","March 2015","No Study Results Posted","SINOCOLO2013","August 2015","Mean Intubation Time (MIT)|Cecal Intubation Rate (CIR)|Pain Score (PS)|Severe Adverse Event Rate (SAER)|Adenoma Detection Rate (ADR)|Polyp Detection Rate (PDR)","https://ClinicalTrials.gov/show/NCT01919463"
4214,"NCT02331836","Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy","Recruiting","No Results Available","Colorectal Polyps|Colorectal Adenomas","Device: Arc Endocuff (AEC 110, 120, 130, 140)|Device: Cap|Device: Standard colonoscope","Helios Albert-Schweitzer-Klinik Northeim","Both","18 Years and older   (Adult, Senior)","","561","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","EC-CUFF-2015","January 2, 2015","February 2015","December 2017","February 17, 2016","February 2016","No Study Results Posted","EC-Cap-SC","August 2017","Adenoma detection rate|Polyp detection rate|Bowel preparation result|Coecum intubation rate|Ileum intubation rate|Coecum intubation time|withdrawal time|mucosal laceration|severe bleeding|perforation","https://ClinicalTrials.gov/show/NCT02331836"
4215,"NCT00051675","Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas","Completed","No Results Available","Adenocarcinoma","Drug: ING-1(heMAb)","XOMA (US) LLC","Both","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INCA104","January 14, 2003","July 2002","September 2003","June 23, 2005","September 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00051675"
4216,"NCT00176618","The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon","Terminated","No Results Available","Aberrant Crypt Foci","Drug: sulindac|Drug: curcumin","University of Medicine and Dentistry of New Jersey|Rutgers, The State University of New Jersey","Both","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","4611|CINJ#120305","September 13, 2005","April 2004","June 2007","December 10, 2009","December 2009","No Study Results Posted","null","June 2007","To evaluate the effects of curcumin or the NSAID sulindac on the number of ACF in the left colon and rectum of normal volunteers found to have them on an initial magnifying chromoendoscopic screening exam|To determine the turnover (proliferation, apoptosis, and differentiation) of colorectal epithelial cells in the crypts in situ in response to each treatment","https://ClinicalTrials.gov/show/NCT00176618"
4217,"NCT02595775","A Trial of an Audit and Feedback Report to Improve Colonoscopy Performance","Enrolling by invitation","No Results Available","Colorectal Polyps","Other: Individualized A/F report|Other: A/F report plus a high intensity intervention|Other: A/F report plus a low intensity intervention|Other: A/F report alone","Sunnybrook Health Sciences Centre|Cancer Care Ontario","Both","18 Years and older   (Adult, Senior)","","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","477-2014","July 10, 2015","September 2015","December 2017","November 2, 2015","October 2015","No Study Results Posted","null","September 2017","Change in polypectomy rate from baseline|Additional outcome 1- Change in cecal intubation rate|Additional outcome 2 - Change in annual colonoscopy volume|Additional outcome 3 - Change in poor bowel preparation rate","https://ClinicalTrials.gov/show/NCT02595775"
4218,"NCT01195506","Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)","Active, not recruiting","No Results Available","Acute Myeloid Leukemia","","Taipei Medical University WanFang Hospital","Both","18 Years to 60 Years   (Adult)","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","99025","September 3, 2010","September 2010","null","October 5, 2010","October 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01195506"
4219,"NCT00755261","Phase II Study of Doxorubicin and Avastin® in Sarcoma.","Terminated","Has Results","Sarcoma|Soft Tissue Sarcoma","Drug: Avastin|Drug: Doxorubicin","Sidney Kimmel Comprehensive Cancer Center","Both","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J07133|NA_00013238|AVF3855s","September 17, 2008","September 2008","November 2010","May 7, 2015","May 2015","April 15, 2015","null","September 2010","RECIST","https://ClinicalTrials.gov/show/NCT00755261"
4220,"NCT01853267","Perianal Abscess Packing Randomized ControlledTrial Pilot Study","Completed","No Results Available","Perianal Abscess","Procedure: Intervention Group (Non-Packing)|Procedure: Control group (Packing)","Imperial College London","Both","18 Years and older   (Adult, Senior)","","14","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Treatment","JRCOMS0513","May 10, 2013","May 2011","December 2012","May 20, 2014","May 2013","No Study Results Posted","null","December 2012","Time to abscess healing","https://ClinicalTrials.gov/show/NCT01853267"
4221,"NCT02836470","A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection","Not yet recruiting","No Results Available","Ileus|Post-Operative Adhesions","Drug: LB1148|Drug: Placebo","Leading BioSciences, Inc","Both","18 Years to 80 Years   (Adult, Senior)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LBS-POI-201","July 13, 2016","September 2016","September 2018","August 29, 2016","August 2016","No Study Results Posted","PROFILE","November 2017","Time to return of gastrointestinal function|Time to Achieve GI-2|Time to Achieve GI-3|Time to resolution of post-operative ileus|Hospital length of stay","https://ClinicalTrials.gov/show/NCT02836470"
4222,"NCT02305251","Patient Preferences of a Resect and Discard Paradigm","Completed","No Results Available","Colonic Polyps","Other: Survey","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","","500","Other","Observational","Time Perspective: Prospective","201202031","November 19, 2014","June 2012","March 2014","November 26, 2014","November 2014","No Study Results Posted","null","March 2014","Number of participants willing to pay out of pocket for pathology costs when a diminutive polyp is found.|The factors that influence patients' decisions to pay or not pay for pathology costs with their own money.","https://ClinicalTrials.gov/show/NCT02305251"
4223,"NCT02811419","I-scan for Sessile Serrated Adenoma Detection","Not yet recruiting","No Results Available","Colorectal Adenomatous Polyps","Device: i-scan|Device: standard high-definition white light","University of California, San Francisco","Both","50 Years to 75 Years   (Adult, Senior)","","1000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","P072016","June 21, 2016","July 2016","June 2018","June 22, 2016","June 2016","No Study Results Posted","null","June 2018","sessile serrated adenoma/polyp detection rate|adenoma detection rate","https://ClinicalTrials.gov/show/NCT02811419"
4224,"NCT02749552","The Role of Values, Acceptance, and Mindfulness Strategies in Long Term Weight Management","Not yet recruiting","No Results Available","Obesity","Behavioral: Acceptance and Commitment Therapy","Nova Scotia Health Authority","Both","19 Years and older   (Adult, Senior)","","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3168","April 8, 2016","May 2016","June 2021","April 20, 2016","April 2016","No Study Results Posted","null","June 2017","health behaviours (self-report questionnaires)|acceptance (self-report questionnaire)|mindfulness (self-report questionnaire)","https://ClinicalTrials.gov/show/NCT02749552"
4225,"NCT02609100","Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy","Recruiting","No Results Available","Gastrointestinal Hemorrhage","Procedure: Video Capsule Endoscopy|Procedure: Colonoscopy|Device: 1.0 X 2.5 cm 'pill' containing a camera","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","","360","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","201507101","November 16, 2015","November 2015","null","November 18, 2015","November 2015","No Study Results Posted","null","November 2017","Proportion of participants with clinically significant findings defined as lesions considered to have a high potential for bleeding to participants with no significant findings from Video Capsule Endoscopy|Proportion of participants with clinically significant findings defined as lesions considered to have a high potential for bleeding to participants with no significant findings from Colonoscopy|Therapeutic yield of video capsule endoscopy|Therapeutic yield of colonoscopy|Volume of blood transfused|Number of diagnostic studies performed for evaluation of gastrointestinal bleeding|Duration of hospital stay|Procedure related adverse events","https://ClinicalTrials.gov/show/NCT02609100"
4226,"NCT02129439","Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients","Recruiting","No Results Available","Colitis, Ulcerative","Drug: SB012|Drug: Placebo","Sterna Biologicals GmbH & Co. KG","Both","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SB012/01/2013","April 30, 2014","April 2014","March 2016","May 19, 2015","April 2014","No Study Results Posted","SECURE","December 2015","Efficacy: Total Mayo score (4 weeks comparison)|Efficacy: Total Mayo score (8 weeks comparison)|Efficacy: Endoscopic Mayo score (4 and 8 weeks comparison)|Efficacy/Pharmacodynamics: Glucocorticoid consumption|Safety: Treatment Emergent Adverse Events (AE) and Serious Adverse Events (SAE)","https://ClinicalTrials.gov/show/NCT02129439"
4227,"NCT02630680","Eziclen Drug Utilisation in Real Life Setting","Recruiting","No Results Available","Bowel Cleansing","Drug: Eziclen®/Izinova®","Ipsen","Both","18 Years and older   (Adult, Senior)","","1285","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","8-79-58800-001","December 11, 2015","October 2015","October 2017","August 31, 2016","August 2016","No Study Results Posted","DUS-BLI800","October 2017","Volume of liquid intake|Number of adverse events","https://ClinicalTrials.gov/show/NCT02630680"
4228,"NCT01526967","Observational Evaluation of the Peristomal Skin Condition in Ostomates","Active, not recruiting","No Results Available","Ostomy","","ConvaTec Inc.","Both","18 Years and older   (Adult, Senior)","","2000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MA-0509-12-U359","February 1, 2012","January 2012","December 2012","December 14, 2012","December 2012","No Study Results Posted","OSMOSE","December 2012","Peristomal skin condition|Level of satisfaction|Accessory usage|Peristomal Skin Condition","https://ClinicalTrials.gov/show/NCT01526967"
4229,"NCT02330159","Feasibility of a Novel Technique for Pilonidal Wound Healing","Recruiting","No Results Available","Pilonidal Disease|Pilonidal Cyst|Pilonidal Sinus","Procedure: Novel Wound Healing Protocol","Southeast Clinical Research Associates, Houston, Texas|ACell Inc.","Both","18 Years and older   (Adult, Senior)","","20","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ACellCSA01","December 29, 2014","February 2015","July 2016","November 17, 2015","November 2015","No Study Results Posted","null","July 2016","Wound Healing|Healthcare costs using the novel protocol|Quality of Life|Disease Recurrence","https://ClinicalTrials.gov/show/NCT02330159"
4230,"NCT02880748","Effect of Water Exchange Method on Adenoma Miss Rates in Patients Undergoing Selective Polypectomy","Recruiting","No Results Available","Adenoma","Other: Water exchange (WE) method|Other: Air insufflation (AI) method.","Fourth Military Medical University","Both","18 Years to 80 Years   (Adult, Senior)","","450","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","KY20162059-2","August 19, 2016","August 2016","August 2017","August 25, 2016","August 2016","No Study Results Posted","null","August 2017","Adenoma miss rate|adenoma-level miss rate|Advanced adenoma miss rate/Miss advanced adenoma per colonoscopy|Adenoma per positive patient (APP)|Quality of Bowel Preparation|Complication rate|Pain Scores on the Visual Analog Scale compared with previous colonoscopy","https://ClinicalTrials.gov/show/NCT02880748"
4231,"NCT01226550","Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan","Completed","No Results Available","Peritoneal Carcinosis (PC)","Procedure: cytoreductive surgery and HIPEC","Hospices Civils de Lyon","Both","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","18","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004.368","October 20, 2010","June 2007","April 2011","December 28, 2011","December 2011","No Study Results Posted","null","April 2011","Morbidity rate|Mortality rate|Intraperitoneal and serumal concentration (pharmacokinetics) of mitomycine C, irinotecan, and its metabolites.","https://ClinicalTrials.gov/show/NCT01226550"
4232,"NCT02758860","Predictive Value of the Diverticular Inflammation and Complication Assessment (DICA) in the Diverticular Disease of the Colon","Not yet recruiting","No Results Available","Colonic Diverticula","Procedure: Colonoscopy","University of Roma La Sapienza","Both","18 Years and older   (Adult, Senior)","","281","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DICA Trial","April 23, 2016","June 2016","December 2019","May 4, 2016","May 2016","No Study Results Posted","null","December 2017","DICA score and diverticulitis|DICA score and surgery|DICA score and therapy","https://ClinicalTrials.gov/show/NCT02758860"
4233,"NCT00450671","Treatment of Perirectal Fistula With Cutting Seton vs. Collagen Plug","Recruiting","No Results Available","Anal Fistula","Procedure: Collagen Plug Placement|Procedure: Seton placement","University of Southern California","Both","18 Years and older   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Seton vs. Surgisis","March 20, 2007","February 2007","February 2012","November 25, 2008","March 2007","No Study Results Posted","null","null","Fistula healing|Treatment failure|Time to fistula healing|Time to treatment failure|Rates of postoperative fecal continence","https://ClinicalTrials.gov/show/NCT00450671"
4234,"NCT01546246","Water Method in Patients With Incomplete Colonoscopy","Withdrawn","No Results Available","Failed or Difficult Intubation|Adenoma|Pain","Other: Water colonoscopy","Fourth Military Medical University","Both","18 Years to 80 Years   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Screening","20120216-6","February 24, 2012","November 2011","December 2014","March 24, 2016","March 2016","No Study Results Posted","null","November 2014","Cecal intubation success rate|Adenoma detection rate|Pain Scores on the Visual Analog Scale|Cecum intubation time","https://ClinicalTrials.gov/show/NCT01546246"
4235,"NCT02248246","Harmonic ACE®+7 Shears in Laparoscopic Colectomy","Completed","Has Results","Benign or Malignant Disease Indicated for Colectomy","Device: Harmonic ACE®+7 Shears","Ethicon Endo-Surgery","Both","18 Years and older   (Adult, Senior)","Phase 4","40","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ENG-14-001","September 22, 2014","August 2014","June 2015","June 16, 2016","June 2016","March 2, 2016","null","February 2015","Percentage of Participants With Hemostasis at the IMA|Percentage of Participants With Hemostasis at the IMV","https://ClinicalTrials.gov/show/NCT02248246"
4236,"NCT00941889","The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata","Completed","Has Results","HIV Positive|Anal Condylomata|Anal Warts|HIV Infections","Drug: Saline|Drug: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine","Washington University School of Medicine","Both","18 Years and older   (Adult, Senior)","","32","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","HRPO 07-0648","July 16, 2009","July 2007","July 2011","June 13, 2016","June 2016","August 20, 2013","null","July 2011","The Primary Endpoint of This Study is Persistence and Recurrence of Anal Warts as Compared Between the Experimental and Control Groups.","https://ClinicalTrials.gov/show/NCT00941889"
